Register Login

ABBVIE INC. (ABBV)

SymbolABBV
NameABBVIE INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, Illinois, 60064-6400, United States
Telephone+1 847 932-7900
Fax—
Email—
Websitehttps://www.abbvie.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001551152
Description

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The companys primary product is Humira, administered via injection.

Additional info from NASDAQ:
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The companys primary product is Humira, administered via injection.

2026-07-17 12:00

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Read more
2026-07-06 20:12

(99% Neutral) ABBVIE INC. (ABBV) Files Form 8-K

Read more
2026-07-06 17:45

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Read more
2026-07-02 21:00

Quaggin Susan E 🟢 acquired 62 shares (1 derivative) of AbbVie Inc. (ABBV) at $251.64 Transaction Date: Jun 30, 2026 | Filing ID: 000008

Read more
2026-06-29 20:52

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Read more
2026-06-29 20:15

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Read more
2026-06-29 07:10

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Read more
2026-06-29 07:00

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Read more
2026-06-26 20:50

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Read more
2026-06-26 12:00

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT03123211 Expanded Access to Veliparib — Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound No_Longer_Available — — ClinicalTrials.gov
NCT03123029 Expanded Access to Venetoclax — Chronic Lymphocytic Leukemia (CLL) Available — — ClinicalTrials.gov
NCT04159597 Expanded Access to Upadacitinib — Crohn Disease Available — — ClinicalTrials.gov
NCT03592576 Expanded Access to Navitoclax — Myelofibrosis No_Longer_Available — — ClinicalTrials.gov
NCT03914261 Expanded Access to Risankizumab — Crohn's Disease No_Longer_Available — — ClinicalTrials.gov
NCT03503890 Expanded Access to Rovalpituzumab Tesirine — Small Cell Lung Cancer No_Longer_Available — — ClinicalTrials.gov
NCT03744546 Expanded Access to ABBV-8E12 — Primary Tauopathy Corticobasal Degeneration Syndrome (CBD) No_Longer_Available — — ClinicalTrials.gov
NCT03123965 Expanded Access to Glecaprevir/ Pibrentasvir — Hepatitis C Virus Infection Approved_For_Marketing — — ClinicalTrials.gov
NCT03123952 Expanded Access to ABT-414 — Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis No_Longer_Available — — ClinicalTrials.gov
NCT03123211 Expanded Access to Veliparib — Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound No_Longer_Available — — ClinicalTrials.gov
NCT03592576 Expanded Access to Navitoclax — Myelofibrosis No_Longer_Available — — ClinicalTrials.gov
NCT03123029 Expanded Access to Venetoclax — Chronic Lymphocytic Leukemia (CLL) Available — — ClinicalTrials.gov
NCT02985658 Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer — Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation No_Longer_Available — — ClinicalTrials.gov
NCT03503890 Expanded Access to Rovalpituzumab Tesirine — Small Cell Lung Cancer No_Longer_Available — — ClinicalTrials.gov
NCT02856438 Early Patient Access Treatment Use Protocol CA204-220 — Multiple Myeloma No_Longer_Available — — ClinicalTrials.gov
NCT01789151 99m-Technetium- Glucosamine in Arthritis — Rheumatoid Arthritis No_Longer_Available — — ClinicalTrials.gov
NCT07310277 Expanded Access to ABBV-706 — Small Cell Lung Cancer Available — — ClinicalTrials.gov
NCT07158827 Expanded Access to Tavapadon — Parkinson Disease Available — — ClinicalTrials.gov
NCT05338606 Expanded Access to Bimatoprost (Durysta) — Open-angle Glaucoma No_Longer_Available — — ClinicalTrials.gov
NCT01789151 99m-Technetium- Glucosamine in Arthritis — Rheumatoid Arthritis No_Longer_Available — — ClinicalTrials.gov
NCT04830202 Expanded Access to Telisotuzumab Vedotin — Non-Small Cell Lung Cancer (NSCLC) Temporarily_Not_Available — — ClinicalTrials.gov
NCT03123965 Expanded Access to Glecaprevir/ Pibrentasvir — Hepatitis C Virus Infection Approved_For_Marketing — — ClinicalTrials.gov
NCT03123952 Expanded Access to ABT-414 — Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis No_Longer_Available — — ClinicalTrials.gov
NCT03123211 Expanded Access to Veliparib — Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound No_Longer_Available — — ClinicalTrials.gov
NCT03123029 Expanded Access to Venetoclax — Chronic Lymphocytic Leukemia (CLL) Available — — ClinicalTrials.gov
NCT04278235 Expanded Access to Elezanumab — Acute Spinal Cord Injury (SCI) No_Longer_Available — — ClinicalTrials.gov
NCT05338606 Expanded Access to Bimatoprost (Durysta) — Open-angle Glaucoma No_Longer_Available — — ClinicalTrials.gov
NCT04830202 Expanded Access to Telisotuzumab Vedotin — Non-Small Cell Lung Cancer (NSCLC) Temporarily_Not_Available — — ClinicalTrials.gov
NCT05692050 Expanded Access to Epcoritamab — Lymphoma No_Longer_Available — — ClinicalTrials.gov
NCT05733650 Expanded Access Program for Epcoritamab — Large B-cell Lymphoma Approved_For_Marketing — — ClinicalTrials.gov
NCT04278235 Expanded Access to Elezanumab — Acute Spinal Cord Injury (SCI) No_Longer_Available — — ClinicalTrials.gov
NCT04830202 Expanded Access to Telisotuzumab Vedotin — Non-Small Cell Lung Cancer (NSCLC) Temporarily_Not_Available — — ClinicalTrials.gov
NCT05692050 Expanded Access to Epcoritamab — Lymphoma No_Longer_Available — — ClinicalTrials.gov
NCT05733650 Expanded Access Program for Epcoritamab — Large B-cell Lymphoma Approved_For_Marketing — — ClinicalTrials.gov
NCT04278235 Expanded Access to Elezanumab — Acute Spinal Cord Injury (SCI) No_Longer_Available — — ClinicalTrials.gov
NCT05982873 Expanded Access to Telisotuzumab Adizutecan — Solid Tumors Available — — ClinicalTrials.gov
NCT06439966 Expanded Access to ABBV-787 — Acute Myeloid Leukemia No_Longer_Available — — ClinicalTrials.gov
NCT06594016 Expanded Access to Fosigotifator — Vanishing White Matter No_Longer_Available — — ClinicalTrials.gov
NCT07310277 Expanded Access to ABBV-706 — Small Cell Lung Cancer Available — — ClinicalTrials.gov
NCT01789151 99m-Technetium- Glucosamine in Arthritis — Rheumatoid Arthritis No_Longer_Available — — ClinicalTrials.gov
NCT07158827 Expanded Access to Tavapadon — Parkinson Disease Available — — ClinicalTrials.gov
NCT07310277 Expanded Access to ABBV-706 — Small Cell Lung Cancer Available — — ClinicalTrials.gov
NCT03914261 Expanded Access to Risankizumab — Crohn's Disease No_Longer_Available — — ClinicalTrials.gov
NCT06594016 Expanded Access to Fosigotifator — Vanishing White Matter No_Longer_Available — — ClinicalTrials.gov
NCT07158827 Expanded Access to Tavapadon — Parkinson Disease Available — — ClinicalTrials.gov
NCT06439966 Expanded Access to ABBV-787 — Acute Myeloid Leukemia No_Longer_Available — — ClinicalTrials.gov
NCT05982873 Expanded Access to Telisotuzumab Adizutecan — Solid Tumors Available — — ClinicalTrials.gov
NCT05733650 Expanded Access Program for Epcoritamab — Large B-cell Lymphoma Approved_For_Marketing — — ClinicalTrials.gov
NCT05692050 Expanded Access to Epcoritamab — Lymphoma No_Longer_Available — — ClinicalTrials.gov
NCT05338606 Expanded Access to Bimatoprost (Durysta) — Open-angle Glaucoma No_Longer_Available — — ClinicalTrials.gov
NCT04159597 Expanded Access to Upadacitinib — Crohn Disease Available — — ClinicalTrials.gov
NCT03744546 Expanded Access to ABBV-8E12 — Primary Tauopathy Corticobasal Degeneration Syndrome (CBD) No_Longer_Available — — ClinicalTrials.gov
NCT04278235 Expanded Access to Elezanumab — Acute Spinal Cord Injury (SCI) No_Longer_Available — — ClinicalTrials.gov
NCT01789151 99m-Technetium- Glucosamine in Arthritis — Rheumatoid Arthritis No_Longer_Available — — ClinicalTrials.gov
NCT03914261 Expanded Access to Risankizumab — Crohn's Disease No_Longer_Available — — ClinicalTrials.gov
NCT04830202 Expanded Access to Telisotuzumab Vedotin — Non-Small Cell Lung Cancer (NSCLC) Temporarily_Not_Available — — ClinicalTrials.gov
NCT02856438 Early Patient Access Treatment Use Protocol CA204-220 — Multiple Myeloma No_Longer_Available — — ClinicalTrials.gov
NCT02985658 Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer — Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation No_Longer_Available — — ClinicalTrials.gov
NCT03123029 Expanded Access to Venetoclax — Chronic Lymphocytic Leukemia (CLL) Available — — ClinicalTrials.gov
NCT03123211 Expanded Access to Veliparib — Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound No_Longer_Available — — ClinicalTrials.gov
NCT03123952 Expanded Access to ABT-414 — Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis No_Longer_Available — — ClinicalTrials.gov
NCT03123965 Expanded Access to Glecaprevir/ Pibrentasvir — Hepatitis C Virus Infection Approved_For_Marketing — — ClinicalTrials.gov
NCT03503890 Expanded Access to Rovalpituzumab Tesirine — Small Cell Lung Cancer No_Longer_Available — — ClinicalTrials.gov
NCT03592576 Expanded Access to Navitoclax — Myelofibrosis No_Longer_Available — — ClinicalTrials.gov
NCT02856438 Early Patient Access Treatment Use Protocol CA204-220 — Multiple Myeloma No_Longer_Available — — ClinicalTrials.gov
NCT06594016 Expanded Access to Fosigotifator — Vanishing White Matter No_Longer_Available — — ClinicalTrials.gov
NCT03744546 Expanded Access to ABBV-8E12 — Primary Tauopathy Corticobasal Degeneration Syndrome (CBD) No_Longer_Available — — ClinicalTrials.gov
NCT07310277 Expanded Access to ABBV-706 — Small Cell Lung Cancer Available — — ClinicalTrials.gov
NCT06439966 Expanded Access to ABBV-787 — Acute Myeloid Leukemia No_Longer_Available — — ClinicalTrials.gov
NCT07158827 Expanded Access to Tavapadon — Parkinson Disease Available — — ClinicalTrials.gov
NCT02985658 Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer — Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation No_Longer_Available — — ClinicalTrials.gov
NCT06594016 Expanded Access to Fosigotifator — Vanishing White Matter No_Longer_Available — — ClinicalTrials.gov
NCT06439966 Expanded Access to ABBV-787 — Acute Myeloid Leukemia No_Longer_Available — — ClinicalTrials.gov
NCT04159597 Expanded Access to Upadacitinib — Crohn Disease Available — — ClinicalTrials.gov
NCT02856438 Early Patient Access Treatment Use Protocol CA204-220 — Multiple Myeloma No_Longer_Available — — ClinicalTrials.gov
NCT03914261 Expanded Access to Risankizumab — Crohn's Disease No_Longer_Available — — ClinicalTrials.gov
NCT05338606 Expanded Access to Bimatoprost (Durysta) — Open-angle Glaucoma No_Longer_Available — — ClinicalTrials.gov
NCT05982873 Expanded Access to Telisotuzumab Adizutecan — Solid Tumors Available — — ClinicalTrials.gov
NCT03744546 Expanded Access to ABBV-8E12 — Primary Tauopathy Corticobasal Degeneration Syndrome (CBD) No_Longer_Available — — ClinicalTrials.gov
NCT02985658 Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer — Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation No_Longer_Available — — ClinicalTrials.gov
NCT04159597 Expanded Access to Upadacitinib — Crohn Disease Available — — ClinicalTrials.gov
NCT03592576 Expanded Access to Navitoclax — Myelofibrosis No_Longer_Available — — ClinicalTrials.gov
NCT03503890 Expanded Access to Rovalpituzumab Tesirine — Small Cell Lung Cancer No_Longer_Available — — ClinicalTrials.gov
NCT05692050 Expanded Access to Epcoritamab — Lymphoma No_Longer_Available — — ClinicalTrials.gov
NCT05733650 Expanded Access Program for Epcoritamab — Large B-cell Lymphoma Approved_For_Marketing — — ClinicalTrials.gov
NCT05982873 Expanded Access to Telisotuzumab Adizutecan — Solid Tumors Available — — ClinicalTrials.gov
NCT03123965 Expanded Access to Glecaprevir/ Pibrentasvir — Hepatitis C Virus Infection Approved_For_Marketing — — ClinicalTrials.gov
NCT03123952 Expanded Access to ABT-414 — Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis No_Longer_Available — — ClinicalTrials.gov
NCT07600151 Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Phase1 Myeloma Multiple Not_Yet_Recruiting 2026-12-01 2036-12-31 ClinicalTrials.gov
NCT07600151 Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Phase1 Myeloma Multiple Not_Yet_Recruiting 2026-12-01 2036-12-31 ClinicalTrials.gov
NCT07600151 Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Phase1 Myeloma Multiple Not_Yet_Recruiting 2026-12-01 2036-12-31 ClinicalTrials.gov
NCT07600151 Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Phase1 Myeloma Multiple Not_Yet_Recruiting 2026-12-01 2036-12-31 ClinicalTrials.gov
NCT07175415 HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients W… Phase1 Acute Lymphoblastic Leukemia Not_Yet_Recruiting 2026-10-01 2032-10-01 ClinicalTrials.gov
NCT07175415 HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients W… Phase1 Acute Lymphoblastic Leukemia Not_Yet_Recruiting 2026-10-01 2032-10-01 ClinicalTrials.gov
NCT07175415 HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients W… Phase1 Acute Lymphoblastic Leukemia Not_Yet_Recruiting 2026-10-01 2032-10-01 ClinicalTrials.gov
NCT07175415 HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients W… Phase1 Acute Lymphoblastic Leukemia Not_Yet_Recruiting 2026-10-01 2032-10-01 ClinicalTrials.gov
NCT07690215 Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Preve… — Migraine Not_Yet_Recruiting 2026-09-01 2028-03-01 ClinicalTrials.gov
NCT07690215 Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Preve… — Migraine Not_Yet_Recruiting 2026-09-01 2028-03-01 ClinicalTrials.gov
NCT07690215 Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Preve… — Migraine Not_Yet_Recruiting 2026-09-01 2028-03-01 ClinicalTrials.gov
NCT07690215 Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Preve… — Migraine Not_Yet_Recruiting 2026-09-01 2028-03-01 ClinicalTrials.gov
NCT07670156 Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutatio… Phase1 JAK1 GOF Not_Yet_Recruiting 2026-08-01 2028-08-01 ClinicalTrials.gov
NCT07670156 Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutatio… Phase1 JAK1 GOF Not_Yet_Recruiting 2026-08-01 2028-08-01 ClinicalTrials.gov
NCT07670156 Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutatio… Phase1 JAK1 GOF Not_Yet_Recruiting 2026-08-01 2028-08-01 ClinicalTrials.gov
NCT07670156 Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutatio… Phase1 JAK1 GOF Not_Yet_Recruiting 2026-08-01 2028-08-01 ClinicalTrials.gov
NCT07581002 A Study to Assess Adverse Events and Change in Disease Activity When Intravenou… Phase2 Acute Myeloid Leukemia Not_Yet_Recruiting 2026-07-22 2032-06-01 ClinicalTrials.gov
NCT07581002 A Study to Assess Adverse Events and Change in Disease Activity When Intravenou… Phase2 Acute Myeloid Leukemia Not_Yet_Recruiting 2026-07-22 2032-06-01 ClinicalTrials.gov
NCT07581002 A Study to Assess Adverse Events and Change in Disease Activity When Intravenou… Phase2 Acute Myeloid Leukemia Not_Yet_Recruiting 2026-07-22 2032-06-01 ClinicalTrials.gov
NCT07581002 A Study to Assess Adverse Events and Change in Disease Activity When Intravenou… Phase2 Acute Myeloid Leukemia Not_Yet_Recruiting 2026-07-22 2032-06-01 ClinicalTrials.gov
NCT07502339 Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis Phase4 UC - Ulcerative Colitis Not_Yet_Recruiting 2026-07-01 2028-08-01 ClinicalTrials.gov
NCT07588568 A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis Phase2 EoE Not_Yet_Recruiting 2026-07-01 2030-06-01 ClinicalTrials.gov
NCT07588568 A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis Phase2 EoE Not_Yet_Recruiting 2026-07-01 2030-06-01 ClinicalTrials.gov
NCT07502339 Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis Phase4 UC - Ulcerative Colitis Not_Yet_Recruiting 2026-07-01 2028-08-01 ClinicalTrials.gov
NCT07502339 Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis Phase4 UC - Ulcerative Colitis Not_Yet_Recruiting 2026-07-01 2028-08-01 ClinicalTrials.gov
NCT07502339 Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis Phase4 UC - Ulcerative Colitis Not_Yet_Recruiting 2026-07-01 2028-08-01 ClinicalTrials.gov
NCT07588568 A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis Phase2 EoE Not_Yet_Recruiting 2026-07-01 2030-06-01 ClinicalTrials.gov
NCT07588568 A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis Phase2 EoE Not_Yet_Recruiting 2026-07-01 2030-06-01 ClinicalTrials.gov
NCT07687602 A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuxim… — Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer Not_Yet_Recruiting 2026-06-30 2031-08-01 ClinicalTrials.gov
NCT07687602 A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuxim… — Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer Not_Yet_Recruiting 2026-06-30 2031-08-01 ClinicalTrials.gov
NCT07680686 Study to Assess How Different Oral Formulations of Ubrogepant Move Through the … Phase1 Healthy Volunteer Not_Yet_Recruiting 2026-06-30 2026-10-01 ClinicalTrials.gov
NCT07680686 Study to Assess How Different Oral Formulations of Ubrogepant Move Through the … Phase1 Healthy Volunteer Not_Yet_Recruiting 2026-06-30 2026-10-01 ClinicalTrials.gov
NCT07687602 A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuxim… — Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer Not_Yet_Recruiting 2026-06-30 2031-08-01 ClinicalTrials.gov
NCT07680686 Study to Assess How Different Oral Formulations of Ubrogepant Move Through the … Phase1 Healthy Volunteer Not_Yet_Recruiting 2026-06-30 2026-10-01 ClinicalTrials.gov
NCT07687602 A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuxim… — Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer Not_Yet_Recruiting 2026-06-30 2031-08-01 ClinicalTrials.gov
NCT07680686 Study to Assess How Different Oral Formulations of Ubrogepant Move Through the … Phase1 Healthy Volunteer Not_Yet_Recruiting 2026-06-30 2026-10-01 ClinicalTrials.gov
NCT07649954 A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresert… Phase1 Healthy Volunteer Not_Yet_Recruiting 2026-06-28 2026-09-01 ClinicalTrials.gov
NCT07649954 A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresert… Phase1 Healthy Volunteer Not_Yet_Recruiting 2026-06-28 2026-09-01 ClinicalTrials.gov
NCT07649954 A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresert… Phase1 Healthy Volunteer Not_Yet_Recruiting 2026-06-28 2026-09-01 ClinicalTrials.gov
NCT07649954 A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresert… Phase1 Healthy Volunteer Not_Yet_Recruiting 2026-06-28 2026-09-01 ClinicalTrials.gov
NCT07040319 Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated … Phase1 Hepatitis C Recruiting 2026-06-25 2027-10-30 ClinicalTrials.gov
NCT07040319 Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated … Phase1 Hepatitis C Recruiting 2026-06-25 2027-10-30 ClinicalTrials.gov
NCT07040319 Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated … Phase1 Hepatitis C Recruiting 2026-06-25 2027-10-30 ClinicalTrials.gov
NCT07040319 Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated … Phase1 Hepatitis C Recruiting 2026-06-25 2027-10-30 ClinicalTrials.gov
NCT07673120 A Study to Assess Safety, Tolerability, and How Single and Multiple Injections … Phase1 Healthy Volunteers Recruiting 2026-06-22 2028-02-01 ClinicalTrials.gov
NCT07673120 A Study to Assess Safety, Tolerability, and How Single and Multiple Injections … Phase1 Healthy Volunteers Recruiting 2026-06-22 2028-02-01 ClinicalTrials.gov
NCT07673120 A Study to Assess Safety, Tolerability, and How Single and Multiple Injections … Phase1 Healthy Volunteers Recruiting 2026-06-22 2028-02-01 ClinicalTrials.gov
NCT07673120 A Study to Assess Safety, Tolerability, and How Single and Multiple Injections … Phase1 Healthy Volunteers Recruiting 2026-06-22 2028-02-01 ClinicalTrials.gov
NCT07673107 Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity … Phase2 Upper Limb Essential Tremor Recruiting 2026-06-18 2028-11-01 ClinicalTrials.gov
NCT07673107 Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity … Phase2 Upper Limb Essential Tremor Recruiting 2026-06-18 2028-11-01 ClinicalTrials.gov
NCT07673107 Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity … Phase2 Upper Limb Essential Tremor Recruiting 2026-06-18 2028-11-01 ClinicalTrials.gov
NCT07673107 Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity … Phase2 Upper Limb Essential Tremor Recruiting 2026-06-18 2028-11-01 ClinicalTrials.gov
NCT07639632 Reduce Inefficiencies in Management of Spasticity Na Stroke Not_Yet_Recruiting 2026-06-15 2029-11-30 ClinicalTrials.gov
NCT07639632 Reduce Inefficiencies in Management of Spasticity Na Stroke Not_Yet_Recruiting 2026-06-15 2029-11-30 ClinicalTrials.gov
NCT07639632 Reduce Inefficiencies in Management of Spasticity Na Stroke Not_Yet_Recruiting 2026-06-15 2029-11-30 ClinicalTrials.gov
NCT07639632 Reduce Inefficiencies in Management of Spasticity Na Stroke Not_Yet_Recruiting 2026-06-15 2029-11-30 ClinicalTrials.gov
NCT07466550 A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizu… Phase1 Healthy Volunteer Recruiting 2026-06-04 2027-01-01 ClinicalTrials.gov
NCT07466550 A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizu… Phase1 Healthy Volunteer Recruiting 2026-06-04 2027-01-01 ClinicalTrials.gov
NCT07466550 A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizu… Phase1 Healthy Volunteer Recruiting 2026-06-04 2027-01-01 ClinicalTrials.gov
NCT07466550 A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizu… Phase1 Healthy Volunteer Recruiting 2026-06-04 2027-01-01 ClinicalTrials.gov
NCT07592273 Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Partici… Phase2 Diabetic Retinopathy Recruiting 2026-06-01 2036-01-01 ClinicalTrials.gov
NCT07592273 Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Partici… Phase2 Diabetic Retinopathy Recruiting 2026-06-01 2036-01-01 ClinicalTrials.gov
NCT07592273 Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Partici… Phase2 Diabetic Retinopathy Recruiting 2026-06-01 2036-01-01 ClinicalTrials.gov
NCT07592273 Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Partici… Phase2 Diabetic Retinopathy Recruiting 2026-06-01 2036-01-01 ClinicalTrials.gov
NCT07604545 A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Ch… — Diabetic Macular Edema Not_Yet_Recruiting 2026-05-30 2027-03-01 ClinicalTrials.gov
NCT07604545 A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Ch… — Diabetic Macular Edema Not_Yet_Recruiting 2026-05-30 2027-03-01 ClinicalTrials.gov
NCT07604545 A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Ch… — Diabetic Macular Edema Not_Yet_Recruiting 2026-05-30 2027-03-01 ClinicalTrials.gov
NCT07604545 A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Ch… — Diabetic Macular Edema Not_Yet_Recruiting 2026-05-30 2027-03-01 ClinicalTrials.gov
NCT07607964 A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effec… Phase1 Systemic Lupus Erythematosus Recruiting 2026-05-28 2029-01-01 ClinicalTrials.gov
NCT07607964 A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effec… Phase1 Systemic Lupus Erythematosus Recruiting 2026-05-28 2029-01-01 ClinicalTrials.gov
NCT07607964 A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effec… Phase1 Systemic Lupus Erythematosus Recruiting 2026-05-28 2029-01-01 ClinicalTrials.gov
NCT07607964 A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effec… Phase1 Systemic Lupus Erythematosus Recruiting 2026-05-28 2029-01-01 ClinicalTrials.gov
NCT07604558 A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injecti… Phase1 Healthy Volunteer Recruiting 2026-05-26 2026-09-01 ClinicalTrials.gov
NCT07604558 A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injecti… Phase1 Healthy Volunteer Recruiting 2026-05-26 2026-09-01 ClinicalTrials.gov
NCT07604558 A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injecti… Phase1 Healthy Volunteer Recruiting 2026-05-26 2026-09-01 ClinicalTrials.gov
NCT07604558 A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injecti… Phase1 Healthy Volunteer Recruiting 2026-05-26 2026-09-01 ClinicalTrials.gov
NCT07525206 A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With… Phase3 Colorectal Cancer Recruiting 2026-05-22 2030-03-01 ClinicalTrials.gov
NCT07525206 A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With… Phase3 Colorectal Cancer Recruiting 2026-05-22 2030-03-01 ClinicalTrials.gov
NCT07525206 A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With… Phase3 Colorectal Cancer Recruiting 2026-05-22 2030-03-01 ClinicalTrials.gov
NCT07525206 A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With… Phase3 Colorectal Cancer Recruiting 2026-05-22 2030-03-01 ClinicalTrials.gov
NCT07306832 A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Mo… Phase1 Acute Myeloid Leukemia Recruiting 2026-05-20 2030-03-01 ClinicalTrials.gov
NCT07306832 A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Mo… Phase1 Acute Myeloid Leukemia Recruiting 2026-05-20 2030-03-01 ClinicalTrials.gov
NCT07306832 A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Mo… Phase1 Acute Myeloid Leukemia Recruiting 2026-05-20 2030-03-01 ClinicalTrials.gov
NCT07306832 A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Mo… Phase1 Acute Myeloid Leukemia Recruiting 2026-05-20 2030-03-01 ClinicalTrials.gov
NCT07599670 A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or… Phase1 Alzheimer's Disease Recruiting 2026-05-15 2030-10-01 ClinicalTrials.gov
NCT07599670 A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or… Phase1 Alzheimer's Disease Recruiting 2026-05-15 2030-10-01 ClinicalTrials.gov
NCT07599670 A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or… Phase1 Alzheimer's Disease Recruiting 2026-05-15 2030-10-01 ClinicalTrials.gov
NCT07599670 A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or… Phase1 Alzheimer's Disease Recruiting 2026-05-15 2030-10-01 ClinicalTrials.gov
NCT07587008 Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body … Phase1 Healthy Volunteers Recruiting 2026-05-12 2026-07-01 ClinicalTrials.gov
NCT07587008 Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body … Phase1 Healthy Volunteers Recruiting 2026-05-12 2026-07-01 ClinicalTrials.gov
NCT07587008 Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body … Phase1 Healthy Volunteers Recruiting 2026-05-12 2026-07-01 ClinicalTrials.gov
NCT07587008 Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body … Phase1 Healthy Volunteers Recruiting 2026-05-12 2026-07-01 ClinicalTrials.gov
NCT07599761 A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adu… Phase1 Healthy Volunteers Recruiting 2026-05-05 2026-07-01 ClinicalTrials.gov
NCT07599761 A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adu… Phase1 Healthy Volunteers Recruiting 2026-05-05 2026-07-01 ClinicalTrials.gov
NCT07599761 A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adu… Phase1 Healthy Volunteers Recruiting 2026-05-05 2026-07-01 ClinicalTrials.gov
NCT07599761 A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adu… Phase1 Healthy Volunteers Recruiting 2026-05-05 2026-07-01 ClinicalTrials.gov
NCT06953934 A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants Phase1 Healthy Volunteer Active_Not_Recruiting 2026-05-04 2026-09-01 ClinicalTrials.gov
NCT06953934 A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants Phase1 Healthy Volunteer Active_Not_Recruiting 2026-05-04 2026-09-01 ClinicalTrials.gov
NCT06953934 A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants Phase1 Healthy Volunteer Active_Not_Recruiting 2026-05-04 2026-09-01 ClinicalTrials.gov
NCT06953934 A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants Phase1 Healthy Volunteer Active_Not_Recruiting 2026-05-04 2026-09-01 ClinicalTrials.gov
NCT07570147 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single As… Phase1 Healthy Volunteer Recruiting 2026-05-01 2027-04-01 ClinicalTrials.gov
NCT07539844 Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female P… — Ovarian Cancer Not_Yet_Recruiting 2026-05-01 2027-03-01 ClinicalTrials.gov
NCT07570147 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single As… Phase1 Healthy Volunteer Recruiting 2026-05-01 2027-04-01 ClinicalTrials.gov
NCT07539844 Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female P… — Ovarian Cancer Not_Yet_Recruiting 2026-05-01 2027-03-01 ClinicalTrials.gov
NCT07570147 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single As… Phase1 Healthy Volunteer Recruiting 2026-05-01 2027-04-01 ClinicalTrials.gov
NCT07539844 Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female P… — Ovarian Cancer Not_Yet_Recruiting 2026-05-01 2027-03-01 ClinicalTrials.gov
NCT07539844 Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female P… — Ovarian Cancer Not_Yet_Recruiting 2026-05-01 2027-03-01 ClinicalTrials.gov
NCT07570147 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single As… Phase1 Healthy Volunteer Recruiting 2026-05-01 2027-04-01 ClinicalTrials.gov
NCT07490301 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With… Phase2 Metastatic Pancreatic Ductal Adenocarcinoma Recruiting 2026-04-30 2031-06-01 ClinicalTrials.gov
NCT07567781 A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavas… Phase1 Healthy Volunteers Active_Not_Recruiting 2026-04-30 2026-07-01 ClinicalTrials.gov
NCT07567781 A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavas… Phase1 Healthy Volunteers Active_Not_Recruiting 2026-04-30 2026-07-01 ClinicalTrials.gov
NCT07490301 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With… Phase2 Metastatic Pancreatic Ductal Adenocarcinoma Recruiting 2026-04-30 2031-06-01 ClinicalTrials.gov
NCT07567781 A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavas… Phase1 Healthy Volunteers Active_Not_Recruiting 2026-04-30 2026-07-01 ClinicalTrials.gov
NCT07490301 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With… Phase2 Metastatic Pancreatic Ductal Adenocarcinoma Recruiting 2026-04-30 2031-06-01 ClinicalTrials.gov
NCT07490301 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With… Phase2 Metastatic Pancreatic Ductal Adenocarcinoma Recruiting 2026-04-30 2031-06-01 ClinicalTrials.gov
NCT07567781 A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavas… Phase1 Healthy Volunteers Active_Not_Recruiting 2026-04-30 2026-07-01 ClinicalTrials.gov
NCT07600762 A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Na… Phase1 Healthy Volunteer Completed 2026-04-21 2026-06-17 ClinicalTrials.gov
NCT07600762 A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Na… Phase1 Healthy Volunteer Completed 2026-04-21 2026-06-17 ClinicalTrials.gov
NCT07600762 A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Na… Phase1 Healthy Volunteer Completed 2026-04-21 2026-06-17 ClinicalTrials.gov
NCT07600762 A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Na… Phase1 Healthy Volunteer Completed 2026-04-21 2026-06-17 ClinicalTrials.gov
NCT07365241 A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenou… Phase3 Small Cell Lung Cancer Not_Yet_Recruiting 2026-04-14 2030-09-01 ClinicalTrials.gov
NCT07365241 A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenou… Phase3 Small Cell Lung Cancer Not_Yet_Recruiting 2026-04-14 2030-09-01 ClinicalTrials.gov
NCT07365241 A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenou… Phase3 Small Cell Lung Cancer Not_Yet_Recruiting 2026-04-14 2030-09-01 ClinicalTrials.gov
NCT07365241 A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenou… Phase3 Small Cell Lung Cancer Not_Yet_Recruiting 2026-04-14 2030-09-01 ClinicalTrials.gov
NCT07514260 A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcuta… Phase1 Healthy Volunteer Recruiting 2026-03-31 2027-01-01 ClinicalTrials.gov
NCT07514260 A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcuta… Phase1 Healthy Volunteer Recruiting 2026-03-31 2027-01-01 ClinicalTrials.gov
NCT07514260 A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcuta… Phase1 Healthy Volunteer Recruiting 2026-03-31 2027-01-01 ClinicalTrials.gov
NCT07514260 A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcuta… Phase1 Healthy Volunteer Recruiting 2026-03-31 2027-01-01 ClinicalTrials.gov
NCT07502417 A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levon… Phase1 Healthy Volunteer Active_Not_Recruiting 2026-03-27 2026-07-01 ClinicalTrials.gov
NCT07502417 A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levon… Phase1 Healthy Volunteer Active_Not_Recruiting 2026-03-27 2026-07-01 ClinicalTrials.gov
NCT07502417 A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levon… Phase1 Healthy Volunteer Active_Not_Recruiting 2026-03-27 2026-07-01 ClinicalTrials.gov
NCT07502417 A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levon… Phase1 Healthy Volunteer Active_Not_Recruiting 2026-03-27 2026-07-01 ClinicalTrials.gov
NCT07387471 Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Particip… Phase2 Waldenstrom Macroglobulinemia Recruiting 2026-03-17 2028-07-01 ClinicalTrials.gov
NCT07387471 Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Particip… Phase2 Waldenstrom Macroglobulinemia Recruiting 2026-03-17 2028-07-01 ClinicalTrials.gov
NCT07387471 Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Particip… Phase2 Waldenstrom Macroglobulinemia Recruiting 2026-03-17 2028-07-01 ClinicalTrials.gov
NCT07387471 Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Particip… Phase2 Waldenstrom Macroglobulinemia Recruiting 2026-03-17 2028-07-01 ClinicalTrials.gov
NCT07382440 A Study to Assess Change in Disease Symptoms in Adult Participants With Advance… — Parkinson's Disease Recruiting 2026-03-09 2028-09-01 ClinicalTrials.gov
NCT07382440 A Study to Assess Change in Disease Symptoms in Adult Participants With Advance… — Parkinson's Disease Recruiting 2026-03-09 2028-09-01 ClinicalTrials.gov
NCT07382440 A Study to Assess Change in Disease Symptoms in Adult Participants With Advance… — Parkinson's Disease Recruiting 2026-03-09 2028-09-01 ClinicalTrials.gov
NCT07382440 A Study to Assess Change in Disease Symptoms in Adult Participants With Advance… — Parkinson's Disease Recruiting 2026-03-09 2028-09-01 ClinicalTrials.gov
NCT07227896 Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes… — Parkinson's Disease Not_Yet_Recruiting 2026-03-01 2027-10-01 ClinicalTrials.gov
NCT07227896 Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes… — Parkinson's Disease Not_Yet_Recruiting 2026-03-01 2027-10-01 ClinicalTrials.gov
NCT07227896 Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes… — Parkinson's Disease Not_Yet_Recruiting 2026-03-01 2027-10-01 ClinicalTrials.gov
NCT07227896 Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes… — Parkinson's Disease Not_Yet_Recruiting 2026-03-01 2027-10-01 ClinicalTrials.gov
NCT07407062 A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participant… — Cancer - Ovarian Not_Yet_Recruiting 2026-02-28 2026-07-01 ClinicalTrials.gov
NCT07407062 A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participant… — Cancer - Ovarian Not_Yet_Recruiting 2026-02-28 2026-07-01 ClinicalTrials.gov
NCT07407062 A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participant… — Cancer - Ovarian Not_Yet_Recruiting 2026-02-28 2026-07-01 ClinicalTrials.gov
NCT07407062 A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participant… — Cancer - Ovarian Not_Yet_Recruiting 2026-02-28 2026-07-01 ClinicalTrials.gov
NCT07409246 A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, a… Phase1 Multiple Myeloma Recruiting 2026-02-27 2031-11-01 ClinicalTrials.gov
NCT07419347 Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data — Hepatitis C Virus (HCV) Recruiting 2026-02-27 2026-06-01 ClinicalTrials.gov
NCT07419347 Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data — Hepatitis C Virus (HCV) Recruiting 2026-02-27 2026-06-01 ClinicalTrials.gov
NCT07409246 A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, a… Phase1 Multiple Myeloma Recruiting 2026-02-27 2031-11-01 ClinicalTrials.gov
NCT07409246 A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, a… Phase1 Multiple Myeloma Recruiting 2026-02-27 2031-11-01 ClinicalTrials.gov
NCT07419347 Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data — Hepatitis C Virus (HCV) Recruiting 2026-02-27 2026-06-01 ClinicalTrials.gov
NCT07409246 A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, a… Phase1 Multiple Myeloma Recruiting 2026-02-27 2031-11-01 ClinicalTrials.gov
NCT07419347 Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data — Hepatitis C Virus (HCV) Recruiting 2026-02-27 2026-06-01 ClinicalTrials.gov
NCT07425899 A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadaciti… Phase1 Healthy Volunteer Recruiting 2026-02-26 2026-08-01 ClinicalTrials.gov
NCT07425899 A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadaciti… Phase1 Healthy Volunteer Recruiting 2026-02-26 2026-08-01 ClinicalTrials.gov
NCT07425899 A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadaciti… Phase1 Healthy Volunteer Recruiting 2026-02-26 2026-08-01 ClinicalTrials.gov
NCT07425899 A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadaciti… Phase1 Healthy Volunteer Recruiting 2026-02-26 2026-08-01 ClinicalTrials.gov
NCT07323641 Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurab… Phase2 Lung Non-Small Cell Carcinoma Recruiting 2026-02-19 2028-02-01 ClinicalTrials.gov
NCT07323641 Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurab… Phase2 Lung Non-Small Cell Carcinoma Recruiting 2026-02-19 2028-02-01 ClinicalTrials.gov
NCT07323641 Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurab… Phase2 Lung Non-Small Cell Carcinoma Recruiting 2026-02-19 2028-02-01 ClinicalTrials.gov
NCT07323641 Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurab… Phase2 Lung Non-Small Cell Carcinoma Recruiting 2026-02-19 2028-02-01 ClinicalTrials.gov
NCT06510309 Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Phase2 Lymphoma Recruiting 2026-02-11 2031-10-01 ClinicalTrials.gov
NCT07414784 A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adve… Phase1 Healthy Volunteer Active_Not_Recruiting 2026-02-11 2026-07-01 ClinicalTrials.gov
NCT07413133 A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relati… Phase1 Healthy Volunteer Completed 2026-02-11 2026-06-19 ClinicalTrials.gov
NCT07413133 A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relati… Phase1 Healthy Volunteer Completed 2026-02-11 2026-06-19 ClinicalTrials.gov
NCT07414784 A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adve… Phase1 Healthy Volunteer Active_Not_Recruiting 2026-02-11 2026-07-01 ClinicalTrials.gov
NCT07413133 A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relati… Phase1 Healthy Volunteer Completed 2026-02-11 2026-06-19 ClinicalTrials.gov
NCT07414784 A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adve… Phase1 Healthy Volunteer Active_Not_Recruiting 2026-02-11 2026-07-01 ClinicalTrials.gov
NCT06510309 Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Phase2 Lymphoma Recruiting 2026-02-11 2031-10-01 ClinicalTrials.gov
NCT07414784 A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adve… Phase1 Healthy Volunteer Active_Not_Recruiting 2026-02-11 2026-07-01 ClinicalTrials.gov
NCT06510309 Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Phase2 Lymphoma Recruiting 2026-02-11 2031-10-01 ClinicalTrials.gov
NCT07413133 A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relati… Phase1 Healthy Volunteer Completed 2026-02-11 2026-06-19 ClinicalTrials.gov
NCT06510309 Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Phase2 Lymphoma Recruiting 2026-02-11 2031-10-01 ClinicalTrials.gov
NCT07217678 Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensiv… Phase4 Glaucoma Recruiting 2026-02-09 2028-01-31 ClinicalTrials.gov
NCT07421258 A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in A… — Crohn's Disease Recruiting 2026-02-09 2026-09-01 ClinicalTrials.gov
NCT07421258 A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in A… — Crohn's Disease Recruiting 2026-02-09 2026-09-01 ClinicalTrials.gov
NCT07217678 Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensiv… Phase4 Glaucoma Recruiting 2026-02-09 2028-01-31 ClinicalTrials.gov
NCT07217678 Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensiv… Phase4 Glaucoma Recruiting 2026-02-09 2028-01-31 ClinicalTrials.gov
NCT07421258 A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in A… — Crohn's Disease Recruiting 2026-02-09 2026-09-01 ClinicalTrials.gov
NCT07421258 A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in A… — Crohn's Disease Recruiting 2026-02-09 2026-09-01 ClinicalTrials.gov
NCT07217678 Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensiv… Phase4 Glaucoma Recruiting 2026-02-09 2028-01-31 ClinicalTrials.gov
NCT07226791 Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity … Phase2 Ventral Hernia Recruiting 2026-02-04 2030-05-01 ClinicalTrials.gov
NCT07226791 Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity … Phase2 Ventral Hernia Recruiting 2026-02-04 2030-05-01 ClinicalTrials.gov
NCT07226791 Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity … Phase2 Ventral Hernia Recruiting 2026-02-04 2030-05-01 ClinicalTrials.gov
NCT07226791 Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity … Phase2 Ventral Hernia Recruiting 2026-02-04 2030-05-01 ClinicalTrials.gov
NCT06696755 A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcap… Phase2 Bipolar I Disorder Recruiting 2026-02-03 2027-11-01 ClinicalTrials.gov
NCT06696755 A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcap… Phase2 Bipolar I Disorder Recruiting 2026-02-03 2027-11-01 ClinicalTrials.gov
NCT06696755 A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcap… Phase2 Bipolar I Disorder Recruiting 2026-02-03 2027-11-01 ClinicalTrials.gov
NCT06696755 A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcap… Phase2 Bipolar I Disorder Recruiting 2026-02-03 2027-11-01 ClinicalTrials.gov
NCT07310290 Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participant… — Migraine Recruiting 2026-01-27 2027-03-01 ClinicalTrials.gov
NCT07310290 Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participant… — Migraine Recruiting 2026-01-27 2027-03-01 ClinicalTrials.gov
NCT07310290 Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participant… — Migraine Recruiting 2026-01-27 2027-03-01 ClinicalTrials.gov
NCT07310290 Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participant… — Migraine Recruiting 2026-01-27 2027-03-01 ClinicalTrials.gov
NCT07230288 Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Ad… Phase2 Idiopathic Pulmonary Fibrosis Recruiting 2026-01-23 2029-09-01 ClinicalTrials.gov
NCT07230288 Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Ad… Phase2 Idiopathic Pulmonary Fibrosis Recruiting 2026-01-23 2029-09-01 ClinicalTrials.gov
NCT07230288 Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Ad… Phase2 Idiopathic Pulmonary Fibrosis Recruiting 2026-01-23 2029-09-01 ClinicalTrials.gov
NCT07230288 Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Ad… Phase2 Idiopathic Pulmonary Fibrosis Recruiting 2026-01-23 2029-09-01 ClinicalTrials.gov
NCT07258771 Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induct… Phase4 Ulcerative Colitis Acute Recruiting 2026-01-16 2030-12-01 ClinicalTrials.gov
NCT07258771 Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induct… Phase4 Ulcerative Colitis Acute Recruiting 2026-01-16 2030-12-01 ClinicalTrials.gov
NCT07258771 Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induct… Phase4 Ulcerative Colitis Acute Recruiting 2026-01-16 2030-12-01 ClinicalTrials.gov
NCT07258771 Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induct… Phase4 Ulcerative Colitis Acute Recruiting 2026-01-16 2030-12-01 ClinicalTrials.gov
NCT07361367 A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Hea… Phase1 Healthy Volunteers Completed 2026-01-15 2026-03-23 ClinicalTrials.gov
NCT07361367 A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Hea… Phase1 Healthy Volunteers Completed 2026-01-15 2026-03-23 ClinicalTrials.gov
NCT07361367 A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Hea… Phase1 Healthy Volunteers Completed 2026-01-15 2026-03-23 ClinicalTrials.gov
NCT07361367 A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Hea… Phase1 Healthy Volunteers Completed 2026-01-15 2026-03-23 ClinicalTrials.gov
NCT07095452 A Study to Assess A Change in Disease Activity and Adverse Events of Intravenou… Phase2 Multiple Myeloma Recruiting 2026-01-08 2042-01-01 ClinicalTrials.gov
NCT07095452 A Study to Assess A Change in Disease Activity and Adverse Events of Intravenou… Phase2 Multiple Myeloma Recruiting 2026-01-08 2042-01-01 ClinicalTrials.gov
NCT07095452 A Study to Assess A Change in Disease Activity and Adverse Events of Intravenou… Phase2 Multiple Myeloma Recruiting 2026-01-08 2042-01-01 ClinicalTrials.gov
NCT07095452 A Study to Assess A Change in Disease Activity and Adverse Events of Intravenou… Phase2 Multiple Myeloma Recruiting 2026-01-08 2042-01-01 ClinicalTrials.gov
NCT07276997 A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcap… Phase2 Major Depressive Disorder Recruiting 2025-12-18 2027-09-01 ClinicalTrials.gov
NCT07276997 A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcap… Phase2 Major Depressive Disorder Recruiting 2025-12-18 2027-09-01 ClinicalTrials.gov
NCT07276997 A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcap… Phase2 Major Depressive Disorder Recruiting 2025-12-18 2027-09-01 ClinicalTrials.gov
NCT07276997 A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcap… Phase2 Major Depressive Disorder Recruiting 2025-12-18 2027-09-01 ClinicalTrials.gov
NCT07306754 A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Heal… Phase1 Healthy Volunteers Recruiting 2025-12-17 2027-05-01 ClinicalTrials.gov
NCT07306754 A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Heal… Phase1 Healthy Volunteers Recruiting 2025-12-17 2027-05-01 ClinicalTrials.gov
NCT07306754 A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Heal… Phase1 Healthy Volunteers Recruiting 2025-12-17 2027-05-01 ClinicalTrials.gov
NCT07306754 A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Heal… Phase1 Healthy Volunteers Recruiting 2025-12-17 2027-05-01 ClinicalTrials.gov
NCT07284381 A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tea… Phase3 Dry Eye Disease Active_Not_Recruiting 2025-12-15 2026-08-01 ClinicalTrials.gov
NCT07284381 A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tea… Phase3 Dry Eye Disease Active_Not_Recruiting 2025-12-15 2026-08-01 ClinicalTrials.gov
NCT07284381 A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tea… Phase3 Dry Eye Disease Active_Not_Recruiting 2025-12-15 2026-08-01 ClinicalTrials.gov
NCT07284381 A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tea… Phase3 Dry Eye Disease Active_Not_Recruiting 2025-12-15 2026-08-01 ClinicalTrials.gov
NCT07007052 Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxo… Phase2 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting 2025-12-11 2031-10-02 ClinicalTrials.gov
NCT07007052 Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxo… Phase2 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting 2025-12-11 2031-10-02 ClinicalTrials.gov
NCT07007052 Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxo… Phase2 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting 2025-12-11 2031-10-02 ClinicalTrials.gov
NCT07007052 Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxo… Phase2 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting 2025-12-11 2031-10-02 ClinicalTrials.gov
NCT07155187 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous … Phase2 Non-Small Cell Lung Cancer Recruiting 2025-12-10 2030-09-01 ClinicalTrials.gov
NCT07155187 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous … Phase2 Non-Small Cell Lung Cancer Recruiting 2025-12-10 2030-09-01 ClinicalTrials.gov
NCT07155187 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous … Phase2 Non-Small Cell Lung Cancer Recruiting 2025-12-10 2030-09-01 ClinicalTrials.gov
NCT07155187 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous … Phase2 Non-Small Cell Lung Cancer Recruiting 2025-12-10 2030-09-01 ClinicalTrials.gov
NCT07097363 Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxoru… Phase2 B-Cell Non-Hodgkin Lymphoma Recruiting 2025-12-07 2030-05-31 ClinicalTrials.gov
NCT07097363 Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxoru… Phase2 B-Cell Non-Hodgkin Lymphoma Recruiting 2025-12-07 2030-05-31 ClinicalTrials.gov
NCT07097363 Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxoru… Phase2 B-Cell Non-Hodgkin Lymphoma Recruiting 2025-12-07 2030-05-31 ClinicalTrials.gov
NCT07097363 Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxoru… Phase2 B-Cell Non-Hodgkin Lymphoma Recruiting 2025-12-07 2030-05-31 ClinicalTrials.gov
NCT06958705 Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monother… Phase2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Recruiting 2025-12-01 2028-02-01 ClinicalTrials.gov
NCT06958705 Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monother… Phase2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Recruiting 2025-12-01 2028-02-01 ClinicalTrials.gov
NCT07196644 A Study to Assess Adverse Events and Change in Disease Activity in Participants… Phase2 Solid Tumors Harboring MET Amplification Recruiting 2025-12-01 2030-12-01 ClinicalTrials.gov
NCT06958705 Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monother… Phase2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Recruiting 2025-12-01 2028-02-01 ClinicalTrials.gov
NCT06958705 Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monother… Phase2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Recruiting 2025-12-01 2028-02-01 ClinicalTrials.gov
NCT07196644 A Study to Assess Adverse Events and Change in Disease Activity in Participants… Phase2 Solid Tumors Harboring MET Amplification Recruiting 2025-12-01 2030-12-01 ClinicalTrials.gov
NCT07196644 A Study to Assess Adverse Events and Change in Disease Activity in Participants… Phase2 Solid Tumors Harboring MET Amplification Recruiting 2025-12-01 2030-12-01 ClinicalTrials.gov
NCT07196644 A Study to Assess Adverse Events and Change in Disease Activity in Participants… Phase2 Solid Tumors Harboring MET Amplification Recruiting 2025-12-01 2030-12-01 ClinicalTrials.gov
NCT07278336 A Study to Assess Adverse Events, Change in Disease Activity and How Intravenou… Phase1 Ovarian Cancer Recruiting 2025-11-27 2029-01-01 ClinicalTrials.gov
NCT07278336 A Study to Assess Adverse Events, Change in Disease Activity and How Intravenou… Phase1 Ovarian Cancer Recruiting 2025-11-27 2029-01-01 ClinicalTrials.gov
NCT07278336 A Study to Assess Adverse Events, Change in Disease Activity and How Intravenou… Phase1 Ovarian Cancer Recruiting 2025-11-27 2029-01-01 ClinicalTrials.gov
NCT07278336 A Study to Assess Adverse Events, Change in Disease Activity and How Intravenou… Phase1 Ovarian Cancer Recruiting 2025-11-27 2029-01-01 ClinicalTrials.gov
NCT07155174 A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Acti… Phase2 Small Cell Lung Cancer Recruiting 2025-11-25 2031-09-01 ClinicalTrials.gov
NCT07155174 A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Acti… Phase2 Small Cell Lung Cancer Recruiting 2025-11-25 2031-09-01 ClinicalTrials.gov
NCT07155174 A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Acti… Phase2 Small Cell Lung Cancer Recruiting 2025-11-25 2031-09-01 ClinicalTrials.gov
NCT07155174 A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Acti… Phase2 Small Cell Lung Cancer Recruiting 2025-11-25 2031-09-01 ClinicalTrials.gov
NCT07232004 A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, … Phase1 Healthy Volunteer Recruiting 2025-11-24 2027-08-01 ClinicalTrials.gov
NCT07232004 A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, … Phase1 Healthy Volunteer Recruiting 2025-11-24 2027-08-01 ClinicalTrials.gov
NCT07232004 A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, … Phase1 Healthy Volunteer Recruiting 2025-11-24 2027-08-01 ClinicalTrials.gov
NCT07232004 A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, … Phase1 Healthy Volunteer Recruiting 2025-11-24 2027-08-01 ClinicalTrials.gov
NCT06890338 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin… Phase2 Epithelial Ovarian Cancer Recruiting 2025-11-21 2030-02-01 ClinicalTrials.gov
NCT06890338 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin… Phase2 Epithelial Ovarian Cancer Recruiting 2025-11-21 2030-02-01 ClinicalTrials.gov
NCT06890338 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin… Phase2 Epithelial Ovarian Cancer Recruiting 2025-11-21 2030-02-01 ClinicalTrials.gov
NCT06890338 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin… Phase2 Epithelial Ovarian Cancer Recruiting 2025-11-21 2030-02-01 ClinicalTrials.gov
NCT07241039 A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral … Phase1 Advanced Squamous Tumors Recruiting 2025-11-20 2030-10-01 ClinicalTrials.gov
NCT07241039 A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral … Phase1 Advanced Squamous Tumors Recruiting 2025-11-20 2030-10-01 ClinicalTrials.gov
NCT07241039 A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral … Phase1 Advanced Squamous Tumors Recruiting 2025-11-20 2030-10-01 ClinicalTrials.gov
NCT07241039 A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral … Phase1 Advanced Squamous Tumors Recruiting 2025-11-20 2030-10-01 ClinicalTrials.gov
NCT07291232 A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharma… Phase1 Obesity Recruiting 2025-11-19 2026-10-01 ClinicalTrials.gov
NCT07291232 A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharma… Phase1 Obesity Recruiting 2025-11-19 2026-10-01 ClinicalTrials.gov
NCT07291232 A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharma… Phase1 Obesity Recruiting 2025-11-19 2026-10-01 ClinicalTrials.gov
NCT07291232 A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharma… Phase1 Obesity Recruiting 2025-11-19 2026-10-01 ClinicalTrials.gov
NCT07284342 A Study to Assess Change in Sleep Disturbances of Adult Participants With Advan… — Advanced Parkinson's Disease Recruiting 2025-11-17 2027-01-01 ClinicalTrials.gov
NCT07284342 A Study to Assess Change in Sleep Disturbances of Adult Participants With Advan… — Advanced Parkinson's Disease Recruiting 2025-11-17 2027-01-01 ClinicalTrials.gov
NCT07284342 A Study to Assess Change in Sleep Disturbances of Adult Participants With Advan… — Advanced Parkinson's Disease Recruiting 2025-11-17 2027-01-01 ClinicalTrials.gov
NCT07284342 A Study to Assess Change in Sleep Disturbances of Adult Participants With Advan… — Advanced Parkinson's Disease Recruiting 2025-11-17 2027-01-01 ClinicalTrials.gov
NCT07059845 A Study to Assess Adverse Events and Change in Disease Activity of Multiple Tre… Phase2 Ovarian Cancer Recruiting 2025-11-13 2029-01-01 ClinicalTrials.gov
NCT07059845 A Study to Assess Adverse Events and Change in Disease Activity of Multiple Tre… Phase2 Ovarian Cancer Recruiting 2025-11-13 2029-01-01 ClinicalTrials.gov
NCT07059845 A Study to Assess Adverse Events and Change in Disease Activity of Multiple Tre… Phase2 Ovarian Cancer Recruiting 2025-11-13 2029-01-01 ClinicalTrials.gov
NCT07059845 A Study to Assess Adverse Events and Change in Disease Activity of Multiple Tre… Phase2 Ovarian Cancer Recruiting 2025-11-13 2029-01-01 ClinicalTrials.gov
NCT07231952 A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström'… Phase2 Waldenstrom Macroglobulinemia Recruiting 2025-11-11 2028-04-11 ClinicalTrials.gov
NCT07231952 A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström'… Phase2 Waldenstrom Macroglobulinemia Recruiting 2025-11-11 2028-04-11 ClinicalTrials.gov
NCT07231952 A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström'… Phase2 Waldenstrom Macroglobulinemia Recruiting 2025-11-11 2028-04-11 ClinicalTrials.gov
NCT07231952 A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström'… Phase2 Waldenstrom Macroglobulinemia Recruiting 2025-11-11 2028-04-11 ClinicalTrials.gov
NCT07007065 Study to Assess the Injection Burden, Adverse Events, Change in Disease Activit… Phase3 Neovascular Age-related Macular Degeneration Recruiting 2025-11-05 2033-03-01 ClinicalTrials.gov
NCT07007065 Study to Assess the Injection Burden, Adverse Events, Change in Disease Activit… Phase3 Neovascular Age-related Macular Degeneration Recruiting 2025-11-05 2033-03-01 ClinicalTrials.gov
NCT07007065 Study to Assess the Injection Burden, Adverse Events, Change in Disease Activit… Phase3 Neovascular Age-related Macular Degeneration Recruiting 2025-11-05 2033-03-01 ClinicalTrials.gov
NCT07007065 Study to Assess the Injection Burden, Adverse Events, Change in Disease Activit… Phase3 Neovascular Age-related Macular Degeneration Recruiting 2025-11-05 2033-03-01 ClinicalTrials.gov
NCT07222709 A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the B… Phase1 Healthy Volunteer Recruiting 2025-10-27 2026-05-01 ClinicalTrials.gov
NCT07222709 A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the B… Phase1 Healthy Volunteer Recruiting 2025-10-27 2026-05-01 ClinicalTrials.gov
NCT07222709 A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the B… Phase1 Healthy Volunteer Recruiting 2025-10-27 2026-05-01 ClinicalTrials.gov
NCT07222709 A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the B… Phase1 Healthy Volunteer Recruiting 2025-10-27 2026-05-01 ClinicalTrials.gov
NCT07207369 A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in A… Phase3 Acne Scars Recruiting 2025-10-24 2029-11-01 ClinicalTrials.gov
NCT07207369 A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in A… Phase3 Acne Scars Recruiting 2025-10-24 2029-11-01 ClinicalTrials.gov
NCT07207369 A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in A… Phase3 Acne Scars Recruiting 2025-10-24 2029-11-01 ClinicalTrials.gov
NCT07207369 A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in A… Phase3 Acne Scars Recruiting 2025-10-24 2029-11-01 ClinicalTrials.gov
NCT07219017 A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Part… Phase1 Healthy Volunteer Completed 2025-10-15 2025-12-09 ClinicalTrials.gov
NCT07197307 Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse… Phase2 Aggressive Diffuse Large B-cell Lymphoma Not_Yet_Recruiting 2025-10-15 2030-01-15 ClinicalTrials.gov
NCT07197307 Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse… Phase2 Aggressive Diffuse Large B-cell Lymphoma Not_Yet_Recruiting 2025-10-15 2030-01-15 ClinicalTrials.gov
NCT07219017 A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Part… Phase1 Healthy Volunteer Completed 2025-10-15 2025-12-09 ClinicalTrials.gov
NCT07197307 Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse… Phase2 Aggressive Diffuse Large B-cell Lymphoma Not_Yet_Recruiting 2025-10-15 2030-01-15 ClinicalTrials.gov
NCT07219017 A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Part… Phase1 Healthy Volunteer Completed 2025-10-15 2025-12-09 ClinicalTrials.gov
NCT07197307 Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse… Phase2 Aggressive Diffuse Large B-cell Lymphoma Not_Yet_Recruiting 2025-10-15 2030-01-15 ClinicalTrials.gov
NCT07219017 A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Part… Phase1 Healthy Volunteer Completed 2025-10-15 2025-12-09 ClinicalTrials.gov
NCT06796998 Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) Phase2 Marginal Zone Lymphoma Recruiting 2025-10-13 2031-04-15 ClinicalTrials.gov
NCT06796998 Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) Phase2 Marginal Zone Lymphoma Recruiting 2025-10-13 2031-04-15 ClinicalTrials.gov
NCT06796998 Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) Phase2 Marginal Zone Lymphoma Recruiting 2025-10-13 2031-04-15 ClinicalTrials.gov
NCT06796998 Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) Phase2 Marginal Zone Lymphoma Recruiting 2025-10-13 2031-04-15 ClinicalTrials.gov
NCT07136116 Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanes… — Ulcerative Colitis Recruiting 2025-10-09 2030-02-01 ClinicalTrials.gov
NCT07136116 Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanes… — Ulcerative Colitis Recruiting 2025-10-09 2030-02-01 ClinicalTrials.gov
NCT07136116 Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanes… — Ulcerative Colitis Recruiting 2025-10-09 2030-02-01 ClinicalTrials.gov
NCT07136116 Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanes… — Ulcerative Colitis Recruiting 2025-10-09 2030-02-01 ClinicalTrials.gov
NCT07219030 A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the… Phase1 Healthy Volunteer Recruiting 2025-10-08 2027-03-01 ClinicalTrials.gov
NCT07219030 A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the… Phase1 Healthy Volunteer Recruiting 2025-10-08 2027-03-01 ClinicalTrials.gov
NCT07219030 A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the… Phase1 Healthy Volunteer Recruiting 2025-10-08 2027-03-01 ClinicalTrials.gov
NCT07219030 A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the… Phase1 Healthy Volunteer Recruiting 2025-10-08 2027-03-01 ClinicalTrials.gov
NCT07220460 Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With … Phase2 Bipolar I or II Disorder Recruiting 2025-09-30 2027-04-01 ClinicalTrials.gov
NCT07220460 Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With … Phase2 Bipolar I or II Disorder Recruiting 2025-09-30 2027-04-01 ClinicalTrials.gov
NCT07220460 Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With … Phase2 Bipolar I or II Disorder Recruiting 2025-09-30 2027-04-01 ClinicalTrials.gov
NCT07220460 Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With … Phase2 Bipolar I or II Disorder Recruiting 2025-09-30 2027-04-01 ClinicalTrials.gov
NCT07186595 A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult … Phase4 Mid Face Volume Deficit Active_Not_Recruiting 2025-09-25 2026-08-01 ClinicalTrials.gov
NCT07186595 A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult … Phase4 Mid Face Volume Deficit Active_Not_Recruiting 2025-09-25 2026-08-01 ClinicalTrials.gov
NCT07186595 A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult … Phase4 Mid Face Volume Deficit Active_Not_Recruiting 2025-09-25 2026-08-01 ClinicalTrials.gov
NCT07186595 A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult … Phase4 Mid Face Volume Deficit Active_Not_Recruiting 2025-09-25 2026-08-01 ClinicalTrials.gov
NCT06931652 Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Tr… Phase2 Primary CNS Lymphoma (PCNSL) Recruiting 2025-09-22 2030-01-01 ClinicalTrials.gov
NCT06931652 Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Tr… Phase2 Primary CNS Lymphoma (PCNSL) Recruiting 2025-09-22 2030-01-01 ClinicalTrials.gov
NCT06931652 Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Tr… Phase2 Primary CNS Lymphoma (PCNSL) Recruiting 2025-09-22 2030-01-01 ClinicalTrials.gov
NCT06931652 Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Tr… Phase2 Primary CNS Lymphoma (PCNSL) Recruiting 2025-09-22 2030-01-01 ClinicalTrials.gov
NCT06742385 Evaluation of a Remote Monitoring Application in the Follow-up of Patients With… Na Crohn Disease Recruiting 2025-09-18 2028-09-18 ClinicalTrials.gov
NCT06742385 Evaluation of a Remote Monitoring Application in the Follow-up of Patients With… Na Crohn Disease Recruiting 2025-09-18 2028-09-18 ClinicalTrials.gov
NCT06742385 Evaluation of a Remote Monitoring Application in the Follow-up of Patients With… Na Crohn Disease Recruiting 2025-09-18 2028-09-18 ClinicalTrials.gov
NCT06742385 Evaluation of a Remote Monitoring Application in the Follow-up of Patients With… Na Crohn Disease Recruiting 2025-09-18 2028-09-18 ClinicalTrials.gov
NCT07172204 Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diag… Phase2 Intensive Chemotherapy Unfit Recruiting 2025-09-16 2029-07-31 ClinicalTrials.gov
NCT07172204 Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diag… Phase2 Intensive Chemotherapy Unfit Recruiting 2025-09-16 2029-07-31 ClinicalTrials.gov
NCT07172204 Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diag… Phase2 Intensive Chemotherapy Unfit Recruiting 2025-09-16 2029-07-31 ClinicalTrials.gov
NCT07172204 Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diag… Phase2 Intensive Chemotherapy Unfit Recruiting 2025-09-16 2029-07-31 ClinicalTrials.gov
NCT05316220 A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine … Phase3 Ulcerative Colitis (UC) Withdrawn 2025-09-15 2026-07-19 ClinicalTrials.gov
NCT05316220 A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine … Phase3 Ulcerative Colitis (UC) Withdrawn 2025-09-15 2026-07-19 ClinicalTrials.gov
NCT05316220 A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine … Phase3 Ulcerative Colitis (UC) Withdrawn 2025-09-15 2026-07-19 ClinicalTrials.gov
NCT05316220 A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine … Phase3 Ulcerative Colitis (UC) Withdrawn 2025-09-15 2026-07-19 ClinicalTrials.gov
NCT07039110 Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Pa… — Plaque Psoriasis Recruiting 2025-09-09 2028-03-01 ClinicalTrials.gov
NCT07039110 Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Pa… — Plaque Psoriasis Recruiting 2025-09-09 2028-03-01 ClinicalTrials.gov
NCT07039110 Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Pa… — Plaque Psoriasis Recruiting 2025-09-09 2028-03-01 ClinicalTrials.gov
NCT07039110 Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Pa… — Plaque Psoriasis Recruiting 2025-09-09 2028-03-01 ClinicalTrials.gov
NCT07141199 A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug… Phase1 Healthy Volunteer Completed 2025-09-02 2026-03-23 ClinicalTrials.gov
NCT07136467 A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Pa… — Non-Segmental Vitiligo (NSV) Recruiting 2025-09-02 2027-08-01 ClinicalTrials.gov
NCT07023289 A Study to Assess Adverse Events and Change in Disease Activity in Adult Partic… Phase2 Colorectal Cancer Recruiting 2025-09-02 2029-11-01 ClinicalTrials.gov
NCT07141199 A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug… Phase1 Healthy Volunteer Completed 2025-09-02 2026-03-23 ClinicalTrials.gov
NCT07136467 A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Pa… — Non-Segmental Vitiligo (NSV) Recruiting 2025-09-02 2027-08-01 ClinicalTrials.gov
NCT07023289 A Study to Assess Adverse Events and Change in Disease Activity in Adult Partic… Phase2 Colorectal Cancer Recruiting 2025-09-02 2029-11-01 ClinicalTrials.gov
NCT07023289 A Study to Assess Adverse Events and Change in Disease Activity in Adult Partic… Phase2 Colorectal Cancer Recruiting 2025-09-02 2029-11-01 ClinicalTrials.gov
NCT07023289 A Study to Assess Adverse Events and Change in Disease Activity in Adult Partic… Phase2 Colorectal Cancer Recruiting 2025-09-02 2029-11-01 ClinicalTrials.gov
NCT07136467 A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Pa… — Non-Segmental Vitiligo (NSV) Recruiting 2025-09-02 2027-08-01 ClinicalTrials.gov
NCT07141199 A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug… Phase1 Healthy Volunteer Completed 2025-09-02 2026-03-23 ClinicalTrials.gov
NCT07141199 A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug… Phase1 Healthy Volunteer Completed 2025-09-02 2026-03-23 ClinicalTrials.gov
NCT07136467 A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Pa… — Non-Segmental Vitiligo (NSV) Recruiting 2025-09-02 2027-08-01 ClinicalTrials.gov
NCT06977724 A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effec… Phase1 Dry Eye Syndrome Recruiting 2025-08-26 2029-03-01 ClinicalTrials.gov
NCT06977724 A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effec… Phase1 Dry Eye Syndrome Recruiting 2025-08-26 2029-03-01 ClinicalTrials.gov
NCT06977724 A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effec… Phase1 Dry Eye Syndrome Recruiting 2025-08-26 2029-03-01 ClinicalTrials.gov
NCT06977724 A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effec… Phase1 Dry Eye Syndrome Recruiting 2025-08-26 2029-03-01 ClinicalTrials.gov
NCT07024797 Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-93… Phase1 Healthy Volunteer Completed 2025-08-21 2025-12-08 ClinicalTrials.gov
NCT07024797 Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-93… Phase1 Healthy Volunteer Completed 2025-08-21 2025-12-08 ClinicalTrials.gov
NCT07024797 Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-93… Phase1 Healthy Volunteer Completed 2025-08-21 2025-12-08 ClinicalTrials.gov
NCT07024797 Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-93… Phase1 Healthy Volunteer Completed 2025-08-21 2025-12-08 ClinicalTrials.gov
NCT07018752 A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell L… Phase1 Peripheral T Cells Lymphoma (PTCL) Recruiting 2025-08-20 2030-01-01 ClinicalTrials.gov
NCT07018752 A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell L… Phase1 Peripheral T Cells Lymphoma (PTCL) Recruiting 2025-08-20 2030-01-01 ClinicalTrials.gov
NCT07018752 A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell L… Phase1 Peripheral T Cells Lymphoma (PTCL) Recruiting 2025-08-20 2030-01-01 ClinicalTrials.gov
NCT07018752 A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell L… Phase1 Peripheral T Cells Lymphoma (PTCL) Recruiting 2025-08-20 2030-01-01 ClinicalTrials.gov
NCT07136103 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenici… Phase1 Healthy Volunteers Completed 2025-08-19 2026-06-11 ClinicalTrials.gov
NCT07136103 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenici… Phase1 Healthy Volunteers Completed 2025-08-19 2026-06-11 ClinicalTrials.gov
NCT07136103 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenici… Phase1 Healthy Volunteers Completed 2025-08-19 2026-06-11 ClinicalTrials.gov
NCT07136103 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenici… Phase1 Healthy Volunteers Completed 2025-08-19 2026-06-11 ClinicalTrials.gov
NCT07160179 Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through… Phase1 Geographic Atrophy Recruiting 2025-08-13 2029-10-01 ClinicalTrials.gov
NCT07160179 Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through… Phase1 Geographic Atrophy Recruiting 2025-08-13 2029-10-01 ClinicalTrials.gov
NCT07160179 Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through… Phase1 Geographic Atrophy Recruiting 2025-08-13 2029-10-01 ClinicalTrials.gov
NCT07160179 Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through… Phase1 Geographic Atrophy Recruiting 2025-08-13 2029-10-01 ClinicalTrials.gov
NCT06896916 Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereb… Phase1 Multiple Myeloma Recruiting 2025-08-07 2036-03-01 ClinicalTrials.gov
NCT06896916 Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereb… Phase1 Multiple Myeloma Recruiting 2025-08-07 2036-03-01 ClinicalTrials.gov
NCT06896916 Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereb… Phase1 Multiple Myeloma Recruiting 2025-08-07 2036-03-01 ClinicalTrials.gov
NCT06896916 Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereb… Phase1 Multiple Myeloma Recruiting 2025-08-07 2036-03-01 ClinicalTrials.gov
NCT07126236 Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Effica… Phase2 Large B Cell Lymphoma Recruiting 2025-08-04 2031-12-01 ClinicalTrials.gov
NCT07145918 A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emra… Phase2 Schizophrenia Recruiting 2025-08-04 2028-02-01 ClinicalTrials.gov
NCT07145918 A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emra… Phase2 Schizophrenia Recruiting 2025-08-04 2028-02-01 ClinicalTrials.gov
NCT07126236 Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Effica… Phase2 Large B Cell Lymphoma Recruiting 2025-08-04 2031-12-01 ClinicalTrials.gov
NCT07145918 A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emra… Phase2 Schizophrenia Recruiting 2025-08-04 2028-02-01 ClinicalTrials.gov
NCT07126236 Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Effica… Phase2 Large B Cell Lymphoma Recruiting 2025-08-04 2031-12-01 ClinicalTrials.gov
NCT07126236 Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Effica… Phase2 Large B Cell Lymphoma Recruiting 2025-08-04 2031-12-01 ClinicalTrials.gov
NCT07145918 A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emra… Phase2 Schizophrenia Recruiting 2025-08-04 2028-02-01 ClinicalTrials.gov
NCT07005102 A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Tel… Phase2 Non-Squamous Non-Small Cell Lung Cancer Recruiting 2025-08-03 2036-11-01 ClinicalTrials.gov
NCT07005102 A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Tel… Phase2 Non-Squamous Non-Small Cell Lung Cancer Recruiting 2025-08-03 2036-11-01 ClinicalTrials.gov
NCT07005102 A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Tel… Phase2 Non-Squamous Non-Small Cell Lung Cancer Recruiting 2025-08-03 2036-11-01 ClinicalTrials.gov
NCT07005102 A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Tel… Phase2 Non-Squamous Non-Small Cell Lung Cancer Recruiting 2025-08-03 2036-11-01 ClinicalTrials.gov
NCT07024784 A Study to Assess Change in Disease Activity and Adverse Events in Adult Partic… Phase2 Gynecologic Cancers Recruiting 2025-07-30 2028-02-01 ClinicalTrials.gov
NCT07024784 A Study to Assess Change in Disease Activity and Adverse Events in Adult Partic… Phase2 Gynecologic Cancers Recruiting 2025-07-30 2028-02-01 ClinicalTrials.gov
NCT07024784 A Study to Assess Change in Disease Activity and Adverse Events in Adult Partic… Phase2 Gynecologic Cancers Recruiting 2025-07-30 2028-02-01 ClinicalTrials.gov
NCT07024784 A Study to Assess Change in Disease Activity and Adverse Events in Adult Partic… Phase2 Gynecologic Cancers Recruiting 2025-07-30 2028-02-01 ClinicalTrials.gov
NCT07071519 A Study to Learn More About How Risankizumab Works in Young Participants With U… Phase3 Ulcerative Colitis Recruiting 2025-07-28 2034-07-01 ClinicalTrials.gov
NCT07071519 A Study to Learn More About How Risankizumab Works in Young Participants With U… Phase3 Ulcerative Colitis Recruiting 2025-07-28 2034-07-01 ClinicalTrials.gov
NCT07071519 A Study to Learn More About How Risankizumab Works in Young Participants With U… Phase3 Ulcerative Colitis Recruiting 2025-07-28 2034-07-01 ClinicalTrials.gov
NCT07071519 A Study to Learn More About How Risankizumab Works in Young Participants With U… Phase3 Ulcerative Colitis Recruiting 2025-07-28 2034-07-01 ClinicalTrials.gov
NCT07044687 Study to Assess Adverse Events and Change in Disease Activity of Oral Venetocla… Phase4 Acute Myeloid Leukemia Recruiting 2025-07-24 2027-11-01 ClinicalTrials.gov
NCT07044687 Study to Assess Adverse Events and Change in Disease Activity of Oral Venetocla… Phase4 Acute Myeloid Leukemia Recruiting 2025-07-24 2027-11-01 ClinicalTrials.gov
NCT07044687 Study to Assess Adverse Events and Change in Disease Activity of Oral Venetocla… Phase4 Acute Myeloid Leukemia Recruiting 2025-07-24 2027-11-01 ClinicalTrials.gov
NCT07044687 Study to Assess Adverse Events and Change in Disease Activity of Oral Venetocla… Phase4 Acute Myeloid Leukemia Recruiting 2025-07-24 2027-11-01 ClinicalTrials.gov
NCT06953960 A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzeto… Phase1 Multiple Myeloma Recruiting 2025-07-23 2030-12-01 ClinicalTrials.gov
NCT06953960 A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzeto… Phase1 Multiple Myeloma Recruiting 2025-07-23 2030-12-01 ClinicalTrials.gov
NCT06953960 A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzeto… Phase1 Multiple Myeloma Recruiting 2025-07-23 2030-12-01 ClinicalTrials.gov
NCT06953960 A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzeto… Phase1 Multiple Myeloma Recruiting 2025-07-23 2030-12-01 ClinicalTrials.gov
NCT07122583 A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inn… Phase4 Non-Surgical Fat Reduction Completed 2025-07-22 2026-06-03 ClinicalTrials.gov
NCT07122583 A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inn… Phase4 Non-Surgical Fat Reduction Completed 2025-07-22 2026-06-03 ClinicalTrials.gov
NCT07122583 A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inn… Phase4 Non-Surgical Fat Reduction Completed 2025-07-22 2026-06-03 ClinicalTrials.gov
NCT07122583 A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inn… Phase4 Non-Surgical Fat Reduction Completed 2025-07-22 2026-06-03 ClinicalTrials.gov
NCT07058051 Cross-sectional Study to Characterize Real World Burden of Disease in Patients … — Non-Segmental Vitiligo Completed 2025-07-17 2025-11-13 ClinicalTrials.gov
NCT07058051 Cross-sectional Study to Characterize Real World Burden of Disease in Patients … — Non-Segmental Vitiligo Completed 2025-07-17 2025-11-13 ClinicalTrials.gov
NCT07058051 Cross-sectional Study to Characterize Real World Burden of Disease in Patients … — Non-Segmental Vitiligo Completed 2025-07-17 2025-11-13 ClinicalTrials.gov
NCT07058051 Cross-sectional Study to Characterize Real World Burden of Disease in Patients … — Non-Segmental Vitiligo Completed 2025-07-17 2025-11-13 ClinicalTrials.gov
NCT07071532 A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body W… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-07-15 2025-11-01 ClinicalTrials.gov
NCT07071532 A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body W… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-07-15 2025-11-01 ClinicalTrials.gov
NCT07071532 A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body W… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-07-15 2025-11-01 ClinicalTrials.gov
NCT07071532 A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body W… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-07-15 2025-11-01 ClinicalTrials.gov
NCT07073079 A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and … — Crohn's Disease Recruiting 2025-07-14 2027-12-01 ClinicalTrials.gov
NCT07073079 A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and … — Crohn's Disease Recruiting 2025-07-14 2027-12-01 ClinicalTrials.gov
NCT07073079 A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and … — Crohn's Disease Recruiting 2025-07-14 2027-12-01 ClinicalTrials.gov
NCT07073079 A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and … — Crohn's Disease Recruiting 2025-07-14 2027-12-01 ClinicalTrials.gov
NCT06972056 Comparative Effectiveness of Migraine Preventive Medications: The APT Compariso… Phase4 Migraine Recruiting 2025-07-09 2029-12-01 ClinicalTrials.gov
NCT06972056 Comparative Effectiveness of Migraine Preventive Medications: The APT Compariso… Phase4 Migraine Recruiting 2025-07-09 2029-12-01 ClinicalTrials.gov
NCT06972056 Comparative Effectiveness of Migraine Preventive Medications: The APT Compariso… Phase4 Migraine Recruiting 2025-07-09 2029-12-01 ClinicalTrials.gov
NCT06972056 Comparative Effectiveness of Migraine Preventive Medications: The APT Compariso… Phase4 Migraine Recruiting 2025-07-09 2029-12-01 ClinicalTrials.gov
NCT06892522 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult … Phase1 Multiple Myeloma Recruiting 2025-06-30 2035-12-01 ClinicalTrials.gov
NCT06892522 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult … Phase1 Multiple Myeloma Recruiting 2025-06-30 2035-12-01 ClinicalTrials.gov
NCT06892522 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult … Phase1 Multiple Myeloma Recruiting 2025-06-30 2035-12-01 ClinicalTrials.gov
NCT06892522 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult … Phase1 Multiple Myeloma Recruiting 2025-06-30 2035-12-01 ClinicalTrials.gov
NCT06972446 A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid A… Phase2 Rheumatoid Arthritis Recruiting 2025-06-20 2027-11-01 ClinicalTrials.gov
NCT06972446 A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid A… Phase2 Rheumatoid Arthritis Recruiting 2025-06-20 2027-11-01 ClinicalTrials.gov
NCT06972446 A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid A… Phase2 Rheumatoid Arthritis Recruiting 2025-06-20 2027-11-01 ClinicalTrials.gov
NCT06972446 A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid A… Phase2 Rheumatoid Arthritis Recruiting 2025-06-20 2027-11-01 ClinicalTrials.gov
NCT07023302 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adu… Phase3 Alopecia Areata Recruiting 2025-06-19 2029-02-01 ClinicalTrials.gov
NCT07023302 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adu… Phase3 Alopecia Areata Recruiting 2025-06-19 2029-02-01 ClinicalTrials.gov
NCT07023302 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adu… Phase3 Alopecia Areata Recruiting 2025-06-19 2029-02-01 ClinicalTrials.gov
NCT07023302 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adu… Phase3 Alopecia Areata Recruiting 2025-06-19 2029-02-01 ClinicalTrials.gov
NCT06880744 A Study to Assess the Change in Disease Activity in Adult Participants With Mod… Phase3 Ulcerative Colitis Active_Not_Recruiting 2025-06-17 2028-09-01 ClinicalTrials.gov
NCT06880744 A Study to Assess the Change in Disease Activity in Adult Participants With Mod… Phase3 Ulcerative Colitis Active_Not_Recruiting 2025-06-17 2028-09-01 ClinicalTrials.gov
NCT06880744 A Study to Assess the Change in Disease Activity in Adult Participants With Mod… Phase3 Ulcerative Colitis Active_Not_Recruiting 2025-06-17 2028-09-01 ClinicalTrials.gov
NCT06880744 A Study to Assess the Change in Disease Activity in Adult Participants With Mod… Phase3 Ulcerative Colitis Active_Not_Recruiting 2025-06-17 2028-09-01 ClinicalTrials.gov
NCT06672705 Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphop… Phase1 Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder Recruiting 2025-06-16 2026-12-31 ClinicalTrials.gov
NCT06672705 Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphop… Phase1 Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder Recruiting 2025-06-16 2026-12-31 ClinicalTrials.gov
NCT06672705 Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphop… Phase1 Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder Recruiting 2025-06-16 2026-12-31 ClinicalTrials.gov
NCT06672705 Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphop… Phase1 Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder Recruiting 2025-06-16 2026-12-31 ClinicalTrials.gov
NCT07007091 A Study to Assess the Relative Bioavailability of Risankizumab Following Subcut… Phase1 Healthy Volunteers Completed 2025-06-12 2026-01-15 ClinicalTrials.gov
NCT07007091 A Study to Assess the Relative Bioavailability of Risankizumab Following Subcut… Phase1 Healthy Volunteers Completed 2025-06-12 2026-01-15 ClinicalTrials.gov
NCT07007091 A Study to Assess the Relative Bioavailability of Risankizumab Following Subcut… Phase1 Healthy Volunteers Completed 2025-06-12 2026-01-15 ClinicalTrials.gov
NCT07007091 A Study to Assess the Relative Bioavailability of Risankizumab Following Subcut… Phase1 Healthy Volunteers Completed 2025-06-12 2026-01-15 ClinicalTrials.gov
NCT06902558 A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of … Phase2 Autosomal Dominant Polycystic Kidney Disease Recruiting 2025-06-09 2029-08-01 ClinicalTrials.gov
NCT06902558 A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of … Phase2 Autosomal Dominant Polycystic Kidney Disease Recruiting 2025-06-09 2029-08-01 ClinicalTrials.gov
NCT06902558 A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of … Phase2 Autosomal Dominant Polycystic Kidney Disease Recruiting 2025-06-09 2029-08-01 ClinicalTrials.gov
NCT06902558 A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of … Phase2 Autosomal Dominant Polycystic Kidney Disease Recruiting 2025-06-09 2029-08-01 ClinicalTrials.gov
NCT06965374 Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes… — Parkinson Disease Recruiting 2025-06-04 2027-06-01 ClinicalTrials.gov
NCT06965374 Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes… — Parkinson Disease Recruiting 2025-06-04 2027-06-01 ClinicalTrials.gov
NCT06965374 Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes… — Parkinson Disease Recruiting 2025-06-04 2027-06-01 ClinicalTrials.gov
NCT06965374 Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes… — Parkinson Disease Recruiting 2025-06-04 2027-06-01 ClinicalTrials.gov
NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants… Phase2 Advanced High-Grade Epithelial Ovarian Cancer Recruiting 2025-05-28 2028-04-01 ClinicalTrials.gov
NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants… Phase2 Advanced High-Grade Epithelial Ovarian Cancer Recruiting 2025-05-28 2028-04-01 ClinicalTrials.gov
NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants… Phase2 Advanced High-Grade Epithelial Ovarian Cancer Recruiting 2025-05-28 2028-04-01 ClinicalTrials.gov
NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants… Phase2 Advanced High-Grade Epithelial Ovarian Cancer Recruiting 2025-05-28 2028-04-01 ClinicalTrials.gov
NCT07032597 A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Ge… Phase3 Mid Face Volume Deficit Active_Not_Recruiting 2025-05-26 2026-10-01 ClinicalTrials.gov
NCT07032597 A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Ge… Phase3 Mid Face Volume Deficit Active_Not_Recruiting 2025-05-26 2026-10-01 ClinicalTrials.gov
NCT07032597 A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Ge… Phase3 Mid Face Volume Deficit Active_Not_Recruiting 2025-05-26 2026-10-01 ClinicalTrials.gov
NCT07032597 A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Ge… Phase3 Mid Face Volume Deficit Active_Not_Recruiting 2025-05-26 2026-10-01 ClinicalTrials.gov
NCT06946524 A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Ad… Phase1 Healthy Volunteers Completed 2025-05-08 2025-11-25 ClinicalTrials.gov
NCT06946524 A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Ad… Phase1 Healthy Volunteers Completed 2025-05-08 2025-11-25 ClinicalTrials.gov
NCT06946524 A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Ad… Phase1 Healthy Volunteers Completed 2025-05-08 2025-11-25 ClinicalTrials.gov
NCT06946524 A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Ad… Phase1 Healthy Volunteers Completed 2025-05-08 2025-11-25 ClinicalTrials.gov
NCT06916507 Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult Ge… — Parkinson's Disease Recruiting 2025-05-06 2027-09-01 ClinicalTrials.gov
NCT06916507 Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult Ge… — Parkinson's Disease Recruiting 2025-05-06 2027-09-01 ClinicalTrials.gov
NCT06916507 Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult Ge… — Parkinson's Disease Recruiting 2025-05-06 2027-09-01 ClinicalTrials.gov
NCT06916507 Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult Ge… — Parkinson's Disease Recruiting 2025-05-06 2027-09-01 ClinicalTrials.gov
NCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-93… Phase2 Generalized Anxiety Disorder (GAD) Recruiting 2025-04-29 2026-11-01 ClinicalTrials.gov
NCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-93… Phase2 Generalized Anxiety Disorder (GAD) Recruiting 2025-04-29 2026-11-01 ClinicalTrials.gov
NCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-93… Phase2 Generalized Anxiety Disorder (GAD) Recruiting 2025-04-29 2026-11-01 ClinicalTrials.gov
NCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-93… Phase2 Generalized Anxiety Disorder (GAD) Recruiting 2025-04-29 2026-11-01 ClinicalTrials.gov
NCT06820463 A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Tel… Phase2 Metastatic Colorectal Cancer Recruiting 2025-04-24 2028-04-01 ClinicalTrials.gov
NCT06820463 A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Tel… Phase2 Metastatic Colorectal Cancer Recruiting 2025-04-24 2028-04-01 ClinicalTrials.gov
NCT06820463 A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Tel… Phase2 Metastatic Colorectal Cancer Recruiting 2025-04-24 2028-04-01 ClinicalTrials.gov
NCT06820463 A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Tel… Phase2 Metastatic Colorectal Cancer Recruiting 2025-04-24 2028-04-01 ClinicalTrials.gov
NCT06937619 A Study to Assess the Relative Bioavailability of Risankizumab Following Subcut… Phase1 Healthy Volunteer Completed 2025-04-21 2025-11-10 ClinicalTrials.gov
NCT06937619 A Study to Assess the Relative Bioavailability of Risankizumab Following Subcut… Phase1 Healthy Volunteer Completed 2025-04-21 2025-11-10 ClinicalTrials.gov
NCT06937619 A Study to Assess the Relative Bioavailability of Risankizumab Following Subcut… Phase1 Healthy Volunteer Completed 2025-04-21 2025-11-10 ClinicalTrials.gov
NCT06937619 A Study to Assess the Relative Bioavailability of Risankizumab Following Subcut… Phase1 Healthy Volunteer Completed 2025-04-21 2025-11-10 ClinicalTrials.gov
NCT07566130 A Study to Assess Adverse Events, Tolerability and How Single and Ascending Ora… Phase1 Healthy Volunteers Completed 2025-04-18 2026-05-07 ClinicalTrials.gov
NCT07566130 A Study to Assess Adverse Events, Tolerability and How Single and Ascending Ora… Phase1 Healthy Volunteers Completed 2025-04-18 2026-05-07 ClinicalTrials.gov
NCT07566130 A Study to Assess Adverse Events, Tolerability and How Single and Ascending Ora… Phase1 Healthy Volunteers Completed 2025-04-18 2026-05-07 ClinicalTrials.gov
NCT07566130 A Study to Assess Adverse Events, Tolerability and How Single and Ascending Ora… Phase1 Healthy Volunteers Completed 2025-04-18 2026-05-07 ClinicalTrials.gov
NCT06660693 Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Ac… Phase3 Colitis, Ulcerative Recruiting 2025-04-16 2027-09-01 ClinicalTrials.gov
NCT06660693 Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Ac… Phase3 Colitis, Ulcerative Recruiting 2025-04-16 2027-09-01 ClinicalTrials.gov
NCT06660693 Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Ac… Phase3 Colitis, Ulcerative Recruiting 2025-04-16 2027-09-01 ClinicalTrials.gov
NCT06660693 Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Ac… Phase3 Colitis, Ulcerative Recruiting 2025-04-16 2027-09-01 ClinicalTrials.gov
NCT06937034 Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Ad… — Parkinson's Disease Recruiting 2025-04-14 2025-12-01 ClinicalTrials.gov
NCT06858813 A Study to Assess Adverse Events and Change in Disease Activity of Intravenousl… Phase1 Hepatocellular Cancer Recruiting 2025-04-14 2030-09-01 ClinicalTrials.gov
NCT06858813 A Study to Assess Adverse Events and Change in Disease Activity of Intravenousl… Phase1 Hepatocellular Cancer Recruiting 2025-04-14 2030-09-01 ClinicalTrials.gov
NCT06937034 Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Ad… — Parkinson's Disease Recruiting 2025-04-14 2025-12-01 ClinicalTrials.gov
NCT06937034 Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Ad… — Parkinson's Disease Recruiting 2025-04-14 2025-12-01 ClinicalTrials.gov
NCT06858813 A Study to Assess Adverse Events and Change in Disease Activity of Intravenousl… Phase1 Hepatocellular Cancer Recruiting 2025-04-14 2030-09-01 ClinicalTrials.gov
NCT06858813 A Study to Assess Adverse Events and Change in Disease Activity of Intravenousl… Phase1 Hepatocellular Cancer Recruiting 2025-04-14 2030-09-01 ClinicalTrials.gov
NCT06937034 Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Ad… — Parkinson's Disease Recruiting 2025-04-14 2025-12-01 ClinicalTrials.gov
NCT06865105 Study of Targeted Therapies for the Treatment of Adult Participants With Active… Phase2 Psoriatic Arthritis Recruiting 2025-04-11 2028-01-01 ClinicalTrials.gov
NCT06865105 Study of Targeted Therapies for the Treatment of Adult Participants With Active… Phase2 Psoriatic Arthritis Recruiting 2025-04-11 2028-01-01 ClinicalTrials.gov
NCT06865105 Study of Targeted Therapies for the Treatment of Adult Participants With Active… Phase2 Psoriatic Arthritis Recruiting 2025-04-11 2028-01-01 ClinicalTrials.gov
NCT06865105 Study of Targeted Therapies for the Treatment of Adult Participants With Active… Phase2 Psoriatic Arthritis Recruiting 2025-04-11 2028-01-01 ClinicalTrials.gov
NCT06838845 An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in … — Ulcerative Colitis Recruiting 2025-04-09 2026-12-01 ClinicalTrials.gov
NCT06838845 An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in … — Ulcerative Colitis Recruiting 2025-04-09 2026-12-01 ClinicalTrials.gov
NCT06838845 An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in … — Ulcerative Colitis Recruiting 2025-04-09 2026-12-01 ClinicalTrials.gov
NCT06838845 An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in … — Ulcerative Colitis Recruiting 2025-04-09 2026-12-01 ClinicalTrials.gov
NCT06895343 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenic… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-04-03 2026-11-01 ClinicalTrials.gov
NCT06895343 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenic… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-04-03 2026-11-01 ClinicalTrials.gov
NCT06895343 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenic… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-04-03 2026-11-01 ClinicalTrials.gov
NCT06895343 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenic… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-04-03 2026-11-01 ClinicalTrials.gov
NCT06536049 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressi… Phase1 Recurrent Diffuse Large B-Cell Lymphoma Recruiting 2025-04-02 2027-10-31 ClinicalTrials.gov
NCT06536049 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressi… Phase1 Recurrent Diffuse Large B-Cell Lymphoma Recruiting 2025-04-02 2027-10-31 ClinicalTrials.gov
NCT06536049 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressi… Phase1 Recurrent Diffuse Large B-Cell Lymphoma Recruiting 2025-04-02 2027-10-31 ClinicalTrials.gov
NCT06536049 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressi… Phase1 Recurrent Diffuse Large B-Cell Lymphoma Recruiting 2025-04-02 2027-10-31 ClinicalTrials.gov
NCT06830759 Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With … — Diffuse Large B-cell Lymphoma Recruiting 2025-03-28 2031-09-01 ClinicalTrials.gov
NCT06830759 Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With … — Diffuse Large B-cell Lymphoma Recruiting 2025-03-28 2031-09-01 ClinicalTrials.gov
NCT06830759 Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With … — Diffuse Large B-cell Lymphoma Recruiting 2025-03-28 2031-09-01 ClinicalTrials.gov
NCT06830759 Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With … — Diffuse Large B-cell Lymphoma Recruiting 2025-03-28 2031-09-01 ClinicalTrials.gov
NCT06895356 A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adu… Phase1 Healthy Volunteer Completed 2025-03-26 2025-06-16 ClinicalTrials.gov
NCT06895356 A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adu… Phase1 Healthy Volunteer Completed 2025-03-26 2025-06-16 ClinicalTrials.gov
NCT06895356 A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adu… Phase1 Healthy Volunteer Completed 2025-03-26 2025-06-16 ClinicalTrials.gov
NCT06895356 A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adu… Phase1 Healthy Volunteer Completed 2025-03-26 2025-06-16 ClinicalTrials.gov
NCT06887010 A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Bo… Phase1 Healthy Volunteer Completed 2025-03-25 2025-09-16 ClinicalTrials.gov
NCT06887010 A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Bo… Phase1 Healthy Volunteer Completed 2025-03-25 2025-09-16 ClinicalTrials.gov
NCT06887010 A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Bo… Phase1 Healthy Volunteer Completed 2025-03-25 2025-09-16 ClinicalTrials.gov
NCT06887010 A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Bo… Phase1 Healthy Volunteer Completed 2025-03-25 2025-09-16 ClinicalTrials.gov
NCT05099471 Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglob… Phase2 Waldenstrom Macroglobulinemia Recruiting 2025-03-21 2033-03-01 ClinicalTrials.gov
NCT05099471 Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglob… Phase2 Waldenstrom Macroglobulinemia Recruiting 2025-03-21 2033-03-01 ClinicalTrials.gov
NCT05099471 Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglob… Phase2 Waldenstrom Macroglobulinemia Recruiting 2025-03-21 2033-03-01 ClinicalTrials.gov
NCT05099471 Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglob… Phase2 Waldenstrom Macroglobulinemia Recruiting 2025-03-21 2033-03-01 ClinicalTrials.gov
NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… Phase1 Non Small Cell Lung Carcinoma Recruiting 2025-03-06 2027-11-01 ClinicalTrials.gov
NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… Phase1 Non Small Cell Lung Carcinoma Recruiting 2025-03-06 2027-11-01 ClinicalTrials.gov
NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… Phase1 Non Small Cell Lung Carcinoma Recruiting 2025-03-06 2027-11-01 ClinicalTrials.gov
NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… Phase1 Non Small Cell Lung Carcinoma Recruiting 2025-03-06 2027-11-01 ClinicalTrials.gov
NCT06764706 Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult P… — Ulcerative Colitis Recruiting 2025-02-27 2028-07-01 ClinicalTrials.gov
NCT06764706 Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult P… — Ulcerative Colitis Recruiting 2025-02-27 2028-07-01 ClinicalTrials.gov
NCT06764706 Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult P… — Ulcerative Colitis Recruiting 2025-02-27 2028-07-01 ClinicalTrials.gov
NCT06764706 Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult P… — Ulcerative Colitis Recruiting 2025-02-27 2028-07-01 ClinicalTrials.gov
NCT06849791 A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adul… Phase1 Healthy Volunteer Completed 2025-02-26 2026-05-08 ClinicalTrials.gov
NCT06849791 A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adul… Phase1 Healthy Volunteer Completed 2025-02-26 2026-05-08 ClinicalTrials.gov
NCT06849791 A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adul… Phase1 Healthy Volunteer Completed 2025-02-26 2026-05-08 ClinicalTrials.gov
NCT06849791 A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adul… Phase1 Healthy Volunteer Completed 2025-02-26 2026-05-08 ClinicalTrials.gov
NCT06834789 A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 … Phase1 Glabellar Lines Completed 2025-02-18 2025-11-03 ClinicalTrials.gov
NCT06834789 A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 … Phase1 Glabellar Lines Completed 2025-02-18 2025-11-03 ClinicalTrials.gov
NCT06834789 A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 … Phase1 Glabellar Lines Completed 2025-02-18 2025-11-03 ClinicalTrials.gov
NCT06834789 A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 … Phase1 Glabellar Lines Completed 2025-02-18 2025-11-03 ClinicalTrials.gov
NCT06810505 A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Diseas… Phase3 Chronic Migraine Recruiting 2025-02-13 2031-03-01 ClinicalTrials.gov
NCT06810505 A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Diseas… Phase3 Chronic Migraine Recruiting 2025-02-13 2031-03-01 ClinicalTrials.gov
NCT06810505 A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Diseas… Phase3 Chronic Migraine Recruiting 2025-02-13 2031-03-01 ClinicalTrials.gov
NCT06810505 A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Diseas… Phase3 Chronic Migraine Recruiting 2025-02-13 2031-03-01 ClinicalTrials.gov
NCT06692881 Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participa… — Migraine Completed 2025-02-12 2026-06-01 ClinicalTrials.gov
NCT06692881 Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participa… — Migraine Completed 2025-02-12 2026-06-01 ClinicalTrials.gov
NCT06692881 Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participa… — Migraine Completed 2025-02-12 2026-06-01 ClinicalTrials.gov
NCT06692881 Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participa… — Migraine Completed 2025-02-12 2026-06-01 ClinicalTrials.gov
NCT06822738 A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implant… Phase3 Primary Open Angle Glaucoma Recruiting 2025-02-11 2028-11-01 ClinicalTrials.gov
NCT06822738 A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implant… Phase3 Primary Open Angle Glaucoma Recruiting 2025-02-11 2028-11-01 ClinicalTrials.gov
NCT06822738 A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implant… Phase3 Primary Open Angle Glaucoma Recruiting 2025-02-11 2028-11-01 ClinicalTrials.gov
NCT06822738 A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implant… Phase3 Primary Open Angle Glaucoma Recruiting 2025-02-11 2028-11-01 ClinicalTrials.gov
NCT06806293 Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity… Phase3 Menstrual Migraine (MM) Active_Not_Recruiting 2025-02-10 2027-07-01 ClinicalTrials.gov
NCT06806293 Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity… Phase3 Menstrual Migraine (MM) Active_Not_Recruiting 2025-02-10 2027-07-01 ClinicalTrials.gov
NCT06806293 Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity… Phase3 Menstrual Migraine (MM) Active_Not_Recruiting 2025-02-10 2027-07-01 ClinicalTrials.gov
NCT06806293 Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity… Phase3 Menstrual Migraine (MM) Active_Not_Recruiting 2025-02-10 2027-07-01 ClinicalTrials.gov
NCT06764693 An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Parti… — Psoriatic Arthritis Recruiting 2025-01-31 2029-02-01 ClinicalTrials.gov
NCT06764693 An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Parti… — Psoriatic Arthritis Recruiting 2025-01-31 2029-02-01 ClinicalTrials.gov
NCT06764693 An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Parti… — Psoriatic Arthritis Recruiting 2025-01-31 2029-02-01 ClinicalTrials.gov
NCT06764693 An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Parti… — Psoriatic Arthritis Recruiting 2025-01-31 2029-02-01 ClinicalTrials.gov
NCT06291220 A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in… Phase1 Chronic Lymphocytic Leukemia Active_Not_Recruiting 2025-01-27 2027-07-01 ClinicalTrials.gov
NCT06291220 A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in… Phase1 Chronic Lymphocytic Leukemia Active_Not_Recruiting 2025-01-27 2027-07-01 ClinicalTrials.gov
NCT06291220 A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in… Phase1 Chronic Lymphocytic Leukemia Active_Not_Recruiting 2025-01-27 2027-07-01 ClinicalTrials.gov
NCT06291220 A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in… Phase1 Chronic Lymphocytic Leukemia Active_Not_Recruiting 2025-01-27 2027-07-01 ClinicalTrials.gov
NCT06774313 A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and I… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-01-22 2026-04-01 ClinicalTrials.gov
NCT06774313 A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and I… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-01-22 2026-04-01 ClinicalTrials.gov
NCT06794866 A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intram… Phase3 Forehead Lines Active_Not_Recruiting 2025-01-22 2026-04-01 ClinicalTrials.gov
NCT06774313 A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and I… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-01-22 2026-04-01 ClinicalTrials.gov
NCT06794866 A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intram… Phase3 Forehead Lines Active_Not_Recruiting 2025-01-22 2026-04-01 ClinicalTrials.gov
NCT06774313 A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and I… Phase1 Healthy Volunteer Active_Not_Recruiting 2025-01-22 2026-04-01 ClinicalTrials.gov
NCT06794866 A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intram… Phase3 Forehead Lines Active_Not_Recruiting 2025-01-22 2026-04-01 ClinicalTrials.gov
NCT06794866 A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intram… Phase3 Forehead Lines Active_Not_Recruiting 2025-01-22 2026-04-01 ClinicalTrials.gov
NCT06568939 A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzum… Phase2 Non-Small Cell Lung Cancer Recruiting 2025-01-20 2028-02-01 ClinicalTrials.gov
NCT06568939 A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzum… Phase2 Non-Small Cell Lung Cancer Recruiting 2025-01-20 2028-02-01 ClinicalTrials.gov
NCT06568939 A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzum… Phase2 Non-Small Cell Lung Cancer Recruiting 2025-01-20 2028-02-01 ClinicalTrials.gov
NCT06632951 Study to Evaluate Adverse Events and Change in Disease Activity When Intravenou… Phase2 Urothelial Carcinoma Active_Not_Recruiting 2025-01-20 2028-08-01 ClinicalTrials.gov
NCT06568939 A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzum… Phase2 Non-Small Cell Lung Cancer Recruiting 2025-01-20 2028-02-01 ClinicalTrials.gov
NCT06632951 Study to Evaluate Adverse Events and Change in Disease Activity When Intravenou… Phase2 Urothelial Carcinoma Active_Not_Recruiting 2025-01-20 2028-08-01 ClinicalTrials.gov
NCT06632951 Study to Evaluate Adverse Events and Change in Disease Activity When Intravenou… Phase2 Urothelial Carcinoma Active_Not_Recruiting 2025-01-20 2028-08-01 ClinicalTrials.gov
NCT06632951 Study to Evaluate Adverse Events and Change in Disease Activity When Intravenou… Phase2 Urothelial Carcinoma Active_Not_Recruiting 2025-01-20 2028-08-01 ClinicalTrials.gov
NCT06667687 Study to Evaluate Adverse Events, Change in Disease Activity, and How Intraveno… Phase1 Non-Hodgkin's Lymphoma Recruiting 2025-01-16 2031-11-01 ClinicalTrials.gov
NCT06783621 A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appeara… Phase4 Facial Contouring Completed 2025-01-16 2026-03-20 ClinicalTrials.gov
NCT06783621 A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appeara… Phase4 Facial Contouring Completed 2025-01-16 2026-03-20 ClinicalTrials.gov
NCT06783621 A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appeara… Phase4 Facial Contouring Completed 2025-01-16 2026-03-20 ClinicalTrials.gov
NCT06667687 Study to Evaluate Adverse Events, Change in Disease Activity, and How Intraveno… Phase1 Non-Hodgkin's Lymphoma Recruiting 2025-01-16 2031-11-01 ClinicalTrials.gov
NCT06667687 Study to Evaluate Adverse Events, Change in Disease Activity, and How Intraveno… Phase1 Non-Hodgkin's Lymphoma Recruiting 2025-01-16 2031-11-01 ClinicalTrials.gov
NCT06667687 Study to Evaluate Adverse Events, Change in Disease Activity, and How Intraveno… Phase1 Non-Hodgkin's Lymphoma Recruiting 2025-01-16 2031-11-01 ClinicalTrials.gov
NCT06783621 A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appeara… Phase4 Facial Contouring Completed 2025-01-16 2026-03-20 ClinicalTrials.gov
NCT06504459 Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azaci… Phase2 Acute Monocytic Leukemia Recruiting 2025-01-03 2028-05-01 ClinicalTrials.gov
NCT06504459 Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azaci… Phase2 Acute Monocytic Leukemia Recruiting 2025-01-03 2028-05-01 ClinicalTrials.gov
NCT06504459 Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azaci… Phase2 Acute Monocytic Leukemia Recruiting 2025-01-03 2028-05-01 ClinicalTrials.gov
NCT06504459 Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azaci… Phase2 Acute Monocytic Leukemia Recruiting 2025-01-03 2028-05-01 ClinicalTrials.gov
NCT06390319 Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diag… Phase2 T-cell Acute Lymphoblastic Leukemia Recruiting 2024-12-27 2033-12-01 ClinicalTrials.gov
NCT06390319 Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diag… Phase2 T-cell Acute Lymphoblastic Leukemia Recruiting 2024-12-27 2033-12-01 ClinicalTrials.gov
NCT06390319 Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diag… Phase2 T-cell Acute Lymphoblastic Leukemia Recruiting 2024-12-27 2033-12-01 ClinicalTrials.gov
NCT06390319 Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diag… Phase2 T-cell Acute Lymphoblastic Leukemia Recruiting 2024-12-27 2033-12-01 ClinicalTrials.gov
NCT06701331 Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids… Phase3 Atopic Dermatitis Active_Not_Recruiting 2024-12-22 2027-01-01 ClinicalTrials.gov
NCT06701331 Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids… Phase3 Atopic Dermatitis Active_Not_Recruiting 2024-12-22 2027-01-01 ClinicalTrials.gov
NCT06701331 Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids… Phase3 Atopic Dermatitis Active_Not_Recruiting 2024-12-22 2027-01-01 ClinicalTrials.gov
NCT06701331 Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids… Phase3 Atopic Dermatitis Active_Not_Recruiting 2024-12-22 2027-01-01 ClinicalTrials.gov
NCT06718101 A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or… Phase2 Atopic Dermatitis Active_Not_Recruiting 2024-12-19 2027-05-01 ClinicalTrials.gov
NCT06742086 A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New… Phase1 Healthy Volunteer Completed 2024-12-19 2025-10-08 ClinicalTrials.gov
NCT06742086 A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New… Phase1 Healthy Volunteer Completed 2024-12-19 2025-10-08 ClinicalTrials.gov
NCT06718101 A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or… Phase2 Atopic Dermatitis Active_Not_Recruiting 2024-12-19 2027-05-01 ClinicalTrials.gov
NCT06742086 A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New… Phase1 Healthy Volunteer Completed 2024-12-19 2025-10-08 ClinicalTrials.gov
NCT06742086 A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New… Phase1 Healthy Volunteer Completed 2024-12-19 2025-10-08 ClinicalTrials.gov
NCT06718101 A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or… Phase2 Atopic Dermatitis Active_Not_Recruiting 2024-12-19 2027-05-01 ClinicalTrials.gov
NCT06718101 A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or… Phase2 Atopic Dermatitis Active_Not_Recruiting 2024-12-19 2027-05-01 ClinicalTrials.gov
NCT06734351 A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Ad… Phase3 Mid Face Volume Deficit Recruiting 2024-12-16 2029-07-01 ClinicalTrials.gov
NCT06734351 A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Ad… Phase3 Mid Face Volume Deficit Recruiting 2024-12-16 2029-07-01 ClinicalTrials.gov
NCT06734351 A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Ad… Phase3 Mid Face Volume Deficit Recruiting 2024-12-16 2029-07-01 ClinicalTrials.gov
NCT06734351 A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Ad… Phase3 Mid Face Volume Deficit Recruiting 2024-12-16 2029-07-01 ClinicalTrials.gov
NCT06628310 A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intraveno… Phase2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Active_Not_Recruiting 2024-12-13 2030-10-01 ClinicalTrials.gov
NCT06628310 A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intraveno… Phase2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Active_Not_Recruiting 2024-12-13 2030-10-01 ClinicalTrials.gov
NCT06628310 A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intraveno… Phase2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Active_Not_Recruiting 2024-12-13 2030-10-01 ClinicalTrials.gov
NCT06628310 A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intraveno… Phase2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Active_Not_Recruiting 2024-12-13 2030-10-01 ClinicalTrials.gov
NCT06158100 Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocy… Phase1 Acute Myeloid Leukemia Suspended 2024-12-04 2027-12-31 ClinicalTrials.gov
NCT06158100 Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocy… Phase1 Acute Myeloid Leukemia Suspended 2024-12-04 2027-12-31 ClinicalTrials.gov
NCT06158100 Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocy… Phase1 Acute Myeloid Leukemia Suspended 2024-12-04 2027-12-31 ClinicalTrials.gov
NCT06158100 Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocy… Phase1 Acute Myeloid Leukemia Suspended 2024-12-04 2027-12-31 ClinicalTrials.gov
NCT06454188 A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in… Phase4 Psoriatic Arthritis Recruiting 2024-12-03 2028-10-01 ClinicalTrials.gov
NCT06454188 A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in… Phase4 Psoriatic Arthritis Recruiting 2024-12-03 2028-10-01 ClinicalTrials.gov
NCT06454188 A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in… Phase4 Psoriatic Arthritis Recruiting 2024-12-03 2028-10-01 ClinicalTrials.gov
NCT06454188 A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in… Phase4 Psoriatic Arthritis Recruiting 2024-12-03 2028-10-01 ClinicalTrials.gov
NCT06078202 A Study to Assess the Relative Bioavailability of Three Immediate-Release Table… Phase1 Healthy Volunteers Withdrawn 2024-12-01 2025-01-31 ClinicalTrials.gov
NCT06078202 A Study to Assess the Relative Bioavailability of Three Immediate-Release Table… Phase1 Healthy Volunteers Withdrawn 2024-12-01 2025-01-31 ClinicalTrials.gov
NCT06078202 A Study to Assess the Relative Bioavailability of Three Immediate-Release Table… Phase1 Healthy Volunteers Withdrawn 2024-12-01 2025-01-31 ClinicalTrials.gov
NCT06078202 A Study to Assess the Relative Bioavailability of Three Immediate-Release Table… Phase1 Healthy Volunteers Withdrawn 2024-12-01 2025-01-31 ClinicalTrials.gov
NCT06660368 BCL2i CLAG-M in R/R Acute Myeloid Leukemia Phase2 Relapsed or Refractory Acute Myeloid Leukemia (AML) Recruiting 2024-11-26 2027-11-01 ClinicalTrials.gov
NCT06660368 BCL2i CLAG-M in R/R Acute Myeloid Leukemia Phase2 Relapsed or Refractory Acute Myeloid Leukemia (AML) Recruiting 2024-11-26 2027-11-01 ClinicalTrials.gov
NCT06722417 A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Thr… Phase1 Healthy Volunteer Completed 2024-11-26 2025-01-17 ClinicalTrials.gov
NCT06722417 A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Thr… Phase1 Healthy Volunteer Completed 2024-11-26 2025-01-17 ClinicalTrials.gov
NCT06722417 A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Thr… Phase1 Healthy Volunteer Completed 2024-11-26 2025-01-17 ClinicalTrials.gov
NCT06660368 BCL2i CLAG-M in R/R Acute Myeloid Leukemia Phase2 Relapsed or Refractory Acute Myeloid Leukemia (AML) Recruiting 2024-11-26 2027-11-01 ClinicalTrials.gov
NCT06543914 Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in A… — Migraine Active_Not_Recruiting 2024-11-26 2029-02-01 ClinicalTrials.gov
NCT06543914 Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in A… — Migraine Active_Not_Recruiting 2024-11-26 2029-02-01 ClinicalTrials.gov
NCT06722417 A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Thr… Phase1 Healthy Volunteer Completed 2024-11-26 2025-01-17 ClinicalTrials.gov
NCT06543914 Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in A… — Migraine Active_Not_Recruiting 2024-11-26 2029-02-01 ClinicalTrials.gov
NCT06660368 BCL2i CLAG-M in R/R Acute Myeloid Leukemia Phase2 Relapsed or Refractory Acute Myeloid Leukemia (AML) Recruiting 2024-11-26 2027-11-01 ClinicalTrials.gov
NCT06543914 Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in A… — Migraine Active_Not_Recruiting 2024-11-26 2029-02-01 ClinicalTrials.gov
NCT06548568 A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Imp… — Diabetic Macular Edema Active_Not_Recruiting 2024-11-13 2027-04-01 ClinicalTrials.gov
NCT06722430 A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Throug… Phase1 Healthy Volunteer Completed 2024-11-13 2025-01-13 ClinicalTrials.gov
NCT06722430 A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Throug… Phase1 Healthy Volunteer Completed 2024-11-13 2025-01-13 ClinicalTrials.gov
NCT06722430 A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Throug… Phase1 Healthy Volunteer Completed 2024-11-13 2025-01-13 ClinicalTrials.gov
NCT06722430 A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Throug… Phase1 Healthy Volunteer Completed 2024-11-13 2025-01-13 ClinicalTrials.gov
NCT06548568 A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Imp… — Diabetic Macular Edema Active_Not_Recruiting 2024-11-13 2027-04-01 ClinicalTrials.gov
NCT06548568 A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Imp… — Diabetic Macular Edema Active_Not_Recruiting 2024-11-13 2027-04-01 ClinicalTrials.gov
NCT06548568 A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Imp… — Diabetic Macular Edema Active_Not_Recruiting 2024-11-13 2027-04-01 ClinicalTrials.gov
NCT06639620 Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa i… — Advanced Parkinson Disease Active_Not_Recruiting 2024-11-12 2027-03-01 ClinicalTrials.gov
NCT06639620 Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa i… — Advanced Parkinson Disease Active_Not_Recruiting 2024-11-12 2027-03-01 ClinicalTrials.gov
NCT06639620 Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa i… — Advanced Parkinson Disease Active_Not_Recruiting 2024-11-12 2027-03-01 ClinicalTrials.gov
NCT06639620 Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa i… — Advanced Parkinson Disease Active_Not_Recruiting 2024-11-12 2027-03-01 ClinicalTrials.gov
NCT06698926 A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Or… Phase1 Healthy Volunteer Completed 2024-11-11 2026-01-09 ClinicalTrials.gov
NCT06698926 A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Or… Phase1 Healthy Volunteer Completed 2024-11-11 2026-01-09 ClinicalTrials.gov
NCT06698926 A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Or… Phase1 Healthy Volunteer Completed 2024-11-11 2026-01-09 ClinicalTrials.gov
NCT06698926 A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Or… Phase1 Healthy Volunteer Completed 2024-11-11 2026-01-09 ClinicalTrials.gov
NCT06614192 A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Inf… Phase3 Metastatic Colorectal Cancer Active_Not_Recruiting 2024-11-08 2027-08-01 ClinicalTrials.gov
NCT06614192 A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Inf… Phase3 Metastatic Colorectal Cancer Active_Not_Recruiting 2024-11-08 2027-08-01 ClinicalTrials.gov
NCT06614192 A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Inf… Phase3 Metastatic Colorectal Cancer Active_Not_Recruiting 2024-11-08 2027-08-01 ClinicalTrials.gov
NCT06614192 A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Inf… Phase3 Metastatic Colorectal Cancer Active_Not_Recruiting 2024-11-08 2027-08-01 ClinicalTrials.gov
NCT06712628 A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a Germa… — Moderate to Severe Rheumatoid Arthritis Recruiting 2024-11-07 2028-12-01 ClinicalTrials.gov
NCT06511882 Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD Phase2 Acute Myeloid Leukemia Recruiting 2024-11-07 2028-08-01 ClinicalTrials.gov
NCT06511882 Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD Phase2 Acute Myeloid Leukemia Recruiting 2024-11-07 2028-08-01 ClinicalTrials.gov
NCT06511882 Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD Phase2 Acute Myeloid Leukemia Recruiting 2024-11-07 2028-08-01 ClinicalTrials.gov
NCT06712628 A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a Germa… — Moderate to Severe Rheumatoid Arthritis Recruiting 2024-11-07 2028-12-01 ClinicalTrials.gov
NCT06712628 A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a Germa… — Moderate to Severe Rheumatoid Arthritis Recruiting 2024-11-07 2028-12-01 ClinicalTrials.gov
NCT06511882 Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD Phase2 Acute Myeloid Leukemia Recruiting 2024-11-07 2028-08-01 ClinicalTrials.gov
NCT06712628 A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a Germa… — Moderate to Severe Rheumatoid Arthritis Recruiting 2024-11-07 2028-12-01 ClinicalTrials.gov
NCT06575192 Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matri… Phase3 Breast Reconstruction Recruiting 2024-11-05 2031-02-01 ClinicalTrials.gov
NCT06575192 Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matri… Phase3 Breast Reconstruction Recruiting 2024-11-05 2031-02-01 ClinicalTrials.gov
NCT06575192 Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matri… Phase3 Breast Reconstruction Recruiting 2024-11-05 2031-02-01 ClinicalTrials.gov
NCT06575192 Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matri… Phase3 Breast Reconstruction Recruiting 2024-11-05 2031-02-01 ClinicalTrials.gov
NCT06644144 P4O2 ILD Extension — Interstitial Lung Disease Recruiting 2024-11-01 2031-10-01 ClinicalTrials.gov
NCT06644144 P4O2 ILD Extension — Interstitial Lung Disease Recruiting 2024-11-01 2031-10-01 ClinicalTrials.gov
NCT06644144 P4O2 ILD Extension — Interstitial Lung Disease Recruiting 2024-11-01 2031-10-01 ClinicalTrials.gov
NCT06644144 P4O2 ILD Extension — Interstitial Lung Disease Recruiting 2024-11-01 2031-10-01 ClinicalTrials.gov
NCT06673238 A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tole… Phase1 Healthy Volunteer Active_Not_Recruiting 2024-10-29 2026-06-01 ClinicalTrials.gov
NCT06673238 A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tole… Phase1 Healthy Volunteer Active_Not_Recruiting 2024-10-29 2026-06-01 ClinicalTrials.gov
NCT06673238 A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tole… Phase1 Healthy Volunteer Active_Not_Recruiting 2024-10-29 2026-06-01 ClinicalTrials.gov
NCT06673238 A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tole… Phase1 Healthy Volunteer Active_Not_Recruiting 2024-10-29 2026-06-01 ClinicalTrials.gov
NCT06618118 A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults Wit… Phase1 Major Depressive Disorder (MDD) Terminated 2024-10-23 2025-09-23 ClinicalTrials.gov
NCT06618118 A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults Wit… Phase1 Major Depressive Disorder (MDD) Terminated 2024-10-23 2025-09-23 ClinicalTrials.gov
NCT06618118 A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults Wit… Phase1 Major Depressive Disorder (MDD) Terminated 2024-10-23 2025-09-23 ClinicalTrials.gov
NCT06618118 A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults Wit… Phase1 Major Depressive Disorder (MDD) Terminated 2024-10-23 2025-09-23 ClinicalTrials.gov
NCT06772194 Taiwan Post-Stroke Disability Study — Stroke Recruiting 2024-10-21 2028-09-30 ClinicalTrials.gov
NCT06772194 Taiwan Post-Stroke Disability Study — Stroke Recruiting 2024-10-21 2028-09-30 ClinicalTrials.gov
NCT06772194 Taiwan Post-Stroke Disability Study — Stroke Recruiting 2024-10-21 2028-09-30 ClinicalTrials.gov
NCT06772194 Taiwan Post-Stroke Disability Study — Stroke Recruiting 2024-10-21 2028-09-30 ClinicalTrials.gov
NCT06605599 Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity … Phase2 Bipolar I Disorder Completed 2024-10-15 2025-12-10 ClinicalTrials.gov
NCT06605599 Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity … Phase2 Bipolar I Disorder Completed 2024-10-15 2025-12-10 ClinicalTrials.gov
NCT06605599 Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity … Phase2 Bipolar I Disorder Completed 2024-10-15 2025-12-10 ClinicalTrials.gov
NCT06605599 Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity … Phase2 Bipolar I Disorder Completed 2024-10-15 2025-12-10 ClinicalTrials.gov
NCT06632938 A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From… Phase1 Healthy Volunteer Completed 2024-10-08 2025-05-15 ClinicalTrials.gov
NCT06632938 A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From… Phase1 Healthy Volunteer Completed 2024-10-08 2025-05-15 ClinicalTrials.gov
NCT06632938 A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From… Phase1 Healthy Volunteer Completed 2024-10-08 2025-05-15 ClinicalTrials.gov
NCT06632938 A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From… Phase1 Healthy Volunteer Completed 2024-10-08 2025-05-15 ClinicalTrials.gov
NCT06602479 A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo … Phase2 Migraine Recruiting 2024-10-07 2027-05-07 ClinicalTrials.gov
NCT06602479 A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo … Phase2 Migraine Recruiting 2024-10-07 2027-05-07 ClinicalTrials.gov
NCT06602479 A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo … Phase2 Migraine Recruiting 2024-10-07 2027-05-07 ClinicalTrials.gov
NCT06602479 A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo … Phase2 Migraine Recruiting 2024-10-07 2027-05-07 ClinicalTrials.gov
NCT06464692 Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab… Phase1 Colorectal Cancer Recruiting 2024-09-30 2028-09-01 ClinicalTrials.gov
NCT06464692 Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab… Phase1 Colorectal Cancer Recruiting 2024-09-30 2028-09-01 ClinicalTrials.gov
NCT06464692 Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab… Phase1 Colorectal Cancer Recruiting 2024-09-30 2028-09-01 ClinicalTrials.gov
NCT06464692 Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab… Phase1 Colorectal Cancer Recruiting 2024-09-30 2028-09-01 ClinicalTrials.gov
NCT06581042 Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Part… — Ulcerative Colitis Recruiting 2024-09-27 2029-09-01 ClinicalTrials.gov
NCT06581042 Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Part… — Ulcerative Colitis Recruiting 2024-09-27 2029-09-01 ClinicalTrials.gov
NCT06581042 Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Part… — Ulcerative Colitis Recruiting 2024-09-27 2029-09-01 ClinicalTrials.gov
NCT06581042 Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Part… — Ulcerative Colitis Recruiting 2024-09-27 2029-09-01 ClinicalTrials.gov
NCT06603558 Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant i… — Chronic Migraine Recruiting 2024-09-24 2029-05-01 ClinicalTrials.gov
NCT06603558 Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant i… — Chronic Migraine Recruiting 2024-09-24 2029-05-01 ClinicalTrials.gov
NCT06603558 Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant i… — Chronic Migraine Recruiting 2024-09-24 2029-05-01 ClinicalTrials.gov
NCT06603558 Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant i… — Chronic Migraine Recruiting 2024-09-24 2029-05-01 ClinicalTrials.gov
NCT06284486 A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhi… Phase1 Acute Myeloid Leukemia Recruiting 2024-09-23 2028-12-30 ClinicalTrials.gov
NCT06284486 A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhi… Phase1 Acute Myeloid Leukemia Recruiting 2024-09-23 2028-12-30 ClinicalTrials.gov
NCT06284486 A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhi… Phase1 Acute Myeloid Leukemia Recruiting 2024-09-23 2028-12-30 ClinicalTrials.gov
NCT06284486 A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhi… Phase1 Acute Myeloid Leukemia Recruiting 2024-09-23 2028-12-30 ClinicalTrials.gov
NCT06487559 A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplima… Phase1 Hepatocellular Carcinoma (HCC) Recruiting 2024-09-11 2027-10-01 ClinicalTrials.gov
NCT06487559 A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplima… Phase1 Hepatocellular Carcinoma (HCC) Recruiting 2024-09-11 2027-10-01 ClinicalTrials.gov
NCT06571266 A Study to Assess the Relative Bioavailability of Two Formulations of Risankizu… Phase1 Healthy Volunteers Completed 2024-09-11 2025-04-16 ClinicalTrials.gov
NCT06571266 A Study to Assess the Relative Bioavailability of Two Formulations of Risankizu… Phase1 Healthy Volunteers Completed 2024-09-11 2025-04-16 ClinicalTrials.gov
NCT06571266 A Study to Assess the Relative Bioavailability of Two Formulations of Risankizu… Phase1 Healthy Volunteers Completed 2024-09-11 2025-04-16 ClinicalTrials.gov
NCT06487559 A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplima… Phase1 Hepatocellular Carcinoma (HCC) Recruiting 2024-09-11 2027-10-01 ClinicalTrials.gov
NCT06571266 A Study to Assess the Relative Bioavailability of Two Formulations of Risankizu… Phase1 Healthy Volunteers Completed 2024-09-11 2025-04-16 ClinicalTrials.gov
NCT06487559 A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplima… Phase1 Hepatocellular Carcinoma (HCC) Recruiting 2024-09-11 2027-10-01 ClinicalTrials.gov
NCT06417775 Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activit… Phase3 Migraine Active_Not_Recruiting 2024-09-10 2027-09-01 ClinicalTrials.gov
NCT06417775 Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activit… Phase3 Migraine Active_Not_Recruiting 2024-09-10 2027-09-01 ClinicalTrials.gov
NCT06417775 Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activit… Phase3 Migraine Active_Not_Recruiting 2024-09-10 2027-09-01 ClinicalTrials.gov
NCT06417775 Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activit… Phase3 Migraine Active_Not_Recruiting 2024-09-10 2027-09-01 ClinicalTrials.gov
NCT06579300 A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pha… Phase1 Healthy Volunteer Terminated 2024-09-04 2025-09-03 ClinicalTrials.gov
NCT06579300 A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pha… Phase1 Healthy Volunteer Terminated 2024-09-04 2025-09-03 ClinicalTrials.gov
NCT06548542 Study of Targeted Therapies for the Treatment of Adult Participants With Modera… Phase2 Crohn's Disease Recruiting 2024-09-04 2030-01-01 ClinicalTrials.gov
NCT06579300 A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pha… Phase1 Healthy Volunteer Terminated 2024-09-04 2025-09-03 ClinicalTrials.gov
NCT06548542 Study of Targeted Therapies for the Treatment of Adult Participants With Modera… Phase2 Crohn's Disease Recruiting 2024-09-04 2030-01-01 ClinicalTrials.gov
NCT06579300 A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pha… Phase1 Healthy Volunteer Terminated 2024-09-04 2025-09-03 ClinicalTrials.gov
NCT06548542 Study of Targeted Therapies for the Treatment of Adult Participants With Modera… Phase2 Crohn's Disease Recruiting 2024-09-04 2030-01-01 ClinicalTrials.gov
NCT06548542 Study of Targeted Therapies for the Treatment of Adult Participants With Modera… Phase2 Crohn's Disease Recruiting 2024-09-04 2030-01-01 ClinicalTrials.gov
NCT06300580 Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupan… Phase1 Healthy Volunteers Completed 2024-08-21 2025-05-26 ClinicalTrials.gov
NCT06300580 Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupan… Phase1 Healthy Volunteers Completed 2024-08-21 2025-05-26 ClinicalTrials.gov
NCT06300580 Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupan… Phase1 Healthy Volunteers Completed 2024-08-21 2025-05-26 ClinicalTrials.gov
NCT06300580 Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupan… Phase1 Healthy Volunteers Completed 2024-08-21 2025-05-26 ClinicalTrials.gov
NCT06461897 A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral … Phase3 Atopic Dermatitis Recruiting 2024-08-19 2030-07-01 ClinicalTrials.gov
NCT06461897 A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral … Phase3 Atopic Dermatitis Recruiting 2024-08-19 2030-07-01 ClinicalTrials.gov
NCT06461897 A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral … Phase3 Atopic Dermatitis Recruiting 2024-08-19 2030-07-01 ClinicalTrials.gov
NCT06461897 A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral … Phase3 Atopic Dermatitis Recruiting 2024-08-19 2030-07-01 ClinicalTrials.gov
NCT06524635 A Study to Assess Molecular Changes in Adult Participants With Moderate to Seve… Phase2 Hidradenitis Suppurativa Recruiting 2024-08-14 2027-02-01 ClinicalTrials.gov
NCT06524635 A Study to Assess Molecular Changes in Adult Participants With Moderate to Seve… Phase2 Hidradenitis Suppurativa Recruiting 2024-08-14 2027-02-01 ClinicalTrials.gov
NCT06524635 A Study to Assess Molecular Changes in Adult Participants With Moderate to Seve… Phase2 Hidradenitis Suppurativa Recruiting 2024-08-14 2027-02-01 ClinicalTrials.gov
NCT06524635 A Study to Assess Molecular Changes in Adult Participants With Moderate to Seve… Phase2 Hidradenitis Suppurativa Recruiting 2024-08-14 2027-02-01 ClinicalTrials.gov
NCT06508658 A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets C… Phase3 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2024-08-13 2028-03-01 ClinicalTrials.gov
NCT06508658 A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets C… Phase3 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2024-08-13 2028-03-01 ClinicalTrials.gov
NCT06508658 A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets C… Phase3 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2024-08-13 2028-03-01 ClinicalTrials.gov
NCT06508658 A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets C… Phase3 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2024-08-13 2028-03-01 ClinicalTrials.gov
NCT06332534 Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pedi… Phase3 Crohn's Disease Recruiting 2024-08-08 2034-12-01 ClinicalTrials.gov
NCT06332534 Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pedi… Phase3 Crohn's Disease Recruiting 2024-08-08 2034-12-01 ClinicalTrials.gov
NCT06332534 Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pedi… Phase3 Crohn's Disease Recruiting 2024-08-08 2034-12-01 ClinicalTrials.gov
NCT06332534 Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pedi… Phase3 Crohn's Disease Recruiting 2024-08-08 2034-12-01 ClinicalTrials.gov
NCT06503536 A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resourc… — Atopic Dermatitis (AD) Completed 2024-08-06 2024-10-31 ClinicalTrials.gov
NCT03938701 Fluorescence Imaging of IBD and RA Using Adalimumab-800CW Phase2 IBD Recruiting 2024-08-06 2026-08-01 ClinicalTrials.gov
NCT03938701 Fluorescence Imaging of IBD and RA Using Adalimumab-800CW Phase2 IBD Recruiting 2024-08-06 2026-08-01 ClinicalTrials.gov
NCT06503536 A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resourc… — Atopic Dermatitis (AD) Completed 2024-08-06 2024-10-31 ClinicalTrials.gov
NCT03938701 Fluorescence Imaging of IBD and RA Using Adalimumab-800CW Phase2 IBD Recruiting 2024-08-06 2026-08-01 ClinicalTrials.gov
NCT06503536 A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resourc… — Atopic Dermatitis (AD) Completed 2024-08-06 2024-10-31 ClinicalTrials.gov
NCT06503536 A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resourc… — Atopic Dermatitis (AD) Completed 2024-08-06 2024-10-31 ClinicalTrials.gov
NCT03938701 Fluorescence Imaging of IBD and RA Using Adalimumab-800CW Phase2 IBD Recruiting 2024-08-06 2026-08-01 ClinicalTrials.gov
NCT06428019 A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participant… Phase3 Chronic Lymphocytic Leukemia Recruiting 2024-08-05 2028-03-01 ClinicalTrials.gov
NCT06428019 A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participant… Phase3 Chronic Lymphocytic Leukemia Recruiting 2024-08-05 2028-03-01 ClinicalTrials.gov
NCT06428019 A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participant… Phase3 Chronic Lymphocytic Leukemia Recruiting 2024-08-05 2028-03-01 ClinicalTrials.gov
NCT06428019 A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participant… Phase3 Chronic Lymphocytic Leukemia Recruiting 2024-08-05 2028-03-01 ClinicalTrials.gov
NCT05894109 Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids Na Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin Withdrawn 2024-08-01 2024-10-01 ClinicalTrials.gov
NCT05894109 Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids Na Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin Withdrawn 2024-08-01 2024-10-01 ClinicalTrials.gov
NCT05894109 Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids Na Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin Withdrawn 2024-08-01 2024-10-01 ClinicalTrials.gov
NCT05894109 Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids Na Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin Withdrawn 2024-08-01 2024-10-01 ClinicalTrials.gov
NCT06365853 A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirv… Phase2 Recurrent Ovarian Cancer Recruiting 2024-07-29 2027-06-01 ClinicalTrials.gov
NCT06365853 A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirv… Phase2 Recurrent Ovarian Cancer Recruiting 2024-07-29 2027-06-01 ClinicalTrials.gov
NCT06365853 A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirv… Phase2 Recurrent Ovarian Cancer Recruiting 2024-07-29 2027-06-01 ClinicalTrials.gov
NCT06365853 A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirv… Phase2 Recurrent Ovarian Cancer Recruiting 2024-07-29 2027-06-01 ClinicalTrials.gov
NCT06487572 A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutane… Phase1 Healthy Volunteers Completed 2024-07-23 2025-02-07 ClinicalTrials.gov
NCT06487572 A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutane… Phase1 Healthy Volunteers Completed 2024-07-23 2025-02-07 ClinicalTrials.gov
NCT06487572 A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutane… Phase1 Healthy Volunteers Completed 2024-07-23 2025-02-07 ClinicalTrials.gov
NCT06487572 A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutane… Phase1 Healthy Volunteers Completed 2024-07-23 2025-02-07 ClinicalTrials.gov
NCT06547125 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JU… Phase2 Skin Quality Deficit Completed 2024-07-18 2026-02-05 ClinicalTrials.gov
NCT06547125 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JU… Phase2 Skin Quality Deficit Completed 2024-07-18 2026-02-05 ClinicalTrials.gov
NCT06547125 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JU… Phase2 Skin Quality Deficit Completed 2024-07-18 2026-02-05 ClinicalTrials.gov
NCT06547125 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JU… Phase2 Skin Quality Deficit Completed 2024-07-18 2026-02-05 ClinicalTrials.gov
NCT06477926 A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended… Phase1 Healthy Volunteers Completed 2024-07-09 2024-09-20 ClinicalTrials.gov
NCT06477926 A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended… Phase1 Healthy Volunteers Completed 2024-07-09 2024-09-20 ClinicalTrials.gov
NCT06477926 A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended… Phase1 Healthy Volunteers Completed 2024-07-09 2024-09-20 ClinicalTrials.gov
NCT06477926 A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended… Phase1 Healthy Volunteers Completed 2024-07-09 2024-09-20 ClinicalTrials.gov
NCT06100744 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug … Phase3 Juvenile Psoriatic Arthritis Recruiting 2024-07-08 2028-10-01 ClinicalTrials.gov
NCT06100744 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug … Phase3 Juvenile Psoriatic Arthritis Recruiting 2024-07-08 2028-10-01 ClinicalTrials.gov
NCT06100744 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug … Phase3 Juvenile Psoriatic Arthritis Recruiting 2024-07-08 2028-10-01 ClinicalTrials.gov
NCT06100744 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug … Phase3 Juvenile Psoriatic Arthritis Recruiting 2024-07-08 2028-10-01 ClinicalTrials.gov
NCT06468228 A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adole… Phase3 Hidradenitis Suppurativa Active_Not_Recruiting 2024-06-27 2026-12-01 ClinicalTrials.gov
NCT06468228 A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adole… Phase3 Hidradenitis Suppurativa Active_Not_Recruiting 2024-06-27 2026-12-01 ClinicalTrials.gov
NCT06468228 A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adole… Phase3 Hidradenitis Suppurativa Active_Not_Recruiting 2024-06-27 2026-12-01 ClinicalTrials.gov
NCT06468228 A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adole… Phase3 Hidradenitis Suppurativa Active_Not_Recruiting 2024-06-27 2026-12-01 ClinicalTrials.gov
NCT06402513 A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogen… Phase1 Healthy Volunteers Completed 2024-06-24 2024-10-08 ClinicalTrials.gov
NCT06402513 A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogen… Phase1 Healthy Volunteers Completed 2024-06-24 2024-10-08 ClinicalTrials.gov
NCT06459297 Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Eve… — Ulcerative Colitis Completed 2024-06-24 2025-12-09 ClinicalTrials.gov
NCT06459297 Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Eve… — Ulcerative Colitis Completed 2024-06-24 2025-12-09 ClinicalTrials.gov
NCT06402513 A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogen… Phase1 Healthy Volunteers Completed 2024-06-24 2024-10-08 ClinicalTrials.gov
NCT06459297 Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Eve… — Ulcerative Colitis Completed 2024-06-24 2025-12-09 ClinicalTrials.gov
NCT06459297 Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Eve… — Ulcerative Colitis Completed 2024-06-24 2025-12-09 ClinicalTrials.gov
NCT06402513 A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogen… Phase1 Healthy Volunteers Completed 2024-06-24 2024-10-08 ClinicalTrials.gov
NCT06223516 Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutane… Phase1 Multiple Myeloma Active_Not_Recruiting 2024-06-17 2027-12-01 ClinicalTrials.gov
NCT06439394 An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Qu… — Dry Eye Completed 2024-06-17 2024-07-18 ClinicalTrials.gov
NCT06443775 An Observational Study to Assess Next Generation Emulsion Preservative Free Eye… — Dry Eye Completed 2024-06-17 2024-10-14 ClinicalTrials.gov
NCT06443775 An Observational Study to Assess Next Generation Emulsion Preservative Free Eye… — Dry Eye Completed 2024-06-17 2024-10-14 ClinicalTrials.gov
NCT06223516 Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutane… Phase1 Multiple Myeloma Active_Not_Recruiting 2024-06-17 2027-12-01 ClinicalTrials.gov
NCT06439394 An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Qu… — Dry Eye Completed 2024-06-17 2024-07-18 ClinicalTrials.gov
NCT06439394 An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Qu… — Dry Eye Completed 2024-06-17 2024-07-18 ClinicalTrials.gov
NCT06223516 Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutane… Phase1 Multiple Myeloma Active_Not_Recruiting 2024-06-17 2027-12-01 ClinicalTrials.gov
NCT06443775 An Observational Study to Assess Next Generation Emulsion Preservative Free Eye… — Dry Eye Completed 2024-06-17 2024-10-14 ClinicalTrials.gov
NCT06223516 Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutane… Phase1 Multiple Myeloma Active_Not_Recruiting 2024-06-17 2027-12-01 ClinicalTrials.gov
NCT06443775 An Observational Study to Assess Next Generation Emulsion Preservative Free Eye… — Dry Eye Completed 2024-06-17 2024-10-14 ClinicalTrials.gov
NCT06439394 An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Qu… — Dry Eye Completed 2024-06-17 2024-07-18 ClinicalTrials.gov
NCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic De… Phase3 Atopic Dermatitis Recruiting 2024-06-14 2027-03-01 ClinicalTrials.gov
NCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic De… Phase3 Atopic Dermatitis Recruiting 2024-06-14 2027-03-01 ClinicalTrials.gov
NCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic De… Phase3 Atopic Dermatitis Recruiting 2024-06-14 2027-03-01 ClinicalTrials.gov
NCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic De… Phase3 Atopic Dermatitis Recruiting 2024-06-14 2027-03-01 ClinicalTrials.gov
NCT06421740 An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adol… — Atopic Dermatitis Recruiting 2024-06-07 2026-06-01 ClinicalTrials.gov
NCT06421740 An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adol… — Atopic Dermatitis Recruiting 2024-06-07 2026-06-01 ClinicalTrials.gov
NCT06421740 An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adol… — Atopic Dermatitis Recruiting 2024-06-07 2026-06-01 ClinicalTrials.gov
NCT06421740 An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adol… — Atopic Dermatitis Recruiting 2024-06-07 2026-06-01 ClinicalTrials.gov
NCT05796388 A Study of Virtual Reality and Linaclotide for IBS-C Na Irritable Bowel Syndrome With Constipation Recruiting 2024-05-31 2026-06-01 ClinicalTrials.gov
NCT06093503 Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standa… Phase3 Non-Small Cell Lung Cancer Withdrawn 2024-05-31 2028-04-11 ClinicalTrials.gov
NCT05796388 A Study of Virtual Reality and Linaclotide for IBS-C Na Irritable Bowel Syndrome With Constipation Recruiting 2024-05-31 2026-06-01 ClinicalTrials.gov
NCT05796388 A Study of Virtual Reality and Linaclotide for IBS-C Na Irritable Bowel Syndrome With Constipation Recruiting 2024-05-31 2026-06-01 ClinicalTrials.gov
NCT06093503 Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standa… Phase3 Non-Small Cell Lung Cancer Withdrawn 2024-05-31 2028-04-11 ClinicalTrials.gov
NCT05796388 A Study of Virtual Reality and Linaclotide for IBS-C Na Irritable Bowel Syndrome With Constipation Recruiting 2024-05-31 2026-06-01 ClinicalTrials.gov
NCT06093503 Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standa… Phase3 Non-Small Cell Lung Cancer Withdrawn 2024-05-31 2028-04-11 ClinicalTrials.gov
NCT06093503 Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standa… Phase3 Non-Small Cell Lung Cancer Withdrawn 2024-05-31 2028-04-11 ClinicalTrials.gov
NCT06390722 A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep… Phase3 Atopic Dermatitis Withdrawn 2024-05-23 2026-07-08 ClinicalTrials.gov
NCT06390722 A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep… Phase3 Atopic Dermatitis Withdrawn 2024-05-23 2026-07-08 ClinicalTrials.gov
NCT06390722 A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep… Phase3 Atopic Dermatitis Withdrawn 2024-05-23 2026-07-08 ClinicalTrials.gov
NCT06390722 A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep… Phase3 Atopic Dermatitis Withdrawn 2024-05-23 2026-07-08 ClinicalTrials.gov
NCT06425003 Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral D… Phase1 Healthy Volunteer Completed 2024-05-21 2024-07-12 ClinicalTrials.gov
NCT06425003 Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral D… Phase1 Healthy Volunteer Completed 2024-05-21 2024-07-12 ClinicalTrials.gov
NCT06425003 Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral D… Phase1 Healthy Volunteer Completed 2024-05-21 2024-07-12 ClinicalTrials.gov
NCT06425003 Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral D… Phase1 Healthy Volunteer Completed 2024-05-21 2024-07-12 ClinicalTrials.gov
NCT06158841 Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Stand… Phase3 Multiple Myeloma Recruiting 2024-05-19 2027-12-01 ClinicalTrials.gov
NCT06158841 Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Stand… Phase3 Multiple Myeloma Recruiting 2024-05-19 2027-12-01 ClinicalTrials.gov
NCT06158841 Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Stand… Phase3 Multiple Myeloma Recruiting 2024-05-19 2027-12-01 ClinicalTrials.gov
NCT06158841 Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Stand… Phase3 Multiple Myeloma Recruiting 2024-05-19 2027-12-01 ClinicalTrials.gov
NCT06414148 MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell… Phase2 Relapsed/Refractory Large B-cell Lymphoma Recruiting 2024-05-14 2028-05-01 ClinicalTrials.gov
NCT06414148 MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell… Phase2 Relapsed/Refractory Large B-cell Lymphoma Recruiting 2024-05-14 2028-05-01 ClinicalTrials.gov
NCT06414148 MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell… Phase2 Relapsed/Refractory Large B-cell Lymphoma Recruiting 2024-05-14 2028-05-01 ClinicalTrials.gov
NCT06414148 MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell… Phase2 Relapsed/Refractory Large B-cell Lymphoma Recruiting 2024-05-14 2028-05-01 ClinicalTrials.gov
NCT06414798 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 O… Phase1 Healthy Volunteers Completed 2024-05-13 2025-02-08 ClinicalTrials.gov
NCT06414798 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 O… Phase1 Healthy Volunteers Completed 2024-05-13 2025-02-08 ClinicalTrials.gov
NCT06414798 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 O… Phase1 Healthy Volunteers Completed 2024-05-13 2025-02-08 ClinicalTrials.gov
NCT06414798 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 O… Phase1 Healthy Volunteers Completed 2024-05-13 2025-02-08 ClinicalTrials.gov
NCT06333860 A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucra… Phase4 Moderate Plaque Psoriasis Completed 2024-05-10 2026-03-19 ClinicalTrials.gov
NCT06333860 A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucra… Phase4 Moderate Plaque Psoriasis Completed 2024-05-10 2026-03-19 ClinicalTrials.gov
NCT06333860 A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucra… Phase4 Moderate Plaque Psoriasis Completed 2024-05-10 2026-03-19 ClinicalTrials.gov
NCT06333860 A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucra… Phase4 Moderate Plaque Psoriasis Completed 2024-05-10 2026-03-19 ClinicalTrials.gov
NCT06406348 A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-175… Phase1 Alzheimer Disease Completed 2024-05-09 2025-04-22 ClinicalTrials.gov
NCT06406348 A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-175… Phase1 Alzheimer Disease Completed 2024-05-09 2025-04-22 ClinicalTrials.gov
NCT06406348 A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-175… Phase1 Alzheimer Disease Completed 2024-05-09 2025-04-22 ClinicalTrials.gov
NCT06406348 A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-175… Phase1 Alzheimer Disease Completed 2024-05-09 2025-04-22 ClinicalTrials.gov
NCT05606757 A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in P… Phase2 Ventral Hernia Withdrawn 2024-05-07 2025-09-26 ClinicalTrials.gov
NCT05606757 A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in P… Phase2 Ventral Hernia Withdrawn 2024-05-07 2025-09-26 ClinicalTrials.gov
NCT05606757 A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in P… Phase2 Ventral Hernia Withdrawn 2024-05-07 2025-09-26 ClinicalTrials.gov
NCT05606757 A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in P… Phase2 Ventral Hernia Withdrawn 2024-05-07 2025-09-26 ClinicalTrials.gov
NCT06399718 A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence… Phase3 Masseter Muscle Prominence Completed 2024-04-30 2025-11-10 ClinicalTrials.gov
NCT06399718 A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence… Phase3 Masseter Muscle Prominence Completed 2024-04-30 2025-11-10 ClinicalTrials.gov
NCT06399718 A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence… Phase3 Masseter Muscle Prominence Completed 2024-04-30 2025-11-10 ClinicalTrials.gov
NCT06399718 A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence… Phase3 Masseter Muscle Prominence Completed 2024-04-30 2025-11-10 ClinicalTrials.gov
NCT06247319 Study to Evaluate the Effectiveness of Risankizumab in Participants With a Rece… — Moderate Plaque Psoriasis Active_Not_Recruiting 2024-04-29 2027-10-01 ClinicalTrials.gov
NCT06247319 Study to Evaluate the Effectiveness of Risankizumab in Participants With a Rece… — Moderate Plaque Psoriasis Active_Not_Recruiting 2024-04-29 2027-10-01 ClinicalTrials.gov
NCT06247319 Study to Evaluate the Effectiveness of Risankizumab in Participants With a Rece… — Moderate Plaque Psoriasis Active_Not_Recruiting 2024-04-29 2027-10-01 ClinicalTrials.gov
NCT06247319 Study to Evaluate the Effectiveness of Risankizumab in Participants With a Rece… — Moderate Plaque Psoriasis Active_Not_Recruiting 2024-04-29 2027-10-01 ClinicalTrials.gov
NCT06345339 A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Sy… Phase2 Hypothyroidism Recruiting 2024-04-26 2028-06-01 ClinicalTrials.gov
NCT06345339 A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Sy… Phase2 Hypothyroidism Recruiting 2024-04-26 2028-06-01 ClinicalTrials.gov
NCT06345339 A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Sy… Phase2 Hypothyroidism Recruiting 2024-04-26 2028-06-01 ClinicalTrials.gov
NCT06345339 A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Sy… Phase2 Hypothyroidism Recruiting 2024-04-26 2028-06-01 ClinicalTrials.gov
NCT06346288 A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adul… Phase4 Inflammatory Bowel Disease Completed 2024-04-24 2026-02-05 ClinicalTrials.gov
NCT06346288 A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adul… Phase4 Inflammatory Bowel Disease Completed 2024-04-24 2026-02-05 ClinicalTrials.gov
NCT06346288 A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adul… Phase4 Inflammatory Bowel Disease Completed 2024-04-24 2026-02-05 ClinicalTrials.gov
NCT06346288 A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adul… Phase4 Inflammatory Bowel Disease Completed 2024-04-24 2026-02-05 ClinicalTrials.gov
NCT06387394 A Study to Assess BOTOX Injections in Adult Participants for the Change of Mass… Phase3 Masseter Muscle Prominence Completed 2024-04-22 2025-11-25 ClinicalTrials.gov
NCT06387394 A Study to Assess BOTOX Injections in Adult Participants for the Change of Mass… Phase3 Masseter Muscle Prominence Completed 2024-04-22 2025-11-25 ClinicalTrials.gov
NCT06387394 A Study to Assess BOTOX Injections in Adult Participants for the Change of Mass… Phase3 Masseter Muscle Prominence Completed 2024-04-22 2025-11-25 ClinicalTrials.gov
NCT06387394 A Study to Assess BOTOX Injections in Adult Participants for the Change of Mass… Phase3 Masseter Muscle Prominence Completed 2024-04-22 2025-11-25 ClinicalTrials.gov
NCT06256367 Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Ac… — Bipolar I Disorder Completed 2024-04-18 2026-01-23 ClinicalTrials.gov
NCT06256367 Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Ac… — Bipolar I Disorder Completed 2024-04-18 2026-01-23 ClinicalTrials.gov
NCT06256367 Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Ac… — Bipolar I Disorder Completed 2024-04-18 2026-01-23 ClinicalTrials.gov
NCT06256367 Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Ac… — Bipolar I Disorder Completed 2024-04-18 2026-01-23 ClinicalTrials.gov
NCT06236438 Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity,… Phase2 Non-Small Cell Lung Cancer Recruiting 2024-04-10 2031-10-01 ClinicalTrials.gov
NCT06236438 Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity,… Phase2 Non-Small Cell Lung Cancer Recruiting 2024-04-10 2031-10-01 ClinicalTrials.gov
NCT06236438 Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity,… Phase2 Non-Small Cell Lung Cancer Recruiting 2024-04-10 2031-10-01 ClinicalTrials.gov
NCT06236438 Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity,… Phase2 Non-Small Cell Lung Cancer Recruiting 2024-04-10 2031-10-01 ClinicalTrials.gov
NCT06773403 Upadacitinib for Prurigo Nodularis Phase4 Prurigo Nodularis Terminated 2024-04-09 2025-06-06 ClinicalTrials.gov
NCT06773403 Upadacitinib for Prurigo Nodularis Phase4 Prurigo Nodularis Terminated 2024-04-09 2025-06-06 ClinicalTrials.gov
NCT06773403 Upadacitinib for Prurigo Nodularis Phase4 Prurigo Nodularis Terminated 2024-04-09 2025-06-06 ClinicalTrials.gov
NCT06773403 Upadacitinib for Prurigo Nodularis Phase4 Prurigo Nodularis Terminated 2024-04-09 2025-06-06 ClinicalTrials.gov
NCT05904106 Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With… Phase2 Acute Myeloid Leukemia Recruiting 2024-04-07 2028-09-01 ClinicalTrials.gov
NCT05904106 Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With… Phase2 Acute Myeloid Leukemia Recruiting 2024-04-07 2028-09-01 ClinicalTrials.gov
NCT05904106 Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With… Phase2 Acute Myeloid Leukemia Recruiting 2024-04-07 2028-09-01 ClinicalTrials.gov
NCT05904106 Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With… Phase2 Acute Myeloid Leukemia Recruiting 2024-04-07 2028-09-01 ClinicalTrials.gov
NCT06158854 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult … Phase1 Immunoglobulin Light Chain (AL) Amyloidosis Recruiting 2024-04-01 2031-08-01 ClinicalTrials.gov
NCT06158854 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult … Phase1 Immunoglobulin Light Chain (AL) Amyloidosis Recruiting 2024-04-01 2031-08-01 ClinicalTrials.gov
NCT06158854 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult … Phase1 Immunoglobulin Light Chain (AL) Amyloidosis Recruiting 2024-04-01 2031-08-01 ClinicalTrials.gov
NCT06158854 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult … Phase1 Immunoglobulin Light Chain (AL) Amyloidosis Recruiting 2024-04-01 2031-08-01 ClinicalTrials.gov
NCT06247540 Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter… Phase2 Recurrent Transformed Chronic Lymphocytic Leukemia Withdrawn 2024-03-29 2031-12-29 ClinicalTrials.gov
NCT06308198 A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants f… Phase3 Glabellar Lines Completed 2024-03-29 2025-02-26 ClinicalTrials.gov
NCT06247540 Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter… Phase2 Recurrent Transformed Chronic Lymphocytic Leukemia Withdrawn 2024-03-29 2031-12-29 ClinicalTrials.gov
NCT06247540 Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter… Phase2 Recurrent Transformed Chronic Lymphocytic Leukemia Withdrawn 2024-03-29 2031-12-29 ClinicalTrials.gov
NCT06308198 A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants f… Phase3 Glabellar Lines Completed 2024-03-29 2025-02-26 ClinicalTrials.gov
NCT06247540 Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter… Phase2 Recurrent Transformed Chronic Lymphocytic Leukemia Withdrawn 2024-03-29 2031-12-29 ClinicalTrials.gov
NCT06308198 A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants f… Phase3 Glabellar Lines Completed 2024-03-29 2025-02-26 ClinicalTrials.gov
NCT06308198 A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants f… Phase3 Glabellar Lines Completed 2024-03-29 2025-02-26 ClinicalTrials.gov
NCT06119217 Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mP… Phase2 Pancreatic Cancer Completed 2024-03-25 2026-03-06 ClinicalTrials.gov
NCT06241313 Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Particip… Phase3 Migraine Active_Not_Recruiting 2024-03-25 2026-11-01 ClinicalTrials.gov
NCT06241313 Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Particip… Phase3 Migraine Active_Not_Recruiting 2024-03-25 2026-11-01 ClinicalTrials.gov
NCT06119217 Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mP… Phase2 Pancreatic Cancer Completed 2024-03-25 2026-03-06 ClinicalTrials.gov
NCT06119217 Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mP… Phase2 Pancreatic Cancer Completed 2024-03-25 2026-03-06 ClinicalTrials.gov
NCT06241313 Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Particip… Phase3 Migraine Active_Not_Recruiting 2024-03-25 2026-11-01 ClinicalTrials.gov
NCT06119217 Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mP… Phase2 Pancreatic Cancer Completed 2024-03-25 2026-03-06 ClinicalTrials.gov
NCT06241313 Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Particip… Phase3 Migraine Active_Not_Recruiting 2024-03-25 2026-11-01 ClinicalTrials.gov
NCT06257875 A Study to Assess Adverse Events and Change in Disease Activity From Intravenou… Phase2 Ulcerative Colitis Active_Not_Recruiting 2024-03-23 2027-09-01 ClinicalTrials.gov
NCT06257875 A Study to Assess Adverse Events and Change in Disease Activity From Intravenou… Phase2 Ulcerative Colitis Active_Not_Recruiting 2024-03-23 2027-09-01 ClinicalTrials.gov
NCT06257875 A Study to Assess Adverse Events and Change in Disease Activity From Intravenou… Phase2 Ulcerative Colitis Active_Not_Recruiting 2024-03-23 2027-09-01 ClinicalTrials.gov
NCT06257875 A Study to Assess Adverse Events and Change in Disease Activity From Intravenou… Phase2 Ulcerative Colitis Active_Not_Recruiting 2024-03-23 2027-09-01 ClinicalTrials.gov
NCT06310876 A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects Phase1 Healthy Completed 2024-03-14 2024-06-26 ClinicalTrials.gov
NCT06310876 A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects Phase1 Healthy Completed 2024-03-14 2024-06-26 ClinicalTrials.gov
NCT06310876 A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects Phase1 Healthy Completed 2024-03-14 2024-06-26 ClinicalTrials.gov
NCT06310876 A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects Phase1 Healthy Completed 2024-03-14 2024-06-26 ClinicalTrials.gov
NCT06318273 A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 M… Phase1 Metastatic Castration-Resistant Prostate Cancer Active_Not_Recruiting 2024-03-08 2027-05-01 ClinicalTrials.gov
NCT06318273 A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 M… Phase1 Metastatic Castration-Resistant Prostate Cancer Active_Not_Recruiting 2024-03-08 2027-05-01 ClinicalTrials.gov
NCT06318273 A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 M… Phase1 Metastatic Castration-Resistant Prostate Cancer Active_Not_Recruiting 2024-03-08 2027-05-01 ClinicalTrials.gov
NCT06318273 A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 M… Phase1 Metastatic Castration-Resistant Prostate Cancer Active_Not_Recruiting 2024-03-08 2027-05-01 ClinicalTrials.gov
NCT06058741 A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tabl… — Acute Myeloid Leukemia Active_Not_Recruiting 2024-03-04 2026-11-01 ClinicalTrials.gov
NCT06058741 A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tabl… — Acute Myeloid Leukemia Active_Not_Recruiting 2024-03-04 2026-11-01 ClinicalTrials.gov
NCT06058741 A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tabl… — Acute Myeloid Leukemia Active_Not_Recruiting 2024-03-04 2026-11-01 ClinicalTrials.gov
NCT06058741 A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tabl… — Acute Myeloid Leukemia Active_Not_Recruiting 2024-03-04 2026-11-01 ClinicalTrials.gov
NCT06278766 A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participan… Phase1 Healthy Volunteer Completed 2024-02-21 2024-04-19 ClinicalTrials.gov
NCT06278766 A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participan… Phase1 Healthy Volunteer Completed 2024-02-21 2024-04-19 ClinicalTrials.gov
NCT06278766 A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participan… Phase1 Healthy Volunteer Completed 2024-02-21 2024-04-19 ClinicalTrials.gov
NCT06278766 A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participan… Phase1 Healthy Volunteer Completed 2024-02-21 2024-04-19 ClinicalTrials.gov
NCT05930275 Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib … — Crohn's Disease Active_Not_Recruiting 2024-02-19 2028-09-01 ClinicalTrials.gov
NCT05930275 Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib … — Crohn's Disease Active_Not_Recruiting 2024-02-19 2028-09-01 ClinicalTrials.gov
NCT05930275 Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib … — Crohn's Disease Active_Not_Recruiting 2024-02-19 2028-09-01 ClinicalTrials.gov
NCT05930275 Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib … — Crohn's Disease Active_Not_Recruiting 2024-02-19 2028-09-01 ClinicalTrials.gov
NCT06158958 A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV… Phase1 Solid Tumors Terminated 2024-02-06 2025-10-22 ClinicalTrials.gov
NCT06158958 A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV… Phase1 Solid Tumors Terminated 2024-02-06 2025-10-22 ClinicalTrials.gov
NCT06158958 A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV… Phase1 Solid Tumors Terminated 2024-02-06 2025-10-22 ClinicalTrials.gov
NCT06158958 A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV… Phase1 Solid Tumors Terminated 2024-02-06 2025-10-22 ClinicalTrials.gov
NCT06218251 A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Adm… Phase4 Upper Facial Lines Completed 2024-02-05 2024-12-17 ClinicalTrials.gov
NCT06218251 A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Adm… Phase4 Upper Facial Lines Completed 2024-02-05 2024-12-17 ClinicalTrials.gov
NCT06218251 A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Adm… Phase4 Upper Facial Lines Completed 2024-02-05 2024-12-17 ClinicalTrials.gov
NCT06218251 A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Adm… Phase4 Upper Facial Lines Completed 2024-02-05 2024-12-17 ClinicalTrials.gov
NCT06477159 Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrin… Phase4 Exocrine Pancreatic Insufficiency Recruiting 2024-02-01 2027-12-31 ClinicalTrials.gov
NCT06477159 Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrin… Phase4 Exocrine Pancreatic Insufficiency Recruiting 2024-02-01 2027-12-31 ClinicalTrials.gov
NCT06477159 Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrin… Phase4 Exocrine Pancreatic Insufficiency Recruiting 2024-02-01 2027-12-31 ClinicalTrials.gov
NCT06477159 Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrin… Phase4 Exocrine Pancreatic Insufficiency Recruiting 2024-02-01 2027-12-31 ClinicalTrials.gov
NCT06148181 A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 M… Phase1 Healthy Volunteers Completed 2024-01-29 2024-12-30 ClinicalTrials.gov
NCT06148181 A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 M… Phase1 Healthy Volunteers Completed 2024-01-29 2024-12-30 ClinicalTrials.gov
NCT06148181 A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 M… Phase1 Healthy Volunteers Completed 2024-01-29 2024-12-30 ClinicalTrials.gov
NCT06148181 A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 M… Phase1 Healthy Volunteers Completed 2024-01-29 2024-12-30 ClinicalTrials.gov
NCT06107426 Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease … — Parkinson's Disease (PD) Active_Not_Recruiting 2024-01-24 2029-05-01 ClinicalTrials.gov
NCT06107426 Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease … — Parkinson's Disease (PD) Active_Not_Recruiting 2024-01-24 2029-05-01 ClinicalTrials.gov
NCT06107426 Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease … — Parkinson's Disease (PD) Active_Not_Recruiting 2024-01-24 2029-05-01 ClinicalTrials.gov
NCT06107426 Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease … — Parkinson's Disease (PD) Active_Not_Recruiting 2024-01-24 2029-05-01 ClinicalTrials.gov
NCT05956509 Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Chan… Phase1 Upper Limb Spasticity Terminated 2024-01-12 2024-06-02 ClinicalTrials.gov
NCT05956509 Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Chan… Phase1 Upper Limb Spasticity Terminated 2024-01-12 2024-06-02 ClinicalTrials.gov
NCT05956509 Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Chan… Phase1 Upper Limb Spasticity Terminated 2024-01-12 2024-06-02 ClinicalTrials.gov
NCT05956509 Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Chan… Phase1 Upper Limb Spasticity Terminated 2024-01-12 2024-06-02 ClinicalTrials.gov
NCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of L… Phase2 Hepatocellular Carcinoma Recruiting 2024-01-11 2030-09-01 ClinicalTrials.gov
NCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of L… Phase2 Hepatocellular Carcinoma Recruiting 2024-01-11 2030-09-01 ClinicalTrials.gov
NCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of L… Phase2 Hepatocellular Carcinoma Recruiting 2024-01-11 2030-09-01 ClinicalTrials.gov
NCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of L… Phase2 Hepatocellular Carcinoma Recruiting 2024-01-11 2030-09-01 ClinicalTrials.gov
NCT05821855 A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN4… Phase4 Open-angle Glaucoma Active_Not_Recruiting 2024-01-09 2030-07-01 ClinicalTrials.gov
NCT05821855 A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN4… Phase4 Open-angle Glaucoma Active_Not_Recruiting 2024-01-09 2030-07-01 ClinicalTrials.gov
NCT05821855 A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN4… Phase4 Open-angle Glaucoma Active_Not_Recruiting 2024-01-09 2030-07-01 ClinicalTrials.gov
NCT05821855 A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN4… Phase4 Open-angle Glaucoma Active_Not_Recruiting 2024-01-09 2030-07-01 ClinicalTrials.gov
NCT05486481 Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis… Phase1 AL Amyloidosis Withdrawn 2024-01-08 2028-12-31 ClinicalTrials.gov
NCT05486481 Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis… Phase1 AL Amyloidosis Withdrawn 2024-01-08 2028-12-31 ClinicalTrials.gov
NCT05486481 Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis… Phase1 AL Amyloidosis Withdrawn 2024-01-08 2028-12-31 ClinicalTrials.gov
NCT05486481 Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis… Phase1 AL Amyloidosis Withdrawn 2024-01-08 2028-12-31 ClinicalTrials.gov
NCT06151561 Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar … Phase1 Moderate to Severe Glabellar Lines Completed 2024-01-05 2024-04-03 ClinicalTrials.gov
NCT06151561 Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar … Phase1 Moderate to Severe Glabellar Lines Completed 2024-01-05 2024-04-03 ClinicalTrials.gov
NCT06151561 Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar … Phase1 Moderate to Severe Glabellar Lines Completed 2024-01-05 2024-04-03 ClinicalTrials.gov
NCT06151561 Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar … Phase1 Moderate to Severe Glabellar Lines Completed 2024-01-05 2024-04-03 ClinicalTrials.gov
NCT06058728 A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn C… — Uterine Fibroids (UF) Withdrawn 2023-12-20 2026-08-01 ClinicalTrials.gov
NCT06058728 A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn C… — Uterine Fibroids (UF) Withdrawn 2023-12-20 2026-08-01 ClinicalTrials.gov
NCT06058728 A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn C… — Uterine Fibroids (UF) Withdrawn 2023-12-20 2026-08-01 ClinicalTrials.gov
NCT06058728 A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn C… — Uterine Fibroids (UF) Withdrawn 2023-12-20 2026-08-01 ClinicalTrials.gov
NCT06118411 A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets… Phase3 Vitiligo Active_Not_Recruiting 2023-12-19 2028-03-01 ClinicalTrials.gov
NCT06145607 A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- C… Phase1 Healthy Completed 2023-12-19 2024-02-26 ClinicalTrials.gov
NCT06151535 A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel fo… Phase2 Skin Quality Deficit Completed 2023-12-19 2025-02-24 ClinicalTrials.gov
NCT06145607 A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- C… Phase1 Healthy Completed 2023-12-19 2024-02-26 ClinicalTrials.gov
NCT06145607 A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- C… Phase1 Healthy Completed 2023-12-19 2024-02-26 ClinicalTrials.gov
NCT06118411 A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets… Phase3 Vitiligo Active_Not_Recruiting 2023-12-19 2028-03-01 ClinicalTrials.gov
NCT06151535 A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel fo… Phase2 Skin Quality Deficit Completed 2023-12-19 2025-02-24 ClinicalTrials.gov
NCT06118411 A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets… Phase3 Vitiligo Active_Not_Recruiting 2023-12-19 2028-03-01 ClinicalTrials.gov
NCT06151535 A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel fo… Phase2 Skin Quality Deficit Completed 2023-12-19 2025-02-24 ClinicalTrials.gov
NCT06145607 A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- C… Phase1 Healthy Completed 2023-12-19 2024-02-26 ClinicalTrials.gov
NCT06151535 A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel fo… Phase2 Skin Quality Deficit Completed 2023-12-19 2025-02-24 ClinicalTrials.gov
NCT06118411 A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets… Phase3 Vitiligo Active_Not_Recruiting 2023-12-19 2028-03-01 ClinicalTrials.gov
NCT06034470 Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) fo… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2023-12-18 2029-05-31 ClinicalTrials.gov
NCT06034470 Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) fo… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2023-12-18 2029-05-31 ClinicalTrials.gov
NCT06034470 Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) fo… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2023-12-18 2029-05-31 ClinicalTrials.gov
NCT06034470 Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) fo… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2023-12-18 2029-05-31 ClinicalTrials.gov
NCT06174688 A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for … Phase3 Forehead Lines Completed 2023-12-12 2024-09-13 ClinicalTrials.gov
NCT06174688 A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for … Phase3 Forehead Lines Completed 2023-12-12 2024-09-13 ClinicalTrials.gov
NCT06174688 A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for … Phase3 Forehead Lines Completed 2023-12-12 2024-09-13 ClinicalTrials.gov
NCT06174688 A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for … Phase3 Forehead Lines Completed 2023-12-12 2024-09-13 ClinicalTrials.gov
NCT05995353 A Study to Assess Adverse Events, Change in Disease Activity, and How Intraveno… Phase3 Crohn's Disease Recruiting 2023-12-11 2029-04-01 ClinicalTrials.gov
NCT05995353 A Study to Assess Adverse Events, Change in Disease Activity, and How Intraveno… Phase3 Crohn's Disease Recruiting 2023-12-11 2029-04-01 ClinicalTrials.gov
NCT05995353 A Study to Assess Adverse Events, Change in Disease Activity, and How Intraveno… Phase3 Crohn's Disease Recruiting 2023-12-11 2029-04-01 ClinicalTrials.gov
NCT05995353 A Study to Assess Adverse Events, Change in Disease Activity, and How Intraveno… Phase3 Crohn's Disease Recruiting 2023-12-11 2029-04-01 ClinicalTrials.gov
NCT05782127 Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk M… Phase1 Untreated Myelodysplastic Syndrome Active_Not_Recruiting 2023-12-06 2028-11-01 ClinicalTrials.gov
NCT05782127 Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk M… Phase1 Untreated Myelodysplastic Syndrome Active_Not_Recruiting 2023-12-06 2028-11-01 ClinicalTrials.gov
NCT05782127 Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk M… Phase1 Untreated Myelodysplastic Syndrome Active_Not_Recruiting 2023-12-06 2028-11-01 ClinicalTrials.gov
NCT05782127 Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk M… Phase1 Untreated Myelodysplastic Syndrome Active_Not_Recruiting 2023-12-06 2028-11-01 ClinicalTrials.gov
NCT05956483 Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unip… — Bipolar I Disorder Completed 2023-12-04 2024-08-16 ClinicalTrials.gov
NCT05956483 Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unip… — Bipolar I Disorder Completed 2023-12-04 2024-08-16 ClinicalTrials.gov
NCT05956483 Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unip… — Bipolar I Disorder Completed 2023-12-04 2024-08-16 ClinicalTrials.gov
NCT05956483 Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unip… — Bipolar I Disorder Completed 2023-12-04 2024-08-16 ClinicalTrials.gov
NCT05916157 An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in… — Parkinson's Disease (PD) Active_Not_Recruiting 2023-11-30 2027-01-01 ClinicalTrials.gov
NCT05587049 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Recruiting 2023-11-30 2026-11-01 ClinicalTrials.gov
NCT05916157 An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in… — Parkinson's Disease (PD) Active_Not_Recruiting 2023-11-30 2027-01-01 ClinicalTrials.gov
NCT05916157 An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in… — Parkinson's Disease (PD) Active_Not_Recruiting 2023-11-30 2027-01-01 ClinicalTrials.gov
NCT05587049 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Recruiting 2023-11-30 2026-11-01 ClinicalTrials.gov
NCT05916157 An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in… — Parkinson's Disease (PD) Active_Not_Recruiting 2023-11-30 2027-01-01 ClinicalTrials.gov
NCT05587049 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Recruiting 2023-11-30 2026-11-01 ClinicalTrials.gov
NCT05587049 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Recruiting 2023-11-30 2026-11-01 ClinicalTrials.gov
NCT06144684 A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokin… Phase1 Healthy Volunteers Completed 2023-11-29 2026-01-05 ClinicalTrials.gov
NCT06144684 A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokin… Phase1 Healthy Volunteers Completed 2023-11-29 2026-01-05 ClinicalTrials.gov
NCT06144684 A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokin… Phase1 Healthy Volunteers Completed 2023-11-29 2026-01-05 ClinicalTrials.gov
NCT06144684 A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokin… Phase1 Healthy Volunteers Completed 2023-11-29 2026-01-05 ClinicalTrials.gov
NCT06137287 A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using… Phase3 Masseter Muscle Prominence Completed 2023-11-22 2025-07-31 ClinicalTrials.gov
NCT06137287 A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using… Phase3 Masseter Muscle Prominence Completed 2023-11-22 2025-07-31 ClinicalTrials.gov
NCT06137287 A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using… Phase3 Masseter Muscle Prominence Completed 2023-11-22 2025-07-31 ClinicalTrials.gov
NCT06137287 A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using… Phase3 Masseter Muscle Prominence Completed 2023-11-22 2025-07-31 ClinicalTrials.gov
NCT05995340 ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars Phase3 Atrophic Acne Scars Active_Not_Recruiting 2023-11-21 2026-08-01 ClinicalTrials.gov
NCT05995340 ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars Phase3 Atrophic Acne Scars Active_Not_Recruiting 2023-11-21 2026-08-01 ClinicalTrials.gov
NCT05995340 ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars Phase3 Atrophic Acne Scars Active_Not_Recruiting 2023-11-21 2026-08-01 ClinicalTrials.gov
NCT05995340 ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars Phase3 Atrophic Acne Scars Active_Not_Recruiting 2023-11-21 2026-08-01 ClinicalTrials.gov
NCT06054425 A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Ma… Phase1 Healthy Volunteers Completed 2023-11-20 2024-05-06 ClinicalTrials.gov
NCT06054425 A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Ma… Phase1 Healthy Volunteers Completed 2023-11-20 2024-05-06 ClinicalTrials.gov
NCT06054425 A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Ma… Phase1 Healthy Volunteers Completed 2023-11-20 2024-05-06 ClinicalTrials.gov
NCT06054425 A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Ma… Phase1 Healthy Volunteers Completed 2023-11-20 2024-05-06 ClinicalTrials.gov
NCT06063967 A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab… Phase3 Crohn's Disease Active_Not_Recruiting 2023-11-15 2027-03-01 ClinicalTrials.gov
NCT06063967 A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab… Phase3 Crohn's Disease Active_Not_Recruiting 2023-11-15 2027-03-01 ClinicalTrials.gov
NCT06063967 A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab… Phase3 Crohn's Disease Active_Not_Recruiting 2023-11-15 2027-03-01 ClinicalTrials.gov
NCT06063967 A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab… Phase3 Crohn's Disease Active_Not_Recruiting 2023-11-15 2027-03-01 ClinicalTrials.gov
NCT06068868 Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABB… Phase1 Acute Myeloid Leukemia Terminated 2023-11-13 2025-02-25 ClinicalTrials.gov
NCT06068868 Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABB… Phase1 Acute Myeloid Leukemia Terminated 2023-11-13 2025-02-25 ClinicalTrials.gov
NCT06068868 Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABB… Phase1 Acute Myeloid Leukemia Terminated 2023-11-13 2025-02-25 ClinicalTrials.gov
NCT06068868 Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABB… Phase1 Acute Myeloid Leukemia Terminated 2023-11-13 2025-02-25 ClinicalTrials.gov
NCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Tre… Phase2 Unresectable Metastatic Colorectal Cancer Active_Not_Recruiting 2023-11-12 2026-12-01 ClinicalTrials.gov
NCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Tre… Phase2 Unresectable Metastatic Colorectal Cancer Active_Not_Recruiting 2023-11-12 2026-12-01 ClinicalTrials.gov
NCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Tre… Phase2 Unresectable Metastatic Colorectal Cancer Active_Not_Recruiting 2023-11-12 2026-12-01 ClinicalTrials.gov
NCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Tre… Phase2 Unresectable Metastatic Colorectal Cancer Active_Not_Recruiting 2023-11-12 2026-12-01 ClinicalTrials.gov
NCT05959070 An Observational Study to Validate the Cumulative Life Course Impairment (CLCI)… — Psoriasis Completed 2023-11-09 2025-03-21 ClinicalTrials.gov
NCT06084481 Study to Assess Adverse Events and Change in Disease Activity in Adult Particip… Phase1 Hepatocellular Carcinoma Active_Not_Recruiting 2023-11-09 2026-07-01 ClinicalTrials.gov
NCT05959070 An Observational Study to Validate the Cumulative Life Course Impairment (CLCI)… — Psoriasis Completed 2023-11-09 2025-03-21 ClinicalTrials.gov
NCT05959070 An Observational Study to Validate the Cumulative Life Course Impairment (CLCI)… — Psoriasis Completed 2023-11-09 2025-03-21 ClinicalTrials.gov
NCT06084481 Study to Assess Adverse Events and Change in Disease Activity in Adult Particip… Phase1 Hepatocellular Carcinoma Active_Not_Recruiting 2023-11-09 2026-07-01 ClinicalTrials.gov
NCT05959070 An Observational Study to Validate the Cumulative Life Course Impairment (CLCI)… — Psoriasis Completed 2023-11-09 2025-03-21 ClinicalTrials.gov
NCT06084481 Study to Assess Adverse Events and Change in Disease Activity in Adult Particip… Phase1 Hepatocellular Carcinoma Active_Not_Recruiting 2023-11-09 2026-07-01 ClinicalTrials.gov
NCT06084481 Study to Assess Adverse Events and Change in Disease Activity in Adult Particip… Phase1 Hepatocellular Carcinoma Active_Not_Recruiting 2023-11-09 2026-07-01 ClinicalTrials.gov
NCT06125795 A Study to Assess Change in Functioning and Health Related Quality of Life in A… — Chronic Lymphocytic Leukemia Recruiting 2023-11-06 2026-07-01 ClinicalTrials.gov
NCT06125795 A Study to Assess Change in Functioning and Health Related Quality of Life in A… — Chronic Lymphocytic Leukemia Recruiting 2023-11-06 2026-07-01 ClinicalTrials.gov
NCT05782907 Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadac… Phase3 Ulcerative Colitis Active_Not_Recruiting 2023-11-06 2031-10-01 ClinicalTrials.gov
NCT06125795 A Study to Assess Change in Functioning and Health Related Quality of Life in A… — Chronic Lymphocytic Leukemia Recruiting 2023-11-06 2026-07-01 ClinicalTrials.gov
NCT05782907 Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadac… Phase3 Ulcerative Colitis Active_Not_Recruiting 2023-11-06 2031-10-01 ClinicalTrials.gov
NCT05782907 Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadac… Phase3 Ulcerative Colitis Active_Not_Recruiting 2023-11-06 2031-10-01 ClinicalTrials.gov
NCT06125795 A Study to Assess Change in Functioning and Health Related Quality of Life in A… — Chronic Lymphocytic Leukemia Recruiting 2023-11-06 2026-07-01 ClinicalTrials.gov
NCT05782907 Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadac… Phase3 Ulcerative Colitis Active_Not_Recruiting 2023-11-06 2031-10-01 ClinicalTrials.gov
NCT06068842 A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Part… — Non Small Cell Lung Cancer Completed 2023-11-03 2024-12-31 ClinicalTrials.gov
NCT06068842 A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Part… — Non Small Cell Lung Cancer Completed 2023-11-03 2024-12-31 ClinicalTrials.gov
NCT06068842 A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Part… — Non Small Cell Lung Cancer Completed 2023-11-03 2024-12-31 ClinicalTrials.gov
NCT06068842 A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Part… — Non Small Cell Lung Cancer Completed 2023-11-03 2024-12-31 ClinicalTrials.gov
NCT05978622 Observational Study of Adult Participants With Diabetic Macular Edema and Subop… — Diabetic Macular Edema Active_Not_Recruiting 2023-10-30 2026-06-01 ClinicalTrials.gov
NCT05978622 Observational Study of Adult Participants With Diabetic Macular Edema and Subop… — Diabetic Macular Edema Active_Not_Recruiting 2023-10-30 2026-06-01 ClinicalTrials.gov
NCT05978622 Observational Study of Adult Participants With Diabetic Macular Edema and Subop… — Diabetic Macular Edema Active_Not_Recruiting 2023-10-30 2026-06-01 ClinicalTrials.gov
NCT05978622 Observational Study of Adult Participants With Diabetic Macular Edema and Subop… — Diabetic Macular Edema Active_Not_Recruiting 2023-10-30 2026-06-01 ClinicalTrials.gov
NCT06126146 An Observational Study to Assess Participant-Reported Real-World Experience of … — Crohn's Disease Completed 2023-10-26 2024-05-16 ClinicalTrials.gov
NCT06126146 An Observational Study to Assess Participant-Reported Real-World Experience of … — Crohn's Disease Completed 2023-10-26 2024-05-16 ClinicalTrials.gov
NCT06126146 An Observational Study to Assess Participant-Reported Real-World Experience of … — Crohn's Disease Completed 2023-10-26 2024-05-16 ClinicalTrials.gov
NCT06126146 An Observational Study to Assess Participant-Reported Real-World Experience of … — Crohn's Disease Completed 2023-10-26 2024-05-16 ClinicalTrials.gov
NCT06332690 OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Impla… — Diabetic Macular Edema Unknown 2023-10-17 2025-12-01 ClinicalTrials.gov
NCT06332690 OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Impla… — Diabetic Macular Edema Unknown 2023-10-17 2025-12-01 ClinicalTrials.gov
NCT06332690 OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Impla… — Diabetic Macular Edema Unknown 2023-10-17 2025-12-01 ClinicalTrials.gov
NCT06068855 A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injection… Phase3 Masseter Muscle Prominence Completed 2023-10-17 2025-11-20 ClinicalTrials.gov
NCT06068855 A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injection… Phase3 Masseter Muscle Prominence Completed 2023-10-17 2025-11-20 ClinicalTrials.gov
NCT06068855 A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injection… Phase3 Masseter Muscle Prominence Completed 2023-10-17 2025-11-20 ClinicalTrials.gov
NCT06332690 OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Impla… — Diabetic Macular Edema Unknown 2023-10-17 2025-12-01 ClinicalTrials.gov
NCT06068855 A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injection… Phase3 Masseter Muscle Prominence Completed 2023-10-17 2025-11-20 ClinicalTrials.gov
NCT06032546 A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug … Phase2 Human Immuno-deficiency Virus (HIV) Disease Terminated 2023-10-12 2025-09-22 ClinicalTrials.gov
NCT06032546 A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug … Phase2 Human Immuno-deficiency Virus (HIV) Disease Terminated 2023-10-12 2025-09-22 ClinicalTrials.gov
NCT06032546 A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug … Phase2 Human Immuno-deficiency Virus (HIV) Disease Terminated 2023-10-12 2025-09-22 ClinicalTrials.gov
NCT06032546 A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug … Phase2 Human Immuno-deficiency Virus (HIV) Disease Terminated 2023-10-12 2025-09-22 ClinicalTrials.gov
NCT06012240 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adu… Phase3 Alopecia Areata Recruiting 2023-10-11 2030-04-01 ClinicalTrials.gov
NCT06012240 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adu… Phase3 Alopecia Areata Recruiting 2023-10-11 2030-04-01 ClinicalTrials.gov
NCT06012240 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adu… Phase3 Alopecia Areata Recruiting 2023-10-11 2030-04-01 ClinicalTrials.gov
NCT06012240 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adu… Phase3 Alopecia Areata Recruiting 2023-10-11 2030-04-01 ClinicalTrials.gov
NCT05748483 Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Ev… Phase3 Migraine Completed 2023-10-07 2026-06-02 ClinicalTrials.gov
NCT05748483 Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Ev… Phase3 Migraine Completed 2023-10-07 2026-06-02 ClinicalTrials.gov
NCT05748483 Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Ev… Phase3 Migraine Completed 2023-10-07 2026-06-02 ClinicalTrials.gov
NCT05748483 Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Ev… Phase3 Migraine Completed 2023-10-07 2026-06-02 ClinicalTrials.gov
NCT06070948 A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy F… Phase1 Healthy Volunteers Withdrawn 2023-10-05 2025-07-28 ClinicalTrials.gov
NCT06070948 A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy F… Phase1 Healthy Volunteers Withdrawn 2023-10-05 2025-07-28 ClinicalTrials.gov
NCT06070948 A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy F… Phase1 Healthy Volunteers Withdrawn 2023-10-05 2025-07-28 ClinicalTrials.gov
NCT06070948 A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy F… Phase1 Healthy Volunteers Withdrawn 2023-10-05 2025-07-28 ClinicalTrials.gov
NCT05768711 Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelo… Phase2 Chronic Myeloid Leukemia Active_Not_Recruiting 2023-10-04 2028-10-01 ClinicalTrials.gov
NCT05768711 Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelo… Phase2 Chronic Myeloid Leukemia Active_Not_Recruiting 2023-10-04 2028-10-01 ClinicalTrials.gov
NCT05768711 Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelo… Phase2 Chronic Myeloid Leukemia Active_Not_Recruiting 2023-10-04 2028-10-01 ClinicalTrials.gov
NCT05768711 Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelo… Phase2 Chronic Myeloid Leukemia Active_Not_Recruiting 2023-10-04 2028-10-01 ClinicalTrials.gov
NCT05887609 An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and … Phase2 Ovary Cancer Recruiting 2023-10-03 2031-01-31 ClinicalTrials.gov
NCT05887609 An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and … Phase2 Ovary Cancer Recruiting 2023-10-03 2031-01-31 ClinicalTrials.gov
NCT05887609 An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and … Phase2 Ovary Cancer Recruiting 2023-10-03 2031-01-31 ClinicalTrials.gov
NCT05887609 An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and … Phase2 Ovary Cancer Recruiting 2023-10-03 2031-01-31 ClinicalTrials.gov
NCT05609630 Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate… Phase3 Juvenile Idiopathic Arthritis Recruiting 2023-10-02 2029-06-01 ClinicalTrials.gov
NCT05609630 Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate… Phase3 Juvenile Idiopathic Arthritis Recruiting 2023-10-02 2029-06-01 ClinicalTrials.gov
NCT05609630 Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate… Phase3 Juvenile Idiopathic Arthritis Recruiting 2023-10-02 2029-06-01 ClinicalTrials.gov
NCT05609630 Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate… Phase3 Juvenile Idiopathic Arthritis Recruiting 2023-10-02 2029-06-01 ClinicalTrials.gov
NCT05990829 Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus W… Phase4 Diabetic Macular Edema Unknown 2023-10-01 2025-04-01 ClinicalTrials.gov
NCT05990829 Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus W… Phase4 Diabetic Macular Edema Unknown 2023-10-01 2025-04-01 ClinicalTrials.gov
NCT05990829 Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus W… Phase4 Diabetic Macular Edema Unknown 2023-10-01 2025-04-01 ClinicalTrials.gov
NCT05990829 Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus W… Phase4 Diabetic Macular Edema Unknown 2023-10-01 2025-04-01 ClinicalTrials.gov
NCT06067568 Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, … Phase1 Healthy Volunteers Completed 2023-09-28 2024-02-26 ClinicalTrials.gov
NCT06067568 Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, … Phase1 Healthy Volunteers Completed 2023-09-28 2024-02-26 ClinicalTrials.gov
NCT06067568 Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, … Phase1 Healthy Volunteers Completed 2023-09-28 2024-02-26 ClinicalTrials.gov
NCT06067568 Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, … Phase1 Healthy Volunteers Completed 2023-09-28 2024-02-26 ClinicalTrials.gov
NCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intraven… Phase2 Hepatocellular Carcinoma Active_Not_Recruiting 2023-09-21 2026-11-01 ClinicalTrials.gov
NCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intraven… Phase2 Hepatocellular Carcinoma Active_Not_Recruiting 2023-09-21 2026-11-01 ClinicalTrials.gov
NCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intraven… Phase2 Hepatocellular Carcinoma Active_Not_Recruiting 2023-09-21 2026-11-01 ClinicalTrials.gov
NCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intraven… Phase2 Hepatocellular Carcinoma Active_Not_Recruiting 2023-09-21 2026-11-01 ClinicalTrials.gov
NCT06150729 Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Dis… — Spasticity Completed 2023-09-08 2025-05-30 ClinicalTrials.gov
NCT06150729 Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Dis… — Spasticity Completed 2023-09-08 2025-05-30 ClinicalTrials.gov
NCT06150729 Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Dis… — Spasticity Completed 2023-09-08 2025-05-30 ClinicalTrials.gov
NCT06150729 Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Dis… — Spasticity Completed 2023-09-08 2025-05-30 ClinicalTrials.gov
NCT06018987 A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adu… Phase2 Nasolabial Folds Completed 2023-09-05 2025-02-03 ClinicalTrials.gov
NCT06018987 A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adu… Phase2 Nasolabial Folds Completed 2023-09-05 2025-02-03 ClinicalTrials.gov
NCT06018987 A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adu… Phase2 Nasolabial Folds Completed 2023-09-05 2025-02-03 ClinicalTrials.gov
NCT06018987 A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adu… Phase2 Nasolabial Folds Completed 2023-09-05 2025-02-03 ClinicalTrials.gov
NCT05701215 Venetoclax After TKI to Target Persisting Stem Cells in CML Phase2 Chronic Myeloid Leukemia Active_Not_Recruiting 2023-08-31 2026-01-31 ClinicalTrials.gov
NCT05701215 Venetoclax After TKI to Target Persisting Stem Cells in CML Phase2 Chronic Myeloid Leukemia Active_Not_Recruiting 2023-08-31 2026-01-31 ClinicalTrials.gov
NCT06024239 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 … Phase1 Healthy Volunteers Completed 2023-08-31 2025-03-04 ClinicalTrials.gov
NCT05701215 Venetoclax After TKI to Target Persisting Stem Cells in CML Phase2 Chronic Myeloid Leukemia Active_Not_Recruiting 2023-08-31 2026-01-31 ClinicalTrials.gov
NCT05701215 Venetoclax After TKI to Target Persisting Stem Cells in CML Phase2 Chronic Myeloid Leukemia Active_Not_Recruiting 2023-08-31 2026-01-31 ClinicalTrials.gov
NCT06024239 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 … Phase1 Healthy Volunteers Completed 2023-08-31 2025-03-04 ClinicalTrials.gov
NCT06024239 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 … Phase1 Healthy Volunteers Completed 2023-08-31 2025-03-04 ClinicalTrials.gov
NCT06024239 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 … Phase1 Healthy Volunteers Completed 2023-08-31 2025-03-04 ClinicalTrials.gov
NCT06009237 A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Hea… Phase1 Healthy Volunteers Terminated 2023-08-23 2023-10-30 ClinicalTrials.gov
NCT06009237 A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Hea… Phase1 Healthy Volunteers Terminated 2023-08-23 2023-10-30 ClinicalTrials.gov
NCT06009237 A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Hea… Phase1 Healthy Volunteers Terminated 2023-08-23 2023-10-30 ClinicalTrials.gov
NCT06009237 A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Hea… Phase1 Healthy Volunteers Terminated 2023-08-23 2023-10-30 ClinicalTrials.gov
NCT05995366 A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participan… Phase1 Healthy Volunteer Completed 2023-08-18 2023-10-13 ClinicalTrials.gov
NCT05959083 Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Chan… — Atopic Dermatitis (AD) Completed 2023-08-18 2026-05-07 ClinicalTrials.gov
NCT05959083 Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Chan… — Atopic Dermatitis (AD) Completed 2023-08-18 2026-05-07 ClinicalTrials.gov
NCT05995366 A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participan… Phase1 Healthy Volunteer Completed 2023-08-18 2023-10-13 ClinicalTrials.gov
NCT05995366 A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participan… Phase1 Healthy Volunteer Completed 2023-08-18 2023-10-13 ClinicalTrials.gov
NCT05959083 Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Chan… — Atopic Dermatitis (AD) Completed 2023-08-18 2026-05-07 ClinicalTrials.gov
NCT05995366 A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participan… Phase1 Healthy Volunteer Completed 2023-08-18 2023-10-13 ClinicalTrials.gov
NCT05959083 Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Chan… — Atopic Dermatitis (AD) Completed 2023-08-18 2026-05-07 ClinicalTrials.gov
NCT05969223 Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab… Phase4 Genital Psoriasis Completed 2023-08-10 2025-11-28 ClinicalTrials.gov
NCT05969223 Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab… Phase4 Genital Psoriasis Completed 2023-08-10 2025-11-28 ClinicalTrials.gov
NCT05969223 Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab… Phase4 Genital Psoriasis Completed 2023-08-10 2025-11-28 ClinicalTrials.gov
NCT05969223 Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab… Phase4 Genital Psoriasis Completed 2023-08-10 2025-11-28 ClinicalTrials.gov
NCT05941442 A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Particip… Phase2 Panic Disorder Completed 2023-07-31 2025-03-31 ClinicalTrials.gov
NCT05941442 A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Particip… Phase2 Panic Disorder Completed 2023-07-31 2025-03-31 ClinicalTrials.gov
NCT05941442 A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Particip… Phase2 Panic Disorder Completed 2023-07-31 2025-03-31 ClinicalTrials.gov
NCT05941442 A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Particip… Phase2 Panic Disorder Completed 2023-07-31 2025-03-31 ClinicalTrials.gov
NCT06023030 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Crohn's Disease Recruiting 2023-07-28 2027-05-01 ClinicalTrials.gov
NCT06023030 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Crohn's Disease Recruiting 2023-07-28 2027-05-01 ClinicalTrials.gov
NCT06023030 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Crohn's Disease Recruiting 2023-07-28 2027-05-01 ClinicalTrials.gov
NCT06023030 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Crohn's Disease Recruiting 2023-07-28 2027-05-01 ClinicalTrials.gov
NCT05955261 A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatri… Phase2 Acute Myeloid Leukemia Suspended 2023-07-25 2034-03-01 ClinicalTrials.gov
NCT05955261 A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatri… Phase2 Acute Myeloid Leukemia Suspended 2023-07-25 2034-03-01 ClinicalTrials.gov
NCT05843643 Program to Assess Adverse Events and Change in Disease Activity of Oral Upadaci… Phase3 Systemic Lupus Erythematosus Active_Not_Recruiting 2023-07-25 2027-10-01 ClinicalTrials.gov
NCT05843643 Program to Assess Adverse Events and Change in Disease Activity of Oral Upadaci… Phase3 Systemic Lupus Erythematosus Active_Not_Recruiting 2023-07-25 2027-10-01 ClinicalTrials.gov
NCT05843643 Program to Assess Adverse Events and Change in Disease Activity of Oral Upadaci… Phase3 Systemic Lupus Erythematosus Active_Not_Recruiting 2023-07-25 2027-10-01 ClinicalTrials.gov
NCT05843643 Program to Assess Adverse Events and Change in Disease Activity of Oral Upadaci… Phase3 Systemic Lupus Erythematosus Active_Not_Recruiting 2023-07-25 2027-10-01 ClinicalTrials.gov
NCT05955261 A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatri… Phase2 Acute Myeloid Leukemia Suspended 2023-07-25 2034-03-01 ClinicalTrials.gov
NCT05955261 A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatri… Phase2 Acute Myeloid Leukemia Suspended 2023-07-25 2034-03-01 ClinicalTrials.gov
NCT05940402 A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Particip… Phase1 Renal Impairment Completed 2023-07-24 2024-12-19 ClinicalTrials.gov
NCT05940402 A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Particip… Phase1 Renal Impairment Completed 2023-07-24 2024-12-19 ClinicalTrials.gov
NCT05940402 A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Particip… Phase1 Renal Impairment Completed 2023-07-24 2024-12-19 ClinicalTrials.gov
NCT05940402 A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Particip… Phase1 Renal Impairment Completed 2023-07-24 2024-12-19 ClinicalTrials.gov
NCT05861427 Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult J… Phase3 Migraine Completed 2023-07-12 2025-03-01 ClinicalTrials.gov
NCT05861427 Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult J… Phase3 Migraine Completed 2023-07-12 2025-03-01 ClinicalTrials.gov
NCT05861427 Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult J… Phase3 Migraine Completed 2023-07-12 2025-03-01 ClinicalTrials.gov
NCT05861427 Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult J… Phase3 Migraine Completed 2023-07-12 2025-03-01 ClinicalTrials.gov
NCT05892757 Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepa… Phase1 Healthy Volunteers Completed 2023-07-11 2024-02-22 ClinicalTrials.gov
NCT05892757 Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepa… Phase1 Healthy Volunteers Completed 2023-07-11 2024-02-22 ClinicalTrials.gov
NCT05892757 Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepa… Phase1 Healthy Volunteers Completed 2023-07-11 2024-02-22 ClinicalTrials.gov
NCT05892757 Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepa… Phase1 Healthy Volunteers Completed 2023-07-11 2024-02-22 ClinicalTrials.gov
NCT05935033 A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of… Phase1 Hepatic Impairment Completed 2023-06-30 2025-02-21 ClinicalTrials.gov
NCT05935033 A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of… Phase1 Hepatic Impairment Completed 2023-06-30 2025-02-21 ClinicalTrials.gov
NCT05935033 A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of… Phase1 Hepatic Impairment Completed 2023-06-30 2025-02-21 ClinicalTrials.gov
NCT05935033 A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of… Phase1 Hepatic Impairment Completed 2023-06-30 2025-02-21 ClinicalTrials.gov
NCT05878067 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in … Phase3 Dry Eye Syndrome Completed 2023-06-27 2023-10-06 ClinicalTrials.gov
NCT05878067 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in … Phase3 Dry Eye Syndrome Completed 2023-06-27 2023-10-06 ClinicalTrials.gov
NCT05878067 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in … Phase3 Dry Eye Syndrome Completed 2023-06-27 2023-10-06 ClinicalTrials.gov
NCT05878067 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in … Phase3 Dry Eye Syndrome Completed 2023-06-27 2023-10-06 ClinicalTrials.gov
NCT05827887 An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Tr… — Migraine Completed 2023-06-25 2026-01-28 ClinicalTrials.gov
NCT05827887 An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Tr… — Migraine Completed 2023-06-25 2026-01-28 ClinicalTrials.gov
NCT05827887 An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Tr… — Migraine Completed 2023-06-25 2026-01-28 ClinicalTrials.gov
NCT05827887 An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Tr… — Migraine Completed 2023-06-25 2026-01-28 ClinicalTrials.gov
NCT05895266 A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult… Phase1 Healthy Volunteer Completed 2023-06-23 2023-11-02 ClinicalTrials.gov
NCT05895266 A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult… Phase1 Healthy Volunteer Completed 2023-06-23 2023-11-02 ClinicalTrials.gov
NCT05895266 A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult… Phase1 Healthy Volunteer Completed 2023-06-23 2023-11-02 ClinicalTrials.gov
NCT05895266 A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult… Phase1 Healthy Volunteer Completed 2023-06-23 2023-11-02 ClinicalTrials.gov
NCT05889182 A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadaci… Phase3 Hidradenitis Suppurativa Recruiting 2023-06-21 2028-09-01 ClinicalTrials.gov
NCT05889182 A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadaci… Phase3 Hidradenitis Suppurativa Recruiting 2023-06-21 2028-09-01 ClinicalTrials.gov
NCT05889182 A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadaci… Phase3 Hidradenitis Suppurativa Recruiting 2023-06-21 2028-09-01 ClinicalTrials.gov
NCT05889182 A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadaci… Phase3 Hidradenitis Suppurativa Recruiting 2023-06-21 2028-09-01 ClinicalTrials.gov
NCT05909553 Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral… Phase1 Healthy Volunteers Completed 2023-06-15 2023-09-22 ClinicalTrials.gov
NCT05814627 Study to Assess Change in Disease Activity and Adverse Events of Oral Upadaciti… Phase3 Rheumatoid Arthritis Active_Not_Recruiting 2023-06-15 2026-07-01 ClinicalTrials.gov
NCT05814627 Study to Assess Change in Disease Activity and Adverse Events of Oral Upadaciti… Phase3 Rheumatoid Arthritis Active_Not_Recruiting 2023-06-15 2026-07-01 ClinicalTrials.gov
NCT05909553 Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral… Phase1 Healthy Volunteers Completed 2023-06-15 2023-09-22 ClinicalTrials.gov
NCT05909553 Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral… Phase1 Healthy Volunteers Completed 2023-06-15 2023-09-22 ClinicalTrials.gov
NCT05909553 Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral… Phase1 Healthy Volunteers Completed 2023-06-15 2023-09-22 ClinicalTrials.gov
NCT05814627 Study to Assess Change in Disease Activity and Adverse Events of Oral Upadaciti… Phase3 Rheumatoid Arthritis Active_Not_Recruiting 2023-06-15 2026-07-01 ClinicalTrials.gov
NCT05814627 Study to Assess Change in Disease Activity and Adverse Events of Oral Upadaciti… Phase3 Rheumatoid Arthritis Active_Not_Recruiting 2023-06-15 2026-07-01 ClinicalTrials.gov
NCT05818709 A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid… Phase3 Facial Volume Deficit Completed 2023-06-14 2025-12-05 ClinicalTrials.gov
NCT05818709 A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid… Phase3 Facial Volume Deficit Completed 2023-06-14 2025-12-05 ClinicalTrials.gov
NCT05818709 A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid… Phase3 Facial Volume Deficit Completed 2023-06-14 2025-12-05 ClinicalTrials.gov
NCT05818709 A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid… Phase3 Facial Volume Deficit Completed 2023-06-14 2025-12-05 ClinicalTrials.gov
NCT05938985 Croatian Version of the Ocular Surface Disease Index Questionnaire (OSDI) — Dry Eye Unknown 2023-06-12 2023-11-02 ClinicalTrials.gov
NCT05938985 Croatian Version of the Ocular Surface Disease Index Questionnaire (OSDI) — Dry Eye Unknown 2023-06-12 2023-11-02 ClinicalTrials.gov
NCT05938985 Croatian Version of the Ocular Surface Disease Index Questionnaire (OSDI) — Dry Eye Unknown 2023-06-12 2023-11-02 ClinicalTrials.gov
NCT05938985 Croatian Version of the Ocular Surface Disease Index Questionnaire (OSDI) — Dry Eye Unknown 2023-06-12 2023-11-02 ClinicalTrials.gov
NCT05841537 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Crohn's Disease Active_Not_Recruiting 2023-06-09 2028-07-01 ClinicalTrials.gov
NCT05753501 Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV… Phase1 Hematologic Cancer Active_Not_Recruiting 2023-06-09 2031-03-01 ClinicalTrials.gov
NCT05753501 Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV… Phase1 Hematologic Cancer Active_Not_Recruiting 2023-06-09 2031-03-01 ClinicalTrials.gov
NCT05841537 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Crohn's Disease Active_Not_Recruiting 2023-06-09 2028-07-01 ClinicalTrials.gov
NCT05841537 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Crohn's Disease Active_Not_Recruiting 2023-06-09 2028-07-01 ClinicalTrials.gov
NCT05753501 Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV… Phase1 Hematologic Cancer Active_Not_Recruiting 2023-06-09 2031-03-01 ClinicalTrials.gov
NCT05841537 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Crohn's Disease Active_Not_Recruiting 2023-06-09 2028-07-01 ClinicalTrials.gov
NCT05753501 Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV… Phase1 Hematologic Cancer Active_Not_Recruiting 2023-06-09 2031-03-01 ClinicalTrials.gov
NCT06362044 A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in … — Chronic Lymphocytic Leukemia Completed 2023-06-07 2024-12-31 ClinicalTrials.gov
NCT06362044 A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in … — Chronic Lymphocytic Leukemia Completed 2023-06-07 2024-12-31 ClinicalTrials.gov
NCT06362044 A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in … — Chronic Lymphocytic Leukemia Completed 2023-06-07 2024-12-31 ClinicalTrials.gov
NCT06362044 A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in … — Chronic Lymphocytic Leukemia Completed 2023-06-07 2024-12-31 ClinicalTrials.gov
NCT05707949 Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in… Phase3 Migraine Prophylaxis Enrolling_By_Invitation 2023-06-05 2032-04-01 ClinicalTrials.gov
NCT05707949 Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in… Phase3 Migraine Prophylaxis Enrolling_By_Invitation 2023-06-05 2032-04-01 ClinicalTrials.gov
NCT05771428 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-55… Phase2 Alzheimer's Disease (AD) Completed 2023-06-05 2024-09-12 ClinicalTrials.gov
NCT05771428 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-55… Phase2 Alzheimer's Disease (AD) Completed 2023-06-05 2024-09-12 ClinicalTrials.gov
NCT05707949 Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in… Phase3 Migraine Prophylaxis Enrolling_By_Invitation 2023-06-05 2032-04-01 ClinicalTrials.gov
NCT05771428 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-55… Phase2 Alzheimer's Disease (AD) Completed 2023-06-05 2024-09-12 ClinicalTrials.gov
NCT05707949 Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in… Phase3 Migraine Prophylaxis Enrolling_By_Invitation 2023-06-05 2032-04-01 ClinicalTrials.gov
NCT05771428 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-55… Phase2 Alzheimer's Disease (AD) Completed 2023-06-05 2024-09-12 ClinicalTrials.gov
NCT06362031 A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource … — Acute Myeloid Leukemia Withdrawn 2023-06-01 2024-04-30 ClinicalTrials.gov
NCT06362031 A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource … — Acute Myeloid Leukemia Withdrawn 2023-06-01 2024-04-30 ClinicalTrials.gov
NCT06362031 A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource … — Acute Myeloid Leukemia Withdrawn 2023-06-01 2024-04-30 ClinicalTrials.gov
NCT06362031 A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource … — Acute Myeloid Leukemia Withdrawn 2023-06-01 2024-04-30 ClinicalTrials.gov
NCT05630885 A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammati… Phase2 HIV-1-infection Completed 2023-05-30 2024-06-19 ClinicalTrials.gov
NCT05630885 A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammati… Phase2 HIV-1-infection Completed 2023-05-30 2024-06-19 ClinicalTrials.gov
NCT05630885 A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammati… Phase2 HIV-1-infection Completed 2023-05-30 2024-06-19 ClinicalTrials.gov
NCT05630885 A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammati… Phase2 HIV-1-infection Completed 2023-05-30 2024-06-19 ClinicalTrials.gov
NCT05507580 A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib T… Phase4 Atopic Dermatitis Completed 2023-05-29 2024-08-15 ClinicalTrials.gov
NCT05507580 A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib T… Phase4 Atopic Dermatitis Completed 2023-05-29 2024-08-15 ClinicalTrials.gov
NCT05507580 A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib T… Phase4 Atopic Dermatitis Completed 2023-05-29 2024-08-15 ClinicalTrials.gov
NCT05507580 A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib T… Phase4 Atopic Dermatitis Completed 2023-05-29 2024-08-15 ClinicalTrials.gov
NCT05833438 Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, No… Phase2 Acute Myeloid Leukemia (AML) Recruiting 2023-05-17 2025-07-01 ClinicalTrials.gov
NCT05833438 Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, No… Phase2 Acute Myeloid Leukemia (AML) Recruiting 2023-05-17 2025-07-01 ClinicalTrials.gov
NCT05833438 Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, No… Phase2 Acute Myeloid Leukemia (AML) Recruiting 2023-05-17 2025-07-01 ClinicalTrials.gov
NCT05833438 Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, No… Phase2 Acute Myeloid Leukemia (AML) Recruiting 2023-05-17 2025-07-01 ClinicalTrials.gov
NCT05711394 A Study to Assess the Adverse Events and Change in Disease Activity of Oral Ato… Phase3 Episodic Migraine Recruiting 2023-05-01 2028-05-01 ClinicalTrials.gov
NCT05711394 A Study to Assess the Adverse Events and Change in Disease Activity of Oral Ato… Phase3 Episodic Migraine Recruiting 2023-05-01 2028-05-01 ClinicalTrials.gov
NCT05711394 A Study to Assess the Adverse Events and Change in Disease Activity of Oral Ato… Phase3 Episodic Migraine Recruiting 2023-05-01 2028-05-01 ClinicalTrials.gov
NCT05711394 A Study to Assess the Adverse Events and Change in Disease Activity of Oral Ato… Phase3 Episodic Migraine Recruiting 2023-05-01 2028-05-01 ClinicalTrials.gov
NCT05760313 A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Pa… Phase2 Functional Constipation Completed 2023-04-27 2025-06-09 ClinicalTrials.gov
NCT05760313 A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Pa… Phase2 Functional Constipation Completed 2023-04-27 2025-06-09 ClinicalTrials.gov
NCT05760313 A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Pa… Phase2 Functional Constipation Completed 2023-04-27 2025-06-09 ClinicalTrials.gov
NCT05760313 A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Pa… Phase2 Functional Constipation Completed 2023-04-27 2025-06-09 ClinicalTrials.gov
NCT05512390 A Study to Assess the Adverse Events, Change in Disease Activity, and How Intra… Phase1 Diffuse Large B-Cell Lymphoma Recruiting 2023-04-26 2027-02-01 ClinicalTrials.gov
NCT05512390 A Study to Assess the Adverse Events, Change in Disease Activity, and How Intra… Phase1 Diffuse Large B-Cell Lymphoma Recruiting 2023-04-26 2027-02-01 ClinicalTrials.gov
NCT05512390 A Study to Assess the Adverse Events, Change in Disease Activity, and How Intra… Phase1 Diffuse Large B-Cell Lymphoma Recruiting 2023-04-26 2027-02-01 ClinicalTrials.gov
NCT05512390 A Study to Assess the Adverse Events, Change in Disease Activity, and How Intra… Phase1 Diffuse Large B-Cell Lymphoma Recruiting 2023-04-26 2027-02-01 ClinicalTrials.gov
NCT05785715 Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to… Phase2 Ulcerative Colitis Terminated 2023-04-24 2025-05-30 ClinicalTrials.gov
NCT05785715 Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to… Phase2 Ulcerative Colitis Terminated 2023-04-24 2025-05-30 ClinicalTrials.gov
NCT05785715 Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to… Phase2 Ulcerative Colitis Terminated 2023-04-24 2025-05-30 ClinicalTrials.gov
NCT05785715 Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to… Phase2 Ulcerative Colitis Terminated 2023-04-24 2025-05-30 ClinicalTrials.gov
NCT05836506 A Study to Assess the Relative Bioavailability of Immediate Release Formulation… Phase1 Healthy Volunteer Completed 2023-04-18 2023-06-20 ClinicalTrials.gov
NCT05836506 A Study to Assess the Relative Bioavailability of Immediate Release Formulation… Phase1 Healthy Volunteer Completed 2023-04-18 2023-06-20 ClinicalTrials.gov
NCT05836506 A Study to Assess the Relative Bioavailability of Immediate Release Formulation… Phase1 Healthy Volunteer Completed 2023-04-18 2023-06-20 ClinicalTrials.gov
NCT05836506 A Study to Assess the Relative Bioavailability of Immediate Release Formulation… Phase1 Healthy Volunteer Completed 2023-04-18 2023-06-20 ClinicalTrials.gov
NCT05741034 A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE… Phase3 Neck Lines Completed 2023-04-07 2024-12-09 ClinicalTrials.gov
NCT05741034 A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE… Phase3 Neck Lines Completed 2023-04-07 2024-12-09 ClinicalTrials.gov
NCT05741034 A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE… Phase3 Neck Lines Completed 2023-04-07 2024-12-09 ClinicalTrials.gov
NCT05741034 A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE… Phase3 Neck Lines Completed 2023-04-07 2024-12-09 ClinicalTrials.gov
NCT05618028 Study to Evaluate Adverse Events and Change in Disease Activity in Adult Partic… Phase1 Diffuse Large B-Cell Lymphoma Recruiting 2023-04-04 2029-07-01 ClinicalTrials.gov
NCT05618028 Study to Evaluate Adverse Events and Change in Disease Activity in Adult Partic… Phase1 Diffuse Large B-Cell Lymphoma Recruiting 2023-04-04 2029-07-01 ClinicalTrials.gov
NCT05618028 Study to Evaluate Adverse Events and Change in Disease Activity in Adult Partic… Phase1 Diffuse Large B-Cell Lymphoma Recruiting 2023-04-04 2029-07-01 ClinicalTrials.gov
NCT05618028 Study to Evaluate Adverse Events and Change in Disease Activity in Adult Partic… Phase1 Diffuse Large B-Cell Lymphoma Recruiting 2023-04-04 2029-07-01 ClinicalTrials.gov
NCT05292664 Venetoclax Basket Trial for High Risk Hematologic Malignancies Phase1 Myelodysplastic Syndromes, de Novo Recruiting 2023-03-29 2030-07-02 ClinicalTrials.gov
NCT05292664 Venetoclax Basket Trial for High Risk Hematologic Malignancies Phase1 Myelodysplastic Syndromes, de Novo Recruiting 2023-03-29 2030-07-02 ClinicalTrials.gov
NCT05292664 Venetoclax Basket Trial for High Risk Hematologic Malignancies Phase1 Myelodysplastic Syndromes, de Novo Recruiting 2023-03-29 2030-07-02 ClinicalTrials.gov
NCT05292664 Venetoclax Basket Trial for High Risk Hematologic Malignancies Phase1 Myelodysplastic Syndromes, de Novo Recruiting 2023-03-29 2030-07-02 ClinicalTrials.gov
NCT05763459 A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects Phase1 Healthy Completed 2023-03-24 2023-06-02 ClinicalTrials.gov
NCT05763459 A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects Phase1 Healthy Completed 2023-03-24 2023-06-02 ClinicalTrials.gov
NCT05763459 A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects Phase1 Healthy Completed 2023-03-24 2023-06-02 ClinicalTrials.gov
NCT05763459 A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects Phase1 Healthy Completed 2023-03-24 2023-06-02 ClinicalTrials.gov
NCT05650632 A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-… Phase1 Multiple Myeloma Recruiting 2023-03-21 2029-08-01 ClinicalTrials.gov
NCT05650632 A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-… Phase1 Multiple Myeloma Recruiting 2023-03-21 2029-08-01 ClinicalTrials.gov
NCT05650632 A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-… Phase1 Multiple Myeloma Recruiting 2023-03-21 2029-08-01 ClinicalTrials.gov
NCT05650632 A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-… Phase1 Multiple Myeloma Recruiting 2023-03-21 2029-08-01 ClinicalTrials.gov
NCT05570006 Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease … Phase2 Ulcerative Colitis Completed 2023-03-16 2024-12-23 ClinicalTrials.gov
NCT05570006 Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease … Phase2 Ulcerative Colitis Completed 2023-03-16 2024-12-23 ClinicalTrials.gov
NCT05570006 Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease … Phase2 Ulcerative Colitis Completed 2023-03-16 2024-12-23 ClinicalTrials.gov
NCT05570006 Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease … Phase2 Ulcerative Colitis Completed 2023-03-16 2024-12-23 ClinicalTrials.gov
NCT05445778 Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in… Phase3 Ovarian Cancer Active_Not_Recruiting 2023-03-15 2032-05-01 ClinicalTrials.gov
NCT05445778 Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in… Phase3 Ovarian Cancer Active_Not_Recruiting 2023-03-15 2032-05-01 ClinicalTrials.gov
NCT05445778 Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in… Phase3 Ovarian Cancer Active_Not_Recruiting 2023-03-15 2032-05-01 ClinicalTrials.gov
NCT05445778 Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in… Phase3 Ovarian Cancer Active_Not_Recruiting 2023-03-15 2032-05-01 ClinicalTrials.gov
NCT05605756 BOTOX Effects on Seizure Severity and Susceptibility Phase4 Drug-resistant Focal Seizure Terminated 2023-03-01 2024-12-01 ClinicalTrials.gov
NCT05605756 BOTOX Effects on Seizure Severity and Susceptibility Phase4 Drug-resistant Focal Seizure Terminated 2023-03-01 2024-12-01 ClinicalTrials.gov
NCT05605756 BOTOX Effects on Seizure Severity and Susceptibility Phase4 Drug-resistant Focal Seizure Terminated 2023-03-01 2024-12-01 ClinicalTrials.gov
NCT05605756 BOTOX Effects on Seizure Severity and Susceptibility Phase4 Drug-resistant Focal Seizure Terminated 2023-03-01 2024-12-01 ClinicalTrials.gov
NCT05669794 An Observational Study to Assess Change in Disease Activity and Use of Upadacit… — Atopic Dermatitis Active_Not_Recruiting 2023-02-21 2027-02-01 ClinicalTrials.gov
NCT05669794 An Observational Study to Assess Change in Disease Activity and Use of Upadacit… — Atopic Dermatitis Active_Not_Recruiting 2023-02-21 2027-02-01 ClinicalTrials.gov
NCT05669794 An Observational Study to Assess Change in Disease Activity and Use of Upadacit… — Atopic Dermatitis Active_Not_Recruiting 2023-02-21 2027-02-01 ClinicalTrials.gov
NCT05669794 An Observational Study to Assess Change in Disease Activity and Use of Upadacit… — Atopic Dermatitis Active_Not_Recruiting 2023-02-21 2027-02-01 ClinicalTrials.gov
NCT05738850 Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the… Phase1 Generalized Anxiety Disorder (GAD) Completed 2023-02-15 2024-05-31 ClinicalTrials.gov
NCT05738850 Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the… Phase1 Generalized Anxiety Disorder (GAD) Completed 2023-02-15 2024-05-31 ClinicalTrials.gov
NCT05738850 Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the… Phase1 Generalized Anxiety Disorder (GAD) Completed 2023-02-15 2024-05-31 ClinicalTrials.gov
NCT05738850 Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the… Phase1 Generalized Anxiety Disorder (GAD) Completed 2023-02-15 2024-05-31 ClinicalTrials.gov
NCT05555953 Effect of Long-term Psoriasis on Patients' Life - CORONATE — Psoriasis Completed 2023-01-26 2024-10-17 ClinicalTrials.gov
NCT05555953 Effect of Long-term Psoriasis on Patients' Life - CORONATE — Psoriasis Completed 2023-01-26 2024-10-17 ClinicalTrials.gov
NCT05555953 Effect of Long-term Psoriasis on Patients' Life - CORONATE — Psoriasis Completed 2023-01-26 2024-10-17 ClinicalTrials.gov
NCT05555953 Effect of Long-term Psoriasis on Patients' Life - CORONATE — Psoriasis Completed 2023-01-26 2024-10-17 ClinicalTrials.gov
NCT05686980 A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Throu… Phase1 Healthy Volunteers Completed 2023-01-17 2023-03-30 ClinicalTrials.gov
NCT05686980 A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Throu… Phase1 Healthy Volunteers Completed 2023-01-17 2023-03-30 ClinicalTrials.gov
NCT05686980 A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Throu… Phase1 Healthy Volunteers Completed 2023-01-17 2023-03-30 ClinicalTrials.gov
NCT05686980 A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Throu… Phase1 Healthy Volunteers Completed 2023-01-17 2023-03-30 ClinicalTrials.gov
NCT05564650 Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome Phase1 Myelodysplastic Syndrome Completed 2023-01-12 2026-05-08 ClinicalTrials.gov
NCT05564650 Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome Phase1 Myelodysplastic Syndrome Completed 2023-01-12 2026-05-08 ClinicalTrials.gov
NCT05564650 Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome Phase1 Myelodysplastic Syndrome Completed 2023-01-12 2026-05-08 ClinicalTrials.gov
NCT05564650 Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome Phase1 Myelodysplastic Syndrome Completed 2023-01-12 2026-05-08 ClinicalTrials.gov
NCT05527184 First in Human Study of IMGN151 in Recurrent Gynaecological Cancers Phase1 Endometrial Cancer Active_Not_Recruiting 2023-01-11 2027-02-01 ClinicalTrials.gov
NCT05527184 First in Human Study of IMGN151 in Recurrent Gynaecological Cancers Phase1 Endometrial Cancer Active_Not_Recruiting 2023-01-11 2027-02-01 ClinicalTrials.gov
NCT05527184 First in Human Study of IMGN151 in Recurrent Gynaecological Cancers Phase1 Endometrial Cancer Active_Not_Recruiting 2023-01-11 2027-02-01 ClinicalTrials.gov
NCT05527184 First in Human Study of IMGN151 in Recurrent Gynaecological Cancers Phase1 Endometrial Cancer Active_Not_Recruiting 2023-01-11 2027-02-01 ClinicalTrials.gov
NCT05158894 Observational Study to Assess Adverse Events When Adult Female Participants Are… — Migraine Recruiting 2023-01-10 2036-01-01 ClinicalTrials.gov
NCT05158894 Observational Study to Assess Adverse Events When Adult Female Participants Are… — Migraine Recruiting 2023-01-10 2036-01-01 ClinicalTrials.gov
NCT05158894 Observational Study to Assess Adverse Events When Adult Female Participants Are… — Migraine Recruiting 2023-01-10 2036-01-01 ClinicalTrials.gov
NCT05158894 Observational Study to Assess Adverse Events When Adult Female Participants Are… — Migraine Recruiting 2023-01-10 2036-01-01 ClinicalTrials.gov
NCT05647551 A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of t… Phase4 Facial Corrections Completed 2023-01-05 2023-10-05 ClinicalTrials.gov
NCT05647551 A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of t… Phase4 Facial Corrections Completed 2023-01-05 2023-10-05 ClinicalTrials.gov
NCT05647551 A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of t… Phase4 Facial Corrections Completed 2023-01-05 2023-10-05 ClinicalTrials.gov
NCT05647551 A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of t… Phase4 Facial Corrections Completed 2023-01-05 2023-10-05 ClinicalTrials.gov
NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of A… Phase2 Alzheimer's Disease Terminated 2023-01-04 2025-02-05 ClinicalTrials.gov
NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of A… Phase2 Alzheimer's Disease Terminated 2023-01-04 2025-02-05 ClinicalTrials.gov
NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of A… Phase2 Alzheimer's Disease Terminated 2023-01-04 2025-02-05 ClinicalTrials.gov
NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of A… Phase2 Alzheimer's Disease Terminated 2023-01-04 2025-02-05 ClinicalTrials.gov
NCT05691699 A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of… Phase1 Healthy Volunteer Completed 2023-01-03 2023-10-23 ClinicalTrials.gov
NCT05691699 A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of… Phase1 Healthy Volunteer Completed 2023-01-03 2023-10-23 ClinicalTrials.gov
NCT05691699 A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of… Phase1 Healthy Volunteer Completed 2023-01-03 2023-10-23 ClinicalTrials.gov
NCT05691699 A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of… Phase1 Healthy Volunteer Completed 2023-01-03 2023-10-23 ClinicalTrials.gov
NCT05652205 A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus… Phase3 Functional Constipation (FC) Completed 2022-12-29 2025-09-02 ClinicalTrials.gov
NCT05652205 A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus… Phase3 Functional Constipation (FC) Completed 2022-12-29 2025-09-02 ClinicalTrials.gov
NCT05652205 A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus… Phase3 Functional Constipation (FC) Completed 2022-12-29 2025-09-02 ClinicalTrials.gov
NCT05652205 A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus… Phase3 Functional Constipation (FC) Completed 2022-12-29 2025-09-02 ClinicalTrials.gov
NCT05791526 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Ulcerative Colitis Completed 2022-12-19 2025-12-09 ClinicalTrials.gov
NCT05791526 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Ulcerative Colitis Completed 2022-12-19 2025-12-09 ClinicalTrials.gov
NCT05791526 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Ulcerative Colitis Completed 2022-12-19 2025-12-09 ClinicalTrials.gov
NCT05791526 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Ulcerative Colitis Completed 2022-12-19 2025-12-09 ClinicalTrials.gov
NCT05653986 An Observational Study to Assess Change in Disease Activity When Ubrogepant Tab… — Migraine Completed 2022-12-18 2024-08-05 ClinicalTrials.gov
NCT05653986 An Observational Study to Assess Change in Disease Activity When Ubrogepant Tab… — Migraine Completed 2022-12-18 2024-08-05 ClinicalTrials.gov
NCT05653986 An Observational Study to Assess Change in Disease Activity When Ubrogepant Tab… — Migraine Completed 2022-12-18 2024-08-05 ClinicalTrials.gov
NCT05653986 An Observational Study to Assess Change in Disease Activity When Ubrogepant Tab… — Migraine Completed 2022-12-18 2024-08-05 ClinicalTrials.gov
NCT05616871 An Observational Study to Assess Change in Disease Activity and Treatment Patte… — Psoriatic Arthritis Active_Not_Recruiting 2022-12-15 2027-07-01 ClinicalTrials.gov
NCT05616871 An Observational Study to Assess Change in Disease Activity and Treatment Patte… — Psoriatic Arthritis Active_Not_Recruiting 2022-12-15 2027-07-01 ClinicalTrials.gov
NCT05616871 An Observational Study to Assess Change in Disease Activity and Treatment Patte… — Psoriatic Arthritis Active_Not_Recruiting 2022-12-15 2027-07-01 ClinicalTrials.gov
NCT05616871 An Observational Study to Assess Change in Disease Activity and Treatment Patte… — Psoriatic Arthritis Active_Not_Recruiting 2022-12-15 2027-07-01 ClinicalTrials.gov
NCT05555979 A Study to Assess Change in Patient Experience in Adult Participants With Chron… — Chronic Lymphocytic Leukemia Completed 2022-12-14 2024-04-10 ClinicalTrials.gov
NCT05555979 A Study to Assess Change in Patient Experience in Adult Participants With Chron… — Chronic Lymphocytic Leukemia Completed 2022-12-14 2024-04-10 ClinicalTrials.gov
NCT05555979 A Study to Assess Change in Patient Experience in Adult Participants With Chron… — Chronic Lymphocytic Leukemia Completed 2022-12-14 2024-04-10 ClinicalTrials.gov
NCT05555979 A Study to Assess Change in Patient Experience in Adult Participants With Chron… — Chronic Lymphocytic Leukemia Completed 2022-12-14 2024-04-10 ClinicalTrials.gov
NCT05451316 A Study to Assess Change in Disease Activity in Adolescents and Adults With Mod… — Atopic Dermatitis Completed 2022-12-08 2024-11-02 ClinicalTrials.gov
NCT05451316 A Study to Assess Change in Disease Activity in Adolescents and Adults With Mod… — Atopic Dermatitis Completed 2022-12-08 2024-11-02 ClinicalTrials.gov
NCT05451316 A Study to Assess Change in Disease Activity in Adolescents and Adults With Mod… — Atopic Dermatitis Completed 2022-12-08 2024-11-02 ClinicalTrials.gov
NCT05451316 A Study to Assess Change in Disease Activity in Adolescents and Adults With Mod… — Atopic Dermatitis Completed 2022-12-08 2024-11-02 ClinicalTrials.gov
NCT05599984 Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 … Phase1 Advanced Solid Tumors Active_Not_Recruiting 2022-12-05 2026-06-01 ClinicalTrials.gov
NCT05599984 Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 … Phase1 Advanced Solid Tumors Active_Not_Recruiting 2022-12-05 2026-06-01 ClinicalTrials.gov
NCT05599984 Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 … Phase1 Advanced Solid Tumors Active_Not_Recruiting 2022-12-05 2026-06-01 ClinicalTrials.gov
NCT05599984 Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 … Phase1 Advanced Solid Tumors Active_Not_Recruiting 2022-12-05 2026-06-01 ClinicalTrials.gov
NCT05644977 A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participant… Phase1 Healthy Participants Completed 2022-12-02 2025-04-14 ClinicalTrials.gov
NCT05644977 A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participant… Phase1 Healthy Participants Completed 2022-12-02 2025-04-14 ClinicalTrials.gov
NCT05644977 A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participant… Phase1 Healthy Participants Completed 2022-12-02 2025-04-14 ClinicalTrials.gov
NCT05644977 A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participant… Phase1 Healthy Participants Completed 2022-12-02 2025-04-14 ClinicalTrials.gov
NCT05624320 Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses Phase4 Presbyopia Withdrawn 2022-12-01 2023-06-30 ClinicalTrials.gov
NCT05624320 Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses Phase4 Presbyopia Withdrawn 2022-12-01 2023-06-30 ClinicalTrials.gov
NCT05624320 Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses Phase4 Presbyopia Withdrawn 2022-12-01 2023-06-30 ClinicalTrials.gov
NCT05624320 Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses Phase4 Presbyopia Withdrawn 2022-12-01 2023-06-30 ClinicalTrials.gov
NCT05601882 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Ora… Phase3 Atopic Dermatitis Completed 2022-11-28 2024-08-08 ClinicalTrials.gov
NCT05601882 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Ora… Phase3 Atopic Dermatitis Completed 2022-11-28 2024-08-08 ClinicalTrials.gov
NCT05601882 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Ora… Phase3 Atopic Dermatitis Completed 2022-11-28 2024-08-08 ClinicalTrials.gov
NCT05601882 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Ora… Phase3 Atopic Dermatitis Completed 2022-11-28 2024-08-08 ClinicalTrials.gov
NCT05226455 Venetoclax in Patients With MDS or AML in Relapse After AHSCT Phase1 MDS Active_Not_Recruiting 2022-11-23 2027-09-01 ClinicalTrials.gov
NCT05226455 Venetoclax in Patients With MDS or AML in Relapse After AHSCT Phase1 MDS Active_Not_Recruiting 2022-11-23 2027-09-01 ClinicalTrials.gov
NCT05226455 Venetoclax in Patients With MDS or AML in Relapse After AHSCT Phase1 MDS Active_Not_Recruiting 2022-11-23 2027-09-01 ClinicalTrials.gov
NCT05226455 Venetoclax in Patients With MDS or AML in Relapse After AHSCT Phase1 MDS Active_Not_Recruiting 2022-11-23 2027-09-01 ClinicalTrials.gov
NCT04334915 Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation… Phase2 HIV Infections Withdrawn 2022-11-22 2024-08-15 ClinicalTrials.gov
NCT04334915 Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation… Phase2 HIV Infections Withdrawn 2022-11-22 2024-08-15 ClinicalTrials.gov
NCT04334915 Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation… Phase2 HIV Infections Withdrawn 2022-11-22 2024-08-15 ClinicalTrials.gov
NCT04334915 Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation… Phase2 HIV Infections Withdrawn 2022-11-22 2024-08-15 ClinicalTrials.gov
NCT05513703 A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab … Phase2 Non Small Cell Lung Cancer Terminated 2022-11-21 2024-10-28 ClinicalTrials.gov
NCT05513703 A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab … Phase2 Non Small Cell Lung Cancer Terminated 2022-11-21 2024-10-28 ClinicalTrials.gov
NCT05513703 A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab … Phase2 Non Small Cell Lung Cancer Terminated 2022-11-21 2024-10-28 ClinicalTrials.gov
NCT05513703 A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab … Phase2 Non Small Cell Lung Cancer Terminated 2022-11-21 2024-10-28 ClinicalTrials.gov
NCT05582681 HCV Test and Treat Utilizing Simplified HCV Patient Education Phase4 Hepatitis C Terminated 2022-11-11 2024-11-22 ClinicalTrials.gov
NCT05582681 HCV Test and Treat Utilizing Simplified HCV Patient Education Phase4 Hepatitis C Terminated 2022-11-11 2024-11-22 ClinicalTrials.gov
NCT05590702 French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Sma… — CLL/SLL Active_Not_Recruiting 2022-11-11 2032-12-01 ClinicalTrials.gov
NCT05582681 HCV Test and Treat Utilizing Simplified HCV Patient Education Phase4 Hepatitis C Terminated 2022-11-11 2024-11-22 ClinicalTrials.gov
NCT05590702 French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Sma… — CLL/SLL Active_Not_Recruiting 2022-11-11 2032-12-01 ClinicalTrials.gov
NCT05582681 HCV Test and Treat Utilizing Simplified HCV Patient Education Phase4 Hepatitis C Terminated 2022-11-11 2024-11-22 ClinicalTrials.gov
NCT05590702 French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Sma… — CLL/SLL Active_Not_Recruiting 2022-11-11 2032-12-01 ClinicalTrials.gov
NCT05590702 French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Sma… — CLL/SLL Active_Not_Recruiting 2022-11-11 2032-12-01 ClinicalTrials.gov
NCT05411211 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Polyarticular Juvenile Idiopathic Arthritis Completed 2022-11-10 2024-09-08 ClinicalTrials.gov
NCT05411211 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Polyarticular Juvenile Idiopathic Arthritis Completed 2022-11-10 2024-09-08 ClinicalTrials.gov
NCT05411211 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Polyarticular Juvenile Idiopathic Arthritis Completed 2022-11-10 2024-09-08 ClinicalTrials.gov
NCT05411211 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Polyarticular Juvenile Idiopathic Arthritis Completed 2022-11-10 2024-09-08 ClinicalTrials.gov
NCT05259839 A Study to Assess Adverse Events and Change in Disease Activity of Intravenousl… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-10-20 2033-09-01 ClinicalTrials.gov
NCT05259839 A Study to Assess Adverse Events and Change in Disease Activity of Intravenousl… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-10-20 2033-09-01 ClinicalTrials.gov
NCT05259839 A Study to Assess Adverse Events and Change in Disease Activity of Intravenousl… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-10-20 2033-09-01 ClinicalTrials.gov
NCT05496348 Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Partic… — Ulcerative Colitis Active_Not_Recruiting 2022-10-20 2027-08-01 ClinicalTrials.gov
NCT05496348 Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Partic… — Ulcerative Colitis Active_Not_Recruiting 2022-10-20 2027-08-01 ClinicalTrials.gov
NCT05496348 Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Partic… — Ulcerative Colitis Active_Not_Recruiting 2022-10-20 2027-08-01 ClinicalTrials.gov
NCT05259839 A Study to Assess Adverse Events and Change in Disease Activity of Intravenousl… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-10-20 2033-09-01 ClinicalTrials.gov
NCT05496348 Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Partic… — Ulcerative Colitis Active_Not_Recruiting 2022-10-20 2027-08-01 ClinicalTrials.gov
NCT05556226 Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Inject… Phase1 ABBV-154 Completed 2022-10-18 2023-02-17 ClinicalTrials.gov
NCT05556226 Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Inject… Phase1 ABBV-154 Completed 2022-10-18 2023-02-17 ClinicalTrials.gov
NCT05556226 Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Inject… Phase1 ABBV-154 Completed 2022-10-18 2023-02-17 ClinicalTrials.gov
NCT05556226 Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Inject… Phase1 ABBV-154 Completed 2022-10-18 2023-02-17 ClinicalTrials.gov
NCT07226752 A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relap… Phase3 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2022-10-08 2028-06-14 ClinicalTrials.gov
NCT07226752 A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relap… Phase3 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2022-10-08 2028-06-14 ClinicalTrials.gov
NCT07226752 A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relap… Phase3 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2022-10-08 2028-06-14 ClinicalTrials.gov
NCT07226752 A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relap… Phase3 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2022-10-08 2028-06-14 ClinicalTrials.gov
NCT05206357 Study of the Adverse Events and Change in Disease State of Pediatric Participan… Phase1 Non-hodgkin Lymphoma Active_Not_Recruiting 2022-10-04 2028-11-01 ClinicalTrials.gov
NCT05206357 Study of the Adverse Events and Change in Disease State of Pediatric Participan… Phase1 Non-hodgkin Lymphoma Active_Not_Recruiting 2022-10-04 2028-11-01 ClinicalTrials.gov
NCT05206357 Study of the Adverse Events and Change in Disease State of Pediatric Participan… Phase1 Non-hodgkin Lymphoma Active_Not_Recruiting 2022-10-04 2028-11-01 ClinicalTrials.gov
NCT05206357 Study of the Adverse Events and Change in Disease State of Pediatric Participan… Phase1 Non-hodgkin Lymphoma Active_Not_Recruiting 2022-10-04 2028-11-01 ClinicalTrials.gov
NCT05183035 Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) Phase3 Acute Myeloid Leukemia Recruiting 2022-10-01 2031-04-01 ClinicalTrials.gov
NCT05183035 Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) Phase3 Acute Myeloid Leukemia Recruiting 2022-10-01 2031-04-01 ClinicalTrials.gov
NCT05183035 Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) Phase3 Acute Myeloid Leukemia Recruiting 2022-10-01 2031-04-01 ClinicalTrials.gov
NCT05183035 Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) Phase3 Acute Myeloid Leukemia Recruiting 2022-10-01 2031-04-01 ClinicalTrials.gov
NCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of F… Phase2 High Grade Ovarian Cancer Active_Not_Recruiting 2022-09-28 2026-11-01 ClinicalTrials.gov
NCT05567029 Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product… Phase1 Healthy Volunteers Completed 2022-09-28 2023-04-20 ClinicalTrials.gov
NCT05567029 Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product… Phase1 Healthy Volunteers Completed 2022-09-28 2023-04-20 ClinicalTrials.gov
NCT05567029 Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product… Phase1 Healthy Volunteers Completed 2022-09-28 2023-04-20 ClinicalTrials.gov
NCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of F… Phase2 High Grade Ovarian Cancer Active_Not_Recruiting 2022-09-28 2026-11-01 ClinicalTrials.gov
NCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of F… Phase2 High Grade Ovarian Cancer Active_Not_Recruiting 2022-09-28 2026-11-01 ClinicalTrials.gov
NCT05567029 Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product… Phase1 Healthy Volunteers Completed 2022-09-28 2023-04-20 ClinicalTrials.gov
NCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of F… Phase2 High Grade Ovarian Cancer Active_Not_Recruiting 2022-09-28 2026-11-01 ClinicalTrials.gov
NCT05538585 A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicafto… Phase1 Healthy Volunteers Completed 2022-09-27 2022-12-21 ClinicalTrials.gov
NCT05538585 A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicafto… Phase1 Healthy Volunteers Completed 2022-09-27 2022-12-21 ClinicalTrials.gov
NCT05538585 A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicafto… Phase1 Healthy Volunteers Completed 2022-09-27 2022-12-21 ClinicalTrials.gov
NCT05538585 A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicafto… Phase1 Healthy Volunteers Completed 2022-09-27 2022-12-21 ClinicalTrials.gov
NCT05530278 A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galic… Phase1 Healthy Volunteers Completed 2022-09-20 2022-11-29 ClinicalTrials.gov
NCT05530278 A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galic… Phase1 Healthy Volunteers Completed 2022-09-20 2022-11-29 ClinicalTrials.gov
NCT05530278 A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galic… Phase1 Healthy Volunteers Completed 2022-09-20 2022-11-29 ClinicalTrials.gov
NCT05530278 A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galic… Phase1 Healthy Volunteers Completed 2022-09-20 2022-11-29 ClinicalTrials.gov
NCT05424562 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Active_Not_Recruiting 2022-09-07 2027-03-01 ClinicalTrials.gov
NCT05454033 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JU… Phase3 Perioral Lines Completed 2022-09-07 2024-09-03 ClinicalTrials.gov
NCT05424562 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Active_Not_Recruiting 2022-09-07 2027-03-01 ClinicalTrials.gov
NCT05454033 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JU… Phase3 Perioral Lines Completed 2022-09-07 2024-09-03 ClinicalTrials.gov
NCT05454033 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JU… Phase3 Perioral Lines Completed 2022-09-07 2024-09-03 ClinicalTrials.gov
NCT05424562 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Active_Not_Recruiting 2022-09-07 2027-03-01 ClinicalTrials.gov
NCT05424562 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Active_Not_Recruiting 2022-09-07 2027-03-01 ClinicalTrials.gov
NCT05454033 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JU… Phase3 Perioral Lines Completed 2022-09-07 2024-09-03 ClinicalTrials.gov
NCT05503082 Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies Phase4 Headache, Migraine Active_Not_Recruiting 2022-09-06 2024-11-01 ClinicalTrials.gov
NCT05503082 Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies Phase4 Headache, Migraine Active_Not_Recruiting 2022-09-06 2024-11-01 ClinicalTrials.gov
NCT05503082 Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies Phase4 Headache, Migraine Active_Not_Recruiting 2022-09-06 2024-11-01 ClinicalTrials.gov
NCT05503082 Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies Phase4 Headache, Migraine Active_Not_Recruiting 2022-09-06 2024-11-01 ClinicalTrials.gov
NCT04872790 Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment… Phase1 B Acute Lymphoblastic Leukemia Recruiting 2022-09-02 2026-12-02 ClinicalTrials.gov
NCT04872790 Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment… Phase1 B Acute Lymphoblastic Leukemia Recruiting 2022-09-02 2026-12-02 ClinicalTrials.gov
NCT05443724 A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult P… Phase2 Schizophrenia Completed 2022-09-02 2025-06-25 ClinicalTrials.gov
NCT05452070 A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Li… Phase3 Mid Face Volume Deficit Completed 2022-09-02 2025-05-08 ClinicalTrials.gov
NCT05443724 A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult P… Phase2 Schizophrenia Completed 2022-09-02 2025-06-25 ClinicalTrials.gov
NCT04872790 Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment… Phase1 B Acute Lymphoblastic Leukemia Recruiting 2022-09-02 2026-12-02 ClinicalTrials.gov
NCT05443724 A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult P… Phase2 Schizophrenia Completed 2022-09-02 2025-06-25 ClinicalTrials.gov
NCT05443724 A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult P… Phase2 Schizophrenia Completed 2022-09-02 2025-06-25 ClinicalTrials.gov
NCT05452070 A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Li… Phase3 Mid Face Volume Deficit Completed 2022-09-02 2025-05-08 ClinicalTrials.gov
NCT04872790 Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment… Phase1 B Acute Lymphoblastic Leukemia Recruiting 2022-09-02 2026-12-02 ClinicalTrials.gov
NCT05452070 A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Li… Phase3 Mid Face Volume Deficit Completed 2022-09-02 2025-05-08 ClinicalTrials.gov
NCT05452070 A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Li… Phase3 Mid Face Volume Deficit Completed 2022-09-02 2025-05-08 ClinicalTrials.gov
NCT05496335 A Study to Evaluate Sequential Administration of AGN-151586 and Onabotulinumtox… Phase1 Glabellar Lines Completed 2022-08-30 2023-05-30 ClinicalTrials.gov
NCT05496335 A Study to Evaluate Sequential Administration of AGN-151586 and Onabotulinumtox… Phase1 Glabellar Lines Completed 2022-08-30 2023-05-30 ClinicalTrials.gov
NCT05496335 A Study to Evaluate Sequential Administration of AGN-151586 and Onabotulinumtox… Phase1 Glabellar Lines Completed 2022-08-30 2023-05-30 ClinicalTrials.gov
NCT05496335 A Study to Evaluate Sequential Administration of AGN-151586 and Onabotulinumtox… Phase1 Glabellar Lines Completed 2022-08-30 2023-05-30 ClinicalTrials.gov
NCT05192889 Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navito… Phase1 Refractory Acute Lymphoblastic Leukemia Active_Not_Recruiting 2022-08-25 2027-02-01 ClinicalTrials.gov
NCT05192889 Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navito… Phase1 Refractory Acute Lymphoblastic Leukemia Active_Not_Recruiting 2022-08-25 2027-02-01 ClinicalTrials.gov
NCT05192889 Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navito… Phase1 Refractory Acute Lymphoblastic Leukemia Active_Not_Recruiting 2022-08-25 2027-02-01 ClinicalTrials.gov
NCT05192889 Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navito… Phase1 Refractory Acute Lymphoblastic Leukemia Active_Not_Recruiting 2022-08-25 2027-02-01 ClinicalTrials.gov
NCT05444972 A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource … — Myelofibrosis Completed 2022-08-23 2023-11-14 ClinicalTrials.gov
NCT05413785 Hepatitis C Treatment in Probation and Parole Office Na Hepatitis C Completed 2022-08-23 2024-05-31 ClinicalTrials.gov
NCT05444972 A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource … — Myelofibrosis Completed 2022-08-23 2023-11-14 ClinicalTrials.gov
NCT05413785 Hepatitis C Treatment in Probation and Parole Office Na Hepatitis C Completed 2022-08-23 2024-05-31 ClinicalTrials.gov
NCT05444972 A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource … — Myelofibrosis Completed 2022-08-23 2023-11-14 ClinicalTrials.gov
NCT05413785 Hepatitis C Treatment in Probation and Parole Office Na Hepatitis C Completed 2022-08-23 2024-05-31 ClinicalTrials.gov
NCT05444972 A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource … — Myelofibrosis Completed 2022-08-23 2023-11-14 ClinicalTrials.gov
NCT05413785 Hepatitis C Treatment in Probation and Parole Office Na Hepatitis C Completed 2022-08-23 2024-05-31 ClinicalTrials.gov
NCT05368558 Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazi… Phase3 Schizophrenia Terminated 2022-08-18 2024-09-20 ClinicalTrials.gov
NCT05368558 Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazi… Phase3 Schizophrenia Terminated 2022-08-18 2024-09-20 ClinicalTrials.gov
NCT05368558 Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazi… Phase3 Schizophrenia Terminated 2022-08-18 2024-09-20 ClinicalTrials.gov
NCT05368558 Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazi… Phase3 Schizophrenia Terminated 2022-08-18 2024-09-20 ClinicalTrials.gov
NCT05451810 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administere… Phase2 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2022-08-17 2027-03-01 ClinicalTrials.gov
NCT05451810 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administere… Phase2 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2022-08-17 2027-03-01 ClinicalTrials.gov
NCT05451810 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administere… Phase2 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2022-08-17 2027-03-01 ClinicalTrials.gov
NCT05451810 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administere… Phase2 Diffuse Large B-Cell Lymphoma Active_Not_Recruiting 2022-08-17 2027-03-01 ClinicalTrials.gov
NCT05291234 A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through… Phase2 Alzheimer's Disease (AD) Completed 2022-08-15 2025-11-19 ClinicalTrials.gov
NCT05291234 A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through… Phase2 Alzheimer's Disease (AD) Completed 2022-08-15 2025-11-19 ClinicalTrials.gov
NCT05494606 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Ulcerative Colitis Active_Not_Recruiting 2022-08-15 2028-03-01 ClinicalTrials.gov
NCT05494606 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Ulcerative Colitis Active_Not_Recruiting 2022-08-15 2028-03-01 ClinicalTrials.gov
NCT05291234 A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through… Phase2 Alzheimer's Disease (AD) Completed 2022-08-15 2025-11-19 ClinicalTrials.gov
NCT05291234 A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through… Phase2 Alzheimer's Disease (AD) Completed 2022-08-15 2025-11-19 ClinicalTrials.gov
NCT05494606 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Ulcerative Colitis Active_Not_Recruiting 2022-08-15 2028-03-01 ClinicalTrials.gov
NCT05494606 An Observational Study to Assess Change in Disease Activity and Adverse Events … — Ulcerative Colitis Active_Not_Recruiting 2022-08-15 2028-03-01 ClinicalTrials.gov
NCT05475821 Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of … Phase1 Healthy Volunteers Terminated 2022-07-25 2022-09-26 ClinicalTrials.gov
NCT05475821 Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of … Phase1 Healthy Volunteers Terminated 2022-07-25 2022-09-26 ClinicalTrials.gov
NCT05475821 Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of … Phase1 Healthy Volunteers Terminated 2022-07-25 2022-09-26 ClinicalTrials.gov
NCT05475821 Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of … Phase1 Healthy Volunteers Terminated 2022-07-25 2022-09-26 ClinicalTrials.gov
NCT05411198 Study to Assess Change in Disease Activity and Adverse Events of Ab Externo App… Phase3 Open-Angle Glaucoma Completed 2022-07-22 2026-02-04 ClinicalTrials.gov
NCT05411198 Study to Assess Change in Disease Activity and Adverse Events of Ab Externo App… Phase3 Open-Angle Glaucoma Completed 2022-07-22 2026-02-04 ClinicalTrials.gov
NCT05411198 Study to Assess Change in Disease Activity and Adverse Events of Ab Externo App… Phase3 Open-Angle Glaucoma Completed 2022-07-22 2026-02-04 ClinicalTrials.gov
NCT05411198 Study to Assess Change in Disease Activity and Adverse Events of Ab Externo App… Phase3 Open-Angle Glaucoma Completed 2022-07-22 2026-02-04 ClinicalTrials.gov
NCT05455294 Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms Phase1 Myeloid Malignancy Active_Not_Recruiting 2022-07-18 2026-12-31 ClinicalTrials.gov
NCT05384483 Cariprazine Versus Placebo for Social Anxiety Disorder Phase4 Social Anxiety Disorder Completed 2022-07-18 2024-04-15 ClinicalTrials.gov
NCT05384483 Cariprazine Versus Placebo for Social Anxiety Disorder Phase4 Social Anxiety Disorder Completed 2022-07-18 2024-04-15 ClinicalTrials.gov
NCT05455294 Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms Phase1 Myeloid Malignancy Active_Not_Recruiting 2022-07-18 2026-12-31 ClinicalTrials.gov
NCT05384483 Cariprazine Versus Placebo for Social Anxiety Disorder Phase4 Social Anxiety Disorder Completed 2022-07-18 2024-04-15 ClinicalTrials.gov
NCT05384483 Cariprazine Versus Placebo for Social Anxiety Disorder Phase4 Social Anxiety Disorder Completed 2022-07-18 2024-04-15 ClinicalTrials.gov
NCT05455294 Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms Phase1 Myeloid Malignancy Active_Not_Recruiting 2022-07-18 2026-12-31 ClinicalTrials.gov
NCT05455294 Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms Phase1 Myeloid Malignancy Active_Not_Recruiting 2022-07-18 2026-12-31 ClinicalTrials.gov
NCT05414201 A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab i… Phase4 Non-infectious Intermediate Posterior- or Pan-uveitis Completed 2022-07-07 2024-06-10 ClinicalTrials.gov
NCT05414201 A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab i… Phase4 Non-infectious Intermediate Posterior- or Pan-uveitis Completed 2022-07-07 2024-06-10 ClinicalTrials.gov
NCT05439616 Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Cha… Phase3 Autism Spectrum Disorder Completed 2022-07-07 2024-10-04 ClinicalTrials.gov
NCT05414201 A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab i… Phase4 Non-infectious Intermediate Posterior- or Pan-uveitis Completed 2022-07-07 2024-06-10 ClinicalTrials.gov
NCT05439616 Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Cha… Phase3 Autism Spectrum Disorder Completed 2022-07-07 2024-10-04 ClinicalTrials.gov
NCT05439616 Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Cha… Phase3 Autism Spectrum Disorder Completed 2022-07-07 2024-10-04 ClinicalTrials.gov
NCT05414201 A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab i… Phase4 Non-infectious Intermediate Posterior- or Pan-uveitis Completed 2022-07-07 2024-06-10 ClinicalTrials.gov
NCT05439616 Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Cha… Phase3 Autism Spectrum Disorder Completed 2022-07-07 2024-10-04 ClinicalTrials.gov
NCT05609643 Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adul… — Ankylosing Spondylitis Completed 2022-07-06 2026-01-29 ClinicalTrials.gov
NCT05376839 A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Bod… Phase1 Hepatic Impairment Terminated 2022-07-06 2022-11-08 ClinicalTrials.gov
NCT05376839 A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Bod… Phase1 Hepatic Impairment Terminated 2022-07-06 2022-11-08 ClinicalTrials.gov
NCT05609643 Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adul… — Ankylosing Spondylitis Completed 2022-07-06 2026-01-29 ClinicalTrials.gov
NCT05376839 A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Bod… Phase1 Hepatic Impairment Terminated 2022-07-06 2022-11-08 ClinicalTrials.gov
NCT05609643 Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adul… — Ankylosing Spondylitis Completed 2022-07-06 2026-01-29 ClinicalTrials.gov
NCT05609643 Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adul… — Ankylosing Spondylitis Completed 2022-07-06 2026-01-29 ClinicalTrials.gov
NCT05376839 A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Bod… Phase1 Hepatic Impairment Terminated 2022-07-06 2022-11-08 ClinicalTrials.gov
NCT05227703 A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Sch… Phase2 Schizophrenia Completed 2022-07-05 2024-09-11 ClinicalTrials.gov
NCT05227703 A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Sch… Phase2 Schizophrenia Completed 2022-07-05 2024-09-11 ClinicalTrials.gov
NCT05227703 A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Sch… Phase2 Schizophrenia Completed 2022-07-05 2024-09-11 ClinicalTrials.gov
NCT05227703 A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Sch… Phase2 Schizophrenia Completed 2022-07-05 2024-09-11 ClinicalTrials.gov
NCT05227690 A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Sch… Phase2 Schizophrenia Completed 2022-06-30 2024-08-26 ClinicalTrials.gov
NCT05227690 A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Sch… Phase2 Schizophrenia Completed 2022-06-30 2024-08-26 ClinicalTrials.gov
NCT05227690 A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Sch… Phase2 Schizophrenia Completed 2022-06-30 2024-08-26 ClinicalTrials.gov
NCT05227690 A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Sch… Phase2 Schizophrenia Completed 2022-06-30 2024-08-26 ClinicalTrials.gov
NCT05394805 A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events … — Crohn's Disease Completed 2022-06-29 2024-12-26 ClinicalTrials.gov
NCT05394805 A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events … — Crohn's Disease Completed 2022-06-29 2024-12-26 ClinicalTrials.gov
NCT05394805 A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events … — Crohn's Disease Completed 2022-06-29 2024-12-26 ClinicalTrials.gov
NCT05394805 A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events … — Crohn's Disease Completed 2022-06-29 2024-12-26 ClinicalTrials.gov
NCT05025423 Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients… Phase2 Mantle Cell Lymphoma Terminated 2022-06-21 2025-05-14 ClinicalTrials.gov
NCT05025423 Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients… Phase2 Mantle Cell Lymphoma Terminated 2022-06-21 2025-05-14 ClinicalTrials.gov
NCT05025423 Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients… Phase2 Mantle Cell Lymphoma Terminated 2022-06-21 2025-05-14 ClinicalTrials.gov
NCT05025423 Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients… Phase2 Mantle Cell Lymphoma Terminated 2022-06-21 2025-05-14 ClinicalTrials.gov
NCT05394792 An Observational Study of Upadacitinib to Assess Change in Disease Activity in … — Atopic Dermatitis Completed 2022-06-01 2024-08-15 ClinicalTrials.gov
NCT05394792 An Observational Study of Upadacitinib to Assess Change in Disease Activity in … — Atopic Dermatitis Completed 2022-06-01 2024-08-15 ClinicalTrials.gov
NCT05394792 An Observational Study of Upadacitinib to Assess Change in Disease Activity in … — Atopic Dermatitis Completed 2022-06-01 2024-08-15 ClinicalTrials.gov
NCT05394792 An Observational Study of Upadacitinib to Assess Change in Disease Activity in … — Atopic Dermatitis Completed 2022-06-01 2024-08-15 ClinicalTrials.gov
NCT05317494 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Recruiting 2022-05-26 2026-12-01 ClinicalTrials.gov
NCT05317494 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Recruiting 2022-05-26 2026-12-01 ClinicalTrials.gov
NCT05317494 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Recruiting 2022-05-26 2026-12-01 ClinicalTrials.gov
NCT05317494 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Recruiting 2022-05-26 2026-12-01 ClinicalTrials.gov
NCT05342584 Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS Phase1 Acute Myeloid Leukemia Recruiting 2022-05-25 2028-12-01 ClinicalTrials.gov
NCT05342584 Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS Phase1 Acute Myeloid Leukemia Recruiting 2022-05-25 2028-12-01 ClinicalTrials.gov
NCT05342584 Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS Phase1 Acute Myeloid Leukemia Recruiting 2022-05-25 2028-12-01 ClinicalTrials.gov
NCT05342584 Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS Phase1 Acute Myeloid Leukemia Recruiting 2022-05-25 2028-12-01 ClinicalTrials.gov
NCT05308654 A Study to Assess the Adverse Events and Change in Disease Activity in Adult Pa… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-05-17 2025-12-01 ClinicalTrials.gov
NCT05308654 A Study to Assess the Adverse Events and Change in Disease Activity in Adult Pa… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-05-17 2025-12-01 ClinicalTrials.gov
NCT05308654 A Study to Assess the Adverse Events and Change in Disease Activity in Adult Pa… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-05-17 2025-12-01 ClinicalTrials.gov
NCT05308654 A Study to Assess the Adverse Events and Change in Disease Activity in Adult Pa… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-05-17 2025-12-01 ClinicalTrials.gov
NCT05316233 A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VO… Phase3 Neck Lines Completed 2022-05-02 2024-09-12 ClinicalTrials.gov
NCT05316233 A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VO… Phase3 Neck Lines Completed 2022-05-02 2024-09-12 ClinicalTrials.gov
NCT05316233 A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VO… Phase3 Neck Lines Completed 2022-05-02 2024-09-12 ClinicalTrials.gov
NCT05316233 A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VO… Phase3 Neck Lines Completed 2022-05-02 2024-09-12 ClinicalTrials.gov
NCT05327920 An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian … — Rheumatoid Arthritis Completed 2022-04-20 2024-04-22 ClinicalTrials.gov
NCT05327920 An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian … — Rheumatoid Arthritis Completed 2022-04-20 2024-04-22 ClinicalTrials.gov
NCT05327920 An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian … — Rheumatoid Arthritis Completed 2022-04-20 2024-04-22 ClinicalTrials.gov
NCT05327920 An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian … — Rheumatoid Arthritis Completed 2022-04-20 2024-04-22 ClinicalTrials.gov
NCT05216250 Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Partici… Phase2 Upper Limb Essential Tremor (UL ET) Completed 2022-04-12 2025-02-03 ClinicalTrials.gov
NCT05216250 Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Partici… Phase2 Upper Limb Essential Tremor (UL ET) Completed 2022-04-12 2025-02-03 ClinicalTrials.gov
NCT05216250 Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Partici… Phase2 Upper Limb Essential Tremor (UL ET) Completed 2022-04-12 2025-02-03 ClinicalTrials.gov
NCT05216250 Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Partici… Phase2 Upper Limb Essential Tremor (UL ET) Completed 2022-04-12 2025-02-03 ClinicalTrials.gov
NCT05296447 Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space f… — Diabetic Retinopathy, DR Enrolling_By_Invitation 2022-04-04 2028-05-01 ClinicalTrials.gov
NCT05296447 Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space f… — Diabetic Retinopathy, DR Enrolling_By_Invitation 2022-04-04 2028-05-01 ClinicalTrials.gov
NCT05296447 Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space f… — Diabetic Retinopathy, DR Enrolling_By_Invitation 2022-04-04 2028-05-01 ClinicalTrials.gov
NCT05296447 Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space f… — Diabetic Retinopathy, DR Enrolling_By_Invitation 2022-04-04 2028-05-01 ClinicalTrials.gov
NCT05141006 Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Even… Phase2 Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Completed 2022-03-29 2024-12-06 ClinicalTrials.gov
NCT05141006 Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Even… Phase2 Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Completed 2022-03-29 2024-12-06 ClinicalTrials.gov
NCT05141006 Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Even… Phase2 Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Completed 2022-03-29 2024-12-06 ClinicalTrials.gov
NCT05141006 Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Even… Phase2 Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Completed 2022-03-29 2024-12-06 ClinicalTrials.gov
NCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetocla… Phase2 Chronic Lymphocytic Leukemia (CLL) Recruiting 2022-03-28 2029-01-01 ClinicalTrials.gov
NCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetocla… Phase2 Chronic Lymphocytic Leukemia (CLL) Recruiting 2022-03-28 2029-01-01 ClinicalTrials.gov
NCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetocla… Phase2 Chronic Lymphocytic Leukemia (CLL) Recruiting 2022-03-28 2029-01-01 ClinicalTrials.gov
NCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetocla… Phase2 Chronic Lymphocytic Leukemia (CLL) Recruiting 2022-03-28 2029-01-01 ClinicalTrials.gov
NCT04928846 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telis… Phase3 Non Small Cell Lung Cancer Recruiting 2022-03-25 2029-02-01 ClinicalTrials.gov
NCT04928846 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telis… Phase3 Non Small Cell Lung Cancer Recruiting 2022-03-25 2029-02-01 ClinicalTrials.gov
NCT04928846 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telis… Phase3 Non Small Cell Lung Cancer Recruiting 2022-03-25 2029-02-01 ClinicalTrials.gov
NCT04928846 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telis… Phase3 Non Small Cell Lung Cancer Recruiting 2022-03-25 2029-02-01 ClinicalTrials.gov
NCT05286229 A Study to Assess Adverse Events and Change in Disease State of Intravenously (… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-03-24 2026-03-01 ClinicalTrials.gov
NCT05286229 A Study to Assess Adverse Events and Change in Disease State of Intravenously (… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-03-24 2026-03-01 ClinicalTrials.gov
NCT05286229 A Study to Assess Adverse Events and Change in Disease State of Intravenously (… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-03-24 2026-03-01 ClinicalTrials.gov
NCT05286229 A Study to Assess Adverse Events and Change in Disease State of Intravenously (… Phase1 Relapsed/Refractory Multiple Myeloma Active_Not_Recruiting 2022-03-24 2026-03-01 ClinicalTrials.gov
NCT05216263 Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adve… Phase3 Chronic Migraine Completed 2022-03-22 2025-05-02 ClinicalTrials.gov
NCT05216263 Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adve… Phase3 Chronic Migraine Completed 2022-03-22 2025-05-02 ClinicalTrials.gov
NCT05216263 Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adve… Phase3 Chronic Migraine Completed 2022-03-22 2025-05-02 ClinicalTrials.gov
NCT05216263 Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adve… Phase3 Chronic Migraine Completed 2022-03-22 2025-05-02 ClinicalTrials.gov
NCT05248867 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscula… Phase3 Glabellar Lines Completed 2022-03-16 2023-03-17 ClinicalTrials.gov
NCT05248867 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscula… Phase3 Glabellar Lines Completed 2022-03-16 2023-03-17 ClinicalTrials.gov
NCT05248867 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscula… Phase3 Glabellar Lines Completed 2022-03-16 2023-03-17 ClinicalTrials.gov
NCT05248867 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscula… Phase3 Glabellar Lines Completed 2022-03-16 2023-03-17 ClinicalTrials.gov
NCT05170646 An Observational Study to Assess the Real-World Effectiveness of Upadacitinib i… — Rheumatoid Arthritis Completed 2022-03-14 2024-01-31 ClinicalTrials.gov
NCT05170646 An Observational Study to Assess the Real-World Effectiveness of Upadacitinib i… — Rheumatoid Arthritis Completed 2022-03-14 2024-01-31 ClinicalTrials.gov
NCT05170646 An Observational Study to Assess the Real-World Effectiveness of Upadacitinib i… — Rheumatoid Arthritis Completed 2022-03-14 2024-01-31 ClinicalTrials.gov
NCT05170646 An Observational Study to Assess the Real-World Effectiveness of Upadacitinib i… — Rheumatoid Arthritis Completed 2022-03-14 2024-01-31 ClinicalTrials.gov
NCT05201248 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneo… Phase1 B-Cell Non-Hodgkin Lymphoma Active_Not_Recruiting 2022-03-10 2025-04-01 ClinicalTrials.gov
NCT05201248 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneo… Phase1 B-Cell Non-Hodgkin Lymphoma Active_Not_Recruiting 2022-03-10 2025-04-01 ClinicalTrials.gov
NCT05201248 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneo… Phase1 B-Cell Non-Hodgkin Lymphoma Active_Not_Recruiting 2022-03-10 2025-04-01 ClinicalTrials.gov
NCT05201248 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneo… Phase1 B-Cell Non-Hodgkin Lymphoma Active_Not_Recruiting 2022-03-10 2025-04-01 ClinicalTrials.gov
NCT05248880 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscula… Phase3 Glabellar Lines Completed 2022-03-08 2023-02-01 ClinicalTrials.gov
NCT05248880 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscula… Phase3 Glabellar Lines Completed 2022-03-08 2023-02-01 ClinicalTrials.gov
NCT05248880 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscula… Phase3 Glabellar Lines Completed 2022-03-08 2023-02-01 ClinicalTrials.gov
NCT05248880 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscula… Phase3 Glabellar Lines Completed 2022-03-08 2023-02-01 ClinicalTrials.gov
NCT05264129 Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atog… Phase4 Episodic Migraine Completed 2022-03-07 2023-04-04 ClinicalTrials.gov
NCT05264129 Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atog… Phase4 Episodic Migraine Completed 2022-03-07 2023-04-04 ClinicalTrials.gov
NCT05264129 Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atog… Phase4 Episodic Migraine Completed 2022-03-07 2023-04-04 ClinicalTrials.gov
NCT05264129 Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atog… Phase4 Episodic Migraine Completed 2022-03-07 2023-04-04 ClinicalTrials.gov
NCT05283135 High Dose Risankizumab for Psoriasis Phase2 Psoriasis Completed 2022-03-01 2024-07-10 ClinicalTrials.gov
NCT05283135 High Dose Risankizumab for Psoriasis Phase2 Psoriasis Completed 2022-03-01 2024-07-10 ClinicalTrials.gov
NCT05283135 High Dose Risankizumab for Psoriasis Phase2 Psoriasis Completed 2022-03-01 2024-07-10 ClinicalTrials.gov
NCT05283135 High Dose Risankizumab for Psoriasis Phase2 Psoriasis Completed 2022-03-01 2024-07-10 ClinicalTrials.gov
NCT05248893 A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult… Phase3 Glabellar Lines Completed 2022-02-25 2023-06-26 ClinicalTrials.gov
NCT05248893 A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult… Phase3 Glabellar Lines Completed 2022-02-25 2023-06-26 ClinicalTrials.gov
NCT05248893 A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult… Phase3 Glabellar Lines Completed 2022-02-25 2023-06-26 ClinicalTrials.gov
NCT05248893 A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult… Phase3 Glabellar Lines Completed 2022-02-25 2023-06-26 ClinicalTrials.gov
NCT04984317 Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence Early_Phase1 Stress Urinary Incontinence Suspended 2022-02-14 2027-08-01 ClinicalTrials.gov
NCT04984317 Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence Early_Phase1 Stress Urinary Incontinence Suspended 2022-02-14 2027-08-01 ClinicalTrials.gov
NCT04984317 Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence Early_Phase1 Stress Urinary Incontinence Suspended 2022-02-14 2027-08-01 ClinicalTrials.gov
NCT04984317 Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence Early_Phase1 Stress Urinary Incontinence Suspended 2022-02-14 2027-08-01 ClinicalTrials.gov
NCT04905810 Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior… Phase2 Acute Myeloid Leukemia Recruiting 2022-02-09 2025-12-01 ClinicalTrials.gov
NCT04905810 Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior… Phase2 Acute Myeloid Leukemia Recruiting 2022-02-09 2025-12-01 ClinicalTrials.gov
NCT04905810 Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior… Phase2 Acute Myeloid Leukemia Recruiting 2022-02-09 2025-12-01 ClinicalTrials.gov
NCT04905810 Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior… Phase2 Acute Myeloid Leukemia Recruiting 2022-02-09 2025-12-01 ClinicalTrials.gov
NCT04797767 Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grad… Phase1 Acute Biphenotypic Leukemia Recruiting 2022-02-04 2028-12-31 ClinicalTrials.gov
NCT04797767 Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grad… Phase1 Acute Biphenotypic Leukemia Recruiting 2022-02-04 2028-12-31 ClinicalTrials.gov
NCT04797767 Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grad… Phase1 Acute Biphenotypic Leukemia Recruiting 2022-02-04 2028-12-31 ClinicalTrials.gov
NCT04797767 Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grad… Phase1 Acute Biphenotypic Leukemia Recruiting 2022-02-04 2028-12-31 ClinicalTrials.gov
NCT05068284 A Study to Evaluate Adverse Events and Change in Disease Activity in Participan… Phase2 Crohn's Disease Terminated 2022-01-31 2023-07-20 ClinicalTrials.gov
NCT05068284 A Study to Evaluate Adverse Events and Change in Disease Activity in Participan… Phase2 Crohn's Disease Terminated 2022-01-31 2023-07-20 ClinicalTrials.gov
NCT05068284 A Study to Evaluate Adverse Events and Change in Disease Activity in Participan… Phase2 Crohn's Disease Terminated 2022-01-31 2023-07-20 ClinicalTrials.gov
NCT05068284 A Study to Evaluate Adverse Events and Change in Disease Activity in Participan… Phase2 Crohn's Disease Terminated 2022-01-31 2023-07-20 ClinicalTrials.gov
NCT05094050 Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcuta… Phase1 Parkinson's Disease Completed 2022-01-18 2023-03-17 ClinicalTrials.gov
NCT05094050 Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcuta… Phase1 Parkinson's Disease Completed 2022-01-18 2023-03-17 ClinicalTrials.gov
NCT05094050 Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcuta… Phase1 Parkinson's Disease Completed 2022-01-18 2023-03-17 ClinicalTrials.gov
NCT05094050 Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcuta… Phase1 Parkinson's Disease Completed 2022-01-18 2023-03-17 ClinicalTrials.gov
NCT04895410 Study to Assess Adverse Events and Change in Disease Activity of Intravenous (I… Phase1 Multiple Myeloma Terminated 2022-01-17 2022-06-24 ClinicalTrials.gov
NCT04895410 Study to Assess Adverse Events and Change in Disease Activity of Intravenous (I… Phase1 Multiple Myeloma Terminated 2022-01-17 2022-06-24 ClinicalTrials.gov
NCT04895410 Study to Assess Adverse Events and Change in Disease Activity of Intravenous (I… Phase1 Multiple Myeloma Terminated 2022-01-17 2022-06-24 ClinicalTrials.gov
NCT04895410 Study to Assess Adverse Events and Change in Disease Activity of Intravenous (I… Phase1 Multiple Myeloma Terminated 2022-01-17 2022-06-24 ClinicalTrials.gov
NCT05127954 Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant … Phase3 Migraine Enrolling_By_Invitation 2022-01-14 2028-01-01 ClinicalTrials.gov
NCT05127954 Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant … Phase3 Migraine Enrolling_By_Invitation 2022-01-14 2028-01-01 ClinicalTrials.gov
NCT05127954 Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant … Phase3 Migraine Enrolling_By_Invitation 2022-01-14 2028-01-01 ClinicalTrials.gov
NCT05127954 Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant … Phase3 Migraine Enrolling_By_Invitation 2022-01-14 2028-01-01 ClinicalTrials.gov
NCT05125302 Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets … Phase3 Migraine Recruiting 2022-01-13 2027-05-01 ClinicalTrials.gov
NCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Phase3 AMD Recruiting 2022-01-13 2027-11-01 ClinicalTrials.gov
NCT05125302 Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets … Phase3 Migraine Recruiting 2022-01-13 2027-05-01 ClinicalTrials.gov
NCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Phase3 AMD Recruiting 2022-01-13 2027-11-01 ClinicalTrials.gov
NCT05125302 Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets … Phase3 Migraine Recruiting 2022-01-13 2027-05-01 ClinicalTrials.gov
NCT05125302 Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets … Phase3 Migraine Recruiting 2022-01-13 2027-05-01 ClinicalTrials.gov
NCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Phase3 AMD Recruiting 2022-01-13 2027-11-01 ClinicalTrials.gov
NCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Phase3 AMD Recruiting 2022-01-13 2027-11-01 ClinicalTrials.gov
NCT04464187 A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Ta… — Endometriosis Terminated 2022-01-06 2025-07-11 ClinicalTrials.gov
NCT04464187 A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Ta… — Endometriosis Terminated 2022-01-06 2025-07-11 ClinicalTrials.gov
NCT05144243 Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax i… Phase4 Acute Myeloid Leukemia (AML) Active_Not_Recruiting 2022-01-06 2026-03-01 ClinicalTrials.gov
NCT05144243 Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax i… Phase4 Acute Myeloid Leukemia (AML) Active_Not_Recruiting 2022-01-06 2026-03-01 ClinicalTrials.gov
NCT04464187 A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Ta… — Endometriosis Terminated 2022-01-06 2025-07-11 ClinicalTrials.gov
NCT05144243 Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax i… Phase4 Acute Myeloid Leukemia (AML) Active_Not_Recruiting 2022-01-06 2026-03-01 ClinicalTrials.gov
NCT04464187 A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Ta… — Endometriosis Terminated 2022-01-06 2025-07-11 ClinicalTrials.gov
NCT05144243 Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax i… Phase4 Acute Myeloid Leukemia (AML) Active_Not_Recruiting 2022-01-06 2026-03-01 ClinicalTrials.gov
NCT05139602 A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-… Phase2 Hidradenitis Suppurativa Active_Not_Recruiting 2021-12-28 2027-12-01 ClinicalTrials.gov
NCT05139602 A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-… Phase2 Hidradenitis Suppurativa Active_Not_Recruiting 2021-12-28 2027-12-01 ClinicalTrials.gov
NCT05139602 A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-… Phase2 Hidradenitis Suppurativa Active_Not_Recruiting 2021-12-28 2027-12-01 ClinicalTrials.gov
NCT05139602 A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-… Phase2 Hidradenitis Suppurativa Active_Not_Recruiting 2021-12-28 2027-12-01 ClinicalTrials.gov
NCT05215639 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Completed 2021-12-27 2025-11-24 ClinicalTrials.gov
NCT05215639 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Completed 2021-12-27 2025-11-24 ClinicalTrials.gov
NCT05215639 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Completed 2021-12-27 2025-11-24 ClinicalTrials.gov
NCT05215639 A Study to Assess Change in Disease State in Adult Participants With Acute Myel… — Acute Myeloid Leukemia Completed 2021-12-27 2025-11-24 ClinicalTrials.gov
NCT05210803 Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space f… — Neovascular Age-Related Macular Degeneration (nAMD) Enrolling_By_Invitation 2021-12-20 2028-03-01 ClinicalTrials.gov
NCT05210803 Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space f… — Neovascular Age-Related Macular Degeneration (nAMD) Enrolling_By_Invitation 2021-12-20 2028-03-01 ClinicalTrials.gov
NCT05210803 Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space f… — Neovascular Age-Related Macular Degeneration (nAMD) Enrolling_By_Invitation 2021-12-20 2028-03-01 ClinicalTrials.gov
NCT05210803 Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space f… — Neovascular Age-Related Macular Degeneration (nAMD) Enrolling_By_Invitation 2021-12-20 2028-03-01 ClinicalTrials.gov
NCT05139836 A Study to Assess Disease Activity in Adolescent and Adult Participants With At… — Atopic Dermatitis Active_Not_Recruiting 2021-12-13 2027-09-01 ClinicalTrials.gov
NCT05139836 A Study to Assess Disease Activity in Adolescent and Adult Participants With At… — Atopic Dermatitis Active_Not_Recruiting 2021-12-13 2027-09-01 ClinicalTrials.gov
NCT05139836 A Study to Assess Disease Activity in Adolescent and Adult Participants With At… — Atopic Dermatitis Active_Not_Recruiting 2021-12-13 2027-09-01 ClinicalTrials.gov
NCT05139836 A Study to Assess Disease Activity in Adolescent and Adult Participants With At… — Atopic Dermatitis Active_Not_Recruiting 2021-12-13 2027-09-01 ClinicalTrials.gov
NCT05048732 Imaging Apoptosis for Lymphoma Treatment Response Early_Phase1 Diffuse Large B Cell Lymphoma Terminated 2021-12-06 2024-02-10 ClinicalTrials.gov
NCT05048732 Imaging Apoptosis for Lymphoma Treatment Response Early_Phase1 Diffuse Large B Cell Lymphoma Terminated 2021-12-06 2024-02-10 ClinicalTrials.gov
NCT05048732 Imaging Apoptosis for Lymphoma Treatment Response Early_Phase1 Diffuse Large B Cell Lymphoma Terminated 2021-12-06 2024-02-10 ClinicalTrials.gov
NCT05048732 Imaging Apoptosis for Lymphoma Treatment Response Early_Phase1 Diffuse Large B Cell Lymphoma Terminated 2021-12-06 2024-02-10 ClinicalTrials.gov
NCT04887857 A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine)… Phase1 Leukemia, Myeloid, Acute Completed 2021-12-01 2024-01-08 ClinicalTrials.gov
NCT04887857 A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine)… Phase1 Leukemia, Myeloid, Acute Completed 2021-12-01 2024-01-08 ClinicalTrials.gov
NCT04887857 A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine)… Phase1 Leukemia, Myeloid, Acute Completed 2021-12-01 2024-01-08 ClinicalTrials.gov
NCT04887857 A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine)… Phase1 Leukemia, Myeloid, Acute Completed 2021-12-01 2024-01-08 ClinicalTrials.gov
NCT05152576 A Study To Assess the Adverse Effects and Change in Condition of Onabotulinumto… Phase2 Forehead Lines Completed 2021-11-29 2022-09-06 ClinicalTrials.gov
NCT05152576 A Study To Assess the Adverse Effects and Change in Condition of Onabotulinumto… Phase2 Forehead Lines Completed 2021-11-29 2022-09-06 ClinicalTrials.gov
NCT05152576 A Study To Assess the Adverse Effects and Change in Condition of Onabotulinumto… Phase2 Forehead Lines Completed 2021-11-29 2022-09-06 ClinicalTrials.gov
NCT05152576 A Study To Assess the Adverse Effects and Change in Condition of Onabotulinumto… Phase2 Forehead Lines Completed 2021-11-29 2022-09-06 ClinicalTrials.gov
NCT05164783 Multicenter Implementation of E-monitoring in Parkinson's Disease Na Parkinson Disease Active_Not_Recruiting 2021-11-23 2025-06-27 ClinicalTrials.gov
NCT05164783 Multicenter Implementation of E-monitoring in Parkinson's Disease Na Parkinson Disease Active_Not_Recruiting 2021-11-23 2025-06-27 ClinicalTrials.gov
NCT05164783 Multicenter Implementation of E-monitoring in Parkinson's Disease Na Parkinson Disease Active_Not_Recruiting 2021-11-23 2025-06-27 ClinicalTrials.gov
NCT05164783 Multicenter Implementation of E-monitoring in Parkinson's Disease Na Parkinson Disease Active_Not_Recruiting 2021-11-23 2025-06-27 ClinicalTrials.gov
NCT05094128 A Study to Assess Disease Activity in Adult Participants With Axial Spondyloart… — Axial Spondylarthritis (r-axSpA) Active_Not_Recruiting 2021-11-22 2027-04-01 ClinicalTrials.gov
NCT05094128 A Study to Assess Disease Activity in Adult Participants With Axial Spondyloart… — Axial Spondylarthritis (r-axSpA) Active_Not_Recruiting 2021-11-22 2027-04-01 ClinicalTrials.gov
NCT05094128 A Study to Assess Disease Activity in Adult Participants With Axial Spondyloart… — Axial Spondylarthritis (r-axSpA) Active_Not_Recruiting 2021-11-22 2027-04-01 ClinicalTrials.gov
NCT05094128 A Study to Assess Disease Activity in Adult Participants With Axial Spondyloart… — Axial Spondylarthritis (r-axSpA) Active_Not_Recruiting 2021-11-22 2027-04-01 ClinicalTrials.gov
NCT05081557 A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitini… — Atopic Dermatitis Active_Not_Recruiting 2021-11-17 2026-10-01 ClinicalTrials.gov
NCT05081557 A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitini… — Atopic Dermatitis Active_Not_Recruiting 2021-11-17 2026-10-01 ClinicalTrials.gov
NCT05081557 A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitini… — Atopic Dermatitis Active_Not_Recruiting 2021-11-17 2026-10-01 ClinicalTrials.gov
NCT05081557 A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitini… — Atopic Dermatitis Active_Not_Recruiting 2021-11-17 2026-10-01 ClinicalTrials.gov
NCT05134649 A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Inject… Phase3 Platysma Prominence Completed 2021-11-16 2023-08-18 ClinicalTrials.gov
NCT05134649 A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Inject… Phase3 Platysma Prominence Completed 2021-11-16 2023-08-18 ClinicalTrials.gov
NCT05044234 A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157… Phase2 Psoriasis Terminated 2021-11-16 2022-11-30 ClinicalTrials.gov
NCT05134649 A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Inject… Phase3 Platysma Prominence Completed 2021-11-16 2023-08-18 ClinicalTrials.gov
NCT05044234 A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157… Phase2 Psoriasis Terminated 2021-11-16 2022-11-30 ClinicalTrials.gov
NCT05134649 A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Inject… Phase3 Platysma Prominence Completed 2021-11-16 2023-08-18 ClinicalTrials.gov
NCT05044234 A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157… Phase2 Psoriasis Terminated 2021-11-16 2022-11-30 ClinicalTrials.gov
NCT05044234 A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157… Phase2 Psoriasis Terminated 2021-11-16 2022-11-30 ClinicalTrials.gov
NCT03400306 A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Fol… Phase1 Cancer - Ovarian Withdrawn 2021-11-15 2021-11-16 ClinicalTrials.gov
NCT03400306 A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Fol… Phase1 Cancer - Ovarian Withdrawn 2021-11-15 2021-11-16 ClinicalTrials.gov
NCT03400306 A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Fol… Phase1 Cancer - Ovarian Withdrawn 2021-11-15 2021-11-16 ClinicalTrials.gov
NCT03400306 A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Fol… Phase1 Cancer - Ovarian Withdrawn 2021-11-15 2021-11-16 ClinicalTrials.gov
NCT04898894 Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric… Phase1 Acute Leukemia of Ambiguous Lineage in Relapse Active_Not_Recruiting 2021-11-15 2027-09-01 ClinicalTrials.gov
NCT05080218 COVID-19 VaccinE Response in Rheumatology Patients Phase4 Rheumatoid Arthritis Completed 2021-11-15 2024-05-28 ClinicalTrials.gov
NCT04898894 Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric… Phase1 Acute Leukemia of Ambiguous Lineage in Relapse Active_Not_Recruiting 2021-11-15 2027-09-01 ClinicalTrials.gov
NCT05080218 COVID-19 VaccinE Response in Rheumatology Patients Phase4 Rheumatoid Arthritis Completed 2021-11-15 2024-05-28 ClinicalTrials.gov
NCT04898894 Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric… Phase1 Acute Leukemia of Ambiguous Lineage in Relapse Active_Not_Recruiting 2021-11-15 2027-09-01 ClinicalTrials.gov
NCT04898894 Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric… Phase1 Acute Leukemia of Ambiguous Lineage in Relapse Active_Not_Recruiting 2021-11-15 2027-09-01 ClinicalTrials.gov
NCT05080218 COVID-19 VaccinE Response in Rheumatology Patients Phase4 Rheumatoid Arthritis Completed 2021-11-15 2024-05-28 ClinicalTrials.gov
NCT05080218 COVID-19 VaccinE Response in Rheumatology Patients Phase4 Rheumatoid Arthritis Completed 2021-11-15 2024-05-28 ClinicalTrials.gov
NCT05105841 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetocla… Phase2 Chronic Lymphocytic Leukemia (CLL) Completed 2021-11-08 2025-10-09 ClinicalTrials.gov
NCT05105841 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetocla… Phase2 Chronic Lymphocytic Leukemia (CLL) Completed 2021-11-08 2025-10-09 ClinicalTrials.gov
NCT05105841 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetocla… Phase2 Chronic Lymphocytic Leukemia (CLL) Completed 2021-11-08 2025-10-09 ClinicalTrials.gov
NCT05105841 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetocla… Phase2 Chronic Lymphocytic Leukemia (CLL) Completed 2021-11-08 2025-10-09 ClinicalTrials.gov
NCT05130554 XEN45 in the Treatment of Chinese Patients With Primary Open-angle Glaucoma Na Glaucoma Unknown 2021-11-07 2022-09-30 ClinicalTrials.gov
NCT05130554 XEN45 in the Treatment of Chinese Patients With Primary Open-angle Glaucoma Na Glaucoma Unknown 2021-11-07 2022-09-30 ClinicalTrials.gov
NCT05130554 XEN45 in the Treatment of Chinese Patients With Primary Open-angle Glaucoma Na Glaucoma Unknown 2021-11-07 2022-09-30 ClinicalTrials.gov
NCT05130554 XEN45 in the Treatment of Chinese Patients With Primary Open-angle Glaucoma Na Glaucoma Unknown 2021-11-07 2022-09-30 ClinicalTrials.gov
NCT05028569 Study of BOTOX Injections in Prevention of Migraine in Adult Participants With … Phase3 Episodic Migraine Terminated 2021-11-05 2024-11-06 ClinicalTrials.gov
NCT05028569 Study of BOTOX Injections in Prevention of Migraine in Adult Participants With … Phase3 Episodic Migraine Terminated 2021-11-05 2024-11-06 ClinicalTrials.gov
NCT05028569 Study of BOTOX Injections in Prevention of Migraine in Adult Participants With … Phase3 Episodic Migraine Terminated 2021-11-05 2024-11-06 ClinicalTrials.gov
NCT05028569 Study of BOTOX Injections in Prevention of Migraine in Adult Participants With … Phase3 Episodic Migraine Terminated 2021-11-05 2024-11-06 ClinicalTrials.gov
NCT05005403 Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With … Phase1 Non-Small Cell Lung Cancer Recruiting 2021-11-01 2027-07-01 ClinicalTrials.gov
NCT05005403 Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With … Phase1 Non-Small Cell Lung Cancer Recruiting 2021-11-01 2027-07-01 ClinicalTrials.gov
NCT05005403 Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With … Phase1 Non-Small Cell Lung Cancer Recruiting 2021-11-01 2027-07-01 ClinicalTrials.gov
NCT05005403 Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With … Phase1 Non-Small Cell Lung Cancer Recruiting 2021-11-01 2027-07-01 ClinicalTrials.gov
NCT05083286 Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines Early_Phase1 Glabellar Frown Lines Unknown 2021-10-20 2022-08-01 ClinicalTrials.gov
NCT05083286 Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines Early_Phase1 Glabellar Frown Lines Unknown 2021-10-20 2022-08-01 ClinicalTrials.gov
NCT05083286 Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines Early_Phase1 Glabellar Frown Lines Unknown 2021-10-20 2022-08-01 ClinicalTrials.gov
NCT05083286 Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines Early_Phase1 Glabellar Frown Lines Unknown 2021-10-20 2022-08-01 ClinicalTrials.gov
NCT05041257 Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Periton… Phase2 Ovarian Cancer Completed 2021-10-19 2024-12-12 ClinicalTrials.gov
NCT05041257 Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Periton… Phase2 Ovarian Cancer Completed 2021-10-19 2024-12-12 ClinicalTrials.gov
NCT05088980 Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lido… Phase3 Infraorbital Hollowing Completed 2021-10-19 2023-11-29 ClinicalTrials.gov
NCT05088980 Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lido… Phase3 Infraorbital Hollowing Completed 2021-10-19 2023-11-29 ClinicalTrials.gov
NCT05041257 Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Periton… Phase2 Ovarian Cancer Completed 2021-10-19 2024-12-12 ClinicalTrials.gov
NCT05088980 Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lido… Phase3 Infraorbital Hollowing Completed 2021-10-19 2023-11-29 ClinicalTrials.gov
NCT05041257 Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Periton… Phase2 Ovarian Cancer Completed 2021-10-19 2024-12-12 ClinicalTrials.gov
NCT05088980 Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lido… Phase3 Infraorbital Hollowing Completed 2021-10-19 2023-11-29 ClinicalTrials.gov
NCT05577000 Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple… Phase1 Refractory Multiple Myeloma Active_Not_Recruiting 2021-10-18 2038-08-31 ClinicalTrials.gov
NCT05577000 Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple… Phase1 Refractory Multiple Myeloma Active_Not_Recruiting 2021-10-18 2038-08-31 ClinicalTrials.gov
NCT05577000 Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple… Phase1 Refractory Multiple Myeloma Active_Not_Recruiting 2021-10-18 2038-08-31 ClinicalTrials.gov
NCT05577000 Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple… Phase1 Refractory Multiple Myeloma Active_Not_Recruiting 2021-10-18 2038-08-31 ClinicalTrials.gov
NCT05069597 Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Partic… Phase4 Cystic Fibrosis Completed 2021-10-14 2023-08-28 ClinicalTrials.gov
NCT05069597 Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Partic… Phase4 Cystic Fibrosis Completed 2021-10-14 2023-08-28 ClinicalTrials.gov
NCT05069597 Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Partic… Phase4 Cystic Fibrosis Completed 2021-10-14 2023-08-28 ClinicalTrials.gov
NCT05069597 Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Partic… Phase4 Cystic Fibrosis Completed 2021-10-14 2023-08-28 ClinicalTrials.gov
NCT05029882 Study to Assess Adverse Events and Change in Disease Activity in Adult Particip… Phase1 Non-Small Cell Lung Cancer Active_Not_Recruiting 2021-10-13 2027-11-01 ClinicalTrials.gov
NCT05119777 HArmonyCa Injectable Gel for Mid Face Soft Tissue Augmentation Phase4 Soft Tissue Augmentation Completed 2021-10-13 2023-09-15 ClinicalTrials.gov
NCT05119777 HArmonyCa Injectable Gel for Mid Face Soft Tissue Augmentation Phase4 Soft Tissue Augmentation Completed 2021-10-13 2023-09-15 ClinicalTrials.gov
NCT05119777 HArmonyCa Injectable Gel for Mid Face Soft Tissue Augmentation Phase4 Soft Tissue Augmentation Completed 2021-10-13 2023-09-15 ClinicalTrials.gov
NCT05029882 Study to Assess Adverse Events and Change in Disease Activity in Adult Particip… Phase1 Non-Small Cell Lung Cancer Active_Not_Recruiting 2021-10-13 2027-11-01 ClinicalTrials.gov
NCT05119777 HArmonyCa Injectable Gel for Mid Face Soft Tissue Augmentation Phase4 Soft Tissue Augmentation Completed 2021-10-13 2023-09-15 ClinicalTrials.gov
NCT05029882 Study to Assess Adverse Events and Change in Disease Activity in Adult Particip… Phase1 Non-Small Cell Lung Cancer Active_Not_Recruiting 2021-10-13 2027-11-01 ClinicalTrials.gov
NCT05029882 Study to Assess Adverse Events and Change in Disease Activity in Adult Particip… Phase1 Non-Small Cell Lung Cancer Active_Not_Recruiting 2021-10-13 2027-11-01 ClinicalTrials.gov
NCT04976777 A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applic… Phase3 Macular Edema Completed 2021-10-12 2022-02-09 ClinicalTrials.gov
NCT04976777 A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applic… Phase3 Macular Edema Completed 2021-10-12 2022-02-09 ClinicalTrials.gov
NCT04976777 A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applic… Phase3 Macular Edema Completed 2021-10-12 2022-02-09 ClinicalTrials.gov
NCT04976777 A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applic… Phase3 Macular Edema Completed 2021-10-12 2022-02-09 ClinicalTrials.gov
NCT05100199 A Study to the Assess the Change in Condition and Adverse Events of Onabotulinu… Phase2 Glabellar Lines Completed 2021-10-06 2022-12-02 ClinicalTrials.gov
NCT05100199 A Study to the Assess the Change in Condition and Adverse Events of Onabotulinu… Phase2 Glabellar Lines Completed 2021-10-06 2022-12-02 ClinicalTrials.gov
NCT05100199 A Study to the Assess the Change in Condition and Adverse Events of Onabotulinu… Phase2 Glabellar Lines Completed 2021-10-06 2022-12-02 ClinicalTrials.gov
NCT05100199 A Study to the Assess the Change in Condition and Adverse Events of Onabotulinu… Phase2 Glabellar Lines Completed 2021-10-06 2022-12-02 ClinicalTrials.gov
NCT05026502 A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control… — Heavy Menstrual Bleeding Terminated 2021-10-05 2022-08-30 ClinicalTrials.gov
NCT05026502 A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control… — Heavy Menstrual Bleeding Terminated 2021-10-05 2022-08-30 ClinicalTrials.gov
NCT05026502 A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control… — Heavy Menstrual Bleeding Terminated 2021-10-05 2022-08-30 ClinicalTrials.gov
NCT05026502 A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control… — Heavy Menstrual Bleeding Terminated 2021-10-05 2022-08-30 ClinicalTrials.gov
NCT05029895 A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacit… — Atopic Dermatitis Completed 2021-09-29 2025-09-17 ClinicalTrials.gov
NCT05029895 A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacit… — Atopic Dermatitis Completed 2021-09-29 2025-09-17 ClinicalTrials.gov
NCT05029895 A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacit… — Atopic Dermatitis Completed 2021-09-29 2025-09-17 ClinicalTrials.gov
NCT05029895 A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacit… — Atopic Dermatitis Completed 2021-09-29 2025-09-17 ClinicalTrials.gov
NCT05016947 Venetoclax Plus Inotuzumab for B-ALL Phase1 B-cell Acute Lymphoblastic Leukemia Active_Not_Recruiting 2021-09-24 2026-12-23 ClinicalTrials.gov
NCT05016947 Venetoclax Plus Inotuzumab for B-ALL Phase1 B-cell Acute Lymphoblastic Leukemia Active_Not_Recruiting 2021-09-24 2026-12-23 ClinicalTrials.gov
NCT05016947 Venetoclax Plus Inotuzumab for B-ALL Phase1 B-cell Acute Lymphoblastic Leukemia Active_Not_Recruiting 2021-09-24 2026-12-23 ClinicalTrials.gov
NCT05016947 Venetoclax Plus Inotuzumab for B-ALL Phase1 B-cell Acute Lymphoblastic Leukemia Active_Not_Recruiting 2021-09-24 2026-12-23 ClinicalTrials.gov
NCT04948645 A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator… Phase1 ALS Terminated 2021-09-22 2025-07-15 ClinicalTrials.gov
NCT04948645 A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator… Phase1 ALS Terminated 2021-09-22 2025-07-15 ClinicalTrials.gov
NCT04948645 A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator… Phase1 ALS Terminated 2021-09-22 2025-07-15 ClinicalTrials.gov
NCT04948645 A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator… Phase1 ALS Terminated 2021-09-22 2025-07-15 ClinicalTrials.gov
NCT04853368 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsu… Phase2 Cystic Fibrosis (CF) Terminated 2021-09-20 2023-06-05 ClinicalTrials.gov
NCT04853368 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsu… Phase2 Cystic Fibrosis (CF) Terminated 2021-09-20 2023-06-05 ClinicalTrials.gov
NCT04853368 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsu… Phase2 Cystic Fibrosis (CF) Terminated 2021-09-20 2023-06-05 ClinicalTrials.gov
NCT04853368 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsu… Phase2 Cystic Fibrosis (CF) Terminated 2021-09-20 2023-06-05 ClinicalTrials.gov
NCT04949828 Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms — Chronic Pancreatitis Completed 2021-09-16 2024-02-29 ClinicalTrials.gov
NCT04949828 Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms — Chronic Pancreatitis Completed 2021-09-16 2024-02-29 ClinicalTrials.gov
NCT04949828 Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms — Chronic Pancreatitis Completed 2021-09-16 2024-02-29 ClinicalTrials.gov
NCT04949828 Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms — Chronic Pancreatitis Completed 2021-09-16 2024-02-29 ClinicalTrials.gov
NCT05077488 VFORM: Prospective, Open Label, Study to Evaluate VOLIFT With Lidocaine Treatme… Phase4 Marionette Lines Forehead Contouring Completed 2021-09-15 2022-11-08 ClinicalTrials.gov
NCT05077488 VFORM: Prospective, Open Label, Study to Evaluate VOLIFT With Lidocaine Treatme… Phase4 Marionette Lines Forehead Contouring Completed 2021-09-15 2022-11-08 ClinicalTrials.gov
NCT05077488 VFORM: Prospective, Open Label, Study to Evaluate VOLIFT With Lidocaine Treatme… Phase4 Marionette Lines Forehead Contouring Completed 2021-09-15 2022-11-08 ClinicalTrials.gov
NCT05077488 VFORM: Prospective, Open Label, Study to Evaluate VOLIFT With Lidocaine Treatme… Phase4 Marionette Lines Forehead Contouring Completed 2021-09-15 2022-11-08 ClinicalTrials.gov
NCT04972968 A Study to Evaluate the Change in Disease State and Adverse Events in Adult Par… Phase2 Polymyalgia Rheumatica Terminated 2021-09-09 2023-07-24 ClinicalTrials.gov
NCT04972968 A Study to Evaluate the Change in Disease State and Adverse Events in Adult Par… Phase2 Polymyalgia Rheumatica Terminated 2021-09-09 2023-07-24 ClinicalTrials.gov
NCT04972968 A Study to Evaluate the Change in Disease State and Adverse Events in Adult Par… Phase2 Polymyalgia Rheumatica Terminated 2021-09-09 2023-07-24 ClinicalTrials.gov
NCT04972968 A Study to Evaluate the Change in Disease State and Adverse Events in Adult Par… Phase2 Polymyalgia Rheumatica Terminated 2021-09-09 2023-07-24 ClinicalTrials.gov
NCT04572763 Copanlisib Plus Venetoclax in R/R DLBCL Phase1 Diffuse Large B Cell Lymphoma Active_Not_Recruiting 2021-09-08 2026-07-29 ClinicalTrials.gov
NCT04572763 Copanlisib Plus Venetoclax in R/R DLBCL Phase1 Diffuse Large B Cell Lymphoma Active_Not_Recruiting 2021-09-08 2026-07-29 ClinicalTrials.gov
NCT04572763 Copanlisib Plus Venetoclax in R/R DLBCL Phase1 Diffuse Large B Cell Lymphoma Active_Not_Recruiting 2021-09-08 2026-07-29 ClinicalTrials.gov
NCT04572763 Copanlisib Plus Venetoclax in R/R DLBCL Phase1 Diffuse Large B Cell Lymphoma Active_Not_Recruiting 2021-09-08 2026-07-29 ClinicalTrials.gov
NCT04983589 A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyo… Phase3 Presbyopia Completed 2021-09-02 2022-02-11 ClinicalTrials.gov
NCT04983589 A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyo… Phase3 Presbyopia Completed 2021-09-02 2022-02-11 ClinicalTrials.gov
NCT04983589 A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyo… Phase3 Presbyopia Completed 2021-09-02 2022-02-11 ClinicalTrials.gov
NCT04983589 A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyo… Phase3 Presbyopia Completed 2021-09-02 2022-02-11 ClinicalTrials.gov
NCT05013424 A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar … Phase2 Glabellar Lines Completed 2021-09-01 2022-07-07 ClinicalTrials.gov
NCT05013424 A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar … Phase2 Glabellar Lines Completed 2021-09-01 2022-07-07 ClinicalTrials.gov
NCT05013424 A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar … Phase2 Glabellar Lines Completed 2021-09-01 2022-07-07 ClinicalTrials.gov
NCT05013424 A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar … Phase2 Glabellar Lines Completed 2021-09-01 2022-07-07 ClinicalTrials.gov
NCT04903626 Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Ad… Phase3 Hepatitis C Virus (HCV) Completed 2021-08-24 2024-09-17 ClinicalTrials.gov
NCT04903626 Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Ad… Phase3 Hepatitis C Virus (HCV) Completed 2021-08-24 2024-09-17 ClinicalTrials.gov
NCT04903626 Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Ad… Phase3 Hepatitis C Virus (HCV) Completed 2021-08-24 2024-09-17 ClinicalTrials.gov
NCT04903626 Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Ad… Phase3 Hepatitis C Virus (HCV) Completed 2021-08-24 2024-09-17 ClinicalTrials.gov
NCT04965272 A Study To Assess Adverse Events and Change in Disease Activity With Oral Carip… Phase2 Generalized Anxiety Disorder Withdrawn 2021-08-18 2021-08-24 ClinicalTrials.gov
NCT04965272 A Study To Assess Adverse Events and Change in Disease Activity With Oral Carip… Phase2 Generalized Anxiety Disorder Withdrawn 2021-08-18 2021-08-24 ClinicalTrials.gov
NCT04965272 A Study To Assess Adverse Events and Change in Disease Activity With Oral Carip… Phase2 Generalized Anxiety Disorder Withdrawn 2021-08-18 2021-08-24 ClinicalTrials.gov
NCT04965272 A Study To Assess Adverse Events and Change in Disease Activity With Oral Carip… Phase2 Generalized Anxiety Disorder Withdrawn 2021-08-18 2021-08-24 ClinicalTrials.gov
NCT04880876 A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With… Phase3 Irritable Bowel Syndrome Enrolling_By_Invitation 2021-08-13 2032-12-01 ClinicalTrials.gov
NCT04880876 A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With… Phase3 Irritable Bowel Syndrome Enrolling_By_Invitation 2021-08-13 2032-12-01 ClinicalTrials.gov
NCT04880876 A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With… Phase3 Irritable Bowel Syndrome Enrolling_By_Invitation 2021-08-13 2032-12-01 ClinicalTrials.gov
NCT04880876 A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With… Phase3 Irritable Bowel Syndrome Enrolling_By_Invitation 2021-08-13 2032-12-01 ClinicalTrials.gov
NCT04994535 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramus… Phase3 Platysma Prominence Completed 2021-08-10 2023-06-14 ClinicalTrials.gov
NCT04994535 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramus… Phase3 Platysma Prominence Completed 2021-08-10 2023-06-14 ClinicalTrials.gov
NCT04994535 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramus… Phase3 Platysma Prominence Completed 2021-08-10 2023-06-14 ClinicalTrials.gov
NCT04994535 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramus… Phase3 Platysma Prominence Completed 2021-08-10 2023-06-14 ClinicalTrials.gov
NCT04677153 Rapid HCV Treatment Access for Persons Who Use Drugs Na Hepatitis C Virus Infection, Response to Therapy of Completed 2021-08-06 2024-09-23 ClinicalTrials.gov
NCT04677153 Rapid HCV Treatment Access for Persons Who Use Drugs Na Hepatitis C Virus Infection, Response to Therapy of Completed 2021-08-06 2024-09-23 ClinicalTrials.gov
NCT04677153 Rapid HCV Treatment Access for Persons Who Use Drugs Na Hepatitis C Virus Infection, Response to Therapy of Completed 2021-08-06 2024-09-23 ClinicalTrials.gov
NCT04677153 Rapid HCV Treatment Access for Persons Who Use Drugs Na Hepatitis C Virus Infection, Response to Therapy of Completed 2021-08-06 2024-09-23 ClinicalTrials.gov
NCT04829747 Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adu… Phase3 Chronic Migraine Completed 2021-08-02 2022-01-20 ClinicalTrials.gov
NCT04829747 Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adu… Phase3 Chronic Migraine Completed 2021-08-02 2022-01-20 ClinicalTrials.gov
NCT04829747 Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adu… Phase3 Chronic Migraine Completed 2021-08-02 2022-01-20 ClinicalTrials.gov
NCT04829747 Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adu… Phase3 Chronic Migraine Completed 2021-08-02 2022-01-20 ClinicalTrials.gov
NCT05420233 The CROCO Study: CROhn's Disease COhort Study Na Crohn Disease Recruiting 2021-08-01 2030-07-01 ClinicalTrials.gov
NCT05420233 The CROCO Study: CROhn's Disease COhort Study Na Crohn Disease Recruiting 2021-08-01 2030-07-01 ClinicalTrials.gov
NCT05420233 The CROCO Study: CROhn's Disease COhort Study Na Crohn Disease Recruiting 2021-08-01 2030-07-01 ClinicalTrials.gov
NCT05420233 The CROCO Study: CROhn's Disease COhort Study Na Crohn Disease Recruiting 2021-08-01 2030-07-01 ClinicalTrials.gov
NCT04846959 Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relati… — Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment Recruiting 2021-07-30 2032-06-01 ClinicalTrials.gov
NCT04846959 Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relati… — Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment Recruiting 2021-07-30 2032-06-01 ClinicalTrials.gov
NCT04846959 Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relati… — Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment Recruiting 2021-07-30 2032-06-01 ClinicalTrials.gov
NCT04846959 Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relati… — Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment Recruiting 2021-07-30 2032-06-01 ClinicalTrials.gov
NCT04862286 Study to Evaluate Adverse Events and Change in Disease Activity in Participants… Phase3 Psoriasis Active_Not_Recruiting 2021-07-24 2028-04-01 ClinicalTrials.gov
NCT04862286 Study to Evaluate Adverse Events and Change in Disease Activity in Participants… Phase3 Psoriasis Active_Not_Recruiting 2021-07-24 2028-04-01 ClinicalTrials.gov
NCT04862286 Study to Evaluate Adverse Events and Change in Disease Activity in Participants… Phase3 Psoriasis Active_Not_Recruiting 2021-07-24 2028-04-01 ClinicalTrials.gov
NCT04862286 Study to Evaluate Adverse Events and Change in Disease Activity in Participants… Phase3 Psoriasis Active_Not_Recruiting 2021-07-24 2028-04-01 ClinicalTrials.gov
NCT04891419 JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese … Phase3 Temple Hollowing Completed 2021-07-20 2023-11-22 ClinicalTrials.gov
NCT04891419 JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese … Phase3 Temple Hollowing Completed 2021-07-20 2023-11-22 ClinicalTrials.gov
NCT04891419 JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese … Phase3 Temple Hollowing Completed 2021-07-20 2023-11-22 ClinicalTrials.gov
NCT04891419 JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese … Phase3 Temple Hollowing Completed 2021-07-20 2023-11-22 ClinicalTrials.gov
NCT04918823 Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device Phase1 Ocular Surface Disease Completed 2021-07-15 2023-04-14 ClinicalTrials.gov
NCT04918823 Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device Phase1 Ocular Surface Disease Completed 2021-07-15 2023-04-14 ClinicalTrials.gov
NCT04918823 Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device Phase1 Ocular Surface Disease Completed 2021-07-15 2023-04-14 ClinicalTrials.gov
NCT04918823 Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device Phase1 Ocular Surface Disease Completed 2021-07-15 2023-04-14 ClinicalTrials.gov
NCT04810598 Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Throu… Phase1 Renal Impairment Completed 2021-07-08 2022-08-16 ClinicalTrials.gov
NCT04949399 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramus… Phase3 Platysma Prominence Completed 2021-07-08 2022-12-20 ClinicalTrials.gov
NCT04810598 Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Throu… Phase1 Renal Impairment Completed 2021-07-08 2022-08-16 ClinicalTrials.gov
NCT04810598 Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Throu… Phase1 Renal Impairment Completed 2021-07-08 2022-08-16 ClinicalTrials.gov
NCT04810598 Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Throu… Phase1 Renal Impairment Completed 2021-07-08 2022-08-16 ClinicalTrials.gov
NCT04949399 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramus… Phase3 Platysma Prominence Completed 2021-07-08 2022-12-20 ClinicalTrials.gov
NCT04949399 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramus… Phase3 Platysma Prominence Completed 2021-07-08 2022-12-20 ClinicalTrials.gov
NCT04949399 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramus… Phase3 Platysma Prominence Completed 2021-07-08 2022-12-20 ClinicalTrials.gov
NCT04721002 Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants Wit… — Multiple Myeloma (MM) Completed 2021-07-07 2023-09-30 ClinicalTrials.gov
NCT04721002 Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants Wit… — Multiple Myeloma (MM) Completed 2021-07-07 2023-09-30 ClinicalTrials.gov
NCT04721002 Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants Wit… — Multiple Myeloma (MM) Completed 2021-07-07 2023-09-30 ClinicalTrials.gov
NCT04721002 Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants Wit… — Multiple Myeloma (MM) Completed 2021-07-07 2023-09-30 ClinicalTrials.gov
NCT05038878 An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to … Phase4 Mild Autonomous Cortisol Excess Terminated 2021-07-06 2022-06-24 ClinicalTrials.gov
NCT05038878 An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to … Phase4 Mild Autonomous Cortisol Excess Terminated 2021-07-06 2022-06-24 ClinicalTrials.gov
NCT05038878 An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to … Phase4 Mild Autonomous Cortisol Excess Terminated 2021-07-06 2022-06-24 ClinicalTrials.gov
NCT05038878 An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to … Phase4 Mild Autonomous Cortisol Excess Terminated 2021-07-06 2022-06-24 ClinicalTrials.gov
NCT04543916 Venetoclax and Irinotecan in Relapsed/Refractory SCLC Phase1 Relapsed Small Cell Lung Cancer Withdrawn 2021-06-30 2028-06-30 ClinicalTrials.gov
NCT04543916 Venetoclax and Irinotecan in Relapsed/Refractory SCLC Phase1 Relapsed Small Cell Lung Cancer Withdrawn 2021-06-30 2028-06-30 ClinicalTrials.gov
NCT04543916 Venetoclax and Irinotecan in Relapsed/Refractory SCLC Phase1 Relapsed Small Cell Lung Cancer Withdrawn 2021-06-30 2028-06-30 ClinicalTrials.gov
NCT04927975 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Table… Phase2 Non-Segmental Vitiligo Completed 2021-06-30 2023-08-29 ClinicalTrials.gov
NCT04927975 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Table… Phase2 Non-Segmental Vitiligo Completed 2021-06-30 2023-08-29 ClinicalTrials.gov
NCT04927975 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Table… Phase2 Non-Segmental Vitiligo Completed 2021-06-30 2023-08-29 ClinicalTrials.gov
NCT04927975 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Table… Phase2 Non-Segmental Vitiligo Completed 2021-06-30 2023-08-29 ClinicalTrials.gov
NCT04543916 Venetoclax and Irinotecan in Relapsed/Refractory SCLC Phase1 Relapsed Small Cell Lung Cancer Withdrawn 2021-06-30 2028-06-30 ClinicalTrials.gov
NCT04912063 Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Use… Phase1 Acute Myeloid Leukemia (AML) Terminated 2021-06-25 2023-05-09 ClinicalTrials.gov
NCT04912063 Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Use… Phase1 Acute Myeloid Leukemia (AML) Terminated 2021-06-25 2023-05-09 ClinicalTrials.gov
NCT04912063 Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Use… Phase1 Acute Myeloid Leukemia (AML) Terminated 2021-06-25 2023-05-09 ClinicalTrials.gov
NCT04912063 Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Use… Phase1 Acute Myeloid Leukemia (AML) Terminated 2021-06-25 2023-05-09 ClinicalTrials.gov
NCT04888585 Study to Evaluate Adverse Events and Change in Disease Activity in Participants… Phase2 Rheumatoid Arthritis (RA) Terminated 2021-06-23 2023-08-04 ClinicalTrials.gov
NCT04799990 Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Give… — Psoriasis Withdrawn 2021-06-23 2022-03-10 ClinicalTrials.gov
NCT04888585 Study to Evaluate Adverse Events and Change in Disease Activity in Participants… Phase2 Rheumatoid Arthritis (RA) Terminated 2021-06-23 2023-08-04 ClinicalTrials.gov
NCT04799990 Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Give… — Psoriasis Withdrawn 2021-06-23 2022-03-10 ClinicalTrials.gov
NCT04888585 Study to Evaluate Adverse Events and Change in Disease Activity in Participants… Phase2 Rheumatoid Arthritis (RA) Terminated 2021-06-23 2023-08-04 ClinicalTrials.gov
NCT04799990 Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Give… — Psoriasis Withdrawn 2021-06-23 2022-03-10 ClinicalTrials.gov
NCT04888585 Study to Evaluate Adverse Events and Change in Disease Activity in Participants… Phase2 Rheumatoid Arthritis (RA) Terminated 2021-06-23 2023-08-04 ClinicalTrials.gov
NCT04799990 Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Give… — Psoriasis Withdrawn 2021-06-23 2022-03-10 ClinicalTrials.gov
NCT04958031 A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subject… Phase2 Apathy in Dementia Terminated 2021-06-22 2025-02-12 ClinicalTrials.gov
NCT04958031 A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subject… Phase2 Apathy in Dementia Terminated 2021-06-22 2025-02-12 ClinicalTrials.gov
NCT04958031 A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subject… Phase2 Apathy in Dementia Terminated 2021-06-22 2025-02-12 ClinicalTrials.gov
NCT04958031 A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subject… Phase2 Apathy in Dementia Terminated 2021-06-22 2025-02-12 ClinicalTrials.gov
NCT04908475 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablet… Phase4 Psoriasis Completed 2021-06-09 2023-04-20 ClinicalTrials.gov
NCT04908475 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablet… Phase4 Psoriasis Completed 2021-06-09 2023-04-20 ClinicalTrials.gov
NCT04908475 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablet… Phase4 Psoriasis Completed 2021-06-09 2023-04-20 ClinicalTrials.gov
NCT04908475 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablet… Phase4 Psoriasis Completed 2021-06-09 2023-04-20 ClinicalTrials.gov
NCT04818385 Study to Assess the Change in Disease State When Subcutaneous Risankizumab Inje… — Psoriasis Completed 2021-05-31 2025-08-01 ClinicalTrials.gov
NCT04818385 Study to Assess the Change in Disease State When Subcutaneous Risankizumab Inje… — Psoriasis Completed 2021-05-31 2025-08-01 ClinicalTrials.gov
NCT04818385 Study to Assess the Change in Disease State When Subcutaneous Risankizumab Inje… — Psoriasis Completed 2021-05-31 2025-08-01 ClinicalTrials.gov
NCT04818385 Study to Assess the Change in Disease State When Subcutaneous Risankizumab Inje… — Psoriasis Completed 2021-05-31 2025-08-01 ClinicalTrials.gov
NCT04813263 Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disea… — Acute Myeloid Leukemia (AML) Completed 2021-05-28 2024-04-30 ClinicalTrials.gov
NCT04807972 Study to Evaluate Adverse Events and Change in Disease Activity When Intravenou… Phase1 Pancreatic Cancer Terminated 2021-05-28 2024-03-25 ClinicalTrials.gov
NCT04807972 Study to Evaluate Adverse Events and Change in Disease Activity When Intravenou… Phase1 Pancreatic Cancer Terminated 2021-05-28 2024-03-25 ClinicalTrials.gov
NCT04813263 Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disea… — Acute Myeloid Leukemia (AML) Completed 2021-05-28 2024-04-30 ClinicalTrials.gov
NCT04807972 Study to Evaluate Adverse Events and Change in Disease Activity When Intravenou… Phase1 Pancreatic Cancer Terminated 2021-05-28 2024-03-25 ClinicalTrials.gov
NCT04807972 Study to Evaluate Adverse Events and Change in Disease Activity When Intravenou… Phase1 Pancreatic Cancer Terminated 2021-05-28 2024-03-25 ClinicalTrials.gov
NCT04813263 Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disea… — Acute Myeloid Leukemia (AML) Completed 2021-05-28 2024-04-30 ClinicalTrials.gov
NCT04813263 Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disea… — Acute Myeloid Leukemia (AML) Completed 2021-05-28 2024-04-30 ClinicalTrials.gov
NCT04913610 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-40… Phase2 Onchocerciasis Terminated 2021-05-22 2023-08-29 ClinicalTrials.gov
NCT04913610 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-40… Phase2 Onchocerciasis Terminated 2021-05-22 2023-08-29 ClinicalTrials.gov
NCT04913610 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-40… Phase2 Onchocerciasis Terminated 2021-05-22 2023-08-29 ClinicalTrials.gov
NCT04913610 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-40… Phase2 Onchocerciasis Terminated 2021-05-22 2023-08-29 ClinicalTrials.gov
NCT04801797 Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Phase2 Acute Myeloid Leukemia Active_Not_Recruiting 2021-05-20 2028-01-01 ClinicalTrials.gov
NCT04801797 Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Phase2 Acute Myeloid Leukemia Active_Not_Recruiting 2021-05-20 2028-01-01 ClinicalTrials.gov
NCT04801797 Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Phase2 Acute Myeloid Leukemia Active_Not_Recruiting 2021-05-20 2028-01-01 ClinicalTrials.gov
NCT04801797 Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Phase2 Acute Myeloid Leukemia Active_Not_Recruiting 2021-05-20 2028-01-01 ClinicalTrials.gov
NCT04837482 A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-1905… Phase3 Presbyopia Completed 2021-05-14 2021-12-07 ClinicalTrials.gov
NCT04837482 A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-1905… Phase3 Presbyopia Completed 2021-05-14 2021-12-07 ClinicalTrials.gov
NCT04837482 A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-1905… Phase3 Presbyopia Completed 2021-05-14 2021-12-07 ClinicalTrials.gov
NCT04837482 A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-1905… Phase3 Presbyopia Completed 2021-05-14 2021-12-07 ClinicalTrials.gov
NCT04416451 A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of… Phase2 Marginal Zone Lymphoma Active_Not_Recruiting 2021-05-04 2027-06-01 ClinicalTrials.gov
NCT04416451 A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of… Phase2 Marginal Zone Lymphoma Active_Not_Recruiting 2021-05-04 2027-06-01 ClinicalTrials.gov
NCT04416451 A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of… Phase2 Marginal Zone Lymphoma Active_Not_Recruiting 2021-05-04 2027-06-01 ClinicalTrials.gov
NCT04416451 A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of… Phase2 Marginal Zone Lymphoma Active_Not_Recruiting 2021-05-04 2027-06-01 ClinicalTrials.gov
NCT04846244 A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthr… — Axial Spondylarthritis (axSpA) Completed 2021-04-30 2025-03-24 ClinicalTrials.gov
NCT04846244 A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthr… — Axial Spondylarthritis (axSpA) Completed 2021-04-30 2025-03-24 ClinicalTrials.gov
NCT04846244 A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthr… — Axial Spondylarthritis (axSpA) Completed 2021-04-30 2025-03-24 ClinicalTrials.gov
NCT04846244 A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthr… — Axial Spondylarthritis (axSpA) Completed 2021-04-30 2025-03-24 ClinicalTrials.gov
NCT04777357 A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cari… Phase3 Depression Recruiting 2021-04-28 2027-03-01 ClinicalTrials.gov
NCT04777357 A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cari… Phase3 Depression Recruiting 2021-04-28 2027-03-01 ClinicalTrials.gov
NCT04777357 A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cari… Phase3 Depression Recruiting 2021-04-28 2027-03-01 ClinicalTrials.gov
NCT04777357 A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cari… Phase3 Depression Recruiting 2021-04-28 2027-03-01 ClinicalTrials.gov
NCT04804254 Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral … Phase1 B-cell Lymphoma Terminated 2021-04-27 2023-01-11 ClinicalTrials.gov
NCT04804254 Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral … Phase1 B-cell Lymphoma Terminated 2021-04-27 2023-01-11 ClinicalTrials.gov
NCT04804254 Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral … Phase1 B-cell Lymphoma Terminated 2021-04-27 2023-01-11 ClinicalTrials.gov
NCT04804254 Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral … Phase1 B-cell Lymphoma Terminated 2021-04-27 2023-01-11 ClinicalTrials.gov
NCT04780516 Study to Assess Change in Disease Symptoms in Adult Participants With Moderate … — Psoriasis Active_Not_Recruiting 2021-04-26 2026-12-01 ClinicalTrials.gov
NCT04780516 Study to Assess Change in Disease Symptoms in Adult Participants With Moderate … — Psoriasis Active_Not_Recruiting 2021-04-26 2026-12-01 ClinicalTrials.gov
NCT04780516 Study to Assess Change in Disease Symptoms in Adult Participants With Moderate … — Psoriasis Active_Not_Recruiting 2021-04-26 2026-12-01 ClinicalTrials.gov
NCT04780516 Study to Assess Change in Disease Symptoms in Adult Participants With Moderate … — Psoriasis Active_Not_Recruiting 2021-04-26 2026-12-01 ClinicalTrials.gov
NCT04721223 JAB-3068 Activity in Adult Patients With Advanced Solid Tumors Phase1 Advanced Solid Tumor Completed 2021-04-26 2023-12-29 ClinicalTrials.gov
NCT04721223 JAB-3068 Activity in Adult Patients With Advanced Solid Tumors Phase1 Advanced Solid Tumor Completed 2021-04-26 2023-12-29 ClinicalTrials.gov
NCT04721223 JAB-3068 Activity in Adult Patients With Advanced Solid Tumors Phase1 Advanced Solid Tumor Completed 2021-04-26 2023-12-29 ClinicalTrials.gov
NCT04721223 JAB-3068 Activity in Adult Patients With Advanced Solid Tumors Phase1 Advanced Solid Tumor Completed 2021-04-26 2023-12-29 ClinicalTrials.gov
NCT04500106 Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assist… — Parkinson's Disease Completed 2021-04-22 2021-10-14 ClinicalTrials.gov
NCT04500106 Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assist… — Parkinson's Disease Completed 2021-04-22 2021-10-14 ClinicalTrials.gov
NCT04500106 Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assist… — Parkinson's Disease Completed 2021-04-22 2021-10-14 ClinicalTrials.gov
NCT04500106 Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assist… — Parkinson's Disease Completed 2021-04-22 2021-10-14 ClinicalTrials.gov
NCT04554966 Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) AB… Phase1 Human Immunodeficiency Virus (HIV) Completed 2021-04-16 2023-08-14 ClinicalTrials.gov
NCT04554966 Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) AB… Phase1 Human Immunodeficiency Virus (HIV) Completed 2021-04-16 2023-08-14 ClinicalTrials.gov
NCT04554966 Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) AB… Phase1 Human Immunodeficiency Virus (HIV) Completed 2021-04-16 2023-08-14 ClinicalTrials.gov
NCT04554966 Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) AB… Phase1 Human Immunodeficiency Virus (HIV) Completed 2021-04-16 2023-08-14 ClinicalTrials.gov
NCT04630652 Risankizumab Long-term Remission Study Phase4 Psoriasis Completed 2021-04-07 2025-05-13 ClinicalTrials.gov
NCT04630652 Risankizumab Long-term Remission Study Phase4 Psoriasis Completed 2021-04-07 2025-05-13 ClinicalTrials.gov
NCT04630652 Risankizumab Long-term Remission Study Phase4 Psoriasis Completed 2021-04-07 2025-05-13 ClinicalTrials.gov
NCT04630652 Risankizumab Long-term Remission Study Phase4 Psoriasis Completed 2021-04-07 2025-05-13 ClinicalTrials.gov
NCT04826523 Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disea… — Acute Myeloid Leukemia (AML) Completed 2021-04-05 2025-10-20 ClinicalTrials.gov
NCT04826523 Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disea… — Acute Myeloid Leukemia (AML) Completed 2021-04-05 2025-10-20 ClinicalTrials.gov
NCT04826523 Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disea… — Acute Myeloid Leukemia (AML) Completed 2021-04-05 2025-10-20 ClinicalTrials.gov
NCT04826523 Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disea… — Acute Myeloid Leukemia (AML) Completed 2021-04-05 2025-10-20 ClinicalTrials.gov
NCT04720976 JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors Phase1 Solid Tumor Completed 2021-03-23 2023-12-19 ClinicalTrials.gov
NCT04720976 JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors Phase1 Solid Tumor Completed 2021-03-23 2023-12-19 ClinicalTrials.gov
NCT04720976 JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors Phase1 Solid Tumor Completed 2021-03-23 2023-12-19 ClinicalTrials.gov
NCT04720976 JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors Phase1 Solid Tumor Completed 2021-03-23 2023-12-19 ClinicalTrials.gov
NCT04827368 Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease — IBD Active_Not_Recruiting 2021-03-22 2026-06-30 ClinicalTrials.gov
NCT04827368 Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease — IBD Active_Not_Recruiting 2021-03-22 2026-06-30 ClinicalTrials.gov
NCT04827368 Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease — IBD Active_Not_Recruiting 2021-03-22 2026-06-30 ClinicalTrials.gov
NCT04827368 Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease — IBD Active_Not_Recruiting 2021-03-22 2026-06-30 ClinicalTrials.gov
NCT04480086 Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With… Phase1 Myelofibrosis (MF) Terminated 2021-03-17 2023-07-28 ClinicalTrials.gov
NCT04480086 Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With… Phase1 Myelofibrosis (MF) Terminated 2021-03-17 2023-07-28 ClinicalTrials.gov
NCT04818515 Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atog… Phase1 Migraine Completed 2021-03-17 2021-06-18 ClinicalTrials.gov
NCT04818515 Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atog… Phase1 Migraine Completed 2021-03-17 2021-06-18 ClinicalTrials.gov
NCT04480086 Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With… Phase1 Myelofibrosis (MF) Terminated 2021-03-17 2023-07-28 ClinicalTrials.gov
NCT04818515 Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atog… Phase1 Migraine Completed 2021-03-17 2021-06-18 ClinicalTrials.gov
NCT04480086 Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With… Phase1 Myelofibrosis (MF) Terminated 2021-03-17 2023-07-28 ClinicalTrials.gov
NCT04818515 Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atog… Phase1 Migraine Completed 2021-03-17 2021-06-18 ClinicalTrials.gov
NCT04799353 Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutan… Phase1 Human Immunodeficiency Virus (HIV) Completed 2021-03-15 2022-10-11 ClinicalTrials.gov
NCT04799353 Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutan… Phase1 Human Immunodeficiency Virus (HIV) Completed 2021-03-15 2022-10-11 ClinicalTrials.gov
NCT04799353 Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutan… Phase1 Human Immunodeficiency Virus (HIV) Completed 2021-03-15 2022-10-11 ClinicalTrials.gov
NCT04799353 Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutan… Phase1 Human Immunodeficiency Virus (HIV) Completed 2021-03-15 2022-10-11 ClinicalTrials.gov
NCT04755595 Combination Facial Aesthetic Treatment in Millennials Phase2 Dermatological Non-Disease Completed 2021-03-09 2021-05-19 ClinicalTrials.gov
NCT04755595 Combination Facial Aesthetic Treatment in Millennials Phase2 Dermatological Non-Disease Completed 2021-03-09 2021-05-19 ClinicalTrials.gov
NCT04755595 Combination Facial Aesthetic Treatment in Millennials Phase2 Dermatological Non-Disease Completed 2021-03-09 2021-05-19 ClinicalTrials.gov
NCT04755595 Combination Facial Aesthetic Treatment in Millennials Phase2 Dermatological Non-Disease Completed 2021-03-09 2021-05-19 ClinicalTrials.gov
NCT04740827 Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral … Phase3 Episodic Migraine Completed 2021-03-05 2022-08-04 ClinicalTrials.gov
NCT04740827 Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral … Phase3 Episodic Migraine Completed 2021-03-05 2022-08-04 ClinicalTrials.gov
NCT04740827 Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral … Phase3 Episodic Migraine Completed 2021-03-05 2022-08-04 ClinicalTrials.gov
NCT04740827 Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral … Phase3 Episodic Migraine Completed 2021-03-05 2022-08-04 ClinicalTrials.gov
NCT04647214 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Impl… — Open-angle Glaucoma Completed 2021-03-03 2024-07-12 ClinicalTrials.gov
NCT04647214 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Impl… — Open-angle Glaucoma Completed 2021-03-03 2024-07-12 ClinicalTrials.gov
NCT04647214 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Impl… — Open-angle Glaucoma Completed 2021-03-03 2024-07-12 ClinicalTrials.gov
NCT04647214 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Impl… — Open-angle Glaucoma Completed 2021-03-03 2024-07-12 ClinicalTrials.gov
NCT04608318 Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus… Phase3 Chronic Lymphoid Leukemia Active_Not_Recruiting 2021-03-01 2027-09-01 ClinicalTrials.gov
NCT04608318 Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus… Phase3 Chronic Lymphoid Leukemia Active_Not_Recruiting 2021-03-01 2027-09-01 ClinicalTrials.gov
NCT04608318 Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus… Phase3 Chronic Lymphoid Leukemia Active_Not_Recruiting 2021-03-01 2027-09-01 ClinicalTrials.gov
NCT04608318 Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus… Phase3 Chronic Lymphoid Leukemia Active_Not_Recruiting 2021-03-01 2027-09-01 ClinicalTrials.gov
NCT04713592 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change i… Phase3 Psoriasis Completed 2021-02-26 2023-04-20 ClinicalTrials.gov
NCT04713592 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change i… Phase3 Psoriasis Completed 2021-02-26 2023-04-20 ClinicalTrials.gov
NCT04713592 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change i… Phase3 Psoriasis Completed 2021-02-26 2023-04-20 ClinicalTrials.gov
NCT04713592 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change i… Phase3 Psoriasis Completed 2021-02-26 2023-04-20 ClinicalTrials.gov
NCT04760769 Open-label Trial in Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2021-02-24 2025-12-01 ClinicalTrials.gov
NCT04760769 Open-label Trial in Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2021-02-24 2025-12-01 ClinicalTrials.gov
NCT04760769 Open-label Trial in Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2021-02-24 2025-12-01 ClinicalTrials.gov
NCT04760769 Open-label Trial in Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2021-02-24 2025-12-01 ClinicalTrials.gov
NCT04721015 Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Os… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2021-02-23 2026-02-01 ClinicalTrials.gov
NCT04721015 Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Os… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2021-02-23 2026-02-01 ClinicalTrials.gov
NCT04721015 Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Os… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2021-02-23 2026-02-01 ClinicalTrials.gov
NCT04721015 Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Os… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2021-02-23 2026-02-01 ClinicalTrials.gov
NCT04832724 RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular … Phase2 Neovascular Age-related Macular Degeneration Completed 2021-02-22 2024-03-18 ClinicalTrials.gov
NCT04832724 RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular … Phase2 Neovascular Age-related Macular Degeneration Completed 2021-02-22 2024-03-18 ClinicalTrials.gov
NCT04832724 RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular … Phase2 Neovascular Age-related Macular Degeneration Completed 2021-02-22 2024-03-18 ClinicalTrials.gov
NCT04832724 RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular … Phase2 Neovascular Age-related Macular Degeneration Completed 2021-02-22 2024-03-18 ClinicalTrials.gov
NCT04686136 A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for th… Phase3 Episodic Migraine Completed 2021-02-19 2025-10-20 ClinicalTrials.gov
NCT04686136 A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for th… Phase3 Episodic Migraine Completed 2021-02-19 2025-10-20 ClinicalTrials.gov
NCT04686136 A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for th… Phase3 Episodic Migraine Completed 2021-02-19 2025-10-20 ClinicalTrials.gov
NCT04686136 A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for th… Phase3 Episodic Migraine Completed 2021-02-19 2025-10-20 ClinicalTrials.gov
NCT04750226 Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Contin… Phase3 Parkinson's Disease (PD) Completed 2021-02-18 2026-04-27 ClinicalTrials.gov
NCT04750226 Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Contin… Phase3 Parkinson's Disease (PD) Completed 2021-02-18 2026-04-27 ClinicalTrials.gov
NCT04750226 Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Contin… Phase3 Parkinson's Disease (PD) Completed 2021-02-18 2026-04-27 ClinicalTrials.gov
NCT04750226 Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Contin… Phase3 Parkinson's Disease (PD) Completed 2021-02-18 2026-04-27 ClinicalTrials.gov
NCT04750213 A Study to Assess Adverse Events and Change in Disease State in Adult Participa… — Pyoderma Gangrenosum Completed 2021-02-12 2024-11-11 ClinicalTrials.gov
NCT04750213 A Study to Assess Adverse Events and Change in Disease State in Adult Participa… — Pyoderma Gangrenosum Completed 2021-02-12 2024-11-11 ClinicalTrials.gov
NCT04750213 A Study to Assess Adverse Events and Change in Disease State in Adult Participa… — Pyoderma Gangrenosum Completed 2021-02-12 2024-11-11 ClinicalTrials.gov
NCT04750213 A Study to Assess Adverse Events and Change in Disease State in Adult Participa… — Pyoderma Gangrenosum Completed 2021-02-12 2024-11-11 ClinicalTrials.gov
NCT04758117 A Study to Assess the Change in Disease State in Adult Participants Being Treat… — Psoriatic Arthritis Completed 2021-02-04 2023-07-26 ClinicalTrials.gov
NCT04687046 A Study of JUVÉDERM VOLUX® Injectable Gel for Chin Enhancement in Chinese Adult… — Chin Retrusion Completed 2021-02-04 2022-02-28 ClinicalTrials.gov
NCT04687046 A Study of JUVÉDERM VOLUX® Injectable Gel for Chin Enhancement in Chinese Adult… — Chin Retrusion Completed 2021-02-04 2022-02-28 ClinicalTrials.gov
NCT04758117 A Study to Assess the Change in Disease State in Adult Participants Being Treat… — Psoriatic Arthritis Completed 2021-02-04 2023-07-26 ClinicalTrials.gov
NCT04758117 A Study to Assess the Change in Disease State in Adult Participants Being Treat… — Psoriatic Arthritis Completed 2021-02-04 2023-07-26 ClinicalTrials.gov
NCT04687046 A Study of JUVÉDERM VOLUX® Injectable Gel for Chin Enhancement in Chinese Adult… — Chin Retrusion Completed 2021-02-04 2022-02-28 ClinicalTrials.gov
NCT04758117 A Study to Assess the Change in Disease State in Adult Participants Being Treat… — Psoriatic Arthritis Completed 2021-02-04 2023-07-26 ClinicalTrials.gov
NCT04687046 A Study of JUVÉDERM VOLUX® Injectable Gel for Chin Enhancement in Chinese Adult… — Chin Retrusion Completed 2021-02-04 2022-02-28 ClinicalTrials.gov
NCT04578756 Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerabili… Phase3 Schizophrenia Completed 2021-02-01 2025-10-06 ClinicalTrials.gov
NCT04578756 Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerabili… Phase3 Schizophrenia Completed 2021-02-01 2025-10-06 ClinicalTrials.gov
NCT04578756 Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerabili… Phase3 Schizophrenia Completed 2021-02-01 2025-10-06 ClinicalTrials.gov
NCT04578756 Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerabili… Phase3 Schizophrenia Completed 2021-02-01 2025-10-06 ClinicalTrials.gov
NCT04541810 A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Chan… — Rheumatoid Arthritis (RA) Completed 2021-01-26 2025-12-31 ClinicalTrials.gov
NCT04541810 A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Chan… — Rheumatoid Arthritis (RA) Completed 2021-01-26 2025-12-31 ClinicalTrials.gov
NCT04541810 A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Chan… — Rheumatoid Arthritis (RA) Completed 2021-01-26 2025-12-31 ClinicalTrials.gov
NCT04541810 A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Chan… — Rheumatoid Arthritis (RA) Completed 2021-01-26 2025-12-31 ClinicalTrials.gov
NCT04655300 Evaluation of Age-related Skin Changes Using Clinical Probe Measurements and Im… — Age-related Skin Changes Completed 2021-01-16 2021-02-05 ClinicalTrials.gov
NCT04655300 Evaluation of Age-related Skin Changes Using Clinical Probe Measurements and Im… — Age-related Skin Changes Completed 2021-01-16 2021-02-05 ClinicalTrials.gov
NCT04655300 Evaluation of Age-related Skin Changes Using Clinical Probe Measurements and Im… — Age-related Skin Changes Completed 2021-01-16 2021-02-05 ClinicalTrials.gov
NCT04655300 Evaluation of Age-related Skin Changes Using Clinical Probe Measurements and Im… — Age-related Skin Changes Completed 2021-01-16 2021-02-05 ClinicalTrials.gov
NCT04277247 Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease Phase2 Dystonia Disorder Unknown 2021-01-12 2022-12-01 ClinicalTrials.gov
NCT05121298 Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clin… Phase3 Rheumatoid Arthritis Unknown 2021-01-12 2024-09-30 ClinicalTrials.gov
NCT04277247 Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease Phase2 Dystonia Disorder Unknown 2021-01-12 2022-12-01 ClinicalTrials.gov
NCT05121298 Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clin… Phase3 Rheumatoid Arthritis Unknown 2021-01-12 2024-09-30 ClinicalTrials.gov
NCT04277247 Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease Phase2 Dystonia Disorder Unknown 2021-01-12 2022-12-01 ClinicalTrials.gov
NCT05121298 Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clin… Phase3 Rheumatoid Arthritis Unknown 2021-01-12 2024-09-30 ClinicalTrials.gov
NCT05121298 Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clin… Phase3 Rheumatoid Arthritis Unknown 2021-01-12 2024-09-30 ClinicalTrials.gov
NCT04277247 Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease Phase2 Dystonia Disorder Unknown 2021-01-12 2022-12-01 ClinicalTrials.gov
NCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administer… Phase2 AMD Active_Not_Recruiting 2020-12-29 2027-11-01 ClinicalTrials.gov
NCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administer… Phase2 AMD Active_Not_Recruiting 2020-12-29 2027-11-01 ClinicalTrials.gov
NCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administer… Phase2 AMD Active_Not_Recruiting 2020-12-29 2027-11-01 ClinicalTrials.gov
NCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administer… Phase2 AMD Active_Not_Recruiting 2020-12-29 2027-11-01 ClinicalTrials.gov
NCT03580044 Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infec… Phase3 Serious Bacterial Infection Terminated 2020-12-25 2023-01-23 ClinicalTrials.gov
NCT03580044 Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infec… Phase3 Serious Bacterial Infection Terminated 2020-12-25 2023-01-23 ClinicalTrials.gov
NCT03580044 Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infec… Phase3 Serious Bacterial Infection Terminated 2020-12-25 2023-01-23 ClinicalTrials.gov
NCT03580044 Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infec… Phase3 Serious Bacterial Infection Terminated 2020-12-25 2023-01-23 ClinicalTrials.gov
NCT04666675 A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Parti… Phase3 Atopic Dermatitis (AD) Withdrawn 2020-12-24 2021-03-23 ClinicalTrials.gov
NCT04666675 A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Parti… Phase3 Atopic Dermatitis (AD) Withdrawn 2020-12-24 2021-03-23 ClinicalTrials.gov
NCT04666675 A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Parti… Phase3 Atopic Dermatitis (AD) Withdrawn 2020-12-24 2021-03-23 ClinicalTrials.gov
NCT04666675 A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Parti… Phase3 Atopic Dermatitis (AD) Withdrawn 2020-12-24 2021-03-23 ClinicalTrials.gov
NCT04843839 CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Thera… Phase2 Congenital Hereditary Endothelial Dystrophy of Cornea Unknown 2020-12-15 2022-12-15 ClinicalTrials.gov
NCT04843839 CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Thera… Phase2 Congenital Hereditary Endothelial Dystrophy of Cornea Unknown 2020-12-15 2022-12-15 ClinicalTrials.gov
NCT04843839 CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Thera… Phase2 Congenital Hereditary Endothelial Dystrophy of Cornea Unknown 2020-12-15 2022-12-15 ClinicalTrials.gov
NCT04843839 CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Thera… Phase2 Congenital Hereditary Endothelial Dystrophy of Cornea Unknown 2020-12-15 2022-12-15 ClinicalTrials.gov
NCT04630990 Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease… — Endometriosis Completed 2020-12-14 2024-03-26 ClinicalTrials.gov
NCT04630990 Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease… — Endometriosis Completed 2020-12-14 2024-03-26 ClinicalTrials.gov
NCT04630990 Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease… — Endometriosis Completed 2020-12-14 2024-03-26 ClinicalTrials.gov
NCT04630990 Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease… — Endometriosis Completed 2020-12-14 2024-03-26 ClinicalTrials.gov
NCT04655261 Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab I… — Chronic Lymphocytic Leukemia (CLL) Terminated 2020-12-12 2021-11-09 ClinicalTrials.gov
NCT04655261 Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab I… — Chronic Lymphocytic Leukemia (CLL) Terminated 2020-12-12 2021-11-09 ClinicalTrials.gov
NCT04655261 Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab I… — Chronic Lymphocytic Leukemia (CLL) Terminated 2020-12-12 2021-11-09 ClinicalTrials.gov
NCT04655261 Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab I… — Chronic Lymphocytic Leukemia (CLL) Terminated 2020-12-12 2021-11-09 ClinicalTrials.gov
NCT04644120 Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-… Phase1 CoronaVirus Disease-2019 (COVID-19) Completed 2020-12-10 2021-08-24 ClinicalTrials.gov
NCT04644120 Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-… Phase1 CoronaVirus Disease-2019 (COVID-19) Completed 2020-12-10 2021-08-24 ClinicalTrials.gov
NCT04644120 Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-… Phase1 CoronaVirus Disease-2019 (COVID-19) Completed 2020-12-10 2021-08-24 ClinicalTrials.gov
NCT04644120 Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-… Phase1 CoronaVirus Disease-2019 (COVID-19) Completed 2020-12-10 2021-08-24 ClinicalTrials.gov
NCT04686786 An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment… Phase2 Seizures Terminated 2020-12-08 2024-12-05 ClinicalTrials.gov
NCT04686786 An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment… Phase2 Seizures Terminated 2020-12-08 2024-12-05 ClinicalTrials.gov
NCT04686786 An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment… Phase2 Seizures Terminated 2020-12-08 2024-12-05 ClinicalTrials.gov
NCT04686786 An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment… Phase2 Seizures Terminated 2020-12-08 2024-12-05 ClinicalTrials.gov
NCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants … Phase2 Diabetic Retinopathy (DR) Active_Not_Recruiting 2020-11-20 2026-12-01 ClinicalTrials.gov
NCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants … Phase2 Diabetic Retinopathy (DR) Active_Not_Recruiting 2020-11-20 2026-12-01 ClinicalTrials.gov
NCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants … Phase2 Diabetic Retinopathy (DR) Active_Not_Recruiting 2020-11-20 2026-12-01 ClinicalTrials.gov
NCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants … Phase2 Diabetic Retinopathy (DR) Active_Not_Recruiting 2020-11-20 2026-12-01 ClinicalTrials.gov
NCT04610762 HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug U… — Hepatitis C, Chronic Completed 2020-11-17 2022-11-17 ClinicalTrials.gov
NCT04610762 HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug U… — Hepatitis C, Chronic Completed 2020-11-17 2022-11-17 ClinicalTrials.gov
NCT04610762 HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug U… — Hepatitis C, Chronic Completed 2020-11-17 2022-11-17 ClinicalTrials.gov
NCT04610762 HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug U… — Hepatitis C, Chronic Completed 2020-11-17 2022-11-17 ClinicalTrials.gov
NCT04631588 Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines Phase1 Facial Fine Lines Completed 2020-11-16 2021-11-03 ClinicalTrials.gov
NCT04631588 Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines Phase1 Facial Fine Lines Completed 2020-11-16 2021-11-03 ClinicalTrials.gov
NCT04499248 AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension Phase1 Open-angle Glaucoma Active_Not_Recruiting 2020-11-16 2029-04-01 ClinicalTrials.gov
NCT04631588 Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines Phase1 Facial Fine Lines Completed 2020-11-16 2021-11-03 ClinicalTrials.gov
NCT04499248 AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension Phase1 Open-angle Glaucoma Active_Not_Recruiting 2020-11-16 2029-04-01 ClinicalTrials.gov
NCT04499248 AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension Phase1 Open-angle Glaucoma Active_Not_Recruiting 2020-11-16 2029-04-01 ClinicalTrials.gov
NCT04499248 AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension Phase1 Open-angle Glaucoma Active_Not_Recruiting 2020-11-16 2029-04-01 ClinicalTrials.gov
NCT04631588 Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines Phase1 Facial Fine Lines Completed 2020-11-16 2021-11-03 ClinicalTrials.gov
NCT04454658 Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination W… Phase1 Myelofibrosis (MF) Active_Not_Recruiting 2020-11-11 2027-01-01 ClinicalTrials.gov
NCT04454658 Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination W… Phase1 Myelofibrosis (MF) Active_Not_Recruiting 2020-11-11 2027-01-01 ClinicalTrials.gov
NCT04454658 Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination W… Phase1 Myelofibrosis (MF) Active_Not_Recruiting 2020-11-11 2027-01-01 ClinicalTrials.gov
NCT04454658 Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination W… Phase1 Myelofibrosis (MF) Active_Not_Recruiting 2020-11-11 2027-01-01 ClinicalTrials.gov
NCT04505566 INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study Phase1 Diabetic Retinopathy Completed 2020-11-09 2026-04-21 ClinicalTrials.gov
NCT04309474 A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in … Phase2 Acute Ischemic Stroke Completed 2020-11-09 2024-12-23 ClinicalTrials.gov
NCT04505566 INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study Phase1 Diabetic Retinopathy Completed 2020-11-09 2026-04-21 ClinicalTrials.gov
NCT04309474 A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in … Phase2 Acute Ischemic Stroke Completed 2020-11-09 2024-12-23 ClinicalTrials.gov
NCT04309474 A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in … Phase2 Acute Ischemic Stroke Completed 2020-11-09 2024-12-23 ClinicalTrials.gov
NCT04309474 A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in … Phase2 Acute Ischemic Stroke Completed 2020-11-09 2024-12-23 ClinicalTrials.gov
NCT04505566 INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study Phase1 Diabetic Retinopathy Completed 2020-11-09 2026-04-21 ClinicalTrials.gov
NCT04505566 INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study Phase1 Diabetic Retinopathy Completed 2020-11-09 2026-04-21 ClinicalTrials.gov
NCT04611230 A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaV… — Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) Completed 2020-11-05 2021-10-27 ClinicalTrials.gov
NCT04570631 Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Al… Phase1 Multiple Myeloma Terminated 2020-11-05 2025-05-05 ClinicalTrials.gov
NCT04092179 Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Phase1 Acute Myeloid Leukemia Terminated 2020-11-05 2023-10-26 ClinicalTrials.gov
NCT04092179 Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Phase1 Acute Myeloid Leukemia Terminated 2020-11-05 2023-10-26 ClinicalTrials.gov
NCT04092179 Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Phase1 Acute Myeloid Leukemia Terminated 2020-11-05 2023-10-26 ClinicalTrials.gov
NCT04092179 Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Phase1 Acute Myeloid Leukemia Terminated 2020-11-05 2023-10-26 ClinicalTrials.gov
NCT04570631 Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Al… Phase1 Multiple Myeloma Terminated 2020-11-05 2025-05-05 ClinicalTrials.gov
NCT04611230 A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaV… — Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) Completed 2020-11-05 2021-10-27 ClinicalTrials.gov
NCT04570631 Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Al… Phase1 Multiple Myeloma Terminated 2020-11-05 2025-05-05 ClinicalTrials.gov
NCT04570631 Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Al… Phase1 Multiple Myeloma Terminated 2020-11-05 2025-05-05 ClinicalTrials.gov
NCT04611230 A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaV… — Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) Completed 2020-11-05 2021-10-27 ClinicalTrials.gov
NCT04611230 A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaV… — Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) Completed 2020-11-05 2021-10-27 ClinicalTrials.gov
NCT04602923 Keratometric Change After XEN, Trabeculectomy and Tube Shunts Na Glaucoma, Open-Angle Completed 2020-11-04 2024-08-07 ClinicalTrials.gov
NCT04602923 Keratometric Change After XEN, Trabeculectomy and Tube Shunts Na Glaucoma, Open-Angle Completed 2020-11-04 2024-08-07 ClinicalTrials.gov
NCT04602923 Keratometric Change After XEN, Trabeculectomy and Tube Shunts Na Glaucoma, Open-Angle Completed 2020-11-04 2024-08-07 ClinicalTrials.gov
NCT04602923 Keratometric Change After XEN, Trabeculectomy and Tube Shunts Na Glaucoma, Open-Angle Completed 2020-11-04 2024-08-07 ClinicalTrials.gov
NCT04380142 Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidop… Phase3 Parkinson's Disease (PD) Completed 2020-10-19 2021-09-29 ClinicalTrials.gov
NCT04380142 Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidop… Phase3 Parkinson's Disease (PD) Completed 2020-10-19 2021-09-29 ClinicalTrials.gov
NCT04380142 Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidop… Phase3 Parkinson's Disease (PD) Completed 2020-10-19 2021-09-29 ClinicalTrials.gov
NCT04380142 Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidop… Phase3 Parkinson's Disease (PD) Completed 2020-10-19 2021-09-29 ClinicalTrials.gov
NCT04497597 A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement … — Rheumatoid Arthritis (RA) Completed 2020-10-16 2024-05-15 ClinicalTrials.gov
NCT04497597 A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement … — Rheumatoid Arthritis (RA) Completed 2020-10-16 2024-05-15 ClinicalTrials.gov
NCT04497597 A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement … — Rheumatoid Arthritis (RA) Completed 2020-10-16 2024-05-15 ClinicalTrials.gov
NCT04497597 A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement … — Rheumatoid Arthritis (RA) Completed 2020-10-16 2024-05-15 ClinicalTrials.gov
NCT04559984 JUVÉDERM VOLUX® for Chin Retrusion in China Phase3 Chin Retrusion Completed 2020-10-15 2022-08-26 ClinicalTrials.gov
NCT04559984 JUVÉDERM VOLUX® for Chin Retrusion in China Phase3 Chin Retrusion Completed 2020-10-15 2022-08-26 ClinicalTrials.gov
NCT04559984 JUVÉDERM VOLUX® for Chin Retrusion in China Phase3 Chin Retrusion Completed 2020-10-15 2022-08-26 ClinicalTrials.gov
NCT04559984 JUVÉDERM VOLUX® for Chin Retrusion in China Phase3 Chin Retrusion Completed 2020-10-15 2022-08-26 ClinicalTrials.gov
NCT04577482 Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or… — Hepatitis C Virus (HCV) Completed 2020-10-07 2022-09-03 ClinicalTrials.gov
NCT04577482 Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or… — Hepatitis C Virus (HCV) Completed 2020-10-07 2022-09-03 ClinicalTrials.gov
NCT04574492 A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms i… — Rheumatoid Arthritis (RA) Completed 2020-10-07 2024-07-30 ClinicalTrials.gov
NCT04574492 A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms i… — Rheumatoid Arthritis (RA) Completed 2020-10-07 2024-07-30 ClinicalTrials.gov
NCT04574492 A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms i… — Rheumatoid Arthritis (RA) Completed 2020-10-07 2024-07-30 ClinicalTrials.gov
NCT04577482 Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or… — Hepatitis C Virus (HCV) Completed 2020-10-07 2022-09-03 ClinicalTrials.gov
NCT04577482 Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or… — Hepatitis C Virus (HCV) Completed 2020-10-07 2022-09-03 ClinicalTrials.gov
NCT04574492 A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms i… — Rheumatoid Arthritis (RA) Completed 2020-10-07 2024-07-30 ClinicalTrials.gov
NCT04509622 A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cyt… Phase3 Acute Myeloid Leukemia (AML) Completed 2020-10-05 2021-04-15 ClinicalTrials.gov
NCT04509622 A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cyt… Phase3 Acute Myeloid Leukemia (AML) Completed 2020-10-05 2021-04-15 ClinicalTrials.gov
NCT04509622 A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cyt… Phase3 Acute Myeloid Leukemia (AML) Completed 2020-10-05 2021-04-15 ClinicalTrials.gov
NCT04509622 A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cyt… Phase3 Acute Myeloid Leukemia (AML) Completed 2020-10-05 2021-04-15 ClinicalTrials.gov
NCT04524611 Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Usteki… Phase3 Crohn's Disease (CD) Active_Not_Recruiting 2020-09-30 2028-02-01 ClinicalTrials.gov
NCT04567589 A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Mi… — Uterine Fibroids Withdrawn 2020-09-30 2021-02-28 ClinicalTrials.gov
NCT04567589 A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Mi… — Uterine Fibroids Withdrawn 2020-09-30 2021-02-28 ClinicalTrials.gov
NCT04524611 Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Usteki… Phase3 Crohn's Disease (CD) Active_Not_Recruiting 2020-09-30 2028-02-01 ClinicalTrials.gov
NCT04567589 A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Mi… — Uterine Fibroids Withdrawn 2020-09-30 2021-02-28 ClinicalTrials.gov
NCT04524611 Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Usteki… Phase3 Crohn's Disease (CD) Active_Not_Recruiting 2020-09-30 2028-02-01 ClinicalTrials.gov
NCT04524611 Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Usteki… Phase3 Crohn's Disease (CD) Active_Not_Recruiting 2020-09-30 2028-02-01 ClinicalTrials.gov
NCT04567589 A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Mi… — Uterine Fibroids Withdrawn 2020-09-30 2021-02-28 ClinicalTrials.gov
NCT04472598 Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet Whe… Phase3 Myelofibrosis (MF) Completed 2020-09-29 2025-01-29 ClinicalTrials.gov
NCT04472598 Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet Whe… Phase3 Myelofibrosis (MF) Completed 2020-09-29 2025-01-29 ClinicalTrials.gov
NCT04472598 Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet Whe… Phase3 Myelofibrosis (MF) Completed 2020-09-29 2025-01-29 ClinicalTrials.gov
NCT04472598 Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet Whe… Phase3 Myelofibrosis (MF) Completed 2020-09-29 2025-01-29 ClinicalTrials.gov
NCT04542499 Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With… Phase3 Parkinson Disease Completed 2020-09-23 2024-02-15 ClinicalTrials.gov
NCT04542499 Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With… Phase3 Parkinson Disease Completed 2020-09-23 2024-02-15 ClinicalTrials.gov
NCT04477486 Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrut… Phase2 Mantle Cell Lymphoma (MCL) Completed 2020-09-23 2025-05-28 ClinicalTrials.gov
NCT04542499 Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With… Phase3 Parkinson Disease Completed 2020-09-23 2024-02-15 ClinicalTrials.gov
NCT04477486 Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrut… Phase2 Mantle Cell Lymphoma (MCL) Completed 2020-09-23 2025-05-28 ClinicalTrials.gov
NCT04477486 Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrut… Phase2 Mantle Cell Lymphoma (MCL) Completed 2020-09-23 2025-05-28 ClinicalTrials.gov
NCT04542499 Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With… Phase3 Parkinson Disease Completed 2020-09-23 2024-02-15 ClinicalTrials.gov
NCT04477486 Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrut… Phase2 Mantle Cell Lymphoma (MCL) Completed 2020-09-23 2025-05-28 ClinicalTrials.gov
NCT04552249 Evaluation of Age-related Skin Changes and Instrument Reliability Using Clinica… — Age-related Skin Changes Completed 2020-09-22 2020-12-18 ClinicalTrials.gov
NCT04552249 Evaluation of Age-related Skin Changes and Instrument Reliability Using Clinica… — Age-related Skin Changes Completed 2020-09-22 2020-12-18 ClinicalTrials.gov
NCT04552249 Evaluation of Age-related Skin Changes and Instrument Reliability Using Clinica… — Age-related Skin Changes Completed 2020-09-22 2020-12-18 ClinicalTrials.gov
NCT04552249 Evaluation of Age-related Skin Changes and Instrument Reliability Using Clinica… — Age-related Skin Changes Completed 2020-09-22 2020-12-18 ClinicalTrials.gov
NCT04064827 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For T… Phase3 Chronic Kidney Disease (CKD) Terminated 2020-09-16 2025-06-09 ClinicalTrials.gov
NCT04064827 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For T… Phase3 Chronic Kidney Disease (CKD) Terminated 2020-09-16 2025-06-09 ClinicalTrials.gov
NCT04064827 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For T… Phase3 Chronic Kidney Disease (CKD) Terminated 2020-09-16 2025-06-09 ClinicalTrials.gov
NCT04064827 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For T… Phase3 Chronic Kidney Disease (CKD) Terminated 2020-09-16 2025-06-09 ClinicalTrials.gov
NCT05274087 Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinj… Phase1 Healthy Volunteers Completed 2020-09-15 2021-04-07 ClinicalTrials.gov
NCT05274087 Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinj… Phase1 Healthy Volunteers Completed 2020-09-15 2021-04-07 ClinicalTrials.gov
NCT05274087 Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinj… Phase1 Healthy Volunteers Completed 2020-09-15 2021-04-07 ClinicalTrials.gov
NCT05274087 Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinj… Phase1 Healthy Volunteers Completed 2020-09-15 2021-04-07 ClinicalTrials.gov
NCT04401748 Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Asse… Phase3 Myelodysplastic Syndrome (MDS) Active_Not_Recruiting 2020-09-10 2026-03-01 ClinicalTrials.gov
NCT04401748 Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Asse… Phase3 Myelodysplastic Syndrome (MDS) Active_Not_Recruiting 2020-09-10 2026-03-01 ClinicalTrials.gov
NCT04401748 Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Asse… Phase3 Myelodysplastic Syndrome (MDS) Active_Not_Recruiting 2020-09-10 2026-03-01 ClinicalTrials.gov
NCT04401748 Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Asse… Phase3 Myelodysplastic Syndrome (MDS) Active_Not_Recruiting 2020-09-10 2026-03-01 ClinicalTrials.gov
NCT04295538 Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To A… Phase2 Spinal Cord Injury (SCI) Completed 2020-09-06 2026-01-26 ClinicalTrials.gov
NCT04295538 Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To A… Phase2 Spinal Cord Injury (SCI) Completed 2020-09-06 2026-01-26 ClinicalTrials.gov
NCT04295538 Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To A… Phase2 Spinal Cord Injury (SCI) Completed 2020-09-06 2026-01-26 ClinicalTrials.gov
NCT04295538 Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To A… Phase2 Spinal Cord Injury (SCI) Completed 2020-09-06 2026-01-26 ClinicalTrials.gov
NCT05274100 Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy… Phase1 Healthy Volunteers Completed 2020-09-01 2021-07-06 ClinicalTrials.gov
NCT04445025 Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Pat… Early_Phase1 Infertility Completed 2020-09-01 2024-12-30 ClinicalTrials.gov
NCT05274100 Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy… Phase1 Healthy Volunteers Completed 2020-09-01 2021-07-06 ClinicalTrials.gov
NCT04445025 Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Pat… Early_Phase1 Infertility Completed 2020-09-01 2024-12-30 ClinicalTrials.gov
NCT05274100 Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy… Phase1 Healthy Volunteers Completed 2020-09-01 2021-07-06 ClinicalTrials.gov
NCT04445025 Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Pat… Early_Phase1 Infertility Completed 2020-09-01 2024-12-30 ClinicalTrials.gov
NCT05274100 Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy… Phase1 Healthy Volunteers Completed 2020-09-01 2021-07-06 ClinicalTrials.gov
NCT04445025 Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Pat… Early_Phase1 Infertility Completed 2020-09-01 2024-12-30 ClinicalTrials.gov
NCT04468984 Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Ver… Phase3 Myelofibrosis (MF) Active_Not_Recruiting 2020-08-31 2026-12-01 ClinicalTrials.gov
NCT04468984 Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Ver… Phase3 Myelofibrosis (MF) Active_Not_Recruiting 2020-08-31 2026-12-01 ClinicalTrials.gov
NCT04468984 Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Ver… Phase3 Myelofibrosis (MF) Active_Not_Recruiting 2020-08-31 2026-12-01 ClinicalTrials.gov
NCT04468984 Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Ver… Phase3 Myelofibrosis (MF) Active_Not_Recruiting 2020-08-31 2026-12-01 ClinicalTrials.gov
NCT04500418 Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients Phase2 Covid19 Terminated 2020-08-25 2021-07-27 ClinicalTrials.gov
NCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants … Phase2 Neovascular Age-Related Macular Degeneration (nAMD) Active_Not_Recruiting 2020-08-25 2027-02-01 ClinicalTrials.gov
NCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants … Phase2 Neovascular Age-Related Macular Degeneration (nAMD) Active_Not_Recruiting 2020-08-25 2027-02-01 ClinicalTrials.gov
NCT04500418 Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients Phase2 Covid19 Terminated 2020-08-25 2021-07-27 ClinicalTrials.gov
NCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants … Phase2 Neovascular Age-Related Macular Degeneration (nAMD) Active_Not_Recruiting 2020-08-25 2027-02-01 ClinicalTrials.gov
NCT04500418 Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients Phase2 Covid19 Terminated 2020-08-25 2021-07-27 ClinicalTrials.gov
NCT04500418 Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients Phase2 Covid19 Terminated 2020-08-25 2021-07-27 ClinicalTrials.gov
NCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants … Phase2 Neovascular Age-Related Macular Degeneration (nAMD) Active_Not_Recruiting 2020-08-25 2027-02-01 ClinicalTrials.gov
NCT04492020 Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the… Phase3 Migraine Completed 2020-08-21 2022-04-19 ClinicalTrials.gov
NCT04492020 Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the… Phase3 Migraine Completed 2020-08-21 2022-04-19 ClinicalTrials.gov
NCT04492020 Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the… Phase3 Migraine Completed 2020-08-21 2022-04-19 ClinicalTrials.gov
NCT04492020 Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the… Phase3 Migraine Completed 2020-08-21 2022-04-19 ClinicalTrials.gov
NCT04333576 Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive … Phase3 Endometriosis Active_Not_Recruiting 2020-08-10 2027-07-01 ClinicalTrials.gov
NCT04333576 Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive … Phase3 Endometriosis Active_Not_Recruiting 2020-08-10 2027-07-01 ClinicalTrials.gov
NCT04333576 Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive … Phase3 Endometriosis Active_Not_Recruiting 2020-08-10 2027-07-01 ClinicalTrials.gov
NCT04333576 Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive … Phase3 Endometriosis Active_Not_Recruiting 2020-08-10 2027-07-01 ClinicalTrials.gov
NCT04336982 A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Mye… Phase1 Leukemia, Myeloid, Acute Terminated 2020-08-05 2024-04-05 ClinicalTrials.gov
NCT04336982 A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Mye… Phase1 Leukemia, Myeloid, Acute Terminated 2020-08-05 2024-04-05 ClinicalTrials.gov
NCT04336982 A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Mye… Phase1 Leukemia, Myeloid, Acute Terminated 2020-08-05 2024-04-05 ClinicalTrials.gov
NCT04336982 A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Mye… Phase1 Leukemia, Myeloid, Acute Terminated 2020-08-05 2024-04-05 ClinicalTrials.gov
NCT04433442 Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyr… — Psoriasis Completed 2020-08-04 2025-06-13 ClinicalTrials.gov
NCT04433442 Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyr… — Psoriasis Completed 2020-08-04 2025-06-13 ClinicalTrials.gov
NCT04433442 Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyr… — Psoriasis Completed 2020-08-04 2025-06-13 ClinicalTrials.gov
NCT04433442 Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyr… — Psoriasis Completed 2020-08-04 2025-06-13 ClinicalTrials.gov
NCT04403763 Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Pre… Phase1 Presbyopia Terminated 2020-07-27 2022-12-05 ClinicalTrials.gov
NCT04403763 Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Pre… Phase1 Presbyopia Terminated 2020-07-27 2022-12-05 ClinicalTrials.gov
NCT04403763 Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Pre… Phase1 Presbyopia Terminated 2020-07-27 2022-12-05 ClinicalTrials.gov
NCT04451772 A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Table… Phase2 Systemic Lupus Erythematosus (SLE) Completed 2020-07-27 2024-01-03 ClinicalTrials.gov
NCT04403763 Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Pre… Phase1 Presbyopia Terminated 2020-07-27 2022-12-05 ClinicalTrials.gov
NCT04451772 A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Table… Phase2 Systemic Lupus Erythematosus (SLE) Completed 2020-07-27 2024-01-03 ClinicalTrials.gov
NCT04451772 A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Table… Phase2 Systemic Lupus Erythematosus (SLE) Completed 2020-07-27 2024-01-03 ClinicalTrials.gov
NCT04451772 A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Table… Phase2 Systemic Lupus Erythematosus (SLE) Completed 2020-07-27 2024-01-03 ClinicalTrials.gov
NCT04451720 Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar P… Phase3 Palmoplantar Pustulosis (PPP) Completed 2020-07-20 2022-11-21 ClinicalTrials.gov
NCT04451720 Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar P… Phase3 Palmoplantar Pustulosis (PPP) Completed 2020-07-20 2022-11-21 ClinicalTrials.gov
NCT04451720 Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar P… Phase3 Palmoplantar Pustulosis (PPP) Completed 2020-07-20 2022-11-21 ClinicalTrials.gov
NCT04451720 Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar P… Phase3 Palmoplantar Pustulosis (PPP) Completed 2020-07-20 2022-11-21 ClinicalTrials.gov
NCT04424641 A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant … Phase1 Locally Advanced or Metastatic Solid Tumor(s) Terminated 2020-07-15 2021-10-29 ClinicalTrials.gov
NCT04424641 A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant … Phase1 Locally Advanced or Metastatic Solid Tumor(s) Terminated 2020-07-15 2021-10-29 ClinicalTrials.gov
NCT04553627 Feasibility of Producing the Appearance of a Gluteal Lift Post Cryolipolysis Na Subcutaneous Fat Unknown 2020-07-15 2021-05-30 ClinicalTrials.gov
NCT04553627 Feasibility of Producing the Appearance of a Gluteal Lift Post Cryolipolysis Na Subcutaneous Fat Unknown 2020-07-15 2021-05-30 ClinicalTrials.gov
NCT04424641 A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant … Phase1 Locally Advanced or Metastatic Solid Tumor(s) Terminated 2020-07-15 2021-10-29 ClinicalTrials.gov
NCT03832361 Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor… Phase2 Endometrial Cancer Recruiting 2020-07-15 2028-10-01 ClinicalTrials.gov
NCT04424641 A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant … Phase1 Locally Advanced or Metastatic Solid Tumor(s) Terminated 2020-07-15 2021-10-29 ClinicalTrials.gov
NCT04553627 Feasibility of Producing the Appearance of a Gluteal Lift Post Cryolipolysis Na Subcutaneous Fat Unknown 2020-07-15 2021-05-30 ClinicalTrials.gov
NCT03832361 Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor… Phase2 Endometrial Cancer Recruiting 2020-07-15 2028-10-01 ClinicalTrials.gov
NCT03832361 Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor… Phase2 Endometrial Cancer Recruiting 2020-07-15 2028-10-01 ClinicalTrials.gov
NCT03832361 Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor… Phase2 Endometrial Cancer Recruiting 2020-07-15 2028-10-01 ClinicalTrials.gov
NCT04553627 Feasibility of Producing the Appearance of a Gluteal Lift Post Cryolipolysis Na Subcutaneous Fat Unknown 2020-07-15 2021-05-30 ClinicalTrials.gov
NCT04430855 A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants W… Phase2 Hidradenitis Suppurativa (HS) Completed 2020-07-14 2022-01-25 ClinicalTrials.gov
NCT04430855 A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants W… Phase2 Hidradenitis Suppurativa (HS) Completed 2020-07-14 2022-01-25 ClinicalTrials.gov
NCT04435600 A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With … Phase3 Psoriasis Completed 2020-07-14 2024-10-15 ClinicalTrials.gov
NCT04430855 A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants W… Phase2 Hidradenitis Suppurativa (HS) Completed 2020-07-14 2022-01-25 ClinicalTrials.gov
NCT04435600 A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With … Phase3 Psoriasis Completed 2020-07-14 2024-10-15 ClinicalTrials.gov
NCT04435600 A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With … Phase3 Psoriasis Completed 2020-07-14 2024-10-15 ClinicalTrials.gov
NCT04430855 A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants W… Phase2 Hidradenitis Suppurativa (HS) Completed 2020-07-14 2022-01-25 ClinicalTrials.gov
NCT04435600 A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With … Phase3 Psoriasis Completed 2020-07-14 2024-10-15 ClinicalTrials.gov
NCT04273139 Ibrutinib + Venetoclax in Untreated WM Phase2 Waldenstrom Macroglobulinemia Active_Not_Recruiting 2020-07-09 2028-02-01 ClinicalTrials.gov
NCT04273139 Ibrutinib + Venetoclax in Untreated WM Phase2 Waldenstrom Macroglobulinemia Active_Not_Recruiting 2020-07-09 2028-02-01 ClinicalTrials.gov
NCT04273139 Ibrutinib + Venetoclax in Untreated WM Phase2 Waldenstrom Macroglobulinemia Active_Not_Recruiting 2020-07-09 2028-02-01 ClinicalTrials.gov
NCT04273139 Ibrutinib + Venetoclax in Untreated WM Phase2 Waldenstrom Macroglobulinemia Active_Not_Recruiting 2020-07-09 2028-02-01 ClinicalTrials.gov
NCT04274907 A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab… Phase1 Non Small Cell Lung Cancer Terminated 2020-06-30 2021-02-02 ClinicalTrials.gov
NCT04274907 A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab… Phase1 Non Small Cell Lung Cancer Terminated 2020-06-30 2021-02-02 ClinicalTrials.gov
NCT04274907 A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab… Phase1 Non Small Cell Lung Cancer Terminated 2020-06-30 2021-02-02 ClinicalTrials.gov
NCT04274907 A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab… Phase1 Non Small Cell Lung Cancer Terminated 2020-06-30 2021-02-02 ClinicalTrials.gov
NCT04382885 Cariprazine Pediatric ASD PK Study Phase1 Autism Spectrum Disorder Completed 2020-06-26 2021-12-10 ClinicalTrials.gov
NCT04382885 Cariprazine Pediatric ASD PK Study Phase1 Autism Spectrum Disorder Completed 2020-06-26 2021-12-10 ClinicalTrials.gov
NCT04382885 Cariprazine Pediatric ASD PK Study Phase1 Autism Spectrum Disorder Completed 2020-06-26 2021-12-10 ClinicalTrials.gov
NCT04382885 Cariprazine Pediatric ASD PK Study Phase1 Autism Spectrum Disorder Completed 2020-06-26 2021-12-10 ClinicalTrials.gov
NCT04437433 A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Pa… Phase3 Chronic Migraine Completed 2020-06-18 2024-06-11 ClinicalTrials.gov
NCT04437433 A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Pa… Phase3 Chronic Migraine Completed 2020-06-18 2024-06-11 ClinicalTrials.gov
NCT04437433 A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Pa… Phase3 Chronic Migraine Completed 2020-06-18 2024-06-11 ClinicalTrials.gov
NCT04437433 A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Pa… Phase3 Chronic Migraine Completed 2020-06-18 2024-06-11 ClinicalTrials.gov
NCT04040621 Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receivin… Phase1 Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia Terminated 2020-06-15 2021-05-07 ClinicalTrials.gov
NCT04040621 Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receivin… Phase1 Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia Terminated 2020-06-15 2021-05-07 ClinicalTrials.gov
NCT04040621 Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receivin… Phase1 Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia Terminated 2020-06-15 2021-05-07 ClinicalTrials.gov
NCT04040621 Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receivin… Phase1 Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia Terminated 2020-06-15 2021-05-07 ClinicalTrials.gov
NCT04285580 A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of… Phase3 Open-Angle Glaucoma Completed 2020-06-11 2022-05-14 ClinicalTrials.gov
NCT04285580 A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of… Phase3 Open-Angle Glaucoma Completed 2020-06-11 2022-05-14 ClinicalTrials.gov
NCT04285580 A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of… Phase3 Open-Angle Glaucoma Completed 2020-06-11 2022-05-14 ClinicalTrials.gov
NCT04285580 A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of… Phase3 Open-Angle Glaucoma Completed 2020-06-11 2022-05-14 ClinicalTrials.gov
NCT04379050 Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure O… Phase3 Parkinson's Disease (PD) Completed 2020-06-08 2026-04-17 ClinicalTrials.gov
NCT04379050 Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure O… Phase3 Parkinson's Disease (PD) Completed 2020-06-08 2026-04-17 ClinicalTrials.gov
NCT04379050 Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure O… Phase3 Parkinson's Disease (PD) Completed 2020-06-08 2026-04-17 ClinicalTrials.gov
NCT04379050 Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure O… Phase3 Parkinson's Disease (PD) Completed 2020-06-08 2026-04-17 ClinicalTrials.gov
NCT04375397 Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Partici… Phase2 CoronaVirus Induced Disease-2019 (COVID-19) Completed 2020-06-06 2021-06-08 ClinicalTrials.gov
NCT04375397 Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Partici… Phase2 CoronaVirus Induced Disease-2019 (COVID-19) Completed 2020-06-06 2021-06-08 ClinicalTrials.gov
NCT04375397 Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Partici… Phase2 CoronaVirus Induced Disease-2019 (COVID-19) Completed 2020-06-06 2021-06-08 ClinicalTrials.gov
NCT04375397 Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Partici… Phase2 CoronaVirus Induced Disease-2019 (COVID-19) Completed 2020-06-06 2021-06-08 ClinicalTrials.gov
NCT04417465 First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In P… Phase1 Advanced Solid Tumors Cancer Completed 2020-06-03 2025-08-21 ClinicalTrials.gov
NCT04417465 First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In P… Phase1 Advanced Solid Tumors Cancer Completed 2020-06-03 2025-08-21 ClinicalTrials.gov
NCT04417465 First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In P… Phase1 Advanced Solid Tumors Cancer Completed 2020-06-03 2025-08-21 ClinicalTrials.gov
NCT04417465 First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In P… Phase1 Advanced Solid Tumors Cancer Completed 2020-06-03 2025-08-21 ClinicalTrials.gov
NCT04372628 Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 Phase2 COVID-19 Completed 2020-06-01 2022-01-18 ClinicalTrials.gov
NCT04372628 Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 Phase2 COVID-19 Completed 2020-06-01 2022-01-18 ClinicalTrials.gov
NCT04372628 Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 Phase2 COVID-19 Completed 2020-06-01 2022-01-18 ClinicalTrials.gov
NCT04372628 Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 Phase2 COVID-19 Completed 2020-06-01 2022-01-18 ClinicalTrials.gov
NCT04352309 Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years a… — Hepatitis C Virus (HCV) Completed 2020-05-29 2021-06-11 ClinicalTrials.gov
NCT04352309 Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years a… — Hepatitis C Virus (HCV) Completed 2020-05-29 2021-06-11 ClinicalTrials.gov
NCT04352309 Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years a… — Hepatitis C Virus (HCV) Completed 2020-05-29 2021-06-11 ClinicalTrials.gov
NCT04352309 Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years a… — Hepatitis C Virus (HCV) Completed 2020-05-29 2021-06-11 ClinicalTrials.gov
NCT04414397 A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple… Phase3 Temple Hollowing Completed 2020-05-28 2022-10-17 ClinicalTrials.gov
NCT04414397 A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple… Phase3 Temple Hollowing Completed 2020-05-28 2022-10-17 ClinicalTrials.gov
NCT04414397 A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple… Phase3 Temple Hollowing Completed 2020-05-28 2022-10-17 ClinicalTrials.gov
NCT04414397 A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple… Phase3 Temple Hollowing Completed 2020-05-28 2022-10-17 ClinicalTrials.gov
NCT04254783 A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on… Phase1 Ulcerative Colitis (UC) Completed 2020-05-27 2022-10-14 ClinicalTrials.gov
NCT04254783 A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on… Phase1 Ulcerative Colitis (UC) Completed 2020-05-27 2022-10-14 ClinicalTrials.gov
NCT04254783 A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on… Phase1 Ulcerative Colitis (UC) Completed 2020-05-27 2022-10-14 ClinicalTrials.gov
NCT04254783 A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on… Phase1 Ulcerative Colitis (UC) Completed 2020-05-27 2022-10-14 ClinicalTrials.gov
NCT04366973 A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir… — Hepatitis C Virus (HCV) Completed 2020-05-26 2023-12-31 ClinicalTrials.gov
NCT04366973 A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir… — Hepatitis C Virus (HCV) Completed 2020-05-26 2023-12-31 ClinicalTrials.gov
NCT04366973 A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir… — Hepatitis C Virus (HCV) Completed 2020-05-26 2023-12-31 ClinicalTrials.gov
NCT04366973 A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir… — Hepatitis C Virus (HCV) Completed 2020-05-26 2023-12-31 ClinicalTrials.gov
NCT04274933 A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combin… Phase1 Breast Cancer Terminated 2020-05-21 2020-10-08 ClinicalTrials.gov
NCT04274933 A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combin… Phase1 Breast Cancer Terminated 2020-05-21 2020-10-08 ClinicalTrials.gov
NCT04274933 A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combin… Phase1 Breast Cancer Terminated 2020-05-21 2020-10-08 ClinicalTrials.gov
NCT04274933 A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combin… Phase1 Breast Cancer Terminated 2020-05-21 2020-10-08 ClinicalTrials.gov
NCT04390581 A Study to Evaluate the Effect of Juvederm Volift With Lidocaine on Aging Hands… Phase4 Skin Depressions Completed 2020-05-20 2022-12-06 ClinicalTrials.gov
NCT04390581 A Study to Evaluate the Effect of Juvederm Volift With Lidocaine on Aging Hands… Phase4 Skin Depressions Completed 2020-05-20 2022-12-06 ClinicalTrials.gov
NCT04390581 A Study to Evaluate the Effect of Juvederm Volift With Lidocaine on Aging Hands… Phase4 Skin Depressions Completed 2020-05-20 2022-12-06 ClinicalTrials.gov
NCT04390581 A Study to Evaluate the Effect of Juvederm Volift With Lidocaine on Aging Hands… Phase4 Skin Depressions Completed 2020-05-20 2022-12-06 ClinicalTrials.gov
NCT04178902 A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With R… Phase1 Multiple Myeloma (MM) Terminated 2020-05-19 2021-04-16 ClinicalTrials.gov
NCT04178902 A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With R… Phase1 Multiple Myeloma (MM) Terminated 2020-05-19 2021-04-16 ClinicalTrials.gov
NCT04178902 A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With R… Phase1 Multiple Myeloma (MM) Terminated 2020-05-19 2021-04-16 ClinicalTrials.gov
NCT04320745 A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal … Phase4 Hypogonadism Completed 2020-05-19 2021-06-24 ClinicalTrials.gov
NCT04320745 A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal … Phase4 Hypogonadism Completed 2020-05-19 2021-06-24 ClinicalTrials.gov
NCT04320745 A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal … Phase4 Hypogonadism Completed 2020-05-19 2021-06-24 ClinicalTrials.gov
NCT04320745 A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal … Phase4 Hypogonadism Completed 2020-05-19 2021-06-24 ClinicalTrials.gov
NCT04178902 A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With R… Phase1 Multiple Myeloma (MM) Terminated 2020-05-19 2021-04-16 ClinicalTrials.gov
NCT04274894 A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pres… Phase4 Hypogonadism Completed 2020-05-12 2022-01-07 ClinicalTrials.gov
NCT04274894 A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pres… Phase4 Hypogonadism Completed 2020-05-12 2022-01-07 ClinicalTrials.gov
NCT04274894 A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pres… Phase4 Hypogonadism Completed 2020-05-12 2022-01-07 ClinicalTrials.gov
NCT04274894 A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pres… Phase4 Hypogonadism Completed 2020-05-12 2022-01-07 ClinicalTrials.gov
NCT04315311 Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pan… Phase4 Exocrine Pancreatic Insufficiency (EPI) Withdrawn 2020-05-06 2021-09-22 ClinicalTrials.gov
NCT04315311 Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pan… Phase4 Exocrine Pancreatic Insufficiency (EPI) Withdrawn 2020-05-06 2021-09-22 ClinicalTrials.gov
NCT04315311 Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pan… Phase4 Exocrine Pancreatic Insufficiency (EPI) Withdrawn 2020-05-06 2021-09-22 ClinicalTrials.gov
NCT04315311 Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pan… Phase4 Exocrine Pancreatic Insufficiency (EPI) Withdrawn 2020-05-06 2021-09-22 ClinicalTrials.gov
NCT04272203 A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Ph… Phase1 Acute Myeloid Leukemia (AML) Terminated 2020-05-05 2022-06-27 ClinicalTrials.gov
NCT04272203 A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Ph… Phase1 Acute Myeloid Leukemia (AML) Terminated 2020-05-05 2022-06-27 ClinicalTrials.gov
NCT04272203 A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Ph… Phase1 Acute Myeloid Leukemia (AML) Terminated 2020-05-05 2022-06-27 ClinicalTrials.gov
NCT04272203 A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Ph… Phase1 Acute Myeloid Leukemia (AML) Terminated 2020-05-05 2022-06-27 ClinicalTrials.gov
NCT04340115 Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan F… — Rheumatoid Arthritis (RA) Completed 2020-04-24 2025-08-15 ClinicalTrials.gov
NCT04340115 Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan F… — Rheumatoid Arthritis (RA) Completed 2020-04-24 2025-08-15 ClinicalTrials.gov
NCT04340115 Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan F… — Rheumatoid Arthritis (RA) Completed 2020-04-24 2025-08-15 ClinicalTrials.gov
NCT04340115 Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan F… — Rheumatoid Arthritis (RA) Completed 2020-04-24 2025-08-15 ClinicalTrials.gov
NCT04411693 Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subje… Phase4 Diabetic Macular Edema Completed 2020-04-10 2024-01-31 ClinicalTrials.gov
NCT04411693 Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subje… Phase4 Diabetic Macular Edema Completed 2020-04-10 2024-01-31 ClinicalTrials.gov
NCT04411693 Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subje… Phase4 Diabetic Macular Edema Completed 2020-04-10 2024-01-31 ClinicalTrials.gov
NCT04411693 Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subje… Phase4 Diabetic Macular Edema Completed 2020-04-10 2024-01-31 ClinicalTrials.gov
NCT04330820 Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxant… Phase1 Relapsed Adult AML Unknown 2020-04-06 2025-08-01 ClinicalTrials.gov
NCT04330820 Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxant… Phase1 Relapsed Adult AML Unknown 2020-04-06 2025-08-01 ClinicalTrials.gov
NCT04330820 Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxant… Phase1 Relapsed Adult AML Unknown 2020-04-06 2025-08-01 ClinicalTrials.gov
NCT04330820 Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxant… Phase1 Relapsed Adult AML Unknown 2020-04-06 2025-08-01 ClinicalTrials.gov
NCT04178317 A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic … — Cancer, Chronic Lymphocytic Leukemia (CLL) Completed 2020-04-02 2025-08-18 ClinicalTrials.gov
NCT04178317 A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic … — Cancer, Chronic Lymphocytic Leukemia (CLL) Completed 2020-04-02 2025-08-18 ClinicalTrials.gov
NCT04261608 A Retrospective Chart Review Study to Evaluate Safety of McGhan Single Lumen Ge… — Breast Augmentation Completed 2020-04-02 2020-07-04 ClinicalTrials.gov
NCT04261608 A Retrospective Chart Review Study to Evaluate Safety of McGhan Single Lumen Ge… — Breast Augmentation Completed 2020-04-02 2020-07-04 ClinicalTrials.gov
NCT04261608 A Retrospective Chart Review Study to Evaluate Safety of McGhan Single Lumen Ge… — Breast Augmentation Completed 2020-04-02 2020-07-04 ClinicalTrials.gov
NCT04178317 A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic … — Cancer, Chronic Lymphocytic Leukemia (CLL) Completed 2020-04-02 2025-08-18 ClinicalTrials.gov
NCT04261608 A Retrospective Chart Review Study to Evaluate Safety of McGhan Single Lumen Ge… — Breast Augmentation Completed 2020-04-02 2020-07-04 ClinicalTrials.gov
NCT04178317 A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic … — Cancer, Chronic Lymphocytic Leukemia (CLL) Completed 2020-04-02 2025-08-18 ClinicalTrials.gov
NCT04306900 TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With … Phase1 Solid Tumor, Adult Completed 2020-03-30 2024-03-27 ClinicalTrials.gov
NCT04306900 TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With … Phase1 Solid Tumor, Adult Completed 2020-03-30 2024-03-27 ClinicalTrials.gov
NCT04306900 TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With … Phase1 Solid Tumor, Adult Completed 2020-03-30 2024-03-27 ClinicalTrials.gov
NCT04306900 TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With … Phase1 Solid Tumor, Adult Completed 2020-03-30 2024-03-27 ClinicalTrials.gov
NCT04102020 A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy … Phase3 Acute Myeloid Leukemia (AML) Completed 2020-03-26 2026-02-20 ClinicalTrials.gov
NCT04102020 A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy … Phase3 Acute Myeloid Leukemia (AML) Completed 2020-03-26 2026-02-20 ClinicalTrials.gov
NCT04102020 A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy … Phase3 Acute Myeloid Leukemia (AML) Completed 2020-03-26 2026-02-20 ClinicalTrials.gov
NCT04102020 A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy … Phase3 Acute Myeloid Leukemia (AML) Completed 2020-03-26 2026-02-20 ClinicalTrials.gov
NCT04330690 Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial Phase3 COVID-19 Unknown 2020-03-18 2024-05-18 ClinicalTrials.gov
NCT04330690 Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial Phase3 COVID-19 Unknown 2020-03-18 2024-05-18 ClinicalTrials.gov
NCT04330690 Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial Phase3 COVID-19 Unknown 2020-03-18 2024-05-18 ClinicalTrials.gov
NCT04330690 Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial Phase3 COVID-19 Unknown 2020-03-18 2024-05-18 ClinicalTrials.gov
NCT04253314 A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leuke… — Acute Myeloid Leukemia (AML) Completed 2020-03-13 2023-02-16 ClinicalTrials.gov
NCT04253314 A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leuke… — Acute Myeloid Leukemia (AML) Completed 2020-03-13 2023-02-16 ClinicalTrials.gov
NCT04253314 A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leuke… — Acute Myeloid Leukemia (AML) Completed 2020-03-13 2023-02-16 ClinicalTrials.gov
NCT04253314 A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leuke… — Acute Myeloid Leukemia (AML) Completed 2020-03-13 2023-02-16 ClinicalTrials.gov
NCT05217472 An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULA… Phase2 Sjogren's Syndrome (SS) Withdrawn 2020-03-06 2022-05-15 ClinicalTrials.gov
NCT05217472 An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULA… Phase2 Sjogren's Syndrome (SS) Withdrawn 2020-03-06 2022-05-15 ClinicalTrials.gov
NCT05217472 An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULA… Phase2 Sjogren's Syndrome (SS) Withdrawn 2020-03-06 2022-05-15 ClinicalTrials.gov
NCT05217472 An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULA… Phase2 Sjogren's Syndrome (SS) Withdrawn 2020-03-06 2022-05-15 ClinicalTrials.gov
NCT04030962 A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Dis… Phase1 Dry Eye Disease Completed 2020-03-04 2022-03-18 ClinicalTrials.gov
NCT04030962 A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Dis… Phase1 Dry Eye Disease Completed 2020-03-04 2022-03-18 ClinicalTrials.gov
NCT04030962 A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Dis… Phase1 Dry Eye Disease Completed 2020-03-04 2022-03-18 ClinicalTrials.gov
NCT04030962 A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Dis… Phase1 Dry Eye Disease Completed 2020-03-04 2022-03-18 ClinicalTrials.gov
NCT04127695 A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With P… Phase1 Parkinson's Disease Withdrawn 2020-03-03 2020-06-16 ClinicalTrials.gov
NCT04127695 A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With P… Phase1 Parkinson's Disease Withdrawn 2020-03-03 2020-06-16 ClinicalTrials.gov
NCT04127695 A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With P… Phase1 Parkinson's Disease Withdrawn 2020-03-03 2020-06-16 ClinicalTrials.gov
NCT04127695 A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With P… Phase1 Parkinson's Disease Withdrawn 2020-03-03 2020-06-16 ClinicalTrials.gov
NCT05401136 Evaluating the Chain of Addiction Care (CAC) — Hepatitis C, Chronic Unknown 2020-03-01 2023-12-01 ClinicalTrials.gov
NCT05401136 Evaluating the Chain of Addiction Care (CAC) — Hepatitis C, Chronic Unknown 2020-03-01 2023-12-01 ClinicalTrials.gov
NCT05401136 Evaluating the Chain of Addiction Care (CAC) — Hepatitis C, Chronic Unknown 2020-03-01 2023-12-01 ClinicalTrials.gov
NCT05401136 Evaluating the Chain of Addiction Care (CAC) — Hepatitis C, Chronic Unknown 2020-03-01 2023-12-01 ClinicalTrials.gov
NCT04161885 A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacit… Phase3 Acute Myeloid Leukemia (AML) Terminated 2020-02-26 2025-09-23 ClinicalTrials.gov
NCT04161885 A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacit… Phase3 Acute Myeloid Leukemia (AML) Terminated 2020-02-26 2025-09-23 ClinicalTrials.gov
NCT04161885 A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacit… Phase3 Acute Myeloid Leukemia (AML) Terminated 2020-02-26 2025-09-23 ClinicalTrials.gov
NCT04161885 A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacit… Phase3 Acute Myeloid Leukemia (AML) Terminated 2020-02-26 2025-09-23 ClinicalTrials.gov
NCT03859869 A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer … Phase4 Exocrine Pancreatic Insufficiency (EPI) Terminated 2020-02-25 2022-03-23 ClinicalTrials.gov
NCT03859869 A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer … Phase4 Exocrine Pancreatic Insufficiency (EPI) Terminated 2020-02-25 2022-03-23 ClinicalTrials.gov
NCT03859869 A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer … Phase4 Exocrine Pancreatic Insufficiency (EPI) Terminated 2020-02-25 2022-03-23 ClinicalTrials.gov
NCT03859869 A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer … Phase4 Exocrine Pancreatic Insufficiency (EPI) Terminated 2020-02-25 2022-03-23 ClinicalTrials.gov
NCT04189627 A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentas… — Hepatitis C Virus (HCV) Completed 2020-02-17 2021-06-24 ClinicalTrials.gov
NCT04262791 A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wri… Phase1 Atopic Dermatitis Terminated 2020-02-17 2022-01-31 ClinicalTrials.gov
NCT04189627 A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentas… — Hepatitis C Virus (HCV) Completed 2020-02-17 2021-06-24 ClinicalTrials.gov
NCT04262791 A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wri… Phase1 Atopic Dermatitis Terminated 2020-02-17 2022-01-31 ClinicalTrials.gov
NCT04262791 A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wri… Phase1 Atopic Dermatitis Terminated 2020-02-17 2022-01-31 ClinicalTrials.gov
NCT04189627 A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentas… — Hepatitis C Virus (HCV) Completed 2020-02-17 2021-06-24 ClinicalTrials.gov
NCT04189627 A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentas… — Hepatitis C Virus (HCV) Completed 2020-02-17 2021-06-24 ClinicalTrials.gov
NCT04262791 A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wri… Phase1 Atopic Dermatitis Terminated 2020-02-17 2022-01-31 ClinicalTrials.gov
NCT04189614 An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7… Phase1 Cancer Terminated 2020-02-13 2026-05-07 ClinicalTrials.gov
NCT04189614 An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7… Phase1 Cancer Terminated 2020-02-13 2026-05-07 ClinicalTrials.gov
NCT04189614 An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7… Phase1 Cancer Terminated 2020-02-13 2026-05-07 ClinicalTrials.gov
NCT04189614 An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7… Phase1 Cancer Terminated 2020-02-13 2026-05-07 ClinicalTrials.gov
NCT04197141 Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionate… Phase2 Prostate Cancer Active_Not_Recruiting 2020-02-07 2027-03-01 ClinicalTrials.gov
NCT04197141 Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionate… Phase2 Prostate Cancer Active_Not_Recruiting 2020-02-07 2027-03-01 ClinicalTrials.gov
NCT04197141 Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionate… Phase2 Prostate Cancer Active_Not_Recruiting 2020-02-07 2027-03-01 ClinicalTrials.gov
NCT04197141 Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionate… Phase2 Prostate Cancer Active_Not_Recruiting 2020-02-07 2027-03-01 ClinicalTrials.gov
NCT04267536 An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiven… — Rheumatoid Arthritis (RA) Completed 2020-02-06 2022-02-01 ClinicalTrials.gov
NCT04267536 An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiven… — Rheumatoid Arthritis (RA) Completed 2020-02-06 2022-02-01 ClinicalTrials.gov
NCT04267536 An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiven… — Rheumatoid Arthritis (RA) Completed 2020-02-06 2022-02-01 ClinicalTrials.gov
NCT04267536 An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiven… — Rheumatoid Arthritis (RA) Completed 2020-02-06 2022-02-01 ClinicalTrials.gov
NCT04161898 A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants Wit… Phase3 Takayasu Arteritis (TAK) Active_Not_Recruiting 2020-02-04 2028-08-01 ClinicalTrials.gov
NCT04161898 A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants Wit… Phase3 Takayasu Arteritis (TAK) Active_Not_Recruiting 2020-02-04 2028-08-01 ClinicalTrials.gov
NCT04161898 A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants Wit… Phase3 Takayasu Arteritis (TAK) Active_Not_Recruiting 2020-02-04 2028-08-01 ClinicalTrials.gov
NCT04161898 A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants Wit… Phase3 Takayasu Arteritis (TAK) Active_Not_Recruiting 2020-02-04 2028-08-01 ClinicalTrials.gov
NCT04198415 A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With … — Cancer Completed 2020-02-03 2022-10-21 ClinicalTrials.gov
NCT04198415 A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With … — Cancer Completed 2020-02-03 2022-10-21 ClinicalTrials.gov
NCT04198415 A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With … — Cancer Completed 2020-02-03 2022-10-21 ClinicalTrials.gov
NCT04198415 A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With … — Cancer Completed 2020-02-03 2022-10-21 ClinicalTrials.gov
NCT04223804 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-1… Phase1 Human Immunodeficiency Virus (HIV) Completed 2020-01-30 2023-02-27 ClinicalTrials.gov
NCT04223804 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-1… Phase1 Human Immunodeficiency Virus (HIV) Completed 2020-01-30 2023-02-27 ClinicalTrials.gov
NCT04223804 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-1… Phase1 Human Immunodeficiency Virus (HIV) Completed 2020-01-30 2023-02-27 ClinicalTrials.gov
NCT04223804 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-1… Phase1 Human Immunodeficiency Virus (HIV) Completed 2020-01-30 2023-02-27 ClinicalTrials.gov
NCT04244175 A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Trea… Phase2 Seizures Completed 2020-01-27 2024-05-21 ClinicalTrials.gov
NCT04244175 A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Trea… Phase2 Seizures Completed 2020-01-27 2024-05-21 ClinicalTrials.gov
NCT04244175 A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Trea… Phase2 Seizures Completed 2020-01-27 2024-05-21 ClinicalTrials.gov
NCT04244175 A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Trea… Phase2 Seizures Completed 2020-01-27 2024-05-21 ClinicalTrials.gov
NCT04196283 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminar… Phase1 Advanced Solid Tumors Cancer Completed 2020-01-22 2022-10-27 ClinicalTrials.gov
NCT04196283 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminar… Phase1 Advanced Solid Tumors Cancer Completed 2020-01-22 2022-10-27 ClinicalTrials.gov
NCT03818542 A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With … Phase1 Head and Neck Cancer Terminated 2020-01-22 2020-09-23 ClinicalTrials.gov
NCT04196283 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminar… Phase1 Advanced Solid Tumors Cancer Completed 2020-01-22 2022-10-27 ClinicalTrials.gov
NCT03818542 A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With … Phase1 Head and Neck Cancer Terminated 2020-01-22 2020-09-23 ClinicalTrials.gov
NCT03818542 A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With … Phase1 Head and Neck Cancer Terminated 2020-01-22 2020-09-23 ClinicalTrials.gov
NCT04196283 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminar… Phase1 Advanced Solid Tumors Cancer Completed 2020-01-22 2022-10-27 ClinicalTrials.gov
NCT03818542 A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With … Phase1 Head and Neck Cancer Terminated 2020-01-22 2020-09-23 ClinicalTrials.gov
NCT04140175 A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic P… — Endometriosis Terminated 2020-01-20 2020-11-19 ClinicalTrials.gov
NCT04140175 A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic P… — Endometriosis Terminated 2020-01-20 2020-11-19 ClinicalTrials.gov
NCT04140175 A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic P… — Endometriosis Terminated 2020-01-20 2020-11-19 ClinicalTrials.gov
NCT04140175 A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic P… — Endometriosis Terminated 2020-01-20 2020-11-19 ClinicalTrials.gov
NCT04195698 Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate … Phase3 Atopic Dermatitis Completed 2020-01-15 2023-09-11 ClinicalTrials.gov
NCT04195698 Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate … Phase3 Atopic Dermatitis Completed 2020-01-15 2023-09-11 ClinicalTrials.gov
NCT04195698 Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate … Phase3 Atopic Dermatitis Completed 2020-01-15 2023-09-11 ClinicalTrials.gov
NCT04195698 Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate … Phase3 Atopic Dermatitis Completed 2020-01-15 2023-09-11 ClinicalTrials.gov
NCT04126031 Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibact… Phase2 Gram-negative Bacterial Infection Terminated 2020-01-14 2022-12-30 ClinicalTrials.gov
NCT04183608 A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing a… Phase4 Ulcerative Colitis Recruiting 2020-01-14 2028-05-01 ClinicalTrials.gov
NCT04126031 Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibact… Phase2 Gram-negative Bacterial Infection Terminated 2020-01-14 2022-12-30 ClinicalTrials.gov
NCT04183608 A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing a… Phase4 Ulcerative Colitis Recruiting 2020-01-14 2028-05-01 ClinicalTrials.gov
NCT03873493 A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants Wi… Phase2 Leukemia Completed 2020-01-14 2021-11-04 ClinicalTrials.gov
NCT04183608 A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing a… Phase4 Ulcerative Colitis Recruiting 2020-01-14 2028-05-01 ClinicalTrials.gov
NCT03873493 A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants Wi… Phase2 Leukemia Completed 2020-01-14 2021-11-04 ClinicalTrials.gov
NCT03873493 A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants Wi… Phase2 Leukemia Completed 2020-01-14 2021-11-04 ClinicalTrials.gov
NCT04183608 A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing a… Phase4 Ulcerative Colitis Recruiting 2020-01-14 2028-05-01 ClinicalTrials.gov
NCT04126031 Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibact… Phase2 Gram-negative Bacterial Infection Terminated 2020-01-14 2022-12-30 ClinicalTrials.gov
NCT03873493 A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants Wi… Phase2 Leukemia Completed 2020-01-14 2021-11-04 ClinicalTrials.gov
NCT04126031 Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibact… Phase2 Gram-negative Bacterial Infection Terminated 2020-01-14 2022-12-30 ClinicalTrials.gov
NCT04159779 A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Tre… — Chronic Lymphocytic Leukemia Active_Not_Recruiting 2020-01-13 2026-06-30 ClinicalTrials.gov
NCT04159779 A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Tre… — Chronic Lymphocytic Leukemia Active_Not_Recruiting 2020-01-13 2026-06-30 ClinicalTrials.gov
NCT04159779 A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Tre… — Chronic Lymphocytic Leukemia Active_Not_Recruiting 2020-01-13 2026-06-30 ClinicalTrials.gov
NCT04159779 A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Tre… — Chronic Lymphocytic Leukemia Active_Not_Recruiting 2020-01-13 2026-06-30 ClinicalTrials.gov
NCT04223193 Flexible-Dose Trial in Early Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2020-01-06 2024-10-01 ClinicalTrials.gov
NCT04223193 Flexible-Dose Trial in Early Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2020-01-06 2024-10-01 ClinicalTrials.gov
NCT04223193 Flexible-Dose Trial in Early Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2020-01-06 2024-10-01 ClinicalTrials.gov
NCT04223193 Flexible-Dose Trial in Early Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2020-01-06 2024-10-01 ClinicalTrials.gov
NCT04240535 Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor An… Phase4 Aging Not_Yet_Recruiting 2020-01-01 2020-07-01 ClinicalTrials.gov
NCT04240535 Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor An… Phase4 Aging Not_Yet_Recruiting 2020-01-01 2020-07-01 ClinicalTrials.gov
NCT04240535 Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor An… Phase4 Aging Not_Yet_Recruiting 2020-01-01 2020-07-01 ClinicalTrials.gov
NCT04240535 Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor An… Phase4 Aging Not_Yet_Recruiting 2020-01-01 2020-07-01 ClinicalTrials.gov
NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemothe… Phase3 Epithelial Ovarian Cancer Completed 2019-12-31 2024-10-29 ClinicalTrials.gov
NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemothe… Phase3 Epithelial Ovarian Cancer Completed 2019-12-31 2024-10-29 ClinicalTrials.gov
NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemothe… Phase3 Epithelial Ovarian Cancer Completed 2019-12-31 2024-10-29 ClinicalTrials.gov
NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemothe… Phase3 Epithelial Ovarian Cancer Completed 2019-12-31 2024-10-29 ClinicalTrials.gov
NCT04214028 A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent … — Hepatitis C Virus (HCV) Completed 2019-12-26 2024-08-01 ClinicalTrials.gov
NCT04214028 A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent … — Hepatitis C Virus (HCV) Completed 2019-12-26 2024-08-01 ClinicalTrials.gov
NCT04214028 A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent … — Hepatitis C Virus (HCV) Completed 2019-12-26 2024-08-01 ClinicalTrials.gov
NCT04214028 A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent … — Hepatitis C Virus (HCV) Completed 2019-12-26 2024-08-01 ClinicalTrials.gov
NCT04303897 Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma — Refractory Glaucoma Completed 2019-12-19 2022-03-03 ClinicalTrials.gov
NCT04303897 Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma — Refractory Glaucoma Completed 2019-12-19 2022-03-03 ClinicalTrials.gov
NCT04303897 Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma — Refractory Glaucoma Completed 2019-12-19 2022-03-03 ClinicalTrials.gov
NCT04303897 Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma — Refractory Glaucoma Completed 2019-12-19 2022-03-03 ClinicalTrials.gov
NCT04201093 Fixed-Dose Trial in Early Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2019-12-13 2024-06-28 ClinicalTrials.gov
NCT04201093 Fixed-Dose Trial in Early Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2019-12-13 2024-06-28 ClinicalTrials.gov
NCT04201093 Fixed-Dose Trial in Early Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2019-12-13 2024-06-28 ClinicalTrials.gov
NCT04201093 Fixed-Dose Trial in Early Parkinson's Disease (PD) Phase3 Parkinson Disease Completed 2019-12-13 2024-06-28 ClinicalTrials.gov
NCT03969888 A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 Phase2 Cystic Fibrosis Completed 2019-12-11 2022-06-09 ClinicalTrials.gov
NCT03969888 A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 Phase2 Cystic Fibrosis Completed 2019-12-11 2022-06-09 ClinicalTrials.gov
NCT03969888 A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 Phase2 Cystic Fibrosis Completed 2019-12-11 2022-06-09 ClinicalTrials.gov
NCT03969888 A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 Phase2 Cystic Fibrosis Completed 2019-12-11 2022-06-09 ClinicalTrials.gov
NCT04080856 Real-World Experience Study of Elagolix For the Treatment of Endometriosis in C… — Endometriosis Completed 2019-12-04 2021-09-27 ClinicalTrials.gov
NCT04080856 Real-World Experience Study of Elagolix For the Treatment of Endometriosis in C… — Endometriosis Completed 2019-12-04 2021-09-27 ClinicalTrials.gov
NCT03993847 CLassification of Axial SpondyloarthritiS Inception Cohort — Spondyloarthritis Completed 2019-12-04 2022-08-22 ClinicalTrials.gov
NCT03993847 CLassification of Axial SpondyloarthritiS Inception Cohort — Spondyloarthritis Completed 2019-12-04 2022-08-22 ClinicalTrials.gov
NCT03993847 CLassification of Axial SpondyloarthritiS Inception Cohort — Spondyloarthritis Completed 2019-12-04 2022-08-22 ClinicalTrials.gov
NCT04080856 Real-World Experience Study of Elagolix For the Treatment of Endometriosis in C… — Endometriosis Completed 2019-12-04 2021-09-27 ClinicalTrials.gov
NCT04080856 Real-World Experience Study of Elagolix For the Treatment of Endometriosis in C… — Endometriosis Completed 2019-12-04 2021-09-27 ClinicalTrials.gov
NCT03993847 CLassification of Axial SpondyloarthritiS Inception Cohort — Spondyloarthritis Completed 2019-12-04 2022-08-22 ClinicalTrials.gov
NCT04169373 A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Sp… Phase3 Spondyloarthritis Completed 2019-11-26 2025-02-28 ClinicalTrials.gov
NCT04169373 A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Sp… Phase3 Spondyloarthritis Completed 2019-11-26 2025-02-28 ClinicalTrials.gov
NCT04169373 A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Sp… Phase3 Spondyloarthritis Completed 2019-11-26 2025-02-28 ClinicalTrials.gov
NCT04169373 A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Sp… Phase3 Spondyloarthritis Completed 2019-11-26 2025-02-28 ClinicalTrials.gov
NCT04042740 Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C… Phase2 Hepatitis C Infection Completed 2019-11-20 2023-08-22 ClinicalTrials.gov
NCT04042740 Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C… Phase2 Hepatitis C Infection Completed 2019-11-20 2023-08-22 ClinicalTrials.gov
NCT04042740 Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C… Phase2 Hepatitis C Infection Completed 2019-11-20 2023-08-22 ClinicalTrials.gov
NCT04042740 Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C… Phase2 Hepatitis C Infection Completed 2019-11-20 2023-08-22 ClinicalTrials.gov
NCT04166058 Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C Phase3 Irritable Bowel Syndrome With Constipation Completed 2019-11-19 2025-06-05 ClinicalTrials.gov
NCT04166058 Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C Phase3 Irritable Bowel Syndrome With Constipation Completed 2019-11-19 2025-06-05 ClinicalTrials.gov
NCT04166058 Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C Phase3 Irritable Bowel Syndrome With Constipation Completed 2019-11-19 2025-06-05 ClinicalTrials.gov
NCT04166058 Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C Phase3 Irritable Bowel Syndrome With Constipation Completed 2019-11-19 2025-06-05 ClinicalTrials.gov
NCT03844815 Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myelo… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2019-11-18 2027-12-10 ClinicalTrials.gov
NCT03844815 Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myelo… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2019-11-18 2027-12-10 ClinicalTrials.gov
NCT03844815 Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myelo… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2019-11-18 2027-12-10 ClinicalTrials.gov
NCT03844815 Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myelo… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2019-11-18 2027-12-10 ClinicalTrials.gov
NCT04102007 A Study of the Safety and Efficacy of Risankizumab in Adult Participants With P… Phase3 Plaque Psoriasis Completed 2019-11-12 2022-11-07 ClinicalTrials.gov
NCT04102007 A Study of the Safety and Efficacy of Risankizumab in Adult Participants With P… Phase3 Plaque Psoriasis Completed 2019-11-12 2022-11-07 ClinicalTrials.gov
NCT04102007 A Study of the Safety and Efficacy of Risankizumab in Adult Participants With P… Phase3 Plaque Psoriasis Completed 2019-11-12 2022-11-07 ClinicalTrials.gov
NCT04102007 A Study of the Safety and Efficacy of Risankizumab in Adult Participants With P… Phase3 Plaque Psoriasis Completed 2019-11-12 2022-11-07 ClinicalTrials.gov
NCT04041050 A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax … Phase1 Myeloproliferative Neoplasm Active_Not_Recruiting 2019-11-08 2026-12-31 ClinicalTrials.gov
NCT04041050 A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax … Phase1 Myeloproliferative Neoplasm Active_Not_Recruiting 2019-11-08 2026-12-31 ClinicalTrials.gov
NCT04041050 A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax … Phase1 Myeloproliferative Neoplasm Active_Not_Recruiting 2019-11-08 2026-12-31 ClinicalTrials.gov
NCT04041050 A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax … Phase1 Myeloproliferative Neoplasm Active_Not_Recruiting 2019-11-08 2026-12-31 ClinicalTrials.gov
NCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants W… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2019-11-06 2027-02-01 ClinicalTrials.gov
NCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants W… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2019-11-06 2027-02-01 ClinicalTrials.gov
NCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants W… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2019-11-06 2027-02-01 ClinicalTrials.gov
NCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants W… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2019-11-06 2027-02-01 ClinicalTrials.gov
NCT05247294 Assessment of Fluctuating Parkinson's Disease With Sensor-based Home Monitoring — Parkinson Disease Completed 2019-11-03 2021-02-24 ClinicalTrials.gov
NCT05247294 Assessment of Fluctuating Parkinson's Disease With Sensor-based Home Monitoring — Parkinson Disease Completed 2019-11-03 2021-02-24 ClinicalTrials.gov
NCT05247294 Assessment of Fluctuating Parkinson's Disease With Sensor-based Home Monitoring — Parkinson Disease Completed 2019-11-03 2021-02-24 ClinicalTrials.gov
NCT05247294 Assessment of Fluctuating Parkinson's Disease With Sensor-based Home Monitoring — Parkinson Disease Completed 2019-11-03 2021-02-24 ClinicalTrials.gov
NCT04138199 A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinav… — HIV-1 Infection Terminated 2019-11-01 2020-07-08 ClinicalTrials.gov
NCT03044795 Response to PARP Inhibitor Predicted by the RAD51 Assay Phase2 Cancer Withdrawn 2019-11-01 2020-11-01 ClinicalTrials.gov
NCT04138199 A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinav… — HIV-1 Infection Terminated 2019-11-01 2020-07-08 ClinicalTrials.gov
NCT03044795 Response to PARP Inhibitor Predicted by the RAD51 Assay Phase2 Cancer Withdrawn 2019-11-01 2020-11-01 ClinicalTrials.gov
NCT04138199 A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinav… — HIV-1 Infection Terminated 2019-11-01 2020-07-08 ClinicalTrials.gov
NCT04138199 A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinav… — HIV-1 Infection Terminated 2019-11-01 2020-07-08 ClinicalTrials.gov
NCT03044795 Response to PARP Inhibitor Predicted by the RAD51 Assay Phase2 Cancer Withdrawn 2019-11-01 2020-11-01 ClinicalTrials.gov
NCT03044795 Response to PARP Inhibitor Predicted by the RAD51 Assay Phase2 Cancer Withdrawn 2019-11-01 2020-11-01 ClinicalTrials.gov
NCT04142450 CoolSculpting® the Upper Arms and Inner Thighs in Participants of Chinese Desce… Na Body Fat Disorder Completed 2019-10-27 2020-02-24 ClinicalTrials.gov
NCT04142450 CoolSculpting® the Upper Arms and Inner Thighs in Participants of Chinese Desce… Na Body Fat Disorder Completed 2019-10-27 2020-02-24 ClinicalTrials.gov
NCT04142450 CoolSculpting® the Upper Arms and Inner Thighs in Participants of Chinese Desce… Na Body Fat Disorder Completed 2019-10-27 2020-02-24 ClinicalTrials.gov
NCT04142450 CoolSculpting® the Upper Arms and Inner Thighs in Participants of Chinese Desce… Na Body Fat Disorder Completed 2019-10-27 2020-02-24 ClinicalTrials.gov
NCT03924947 A Study to Compare US Marketed Creon Manufactured With a Modernized Process at … Phase4 Cystic Fibrosis Completed 2019-10-23 2022-07-11 ClinicalTrials.gov
NCT03924947 A Study to Compare US Marketed Creon Manufactured With a Modernized Process at … Phase4 Cystic Fibrosis Completed 2019-10-23 2022-07-11 ClinicalTrials.gov
NCT03924947 A Study to Compare US Marketed Creon Manufactured With a Modernized Process at … Phase4 Cystic Fibrosis Completed 2019-10-23 2022-07-11 ClinicalTrials.gov
NCT03924947 A Study to Compare US Marketed Creon Manufactured With a Modernized Process at … Phase4 Cystic Fibrosis Completed 2019-10-23 2022-07-11 ClinicalTrials.gov
NCT04110145 Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional… Phase2 Functional Constipation Completed 2019-10-14 2021-04-20 ClinicalTrials.gov
NCT04110145 Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional… Phase2 Functional Constipation Completed 2019-10-14 2021-04-20 ClinicalTrials.gov
NCT04110145 Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional… Phase2 Functional Constipation Completed 2019-10-14 2021-04-20 ClinicalTrials.gov
NCT04110145 Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional… Phase2 Functional Constipation Completed 2019-10-14 2021-04-20 ClinicalTrials.gov
NCT04124705 A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previous… Phase2 Hypothyroidism Completed 2019-10-11 2021-06-22 ClinicalTrials.gov
NCT04124705 A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previous… Phase2 Hypothyroidism Completed 2019-10-11 2021-06-22 ClinicalTrials.gov
NCT04124705 A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previous… Phase2 Hypothyroidism Completed 2019-10-11 2021-06-22 ClinicalTrials.gov
NCT04124705 A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previous… Phase2 Hypothyroidism Completed 2019-10-11 2021-06-22 ClinicalTrials.gov
NCT04206293 A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite I… Na Healthy Adults Completed 2019-10-08 2020-07-29 ClinicalTrials.gov
NCT04206293 A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite I… Na Healthy Adults Completed 2019-10-08 2020-07-29 ClinicalTrials.gov
NCT04206293 A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite I… Na Healthy Adults Completed 2019-10-08 2020-07-29 ClinicalTrials.gov
NCT04206293 A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite I… Na Healthy Adults Completed 2019-10-08 2020-07-29 ClinicalTrials.gov
NCT04026113 Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age… Phase3 Functional Constipation Completed 2019-10-01 2024-05-29 ClinicalTrials.gov
NCT04026113 Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age… Phase3 Functional Constipation Completed 2019-10-01 2024-05-29 ClinicalTrials.gov
NCT04026113 Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age… Phase3 Functional Constipation Completed 2019-10-01 2024-05-29 ClinicalTrials.gov
NCT04026113 Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age… Phase3 Functional Constipation Completed 2019-10-01 2024-05-29 ClinicalTrials.gov
NCT04010968 Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients W… Phase2 Intermediate Risk Chronic Lymphocytic Leukemia Completed 2019-09-27 2025-01-30 ClinicalTrials.gov
NCT04010968 Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients W… Phase2 Intermediate Risk Chronic Lymphocytic Leukemia Completed 2019-09-27 2025-01-30 ClinicalTrials.gov
NCT04010968 Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients W… Phase2 Intermediate Risk Chronic Lymphocytic Leukemia Completed 2019-09-27 2025-01-30 ClinicalTrials.gov
NCT04010968 Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients W… Phase2 Intermediate Risk Chronic Lymphocytic Leukemia Completed 2019-09-27 2025-01-30 ClinicalTrials.gov
NCT04096326 AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines Phase2 Glabellar Lines Completed 2019-09-26 2020-09-09 ClinicalTrials.gov
NCT04179474 Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenum… Phase1 Migraine Completed 2019-09-26 2019-12-23 ClinicalTrials.gov
NCT04096326 AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines Phase2 Glabellar Lines Completed 2019-09-26 2020-09-09 ClinicalTrials.gov
NCT04096326 AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines Phase2 Glabellar Lines Completed 2019-09-26 2020-09-09 ClinicalTrials.gov
NCT04179474 Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenum… Phase1 Migraine Completed 2019-09-26 2019-12-23 ClinicalTrials.gov
NCT04096326 AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines Phase2 Glabellar Lines Completed 2019-09-26 2020-09-09 ClinicalTrials.gov
NCT04179474 Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenum… Phase1 Migraine Completed 2019-09-26 2019-12-23 ClinicalTrials.gov
NCT04179474 Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenum… Phase1 Migraine Completed 2019-09-26 2019-12-23 ClinicalTrials.gov
NCT03848143 Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pa… Phase2 Neuropathic Pain Completed 2019-09-11 2025-06-30 ClinicalTrials.gov
NCT03848143 Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pa… Phase2 Neuropathic Pain Completed 2019-09-11 2025-06-30 ClinicalTrials.gov
NCT03848143 Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pa… Phase2 Neuropathic Pain Completed 2019-09-11 2025-06-30 ClinicalTrials.gov
NCT03848143 Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pa… Phase2 Neuropathic Pain Completed 2019-09-11 2025-06-30 ClinicalTrials.gov
NCT04070768 Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax i… Phase1 Acute Myeloid Leukemia Completed 2019-09-06 2024-02-20 ClinicalTrials.gov
NCT03844048 An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Veneto… Phase3 Chronic Lymphocytic Leukemia Active_Not_Recruiting 2019-09-06 2027-08-01 ClinicalTrials.gov
NCT03844048 An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Veneto… Phase3 Chronic Lymphocytic Leukemia Active_Not_Recruiting 2019-09-06 2027-08-01 ClinicalTrials.gov
NCT03844048 An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Veneto… Phase3 Chronic Lymphocytic Leukemia Active_Not_Recruiting 2019-09-06 2027-08-01 ClinicalTrials.gov
NCT04070768 Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax i… Phase1 Acute Myeloid Leukemia Completed 2019-09-06 2024-02-20 ClinicalTrials.gov
NCT03844048 An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Veneto… Phase3 Chronic Lymphocytic Leukemia Active_Not_Recruiting 2019-09-06 2027-08-01 ClinicalTrials.gov
NCT04070768 Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax i… Phase1 Acute Myeloid Leukemia Completed 2019-09-06 2024-02-20 ClinicalTrials.gov
NCT04070768 Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax i… Phase1 Acute Myeloid Leukemia Completed 2019-09-06 2024-02-20 ClinicalTrials.gov
NCT04073303 BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Promi… Phase3 Masseter Muscle Prominence Completed 2019-08-29 2022-11-10 ClinicalTrials.gov
NCT04073303 BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Promi… Phase3 Masseter Muscle Prominence Completed 2019-08-29 2022-11-10 ClinicalTrials.gov
NCT04073303 BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Promi… Phase3 Masseter Muscle Prominence Completed 2019-08-29 2022-11-10 ClinicalTrials.gov
NCT04073303 BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Promi… Phase3 Masseter Muscle Prominence Completed 2019-08-29 2022-11-10 ClinicalTrials.gov
NCT03874052 Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Trea… Phase1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Recruiting 2019-08-16 2027-12-31 ClinicalTrials.gov
NCT03874052 Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Trea… Phase1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Recruiting 2019-08-16 2027-12-31 ClinicalTrials.gov
NCT03874052 Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Trea… Phase1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Recruiting 2019-08-16 2027-12-31 ClinicalTrials.gov
NCT03874052 Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Trea… Phase1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Recruiting 2019-08-16 2027-12-31 ClinicalTrials.gov
NCT03941964 A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or D… Phase3 Acute Myeloid Leukemia (AML) Completed 2019-08-15 2022-03-14 ClinicalTrials.gov
NCT03941964 A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or D… Phase3 Acute Myeloid Leukemia (AML) Completed 2019-08-15 2022-03-14 ClinicalTrials.gov
NCT03941964 A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or D… Phase3 Acute Myeloid Leukemia (AML) Completed 2019-08-15 2022-03-14 ClinicalTrials.gov
NCT03941964 A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or D… Phase3 Acute Myeloid Leukemia (AML) Completed 2019-08-15 2022-03-14 ClinicalTrials.gov
NCT03951077 Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syn… Phase2 Polycystic Ovary Syndrome Completed 2019-08-12 2021-02-10 ClinicalTrials.gov
NCT03951077 Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syn… Phase2 Polycystic Ovary Syndrome Completed 2019-08-12 2021-02-10 ClinicalTrials.gov
NCT03951077 Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syn… Phase2 Polycystic Ovary Syndrome Completed 2019-08-12 2021-02-10 ClinicalTrials.gov
NCT03951077 Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syn… Phase2 Polycystic Ovary Syndrome Completed 2019-08-12 2021-02-10 ClinicalTrials.gov
NCT03987958 A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid… — Acute Myeloid Leukemia Active_Not_Recruiting 2019-08-08 2027-07-01 ClinicalTrials.gov
NCT03987958 A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid… — Acute Myeloid Leukemia Active_Not_Recruiting 2019-08-08 2027-07-01 ClinicalTrials.gov
NCT03987958 A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid… — Acute Myeloid Leukemia Active_Not_Recruiting 2019-08-08 2027-07-01 ClinicalTrials.gov
NCT03987958 A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid… — Acute Myeloid Leukemia Active_Not_Recruiting 2019-08-08 2027-07-01 ClinicalTrials.gov
NCT03751436 Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Re… Phase1 Castration Levels of Testosterone Completed 2019-08-02 2023-08-11 ClinicalTrials.gov
NCT03751436 Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Re… Phase1 Castration Levels of Testosterone Completed 2019-08-02 2023-08-11 ClinicalTrials.gov
NCT03751436 Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Re… Phase1 Castration Levels of Testosterone Completed 2019-08-02 2023-08-11 ClinicalTrials.gov
NCT03751436 Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Re… Phase1 Castration Levels of Testosterone Completed 2019-08-02 2023-08-11 ClinicalTrials.gov
NCT03557619 A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgest… Phase1 Hematologic Malignancies Recruiting 2019-07-30 2026-03-21 ClinicalTrials.gov
NCT03557619 A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgest… Phase1 Hematologic Malignancies Recruiting 2019-07-30 2026-03-21 ClinicalTrials.gov
NCT03557619 A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgest… Phase1 Hematologic Malignancies Recruiting 2019-07-30 2026-03-21 ClinicalTrials.gov
NCT03557619 A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgest… Phase1 Hematologic Malignancies Recruiting 2019-07-30 2026-03-21 ClinicalTrials.gov
NCT03909100 International CoolSculpting: Study to Evaluate Patient Satisfaction for Non-Inv… Na Non-invasive Fat Reduction Completed 2019-07-29 2020-02-28 ClinicalTrials.gov
NCT03909100 International CoolSculpting: Study to Evaluate Patient Satisfaction for Non-Inv… Na Non-invasive Fat Reduction Completed 2019-07-29 2020-02-28 ClinicalTrials.gov
NCT03909100 International CoolSculpting: Study to Evaluate Patient Satisfaction for Non-Inv… Na Non-invasive Fat Reduction Completed 2019-07-29 2020-02-28 ClinicalTrials.gov
NCT03909100 International CoolSculpting: Study to Evaluate Patient Satisfaction for Non-Inv… Na Non-invasive Fat Reduction Completed 2019-07-29 2020-02-28 ClinicalTrials.gov
NCT04089722 Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissu… Phase4 Brassiere Strap Fat (BSF) Completed 2019-07-26 2020-10-22 ClinicalTrials.gov
NCT04089722 Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissu… Phase4 Brassiere Strap Fat (BSF) Completed 2019-07-26 2020-10-22 ClinicalTrials.gov
NCT04089722 Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissu… Phase4 Brassiere Strap Fat (BSF) Completed 2019-07-26 2020-10-22 ClinicalTrials.gov
NCT04089722 Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissu… Phase4 Brassiere Strap Fat (BSF) Completed 2019-07-26 2020-10-22 ClinicalTrials.gov
NCT03978520 A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib… Phase2 Systemic Lupus Erythematosus (SLE) Completed 2019-07-25 2022-07-14 ClinicalTrials.gov
NCT03978520 A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib… Phase2 Systemic Lupus Erythematosus (SLE) Completed 2019-07-25 2022-07-14 ClinicalTrials.gov
NCT03908307 Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein… Phase4 Macular Edema Completed 2019-07-25 2021-09-26 ClinicalTrials.gov
NCT03978520 A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib… Phase2 Systemic Lupus Erythematosus (SLE) Completed 2019-07-25 2022-07-14 ClinicalTrials.gov
NCT03908307 Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein… Phase4 Macular Edema Completed 2019-07-25 2021-09-26 ClinicalTrials.gov
NCT03908307 Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein… Phase4 Macular Edema Completed 2019-07-25 2021-09-26 ClinicalTrials.gov
NCT03978520 A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib… Phase2 Systemic Lupus Erythematosus (SLE) Completed 2019-07-25 2022-07-14 ClinicalTrials.gov
NCT03908307 Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein… Phase4 Macular Edema Completed 2019-07-25 2021-09-26 ClinicalTrials.gov
NCT03855865 Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) Phase3 Depressive Disorder, Major Withdrawn 2019-07-01 2020-12-31 ClinicalTrials.gov
NCT03982394 Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis — Chronic Plaque Psoriasis Completed 2019-07-01 2025-09-02 ClinicalTrials.gov
NCT03855865 Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) Phase3 Depressive Disorder, Major Withdrawn 2019-07-01 2020-12-31 ClinicalTrials.gov
NCT03982394 Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis — Chronic Plaque Psoriasis Completed 2019-07-01 2025-09-02 ClinicalTrials.gov
NCT03982394 Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis — Chronic Plaque Psoriasis Completed 2019-07-01 2025-09-02 ClinicalTrials.gov
NCT03855865 Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) Phase3 Depressive Disorder, Major Withdrawn 2019-07-01 2020-12-31 ClinicalTrials.gov
NCT03982394 Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis — Chronic Plaque Psoriasis Completed 2019-07-01 2025-09-02 ClinicalTrials.gov
NCT03855865 Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) Phase3 Depressive Disorder, Major Withdrawn 2019-07-01 2020-12-31 ClinicalTrials.gov
NCT05268068 A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizu… Phase1 Healthy Volunteers Completed 2019-06-27 2020-04-26 ClinicalTrials.gov
NCT05268068 A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizu… Phase1 Healthy Volunteers Completed 2019-06-27 2020-04-26 ClinicalTrials.gov
NCT05268068 A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizu… Phase1 Healthy Volunteers Completed 2019-06-27 2020-04-26 ClinicalTrials.gov
NCT05268068 A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizu… Phase1 Healthy Volunteers Completed 2019-06-27 2020-04-26 ClinicalTrials.gov
NCT03925441 Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Pla… — Psoriasis Completed 2019-06-25 2019-08-06 ClinicalTrials.gov
NCT03925441 Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Pla… — Psoriasis Completed 2019-06-25 2019-08-06 ClinicalTrials.gov
NCT03925441 Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Pla… — Psoriasis Completed 2019-06-25 2019-08-06 ClinicalTrials.gov
NCT03925441 Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Pla… — Psoriasis Completed 2019-06-25 2019-08-06 ClinicalTrials.gov
NCT03725007 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadaciti… Phase1 Juvenile Idiopathic Arthritis (JIA) Active_Not_Recruiting 2019-06-24 2027-05-01 ClinicalTrials.gov
NCT03827564 Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in … Na Dry Eye Syndromes Terminated 2019-06-24 2020-06-08 ClinicalTrials.gov
NCT03933735 A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma Phase1 Multiple Myeloma Active_Not_Recruiting 2019-06-24 2026-05-01 ClinicalTrials.gov
NCT03725007 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadaciti… Phase1 Juvenile Idiopathic Arthritis (JIA) Active_Not_Recruiting 2019-06-24 2027-05-01 ClinicalTrials.gov
NCT03933735 A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma Phase1 Multiple Myeloma Active_Not_Recruiting 2019-06-24 2026-05-01 ClinicalTrials.gov
NCT03725007 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadaciti… Phase1 Juvenile Idiopathic Arthritis (JIA) Active_Not_Recruiting 2019-06-24 2027-05-01 ClinicalTrials.gov
NCT03827564 Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in … Na Dry Eye Syndromes Terminated 2019-06-24 2020-06-08 ClinicalTrials.gov
NCT03933735 A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma Phase1 Multiple Myeloma Active_Not_Recruiting 2019-06-24 2026-05-01 ClinicalTrials.gov
NCT03933735 A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma Phase1 Multiple Myeloma Active_Not_Recruiting 2019-06-24 2026-05-01 ClinicalTrials.gov
NCT03827564 Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in … Na Dry Eye Syndromes Terminated 2019-06-24 2020-06-08 ClinicalTrials.gov
NCT03827564 Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in … Na Dry Eye Syndromes Terminated 2019-06-24 2020-06-08 ClinicalTrials.gov
NCT03725007 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadaciti… Phase1 Juvenile Idiopathic Arthritis (JIA) Active_Not_Recruiting 2019-06-24 2027-05-01 ClinicalTrials.gov
NCT03955783 Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High … Phase1 Diffuse Large B-cell Lymphoma Completed 2019-06-21 2024-09-01 ClinicalTrials.gov
NCT03955783 Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High … Phase1 Diffuse Large B-cell Lymphoma Completed 2019-06-21 2024-09-01 ClinicalTrials.gov
NCT03955783 Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High … Phase1 Diffuse Large B-cell Lymphoma Completed 2019-06-21 2024-09-01 ClinicalTrials.gov
NCT03955783 Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High … Phase1 Diffuse Large B-cell Lymphoma Completed 2019-06-21 2024-09-01 ClinicalTrials.gov
NCT03922607 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 i… Phase1 Psoriasis Completed 2019-06-11 2021-04-13 ClinicalTrials.gov
NCT03757533 Health Coaching as a Tool for Improving Medication Adherence in Adult Patients … Na Inflammatory Bowel Diseases Completed 2019-06-11 2023-07-21 ClinicalTrials.gov
NCT03757533 Health Coaching as a Tool for Improving Medication Adherence in Adult Patients … Na Inflammatory Bowel Diseases Completed 2019-06-11 2023-07-21 ClinicalTrials.gov
NCT03922607 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 i… Phase1 Psoriasis Completed 2019-06-11 2021-04-13 ClinicalTrials.gov
NCT03922607 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 i… Phase1 Psoriasis Completed 2019-06-11 2021-04-13 ClinicalTrials.gov
NCT03922607 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 i… Phase1 Psoriasis Completed 2019-06-11 2021-04-13 ClinicalTrials.gov
NCT03757533 Health Coaching as a Tool for Improving Medication Adherence in Adult Patients … Na Inflammatory Bowel Diseases Completed 2019-06-11 2023-07-21 ClinicalTrials.gov
NCT03757533 Health Coaching as a Tool for Improving Medication Adherence in Adult Patients … Na Inflammatory Bowel Diseases Completed 2019-06-11 2023-07-21 ClinicalTrials.gov
NCT03875508 A Study to Assess Usability of Risankizumab Autoinjector Combination Product in… Phase3 Psoriasis Completed 2019-06-04 2020-08-25 ClinicalTrials.gov
NCT03875508 A Study to Assess Usability of Risankizumab Autoinjector Combination Product in… Phase3 Psoriasis Completed 2019-06-04 2020-08-25 ClinicalTrials.gov
NCT03875508 A Study to Assess Usability of Risankizumab Autoinjector Combination Product in… Phase3 Psoriasis Completed 2019-06-04 2020-08-25 ClinicalTrials.gov
NCT03875508 A Study to Assess Usability of Risankizumab Autoinjector Combination Product in… Phase3 Psoriasis Completed 2019-06-04 2020-08-25 ClinicalTrials.gov
NCT03926169 A Global Study Comparing Risankizumab to Placebo in Adult Participants With Mod… Phase2 Hidradenitis Suppurativa Completed 2019-06-03 2021-08-02 ClinicalTrials.gov
NCT03926169 A Global Study Comparing Risankizumab to Placebo in Adult Participants With Mod… Phase2 Hidradenitis Suppurativa Completed 2019-06-03 2021-08-02 ClinicalTrials.gov
NCT03926169 A Global Study Comparing Risankizumab to Placebo in Adult Participants With Mod… Phase2 Hidradenitis Suppurativa Completed 2019-06-03 2021-08-02 ClinicalTrials.gov
NCT03926169 A Global Study Comparing Risankizumab to Placebo in Adult Participants With Mod… Phase2 Hidradenitis Suppurativa Completed 2019-06-03 2021-08-02 ClinicalTrials.gov
NCT03999801 Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy Phase2 Neovascular Age-related Macular Degeneration Enrolling_By_Invitation 2019-05-31 2028-12-01 ClinicalTrials.gov
NCT03999801 Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy Phase2 Neovascular Age-related Macular Degeneration Enrolling_By_Invitation 2019-05-31 2028-12-01 ClinicalTrials.gov
NCT03999801 Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy Phase2 Neovascular Age-related Macular Degeneration Enrolling_By_Invitation 2019-05-31 2028-12-01 ClinicalTrials.gov
NCT03999801 Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy Phase2 Neovascular Age-related Macular Degeneration Enrolling_By_Invitation 2019-05-31 2028-12-01 ClinicalTrials.gov
NCT03924323 A Study of Escitalopram in the Treatment of Children and Adolescents With Gener… Phase4 Anxiety Disorders,Generalized Anxiety Disorder Completed 2019-05-30 2021-09-20 ClinicalTrials.gov
NCT03924323 A Study of Escitalopram in the Treatment of Children and Adolescents With Gener… Phase4 Anxiety Disorders,Generalized Anxiety Disorder Completed 2019-05-30 2021-09-20 ClinicalTrials.gov
NCT03924323 A Study of Escitalopram in the Treatment of Children and Adolescents With Gener… Phase4 Anxiety Disorders,Generalized Anxiety Disorder Completed 2019-05-30 2021-09-20 ClinicalTrials.gov
NCT03924323 A Study of Escitalopram in the Treatment of Children and Adolescents With Gener… Phase4 Anxiety Disorders,Generalized Anxiety Disorder Completed 2019-05-30 2021-09-20 ClinicalTrials.gov
NCT03893955 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminar… Phase1 Cancer Active_Not_Recruiting 2019-05-21 2026-03-01 ClinicalTrials.gov
NCT03893955 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminar… Phase1 Cancer Active_Not_Recruiting 2019-05-21 2026-03-01 ClinicalTrials.gov
NCT03893955 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminar… Phase1 Cancer Active_Not_Recruiting 2019-05-21 2026-03-01 ClinicalTrials.gov
NCT03893955 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminar… Phase1 Cancer Active_Not_Recruiting 2019-05-21 2026-03-01 ClinicalTrials.gov
NCT03861936 BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence Phase2 Masseter Muscle Prominence Completed 2019-05-16 2020-07-02 ClinicalTrials.gov
NCT03861936 BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence Phase2 Masseter Muscle Prominence Completed 2019-05-16 2020-07-02 ClinicalTrials.gov
NCT03861936 BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence Phase2 Masseter Muscle Prominence Completed 2019-05-16 2020-07-02 ClinicalTrials.gov
NCT03861936 BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence Phase2 Masseter Muscle Prominence Completed 2019-05-16 2020-07-02 ClinicalTrials.gov
NCT03875482 A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation i… Phase3 Psoriasis Completed 2019-05-13 2020-07-15 ClinicalTrials.gov
NCT03823378 A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study W… Phase2 Rheumatoid Arthritis (RA) Terminated 2019-05-13 2020-09-09 ClinicalTrials.gov
NCT03875482 A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation i… Phase3 Psoriasis Completed 2019-05-13 2020-07-15 ClinicalTrials.gov
NCT03823378 A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study W… Phase2 Rheumatoid Arthritis (RA) Terminated 2019-05-13 2020-09-09 ClinicalTrials.gov
NCT03875482 A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation i… Phase3 Psoriasis Completed 2019-05-13 2020-07-15 ClinicalTrials.gov
NCT03875482 A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation i… Phase3 Psoriasis Completed 2019-05-13 2020-07-15 ClinicalTrials.gov
NCT03823378 A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study W… Phase2 Rheumatoid Arthritis (RA) Terminated 2019-05-13 2020-09-09 ClinicalTrials.gov
NCT03823378 A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study W… Phase2 Rheumatoid Arthritis (RA) Terminated 2019-05-13 2020-09-09 ClinicalTrials.gov
NCT03939312 Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atoge… Phase3 Episodic Migraine Completed 2019-05-06 2021-03-31 ClinicalTrials.gov
NCT03939312 Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atoge… Phase3 Episodic Migraine Completed 2019-05-06 2021-03-31 ClinicalTrials.gov
NCT03939312 Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atoge… Phase3 Episodic Migraine Completed 2019-05-06 2021-03-31 ClinicalTrials.gov
NCT03939312 Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atoge… Phase3 Episodic Migraine Completed 2019-05-06 2021-03-31 ClinicalTrials.gov
NCT03894956 Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in … — Hidradenitis Suppurativa (HS) Completed 2019-05-02 2021-11-10 ClinicalTrials.gov
NCT03894956 Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in … — Hidradenitis Suppurativa (HS) Completed 2019-05-02 2021-11-10 ClinicalTrials.gov
NCT03894956 Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in … — Hidradenitis Suppurativa (HS) Completed 2019-05-02 2021-11-10 ClinicalTrials.gov
NCT03894956 Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in … — Hidradenitis Suppurativa (HS) Completed 2019-05-02 2021-11-10 ClinicalTrials.gov
NCT03785184 A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of … Phase2 Multiple Myeloma Withdrawn 2019-04-29 2019-08-22 ClinicalTrials.gov
NCT03781167 A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Pa… Phase3 Parkinson's Disease (PD) Completed 2019-04-29 2022-08-17 ClinicalTrials.gov
NCT03785184 A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of … Phase2 Multiple Myeloma Withdrawn 2019-04-29 2019-08-22 ClinicalTrials.gov
NCT03785184 A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of … Phase2 Multiple Myeloma Withdrawn 2019-04-29 2019-08-22 ClinicalTrials.gov
NCT03785184 A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of … Phase2 Multiple Myeloma Withdrawn 2019-04-29 2019-08-22 ClinicalTrials.gov
NCT03781167 A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Pa… Phase3 Parkinson's Disease (PD) Completed 2019-04-29 2022-08-17 ClinicalTrials.gov
NCT03781167 A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Pa… Phase3 Parkinson's Disease (PD) Completed 2019-04-29 2022-08-17 ClinicalTrials.gov
NCT03781167 A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Pa… Phase3 Parkinson's Disease (PD) Completed 2019-04-29 2022-08-17 ClinicalTrials.gov
NCT03915067 BOTOX® for the Treatment of Platysma Prominence Phase2 Platysma Prominence Completed 2019-04-23 2020-04-16 ClinicalTrials.gov
NCT03915067 BOTOX® for the Treatment of Platysma Prominence Phase2 Platysma Prominence Completed 2019-04-23 2020-04-16 ClinicalTrials.gov
NCT03915067 BOTOX® for the Treatment of Platysma Prominence Phase2 Platysma Prominence Completed 2019-04-23 2020-04-16 ClinicalTrials.gov
NCT03915067 BOTOX® for the Treatment of Platysma Prominence Phase2 Platysma Prominence Completed 2019-04-23 2020-04-16 ClinicalTrials.gov
NCT03842566 Evaluation of Age-Related Skin Changes — Age-related Skin Changes Completed 2019-04-18 2019-07-12 ClinicalTrials.gov
NCT03842566 Evaluation of Age-Related Skin Changes — Age-related Skin Changes Completed 2019-04-18 2019-07-12 ClinicalTrials.gov
NCT03842566 Evaluation of Age-Related Skin Changes — Age-related Skin Changes Completed 2019-04-18 2019-07-12 ClinicalTrials.gov
NCT03842566 Evaluation of Age-Related Skin Changes — Age-related Skin Changes Completed 2019-04-18 2019-07-12 ClinicalTrials.gov
NCT03954444 A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" Phase3 Rosacea Completed 2019-04-15 2020-02-27 ClinicalTrials.gov
NCT03954444 A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" Phase3 Rosacea Completed 2019-04-15 2020-02-27 ClinicalTrials.gov
NCT03954444 A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" Phase3 Rosacea Completed 2019-04-15 2020-02-27 ClinicalTrials.gov
NCT03954444 A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" Phase3 Rosacea Completed 2019-04-15 2020-02-27 ClinicalTrials.gov
NCT03886220 A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of H… Phase4 Uterine Fibroids Completed 2019-04-12 2021-04-28 ClinicalTrials.gov
NCT03886220 A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of H… Phase4 Uterine Fibroids Completed 2019-04-12 2021-04-28 ClinicalTrials.gov
NCT03886220 A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of H… Phase4 Uterine Fibroids Completed 2019-04-12 2021-04-28 ClinicalTrials.gov
NCT03886220 A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of H… Phase4 Uterine Fibroids Completed 2019-04-12 2021-04-28 ClinicalTrials.gov
NCT03781726 Multi-center Study to Transplant Hepatitis-C Infected Kidneys Phase4 Renal Failure Chronic Completed 2019-04-10 2021-12-31 ClinicalTrials.gov
NCT03781726 Multi-center Study to Transplant Hepatitis-C Infected Kidneys Phase4 Renal Failure Chronic Completed 2019-04-10 2021-12-31 ClinicalTrials.gov
NCT03781726 Multi-center Study to Transplant Hepatitis-C Infected Kidneys Phase4 Renal Failure Chronic Completed 2019-04-10 2021-12-31 ClinicalTrials.gov
NCT03781726 Multi-center Study to Transplant Hepatitis-C Infected Kidneys Phase4 Renal Failure Chronic Completed 2019-04-10 2021-12-31 ClinicalTrials.gov
NCT03868254 Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (… — Glaucoma Completed 2019-04-05 2019-10-25 ClinicalTrials.gov
NCT03868254 Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (… — Glaucoma Completed 2019-04-05 2019-10-25 ClinicalTrials.gov
NCT03868254 Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (… — Glaucoma Completed 2019-04-05 2019-10-25 ClinicalTrials.gov
NCT03868254 Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (… — Glaucoma Completed 2019-04-05 2019-10-25 ClinicalTrials.gov
NCT05283681 A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe o… Phase1 Healthy Volunteers Completed 2019-04-02 2019-11-11 ClinicalTrials.gov
NCT05283681 A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe o… Phase1 Healthy Volunteers Completed 2019-04-02 2019-11-11 ClinicalTrials.gov
NCT05283681 A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe o… Phase1 Healthy Volunteers Completed 2019-04-02 2019-11-11 ClinicalTrials.gov
NCT05283681 A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe o… Phase1 Healthy Volunteers Completed 2019-04-02 2019-11-11 ClinicalTrials.gov
NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) Phase1 Relapsed Refractory Multiple Myeloma Completed 2019-04-01 2024-12-31 ClinicalTrials.gov
NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) Phase1 Relapsed Refractory Multiple Myeloma Completed 2019-04-01 2024-12-31 ClinicalTrials.gov
NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) Phase1 Relapsed Refractory Multiple Myeloma Completed 2019-04-01 2024-12-31 ClinicalTrials.gov
NCT03489265 Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fec… Phase2 Fecal Incontinence Withdrawn 2019-04-01 2020-03-01 ClinicalTrials.gov
NCT03489265 Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fec… Phase2 Fecal Incontinence Withdrawn 2019-04-01 2020-03-01 ClinicalTrials.gov
NCT03969537 Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neuroto… — Cervical Dystonia Completed 2019-04-01 2020-06-04 ClinicalTrials.gov
NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) Phase1 Relapsed Refractory Multiple Myeloma Completed 2019-04-01 2024-12-31 ClinicalTrials.gov
NCT03969537 Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neuroto… — Cervical Dystonia Completed 2019-04-01 2020-06-04 ClinicalTrials.gov
NCT03489265 Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fec… Phase2 Fecal Incontinence Withdrawn 2019-04-01 2020-03-01 ClinicalTrials.gov
NCT03969537 Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neuroto… — Cervical Dystonia Completed 2019-04-01 2020-06-04 ClinicalTrials.gov
NCT03489265 Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fec… Phase2 Fecal Incontinence Withdrawn 2019-04-01 2020-03-01 ClinicalTrials.gov
NCT03969537 Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neuroto… — Cervical Dystonia Completed 2019-04-01 2020-06-04 ClinicalTrials.gov
NCT03823391 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of… Phase2 Rheumatoid Arthritis (RA) Completed 2019-03-27 2020-08-26 ClinicalTrials.gov
NCT03823391 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of… Phase2 Rheumatoid Arthritis (RA) Completed 2019-03-27 2020-08-26 ClinicalTrials.gov
NCT03891446 Long-term Safety and Efficacy Extension Trial of Bimatoprost SR Phase3 Open-Angle Glaucoma Completed 2019-03-27 2026-06-19 ClinicalTrials.gov
NCT03891446 Long-term Safety and Efficacy Extension Trial of Bimatoprost SR Phase3 Open-Angle Glaucoma Completed 2019-03-27 2026-06-19 ClinicalTrials.gov
NCT03823391 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of… Phase2 Rheumatoid Arthritis (RA) Completed 2019-03-27 2020-08-26 ClinicalTrials.gov
NCT03891446 Long-term Safety and Efficacy Extension Trial of Bimatoprost SR Phase3 Open-Angle Glaucoma Completed 2019-03-27 2026-06-19 ClinicalTrials.gov
NCT03823391 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of… Phase2 Rheumatoid Arthritis (RA) Completed 2019-03-27 2020-08-26 ClinicalTrials.gov
NCT03891446 Long-term Safety and Efficacy Extension Trial of Bimatoprost SR Phase3 Open-Angle Glaucoma Completed 2019-03-27 2026-06-19 ClinicalTrials.gov
NCT03695185 A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is… Phase2 Ulcerative Colitis (UC) Completed 2019-03-26 2022-01-10 ClinicalTrials.gov
NCT03695185 A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is… Phase2 Ulcerative Colitis (UC) Completed 2019-03-26 2022-01-10 ClinicalTrials.gov
NCT03695185 A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is… Phase2 Ulcerative Colitis (UC) Completed 2019-03-26 2022-01-10 ClinicalTrials.gov
NCT03695185 A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is… Phase2 Ulcerative Colitis (UC) Completed 2019-03-26 2022-01-10 ClinicalTrials.gov
NCT03675308 A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic… Phase3 Psoriatic Arthritis Active_Not_Recruiting 2019-03-25 2026-09-28 ClinicalTrials.gov
NCT03675308 A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic… Phase3 Psoriatic Arthritis Active_Not_Recruiting 2019-03-25 2026-09-28 ClinicalTrials.gov
NCT03879837 Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inha… Phase3 Asthma Completed 2019-03-25 2021-07-09 ClinicalTrials.gov
NCT03879837 Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inha… Phase3 Asthma Completed 2019-03-25 2021-07-09 ClinicalTrials.gov
NCT03675308 A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic… Phase3 Psoriatic Arthritis Active_Not_Recruiting 2019-03-25 2026-09-28 ClinicalTrials.gov
NCT03879837 Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inha… Phase3 Asthma Completed 2019-03-25 2021-07-09 ClinicalTrials.gov
NCT03675308 A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic… Phase3 Psoriatic Arthritis Active_Not_Recruiting 2019-03-25 2026-09-28 ClinicalTrials.gov
NCT03879837 Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inha… Phase3 Asthma Completed 2019-03-25 2021-07-09 ClinicalTrials.gov
NCT03712787 An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD) Phase2 Alzheimer's Disease Terminated 2019-03-22 2021-09-30 ClinicalTrials.gov
NCT03712787 An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD) Phase2 Alzheimer's Disease Terminated 2019-03-22 2021-09-30 ClinicalTrials.gov
NCT03712787 An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD) Phase2 Alzheimer's Disease Terminated 2019-03-22 2021-09-30 ClinicalTrials.gov
NCT03712787 An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD) Phase2 Alzheimer's Disease Terminated 2019-03-22 2021-09-30 ClinicalTrials.gov
NCT03797261 A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematolo… Phase1 Acute Myeloid Leukemia Terminated 2019-03-18 2019-12-30 ClinicalTrials.gov
NCT03797261 A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematolo… Phase1 Acute Myeloid Leukemia Terminated 2019-03-18 2019-12-30 ClinicalTrials.gov
NCT03797261 A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematolo… Phase1 Acute Myeloid Leukemia Terminated 2019-03-18 2019-12-30 ClinicalTrials.gov
NCT03797261 A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematolo… Phase1 Acute Myeloid Leukemia Terminated 2019-03-18 2019-12-30 ClinicalTrials.gov
NCT05486195 A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Includin… Phase1 Cognitive Disorders Completed 2019-03-14 2020-03-11 ClinicalTrials.gov
NCT05486195 A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Includin… Phase1 Cognitive Disorders Completed 2019-03-14 2020-03-11 ClinicalTrials.gov
NCT05486195 A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Includin… Phase1 Cognitive Disorders Completed 2019-03-14 2020-03-11 ClinicalTrials.gov
NCT05486195 A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Includin… Phase1 Cognitive Disorders Completed 2019-03-14 2020-03-11 ClinicalTrials.gov
NCT03855137 Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic M… Phase3 Chronic Migraine Completed 2019-03-11 2022-01-20 ClinicalTrials.gov
NCT03855137 Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic M… Phase3 Chronic Migraine Completed 2019-03-11 2022-01-20 ClinicalTrials.gov
NCT03855137 Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic M… Phase3 Chronic Migraine Completed 2019-03-11 2022-01-20 ClinicalTrials.gov
NCT03855137 Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic M… Phase3 Chronic Migraine Completed 2019-03-11 2022-01-20 ClinicalTrials.gov
NCT03671148 A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic… Phase3 Psoriatic Arthritis (PsA) Completed 2019-03-07 2026-06-04 ClinicalTrials.gov
NCT03671148 A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic… Phase3 Psoriatic Arthritis (PsA) Completed 2019-03-07 2026-06-04 ClinicalTrials.gov
NCT03671148 A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic… Phase3 Psoriatic Arthritis (PsA) Completed 2019-03-07 2026-06-04 ClinicalTrials.gov
NCT03671148 A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic… Phase3 Psoriatic Arthritis (PsA) Completed 2019-03-07 2026-06-04 ClinicalTrials.gov
NCT03372941 Hospital Avoidance Strategies for ABSSSI Phase4 Skin Infection Terminated 2019-03-04 2021-10-14 ClinicalTrials.gov
NCT03372941 Hospital Avoidance Strategies for ABSSSI Phase4 Skin Infection Terminated 2019-03-04 2021-10-14 ClinicalTrials.gov
NCT03372941 Hospital Avoidance Strategies for ABSSSI Phase4 Skin Infection Terminated 2019-03-04 2021-10-14 ClinicalTrials.gov
NCT03372941 Hospital Avoidance Strategies for ABSSSI Phase4 Skin Infection Terminated 2019-03-04 2021-10-14 ClinicalTrials.gov
NCT03779841 Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial… Phase2 Post-Operative Atrial Fibrillation Completed 2019-03-01 2023-03-06 ClinicalTrials.gov
NCT03857542 A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in… Phase3 Presbyopia Completed 2019-03-01 2020-09-10 ClinicalTrials.gov
NCT03779841 Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial… Phase2 Post-Operative Atrial Fibrillation Completed 2019-03-01 2023-03-06 ClinicalTrials.gov
NCT03779841 Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial… Phase2 Post-Operative Atrial Fibrillation Completed 2019-03-01 2023-03-06 ClinicalTrials.gov
NCT03779841 Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial… Phase2 Post-Operative Atrial Fibrillation Completed 2019-03-01 2023-03-06 ClinicalTrials.gov
NCT03857542 A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in… Phase3 Presbyopia Completed 2019-03-01 2020-09-10 ClinicalTrials.gov
NCT03857542 A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in… Phase3 Presbyopia Completed 2019-03-01 2020-09-10 ClinicalTrials.gov
NCT03857542 A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in… Phase3 Presbyopia Completed 2019-03-01 2020-09-10 ClinicalTrials.gov
NCT03868163 Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprev… — Chronic Hepatitis C (CHC) Completed 2019-02-28 2020-09-04 ClinicalTrials.gov
NCT03850782 Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Ope… Phase3 Open-Angle Glaucoma Completed 2019-02-28 2025-08-08 ClinicalTrials.gov
NCT03850782 Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Ope… Phase3 Open-Angle Glaucoma Completed 2019-02-28 2025-08-08 ClinicalTrials.gov
NCT03868163 Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprev… — Chronic Hepatitis C (CHC) Completed 2019-02-28 2020-09-04 ClinicalTrials.gov
NCT03868163 Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprev… — Chronic Hepatitis C (CHC) Completed 2019-02-28 2020-09-04 ClinicalTrials.gov
NCT03850782 Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Ope… Phase3 Open-Angle Glaucoma Completed 2019-02-28 2025-08-08 ClinicalTrials.gov
NCT03850782 Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Ope… Phase3 Open-Angle Glaucoma Completed 2019-02-28 2025-08-08 ClinicalTrials.gov
NCT03868163 Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprev… — Chronic Hepatitis C (CHC) Completed 2019-02-28 2020-09-04 ClinicalTrials.gov
NCT03737812 A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard … Phase2 Multiple Sclerosis (MS) Completed 2019-02-27 2021-08-30 ClinicalTrials.gov
NCT03737812 A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard … Phase2 Multiple Sclerosis (MS) Completed 2019-02-27 2021-08-30 ClinicalTrials.gov
NCT03737812 A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard … Phase2 Multiple Sclerosis (MS) Completed 2019-02-27 2021-08-30 ClinicalTrials.gov
NCT03737812 A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard … Phase2 Multiple Sclerosis (MS) Completed 2019-02-27 2021-08-30 ClinicalTrials.gov
NCT03873857 A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Rela… — Chronic Lymphocytic Leukemia (CLL) Completed 2019-02-25 2022-09-12 ClinicalTrials.gov
NCT03852810 Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glau… — Glaucoma Completed 2019-02-25 2020-12-09 ClinicalTrials.gov
NCT03873857 A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Rela… — Chronic Lymphocytic Leukemia (CLL) Completed 2019-02-25 2022-09-12 ClinicalTrials.gov
NCT03852810 Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glau… — Glaucoma Completed 2019-02-25 2020-12-09 ClinicalTrials.gov
NCT03873857 A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Rela… — Chronic Lymphocytic Leukemia (CLL) Completed 2019-02-25 2022-09-12 ClinicalTrials.gov
NCT03852810 Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glau… — Glaucoma Completed 2019-02-25 2020-12-09 ClinicalTrials.gov
NCT03852810 Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glau… — Glaucoma Completed 2019-02-25 2020-12-09 ClinicalTrials.gov
NCT03873857 A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Rela… — Chronic Lymphocytic Leukemia (CLL) Completed 2019-02-25 2022-09-12 ClinicalTrials.gov
NCT03738397 A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Pa… Phase3 Atopic Dermatitis Completed 2019-02-21 2020-12-09 ClinicalTrials.gov
NCT03821935 Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended P… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2019-02-21 2027-06-01 ClinicalTrials.gov
NCT03738397 A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Pa… Phase3 Atopic Dermatitis Completed 2019-02-21 2020-12-09 ClinicalTrials.gov
NCT03821935 Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended P… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2019-02-21 2027-06-01 ClinicalTrials.gov
NCT03738397 A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Pa… Phase3 Atopic Dermatitis Completed 2019-02-21 2020-12-09 ClinicalTrials.gov
NCT03738397 A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Pa… Phase3 Atopic Dermatitis Completed 2019-02-21 2020-12-09 ClinicalTrials.gov
NCT03821935 Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended P… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2019-02-21 2027-06-01 ClinicalTrials.gov
NCT03821935 Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended P… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2019-02-21 2027-06-01 ClinicalTrials.gov
NCT03659669 A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chr… — Chronic Lymphocytic Leukemia (CLL) Suspended 2019-02-10 2027-02-28 ClinicalTrials.gov
NCT03659669 A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chr… — Chronic Lymphocytic Leukemia (CLL) Suspended 2019-02-10 2027-02-28 ClinicalTrials.gov
NCT03659669 A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chr… — Chronic Lymphocytic Leukemia (CLL) Suspended 2019-02-10 2027-02-28 ClinicalTrials.gov
NCT03659669 A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chr… — Chronic Lymphocytic Leukemia (CLL) Suspended 2019-02-10 2027-02-28 ClinicalTrials.gov
NCT03646604 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitin… Phase1 Atopic Dermatitis Completed 2019-01-31 2024-08-29 ClinicalTrials.gov
NCT03646604 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitin… Phase1 Atopic Dermatitis Completed 2019-01-31 2024-08-29 ClinicalTrials.gov
NCT03646604 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitin… Phase1 Atopic Dermatitis Completed 2019-01-31 2024-08-29 ClinicalTrials.gov
NCT03646604 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitin… Phase1 Atopic Dermatitis Completed 2019-01-31 2024-08-29 ClinicalTrials.gov
NCT03725202 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants Wit… Phase3 Giant Cell Arteritis (GCA) Completed 2019-01-24 2025-03-11 ClinicalTrials.gov
NCT03725202 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants Wit… Phase3 Giant Cell Arteritis (GCA) Completed 2019-01-24 2025-03-11 ClinicalTrials.gov
NCT03725202 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants Wit… Phase3 Giant Cell Arteritis (GCA) Completed 2019-01-24 2025-03-11 ClinicalTrials.gov
NCT03725202 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants Wit… Phase3 Giant Cell Arteritis (GCA) Completed 2019-01-24 2025-03-11 ClinicalTrials.gov
NCT03712449 A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and… Phase4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality Completed 2019-01-22 2020-07-29 ClinicalTrials.gov
NCT03712449 A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and… Phase4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality Completed 2019-01-22 2020-07-29 ClinicalTrials.gov
NCT03712449 A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and… Phase4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality Completed 2019-01-22 2020-07-29 ClinicalTrials.gov
NCT03712449 A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and… Phase4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality Completed 2019-01-22 2020-07-29 ClinicalTrials.gov
NCT03701919 Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After … Phase4 Bariatric Surgery Completed 2019-01-07 2022-11-11 ClinicalTrials.gov
NCT03701919 Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After … Phase4 Bariatric Surgery Completed 2019-01-07 2022-11-11 ClinicalTrials.gov
NCT03701919 Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After … Phase4 Bariatric Surgery Completed 2019-01-07 2022-11-11 ClinicalTrials.gov
NCT03701919 Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After … Phase4 Bariatric Surgery Completed 2019-01-07 2022-11-11 ClinicalTrials.gov
NCT03706040 A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Sev… Phase2 Dermatitis Completed 2018-12-27 2021-04-26 ClinicalTrials.gov
NCT03706040 A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Sev… Phase2 Dermatitis Completed 2018-12-27 2021-04-26 ClinicalTrials.gov
NCT03706040 A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Sev… Phase2 Dermatitis Completed 2018-12-27 2021-04-26 ClinicalTrials.gov
NCT03706040 A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Sev… Phase2 Dermatitis Completed 2018-12-27 2021-04-26 ClinicalTrials.gov
NCT03804268 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participa… Phase3 Presbyopia Completed 2018-12-21 2019-10-31 ClinicalTrials.gov
NCT03804268 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participa… Phase3 Presbyopia Completed 2018-12-21 2019-10-31 ClinicalTrials.gov
NCT03804268 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participa… Phase3 Presbyopia Completed 2018-12-21 2019-10-31 ClinicalTrials.gov
NCT03804268 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participa… Phase3 Presbyopia Completed 2018-12-21 2019-10-31 ClinicalTrials.gov
NCT03786380 Diabetic Gastroparesis Study 05 Phase3 Gastroparesis Terminated 2018-12-20 2020-10-05 ClinicalTrials.gov
NCT03786380 Diabetic Gastroparesis Study 05 Phase3 Gastroparesis Terminated 2018-12-20 2020-10-05 ClinicalTrials.gov
NCT03786380 Diabetic Gastroparesis Study 05 Phase3 Gastroparesis Terminated 2018-12-20 2020-10-05 ClinicalTrials.gov
NCT03786380 Diabetic Gastroparesis Study 05 Phase3 Gastroparesis Terminated 2018-12-20 2020-10-05 ClinicalTrials.gov
NCT03796728 A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for L… Phase4 Lip Augmentation Completed 2018-12-19 2020-06-09 ClinicalTrials.gov
NCT03796728 A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for L… Phase4 Lip Augmentation Completed 2018-12-19 2020-06-09 ClinicalTrials.gov
NCT03796728 A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for L… Phase4 Lip Augmentation Completed 2018-12-19 2020-06-09 ClinicalTrials.gov
NCT03796728 A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for L… Phase4 Lip Augmentation Completed 2018-12-19 2020-06-09 ClinicalTrials.gov
NCT03777059 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of M… Phase3 Episodic Migraine Completed 2018-12-14 2020-06-19 ClinicalTrials.gov
NCT03777059 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of M… Phase3 Episodic Migraine Completed 2018-12-14 2020-06-19 ClinicalTrials.gov
NCT03777059 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of M… Phase3 Episodic Migraine Completed 2018-12-14 2020-06-19 ClinicalTrials.gov
NCT03777059 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of M… Phase3 Episodic Migraine Completed 2018-12-14 2020-06-19 ClinicalTrials.gov
NCT03737851 A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard … Phase2 Multiple Sclerosis (MS) Completed 2018-12-11 2021-09-09 ClinicalTrials.gov
NCT03737851 A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard … Phase2 Multiple Sclerosis (MS) Completed 2018-12-11 2021-09-09 ClinicalTrials.gov
NCT03737851 A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard … Phase2 Multiple Sclerosis (MS) Completed 2018-12-11 2021-09-09 ClinicalTrials.gov
NCT03737851 A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard … Phase2 Multiple Sclerosis (MS) Completed 2018-12-11 2021-09-09 ClinicalTrials.gov
NCT03767400 Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluati… — Skin Care Completed 2018-12-07 2019-07-30 ClinicalTrials.gov
NCT03767400 Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluati… — Skin Care Completed 2018-12-07 2019-07-30 ClinicalTrials.gov
NCT03767400 Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluati… — Skin Care Completed 2018-12-07 2019-07-30 ClinicalTrials.gov
NCT03767400 Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluati… — Skin Care Completed 2018-12-07 2019-07-30 ClinicalTrials.gov
NCT03653026 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants Wi… Phase3 Ulcerative Colitis (UC) Completed 2018-12-06 2021-01-14 ClinicalTrials.gov
NCT03653026 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants Wi… Phase3 Ulcerative Colitis (UC) Completed 2018-12-06 2021-01-14 ClinicalTrials.gov
NCT03653026 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants Wi… Phase3 Ulcerative Colitis (UC) Completed 2018-12-06 2021-01-14 ClinicalTrials.gov
NCT03653026 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants Wi… Phase3 Ulcerative Colitis (UC) Completed 2018-12-06 2021-01-14 ClinicalTrials.gov
NCT03756883 Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salme… Phase3 Asthma Completed 2018-12-03 2019-11-10 ClinicalTrials.gov
NCT03756883 Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salme… Phase3 Asthma Completed 2018-12-03 2019-11-10 ClinicalTrials.gov
NCT03756883 Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salme… Phase3 Asthma Completed 2018-12-03 2019-11-10 ClinicalTrials.gov
NCT03756883 Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salme… Phase3 Asthma Completed 2018-12-03 2019-11-10 ClinicalTrials.gov
NCT03719885 TrueTear in Sjogren's Disease Patients Na Dry Eye Syndromes Completed 2018-12-01 2019-12-31 ClinicalTrials.gov
NCT03719885 TrueTear in Sjogren's Disease Patients Na Dry Eye Syndromes Completed 2018-12-01 2019-12-31 ClinicalTrials.gov
NCT03719885 TrueTear in Sjogren's Disease Patients Na Dry Eye Syndromes Completed 2018-12-01 2019-12-31 ClinicalTrials.gov
NCT03719885 TrueTear in Sjogren's Disease Patients Na Dry Eye Syndromes Completed 2018-12-01 2019-12-31 ClinicalTrials.gov
NCT03573024 Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Le… Phase2 Acute Myeloid Leukemia Completed 2018-11-28 2026-02-19 ClinicalTrials.gov
NCT03573024 Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Le… Phase2 Acute Myeloid Leukemia Completed 2018-11-28 2026-02-19 ClinicalTrials.gov
NCT03573024 Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Le… Phase2 Acute Myeloid Leukemia Completed 2018-11-28 2026-02-19 ClinicalTrials.gov
NCT03573024 Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Le… Phase2 Acute Myeloid Leukemia Completed 2018-11-28 2026-02-19 ClinicalTrials.gov
NCT03832179 Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema … Phase4 Diabetic Macular Edema Completed 2018-11-15 2024-03-30 ClinicalTrials.gov
NCT03832179 Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema … Phase4 Diabetic Macular Edema Completed 2018-11-15 2024-03-30 ClinicalTrials.gov
NCT03832179 Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema … Phase4 Diabetic Macular Edema Completed 2018-11-15 2024-03-30 ClinicalTrials.gov
NCT03832179 Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema … Phase4 Diabetic Macular Edema Completed 2018-11-15 2024-03-30 ClinicalTrials.gov
NCT03712137 Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for … Phase3 Jawline Definition Completed 2018-11-12 2021-01-26 ClinicalTrials.gov
NCT03712137 Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for … Phase3 Jawline Definition Completed 2018-11-12 2021-01-26 ClinicalTrials.gov
NCT03712137 Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for … Phase3 Jawline Definition Completed 2018-11-12 2021-01-26 ClinicalTrials.gov
NCT03712137 Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for … Phase3 Jawline Definition Completed 2018-11-12 2021-01-26 ClinicalTrials.gov
NCT03739203 The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerabilit… Phase3 Major Depressive Disorder Completed 2018-11-10 2021-09-06 ClinicalTrials.gov
NCT03739203 The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerabilit… Phase3 Major Depressive Disorder Completed 2018-11-10 2021-09-06 ClinicalTrials.gov
NCT03739203 The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerabilit… Phase3 Major Depressive Disorder Completed 2018-11-10 2021-09-06 ClinicalTrials.gov
NCT03739203 The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerabilit… Phase3 Major Depressive Disorder Completed 2018-11-10 2021-09-06 ClinicalTrials.gov
NCT03738215 Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to … Phase3 Major Depressive Disorder Completed 2018-11-09 2021-09-30 ClinicalTrials.gov
NCT03738215 Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to … Phase3 Major Depressive Disorder Completed 2018-11-09 2021-09-30 ClinicalTrials.gov
NCT03738215 Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to … Phase3 Major Depressive Disorder Completed 2018-11-09 2021-09-30 ClinicalTrials.gov
NCT03738215 Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to … Phase3 Major Depressive Disorder Completed 2018-11-09 2021-09-30 ClinicalTrials.gov
NCT03814733 Assessment of Effect of Rapastinel on Driving Performance Phase1 Driving Performance Completed 2018-11-05 2019-04-03 ClinicalTrials.gov
NCT03814733 Assessment of Effect of Rapastinel on Driving Performance Phase1 Driving Performance Completed 2018-11-05 2019-04-03 ClinicalTrials.gov
NCT03814733 Assessment of Effect of Rapastinel on Driving Performance Phase1 Driving Performance Completed 2018-11-05 2019-04-03 ClinicalTrials.gov
NCT03814733 Assessment of Effect of Rapastinel on Driving Performance Phase1 Driving Performance Completed 2018-11-05 2019-04-03 ClinicalTrials.gov
NCT03799900 Assessment of Abuse Potential of Rapastinel in Humans Phase1 Human Abuse Potential Completed 2018-11-01 2019-03-29 ClinicalTrials.gov
NCT03799900 Assessment of Abuse Potential of Rapastinel in Humans Phase1 Human Abuse Potential Completed 2018-11-01 2019-03-29 ClinicalTrials.gov
NCT03799900 Assessment of Abuse Potential of Rapastinel in Humans Phase1 Human Abuse Potential Completed 2018-11-01 2019-03-29 ClinicalTrials.gov
NCT03799900 Assessment of Abuse Potential of Rapastinel in Humans Phase1 Human Abuse Potential Completed 2018-11-01 2019-03-29 ClinicalTrials.gov
NCT03675776 Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (… Phase3 Depressive Disorder, Major Terminated 2018-10-30 2019-07-11 ClinicalTrials.gov
NCT03675776 Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (… Phase3 Depressive Disorder, Major Terminated 2018-10-30 2019-07-11 ClinicalTrials.gov
NCT03675776 Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (… Phase3 Depressive Disorder, Major Terminated 2018-10-30 2019-07-11 ClinicalTrials.gov
NCT03675776 Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (… Phase3 Depressive Disorder, Major Terminated 2018-10-30 2019-07-11 ClinicalTrials.gov
NCT03661138 A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticos… Phase3 Atopic Dermatitis Completed 2018-10-27 2022-08-19 ClinicalTrials.gov
NCT03661138 A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticos… Phase3 Atopic Dermatitis Completed 2018-10-27 2022-08-19 ClinicalTrials.gov
NCT03661138 A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticos… Phase3 Atopic Dermatitis Completed 2018-10-27 2022-08-19 ClinicalTrials.gov
NCT03661138 A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticos… Phase3 Atopic Dermatitis Completed 2018-10-27 2022-08-19 ClinicalTrials.gov
NCT03695237 A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children Wi… Phase3 Central Precocious Puberty (CPP) Completed 2018-10-24 2023-11-29 ClinicalTrials.gov
NCT03639194 A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Par… Phase1 Small Cell Lung Cancer Completed 2018-10-24 2024-01-25 ClinicalTrials.gov
NCT03695237 A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children Wi… Phase3 Central Precocious Puberty (CPP) Completed 2018-10-24 2023-11-29 ClinicalTrials.gov
NCT03639194 A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Par… Phase1 Small Cell Lung Cancer Completed 2018-10-24 2024-01-25 ClinicalTrials.gov
NCT03639194 A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Par… Phase1 Small Cell Lung Cancer Completed 2018-10-24 2024-01-25 ClinicalTrials.gov
NCT03639194 A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Par… Phase1 Small Cell Lung Cancer Completed 2018-10-24 2024-01-25 ClinicalTrials.gov
NCT03695237 A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children Wi… Phase3 Central Precocious Puberty (CPP) Completed 2018-10-24 2023-11-29 ClinicalTrials.gov
NCT03695237 A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children Wi… Phase3 Central Precocious Puberty (CPP) Completed 2018-10-24 2023-11-29 ClinicalTrials.gov
NCT03539744 A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamet… Phase3 Multiple Myeloma Active_Not_Recruiting 2018-10-22 2027-11-01 ClinicalTrials.gov
NCT03539744 A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamet… Phase3 Multiple Myeloma Active_Not_Recruiting 2018-10-22 2027-11-01 ClinicalTrials.gov
NCT03539744 A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamet… Phase3 Multiple Myeloma Active_Not_Recruiting 2018-10-22 2027-11-01 ClinicalTrials.gov
NCT03539744 A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamet… Phase3 Multiple Myeloma Active_Not_Recruiting 2018-10-22 2027-11-01 ClinicalTrials.gov
NCT03693586 Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients At… — Chronic Hepatitis c Completed 2018-10-19 2022-03-08 ClinicalTrials.gov
NCT03693586 Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients At… — Chronic Hepatitis c Completed 2018-10-19 2022-03-08 ClinicalTrials.gov
NCT03693586 Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients At… — Chronic Hepatitis c Completed 2018-10-19 2022-03-08 ClinicalTrials.gov
NCT03693586 Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients At… — Chronic Hepatitis c Completed 2018-10-19 2022-03-08 ClinicalTrials.gov
NCT03567616 A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Par… Phase2 Multiple Myeloma Terminated 2018-10-18 2020-06-18 ClinicalTrials.gov
NCT03625505 A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteri… Phase1 Acute Myeloid Leukemia (AML) Completed 2018-10-18 2021-08-31 ClinicalTrials.gov
NCT03567616 A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Par… Phase2 Multiple Myeloma Terminated 2018-10-18 2020-06-18 ClinicalTrials.gov
NCT03567616 A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Par… Phase2 Multiple Myeloma Terminated 2018-10-18 2020-06-18 ClinicalTrials.gov
NCT03625505 A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteri… Phase1 Acute Myeloid Leukemia (AML) Completed 2018-10-18 2021-08-31 ClinicalTrials.gov
NCT03625505 A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteri… Phase1 Acute Myeloid Leukemia (AML) Completed 2018-10-18 2021-08-31 ClinicalTrials.gov
NCT03625505 A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteri… Phase1 Acute Myeloid Leukemia (AML) Completed 2018-10-18 2021-08-31 ClinicalTrials.gov
NCT03567616 A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Par… Phase2 Multiple Myeloma Terminated 2018-10-18 2020-06-18 ClinicalTrials.gov
NCT03709758 Venetoclax in Combination With Intensive Induction and Consolidation Chemothera… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2018-10-17 2026-09-01 ClinicalTrials.gov
NCT03709758 Venetoclax in Combination With Intensive Induction and Consolidation Chemothera… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2018-10-17 2026-09-01 ClinicalTrials.gov
NCT03709758 Venetoclax in Combination With Intensive Induction and Consolidation Chemothera… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2018-10-17 2026-09-01 ClinicalTrials.gov
NCT03709758 Venetoclax in Combination With Intensive Induction and Consolidation Chemothera… Phase1 Acute Myeloid Leukemia Active_Not_Recruiting 2018-10-17 2026-09-01 ClinicalTrials.gov
NCT03539536 Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treat… Phase2 Non-small Cell Lung Cancer Active_Not_Recruiting 2018-10-10 2026-08-01 ClinicalTrials.gov
NCT03539536 Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treat… Phase2 Non-small Cell Lung Cancer Active_Not_Recruiting 2018-10-10 2026-08-01 ClinicalTrials.gov
NCT03661697 Combination Versus Laser Treatment Only Na Photoaging Completed 2018-10-10 2019-03-07 ClinicalTrials.gov
NCT03661697 Combination Versus Laser Treatment Only Na Photoaging Completed 2018-10-10 2019-03-07 ClinicalTrials.gov
NCT03661697 Combination Versus Laser Treatment Only Na Photoaging Completed 2018-10-10 2019-03-07 ClinicalTrials.gov
NCT03539536 Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treat… Phase2 Non-small Cell Lung Cancer Active_Not_Recruiting 2018-10-10 2026-08-01 ClinicalTrials.gov
NCT03539536 Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treat… Phase2 Non-small Cell Lung Cancer Active_Not_Recruiting 2018-10-10 2026-08-01 ClinicalTrials.gov
NCT03661697 Combination Versus Laser Treatment Only Na Photoaging Completed 2018-10-10 2019-03-07 ClinicalTrials.gov
NCT03682705 A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combinat… Phase2 Rheumatoid Arthritis (RA) Completed 2018-10-08 2020-03-26 ClinicalTrials.gov
NCT03700320 Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg… Phase3 Episodic Migraine Completed 2018-10-08 2020-05-21 ClinicalTrials.gov
NCT03700320 Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg… Phase3 Episodic Migraine Completed 2018-10-08 2020-05-21 ClinicalTrials.gov
NCT03682705 A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combinat… Phase2 Rheumatoid Arthritis (RA) Completed 2018-10-08 2020-03-26 ClinicalTrials.gov
NCT03700320 Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg… Phase3 Episodic Migraine Completed 2018-10-08 2020-05-21 ClinicalTrials.gov
NCT03682705 A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combinat… Phase2 Rheumatoid Arthritis (RA) Completed 2018-10-08 2020-03-26 ClinicalTrials.gov
NCT03700320 Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg… Phase3 Episodic Migraine Completed 2018-10-08 2020-05-21 ClinicalTrials.gov
NCT03682705 A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combinat… Phase2 Rheumatoid Arthritis (RA) Completed 2018-10-08 2020-03-26 ClinicalTrials.gov
NCT03637517 Malaria: Relative Bioavailability and Food Effect of DSM265 Phase1 Healthy Volunteers Completed 2018-10-03 2018-11-19 ClinicalTrials.gov
NCT03637517 Malaria: Relative Bioavailability and Food Effect of DSM265 Phase1 Healthy Volunteers Completed 2018-10-03 2018-11-19 ClinicalTrials.gov
NCT03637517 Malaria: Relative Bioavailability and Food Effect of DSM265 Phase1 Healthy Volunteers Completed 2018-10-03 2018-11-19 ClinicalTrials.gov
NCT03637517 Malaria: Relative Bioavailability and Food Effect of DSM265 Phase1 Healthy Volunteers Completed 2018-10-03 2018-11-19 ClinicalTrials.gov
NCT03654885 XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study… Phase4 Glaucoma Completed 2018-10-01 2021-05-13 ClinicalTrials.gov
NCT03631368 Treatment of Hypertrophic Scars With Intradermal Botox Phase2 Hypertrophic Scar Unknown 2018-10-01 2019-05-31 ClinicalTrials.gov
NCT03654885 XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study… Phase4 Glaucoma Completed 2018-10-01 2021-05-13 ClinicalTrials.gov
NCT03631368 Treatment of Hypertrophic Scars With Intradermal Botox Phase2 Hypertrophic Scar Unknown 2018-10-01 2019-05-31 ClinicalTrials.gov
NCT03654885 XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study… Phase4 Glaucoma Completed 2018-10-01 2021-05-13 ClinicalTrials.gov
NCT03654885 XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study… Phase4 Glaucoma Completed 2018-10-01 2021-05-13 ClinicalTrials.gov
NCT03631368 Treatment of Hypertrophic Scars With Intradermal Botox Phase2 Hypertrophic Scar Unknown 2018-10-01 2019-05-31 ClinicalTrials.gov
NCT03631368 Treatment of Hypertrophic Scars With Intradermal Botox Phase2 Hypertrophic Scar Unknown 2018-10-01 2019-05-31 ClinicalTrials.gov
NCT02786563 Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adali… — Rheumatoid Arthritis (RA) Withdrawn 2018-09-30 2018-11-21 ClinicalTrials.gov
NCT02786563 Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adali… — Rheumatoid Arthritis (RA) Withdrawn 2018-09-30 2018-11-21 ClinicalTrials.gov
NCT02786563 Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adali… — Rheumatoid Arthritis (RA) Withdrawn 2018-09-30 2018-11-21 ClinicalTrials.gov
NCT02786563 Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adali… — Rheumatoid Arthritis (RA) Withdrawn 2018-09-30 2018-11-21 ClinicalTrials.gov
NCT03740230 An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic… — Hepatitis C Completed 2018-09-26 2023-07-21 ClinicalTrials.gov
NCT03740230 An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic… — Hepatitis C Completed 2018-09-26 2023-07-21 ClinicalTrials.gov
NCT03740230 An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic… — Hepatitis C Completed 2018-09-26 2023-07-21 ClinicalTrials.gov
NCT03740230 An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic… — Hepatitis C Completed 2018-09-26 2023-07-21 ClinicalTrials.gov
NCT03517540 Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN45… Phase2 Non-alcoholic Steatohepatitis (NASH) Completed 2018-09-11 2020-10-15 ClinicalTrials.gov
NCT03517540 Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN45… Phase2 Non-alcoholic Steatohepatitis (NASH) Completed 2018-09-11 2020-10-15 ClinicalTrials.gov
NCT03517540 Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN45… Phase2 Non-alcoholic Steatohepatitis (NASH) Completed 2018-09-11 2020-10-15 ClinicalTrials.gov
NCT03517540 Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN45… Phase2 Non-alcoholic Steatohepatitis (NASH) Completed 2018-09-11 2020-10-15 ClinicalTrials.gov
NCT03543358 A Long-Term Study of Rovalpituzumab Tesirine Phase2 Cancer Completed 2018-09-10 2019-11-26 ClinicalTrials.gov
NCT03543358 A Long-Term Study of Rovalpituzumab Tesirine Phase2 Cancer Completed 2018-09-10 2019-11-26 ClinicalTrials.gov
NCT03543358 A Long-Term Study of Rovalpituzumab Tesirine Phase2 Cancer Completed 2018-09-10 2019-11-26 ClinicalTrials.gov
NCT03543358 A Long-Term Study of Rovalpituzumab Tesirine Phase2 Cancer Completed 2018-09-10 2019-11-26 ClinicalTrials.gov
NCT03567876 Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elde… Phase2 Lymphoma, Mantle-Cell Completed 2018-09-03 2025-10-15 ClinicalTrials.gov
NCT03567876 Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elde… Phase2 Lymphoma, Mantle-Cell Completed 2018-09-03 2025-10-15 ClinicalTrials.gov
NCT03567876 Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elde… Phase2 Lymphoma, Mantle-Cell Completed 2018-09-03 2025-10-15 ClinicalTrials.gov
NCT03567876 Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elde… Phase2 Lymphoma, Mantle-Cell Completed 2018-09-03 2025-10-15 ClinicalTrials.gov
NCT03398135 A Study to Assess the Efficacy and Safety of Risankizumab in Participants With … Phase3 Ulcerative Colitis (UC) Active_Not_Recruiting 2018-08-28 2029-02-01 ClinicalTrials.gov
NCT03398135 A Study to Assess the Efficacy and Safety of Risankizumab in Participants With … Phase3 Ulcerative Colitis (UC) Active_Not_Recruiting 2018-08-28 2029-02-01 ClinicalTrials.gov
NCT03398135 A Study to Assess the Efficacy and Safety of Risankizumab in Participants With … Phase3 Ulcerative Colitis (UC) Active_Not_Recruiting 2018-08-28 2029-02-01 ClinicalTrials.gov
NCT03398135 A Study to Assess the Efficacy and Safety of Risankizumab in Participants With … Phase3 Ulcerative Colitis (UC) Active_Not_Recruiting 2018-08-28 2029-02-01 ClinicalTrials.gov
NCT03485547 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid … Phase1 Blastic Plasmacytoid Dendritic Cell Neoplasm Completed 2018-08-23 2025-04-16 ClinicalTrials.gov
NCT03668600 Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major … Phase3 Depressive Disorder, Major Terminated 2018-08-23 2019-07-03 ClinicalTrials.gov
NCT03668600 Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major … Phase3 Depressive Disorder, Major Terminated 2018-08-23 2019-07-03 ClinicalTrials.gov
NCT03485547 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid … Phase1 Blastic Plasmacytoid Dendritic Cell Neoplasm Completed 2018-08-23 2025-04-16 ClinicalTrials.gov
NCT03485547 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid … Phase1 Blastic Plasmacytoid Dendritic Cell Neoplasm Completed 2018-08-23 2025-04-16 ClinicalTrials.gov
NCT03668600 Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major … Phase3 Depressive Disorder, Major Terminated 2018-08-23 2019-07-03 ClinicalTrials.gov
NCT03485547 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid … Phase1 Blastic Plasmacytoid Dendritic Cell Neoplasm Completed 2018-08-23 2025-04-16 ClinicalTrials.gov
NCT03668600 Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major … Phase3 Depressive Disorder, Major Terminated 2018-08-23 2019-07-03 ClinicalTrials.gov
NCT03637348 Effect of TrueTear Corneal Surface Imaging Na Cataract Completed 2018-08-13 2019-07-08 ClinicalTrials.gov
NCT03569293 Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Se… Phase3 Atopic Dermatitis Completed 2018-08-13 2025-10-10 ClinicalTrials.gov
NCT03569293 Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Se… Phase3 Atopic Dermatitis Completed 2018-08-13 2025-10-10 ClinicalTrials.gov
NCT03637348 Effect of TrueTear Corneal Surface Imaging Na Cataract Completed 2018-08-13 2019-07-08 ClinicalTrials.gov
NCT03637348 Effect of TrueTear Corneal Surface Imaging Na Cataract Completed 2018-08-13 2019-07-08 ClinicalTrials.gov
NCT03569293 Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Se… Phase3 Atopic Dermatitis Completed 2018-08-13 2025-10-10 ClinicalTrials.gov
NCT03569293 Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Se… Phase3 Atopic Dermatitis Completed 2018-08-13 2025-10-10 ClinicalTrials.gov
NCT03637348 Effect of TrueTear Corneal Surface Imaging Na Cataract Completed 2018-08-13 2019-07-08 ClinicalTrials.gov
NCT03406156 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Ex… Phase3 Chronic Lymphocytic Leukemia (CLL) Completed 2018-08-10 2023-07-12 ClinicalTrials.gov
NCT03406156 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Ex… Phase3 Chronic Lymphocytic Leukemia (CLL) Completed 2018-08-10 2023-07-12 ClinicalTrials.gov
NCT03406156 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Ex… Phase3 Chronic Lymphocytic Leukemia (CLL) Completed 2018-08-10 2023-07-12 ClinicalTrials.gov
NCT03406156 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Ex… Phase3 Chronic Lymphocytic Leukemia (CLL) Completed 2018-08-10 2023-07-12 ClinicalTrials.gov
NCT03568318 A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in… Phase3 Atopic Dermatitis Active_Not_Recruiting 2018-08-09 2030-10-23 ClinicalTrials.gov
NCT03568318 A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in… Phase3 Atopic Dermatitis Active_Not_Recruiting 2018-08-09 2030-10-23 ClinicalTrials.gov
NCT03568318 A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in… Phase3 Atopic Dermatitis Active_Not_Recruiting 2018-08-09 2030-10-23 ClinicalTrials.gov
NCT03568318 A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in… Phase3 Atopic Dermatitis Active_Not_Recruiting 2018-08-09 2030-10-23 ClinicalTrials.gov
NCT03594721 Clinical Trial Evaluation of a Test Serum Post HEV (High Energy Visible) Light … Na Blue Light Damage Completed 2018-08-06 2018-08-30 ClinicalTrials.gov
NCT03594721 Clinical Trial Evaluation of a Test Serum Post HEV (High Energy Visible) Light … Na Blue Light Damage Completed 2018-08-06 2018-08-30 ClinicalTrials.gov
NCT03594721 Clinical Trial Evaluation of a Test Serum Post HEV (High Energy Visible) Light … Na Blue Light Damage Completed 2018-08-06 2018-08-30 ClinicalTrials.gov
NCT03594721 Clinical Trial Evaluation of a Test Serum Post HEV (High Energy Visible) Light … Na Blue Light Damage Completed 2018-08-06 2018-08-30 ClinicalTrials.gov
NCT03614156 Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With M… Phase3 Depressive Disorder, Major Terminated 2018-08-02 2019-07-11 ClinicalTrials.gov
NCT03614156 Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With M… Phase3 Depressive Disorder, Major Terminated 2018-08-02 2019-07-11 ClinicalTrials.gov
NCT03614156 Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With M… Phase3 Depressive Disorder, Major Terminated 2018-08-02 2019-07-11 ClinicalTrials.gov
NCT03614156 Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With M… Phase3 Depressive Disorder, Major Terminated 2018-08-02 2019-07-11 ClinicalTrials.gov
NCT03584958 Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries — Glaucoma Unknown 2018-08-01 2023-06-30 ClinicalTrials.gov
NCT03584958 Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries — Glaucoma Unknown 2018-08-01 2023-06-30 ClinicalTrials.gov
NCT03584958 Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries — Glaucoma Unknown 2018-08-01 2023-06-30 ClinicalTrials.gov
NCT03584958 Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries — Glaucoma Unknown 2018-08-01 2023-06-30 ClinicalTrials.gov
NCT03593213 Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine… Phase3 Schizophrenia Terminated 2018-07-30 2021-02-11 ClinicalTrials.gov
NCT03419403 UNITE Study: Understanding New Interventions With GBM ThErapy Phase3 Glioblastoma Multiforme Terminated 2018-07-30 2020-03-03 ClinicalTrials.gov
NCT03219437 A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Su… Phase3 Psoriasis Completed 2018-07-30 2021-11-26 ClinicalTrials.gov
NCT03419403 UNITE Study: Understanding New Interventions With GBM ThErapy Phase3 Glioblastoma Multiforme Terminated 2018-07-30 2020-03-03 ClinicalTrials.gov
NCT03593213 Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine… Phase3 Schizophrenia Terminated 2018-07-30 2021-02-11 ClinicalTrials.gov
NCT03219437 A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Su… Phase3 Psoriasis Completed 2018-07-30 2021-11-26 ClinicalTrials.gov
NCT03593213 Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine… Phase3 Schizophrenia Terminated 2018-07-30 2021-02-11 ClinicalTrials.gov
NCT03593213 Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine… Phase3 Schizophrenia Terminated 2018-07-30 2021-02-11 ClinicalTrials.gov
NCT03419403 UNITE Study: Understanding New Interventions With GBM ThErapy Phase3 Glioblastoma Multiforme Terminated 2018-07-30 2020-03-03 ClinicalTrials.gov
NCT03219437 A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Su… Phase3 Psoriasis Completed 2018-07-30 2021-11-26 ClinicalTrials.gov
NCT03219437 A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Su… Phase3 Psoriasis Completed 2018-07-30 2021-11-26 ClinicalTrials.gov
NCT03419403 UNITE Study: Understanding New Interventions With GBM ThErapy Phase3 Glioblastoma Multiforme Terminated 2018-07-30 2020-03-03 ClinicalTrials.gov
NCT03607422 A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Sev… Phase3 Atopic Dermatitis Completed 2018-07-27 2025-11-11 ClinicalTrials.gov
NCT03607422 A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Sev… Phase3 Atopic Dermatitis Completed 2018-07-27 2025-11-11 ClinicalTrials.gov
NCT03607422 A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Sev… Phase3 Atopic Dermatitis Completed 2018-07-27 2025-11-11 ClinicalTrials.gov
NCT03607422 A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Sev… Phase3 Atopic Dermatitis Completed 2018-07-27 2025-11-11 ClinicalTrials.gov
NCT03484520 A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refract… Phase1 Cancer - Acute Myeloid Leukemia Terminated 2018-07-23 2022-12-01 ClinicalTrials.gov
NCT03484520 A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refract… Phase1 Cancer - Acute Myeloid Leukemia Terminated 2018-07-23 2022-12-01 ClinicalTrials.gov
NCT03484520 A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refract… Phase1 Cancer - Acute Myeloid Leukemia Terminated 2018-07-23 2022-12-01 ClinicalTrials.gov
NCT03484520 A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refract… Phase1 Cancer - Acute Myeloid Leukemia Terminated 2018-07-23 2022-12-01 ClinicalTrials.gov
NCT03518047 Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian … Phase3 Psoriasis Completed 2018-07-19 2020-02-11 ClinicalTrials.gov
NCT03362931 Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients Wit… Phase3 Glaucoma Completed 2018-07-19 2022-03-18 ClinicalTrials.gov
NCT03362931 Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients Wit… Phase3 Glaucoma Completed 2018-07-19 2022-03-18 ClinicalTrials.gov
NCT03518047 Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian … Phase3 Psoriasis Completed 2018-07-19 2020-02-11 ClinicalTrials.gov
NCT03362931 Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients Wit… Phase3 Glaucoma Completed 2018-07-19 2022-03-18 ClinicalTrials.gov
NCT03518047 Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian … Phase3 Psoriasis Completed 2018-07-19 2020-02-11 ClinicalTrials.gov
NCT03518047 Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian … Phase3 Psoriasis Completed 2018-07-19 2020-02-11 ClinicalTrials.gov
NCT03362931 Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients Wit… Phase3 Glaucoma Completed 2018-07-19 2022-03-18 ClinicalTrials.gov
NCT03595059 A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults Wi… Phase1 Advanced Solid Tumors Completed 2018-07-13 2025-09-12 ClinicalTrials.gov
NCT03595059 A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults Wi… Phase1 Advanced Solid Tumors Completed 2018-07-13 2025-09-12 ClinicalTrials.gov
NCT03595059 A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults Wi… Phase1 Advanced Solid Tumors Completed 2018-07-13 2025-09-12 ClinicalTrials.gov
NCT03595059 A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults Wi… Phase1 Advanced Solid Tumors Completed 2018-07-13 2025-09-12 ClinicalTrials.gov
NCT03367429 The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Hum… Phase4 Stroke Terminated 2018-06-15 2019-09-18 ClinicalTrials.gov
NCT03573297 A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients… Phase3 Bipolar I Disorder Completed 2018-06-15 2022-09-05 ClinicalTrials.gov
NCT03367429 The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Hum… Phase4 Stroke Terminated 2018-06-15 2019-09-18 ClinicalTrials.gov
NCT03560518 Study of Rapastinel as Monotherapy in Patients With MDD Phase3 Depressive Disorder, Major Terminated 2018-06-15 2019-07-08 ClinicalTrials.gov
NCT03560518 Study of Rapastinel as Monotherapy in Patients With MDD Phase3 Depressive Disorder, Major Terminated 2018-06-15 2019-07-08 ClinicalTrials.gov
NCT03560518 Study of Rapastinel as Monotherapy in Patients With MDD Phase3 Depressive Disorder, Major Terminated 2018-06-15 2019-07-08 ClinicalTrials.gov
NCT03573297 A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients… Phase3 Bipolar I Disorder Completed 2018-06-15 2022-09-05 ClinicalTrials.gov
NCT03573297 A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients… Phase3 Bipolar I Disorder Completed 2018-06-15 2022-09-05 ClinicalTrials.gov
NCT03367429 The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Hum… Phase4 Stroke Terminated 2018-06-15 2019-09-18 ClinicalTrials.gov
NCT03367429 The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Hum… Phase4 Stroke Terminated 2018-06-15 2019-09-18 ClinicalTrials.gov
NCT03573297 A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients… Phase3 Bipolar I Disorder Completed 2018-06-15 2022-09-05 ClinicalTrials.gov
NCT03560518 Study of Rapastinel as Monotherapy in Patients With MDD Phase3 Depressive Disorder, Major Terminated 2018-06-15 2019-07-08 ClinicalTrials.gov
NCT03219216 A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (… Phase3 Hepatitis C Virus (HCV) Completed 2018-06-06 2019-03-11 ClinicalTrials.gov
NCT03219216 A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (… Phase3 Hepatitis C Virus (HCV) Completed 2018-06-06 2019-03-11 ClinicalTrials.gov
NCT03219216 A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (… Phase3 Hepatitis C Virus (HCV) Completed 2018-06-06 2019-03-11 ClinicalTrials.gov
NCT03219216 A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (… Phase3 Hepatitis C Virus (HCV) Completed 2018-06-06 2019-03-11 ClinicalTrials.gov
NCT03505892 A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patient… — Ankylosing Spondylitis (AS) Completed 2018-06-05 2021-10-25 ClinicalTrials.gov
NCT03505892 A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patient… — Ankylosing Spondylitis (AS) Completed 2018-06-05 2021-10-25 ClinicalTrials.gov
NCT03505892 A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patient… — Ankylosing Spondylitis (AS) Completed 2018-06-05 2021-10-25 ClinicalTrials.gov
NCT03505892 A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patient… — Ankylosing Spondylitis (AS) Completed 2018-06-05 2021-10-25 ClinicalTrials.gov
NCT03559972 Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects… Na Facial Photodamage Completed 2018-06-04 2018-12-03 ClinicalTrials.gov
NCT03559972 Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects… Na Facial Photodamage Completed 2018-06-04 2018-12-03 ClinicalTrials.gov
NCT03559972 Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects… Na Facial Photodamage Completed 2018-06-04 2018-12-03 ClinicalTrials.gov
NCT03559972 Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects… Na Facial Photodamage Completed 2018-06-04 2018-12-03 ClinicalTrials.gov
NCT03441555 A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute … Phase1 Acute Myeloid Leukemia (AML) Completed 2018-05-30 2021-01-25 ClinicalTrials.gov
NCT03441555 A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute … Phase1 Acute Myeloid Leukemia (AML) Completed 2018-05-30 2021-01-25 ClinicalTrials.gov
NCT03441555 A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute … Phase1 Acute Myeloid Leukemia (AML) Completed 2018-05-30 2021-01-25 ClinicalTrials.gov
NCT03441555 A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute … Phase1 Acute Myeloid Leukemia (AML) Completed 2018-05-30 2021-01-25 ClinicalTrials.gov
NCT03539549 A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participa… Phase2 Macular Degeneration Completed 2018-05-25 2019-02-27 ClinicalTrials.gov
NCT03539549 A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participa… Phase2 Macular Degeneration Completed 2018-05-25 2019-02-27 ClinicalTrials.gov
NCT03539549 A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participa… Phase2 Macular Degeneration Completed 2018-05-25 2019-02-27 ClinicalTrials.gov
NCT03539549 A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participa… Phase2 Macular Degeneration Completed 2018-05-25 2019-02-27 ClinicalTrials.gov
NCT03543566 Bladder Antimuscarinic Medication and Accidental Bowel Leakage — Urinary Incontinence, Urge Completed 2018-05-21 2019-01-18 ClinicalTrials.gov
NCT03543566 Bladder Antimuscarinic Medication and Accidental Bowel Leakage — Urinary Incontinence, Urge Completed 2018-05-21 2019-01-18 ClinicalTrials.gov
NCT03543566 Bladder Antimuscarinic Medication and Accidental Bowel Leakage — Urinary Incontinence, Urge Completed 2018-05-21 2019-01-18 ClinicalTrials.gov
NCT03543566 Bladder Antimuscarinic Medication and Accidental Bowel Leakage — Urinary Incontinence, Urge Completed 2018-05-21 2019-01-18 ClinicalTrials.gov
NCT03339089 Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients W… — Ankylosing Spondylitis (AS) Completed 2018-05-18 2021-07-08 ClinicalTrials.gov
NCT03339089 Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients W… — Ankylosing Spondylitis (AS) Completed 2018-05-18 2021-07-08 ClinicalTrials.gov
NCT03339089 Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients W… — Ankylosing Spondylitis (AS) Completed 2018-05-18 2021-07-08 ClinicalTrials.gov
NCT03339089 Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients W… — Ankylosing Spondylitis (AS) Completed 2018-05-18 2021-07-08 ClinicalTrials.gov
NCT03478787 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque… Phase3 Psoriasis Completed 2018-05-08 2020-07-08 ClinicalTrials.gov
NCT03478787 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque… Phase3 Psoriasis Completed 2018-05-08 2020-07-08 ClinicalTrials.gov
NCT03478787 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque… Phase3 Psoriasis Completed 2018-05-08 2020-07-08 ClinicalTrials.gov
NCT03478787 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque… Phase3 Psoriasis Completed 2018-05-08 2020-07-08 ClinicalTrials.gov
NCT03383263 A Study to Assess Persistence, Adherence and Changes in Disease Activity in the… — Polyarticular Juvenile Arthritis Completed 2018-05-04 2020-09-14 ClinicalTrials.gov
NCT03383263 A Study to Assess Persistence, Adherence and Changes in Disease Activity in the… — Polyarticular Juvenile Arthritis Completed 2018-05-04 2020-09-14 ClinicalTrials.gov
NCT03383263 A Study to Assess Persistence, Adherence and Changes in Disease Activity in the… — Polyarticular Juvenile Arthritis Completed 2018-05-04 2020-09-14 ClinicalTrials.gov
NCT03383263 A Study to Assess Persistence, Adherence and Changes in Disease Activity in the… — Polyarticular Juvenile Arthritis Completed 2018-05-04 2020-09-14 ClinicalTrials.gov
NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the… Phase4 Hypogonadism Completed 2018-05-03 2023-01-19 ClinicalTrials.gov
NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the… Phase4 Hypogonadism Completed 2018-05-03 2023-01-19 ClinicalTrials.gov
NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the… Phase4 Hypogonadism Completed 2018-05-03 2023-01-19 ClinicalTrials.gov
NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the… Phase4 Hypogonadism Completed 2018-05-03 2023-01-19 ClinicalTrials.gov
NCT03374917 A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerab… Phase1 Parkinson's Disease (PD) Completed 2018-04-18 2019-03-04 ClinicalTrials.gov
NCT03374917 A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerab… Phase1 Parkinson's Disease (PD) Completed 2018-04-18 2019-03-04 ClinicalTrials.gov
NCT03374917 A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerab… Phase1 Parkinson's Disease (PD) Completed 2018-04-18 2019-03-04 ClinicalTrials.gov
NCT03374917 A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerab… Phase1 Parkinson's Disease (PD) Completed 2018-04-18 2019-03-04 ClinicalTrials.gov
NCT03413319 Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (P… Phase1 Progressive Supranuclear Palsy (PSP) Completed 2018-04-17 2019-11-20 ClinicalTrials.gov
NCT03413319 Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (P… Phase1 Progressive Supranuclear Palsy (PSP) Completed 2018-04-17 2019-11-20 ClinicalTrials.gov
NCT03413319 Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (P… Phase1 Progressive Supranuclear Palsy (PSP) Completed 2018-04-17 2019-11-20 ClinicalTrials.gov
NCT03413319 Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (P… Phase1 Progressive Supranuclear Palsy (PSP) Completed 2018-04-17 2019-11-20 ClinicalTrials.gov
NCT03469258 Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy f… Phase2 Pancreatic Cancer Terminated 2018-04-13 2019-10-01 ClinicalTrials.gov
NCT03469258 Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy f… Phase2 Pancreatic Cancer Terminated 2018-04-13 2019-10-01 ClinicalTrials.gov
NCT03469258 Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy f… Phase2 Pancreatic Cancer Terminated 2018-04-13 2019-10-01 ClinicalTrials.gov
NCT03469258 Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy f… Phase2 Pancreatic Cancer Terminated 2018-04-13 2019-10-01 ClinicalTrials.gov
NCT03105102 A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's… Phase3 Crohn's Disease Active_Not_Recruiting 2018-04-09 2026-05-01 ClinicalTrials.gov
NCT03105102 A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's… Phase3 Crohn's Disease Active_Not_Recruiting 2018-04-09 2026-05-01 ClinicalTrials.gov
NCT03105102 A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's… Phase3 Crohn's Disease Active_Not_Recruiting 2018-04-09 2026-05-01 ClinicalTrials.gov
NCT03105102 A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's… Phase3 Crohn's Disease Active_Not_Recruiting 2018-04-09 2026-05-01 ClinicalTrials.gov
NCT03314181 A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (… Phase2 Multiple Myeloma Active_Not_Recruiting 2018-04-02 2031-05-01 ClinicalTrials.gov
NCT03314181 A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (… Phase2 Multiple Myeloma Active_Not_Recruiting 2018-04-02 2031-05-01 ClinicalTrials.gov
NCT03314181 A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (… Phase2 Multiple Myeloma Active_Not_Recruiting 2018-04-02 2031-05-01 ClinicalTrials.gov
NCT03314181 A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (… Phase2 Multiple Myeloma Active_Not_Recruiting 2018-04-02 2031-05-01 ClinicalTrials.gov
NCT03361176 Kybella With Triamcinolone Phase4 Adiposity Completed 2018-03-26 2018-12-18 ClinicalTrials.gov
NCT03361176 Kybella With Triamcinolone Phase4 Adiposity Completed 2018-03-26 2018-12-18 ClinicalTrials.gov
NCT03361176 Kybella With Triamcinolone Phase4 Adiposity Completed 2018-03-26 2018-12-18 ClinicalTrials.gov
NCT03361176 Kybella With Triamcinolone Phase4 Adiposity Completed 2018-03-26 2018-12-18 ClinicalTrials.gov
NCT03345823 A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upada… Phase3 Crohn's Disease Active_Not_Recruiting 2018-03-21 2027-09-01 ClinicalTrials.gov
NCT03345823 A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upada… Phase3 Crohn's Disease Active_Not_Recruiting 2018-03-21 2027-09-01 ClinicalTrials.gov
NCT03345823 A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upada… Phase3 Crohn's Disease Active_Not_Recruiting 2018-03-21 2027-09-01 ClinicalTrials.gov
NCT03345823 A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upada… Phase3 Crohn's Disease Active_Not_Recruiting 2018-03-21 2027-09-01 ClinicalTrials.gov
NCT03368859 A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Me… Phase2 Cancer Terminated 2018-03-20 2019-12-18 ClinicalTrials.gov
NCT03368859 A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Me… Phase2 Cancer Terminated 2018-03-20 2019-12-18 ClinicalTrials.gov
NCT03368859 A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Me… Phase2 Cancer Terminated 2018-03-20 2019-12-18 ClinicalTrials.gov
NCT03368859 A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Me… Phase2 Cancer Terminated 2018-03-20 2019-12-18 ClinicalTrials.gov
NCT03360006 A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants … Phase1 Acute Myeloid Leukemia (AML) Terminated 2018-03-16 2020-12-19 ClinicalTrials.gov
NCT03360006 A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants … Phase1 Acute Myeloid Leukemia (AML) Terminated 2018-03-16 2020-12-19 ClinicalTrials.gov
NCT03360006 A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants … Phase1 Acute Myeloid Leukemia (AML) Terminated 2018-03-16 2020-12-19 ClinicalTrials.gov
NCT03360006 A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants … Phase1 Acute Myeloid Leukemia (AML) Terminated 2018-03-16 2020-12-19 ClinicalTrials.gov
NCT03334487 Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later… Phase3 Small Cell Lung Cancer Withdrawn 2018-03-15 2018-12-20 ClinicalTrials.gov
NCT03334487 Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later… Phase3 Small Cell Lung Cancer Withdrawn 2018-03-15 2018-12-20 ClinicalTrials.gov
NCT03334487 Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later… Phase3 Small Cell Lung Cancer Withdrawn 2018-03-15 2018-12-20 ClinicalTrials.gov
NCT03334487 Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later… Phase3 Small Cell Lung Cancer Withdrawn 2018-03-15 2018-12-20 ClinicalTrials.gov
NCT03065582 The Effect of Topical Sunscreen Plus Antioxidant Against the Visible Light Biol… Na Pigmentation Completed 2018-03-13 2019-04-22 ClinicalTrials.gov
NCT03487900 Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD P… Na CD Unknown 2018-03-13 2023-12-31 ClinicalTrials.gov
NCT03065582 The Effect of Topical Sunscreen Plus Antioxidant Against the Visible Light Biol… Na Pigmentation Completed 2018-03-13 2019-04-22 ClinicalTrials.gov
NCT03487900 Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD P… Na CD Unknown 2018-03-13 2023-12-31 ClinicalTrials.gov
NCT03065582 The Effect of Topical Sunscreen Plus Antioxidant Against the Visible Light Biol… Na Pigmentation Completed 2018-03-13 2019-04-22 ClinicalTrials.gov
NCT03065582 The Effect of Topical Sunscreen Plus Antioxidant Against the Visible Light Biol… Na Pigmentation Completed 2018-03-13 2019-04-22 ClinicalTrials.gov
NCT03498625 Crohn's Disease Endoscopic REmission Definition in an Objective Way Na CD Completed 2018-03-13 2021-12-31 ClinicalTrials.gov
NCT03487900 Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD P… Na CD Unknown 2018-03-13 2023-12-31 ClinicalTrials.gov
NCT03498625 Crohn's Disease Endoscopic REmission Definition in an Objective Way Na CD Completed 2018-03-13 2021-12-31 ClinicalTrials.gov
NCT03498625 Crohn's Disease Endoscopic REmission Definition in an Objective Way Na CD Completed 2018-03-13 2021-12-31 ClinicalTrials.gov
NCT03487900 Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD P… Na CD Unknown 2018-03-13 2023-12-31 ClinicalTrials.gov
NCT03498625 Crohn's Disease Endoscopic REmission Definition in an Objective Way Na CD Completed 2018-03-13 2021-12-31 ClinicalTrials.gov
NCT03415035 Study Venetoclax Effectiveness and Real-Life Treatment Management in Participan… — Cancer - Chronic Lymphocytic Leukemia Active_Not_Recruiting 2018-03-09 2026-06-01 ClinicalTrials.gov
NCT03415035 Study Venetoclax Effectiveness and Real-Life Treatment Management in Participan… — Cancer - Chronic Lymphocytic Leukemia Active_Not_Recruiting 2018-03-09 2026-06-01 ClinicalTrials.gov
NCT03415035 Study Venetoclax Effectiveness and Real-Life Treatment Management in Participan… — Cancer - Chronic Lymphocytic Leukemia Active_Not_Recruiting 2018-03-09 2026-06-01 ClinicalTrials.gov
NCT03415035 Study Venetoclax Effectiveness and Real-Life Treatment Management in Participan… — Cancer - Chronic Lymphocytic Leukemia Active_Not_Recruiting 2018-03-09 2026-06-01 ClinicalTrials.gov
NCT03398148 A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to … Phase2 Ulcerative Colitis (UC) Completed 2018-03-07 2023-05-11 ClinicalTrials.gov
NCT03398148 A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to … Phase2 Ulcerative Colitis (UC) Completed 2018-03-07 2023-05-11 ClinicalTrials.gov
NCT03398148 A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to … Phase2 Ulcerative Colitis (UC) Completed 2018-03-07 2023-05-11 ClinicalTrials.gov
NCT03398148 A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to … Phase2 Ulcerative Colitis (UC) Completed 2018-03-07 2023-05-11 ClinicalTrials.gov
NCT03249311 Levomilnacipran in Healthy Males Phase4 None (i.e. Healthy Volunteers) Unknown 2018-03-02 2022-05-01 ClinicalTrials.gov
NCT03249311 Levomilnacipran in Healthy Males Phase4 None (i.e. Healthy Volunteers) Unknown 2018-03-02 2022-05-01 ClinicalTrials.gov
NCT03249311 Levomilnacipran in Healthy Males Phase4 None (i.e. Healthy Volunteers) Unknown 2018-03-02 2022-05-01 ClinicalTrials.gov
NCT03249311 Levomilnacipran in Healthy Males Phase4 None (i.e. Healthy Volunteers) Unknown 2018-03-02 2022-05-01 ClinicalTrials.gov
NCT03441581 Eluxadoline Bile Acid Malabsorption (BAM) Study Phase4 Irritable Bowel Syndrome With Diarrhea Completed 2018-02-23 2020-04-28 ClinicalTrials.gov
NCT03441581 Eluxadoline Bile Acid Malabsorption (BAM) Study Phase4 Irritable Bowel Syndrome With Diarrhea Completed 2018-02-23 2020-04-28 ClinicalTrials.gov
NCT03441581 Eluxadoline Bile Acid Malabsorption (BAM) Study Phase4 Irritable Bowel Syndrome With Diarrhea Completed 2018-02-23 2020-04-28 ClinicalTrials.gov
NCT03441581 Eluxadoline Bile Acid Malabsorption (BAM) Study Phase4 Irritable Bowel Syndrome With Diarrhea Completed 2018-02-23 2020-04-28 ClinicalTrials.gov
NCT03426345 Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With D… Phase3 Gastroparesis Terminated 2018-02-16 2020-07-16 ClinicalTrials.gov
NCT03426345 Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With D… Phase3 Gastroparesis Terminated 2018-02-16 2020-07-16 ClinicalTrials.gov
NCT03426345 Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With D… Phase3 Gastroparesis Terminated 2018-02-16 2020-07-16 ClinicalTrials.gov
NCT03426345 Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With D… Phase3 Gastroparesis Terminated 2018-02-16 2020-07-16 ClinicalTrials.gov
NCT03097835 Evaluation of Skin Quality Improvement Phase2 Skin Quality Completed 2018-02-12 2018-07-26 ClinicalTrials.gov
NCT03097835 Evaluation of Skin Quality Improvement Phase2 Skin Quality Completed 2018-02-12 2018-07-26 ClinicalTrials.gov
NCT03097835 Evaluation of Skin Quality Improvement Phase2 Skin Quality Completed 2018-02-12 2018-07-26 ClinicalTrials.gov
NCT03097835 Evaluation of Skin Quality Improvement Phase2 Skin Quality Completed 2018-02-12 2018-07-26 ClinicalTrials.gov
NCT03438266 A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel f… Na Age-related Volume Deficit in the Mid-face Completed 2018-02-05 2018-08-02 ClinicalTrials.gov
NCT03438266 A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel f… Na Age-related Volume Deficit in the Mid-face Completed 2018-02-05 2018-08-02 ClinicalTrials.gov
NCT03438266 A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel f… Na Age-related Volume Deficit in the Mid-face Completed 2018-02-05 2018-08-02 ClinicalTrials.gov
NCT03438266 A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel f… Na Age-related Volume Deficit in the Mid-face Completed 2018-02-05 2018-08-02 ClinicalTrials.gov
NCT03430986 Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Improvement of… Na Nose Enhancement Completed 2018-02-02 2019-12-04 ClinicalTrials.gov
NCT03430986 Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Improvement of… Na Nose Enhancement Completed 2018-02-02 2019-12-04 ClinicalTrials.gov
NCT03425253 Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Ov… Phase4 Contour Completed 2018-02-02 2019-12-05 ClinicalTrials.gov
NCT03425253 Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Ov… Phase4 Contour Completed 2018-02-02 2019-12-05 ClinicalTrials.gov
NCT03425253 Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Ov… Phase4 Contour Completed 2018-02-02 2019-12-05 ClinicalTrials.gov
NCT03425253 Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Ov… Phase4 Contour Completed 2018-02-02 2019-12-05 ClinicalTrials.gov
NCT03430986 Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Improvement of… Na Nose Enhancement Completed 2018-02-02 2019-12-04 ClinicalTrials.gov
NCT03430986 Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Improvement of… Na Nose Enhancement Completed 2018-02-02 2019-12-04 ClinicalTrials.gov
NCT03211390 Using Telemedicine to Improve Spasticity Diagnosis Rates — Spasticity, Muscle Completed 2018-01-30 2018-08-01 ClinicalTrials.gov
NCT03211390 Using Telemedicine to Improve Spasticity Diagnosis Rates — Spasticity, Muscle Completed 2018-01-30 2018-08-01 ClinicalTrials.gov
NCT03211390 Using Telemedicine to Improve Spasticity Diagnosis Rates — Spasticity, Muscle Completed 2018-01-30 2018-08-01 ClinicalTrials.gov
NCT03250988 Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Lo… — Spasticity, Muscle Completed 2018-01-30 2018-08-01 ClinicalTrials.gov
NCT03211390 Using Telemedicine to Improve Spasticity Diagnosis Rates — Spasticity, Muscle Completed 2018-01-30 2018-08-01 ClinicalTrials.gov
NCT03250988 Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Lo… — Spasticity, Muscle Completed 2018-01-30 2018-08-01 ClinicalTrials.gov
NCT03250988 Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Lo… — Spasticity, Muscle Completed 2018-01-30 2018-08-01 ClinicalTrials.gov
NCT03250988 Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Lo… — Spasticity, Muscle Completed 2018-01-30 2018-08-01 ClinicalTrials.gov
NCT03418545 A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel t… Phase3 Infraorbital Hollowing Completed 2018-01-26 2019-08-22 ClinicalTrials.gov
NCT03418545 A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel t… Phase3 Infraorbital Hollowing Completed 2018-01-26 2019-08-22 ClinicalTrials.gov
NCT03418545 A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel t… Phase3 Infraorbital Hollowing Completed 2018-01-26 2019-08-22 ClinicalTrials.gov
NCT03418545 A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel t… Phase3 Infraorbital Hollowing Completed 2018-01-26 2019-08-22 ClinicalTrials.gov
NCT03339102 Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious In… — Non-infectious Intermediate, Posterior and Panuveitis Completed 2018-01-25 2020-07-16 ClinicalTrials.gov
NCT03339102 Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious In… — Non-infectious Intermediate, Posterior and Panuveitis Completed 2018-01-25 2020-07-16 ClinicalTrials.gov
NCT03339102 Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious In… — Non-infectious Intermediate, Posterior and Panuveitis Completed 2018-01-25 2020-07-16 ClinicalTrials.gov
NCT03339102 Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious In… — Non-infectious Intermediate, Posterior and Panuveitis Completed 2018-01-25 2020-07-16 ClinicalTrials.gov
NCT03391765 An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Phase2 Progressive Supranuclear Palsy (PSP) Terminated 2018-01-24 2019-12-13 ClinicalTrials.gov
NCT03391765 An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Phase2 Progressive Supranuclear Palsy (PSP) Terminated 2018-01-24 2019-12-13 ClinicalTrials.gov
NCT03391765 An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Phase2 Progressive Supranuclear Palsy (PSP) Terminated 2018-01-24 2019-12-13 ClinicalTrials.gov
NCT03420781 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 Phase3 Gastroparesis Terminated 2018-01-24 2020-10-30 ClinicalTrials.gov
NCT03420781 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 Phase3 Gastroparesis Terminated 2018-01-24 2020-10-30 ClinicalTrials.gov
NCT03391765 An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Phase2 Progressive Supranuclear Palsy (PSP) Terminated 2018-01-24 2019-12-13 ClinicalTrials.gov
NCT03420781 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 Phase3 Gastroparesis Terminated 2018-01-24 2020-10-30 ClinicalTrials.gov
NCT03420781 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 Phase3 Gastroparesis Terminated 2018-01-24 2020-10-30 ClinicalTrials.gov
NCT03364725 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Phase4 Hepatitis C Unknown 2018-01-15 2019-03-01 ClinicalTrials.gov
NCT03193359 Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in … Phase3 Migraine Disorders Withdrawn 2018-01-15 2021-09-09 ClinicalTrials.gov
NCT03364725 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Phase4 Hepatitis C Unknown 2018-01-15 2019-03-01 ClinicalTrials.gov
NCT03364725 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Phase4 Hepatitis C Unknown 2018-01-15 2019-03-01 ClinicalTrials.gov
NCT03193359 Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in … Phase3 Migraine Disorders Withdrawn 2018-01-15 2021-09-09 ClinicalTrials.gov
NCT03193359 Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in … Phase3 Migraine Disorders Withdrawn 2018-01-15 2021-09-09 ClinicalTrials.gov
NCT03193359 Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in … Phase3 Migraine Disorders Withdrawn 2018-01-15 2021-09-09 ClinicalTrials.gov
NCT03364725 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Phase4 Hepatitis C Unknown 2018-01-15 2019-03-01 ClinicalTrials.gov
NCT03310190 Study to Describe the Management and the Use of Healthcare Resources in Patient… — Chronic Lymphocytic Leukemia Completed 2018-01-10 2022-04-30 ClinicalTrials.gov
NCT03310190 Study to Describe the Management and the Use of Healthcare Resources in Patient… — Chronic Lymphocytic Leukemia Completed 2018-01-10 2022-04-30 ClinicalTrials.gov
NCT03310190 Study to Describe the Management and the Use of Healthcare Resources in Patient… — Chronic Lymphocytic Leukemia Completed 2018-01-10 2022-04-30 ClinicalTrials.gov
NCT03310190 Study to Describe the Management and the Use of Healthcare Resources in Patient… — Chronic Lymphocytic Leukemia Completed 2018-01-10 2022-04-30 ClinicalTrials.gov
NCT03316794 A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) Phase1 Breast Cancer Terminated 2018-01-04 2018-10-05 ClinicalTrials.gov
NCT03544593 The Volumetric Analysis of Fat Grafting Na Autologous Fat Grafting Unknown 2018-01-04 2019-03-01 ClinicalTrials.gov
NCT03544593 The Volumetric Analysis of Fat Grafting Na Autologous Fat Grafting Unknown 2018-01-04 2019-03-01 ClinicalTrials.gov
NCT03316794 A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) Phase1 Breast Cancer Terminated 2018-01-04 2018-10-05 ClinicalTrials.gov
NCT03316794 A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) Phase1 Breast Cancer Terminated 2018-01-04 2018-10-05 ClinicalTrials.gov
NCT03544593 The Volumetric Analysis of Fat Grafting Na Autologous Fat Grafting Unknown 2018-01-04 2019-03-01 ClinicalTrials.gov
NCT03544593 The Volumetric Analysis of Fat Grafting Na Autologous Fat Grafting Unknown 2018-01-04 2019-03-01 ClinicalTrials.gov
NCT03316794 A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) Phase1 Breast Cancer Terminated 2018-01-04 2018-10-05 ClinicalTrials.gov
NCT02955212 A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countri… Phase3 Rheumatoid Arthritis (RA) Completed 2018-01-03 2020-09-03 ClinicalTrials.gov
NCT02955212 A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countri… Phase3 Rheumatoid Arthritis (RA) Completed 2018-01-03 2020-09-03 ClinicalTrials.gov
NCT02955212 A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countri… Phase3 Rheumatoid Arthritis (RA) Completed 2018-01-03 2020-09-03 ClinicalTrials.gov
NCT02955212 A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countri… Phase3 Rheumatoid Arthritis (RA) Completed 2018-01-03 2020-09-03 ClinicalTrials.gov
NCT03386513 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Phase1 Blastic Plasmacytoid Dendritic Cell Neoplasm Active_Not_Recruiting 2018-01-02 2026-12-30 ClinicalTrials.gov
NCT03386513 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Phase1 Blastic Plasmacytoid Dendritic Cell Neoplasm Active_Not_Recruiting 2018-01-02 2026-12-30 ClinicalTrials.gov
NCT03386513 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Phase1 Blastic Plasmacytoid Dendritic Cell Neoplasm Active_Not_Recruiting 2018-01-02 2026-12-30 ClinicalTrials.gov
NCT03386513 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Phase1 Blastic Plasmacytoid Dendritic Cell Neoplasm Active_Not_Recruiting 2018-01-02 2026-12-30 ClinicalTrials.gov
NCT03549416 BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Op… — Atopic Dermatitis Recruiting 2018-01-01 2028-12-31 ClinicalTrials.gov
NCT03549416 BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Op… — Atopic Dermatitis Recruiting 2018-01-01 2028-12-31 ClinicalTrials.gov
NCT03549416 BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Op… — Atopic Dermatitis Recruiting 2018-01-01 2028-12-31 ClinicalTrials.gov
NCT03549416 BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Op… — Atopic Dermatitis Recruiting 2018-01-01 2028-12-31 ClinicalTrials.gov
NCT03343067 A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endome… Phase3 Endometriosis Terminated 2017-12-27 2018-10-23 ClinicalTrials.gov
NCT03341871 Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepa… — Hepatitis C Virus (HCV) Completed 2017-12-27 2020-09-15 ClinicalTrials.gov
NCT03343067 A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endome… Phase3 Endometriosis Terminated 2017-12-27 2018-10-23 ClinicalTrials.gov
NCT03343067 A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endome… Phase3 Endometriosis Terminated 2017-12-27 2018-10-23 ClinicalTrials.gov
NCT03341871 Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepa… — Hepatitis C Virus (HCV) Completed 2017-12-27 2020-09-15 ClinicalTrials.gov
NCT03343067 A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endome… Phase3 Endometriosis Terminated 2017-12-27 2018-10-23 ClinicalTrials.gov
NCT03341871 Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepa… — Hepatitis C Virus (HCV) Completed 2017-12-27 2020-09-15 ClinicalTrials.gov
NCT03341871 Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepa… — Hepatitis C Virus (HCV) Completed 2017-12-27 2020-09-15 ClinicalTrials.gov
NCT03104413 A Study to Assess the Efficacy and Safety of Risankizumab in Participants With … Phase3 Crohn's Disease Completed 2017-12-18 2021-05-19 ClinicalTrials.gov
NCT03104413 A Study to Assess the Efficacy and Safety of Risankizumab in Participants With … Phase3 Crohn's Disease Completed 2017-12-18 2021-05-19 ClinicalTrials.gov
NCT03104413 A Study to Assess the Efficacy and Safety of Risankizumab in Participants With … Phase3 Crohn's Disease Completed 2017-12-18 2021-05-19 ClinicalTrials.gov
NCT03104413 A Study to Assess the Efficacy and Safety of Risankizumab in Participants With … Phase3 Crohn's Disease Completed 2017-12-18 2021-05-19 ClinicalTrials.gov
NCT03352453 A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Majo… Phase2 Depressive Disorder, Major Terminated 2017-12-15 2019-06-21 ClinicalTrials.gov
NCT03352453 A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Majo… Phase2 Depressive Disorder, Major Terminated 2017-12-15 2019-06-21 ClinicalTrials.gov
NCT03352453 A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Majo… Phase2 Depressive Disorder, Major Terminated 2017-12-15 2019-06-21 ClinicalTrials.gov
NCT03352453 A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Majo… Phase2 Depressive Disorder, Major Terminated 2017-12-15 2019-06-21 ClinicalTrials.gov
NCT03362879 COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbid… — Parkinson's Disease (PD) Completed 2017-12-14 2018-12-17 ClinicalTrials.gov
NCT03362879 COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbid… — Parkinson's Disease (PD) Completed 2017-12-14 2018-12-17 ClinicalTrials.gov
NCT03362879 COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbid… — Parkinson's Disease (PD) Completed 2017-12-14 2018-12-17 ClinicalTrials.gov
NCT03362879 COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbid… — Parkinson's Disease (PD) Completed 2017-12-14 2018-12-17 ClinicalTrials.gov
NCT03258814 A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of C… — Axial Spondyloarthritis Terminated 2017-12-08 2018-09-14 ClinicalTrials.gov
NCT03258814 A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of C… — Axial Spondyloarthritis Terminated 2017-12-08 2018-09-14 ClinicalTrials.gov
NCT03258814 A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of C… — Axial Spondyloarthritis Terminated 2017-12-08 2018-09-14 ClinicalTrials.gov
NCT03258814 A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of C… — Axial Spondyloarthritis Terminated 2017-12-08 2018-09-14 ClinicalTrials.gov
NCT03345849 A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderat… Phase3 Crohn's Disease Completed 2017-12-07 2022-01-13 ClinicalTrials.gov
NCT03345849 A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderat… Phase3 Crohn's Disease Completed 2017-12-07 2022-01-13 ClinicalTrials.gov
NCT03345849 A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderat… Phase3 Crohn's Disease Completed 2017-12-07 2022-01-13 ClinicalTrials.gov
NCT03345849 A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderat… Phase3 Crohn's Disease Completed 2017-12-07 2022-01-13 ClinicalTrials.gov
NCT03342144 Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemi… — Chronic Lymphocytic Leukemia (CLL) Recruiting 2017-12-04 2030-12-01 ClinicalTrials.gov
NCT03342144 Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemi… — Chronic Lymphocytic Leukemia (CLL) Recruiting 2017-12-04 2030-12-01 ClinicalTrials.gov
NCT03342144 Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemi… — Chronic Lymphocytic Leukemia (CLL) Recruiting 2017-12-04 2030-12-01 ClinicalTrials.gov
NCT03342144 Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemi… — Chronic Lymphocytic Leukemia (CLL) Recruiting 2017-12-04 2030-12-01 ClinicalTrials.gov
NCT03345836 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants Wi… Phase3 Crohn's Disease Completed 2017-11-29 2021-08-11 ClinicalTrials.gov
NCT03379428 Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Phase1 Breast Neoplasms Active_Not_Recruiting 2017-11-29 2025-01-01 ClinicalTrials.gov
NCT03345836 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants Wi… Phase3 Crohn's Disease Completed 2017-11-29 2021-08-11 ClinicalTrials.gov
NCT03345836 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants Wi… Phase3 Crohn's Disease Completed 2017-11-29 2021-08-11 ClinicalTrials.gov
NCT03379428 Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Phase1 Breast Neoplasms Active_Not_Recruiting 2017-11-29 2025-01-01 ClinicalTrials.gov
NCT03345836 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants Wi… Phase3 Crohn's Disease Completed 2017-11-29 2021-08-11 ClinicalTrials.gov
NCT03379428 Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Phase1 Breast Neoplasms Active_Not_Recruiting 2017-11-29 2025-01-01 ClinicalTrials.gov
NCT03379428 Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Phase1 Breast Neoplasms Active_Not_Recruiting 2017-11-29 2025-01-01 ClinicalTrials.gov
NCT03335852 Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japane… Phase1 Macular Degeneration Completed 2017-11-28 2018-10-08 ClinicalTrials.gov
NCT03335852 Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japane… Phase1 Macular Degeneration Completed 2017-11-28 2018-10-08 ClinicalTrials.gov
NCT03335852 Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japane… Phase1 Macular Degeneration Completed 2017-11-28 2018-10-08 ClinicalTrials.gov
NCT03335852 Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japane… Phase1 Macular Degeneration Completed 2017-11-28 2018-10-08 ClinicalTrials.gov
NCT03181126 A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjec… Phase1 Acute Lymphoblastic Leukemia (ALL) Completed 2017-11-27 2020-11-14 ClinicalTrials.gov
NCT03181126 A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjec… Phase1 Acute Lymphoblastic Leukemia (ALL) Completed 2017-11-27 2020-11-14 ClinicalTrials.gov
NCT03181126 A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjec… Phase1 Acute Lymphoblastic Leukemia (ALL) Completed 2017-11-27 2020-11-14 ClinicalTrials.gov
NCT03181126 A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjec… Phase1 Acute Lymphoblastic Leukemia (ALL) Completed 2017-11-27 2020-11-14 ClinicalTrials.gov
NCT03223012 Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and … — Crohn's Disease Completed 2017-11-15 2019-02-28 ClinicalTrials.gov
NCT03223012 Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and … — Crohn's Disease Completed 2017-11-15 2019-02-28 ClinicalTrials.gov
NCT03339128 Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bo… Phase2 Irritable Bowel Syndrome Recruiting 2017-11-15 2026-12-01 ClinicalTrials.gov
NCT03339128 Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bo… Phase2 Irritable Bowel Syndrome Recruiting 2017-11-15 2026-12-01 ClinicalTrials.gov
NCT03223012 Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and … — Crohn's Disease Completed 2017-11-15 2019-02-28 ClinicalTrials.gov
NCT03339128 Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bo… Phase2 Irritable Bowel Syndrome Recruiting 2017-11-15 2026-12-01 ClinicalTrials.gov
NCT03223012 Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and … — Crohn's Disease Completed 2017-11-15 2019-02-28 ClinicalTrials.gov
NCT03339128 Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bo… Phase2 Irritable Bowel Syndrome Recruiting 2017-11-15 2026-12-01 ClinicalTrials.gov
NCT03303599 Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibren… — Hepatitis C Completed 2017-11-13 2020-01-24 ClinicalTrials.gov
NCT03303599 Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibren… — Hepatitis C Completed 2017-11-13 2020-01-24 ClinicalTrials.gov
NCT03303599 Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibren… — Hepatitis C Completed 2017-11-13 2020-01-24 ClinicalTrials.gov
NCT03303599 Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibren… — Hepatitis C Completed 2017-11-13 2020-01-24 ClinicalTrials.gov
NCT03332342 Closed Eye Neutrophils in Dry Eye Disease Na Dry Eye Completed 2017-11-08 2019-05-14 ClinicalTrials.gov
NCT03236857 A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young… Phase1 Malignancies Completed 2017-11-08 2023-04-19 ClinicalTrials.gov
NCT03332342 Closed Eye Neutrophils in Dry Eye Disease Na Dry Eye Completed 2017-11-08 2019-05-14 ClinicalTrials.gov
NCT03332342 Closed Eye Neutrophils in Dry Eye Disease Na Dry Eye Completed 2017-11-08 2019-05-14 ClinicalTrials.gov
NCT03332342 Closed Eye Neutrophils in Dry Eye Disease Na Dry Eye Completed 2017-11-08 2019-05-14 ClinicalTrials.gov
NCT03236857 A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young… Phase1 Malignancies Completed 2017-11-08 2023-04-19 ClinicalTrials.gov
NCT03236857 A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young… Phase1 Malignancies Completed 2017-11-08 2023-04-19 ClinicalTrials.gov
NCT03236857 A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young… Phase1 Malignancies Completed 2017-11-08 2023-04-19 ClinicalTrials.gov
NCT03311477 A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Partic… Phase1 Advanced Solid Tumors Cancer Completed 2017-11-06 2019-03-04 ClinicalTrials.gov
NCT03311477 A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Partic… Phase1 Advanced Solid Tumors Cancer Completed 2017-11-06 2019-03-04 ClinicalTrials.gov
NCT03311477 A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Partic… Phase1 Advanced Solid Tumors Cancer Completed 2017-11-06 2019-03-04 ClinicalTrials.gov
NCT03311477 A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Partic… Phase1 Advanced Solid Tumors Cancer Completed 2017-11-06 2019-03-04 ClinicalTrials.gov
NCT03222609 A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combinat… Phase2 Myelofibrosis (MF) Completed 2017-10-31 2025-01-29 ClinicalTrials.gov
NCT03222609 A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combinat… Phase2 Myelofibrosis (MF) Completed 2017-10-31 2025-01-29 ClinicalTrials.gov
NCT03222609 A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combinat… Phase2 Myelofibrosis (MF) Completed 2017-10-31 2025-01-29 ClinicalTrials.gov
NCT03222609 A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combinat… Phase2 Myelofibrosis (MF) Completed 2017-10-31 2025-01-29 ClinicalTrials.gov
NCT03319901 Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients… Phase1 Leukemia Active_Not_Recruiting 2017-10-30 2028-05-30 ClinicalTrials.gov
NCT03319901 Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients… Phase1 Leukemia Active_Not_Recruiting 2017-10-30 2028-05-30 ClinicalTrials.gov
NCT03319901 Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients… Phase1 Leukemia Active_Not_Recruiting 2017-10-30 2028-05-30 ClinicalTrials.gov
NCT03319901 Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients… Phase1 Leukemia Active_Not_Recruiting 2017-10-30 2028-05-30 ClinicalTrials.gov
NCT03311464 A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of P… Phase3 Pyoderma Gangrenosum Completed 2017-10-27 2020-04-21 ClinicalTrials.gov
NCT03311464 A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of P… Phase3 Pyoderma Gangrenosum Completed 2017-10-27 2020-04-21 ClinicalTrials.gov
NCT03311464 A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of P… Phase3 Pyoderma Gangrenosum Completed 2017-10-27 2020-04-21 ClinicalTrials.gov
NCT03311464 A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of P… Phase3 Pyoderma Gangrenosum Completed 2017-10-27 2020-04-21 ClinicalTrials.gov
NCT03178487 A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Activ… Phase2 Ankylosing Spondylitis (AS) Completed 2017-10-24 2022-02-17 ClinicalTrials.gov
NCT03178487 A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Activ… Phase2 Ankylosing Spondylitis (AS) Completed 2017-10-24 2022-02-17 ClinicalTrials.gov
NCT03178487 A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Activ… Phase2 Ankylosing Spondylitis (AS) Completed 2017-10-24 2022-02-17 ClinicalTrials.gov
NCT03178487 A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Activ… Phase2 Ankylosing Spondylitis (AS) Completed 2017-10-24 2022-02-17 ClinicalTrials.gov
NCT03003338 MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After T… Phase4 Hepatitis C, Chronic Terminated 2017-10-24 2018-10-22 ClinicalTrials.gov
NCT03003338 MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After T… Phase4 Hepatitis C, Chronic Terminated 2017-10-24 2018-10-22 ClinicalTrials.gov
NCT03003338 MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After T… Phase4 Hepatitis C, Chronic Terminated 2017-10-24 2018-10-22 ClinicalTrials.gov
NCT03003338 MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After T… Phase4 Hepatitis C, Chronic Terminated 2017-10-24 2018-10-22 ClinicalTrials.gov
NCT05305222 A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokineti… Phase1 Healthy Volunteers Completed 2017-10-23 2018-06-15 ClinicalTrials.gov
NCT05305222 A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokineti… Phase1 Healthy Volunteers Completed 2017-10-23 2018-06-15 ClinicalTrials.gov
NCT05305222 A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokineti… Phase1 Healthy Volunteers Completed 2017-10-23 2018-06-15 ClinicalTrials.gov
NCT05305222 A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokineti… Phase1 Healthy Volunteers Completed 2017-10-23 2018-06-15 ClinicalTrials.gov
NCT03274999 Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use Na Dry Eye Syndromes Terminated 2017-10-18 2017-11-09 ClinicalTrials.gov
NCT03274999 Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use Na Dry Eye Syndromes Terminated 2017-10-18 2017-11-09 ClinicalTrials.gov
NCT03274999 Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use Na Dry Eye Syndromes Terminated 2017-10-18 2017-11-09 ClinicalTrials.gov
NCT03274999 Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use Na Dry Eye Syndromes Terminated 2017-10-18 2017-11-09 ClinicalTrials.gov
NCT02966756 A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymph… Phase2 Chronic Lymphocytic Leukemia (CLL) Recruiting 2017-10-12 2029-05-01 ClinicalTrials.gov
NCT02966756 A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymph… Phase2 Chronic Lymphocytic Leukemia (CLL) Recruiting 2017-10-12 2029-05-01 ClinicalTrials.gov
NCT02966756 A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymph… Phase2 Chronic Lymphocytic Leukemia (CLL) Recruiting 2017-10-12 2029-05-01 ClinicalTrials.gov
NCT02966756 A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymph… Phase2 Chronic Lymphocytic Leukemia (CLL) Recruiting 2017-10-12 2029-05-01 ClinicalTrials.gov
NCT03234712 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABB… Phase1 Advanced Solid Tumors Cancer Completed 2017-10-10 2021-04-14 ClinicalTrials.gov
NCT03234712 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABB… Phase1 Advanced Solid Tumors Cancer Completed 2017-10-10 2021-04-14 ClinicalTrials.gov
NCT03234712 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABB… Phase1 Advanced Solid Tumors Cancer Completed 2017-10-10 2021-04-14 ClinicalTrials.gov
NCT03234712 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABB… Phase1 Advanced Solid Tumors Cancer Completed 2017-10-10 2021-04-14 ClinicalTrials.gov
NCT03220841 Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Phase4 Crohn Disease Unknown 2017-10-09 2021-09-01 ClinicalTrials.gov
NCT03220841 Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Phase4 Crohn Disease Unknown 2017-10-09 2021-09-01 ClinicalTrials.gov
NCT03220841 Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Phase4 Crohn Disease Unknown 2017-10-09 2021-09-01 ClinicalTrials.gov
NCT03220841 Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Phase4 Crohn Disease Unknown 2017-10-09 2021-09-01 ClinicalTrials.gov
NCT03301649 Clinical Endpoint Study of Ivermectin 0.5% Lotion Phase3 Head Lice Completed 2017-10-07 2018-03-12 ClinicalTrials.gov
NCT03301649 Clinical Endpoint Study of Ivermectin 0.5% Lotion Phase3 Head Lice Completed 2017-10-07 2018-03-12 ClinicalTrials.gov
NCT03301649 Clinical Endpoint Study of Ivermectin 0.5% Lotion Phase3 Head Lice Completed 2017-10-07 2018-03-12 ClinicalTrials.gov
NCT03301649 Clinical Endpoint Study of Ivermectin 0.5% Lotion Phase3 Head Lice Completed 2017-10-07 2018-03-12 ClinicalTrials.gov
NCT03222583 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-49… Phase3 Hepatitis C Virus (HCV) Completed 2017-10-04 2019-02-15 ClinicalTrials.gov
NCT03222583 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-49… Phase3 Hepatitis C Virus (HCV) Completed 2017-10-04 2019-02-15 ClinicalTrials.gov
NCT03222583 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-49… Phase3 Hepatitis C Virus (HCV) Completed 2017-10-04 2019-02-15 ClinicalTrials.gov
NCT03222583 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-49… Phase3 Hepatitis C Virus (HCV) Completed 2017-10-04 2019-02-15 ClinicalTrials.gov
NCT03373162 Functional Effects of Botox on the Brain Using MRS and fMRI Phase4 Healthy Completed 2017-09-30 2018-03-16 ClinicalTrials.gov
NCT03373162 Functional Effects of Botox on the Brain Using MRS and fMRI Phase4 Healthy Completed 2017-09-30 2018-03-16 ClinicalTrials.gov
NCT03373162 Functional Effects of Botox on the Brain Using MRS and fMRI Phase4 Healthy Completed 2017-09-30 2018-03-16 ClinicalTrials.gov
NCT03373162 Functional Effects of Botox on the Brain Using MRS and fMRI Phase4 Healthy Completed 2017-09-30 2018-03-16 ClinicalTrials.gov
NCT03285308 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 Phase3 Gastroparesis Terminated 2017-09-29 2020-07-08 ClinicalTrials.gov
NCT03235349 Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-… Phase3 Hepatitis C Virus (HCV) Completed 2017-09-29 2019-02-25 ClinicalTrials.gov
NCT03235349 Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-… Phase3 Hepatitis C Virus (HCV) Completed 2017-09-29 2019-02-25 ClinicalTrials.gov
NCT03235349 Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-… Phase3 Hepatitis C Virus (HCV) Completed 2017-09-29 2019-02-25 ClinicalTrials.gov
NCT03235349 Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-… Phase3 Hepatitis C Virus (HCV) Completed 2017-09-29 2019-02-25 ClinicalTrials.gov
NCT03285308 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 Phase3 Gastroparesis Terminated 2017-09-29 2020-07-08 ClinicalTrials.gov
NCT03285308 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 Phase3 Gastroparesis Terminated 2017-09-29 2020-07-08 ClinicalTrials.gov
NCT03285308 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 Phase3 Gastroparesis Terminated 2017-09-29 2020-07-08 ClinicalTrials.gov
NCT03017014 A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children … — Crohn's Disease Terminated 2017-09-26 2019-10-14 ClinicalTrials.gov
NCT03017014 A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children … — Crohn's Disease Terminated 2017-09-26 2019-10-14 ClinicalTrials.gov
NCT03017014 A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children … — Crohn's Disease Terminated 2017-09-26 2019-10-14 ClinicalTrials.gov
NCT03017014 A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children … — Crohn's Disease Terminated 2017-09-26 2019-10-14 ClinicalTrials.gov
NCT03302559 Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical … Na Skin Care Completed 2017-09-18 2018-04-30 ClinicalTrials.gov
NCT03302559 Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical … Na Skin Care Completed 2017-09-18 2018-04-30 ClinicalTrials.gov
NCT03302559 Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical … Na Skin Care Completed 2017-09-18 2018-04-30 ClinicalTrials.gov
NCT03302559 Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical … Na Skin Care Completed 2017-09-18 2018-04-30 ClinicalTrials.gov
NCT03253185 A Study of SC-007 in Subjects With Advanced Cancer Phase1 Colorectal Cancer (CRC) Terminated 2017-09-13 2018-04-02 ClinicalTrials.gov
NCT03271489 Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone … Phase3 Heavy Menstrual Bleeding Completed 2017-09-13 2024-06-28 ClinicalTrials.gov
NCT03253185 A Study of SC-007 in Subjects With Advanced Cancer Phase1 Colorectal Cancer (CRC) Terminated 2017-09-13 2018-04-02 ClinicalTrials.gov
NCT03253185 A Study of SC-007 in Subjects With Advanced Cancer Phase1 Colorectal Cancer (CRC) Terminated 2017-09-13 2018-04-02 ClinicalTrials.gov
NCT03253185 A Study of SC-007 in Subjects With Advanced Cancer Phase1 Colorectal Cancer (CRC) Terminated 2017-09-13 2018-04-02 ClinicalTrials.gov
NCT03271489 Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone … Phase3 Heavy Menstrual Bleeding Completed 2017-09-13 2024-06-28 ClinicalTrials.gov
NCT03271489 Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone … Phase3 Heavy Menstrual Bleeding Completed 2017-09-13 2024-06-28 ClinicalTrials.gov
NCT03271489 Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone … Phase3 Heavy Menstrual Bleeding Completed 2017-09-13 2024-06-28 ClinicalTrials.gov
NCT05283694 A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous … Phase1 Healthy Volunteers Completed 2017-09-11 2018-06-12 ClinicalTrials.gov
NCT05283694 A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous … Phase1 Healthy Volunteers Completed 2017-09-11 2018-06-12 ClinicalTrials.gov
NCT05283694 A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous … Phase1 Healthy Volunteers Completed 2017-09-11 2018-06-12 ClinicalTrials.gov
NCT05283694 A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous … Phase1 Healthy Volunteers Completed 2017-09-11 2018-06-12 ClinicalTrials.gov
NCT03236870 A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimuma… — Psoriasis Completed 2017-09-08 2020-08-25 ClinicalTrials.gov
NCT03236870 A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimuma… — Psoriasis Completed 2017-09-08 2020-08-25 ClinicalTrials.gov
NCT03236870 A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimuma… — Psoriasis Completed 2017-09-08 2020-08-25 ClinicalTrials.gov
NCT03236870 A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimuma… — Psoriasis Completed 2017-09-08 2020-08-25 ClinicalTrials.gov
NCT02951117 A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Pa… Phase1 Multiple Myeloma Withdrawn 2017-08-31 2021-04-28 ClinicalTrials.gov
NCT02951117 A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Pa… Phase1 Multiple Myeloma Withdrawn 2017-08-31 2021-04-28 ClinicalTrials.gov
NCT02951117 A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Pa… Phase1 Multiple Myeloma Withdrawn 2017-08-31 2021-04-28 ClinicalTrials.gov
NCT02951117 A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Pa… Phase1 Multiple Myeloma Withdrawn 2017-08-31 2021-04-28 ClinicalTrials.gov
NCT03155113 Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) … Na Chronic Hepatitis C Completed 2017-08-30 2019-12-31 ClinicalTrials.gov
NCT03155113 Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) … Na Chronic Hepatitis C Completed 2017-08-30 2019-12-31 ClinicalTrials.gov
NCT03155113 Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) … Na Chronic Hepatitis C Completed 2017-08-30 2019-12-31 ClinicalTrials.gov
NCT03155113 Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) … Na Chronic Hepatitis C Completed 2017-08-30 2019-12-31 ClinicalTrials.gov
NCT03255382 A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subject… Phase3 Psoriasis Completed 2017-08-22 2018-07-06 ClinicalTrials.gov
NCT03255382 A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subject… Phase3 Psoriasis Completed 2017-08-22 2018-07-06 ClinicalTrials.gov
NCT03255382 A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subject… Phase3 Psoriasis Completed 2017-08-22 2018-07-06 ClinicalTrials.gov
NCT03255382 A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subject… Phase3 Psoriasis Completed 2017-08-22 2018-07-06 ClinicalTrials.gov
NCT03201718 A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Sta… — Hepatitis C Virus (HCV) Completed 2017-08-17 2019-10-11 ClinicalTrials.gov
NCT03194269 Long Term Prospective Uncontrolled Study Of Earfold™ For The Treatment Of Promi… Phase4 Prominent Ears Completed 2017-08-17 2021-09-07 ClinicalTrials.gov
NCT03201718 A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Sta… — Hepatitis C Virus (HCV) Completed 2017-08-17 2019-10-11 ClinicalTrials.gov
NCT03201718 A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Sta… — Hepatitis C Virus (HCV) Completed 2017-08-17 2019-10-11 ClinicalTrials.gov
NCT03194269 Long Term Prospective Uncontrolled Study Of Earfold™ For The Treatment Of Promi… Phase4 Prominent Ears Completed 2017-08-17 2021-09-07 ClinicalTrials.gov
NCT03194269 Long Term Prospective Uncontrolled Study Of Earfold™ For The Treatment Of Promi… Phase4 Prominent Ears Completed 2017-08-17 2021-09-07 ClinicalTrials.gov
NCT03201718 A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Sta… — Hepatitis C Virus (HCV) Completed 2017-08-17 2019-10-11 ClinicalTrials.gov
NCT03194269 Long Term Prospective Uncontrolled Study Of Earfold™ For The Treatment Of Promi… Phase4 Prominent Ears Completed 2017-08-17 2021-09-07 ClinicalTrials.gov
NCT03048721 Skin Tape Harvesting for Transcriptomics Analysis Na Psoriasis Completed 2017-08-14 2018-09-24 ClinicalTrials.gov
NCT03048721 Skin Tape Harvesting for Transcriptomics Analysis Na Psoriasis Completed 2017-08-14 2018-09-24 ClinicalTrials.gov
NCT03048721 Skin Tape Harvesting for Transcriptomics Analysis Na Psoriasis Completed 2017-08-14 2018-09-24 ClinicalTrials.gov
NCT03048721 Skin Tape Harvesting for Transcriptomics Analysis Na Psoriasis Completed 2017-08-14 2018-09-24 ClinicalTrials.gov
NCT03212521 Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve A… Phase3 Hepatitis C Virus (HCV) Completed 2017-08-07 2018-08-13 ClinicalTrials.gov
NCT03212521 Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve A… Phase3 Hepatitis C Virus (HCV) Completed 2017-08-07 2018-08-13 ClinicalTrials.gov
NCT03212521 Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve A… Phase3 Hepatitis C Virus (HCV) Completed 2017-08-07 2018-08-13 ClinicalTrials.gov
NCT03212521 Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve A… Phase3 Hepatitis C Virus (HCV) Completed 2017-08-07 2018-08-13 ClinicalTrials.gov
NCT03226769 Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease Na Meibomian Glands Completed 2017-07-26 2017-12-12 ClinicalTrials.gov
NCT03226769 Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease Na Meibomian Glands Completed 2017-07-26 2017-12-12 ClinicalTrials.gov
NCT03226769 Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease Na Meibomian Glands Completed 2017-07-26 2017-12-12 ClinicalTrials.gov
NCT03226769 Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease Na Meibomian Glands Completed 2017-07-26 2017-12-12 ClinicalTrials.gov
NCT03233438 Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and… Phase4 Bacterial Infections Completed 2017-07-24 2018-10-30 ClinicalTrials.gov
NCT03233438 Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and… Phase4 Bacterial Infections Completed 2017-07-24 2018-10-30 ClinicalTrials.gov
NCT03233438 Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and… Phase4 Bacterial Infections Completed 2017-07-24 2018-10-30 ClinicalTrials.gov
NCT03233438 Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and… Phase4 Bacterial Infections Completed 2017-07-24 2018-10-30 ClinicalTrials.gov
NCT03213457 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participant… Phase3 Endometriosis Completed 2017-07-07 2023-12-06 ClinicalTrials.gov
NCT03213457 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participant… Phase3 Endometriosis Completed 2017-07-07 2023-12-06 ClinicalTrials.gov
NCT03213457 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participant… Phase3 Endometriosis Completed 2017-07-07 2023-12-06 ClinicalTrials.gov
NCT03213457 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participant… Phase3 Endometriosis Completed 2017-07-07 2023-12-06 ClinicalTrials.gov
NCT03193346 BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants… Phase3 Migraine Disorders Withdrawn 2017-07-03 2021-03-25 ClinicalTrials.gov
NCT03193346 BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants… Phase3 Migraine Disorders Withdrawn 2017-07-03 2021-03-25 ClinicalTrials.gov
NCT03145909 A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV… Phase1 Advanced Solid Tumors Cancer Terminated 2017-07-03 2018-11-27 ClinicalTrials.gov
NCT03208673 Optive Brand For Day And Night Dry Eye Management Na Dry Eye Completed 2017-07-03 2017-09-06 ClinicalTrials.gov
NCT03145909 A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV… Phase1 Advanced Solid Tumors Cancer Terminated 2017-07-03 2018-11-27 ClinicalTrials.gov
NCT03208673 Optive Brand For Day And Night Dry Eye Management Na Dry Eye Completed 2017-07-03 2017-09-06 ClinicalTrials.gov
NCT03193346 BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants… Phase3 Migraine Disorders Withdrawn 2017-07-03 2021-03-25 ClinicalTrials.gov
NCT03145909 A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV… Phase1 Advanced Solid Tumors Cancer Terminated 2017-07-03 2018-11-27 ClinicalTrials.gov
NCT03145909 A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV… Phase1 Advanced Solid Tumors Cancer Terminated 2017-07-03 2018-11-27 ClinicalTrials.gov
NCT03208673 Optive Brand For Day And Night Dry Eye Management Na Dry Eye Completed 2017-07-03 2017-09-06 ClinicalTrials.gov
NCT03193346 BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants… Phase3 Migraine Disorders Withdrawn 2017-07-03 2021-03-25 ClinicalTrials.gov
NCT03208673 Optive Brand For Day And Night Dry Eye Management Na Dry Eye Completed 2017-07-03 2017-09-06 ClinicalTrials.gov
NCT03050905 Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r … Phase4 HCV Coinfection Completed 2017-06-22 2018-11-28 ClinicalTrials.gov
NCT03050905 Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r … Phase4 HCV Coinfection Completed 2017-06-22 2018-11-28 ClinicalTrials.gov
NCT03050905 Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r … Phase4 HCV Coinfection Completed 2017-06-22 2018-11-28 ClinicalTrials.gov
NCT03050905 Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r … Phase4 HCV Coinfection Completed 2017-06-22 2018-11-28 ClinicalTrials.gov
NCT03063398 Post Acute Pancreatitis Pancreatic Exocrine Insufficiency — Acute Pancreatitis Completed 2017-06-21 2024-06-30 ClinicalTrials.gov
NCT03063398 Post Acute Pancreatitis Pancreatic Exocrine Insufficiency — Acute Pancreatitis Completed 2017-06-21 2024-06-30 ClinicalTrials.gov
NCT03063398 Post Acute Pancreatitis Pancreatic Exocrine Insufficiency — Acute Pancreatitis Completed 2017-06-21 2024-06-30 ClinicalTrials.gov
NCT03063398 Post Acute Pancreatitis Pancreatic Exocrine Insufficiency — Acute Pancreatitis Completed 2017-06-21 2024-06-30 ClinicalTrials.gov
NCT03155243 Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource… — Uveitis Completed 2017-06-20 2020-02-24 ClinicalTrials.gov
NCT03155243 Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource… — Uveitis Completed 2017-06-20 2020-02-24 ClinicalTrials.gov
NCT03155243 Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource… — Uveitis Completed 2017-06-20 2020-02-24 ClinicalTrials.gov
NCT03155243 Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource… — Uveitis Completed 2017-06-20 2020-02-24 ClinicalTrials.gov
NCT03138408 SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tu… Phase1 Cancer Terminated 2017-06-14 2019-05-02 ClinicalTrials.gov
NCT03138408 SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tu… Phase1 Cancer Terminated 2017-06-14 2019-05-02 ClinicalTrials.gov
NCT03138408 SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tu… Phase1 Cancer Terminated 2017-06-14 2019-05-02 ClinicalTrials.gov
NCT03138408 SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tu… Phase1 Cancer Terminated 2017-06-14 2019-05-02 ClinicalTrials.gov
NCT03347747 Facial Asymmetrical Clinical Evaluation Study — Loss of Facial Adipose Tissue Unknown 2017-06-09 2018-07-31 ClinicalTrials.gov
NCT03347747 Facial Asymmetrical Clinical Evaluation Study — Loss of Facial Adipose Tissue Unknown 2017-06-09 2018-07-31 ClinicalTrials.gov
NCT03347747 Facial Asymmetrical Clinical Evaluation Study — Loss of Facial Adipose Tissue Unknown 2017-06-09 2018-07-31 ClinicalTrials.gov
NCT03347747 Facial Asymmetrical Clinical Evaluation Study — Loss of Facial Adipose Tissue Unknown 2017-06-09 2018-07-31 ClinicalTrials.gov
NCT03061188 Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumor… Phase1 Advanced Solid Neoplasm Completed 2017-05-23 2020-08-04 ClinicalTrials.gov
NCT03069352 A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose C… Phase3 Acute Myeloid Leukemia (AML) Completed 2017-05-23 2025-08-21 ClinicalTrials.gov
NCT03061188 Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumor… Phase1 Advanced Solid Neoplasm Completed 2017-05-23 2020-08-04 ClinicalTrials.gov
NCT03061188 Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumor… Phase1 Advanced Solid Neoplasm Completed 2017-05-23 2020-08-04 ClinicalTrials.gov
NCT03061188 Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumor… Phase1 Advanced Solid Neoplasm Completed 2017-05-23 2020-08-04 ClinicalTrials.gov
NCT03069352 A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose C… Phase3 Acute Myeloid Leukemia (AML) Completed 2017-05-23 2025-08-21 ClinicalTrials.gov
NCT03069352 A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose C… Phase3 Acute Myeloid Leukemia (AML) Completed 2017-05-23 2025-08-21 ClinicalTrials.gov
NCT03069352 A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose C… Phase3 Acute Myeloid Leukemia (AML) Completed 2017-05-23 2025-08-21 ClinicalTrials.gov
NCT03033498 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutane… Phase1 Parkinson's Disease (PD) Completed 2017-05-17 2019-06-08 ClinicalTrials.gov
NCT03033498 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutane… Phase1 Parkinson's Disease (PD) Completed 2017-05-17 2019-06-08 ClinicalTrials.gov
NCT03033498 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutane… Phase1 Parkinson's Disease (PD) Completed 2017-05-17 2019-06-08 ClinicalTrials.gov
NCT03033498 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutane… Phase1 Parkinson's Disease (PD) Completed 2017-05-17 2019-06-08 ClinicalTrials.gov
NCT03091439 Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients W… Phase2 Osteomyelitis Terminated 2017-05-15 2017-08-31 ClinicalTrials.gov
NCT03091439 Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients W… Phase2 Osteomyelitis Terminated 2017-05-15 2017-08-31 ClinicalTrials.gov
NCT03091439 Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients W… Phase2 Osteomyelitis Terminated 2017-05-15 2017-08-31 ClinicalTrials.gov
NCT03091439 Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients W… Phase2 Osteomyelitis Terminated 2017-05-15 2017-08-31 ClinicalTrials.gov
NCT03148756 Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Ther… Phase2 Endocarditis Terminated 2017-05-12 2017-08-04 ClinicalTrials.gov
NCT03148756 Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Ther… Phase2 Endocarditis Terminated 2017-05-12 2017-08-04 ClinicalTrials.gov
NCT03148756 Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Ther… Phase2 Endocarditis Terminated 2017-05-12 2017-08-04 ClinicalTrials.gov
NCT03148756 Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Ther… Phase2 Endocarditis Terminated 2017-05-12 2017-08-04 ClinicalTrials.gov
NCT03105128 A Study of the Efficacy and Safety of Risankizumab in Participants With Moderat… Phase3 Crohn's Disease Completed 2017-05-10 2021-04-14 ClinicalTrials.gov
NCT03105128 A Study of the Efficacy and Safety of Risankizumab in Participants With Moderat… Phase3 Crohn's Disease Completed 2017-05-10 2021-04-14 ClinicalTrials.gov
NCT03105128 A Study of the Efficacy and Safety of Risankizumab in Participants With Moderat… Phase3 Crohn's Disease Completed 2017-05-10 2021-04-14 ClinicalTrials.gov
NCT03105128 A Study of the Efficacy and Safety of Risankizumab in Participants With Moderat… Phase3 Crohn's Disease Completed 2017-05-10 2021-04-14 ClinicalTrials.gov
NCT03145948 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 i… Phase1 Psoriasis Terminated 2017-05-09 2017-08-16 ClinicalTrials.gov
NCT03086343 A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoi… Phase3 Rheumatoid Arthritis (RA) Completed 2017-05-09 2023-06-06 ClinicalTrials.gov
NCT03086343 A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoi… Phase3 Rheumatoid Arthritis (RA) Completed 2017-05-09 2023-06-06 ClinicalTrials.gov
NCT03086343 A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoi… Phase3 Rheumatoid Arthritis (RA) Completed 2017-05-09 2023-06-06 ClinicalTrials.gov
NCT03086343 A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoi… Phase3 Rheumatoid Arthritis (RA) Completed 2017-05-09 2023-06-06 ClinicalTrials.gov
NCT03145948 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 i… Phase1 Psoriasis Terminated 2017-05-09 2017-08-16 ClinicalTrials.gov
NCT03145948 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 i… Phase1 Psoriasis Terminated 2017-05-09 2017-08-16 ClinicalTrials.gov
NCT03145948 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 i… Phase1 Psoriasis Terminated 2017-05-09 2017-08-16 ClinicalTrials.gov
NCT03104374 A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active… Phase3 Psoriatic Arthritis Completed 2017-05-01 2024-09-30 ClinicalTrials.gov
NCT03187873 Chamas for Change Validation Na Pregnancy Related Unknown 2017-05-01 2018-12-01 ClinicalTrials.gov
NCT03104374 A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active… Phase3 Psoriatic Arthritis Completed 2017-05-01 2024-09-30 ClinicalTrials.gov
NCT03187873 Chamas for Change Validation Na Pregnancy Related Unknown 2017-05-01 2018-12-01 ClinicalTrials.gov
NCT03104374 A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active… Phase3 Psoriatic Arthritis Completed 2017-05-01 2024-09-30 ClinicalTrials.gov
NCT03187873 Chamas for Change Validation Na Pregnancy Related Unknown 2017-05-01 2018-12-01 ClinicalTrials.gov
NCT03104374 A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active… Phase3 Psoriatic Arthritis Completed 2017-05-01 2024-09-30 ClinicalTrials.gov
NCT03187873 Chamas for Change Validation Na Pregnancy Related Unknown 2017-05-01 2018-12-01 ClinicalTrials.gov
NCT03086239 A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese P… Phase1 Small Cell Lung Cancer Completed 2017-04-28 2018-08-20 ClinicalTrials.gov
NCT03089944 A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With … Phase3 Hepatitis C Virus (HCV) Completed 2017-04-28 2019-11-08 ClinicalTrials.gov
NCT03086239 A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese P… Phase1 Small Cell Lung Cancer Completed 2017-04-28 2018-08-20 ClinicalTrials.gov
NCT03089944 A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With … Phase3 Hepatitis C Virus (HCV) Completed 2017-04-28 2019-11-08 ClinicalTrials.gov
NCT03086239 A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese P… Phase1 Small Cell Lung Cancer Completed 2017-04-28 2018-08-20 ClinicalTrials.gov
NCT03089944 A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With … Phase3 Hepatitis C Virus (HCV) Completed 2017-04-28 2019-11-08 ClinicalTrials.gov
NCT03089944 A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With … Phase3 Hepatitis C Virus (HCV) Completed 2017-04-28 2019-11-08 ClinicalTrials.gov
NCT03086239 A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese P… Phase1 Small Cell Lung Cancer Completed 2017-04-28 2018-08-20 ClinicalTrials.gov
NCT03104400 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Partic… Phase3 Psoriatic Arthritis Completed 2017-04-27 2024-09-09 ClinicalTrials.gov
NCT03104400 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Partic… Phase3 Psoriatic Arthritis Completed 2017-04-27 2024-09-09 ClinicalTrials.gov
NCT03104400 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Partic… Phase3 Psoriatic Arthritis Completed 2017-04-27 2024-09-09 ClinicalTrials.gov
NCT03104400 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Partic… Phase3 Psoriatic Arthritis Completed 2017-04-27 2024-09-09 ClinicalTrials.gov
NCT03166618 Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction o… Na Temple Hollowing Terminated 2017-04-24 2017-07-21 ClinicalTrials.gov
NCT03166618 Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction o… Na Temple Hollowing Terminated 2017-04-24 2017-07-21 ClinicalTrials.gov
NCT03166618 Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction o… Na Temple Hollowing Terminated 2017-04-24 2017-07-21 ClinicalTrials.gov
NCT03166618 Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction o… Na Temple Hollowing Terminated 2017-04-24 2017-07-21 ClinicalTrials.gov
NCT03092375 Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previo… Phase3 Hepatitis C Completed 2017-04-20 2020-02-06 ClinicalTrials.gov
NCT03092375 Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previo… Phase3 Hepatitis C Completed 2017-04-20 2020-02-06 ClinicalTrials.gov
NCT03092375 Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previo… Phase3 Hepatitis C Completed 2017-04-20 2020-02-06 ClinicalTrials.gov
NCT03092375 Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previo… Phase3 Hepatitis C Completed 2017-04-20 2020-02-06 ClinicalTrials.gov
NCT02881567 Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Nata… Phase3 Relapsing-Remitting Multiple Sclerosis (RRMS) Terminated 2017-04-18 2018-09-12 ClinicalTrials.gov
NCT02881567 Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Nata… Phase3 Relapsing-Remitting Multiple Sclerosis (RRMS) Terminated 2017-04-18 2018-09-12 ClinicalTrials.gov
NCT02881567 Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Nata… Phase3 Relapsing-Remitting Multiple Sclerosis (RRMS) Terminated 2017-04-18 2018-09-12 ClinicalTrials.gov
NCT02881567 Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Nata… Phase3 Relapsing-Remitting Multiple Sclerosis (RRMS) Terminated 2017-04-18 2018-09-12 ClinicalTrials.gov
NCT03061812 Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advan… Phase3 Small Cell Lung Cancer Completed 2017-04-11 2020-02-12 ClinicalTrials.gov
NCT03061812 Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advan… Phase3 Small Cell Lung Cancer Completed 2017-04-11 2020-02-12 ClinicalTrials.gov
NCT03061812 Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advan… Phase3 Small Cell Lung Cancer Completed 2017-04-11 2020-02-12 ClinicalTrials.gov
NCT03061812 Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advan… Phase3 Small Cell Lung Cancer Completed 2017-04-11 2020-02-12 ClinicalTrials.gov
NCT03217734 MAP Study: Methotrexate and Adalimumab in Psoriasis Phase2 Psoriasis Completed 2017-04-10 2018-12-31 ClinicalTrials.gov
NCT03217734 MAP Study: Methotrexate and Adalimumab in Psoriasis Phase2 Psoriasis Completed 2017-04-10 2018-12-31 ClinicalTrials.gov
NCT03217734 MAP Study: Methotrexate and Adalimumab in Psoriasis Phase2 Psoriasis Completed 2017-04-10 2018-12-31 ClinicalTrials.gov
NCT03217734 MAP Study: Methotrexate and Adalimumab in Psoriasis Phase2 Psoriasis Completed 2017-04-10 2018-12-31 ClinicalTrials.gov
NCT03099083 Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab — Psoriasis Completed 2017-03-31 2019-04-05 ClinicalTrials.gov
NCT03099083 Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab — Psoriasis Completed 2017-03-31 2019-04-05 ClinicalTrials.gov
NCT03099083 Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab — Psoriasis Completed 2017-03-31 2019-04-05 ClinicalTrials.gov
NCT03099083 Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab — Psoriasis Completed 2017-03-31 2019-04-05 ClinicalTrials.gov
NCT02814916 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infect… Phase3 Methicillin-Resistant Staphylococcus Aureus Completed 2017-03-30 2024-01-01 ClinicalTrials.gov
NCT03026166 A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab a… Phase1 Small Cell Lung Cancer Terminated 2017-03-30 2019-07-03 ClinicalTrials.gov
NCT02814916 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infect… Phase3 Methicillin-Resistant Staphylococcus Aureus Completed 2017-03-30 2024-01-01 ClinicalTrials.gov
NCT03026166 A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab a… Phase1 Small Cell Lung Cancer Terminated 2017-03-30 2019-07-03 ClinicalTrials.gov
NCT03026166 A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab a… Phase1 Small Cell Lung Cancer Terminated 2017-03-30 2019-07-03 ClinicalTrials.gov
NCT02814916 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infect… Phase3 Methicillin-Resistant Staphylococcus Aureus Completed 2017-03-30 2024-01-01 ClinicalTrials.gov
NCT03026166 A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab a… Phase1 Small Cell Lung Cancer Terminated 2017-03-30 2019-07-03 ClinicalTrials.gov
NCT02814916 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infect… Phase3 Methicillin-Resistant Staphylococcus Aureus Completed 2017-03-30 2024-01-01 ClinicalTrials.gov
NCT03069365 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adul… Phase3 Hepatitis C Virus (HCV) Completed 2017-03-28 2018-06-05 ClinicalTrials.gov
NCT03069365 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adul… Phase3 Hepatitis C Virus (HCV) Completed 2017-03-28 2018-06-05 ClinicalTrials.gov
NCT03069365 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adul… Phase3 Hepatitis C Virus (HCV) Completed 2017-03-28 2018-06-05 ClinicalTrials.gov
NCT03069365 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adul… Phase3 Hepatitis C Virus (HCV) Completed 2017-03-28 2018-06-05 ClinicalTrials.gov
NCT03097029 Use of Pancreatic Enzymes in Short Bowel Syndrome Phase2 Short Bowel Syndrome Completed 2017-03-24 2019-02-01 ClinicalTrials.gov
NCT03097029 Use of Pancreatic Enzymes in Short Bowel Syndrome Phase2 Short Bowel Syndrome Completed 2017-03-24 2019-02-01 ClinicalTrials.gov
NCT03097029 Use of Pancreatic Enzymes in Short Bowel Syndrome Phase2 Short Bowel Syndrome Completed 2017-03-24 2019-02-01 ClinicalTrials.gov
NCT03097029 Use of Pancreatic Enzymes in Short Bowel Syndrome Phase2 Short Bowel Syndrome Completed 2017-03-24 2019-02-01 ClinicalTrials.gov
NCT03071757 A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Singl… Phase1 Advanced Solid Tumors Cancer Completed 2017-03-21 2022-04-13 ClinicalTrials.gov
NCT03071757 A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Singl… Phase1 Advanced Solid Tumors Cancer Completed 2017-03-21 2022-04-13 ClinicalTrials.gov
NCT03071757 A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Singl… Phase1 Advanced Solid Tumors Cancer Completed 2017-03-21 2022-04-13 ClinicalTrials.gov
NCT03071757 A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Singl… Phase1 Advanced Solid Tumors Cancer Completed 2017-03-21 2022-04-13 ClinicalTrials.gov
NCT03067129 A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/P… Phase2 Hepatitis C Virus (HCV) Completed 2017-03-20 2022-09-12 ClinicalTrials.gov
NCT03082209 A Study of the Safety and Tolerability of ABBV-621 in Participants With Previou… Phase1 Advanced Solid Tumors Completed 2017-03-20 2022-01-21 ClinicalTrials.gov
NCT03053180 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombita… — Chronic Hepatitis C Completed 2017-03-20 2017-12-18 ClinicalTrials.gov
NCT03082209 A Study of the Safety and Tolerability of ABBV-621 in Participants With Previou… Phase1 Advanced Solid Tumors Completed 2017-03-20 2022-01-21 ClinicalTrials.gov
NCT03067129 A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/P… Phase2 Hepatitis C Virus (HCV) Completed 2017-03-20 2022-09-12 ClinicalTrials.gov
NCT03067129 A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/P… Phase2 Hepatitis C Virus (HCV) Completed 2017-03-20 2022-09-12 ClinicalTrials.gov
NCT03053180 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombita… — Chronic Hepatitis C Completed 2017-03-20 2017-12-18 ClinicalTrials.gov
NCT03053180 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombita… — Chronic Hepatitis C Completed 2017-03-20 2017-12-18 ClinicalTrials.gov
NCT03082209 A Study of the Safety and Tolerability of ABBV-621 in Participants With Previou… Phase1 Advanced Solid Tumors Completed 2017-03-20 2022-01-21 ClinicalTrials.gov
NCT03053180 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombita… — Chronic Hepatitis C Completed 2017-03-20 2017-12-18 ClinicalTrials.gov
NCT03067129 A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/P… Phase2 Hepatitis C Virus (HCV) Completed 2017-03-20 2022-09-12 ClinicalTrials.gov
NCT03082209 A Study of the Safety and Tolerability of ABBV-621 in Participants With Previou… Phase1 Advanced Solid Tumors Completed 2017-03-20 2022-01-21 ClinicalTrials.gov
NCT02874066 PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis Phase4 Hepatitis Viruses Completed 2017-03-13 2018-12-25 ClinicalTrials.gov
NCT02874066 PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis Phase4 Hepatitis Viruses Completed 2017-03-13 2018-12-25 ClinicalTrials.gov
NCT02874066 PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis Phase4 Hepatitis Viruses Completed 2017-03-13 2018-12-25 ClinicalTrials.gov
NCT02874066 PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis Phase4 Hepatitis Viruses Completed 2017-03-13 2018-12-25 ClinicalTrials.gov
NCT03001115 Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Su… — Hidradenitis Suppurativa (HS) Completed 2017-03-10 2019-07-31 ClinicalTrials.gov
NCT03001115 Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Su… — Hidradenitis Suppurativa (HS) Completed 2017-03-10 2019-07-31 ClinicalTrials.gov
NCT03001115 Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Su… — Hidradenitis Suppurativa (HS) Completed 2017-03-10 2019-07-31 ClinicalTrials.gov
NCT03001115 Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Su… — Hidradenitis Suppurativa (HS) Completed 2017-03-10 2019-07-31 ClinicalTrials.gov
NCT03035279 A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Co… Phase1 Colorectal Cancer Terminated 2017-03-08 2019-03-28 ClinicalTrials.gov
NCT03035279 A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Co… Phase1 Colorectal Cancer Terminated 2017-03-08 2019-03-28 ClinicalTrials.gov
NCT03035279 A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Co… Phase1 Colorectal Cancer Terminated 2017-03-08 2019-03-28 ClinicalTrials.gov
NCT03035279 A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Co… Phase1 Colorectal Cancer Terminated 2017-03-08 2019-03-28 ClinicalTrials.gov
NCT02966782 A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Part… Phase1 Myelodysplastic Syndromes (MDS) Completed 2017-03-07 2023-04-05 ClinicalTrials.gov
NCT02966782 A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Part… Phase1 Myelodysplastic Syndromes (MDS) Completed 2017-03-07 2023-04-05 ClinicalTrials.gov
NCT02966782 A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Part… Phase1 Myelodysplastic Syndromes (MDS) Completed 2017-03-07 2023-04-05 ClinicalTrials.gov
NCT02966782 A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Part… Phase1 Myelodysplastic Syndromes (MDS) Completed 2017-03-07 2023-04-05 ClinicalTrials.gov
NCT03002818 Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus … — Chronic Hepatitis C Virus (HCV) Completed 2017-03-01 2018-04-25 ClinicalTrials.gov
NCT03002818 Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus … — Chronic Hepatitis C Virus (HCV) Completed 2017-03-01 2018-04-25 ClinicalTrials.gov
NCT03002818 Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus … — Chronic Hepatitis C Virus (HCV) Completed 2017-03-01 2018-04-25 ClinicalTrials.gov
NCT03002818 Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus … — Chronic Hepatitis C Virus (HCV) Completed 2017-03-01 2018-04-25 ClinicalTrials.gov
NCT02956382 Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma Phase1 Refractory Follicular Lymphoma Completed 2017-03-01 2024-03-07 ClinicalTrials.gov
NCT02956382 Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma Phase1 Refractory Follicular Lymphoma Completed 2017-03-01 2024-03-07 ClinicalTrials.gov
NCT04196647 Guideline for Hometitration With Duodopa for Parkinson Patients — Parkinson Disease Completed 2017-03-01 2022-06-30 ClinicalTrials.gov
NCT04196647 Guideline for Hometitration With Duodopa for Parkinson Patients — Parkinson Disease Completed 2017-03-01 2022-06-30 ClinicalTrials.gov
NCT04196647 Guideline for Hometitration With Duodopa for Parkinson Patients — Parkinson Disease Completed 2017-03-01 2022-06-30 ClinicalTrials.gov
NCT04196647 Guideline for Hometitration With Duodopa for Parkinson Patients — Parkinson Disease Completed 2017-03-01 2022-06-30 ClinicalTrials.gov
NCT02956382 Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma Phase1 Refractory Follicular Lymphoma Completed 2017-03-01 2024-03-07 ClinicalTrials.gov
NCT02956382 Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma Phase1 Refractory Follicular Lymphoma Completed 2017-03-01 2024-03-07 ClinicalTrials.gov
NCT03047395 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Mo… Phase3 Psoriasis Completed 2017-02-27 2023-11-29 ClinicalTrials.gov
NCT03047395 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Mo… Phase3 Psoriasis Completed 2017-02-27 2023-11-29 ClinicalTrials.gov
NCT03047395 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Mo… Phase3 Psoriasis Completed 2017-02-27 2023-11-29 ClinicalTrials.gov
NCT03047395 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Mo… Phase3 Psoriasis Completed 2017-02-27 2023-11-29 ClinicalTrials.gov
NCT02851069 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2017-02-23 2018-08-30 ClinicalTrials.gov
NCT02851069 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2017-02-23 2018-08-30 ClinicalTrials.gov
NCT02851069 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2017-02-23 2018-08-30 ClinicalTrials.gov
NCT02851069 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2017-02-23 2018-08-30 ClinicalTrials.gov
NCT02988960 A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanc… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2017-02-22 2026-09-01 ClinicalTrials.gov
NCT02988960 A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanc… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2017-02-22 2026-09-01 ClinicalTrials.gov
NCT02988960 A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanc… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2017-02-22 2026-09-01 ClinicalTrials.gov
NCT02988960 A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanc… Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2017-02-22 2026-09-01 ClinicalTrials.gov
NCT02799381 A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levod… Phase3 Parkinson's Disease (PD) Completed 2017-02-09 2019-09-19 ClinicalTrials.gov
NCT02799381 A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levod… Phase3 Parkinson's Disease (PD) Completed 2017-02-09 2019-09-19 ClinicalTrials.gov
NCT02799381 A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levod… Phase3 Parkinson's Disease (PD) Completed 2017-02-09 2019-09-19 ClinicalTrials.gov
NCT02799381 A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levod… Phase3 Parkinson's Disease (PD) Completed 2017-02-09 2019-09-19 ClinicalTrials.gov
NCT04619303 Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO Phase4 Diabetic Macular Edema Completed 2017-02-07 2020-02-14 ClinicalTrials.gov
NCT03180593 Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patien… Phase4 Hypertension Complicated Completed 2017-02-07 2018-01-25 ClinicalTrials.gov
NCT03033511 A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line… Phase3 Small Cell Lung Cancer Terminated 2017-02-07 2019-11-20 ClinicalTrials.gov
NCT03180593 Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patien… Phase4 Hypertension Complicated Completed 2017-02-07 2018-01-25 ClinicalTrials.gov
NCT03180593 Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patien… Phase4 Hypertension Complicated Completed 2017-02-07 2018-01-25 ClinicalTrials.gov
NCT04619303 Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO Phase4 Diabetic Macular Edema Completed 2017-02-07 2020-02-14 ClinicalTrials.gov
NCT03033511 A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line… Phase3 Small Cell Lung Cancer Terminated 2017-02-07 2019-11-20 ClinicalTrials.gov
NCT03033511 A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line… Phase3 Small Cell Lung Cancer Terminated 2017-02-07 2019-11-20 ClinicalTrials.gov
NCT04619303 Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO Phase4 Diabetic Macular Edema Completed 2017-02-07 2020-02-14 ClinicalTrials.gov
NCT03180593 Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patien… Phase4 Hypertension Complicated Completed 2017-02-07 2018-01-25 ClinicalTrials.gov
NCT03033511 A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line… Phase3 Small Cell Lung Cancer Terminated 2017-02-07 2019-11-20 ClinicalTrials.gov
NCT04619303 Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO Phase4 Diabetic Macular Edema Completed 2017-02-07 2020-02-14 ClinicalTrials.gov
NCT02993523 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Tre… Phase3 Acute Myeloid Leukemia (AML) Active_Not_Recruiting 2017-02-02 2026-06-15 ClinicalTrials.gov
NCT02993523 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Tre… Phase3 Acute Myeloid Leukemia (AML) Active_Not_Recruiting 2017-02-02 2026-06-15 ClinicalTrials.gov
NCT02993523 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Tre… Phase3 Acute Myeloid Leukemia (AML) Active_Not_Recruiting 2017-02-02 2026-06-15 ClinicalTrials.gov
NCT02993523 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Tre… Phase3 Acute Myeloid Leukemia (AML) Active_Not_Recruiting 2017-02-02 2026-06-15 ClinicalTrials.gov
NCT02946034 Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and He… Phase4 Chronic Kidney Disease Completed 2017-02-01 2020-09-16 ClinicalTrials.gov
NCT02946034 Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and He… Phase4 Chronic Kidney Disease Completed 2017-02-01 2020-09-16 ClinicalTrials.gov
NCT02946034 Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and He… Phase4 Chronic Kidney Disease Completed 2017-02-01 2020-09-16 ClinicalTrials.gov
NCT02946034 Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and He… Phase4 Chronic Kidney Disease Completed 2017-02-01 2020-09-16 ClinicalTrials.gov
NCT03006068 A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494)… Phase3 Ulcerative Colitis (UC) Active_Not_Recruiting 2017-01-31 2027-07-01 ClinicalTrials.gov
NCT03006068 A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494)… Phase3 Ulcerative Colitis (UC) Active_Not_Recruiting 2017-01-31 2027-07-01 ClinicalTrials.gov
NCT03006068 A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494)… Phase3 Ulcerative Colitis (UC) Active_Not_Recruiting 2017-01-31 2027-07-01 ClinicalTrials.gov
NCT03006068 A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494)… Phase3 Ulcerative Colitis (UC) Active_Not_Recruiting 2017-01-31 2027-07-01 ClinicalTrials.gov
NCT03022045 A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risanki… Phase3 Psoriasis Completed 2017-01-26 2020-11-19 ClinicalTrials.gov
NCT02880956 A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With E… Phase2 Alzheimer's Disease Completed 2017-01-26 2021-07-28 ClinicalTrials.gov
NCT03022045 A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risanki… Phase3 Psoriasis Completed 2017-01-26 2020-11-19 ClinicalTrials.gov
NCT02880956 A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With E… Phase2 Alzheimer's Disease Completed 2017-01-26 2021-07-28 ClinicalTrials.gov
NCT02880956 A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With E… Phase2 Alzheimer's Disease Completed 2017-01-26 2021-07-28 ClinicalTrials.gov
NCT03022045 A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risanki… Phase3 Psoriasis Completed 2017-01-26 2020-11-19 ClinicalTrials.gov
NCT03022045 A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risanki… Phase3 Psoriasis Completed 2017-01-26 2020-11-19 ClinicalTrials.gov
NCT02880956 A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With E… Phase2 Alzheimer's Disease Completed 2017-01-26 2021-07-28 ClinicalTrials.gov
NCT02951975 Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segmen… — Non-infectious Uveitis Terminated 2017-01-25 2018-12-19 ClinicalTrials.gov
NCT02951975 Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segmen… — Non-infectious Uveitis Terminated 2017-01-25 2018-12-19 ClinicalTrials.gov
NCT02966795 A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus… Phase3 Hepatitis C Virus (HCV) Completed 2017-01-25 2018-08-29 ClinicalTrials.gov
NCT02966795 A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus… Phase3 Hepatitis C Virus (HCV) Completed 2017-01-25 2018-08-29 ClinicalTrials.gov
NCT02951975 Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segmen… — Non-infectious Uveitis Terminated 2017-01-25 2018-12-19 ClinicalTrials.gov
NCT02966795 A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus… Phase3 Hepatitis C Virus (HCV) Completed 2017-01-25 2018-08-29 ClinicalTrials.gov
NCT02966795 A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus… Phase3 Hepatitis C Virus (HCV) Completed 2017-01-25 2018-08-29 ClinicalTrials.gov
NCT02951975 Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segmen… — Non-infectious Uveitis Terminated 2017-01-25 2018-12-19 ClinicalTrials.gov
NCT02899052 Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Partic… Phase2 Multiple Myeloma Active_Not_Recruiting 2017-01-19 2027-06-01 ClinicalTrials.gov
NCT02899052 Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Partic… Phase2 Multiple Myeloma Active_Not_Recruiting 2017-01-19 2027-06-01 ClinicalTrials.gov
NCT02899052 Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Partic… Phase2 Multiple Myeloma Active_Not_Recruiting 2017-01-19 2027-06-01 ClinicalTrials.gov
NCT02899052 Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Partic… Phase2 Multiple Myeloma Active_Not_Recruiting 2017-01-19 2027-06-01 ClinicalTrials.gov
NCT03261102 TDM Guided Early Optimization of ADAL in Crohn's Disease Na Crohn Disease Active_Not_Recruiting 2017-01-17 2025-06-01 ClinicalTrials.gov
NCT03261102 TDM Guided Early Optimization of ADAL in Crohn's Disease Na Crohn Disease Active_Not_Recruiting 2017-01-17 2025-06-01 ClinicalTrials.gov
NCT03261102 TDM Guided Early Optimization of ADAL in Crohn's Disease Na Crohn Disease Active_Not_Recruiting 2017-01-17 2025-06-01 ClinicalTrials.gov
NCT03261102 TDM Guided Early Optimization of ADAL in Crohn's Disease Na Crohn Disease Active_Not_Recruiting 2017-01-17 2025-06-01 ClinicalTrials.gov
NCT02495168 Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/F… Phase3 Asthma Completed 2017-01-13 2018-05-31 ClinicalTrials.gov
NCT02495168 Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/F… Phase3 Asthma Completed 2017-01-13 2018-05-31 ClinicalTrials.gov
NCT02495168 Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/F… Phase3 Asthma Completed 2017-01-13 2018-05-31 ClinicalTrials.gov
NCT02495168 Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/F… Phase3 Asthma Completed 2017-01-13 2018-05-31 ClinicalTrials.gov
NCT02942290 A Study Evaluating Venetoclax in Combination With Azacitidine in Participants W… Phase1 Myelodysplastic Syndromes (MDS) Active_Not_Recruiting 2017-01-12 2027-01-01 ClinicalTrials.gov
NCT02942290 A Study Evaluating Venetoclax in Combination With Azacitidine in Participants W… Phase1 Myelodysplastic Syndromes (MDS) Active_Not_Recruiting 2017-01-12 2027-01-01 ClinicalTrials.gov
NCT02942290 A Study Evaluating Venetoclax in Combination With Azacitidine in Participants W… Phase1 Myelodysplastic Syndromes (MDS) Active_Not_Recruiting 2017-01-12 2027-01-01 ClinicalTrials.gov
NCT02942290 A Study Evaluating Venetoclax in Combination With Azacitidine in Participants W… Phase1 Myelodysplastic Syndromes (MDS) Active_Not_Recruiting 2017-01-12 2027-01-01 ClinicalTrials.gov
NCT03254121 Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients Wi… — Hepatocellular Carcinoma Completed 2017-01-01 2020-09-01 ClinicalTrials.gov
NCT04358991 Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receivi… — Bacterial Infections Completed 2017-01-01 2019-12-31 ClinicalTrials.gov
NCT04358991 Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receivi… — Bacterial Infections Completed 2017-01-01 2019-12-31 ClinicalTrials.gov
NCT03254121 Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients Wi… — Hepatocellular Carcinoma Completed 2017-01-01 2020-09-01 ClinicalTrials.gov
NCT04358991 Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receivi… — Bacterial Infections Completed 2017-01-01 2019-12-31 ClinicalTrials.gov
NCT03254121 Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients Wi… — Hepatocellular Carcinoma Completed 2017-01-01 2020-09-01 ClinicalTrials.gov
NCT03254121 Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients Wi… — Hepatocellular Carcinoma Completed 2017-01-01 2020-09-01 ClinicalTrials.gov
NCT04358991 Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receivi… — Bacterial Infections Completed 2017-01-01 2019-12-31 ClinicalTrials.gov
NCT02944396 Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemother… Phase1 Non-Small Cell Lung Cancer Completed 2016-12-23 2019-10-02 ClinicalTrials.gov
NCT02944396 Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemother… Phase1 Non-Small Cell Lung Cancer Completed 2016-12-23 2019-10-02 ClinicalTrials.gov
NCT02944396 Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemother… Phase1 Non-Small Cell Lung Cancer Completed 2016-12-23 2019-10-02 ClinicalTrials.gov
NCT02944396 Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemother… Phase1 Non-Small Cell Lung Cancer Completed 2016-12-23 2019-10-02 ClinicalTrials.gov
NCT02988674 A Study to Assess Retention Rate, Persistence and Adherence in Population of Sp… — Spondylarthritis Completed 2016-12-22 2019-10-16 ClinicalTrials.gov
NCT02988674 A Study to Assess Retention Rate, Persistence and Adherence in Population of Sp… — Spondylarthritis Completed 2016-12-22 2019-10-16 ClinicalTrials.gov
NCT02988674 A Study to Assess Retention Rate, Persistence and Adherence in Population of Sp… — Spondylarthritis Completed 2016-12-22 2019-10-16 ClinicalTrials.gov
NCT02988674 A Study to Assess Retention Rate, Persistence and Adherence in Population of Sp… — Spondylarthritis Completed 2016-12-22 2019-10-16 ClinicalTrials.gov
NCT02896985 Observational Study Evaluating the Effectiveness of Drug Concentration to Predi… — Crohn's Disease Completed 2016-12-16 2020-03-11 ClinicalTrials.gov
NCT02896985 Observational Study Evaluating the Effectiveness of Drug Concentration to Predi… — Crohn's Disease Completed 2016-12-16 2020-03-11 ClinicalTrials.gov
NCT02896985 Observational Study Evaluating the Effectiveness of Drug Concentration to Predi… — Crohn's Disease Completed 2016-12-16 2020-03-11 ClinicalTrials.gov
NCT02896985 Observational Study Evaluating the Effectiveness of Drug Concentration to Predi… — Crohn's Disease Completed 2016-12-16 2020-03-11 ClinicalTrials.gov
NCT02986373 A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects… Phase2 Psoriatic Arthritis Completed 2016-12-15 2018-07-30 ClinicalTrials.gov
NCT02986373 A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects… Phase2 Psoriatic Arthritis Completed 2016-12-15 2018-07-30 ClinicalTrials.gov
NCT02986373 A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects… Phase2 Psoriatic Arthritis Completed 2016-12-15 2018-07-30 ClinicalTrials.gov
NCT02986373 A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects… Phase2 Psoriatic Arthritis Completed 2016-12-15 2018-07-30 ClinicalTrials.gov
NCT03000257 A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2016-12-14 2022-03-29 ClinicalTrials.gov
NCT03000257 A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2016-12-14 2022-03-29 ClinicalTrials.gov
NCT03000257 A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2016-12-14 2022-03-29 ClinicalTrials.gov
NCT03000257 A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2016-12-14 2022-03-29 ClinicalTrials.gov
NCT02977507 Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topica… Na Melasma Completed 2016-12-13 2017-10-09 ClinicalTrials.gov
NCT02980731 A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects… Phase3 Chronic Lymphocytic Leukemia (CLL) Completed 2016-12-13 2021-12-29 ClinicalTrials.gov
NCT02965846 Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Phase3 Dry Eye Syndromes Terminated 2016-12-13 2017-06-13 ClinicalTrials.gov
NCT02950051 Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus… Phase3 Chronic Lymphocytic Leukemia Completed 2016-12-13 2024-02-29 ClinicalTrials.gov
NCT02965846 Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Phase3 Dry Eye Syndromes Terminated 2016-12-13 2017-06-13 ClinicalTrials.gov
NCT02950051 Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus… Phase3 Chronic Lymphocytic Leukemia Completed 2016-12-13 2024-02-29 ClinicalTrials.gov
NCT02950051 Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus… Phase3 Chronic Lymphocytic Leukemia Completed 2016-12-13 2024-02-29 ClinicalTrials.gov
NCT02980731 A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects… Phase3 Chronic Lymphocytic Leukemia (CLL) Completed 2016-12-13 2021-12-29 ClinicalTrials.gov
NCT02980731 A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects… Phase3 Chronic Lymphocytic Leukemia (CLL) Completed 2016-12-13 2021-12-29 ClinicalTrials.gov
NCT02977507 Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topica… Na Melasma Completed 2016-12-13 2017-10-09 ClinicalTrials.gov
NCT02977507 Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topica… Na Melasma Completed 2016-12-13 2017-10-09 ClinicalTrials.gov
NCT02950051 Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus… Phase3 Chronic Lymphocytic Leukemia Completed 2016-12-13 2024-02-29 ClinicalTrials.gov
NCT02965846 Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Phase3 Dry Eye Syndromes Terminated 2016-12-13 2017-06-13 ClinicalTrials.gov
NCT02977507 Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topica… Na Melasma Completed 2016-12-13 2017-10-09 ClinicalTrials.gov
NCT02965846 Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Phase3 Dry Eye Syndromes Terminated 2016-12-13 2017-06-13 ClinicalTrials.gov
NCT02980731 A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects… Phase3 Chronic Lymphocytic Leukemia (CLL) Completed 2016-12-13 2021-12-29 ClinicalTrials.gov
NCT02985879 A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-… Phase2 Progressive Supranuclear Palsy Terminated 2016-12-12 2019-11-20 ClinicalTrials.gov
NCT02985879 A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-… Phase2 Progressive Supranuclear Palsy Terminated 2016-12-12 2019-11-20 ClinicalTrials.gov
NCT03052764 Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®)… Phase4 Urinary Bladder, Overactive Completed 2016-12-12 2018-12-10 ClinicalTrials.gov
NCT02985879 A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-… Phase2 Progressive Supranuclear Palsy Terminated 2016-12-12 2019-11-20 ClinicalTrials.gov
NCT03052764 Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®)… Phase4 Urinary Bladder, Overactive Completed 2016-12-12 2018-12-10 ClinicalTrials.gov
NCT03052764 Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®)… Phase4 Urinary Bladder, Overactive Completed 2016-12-12 2018-12-10 ClinicalTrials.gov
NCT02985879 A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-… Phase2 Progressive Supranuclear Palsy Terminated 2016-12-12 2019-11-20 ClinicalTrials.gov
NCT03052764 Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®)… Phase4 Urinary Bladder, Overactive Completed 2016-12-12 2018-12-10 ClinicalTrials.gov
NCT03000075 BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate… Phase2 Psoriasis Completed 2016-12-02 2018-06-20 ClinicalTrials.gov
NCT03000075 BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate… Phase2 Psoriasis Completed 2016-12-02 2018-06-20 ClinicalTrials.gov
NCT03000075 BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate… Phase2 Psoriasis Completed 2016-12-02 2018-06-20 ClinicalTrials.gov
NCT03000075 BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate… Phase2 Psoriasis Completed 2016-12-02 2018-06-20 ClinicalTrials.gov
NCT02939989 Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) i… Phase3 Hepatitis C Virus Infection Completed 2016-11-21 2021-07-30 ClinicalTrials.gov
NCT02939989 Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) i… Phase3 Hepatitis C Virus Infection Completed 2016-11-21 2021-07-30 ClinicalTrials.gov
NCT02939989 Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) i… Phase3 Hepatitis C Virus Infection Completed 2016-11-21 2021-07-30 ClinicalTrials.gov
NCT02939989 Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) i… Phase3 Hepatitis C Virus Infection Completed 2016-11-21 2021-07-30 ClinicalTrials.gov
NCT02955251 A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Cancer Completed 2016-11-18 2019-10-29 ClinicalTrials.gov
NCT02955251 A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Cancer Completed 2016-11-18 2019-10-29 ClinicalTrials.gov
NCT02955251 A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Cancer Completed 2016-11-18 2019-10-29 ClinicalTrials.gov
NCT02955251 A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Cancer Completed 2016-11-18 2019-10-29 ClinicalTrials.gov
NCT02916017 HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Post… — Uveitis Completed 2016-11-15 2020-10-14 ClinicalTrials.gov
NCT02916017 HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Post… — Uveitis Completed 2016-11-15 2020-10-14 ClinicalTrials.gov
NCT02916017 HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Post… — Uveitis Completed 2016-11-15 2020-10-14 ClinicalTrials.gov
NCT02916017 HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Post… — Uveitis Completed 2016-11-15 2020-10-14 ClinicalTrials.gov
NCT02951988 A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Pat… Phase3 Depressive Disorder, Major Completed 2016-11-13 2019-02-22 ClinicalTrials.gov
NCT02951988 A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Pat… Phase3 Depressive Disorder, Major Completed 2016-11-13 2019-02-22 ClinicalTrials.gov
NCT02951988 A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Pat… Phase3 Depressive Disorder, Major Completed 2016-11-13 2019-02-22 ClinicalTrials.gov
NCT02951988 A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Pat… Phase3 Depressive Disorder, Major Completed 2016-11-13 2019-02-22 ClinicalTrials.gov
NCT02968173 A Study to Assess the Safety and Effectiveness of Palivizumab Administered to C… Phase3 Respiratory Syncytial Virus (RSV) Completed 2016-11-09 2017-07-13 ClinicalTrials.gov
NCT02968173 A Study to Assess the Safety and Effectiveness of Palivizumab Administered to C… Phase3 Respiratory Syncytial Virus (RSV) Completed 2016-11-09 2017-07-13 ClinicalTrials.gov
NCT02968173 A Study to Assess the Safety and Effectiveness of Palivizumab Administered to C… Phase3 Respiratory Syncytial Virus (RSV) Completed 2016-11-09 2017-07-13 ClinicalTrials.gov
NCT02968173 A Study to Assess the Safety and Effectiveness of Palivizumab Administered to C… Phase3 Respiratory Syncytial Virus (RSV) Completed 2016-11-09 2017-07-13 ClinicalTrials.gov
NCT02943577 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-M… Phase3 Depressive Disorder, Major Completed 2016-11-02 2018-11-21 ClinicalTrials.gov
NCT02943577 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-M… Phase3 Depressive Disorder, Major Completed 2016-11-02 2018-11-21 ClinicalTrials.gov
NCT02943577 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-M… Phase3 Depressive Disorder, Major Completed 2016-11-02 2018-11-21 ClinicalTrials.gov
NCT02943577 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-M… Phase3 Depressive Disorder, Major Completed 2016-11-02 2018-11-21 ClinicalTrials.gov
NCT02910921 Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitb… — Migraine Disorders Completed 2016-11-01 2018-07-31 ClinicalTrials.gov
NCT02910921 Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitb… — Migraine Disorders Completed 2016-11-01 2018-07-31 ClinicalTrials.gov
NCT02910921 Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitb… — Migraine Disorders Completed 2016-11-01 2018-07-31 ClinicalTrials.gov
NCT02910921 Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitb… — Migraine Disorders Completed 2016-11-01 2018-07-31 ClinicalTrials.gov
NCT02830776 Topical Bimatoprost for Chemical Blepharoplasty Early_Phase1 Dermatochalasis Completed 2016-11-01 2017-06-30 ClinicalTrials.gov
NCT02830776 Topical Bimatoprost for Chemical Blepharoplasty Early_Phase1 Dermatochalasis Completed 2016-11-01 2017-06-30 ClinicalTrials.gov
NCT02830776 Topical Bimatoprost for Chemical Blepharoplasty Early_Phase1 Dermatochalasis Completed 2016-11-01 2017-06-30 ClinicalTrials.gov
NCT02830776 Topical Bimatoprost for Chemical Blepharoplasty Early_Phase1 Dermatochalasis Completed 2016-11-01 2017-06-30 ClinicalTrials.gov
NCT02959970 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Pat… Phase4 Acne Vulgaris Completed 2016-10-31 2018-03-09 ClinicalTrials.gov
NCT02959970 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Pat… Phase4 Acne Vulgaris Completed 2016-10-31 2018-03-09 ClinicalTrials.gov
NCT02959970 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Pat… Phase4 Acne Vulgaris Completed 2016-10-31 2018-03-09 ClinicalTrials.gov
NCT02959970 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Pat… Phase4 Acne Vulgaris Completed 2016-10-31 2018-03-09 ClinicalTrials.gov
NCT02945228 Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotyp… — Chronic Hepatitis C Virus Completed 2016-10-26 2019-07-26 ClinicalTrials.gov
NCT02945228 Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotyp… — Chronic Hepatitis C Virus Completed 2016-10-26 2019-07-26 ClinicalTrials.gov
NCT02945228 Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotyp… — Chronic Hepatitis C Virus Completed 2016-10-26 2019-07-26 ClinicalTrials.gov
NCT02945228 Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotyp… — Chronic Hepatitis C Virus Completed 2016-10-26 2019-07-26 ClinicalTrials.gov
NCT02925117 A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe At… Phase2 Atopic Dermatitis Completed 2016-10-25 2019-01-31 ClinicalTrials.gov
NCT02925117 A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe At… Phase2 Atopic Dermatitis Completed 2016-10-25 2019-01-31 ClinicalTrials.gov
NCT02959983 Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarr… Phase4 Irritable Bowel Syndrome With Diarrhea Completed 2016-10-25 2018-01-22 ClinicalTrials.gov
NCT02925117 A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe At… Phase2 Atopic Dermatitis Completed 2016-10-25 2019-01-31 ClinicalTrials.gov
NCT02959983 Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarr… Phase4 Irritable Bowel Syndrome With Diarrhea Completed 2016-10-25 2018-01-22 ClinicalTrials.gov
NCT02925117 A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe At… Phase2 Atopic Dermatitis Completed 2016-10-25 2019-01-31 ClinicalTrials.gov
NCT02959983 Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarr… Phase4 Irritable Bowel Syndrome With Diarrhea Completed 2016-10-25 2018-01-22 ClinicalTrials.gov
NCT02959983 Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarr… Phase4 Irritable Bowel Syndrome With Diarrhea Completed 2016-10-25 2018-01-22 ClinicalTrials.gov
NCT02601885 A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple S… Phase1 Multiple Sclerosis Completed 2016-10-18 2018-04-20 ClinicalTrials.gov
NCT02601885 A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple S… Phase1 Multiple Sclerosis Completed 2016-10-18 2018-04-20 ClinicalTrials.gov
NCT02601885 A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple S… Phase1 Multiple Sclerosis Completed 2016-10-18 2018-04-20 ClinicalTrials.gov
NCT02601885 A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple S… Phase1 Multiple Sclerosis Completed 2016-10-18 2018-04-20 ClinicalTrials.gov
NCT02932943 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-M… Phase3 Depressive Disorder, Major Completed 2016-10-15 2018-11-08 ClinicalTrials.gov
NCT02932943 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-M… Phase3 Depressive Disorder, Major Completed 2016-10-15 2018-11-08 ClinicalTrials.gov
NCT02932943 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-M… Phase3 Depressive Disorder, Major Completed 2016-10-15 2018-11-08 ClinicalTrials.gov
NCT02932943 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-M… Phase3 Depressive Disorder, Major Completed 2016-10-15 2018-11-08 ClinicalTrials.gov
NCT02849704 Fat Malabsorption in Chronic Pancreatitis Phase2 Chronic Pancreatitis Completed 2016-10-13 2017-11-01 ClinicalTrials.gov
NCT02849704 Fat Malabsorption in Chronic Pancreatitis Phase2 Chronic Pancreatitis Completed 2016-10-13 2017-11-01 ClinicalTrials.gov
NCT02849704 Fat Malabsorption in Chronic Pancreatitis Phase2 Chronic Pancreatitis Completed 2016-10-13 2017-11-01 ClinicalTrials.gov
NCT02849704 Fat Malabsorption in Chronic Pancreatitis Phase2 Chronic Pancreatitis Completed 2016-10-13 2017-11-01 ClinicalTrials.gov
NCT02819999 A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Pa… Phase1 Small Cell Lung Cancer Terminated 2016-10-01 2019-05-31 ClinicalTrials.gov
NCT02819999 A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Pa… Phase1 Small Cell Lung Cancer Terminated 2016-10-01 2019-05-31 ClinicalTrials.gov
NCT02819999 A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Pa… Phase1 Small Cell Lung Cancer Terminated 2016-10-01 2019-05-31 ClinicalTrials.gov
NCT02819999 A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Pa… Phase1 Small Cell Lung Cancer Terminated 2016-10-01 2019-05-31 ClinicalTrials.gov
NCT02860065 CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase2 Alzheimer's Disease Withdrawn 2016-09-30 2017-06-30 ClinicalTrials.gov
NCT02860065 CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase2 Alzheimer's Disease Withdrawn 2016-09-30 2017-06-30 ClinicalTrials.gov
NCT02860065 CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase2 Alzheimer's Disease Withdrawn 2016-09-30 2017-06-30 ClinicalTrials.gov
NCT02860065 CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase2 Alzheimer's Disease Withdrawn 2016-09-30 2017-06-30 ClinicalTrials.gov
NCT02819635 A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induc… Phase2 Ulcerative Colitis (UC) Completed 2016-09-26 2021-12-13 ClinicalTrials.gov
NCT02819635 A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induc… Phase2 Ulcerative Colitis (UC) Completed 2016-09-26 2021-12-13 ClinicalTrials.gov
NCT02819635 A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induc… Phase2 Ulcerative Colitis (UC) Completed 2016-09-26 2021-12-13 ClinicalTrials.gov
NCT02819635 A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induc… Phase2 Ulcerative Colitis (UC) Completed 2016-09-26 2021-12-13 ClinicalTrials.gov
NCT02709889 Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase1 Malignant Melanoma Terminated 2016-09-23 2019-08-27 ClinicalTrials.gov
NCT02709889 Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase1 Malignant Melanoma Terminated 2016-09-23 2019-08-27 ClinicalTrials.gov
NCT02709889 Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase1 Malignant Melanoma Terminated 2016-09-23 2019-08-27 ClinicalTrials.gov
NCT02709889 Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase1 Malignant Melanoma Terminated 2016-09-23 2019-08-27 ClinicalTrials.gov
NCT02896920 Canadian Humira Post Marketing Observational Epidemiological Study : Assessing … — Hidradenitis Suppurativa (HS) Completed 2016-09-20 2019-04-29 ClinicalTrials.gov
NCT02896920 Canadian Humira Post Marketing Observational Epidemiological Study : Assessing … — Hidradenitis Suppurativa (HS) Completed 2016-09-20 2019-04-29 ClinicalTrials.gov
NCT02896920 Canadian Humira Post Marketing Observational Epidemiological Study : Assessing … — Hidradenitis Suppurativa (HS) Completed 2016-09-20 2019-04-29 ClinicalTrials.gov
NCT02896920 Canadian Humira Post Marketing Observational Epidemiological Study : Assessing … — Hidradenitis Suppurativa (HS) Completed 2016-09-20 2019-04-29 ClinicalTrials.gov
NCT02871440 A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evapora… Phase3 Dry Eye Syndromes Completed 2016-09-19 2017-09-18 ClinicalTrials.gov
NCT02871440 A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evapora… Phase3 Dry Eye Syndromes Completed 2016-09-19 2017-09-18 ClinicalTrials.gov
NCT02871440 A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evapora… Phase3 Dry Eye Syndromes Completed 2016-09-19 2017-09-18 ClinicalTrials.gov
NCT02871440 A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evapora… Phase3 Dry Eye Syndromes Completed 2016-09-19 2017-09-18 ClinicalTrials.gov
NCT02772601 This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of F… Phase1 Psoriasis Completed 2016-09-15 2017-09-22 ClinicalTrials.gov
NCT02772601 This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of F… Phase1 Psoriasis Completed 2016-09-15 2017-09-22 ClinicalTrials.gov
NCT02772601 This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of F… Phase1 Psoriasis Completed 2016-09-15 2017-09-22 ClinicalTrials.gov
NCT02772601 This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of F… Phase1 Psoriasis Completed 2016-09-15 2017-09-22 ClinicalTrials.gov
NCT02925494 An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopa… Phase3 Uterine Fibroids Completed 2016-09-14 2019-03-22 ClinicalTrials.gov
NCT02925494 An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopa… Phase3 Uterine Fibroids Completed 2016-09-14 2019-03-22 ClinicalTrials.gov
NCT02925494 An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopa… Phase3 Uterine Fibroids Completed 2016-09-14 2019-03-22 ClinicalTrials.gov
NCT02925494 An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopa… Phase3 Uterine Fibroids Completed 2016-09-14 2019-03-22 ClinicalTrials.gov
NCT02873221 An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogep… Phase3 Migraine, With or Without Aura Completed 2016-09-13 2018-08-02 ClinicalTrials.gov
NCT02873221 An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogep… Phase3 Migraine, With or Without Aura Completed 2016-09-13 2018-08-02 ClinicalTrials.gov
NCT02873221 An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogep… Phase3 Migraine, With or Without Aura Completed 2016-09-13 2018-08-02 ClinicalTrials.gov
NCT02873221 An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogep… Phase3 Migraine, With or Without Aura Completed 2016-09-13 2018-08-02 ClinicalTrials.gov
NCT02897115 A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking… Phase4 Axial Spondyloarthritis Terminated 2016-09-12 2017-12-21 ClinicalTrials.gov
NCT02897115 A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking… Phase4 Axial Spondyloarthritis Terminated 2016-09-12 2017-12-21 ClinicalTrials.gov
NCT02906488 Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Pa… — Parkinson's Disease Completed 2016-09-12 2025-07-24 ClinicalTrials.gov
NCT02897115 A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking… Phase4 Axial Spondyloarthritis Terminated 2016-09-12 2017-12-21 ClinicalTrials.gov
NCT02897115 A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking… Phase4 Axial Spondyloarthritis Terminated 2016-09-12 2017-12-21 ClinicalTrials.gov
NCT02906488 Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Pa… — Parkinson's Disease Completed 2016-09-12 2025-07-24 ClinicalTrials.gov
NCT02906488 Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Pa… — Parkinson's Disease Completed 2016-09-12 2025-07-24 ClinicalTrials.gov
NCT02906488 Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Pa… — Parkinson's Disease Completed 2016-09-12 2025-07-24 ClinicalTrials.gov
NCT02848326 Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepan… Phase2 Migraine, With or Without Aura Completed 2016-09-06 2018-04-23 ClinicalTrials.gov
NCT02848326 Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepan… Phase2 Migraine, With or Without Aura Completed 2016-09-06 2018-04-23 ClinicalTrials.gov
NCT02904902 Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurati… Phase3 Hidradenitis Suppurativa Completed 2016-09-06 2019-05-30 ClinicalTrials.gov
NCT02904902 Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurati… Phase3 Hidradenitis Suppurativa Completed 2016-09-06 2019-05-30 ClinicalTrials.gov
NCT02904902 Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurati… Phase3 Hidradenitis Suppurativa Completed 2016-09-06 2019-05-30 ClinicalTrials.gov
NCT02848326 Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepan… Phase2 Migraine, With or Without Aura Completed 2016-09-06 2018-04-23 ClinicalTrials.gov
NCT02848326 Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepan… Phase2 Migraine, With or Without Aura Completed 2016-09-06 2018-04-23 ClinicalTrials.gov
NCT02904902 Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurati… Phase3 Hidradenitis Suppurativa Completed 2016-09-06 2019-05-30 ClinicalTrials.gov
NCT02758665 Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL Phase2 Leukemia, Lymphocytic, Chronic Completed 2016-09-01 2022-03-01 ClinicalTrials.gov
NCT02806362 Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b … Phase3 Chronic Hepatitis C Virus Withdrawn 2016-09-01 2018-08-01 ClinicalTrials.gov
NCT02806362 Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b … Phase3 Chronic Hepatitis C Virus Withdrawn 2016-09-01 2018-08-01 ClinicalTrials.gov
NCT02758665 Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL Phase2 Leukemia, Lymphocytic, Chronic Completed 2016-09-01 2022-03-01 ClinicalTrials.gov
NCT02758665 Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL Phase2 Leukemia, Lymphocytic, Chronic Completed 2016-09-01 2022-03-01 ClinicalTrials.gov
NCT02806362 Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b … Phase3 Chronic Hepatitis C Virus Withdrawn 2016-09-01 2018-08-01 ClinicalTrials.gov
NCT02806362 Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b … Phase3 Chronic Hepatitis C Virus Withdrawn 2016-09-01 2018-08-01 ClinicalTrials.gov
NCT02758665 Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL Phase2 Leukemia, Lymphocytic, Chronic Completed 2016-09-01 2022-03-01 ClinicalTrials.gov
NCT02867709 Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of… Phase3 Migraine, With or Without Aura Completed 2016-08-26 2018-02-26 ClinicalTrials.gov
NCT02867709 Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of… Phase3 Migraine, With or Without Aura Completed 2016-08-26 2018-02-26 ClinicalTrials.gov
NCT02867709 Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of… Phase3 Migraine, With or Without Aura Completed 2016-08-26 2018-02-26 ClinicalTrials.gov
NCT02867709 Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of… Phase3 Migraine, With or Without Aura Completed 2016-08-26 2018-02-26 ClinicalTrials.gov
NCT03200912 An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.01… Phase3 ACTINIC KERATOSIS Completed 2016-08-19 2017-03-22 ClinicalTrials.gov
NCT03200912 An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.01… Phase3 ACTINIC KERATOSIS Completed 2016-08-19 2017-03-22 ClinicalTrials.gov
NCT03200912 An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.01… Phase3 ACTINIC KERATOSIS Completed 2016-08-19 2017-03-22 ClinicalTrials.gov
NCT03200912 An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.01… Phase3 ACTINIC KERATOSIS Completed 2016-08-19 2017-03-22 ClinicalTrials.gov
NCT02726581 An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexameth… Phase3 Multiple Myeloma Completed 2016-08-10 2022-03-09 ClinicalTrials.gov
NCT02726581 An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexameth… Phase3 Multiple Myeloma Completed 2016-08-10 2022-03-09 ClinicalTrials.gov
NCT02726581 An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexameth… Phase3 Multiple Myeloma Completed 2016-08-10 2022-03-09 ClinicalTrials.gov
NCT02726581 An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexameth… Phase3 Multiple Myeloma Completed 2016-08-10 2022-03-09 ClinicalTrials.gov
NCT02478320 Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid … Phase2 Advanced Cancers Terminated 2016-08-05 2022-05-12 ClinicalTrials.gov
NCT02478320 Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid … Phase2 Advanced Cancers Terminated 2016-08-05 2022-05-12 ClinicalTrials.gov
NCT02814175 A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness o… Phase4 Psoriatic Arthritis Completed 2016-08-05 2020-03-19 ClinicalTrials.gov
NCT02478320 Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid … Phase2 Advanced Cancers Terminated 2016-08-05 2022-05-12 ClinicalTrials.gov
NCT02814175 A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness o… Phase4 Psoriatic Arthritis Completed 2016-08-05 2020-03-19 ClinicalTrials.gov
NCT02814175 A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness o… Phase4 Psoriatic Arthritis Completed 2016-08-05 2020-03-19 ClinicalTrials.gov
NCT02814175 A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness o… Phase4 Psoriatic Arthritis Completed 2016-08-05 2020-03-19 ClinicalTrials.gov
NCT02478320 Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid … Phase2 Advanced Cancers Terminated 2016-08-05 2022-05-12 ClinicalTrials.gov
NCT04084145 National Unified Renal Translation Research Enterprise - Chronic Kidney Disease — Chronic Kidney Diseases Active_Not_Recruiting 2016-07-27 2032-12-31 ClinicalTrials.gov
NCT04084145 National Unified Renal Translation Research Enterprise - Chronic Kidney Disease — Chronic Kidney Diseases Active_Not_Recruiting 2016-07-27 2032-12-31 ClinicalTrials.gov
NCT04084145 National Unified Renal Translation Research Enterprise - Chronic Kidney Disease — Chronic Kidney Diseases Active_Not_Recruiting 2016-07-27 2032-12-31 ClinicalTrials.gov
NCT04084145 National Unified Renal Translation Research Enterprise - Chronic Kidney Disease — Chronic Kidney Diseases Active_Not_Recruiting 2016-07-27 2032-12-31 ClinicalTrials.gov
NCT02828020 Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatm… Phase3 Migraine, With or Without Aura Completed 2016-07-22 2017-12-14 ClinicalTrials.gov
NCT02828020 Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatm… Phase3 Migraine, With or Without Aura Completed 2016-07-22 2017-12-14 ClinicalTrials.gov
NCT02828020 Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatm… Phase3 Migraine, With or Without Aura Completed 2016-07-22 2017-12-14 ClinicalTrials.gov
NCT02828020 Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatm… Phase3 Migraine, With or Without Aura Completed 2016-07-22 2017-12-14 ClinicalTrials.gov
NCT03287791 A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Fin… Phase3 Rosacea Completed 2016-07-19 2017-06-22 ClinicalTrials.gov
NCT03287791 A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Fin… Phase3 Rosacea Completed 2016-07-19 2017-06-22 ClinicalTrials.gov
NCT03287791 A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Fin… Phase3 Rosacea Completed 2016-07-19 2017-06-22 ClinicalTrials.gov
NCT03287791 A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Fin… Phase3 Rosacea Completed 2016-07-19 2017-06-22 ClinicalTrials.gov
NCT02808975 Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Pe… Phase4 Hidradenitis Suppurativa (HS) Completed 2016-07-18 2019-10-16 ClinicalTrials.gov
NCT02808975 Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Pe… Phase4 Hidradenitis Suppurativa (HS) Completed 2016-07-18 2019-10-16 ClinicalTrials.gov
NCT02808975 Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Pe… Phase4 Hidradenitis Suppurativa (HS) Completed 2016-07-18 2019-10-16 ClinicalTrials.gov
NCT02808975 Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Pe… Phase4 Hidradenitis Suppurativa (HS) Completed 2016-07-18 2019-10-16 ClinicalTrials.gov
NCT02719613 Continuing Treatment for Participants Who Have Participated in a Prior Protocol… Phase2 Multiple Myeloma Completed 2016-07-15 2026-02-23 ClinicalTrials.gov
NCT02719613 Continuing Treatment for Participants Who Have Participated in a Prior Protocol… Phase2 Multiple Myeloma Completed 2016-07-15 2026-02-23 ClinicalTrials.gov
NCT02719613 Continuing Treatment for Participants Who Have Participated in a Prior Protocol… Phase2 Multiple Myeloma Completed 2016-07-15 2026-02-23 ClinicalTrials.gov
NCT02719613 Continuing Treatment for Participants Who Have Participated in a Prior Protocol… Phase2 Multiple Myeloma Completed 2016-07-15 2026-02-23 ClinicalTrials.gov
NCT02807402 Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin i… — Chronic Hepatitis C Completed 2016-07-14 2017-08-04 ClinicalTrials.gov
NCT02807402 Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin i… — Chronic Hepatitis C Completed 2016-07-14 2017-08-04 ClinicalTrials.gov
NCT02807402 Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin i… — Chronic Hepatitis C Completed 2016-07-14 2017-08-04 ClinicalTrials.gov
NCT02807402 Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin i… — Chronic Hepatitis C Completed 2016-07-14 2017-08-04 ClinicalTrials.gov
NCT02755597 A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Re… Phase3 Relapsed/Refractory Multiple Myeloma Completed 2016-07-11 2022-08-15 ClinicalTrials.gov
NCT02755597 A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Re… Phase3 Relapsed/Refractory Multiple Myeloma Completed 2016-07-11 2022-08-15 ClinicalTrials.gov
NCT02755597 A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Re… Phase3 Relapsed/Refractory Multiple Myeloma Completed 2016-07-11 2022-08-15 ClinicalTrials.gov
NCT02755597 A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Re… Phase3 Relapsed/Refractory Multiple Myeloma Completed 2016-07-11 2022-08-15 ClinicalTrials.gov
NCT02803138 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-07-07 2018-10-21 ClinicalTrials.gov
NCT02803138 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-07-07 2018-10-21 ClinicalTrials.gov
NCT02803138 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-07-07 2018-10-21 ClinicalTrials.gov
NCT02803138 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-07-07 2018-10-21 ClinicalTrials.gov
NCT02863705 Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Gla… Phase4 Glaucoma, Open-Angle Completed 2016-07-05 2018-07-25 ClinicalTrials.gov
NCT02863705 Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Gla… Phase4 Glaucoma, Open-Angle Completed 2016-07-05 2018-07-25 ClinicalTrials.gov
NCT02863705 Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Gla… Phase4 Glaucoma, Open-Angle Completed 2016-07-05 2018-07-25 ClinicalTrials.gov
NCT02863705 Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Gla… Phase4 Glaucoma, Open-Angle Completed 2016-07-05 2018-07-25 ClinicalTrials.gov
NCT02786576 Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Pati… — Hidradenitis Suppurativa Completed 2016-07-05 2019-01-07 ClinicalTrials.gov
NCT02786576 Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Pati… — Hidradenitis Suppurativa Completed 2016-07-05 2019-01-07 ClinicalTrials.gov
NCT02786576 Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Pati… — Hidradenitis Suppurativa Completed 2016-07-05 2019-01-07 ClinicalTrials.gov
NCT02786576 Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Pati… — Hidradenitis Suppurativa Completed 2016-07-05 2019-01-07 ClinicalTrials.gov
NCT02640833 A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chr… Phase1 Chronic Lymphocytic Leukemia Withdrawn 2016-07-01 2021-02-01 ClinicalTrials.gov
NCT02848300 Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of … Phase1 Androgenetic Alopecia Completed 2016-07-01 2016-10-01 ClinicalTrials.gov
NCT02848300 Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of … Phase1 Androgenetic Alopecia Completed 2016-07-01 2016-10-01 ClinicalTrials.gov
NCT02640833 A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chr… Phase1 Chronic Lymphocytic Leukemia Withdrawn 2016-07-01 2021-02-01 ClinicalTrials.gov
NCT02640833 A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chr… Phase1 Chronic Lymphocytic Leukemia Withdrawn 2016-07-01 2021-02-01 ClinicalTrials.gov
NCT02848300 Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of … Phase1 Androgenetic Alopecia Completed 2016-07-01 2016-10-01 ClinicalTrials.gov
NCT02640833 A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chr… Phase1 Chronic Lymphocytic Leukemia Withdrawn 2016-07-01 2021-02-01 ClinicalTrials.gov
NCT02848300 Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of … Phase1 Androgenetic Alopecia Completed 2016-07-01 2016-10-01 ClinicalTrials.gov
NCT02555982 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essen… Phase3 Essential Head Tremor Completed 2016-06-27 2022-09-01 ClinicalTrials.gov
NCT02555982 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essen… Phase3 Essential Head Tremor Completed 2016-06-27 2022-09-01 ClinicalTrials.gov
NCT02555982 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essen… Phase3 Essential Head Tremor Completed 2016-06-27 2022-09-01 ClinicalTrials.gov
NCT02555982 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essen… Phase3 Essential Head Tremor Completed 2016-06-27 2022-09-01 ClinicalTrials.gov
NCT02756611 A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refracto… Phase3 Chronic Lymphocytic Leukemia Completed 2016-06-22 2022-03-11 ClinicalTrials.gov
NCT02756611 A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refracto… Phase3 Chronic Lymphocytic Leukemia Completed 2016-06-22 2022-03-11 ClinicalTrials.gov
NCT02756611 A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refracto… Phase3 Chronic Lymphocytic Leukemia Completed 2016-06-22 2022-03-11 ClinicalTrials.gov
NCT02756611 A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refracto… Phase3 Chronic Lymphocytic Leukemia Completed 2016-06-22 2022-03-11 ClinicalTrials.gov
NCT02713295 A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, … — Moderate to Severe Plaque Psoriasis Completed 2016-06-16 2019-04-19 ClinicalTrials.gov
NCT02713295 A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, … — Moderate to Severe Plaque Psoriasis Completed 2016-06-16 2019-04-19 ClinicalTrials.gov
NCT02713295 A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, … — Moderate to Severe Plaque Psoriasis Completed 2016-06-16 2019-04-19 ClinicalTrials.gov
NCT02713295 A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, … — Moderate to Severe Plaque Psoriasis Completed 2016-06-16 2019-04-19 ClinicalTrials.gov
NCT02840461 Clinical Endpoint Study of Ivermectin 1% Cream Phase3 Moderate to Severe Papulopustular Rosacea Completed 2016-06-01 2016-12-01 ClinicalTrials.gov
NCT02786537 Study of Oral Treatments for Hepatitis C Phase4 Chronic Hepatitis C Completed 2016-06-01 2020-09-02 ClinicalTrials.gov
NCT02634008 Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P Phase3 Hepatitis C, Acute Completed 2016-06-01 2021-04-30 ClinicalTrials.gov
NCT02634008 Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P Phase3 Hepatitis C, Acute Completed 2016-06-01 2021-04-30 ClinicalTrials.gov
NCT02840461 Clinical Endpoint Study of Ivermectin 1% Cream Phase3 Moderate to Severe Papulopustular Rosacea Completed 2016-06-01 2016-12-01 ClinicalTrials.gov
NCT02840461 Clinical Endpoint Study of Ivermectin 1% Cream Phase3 Moderate to Severe Papulopustular Rosacea Completed 2016-06-01 2016-12-01 ClinicalTrials.gov
NCT02786537 Study of Oral Treatments for Hepatitis C Phase4 Chronic Hepatitis C Completed 2016-06-01 2020-09-02 ClinicalTrials.gov
NCT02786537 Study of Oral Treatments for Hepatitis C Phase4 Chronic Hepatitis C Completed 2016-06-01 2020-09-02 ClinicalTrials.gov
NCT02786537 Study of Oral Treatments for Hepatitis C Phase4 Chronic Hepatitis C Completed 2016-06-01 2020-09-02 ClinicalTrials.gov
NCT02634008 Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P Phase3 Hepatitis C, Acute Completed 2016-06-01 2021-04-30 ClinicalTrials.gov
NCT02634008 Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P Phase3 Hepatitis C, Acute Completed 2016-06-01 2021-04-30 ClinicalTrials.gov
NCT02840461 Clinical Endpoint Study of Ivermectin 1% Cream Phase3 Moderate to Severe Papulopustular Rosacea Completed 2016-06-01 2016-12-01 ClinicalTrials.gov
NCT02780115 A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Pa… Phase2 Presbyopia Completed 2016-05-26 2017-10-31 ClinicalTrials.gov
NCT02780115 A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Pa… Phase2 Presbyopia Completed 2016-05-26 2017-10-31 ClinicalTrials.gov
NCT02780115 A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Pa… Phase2 Presbyopia Completed 2016-05-26 2017-10-31 ClinicalTrials.gov
NCT02780115 A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Pa… Phase2 Presbyopia Completed 2016-05-26 2017-10-31 ClinicalTrials.gov
NCT02798315 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patie… — Chronic Hepatitis C Completed 2016-05-25 2017-06-12 ClinicalTrials.gov
NCT02798315 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patie… — Chronic Hepatitis C Completed 2016-05-25 2017-06-12 ClinicalTrials.gov
NCT02798315 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patie… — Chronic Hepatitis C Completed 2016-05-25 2017-06-12 ClinicalTrials.gov
NCT02798315 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patie… — Chronic Hepatitis C Completed 2016-05-25 2017-06-12 ClinicalTrials.gov
NCT02782663 A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeate… Phase2 Crohn's Disease (CD) Completed 2016-05-18 2025-07-18 ClinicalTrials.gov
NCT02782663 A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeate… Phase2 Crohn's Disease (CD) Completed 2016-05-18 2025-07-18 ClinicalTrials.gov
NCT02782663 A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeate… Phase2 Crohn's Disease (CD) Completed 2016-05-18 2025-07-18 ClinicalTrials.gov
NCT03294538 Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Crea… Phase3 Atrophic Vaginitis Completed 2016-05-18 2017-02-15 ClinicalTrials.gov
NCT03294538 Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Crea… Phase3 Atrophic Vaginitis Completed 2016-05-18 2017-02-15 ClinicalTrials.gov
NCT02782663 A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeate… Phase2 Crohn's Disease (CD) Completed 2016-05-18 2025-07-18 ClinicalTrials.gov
NCT03294538 Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Crea… Phase3 Atrophic Vaginitis Completed 2016-05-18 2017-02-15 ClinicalTrials.gov
NCT03294538 Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Crea… Phase3 Atrophic Vaginitis Completed 2016-05-18 2017-02-15 ClinicalTrials.gov
NCT02738138 A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-… Phase3 Hepatitis C Virus Infection Completed 2016-05-17 2017-06-07 ClinicalTrials.gov
NCT02738138 A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-… Phase3 Hepatitis C Virus Infection Completed 2016-05-17 2017-06-07 ClinicalTrials.gov
NCT02738138 A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-… Phase3 Hepatitis C Virus Infection Completed 2016-05-17 2017-06-07 ClinicalTrials.gov
NCT02738138 A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-… Phase3 Hepatitis C Virus Infection Completed 2016-05-17 2017-06-07 ClinicalTrials.gov
NCT02677324 Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström … Phase2 Waldenstrom Macroglobulinemia Completed 2016-05-09 2022-02-07 ClinicalTrials.gov
NCT02677324 Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström … Phase2 Waldenstrom Macroglobulinemia Completed 2016-05-09 2022-02-07 ClinicalTrials.gov
NCT02677324 Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström … Phase2 Waldenstrom Macroglobulinemia Completed 2016-05-09 2022-02-07 ClinicalTrials.gov
NCT02677324 Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström … Phase2 Waldenstrom Macroglobulinemia Completed 2016-05-09 2022-02-07 ClinicalTrials.gov
NCT02750384 Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects Phase1 Healthy Volunteers Terminated 2016-05-01 2016-07-01 ClinicalTrials.gov
NCT02750384 Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects Phase1 Healthy Volunteers Terminated 2016-05-01 2016-07-01 ClinicalTrials.gov
NCT02750384 Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects Phase1 Healthy Volunteers Terminated 2016-05-01 2016-07-01 ClinicalTrials.gov
NCT02668640 Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China — Rheumatoid Arthritis Completed 2016-05-01 2018-08-13 ClinicalTrials.gov
NCT02668640 Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China — Rheumatoid Arthritis Completed 2016-05-01 2018-08-13 ClinicalTrials.gov
NCT02668640 Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China — Rheumatoid Arthritis Completed 2016-05-01 2018-08-13 ClinicalTrials.gov
NCT02668640 Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China — Rheumatoid Arthritis Completed 2016-05-01 2018-08-13 ClinicalTrials.gov
NCT02750384 Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects Phase1 Healthy Volunteers Terminated 2016-05-01 2016-07-01 ClinicalTrials.gov
NCT02738125 Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real L… — Ulcerative Colitis (UC) Completed 2016-04-29 2023-12-15 ClinicalTrials.gov
NCT02738125 Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real L… — Ulcerative Colitis (UC) Completed 2016-04-29 2023-12-15 ClinicalTrials.gov
NCT02738125 Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real L… — Ulcerative Colitis (UC) Completed 2016-04-29 2023-12-15 ClinicalTrials.gov
NCT02595528 A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With… Phase2 Presbyopia Completed 2016-04-29 2017-10-18 ClinicalTrials.gov
NCT02595528 A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With… Phase2 Presbyopia Completed 2016-04-29 2017-10-18 ClinicalTrials.gov
NCT02595528 A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With… Phase2 Presbyopia Completed 2016-04-29 2017-10-18 ClinicalTrials.gov
NCT02738125 Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real L… — Ulcerative Colitis (UC) Completed 2016-04-29 2023-12-15 ClinicalTrials.gov
NCT02595528 A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With… Phase2 Presbyopia Completed 2016-04-29 2017-10-18 ClinicalTrials.gov
NCT02692703 A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Li… Phase3 Chronic Hepatitis C Completed 2016-04-22 2017-06-29 ClinicalTrials.gov
NCT02692703 A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Li… Phase3 Chronic Hepatitis C Completed 2016-04-22 2017-06-29 ClinicalTrials.gov
NCT02692703 A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Li… Phase3 Chronic Hepatitis C Completed 2016-04-22 2017-06-29 ClinicalTrials.gov
NCT02692703 A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Li… Phase3 Chronic Hepatitis C Completed 2016-04-22 2017-06-29 ClinicalTrials.gov
NCT02669940 Observational, Multi-Center Study of the Real World Evidence of the Effectivene… — Chronic Hepatitis C Completed 2016-04-15 2017-07-04 ClinicalTrials.gov
NCT02669940 Observational, Multi-Center Study of the Real World Evidence of the Effectivene… — Chronic Hepatitis C Completed 2016-04-15 2017-07-04 ClinicalTrials.gov
NCT02669940 Observational, Multi-Center Study of the Real World Evidence of the Effectivene… — Chronic Hepatitis C Completed 2016-04-15 2017-07-04 ClinicalTrials.gov
NCT02669940 Observational, Multi-Center Study of the Real World Evidence of the Effectivene… — Chronic Hepatitis C Completed 2016-04-15 2017-07-04 ClinicalTrials.gov
NCT02723084 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adul… Phase3 Chronic Hepatitis C Virus Completed 2016-04-08 2017-03-24 ClinicalTrials.gov
NCT02723084 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adul… Phase3 Chronic Hepatitis C Virus Completed 2016-04-08 2017-03-24 ClinicalTrials.gov
NCT02723084 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adul… Phase3 Chronic Hepatitis C Virus Completed 2016-04-08 2017-03-24 ClinicalTrials.gov
NCT02723084 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adul… Phase3 Chronic Hepatitis C Virus Completed 2016-04-08 2017-03-24 ClinicalTrials.gov
NCT02750800 Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie… — Rheumatoid Arthritis Completed 2016-04-07 2018-04-03 ClinicalTrials.gov
NCT02750800 Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie… — Rheumatoid Arthritis Completed 2016-04-07 2018-04-03 ClinicalTrials.gov
NCT02750800 Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie… — Rheumatoid Arthritis Completed 2016-04-07 2018-04-03 ClinicalTrials.gov
NCT02739828 Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish … — Hidradenitis Suppurativa Completed 2016-04-07 2018-03-28 ClinicalTrials.gov
NCT02739828 Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish … — Hidradenitis Suppurativa Completed 2016-04-07 2018-03-28 ClinicalTrials.gov
NCT02750800 Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie… — Rheumatoid Arthritis Completed 2016-04-07 2018-04-03 ClinicalTrials.gov
NCT02739828 Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish … — Hidradenitis Suppurativa Completed 2016-04-07 2018-03-28 ClinicalTrials.gov
NCT02739828 Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish … — Hidradenitis Suppurativa Completed 2016-04-07 2018-03-28 ClinicalTrials.gov
NCT02725866 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-04-05 2017-10-31 ClinicalTrials.gov
NCT02725866 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-04-05 2017-10-31 ClinicalTrials.gov
NCT02725866 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-04-05 2017-10-31 ClinicalTrials.gov
NCT02725866 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-04-05 2017-10-31 ClinicalTrials.gov
NCT02719171 BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Pso… Phase2 Arthritis, Psoriatic Completed 2016-04-01 2017-08-01 ClinicalTrials.gov
NCT02719171 BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Pso… Phase2 Arthritis, Psoriatic Completed 2016-04-01 2017-08-01 ClinicalTrials.gov
NCT02688790 Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients W… Phase1 Bacterial Infections Terminated 2016-04-01 2019-04-03 ClinicalTrials.gov
NCT02719171 BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Pso… Phase2 Arthritis, Psoriatic Completed 2016-04-01 2017-08-01 ClinicalTrials.gov
NCT02719171 BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Pso… Phase2 Arthritis, Psoriatic Completed 2016-04-01 2017-08-01 ClinicalTrials.gov
NCT02688790 Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients W… Phase1 Bacterial Infections Terminated 2016-04-01 2019-04-03 ClinicalTrials.gov
NCT03241563 Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for R… Phase4 Fat Reduction Completed 2016-04-01 2017-02-01 ClinicalTrials.gov
NCT03241563 Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for R… Phase4 Fat Reduction Completed 2016-04-01 2017-02-01 ClinicalTrials.gov
NCT02688790 Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients W… Phase1 Bacterial Infections Terminated 2016-04-01 2019-04-03 ClinicalTrials.gov
NCT03241563 Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for R… Phase4 Fat Reduction Completed 2016-04-01 2017-02-01 ClinicalTrials.gov
NCT02688790 Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients W… Phase1 Bacterial Infections Terminated 2016-04-01 2019-04-03 ClinicalTrials.gov
NCT03241563 Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for R… Phase4 Fat Reduction Completed 2016-04-01 2017-02-01 ClinicalTrials.gov
NCT02706951 A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Mono… Phase3 Rheumatoid Arthritis Completed 2016-03-23 2022-08-10 ClinicalTrials.gov
NCT02706951 A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Mono… Phase3 Rheumatoid Arthritis Completed 2016-03-23 2022-08-10 ClinicalTrials.gov
NCT02706951 A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Mono… Phase3 Rheumatoid Arthritis Completed 2016-03-23 2022-08-10 ClinicalTrials.gov
NCT02706951 A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Mono… Phase3 Rheumatoid Arthritis Completed 2016-03-23 2022-08-10 ClinicalTrials.gov
NCT02720523 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid … Phase2 Rheumatoid Arthritis Completed 2016-03-22 2022-06-07 ClinicalTrials.gov
NCT02720523 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid … Phase2 Rheumatoid Arthritis Completed 2016-03-22 2022-06-07 ClinicalTrials.gov
NCT02720523 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid … Phase2 Rheumatoid Arthritis Completed 2016-03-22 2022-06-07 ClinicalTrials.gov
NCT02720523 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid … Phase2 Rheumatoid Arthritis Completed 2016-03-22 2022-06-07 ClinicalTrials.gov
NCT02654132 An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethas… Phase2 Multiple Myeloma Completed 2016-03-18 2021-10-21 ClinicalTrials.gov
NCT02654132 An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethas… Phase2 Multiple Myeloma Completed 2016-03-18 2021-10-21 ClinicalTrials.gov
NCT02654132 An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethas… Phase2 Multiple Myeloma Completed 2016-03-18 2021-10-21 ClinicalTrials.gov
NCT02654132 An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethas… Phase2 Multiple Myeloma Completed 2016-03-18 2021-10-21 ClinicalTrials.gov
NCT02706847 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid … Phase3 Rheumatoid Arthritis Completed 2016-03-15 2022-02-08 ClinicalTrials.gov
NCT02706847 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid … Phase3 Rheumatoid Arthritis Completed 2016-03-15 2022-02-08 ClinicalTrials.gov
NCT02706847 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid … Phase3 Rheumatoid Arthritis Completed 2016-03-15 2022-02-08 ClinicalTrials.gov
NCT02706847 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid … Phase3 Rheumatoid Arthritis Completed 2016-03-15 2022-02-08 ClinicalTrials.gov
NCT03052231 Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibro… Na Medication Adherence Completed 2016-03-01 2017-02-01 ClinicalTrials.gov
NCT02676310 Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgene… Phase1 Alopecia Terminated 2016-03-01 2017-03-01 ClinicalTrials.gov
NCT02684357 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Mod… Phase3 Psoriasis Completed 2016-03-01 2017-09-01 ClinicalTrials.gov
NCT02684357 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Mod… Phase3 Psoriasis Completed 2016-03-01 2017-09-01 ClinicalTrials.gov
NCT03052231 Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibro… Na Medication Adherence Completed 2016-03-01 2017-02-01 ClinicalTrials.gov
NCT02684357 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Mod… Phase3 Psoriasis Completed 2016-03-01 2017-09-01 ClinicalTrials.gov
NCT02694523 BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in… Phase3 Psoriasis Completed 2016-03-01 2017-08-01 ClinicalTrials.gov
NCT02676310 Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgene… Phase1 Alopecia Terminated 2016-03-01 2017-03-01 ClinicalTrials.gov
NCT02676310 Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgene… Phase1 Alopecia Terminated 2016-03-01 2017-03-01 ClinicalTrials.gov
NCT02694523 BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in… Phase3 Psoriasis Completed 2016-03-01 2017-08-01 ClinicalTrials.gov
NCT02694523 BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in… Phase3 Psoriasis Completed 2016-03-01 2017-08-01 ClinicalTrials.gov
NCT03710252 A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Stu… Phase4 Chronic Hepatitis C Completed 2016-03-01 2017-09-01 ClinicalTrials.gov
NCT02676310 Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgene… Phase1 Alopecia Terminated 2016-03-01 2017-03-01 ClinicalTrials.gov
NCT02684357 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Mod… Phase3 Psoriasis Completed 2016-03-01 2017-09-01 ClinicalTrials.gov
NCT03052231 Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibro… Na Medication Adherence Completed 2016-03-01 2017-02-01 ClinicalTrials.gov
NCT03710252 A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Stu… Phase4 Chronic Hepatitis C Completed 2016-03-01 2017-09-01 ClinicalTrials.gov
NCT03052231 Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibro… Na Medication Adherence Completed 2016-03-01 2017-02-01 ClinicalTrials.gov
NCT03710252 A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Stu… Phase4 Chronic Hepatitis C Completed 2016-03-01 2017-09-01 ClinicalTrials.gov
NCT03710252 A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Stu… Phase4 Chronic Hepatitis C Completed 2016-03-01 2017-09-01 ClinicalTrials.gov
NCT02694523 BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in… Phase3 Psoriasis Completed 2016-03-01 2017-08-01 ClinicalTrials.gov
NCT02672852 BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With… Phase3 Psoriasis Completed 2016-02-29 2018-07-26 ClinicalTrials.gov
NCT02672852 BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With… Phase3 Psoriasis Completed 2016-02-29 2018-07-26 ClinicalTrials.gov
NCT02672852 BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With… Phase3 Psoriasis Completed 2016-02-29 2018-07-26 ClinicalTrials.gov
NCT02672852 BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With… Phase3 Psoriasis Completed 2016-02-29 2018-07-26 ClinicalTrials.gov
NCT02636946 A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients W… Phase3 Glaucoma Completed 2016-02-24 2021-01-26 ClinicalTrials.gov
NCT02636946 A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients W… Phase3 Glaucoma Completed 2016-02-24 2021-01-26 ClinicalTrials.gov
NCT02636946 A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients W… Phase3 Glaucoma Completed 2016-02-24 2021-01-26 ClinicalTrials.gov
NCT02636946 A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients W… Phase3 Glaucoma Completed 2016-02-24 2021-01-26 ClinicalTrials.gov
NCT02706873 A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Mon… Phase3 Rheumatoid Arthritis Completed 2016-02-23 2022-11-10 ClinicalTrials.gov
NCT02706873 A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Mon… Phase3 Rheumatoid Arthritis Completed 2016-02-23 2022-11-10 ClinicalTrials.gov
NCT02706873 A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Mon… Phase3 Rheumatoid Arthritis Completed 2016-02-23 2022-11-10 ClinicalTrials.gov
NCT02706873 A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Mon… Phase3 Rheumatoid Arthritis Completed 2016-02-23 2022-11-10 ClinicalTrials.gov
NCT02707952 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adul… Phase3 Chronic Hepatitis C Virus Completed 2016-02-22 2017-02-09 ClinicalTrials.gov
NCT02707952 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adul… Phase3 Chronic Hepatitis C Virus Completed 2016-02-22 2017-02-09 ClinicalTrials.gov
NCT02707952 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adul… Phase3 Chronic Hepatitis C Virus Completed 2016-02-22 2017-02-09 ClinicalTrials.gov
NCT02707952 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adul… Phase3 Chronic Hepatitis C Virus Completed 2016-02-22 2017-02-09 ClinicalTrials.gov
NCT02687828 A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effect… — Intestinal Behcet's Disease (BD) Completed 2016-02-18 2020-03-30 ClinicalTrials.gov
NCT02687828 A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effect… — Intestinal Behcet's Disease (BD) Completed 2016-02-18 2020-03-30 ClinicalTrials.gov
NCT02687828 A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effect… — Intestinal Behcet's Disease (BD) Completed 2016-02-18 2020-03-30 ClinicalTrials.gov
NCT02687828 A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effect… — Intestinal Behcet's Disease (BD) Completed 2016-02-18 2020-03-30 ClinicalTrials.gov
NCT02691494 Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Ace… Phase3 Uterine Fibroids Completed 2016-02-03 2019-01-23 ClinicalTrials.gov
NCT02691494 Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Ace… Phase3 Uterine Fibroids Completed 2016-02-03 2019-01-23 ClinicalTrials.gov
NCT02691494 Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Ace… Phase3 Uterine Fibroids Completed 2016-02-03 2019-01-23 ClinicalTrials.gov
NCT02691494 Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Ace… Phase3 Uterine Fibroids Completed 2016-02-03 2019-01-23 ClinicalTrials.gov
NCT02322723 Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HU… — Rheumatoid Arthritis Withdrawn 2016-02-01 2020-02-01 ClinicalTrials.gov
NCT02639052 Itch Relieving Effect of Botox: a Study in Healthy Subjects Phase1 Pruritus Completed 2016-02-01 2017-01-01 ClinicalTrials.gov
NCT02684370 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab… Phase3 Psoriasis Completed 2016-02-01 2017-09-01 ClinicalTrials.gov
NCT02673047 Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontin… — Urinary Bladder, Overactive Completed 2016-02-01 2016-08-01 ClinicalTrials.gov
NCT02322723 Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HU… — Rheumatoid Arthritis Withdrawn 2016-02-01 2020-02-01 ClinicalTrials.gov
NCT02684370 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab… Phase3 Psoriasis Completed 2016-02-01 2017-09-01 ClinicalTrials.gov
NCT02673047 Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontin… — Urinary Bladder, Overactive Completed 2016-02-01 2016-08-01 ClinicalTrials.gov
NCT02322723 Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HU… — Rheumatoid Arthritis Withdrawn 2016-02-01 2020-02-01 ClinicalTrials.gov
NCT02684370 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab… Phase3 Psoriasis Completed 2016-02-01 2017-09-01 ClinicalTrials.gov
NCT02639052 Itch Relieving Effect of Botox: a Study in Healthy Subjects Phase1 Pruritus Completed 2016-02-01 2017-01-01 ClinicalTrials.gov
NCT02322723 Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HU… — Rheumatoid Arthritis Withdrawn 2016-02-01 2020-02-01 ClinicalTrials.gov
NCT02639052 Itch Relieving Effect of Botox: a Study in Healthy Subjects Phase1 Pruritus Completed 2016-02-01 2017-01-01 ClinicalTrials.gov
NCT02673047 Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontin… — Urinary Bladder, Overactive Completed 2016-02-01 2016-08-01 ClinicalTrials.gov
NCT02684370 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab… Phase3 Psoriasis Completed 2016-02-01 2017-09-01 ClinicalTrials.gov
NCT02673047 Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontin… — Urinary Bladder, Overactive Completed 2016-02-01 2016-08-01 ClinicalTrials.gov
NCT02639052 Itch Relieving Effect of Botox: a Study in Healthy Subjects Phase1 Pruritus Completed 2016-02-01 2017-01-01 ClinicalTrials.gov
NCT02674568 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment… Phase2 Small Cell Lung Cancer Completed 2016-01-25 2018-10-19 ClinicalTrials.gov
NCT02674568 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment… Phase2 Small Cell Lung Cancer Completed 2016-01-25 2018-10-19 ClinicalTrials.gov
NCT02558283 A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® … Na Nasolabial Fold Completed 2016-01-25 2017-06-19 ClinicalTrials.gov
NCT02558283 A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® … Na Nasolabial Fold Completed 2016-01-25 2017-06-19 ClinicalTrials.gov
NCT02558283 A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® … Na Nasolabial Fold Completed 2016-01-25 2017-06-19 ClinicalTrials.gov
NCT02674568 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment… Phase2 Small Cell Lung Cancer Completed 2016-01-25 2018-10-19 ClinicalTrials.gov
NCT02674568 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment… Phase2 Small Cell Lung Cancer Completed 2016-01-25 2018-10-19 ClinicalTrials.gov
NCT02558283 A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® … Na Nasolabial Fold Completed 2016-01-25 2017-06-19 ClinicalTrials.gov
NCT02817594 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-01-20 2018-03-07 ClinicalTrials.gov
NCT02817594 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-01-20 2018-03-07 ClinicalTrials.gov
NCT02817594 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-01-20 2018-03-07 ClinicalTrials.gov
NCT02817594 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2016-01-20 2018-03-07 ClinicalTrials.gov
NCT02581020 The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-a… — Hepatitis C Virus Completed 2016-01-14 2020-12-08 ClinicalTrials.gov
NCT02581020 The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-a… — Hepatitis C Virus Completed 2016-01-14 2020-12-08 ClinicalTrials.gov
NCT02581020 The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-a… — Hepatitis C Virus Completed 2016-01-14 2020-12-08 ClinicalTrials.gov
NCT02581020 The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-a… — Hepatitis C Virus Completed 2016-01-14 2020-12-08 ClinicalTrials.gov
NCT02121262 A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in P… Phase3 Macular Edema Completed 2016-01-08 2019-11-01 ClinicalTrials.gov
NCT02121262 A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in P… Phase3 Macular Edema Completed 2016-01-08 2019-11-01 ClinicalTrials.gov
NCT02121262 A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in P… Phase3 Macular Edema Completed 2016-01-08 2019-11-01 ClinicalTrials.gov
NCT02121262 A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in P… Phase3 Macular Edema Completed 2016-01-08 2019-11-01 ClinicalTrials.gov
NCT02498418 Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea Phase3 Diarrhea Completed 2016-01-06 2017-02-28 ClinicalTrials.gov
NCT02498418 Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea Phase3 Diarrhea Completed 2016-01-06 2017-02-28 ClinicalTrials.gov
NCT02498418 Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea Phase3 Diarrhea Completed 2016-01-06 2017-02-28 ClinicalTrials.gov
NCT02498418 Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea Phase3 Diarrhea Completed 2016-01-06 2017-02-28 ClinicalTrials.gov
NCT02629172 Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1 — Chronic Hepatitis C Virus Completed 2016-01-05 2019-02-28 ClinicalTrials.gov
NCT02629172 Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1 — Chronic Hepatitis C Virus Completed 2016-01-05 2019-02-28 ClinicalTrials.gov
NCT02629172 Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1 — Chronic Hepatitis C Virus Completed 2016-01-05 2019-02-28 ClinicalTrials.gov
NCT02629172 Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1 — Chronic Hepatitis C Virus Completed 2016-01-05 2019-02-28 ClinicalTrials.gov
NCT02611713 Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Pati… — Advanced Parkinson's Disease Completed 2016-01-04 2020-12-24 ClinicalTrials.gov
NCT02611713 Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Pati… — Advanced Parkinson's Disease Completed 2016-01-04 2020-12-24 ClinicalTrials.gov
NCT02611713 Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Pati… — Advanced Parkinson's Disease Completed 2016-01-04 2020-12-24 ClinicalTrials.gov
NCT02611713 Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Pati… — Advanced Parkinson's Disease Completed 2016-01-04 2020-12-24 ClinicalTrials.gov
NCT02634541 Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis Phase4 Ankylosing Spondyloarthritis Unknown 2016-01-01 2017-12-01 ClinicalTrials.gov
NCT02634541 Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis Phase4 Ankylosing Spondyloarthritis Unknown 2016-01-01 2017-12-01 ClinicalTrials.gov
NCT02634541 Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis Phase4 Ankylosing Spondyloarthritis Unknown 2016-01-01 2017-12-01 ClinicalTrials.gov
NCT02634541 Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis Phase4 Ankylosing Spondyloarthritis Unknown 2016-01-01 2017-12-01 ClinicalTrials.gov
NCT02654054 Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Ace… Phase3 Uterine Fibroids Completed 2015-12-22 2018-12-12 ClinicalTrials.gov
NCT02654054 Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Ace… Phase3 Uterine Fibroids Completed 2015-12-22 2018-12-12 ClinicalTrials.gov
NCT02654054 Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Ace… Phase3 Uterine Fibroids Completed 2015-12-22 2018-12-12 ClinicalTrials.gov
NCT02654054 Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Ace… Phase3 Uterine Fibroids Completed 2015-12-22 2018-12-12 ClinicalTrials.gov
NCT02581202 The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatme… — HIV-1 Infection Completed 2015-12-21 2017-05-27 ClinicalTrials.gov
NCT02581202 The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatme… — HIV-1 Infection Completed 2015-12-21 2017-05-27 ClinicalTrials.gov
NCT02581202 The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatme… — HIV-1 Infection Completed 2015-12-21 2017-05-27 ClinicalTrials.gov
NCT02581202 The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatme… — HIV-1 Infection Completed 2015-12-21 2017-05-27 ClinicalTrials.gov
NCT02675426 A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid A… Phase3 Rheumatoid Arthritis Completed 2015-12-17 2022-03-10 ClinicalTrials.gov
NCT02675426 A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid A… Phase3 Rheumatoid Arthritis Completed 2015-12-17 2022-03-10 ClinicalTrials.gov
NCT02675426 A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid A… Phase3 Rheumatoid Arthritis Completed 2015-12-17 2022-03-10 ClinicalTrials.gov
NCT02675426 A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid A… Phase3 Rheumatoid Arthritis Completed 2015-12-17 2022-03-10 ClinicalTrials.gov
NCT02618928 The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavi… — Chronic Hepatitis C Completed 2015-12-15 2018-03-29 ClinicalTrials.gov
NCT02618928 The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavi… — Chronic Hepatitis C Completed 2015-12-15 2018-03-29 ClinicalTrials.gov
NCT02618928 The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavi… — Chronic Hepatitis C Completed 2015-12-15 2018-03-29 ClinicalTrials.gov
NCT02618928 The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavi… — Chronic Hepatitis C Completed 2015-12-15 2018-03-29 ClinicalTrials.gov
NCT02556736 AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa Phase1 Advanced Retinitis Pigmentosa Completed 2015-12-14 2024-10-21 ClinicalTrials.gov
NCT02556736 AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa Phase1 Advanced Retinitis Pigmentosa Completed 2015-12-14 2024-10-21 ClinicalTrials.gov
NCT02556736 AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa Phase1 Advanced Retinitis Pigmentosa Completed 2015-12-14 2024-10-21 ClinicalTrials.gov
NCT02556736 AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa Phase1 Advanced Retinitis Pigmentosa Completed 2015-12-14 2024-10-21 ClinicalTrials.gov
NCT02642432 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With C… Phase3 Hepatitis C Virus Infection Completed 2015-12-07 2017-02-10 ClinicalTrials.gov
NCT02642432 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With C… Phase3 Hepatitis C Virus Infection Completed 2015-12-07 2017-02-10 ClinicalTrials.gov
NCT02642432 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With C… Phase3 Hepatitis C Virus Infection Completed 2015-12-07 2017-02-10 ClinicalTrials.gov
NCT02642432 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With C… Phase3 Hepatitis C Virus Infection Completed 2015-12-07 2017-02-10 ClinicalTrials.gov
NCT02615145 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2015-12-03 2018-03-26 ClinicalTrials.gov
NCT02615145 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2015-12-03 2018-03-26 ClinicalTrials.gov
NCT02615145 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2015-12-03 2018-03-26 ClinicalTrials.gov
NCT02615145 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2015-12-03 2018-03-26 ClinicalTrials.gov
NCT02573740 Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown … Phase1 Alzheimer's Disease Terminated 2015-12-01 2016-06-01 ClinicalTrials.gov
NCT02417077 Perception of Facial Expression in Subjects With and Without Crow's Feet Lines — Healthy Volunteers Completed 2015-12-01 2015-12-01 ClinicalTrials.gov
NCT02417077 Perception of Facial Expression in Subjects With and Without Crow's Feet Lines — Healthy Volunteers Completed 2015-12-01 2015-12-01 ClinicalTrials.gov
NCT02417077 Perception of Facial Expression in Subjects With and Without Crow's Feet Lines — Healthy Volunteers Completed 2015-12-01 2015-12-01 ClinicalTrials.gov
NCT02651194 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impai… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2015-12-01 2017-01-01 ClinicalTrials.gov
NCT02640157 A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed Wi… Phase3 Chronic Hepatitis C Completed 2015-12-01 2017-02-01 ClinicalTrials.gov
NCT02629159 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults… Phase3 Rheumatoid Arthritis Active_Not_Recruiting 2015-12-01 2027-09-30 ClinicalTrials.gov
NCT02417077 Perception of Facial Expression in Subjects With and Without Crow's Feet Lines — Healthy Volunteers Completed 2015-12-01 2015-12-01 ClinicalTrials.gov
NCT02651194 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impai… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2015-12-01 2017-01-01 ClinicalTrials.gov
NCT02640157 A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed Wi… Phase3 Chronic Hepatitis C Completed 2015-12-01 2017-02-01 ClinicalTrials.gov
NCT02629159 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults… Phase3 Rheumatoid Arthritis Active_Not_Recruiting 2015-12-01 2027-09-30 ClinicalTrials.gov
NCT02573740 Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown … Phase1 Alzheimer's Disease Terminated 2015-12-01 2016-06-01 ClinicalTrials.gov
NCT02629159 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults… Phase3 Rheumatoid Arthritis Active_Not_Recruiting 2015-12-01 2027-09-30 ClinicalTrials.gov
NCT02640157 A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed Wi… Phase3 Chronic Hepatitis C Completed 2015-12-01 2017-02-01 ClinicalTrials.gov
NCT02651194 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impai… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2015-12-01 2017-01-01 ClinicalTrials.gov
NCT02573740 Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown … Phase1 Alzheimer's Disease Terminated 2015-12-01 2016-06-01 ClinicalTrials.gov
NCT02573740 Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown … Phase1 Alzheimer's Disease Terminated 2015-12-01 2016-06-01 ClinicalTrials.gov
NCT02629159 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults… Phase3 Rheumatoid Arthritis Active_Not_Recruiting 2015-12-01 2027-09-30 ClinicalTrials.gov
NCT02640157 A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed Wi… Phase3 Chronic Hepatitis C Completed 2015-12-01 2017-02-01 ClinicalTrials.gov
NCT02651194 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impai… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2015-12-01 2017-01-01 ClinicalTrials.gov
NCT02636608 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2015-11-27 2018-05-23 ClinicalTrials.gov
NCT02636608 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2015-11-27 2018-05-23 ClinicalTrials.gov
NCT02636608 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2015-11-27 2018-05-23 ClinicalTrials.gov
NCT02636608 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasa… — Chronic Hepatitis C Completed 2015-11-27 2018-05-23 ClinicalTrials.gov
NCT02632175 Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ul… Phase3 Ulcerative Colitis Completed 2015-11-26 2025-04-08 ClinicalTrials.gov
NCT02632175 Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ul… Phase3 Ulcerative Colitis Completed 2015-11-26 2025-04-08 ClinicalTrials.gov
NCT02640547 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir,… — Chronic Hepatitis C Completed 2015-11-26 2017-03-29 ClinicalTrials.gov
NCT02632175 Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ul… Phase3 Ulcerative Colitis Completed 2015-11-26 2025-04-08 ClinicalTrials.gov
NCT02640547 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir,… — Chronic Hepatitis C Completed 2015-11-26 2017-03-29 ClinicalTrials.gov
NCT02640547 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir,… — Chronic Hepatitis C Completed 2015-11-26 2017-03-29 ClinicalTrials.gov
NCT02640547 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir,… — Chronic Hepatitis C Completed 2015-11-26 2017-03-29 ClinicalTrials.gov
NCT02632175 Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ul… Phase3 Ulcerative Colitis Completed 2015-11-26 2025-04-08 ClinicalTrials.gov
NCT02582632 A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatmen… Phase3 Hepatitis C Infection Completed 2015-11-24 2016-12-01 ClinicalTrials.gov
NCT02582632 A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatmen… Phase3 Hepatitis C Infection Completed 2015-11-24 2016-12-01 ClinicalTrials.gov
NCT02582632 A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatmen… Phase3 Hepatitis C Infection Completed 2015-11-24 2016-12-01 ClinicalTrials.gov
NCT02582632 A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatmen… Phase3 Hepatitis C Infection Completed 2015-11-24 2016-12-01 ClinicalTrials.gov
NCT02627924 Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab — Rheumatoid Arthritis Completed 2015-11-18 2017-12-28 ClinicalTrials.gov
NCT02627924 Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab — Rheumatoid Arthritis Completed 2015-11-18 2017-12-28 ClinicalTrials.gov
NCT02627924 Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab — Rheumatoid Arthritis Completed 2015-11-18 2017-12-28 ClinicalTrials.gov
NCT02627924 Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab — Rheumatoid Arthritis Completed 2015-11-18 2017-12-28 ClinicalTrials.gov
NCT02571712 Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glau… Phase4 Glaucoma, Open-Angle Completed 2015-11-10 2018-06-21 ClinicalTrials.gov
NCT02571712 Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glau… Phase4 Glaucoma, Open-Angle Completed 2015-11-10 2018-06-21 ClinicalTrials.gov
NCT02571712 Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glau… Phase4 Glaucoma, Open-Angle Completed 2015-11-10 2018-06-21 ClinicalTrials.gov
NCT02571712 Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glau… Phase4 Glaucoma, Open-Angle Completed 2015-11-10 2018-06-21 ClinicalTrials.gov
NCT02582671 The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patien… — Chronic Hepatitis C Completed 2015-11-05 2017-11-29 ClinicalTrials.gov
NCT02616380 Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan — Rheumatoid Arthritis Completed 2015-11-05 2017-11-23 ClinicalTrials.gov
NCT02616380 Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan — Rheumatoid Arthritis Completed 2015-11-05 2017-11-23 ClinicalTrials.gov
NCT02582671 The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patien… — Chronic Hepatitis C Completed 2015-11-05 2017-11-29 ClinicalTrials.gov
NCT02616380 Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan — Rheumatoid Arthritis Completed 2015-11-05 2017-11-23 ClinicalTrials.gov
NCT02582671 The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patien… — Chronic Hepatitis C Completed 2015-11-05 2017-11-29 ClinicalTrials.gov
NCT02616380 Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan — Rheumatoid Arthritis Completed 2015-11-05 2017-11-23 ClinicalTrials.gov
NCT02582671 The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patien… — Chronic Hepatitis C Completed 2015-11-05 2017-11-29 ClinicalTrials.gov
NCT02598570 Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lym… Phase1 Lymphoma Completed 2015-11-01 2017-02-01 ClinicalTrials.gov
NCT02636595 The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C V… Phase3 Hepatitis C Virus Completed 2015-11-01 2017-01-01 ClinicalTrials.gov
NCT02601287 A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary… Phase4 Urinary Incontinence Completed 2015-11-01 2016-07-01 ClinicalTrials.gov
NCT02651220 Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus E… Phase3 Acne Completed 2015-11-01 2016-10-01 ClinicalTrials.gov
NCT02684084 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Respond… Phase4 Diabetic Macular Edema Terminated 2015-11-01 2016-12-01 ClinicalTrials.gov
NCT02684084 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Respond… Phase4 Diabetic Macular Edema Terminated 2015-11-01 2016-12-01 ClinicalTrials.gov
NCT02651220 Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus E… Phase3 Acne Completed 2015-11-01 2016-10-01 ClinicalTrials.gov
NCT02601287 A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary… Phase4 Urinary Incontinence Completed 2015-11-01 2016-07-01 ClinicalTrials.gov
NCT02601287 A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary… Phase4 Urinary Incontinence Completed 2015-11-01 2016-07-01 ClinicalTrials.gov
NCT02651220 Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus E… Phase3 Acne Completed 2015-11-01 2016-10-01 ClinicalTrials.gov
NCT02684084 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Respond… Phase4 Diabetic Macular Edema Terminated 2015-11-01 2016-12-01 ClinicalTrials.gov
NCT02640482 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With C… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2015-11-01 2017-02-01 ClinicalTrials.gov
NCT02636595 The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C V… Phase3 Hepatitis C Virus Completed 2015-11-01 2017-01-01 ClinicalTrials.gov
NCT02598570 Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lym… Phase1 Lymphoma Completed 2015-11-01 2017-02-01 ClinicalTrials.gov
NCT02601287 A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary… Phase4 Urinary Incontinence Completed 2015-11-01 2016-07-01 ClinicalTrials.gov
NCT02640482 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With C… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2015-11-01 2017-02-01 ClinicalTrials.gov
NCT02636595 The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C V… Phase3 Hepatitis C Virus Completed 2015-11-01 2017-01-01 ClinicalTrials.gov
NCT02651220 Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus E… Phase3 Acne Completed 2015-11-01 2016-10-01 ClinicalTrials.gov
NCT02598570 Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lym… Phase1 Lymphoma Completed 2015-11-01 2017-02-01 ClinicalTrials.gov
NCT02640482 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With C… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2015-11-01 2017-02-01 ClinicalTrials.gov
NCT02636595 The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C V… Phase3 Hepatitis C Virus Completed 2015-11-01 2017-01-01 ClinicalTrials.gov
NCT02598570 Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lym… Phase1 Lymphoma Completed 2015-11-01 2017-02-01 ClinicalTrials.gov
NCT02684084 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Respond… Phase4 Diabetic Macular Edema Terminated 2015-11-01 2016-12-01 ClinicalTrials.gov
NCT02640482 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With C… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2015-11-01 2017-02-01 ClinicalTrials.gov
NCT02609659 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in S… Phase3 Hepatitis C Virus (HCV) Completed 2015-10-28 2016-12-28 ClinicalTrials.gov
NCT02486406 A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subje… Phase2 Chronic Hepatitis C Infection Completed 2015-10-28 2020-11-19 ClinicalTrials.gov
NCT02609659 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in S… Phase3 Hepatitis C Virus (HCV) Completed 2015-10-28 2016-12-28 ClinicalTrials.gov
NCT02334683 Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatmen… Na Spasticity Completed 2015-10-28 2020-03-03 ClinicalTrials.gov
NCT02486406 A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subje… Phase2 Chronic Hepatitis C Infection Completed 2015-10-28 2020-11-19 ClinicalTrials.gov
NCT02334683 Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatmen… Na Spasticity Completed 2015-10-28 2020-03-03 ClinicalTrials.gov
NCT02486406 A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subje… Phase2 Chronic Hepatitis C Infection Completed 2015-10-28 2020-11-19 ClinicalTrials.gov
NCT02609659 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in S… Phase3 Hepatitis C Virus (HCV) Completed 2015-10-28 2016-12-28 ClinicalTrials.gov
NCT02334683 Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatmen… Na Spasticity Completed 2015-10-28 2020-03-03 ClinicalTrials.gov
NCT02486406 A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subje… Phase2 Chronic Hepatitis C Infection Completed 2015-10-28 2020-11-19 ClinicalTrials.gov
NCT02609659 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in S… Phase3 Hepatitis C Virus (HCV) Completed 2015-10-28 2016-12-28 ClinicalTrials.gov
NCT02334683 Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatmen… Na Spasticity Completed 2015-10-28 2020-03-03 ClinicalTrials.gov
NCT02549092 A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Thera… Phase3 Advanced Parkinson's Disease Completed 2015-10-26 2022-11-18 ClinicalTrials.gov
NCT02549092 A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Thera… Phase3 Advanced Parkinson's Disease Completed 2015-10-26 2022-11-18 ClinicalTrials.gov
NCT02549092 A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Thera… Phase3 Advanced Parkinson's Disease Completed 2015-10-26 2022-11-18 ClinicalTrials.gov
NCT02549092 A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Thera… Phase3 Advanced Parkinson's Disease Completed 2015-10-26 2022-11-18 ClinicalTrials.gov
NCT02485600 Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-tr… — Parkinson Disease (PD) Completed 2015-10-19 2020-02-26 ClinicalTrials.gov
NCT02485600 Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-tr… — Parkinson Disease (PD) Completed 2015-10-19 2020-02-26 ClinicalTrials.gov
NCT02485600 Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-tr… — Parkinson Disease (PD) Completed 2015-10-19 2020-02-26 ClinicalTrials.gov
NCT02485600 Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-tr… — Parkinson Disease (PD) Completed 2015-10-19 2020-02-26 ClinicalTrials.gov
NCT02581189 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patie… — Chronic Hepatitis C Completed 2015-10-13 2017-12-20 ClinicalTrials.gov
NCT02581189 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patie… — Chronic Hepatitis C Completed 2015-10-13 2017-12-20 ClinicalTrials.gov
NCT02581189 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patie… — Chronic Hepatitis C Completed 2015-10-13 2017-12-20 ClinicalTrials.gov
NCT02581189 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patie… — Chronic Hepatitis C Completed 2015-10-13 2017-12-20 ClinicalTrials.gov
NCT02581163 Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin … — Chronic Hepatitis C, Genotype 1 or 4 Completed 2015-10-07 2018-02-12 ClinicalTrials.gov
NCT02549196 A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type Phase2 Dementia of Alzheimer's Type Completed 2015-10-07 2017-09-28 ClinicalTrials.gov
NCT02581163 Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin … — Chronic Hepatitis C, Genotype 1 or 4 Completed 2015-10-07 2018-02-12 ClinicalTrials.gov
NCT02549196 A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type Phase2 Dementia of Alzheimer's Type Completed 2015-10-07 2017-09-28 ClinicalTrials.gov
NCT02549196 A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type Phase2 Dementia of Alzheimer's Type Completed 2015-10-07 2017-09-28 ClinicalTrials.gov
NCT02581163 Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin … — Chronic Hepatitis C, Genotype 1 or 4 Completed 2015-10-07 2018-02-12 ClinicalTrials.gov
NCT02549196 A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type Phase2 Dementia of Alzheimer's Type Completed 2015-10-07 2017-09-28 ClinicalTrials.gov
NCT02581163 Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin … — Chronic Hepatitis C, Genotype 1 or 4 Completed 2015-10-07 2018-02-12 ClinicalTrials.gov
NCT02582658 Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic … — Chronic Hepatitis C Completed 2015-10-06 2017-01-12 ClinicalTrials.gov
NCT02582658 Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic … — Chronic Hepatitis C Completed 2015-10-06 2017-01-12 ClinicalTrials.gov
NCT02582658 Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic … — Chronic Hepatitis C Completed 2015-10-06 2017-01-12 ClinicalTrials.gov
NCT02582658 Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic … — Chronic Hepatitis C Completed 2015-10-06 2017-01-12 ClinicalTrials.gov
NCT02429895 A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active … Phase2 Psoriatic Arthritis Terminated 2015-10-01 2016-05-01 ClinicalTrials.gov
NCT02429895 A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active … Phase2 Psoriatic Arthritis Terminated 2015-10-01 2016-05-01 ClinicalTrials.gov
NCT02606630 [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 55… Phase1 Multiple Sclerosis Terminated 2015-10-01 2015-12-01 ClinicalTrials.gov
NCT02604017 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With… Phase3 Chronic Hepatitis C Completed 2015-10-01 2017-01-01 ClinicalTrials.gov
NCT02606630 [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 55… Phase1 Multiple Sclerosis Terminated 2015-10-01 2015-12-01 ClinicalTrials.gov
NCT02429895 A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active … Phase2 Psoriatic Arthritis Terminated 2015-10-01 2016-05-01 ClinicalTrials.gov
NCT02606630 [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 55… Phase1 Multiple Sclerosis Terminated 2015-10-01 2015-12-01 ClinicalTrials.gov
NCT02429895 A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active … Phase2 Psoriatic Arthritis Terminated 2015-10-01 2016-05-01 ClinicalTrials.gov
NCT02604017 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With… Phase3 Chronic Hepatitis C Completed 2015-10-01 2017-01-01 ClinicalTrials.gov
NCT02604017 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With… Phase3 Chronic Hepatitis C Completed 2015-10-01 2017-01-01 ClinicalTrials.gov
NCT02604017 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With… Phase3 Chronic Hepatitis C Completed 2015-10-01 2017-01-01 ClinicalTrials.gov
NCT02606630 [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 55… Phase1 Multiple Sclerosis Terminated 2015-10-01 2015-12-01 ClinicalTrials.gov
NCT02487199 Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Geno… Phase3 Hepatitis C Virus (HCV) Completed 2015-09-30 2016-12-05 ClinicalTrials.gov
NCT02487199 Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Geno… Phase3 Hepatitis C Virus (HCV) Completed 2015-09-30 2016-12-05 ClinicalTrials.gov
NCT02487199 Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Geno… Phase3 Hepatitis C Virus (HCV) Completed 2015-09-30 2016-12-05 ClinicalTrials.gov
NCT02487199 Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Geno… Phase3 Hepatitis C Virus (HCV) Completed 2015-09-30 2016-12-05 ClinicalTrials.gov
NCT02533375 Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects Wit… Phase3 Generalized Pustular Psoriasis (GPP) Completed 2015-09-28 2017-07-20 ClinicalTrials.gov
NCT02533375 Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects Wit… Phase3 Generalized Pustular Psoriasis (GPP) Completed 2015-09-28 2017-07-20 ClinicalTrials.gov
NCT02533375 Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects Wit… Phase3 Generalized Pustular Psoriasis (GPP) Completed 2015-09-28 2017-07-20 ClinicalTrials.gov
NCT02533375 Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects Wit… Phase3 Generalized Pustular Psoriasis (GPP) Completed 2015-09-28 2017-07-20 ClinicalTrials.gov
NCT02578238 Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) … — Pediatric Crohn's Disease Completed 2015-09-24 2017-05-31 ClinicalTrials.gov
NCT02578238 Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) … — Pediatric Crohn's Disease Completed 2015-09-24 2017-05-31 ClinicalTrials.gov
NCT02578238 Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) … — Pediatric Crohn's Disease Completed 2015-09-24 2017-05-31 ClinicalTrials.gov
NCT02578238 Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) … — Pediatric Crohn's Disease Completed 2015-09-24 2017-05-31 ClinicalTrials.gov
NCT02565758 ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2015-09-18 2019-03-25 ClinicalTrials.gov
NCT02565758 ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2015-09-18 2019-03-25 ClinicalTrials.gov
NCT02565758 ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2015-09-18 2019-03-25 ClinicalTrials.gov
NCT02565758 ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2015-09-18 2019-03-25 ClinicalTrials.gov
NCT02513459 A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients W… Phase2 Crohn Disease Completed 2015-09-16 2019-06-19 ClinicalTrials.gov
NCT02513459 A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients W… Phase2 Crohn Disease Completed 2015-09-16 2019-06-19 ClinicalTrials.gov
NCT02513459 A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients W… Phase2 Crohn Disease Completed 2015-09-16 2019-06-19 ClinicalTrials.gov
NCT02513459 A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients W… Phase2 Crohn Disease Completed 2015-09-16 2019-06-19 ClinicalTrials.gov
NCT02471105 Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit … Phase4 Ocular Hypertension Unknown 2015-09-01 2017-12-01 ClinicalTrials.gov
NCT02877069 Safety and Effectiveness of VYC-12 Hyaluronic Acid Injectable Gel for Treatment… Phase4 Skin Roughness Completed 2015-09-01 2016-10-01 ClinicalTrials.gov
NCT02471105 Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit … Phase4 Ocular Hypertension Unknown 2015-09-01 2017-12-01 ClinicalTrials.gov
NCT02534870 Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-2… Phase1 Healthy Volunteer Completed 2015-09-01 2015-09-01 ClinicalTrials.gov
NCT02471105 Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit … Phase4 Ocular Hypertension Unknown 2015-09-01 2017-12-01 ClinicalTrials.gov
NCT02877069 Safety and Effectiveness of VYC-12 Hyaluronic Acid Injectable Gel for Treatment… Phase4 Skin Roughness Completed 2015-09-01 2016-10-01 ClinicalTrials.gov
NCT02877069 Safety and Effectiveness of VYC-12 Hyaluronic Acid Injectable Gel for Treatment… Phase4 Skin Roughness Completed 2015-09-01 2016-10-01 ClinicalTrials.gov
NCT02471105 Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit … Phase4 Ocular Hypertension Unknown 2015-09-01 2017-12-01 ClinicalTrials.gov
NCT02534870 Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-2… Phase1 Healthy Volunteer Completed 2015-09-01 2015-09-01 ClinicalTrials.gov
NCT02792803 A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in … Phase4 POAG Unknown 2015-09-01 2017-09-01 ClinicalTrials.gov
NCT02792803 A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in … Phase4 POAG Unknown 2015-09-01 2017-09-01 ClinicalTrials.gov
NCT02792803 A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in … Phase4 POAG Unknown 2015-09-01 2017-09-01 ClinicalTrials.gov
NCT02792803 A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in … Phase4 POAG Unknown 2015-09-01 2017-09-01 ClinicalTrials.gov
NCT02534870 Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-2… Phase1 Healthy Volunteer Completed 2015-09-01 2015-09-01 ClinicalTrials.gov
NCT02877069 Safety and Effectiveness of VYC-12 Hyaluronic Acid Injectable Gel for Treatment… Phase4 Skin Roughness Completed 2015-09-01 2016-10-01 ClinicalTrials.gov
NCT02534870 Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-2… Phase1 Healthy Volunteer Completed 2015-09-01 2015-09-01 ClinicalTrials.gov
NCT02507687 Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculopl… Phase3 Glaucoma, Open-Angle Completed 2015-08-27 2023-05-31 ClinicalTrials.gov
NCT02507687 Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculopl… Phase3 Glaucoma, Open-Angle Completed 2015-08-27 2023-05-31 ClinicalTrials.gov
NCT02507687 Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculopl… Phase3 Glaucoma, Open-Angle Completed 2015-08-27 2023-05-31 ClinicalTrials.gov
NCT02507687 Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculopl… Phase3 Glaucoma, Open-Angle Completed 2015-08-27 2023-05-31 ClinicalTrials.gov
NCT02590263 Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma Phase1 Malignant Glioma Completed 2015-08-24 2020-08-27 ClinicalTrials.gov
NCT02590263 Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma Phase1 Malignant Glioma Completed 2015-08-24 2020-08-27 ClinicalTrials.gov
NCT02590263 Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma Phase1 Malignant Glioma Completed 2015-08-24 2020-08-27 ClinicalTrials.gov
NCT02590263 Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma Phase1 Malignant Glioma Completed 2015-08-24 2020-08-27 ClinicalTrials.gov
NCT02506179 Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis — Ulcerative Colitis Completed 2015-08-18 2020-02-10 ClinicalTrials.gov
NCT02506179 Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis — Ulcerative Colitis Completed 2015-08-18 2020-02-10 ClinicalTrials.gov
NCT02506179 Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis — Ulcerative Colitis Completed 2015-08-18 2020-02-10 ClinicalTrials.gov
NCT02506179 Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis — Ulcerative Colitis Completed 2015-08-18 2020-02-10 ClinicalTrials.gov
NCT02499783 Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects Wit… Phase3 Crohn's Disease Completed 2015-08-17 2017-12-15 ClinicalTrials.gov
NCT02499783 Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects Wit… Phase3 Crohn's Disease Completed 2015-08-17 2017-12-15 ClinicalTrials.gov
NCT02499783 Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects Wit… Phase3 Crohn's Disease Completed 2015-08-17 2017-12-15 ClinicalTrials.gov
NCT02499783 Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects Wit… Phase3 Crohn's Disease Completed 2015-08-17 2017-12-15 ClinicalTrials.gov
NCT02495857 A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthrit… Na Osteoarthritis Completed 2015-08-15 2016-12-05 ClinicalTrials.gov
NCT02495857 A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthrit… Na Osteoarthritis Completed 2015-08-15 2016-12-05 ClinicalTrials.gov
NCT02495857 A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthrit… Na Osteoarthritis Completed 2015-08-15 2016-12-05 ClinicalTrials.gov
NCT02495857 A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthrit… Na Osteoarthritis Completed 2015-08-15 2016-12-05 ClinicalTrials.gov
NCT02392026 Safety and Tolerability of Metronidazole Gel 1.3% Phase4 Vaginosis, Bacterial Completed 2015-08-12 2016-10-05 ClinicalTrials.gov
NCT02392026 Safety and Tolerability of Metronidazole Gel 1.3% Phase4 Vaginosis, Bacterial Completed 2015-08-12 2016-10-05 ClinicalTrials.gov
NCT02392026 Safety and Tolerability of Metronidazole Gel 1.3% Phase4 Vaginosis, Bacterial Completed 2015-08-12 2016-10-05 ClinicalTrials.gov
NCT02392026 Safety and Tolerability of Metronidazole Gel 1.3% Phase4 Vaginosis, Bacterial Completed 2015-08-12 2016-10-05 ClinicalTrials.gov
NCT03724292 An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers Phase1 Psoriasis Completed 2015-08-01 2016-03-08 ClinicalTrials.gov
NCT02245958 A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervic… — Cervical Dystonia Completed 2015-08-01 2015-12-01 ClinicalTrials.gov
NCT02526641 Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of… — Hepatitis C Completed 2015-08-01 2020-11-01 ClinicalTrials.gov
NCT02557971 Urinary Retention Rates in Clinical Practice After Treatment With Onabotulinumt… — Urinary Bladder, Overactive Completed 2015-08-01 2016-07-01 ClinicalTrials.gov
NCT02555709 An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psori… Phase1 Psoriasis Completed 2015-08-01 2016-03-01 ClinicalTrials.gov
NCT02557971 Urinary Retention Rates in Clinical Practice After Treatment With Onabotulinumt… — Urinary Bladder, Overactive Completed 2015-08-01 2016-07-01 ClinicalTrials.gov
NCT02557971 Urinary Retention Rates in Clinical Practice After Treatment With Onabotulinumt… — Urinary Bladder, Overactive Completed 2015-08-01 2016-07-01 ClinicalTrials.gov
NCT02245958 A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervic… — Cervical Dystonia Completed 2015-08-01 2015-12-01 ClinicalTrials.gov
NCT02555709 An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psori… Phase1 Psoriasis Completed 2015-08-01 2016-03-01 ClinicalTrials.gov
NCT03724292 An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers Phase1 Psoriasis Completed 2015-08-01 2016-03-08 ClinicalTrials.gov
NCT03724292 An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers Phase1 Psoriasis Completed 2015-08-01 2016-03-08 ClinicalTrials.gov
NCT02555709 An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psori… Phase1 Psoriasis Completed 2015-08-01 2016-03-01 ClinicalTrials.gov
NCT02557971 Urinary Retention Rates in Clinical Practice After Treatment With Onabotulinumt… — Urinary Bladder, Overactive Completed 2015-08-01 2016-07-01 ClinicalTrials.gov
NCT02245958 A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervic… — Cervical Dystonia Completed 2015-08-01 2015-12-01 ClinicalTrials.gov
NCT02555709 An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psori… Phase1 Psoriasis Completed 2015-08-01 2016-03-01 ClinicalTrials.gov
NCT03724292 An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers Phase1 Psoriasis Completed 2015-08-01 2016-03-08 ClinicalTrials.gov
NCT02596217 Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) … Phase1 Healthy Completed 2015-08-01 2017-06-01 ClinicalTrials.gov
NCT02596217 Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) … Phase1 Healthy Completed 2015-08-01 2017-06-01 ClinicalTrials.gov
NCT02245958 A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervic… — Cervical Dystonia Completed 2015-08-01 2015-12-01 ClinicalTrials.gov
NCT02526641 Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of… — Hepatitis C Completed 2015-08-01 2020-11-01 ClinicalTrials.gov
NCT02596217 Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) … Phase1 Healthy Completed 2015-08-01 2017-06-01 ClinicalTrials.gov
NCT02596217 Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) … Phase1 Healthy Completed 2015-08-01 2017-06-01 ClinicalTrials.gov
NCT02526641 Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of… — Hepatitis C Completed 2015-08-01 2020-11-01 ClinicalTrials.gov
NCT02526641 Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of… — Hepatitis C Completed 2015-08-01 2020-11-01 ClinicalTrials.gov
NCT02580578 A Multicenter Prospective Non-Interventional Study Assessing the Management of … — Leiomyoma Completed 2015-07-31 2020-01-31 ClinicalTrials.gov
NCT02580578 A Multicenter Prospective Non-Interventional Study Assessing the Management of … — Leiomyoma Completed 2015-07-31 2020-01-31 ClinicalTrials.gov
NCT02580578 A Multicenter Prospective Non-Interventional Study Assessing the Management of … — Leiomyoma Completed 2015-07-31 2020-01-31 ClinicalTrials.gov
NCT02580578 A Multicenter Prospective Non-Interventional Study Assessing the Management of … — Leiomyoma Completed 2015-07-31 2020-01-31 ClinicalTrials.gov
NCT02554981 Evaluation of Maintaining Visual Performance in Participants Who Engage in Elec… Phase4 Dry Eye Syndromes Completed 2015-07-21 2016-03-24 ClinicalTrials.gov
NCT02554981 Evaluation of Maintaining Visual Performance in Participants Who Engage in Elec… Phase4 Dry Eye Syndromes Completed 2015-07-21 2016-03-24 ClinicalTrials.gov
NCT02554981 Evaluation of Maintaining Visual Performance in Participants Who Engage in Elec… Phase4 Dry Eye Syndromes Completed 2015-07-21 2016-03-24 ClinicalTrials.gov
NCT02554981 Evaluation of Maintaining Visual Performance in Participants Who Engage in Elec… Phase4 Dry Eye Syndromes Completed 2015-07-21 2016-03-24 ClinicalTrials.gov
NCT02517528 ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With… Phase3 Chronic Hepatitis C Virus (HCV) Completed 2015-07-20 2017-03-16 ClinicalTrials.gov
NCT02517528 ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With… Phase3 Chronic Hepatitis C Virus (HCV) Completed 2015-07-20 2017-03-16 ClinicalTrials.gov
NCT02517528 ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With… Phase3 Chronic Hepatitis C Virus (HCV) Completed 2015-07-20 2017-03-16 ClinicalTrials.gov
NCT02517528 ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With… Phase3 Chronic Hepatitis C Virus (HCV) Completed 2015-07-20 2017-03-16 ClinicalTrials.gov
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Thera… Phase3 Ovarian Cancer Terminated 2015-07-14 2023-10-05 ClinicalTrials.gov
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Thera… Phase3 Ovarian Cancer Terminated 2015-07-14 2023-10-05 ClinicalTrials.gov
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Thera… Phase3 Ovarian Cancer Terminated 2015-07-14 2023-10-05 ClinicalTrials.gov
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Thera… Phase3 Ovarian Cancer Terminated 2015-07-14 2023-10-05 ClinicalTrials.gov
NCT02451839 An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disabil… — Crohn's Disease Completed 2015-07-06 2017-12-05 ClinicalTrials.gov
NCT02451839 An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disabil… — Crohn's Disease Completed 2015-07-06 2017-12-05 ClinicalTrials.gov
NCT02451839 An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disabil… — Crohn's Disease Completed 2015-07-06 2017-12-05 ClinicalTrials.gov
NCT02451839 An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disabil… — Crohn's Disease Completed 2015-07-06 2017-12-05 ClinicalTrials.gov
NCT02734173 Pilot HCV Direct Acting Antiviral Therapy and Metabolism Phase4 Hepatitis C Completed 2015-07-01 2017-05-31 ClinicalTrials.gov
NCT02483104 Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Sub… Phase1 Ovarian Cancer Completed 2015-07-01 2016-07-01 ClinicalTrials.gov
NCT02531178 A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Sub… Phase1 Rheumatoid Arthritis Completed 2015-07-01 2016-02-01 ClinicalTrials.gov
NCT02162472 Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis — Psoriasis Completed 2015-07-01 2021-12-31 ClinicalTrials.gov
NCT02734173 Pilot HCV Direct Acting Antiviral Therapy and Metabolism Phase4 Hepatitis C Completed 2015-07-01 2017-05-31 ClinicalTrials.gov
NCT02162472 Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis — Psoriasis Completed 2015-07-01 2021-12-31 ClinicalTrials.gov
NCT02517515 ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve an… Phase3 Hepatitis C Virus (HCV) Completed 2015-07-01 2017-06-01 ClinicalTrials.gov
NCT02504099 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With o… Phase3 Chronic Hepatitis C Infection Terminated 2015-07-01 2016-12-01 ClinicalTrials.gov
NCT02531178 A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Sub… Phase1 Rheumatoid Arthritis Completed 2015-07-01 2016-02-01 ClinicalTrials.gov
NCT02517515 ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve an… Phase3 Hepatitis C Virus (HCV) Completed 2015-07-01 2017-06-01 ClinicalTrials.gov
NCT02531178 A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Sub… Phase1 Rheumatoid Arthritis Completed 2015-07-01 2016-02-01 ClinicalTrials.gov
NCT02517515 ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve an… Phase3 Hepatitis C Virus (HCV) Completed 2015-07-01 2017-06-01 ClinicalTrials.gov
NCT02734173 Pilot HCV Direct Acting Antiviral Therapy and Metabolism Phase4 Hepatitis C Completed 2015-07-01 2017-05-31 ClinicalTrials.gov
NCT02483104 Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Sub… Phase1 Ovarian Cancer Completed 2015-07-01 2016-07-01 ClinicalTrials.gov
NCT02162472 Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis — Psoriasis Completed 2015-07-01 2021-12-31 ClinicalTrials.gov
NCT02504099 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With o… Phase3 Chronic Hepatitis C Infection Terminated 2015-07-01 2016-12-01 ClinicalTrials.gov
NCT02162472 Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis — Psoriasis Completed 2015-07-01 2021-12-31 ClinicalTrials.gov
NCT02531178 A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Sub… Phase1 Rheumatoid Arthritis Completed 2015-07-01 2016-02-01 ClinicalTrials.gov
NCT02483104 Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Sub… Phase1 Ovarian Cancer Completed 2015-07-01 2016-07-01 ClinicalTrials.gov
NCT02504099 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With o… Phase3 Chronic Hepatitis C Infection Terminated 2015-07-01 2016-12-01 ClinicalTrials.gov
NCT02504099 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With o… Phase3 Chronic Hepatitis C Infection Terminated 2015-07-01 2016-12-01 ClinicalTrials.gov
NCT02483104 Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Sub… Phase1 Ovarian Cancer Completed 2015-07-01 2016-07-01 ClinicalTrials.gov
NCT02517515 ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve an… Phase3 Hepatitis C Virus (HCV) Completed 2015-07-01 2017-06-01 ClinicalTrials.gov
NCT02734173 Pilot HCV Direct Acting Antiviral Therapy and Metabolism Phase4 Hepatitis C Completed 2015-07-01 2017-05-31 ClinicalTrials.gov
NCT02462486 Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-rela… Phase3 Macular Degeneration Completed 2015-06-25 2019-06-06 ClinicalTrials.gov
NCT02462486 Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-rela… Phase3 Macular Degeneration Completed 2015-06-25 2019-06-06 ClinicalTrials.gov
NCT02462486 Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-rela… Phase3 Macular Degeneration Completed 2015-06-25 2019-06-06 ClinicalTrials.gov
NCT02462486 Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-rela… Phase3 Macular Degeneration Completed 2015-06-25 2019-06-06 ClinicalTrials.gov
NCT02443298 Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Sever… Phase2 Asthma Completed 2015-06-23 2018-02-02 ClinicalTrials.gov
NCT02443298 Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Sever… Phase2 Asthma Completed 2015-06-23 2018-02-02 ClinicalTrials.gov
NCT02443298 Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Sever… Phase2 Asthma Completed 2015-06-23 2018-02-02 ClinicalTrials.gov
NCT02443298 Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Sever… Phase2 Asthma Completed 2015-06-23 2018-02-02 ClinicalTrials.gov
NCT02441283 A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-5… Phase2 Hepatitis C Completed 2015-06-22 2019-10-15 ClinicalTrials.gov
NCT02441283 A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-5… Phase2 Hepatitis C Completed 2015-06-22 2019-10-15 ClinicalTrials.gov
NCT02441283 A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-5… Phase2 Hepatitis C Completed 2015-06-22 2019-10-15 ClinicalTrials.gov
NCT02441283 A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-5… Phase2 Hepatitis C Completed 2015-06-22 2019-10-15 ClinicalTrials.gov
NCT02499263 A Prospective Non-interventional Multicenter Study to Evaluate the Effectivenes… — Ulcerative Colitis Completed 2015-06-11 2018-09-17 ClinicalTrials.gov
NCT02499263 A Prospective Non-interventional Multicenter Study to Evaluate the Effectivenes… — Ulcerative Colitis Completed 2015-06-11 2018-09-17 ClinicalTrials.gov
NCT02499263 A Prospective Non-interventional Multicenter Study to Evaluate the Effectivenes… — Ulcerative Colitis Completed 2015-06-11 2018-09-17 ClinicalTrials.gov
NCT02499263 A Prospective Non-interventional Multicenter Study to Evaluate the Effectivenes… — Ulcerative Colitis Completed 2015-06-11 2018-09-17 ClinicalTrials.gov
NCT02448043 Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pre… Na Nail Growth Cessation Completed 2015-06-04 2016-05-06 ClinicalTrials.gov
NCT02448043 Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pre… Na Nail Growth Cessation Completed 2015-06-04 2016-05-06 ClinicalTrials.gov
NCT02448043 Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pre… Na Nail Growth Cessation Completed 2015-06-04 2016-05-06 ClinicalTrials.gov
NCT02448043 Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pre… Na Nail Growth Cessation Completed 2015-06-04 2016-05-06 ClinicalTrials.gov
NCT02335905 Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Oste… Phase1 Hematogenously Acquired Staphylococcus Aureus Osteomyelitis Completed 2015-06-03 2020-06-16 ClinicalTrials.gov
NCT02335905 Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Oste… Phase1 Hematogenously Acquired Staphylococcus Aureus Osteomyelitis Completed 2015-06-03 2020-06-16 ClinicalTrials.gov
NCT02335905 Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Oste… Phase1 Hematogenously Acquired Staphylococcus Aureus Osteomyelitis Completed 2015-06-03 2020-06-16 ClinicalTrials.gov
NCT02335905 Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Oste… Phase1 Hematogenously Acquired Staphylococcus Aureus Osteomyelitis Completed 2015-06-03 2020-06-16 ClinicalTrials.gov
NCT02435914 Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Su… Phase2 Dry Eye Syndromes Completed 2015-06-01 2016-01-01 ClinicalTrials.gov
NCT02471651 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Mac… Phase4 Diabetic Macular Edema Completed 2015-06-01 2018-10-24 ClinicalTrials.gov
NCT02420730 Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Par… Phase1 Healthy Volunteers Completed 2015-06-01 2016-03-01 ClinicalTrials.gov
NCT02435914 Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Su… Phase2 Dry Eye Syndromes Completed 2015-06-01 2016-01-01 ClinicalTrials.gov
NCT02435914 Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Su… Phase2 Dry Eye Syndromes Completed 2015-06-01 2016-01-01 ClinicalTrials.gov
NCT02476617 Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) … Phase3 Chronic Hepatitis C Completed 2015-06-01 2016-12-01 ClinicalTrials.gov
NCT02471651 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Mac… Phase4 Diabetic Macular Edema Completed 2015-06-01 2018-10-24 ClinicalTrials.gov
NCT02461745 Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation… Phase4 Hepatitis C, Chronic Completed 2015-06-01 2017-05-01 ClinicalTrials.gov
NCT02420730 Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Par… Phase1 Healthy Volunteers Completed 2015-06-01 2016-03-01 ClinicalTrials.gov
NCT02493855 Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV… Phase2 Chronic Hepatitis C Completed 2015-06-01 2016-12-01 ClinicalTrials.gov
NCT02461745 Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation… Phase4 Hepatitis C, Chronic Completed 2015-06-01 2017-05-01 ClinicalTrials.gov
NCT02420730 Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Par… Phase1 Healthy Volunteers Completed 2015-06-01 2016-03-01 ClinicalTrials.gov
NCT02435914 Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Su… Phase2 Dry Eye Syndromes Completed 2015-06-01 2016-01-01 ClinicalTrials.gov
NCT02420730 Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Par… Phase1 Healthy Volunteers Completed 2015-06-01 2016-03-01 ClinicalTrials.gov
NCT02476617 Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) … Phase3 Chronic Hepatitis C Completed 2015-06-01 2016-12-01 ClinicalTrials.gov
NCT02476617 Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) … Phase3 Chronic Hepatitis C Completed 2015-06-01 2016-12-01 ClinicalTrials.gov
NCT02471651 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Mac… Phase4 Diabetic Macular Edema Completed 2015-06-01 2018-10-24 ClinicalTrials.gov
NCT02493855 Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV… Phase2 Chronic Hepatitis C Completed 2015-06-01 2016-12-01 ClinicalTrials.gov
NCT02476617 Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) … Phase3 Chronic Hepatitis C Completed 2015-06-01 2016-12-01 ClinicalTrials.gov
NCT02493855 Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV… Phase2 Chronic Hepatitis C Completed 2015-06-01 2016-12-01 ClinicalTrials.gov
NCT02461745 Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation… Phase4 Hepatitis C, Chronic Completed 2015-06-01 2017-05-01 ClinicalTrials.gov
NCT02471651 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Mac… Phase4 Diabetic Macular Edema Completed 2015-06-01 2018-10-24 ClinicalTrials.gov
NCT02461745 Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation… Phase4 Hepatitis C, Chronic Completed 2015-06-01 2017-05-01 ClinicalTrials.gov
NCT02493855 Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV… Phase2 Chronic Hepatitis C Completed 2015-06-01 2016-12-01 ClinicalTrials.gov
NCT02411110 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bla… Phase2 Cystitis, Interstitial Completed 2015-05-21 2017-01-09 ClinicalTrials.gov
NCT02411110 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bla… Phase2 Cystitis, Interstitial Completed 2015-05-21 2017-01-09 ClinicalTrials.gov
NCT02411110 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bla… Phase2 Cystitis, Interstitial Completed 2015-05-21 2017-01-09 ClinicalTrials.gov
NCT02411110 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bla… Phase2 Cystitis, Interstitial Completed 2015-05-21 2017-01-09 ClinicalTrials.gov
NCT02442284 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Completed 2015-05-13 2016-10-31 ClinicalTrials.gov
NCT02442284 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Completed 2015-05-13 2016-10-31 ClinicalTrials.gov
NCT02442284 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Completed 2015-05-13 2016-10-31 ClinicalTrials.gov
NCT02442284 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Completed 2015-05-13 2016-10-31 ClinicalTrials.gov
NCT02462525 Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With… Phase1 Multiple Myeloma Terminated 2015-05-06 2017-12-06 ClinicalTrials.gov
NCT02401503 Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Indu… Phase2 Chronic Lymphocytic Leucemia Completed 2015-05-06 2024-12-17 ClinicalTrials.gov
NCT02401503 Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Indu… Phase2 Chronic Lymphocytic Leucemia Completed 2015-05-06 2024-12-17 ClinicalTrials.gov
NCT02401503 Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Indu… Phase2 Chronic Lymphocytic Leucemia Completed 2015-05-06 2024-12-17 ClinicalTrials.gov
NCT02401503 Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Indu… Phase2 Chronic Lymphocytic Leucemia Completed 2015-05-06 2024-12-17 ClinicalTrials.gov
NCT02462525 Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With… Phase1 Multiple Myeloma Terminated 2015-05-06 2017-12-06 ClinicalTrials.gov
NCT02462525 Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With… Phase1 Multiple Myeloma Terminated 2015-05-06 2017-12-06 ClinicalTrials.gov
NCT02462525 Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With… Phase1 Multiple Myeloma Terminated 2015-05-06 2017-12-06 ClinicalTrials.gov
NCT02255422 RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR Phase2 MItochondrial Myopathies Completed 2015-05-05 2017-11-30 ClinicalTrials.gov
NCT02255422 RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR Phase2 MItochondrial Myopathies Completed 2015-05-05 2017-11-30 ClinicalTrials.gov
NCT02255422 RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR Phase2 MItochondrial Myopathies Completed 2015-05-05 2017-11-30 ClinicalTrials.gov
NCT02255422 RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR Phase2 MItochondrial Myopathies Completed 2015-05-05 2017-11-30 ClinicalTrials.gov
NCT02475369 Pancreatic Enzyme Supplementation for Celiac Disease Phase4 Celiac Disease Terminated 2015-05-01 2019-12-01 ClinicalTrials.gov
NCT02616614 Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide G… Phase3 Acne Vulgaris Completed 2015-05-01 2015-11-01 ClinicalTrials.gov
NCT02446314 An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueber… Na Cognitive Decline Completed 2015-05-01 2017-07-01 ClinicalTrials.gov
NCT02475369 Pancreatic Enzyme Supplementation for Celiac Disease Phase4 Celiac Disease Terminated 2015-05-01 2019-12-01 ClinicalTrials.gov
NCT02616614 Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide G… Phase3 Acne Vulgaris Completed 2015-05-01 2015-11-01 ClinicalTrials.gov
NCT02446314 An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueber… Na Cognitive Decline Completed 2015-05-01 2017-07-01 ClinicalTrials.gov
NCT02446314 An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueber… Na Cognitive Decline Completed 2015-05-01 2017-07-01 ClinicalTrials.gov
NCT02446314 An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueber… Na Cognitive Decline Completed 2015-05-01 2017-07-01 ClinicalTrials.gov
NCT02616614 Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide G… Phase3 Acne Vulgaris Completed 2015-05-01 2015-11-01 ClinicalTrials.gov
NCT02616614 Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide G… Phase3 Acne Vulgaris Completed 2015-05-01 2015-11-01 ClinicalTrials.gov
NCT02475369 Pancreatic Enzyme Supplementation for Celiac Disease Phase4 Celiac Disease Terminated 2015-05-01 2019-12-01 ClinicalTrials.gov
NCT02475369 Pancreatic Enzyme Supplementation for Celiac Disease Phase4 Celiac Disease Terminated 2015-05-01 2019-12-01 ClinicalTrials.gov
NCT02412371 A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination Wi… Phase1 Non-small Cell Lung Cancer Stage III Terminated 2015-04-30 2019-08-05 ClinicalTrials.gov
NCT02412371 A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination Wi… Phase1 Non-small Cell Lung Cancer Stage III Terminated 2015-04-30 2019-08-05 ClinicalTrials.gov
NCT02412371 A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination Wi… Phase1 Non-small Cell Lung Cancer Stage III Terminated 2015-04-30 2019-08-05 ClinicalTrials.gov
NCT02412371 A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination Wi… Phase1 Non-small Cell Lung Cancer Stage III Terminated 2015-04-30 2019-08-05 ClinicalTrials.gov
NCT02349451 A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122… Phase2 Psoriatic Arthritis Completed 2015-04-28 2016-07-04 ClinicalTrials.gov
NCT02349451 A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122… Phase2 Psoriatic Arthritis Completed 2015-04-28 2016-07-04 ClinicalTrials.gov
NCT02349451 A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122… Phase2 Psoriatic Arthritis Completed 2015-04-28 2016-07-04 ClinicalTrials.gov
NCT02349451 A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122… Phase2 Psoriatic Arthritis Completed 2015-04-28 2016-07-04 ClinicalTrials.gov
NCT02442271 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adul… Phase3 Chronic Hepatitis C Infection Completed 2015-04-27 2016-09-26 ClinicalTrials.gov
NCT02442271 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adul… Phase3 Chronic Hepatitis C Infection Completed 2015-04-27 2016-09-26 ClinicalTrials.gov
NCT02442271 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adul… Phase3 Chronic Hepatitis C Infection Completed 2015-04-27 2016-09-26 ClinicalTrials.gov
NCT02442271 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adul… Phase3 Chronic Hepatitis C Infection Completed 2015-04-27 2016-09-26 ClinicalTrials.gov
NCT02381444 Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Cont… — Parkinson's Disease (PD) Completed 2015-04-17 2020-01-07 ClinicalTrials.gov
NCT02381444 Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Cont… — Parkinson's Disease (PD) Completed 2015-04-17 2020-01-07 ClinicalTrials.gov
NCT02381444 Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Cont… — Parkinson's Disease (PD) Completed 2015-04-17 2020-01-07 ClinicalTrials.gov
NCT02381444 Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Cont… — Parkinson's Disease (PD) Completed 2015-04-17 2020-01-07 ClinicalTrials.gov
NCT02395042 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis Wit… Phase2 Cystitis, Interstitial Completed 2015-04-15 2017-11-20 ClinicalTrials.gov
NCT02395042 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis Wit… Phase2 Cystitis, Interstitial Completed 2015-04-15 2017-11-20 ClinicalTrials.gov
NCT02395042 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis Wit… Phase2 Cystitis, Interstitial Completed 2015-04-15 2017-11-20 ClinicalTrials.gov
NCT02395042 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis Wit… Phase2 Cystitis, Interstitial Completed 2015-04-15 2017-11-20 ClinicalTrials.gov
NCT02391480 A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With… Phase1 Cancer Completed 2015-04-14 2019-07-05 ClinicalTrials.gov
NCT02391480 A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With… Phase1 Cancer Completed 2015-04-14 2019-07-05 ClinicalTrials.gov
NCT02391480 A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With… Phase1 Cancer Completed 2015-04-14 2019-07-05 ClinicalTrials.gov
NCT02391480 A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With… Phase1 Cancer Completed 2015-04-14 2019-07-05 ClinicalTrials.gov
NCT02118714 Atrasentan Spermatogenesis and Testicular Function Phase2 Nephropathy Completed 2015-04-06 2018-07-16 ClinicalTrials.gov
NCT02118714 Atrasentan Spermatogenesis and Testicular Function Phase2 Nephropathy Completed 2015-04-06 2018-07-16 ClinicalTrials.gov
NCT02118714 Atrasentan Spermatogenesis and Testicular Function Phase2 Nephropathy Completed 2015-04-06 2018-07-16 ClinicalTrials.gov
NCT02118714 Atrasentan Spermatogenesis and Testicular Function Phase2 Nephropathy Completed 2015-04-06 2018-07-16 ClinicalTrials.gov
NCT02419560 Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL Phase1 Lymphoma, Mantle-Cell Completed 2015-04-01 2021-05-01 ClinicalTrials.gov
NCT02414633 Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Produ… — Psoriatic Arthritis Completed 2015-04-01 2017-03-13 ClinicalTrials.gov
NCT03288337 Impact of Hidradenitis Suppurativa on Quality of Life Functions — Hidradenitis Suppurativa Completed 2015-04-01 2022-09-06 ClinicalTrials.gov
NCT02446717 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and A… Phase2 Chronic Hepatitis C Completed 2015-04-01 2017-01-01 ClinicalTrials.gov
NCT02446717 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and A… Phase2 Chronic Hepatitis C Completed 2015-04-01 2017-01-01 ClinicalTrials.gov
NCT02433340 Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Art… Phase2 Rheumatoid Arthritis Completed 2015-04-01 2016-05-01 ClinicalTrials.gov
NCT03288337 Impact of Hidradenitis Suppurativa on Quality of Life Functions — Hidradenitis Suppurativa Completed 2015-04-01 2022-09-06 ClinicalTrials.gov
NCT02446717 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and A… Phase2 Chronic Hepatitis C Completed 2015-04-01 2017-01-01 ClinicalTrials.gov
NCT03288337 Impact of Hidradenitis Suppurativa on Quality of Life Functions — Hidradenitis Suppurativa Completed 2015-04-01 2022-09-06 ClinicalTrials.gov
NCT02446717 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and A… Phase2 Chronic Hepatitis C Completed 2015-04-01 2017-01-01 ClinicalTrials.gov
NCT02419560 Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL Phase1 Lymphoma, Mantle-Cell Completed 2015-04-01 2021-05-01 ClinicalTrials.gov
NCT02419560 Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL Phase1 Lymphoma, Mantle-Cell Completed 2015-04-01 2021-05-01 ClinicalTrials.gov
NCT02433340 Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Art… Phase2 Rheumatoid Arthritis Completed 2015-04-01 2016-05-01 ClinicalTrials.gov
NCT02419560 Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL Phase1 Lymphoma, Mantle-Cell Completed 2015-04-01 2021-05-01 ClinicalTrials.gov
NCT03288337 Impact of Hidradenitis Suppurativa on Quality of Life Functions — Hidradenitis Suppurativa Completed 2015-04-01 2022-09-06 ClinicalTrials.gov
NCT02414633 Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Produ… — Psoriatic Arthritis Completed 2015-04-01 2017-03-13 ClinicalTrials.gov
NCT02414633 Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Produ… — Psoriatic Arthritis Completed 2015-04-01 2017-03-13 ClinicalTrials.gov
NCT02433340 Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Art… Phase2 Rheumatoid Arthritis Completed 2015-04-01 2016-05-01 ClinicalTrials.gov
NCT02433340 Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Art… Phase2 Rheumatoid Arthritis Completed 2015-04-01 2016-05-01 ClinicalTrials.gov
NCT02414633 Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Produ… — Psoriatic Arthritis Completed 2015-04-01 2017-03-13 ClinicalTrials.gov
NCT02413346 A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in th… Phase3 Acne Vulgaris Completed 2015-03-20 2016-08-26 ClinicalTrials.gov
NCT02413346 A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in th… Phase3 Acne Vulgaris Completed 2015-03-20 2016-08-26 ClinicalTrials.gov
NCT02413346 A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in th… Phase3 Acne Vulgaris Completed 2015-03-20 2016-08-26 ClinicalTrials.gov
NCT02413346 A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in th… Phase3 Acne Vulgaris Completed 2015-03-20 2016-08-26 ClinicalTrials.gov
NCT02365649 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 fo… Phase2 Crohn's Disease Completed 2015-03-17 2017-08-03 ClinicalTrials.gov
NCT02365649 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 fo… Phase2 Crohn's Disease Completed 2015-03-17 2017-08-03 ClinicalTrials.gov
NCT02365649 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 fo… Phase2 Crohn's Disease Completed 2015-03-17 2017-08-03 ClinicalTrials.gov
NCT02365649 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 fo… Phase2 Crohn's Disease Completed 2015-03-17 2017-08-03 ClinicalTrials.gov
NCT02399345 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir… Phase3 Chronic Hepatitis C Virus (HCV Infection Genotype 1) Completed 2015-03-01 2015-11-01 ClinicalTrials.gov
NCT02442258 Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and … Phase1 Renal Impairment Completed 2015-03-01 2015-12-01 ClinicalTrials.gov
NCT02399345 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir… Phase3 Chronic Hepatitis C Virus (HCV Infection Genotype 1) Completed 2015-03-01 2015-11-01 ClinicalTrials.gov
NCT02471118 Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA) Phase2 Osteoarthritis, Knee Completed 2015-03-01 2021-03-01 ClinicalTrials.gov
NCT02384538 A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With… Phase2 Erosive Hand Osteoarthritis Completed 2015-03-01 2016-07-01 ClinicalTrials.gov
NCT02384538 A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With… Phase2 Erosive Hand Osteoarthritis Completed 2015-03-01 2016-07-01 ClinicalTrials.gov
NCT02399345 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir… Phase3 Chronic Hepatitis C Virus (HCV Infection Genotype 1) Completed 2015-03-01 2015-11-01 ClinicalTrials.gov
NCT02471118 Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA) Phase2 Osteoarthritis, Knee Completed 2015-03-01 2021-03-01 ClinicalTrials.gov
NCT02442258 Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and … Phase1 Renal Impairment Completed 2015-03-01 2015-12-01 ClinicalTrials.gov
NCT02415959 Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insu… Phase2 Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis Completed 2015-03-01 2015-07-01 ClinicalTrials.gov
NCT02399345 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir… Phase3 Chronic Hepatitis C Virus (HCV Infection Genotype 1) Completed 2015-03-01 2015-11-01 ClinicalTrials.gov
NCT02384538 A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With… Phase2 Erosive Hand Osteoarthritis Completed 2015-03-01 2016-07-01 ClinicalTrials.gov
NCT02415959 Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insu… Phase2 Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis Completed 2015-03-01 2015-07-01 ClinicalTrials.gov
NCT02384538 A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With… Phase2 Erosive Hand Osteoarthritis Completed 2015-03-01 2016-07-01 ClinicalTrials.gov
NCT02415959 Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insu… Phase2 Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis Completed 2015-03-01 2015-07-01 ClinicalTrials.gov
NCT02442258 Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and … Phase1 Renal Impairment Completed 2015-03-01 2015-12-01 ClinicalTrials.gov
NCT02442258 Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and … Phase1 Renal Impairment Completed 2015-03-01 2015-12-01 ClinicalTrials.gov
NCT02471118 Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA) Phase2 Osteoarthritis, Knee Completed 2015-03-01 2021-03-01 ClinicalTrials.gov
NCT02471118 Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA) Phase2 Osteoarthritis, Knee Completed 2015-03-01 2021-03-01 ClinicalTrials.gov
NCT02415959 Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insu… Phase2 Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis Completed 2015-03-01 2015-07-01 ClinicalTrials.gov
NCT02559908 A Study of Hyaluronic Acid Injectable Gel (VYC-25L) for Restoration and Creatio… Na Chin Retrusion Completed 2015-02-26 2017-12-01 ClinicalTrials.gov
NCT02559908 A Study of Hyaluronic Acid Injectable Gel (VYC-25L) for Restoration and Creatio… Na Chin Retrusion Completed 2015-02-26 2017-12-01 ClinicalTrials.gov
NCT02559908 A Study of Hyaluronic Acid Injectable Gel (VYC-25L) for Restoration and Creatio… Na Chin Retrusion Completed 2015-02-26 2017-12-01 ClinicalTrials.gov
NCT02559908 A Study of Hyaluronic Acid Injectable Gel (VYC-25L) for Restoration and Creatio… Na Chin Retrusion Completed 2015-02-26 2017-12-01 ClinicalTrials.gov
NCT02272803 Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for New… Phase2 Multiple Myeloma Completed 2015-02-20 2021-07-21 ClinicalTrials.gov
NCT02272803 Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for New… Phase2 Multiple Myeloma Completed 2015-02-20 2021-07-21 ClinicalTrials.gov
NCT02272803 Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for New… Phase2 Multiple Myeloma Completed 2015-02-20 2021-07-21 ClinicalTrials.gov
NCT02272803 Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for New… Phase2 Multiple Myeloma Completed 2015-02-20 2021-07-21 ClinicalTrials.gov
NCT02343406 Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozo… Phase2 Glioblastoma Completed 2015-02-17 2019-06-24 ClinicalTrials.gov
NCT02343406 Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozo… Phase2 Glioblastoma Completed 2015-02-17 2019-06-24 ClinicalTrials.gov
NCT02343406 Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozo… Phase2 Glioblastoma Completed 2015-02-17 2019-06-24 ClinicalTrials.gov
NCT02343406 Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozo… Phase2 Glioblastoma Completed 2015-02-17 2019-06-24 ClinicalTrials.gov
NCT02356562 A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofo… Phase2 Chronic Hepatitis C Infection Completed 2015-02-03 2017-07-07 ClinicalTrials.gov
NCT02356562 A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofo… Phase2 Chronic Hepatitis C Infection Completed 2015-02-03 2017-07-07 ClinicalTrials.gov
NCT02356562 A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofo… Phase2 Chronic Hepatitis C Infection Completed 2015-02-03 2017-07-07 ClinicalTrials.gov
NCT02356562 A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofo… Phase2 Chronic Hepatitis C Infection Completed 2015-02-03 2017-07-07 ClinicalTrials.gov
NCT02399657 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macul… Phase4 Diabetes Mellitus Unknown 2015-02-01 2016-12-01 ClinicalTrials.gov
NCT02366364 Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Health… Phase1 Major Depressive Disorder Completed 2015-02-01 2015-04-01 ClinicalTrials.gov
NCT02399657 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macul… Phase4 Diabetes Mellitus Unknown 2015-02-01 2016-12-01 ClinicalTrials.gov
NCT02366364 Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Health… Phase1 Major Depressive Disorder Completed 2015-02-01 2015-04-01 ClinicalTrials.gov
NCT02399657 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macul… Phase4 Diabetes Mellitus Unknown 2015-02-01 2016-12-01 ClinicalTrials.gov
NCT02791308 Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subject… Phase3 Atopic Dermatitis Completed 2015-02-01 2016-07-01 ClinicalTrials.gov
NCT02791308 Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subject… Phase3 Atopic Dermatitis Completed 2015-02-01 2016-07-01 ClinicalTrials.gov
NCT02399657 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macul… Phase4 Diabetes Mellitus Unknown 2015-02-01 2016-12-01 ClinicalTrials.gov
NCT02366364 Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Health… Phase1 Major Depressive Disorder Completed 2015-02-01 2015-04-01 ClinicalTrials.gov
NCT02366364 Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Health… Phase1 Major Depressive Disorder Completed 2015-02-01 2015-04-01 ClinicalTrials.gov
NCT02791308 Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subject… Phase3 Atopic Dermatitis Completed 2015-02-01 2016-07-01 ClinicalTrials.gov
NCT02791308 Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subject… Phase3 Atopic Dermatitis Completed 2015-02-01 2016-07-01 ClinicalTrials.gov
NCT02255435 A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in Peo… Phase2 Friedreich Ataxia Completed 2015-01-31 2025-12-19 ClinicalTrials.gov
NCT02255435 A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in Peo… Phase2 Friedreich Ataxia Completed 2015-01-31 2025-12-19 ClinicalTrials.gov
NCT02255435 A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in Peo… Phase2 Friedreich Ataxia Completed 2015-01-31 2025-12-19 ClinicalTrials.gov
NCT02255435 A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in Peo… Phase2 Friedreich Ataxia Completed 2015-01-31 2025-12-19 ClinicalTrials.gov
NCT02357420 Safety and Efficacy of Relamorelin Administered to Participants With Vomiting S… Phase2 Diabetes Mellitus Completed 2015-01-29 2016-06-09 ClinicalTrials.gov
NCT02357420 Safety and Efficacy of Relamorelin Administered to Participants With Vomiting S… Phase2 Diabetes Mellitus Completed 2015-01-29 2016-06-09 ClinicalTrials.gov
NCT02357420 Safety and Efficacy of Relamorelin Administered to Participants With Vomiting S… Phase2 Diabetes Mellitus Completed 2015-01-29 2016-06-09 ClinicalTrials.gov
NCT02357420 Safety and Efficacy of Relamorelin Administered to Participants With Vomiting S… Phase2 Diabetes Mellitus Completed 2015-01-29 2016-06-09 ClinicalTrials.gov
NCT02362074 Progress at Work - The Impact of Adalimumab on Work Related Productivity in Pat… — Rheumatoid Arthritis Completed 2015-01-21 2020-03-06 ClinicalTrials.gov
NCT02362074 Progress at Work - The Impact of Adalimumab on Work Related Productivity in Pat… — Rheumatoid Arthritis Completed 2015-01-21 2020-03-06 ClinicalTrials.gov
NCT02362074 Progress at Work - The Impact of Adalimumab on Work Related Productivity in Pat… — Rheumatoid Arthritis Completed 2015-01-21 2020-03-06 ClinicalTrials.gov
NCT02362074 Progress at Work - The Impact of Adalimumab on Work Related Productivity in Pat… — Rheumatoid Arthritis Completed 2015-01-21 2020-03-06 ClinicalTrials.gov
NCT02213289 PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A … Phase2 Adenocarcinoma Completed 2015-01-20 2020-08-20 ClinicalTrials.gov
NCT02213289 PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A … Phase2 Adenocarcinoma Completed 2015-01-20 2020-08-20 ClinicalTrials.gov
NCT02213289 PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A … Phase2 Adenocarcinoma Completed 2015-01-20 2020-08-20 ClinicalTrials.gov
NCT02213289 PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A … Phase2 Adenocarcinoma Completed 2015-01-20 2020-08-20 ClinicalTrials.gov
NCT02365662 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Adv… Phase1 Head and Neck Squamous Cell Carcinoma Terminated 2015-01-09 2018-03-15 ClinicalTrials.gov
NCT02365662 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Adv… Phase1 Head and Neck Squamous Cell Carcinoma Terminated 2015-01-09 2018-03-15 ClinicalTrials.gov
NCT02365662 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Adv… Phase1 Head and Neck Squamous Cell Carcinoma Terminated 2015-01-09 2018-03-15 ClinicalTrials.gov
NCT02365662 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Adv… Phase1 Head and Neck Squamous Cell Carcinoma Terminated 2015-01-09 2018-03-15 ClinicalTrials.gov
NCT02434666 Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's T… Phase2 Dementia of the Alzheimer's Type Completed 2015-01-08 2016-11-22 ClinicalTrials.gov
NCT02434666 Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's T… Phase2 Dementia of the Alzheimer's Type Completed 2015-01-08 2016-11-22 ClinicalTrials.gov
NCT02434666 Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's T… Phase2 Dementia of the Alzheimer's Type Completed 2015-01-08 2016-11-22 ClinicalTrials.gov
NCT02434666 Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's T… Phase2 Dementia of the Alzheimer's Type Completed 2015-01-08 2016-11-22 ClinicalTrials.gov
NCT02198651 A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imag… Phase4 Rheumatoid Arthritis Completed 2015-01-05 2018-08-08 ClinicalTrials.gov
NCT02198651 A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imag… Phase4 Rheumatoid Arthritis Completed 2015-01-05 2018-08-08 ClinicalTrials.gov
NCT02198651 A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imag… Phase4 Rheumatoid Arthritis Completed 2015-01-05 2018-08-08 ClinicalTrials.gov
NCT02198651 A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imag… Phase4 Rheumatoid Arthritis Completed 2015-01-05 2018-08-08 ClinicalTrials.gov
NCT02573324 A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With… Phase3 Glioblastoma Completed 2015-01-04 2022-04-04 ClinicalTrials.gov
NCT02573324 A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With… Phase3 Glioblastoma Completed 2015-01-04 2022-04-04 ClinicalTrials.gov
NCT02573324 A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With… Phase3 Glioblastoma Completed 2015-01-04 2022-04-04 ClinicalTrials.gov
NCT02573324 A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With… Phase3 Glioblastoma Completed 2015-01-04 2022-04-04 ClinicalTrials.gov
NCT02165111 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Phase3 Scleroderma Completed 2015-01-01 2015-09-01 ClinicalTrials.gov
NCT02165111 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Phase3 Scleroderma Completed 2015-01-01 2015-09-01 ClinicalTrials.gov
NCT02165111 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Phase3 Scleroderma Completed 2015-01-01 2015-09-01 ClinicalTrials.gov
NCT02165111 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Phase3 Scleroderma Completed 2015-01-01 2015-09-01 ClinicalTrials.gov
NCT02242942 Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab +… Phase3 Lymphocytic Leukemia, Chronic Completed 2014-12-31 2025-08-27 ClinicalTrials.gov
NCT02242942 Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab +… Phase3 Lymphocytic Leukemia, Chronic Completed 2014-12-31 2025-08-27 ClinicalTrials.gov
NCT02333383 Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis … — Ankylosing Spondylitis Completed 2014-12-31 2017-08-08 ClinicalTrials.gov
NCT02242942 Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab +… Phase3 Lymphocytic Leukemia, Chronic Completed 2014-12-31 2025-08-27 ClinicalTrials.gov
NCT02242942 Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab +… Phase3 Lymphocytic Leukemia, Chronic Completed 2014-12-31 2025-08-27 ClinicalTrials.gov
NCT02333383 Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis … — Ankylosing Spondylitis Completed 2014-12-31 2017-08-08 ClinicalTrials.gov
NCT02287233 A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatm… Phase1 Acute Myelogenous Leukemia Completed 2014-12-31 2021-08-10 ClinicalTrials.gov
NCT02287233 A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatm… Phase1 Acute Myelogenous Leukemia Completed 2014-12-31 2021-08-10 ClinicalTrials.gov
NCT02287233 A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatm… Phase1 Acute Myelogenous Leukemia Completed 2014-12-31 2021-08-10 ClinicalTrials.gov
NCT02333383 Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis … — Ankylosing Spondylitis Completed 2014-12-31 2017-08-08 ClinicalTrials.gov
NCT02287233 A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatm… Phase1 Acute Myelogenous Leukemia Completed 2014-12-31 2021-08-10 ClinicalTrials.gov
NCT02333383 Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis … — Ankylosing Spondylitis Completed 2014-12-31 2017-08-08 ClinicalTrials.gov
NCT02292719 A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Wit… Phase2 Chronic Hepatitis C Virus Infection Completed 2014-12-19 2017-07-14 ClinicalTrials.gov
NCT02292719 A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Wit… Phase2 Chronic Hepatitis C Virus Infection Completed 2014-12-19 2017-07-14 ClinicalTrials.gov
NCT02292719 A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Wit… Phase2 Chronic Hepatitis C Virus Infection Completed 2014-12-19 2017-07-14 ClinicalTrials.gov
NCT02292719 A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Wit… Phase2 Chronic Hepatitis C Virus Infection Completed 2014-12-19 2017-07-14 ClinicalTrials.gov
NCT02320149 Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne Phase3 Acne Vulgaris Completed 2014-12-18 2017-02-01 ClinicalTrials.gov
NCT02320149 Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne Phase3 Acne Vulgaris Completed 2014-12-18 2017-02-01 ClinicalTrials.gov
NCT02320149 Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne Phase3 Acne Vulgaris Completed 2014-12-18 2017-02-01 ClinicalTrials.gov
NCT02320149 Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne Phase3 Acne Vulgaris Completed 2014-12-18 2017-02-01 ClinicalTrials.gov
NCT03341780 Standard Amblyopia Therapy in Adult Amblyopes — Amblyopia Completed 2014-12-16 2016-10-24 ClinicalTrials.gov
NCT03341780 Standard Amblyopia Therapy in Adult Amblyopes — Amblyopia Completed 2014-12-16 2016-10-24 ClinicalTrials.gov
NCT03341780 Standard Amblyopia Therapy in Adult Amblyopes — Amblyopia Completed 2014-12-16 2016-10-24 ClinicalTrials.gov
NCT03341780 Standard Amblyopia Therapy in Adult Amblyopes — Amblyopia Completed 2014-12-16 2016-10-24 ClinicalTrials.gov
NCT02250651 Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open… Phase3 Glaucoma, Open-Angle Completed 2014-12-15 2020-07-22 ClinicalTrials.gov
NCT02250651 Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open… Phase3 Glaucoma, Open-Angle Completed 2014-12-15 2020-07-22 ClinicalTrials.gov
NCT02247804 Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants… Phase3 Glaucoma, Open-Angle Completed 2014-12-15 2019-07-19 ClinicalTrials.gov
NCT02250651 Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open… Phase3 Glaucoma, Open-Angle Completed 2014-12-15 2020-07-22 ClinicalTrials.gov
NCT02247804 Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants… Phase3 Glaucoma, Open-Angle Completed 2014-12-15 2019-07-19 ClinicalTrials.gov
NCT02247804 Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants… Phase3 Glaucoma, Open-Angle Completed 2014-12-15 2019-07-19 ClinicalTrials.gov
NCT02250651 Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open… Phase3 Glaucoma, Open-Angle Completed 2014-12-15 2020-07-22 ClinicalTrials.gov
NCT02247804 Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants… Phase3 Glaucoma, Open-Angle Completed 2014-12-15 2019-07-19 ClinicalTrials.gov
NCT02505776 Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Tr… — Eyelash Hypotrichosis Completed 2014-12-08 2018-05-21 ClinicalTrials.gov
NCT02505776 Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Tr… — Eyelash Hypotrichosis Completed 2014-12-08 2018-05-21 ClinicalTrials.gov
NCT02505776 Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Tr… — Eyelash Hypotrichosis Completed 2014-12-08 2018-05-21 ClinicalTrials.gov
NCT02505776 Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Tr… — Eyelash Hypotrichosis Completed 2014-12-08 2018-05-21 ClinicalTrials.gov
NCT02305758 Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or With… Phase2 Untreated Metastatic Colorectal Cancer Completed 2014-12-02 2017-09-22 ClinicalTrials.gov
NCT02305758 Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or With… Phase2 Untreated Metastatic Colorectal Cancer Completed 2014-12-02 2017-09-22 ClinicalTrials.gov
NCT02305758 Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or With… Phase2 Untreated Metastatic Colorectal Cancer Completed 2014-12-02 2017-09-22 ClinicalTrials.gov
NCT02305758 Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or With… Phase2 Untreated Metastatic Colorectal Cancer Completed 2014-12-02 2017-09-22 ClinicalTrials.gov
NCT02539849 Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii… Na Crohn Disease Completed 2014-12-01 2017-12-19 ClinicalTrials.gov
NCT02455050 A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Gente… Phase3 Dry Eye Syndromes Completed 2014-12-01 2015-08-01 ClinicalTrials.gov
NCT02539849 Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii… Na Crohn Disease Completed 2014-12-01 2017-12-19 ClinicalTrials.gov
NCT02330016 Juvederm Voluma® XC for the Treatment of Hypoplastic Chin Na Mandibular Hypoplasia Unknown 2014-12-01 2015-10-01 ClinicalTrials.gov
NCT02455050 A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Gente… Phase3 Dry Eye Syndromes Completed 2014-12-01 2015-08-01 ClinicalTrials.gov
NCT02330016 Juvederm Voluma® XC for the Treatment of Hypoplastic Chin Na Mandibular Hypoplasia Unknown 2014-12-01 2015-10-01 ClinicalTrials.gov
NCT02187861 A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendam… Phase2 Follicular Lymphoma Completed 2014-12-01 2018-03-16 ClinicalTrials.gov
NCT02297100 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis Phase4 Interstitial Cystitis Completed 2014-12-01 2018-01-10 ClinicalTrials.gov
NCT02455050 A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Gente… Phase3 Dry Eye Syndromes Completed 2014-12-01 2015-08-01 ClinicalTrials.gov
NCT02297100 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis Phase4 Interstitial Cystitis Completed 2014-12-01 2018-01-10 ClinicalTrials.gov
NCT02297100 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis Phase4 Interstitial Cystitis Completed 2014-12-01 2018-01-10 ClinicalTrials.gov
NCT02330016 Juvederm Voluma® XC for the Treatment of Hypoplastic Chin Na Mandibular Hypoplasia Unknown 2014-12-01 2015-10-01 ClinicalTrials.gov
NCT02455050 A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Gente… Phase3 Dry Eye Syndromes Completed 2014-12-01 2015-08-01 ClinicalTrials.gov
NCT02539849 Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii… Na Crohn Disease Completed 2014-12-01 2017-12-19 ClinicalTrials.gov
NCT02187861 A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendam… Phase2 Follicular Lymphoma Completed 2014-12-01 2018-03-16 ClinicalTrials.gov
NCT02297100 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis Phase4 Interstitial Cystitis Completed 2014-12-01 2018-01-10 ClinicalTrials.gov
NCT02187861 A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendam… Phase2 Follicular Lymphoma Completed 2014-12-01 2018-03-16 ClinicalTrials.gov
NCT02187861 A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendam… Phase2 Follicular Lymphoma Completed 2014-12-01 2018-03-16 ClinicalTrials.gov
NCT02330016 Juvederm Voluma® XC for the Treatment of Hypoplastic Chin Na Mandibular Hypoplasia Unknown 2014-12-01 2015-10-01 ClinicalTrials.gov
NCT02539849 Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii… Na Crohn Disease Completed 2014-12-01 2017-12-19 ClinicalTrials.gov
NCT02219477 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Completed 2014-11-24 2017-03-03 ClinicalTrials.gov
NCT02219477 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Completed 2014-11-24 2017-03-03 ClinicalTrials.gov
NCT02219477 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Completed 2014-11-24 2017-03-03 ClinicalTrials.gov
NCT02219477 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Completed 2014-11-24 2017-03-03 ClinicalTrials.gov
NCT02203851 Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risanki… Phase2 Psoriasis Completed 2014-11-20 2018-09-04 ClinicalTrials.gov
NCT02203851 Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risanki… Phase2 Psoriasis Completed 2014-11-20 2018-09-04 ClinicalTrials.gov
NCT02203851 Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risanki… Phase2 Psoriasis Completed 2014-11-20 2018-09-04 ClinicalTrials.gov
NCT02203851 Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risanki… Phase2 Psoriasis Completed 2014-11-20 2018-09-04 ClinicalTrials.gov
NCT02313454 Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal N… Na Dry Eye Syndromes Completed 2014-11-17 2015-04-08 ClinicalTrials.gov
NCT02313454 Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal N… Na Dry Eye Syndromes Completed 2014-11-17 2015-04-08 ClinicalTrials.gov
NCT02313454 Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal N… Na Dry Eye Syndromes Completed 2014-11-17 2015-04-08 ClinicalTrials.gov
NCT02313454 Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal N… Na Dry Eye Syndromes Completed 2014-11-17 2015-04-08 ClinicalTrials.gov
NCT02247401 Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribaviri… Phase3 HCV Completed 2014-11-04 2016-08-01 ClinicalTrials.gov
NCT02247401 Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribaviri… Phase3 HCV Completed 2014-11-04 2016-08-01 ClinicalTrials.gov
NCT02247401 Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribaviri… Phase3 HCV Completed 2014-11-04 2016-08-01 ClinicalTrials.gov
NCT02247401 Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribaviri… Phase3 HCV Completed 2014-11-04 2016-08-01 ClinicalTrials.gov
NCT02348476 A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hy… — Open-Angle Glaucoma Completed 2014-11-01 2015-04-01 ClinicalTrials.gov
NCT02058836 Botulinum Toxin for the Management of Chronic Orchialgia Phase2 Chronic Testicular Pain Completed 2014-11-01 2016-10-18 ClinicalTrials.gov
NCT02348476 A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hy… — Open-Angle Glaucoma Completed 2014-11-01 2015-04-01 ClinicalTrials.gov
NCT02348476 A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hy… — Open-Angle Glaucoma Completed 2014-11-01 2015-04-01 ClinicalTrials.gov
NCT02058836 Botulinum Toxin for the Management of Chronic Orchialgia Phase2 Chronic Testicular Pain Completed 2014-11-01 2016-10-18 ClinicalTrials.gov
NCT02058836 Botulinum Toxin for the Management of Chronic Orchialgia Phase2 Chronic Testicular Pain Completed 2014-11-01 2016-10-18 ClinicalTrials.gov
NCT02348476 A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hy… — Open-Angle Glaucoma Completed 2014-11-01 2015-04-01 ClinicalTrials.gov
NCT02058836 Botulinum Toxin for the Management of Chronic Orchialgia Phase2 Chronic Testicular Pain Completed 2014-11-01 2016-10-18 ClinicalTrials.gov
NCT02219490 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonav… Phase3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 Completed 2014-10-30 2021-05-13 ClinicalTrials.gov
NCT02219490 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonav… Phase3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 Completed 2014-10-30 2021-05-13 ClinicalTrials.gov
NCT02219490 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonav… Phase3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 Completed 2014-10-30 2021-05-13 ClinicalTrials.gov
NCT02219490 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonav… Phase3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 Completed 2014-10-30 2021-05-13 ClinicalTrials.gov
NCT02265237 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvi… Phase3 Hepatitis C Virus Completed 2014-10-28 2017-04-07 ClinicalTrials.gov
NCT02265237 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvi… Phase3 Hepatitis C Virus Completed 2014-10-28 2017-04-07 ClinicalTrials.gov
NCT02265237 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvi… Phase3 Hepatitis C Virus Completed 2014-10-28 2017-04-07 ClinicalTrials.gov
NCT02265237 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvi… Phase3 Hepatitis C Virus Completed 2014-10-28 2017-04-07 ClinicalTrials.gov
NCT02261493 A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides Phase3 Facial Rhytides Completed 2014-10-27 2016-04-20 ClinicalTrials.gov
NCT02261493 A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides Phase3 Facial Rhytides Completed 2014-10-27 2016-04-20 ClinicalTrials.gov
NCT02261493 A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides Phase3 Facial Rhytides Completed 2014-10-27 2016-04-20 ClinicalTrials.gov
NCT02261493 A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides Phase3 Facial Rhytides Completed 2014-10-27 2016-04-20 ClinicalTrials.gov
NCT02289690 Dose Escalation and Double-blind Study of Veliparib in Combination With Carbopl… Phase1 Small Cell Lung Cancer Completed 2014-10-13 2019-04-17 ClinicalTrials.gov
NCT02065557 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe… Phase3 Ulcerative Colitis Completed 2014-10-13 2020-02-07 ClinicalTrials.gov
NCT02065557 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe… Phase3 Ulcerative Colitis Completed 2014-10-13 2020-02-07 ClinicalTrials.gov
NCT02289690 Dose Escalation and Double-blind Study of Veliparib in Combination With Carbopl… Phase1 Small Cell Lung Cancer Completed 2014-10-13 2019-04-17 ClinicalTrials.gov
NCT02065557 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe… Phase3 Ulcerative Colitis Completed 2014-10-13 2020-02-07 ClinicalTrials.gov
NCT02289690 Dose Escalation and Double-blind Study of Veliparib in Combination With Carbopl… Phase1 Small Cell Lung Cancer Completed 2014-10-13 2019-04-17 ClinicalTrials.gov
NCT02289690 Dose Escalation and Double-blind Study of Veliparib in Combination With Carbopl… Phase1 Small Cell Lung Cancer Completed 2014-10-13 2019-04-17 ClinicalTrials.gov
NCT02065557 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe… Phase3 Ulcerative Colitis Completed 2014-10-13 2020-02-07 ClinicalTrials.gov
NCT02203773 Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chem… Phase1 Acute Myelogenous Leukemia Terminated 2014-10-06 2022-06-16 ClinicalTrials.gov
NCT02203773 Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chem… Phase1 Acute Myelogenous Leukemia Terminated 2014-10-06 2022-06-16 ClinicalTrials.gov
NCT02203773 Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chem… Phase1 Acute Myelogenous Leukemia Terminated 2014-10-06 2022-06-16 ClinicalTrials.gov
NCT02203773 Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chem… Phase1 Acute Myelogenous Leukemia Terminated 2014-10-06 2022-06-16 ClinicalTrials.gov
NCT02230956 BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis Phase2 Osteoarthritis Completed 2014-10-01 2016-03-01 ClinicalTrials.gov
NCT02289729 Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa I… — Parkinson's Disease Completed 2014-10-01 2016-11-01 ClinicalTrials.gov
NCT02296905 Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal a… Phase1 Hepatic Impairment Completed 2014-10-01 2015-09-01 ClinicalTrials.gov
NCT02070302 BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Synd… Phase2 Carpal Tunnel Syndrome Completed 2014-10-01 2016-02-01 ClinicalTrials.gov
NCT02070302 BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Synd… Phase2 Carpal Tunnel Syndrome Completed 2014-10-01 2016-02-01 ClinicalTrials.gov
NCT02282982 Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalizati… — Respiratory Syncytial Virus (RSV) Completed 2014-10-01 2015-05-01 ClinicalTrials.gov
NCT02289729 Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa I… — Parkinson's Disease Completed 2014-10-01 2016-11-01 ClinicalTrials.gov
NCT02296905 Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal a… Phase1 Hepatic Impairment Completed 2014-10-01 2015-09-01 ClinicalTrials.gov
NCT02305953 Cytokines and Vascular Inflammation in Psoriasis — Vascular Inflammation Completed 2014-10-01 2014-10-01 ClinicalTrials.gov
NCT02296905 Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal a… Phase1 Hepatic Impairment Completed 2014-10-01 2015-09-01 ClinicalTrials.gov
NCT02230956 BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis Phase2 Osteoarthritis Completed 2014-10-01 2016-03-01 ClinicalTrials.gov
NCT02070302 BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Synd… Phase2 Carpal Tunnel Syndrome Completed 2014-10-01 2016-02-01 ClinicalTrials.gov
NCT02070302 BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Synd… Phase2 Carpal Tunnel Syndrome Completed 2014-10-01 2016-02-01 ClinicalTrials.gov
NCT02230956 BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis Phase2 Osteoarthritis Completed 2014-10-01 2016-03-01 ClinicalTrials.gov
NCT02305953 Cytokines and Vascular Inflammation in Psoriasis — Vascular Inflammation Completed 2014-10-01 2014-10-01 ClinicalTrials.gov
NCT02282982 Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalizati… — Respiratory Syncytial Virus (RSV) Completed 2014-10-01 2015-05-01 ClinicalTrials.gov
NCT02289729 Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa I… — Parkinson's Disease Completed 2014-10-01 2016-11-01 ClinicalTrials.gov
NCT02282982 Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalizati… — Respiratory Syncytial Virus (RSV) Completed 2014-10-01 2015-05-01 ClinicalTrials.gov
NCT02282982 Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalizati… — Respiratory Syncytial Virus (RSV) Completed 2014-10-01 2015-05-01 ClinicalTrials.gov
NCT02230956 BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis Phase2 Osteoarthritis Completed 2014-10-01 2016-03-01 ClinicalTrials.gov
NCT02305953 Cytokines and Vascular Inflammation in Psoriasis — Vascular Inflammation Completed 2014-10-01 2014-10-01 ClinicalTrials.gov
NCT02289729 Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa I… — Parkinson's Disease Completed 2014-10-01 2016-11-01 ClinicalTrials.gov
NCT02296905 Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal a… Phase1 Hepatic Impairment Completed 2014-10-01 2015-09-01 ClinicalTrials.gov
NCT02305953 Cytokines and Vascular Inflammation in Psoriasis — Vascular Inflammation Completed 2014-10-01 2014-10-01 ClinicalTrials.gov
NCT02264990 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's… Phase3 Non-squamous Non-small Cell Lung Cancer Completed 2014-09-30 2020-02-21 ClinicalTrials.gov
NCT02264990 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's… Phase3 Non-squamous Non-small Cell Lung Cancer Completed 2014-09-30 2020-02-21 ClinicalTrials.gov
NCT02264990 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's… Phase3 Non-squamous Non-small Cell Lung Cancer Completed 2014-09-30 2020-02-21 ClinicalTrials.gov
NCT02264990 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's… Phase3 Non-squamous Non-small Cell Lung Cancer Completed 2014-09-30 2020-02-21 ClinicalTrials.gov
NCT02207088 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Gen… Phase3 Chronic Hepatitis C Completed 2014-09-23 2016-12-06 ClinicalTrials.gov
NCT02207088 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Gen… Phase3 Chronic Hepatitis C Completed 2014-09-23 2016-12-06 ClinicalTrials.gov
NCT02207088 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Gen… Phase3 Chronic Hepatitis C Completed 2014-09-23 2016-12-06 ClinicalTrials.gov
NCT02207088 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Gen… Phase3 Chronic Hepatitis C Completed 2014-09-23 2016-12-06 ClinicalTrials.gov
NCT02265731 Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase1 Non-Hodgkin Lymphoma (NHL) Completed 2014-09-22 2021-03-12 ClinicalTrials.gov
NCT02265731 Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase1 Non-Hodgkin Lymphoma (NHL) Completed 2014-09-22 2021-03-12 ClinicalTrials.gov
NCT02265731 Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase1 Non-Hodgkin Lymphoma (NHL) Completed 2014-09-22 2021-03-12 ClinicalTrials.gov
NCT02265731 Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase1 Non-Hodgkin Lymphoma (NHL) Completed 2014-09-22 2021-03-12 ClinicalTrials.gov
NCT02243293 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administra… Phase2 Chronic Hepatitis C Completed 2014-09-19 2017-02-23 ClinicalTrials.gov
NCT02243293 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administra… Phase2 Chronic Hepatitis C Completed 2014-09-19 2017-02-23 ClinicalTrials.gov
NCT02243293 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administra… Phase2 Chronic Hepatitis C Completed 2014-09-19 2017-02-23 ClinicalTrials.gov
NCT02243293 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administra… Phase2 Chronic Hepatitis C Completed 2014-09-19 2017-02-23 ClinicalTrials.gov
NCT02141282 A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in … Phase2 Chronic Lymphocytic Leukemia Completed 2014-09-10 2021-12-22 ClinicalTrials.gov
NCT02141282 A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in … Phase2 Chronic Lymphocytic Leukemia Completed 2014-09-10 2021-12-22 ClinicalTrials.gov
NCT02141282 A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in … Phase2 Chronic Lymphocytic Leukemia Completed 2014-09-10 2021-12-22 ClinicalTrials.gov
NCT02141282 A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in … Phase2 Chronic Lymphocytic Leukemia Completed 2014-09-10 2021-12-22 ClinicalTrials.gov
NCT02192099 Open Label Extension for GLYX13-C-202, NCT01684163 Phase2 Major Depressive Disorder Terminated 2014-09-08 2018-11-08 ClinicalTrials.gov
NCT02192099 Open Label Extension for GLYX13-C-202, NCT01684163 Phase2 Major Depressive Disorder Terminated 2014-09-08 2018-11-08 ClinicalTrials.gov
NCT02192099 Open Label Extension for GLYX13-C-202, NCT01684163 Phase2 Major Depressive Disorder Terminated 2014-09-08 2018-11-08 ClinicalTrials.gov
NCT02192099 Open Label Extension for GLYX13-C-202, NCT01684163 Phase2 Major Depressive Disorder Terminated 2014-09-08 2018-11-08 ClinicalTrials.gov
NCT02158507 Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Meta… Na Metastatic Triple Negative Breast Cancer Completed 2014-09-04 2021-07-22 ClinicalTrials.gov
NCT02158507 Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Meta… Na Metastatic Triple Negative Breast Cancer Completed 2014-09-04 2021-07-22 ClinicalTrials.gov
NCT02158507 Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Meta… Na Metastatic Triple Negative Breast Cancer Completed 2014-09-04 2021-07-22 ClinicalTrials.gov
NCT02158507 Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Meta… Na Metastatic Triple Negative Breast Cancer Completed 2014-09-04 2021-07-22 ClinicalTrials.gov
NCT02220738 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in … Phase1 Alzheimer's Disease Terminated 2014-09-01 2016-03-01 ClinicalTrials.gov
NCT02220738 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in … Phase1 Alzheimer's Disease Terminated 2014-09-01 2016-03-01 ClinicalTrials.gov
NCT02216422 A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adul… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2014-09-01 2015-12-01 ClinicalTrials.gov
NCT02219503 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Infection Completed 2014-09-01 2015-09-01 ClinicalTrials.gov
NCT02181504 A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Mac… Phase2 Macular Degeneration Completed 2014-09-01 2015-12-01 ClinicalTrials.gov
NCT02195687 BOTOX® in the Treatment of Crow's Feet Lines in China Phase3 Lateral Canthal Lines Completed 2014-09-01 2015-06-01 ClinicalTrials.gov
NCT02195687 BOTOX® in the Treatment of Crow's Feet Lines in China Phase3 Lateral Canthal Lines Completed 2014-09-01 2015-06-01 ClinicalTrials.gov
NCT02181504 A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Mac… Phase2 Macular Degeneration Completed 2014-09-01 2015-12-01 ClinicalTrials.gov
NCT01920945 OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open … Phase2 New Daily Persistent Headache Terminated 2014-09-01 2016-10-01 ClinicalTrials.gov
NCT02220738 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in … Phase1 Alzheimer's Disease Terminated 2014-09-01 2016-03-01 ClinicalTrials.gov
NCT02219503 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Infection Completed 2014-09-01 2015-09-01 ClinicalTrials.gov
NCT02216422 A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adul… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2014-09-01 2015-12-01 ClinicalTrials.gov
NCT02095574 A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in A… Phase1 Relapsed/Refractory Non-Hodgkin's Lymphoma Withdrawn 2014-09-01 2015-01-01 ClinicalTrials.gov
NCT02095574 A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in A… Phase1 Relapsed/Refractory Non-Hodgkin's Lymphoma Withdrawn 2014-09-01 2015-01-01 ClinicalTrials.gov
NCT02216422 A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adul… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2014-09-01 2015-12-01 ClinicalTrials.gov
NCT02219503 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Infection Completed 2014-09-01 2015-09-01 ClinicalTrials.gov
NCT01920945 OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open … Phase2 New Daily Persistent Headache Terminated 2014-09-01 2016-10-01 ClinicalTrials.gov
NCT01920945 OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open … Phase2 New Daily Persistent Headache Terminated 2014-09-01 2016-10-01 ClinicalTrials.gov
NCT02181504 A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Mac… Phase2 Macular Degeneration Completed 2014-09-01 2015-12-01 ClinicalTrials.gov
NCT02181504 A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Mac… Phase2 Macular Degeneration Completed 2014-09-01 2015-12-01 ClinicalTrials.gov
NCT02195687 BOTOX® in the Treatment of Crow's Feet Lines in China Phase3 Lateral Canthal Lines Completed 2014-09-01 2015-06-01 ClinicalTrials.gov
NCT02195687 BOTOX® in the Treatment of Crow's Feet Lines in China Phase3 Lateral Canthal Lines Completed 2014-09-01 2015-06-01 ClinicalTrials.gov
NCT02095574 A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in A… Phase1 Relapsed/Refractory Non-Hodgkin's Lymphoma Withdrawn 2014-09-01 2015-01-01 ClinicalTrials.gov
NCT01920945 OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open … Phase2 New Daily Persistent Headache Terminated 2014-09-01 2016-10-01 ClinicalTrials.gov
NCT02220738 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in … Phase1 Alzheimer's Disease Terminated 2014-09-01 2016-03-01 ClinicalTrials.gov
NCT02095574 A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in A… Phase1 Relapsed/Refractory Non-Hodgkin's Lymphoma Withdrawn 2014-09-01 2015-01-01 ClinicalTrials.gov
NCT02216422 A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adul… Phase3 Chronic Hepatitis C Virus (HCV) Infection Completed 2014-09-01 2015-12-01 ClinicalTrials.gov
NCT02219503 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavi… Phase3 Chronic Hepatitis C Infection Completed 2014-09-01 2015-09-01 ClinicalTrials.gov
NCT02130362 A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiven… — Crohn's Disease Active_Not_Recruiting 2014-08-28 2030-11-01 ClinicalTrials.gov
NCT02130362 A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiven… — Crohn's Disease Active_Not_Recruiting 2014-08-28 2030-11-01 ClinicalTrials.gov
NCT02130362 A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiven… — Crohn's Disease Active_Not_Recruiting 2014-08-28 2030-11-01 ClinicalTrials.gov
NCT02130362 A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiven… — Crohn's Disease Active_Not_Recruiting 2014-08-28 2030-11-01 ClinicalTrials.gov
NCT02185014 Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Rep… Phase3 Crohn's Disease Completed 2014-08-12 2017-11-03 ClinicalTrials.gov
NCT02185014 Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Rep… Phase3 Crohn's Disease Completed 2014-08-12 2017-11-03 ClinicalTrials.gov
NCT02185014 Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Rep… Phase3 Crohn's Disease Completed 2014-08-12 2017-11-03 ClinicalTrials.gov
NCT02185014 Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Rep… Phase3 Crohn's Disease Completed 2014-08-12 2017-11-03 ClinicalTrials.gov
NCT02191579 Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention o… Phase4 Migraine Disorders Completed 2014-08-05 2017-09-01 ClinicalTrials.gov
NCT02191579 Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention o… Phase4 Migraine Disorders Completed 2014-08-05 2017-09-01 ClinicalTrials.gov
NCT02196701 Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real… Phase3 Psoriasis Completed 2014-08-05 2017-03-17 ClinicalTrials.gov
NCT02191579 Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention o… Phase4 Migraine Disorders Completed 2014-08-05 2017-09-01 ClinicalTrials.gov
NCT02191579 Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention o… Phase4 Migraine Disorders Completed 2014-08-05 2017-09-01 ClinicalTrials.gov
NCT02196701 Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real… Phase3 Psoriasis Completed 2014-08-05 2017-03-17 ClinicalTrials.gov
NCT02196701 Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real… Phase3 Psoriasis Completed 2014-08-05 2017-03-17 ClinicalTrials.gov
NCT02196701 Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real… Phase3 Psoriasis Completed 2014-08-05 2017-03-17 ClinicalTrials.gov
NCT02293798 Circumferential Periareolar Mastopexy Using SERI Surgical Scaffold Na Mastopexy Completed 2014-08-01 2016-06-01 ClinicalTrials.gov
NCT02218034 Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne V… Phase1 Acne Vulgaris Completed 2014-08-01 2015-03-01 ClinicalTrials.gov
NCT02173405 Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic P… Phase1 Myofascial Pain Syndromes Completed 2014-08-01 2016-09-01 ClinicalTrials.gov
NCT02167035 Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily… Phase4 Glaucoma Completed 2014-08-01 2018-03-01 ClinicalTrials.gov
NCT02145689 Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Li… Phase3 Muscle Spasticity Withdrawn 2014-08-01 2017-05-01 ClinicalTrials.gov
NCT02145689 Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Li… Phase3 Muscle Spasticity Withdrawn 2014-08-01 2017-05-01 ClinicalTrials.gov
NCT02167035 Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily… Phase4 Glaucoma Completed 2014-08-01 2018-03-01 ClinicalTrials.gov
NCT02173405 Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic P… Phase1 Myofascial Pain Syndromes Completed 2014-08-01 2016-09-01 ClinicalTrials.gov
NCT02218034 Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne V… Phase1 Acne Vulgaris Completed 2014-08-01 2015-03-01 ClinicalTrials.gov
NCT02293798 Circumferential Periareolar Mastopexy Using SERI Surgical Scaffold Na Mastopexy Completed 2014-08-01 2016-06-01 ClinicalTrials.gov
NCT02243280 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administra… Phase2 Chronic Hepatitis C Completed 2014-08-01 2016-02-01 ClinicalTrials.gov
NCT02293798 Circumferential Periareolar Mastopexy Using SERI Surgical Scaffold Na Mastopexy Completed 2014-08-01 2016-06-01 ClinicalTrials.gov
NCT02218034 Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne V… Phase1 Acne Vulgaris Completed 2014-08-01 2015-03-01 ClinicalTrials.gov
NCT02173405 Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic P… Phase1 Myofascial Pain Syndromes Completed 2014-08-01 2016-09-01 ClinicalTrials.gov
NCT02167035 Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily… Phase4 Glaucoma Completed 2014-08-01 2018-03-01 ClinicalTrials.gov
NCT02243280 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administra… Phase2 Chronic Hepatitis C Completed 2014-08-01 2016-02-01 ClinicalTrials.gov
NCT02145689 Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Li… Phase3 Muscle Spasticity Withdrawn 2014-08-01 2017-05-01 ClinicalTrials.gov
NCT02243280 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administra… Phase2 Chronic Hepatitis C Completed 2014-08-01 2016-02-01 ClinicalTrials.gov
NCT02293798 Circumferential Periareolar Mastopexy Using SERI Surgical Scaffold Na Mastopexy Completed 2014-08-01 2016-06-01 ClinicalTrials.gov
NCT02243280 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administra… Phase2 Chronic Hepatitis C Completed 2014-08-01 2016-02-01 ClinicalTrials.gov
NCT02218034 Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne V… Phase1 Acne Vulgaris Completed 2014-08-01 2015-03-01 ClinicalTrials.gov
NCT02173405 Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic P… Phase1 Myofascial Pain Syndromes Completed 2014-08-01 2016-09-01 ClinicalTrials.gov
NCT02167035 Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily… Phase4 Glaucoma Completed 2014-08-01 2018-03-01 ClinicalTrials.gov
NCT02145689 Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Li… Phase3 Muscle Spasticity Withdrawn 2014-08-01 2017-05-01 ClinicalTrials.gov
NCT02185053 A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia Phase2 Alzheimer's Disease Completed 2014-07-31 2016-07-31 ClinicalTrials.gov
NCT02185053 A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia Phase2 Alzheimer's Disease Completed 2014-07-31 2016-07-31 ClinicalTrials.gov
NCT02185053 A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia Phase2 Alzheimer's Disease Completed 2014-07-31 2016-07-31 ClinicalTrials.gov
NCT02185053 A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia Phase2 Alzheimer's Disease Completed 2014-07-31 2016-07-31 ClinicalTrials.gov
NCT02188173 An Observational Study of OZURDEX® in Diabetic Macular Edema (DME) — Macular Edema Completed 2014-07-01 2016-05-01 ClinicalTrials.gov
NCT02092389 Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Sufferi… — Moderate to Severe Ulcerative Colitis Terminated 2014-07-01 2016-03-01 ClinicalTrials.gov
NCT02210663 A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced So… Phase1 Advanced Solid Tumors Completed 2014-07-01 2016-07-01 ClinicalTrials.gov
NCT02186119 A Study of Abicipar Pegol in Patients With Diabetic Macular Edema Phase2 Macular Edema Completed 2014-07-01 2015-06-01 ClinicalTrials.gov
NCT02181530 Retrospective Data Collection Study in Patients With Macular Oedema Receiving O… — Macular Edema Completed 2014-07-01 2014-10-01 ClinicalTrials.gov
NCT02181517 A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Dege… Phase2 Macular Degeneration Completed 2014-07-01 2015-03-01 ClinicalTrials.gov
NCT02289352 Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design St… Phase3 Rosacea Completed 2014-07-01 2014-12-01 ClinicalTrials.gov
NCT02289352 Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design St… Phase3 Rosacea Completed 2014-07-01 2014-12-01 ClinicalTrials.gov
NCT02141997 A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexa… Phase2 Rheumatoid Arthritis Completed 2014-07-01 2015-11-01 ClinicalTrials.gov
NCT02197806 Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia Phase2 Presbyopia Completed 2014-07-01 2014-11-01 ClinicalTrials.gov
NCT02188173 An Observational Study of OZURDEX® in Diabetic Macular Edema (DME) — Macular Edema Completed 2014-07-01 2016-05-01 ClinicalTrials.gov
NCT02186119 A Study of Abicipar Pegol in Patients With Diabetic Macular Edema Phase2 Macular Edema Completed 2014-07-01 2015-06-01 ClinicalTrials.gov
NCT02092389 Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Sufferi… — Moderate to Severe Ulcerative Colitis Terminated 2014-07-01 2016-03-01 ClinicalTrials.gov
NCT02197806 Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia Phase2 Presbyopia Completed 2014-07-01 2014-11-01 ClinicalTrials.gov
NCT02181530 Retrospective Data Collection Study in Patients With Macular Oedema Receiving O… — Macular Edema Completed 2014-07-01 2014-10-01 ClinicalTrials.gov
NCT02210663 A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced So… Phase1 Advanced Solid Tumors Completed 2014-07-01 2016-07-01 ClinicalTrials.gov
NCT02186119 A Study of Abicipar Pegol in Patients With Diabetic Macular Edema Phase2 Macular Edema Completed 2014-07-01 2015-06-01 ClinicalTrials.gov
NCT02181530 Retrospective Data Collection Study in Patients With Macular Oedema Receiving O… — Macular Edema Completed 2014-07-01 2014-10-01 ClinicalTrials.gov
NCT02181517 A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Dege… Phase2 Macular Degeneration Completed 2014-07-01 2015-03-01 ClinicalTrials.gov
NCT02181517 A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Dege… Phase2 Macular Degeneration Completed 2014-07-01 2015-03-01 ClinicalTrials.gov
NCT02092389 Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Sufferi… — Moderate to Severe Ulcerative Colitis Terminated 2014-07-01 2016-03-01 ClinicalTrials.gov
NCT02141997 A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexa… Phase2 Rheumatoid Arthritis Completed 2014-07-01 2015-11-01 ClinicalTrials.gov
NCT02210663 A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced So… Phase1 Advanced Solid Tumors Completed 2014-07-01 2016-07-01 ClinicalTrials.gov
NCT02141997 A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexa… Phase2 Rheumatoid Arthritis Completed 2014-07-01 2015-11-01 ClinicalTrials.gov
NCT02092389 Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Sufferi… — Moderate to Severe Ulcerative Colitis Terminated 2014-07-01 2016-03-01 ClinicalTrials.gov
NCT02181517 A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Dege… Phase2 Macular Degeneration Completed 2014-07-01 2015-03-01 ClinicalTrials.gov
NCT02289352 Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design St… Phase3 Rosacea Completed 2014-07-01 2014-12-01 ClinicalTrials.gov
NCT02210663 A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced So… Phase1 Advanced Solid Tumors Completed 2014-07-01 2016-07-01 ClinicalTrials.gov
NCT02181530 Retrospective Data Collection Study in Patients With Macular Oedema Receiving O… — Macular Edema Completed 2014-07-01 2014-10-01 ClinicalTrials.gov
NCT02141997 A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexa… Phase2 Rheumatoid Arthritis Completed 2014-07-01 2015-11-01 ClinicalTrials.gov
NCT02186119 A Study of Abicipar Pegol in Patients With Diabetic Macular Edema Phase2 Macular Edema Completed 2014-07-01 2015-06-01 ClinicalTrials.gov
NCT02188173 An Observational Study of OZURDEX® in Diabetic Macular Edema (DME) — Macular Edema Completed 2014-07-01 2016-05-01 ClinicalTrials.gov
NCT02197806 Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia Phase2 Presbyopia Completed 2014-07-01 2014-11-01 ClinicalTrials.gov
NCT02197806 Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia Phase2 Presbyopia Completed 2014-07-01 2014-11-01 ClinicalTrials.gov
NCT02188173 An Observational Study of OZURDEX® in Diabetic Macular Edema (DME) — Macular Edema Completed 2014-07-01 2016-05-01 ClinicalTrials.gov
NCT02289352 Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design St… Phase3 Rosacea Completed 2014-07-01 2014-12-01 ClinicalTrials.gov
NCT02142959 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE Phase2 Breast Cancer Completed 2014-06-30 2015-04-30 ClinicalTrials.gov
NCT02176356 Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, J… Phase4 Facial Rhytides Completed 2014-06-30 2015-05-03 ClinicalTrials.gov
NCT02176356 Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, J… Phase4 Facial Rhytides Completed 2014-06-30 2015-05-03 ClinicalTrials.gov
NCT02176356 Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, J… Phase4 Facial Rhytides Completed 2014-06-30 2015-05-03 ClinicalTrials.gov
NCT02176356 Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, J… Phase4 Facial Rhytides Completed 2014-06-30 2015-05-03 ClinicalTrials.gov
NCT02142959 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE Phase2 Breast Cancer Completed 2014-06-30 2015-04-30 ClinicalTrials.gov
NCT02142959 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE Phase2 Breast Cancer Completed 2014-06-30 2015-04-30 ClinicalTrials.gov
NCT02142959 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE Phase2 Breast Cancer Completed 2014-06-30 2015-04-30 ClinicalTrials.gov
NCT02167945 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonav… Phase3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 Completed 2014-06-12 2021-05-13 ClinicalTrials.gov
NCT02167945 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonav… Phase3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 Completed 2014-06-12 2021-05-13 ClinicalTrials.gov
NCT02167945 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonav… Phase3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 Completed 2014-06-12 2021-05-13 ClinicalTrials.gov
NCT02167945 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonav… Phase3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 Completed 2014-06-12 2021-05-13 ClinicalTrials.gov
NCT02161146 AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis Phase3 Conjunctivitis, Allergic Completed 2014-06-04 2014-12-20 ClinicalTrials.gov
NCT02087904 A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981… Phase2 Knee Osteoarthritis Completed 2014-06-04 2016-12-13 ClinicalTrials.gov
NCT02161146 AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis Phase3 Conjunctivitis, Allergic Completed 2014-06-04 2014-12-20 ClinicalTrials.gov
NCT02087904 A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981… Phase2 Knee Osteoarthritis Completed 2014-06-04 2016-12-13 ClinicalTrials.gov
NCT02087904 A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981… Phase2 Knee Osteoarthritis Completed 2014-06-04 2016-12-13 ClinicalTrials.gov
NCT02161146 AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis Phase3 Conjunctivitis, Allergic Completed 2014-06-04 2014-12-20 ClinicalTrials.gov
NCT02161146 AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis Phase3 Conjunctivitis, Allergic Completed 2014-06-04 2014-12-20 ClinicalTrials.gov
NCT02087904 A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981… Phase2 Knee Osteoarthritis Completed 2014-06-04 2016-12-13 ClinicalTrials.gov
NCT02267746 A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0… Phase3 Acne Vulgaris Completed 2014-06-01 2014-09-01 ClinicalTrials.gov
NCT02148718 Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease Phase4 Moderate to Severe Crohn's Disease Completed 2014-06-01 2017-01-01 ClinicalTrials.gov
NCT02267746 A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0… Phase3 Acne Vulgaris Completed 2014-06-01 2014-09-01 ClinicalTrials.gov
NCT02161159 An Observational Study of BOTOX® for the Management of Urinary Incontinence in … — Urinary Incontinence Completed 2014-06-01 2016-01-01 ClinicalTrials.gov
NCT02161159 An Observational Study of BOTOX® for the Management of Urinary Incontinence in … — Urinary Incontinence Completed 2014-06-01 2016-01-01 ClinicalTrials.gov
NCT02148718 Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease Phase4 Moderate to Severe Crohn's Disease Completed 2014-06-01 2017-01-01 ClinicalTrials.gov
NCT02148718 Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease Phase4 Moderate to Severe Crohn's Disease Completed 2014-06-01 2017-01-01 ClinicalTrials.gov
NCT02161159 An Observational Study of BOTOX® for the Management of Urinary Incontinence in … — Urinary Incontinence Completed 2014-06-01 2016-01-01 ClinicalTrials.gov
NCT02267746 A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0… Phase3 Acne Vulgaris Completed 2014-06-01 2014-09-01 ClinicalTrials.gov
NCT02161159 An Observational Study of BOTOX® for the Management of Urinary Incontinence in … — Urinary Incontinence Completed 2014-06-01 2016-01-01 ClinicalTrials.gov
NCT02148718 Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease Phase4 Moderate to Severe Crohn's Disease Completed 2014-06-01 2017-01-01 ClinicalTrials.gov
NCT02267746 A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0… Phase3 Acne Vulgaris Completed 2014-06-01 2014-09-01 ClinicalTrials.gov
NCT02128113 RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Lo… Phase2 Corneal Endothelial Cell Loss Completed 2014-05-31 2015-04-30 ClinicalTrials.gov
NCT02128113 RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Lo… Phase2 Corneal Endothelial Cell Loss Completed 2014-05-31 2015-04-30 ClinicalTrials.gov
NCT02128113 RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Lo… Phase2 Corneal Endothelial Cell Loss Completed 2014-05-31 2015-04-30 ClinicalTrials.gov
NCT02128113 RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Lo… Phase2 Corneal Endothelial Cell Loss Completed 2014-05-31 2015-04-30 ClinicalTrials.gov
NCT02143713 Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women… Phase3 Endometriosis Completed 2014-05-27 2017-05-23 ClinicalTrials.gov
NCT02143713 Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women… Phase3 Endometriosis Completed 2014-05-27 2017-05-23 ClinicalTrials.gov
NCT02143713 Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women… Phase3 Endometriosis Completed 2014-05-27 2017-05-23 ClinicalTrials.gov
NCT02143713 Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women… Phase3 Endometriosis Completed 2014-05-27 2017-05-23 ClinicalTrials.gov
NCT02097121 OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive … Phase3 Urinary Incontinence Terminated 2014-05-23 2022-02-10 ClinicalTrials.gov
NCT02097121 OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive … Phase3 Urinary Incontinence Terminated 2014-05-23 2022-02-10 ClinicalTrials.gov
NCT02097121 OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive … Phase3 Urinary Incontinence Terminated 2014-05-23 2022-02-10 ClinicalTrials.gov
NCT02097121 OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive … Phase3 Urinary Incontinence Terminated 2014-05-23 2022-02-10 ClinicalTrials.gov
NCT02176421 A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Tr… Na Infra-orbital Skin Depressions Completed 2014-05-15 2015-07-03 ClinicalTrials.gov
NCT02176421 A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Tr… Na Infra-orbital Skin Depressions Completed 2014-05-15 2015-07-03 ClinicalTrials.gov
NCT02176421 A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Tr… Na Infra-orbital Skin Depressions Completed 2014-05-15 2015-07-03 ClinicalTrials.gov
NCT02176421 A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Tr… Na Infra-orbital Skin Depressions Completed 2014-05-15 2015-07-03 ClinicalTrials.gov
NCT02087085 A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic A… Phase2 Geographic Atrophy Terminated 2014-05-09 2018-03-30 ClinicalTrials.gov
NCT02087085 A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic A… Phase2 Geographic Atrophy Terminated 2014-05-09 2018-03-30 ClinicalTrials.gov
NCT02087085 A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic A… Phase2 Geographic Atrophy Terminated 2014-05-09 2018-03-30 ClinicalTrials.gov
NCT02087085 A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic A… Phase2 Geographic Atrophy Terminated 2014-05-09 2018-03-30 ClinicalTrials.gov
NCT02155543 A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Health… Phase1 Healthy Volunteers Completed 2014-05-01 2015-01-01 ClinicalTrials.gov
NCT02324270 Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ank… Phase3 Ankle Sprain Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02065570 Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Mod… Phase3 Crohn's Disease Completed 2014-05-01 2020-01-30 ClinicalTrials.gov
NCT02097719 Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0… Phase4 Glaucoma Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02145650 Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Ne… — Muscle Spasticity Withdrawn 2014-05-01 2015-08-01 ClinicalTrials.gov
NCT02324270 Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ank… Phase3 Ankle Sprain Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02131636 Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associat… Phase3 Erythema Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02065570 Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Mod… Phase3 Crohn's Disease Completed 2014-05-01 2020-01-30 ClinicalTrials.gov
NCT02132572 Retrospective Study of Incidence and Etiology of Reoperation After Primary Augm… — Breast Implantation Completed 2014-05-01 2014-10-01 ClinicalTrials.gov
NCT02155543 A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Health… Phase1 Healthy Volunteers Completed 2014-05-01 2015-01-01 ClinicalTrials.gov
NCT02131636 Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associat… Phase3 Erythema Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02065570 Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Mod… Phase3 Crohn's Disease Completed 2014-05-01 2020-01-30 ClinicalTrials.gov
NCT02132572 Retrospective Study of Incidence and Etiology of Reoperation After Primary Augm… — Breast Implantation Completed 2014-05-01 2014-10-01 ClinicalTrials.gov
NCT02097719 Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0… Phase4 Glaucoma Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02141984 Surveillance of Humira in Korean JIA Patients — Polyarticular Juvenile Idiopathic Arthritis Completed 2014-05-01 2016-04-01 ClinicalTrials.gov
NCT02155543 A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Health… Phase1 Healthy Volunteers Completed 2014-05-01 2015-01-01 ClinicalTrials.gov
NCT02141984 Surveillance of Humira in Korean JIA Patients — Polyarticular Juvenile Idiopathic Arthritis Completed 2014-05-01 2016-04-01 ClinicalTrials.gov
NCT02145676 OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity Phase3 Muscle Spasticity Terminated 2014-05-01 2015-12-01 ClinicalTrials.gov
NCT02141984 Surveillance of Humira in Korean JIA Patients — Polyarticular Juvenile Idiopathic Arthritis Completed 2014-05-01 2016-04-01 ClinicalTrials.gov
NCT02097719 Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0… Phase4 Glaucoma Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02145650 Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Ne… — Muscle Spasticity Withdrawn 2014-05-01 2015-08-01 ClinicalTrials.gov
NCT02324270 Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ank… Phase3 Ankle Sprain Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02145676 OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity Phase3 Muscle Spasticity Terminated 2014-05-01 2015-12-01 ClinicalTrials.gov
NCT02324270 Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ank… Phase3 Ankle Sprain Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02132572 Retrospective Study of Incidence and Etiology of Reoperation After Primary Augm… — Breast Implantation Completed 2014-05-01 2014-10-01 ClinicalTrials.gov
NCT02132572 Retrospective Study of Incidence and Etiology of Reoperation After Primary Augm… — Breast Implantation Completed 2014-05-01 2014-10-01 ClinicalTrials.gov
NCT02145676 OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity Phase3 Muscle Spasticity Terminated 2014-05-01 2015-12-01 ClinicalTrials.gov
NCT02145676 OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity Phase3 Muscle Spasticity Terminated 2014-05-01 2015-12-01 ClinicalTrials.gov
NCT02155543 A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Health… Phase1 Healthy Volunteers Completed 2014-05-01 2015-01-01 ClinicalTrials.gov
NCT02131636 Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associat… Phase3 Erythema Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02065570 Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Mod… Phase3 Crohn's Disease Completed 2014-05-01 2020-01-30 ClinicalTrials.gov
NCT02141984 Surveillance of Humira in Korean JIA Patients — Polyarticular Juvenile Idiopathic Arthritis Completed 2014-05-01 2016-04-01 ClinicalTrials.gov
NCT02097719 Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0… Phase4 Glaucoma Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02145650 Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Ne… — Muscle Spasticity Withdrawn 2014-05-01 2015-08-01 ClinicalTrials.gov
NCT02131636 Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associat… Phase3 Erythema Completed 2014-05-01 2014-12-01 ClinicalTrials.gov
NCT02145650 Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Ne… — Muscle Spasticity Withdrawn 2014-05-01 2015-08-01 ClinicalTrials.gov
NCT02013791 Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in … Phase2 Dry Eye Syndromes Terminated 2014-04-29 2017-04-12 ClinicalTrials.gov
NCT02013791 Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in … Phase2 Dry Eye Syndromes Terminated 2014-04-29 2017-04-12 ClinicalTrials.gov
NCT02013791 Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in … Phase2 Dry Eye Syndromes Terminated 2014-04-29 2017-04-12 ClinicalTrials.gov
NCT02013791 Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in … Phase2 Dry Eye Syndromes Terminated 2014-04-29 2017-04-12 ClinicalTrials.gov
NCT02106546 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus C… Phase3 Squamous Non-Small Cell Lung Cancer Completed 2014-04-10 2019-11-20 ClinicalTrials.gov
NCT02106546 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus C… Phase3 Squamous Non-Small Cell Lung Cancer Completed 2014-04-10 2019-11-20 ClinicalTrials.gov
NCT02106546 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus C… Phase3 Squamous Non-Small Cell Lung Cancer Completed 2014-04-10 2019-11-20 ClinicalTrials.gov
NCT02106546 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus C… Phase3 Squamous Non-Small Cell Lung Cancer Completed 2014-04-10 2019-11-20 ClinicalTrials.gov
NCT02163694 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel Wi… Phase3 Metastatic Breast Cancer Completed 2014-04-08 2024-01-25 ClinicalTrials.gov
NCT02163694 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel Wi… Phase3 Metastatic Breast Cancer Completed 2014-04-08 2024-01-25 ClinicalTrials.gov
NCT02163694 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel Wi… Phase3 Metastatic Breast Cancer Completed 2014-04-08 2024-01-25 ClinicalTrials.gov
NCT02163694 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel Wi… Phase3 Metastatic Breast Cancer Completed 2014-04-08 2024-01-25 ClinicalTrials.gov
NCT02121847 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Ther… Phase4 Dry Eye Syndromes Completed 2014-04-03 2014-09-23 ClinicalTrials.gov
NCT02121847 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Ther… Phase4 Dry Eye Syndromes Completed 2014-04-03 2014-09-23 ClinicalTrials.gov
NCT02121847 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Ther… Phase4 Dry Eye Syndromes Completed 2014-04-03 2014-09-23 ClinicalTrials.gov
NCT02121847 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Ther… Phase4 Dry Eye Syndromes Completed 2014-04-03 2014-09-23 ClinicalTrials.gov
NCT02032277 A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carbopla… Phase3 Triple Negative Breast Cancer Completed 2014-04-02 2020-11-12 ClinicalTrials.gov
NCT02032277 A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carbopla… Phase3 Triple Negative Breast Cancer Completed 2014-04-02 2020-11-12 ClinicalTrials.gov
NCT02032277 A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carbopla… Phase3 Triple Negative Breast Cancer Completed 2014-04-02 2020-11-12 ClinicalTrials.gov
NCT02032277 A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carbopla… Phase3 Triple Negative Breast Cancer Completed 2014-04-02 2020-11-12 ClinicalTrials.gov
NCT02037425 Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine Phase4 Chronic Migraine Completed 2014-04-01 2015-09-01 ClinicalTrials.gov
NCT02117752 Dermal Tolerability of Dapsone Gel in Healthy Volunteers Phase1 Healthy Volunteers Completed 2014-04-01 2014-07-01 ClinicalTrials.gov
NCT02037425 Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine Phase4 Chronic Migraine Completed 2014-04-01 2015-09-01 ClinicalTrials.gov
NCT02108483 Phototoxicity Test of Dapsone Gel in Healthy Volunteers Phase1 Healthy Volunteers Completed 2014-04-01 2014-05-01 ClinicalTrials.gov
NCT02095158 A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Ery… Phase3 Erythema Completed 2014-04-01 2015-09-01 ClinicalTrials.gov
NCT02095158 A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Ery… Phase3 Erythema Completed 2014-04-01 2015-09-01 ClinicalTrials.gov
NCT02117752 Dermal Tolerability of Dapsone Gel in Healthy Volunteers Phase1 Healthy Volunteers Completed 2014-04-01 2014-07-01 ClinicalTrials.gov
NCT01471054 Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque … Phase2 Macular Edema Terminated 2014-04-01 2015-07-01 ClinicalTrials.gov
NCT01969682 A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 Phase1 Non-Hodgkin's Lymphoma Withdrawn 2014-04-01 2014-05-01 ClinicalTrials.gov
NCT02095158 A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Ery… Phase3 Erythema Completed 2014-04-01 2015-09-01 ClinicalTrials.gov
NCT01471054 Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque … Phase2 Macular Edema Terminated 2014-04-01 2015-07-01 ClinicalTrials.gov
NCT02037425 Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine Phase4 Chronic Migraine Completed 2014-04-01 2015-09-01 ClinicalTrials.gov
NCT01471054 Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque … Phase2 Macular Edema Terminated 2014-04-01 2015-07-01 ClinicalTrials.gov
NCT02117752 Dermal Tolerability of Dapsone Gel in Healthy Volunteers Phase1 Healthy Volunteers Completed 2014-04-01 2014-07-01 ClinicalTrials.gov
NCT02117752 Dermal Tolerability of Dapsone Gel in Healthy Volunteers Phase1 Healthy Volunteers Completed 2014-04-01 2014-07-01 ClinicalTrials.gov
NCT02095158 A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Ery… Phase3 Erythema Completed 2014-04-01 2015-09-01 ClinicalTrials.gov
NCT02108483 Phototoxicity Test of Dapsone Gel in Healthy Volunteers Phase1 Healthy Volunteers Completed 2014-04-01 2014-05-01 ClinicalTrials.gov
NCT01969682 A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 Phase1 Non-Hodgkin's Lymphoma Withdrawn 2014-04-01 2014-05-01 ClinicalTrials.gov
NCT02068222 A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and AB… Phase2 Chronic Hepatitis C Completed 2014-04-01 2015-03-01 ClinicalTrials.gov
NCT02068222 A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and AB… Phase2 Chronic Hepatitis C Completed 2014-04-01 2015-03-01 ClinicalTrials.gov
NCT02068222 A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and AB… Phase2 Chronic Hepatitis C Completed 2014-04-01 2015-03-01 ClinicalTrials.gov
NCT01471054 Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque … Phase2 Macular Edema Terminated 2014-04-01 2015-07-01 ClinicalTrials.gov
NCT01969682 A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 Phase1 Non-Hodgkin's Lymphoma Withdrawn 2014-04-01 2014-05-01 ClinicalTrials.gov
NCT02068222 A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and AB… Phase2 Chronic Hepatitis C Completed 2014-04-01 2015-03-01 ClinicalTrials.gov
NCT02108483 Phototoxicity Test of Dapsone Gel in Healthy Volunteers Phase1 Healthy Volunteers Completed 2014-04-01 2014-05-01 ClinicalTrials.gov
NCT01969682 A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 Phase1 Non-Hodgkin's Lymphoma Withdrawn 2014-04-01 2014-05-01 ClinicalTrials.gov
NCT02108483 Phototoxicity Test of Dapsone Gel in Healthy Volunteers Phase1 Healthy Volunteers Completed 2014-04-01 2014-05-01 ClinicalTrials.gov
NCT02037425 Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine Phase4 Chronic Migraine Completed 2014-04-01 2015-09-01 ClinicalTrials.gov
NCT02147197 A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal … Phase3 Leiomyoma Completed 2014-03-31 2016-03-29 ClinicalTrials.gov
NCT02087878 A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bo… — Crohn's Disease Withdrawn 2014-03-31 2019-09-30 ClinicalTrials.gov
NCT02087878 A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bo… — Crohn's Disease Withdrawn 2014-03-31 2019-09-30 ClinicalTrials.gov
NCT02147197 A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal … Phase3 Leiomyoma Completed 2014-03-31 2016-03-29 ClinicalTrials.gov
NCT02147197 A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal … Phase3 Leiomyoma Completed 2014-03-31 2016-03-29 ClinicalTrials.gov
NCT02087878 A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bo… — Crohn's Disease Withdrawn 2014-03-31 2019-09-30 ClinicalTrials.gov
NCT02147197 A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal … Phase3 Leiomyoma Completed 2014-03-31 2016-03-29 ClinicalTrials.gov
NCT02087878 A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bo… — Crohn's Disease Withdrawn 2014-03-31 2019-09-30 ClinicalTrials.gov
NCT02065622 Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in … Phase3 Ulcerative Colitis (UC) Completed 2014-03-27 2019-11-11 ClinicalTrials.gov
NCT02065622 Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in … Phase3 Ulcerative Colitis (UC) Completed 2014-03-27 2019-11-11 ClinicalTrials.gov
NCT02065622 Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in … Phase3 Ulcerative Colitis (UC) Completed 2014-03-27 2019-11-11 ClinicalTrials.gov
NCT02065622 Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in … Phase3 Ulcerative Colitis (UC) Completed 2014-03-27 2019-11-11 ClinicalTrials.gov
NCT02066389 A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given W… Phase2 Rheumatoid Arthritis Completed 2014-03-26 2015-07-02 ClinicalTrials.gov
NCT02066389 A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given W… Phase2 Rheumatoid Arthritis Completed 2014-03-26 2015-07-02 ClinicalTrials.gov
NCT02066389 A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given W… Phase2 Rheumatoid Arthritis Completed 2014-03-26 2015-07-02 ClinicalTrials.gov
NCT02066389 A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given W… Phase2 Rheumatoid Arthritis Completed 2014-03-26 2015-07-02 ClinicalTrials.gov
NCT02005471 A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bend… Phase3 Chronic Lymphocytic Leukemia Completed 2014-03-17 2022-08-03 ClinicalTrials.gov
NCT02005471 A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bend… Phase3 Chronic Lymphocytic Leukemia Completed 2014-03-17 2022-08-03 ClinicalTrials.gov
NCT02005471 A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bend… Phase3 Chronic Lymphocytic Leukemia Completed 2014-03-17 2022-08-03 ClinicalTrials.gov
NCT02005471 A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bend… Phase3 Chronic Lymphocytic Leukemia Completed 2014-03-17 2022-08-03 ClinicalTrials.gov
NCT02082249 An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV18… Phase3 Advanced Parkinson's Disease Completed 2014-03-10 2019-10-31 ClinicalTrials.gov
NCT02082249 An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV18… Phase3 Advanced Parkinson's Disease Completed 2014-03-10 2019-10-31 ClinicalTrials.gov
NCT02082249 An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV18… Phase3 Advanced Parkinson's Disease Completed 2014-03-10 2019-10-31 ClinicalTrials.gov
NCT02082249 An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV18… Phase3 Advanced Parkinson's Disease Completed 2014-03-10 2019-10-31 ClinicalTrials.gov
NCT02067793 Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder Phase2 Major Depressive Disorder Completed 2014-03-01 2015-02-01 ClinicalTrials.gov
NCT02082197 An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men Phase3 Hypogonadism Withdrawn 2014-03-01 2015-06-01 ClinicalTrials.gov
NCT02082262 AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Aller… Phase3 Conjunctivitis, Allergic Completed 2014-03-01 2014-07-01 ClinicalTrials.gov
NCT02199964 The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surfa… Na Dry Eye Terminated 2014-03-01 2015-12-01 ClinicalTrials.gov
NCT02082262 AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Aller… Phase3 Conjunctivitis, Allergic Completed 2014-03-01 2014-07-01 ClinicalTrials.gov
NCT02199964 The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surfa… Na Dry Eye Terminated 2014-03-01 2015-12-01 ClinicalTrials.gov
NCT02199964 The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surfa… Na Dry Eye Terminated 2014-03-01 2015-12-01 ClinicalTrials.gov
NCT01946126 A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Mig… — Migraine Disorders Completed 2014-03-01 2014-04-01 ClinicalTrials.gov
NCT02067793 Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder Phase2 Major Depressive Disorder Completed 2014-03-01 2015-02-01 ClinicalTrials.gov
NCT02082197 An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men Phase3 Hypogonadism Withdrawn 2014-03-01 2015-06-01 ClinicalTrials.gov
NCT01946126 A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Mig… — Migraine Disorders Completed 2014-03-01 2014-04-01 ClinicalTrials.gov
NCT02199964 The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surfa… Na Dry Eye Terminated 2014-03-01 2015-12-01 ClinicalTrials.gov
NCT02082262 AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Aller… Phase3 Conjunctivitis, Allergic Completed 2014-03-01 2014-07-01 ClinicalTrials.gov
NCT01946126 A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Mig… — Migraine Disorders Completed 2014-03-01 2014-04-01 ClinicalTrials.gov
NCT02067793 Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder Phase2 Major Depressive Disorder Completed 2014-03-01 2015-02-01 ClinicalTrials.gov
NCT02082197 An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men Phase3 Hypogonadism Withdrawn 2014-03-01 2015-06-01 ClinicalTrials.gov
NCT02067793 Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder Phase2 Major Depressive Disorder Completed 2014-03-01 2015-02-01 ClinicalTrials.gov
NCT02082197 An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men Phase3 Hypogonadism Withdrawn 2014-03-01 2015-06-01 ClinicalTrials.gov
NCT02082262 AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Aller… Phase3 Conjunctivitis, Allergic Completed 2014-03-01 2014-07-01 ClinicalTrials.gov
NCT01946126 A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Mig… — Migraine Disorders Completed 2014-03-01 2014-04-01 ClinicalTrials.gov
NCT02065375 RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain… Phase2 Inflammation and Pain Following Ocular Surgery Completed 2014-02-28 2014-09-30 ClinicalTrials.gov
NCT02065375 RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain… Phase2 Inflammation and Pain Following Ocular Surgery Completed 2014-02-28 2014-09-30 ClinicalTrials.gov
NCT02065375 RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain… Phase2 Inflammation and Pain Following Ocular Surgery Completed 2014-02-28 2014-09-30 ClinicalTrials.gov
NCT02065375 RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain… Phase2 Inflammation and Pain Following Ocular Surgery Completed 2014-02-28 2014-09-30 ClinicalTrials.gov
NCT01945866 Phase II Combination Steroid and Anti-VEGF for Persistent DME Phase2 Diabetic Macular Edema Completed 2014-02-01 2017-06-05 ClinicalTrials.gov
NCT02048605 Training of Psychosocial Skills Based on Cognitive Behavioural Therapy for Pati… Na Parkinson's Disease Completed 2014-02-01 2017-01-01 ClinicalTrials.gov
NCT02031276 Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in P… Phase2 Crohn Disease Completed 2014-02-01 2016-11-01 ClinicalTrials.gov
NCT02010788 Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat U… — Urinary Incontinence Completed 2014-02-01 2016-07-01 ClinicalTrials.gov
NCT02031276 Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in P… Phase2 Crohn Disease Completed 2014-02-01 2016-11-01 ClinicalTrials.gov
NCT01945866 Phase II Combination Steroid and Anti-VEGF for Persistent DME Phase2 Diabetic Macular Edema Completed 2014-02-01 2017-06-05 ClinicalTrials.gov
NCT01945866 Phase II Combination Steroid and Anti-VEGF for Persistent DME Phase2 Diabetic Macular Edema Completed 2014-02-01 2017-06-05 ClinicalTrials.gov
NCT02048605 Training of Psychosocial Skills Based on Cognitive Behavioural Therapy for Pati… Na Parkinson's Disease Completed 2014-02-01 2017-01-01 ClinicalTrials.gov
NCT02010788 Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat U… — Urinary Incontinence Completed 2014-02-01 2016-07-01 ClinicalTrials.gov
NCT01945866 Phase II Combination Steroid and Anti-VEGF for Persistent DME Phase2 Diabetic Macular Edema Completed 2014-02-01 2017-06-05 ClinicalTrials.gov
NCT02031276 Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in P… Phase2 Crohn Disease Completed 2014-02-01 2016-11-01 ClinicalTrials.gov
NCT02031276 Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in P… Phase2 Crohn Disease Completed 2014-02-01 2016-11-01 ClinicalTrials.gov
NCT02048605 Training of Psychosocial Skills Based on Cognitive Behavioural Therapy for Pati… Na Parkinson's Disease Completed 2014-02-01 2017-01-01 ClinicalTrials.gov
NCT02048605 Training of Psychosocial Skills Based on Cognitive Behavioural Therapy for Pati… Na Parkinson's Disease Completed 2014-02-01 2017-01-01 ClinicalTrials.gov
NCT02010788 Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat U… — Urinary Incontinence Completed 2014-02-01 2016-07-01 ClinicalTrials.gov
NCT02010788 Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat U… — Urinary Incontinence Completed 2014-02-01 2016-07-01 ClinicalTrials.gov
NCT02047110 BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spon… Phase2 Ankylosing Spondylitis (AS) Completed 2014-01-28 2016-07-25 ClinicalTrials.gov
NCT02072928 Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neu… — Urinary Incontinence Completed 2014-01-28 2015-09-30 ClinicalTrials.gov
NCT02047110 BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spon… Phase2 Ankylosing Spondylitis (AS) Completed 2014-01-28 2016-07-25 ClinicalTrials.gov
NCT02072928 Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neu… — Urinary Incontinence Completed 2014-01-28 2015-09-30 ClinicalTrials.gov
NCT02047110 BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spon… Phase2 Ankylosing Spondylitis (AS) Completed 2014-01-28 2016-07-25 ClinicalTrials.gov
NCT02072928 Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neu… — Urinary Incontinence Completed 2014-01-28 2015-09-30 ClinicalTrials.gov
NCT02047110 BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spon… Phase2 Ankylosing Spondylitis (AS) Completed 2014-01-28 2016-07-25 ClinicalTrials.gov
NCT02072928 Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neu… — Urinary Incontinence Completed 2014-01-28 2015-09-30 ClinicalTrials.gov
NCT02049138 An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitini… Phase2 Rheumatoid Arthritis Completed 2014-01-24 2021-07-29 ClinicalTrials.gov
NCT02049138 An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitini… Phase2 Rheumatoid Arthritis Completed 2014-01-24 2021-07-29 ClinicalTrials.gov
NCT02049138 An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitini… Phase2 Rheumatoid Arthritis Completed 2014-01-24 2021-07-29 ClinicalTrials.gov
NCT02049138 An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitini… Phase2 Rheumatoid Arthritis Completed 2014-01-24 2021-07-29 ClinicalTrials.gov
NCT02010775 Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy Phase2 Masseter Muscle Hypertrophy Completed 2014-01-20 2017-11-29 ClinicalTrials.gov
NCT02010775 Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy Phase2 Masseter Muscle Hypertrophy Completed 2014-01-20 2017-11-29 ClinicalTrials.gov
NCT02010775 Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy Phase2 Masseter Muscle Hypertrophy Completed 2014-01-20 2017-11-29 ClinicalTrials.gov
NCT02010775 Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy Phase2 Masseter Muscle Hypertrophy Completed 2014-01-20 2017-11-29 ClinicalTrials.gov
NCT02099058 A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy … Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2014-01-15 2026-08-01 ClinicalTrials.gov
NCT02099058 A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy … Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2014-01-15 2026-08-01 ClinicalTrials.gov
NCT02099058 A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy … Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2014-01-15 2026-08-01 ClinicalTrials.gov
NCT02099058 A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy … Phase1 Advanced Solid Tumors Cancer Active_Not_Recruiting 2014-01-15 2026-08-01 ClinicalTrials.gov
NCT01671904 A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamust… Phase1 Chronic Lymphocytic Leukemia Completed 2014-01-13 2020-08-11 ClinicalTrials.gov
NCT01671904 A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamust… Phase1 Chronic Lymphocytic Leukemia Completed 2014-01-13 2020-08-11 ClinicalTrials.gov
NCT01671904 A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamust… Phase1 Chronic Lymphocytic Leukemia Completed 2014-01-13 2020-08-11 ClinicalTrials.gov
NCT01671904 A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamust… Phase1 Chronic Lymphocytic Leukemia Completed 2014-01-13 2020-08-11 ClinicalTrials.gov
NCT02028169 To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Imp… — Psoriatic Arthritis Completed 2014-01-01 2016-04-01 ClinicalTrials.gov
NCT02016482 A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chro… Phase3 Nail Psoriasis Completed 2014-01-01 2016-04-01 ClinicalTrials.gov
NCT02049476 Study of the Effectiveness of Ozurdex for the Control of Uveitis Phase4 Uveitis, Intermediate Completed 2014-01-01 2018-06-30 ClinicalTrials.gov
NCT02036424 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given … Phase4 Diabetic Macular Edema Completed 2014-01-01 2015-08-01 ClinicalTrials.gov
NCT02052362 Bioavailability of ABT-450 and ABT-267 With Ritonavir Phase1 Absolute Bioavailability Completed 2014-01-01 2014-02-01 ClinicalTrials.gov
NCT02036424 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given … Phase4 Diabetic Macular Edema Completed 2014-01-01 2015-08-01 ClinicalTrials.gov
NCT02036424 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given … Phase4 Diabetic Macular Edema Completed 2014-01-01 2015-08-01 ClinicalTrials.gov
NCT02052362 Bioavailability of ABT-450 and ABT-267 With Ritonavir Phase1 Absolute Bioavailability Completed 2014-01-01 2014-02-01 ClinicalTrials.gov
NCT02028169 To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Imp… — Psoriatic Arthritis Completed 2014-01-01 2016-04-01 ClinicalTrials.gov
NCT02023112 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-45… Phase3 Hepatitis C Virus Completed 2014-01-01 2015-09-01 ClinicalTrials.gov
NCT01939977 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyr… Phase4 Secondary Hyperparathyroidism Due to Renal Causes Completed 2014-01-01 2015-12-01 ClinicalTrials.gov
NCT02210689 A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate… Phase3 BACTERIAL VAGINOSIS Completed 2014-01-01 2014-12-01 ClinicalTrials.gov
NCT02016482 A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chro… Phase3 Nail Psoriasis Completed 2014-01-01 2016-04-01 ClinicalTrials.gov
NCT01939977 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyr… Phase4 Secondary Hyperparathyroidism Due to Renal Causes Completed 2014-01-01 2015-12-01 ClinicalTrials.gov
NCT02049476 Study of the Effectiveness of Ozurdex for the Control of Uveitis Phase4 Uveitis, Intermediate Completed 2014-01-01 2018-06-30 ClinicalTrials.gov
NCT02210689 A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate… Phase3 BACTERIAL VAGINOSIS Completed 2014-01-01 2014-12-01 ClinicalTrials.gov
NCT01939977 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyr… Phase4 Secondary Hyperparathyroidism Due to Renal Causes Completed 2014-01-01 2015-12-01 ClinicalTrials.gov
NCT02016482 A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chro… Phase3 Nail Psoriasis Completed 2014-01-01 2016-04-01 ClinicalTrials.gov
NCT02023112 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-45… Phase3 Hepatitis C Virus Completed 2014-01-01 2015-09-01 ClinicalTrials.gov
NCT02028169 To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Imp… — Psoriatic Arthritis Completed 2014-01-01 2016-04-01 ClinicalTrials.gov
NCT02049476 Study of the Effectiveness of Ozurdex for the Control of Uveitis Phase4 Uveitis, Intermediate Completed 2014-01-01 2018-06-30 ClinicalTrials.gov
NCT02052362 Bioavailability of ABT-450 and ABT-267 With Ritonavir Phase1 Absolute Bioavailability Completed 2014-01-01 2014-02-01 ClinicalTrials.gov
NCT02028169 To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Imp… — Psoriatic Arthritis Completed 2014-01-01 2016-04-01 ClinicalTrials.gov
NCT02023112 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-45… Phase3 Hepatitis C Virus Completed 2014-01-01 2015-09-01 ClinicalTrials.gov
NCT02052362 Bioavailability of ABT-450 and ABT-267 With Ritonavir Phase1 Absolute Bioavailability Completed 2014-01-01 2014-02-01 ClinicalTrials.gov
NCT02049476 Study of the Effectiveness of Ozurdex for the Control of Uveitis Phase4 Uveitis, Intermediate Completed 2014-01-01 2018-06-30 ClinicalTrials.gov
NCT02036424 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given … Phase4 Diabetic Macular Edema Completed 2014-01-01 2015-08-01 ClinicalTrials.gov
NCT01939977 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyr… Phase4 Secondary Hyperparathyroidism Due to Renal Causes Completed 2014-01-01 2015-12-01 ClinicalTrials.gov
NCT02210689 A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate… Phase3 BACTERIAL VAGINOSIS Completed 2014-01-01 2014-12-01 ClinicalTrials.gov
NCT02210689 A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate… Phase3 BACTERIAL VAGINOSIS Completed 2014-01-01 2014-12-01 ClinicalTrials.gov
NCT02016482 A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chro… Phase3 Nail Psoriasis Completed 2014-01-01 2016-04-01 ClinicalTrials.gov
NCT02023112 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-45… Phase3 Hepatitis C Virus Completed 2014-01-01 2015-09-01 ClinicalTrials.gov
NCT02029716 RTA 408 Lotion in Healthy Volunteers Phase1 Healthy Completed 2013-12-31 2014-04-01 ClinicalTrials.gov
NCT02029729 RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER Phase1 Metastatic or Incurable Non-small Cell Lung Cancer Completed 2013-12-31 2015-10-01 ClinicalTrials.gov
NCT02029716 RTA 408 Lotion in Healthy Volunteers Phase1 Healthy Completed 2013-12-31 2014-04-01 ClinicalTrials.gov
NCT02029729 RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER Phase1 Metastatic or Incurable Non-small Cell Lung Cancer Completed 2013-12-31 2015-10-01 ClinicalTrials.gov
NCT02029729 RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER Phase1 Metastatic or Incurable Non-small Cell Lung Cancer Completed 2013-12-31 2015-10-01 ClinicalTrials.gov
NCT02029729 RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER Phase1 Metastatic or Incurable Non-small Cell Lung Cancer Completed 2013-12-31 2015-10-01 ClinicalTrials.gov
NCT02029716 RTA 408 Lotion in Healthy Volunteers Phase1 Healthy Completed 2013-12-31 2014-04-01 ClinicalTrials.gov
NCT02029716 RTA 408 Lotion in Healthy Volunteers Phase1 Healthy Completed 2013-12-31 2014-04-01 ClinicalTrials.gov
NCT01969695 An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma Phase1 Non-Hodgkin's Lymphoma Completed 2013-12-20 2019-12-16 ClinicalTrials.gov
NCT01969695 An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma Phase1 Non-Hodgkin's Lymphoma Completed 2013-12-20 2019-12-16 ClinicalTrials.gov
NCT01969695 An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma Phase1 Non-Hodgkin's Lymphoma Completed 2013-12-20 2019-12-16 ClinicalTrials.gov
NCT01969695 An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma Phase1 Non-Hodgkin's Lymphoma Completed 2013-12-20 2019-12-16 ClinicalTrials.gov
NCT02033551 A Study Evaluating Veliparib as a Single Agent or in Combination With Chemother… Phase1 Breast Cancer Completed 2013-12-01 2016-09-01 ClinicalTrials.gov
NCT01969669 A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 Phase1 Non-Hodgkin's Lymphoma Completed 2013-12-01 2014-09-01 ClinicalTrials.gov
NCT02056184 Targeted Ultrasound in Rheumatoid Arthritis Phase4 Rheumatoid Arthritis Completed 2013-12-01 2019-07-01 ClinicalTrials.gov
NCT02015793 Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Mo… Phase2 Crohn's Disease Completed 2013-12-01 2015-02-01 ClinicalTrials.gov
NCT02032407 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris Phase4 Acne Vulgaris Completed 2013-12-01 2014-09-01 ClinicalTrials.gov
NCT02016690 Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation i… — Respiratory Syncytial Virus Infection Completed 2013-12-01 2015-12-01 ClinicalTrials.gov
NCT02023099 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450… Phase3 Chronic Hepatitis C Infection Completed 2013-12-01 2015-10-01 ClinicalTrials.gov
NCT02032407 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris Phase4 Acne Vulgaris Completed 2013-12-01 2014-09-01 ClinicalTrials.gov
NCT02033551 A Study Evaluating Veliparib as a Single Agent or in Combination With Chemother… Phase1 Breast Cancer Completed 2013-12-01 2016-09-01 ClinicalTrials.gov
NCT02056184 Targeted Ultrasound in Rheumatoid Arthritis Phase4 Rheumatoid Arthritis Completed 2013-12-01 2019-07-01 ClinicalTrials.gov
NCT02015793 Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Mo… Phase2 Crohn's Disease Completed 2013-12-01 2015-02-01 ClinicalTrials.gov
NCT02056184 Targeted Ultrasound in Rheumatoid Arthritis Phase4 Rheumatoid Arthritis Completed 2013-12-01 2019-07-01 ClinicalTrials.gov
NCT02056184 Targeted Ultrasound in Rheumatoid Arthritis Phase4 Rheumatoid Arthritis Completed 2013-12-01 2019-07-01 ClinicalTrials.gov
NCT01969669 A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 Phase1 Non-Hodgkin's Lymphoma Completed 2013-12-01 2014-09-01 ClinicalTrials.gov
NCT02023099 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450… Phase3 Chronic Hepatitis C Infection Completed 2013-12-01 2015-10-01 ClinicalTrials.gov
NCT02016690 Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation i… — Respiratory Syncytial Virus Infection Completed 2013-12-01 2015-12-01 ClinicalTrials.gov
NCT02015793 Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Mo… Phase2 Crohn's Disease Completed 2013-12-01 2015-02-01 ClinicalTrials.gov
NCT01969669 A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 Phase1 Non-Hodgkin's Lymphoma Completed 2013-12-01 2014-09-01 ClinicalTrials.gov
NCT02023099 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450… Phase3 Chronic Hepatitis C Infection Completed 2013-12-01 2015-10-01 ClinicalTrials.gov
NCT02016690 Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation i… — Respiratory Syncytial Virus Infection Completed 2013-12-01 2015-12-01 ClinicalTrials.gov
NCT02033551 A Study Evaluating Veliparib as a Single Agent or in Combination With Chemother… Phase1 Breast Cancer Completed 2013-12-01 2016-09-01 ClinicalTrials.gov
NCT02015793 Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Mo… Phase2 Crohn's Disease Completed 2013-12-01 2015-02-01 ClinicalTrials.gov
NCT02016690 Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation i… — Respiratory Syncytial Virus Infection Completed 2013-12-01 2015-12-01 ClinicalTrials.gov
NCT02032407 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris Phase4 Acne Vulgaris Completed 2013-12-01 2014-09-01 ClinicalTrials.gov
NCT02033551 A Study Evaluating Veliparib as a Single Agent or in Combination With Chemother… Phase1 Breast Cancer Completed 2013-12-01 2016-09-01 ClinicalTrials.gov
NCT02032407 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris Phase4 Acne Vulgaris Completed 2013-12-01 2014-09-01 ClinicalTrials.gov
NCT01969669 A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 Phase1 Non-Hodgkin's Lymphoma Completed 2013-12-01 2014-09-01 ClinicalTrials.gov
NCT02023099 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450… Phase3 Chronic Hepatitis C Infection Completed 2013-12-01 2015-10-01 ClinicalTrials.gov
NCT02055820 A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Comb… Phase1 Lymphoma, Non-Hodgkin Completed 2013-11-17 2019-06-28 ClinicalTrials.gov
NCT02055820 A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Comb… Phase1 Lymphoma, Non-Hodgkin Completed 2013-11-17 2019-06-28 ClinicalTrials.gov
NCT02055820 A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Comb… Phase1 Lymphoma, Non-Hodgkin Completed 2013-11-17 2019-06-28 ClinicalTrials.gov
NCT02055820 A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Comb… Phase1 Lymphoma, Non-Hodgkin Completed 2013-11-17 2019-06-28 ClinicalTrials.gov
NCT01966003 Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With… Phase3 Non-small Cell Lung Cancer Metastatic Completed 2013-11-11 2015-07-23 ClinicalTrials.gov
NCT01966003 Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With… Phase3 Non-small Cell Lung Cancer Metastatic Completed 2013-11-11 2015-07-23 ClinicalTrials.gov
NCT01966003 Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With… Phase3 Non-small Cell Lung Cancer Metastatic Completed 2013-11-11 2015-07-23 ClinicalTrials.gov
NCT01966003 Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With… Phase3 Non-small Cell Lung Cancer Metastatic Completed 2013-11-11 2015-07-23 ClinicalTrials.gov
NCT01974323 Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris Phase3 Acne Vulgaris Completed 2013-11-01 2014-10-01 ClinicalTrials.gov
NCT01974141 A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris Phase3 Acne Vulgaris Completed 2013-11-01 2014-10-01 ClinicalTrials.gov
NCT02052349 Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects Phase1 Relative Bioavailability Completed 2013-11-01 2013-12-01 ClinicalTrials.gov
NCT02052349 Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects Phase1 Relative Bioavailability Completed 2013-11-01 2013-12-01 ClinicalTrials.gov
NCT02009631 A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With … Phase1 Breast Cancer Completed 2013-11-01 2014-12-01 ClinicalTrials.gov
NCT01995071 A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-49… Phase2 Chronic Hepatitis C Completed 2013-11-01 2015-06-01 ClinicalTrials.gov
NCT01994837 A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) Phase2 Acute Myelogenous Leukemia Completed 2013-11-01 2014-12-01 ClinicalTrials.gov
NCT01994837 A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) Phase2 Acute Myelogenous Leukemia Completed 2013-11-01 2014-12-01 ClinicalTrials.gov
NCT01995071 A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-49… Phase2 Chronic Hepatitis C Completed 2013-11-01 2015-06-01 ClinicalTrials.gov
NCT02009631 A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With … Phase1 Breast Cancer Completed 2013-11-01 2014-12-01 ClinicalTrials.gov
NCT02052349 Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects Phase1 Relative Bioavailability Completed 2013-11-01 2013-12-01 ClinicalTrials.gov
NCT01974323 Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris Phase3 Acne Vulgaris Completed 2013-11-01 2014-10-01 ClinicalTrials.gov
NCT01974141 A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris Phase3 Acne Vulgaris Completed 2013-11-01 2014-10-01 ClinicalTrials.gov
NCT01974141 A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris Phase3 Acne Vulgaris Completed 2013-11-01 2014-10-01 ClinicalTrials.gov
NCT01974323 Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris Phase3 Acne Vulgaris Completed 2013-11-01 2014-10-01 ClinicalTrials.gov
NCT02052349 Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects Phase1 Relative Bioavailability Completed 2013-11-01 2013-12-01 ClinicalTrials.gov
NCT02009631 A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With … Phase1 Breast Cancer Completed 2013-11-01 2014-12-01 ClinicalTrials.gov
NCT01995071 A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-49… Phase2 Chronic Hepatitis C Completed 2013-11-01 2015-06-01 ClinicalTrials.gov
NCT01994837 A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) Phase2 Acute Myelogenous Leukemia Completed 2013-11-01 2014-12-01 ClinicalTrials.gov
NCT01994837 A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) Phase2 Acute Myelogenous Leukemia Completed 2013-11-01 2014-12-01 ClinicalTrials.gov
NCT01995071 A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-49… Phase2 Chronic Hepatitis C Completed 2013-11-01 2015-06-01 ClinicalTrials.gov
NCT02009631 A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With … Phase1 Breast Cancer Completed 2013-11-01 2014-12-01 ClinicalTrials.gov
NCT01974141 A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris Phase3 Acne Vulgaris Completed 2013-11-01 2014-10-01 ClinicalTrials.gov
NCT01974323 Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris Phase3 Acne Vulgaris Completed 2013-11-01 2014-10-01 ClinicalTrials.gov
NCT01976663 A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Mode… Na Moderate to Severe Nasolabial Folds Completed 2013-10-29 2015-10-26 ClinicalTrials.gov
NCT01976663 A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Mode… Na Moderate to Severe Nasolabial Folds Completed 2013-10-29 2015-10-26 ClinicalTrials.gov
NCT01976663 A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Mode… Na Moderate to Severe Nasolabial Folds Completed 2013-10-29 2015-10-26 ClinicalTrials.gov
NCT01976663 A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Mode… Na Moderate to Severe Nasolabial Folds Completed 2013-10-29 2015-10-26 ClinicalTrials.gov
NCT01945489 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With… Phase4 Overactive Bladder Completed 2013-10-28 2017-01-05 ClinicalTrials.gov
NCT01945489 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With… Phase4 Overactive Bladder Completed 2013-10-28 2017-01-05 ClinicalTrials.gov
NCT01945489 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With… Phase4 Overactive Bladder Completed 2013-10-28 2017-01-05 ClinicalTrials.gov
NCT01945489 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With… Phase4 Overactive Bladder Completed 2013-10-28 2017-01-05 ClinicalTrials.gov
NCT01970397 JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines Na Patients With Moderate to Severe Perioral Lines Completed 2013-10-21 2014-08-04 ClinicalTrials.gov
NCT01970397 JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines Na Patients With Moderate to Severe Perioral Lines Completed 2013-10-21 2014-08-04 ClinicalTrials.gov
NCT01970397 JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines Na Patients With Moderate to Severe Perioral Lines Completed 2013-10-21 2014-08-04 ClinicalTrials.gov
NCT01970397 JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines Na Patients With Moderate to Severe Perioral Lines Completed 2013-10-21 2014-08-04 ClinicalTrials.gov
NCT01930786 An Adult Spasticity Registry of OnabotulinumtoxinA Treatment — Muscle Spasticity Completed 2013-10-16 2017-10-09 ClinicalTrials.gov
NCT01930786 An Adult Spasticity Registry of OnabotulinumtoxinA Treatment — Muscle Spasticity Completed 2013-10-16 2017-10-09 ClinicalTrials.gov
NCT01930786 An Adult Spasticity Registry of OnabotulinumtoxinA Treatment — Muscle Spasticity Completed 2013-10-16 2017-10-09 ClinicalTrials.gov
NCT01930786 An Adult Spasticity Registry of OnabotulinumtoxinA Treatment — Muscle Spasticity Completed 2013-10-16 2017-10-09 ClinicalTrials.gov
NCT02120898 A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participan… Phase3 Actinic Keratosis Completed 2013-10-10 2014-04-30 ClinicalTrials.gov
NCT02120898 A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participan… Phase3 Actinic Keratosis Completed 2013-10-10 2014-04-30 ClinicalTrials.gov
NCT02120898 A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participan… Phase3 Actinic Keratosis Completed 2013-10-10 2014-04-30 ClinicalTrials.gov
NCT02120898 A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participan… Phase3 Actinic Keratosis Completed 2013-10-10 2014-04-30 ClinicalTrials.gov
NCT01908478 Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation The… Phase1 Pancreatic Cancer Completed 2013-10-02 2020-07-06 ClinicalTrials.gov
NCT01908478 Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation The… Phase1 Pancreatic Cancer Completed 2013-10-02 2020-07-06 ClinicalTrials.gov
NCT01908478 Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation The… Phase1 Pancreatic Cancer Completed 2013-10-02 2020-07-06 ClinicalTrials.gov
NCT01908478 Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation The… Phase1 Pancreatic Cancer Completed 2013-10-02 2020-07-06 ClinicalTrials.gov
NCT01999192 Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-I… Phase2 Rheumatoid Arthritis Terminated 2013-10-01 2015-07-01 ClinicalTrials.gov
NCT01674413 Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) Phase3 Crohn's Disease Withdrawn 2013-10-01 2016-03-01 ClinicalTrials.gov
NCT01999192 Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-I… Phase2 Rheumatoid Arthritis Terminated 2013-10-01 2015-07-01 ClinicalTrials.gov
NCT01674413 Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) Phase3 Crohn's Disease Withdrawn 2013-10-01 2016-03-01 ClinicalTrials.gov
NCT02138461 Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops — Glaucoma Completed 2013-10-01 2014-09-01 ClinicalTrials.gov
NCT01999192 Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-I… Phase2 Rheumatoid Arthritis Terminated 2013-10-01 2015-07-01 ClinicalTrials.gov
NCT02138461 Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops — Glaucoma Completed 2013-10-01 2014-09-01 ClinicalTrials.gov
NCT01960855 A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexat… Phase2 Rheumatoid Arthritis Completed 2013-10-01 2015-07-01 ClinicalTrials.gov
NCT01960842 A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monothera… Phase3 Advanced Parkinson's Disease Completed 2013-10-01 2015-03-01 ClinicalTrials.gov
NCT01929746 Daclizumab Japanese PK Study Phase1 Healthy Completed 2013-10-01 2014-03-01 ClinicalTrials.gov
NCT01929746 Daclizumab Japanese PK Study Phase1 Healthy Completed 2013-10-01 2014-03-01 ClinicalTrials.gov
NCT02016612 Seri Surgical Scaffold Support of the Lower Pole of the Breast Na Recurrent Ptosis of the Breast Completed 2013-10-01 2016-11-30 ClinicalTrials.gov
NCT01960842 A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monothera… Phase3 Advanced Parkinson's Disease Completed 2013-10-01 2015-03-01 ClinicalTrials.gov
NCT01960855 A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexat… Phase2 Rheumatoid Arthritis Completed 2013-10-01 2015-07-01 ClinicalTrials.gov
NCT01999192 Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-I… Phase2 Rheumatoid Arthritis Terminated 2013-10-01 2015-07-01 ClinicalTrials.gov
NCT01674413 Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) Phase3 Crohn's Disease Withdrawn 2013-10-01 2016-03-01 ClinicalTrials.gov
NCT01929746 Daclizumab Japanese PK Study Phase1 Healthy Completed 2013-10-01 2014-03-01 ClinicalTrials.gov
NCT02138461 Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops — Glaucoma Completed 2013-10-01 2014-09-01 ClinicalTrials.gov
NCT01960855 A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexat… Phase2 Rheumatoid Arthritis Completed 2013-10-01 2015-07-01 ClinicalTrials.gov
NCT02138461 Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops — Glaucoma Completed 2013-10-01 2014-09-01 ClinicalTrials.gov
NCT01960842 A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monothera… Phase3 Advanced Parkinson's Disease Completed 2013-10-01 2015-03-01 ClinicalTrials.gov
NCT02016612 Seri Surgical Scaffold Support of the Lower Pole of the Breast Na Recurrent Ptosis of the Breast Completed 2013-10-01 2016-11-30 ClinicalTrials.gov
NCT02016612 Seri Surgical Scaffold Support of the Lower Pole of the Breast Na Recurrent Ptosis of the Breast Completed 2013-10-01 2016-11-30 ClinicalTrials.gov
NCT01674413 Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) Phase3 Crohn's Disease Withdrawn 2013-10-01 2016-03-01 ClinicalTrials.gov
NCT02016612 Seri Surgical Scaffold Support of the Lower Pole of the Breast Na Recurrent Ptosis of the Breast Completed 2013-10-01 2016-11-30 ClinicalTrials.gov
NCT01929746 Daclizumab Japanese PK Study Phase1 Healthy Completed 2013-10-01 2014-03-01 ClinicalTrials.gov
NCT01960842 A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monothera… Phase3 Advanced Parkinson's Disease Completed 2013-10-01 2015-03-01 ClinicalTrials.gov
NCT01960855 A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexat… Phase2 Rheumatoid Arthritis Completed 2013-10-01 2015-07-01 ClinicalTrials.gov
NCT01960881 Evaluation of Diet and Exercise in Prostate Cancer Patients — Prostate Cancer Completed 2013-09-19 2021-08-10 ClinicalTrials.gov
NCT01960881 Evaluation of Diet and Exercise in Prostate Cancer Patients — Prostate Cancer Completed 2013-09-19 2021-08-10 ClinicalTrials.gov
NCT01960881 Evaluation of Diet and Exercise in Prostate Cancer Patients — Prostate Cancer Completed 2013-09-19 2021-08-10 ClinicalTrials.gov
NCT01960881 Evaluation of Diet and Exercise in Prostate Cancer Patients — Prostate Cancer Completed 2013-09-19 2021-08-10 ClinicalTrials.gov
NCT01931670 A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subje… Phase3 Endometriosis Completed 2013-09-09 2016-12-19 ClinicalTrials.gov
NCT01931670 A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subje… Phase3 Endometriosis Completed 2013-09-09 2016-12-19 ClinicalTrials.gov
NCT01931670 A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subje… Phase3 Endometriosis Completed 2013-09-09 2016-12-19 ClinicalTrials.gov
NCT01931670 A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subje… Phase3 Endometriosis Completed 2013-09-09 2016-12-19 ClinicalTrials.gov
NCT01564732 Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Ad… Na Morbid Obesity Terminated 2013-09-01 2015-04-01 ClinicalTrials.gov
NCT01564732 Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Ad… Na Morbid Obesity Terminated 2013-09-01 2015-04-01 ClinicalTrials.gov
NCT01958827 A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's D… Phase3 Crohn's Disease Completed 2013-09-01 2015-10-01 ClinicalTrials.gov
NCT01969162 Tear Collection in Adult Volunteers — Healthy Volunteers Completed 2013-09-01 2013-11-01 ClinicalTrials.gov
NCT01958827 A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's D… Phase3 Crohn's Disease Completed 2013-09-01 2015-10-01 ClinicalTrials.gov
NCT01956032 Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources — Parkinson's Disease Completed 2013-09-01 2014-11-01 ClinicalTrials.gov
NCT01969162 Tear Collection in Adult Volunteers — Healthy Volunteers Completed 2013-09-01 2013-11-01 ClinicalTrials.gov
NCT01969162 Tear Collection in Adult Volunteers — Healthy Volunteers Completed 2013-09-01 2013-11-01 ClinicalTrials.gov
NCT01958827 A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's D… Phase3 Crohn's Disease Completed 2013-09-01 2015-10-01 ClinicalTrials.gov
NCT01956032 Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources — Parkinson's Disease Completed 2013-09-01 2014-11-01 ClinicalTrials.gov
NCT03079375 The Pharmacist Follows You and Your Medication From Hospital to Your Daily Life… Na Cross-Sectional Study Completed 2013-09-01 2015-10-24 ClinicalTrials.gov
NCT01969162 Tear Collection in Adult Volunteers — Healthy Volunteers Completed 2013-09-01 2013-11-01 ClinicalTrials.gov
NCT03079375 The Pharmacist Follows You and Your Medication From Hospital to Your Daily Life… Na Cross-Sectional Study Completed 2013-09-01 2015-10-24 ClinicalTrials.gov
NCT01564732 Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Ad… Na Morbid Obesity Terminated 2013-09-01 2015-04-01 ClinicalTrials.gov
NCT01956032 Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources — Parkinson's Disease Completed 2013-09-01 2014-11-01 ClinicalTrials.gov
NCT01956032 Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources — Parkinson's Disease Completed 2013-09-01 2014-11-01 ClinicalTrials.gov
NCT01564732 Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Ad… Na Morbid Obesity Terminated 2013-09-01 2015-04-01 ClinicalTrials.gov
NCT03079375 The Pharmacist Follows You and Your Medication From Hospital to Your Daily Life… Na Cross-Sectional Study Completed 2013-09-01 2015-10-24 ClinicalTrials.gov
NCT03079375 The Pharmacist Follows You and Your Medication From Hospital to Your Daily Life… Na Cross-Sectional Study Completed 2013-09-01 2015-10-24 ClinicalTrials.gov
NCT01958827 A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's D… Phase3 Crohn's Disease Completed 2013-09-01 2015-10-01 ClinicalTrials.gov
NCT01939197 A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/… Phase2 Hepatitis C Virus Infection Completed 2013-08-30 2016-10-25 ClinicalTrials.gov
NCT01939197 A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/… Phase2 Hepatitis C Virus Infection Completed 2013-08-30 2016-10-25 ClinicalTrials.gov
NCT01939197 A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/… Phase2 Hepatitis C Virus Infection Completed 2013-08-30 2016-10-25 ClinicalTrials.gov
NCT01939197 A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/… Phase2 Hepatitis C Virus Infection Completed 2013-08-30 2016-10-25 ClinicalTrials.gov
NCT01886690 A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With R… Phase3 Bilateral LASIK Surgery Completed 2013-08-20 2014-08-18 ClinicalTrials.gov
NCT01886690 A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With R… Phase3 Bilateral LASIK Surgery Completed 2013-08-20 2014-08-18 ClinicalTrials.gov
NCT01886690 A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With R… Phase3 Bilateral LASIK Surgery Completed 2013-08-20 2014-08-18 ClinicalTrials.gov
NCT01886690 A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With R… Phase3 Bilateral LASIK Surgery Completed 2013-08-20 2014-08-18 ClinicalTrials.gov
NCT01933919 A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With … Phase3 Obsessive Compulsive Disorder Completed 2013-08-14 2016-07-01 ClinicalTrials.gov
NCT01933919 A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With … Phase3 Obsessive Compulsive Disorder Completed 2013-08-14 2016-07-01 ClinicalTrials.gov
NCT01933919 A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With … Phase3 Obsessive Compulsive Disorder Completed 2013-08-14 2016-07-01 ClinicalTrials.gov
NCT01933919 A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With … Phase3 Obsessive Compulsive Disorder Completed 2013-08-14 2016-07-01 ClinicalTrials.gov
NCT01947816 Special Investigation in Patients With Ulcerative Colitis — Ulcerative Colitis Completed 2013-08-09 2018-02-15 ClinicalTrials.gov
NCT01947816 Special Investigation in Patients With Ulcerative Colitis — Ulcerative Colitis Completed 2013-08-09 2018-02-15 ClinicalTrials.gov
NCT01947816 Special Investigation in Patients With Ulcerative Colitis — Ulcerative Colitis Completed 2013-08-09 2018-02-15 ClinicalTrials.gov
NCT01947816 Special Investigation in Patients With Ulcerative Colitis — Ulcerative Colitis Completed 2013-08-09 2018-02-15 ClinicalTrials.gov
NCT01946074 A Study of ABT-165 in Subjects With Solid Tumors Phase1 Advanced Solid Tumors Completed 2013-08-08 2022-09-28 ClinicalTrials.gov
NCT01946074 A Study of ABT-165 in Subjects With Solid Tumors Phase1 Advanced Solid Tumors Completed 2013-08-08 2022-09-28 ClinicalTrials.gov
NCT01946074 A Study of ABT-165 in Subjects With Solid Tumors Phase1 Advanced Solid Tumors Completed 2013-08-08 2022-09-28 ClinicalTrials.gov
NCT01946074 A Study of ABT-165 in Subjects With Solid Tumors Phase1 Advanced Solid Tumors Completed 2013-08-08 2022-09-28 ClinicalTrials.gov
NCT01917006 A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation Phase2 Premature Ejaculation Terminated 2013-08-07 2017-08-15 ClinicalTrials.gov
NCT01917006 A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation Phase2 Premature Ejaculation Terminated 2013-08-07 2017-08-15 ClinicalTrials.gov
NCT01917006 A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation Phase2 Premature Ejaculation Terminated 2013-08-07 2017-08-15 ClinicalTrials.gov
NCT01917006 A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation Phase2 Premature Ejaculation Terminated 2013-08-07 2017-08-15 ClinicalTrials.gov
NCT01918371 A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injecti… — Retinal Vein Occlusion Completed 2013-08-02 2014-09-04 ClinicalTrials.gov
NCT01918371 A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injecti… — Retinal Vein Occlusion Completed 2013-08-02 2014-09-04 ClinicalTrials.gov
NCT01918371 A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injecti… — Retinal Vein Occlusion Completed 2013-08-02 2014-09-04 ClinicalTrials.gov
NCT01918371 A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injecti… — Retinal Vein Occlusion Completed 2013-08-02 2014-09-04 ClinicalTrials.gov
NCT01930799 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Pat… Phase4 Multiple Sclerosis Completed 2013-08-01 2015-03-01 ClinicalTrials.gov
NCT01904721 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Phase2 Alopecia Completed 2013-08-01 2015-01-01 ClinicalTrials.gov
NCT01930799 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Pat… Phase4 Multiple Sclerosis Completed 2013-08-01 2015-03-01 ClinicalTrials.gov
NCT01942226 Investigation on Medical Management of Dry Eye Patients — Dry Eye Syndrome Completed 2013-08-01 2013-12-01 ClinicalTrials.gov
NCT01904721 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Phase2 Alopecia Completed 2013-08-01 2015-01-01 ClinicalTrials.gov
NCT01942226 Investigation on Medical Management of Dry Eye Patients — Dry Eye Syndrome Completed 2013-08-01 2013-12-01 ClinicalTrials.gov
NCT01930799 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Pat… Phase4 Multiple Sclerosis Completed 2013-08-01 2015-03-01 ClinicalTrials.gov
NCT01942226 Investigation on Medical Management of Dry Eye Patients — Dry Eye Syndrome Completed 2013-08-01 2013-12-01 ClinicalTrials.gov
NCT01904721 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Phase2 Alopecia Completed 2013-08-01 2015-01-01 ClinicalTrials.gov
NCT01930799 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Pat… Phase4 Multiple Sclerosis Completed 2013-08-01 2015-03-01 ClinicalTrials.gov
NCT01858519 Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fi… — Cystic Fibrosis Completed 2013-08-01 2016-09-01 ClinicalTrials.gov
NCT01858519 Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fi… — Cystic Fibrosis Completed 2013-08-01 2016-09-01 ClinicalTrials.gov
NCT01904721 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Phase2 Alopecia Completed 2013-08-01 2015-01-01 ClinicalTrials.gov
NCT01942226 Investigation on Medical Management of Dry Eye Patients — Dry Eye Syndrome Completed 2013-08-01 2013-12-01 ClinicalTrials.gov
NCT01858519 Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fi… — Cystic Fibrosis Completed 2013-08-01 2016-09-01 ClinicalTrials.gov
NCT01858519 Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fi… — Cystic Fibrosis Completed 2013-08-01 2016-09-01 ClinicalTrials.gov
NCT01903720 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch… Phase4 Macular Edema Completed 2013-07-16 2015-03-30 ClinicalTrials.gov
NCT01903720 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch… Phase4 Macular Edema Completed 2013-07-16 2015-03-30 ClinicalTrials.gov
NCT01903720 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch… Phase4 Macular Edema Completed 2013-07-16 2015-03-30 ClinicalTrials.gov
NCT01903720 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch… Phase4 Macular Edema Completed 2013-07-16 2015-03-30 ClinicalTrials.gov
NCT01852045 Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic… Phase3 Urinary Incontinence Completed 2013-07-02 2018-10-11 ClinicalTrials.gov
NCT01852045 Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic… Phase3 Urinary Incontinence Completed 2013-07-02 2018-10-11 ClinicalTrials.gov
NCT01852045 Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic… Phase3 Urinary Incontinence Completed 2013-07-02 2018-10-11 ClinicalTrials.gov
NCT01852045 Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic… Phase3 Urinary Incontinence Completed 2013-07-02 2018-10-11 ClinicalTrials.gov
NCT01879683 A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women… Phase1 Chronic Interstitial Cystitis Completed 2013-07-01 2014-06-01 ClinicalTrials.gov
NCT01893996 Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Contr… Phase4 Rheumatoid Arthritis Completed 2013-07-01 2017-07-01 ClinicalTrials.gov
NCT01908010 Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-… Phase1 Alzheimer's Disease Completed 2013-07-01 2013-11-01 ClinicalTrials.gov
NCT02120924 A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Pa… Phase3 Rosacea Completed 2013-07-01 2014-09-01 ClinicalTrials.gov
NCT01284166 Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochlorid… Phase3 Glaucoma Withdrawn 2013-07-01 2014-05-01 ClinicalTrials.gov
NCT01821573 Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps … Phase3 COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO Completed 2013-07-01 2019-05-23 ClinicalTrials.gov
NCT01821573 Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps … Phase3 COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO Completed 2013-07-01 2019-05-23 ClinicalTrials.gov
NCT01879683 A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women… Phase1 Chronic Interstitial Cystitis Completed 2013-07-01 2014-06-01 ClinicalTrials.gov
NCT01853033 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple S… Phase1 Rheumatoid Arthritis Completed 2013-07-01 2014-05-01 ClinicalTrials.gov
NCT02120924 A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Pa… Phase3 Rosacea Completed 2013-07-01 2014-09-01 ClinicalTrials.gov
NCT01879683 A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women… Phase1 Chronic Interstitial Cystitis Completed 2013-07-01 2014-06-01 ClinicalTrials.gov
NCT01853033 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple S… Phase1 Rheumatoid Arthritis Completed 2013-07-01 2014-05-01 ClinicalTrials.gov
NCT01853033 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple S… Phase1 Rheumatoid Arthritis Completed 2013-07-01 2014-05-01 ClinicalTrials.gov
NCT01284166 Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochlorid… Phase3 Glaucoma Withdrawn 2013-07-01 2014-05-01 ClinicalTrials.gov
NCT01853033 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple S… Phase1 Rheumatoid Arthritis Completed 2013-07-01 2014-05-01 ClinicalTrials.gov
NCT01284166 Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochlorid… Phase3 Glaucoma Withdrawn 2013-07-01 2014-05-01 ClinicalTrials.gov
NCT01893996 Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Contr… Phase4 Rheumatoid Arthritis Completed 2013-07-01 2017-07-01 ClinicalTrials.gov
NCT01893996 Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Contr… Phase4 Rheumatoid Arthritis Completed 2013-07-01 2017-07-01 ClinicalTrials.gov
NCT01908010 Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-… Phase1 Alzheimer's Disease Completed 2013-07-01 2013-11-01 ClinicalTrials.gov
NCT01908010 Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-… Phase1 Alzheimer's Disease Completed 2013-07-01 2013-11-01 ClinicalTrials.gov
NCT01879683 A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women… Phase1 Chronic Interstitial Cystitis Completed 2013-07-01 2014-06-01 ClinicalTrials.gov
NCT01893996 Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Contr… Phase4 Rheumatoid Arthritis Completed 2013-07-01 2017-07-01 ClinicalTrials.gov
NCT01908010 Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-… Phase1 Alzheimer's Disease Completed 2013-07-01 2013-11-01 ClinicalTrials.gov
NCT02120924 A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Pa… Phase3 Rosacea Completed 2013-07-01 2014-09-01 ClinicalTrials.gov
NCT02120924 A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Pa… Phase3 Rosacea Completed 2013-07-01 2014-09-01 ClinicalTrials.gov
NCT01284166 Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochlorid… Phase3 Glaucoma Withdrawn 2013-07-01 2014-05-01 ClinicalTrials.gov
NCT01821573 Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps … Phase3 COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO Completed 2013-07-01 2019-05-23 ClinicalTrials.gov
NCT01821573 Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps … Phase3 COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO Completed 2013-07-01 2019-05-23 ClinicalTrials.gov
NCT01889186 A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Prev… Phase2 Chronic Lymphocytic Leukemia Completed 2013-06-27 2020-12-15 ClinicalTrials.gov
NCT01889186 A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Prev… Phase2 Chronic Lymphocytic Leukemia Completed 2013-06-27 2020-12-15 ClinicalTrials.gov
NCT01889186 A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Prev… Phase2 Chronic Lymphocytic Leukemia Completed 2013-06-27 2020-12-15 ClinicalTrials.gov
NCT01889186 A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Prev… Phase2 Chronic Lymphocytic Leukemia Completed 2013-06-27 2020-12-15 ClinicalTrials.gov
NCT01845818 Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to … — Ankylosing Spondylitis Completed 2013-06-05 2017-06-23 ClinicalTrials.gov
NCT01845818 Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to … — Ankylosing Spondylitis Completed 2013-06-05 2017-06-23 ClinicalTrials.gov
NCT01845818 Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to … — Ankylosing Spondylitis Completed 2013-06-05 2017-06-23 ClinicalTrials.gov
NCT01845818 Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to … — Ankylosing Spondylitis Completed 2013-06-05 2017-06-23 ClinicalTrials.gov
NCT01881126 An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travopros… Phase4 Glaucoma Completed 2013-06-01 2014-10-01 ClinicalTrials.gov
NCT01863953 A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in… Phase2 Glaucoma Completed 2013-06-01 2013-12-01 ClinicalTrials.gov
NCT01787669 Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal De… Phase2 Diabetes Completed 2013-06-01 2017-10-01 ClinicalTrials.gov
NCT01828476 Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treati… Phase2 Prostate Cancer Terminated 2013-06-01 2016-03-03 ClinicalTrials.gov
NCT01854528 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compare… Phase3 Chronic Hepatitis C Infection Completed 2013-06-01 2015-07-01 ClinicalTrials.gov
NCT01828476 Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treati… Phase2 Prostate Cancer Terminated 2013-06-01 2016-03-03 ClinicalTrials.gov
NCT01854528 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compare… Phase3 Chronic Hepatitis C Infection Completed 2013-06-01 2015-07-01 ClinicalTrials.gov
NCT01854528 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compare… Phase3 Chronic Hepatitis C Infection Completed 2013-06-01 2015-07-01 ClinicalTrials.gov
NCT01828476 Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treati… Phase2 Prostate Cancer Terminated 2013-06-01 2016-03-03 ClinicalTrials.gov
NCT01882413 A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients… — Dry Eye Syndromes Completed 2013-06-01 2014-03-01 ClinicalTrials.gov
NCT01881126 An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travopros… Phase4 Glaucoma Completed 2013-06-01 2014-10-01 ClinicalTrials.gov
NCT01863953 A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in… Phase2 Glaucoma Completed 2013-06-01 2013-12-01 ClinicalTrials.gov
NCT01787669 Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal De… Phase2 Diabetes Completed 2013-06-01 2017-10-01 ClinicalTrials.gov
NCT01828476 Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treati… Phase2 Prostate Cancer Terminated 2013-06-01 2016-03-03 ClinicalTrials.gov
NCT01854528 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compare… Phase3 Chronic Hepatitis C Infection Completed 2013-06-01 2015-07-01 ClinicalTrials.gov
NCT01787669 Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal De… Phase2 Diabetes Completed 2013-06-01 2017-10-01 ClinicalTrials.gov
NCT01863953 A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in… Phase2 Glaucoma Completed 2013-06-01 2013-12-01 ClinicalTrials.gov
NCT01881126 An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travopros… Phase4 Glaucoma Completed 2013-06-01 2014-10-01 ClinicalTrials.gov
NCT01882413 A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients… — Dry Eye Syndromes Completed 2013-06-01 2014-03-01 ClinicalTrials.gov
NCT01787669 Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal De… Phase2 Diabetes Completed 2013-06-01 2017-10-01 ClinicalTrials.gov
NCT01863953 A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in… Phase2 Glaucoma Completed 2013-06-01 2013-12-01 ClinicalTrials.gov
NCT01881126 An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travopros… Phase4 Glaucoma Completed 2013-06-01 2014-10-01 ClinicalTrials.gov
NCT01882413 A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients… — Dry Eye Syndromes Completed 2013-06-01 2014-03-01 ClinicalTrials.gov
NCT01882413 A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients… — Dry Eye Syndromes Completed 2013-06-01 2014-03-01 ClinicalTrials.gov
NCT01844388 A Study to Compare a New Eye Drop Formulation With Refresh Contacts® Phase3 Contact Lens Lubrication Completed 2013-05-29 2013-12-02 ClinicalTrials.gov
NCT01844388 A Study to Compare a New Eye Drop Formulation With Refresh Contacts® Phase3 Contact Lens Lubrication Completed 2013-05-29 2013-12-02 ClinicalTrials.gov
NCT01844388 A Study to Compare a New Eye Drop Formulation With Refresh Contacts® Phase3 Contact Lens Lubrication Completed 2013-05-29 2013-12-02 ClinicalTrials.gov
NCT01844388 A Study to Compare a New Eye Drop Formulation With Refresh Contacts® Phase3 Contact Lens Lubrication Completed 2013-05-29 2013-12-02 ClinicalTrials.gov
NCT01960790 Special Investigation in Patients With Intestinal Behcet's Disease (All Case In… — Behcet's Disease Completed 2013-05-25 2017-05-15 ClinicalTrials.gov
NCT01960790 Special Investigation in Patients With Intestinal Behcet's Disease (All Case In… — Behcet's Disease Completed 2013-05-25 2017-05-15 ClinicalTrials.gov
NCT01960790 Special Investigation in Patients With Intestinal Behcet's Disease (All Case In… — Behcet's Disease Completed 2013-05-25 2017-05-15 ClinicalTrials.gov
NCT01960790 Special Investigation in Patients With Intestinal Behcet's Disease (All Case In… — Behcet's Disease Completed 2013-05-25 2017-05-15 ClinicalTrials.gov
NCT01858532 Study Of Diabetic Nephropathy With Atrasentan Phase3 Diabetic Nephropathy Terminated 2013-05-17 2018-03-29 ClinicalTrials.gov
NCT01858532 Study Of Diabetic Nephropathy With Atrasentan Phase3 Diabetic Nephropathy Terminated 2013-05-17 2018-03-29 ClinicalTrials.gov
NCT01858532 Study Of Diabetic Nephropathy With Atrasentan Phase3 Diabetic Nephropathy Terminated 2013-05-17 2018-03-29 ClinicalTrials.gov
NCT01858532 Study Of Diabetic Nephropathy With Atrasentan Phase3 Diabetic Nephropathy Terminated 2013-05-17 2018-03-29 ClinicalTrials.gov
NCT01870440 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Phase4 Macular Edema Completed 2013-05-01 2015-02-01 ClinicalTrials.gov
NCT01891487 Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning… Phase4 Hypotrichosis Completed 2013-05-01 2015-01-01 ClinicalTrials.gov
NCT02035800 Bone Resorption, Osteoclastogenesis and Adalimumab Phase4 RheumatoId Arthritis Unknown 2013-05-01 2019-12-01 ClinicalTrials.gov
NCT01870440 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Phase4 Macular Edema Completed 2013-05-01 2015-02-01 ClinicalTrials.gov
NCT01854905 An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusi… — Dry Eye Syndromes Completed 2013-05-01 2013-09-01 ClinicalTrials.gov
NCT01891487 Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning… Phase4 Hypotrichosis Completed 2013-05-01 2015-01-01 ClinicalTrials.gov
NCT02035800 Bone Resorption, Osteoclastogenesis and Adalimumab Phase4 RheumatoId Arthritis Unknown 2013-05-01 2019-12-01 ClinicalTrials.gov
NCT01897519 A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prev… Phase2 Cardiothoracic Surgery Terminated 2013-05-01 2014-05-01 ClinicalTrials.gov
NCT01814761 A Study of Bimatoprost 0.01% in the Clinical Setting — Glaucoma, Primary Open Angle Completed 2013-05-01 2014-08-01 ClinicalTrials.gov
NCT01814761 A Study of Bimatoprost 0.01% in the Clinical Setting — Glaucoma, Primary Open Angle Completed 2013-05-01 2014-08-01 ClinicalTrials.gov
NCT01749410 A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinum… — Chronic Migraine, Headaches Completed 2013-05-01 2014-05-01 ClinicalTrials.gov
NCT01897519 A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prev… Phase2 Cardiothoracic Surgery Terminated 2013-05-01 2014-05-01 ClinicalTrials.gov
NCT01856556 Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers Phase1 Healthy Completed 2013-05-01 2014-11-01 ClinicalTrials.gov
NCT01814761 A Study of Bimatoprost 0.01% in the Clinical Setting — Glaucoma, Primary Open Angle Completed 2013-05-01 2014-08-01 ClinicalTrials.gov
NCT01749410 A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinum… — Chronic Migraine, Headaches Completed 2013-05-01 2014-05-01 ClinicalTrials.gov
NCT01897519 A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prev… Phase2 Cardiothoracic Surgery Terminated 2013-05-01 2014-05-01 ClinicalTrials.gov
NCT01749410 A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinum… — Chronic Migraine, Headaches Completed 2013-05-01 2014-05-01 ClinicalTrials.gov
NCT01860846 Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of L… — Crohn's Disease Completed 2013-05-01 2016-02-01 ClinicalTrials.gov
NCT01854905 An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusi… — Dry Eye Syndromes Completed 2013-05-01 2013-09-01 ClinicalTrials.gov
NCT01897519 A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prev… Phase2 Cardiothoracic Surgery Terminated 2013-05-01 2014-05-01 ClinicalTrials.gov
NCT01854905 An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusi… — Dry Eye Syndromes Completed 2013-05-01 2013-09-01 ClinicalTrials.gov
NCT01856556 Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers Phase1 Healthy Completed 2013-05-01 2014-11-01 ClinicalTrials.gov
NCT01749410 A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinum… — Chronic Migraine, Headaches Completed 2013-05-01 2014-05-01 ClinicalTrials.gov
NCT01856556 Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers Phase1 Healthy Completed 2013-05-01 2014-11-01 ClinicalTrials.gov
NCT01860846 Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of L… — Crohn's Disease Completed 2013-05-01 2016-02-01 ClinicalTrials.gov
NCT02035800 Bone Resorption, Osteoclastogenesis and Adalimumab Phase4 RheumatoId Arthritis Unknown 2013-05-01 2019-12-01 ClinicalTrials.gov
NCT02035800 Bone Resorption, Osteoclastogenesis and Adalimumab Phase4 RheumatoId Arthritis Unknown 2013-05-01 2019-12-01 ClinicalTrials.gov
NCT01854905 An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusi… — Dry Eye Syndromes Completed 2013-05-01 2013-09-01 ClinicalTrials.gov
NCT01891487 Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning… Phase4 Hypotrichosis Completed 2013-05-01 2015-01-01 ClinicalTrials.gov
NCT01870440 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Phase4 Macular Edema Completed 2013-05-01 2015-02-01 ClinicalTrials.gov
NCT01814761 A Study of Bimatoprost 0.01% in the Clinical Setting — Glaucoma, Primary Open Angle Completed 2013-05-01 2014-08-01 ClinicalTrials.gov
NCT01856556 Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers Phase1 Healthy Completed 2013-05-01 2014-11-01 ClinicalTrials.gov
NCT01860846 Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of L… — Crohn's Disease Completed 2013-05-01 2016-02-01 ClinicalTrials.gov
NCT01860846 Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of L… — Crohn's Disease Completed 2013-05-01 2016-02-01 ClinicalTrials.gov
NCT01870440 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Phase4 Macular Edema Completed 2013-05-01 2015-02-01 ClinicalTrials.gov
NCT01891487 Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning… Phase4 Hypotrichosis Completed 2013-05-01 2015-01-01 ClinicalTrials.gov
NCT01901146 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HE… Phase3 Breast Cancer Completed 2013-04-29 2017-01-27 ClinicalTrials.gov
NCT01848561 A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Sev… — Ulcerative Colitis (UC) Active_Not_Recruiting 2013-04-29 2028-06-01 ClinicalTrials.gov
NCT01901146 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HE… Phase3 Breast Cancer Completed 2013-04-29 2017-01-27 ClinicalTrials.gov
NCT01901146 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HE… Phase3 Breast Cancer Completed 2013-04-29 2017-01-27 ClinicalTrials.gov
NCT01901146 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HE… Phase3 Breast Cancer Completed 2013-04-29 2017-01-27 ClinicalTrials.gov
NCT01848561 A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Sev… — Ulcerative Colitis (UC) Active_Not_Recruiting 2013-04-29 2028-06-01 ClinicalTrials.gov
NCT01848561 A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Sev… — Ulcerative Colitis (UC) Active_Not_Recruiting 2013-04-29 2028-06-01 ClinicalTrials.gov
NCT01848561 A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Sev… — Ulcerative Colitis (UC) Active_Not_Recruiting 2013-04-29 2028-06-01 ClinicalTrials.gov
NCT01808118 Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiog… Phase3 Axial Spondyloarthritis Completed 2013-04-16 2017-04-14 ClinicalTrials.gov
NCT01808118 Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiog… Phase3 Axial Spondyloarthritis Completed 2013-04-16 2017-04-14 ClinicalTrials.gov
NCT01808118 Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiog… Phase3 Axial Spondyloarthritis Completed 2013-04-16 2017-04-14 ClinicalTrials.gov
NCT01808118 Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiog… Phase3 Axial Spondyloarthritis Completed 2013-04-16 2017-04-14 ClinicalTrials.gov
NCT01817530 Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) … Phase2 Heavy Uterine Bleeding Completed 2013-04-08 2015-12-01 ClinicalTrials.gov
NCT01817530 Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) … Phase2 Heavy Uterine Bleeding Completed 2013-04-08 2015-12-01 ClinicalTrials.gov
NCT01817530 Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) … Phase2 Heavy Uterine Bleeding Completed 2013-04-08 2015-12-01 ClinicalTrials.gov
NCT01817530 Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) … Phase2 Heavy Uterine Bleeding Completed 2013-04-08 2015-12-01 ClinicalTrials.gov
NCT01800695 Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Gliobla… Phase1 Glioblastoma Multiforme Completed 2013-04-02 2017-06-19 ClinicalTrials.gov
NCT01800695 Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Gliobla… Phase1 Glioblastoma Multiforme Completed 2013-04-02 2017-06-19 ClinicalTrials.gov
NCT01800695 Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Gliobla… Phase1 Glioblastoma Multiforme Completed 2013-04-02 2017-06-19 ClinicalTrials.gov
NCT01800695 Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Gliobla… Phase1 Glioblastoma Multiforme Completed 2013-04-02 2017-06-19 ClinicalTrials.gov
NCT01853085 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Swi… — Glaucoma, Primary Open Angle Completed 2013-04-01 2014-03-01 ClinicalTrials.gov
NCT01853085 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Swi… — Glaucoma, Primary Open Angle Completed 2013-04-01 2014-03-01 ClinicalTrials.gov
NCT01911845 An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-… Phase2 Chronic Hepatitis C Infection Completed 2013-04-01 2014-09-01 ClinicalTrials.gov
NCT01911845 An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-… Phase2 Chronic Hepatitis C Infection Completed 2013-04-01 2014-09-01 ClinicalTrials.gov
NCT01911845 An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-… Phase2 Chronic Hepatitis C Infection Completed 2013-04-01 2014-09-01 ClinicalTrials.gov
NCT01853085 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Swi… — Glaucoma, Primary Open Angle Completed 2013-04-01 2014-03-01 ClinicalTrials.gov
NCT01866592 Vascular Inflammation in Psoriasis - Extension Study Phase4 Psoriasis Completed 2013-04-01 2016-10-27 ClinicalTrials.gov
NCT01826812 Impairment of Reading Ability in Dry Eye Patients — Dry Eye Syndromes Completed 2013-04-01 2015-11-01 ClinicalTrials.gov
NCT01833130 Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Trea… Phase4 Chronic Migraine Completed 2013-04-01 2014-09-01 ClinicalTrials.gov
NCT01826812 Impairment of Reading Ability in Dry Eye Patients — Dry Eye Syndromes Completed 2013-04-01 2015-11-01 ClinicalTrials.gov
NCT01853085 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Swi… — Glaucoma, Primary Open Angle Completed 2013-04-01 2014-03-01 ClinicalTrials.gov
NCT01833130 Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Trea… Phase4 Chronic Migraine Completed 2013-04-01 2014-09-01 ClinicalTrials.gov
NCT01833130 Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Trea… Phase4 Chronic Migraine Completed 2013-04-01 2014-09-01 ClinicalTrials.gov
NCT01866592 Vascular Inflammation in Psoriasis - Extension Study Phase4 Psoriasis Completed 2013-04-01 2016-10-27 ClinicalTrials.gov
NCT01833130 Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Trea… Phase4 Chronic Migraine Completed 2013-04-01 2014-09-01 ClinicalTrials.gov
NCT01826812 Impairment of Reading Ability in Dry Eye Patients — Dry Eye Syndromes Completed 2013-04-01 2015-11-01 ClinicalTrials.gov
NCT01911845 An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-… Phase2 Chronic Hepatitis C Infection Completed 2013-04-01 2014-09-01 ClinicalTrials.gov
NCT01866592 Vascular Inflammation in Psoriasis - Extension Study Phase4 Psoriasis Completed 2013-04-01 2016-10-27 ClinicalTrials.gov
NCT01866592 Vascular Inflammation in Psoriasis - Extension Study Phase4 Psoriasis Completed 2013-04-01 2016-10-27 ClinicalTrials.gov
NCT01826812 Impairment of Reading Ability in Dry Eye Patients — Dry Eye Syndromes Completed 2013-04-01 2015-11-01 ClinicalTrials.gov
NCT01853306 A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of V… Phase1 Oncology Completed 2013-03-18 2017-06-29 ClinicalTrials.gov
NCT01853306 A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of V… Phase1 Oncology Completed 2013-03-18 2017-06-29 ClinicalTrials.gov
NCT01853306 A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of V… Phase1 Oncology Completed 2013-03-18 2017-06-29 ClinicalTrials.gov
NCT01853306 A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of V… Phase1 Oncology Completed 2013-03-18 2017-06-29 ClinicalTrials.gov
NCT01735214 An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or O… — Glaucoma, Open-Angle Completed 2013-03-07 2014-04-10 ClinicalTrials.gov
NCT01735214 An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or O… — Glaucoma, Open-Angle Completed 2013-03-07 2014-04-10 ClinicalTrials.gov
NCT01735214 An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or O… — Glaucoma, Open-Angle Completed 2013-03-07 2014-04-10 ClinicalTrials.gov
NCT01735214 An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or O… — Glaucoma, Open-Angle Completed 2013-03-07 2014-04-10 ClinicalTrials.gov
NCT01814670 Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderat… Phase4 Glabellar Rhytides Completed 2013-03-06 2014-10-29 ClinicalTrials.gov
NCT01814670 Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderat… Phase4 Glabellar Rhytides Completed 2013-03-06 2014-10-29 ClinicalTrials.gov
NCT01814670 Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderat… Phase4 Glabellar Rhytides Completed 2013-03-06 2014-10-29 ClinicalTrials.gov
NCT01814670 Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderat… Phase4 Glabellar Rhytides Completed 2013-03-06 2014-10-29 ClinicalTrials.gov
NCT01824303 Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Intersti… Phase2 Interstitial Cystitis Terminated 2013-03-01 2014-12-01 ClinicalTrials.gov
NCT01834638 Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Ext… Phase2 Schizophrenia Terminated 2013-03-01 2014-11-01 ClinicalTrials.gov
NCT01833533 A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a In… Phase3 Chronic Hepatitis C Infection Completed 2013-03-01 2014-09-01 ClinicalTrials.gov
NCT01854697 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compare… Phase3 Chronic Hepatitis C Infection Completed 2013-03-01 2015-07-01 ClinicalTrials.gov
NCT01736176 A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel … Phase3 Advanced Parkinson's Disease Completed 2013-03-01 2015-12-01 ClinicalTrials.gov
NCT01736176 A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel … Phase3 Advanced Parkinson's Disease Completed 2013-03-01 2015-12-01 ClinicalTrials.gov
NCT01824303 Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Intersti… Phase2 Interstitial Cystitis Terminated 2013-03-01 2014-12-01 ClinicalTrials.gov
NCT03088449 Personalising Anti-TNF Therapy in Crohns Disease (PANTS) — Crohn Disease Unknown 2013-03-01 2019-07-30 ClinicalTrials.gov
NCT01834638 Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Ext… Phase2 Schizophrenia Terminated 2013-03-01 2014-11-01 ClinicalTrials.gov
NCT01821534 Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classi… — Healthy Volunteers Completed 2013-03-01 2013-05-01 ClinicalTrials.gov
NCT01833533 A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a In… Phase3 Chronic Hepatitis C Infection Completed 2013-03-01 2014-09-01 ClinicalTrials.gov
NCT01736176 A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel … Phase3 Advanced Parkinson's Disease Completed 2013-03-01 2015-12-01 ClinicalTrials.gov
NCT01854697 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compare… Phase3 Chronic Hepatitis C Infection Completed 2013-03-01 2015-07-01 ClinicalTrials.gov
NCT01785836 An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment … Phase1 Acne Vulgaris Withdrawn 2013-03-01 2013-10-01 ClinicalTrials.gov
NCT01833533 A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a In… Phase3 Chronic Hepatitis C Infection Completed 2013-03-01 2014-09-01 ClinicalTrials.gov
NCT01834638 Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Ext… Phase2 Schizophrenia Terminated 2013-03-01 2014-11-01 ClinicalTrials.gov
NCT01834638 Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Ext… Phase2 Schizophrenia Terminated 2013-03-01 2014-11-01 ClinicalTrials.gov
NCT01854697 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compare… Phase3 Chronic Hepatitis C Infection Completed 2013-03-01 2015-07-01 ClinicalTrials.gov
NCT01833533 A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a In… Phase3 Chronic Hepatitis C Infection Completed 2013-03-01 2014-09-01 ClinicalTrials.gov
NCT01767519 A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients… Phase3 Overactive Bladder Completed 2013-03-01 2015-03-18 ClinicalTrials.gov
NCT03088449 Personalising Anti-TNF Therapy in Crohns Disease (PANTS) — Crohn Disease Unknown 2013-03-01 2019-07-30 ClinicalTrials.gov
NCT01767519 A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients… Phase3 Overactive Bladder Completed 2013-03-01 2015-03-18 ClinicalTrials.gov
NCT03088449 Personalising Anti-TNF Therapy in Crohns Disease (PANTS) — Crohn Disease Unknown 2013-03-01 2019-07-30 ClinicalTrials.gov
NCT01767519 A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients… Phase3 Overactive Bladder Completed 2013-03-01 2015-03-18 ClinicalTrials.gov
NCT01785836 An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment … Phase1 Acne Vulgaris Withdrawn 2013-03-01 2013-10-01 ClinicalTrials.gov
NCT01821534 Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classi… — Healthy Volunteers Completed 2013-03-01 2013-05-01 ClinicalTrials.gov
NCT03088449 Personalising Anti-TNF Therapy in Crohns Disease (PANTS) — Crohn Disease Unknown 2013-03-01 2019-07-30 ClinicalTrials.gov
NCT01785836 An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment … Phase1 Acne Vulgaris Withdrawn 2013-03-01 2013-10-01 ClinicalTrials.gov
NCT01736176 A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel … Phase3 Advanced Parkinson's Disease Completed 2013-03-01 2015-12-01 ClinicalTrials.gov
NCT01767519 A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients… Phase3 Overactive Bladder Completed 2013-03-01 2015-03-18 ClinicalTrials.gov
NCT01821534 Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classi… — Healthy Volunteers Completed 2013-03-01 2013-05-01 ClinicalTrials.gov
NCT01785836 An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment … Phase1 Acne Vulgaris Withdrawn 2013-03-01 2013-10-01 ClinicalTrials.gov
NCT01821534 Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classi… — Healthy Volunteers Completed 2013-03-01 2013-05-01 ClinicalTrials.gov
NCT01824303 Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Intersti… Phase2 Interstitial Cystitis Terminated 2013-03-01 2014-12-01 ClinicalTrials.gov
NCT01824303 Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Intersti… Phase2 Interstitial Cystitis Terminated 2013-03-01 2014-12-01 ClinicalTrials.gov
NCT01854697 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compare… Phase3 Chronic Hepatitis C Infection Completed 2013-03-01 2015-07-01 ClinicalTrials.gov
NCT01782495 A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients Phase2 Chronic Hepatitis C Infection Completed 2013-02-25 2017-07-13 ClinicalTrials.gov
NCT01782495 A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients Phase2 Chronic Hepatitis C Infection Completed 2013-02-25 2017-07-13 ClinicalTrials.gov
NCT01782495 A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients Phase2 Chronic Hepatitis C Infection Completed 2013-02-25 2017-07-13 ClinicalTrials.gov
NCT01782495 A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients Phase2 Chronic Hepatitis C Infection Completed 2013-02-25 2017-07-13 ClinicalTrials.gov
NCT01641367 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combinatio… Phase4 HIV-1 Infection Completed 2013-02-22 2018-12-31 ClinicalTrials.gov
NCT01641367 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combinatio… Phase4 HIV-1 Infection Completed 2013-02-22 2018-12-31 ClinicalTrials.gov
NCT01641367 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combinatio… Phase4 HIV-1 Infection Completed 2013-02-22 2018-12-31 ClinicalTrials.gov
NCT01641367 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combinatio… Phase4 HIV-1 Infection Completed 2013-02-22 2018-12-31 ClinicalTrials.gov
NCT01797965 Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Comp… Phase3 Relapsing-Remitting Multiple Sclerosis Terminated 2013-02-15 2018-09-24 ClinicalTrials.gov
NCT01797965 Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Comp… Phase3 Relapsing-Remitting Multiple Sclerosis Terminated 2013-02-15 2018-09-24 ClinicalTrials.gov
NCT01797965 Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Comp… Phase3 Relapsing-Remitting Multiple Sclerosis Terminated 2013-02-15 2018-09-24 ClinicalTrials.gov
NCT01797965 Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Comp… Phase3 Relapsing-Remitting Multiple Sclerosis Terminated 2013-02-15 2018-09-24 ClinicalTrials.gov
NCT01768858 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis… — Rheumatoid Arthritis Completed 2013-02-05 2017-08-13 ClinicalTrials.gov
NCT01768858 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis… — Rheumatoid Arthritis Completed 2013-02-05 2017-08-13 ClinicalTrials.gov
NCT01768858 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis… — Rheumatoid Arthritis Completed 2013-02-05 2017-08-13 ClinicalTrials.gov
NCT01768858 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis… — Rheumatoid Arthritis Completed 2013-02-05 2017-08-13 ClinicalTrials.gov
NCT01613014 ABT-436 for Alcohol Dependence Phase2 Alcohol Dependence Completed 2013-02-01 2015-07-01 ClinicalTrials.gov
NCT01850823 Clinical Equivalence Study of Mometasone Nasal Spray Phase3 Seasonal Allergic Rhinitis Completed 2013-02-01 2013-12-01 ClinicalTrials.gov
NCT01797094 BOTOX® in the Treatment of Upper Facial Lines in Japan Phase3 Upper Facial Rhytides Completed 2013-02-01 2014-07-01 ClinicalTrials.gov
NCT01804517 Impact of a Nurse for Migraine Management: the IMPACT Project — Migraine Without Aura Completed 2013-02-01 2015-11-01 ClinicalTrials.gov
NCT01613014 ABT-436 for Alcohol Dependence Phase2 Alcohol Dependence Completed 2013-02-01 2015-07-01 ClinicalTrials.gov
NCT01879449 Prevalence of Spasticity in Veterans Living in a Long-term Care Facility — Spasticity Completed 2013-02-01 2014-05-01 ClinicalTrials.gov
NCT01613014 ABT-436 for Alcohol Dependence Phase2 Alcohol Dependence Completed 2013-02-01 2015-07-01 ClinicalTrials.gov
NCT01797094 BOTOX® in the Treatment of Upper Facial Lines in Japan Phase3 Upper Facial Rhytides Completed 2013-02-01 2014-07-01 ClinicalTrials.gov
NCT01804517 Impact of a Nurse for Migraine Management: the IMPACT Project — Migraine Without Aura Completed 2013-02-01 2015-11-01 ClinicalTrials.gov
NCT01613014 ABT-436 for Alcohol Dependence Phase2 Alcohol Dependence Completed 2013-02-01 2015-07-01 ClinicalTrials.gov
NCT01747655 A Post Marketing Observational Study of Activities of Daily Living in Advanced … — Parkinson's Disease Completed 2013-02-01 2015-07-01 ClinicalTrials.gov
NCT01747655 A Post Marketing Observational Study of Activities of Daily Living in Advanced … — Parkinson's Disease Completed 2013-02-01 2015-07-01 ClinicalTrials.gov
NCT01747655 A Post Marketing Observational Study of Activities of Daily Living in Advanced … — Parkinson's Disease Completed 2013-02-01 2015-07-01 ClinicalTrials.gov
NCT01879449 Prevalence of Spasticity in Veterans Living in a Long-term Care Facility — Spasticity Completed 2013-02-01 2014-05-01 ClinicalTrials.gov
NCT01850823 Clinical Equivalence Study of Mometasone Nasal Spray Phase3 Seasonal Allergic Rhinitis Completed 2013-02-01 2013-12-01 ClinicalTrials.gov
NCT01879449 Prevalence of Spasticity in Veterans Living in a Long-term Care Facility — Spasticity Completed 2013-02-01 2014-05-01 ClinicalTrials.gov
NCT01850823 Clinical Equivalence Study of Mometasone Nasal Spray Phase3 Seasonal Allergic Rhinitis Completed 2013-02-01 2013-12-01 ClinicalTrials.gov
NCT01783730 Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing… — Rheumatoid Arthritis Completed 2013-02-01 2015-09-01 ClinicalTrials.gov
NCT01804517 Impact of a Nurse for Migraine Management: the IMPACT Project — Migraine Without Aura Completed 2013-02-01 2015-11-01 ClinicalTrials.gov
NCT01783730 Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing… — Rheumatoid Arthritis Completed 2013-02-01 2015-09-01 ClinicalTrials.gov
NCT01797094 BOTOX® in the Treatment of Upper Facial Lines in Japan Phase3 Upper Facial Rhytides Completed 2013-02-01 2014-07-01 ClinicalTrials.gov
NCT01747655 A Post Marketing Observational Study of Activities of Daily Living in Advanced … — Parkinson's Disease Completed 2013-02-01 2015-07-01 ClinicalTrials.gov
NCT01777165 A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prev… Phase2 Acute Kidney Injury Completed 2013-02-01 2014-03-01 ClinicalTrials.gov
NCT01804517 Impact of a Nurse for Migraine Management: the IMPACT Project — Migraine Without Aura Completed 2013-02-01 2015-11-01 ClinicalTrials.gov
NCT01850823 Clinical Equivalence Study of Mometasone Nasal Spray Phase3 Seasonal Allergic Rhinitis Completed 2013-02-01 2013-12-01 ClinicalTrials.gov
NCT01797094 BOTOX® in the Treatment of Upper Facial Lines in Japan Phase3 Upper Facial Rhytides Completed 2013-02-01 2014-07-01 ClinicalTrials.gov
NCT01783730 Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing… — Rheumatoid Arthritis Completed 2013-02-01 2015-09-01 ClinicalTrials.gov
NCT01777165 A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prev… Phase2 Acute Kidney Injury Completed 2013-02-01 2014-03-01 ClinicalTrials.gov
NCT01879449 Prevalence of Spasticity in Veterans Living in a Long-term Care Facility — Spasticity Completed 2013-02-01 2014-05-01 ClinicalTrials.gov
NCT01783730 Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing… — Rheumatoid Arthritis Completed 2013-02-01 2015-09-01 ClinicalTrials.gov
NCT01777165 A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prev… Phase2 Acute Kidney Injury Completed 2013-02-01 2014-03-01 ClinicalTrials.gov
NCT01777165 A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prev… Phase2 Acute Kidney Injury Completed 2013-02-01 2014-03-01 ClinicalTrials.gov
NCT01777620 A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytid… Phase4 Facial Rhytides Completed 2013-01-31 2013-07-31 ClinicalTrials.gov
NCT01777620 A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytid… Phase4 Facial Rhytides Completed 2013-01-31 2013-07-31 ClinicalTrials.gov
NCT01777620 A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytid… Phase4 Facial Rhytides Completed 2013-01-31 2013-07-31 ClinicalTrials.gov
NCT01777620 A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytid… Phase4 Facial Rhytides Completed 2013-01-31 2013-07-31 ClinicalTrials.gov
NCT01797081 BOTOX® in the Treatment of Crow's Feet Lines in Japan Phase3 Lateral Canthus Rhytides Completed 2013-01-31 2014-07-07 ClinicalTrials.gov
NCT01797081 BOTOX® in the Treatment of Crow's Feet Lines in Japan Phase3 Lateral Canthus Rhytides Completed 2013-01-31 2014-07-07 ClinicalTrials.gov
NCT01797081 BOTOX® in the Treatment of Crow's Feet Lines in Japan Phase3 Lateral Canthus Rhytides Completed 2013-01-31 2014-07-07 ClinicalTrials.gov
NCT01797081 BOTOX® in the Treatment of Crow's Feet Lines in Japan Phase3 Lateral Canthus Rhytides Completed 2013-01-31 2014-07-07 ClinicalTrials.gov
NCT01773122 Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris Phase1 Acne Vulgaris Completed 2013-01-21 2013-05-05 ClinicalTrials.gov
NCT01773122 Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris Phase1 Acne Vulgaris Completed 2013-01-21 2013-05-05 ClinicalTrials.gov
NCT01773122 Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris Phase1 Acne Vulgaris Completed 2013-01-21 2013-05-05 ClinicalTrials.gov
NCT01773122 Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris Phase1 Acne Vulgaris Completed 2013-01-21 2013-05-05 ClinicalTrials.gov
NCT01814774 A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervica… — Cervical Dystonia Completed 2013-01-01 2013-07-01 ClinicalTrials.gov
NCT01780636 Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Pub… Phase2 Non-relaxing Puborectalis Syndrome Terminated 2013-01-01 2014-07-01 ClinicalTrials.gov
NCT01678924 A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralg… Phase2 Neuralgia, Postherpetic Terminated 2013-01-01 2015-09-01 ClinicalTrials.gov
NCT01425320 Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne Phase1 Acne Vulgaris Withdrawn 2013-01-01 2013-06-01 ClinicalTrials.gov
NCT01781962 A Study of Quantitative Assessments of Angle Width in Chinese Patients With Ope… — Open-angle Glaucoma Terminated 2013-01-01 2013-06-01 ClinicalTrials.gov
NCT01425320 Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne Phase1 Acne Vulgaris Withdrawn 2013-01-01 2013-06-01 ClinicalTrials.gov
NCT01780636 Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Pub… Phase2 Non-relaxing Puborectalis Syndrome Terminated 2013-01-01 2014-07-01 ClinicalTrials.gov
NCT01781962 A Study of Quantitative Assessments of Angle Width in Chinese Patients With Ope… — Open-angle Glaucoma Terminated 2013-01-01 2013-06-01 ClinicalTrials.gov
NCT02036541 AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma Na Glaucoma Completed 2013-01-01 2016-08-01 ClinicalTrials.gov
NCT01780636 Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Pub… Phase2 Non-relaxing Puborectalis Syndrome Terminated 2013-01-01 2014-07-01 ClinicalTrials.gov
NCT01781962 A Study of Quantitative Assessments of Angle Width in Chinese Patients With Ope… — Open-angle Glaucoma Terminated 2013-01-01 2013-06-01 ClinicalTrials.gov
NCT02004067 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Dis… Phase4 Primary Sjogren Syndrome Completed 2013-01-01 2016-08-01 ClinicalTrials.gov
NCT02004067 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Dis… Phase4 Primary Sjogren Syndrome Completed 2013-01-01 2016-08-01 ClinicalTrials.gov
NCT01759264 An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Mod… — Crohn's Disease Completed 2013-01-01 2014-05-01 ClinicalTrials.gov
NCT02004067 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Dis… Phase4 Primary Sjogren Syndrome Completed 2013-01-01 2016-08-01 ClinicalTrials.gov
NCT01758289 Post Marketing Observational Study on Paricalcitol IV Administered to Venezuela… — Chronic Kidney Disease Stage V Terminated 2013-01-01 2013-11-01 ClinicalTrials.gov
NCT02036541 AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma Na Glaucoma Completed 2013-01-01 2016-08-01 ClinicalTrials.gov
NCT01425320 Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne Phase1 Acne Vulgaris Withdrawn 2013-01-01 2013-06-01 ClinicalTrials.gov
NCT02036541 AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma Na Glaucoma Completed 2013-01-01 2016-08-01 ClinicalTrials.gov
NCT01759264 An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Mod… — Crohn's Disease Completed 2013-01-01 2014-05-01 ClinicalTrials.gov
NCT01814774 A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervica… — Cervical Dystonia Completed 2013-01-01 2013-07-01 ClinicalTrials.gov
NCT01678924 A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralg… Phase2 Neuralgia, Postherpetic Terminated 2013-01-01 2015-09-01 ClinicalTrials.gov
NCT01678924 A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralg… Phase2 Neuralgia, Postherpetic Terminated 2013-01-01 2015-09-01 ClinicalTrials.gov
NCT01780636 Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Pub… Phase2 Non-relaxing Puborectalis Syndrome Terminated 2013-01-01 2014-07-01 ClinicalTrials.gov
NCT01425320 Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne Phase1 Acne Vulgaris Withdrawn 2013-01-01 2013-06-01 ClinicalTrials.gov
NCT01781962 A Study of Quantitative Assessments of Angle Width in Chinese Patients With Ope… — Open-angle Glaucoma Terminated 2013-01-01 2013-06-01 ClinicalTrials.gov
NCT02004067 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Dis… Phase4 Primary Sjogren Syndrome Completed 2013-01-01 2016-08-01 ClinicalTrials.gov
NCT01758289 Post Marketing Observational Study on Paricalcitol IV Administered to Venezuela… — Chronic Kidney Disease Stage V Terminated 2013-01-01 2013-11-01 ClinicalTrials.gov
NCT01814774 A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervica… — Cervical Dystonia Completed 2013-01-01 2013-07-01 ClinicalTrials.gov
NCT01814774 A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervica… — Cervical Dystonia Completed 2013-01-01 2013-07-01 ClinicalTrials.gov
NCT02036541 AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma Na Glaucoma Completed 2013-01-01 2016-08-01 ClinicalTrials.gov
NCT01758289 Post Marketing Observational Study on Paricalcitol IV Administered to Venezuela… — Chronic Kidney Disease Stage V Terminated 2013-01-01 2013-11-01 ClinicalTrials.gov
NCT01759264 An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Mod… — Crohn's Disease Completed 2013-01-01 2014-05-01 ClinicalTrials.gov
NCT01758289 Post Marketing Observational Study on Paricalcitol IV Administered to Venezuela… — Chronic Kidney Disease Stage V Terminated 2013-01-01 2013-11-01 ClinicalTrials.gov
NCT01759264 An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Mod… — Crohn's Disease Completed 2013-01-01 2014-05-01 ClinicalTrials.gov
NCT01678924 A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralg… Phase2 Neuralgia, Postherpetic Terminated 2013-01-01 2015-09-01 ClinicalTrials.gov
NCT01760954 Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With … Phase3 Endometriosis Completed 2012-12-28 2016-04-15 ClinicalTrials.gov
NCT01760954 Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With … Phase3 Endometriosis Completed 2012-12-28 2016-04-15 ClinicalTrials.gov
NCT01760954 Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With … Phase3 Endometriosis Completed 2012-12-28 2016-04-15 ClinicalTrials.gov
NCT01760954 Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With … Phase3 Endometriosis Completed 2012-12-28 2016-04-15 ClinicalTrials.gov
NCT01609933 A Study to Evaluate the Safety and Effect of Treatment With Experimental Antivi… Phase2 Chronic Hepatitis C Completed 2012-12-18 2017-05-03 ClinicalTrials.gov
NCT01609933 A Study to Evaluate the Safety and Effect of Treatment With Experimental Antivi… Phase2 Chronic Hepatitis C Completed 2012-12-18 2017-05-03 ClinicalTrials.gov
NCT01609933 A Study to Evaluate the Safety and Effect of Treatment With Experimental Antivi… Phase2 Chronic Hepatitis C Completed 2012-12-18 2017-05-03 ClinicalTrials.gov
NCT01609933 A Study to Evaluate the Safety and Effect of Treatment With Experimental Antivi… Phase2 Chronic Hepatitis C Completed 2012-12-18 2017-05-03 ClinicalTrials.gov
NCT01785069 Safety and Effectiveness of NATRELLE® 410 Highly Cohesive, Anatomically Shaped,… Na Breast Augmentation Terminated 2012-12-10 2015-11-30 ClinicalTrials.gov
NCT01785069 Safety and Effectiveness of NATRELLE® 410 Highly Cohesive, Anatomically Shaped,… Na Breast Augmentation Terminated 2012-12-10 2015-11-30 ClinicalTrials.gov
NCT01785069 Safety and Effectiveness of NATRELLE® 410 Highly Cohesive, Anatomically Shaped,… Na Breast Augmentation Terminated 2012-12-10 2015-11-30 ClinicalTrials.gov
NCT01785069 Safety and Effectiveness of NATRELLE® 410 Highly Cohesive, Anatomically Shaped,… Na Breast Augmentation Terminated 2012-12-10 2015-11-30 ClinicalTrials.gov
NCT01744327 TL1A Expression in Psoriatic Skin — Psoriasis Unknown 2012-12-01 — ClinicalTrials.gov
NCT01767116 A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b In… Phase3 Chronic Hepatitis C Infection Completed 2012-12-01 2014-08-01 ClinicalTrials.gov
NCT01767116 A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b In… Phase3 Chronic Hepatitis C Infection Completed 2012-12-01 2014-08-01 ClinicalTrials.gov
NCT01749631 Investigation of the Effectiveness of Sevoflurane Anaesthesia in Difficult to I… — Intubation; Difficult Completed 2012-12-01 2015-02-01 ClinicalTrials.gov
NCT01756235 Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab… — Rheumatoid Arthritis Completed 2012-12-01 2015-10-01 ClinicalTrials.gov
NCT01752855 Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-39… Phase2 Rheumatoid Arthritis Completed 2012-12-01 2013-10-01 ClinicalTrials.gov
NCT01735201 AGN-199201 for the Treatment of Erythema With Rosacea Phase2 Rosacea Completed 2012-12-01 2013-06-01 ClinicalTrials.gov
NCT01749631 Investigation of the Effectiveness of Sevoflurane Anaesthesia in Difficult to I… — Intubation; Difficult Completed 2012-12-01 2015-02-01 ClinicalTrials.gov
NCT01754727 Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utiliza… — Ankylosing Spondylitis Completed 2012-12-01 2015-10-01 ClinicalTrials.gov
NCT01744327 TL1A Expression in Psoriatic Skin — Psoriasis Unknown 2012-12-01 — ClinicalTrials.gov
NCT01767116 A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b In… Phase3 Chronic Hepatitis C Infection Completed 2012-12-01 2014-08-01 ClinicalTrials.gov
NCT01735201 AGN-199201 for the Treatment of Erythema With Rosacea Phase2 Rosacea Completed 2012-12-01 2013-06-01 ClinicalTrials.gov
NCT01756235 Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab… — Rheumatoid Arthritis Completed 2012-12-01 2015-10-01 ClinicalTrials.gov
NCT01756235 Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab… — Rheumatoid Arthritis Completed 2012-12-01 2015-10-01 ClinicalTrials.gov
NCT01752855 Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-39… Phase2 Rheumatoid Arthritis Completed 2012-12-01 2013-10-01 ClinicalTrials.gov
NCT01754727 Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utiliza… — Ankylosing Spondylitis Completed 2012-12-01 2015-10-01 ClinicalTrials.gov
NCT01749631 Investigation of the Effectiveness of Sevoflurane Anaesthesia in Difficult to I… — Intubation; Difficult Completed 2012-12-01 2015-02-01 ClinicalTrials.gov
NCT01735201 AGN-199201 for the Treatment of Erythema With Rosacea Phase2 Rosacea Completed 2012-12-01 2013-06-01 ClinicalTrials.gov
NCT01754727 Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utiliza… — Ankylosing Spondylitis Completed 2012-12-01 2015-10-01 ClinicalTrials.gov
NCT01735201 AGN-199201 for the Treatment of Erythema With Rosacea Phase2 Rosacea Completed 2012-12-01 2013-06-01 ClinicalTrials.gov
NCT01767116 A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b In… Phase3 Chronic Hepatitis C Infection Completed 2012-12-01 2014-08-01 ClinicalTrials.gov
NCT01756235 Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab… — Rheumatoid Arthritis Completed 2012-12-01 2015-10-01 ClinicalTrials.gov
NCT01754727 Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utiliza… — Ankylosing Spondylitis Completed 2012-12-01 2015-10-01 ClinicalTrials.gov
NCT01744327 TL1A Expression in Psoriatic Skin — Psoriasis Unknown 2012-12-01 — ClinicalTrials.gov
NCT01749631 Investigation of the Effectiveness of Sevoflurane Anaesthesia in Difficult to I… — Intubation; Difficult Completed 2012-12-01 2015-02-01 ClinicalTrials.gov
NCT01752855 Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-39… Phase2 Rheumatoid Arthritis Completed 2012-12-01 2013-10-01 ClinicalTrials.gov
NCT01752855 Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-39… Phase2 Rheumatoid Arthritis Completed 2012-12-01 2013-10-01 ClinicalTrials.gov
NCT01744327 TL1A Expression in Psoriatic Skin — Psoriasis Unknown 2012-12-01 — ClinicalTrials.gov
NCT01685892 A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chr… Phase1 Lymphocytic Leukemia, Chronic Completed 2012-11-29 2019-08-23 ClinicalTrials.gov
NCT01685892 A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chr… Phase1 Lymphocytic Leukemia, Chronic Completed 2012-11-29 2019-08-23 ClinicalTrials.gov
NCT01685892 A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chr… Phase1 Lymphocytic Leukemia, Chronic Completed 2012-11-29 2019-08-23 ClinicalTrials.gov
NCT01685892 A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chr… Phase1 Lymphocytic Leukemia, Chronic Completed 2012-11-29 2019-08-23 ClinicalTrials.gov
NCT01794507 A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Borte… Phase1 Relapsed/Refractory Multiple Myeloma Completed 2012-11-19 2019-07-16 ClinicalTrials.gov
NCT01794507 A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Borte… Phase1 Relapsed/Refractory Multiple Myeloma Completed 2012-11-19 2019-07-16 ClinicalTrials.gov
NCT01794507 A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Borte… Phase1 Relapsed/Refractory Multiple Myeloma Completed 2012-11-19 2019-07-16 ClinicalTrials.gov
NCT01794507 A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Borte… Phase1 Relapsed/Refractory Multiple Myeloma Completed 2012-11-19 2019-07-16 ClinicalTrials.gov
NCT01603641 BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity Phase3 Pediatrics Completed 2012-11-05 2018-08-25 ClinicalTrials.gov
NCT01603641 BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity Phase3 Pediatrics Completed 2012-11-05 2018-08-25 ClinicalTrials.gov
NCT01603641 BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity Phase3 Pediatrics Completed 2012-11-05 2018-08-25 ClinicalTrials.gov
NCT01603641 BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity Phase3 Pediatrics Completed 2012-11-05 2018-08-25 ClinicalTrials.gov
NCT02252744 Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis — Dry Eye Syndromes Completed 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT01716585 A Study to Evaluate Chronic Hepatitis C Infection Phase3 Chronic Hepatitis C Infection Completed 2012-11-01 2014-10-01 ClinicalTrials.gov
NCT01684163 Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to … Phase2 Major Depressive Disorder Completed 2012-11-01 2014-06-01 ClinicalTrials.gov
NCT01732757 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo… Phase4 Conjunctivitis, Allergic Completed 2012-11-01 2012-12-01 ClinicalTrials.gov
NCT01716585 A Study to Evaluate Chronic Hepatitis C Infection Phase3 Chronic Hepatitis C Infection Completed 2012-11-01 2014-10-01 ClinicalTrials.gov
NCT01684163 Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to … Phase2 Major Depressive Disorder Completed 2012-11-01 2014-06-01 ClinicalTrials.gov
NCT01716585 A Study to Evaluate Chronic Hepatitis C Infection Phase3 Chronic Hepatitis C Infection Completed 2012-11-01 2014-10-01 ClinicalTrials.gov
NCT01741493 A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evalu… Phase1 Rheumatoid Arthritis Completed 2012-11-01 2013-12-01 ClinicalTrials.gov
NCT01749423 A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Pr… — Chronic Migraine, Headache Withdrawn 2012-11-01 2013-12-01 ClinicalTrials.gov
NCT01741493 A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evalu… Phase1 Rheumatoid Arthritis Completed 2012-11-01 2013-12-01 ClinicalTrials.gov
NCT01749423 A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Pr… — Chronic Migraine, Headache Withdrawn 2012-11-01 2013-12-01 ClinicalTrials.gov
NCT01698554 Bimatoprost in the Treatment of Eyelash Hypotrichosis Phase3 Idiopathic Eyelash Hypotrichosis Completed 2012-11-01 2014-03-01 ClinicalTrials.gov
NCT01715415 A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adul… Phase3 Chronic Hepatitis C Infection Completed 2012-11-01 2014-10-01 ClinicalTrials.gov
NCT01673191 A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intr… Phase2 Macular Edema Completed 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT01760980 Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditio… Phase1 Healthy Withdrawn 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT01673191 A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intr… Phase2 Macular Edema Completed 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT01732757 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo… Phase4 Conjunctivitis, Allergic Completed 2012-11-01 2012-12-01 ClinicalTrials.gov
NCT01698554 Bimatoprost in the Treatment of Eyelash Hypotrichosis Phase3 Idiopathic Eyelash Hypotrichosis Completed 2012-11-01 2014-03-01 ClinicalTrials.gov
NCT01673191 A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intr… Phase2 Macular Edema Completed 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT01760980 Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditio… Phase1 Healthy Withdrawn 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT01698554 Bimatoprost in the Treatment of Eyelash Hypotrichosis Phase3 Idiopathic Eyelash Hypotrichosis Completed 2012-11-01 2014-03-01 ClinicalTrials.gov
NCT01673191 A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intr… Phase2 Macular Edema Completed 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT01684163 Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to … Phase2 Major Depressive Disorder Completed 2012-11-01 2014-06-01 ClinicalTrials.gov
NCT01964105 3D Breast Imaging for Cosmetic and Reconstructive Breast Surgery Na Hypomastia Completed 2012-11-01 2017-05-16 ClinicalTrials.gov
NCT02252744 Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis — Dry Eye Syndromes Completed 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT02252744 Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis — Dry Eye Syndromes Completed 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT01964105 3D Breast Imaging for Cosmetic and Reconstructive Breast Surgery Na Hypomastia Completed 2012-11-01 2017-05-16 ClinicalTrials.gov
NCT01741493 A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evalu… Phase1 Rheumatoid Arthritis Completed 2012-11-01 2013-12-01 ClinicalTrials.gov
NCT01749423 A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Pr… — Chronic Migraine, Headache Withdrawn 2012-11-01 2013-12-01 ClinicalTrials.gov
NCT01732757 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo… Phase4 Conjunctivitis, Allergic Completed 2012-11-01 2012-12-01 ClinicalTrials.gov
NCT02252744 Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis — Dry Eye Syndromes Completed 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT01760980 Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditio… Phase1 Healthy Withdrawn 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT01684163 Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to … Phase2 Major Depressive Disorder Completed 2012-11-01 2014-06-01 ClinicalTrials.gov
NCT01715415 A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adul… Phase3 Chronic Hepatitis C Infection Completed 2012-11-01 2014-10-01 ClinicalTrials.gov
NCT01715415 A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adul… Phase3 Chronic Hepatitis C Infection Completed 2012-11-01 2014-10-01 ClinicalTrials.gov
NCT01964105 3D Breast Imaging for Cosmetic and Reconstructive Breast Surgery Na Hypomastia Completed 2012-11-01 2017-05-16 ClinicalTrials.gov
NCT01741493 A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evalu… Phase1 Rheumatoid Arthritis Completed 2012-11-01 2013-12-01 ClinicalTrials.gov
NCT01698554 Bimatoprost in the Treatment of Eyelash Hypotrichosis Phase3 Idiopathic Eyelash Hypotrichosis Completed 2012-11-01 2014-03-01 ClinicalTrials.gov
NCT01732757 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo… Phase4 Conjunctivitis, Allergic Completed 2012-11-01 2012-12-01 ClinicalTrials.gov
NCT01716585 A Study to Evaluate Chronic Hepatitis C Infection Phase3 Chronic Hepatitis C Infection Completed 2012-11-01 2014-10-01 ClinicalTrials.gov
NCT01749423 A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Pr… — Chronic Migraine, Headache Withdrawn 2012-11-01 2013-12-01 ClinicalTrials.gov
NCT01760980 Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditio… Phase1 Healthy Withdrawn 2012-11-01 2014-12-01 ClinicalTrials.gov
NCT01964105 3D Breast Imaging for Cosmetic and Reconstructive Breast Surgery Na Hypomastia Completed 2012-11-01 2017-05-16 ClinicalTrials.gov
NCT01715415 A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adul… Phase3 Chronic Hepatitis C Infection Completed 2012-11-01 2014-10-01 ClinicalTrials.gov
NCT01603615 BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity Phase3 Pediatrics Completed 2012-10-30 2018-09-03 ClinicalTrials.gov
NCT01603615 BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity Phase3 Pediatrics Completed 2012-10-30 2018-09-03 ClinicalTrials.gov
NCT01603615 BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity Phase3 Pediatrics Completed 2012-10-30 2018-09-03 ClinicalTrials.gov
NCT01603615 BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity Phase3 Pediatrics Completed 2012-10-30 2018-09-03 ClinicalTrials.gov
NCT01736189 Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Met… — Rheumatoid Arthritis Completed 2012-10-11 2018-04-16 ClinicalTrials.gov
NCT01736189 Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Met… — Rheumatoid Arthritis Completed 2012-10-11 2018-04-16 ClinicalTrials.gov
NCT01736189 Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Met… — Rheumatoid Arthritis Completed 2012-10-11 2018-04-16 ClinicalTrials.gov
NCT01736189 Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Met… — Rheumatoid Arthritis Completed 2012-10-11 2018-04-16 ClinicalTrials.gov
NCT01794520 Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple M… Phase1 Relapsed/Refractory Multiple Myeloma Completed 2012-10-10 2021-11-29 ClinicalTrials.gov
NCT01794520 Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple M… Phase1 Relapsed/Refractory Multiple Myeloma Completed 2012-10-10 2021-11-29 ClinicalTrials.gov
NCT01794520 Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple M… Phase1 Relapsed/Refractory Multiple Myeloma Completed 2012-10-10 2021-11-29 ClinicalTrials.gov
NCT01794520 Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple M… Phase1 Relapsed/Refractory Multiple Myeloma Completed 2012-10-10 2021-11-29 ClinicalTrials.gov
NCT01662492 A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents Wit… Phase3 Migraine Disorders Completed 2012-10-01 2016-08-01 ClinicalTrials.gov
NCT01684436 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Phase4 Dry Eye Completed 2012-10-01 2013-07-31 ClinicalTrials.gov
NCT01662492 A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents Wit… Phase3 Migraine Disorders Completed 2012-10-01 2016-08-01 ClinicalTrials.gov
NCT01700387 A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Place… Phase4 Chronic Migraine Completed 2012-10-01 2014-08-01 ClinicalTrials.gov
NCT01701518 A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Su… Na Epiretinal Membrane Unknown 2012-10-01 2016-12-01 ClinicalTrials.gov
NCT01741727 A Study of ABT-414 in Subjects With Solid Tumors Phase1 Squamous Cell Tumors Completed 2012-10-01 2015-11-01 ClinicalTrials.gov
NCT01741727 A Study of ABT-414 in Subjects With Solid Tumors Phase1 Squamous Cell Tumors Completed 2012-10-01 2015-11-01 ClinicalTrials.gov
NCT01684436 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Phase4 Dry Eye Completed 2012-10-01 2013-07-31 ClinicalTrials.gov
NCT01701518 A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Su… Na Epiretinal Membrane Unknown 2012-10-01 2016-12-01 ClinicalTrials.gov
NCT01741727 A Study of ABT-414 in Subjects With Solid Tumors Phase1 Squamous Cell Tumors Completed 2012-10-01 2015-11-01 ClinicalTrials.gov
NCT01754766 AGN-229666 for the Treatment of Allergic Conjunctivitis Phase2 Allergic Conjunctivitis Completed 2012-10-01 2013-02-01 ClinicalTrials.gov
NCT01700387 A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Place… Phase4 Chronic Migraine Completed 2012-10-01 2014-08-01 ClinicalTrials.gov
NCT01701518 A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Su… Na Epiretinal Membrane Unknown 2012-10-01 2016-12-01 ClinicalTrials.gov
NCT01754766 AGN-229666 for the Treatment of Allergic Conjunctivitis Phase2 Allergic Conjunctivitis Completed 2012-10-01 2013-02-01 ClinicalTrials.gov
NCT01700387 A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Place… Phase4 Chronic Migraine Completed 2012-10-01 2014-08-01 ClinicalTrials.gov
NCT01754766 AGN-229666 for the Treatment of Allergic Conjunctivitis Phase2 Allergic Conjunctivitis Completed 2012-10-01 2013-02-01 ClinicalTrials.gov
NCT01741727 A Study of ABT-414 in Subjects With Solid Tumors Phase1 Squamous Cell Tumors Completed 2012-10-01 2015-11-01 ClinicalTrials.gov
NCT01684436 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Phase4 Dry Eye Completed 2012-10-01 2013-07-31 ClinicalTrials.gov
NCT01754766 AGN-229666 for the Treatment of Allergic Conjunctivitis Phase2 Allergic Conjunctivitis Completed 2012-10-01 2013-02-01 ClinicalTrials.gov
NCT01662492 A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents Wit… Phase3 Migraine Disorders Completed 2012-10-01 2016-08-01 ClinicalTrials.gov
NCT01701518 A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Su… Na Epiretinal Membrane Unknown 2012-10-01 2016-12-01 ClinicalTrials.gov
NCT01700387 A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Place… Phase4 Chronic Migraine Completed 2012-10-01 2014-08-01 ClinicalTrials.gov
NCT01684436 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Phase4 Dry Eye Completed 2012-10-01 2013-07-31 ClinicalTrials.gov
NCT01662492 A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents Wit… Phase3 Migraine Disorders Completed 2012-10-01 2016-08-01 ClinicalTrials.gov
NCT01660802 Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Ma… Phase3 Macular Edema Completed 2012-09-04 2014-05-20 ClinicalTrials.gov
NCT01660802 Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Ma… Phase3 Macular Edema Completed 2012-09-04 2014-05-20 ClinicalTrials.gov
NCT01660802 Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Ma… Phase3 Macular Edema Completed 2012-09-04 2014-05-20 ClinicalTrials.gov
NCT01660802 Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Ma… Phase3 Macular Edema Completed 2012-09-04 2014-05-20 ClinicalTrials.gov
NCT01805323 A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema — Macular Edema Completed 2012-09-01 2013-04-15 ClinicalTrials.gov
NCT01805323 A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema — Macular Edema Completed 2012-09-01 2013-04-15 ClinicalTrials.gov
NCT01690195 Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild… Phase2 Alzheimer's Disease Terminated 2012-09-01 2014-02-01 ClinicalTrials.gov
NCT01711424 An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease — Dry Eye Syndromes Completed 2012-09-01 2013-03-01 ClinicalTrials.gov
NCT01668511 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple S… Phase1 Osteoarthritis Completed 2012-09-01 2013-10-01 ClinicalTrials.gov
NCT01690195 Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild… Phase2 Alzheimer's Disease Terminated 2012-09-01 2014-02-01 ClinicalTrials.gov
NCT01805323 A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema — Macular Edema Completed 2012-09-01 2013-04-15 ClinicalTrials.gov
NCT01805323 A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema — Macular Edema Completed 2012-09-01 2013-04-15 ClinicalTrials.gov
NCT01668511 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple S… Phase1 Osteoarthritis Completed 2012-09-01 2013-10-01 ClinicalTrials.gov
NCT01711424 An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease — Dry Eye Syndromes Completed 2012-09-01 2013-03-01 ClinicalTrials.gov
NCT01690195 Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild… Phase2 Alzheimer's Disease Terminated 2012-09-01 2014-02-01 ClinicalTrials.gov
NCT01711424 An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease — Dry Eye Syndromes Completed 2012-09-01 2013-03-01 ClinicalTrials.gov
NCT01668511 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple S… Phase1 Osteoarthritis Completed 2012-09-01 2013-10-01 ClinicalTrials.gov
NCT01711424 An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease — Dry Eye Syndromes Completed 2012-09-01 2013-03-01 ClinicalTrials.gov
NCT01668511 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple S… Phase1 Osteoarthritis Completed 2012-09-01 2013-10-01 ClinicalTrials.gov
NCT01690195 Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild… Phase2 Alzheimer's Disease Terminated 2012-09-01 2014-02-01 ClinicalTrials.gov
NCT01633788 A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction Phase2 Meibomian Gland Dysfunction Completed 2012-08-22 2015-02-05 ClinicalTrials.gov
NCT01633788 A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction Phase2 Meibomian Gland Dysfunction Completed 2012-08-22 2015-02-05 ClinicalTrials.gov
NCT01633788 A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction Phase2 Meibomian Gland Dysfunction Completed 2012-08-22 2015-02-05 ClinicalTrials.gov
NCT01633788 A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction Phase2 Meibomian Gland Dysfunction Completed 2012-08-22 2015-02-05 ClinicalTrials.gov
NCT01679015 Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Ey… — Dry Eyes Completed 2012-08-01 2014-02-01 ClinicalTrials.gov
NCT01670240 Adalimumab in the Treatment of Chronic Pouchitis Phase3 Ulcerative Colitis Completed 2012-08-01 2016-01-01 ClinicalTrials.gov
NCT01678755 A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in … Phase2 Schizophrenia Completed 2012-08-01 2014-03-01 ClinicalTrials.gov
NCT01674725 A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Rit… Phase3 Chronic Hepatitis C Infection Completed 2012-08-01 2014-10-01 ClinicalTrials.gov
NCT01685203 A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With … Phase2 Hepatitis C, Chronic Completed 2012-08-01 2015-02-01 ClinicalTrials.gov
NCT01679015 Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Ey… — Dry Eyes Completed 2012-08-01 2014-02-01 ClinicalTrials.gov
NCT01657370 A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-… Phase2 Migraine Completed 2012-08-01 2012-12-01 ClinicalTrials.gov
NCT01657370 A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-… Phase2 Migraine Completed 2012-08-01 2012-12-01 ClinicalTrials.gov
NCT01591746 Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction Phase3 Breast Cancer Completed 2012-08-01 2017-07-18 ClinicalTrials.gov
NCT01670240 Adalimumab in the Treatment of Chronic Pouchitis Phase3 Ulcerative Colitis Completed 2012-08-01 2016-01-01 ClinicalTrials.gov
NCT01674725 A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Rit… Phase3 Chronic Hepatitis C Infection Completed 2012-08-01 2014-10-01 ClinicalTrials.gov
NCT01679015 Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Ey… — Dry Eyes Completed 2012-08-01 2014-02-01 ClinicalTrials.gov
NCT01678755 A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in … Phase2 Schizophrenia Completed 2012-08-01 2014-03-01 ClinicalTrials.gov
NCT01682460 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Phase4 Glaucoma Completed 2012-08-01 2013-04-01 ClinicalTrials.gov
NCT01591746 Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction Phase3 Breast Cancer Completed 2012-08-01 2017-07-18 ClinicalTrials.gov
NCT01591746 Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction Phase3 Breast Cancer Completed 2012-08-01 2017-07-18 ClinicalTrials.gov
NCT01685203 A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With … Phase2 Hepatitis C, Chronic Completed 2012-08-01 2015-02-01 ClinicalTrials.gov
NCT01678755 A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in … Phase2 Schizophrenia Completed 2012-08-01 2014-03-01 ClinicalTrials.gov
NCT01670240 Adalimumab in the Treatment of Chronic Pouchitis Phase3 Ulcerative Colitis Completed 2012-08-01 2016-01-01 ClinicalTrials.gov
NCT01685203 A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With … Phase2 Hepatitis C, Chronic Completed 2012-08-01 2015-02-01 ClinicalTrials.gov
NCT01674725 A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Rit… Phase3 Chronic Hepatitis C Infection Completed 2012-08-01 2014-10-01 ClinicalTrials.gov
NCT01678755 A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in … Phase2 Schizophrenia Completed 2012-08-01 2014-03-01 ClinicalTrials.gov
NCT01674725 A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Rit… Phase3 Chronic Hepatitis C Infection Completed 2012-08-01 2014-10-01 ClinicalTrials.gov
NCT01685203 A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With … Phase2 Hepatitis C, Chronic Completed 2012-08-01 2015-02-01 ClinicalTrials.gov
NCT01646073 Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis Phase3 Plaque Psoriasis Completed 2012-08-01 2013-12-01 ClinicalTrials.gov
NCT01670240 Adalimumab in the Treatment of Chronic Pouchitis Phase3 Ulcerative Colitis Completed 2012-08-01 2016-01-01 ClinicalTrials.gov
NCT01646073 Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis Phase3 Plaque Psoriasis Completed 2012-08-01 2013-12-01 ClinicalTrials.gov
NCT01646073 Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis Phase3 Plaque Psoriasis Completed 2012-08-01 2013-12-01 ClinicalTrials.gov
NCT01646073 Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis Phase3 Plaque Psoriasis Completed 2012-08-01 2013-12-01 ClinicalTrials.gov
NCT01591746 Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction Phase3 Breast Cancer Completed 2012-08-01 2017-07-18 ClinicalTrials.gov
NCT01682460 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Phase4 Glaucoma Completed 2012-08-01 2013-04-01 ClinicalTrials.gov
NCT01657370 A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-… Phase2 Migraine Completed 2012-08-01 2012-12-01 ClinicalTrials.gov
NCT01682460 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Phase4 Glaucoma Completed 2012-08-01 2013-04-01 ClinicalTrials.gov
NCT01657370 A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-… Phase2 Migraine Completed 2012-08-01 2012-12-01 ClinicalTrials.gov
NCT01679015 Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Ey… — Dry Eyes Completed 2012-08-01 2014-02-01 ClinicalTrials.gov
NCT01682460 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Phase4 Glaucoma Completed 2012-08-01 2013-04-01 ClinicalTrials.gov
NCT01652157 Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Suppl… — Fibrosing Colonopathy Terminated 2012-07-31 2020-04-08 ClinicalTrials.gov
NCT01652157 Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Suppl… — Fibrosing Colonopathy Terminated 2012-07-31 2020-04-08 ClinicalTrials.gov
NCT01652157 Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Suppl… — Fibrosing Colonopathy Terminated 2012-07-31 2020-04-08 ClinicalTrials.gov
NCT01652157 Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Suppl… — Fibrosing Colonopathy Terminated 2012-07-31 2020-04-08 ClinicalTrials.gov
NCT01682616 A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combinati… Phase1 Small Lymphocytic Lymphoma Completed 2012-07-25 2022-06-23 ClinicalTrials.gov
NCT01682616 A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combinati… Phase1 Small Lymphocytic Lymphoma Completed 2012-07-25 2022-06-23 ClinicalTrials.gov
NCT01682616 A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combinati… Phase1 Small Lymphocytic Lymphoma Completed 2012-07-25 2022-06-23 ClinicalTrials.gov
NCT01682616 A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combinati… Phase1 Small Lymphocytic Lymphoma Completed 2012-07-25 2022-06-23 ClinicalTrials.gov
NCT01686581 An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine — Migraine Disorders Completed 2012-07-23 2016-10-12 ClinicalTrials.gov
NCT01686581 An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine — Migraine Disorders Completed 2012-07-23 2016-10-12 ClinicalTrials.gov
NCT01686581 An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine — Migraine Disorders Completed 2012-07-23 2016-10-12 ClinicalTrials.gov
NCT01686581 An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine — Migraine Disorders Completed 2012-07-23 2016-10-12 ClinicalTrials.gov
NCT01603602 BOTOX® Treatment in Pediatric Upper Limb Spasticity Phase3 Pediatrics Completed 2012-07-12 2017-07-06 ClinicalTrials.gov
NCT01603602 BOTOX® Treatment in Pediatric Upper Limb Spasticity Phase3 Pediatrics Completed 2012-07-12 2017-07-06 ClinicalTrials.gov
NCT01603602 BOTOX® Treatment in Pediatric Upper Limb Spasticity Phase3 Pediatrics Completed 2012-07-12 2017-07-06 ClinicalTrials.gov
NCT01603602 BOTOX® Treatment in Pediatric Upper Limb Spasticity Phase3 Pediatrics Completed 2012-07-12 2017-07-06 ClinicalTrials.gov
NCT01655862 A Prospective, Observational Study of Patients With Cervical Dystonia (Dystonie… — Torticollis Completed 2012-07-01 2017-02-01 ClinicalTrials.gov
NCT01655862 A Prospective, Observational Study of Patients With Cervical Dystonia (Dystonie… — Torticollis Completed 2012-07-01 2017-02-01 ClinicalTrials.gov
NCT01613248 A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) Phase2 Migraine Completed 2012-07-01 2012-12-01 ClinicalTrials.gov
NCT01648530 Chronic Migraine Epidemiology and Outcomes Study — Migraine Disorders Completed 2012-07-01 2013-11-01 ClinicalTrials.gov
NCT01613248 A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) Phase2 Migraine Completed 2012-07-01 2012-12-01 ClinicalTrials.gov
NCT01613716 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membr… Phase4 Diabetic Macular Edema Completed 2012-07-01 2017-02-01 ClinicalTrials.gov
NCT01613716 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membr… Phase4 Diabetic Macular Edema Completed 2012-07-01 2017-02-01 ClinicalTrials.gov
NCT01892228 Pilot Study of Immediate HIV Treatment in Guangxi, China Na HIV Unknown 2012-07-01 2015-07-01 ClinicalTrials.gov
NCT01715857 Clinical Practice of Inhalation Anesthesia With Sevoflurane in China — Anesthesia, General Completed 2012-07-01 2013-07-01 ClinicalTrials.gov
NCT01648530 Chronic Migraine Epidemiology and Outcomes Study — Migraine Disorders Completed 2012-07-01 2013-11-01 ClinicalTrials.gov
NCT01892228 Pilot Study of Immediate HIV Treatment in Guangxi, China Na HIV Unknown 2012-07-01 2015-07-01 ClinicalTrials.gov
NCT01613716 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membr… Phase4 Diabetic Macular Edema Completed 2012-07-01 2017-02-01 ClinicalTrials.gov
NCT01613248 A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) Phase2 Migraine Completed 2012-07-01 2012-12-01 ClinicalTrials.gov
NCT01613716 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membr… Phase4 Diabetic Macular Edema Completed 2012-07-01 2017-02-01 ClinicalTrials.gov
NCT01613248 A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) Phase2 Migraine Completed 2012-07-01 2012-12-01 ClinicalTrials.gov
NCT01672983 A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese … Phase2 Chronic Hepatitis C Infection Completed 2012-07-01 2014-05-01 ClinicalTrials.gov
NCT01617018 Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatme… — Psoriasis Completed 2012-07-01 2021-09-05 ClinicalTrials.gov
NCT01617018 Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatme… — Psoriasis Completed 2012-07-01 2021-09-05 ClinicalTrials.gov
NCT01672983 A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese … Phase2 Chronic Hepatitis C Infection Completed 2012-07-01 2014-05-01 ClinicalTrials.gov
NCT01892228 Pilot Study of Immediate HIV Treatment in Guangxi, China Na HIV Unknown 2012-07-01 2015-07-01 ClinicalTrials.gov
NCT01617018 Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatme… — Psoriasis Completed 2012-07-01 2021-09-05 ClinicalTrials.gov
NCT01892228 Pilot Study of Immediate HIV Treatment in Guangxi, China Na HIV Unknown 2012-07-01 2015-07-01 ClinicalTrials.gov
NCT01617018 Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatme… — Psoriasis Completed 2012-07-01 2021-09-05 ClinicalTrials.gov
NCT01655862 A Prospective, Observational Study of Patients With Cervical Dystonia (Dystonie… — Torticollis Completed 2012-07-01 2017-02-01 ClinicalTrials.gov
NCT01715857 Clinical Practice of Inhalation Anesthesia With Sevoflurane in China — Anesthesia, General Completed 2012-07-01 2013-07-01 ClinicalTrials.gov
NCT01672983 A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese … Phase2 Chronic Hepatitis C Infection Completed 2012-07-01 2014-05-01 ClinicalTrials.gov
NCT01648530 Chronic Migraine Epidemiology and Outcomes Study — Migraine Disorders Completed 2012-07-01 2013-11-01 ClinicalTrials.gov
NCT01715857 Clinical Practice of Inhalation Anesthesia With Sevoflurane in China — Anesthesia, General Completed 2012-07-01 2013-07-01 ClinicalTrials.gov
NCT01655862 A Prospective, Observational Study of Patients With Cervical Dystonia (Dystonie… — Torticollis Completed 2012-07-01 2017-02-01 ClinicalTrials.gov
NCT01648530 Chronic Migraine Epidemiology and Outcomes Study — Migraine Disorders Completed 2012-07-01 2013-11-01 ClinicalTrials.gov
NCT01672983 A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese … Phase2 Chronic Hepatitis C Infection Completed 2012-07-01 2014-05-01 ClinicalTrials.gov
NCT01715857 Clinical Practice of Inhalation Anesthesia With Sevoflurane in China — Anesthesia, General Completed 2012-07-01 2013-07-01 ClinicalTrials.gov
NCT01628549 Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycl… Phase2 Acne Vulgaris Completed 2012-06-30 2013-01-31 ClinicalTrials.gov
NCT01628549 Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycl… Phase2 Acne Vulgaris Completed 2012-06-30 2013-01-31 ClinicalTrials.gov
NCT01628549 Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycl… Phase2 Acne Vulgaris Completed 2012-06-30 2013-01-31 ClinicalTrials.gov
NCT01628549 Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycl… Phase2 Acne Vulgaris Completed 2012-06-30 2013-01-31 ClinicalTrials.gov
NCT01639755 European New Texture Implant Clinical Experience With Shaped Breast Implants Phase4 Breast Augmentation Completed 2012-06-18 2017-10-16 ClinicalTrials.gov
NCT01639742 European New Texture Implant Clinical Experience With Round Breast Implants Na Breast Augmentation Completed 2012-06-18 2017-10-12 ClinicalTrials.gov
NCT01639755 European New Texture Implant Clinical Experience With Shaped Breast Implants Phase4 Breast Augmentation Completed 2012-06-18 2017-10-16 ClinicalTrials.gov
NCT01639742 European New Texture Implant Clinical Experience With Round Breast Implants Na Breast Augmentation Completed 2012-06-18 2017-10-12 ClinicalTrials.gov
NCT01639755 European New Texture Implant Clinical Experience With Shaped Breast Implants Phase4 Breast Augmentation Completed 2012-06-18 2017-10-16 ClinicalTrials.gov
NCT01639742 European New Texture Implant Clinical Experience With Round Breast Implants Na Breast Augmentation Completed 2012-06-18 2017-10-12 ClinicalTrials.gov
NCT01639742 European New Texture Implant Clinical Experience With Round Breast Implants Na Breast Augmentation Completed 2012-06-18 2017-10-12 ClinicalTrials.gov
NCT01639755 European New Texture Implant Clinical Experience With Shaped Breast Implants Phase4 Breast Augmentation Completed 2012-06-18 2017-10-16 ClinicalTrials.gov
NCT01600716 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary In… Phase3 Urinary Incontinence Completed 2012-06-13 2015-03-27 ClinicalTrials.gov
NCT01600716 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary In… Phase3 Urinary Incontinence Completed 2012-06-13 2015-03-27 ClinicalTrials.gov
NCT01600716 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary In… Phase3 Urinary Incontinence Completed 2012-06-13 2015-03-27 ClinicalTrials.gov
NCT01600716 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary In… Phase3 Urinary Incontinence Completed 2012-06-13 2015-03-27 ClinicalTrials.gov
NCT01557777 Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic L… Phase2 Chronic Lymphocytic Leukemia Completed 2012-06-01 2013-07-01 ClinicalTrials.gov
NCT01680497 Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Naso… Na Moderate to Severe Nasolabial Folds Completed 2012-06-01 2014-03-06 ClinicalTrials.gov
NCT01589419 A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of V… Phase1 Locally Advanced Rectal Cancer Completed 2012-06-01 2015-01-01 ClinicalTrials.gov
NCT01605942 A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postope… Phase1 Cataract Terminated 2012-06-01 2012-09-01 ClinicalTrials.gov
NCT01557777 Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic L… Phase2 Chronic Lymphocytic Leukemia Completed 2012-06-01 2013-07-01 ClinicalTrials.gov
NCT01680497 Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Naso… Na Moderate to Severe Nasolabial Folds Completed 2012-06-01 2014-03-06 ClinicalTrials.gov
NCT01557777 Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic L… Phase2 Chronic Lymphocytic Leukemia Completed 2012-06-01 2013-07-01 ClinicalTrials.gov
NCT01589419 A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of V… Phase1 Locally Advanced Rectal Cancer Completed 2012-06-01 2015-01-01 ClinicalTrials.gov
NCT01712178 A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Ad… Phase2 Rheumatoid Arthritis Completed 2012-06-01 2013-05-01 ClinicalTrials.gov
NCT01712178 A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Ad… Phase2 Rheumatoid Arthritis Completed 2012-06-01 2013-05-01 ClinicalTrials.gov
NCT01600729 Reliability of the Facial Wrinkle Scale in Japanese Subjects — Facial Rhytides Completed 2012-06-01 2012-07-01 ClinicalTrials.gov
NCT01600729 Reliability of the Facial Wrinkle Scale in Japanese Subjects — Facial Rhytides Completed 2012-06-01 2012-07-01 ClinicalTrials.gov
NCT01557777 Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic L… Phase2 Chronic Lymphocytic Leukemia Completed 2012-06-01 2013-07-01 ClinicalTrials.gov
NCT01680497 Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Naso… Na Moderate to Severe Nasolabial Folds Completed 2012-06-01 2014-03-06 ClinicalTrials.gov
NCT01605942 A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postope… Phase1 Cataract Terminated 2012-06-01 2012-09-01 ClinicalTrials.gov
NCT01589419 A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of V… Phase1 Locally Advanced Rectal Cancer Completed 2012-06-01 2015-01-01 ClinicalTrials.gov
NCT01605942 A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postope… Phase1 Cataract Terminated 2012-06-01 2012-09-01 ClinicalTrials.gov
NCT01605942 A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postope… Phase1 Cataract Terminated 2012-06-01 2012-09-01 ClinicalTrials.gov
NCT01680497 Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Naso… Na Moderate to Severe Nasolabial Folds Completed 2012-06-01 2014-03-06 ClinicalTrials.gov
NCT01712178 A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Ad… Phase2 Rheumatoid Arthritis Completed 2012-06-01 2013-05-01 ClinicalTrials.gov
NCT01600729 Reliability of the Facial Wrinkle Scale in Japanese Subjects — Facial Rhytides Completed 2012-06-01 2012-07-01 ClinicalTrials.gov
NCT01600729 Reliability of the Facial Wrinkle Scale in Japanese Subjects — Facial Rhytides Completed 2012-06-01 2012-07-01 ClinicalTrials.gov
NCT01589419 A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of V… Phase1 Locally Advanced Rectal Cancer Completed 2012-06-01 2015-01-01 ClinicalTrials.gov
NCT01712178 A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Ad… Phase2 Rheumatoid Arthritis Completed 2012-06-01 2013-05-01 ClinicalTrials.gov
NCT01620528 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects Wi… Phase3 Endometriosis Completed 2012-05-22 2015-09-28 ClinicalTrials.gov
NCT01620528 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects Wi… Phase3 Endometriosis Completed 2012-05-22 2015-09-28 ClinicalTrials.gov
NCT01620528 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects Wi… Phase3 Endometriosis Completed 2012-05-22 2015-09-28 ClinicalTrials.gov
NCT01620528 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects Wi… Phase3 Endometriosis Completed 2012-05-22 2015-09-28 ClinicalTrials.gov
NCT01594229 A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination Wi… Phase1 Non-Hodgkin's Lymphoma Completed 2012-05-21 2020-07-14 ClinicalTrials.gov
NCT01594229 A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination Wi… Phase1 Non-Hodgkin's Lymphoma Completed 2012-05-21 2020-07-14 ClinicalTrials.gov
NCT01594229 A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination Wi… Phase1 Non-Hodgkin's Lymphoma Completed 2012-05-21 2020-07-14 ClinicalTrials.gov
NCT01594229 A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination Wi… Phase1 Non-Hodgkin's Lymphoma Completed 2012-05-21 2020-07-14 ClinicalTrials.gov
NCT01506947 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lower… Phase4 Moderate to Severe Secondary Hyperparathyroidism Completed 2012-05-10 2016-04-07 ClinicalTrials.gov
NCT01506947 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lower… Phase4 Moderate to Severe Secondary Hyperparathyroidism Completed 2012-05-10 2016-04-07 ClinicalTrials.gov
NCT01506947 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lower… Phase4 Moderate to Severe Secondary Hyperparathyroidism Completed 2012-05-10 2016-04-07 ClinicalTrials.gov
NCT01506947 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lower… Phase4 Moderate to Severe Secondary Hyperparathyroidism Completed 2012-05-10 2016-04-07 ClinicalTrials.gov
NCT01644396 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adal… Phase4 Moderate to Severe Plaque Psoriasis Completed 2012-05-01 2013-09-01 ClinicalTrials.gov
NCT01589471 The Value of Botox-A for Management of Low Anterior Resection Syndrome Phase2 Low Anterior Resection Syndrome Completed 2012-05-01 2015-11-01 ClinicalTrials.gov
NCT01550965 A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Ut… Phase3 Ulcerative Colitis Completed 2012-05-01 2015-04-01 ClinicalTrials.gov
NCT01632150 Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in… Phase2 Relapsed and/or Refractory Multiple Myeloma Completed 2012-05-01 2016-03-01 ClinicalTrials.gov
NCT01589471 The Value of Botox-A for Management of Low Anterior Resection Syndrome Phase2 Low Anterior Resection Syndrome Completed 2012-05-01 2015-11-01 ClinicalTrials.gov
NCT01655680 A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizoph… Phase2 Schizophrenia Completed 2012-05-01 2014-07-01 ClinicalTrials.gov
NCT01636765 Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessmen… — Erythema Completed 2012-05-01 2012-07-01 ClinicalTrials.gov
NCT01617928 A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese… Phase1 Solid Tumors Completed 2012-05-01 2013-07-01 ClinicalTrials.gov
NCT01575054 BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity Phase3 Muscle Spasticity Completed 2012-05-01 2015-07-01 ClinicalTrials.gov
NCT01575054 BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity Phase3 Muscle Spasticity Completed 2012-05-01 2015-07-01 ClinicalTrials.gov
NCT01589471 The Value of Botox-A for Management of Low Anterior Resection Syndrome Phase2 Low Anterior Resection Syndrome Completed 2012-05-01 2015-11-01 ClinicalTrials.gov
NCT01575054 BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity Phase3 Muscle Spasticity Completed 2012-05-01 2015-07-01 ClinicalTrials.gov
NCT01632150 Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in… Phase2 Relapsed and/or Refractory Multiple Myeloma Completed 2012-05-01 2016-03-01 ClinicalTrials.gov
NCT01655680 A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizoph… Phase2 Schizophrenia Completed 2012-05-01 2014-07-01 ClinicalTrials.gov
NCT01550965 A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Ut… Phase3 Ulcerative Colitis Completed 2012-05-01 2015-04-01 ClinicalTrials.gov
NCT01550965 A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Ut… Phase3 Ulcerative Colitis Completed 2012-05-01 2015-04-01 ClinicalTrials.gov
NCT01636765 Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessmen… — Erythema Completed 2012-05-01 2012-07-01 ClinicalTrials.gov
NCT01644396 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adal… Phase4 Moderate to Severe Plaque Psoriasis Completed 2012-05-01 2013-09-01 ClinicalTrials.gov
NCT01646151 A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Prima… — Glaucoma, Open-Angle Completed 2012-05-01 2013-04-01 ClinicalTrials.gov
NCT01617928 A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese… Phase1 Solid Tumors Completed 2012-05-01 2013-07-01 ClinicalTrials.gov
NCT01550965 A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Ut… Phase3 Ulcerative Colitis Completed 2012-05-01 2015-04-01 ClinicalTrials.gov
NCT01646151 A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Prima… — Glaucoma, Open-Angle Completed 2012-05-01 2013-04-01 ClinicalTrials.gov
NCT01632150 Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in… Phase2 Relapsed and/or Refractory Multiple Myeloma Completed 2012-05-01 2016-03-01 ClinicalTrials.gov
NCT01655680 A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizoph… Phase2 Schizophrenia Completed 2012-05-01 2014-07-01 ClinicalTrials.gov
NCT01636765 Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessmen… — Erythema Completed 2012-05-01 2012-07-01 ClinicalTrials.gov
NCT01644396 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adal… Phase4 Moderate to Severe Plaque Psoriasis Completed 2012-05-01 2013-09-01 ClinicalTrials.gov
NCT01636765 Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessmen… — Erythema Completed 2012-05-01 2012-07-01 ClinicalTrials.gov
NCT01646151 A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Prima… — Glaucoma, Open-Angle Completed 2012-05-01 2013-04-01 ClinicalTrials.gov
NCT01644396 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adal… Phase4 Moderate to Severe Plaque Psoriasis Completed 2012-05-01 2013-09-01 ClinicalTrials.gov
NCT01617928 A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese… Phase1 Solid Tumors Completed 2012-05-01 2013-07-01 ClinicalTrials.gov
NCT01646151 A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Prima… — Glaucoma, Open-Angle Completed 2012-05-01 2013-04-01 ClinicalTrials.gov
NCT01575054 BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity Phase3 Muscle Spasticity Completed 2012-05-01 2015-07-01 ClinicalTrials.gov
NCT01617928 A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese… Phase1 Solid Tumors Completed 2012-05-01 2013-07-01 ClinicalTrials.gov
NCT01589471 The Value of Botox-A for Management of Low Anterior Resection Syndrome Phase2 Low Anterior Resection Syndrome Completed 2012-05-01 2015-11-01 ClinicalTrials.gov
NCT01655680 A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizoph… Phase2 Schizophrenia Completed 2012-05-01 2014-07-01 ClinicalTrials.gov
NCT01632150 Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in… Phase2 Relapsed and/or Refractory Multiple Myeloma Completed 2012-05-01 2016-03-01 ClinicalTrials.gov
NCT01571557 A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema … — Macular Edema Completed 2012-04-30 2014-06-30 ClinicalTrials.gov
NCT01571557 A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema … — Macular Edema Completed 2012-04-30 2014-06-30 ClinicalTrials.gov
NCT01571557 A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema … — Macular Edema Completed 2012-04-30 2014-06-30 ClinicalTrials.gov
NCT01571557 A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema … — Macular Edema Completed 2012-04-30 2014-06-30 ClinicalTrials.gov
NCT01608672 Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX® — Glabellar Lines Completed 2012-04-01 2012-12-31 ClinicalTrials.gov
NCT01577550 Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psor… Phase1 Psoriasis Completed 2012-04-01 2014-05-01 ClinicalTrials.gov
NCT01608672 Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX® — Glabellar Lines Completed 2012-04-01 2012-12-31 ClinicalTrials.gov
NCT01608672 Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX® — Glabellar Lines Completed 2012-04-01 2012-12-31 ClinicalTrials.gov
NCT01589510 A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) o… — Glaucoma, Open-Angle Completed 2012-04-01 2013-02-01 ClinicalTrials.gov
NCT01589432 A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electri… Phase2 Diabetic Neuropathic Pain Completed 2012-04-01 2012-11-01 ClinicalTrials.gov
NCT01579279 A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects Wit… Phase2 Diabetic Neuropathic Pain Terminated 2012-04-01 2012-05-01 ClinicalTrials.gov
NCT01579084 Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With… Phase1 Rosacea Completed 2012-04-01 2012-06-01 ClinicalTrials.gov
NCT01571232 Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Phase2 Diabetic Macular Edema Completed 2012-04-01 2015-03-01 ClinicalTrials.gov
NCT01579305 Safety and Effectiveness of Juvéderm® Volbella With Lidocaine Versus Restylane-… Na Lip Volume Enhancement Completed 2012-04-01 2014-01-01 ClinicalTrials.gov
NCT01589510 A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) o… — Glaucoma, Open-Angle Completed 2012-04-01 2013-02-01 ClinicalTrials.gov
NCT01579305 Safety and Effectiveness of Juvéderm® Volbella With Lidocaine Versus Restylane-… Na Lip Volume Enhancement Completed 2012-04-01 2014-01-01 ClinicalTrials.gov
NCT01589432 A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electri… Phase2 Diabetic Neuropathic Pain Completed 2012-04-01 2012-11-01 ClinicalTrials.gov
NCT01579279 A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects Wit… Phase2 Diabetic Neuropathic Pain Terminated 2012-04-01 2012-05-01 ClinicalTrials.gov
NCT01579084 Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With… Phase1 Rosacea Completed 2012-04-01 2012-06-01 ClinicalTrials.gov
NCT01571232 Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Phase2 Diabetic Macular Edema Completed 2012-04-01 2015-03-01 ClinicalTrials.gov
NCT01577550 Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psor… Phase1 Psoriasis Completed 2012-04-01 2014-05-01 ClinicalTrials.gov
NCT01635764 Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of H… Phase3 Hidradenitis Suppurativa Completed 2012-04-01 2016-08-01 ClinicalTrials.gov
NCT01635764 Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of H… Phase3 Hidradenitis Suppurativa Completed 2012-04-01 2016-08-01 ClinicalTrials.gov
NCT01579305 Safety and Effectiveness of Juvéderm® Volbella With Lidocaine Versus Restylane-… Na Lip Volume Enhancement Completed 2012-04-01 2014-01-01 ClinicalTrials.gov
NCT01571232 Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Phase2 Diabetic Macular Edema Completed 2012-04-01 2015-03-01 ClinicalTrials.gov
NCT01579084 Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With… Phase1 Rosacea Completed 2012-04-01 2012-06-01 ClinicalTrials.gov
NCT01579279 A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects Wit… Phase2 Diabetic Neuropathic Pain Terminated 2012-04-01 2012-05-01 ClinicalTrials.gov
NCT01589432 A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electri… Phase2 Diabetic Neuropathic Pain Completed 2012-04-01 2012-11-01 ClinicalTrials.gov
NCT01589510 A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) o… — Glaucoma, Open-Angle Completed 2012-04-01 2013-02-01 ClinicalTrials.gov
NCT01608672 Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX® — Glabellar Lines Completed 2012-04-01 2012-12-31 ClinicalTrials.gov
NCT01579305 Safety and Effectiveness of Juvéderm® Volbella With Lidocaine Versus Restylane-… Na Lip Volume Enhancement Completed 2012-04-01 2014-01-01 ClinicalTrials.gov
NCT01577550 Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psor… Phase1 Psoriasis Completed 2012-04-01 2014-05-01 ClinicalTrials.gov
NCT01571232 Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Phase2 Diabetic Macular Edema Completed 2012-04-01 2015-03-01 ClinicalTrials.gov
NCT01577550 Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psor… Phase1 Psoriasis Completed 2012-04-01 2014-05-01 ClinicalTrials.gov
NCT01589432 A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electri… Phase2 Diabetic Neuropathic Pain Completed 2012-04-01 2012-11-01 ClinicalTrials.gov
NCT01579084 Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With… Phase1 Rosacea Completed 2012-04-01 2012-06-01 ClinicalTrials.gov
NCT01635764 Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of H… Phase3 Hidradenitis Suppurativa Completed 2012-04-01 2016-08-01 ClinicalTrials.gov
NCT01589510 A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) o… — Glaucoma, Open-Angle Completed 2012-04-01 2013-02-01 ClinicalTrials.gov
NCT01635764 Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of H… Phase3 Hidradenitis Suppurativa Completed 2012-04-01 2016-08-01 ClinicalTrials.gov
NCT01579279 A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects Wit… Phase2 Diabetic Neuropathic Pain Terminated 2012-04-01 2012-05-01 ClinicalTrials.gov
NCT01492400 Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With … Phase2 Macular Edema Completed 2012-03-09 2014-02-13 ClinicalTrials.gov
NCT01492400 Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With … Phase2 Macular Edema Completed 2012-03-09 2014-02-13 ClinicalTrials.gov
NCT01492400 Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With … Phase2 Macular Edema Completed 2012-03-09 2014-02-13 ClinicalTrials.gov
NCT01492400 Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With … Phase2 Macular Edema Completed 2012-03-09 2014-02-13 ClinicalTrials.gov
NCT01561313 Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. Phase2 Rheumatoid Arthritis Completed 2012-03-01 2012-11-01 ClinicalTrials.gov
NCT01561313 Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. Phase2 Rheumatoid Arthritis Completed 2012-03-01 2012-11-01 ClinicalTrials.gov
NCT01549834 Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate A… Phase2 Alzheimer's Disease Completed 2012-03-01 2013-10-01 ClinicalTrials.gov
NCT01549834 Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate A… Phase2 Alzheimer's Disease Completed 2012-03-01 2013-10-01 ClinicalTrials.gov
NCT01549834 Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate A… Phase2 Alzheimer's Disease Completed 2012-03-01 2013-10-01 ClinicalTrials.gov
NCT01561313 Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. Phase2 Rheumatoid Arthritis Completed 2012-03-01 2012-11-01 ClinicalTrials.gov
NCT01594970 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma… Phase4 Glaucoma, Open-Angle Completed 2012-03-01 2013-01-01 ClinicalTrials.gov
NCT01594970 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma… Phase4 Glaucoma, Open-Angle Completed 2012-03-01 2013-01-01 ClinicalTrials.gov
NCT01594970 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma… Phase4 Glaucoma, Open-Angle Completed 2012-03-01 2013-01-01 ClinicalTrials.gov
NCT01561313 Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. Phase2 Rheumatoid Arthritis Completed 2012-03-01 2012-11-01 ClinicalTrials.gov
NCT01549834 Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate A… Phase2 Alzheimer's Disease Completed 2012-03-01 2013-10-01 ClinicalTrials.gov
NCT01594970 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma… Phase4 Glaucoma, Open-Angle Completed 2012-03-01 2013-01-01 ClinicalTrials.gov
NCT03682471 Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX… — Subcutaneous Fat Completed 2012-02-14 2013-12-13 ClinicalTrials.gov
NCT03682471 Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX… — Subcutaneous Fat Completed 2012-02-14 2013-12-13 ClinicalTrials.gov
NCT03682471 Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX… — Subcutaneous Fat Completed 2012-02-14 2013-12-13 ClinicalTrials.gov
NCT03682471 Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX… — Subcutaneous Fat Completed 2012-02-14 2013-12-13 ClinicalTrials.gov
NCT01560104 A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combinati… Phase2 Non-Small -Cell Lung Cancer Completed 2012-02-01 2014-09-01 ClinicalTrials.gov
NCT01527916 Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate A… Phase2 Alzheimer's Disease Completed 2012-02-01 2013-11-01 ClinicalTrials.gov
NCT01543061 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With … Phase4 Contact Lens Related Dry Eye Syndrome Completed 2012-02-01 2012-12-01 ClinicalTrials.gov
NCT01559064 The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face — Age-related Volume Deficit in the Mid-face Completed 2012-02-01 2012-08-01 ClinicalTrials.gov
NCT01527916 Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate A… Phase2 Alzheimer's Disease Completed 2012-02-01 2013-11-01 ClinicalTrials.gov
NCT01559064 The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face — Age-related Volume Deficit in the Mid-face Completed 2012-02-01 2012-08-01 ClinicalTrials.gov
NCT01543061 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With … Phase4 Contact Lens Related Dry Eye Syndrome Completed 2012-02-01 2012-12-01 ClinicalTrials.gov
NCT01540370 Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Oc… — Glaucoma, Open-Angle Completed 2012-02-01 2012-07-01 ClinicalTrials.gov
NCT01540370 Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Oc… — Glaucoma, Open-Angle Completed 2012-02-01 2012-07-01 ClinicalTrials.gov
NCT01559064 The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face — Age-related Volume Deficit in the Mid-face Completed 2012-02-01 2012-08-01 ClinicalTrials.gov
NCT01560104 A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combinati… Phase2 Non-Small -Cell Lung Cancer Completed 2012-02-01 2014-09-01 ClinicalTrials.gov
NCT01543061 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With … Phase4 Contact Lens Related Dry Eye Syndrome Completed 2012-02-01 2012-12-01 ClinicalTrials.gov
NCT01543061 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With … Phase4 Contact Lens Related Dry Eye Syndrome Completed 2012-02-01 2012-12-01 ClinicalTrials.gov
NCT01540370 Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Oc… — Glaucoma, Open-Angle Completed 2012-02-01 2012-07-01 ClinicalTrials.gov
NCT01560104 A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combinati… Phase2 Non-Small -Cell Lung Cancer Completed 2012-02-01 2014-09-01 ClinicalTrials.gov
NCT01527916 Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate A… Phase2 Alzheimer's Disease Completed 2012-02-01 2013-11-01 ClinicalTrials.gov
NCT01527916 Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate A… Phase2 Alzheimer's Disease Completed 2012-02-01 2013-11-01 ClinicalTrials.gov
NCT01540370 Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Oc… — Glaucoma, Open-Angle Completed 2012-02-01 2012-07-01 ClinicalTrials.gov
NCT01560104 A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combinati… Phase2 Non-Small -Cell Lung Cancer Completed 2012-02-01 2014-09-01 ClinicalTrials.gov
NCT01559064 The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face — Age-related Volume Deficit in the Mid-face Completed 2012-02-01 2012-08-01 ClinicalTrials.gov
NCT01506609 Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Tem… Phase2 Metastatic Breast Cancer Completed 2012-01-23 2020-09-02 ClinicalTrials.gov
NCT01506609 Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Tem… Phase2 Metastatic Breast Cancer Completed 2012-01-23 2020-09-02 ClinicalTrials.gov
NCT01506609 Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Tem… Phase2 Metastatic Breast Cancer Completed 2012-01-23 2020-09-02 ClinicalTrials.gov
NCT01506609 Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Tem… Phase2 Metastatic Breast Cancer Completed 2012-01-23 2020-09-02 ClinicalTrials.gov
NCT01393964 Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subje… Phase1 Multiple Myeloma Completed 2012-01-06 2016-07-18 ClinicalTrials.gov
NCT01393964 Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subje… Phase1 Multiple Myeloma Completed 2012-01-06 2016-07-18 ClinicalTrials.gov
NCT01393964 Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subje… Phase1 Multiple Myeloma Completed 2012-01-06 2016-07-18 ClinicalTrials.gov
NCT01393964 Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subje… Phase1 Multiple Myeloma Completed 2012-01-06 2016-07-18 ClinicalTrials.gov
NCT01469221 Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle… Phase3 Bladder Cancer Terminated 2012-01-01 2013-04-01 ClinicalTrials.gov
NCT02922192 Incidence of Hospitalizations for Serious Infections in Patients Receiving Biol… — Rheumatoid Arthritis Completed 2012-01-01 2020-06-01 ClinicalTrials.gov
NCT01537198 Surveillance of Synagis in Korean Pediatric Patients — Respiratory Syncytial Virus Infection Completed 2012-01-01 2014-06-01 ClinicalTrials.gov
NCT01502423 A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimu… Phase2 Rheumatoid Arthritis Completed 2012-01-01 2012-11-01 ClinicalTrials.gov
NCT01502423 A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimu… Phase2 Rheumatoid Arthritis Completed 2012-01-01 2012-11-01 ClinicalTrials.gov
NCT01537198 Surveillance of Synagis in Korean Pediatric Patients — Respiratory Syncytial Virus Infection Completed 2012-01-01 2014-06-01 ClinicalTrials.gov
NCT02922192 Incidence of Hospitalizations for Serious Infections in Patients Receiving Biol… — Rheumatoid Arthritis Completed 2012-01-01 2020-06-01 ClinicalTrials.gov
NCT01537198 Surveillance of Synagis in Korean Pediatric Patients — Respiratory Syncytial Virus Infection Completed 2012-01-01 2014-06-01 ClinicalTrials.gov
NCT02922192 Incidence of Hospitalizations for Serious Infections in Patients Receiving Biol… — Rheumatoid Arthritis Completed 2012-01-01 2020-06-01 ClinicalTrials.gov
NCT01469221 Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle… Phase3 Bladder Cancer Terminated 2012-01-01 2013-04-01 ClinicalTrials.gov
NCT01502423 A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimu… Phase2 Rheumatoid Arthritis Completed 2012-01-01 2012-11-01 ClinicalTrials.gov
NCT01518257 Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthr… Phase1 Osteoarthritis Completed 2012-01-01 2013-01-01 ClinicalTrials.gov
NCT01518257 Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthr… Phase1 Osteoarthritis Completed 2012-01-01 2013-01-01 ClinicalTrials.gov
NCT01537198 Surveillance of Synagis in Korean Pediatric Patients — Respiratory Syncytial Virus Infection Completed 2012-01-01 2014-06-01 ClinicalTrials.gov
NCT01741142 Efficacy and Safety Study of ABT-436 in Major Depressive Disorder Phase2 Major Depressive Disorder Terminated 2012-01-01 2015-08-01 ClinicalTrials.gov
NCT01469221 Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle… Phase3 Bladder Cancer Terminated 2012-01-01 2013-04-01 ClinicalTrials.gov
NCT01741142 Efficacy and Safety Study of ABT-436 in Major Depressive Disorder Phase2 Major Depressive Disorder Terminated 2012-01-01 2015-08-01 ClinicalTrials.gov
NCT01518257 Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthr… Phase1 Osteoarthritis Completed 2012-01-01 2013-01-01 ClinicalTrials.gov
NCT01518257 Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthr… Phase1 Osteoarthritis Completed 2012-01-01 2013-01-01 ClinicalTrials.gov
NCT01469221 Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle… Phase3 Bladder Cancer Terminated 2012-01-01 2013-04-01 ClinicalTrials.gov
NCT02922192 Incidence of Hospitalizations for Serious Infections in Patients Receiving Biol… — Rheumatoid Arthritis Completed 2012-01-01 2020-06-01 ClinicalTrials.gov
NCT01741142 Efficacy and Safety Study of ABT-436 in Major Depressive Disorder Phase2 Major Depressive Disorder Terminated 2012-01-01 2015-08-01 ClinicalTrials.gov
NCT01502423 A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimu… Phase2 Rheumatoid Arthritis Completed 2012-01-01 2012-11-01 ClinicalTrials.gov
NCT01741142 Efficacy and Safety Study of ABT-436 in Major Depressive Disorder Phase2 Major Depressive Disorder Terminated 2012-01-01 2015-08-01 ClinicalTrials.gov
NCT01441973 Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma Phase2 Smoldering Multiple Myeloma Completed 2011-12-28 2017-01-17 ClinicalTrials.gov
NCT01441973 Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma Phase2 Smoldering Multiple Myeloma Completed 2011-12-28 2017-01-17 ClinicalTrials.gov
NCT01441973 Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma Phase2 Smoldering Multiple Myeloma Completed 2011-12-28 2017-01-17 ClinicalTrials.gov
NCT01441973 Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma Phase2 Smoldering Multiple Myeloma Completed 2011-12-28 2017-01-17 ClinicalTrials.gov
NCT01464333 Special Investigation (Long-term Investigation) in Patients With Crohn's Disease — Crohn's Disease Completed 2011-12-16 2018-03-31 ClinicalTrials.gov
NCT01464333 Special Investigation (Long-term Investigation) in Patients With Crohn's Disease — Crohn's Disease Completed 2011-12-16 2018-03-31 ClinicalTrials.gov
NCT01464333 Special Investigation (Long-term Investigation) in Patients With Crohn's Disease — Crohn's Disease Completed 2011-12-16 2018-03-31 ClinicalTrials.gov
NCT01464333 Special Investigation (Long-term Investigation) in Patients With Crohn's Disease — Crohn's Disease Completed 2011-12-16 2018-03-31 ClinicalTrials.gov
NCT01518270 Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy… — Health Completed 2011-12-01 2011-12-16 ClinicalTrials.gov
NCT01464021 A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimuma… — Arthritis Terminated 2011-12-01 2012-12-01 ClinicalTrials.gov
NCT01516892 A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With… Phase4 Migraine Disorders Completed 2011-12-01 2015-11-01 ClinicalTrials.gov
NCT01464021 A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimuma… — Arthritis Terminated 2011-12-01 2012-12-01 ClinicalTrials.gov
NCT01518270 Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy… — Health Completed 2011-12-01 2011-12-16 ClinicalTrials.gov
NCT01428115 Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimum… — Severe Crohn's Disease Completed 2011-12-01 2013-10-01 ClinicalTrials.gov
NCT01428115 Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimum… — Severe Crohn's Disease Completed 2011-12-01 2013-10-01 ClinicalTrials.gov
NCT01428115 Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimum… — Severe Crohn's Disease Completed 2011-12-01 2013-10-01 ClinicalTrials.gov
NCT01464021 A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimuma… — Arthritis Terminated 2011-12-01 2012-12-01 ClinicalTrials.gov
NCT01464021 A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimuma… — Arthritis Terminated 2011-12-01 2012-12-01 ClinicalTrials.gov
NCT01518270 Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy… — Health Completed 2011-12-01 2011-12-16 ClinicalTrials.gov
NCT01516892 A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With… Phase4 Migraine Disorders Completed 2011-12-01 2015-11-01 ClinicalTrials.gov
NCT01518270 Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy… — Health Completed 2011-12-01 2011-12-16 ClinicalTrials.gov
NCT01428115 Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimum… — Severe Crohn's Disease Completed 2011-12-01 2013-10-01 ClinicalTrials.gov
NCT01516892 A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With… Phase4 Migraine Disorders Completed 2011-12-01 2015-11-01 ClinicalTrials.gov
NCT01516892 A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With… Phase4 Migraine Disorders Completed 2011-12-01 2015-11-01 ClinicalTrials.gov
NCT01478048 Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relap… Phase2 Multiple Myeloma Completed 2011-11-30 2017-04-21 ClinicalTrials.gov
NCT01478048 Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relap… Phase2 Multiple Myeloma Completed 2011-11-30 2017-04-21 ClinicalTrials.gov
NCT01478048 Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relap… Phase2 Multiple Myeloma Completed 2011-11-30 2017-04-21 ClinicalTrials.gov
NCT01478048 Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relap… Phase2 Multiple Myeloma Completed 2011-11-30 2017-04-21 ClinicalTrials.gov
NCT01618266 Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Ret… — Macular Edema Completed 2011-11-01 2014-10-01 ClinicalTrials.gov
NCT01945892 Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Synd… — Macular Edema Completed 2011-11-01 2013-07-01 ClinicalTrials.gov
NCT01618266 Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Ret… — Macular Edema Completed 2011-11-01 2014-10-01 ClinicalTrials.gov
NCT01489904 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Dr… Phase2 Sialorrhea Unknown 2011-11-01 2012-11-01 ClinicalTrials.gov
NCT01475253 Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of L… Phase2 Interstitial Cystitis Terminated 2011-11-01 2012-12-01 ClinicalTrials.gov
NCT01618266 Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Ret… — Macular Edema Completed 2011-11-01 2014-10-01 ClinicalTrials.gov
NCT01475253 Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of L… Phase2 Interstitial Cystitis Terminated 2011-11-01 2012-12-01 ClinicalTrials.gov
NCT01489904 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Dr… Phase2 Sialorrhea Unknown 2011-11-01 2012-11-01 ClinicalTrials.gov
NCT01474876 Multi-country Post-Marketing Observational Study on Maintenance of Effectivenes… — Ankylosing Spondylitis Completed 2011-11-01 2014-05-01 ClinicalTrials.gov
NCT01945892 Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Synd… — Macular Edema Completed 2011-11-01 2013-07-01 ClinicalTrials.gov
NCT01474876 Multi-country Post-Marketing Observational Study on Maintenance of Effectivenes… — Ankylosing Spondylitis Completed 2011-11-01 2014-05-01 ClinicalTrials.gov
NCT01468207 Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Phase3 Hidradenitis Suppurativa (HS) Completed 2011-11-01 2014-01-01 ClinicalTrials.gov
NCT01468233 Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppur… Phase3 Hidradenitis Suppurativa (HS) Completed 2011-11-01 2014-04-01 ClinicalTrials.gov
NCT01468207 Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Phase3 Hidradenitis Suppurativa (HS) Completed 2011-11-01 2014-01-01 ClinicalTrials.gov
NCT01468233 Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppur… Phase3 Hidradenitis Suppurativa (HS) Completed 2011-11-01 2014-04-01 ClinicalTrials.gov
NCT01468233 Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppur… Phase3 Hidradenitis Suppurativa (HS) Completed 2011-11-01 2014-04-01 ClinicalTrials.gov
NCT01468207 Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Phase3 Hidradenitis Suppurativa (HS) Completed 2011-11-01 2014-01-01 ClinicalTrials.gov
NCT01945892 Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Synd… — Macular Edema Completed 2011-11-01 2013-07-01 ClinicalTrials.gov
NCT01618266 Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Ret… — Macular Edema Completed 2011-11-01 2014-10-01 ClinicalTrials.gov
NCT01489904 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Dr… Phase2 Sialorrhea Unknown 2011-11-01 2012-11-01 ClinicalTrials.gov
NCT01475253 Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of L… Phase2 Interstitial Cystitis Terminated 2011-11-01 2012-12-01 ClinicalTrials.gov
NCT01474876 Multi-country Post-Marketing Observational Study on Maintenance of Effectivenes… — Ankylosing Spondylitis Completed 2011-11-01 2014-05-01 ClinicalTrials.gov
NCT01474876 Multi-country Post-Marketing Observational Study on Maintenance of Effectivenes… — Ankylosing Spondylitis Completed 2011-11-01 2014-05-01 ClinicalTrials.gov
NCT01468207 Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Phase3 Hidradenitis Suppurativa (HS) Completed 2011-11-01 2014-01-01 ClinicalTrials.gov
NCT01468233 Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppur… Phase3 Hidradenitis Suppurativa (HS) Completed 2011-11-01 2014-04-01 ClinicalTrials.gov
NCT01475253 Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of L… Phase2 Interstitial Cystitis Terminated 2011-11-01 2012-12-01 ClinicalTrials.gov
NCT01489904 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Dr… Phase2 Sialorrhea Unknown 2011-11-01 2012-11-01 ClinicalTrials.gov
NCT01945892 Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Synd… — Macular Edema Completed 2011-11-01 2013-07-01 ClinicalTrials.gov
NCT01427751 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Br… Phase4 Retinal Vein Occlusion Completed 2011-10-11 2014-11-04 ClinicalTrials.gov
NCT01427751 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Br… Phase4 Retinal Vein Occlusion Completed 2011-10-11 2014-11-04 ClinicalTrials.gov
NCT01427751 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Br… Phase4 Retinal Vein Occlusion Completed 2011-10-11 2014-11-04 ClinicalTrials.gov
NCT01427751 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Br… Phase4 Retinal Vein Occlusion Completed 2011-10-11 2014-11-04 ClinicalTrials.gov
NCT01472016 Study of ABT-700 in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2011-10-06 2017-04-27 ClinicalTrials.gov
NCT01472016 Study of ABT-700 in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2011-10-06 2017-04-27 ClinicalTrials.gov
NCT01472016 Study of ABT-700 in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2011-10-06 2017-04-27 ClinicalTrials.gov
NCT01472016 Study of ABT-700 in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2011-10-06 2017-04-27 ClinicalTrials.gov
NCT01445626 A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intra… — Macular Edema Completed 2011-10-01 2012-01-01 ClinicalTrials.gov
NCT01449682 Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Tre… Phase3 Retinal Vein Occlusion Completed 2011-10-01 2013-02-01 ClinicalTrials.gov
NCT01406119 An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2011-10-01 2017-01-01 ClinicalTrials.gov
NCT01459588 Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subject… Phase3 Dry Eye Syndromes Completed 2011-10-01 2012-02-15 ClinicalTrials.gov
NCT01470118 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Phase4 Conjunctivitis, Allergic Completed 2011-10-01 2011-12-01 ClinicalTrials.gov
NCT01464827 ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in… Phase2 Chronic Hepatitis C Completed 2011-10-01 2013-09-01 ClinicalTrials.gov
NCT01459588 Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subject… Phase3 Dry Eye Syndromes Completed 2011-10-01 2012-02-15 ClinicalTrials.gov
NCT01470118 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Phase4 Conjunctivitis, Allergic Completed 2011-10-01 2011-12-01 ClinicalTrials.gov
NCT01449682 Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Tre… Phase3 Retinal Vein Occlusion Completed 2011-10-01 2013-02-01 ClinicalTrials.gov
NCT01382212 A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects A… Phase3 End-Stage Renal Disease Completed 2011-10-01 2015-04-01 ClinicalTrials.gov
NCT01459588 Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subject… Phase3 Dry Eye Syndromes Completed 2011-10-01 2012-02-15 ClinicalTrials.gov
NCT01449682 Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Tre… Phase3 Retinal Vein Occlusion Completed 2011-10-01 2013-02-01 ClinicalTrials.gov
NCT01448525 Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Promi… Phase4 Hypotrichosis Completed 2011-10-01 2012-04-01 ClinicalTrials.gov
NCT01423539 A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients Wit… Phase2 Diffuse Large B-Cell Lymphoma Withdrawn 2011-10-01 2014-02-01 ClinicalTrials.gov
NCT01423539 A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients Wit… Phase2 Diffuse Large B-Cell Lymphoma Withdrawn 2011-10-01 2014-02-01 ClinicalTrials.gov
NCT01382212 A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects A… Phase3 End-Stage Renal Disease Completed 2011-10-01 2015-04-01 ClinicalTrials.gov
NCT01382212 A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects A… Phase3 End-Stage Renal Disease Completed 2011-10-01 2015-04-01 ClinicalTrials.gov
NCT01568008 Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glauc… — Open-Angle Glaucoma Completed 2011-10-01 2012-09-01 ClinicalTrials.gov
NCT01406119 An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2011-10-01 2017-01-01 ClinicalTrials.gov
NCT01568008 Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glauc… — Open-Angle Glaucoma Completed 2011-10-01 2012-09-01 ClinicalTrials.gov
NCT01406119 An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2011-10-01 2017-01-01 ClinicalTrials.gov
NCT01464827 ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in… Phase2 Chronic Hepatitis C Completed 2011-10-01 2013-09-01 ClinicalTrials.gov
NCT01464827 ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in… Phase2 Chronic Hepatitis C Completed 2011-10-01 2013-09-01 ClinicalTrials.gov
NCT01382212 A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects A… Phase3 End-Stage Renal Disease Completed 2011-10-01 2015-04-01 ClinicalTrials.gov
NCT01464827 ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in… Phase2 Chronic Hepatitis C Completed 2011-10-01 2013-09-01 ClinicalTrials.gov
NCT01406119 An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumors Completed 2011-10-01 2017-01-01 ClinicalTrials.gov
NCT01470118 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Phase4 Conjunctivitis, Allergic Completed 2011-10-01 2011-12-01 ClinicalTrials.gov
NCT01568008 Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glauc… — Open-Angle Glaucoma Completed 2011-10-01 2012-09-01 ClinicalTrials.gov
NCT01470118 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Phase4 Conjunctivitis, Allergic Completed 2011-10-01 2011-12-01 ClinicalTrials.gov
NCT01423539 A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients Wit… Phase2 Diffuse Large B-Cell Lymphoma Withdrawn 2011-10-01 2014-02-01 ClinicalTrials.gov
NCT01423539 A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients Wit… Phase2 Diffuse Large B-Cell Lymphoma Withdrawn 2011-10-01 2014-02-01 ClinicalTrials.gov
NCT01445626 A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intra… — Macular Edema Completed 2011-10-01 2012-01-01 ClinicalTrials.gov
NCT01459588 Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subject… Phase3 Dry Eye Syndromes Completed 2011-10-01 2012-02-15 ClinicalTrials.gov
NCT01449682 Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Tre… Phase3 Retinal Vein Occlusion Completed 2011-10-01 2013-02-01 ClinicalTrials.gov
NCT01448525 Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Promi… Phase4 Hypotrichosis Completed 2011-10-01 2012-04-01 ClinicalTrials.gov
NCT01445626 A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intra… — Macular Edema Completed 2011-10-01 2012-01-01 ClinicalTrials.gov
NCT01568008 Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glauc… — Open-Angle Glaucoma Completed 2011-10-01 2012-09-01 ClinicalTrials.gov
NCT01445626 A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intra… — Macular Edema Completed 2011-10-01 2012-01-01 ClinicalTrials.gov
NCT01448525 Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Promi… Phase4 Hypotrichosis Completed 2011-10-01 2012-04-01 ClinicalTrials.gov
NCT01448525 Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Promi… Phase4 Hypotrichosis Completed 2011-10-01 2012-04-01 ClinicalTrials.gov
NCT01432379 BOTOX® Prophylaxis in Patients With Chronic Migraine — Migraine Disorders Completed 2011-09-09 2015-05-12 ClinicalTrials.gov
NCT01432379 BOTOX® Prophylaxis in Patients With Chronic Migraine — Migraine Disorders Completed 2011-09-09 2015-05-12 ClinicalTrials.gov
NCT01432379 BOTOX® Prophylaxis in Patients With Chronic Migraine — Migraine Disorders Completed 2011-09-09 2015-05-12 ClinicalTrials.gov
NCT01432379 BOTOX® Prophylaxis in Patients With Chronic Migraine — Migraine Disorders Completed 2011-09-09 2015-05-12 ClinicalTrials.gov
NCT01441635 Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Blee… Phase2 Heavy Uterine Bleeding Completed 2011-09-08 2014-05-17 ClinicalTrials.gov
NCT01441635 Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Blee… Phase2 Heavy Uterine Bleeding Completed 2011-09-08 2014-05-17 ClinicalTrials.gov
NCT01441635 Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Blee… Phase2 Heavy Uterine Bleeding Completed 2011-09-08 2014-05-17 ClinicalTrials.gov
NCT01441635 Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Blee… Phase2 Heavy Uterine Bleeding Completed 2011-09-08 2014-05-17 ClinicalTrials.gov
NCT01458535 A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together… Phase2 Hepatitis C Virus Completed 2011-09-01 2013-05-01 ClinicalTrials.gov
NCT01397409 Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) Phase2 Age-related Macular Degeneration Completed 2011-09-01 2014-04-30 ClinicalTrials.gov
NCT01458535 A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together… Phase2 Hepatitis C Virus Completed 2011-09-01 2013-05-01 ClinicalTrials.gov
NCT01441895 Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction … — Cataract Unknown 2011-09-01 2016-12-01 ClinicalTrials.gov
NCT01397409 Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) Phase2 Age-related Macular Degeneration Completed 2011-09-01 2014-04-30 ClinicalTrials.gov
NCT03023748 Intravenous Paricalcitol in Chronic Hemodialysis Patients Phase4 Endstage Renal Disease Unknown 2011-09-01 2018-01-01 ClinicalTrials.gov
NCT01441895 Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction … — Cataract Unknown 2011-09-01 2016-12-01 ClinicalTrials.gov
NCT01397409 Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) Phase2 Age-related Macular Degeneration Completed 2011-09-01 2014-04-30 ClinicalTrials.gov
NCT01741246 Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomog… — Migraine Completed 2011-09-01 2015-06-01 ClinicalTrials.gov
NCT01741246 Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomog… — Migraine Completed 2011-09-01 2015-06-01 ClinicalTrials.gov
NCT01441895 Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction … — Cataract Unknown 2011-09-01 2016-12-01 ClinicalTrials.gov
NCT01426113 A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paedia… Phase3 Glaucoma Terminated 2011-09-01 2014-10-01 ClinicalTrials.gov
NCT01741246 Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomog… — Migraine Completed 2011-09-01 2015-06-01 ClinicalTrials.gov
NCT01397409 Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) Phase2 Age-related Macular Degeneration Completed 2011-09-01 2014-04-30 ClinicalTrials.gov
NCT01741246 Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomog… — Migraine Completed 2011-09-01 2015-06-01 ClinicalTrials.gov
NCT01458535 A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together… Phase2 Hepatitis C Virus Completed 2011-09-01 2013-05-01 ClinicalTrials.gov
NCT03023748 Intravenous Paricalcitol in Chronic Hemodialysis Patients Phase4 Endstage Renal Disease Unknown 2011-09-01 2018-01-01 ClinicalTrials.gov
NCT01458535 A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together… Phase2 Hepatitis C Virus Completed 2011-09-01 2013-05-01 ClinicalTrials.gov
NCT01426113 A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paedia… Phase3 Glaucoma Terminated 2011-09-01 2014-10-01 ClinicalTrials.gov
NCT01441895 Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction … — Cataract Unknown 2011-09-01 2016-12-01 ClinicalTrials.gov
NCT03023748 Intravenous Paricalcitol in Chronic Hemodialysis Patients Phase4 Endstage Renal Disease Unknown 2011-09-01 2018-01-01 ClinicalTrials.gov
NCT03023748 Intravenous Paricalcitol in Chronic Hemodialysis Patients Phase4 Endstage Renal Disease Unknown 2011-09-01 2018-01-01 ClinicalTrials.gov
NCT01426113 A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paedia… Phase3 Glaucoma Terminated 2011-09-01 2014-10-01 ClinicalTrials.gov
NCT01426113 A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paedia… Phase3 Glaucoma Terminated 2011-09-01 2014-10-01 ClinicalTrials.gov
NCT01387815 Canadian Humira Post Marketing Observational Epidemiological Study: Assessing E… — Psoriasis Completed 2011-08-16 2018-06-29 ClinicalTrials.gov
NCT01387815 Canadian Humira Post Marketing Observational Epidemiological Study: Assessing E… — Psoriasis Completed 2011-08-16 2018-06-29 ClinicalTrials.gov
NCT01387815 Canadian Humira Post Marketing Observational Epidemiological Study: Assessing E… — Psoriasis Completed 2011-08-16 2018-06-29 ClinicalTrials.gov
NCT01387815 Canadian Humira Post Marketing Observational Epidemiological Study: Assessing E… — Psoriasis Completed 2011-08-16 2018-06-29 ClinicalTrials.gov
NCT01335399 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to… Phase3 Multiple Myeloma Completed 2011-08-04 2021-09-03 ClinicalTrials.gov
NCT01335399 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to… Phase3 Multiple Myeloma Completed 2011-08-04 2021-09-03 ClinicalTrials.gov
NCT01335399 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to… Phase3 Multiple Myeloma Completed 2011-08-04 2021-09-03 ClinicalTrials.gov
NCT01335399 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to… Phase3 Multiple Myeloma Completed 2011-08-04 2021-09-03 ClinicalTrials.gov
NCT01424319 Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With At… Phase2 Chronic Kidney Disease Completed 2011-08-01 2012-07-01 ClinicalTrials.gov
NCT01368042 Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous — Chronic Kidney Disease Completed 2011-08-01 2013-06-01 ClinicalTrials.gov
NCT01401452 Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients Wit… — Moderate to Severe Plaque Psoriasis Completed 2011-08-01 2016-05-01 ClinicalTrials.gov
NCT01424319 Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With At… Phase2 Chronic Kidney Disease Completed 2011-08-01 2012-07-01 ClinicalTrials.gov
NCT01390961 Comparison of Tolerability Between Two Allergy Drops Phase4 Allergic Conjunctivitis Unknown 2011-08-01 2012-01-01 ClinicalTrials.gov
NCT01410201 Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane Na Epiretinal Membrane Terminated 2011-08-01 2016-01-01 ClinicalTrials.gov
NCT01412086 Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale — Healthy Volunteers Completed 2011-08-01 2011-09-01 ClinicalTrials.gov
NCT01401452 Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients Wit… — Moderate to Severe Plaque Psoriasis Completed 2011-08-01 2016-05-01 ClinicalTrials.gov
NCT01387789 A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of L… — Rheumatoid Arthritis Completed 2011-08-01 2013-03-01 ClinicalTrials.gov
NCT01401452 Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients Wit… — Moderate to Severe Plaque Psoriasis Completed 2011-08-01 2016-05-01 ClinicalTrials.gov
NCT01424319 Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With At… Phase2 Chronic Kidney Disease Completed 2011-08-01 2012-07-01 ClinicalTrials.gov
NCT01368042 Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous — Chronic Kidney Disease Completed 2011-08-01 2013-06-01 ClinicalTrials.gov
NCT01466062 Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children … Phase3 Respiratory Syncytial Virus Infection Completed 2011-08-01 2012-04-01 ClinicalTrials.gov
NCT00706940 Tear Dynamics After Restasis Treatment in Dry Eye Patients — Dry Eye Completed 2011-08-01 2016-12-31 ClinicalTrials.gov
NCT00706940 Tear Dynamics After Restasis Treatment in Dry Eye Patients — Dry Eye Completed 2011-08-01 2016-12-31 ClinicalTrials.gov
NCT01466062 Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children … Phase3 Respiratory Syncytial Virus Infection Completed 2011-08-01 2012-04-01 ClinicalTrials.gov
NCT01466062 Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children … Phase3 Respiratory Syncytial Virus Infection Completed 2011-08-01 2012-04-01 ClinicalTrials.gov
NCT01412086 Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale — Healthy Volunteers Completed 2011-08-01 2011-09-01 ClinicalTrials.gov
NCT01410201 Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane Na Epiretinal Membrane Terminated 2011-08-01 2016-01-01 ClinicalTrials.gov
NCT00706940 Tear Dynamics After Restasis Treatment in Dry Eye Patients — Dry Eye Completed 2011-08-01 2016-12-31 ClinicalTrials.gov
NCT01390961 Comparison of Tolerability Between Two Allergy Drops Phase4 Allergic Conjunctivitis Unknown 2011-08-01 2012-01-01 ClinicalTrials.gov
NCT01387789 A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of L… — Rheumatoid Arthritis Completed 2011-08-01 2013-03-01 ClinicalTrials.gov
NCT01368042 Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous — Chronic Kidney Disease Completed 2011-08-01 2013-06-01 ClinicalTrials.gov
NCT00706940 Tear Dynamics After Restasis Treatment in Dry Eye Patients — Dry Eye Completed 2011-08-01 2016-12-31 ClinicalTrials.gov
NCT01424319 Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With At… Phase2 Chronic Kidney Disease Completed 2011-08-01 2012-07-01 ClinicalTrials.gov
NCT01412086 Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale — Healthy Volunteers Completed 2011-08-01 2011-09-01 ClinicalTrials.gov
NCT01401452 Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients Wit… — Moderate to Severe Plaque Psoriasis Completed 2011-08-01 2016-05-01 ClinicalTrials.gov
NCT01368042 Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous — Chronic Kidney Disease Completed 2011-08-01 2013-06-01 ClinicalTrials.gov
NCT01387789 A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of L… — Rheumatoid Arthritis Completed 2011-08-01 2013-03-01 ClinicalTrials.gov
NCT01410201 Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane Na Epiretinal Membrane Terminated 2011-08-01 2016-01-01 ClinicalTrials.gov
NCT01390961 Comparison of Tolerability Between Two Allergy Drops Phase4 Allergic Conjunctivitis Unknown 2011-08-01 2012-01-01 ClinicalTrials.gov
NCT01466062 Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children … Phase3 Respiratory Syncytial Virus Infection Completed 2011-08-01 2012-04-01 ClinicalTrials.gov
NCT01412086 Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale — Healthy Volunteers Completed 2011-08-01 2011-09-01 ClinicalTrials.gov
NCT01410201 Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane Na Epiretinal Membrane Terminated 2011-08-01 2016-01-01 ClinicalTrials.gov
NCT01390961 Comparison of Tolerability Between Two Allergy Drops Phase4 Allergic Conjunctivitis Unknown 2011-08-01 2012-01-01 ClinicalTrials.gov
NCT01387789 A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of L… — Rheumatoid Arthritis Completed 2011-08-01 2013-03-01 ClinicalTrials.gov
NCT01410565 Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-M… Phase3 Bladder Cancer Terminated 2011-07-01 2014-03-01 ClinicalTrials.gov
NCT01282203 Evaluation of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevoran… — Anesthesia, General Completed 2011-07-01 2011-11-01 ClinicalTrials.gov
NCT01401478 Observational Program of Zemplar in Patients With End Stage Chronic Kidney Dise… — Secondary Hyperparathyroidism Completed 2011-07-01 2013-01-01 ClinicalTrials.gov
NCT01412021 Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Ar… — Arthritis, Juvenile Rheumatoid Completed 2011-07-01 2018-04-02 ClinicalTrials.gov
NCT01149291 A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialy… — Secondary Hyperparathyroidism Completed 2011-07-01 2014-12-01 ClinicalTrials.gov
NCT01391286 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy… Phase3 Eyelash Hypotrichosis Completed 2011-07-01 2012-05-25 ClinicalTrials.gov
NCT01391273 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypo… Phase3 Eyelash Hypotrichosis Completed 2011-07-01 2012-05-19 ClinicalTrials.gov
NCT01411696 Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for R… — Retinal Vein Occlusion Completed 2011-07-01 2012-03-01 ClinicalTrials.gov
NCT01384851 Efficacy of the Chronic Application of Tear Formulations Na Dry Eye Unknown 2011-07-01 2011-11-01 ClinicalTrials.gov
NCT01412021 Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Ar… — Arthritis, Juvenile Rheumatoid Completed 2011-07-01 2018-04-02 ClinicalTrials.gov
NCT01410565 Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-M… Phase3 Bladder Cancer Terminated 2011-07-01 2014-03-01 ClinicalTrials.gov
NCT01501799 A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl … Na Acne Vulgaris Completed 2011-07-01 2011-12-01 ClinicalTrials.gov
NCT01384851 Efficacy of the Chronic Application of Tear Formulations Na Dry Eye Unknown 2011-07-01 2011-11-01 ClinicalTrials.gov
NCT01149291 A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialy… — Secondary Hyperparathyroidism Completed 2011-07-01 2014-12-01 ClinicalTrials.gov
NCT01149291 A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialy… — Secondary Hyperparathyroidism Completed 2011-07-01 2014-12-01 ClinicalTrials.gov
NCT01384851 Efficacy of the Chronic Application of Tear Formulations Na Dry Eye Unknown 2011-07-01 2011-11-01 ClinicalTrials.gov
NCT01401478 Observational Program of Zemplar in Patients With End Stage Chronic Kidney Dise… — Secondary Hyperparathyroidism Completed 2011-07-01 2013-01-01 ClinicalTrials.gov
NCT01282203 Evaluation of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevoran… — Anesthesia, General Completed 2011-07-01 2011-11-01 ClinicalTrials.gov
NCT01411696 Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for R… — Retinal Vein Occlusion Completed 2011-07-01 2012-03-01 ClinicalTrials.gov
NCT01410565 Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-M… Phase3 Bladder Cancer Terminated 2011-07-01 2014-03-01 ClinicalTrials.gov
NCT01501799 A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl … Na Acne Vulgaris Completed 2011-07-01 2011-12-01 ClinicalTrials.gov
NCT01384851 Efficacy of the Chronic Application of Tear Formulations Na Dry Eye Unknown 2011-07-01 2011-11-01 ClinicalTrials.gov
NCT01501799 A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl … Na Acne Vulgaris Completed 2011-07-01 2011-12-01 ClinicalTrials.gov
NCT01391286 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy… Phase3 Eyelash Hypotrichosis Completed 2011-07-01 2012-05-25 ClinicalTrials.gov
NCT02020512 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma an… Phase4 Glaucoma, Open-Angle Completed 2011-07-01 2012-12-01 ClinicalTrials.gov
NCT01412021 Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Ar… — Arthritis, Juvenile Rheumatoid Completed 2011-07-01 2018-04-02 ClinicalTrials.gov
NCT01391273 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypo… Phase3 Eyelash Hypotrichosis Completed 2011-07-01 2012-05-19 ClinicalTrials.gov
NCT01401478 Observational Program of Zemplar in Patients With End Stage Chronic Kidney Dise… — Secondary Hyperparathyroidism Completed 2011-07-01 2013-01-01 ClinicalTrials.gov
NCT01282203 Evaluation of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevoran… — Anesthesia, General Completed 2011-07-01 2011-11-01 ClinicalTrials.gov
NCT01411696 Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for R… — Retinal Vein Occlusion Completed 2011-07-01 2012-03-01 ClinicalTrials.gov
NCT01410565 Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-M… Phase3 Bladder Cancer Terminated 2011-07-01 2014-03-01 ClinicalTrials.gov
NCT01391286 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy… Phase3 Eyelash Hypotrichosis Completed 2011-07-01 2012-05-25 ClinicalTrials.gov
NCT01401478 Observational Program of Zemplar in Patients With End Stage Chronic Kidney Dise… — Secondary Hyperparathyroidism Completed 2011-07-01 2013-01-01 ClinicalTrials.gov
NCT01391286 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy… Phase3 Eyelash Hypotrichosis Completed 2011-07-01 2012-05-25 ClinicalTrials.gov
NCT01149291 A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialy… — Secondary Hyperparathyroidism Completed 2011-07-01 2014-12-01 ClinicalTrials.gov
NCT01501799 A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl … Na Acne Vulgaris Completed 2011-07-01 2011-12-01 ClinicalTrials.gov
NCT01282203 Evaluation of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevoran… — Anesthesia, General Completed 2011-07-01 2011-11-01 ClinicalTrials.gov
NCT01391273 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypo… Phase3 Eyelash Hypotrichosis Completed 2011-07-01 2012-05-19 ClinicalTrials.gov
NCT01412021 Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Ar… — Arthritis, Juvenile Rheumatoid Completed 2011-07-01 2018-04-02 ClinicalTrials.gov
NCT01411696 Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for R… — Retinal Vein Occlusion Completed 2011-07-01 2012-03-01 ClinicalTrials.gov
NCT02020512 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma an… Phase4 Glaucoma, Open-Angle Completed 2011-07-01 2012-12-01 ClinicalTrials.gov
NCT02020512 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma an… Phase4 Glaucoma, Open-Angle Completed 2011-07-01 2012-12-01 ClinicalTrials.gov
NCT02020512 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma an… Phase4 Glaucoma, Open-Angle Completed 2011-07-01 2012-12-01 ClinicalTrials.gov
NCT01391273 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypo… Phase3 Eyelash Hypotrichosis Completed 2011-07-01 2012-05-19 ClinicalTrials.gov
NCT01387802 Canadian Humira Post Marketing Observational Epidemiological Study: Assessing E… — Ankylosing Spondylitis Completed 2011-06-29 2019-12-16 ClinicalTrials.gov
NCT01387802 Canadian Humira Post Marketing Observational Epidemiological Study: Assessing E… — Ankylosing Spondylitis Completed 2011-06-29 2019-12-16 ClinicalTrials.gov
NCT01387802 Canadian Humira Post Marketing Observational Epidemiological Study: Assessing E… — Ankylosing Spondylitis Completed 2011-06-29 2019-12-16 ClinicalTrials.gov
NCT01387802 Canadian Humira Post Marketing Observational Epidemiological Study: Assessing E… — Ankylosing Spondylitis Completed 2011-06-29 2019-12-16 ClinicalTrials.gov
NCT01386684 Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian… — Prostate Cancer Completed 2011-06-28 2016-09-08 ClinicalTrials.gov
NCT01386684 Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian… — Prostate Cancer Completed 2011-06-28 2016-09-08 ClinicalTrials.gov
NCT01386684 Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian… — Prostate Cancer Completed 2011-06-28 2016-09-08 ClinicalTrials.gov
NCT01386684 Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian… — Prostate Cancer Completed 2011-06-28 2016-09-08 ClinicalTrials.gov
NCT01239797 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to… Phase3 Lymphoma Completed 2011-06-20 2021-04-21 ClinicalTrials.gov
NCT01239797 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to… Phase3 Lymphoma Completed 2011-06-20 2021-04-21 ClinicalTrials.gov
NCT01239797 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to… Phase3 Lymphoma Completed 2011-06-20 2021-04-21 ClinicalTrials.gov
NCT01239797 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to… Phase3 Lymphoma Completed 2011-06-20 2021-04-21 ClinicalTrials.gov
NCT01391299 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehe… Na Facial Rhytides Completed 2011-06-01 2012-02-28 ClinicalTrials.gov
NCT01325337 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgeni… Phase2 Alopecia Completed 2011-06-01 2012-09-01 ClinicalTrials.gov
NCT01346488 Special Investigation in Patients With Rheumatoid Arthritis (Working Productivi… — Rheumatoid Arthritis Completed 2011-06-01 2016-01-01 ClinicalTrials.gov
NCT01403038 An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females Phase1 Folliculogenesis Completed 2011-06-01 2012-11-01 ClinicalTrials.gov
NCT01364922 Phase 2 Chronic Low Back Pain Study Phase2 Chronic Low Back Pain Completed 2011-06-01 2011-10-01 ClinicalTrials.gov
NCT01328158 Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patien… — Human Immunodeficiency Virus Infection Completed 2011-06-01 2013-12-01 ClinicalTrials.gov
NCT01364922 Phase 2 Chronic Low Back Pain Study Phase2 Chronic Low Back Pain Completed 2011-06-01 2011-10-01 ClinicalTrials.gov
NCT01391312 Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to S… Phase4 Glabellar Frown Lines Completed 2011-06-01 2011-10-01 ClinicalTrials.gov
NCT01325337 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgeni… Phase2 Alopecia Completed 2011-06-01 2012-09-01 ClinicalTrials.gov
NCT01325350 Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female … Phase2 Alopecia Completed 2011-06-01 2012-09-01 ClinicalTrials.gov
NCT01328158 Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patien… — Human Immunodeficiency Virus Infection Completed 2011-06-01 2013-12-01 ClinicalTrials.gov
NCT01413893 An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastat… Phase1 Advanced Solid Tumors Completed 2011-06-01 2012-06-01 ClinicalTrials.gov
NCT01391299 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehe… Na Facial Rhytides Completed 2011-06-01 2012-02-28 ClinicalTrials.gov
NCT01403038 An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females Phase1 Folliculogenesis Completed 2011-06-01 2012-11-01 ClinicalTrials.gov
NCT01380704 Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder Phase1 Major Depressive Disorder Completed 2011-06-01 2011-09-01 ClinicalTrials.gov
NCT01325350 Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female … Phase2 Alopecia Completed 2011-06-01 2012-09-01 ClinicalTrials.gov
NCT01413893 An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastat… Phase1 Advanced Solid Tumors Completed 2011-06-01 2012-06-01 ClinicalTrials.gov
NCT01413893 An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastat… Phase1 Advanced Solid Tumors Completed 2011-06-01 2012-06-01 ClinicalTrials.gov
NCT01387074 Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spas… — Muscle Spasticity Completed 2011-06-01 2013-01-01 ClinicalTrials.gov
NCT01383005 Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) — Human Immunodeficiency Virus Infection Completed 2011-06-01 2011-12-01 ClinicalTrials.gov
NCT01380704 Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder Phase1 Major Depressive Disorder Completed 2011-06-01 2011-09-01 ClinicalTrials.gov
NCT01391312 Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to S… Phase4 Glabellar Frown Lines Completed 2011-06-01 2011-10-01 ClinicalTrials.gov
NCT01364922 Phase 2 Chronic Low Back Pain Study Phase2 Chronic Low Back Pain Completed 2011-06-01 2011-10-01 ClinicalTrials.gov
NCT01413893 An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastat… Phase1 Advanced Solid Tumors Completed 2011-06-01 2012-06-01 ClinicalTrials.gov
NCT01328158 Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patien… — Human Immunodeficiency Virus Infection Completed 2011-06-01 2013-12-01 ClinicalTrials.gov
NCT01328158 Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patien… — Human Immunodeficiency Virus Infection Completed 2011-06-01 2013-12-01 ClinicalTrials.gov
NCT01325350 Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female … Phase2 Alopecia Completed 2011-06-01 2012-09-01 ClinicalTrials.gov
NCT01325337 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgeni… Phase2 Alopecia Completed 2011-06-01 2012-09-01 ClinicalTrials.gov
NCT01391299 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehe… Na Facial Rhytides Completed 2011-06-01 2012-02-28 ClinicalTrials.gov
NCT01346488 Special Investigation in Patients With Rheumatoid Arthritis (Working Productivi… — Rheumatoid Arthritis Completed 2011-06-01 2016-01-01 ClinicalTrials.gov
NCT01380704 Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder Phase1 Major Depressive Disorder Completed 2011-06-01 2011-09-01 ClinicalTrials.gov
NCT01383005 Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) — Human Immunodeficiency Virus Infection Completed 2011-06-01 2011-12-01 ClinicalTrials.gov
NCT01391299 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehe… Na Facial Rhytides Completed 2011-06-01 2012-02-28 ClinicalTrials.gov
NCT01383005 Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) — Human Immunodeficiency Virus Infection Completed 2011-06-01 2011-12-01 ClinicalTrials.gov
NCT01325337 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgeni… Phase2 Alopecia Completed 2011-06-01 2012-09-01 ClinicalTrials.gov
NCT01325350 Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female … Phase2 Alopecia Completed 2011-06-01 2012-09-01 ClinicalTrials.gov
NCT01380704 Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder Phase1 Major Depressive Disorder Completed 2011-06-01 2011-09-01 ClinicalTrials.gov
NCT01346488 Special Investigation in Patients With Rheumatoid Arthritis (Working Productivi… — Rheumatoid Arthritis Completed 2011-06-01 2016-01-01 ClinicalTrials.gov
NCT01364922 Phase 2 Chronic Low Back Pain Study Phase2 Chronic Low Back Pain Completed 2011-06-01 2011-10-01 ClinicalTrials.gov
NCT01391312 Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to S… Phase4 Glabellar Frown Lines Completed 2011-06-01 2011-10-01 ClinicalTrials.gov
NCT01403038 An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females Phase1 Folliculogenesis Completed 2011-06-01 2012-11-01 ClinicalTrials.gov
NCT01383005 Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) — Human Immunodeficiency Virus Infection Completed 2011-06-01 2011-12-01 ClinicalTrials.gov
NCT01391312 Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to S… Phase4 Glabellar Frown Lines Completed 2011-06-01 2011-10-01 ClinicalTrials.gov
NCT01387074 Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spas… — Muscle Spasticity Completed 2011-06-01 2013-01-01 ClinicalTrials.gov
NCT01387074 Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spas… — Muscle Spasticity Completed 2011-06-01 2013-01-01 ClinicalTrials.gov
NCT01387074 Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spas… — Muscle Spasticity Completed 2011-06-01 2013-01-01 ClinicalTrials.gov
NCT01346488 Special Investigation in Patients With Rheumatoid Arthritis (Working Productivi… — Rheumatoid Arthritis Completed 2011-06-01 2016-01-01 ClinicalTrials.gov
NCT01403038 An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females Phase1 Folliculogenesis Completed 2011-06-01 2012-11-01 ClinicalTrials.gov
NCT01298700 Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma o… Phase4 Glaucoma Completed 2011-05-31 2016-12-06 ClinicalTrials.gov
NCT01298700 Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma o… Phase4 Glaucoma Completed 2011-05-31 2016-12-06 ClinicalTrials.gov
NCT01298700 Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma o… Phase4 Glaucoma Completed 2011-05-31 2016-12-06 ClinicalTrials.gov
NCT01298700 Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma o… Phase4 Glaucoma Completed 2011-05-31 2016-12-06 ClinicalTrials.gov
NCT01328626 A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjec… Phase1 Chronic Lymphocytic Leukemia Completed 2011-05-23 2020-05-08 ClinicalTrials.gov
NCT01328626 A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjec… Phase1 Chronic Lymphocytic Leukemia Completed 2011-05-23 2020-05-08 ClinicalTrials.gov
NCT01328626 A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjec… Phase1 Chronic Lymphocytic Leukemia Completed 2011-05-23 2020-05-08 ClinicalTrials.gov
NCT01328626 A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjec… Phase1 Chronic Lymphocytic Leukemia Completed 2011-05-23 2020-05-08 ClinicalTrials.gov
NCT01192568 Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neuro… Phase4 Overactive Detrusor Completed 2011-05-17 2023-10-24 ClinicalTrials.gov
NCT01192568 Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neuro… Phase4 Overactive Detrusor Completed 2011-05-17 2023-10-24 ClinicalTrials.gov
NCT01192568 Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neuro… Phase4 Overactive Detrusor Completed 2011-05-17 2023-10-24 ClinicalTrials.gov
NCT01192568 Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neuro… Phase4 Overactive Detrusor Completed 2011-05-17 2023-10-24 ClinicalTrials.gov
NCT01339650 Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 a… Phase1 Fallopian Tube Completed 2011-05-06 2017-11-30 ClinicalTrials.gov
NCT01339650 Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 a… Phase1 Fallopian Tube Completed 2011-05-06 2017-11-30 ClinicalTrials.gov
NCT01339650 Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 a… Phase1 Fallopian Tube Completed 2011-05-06 2017-11-30 ClinicalTrials.gov
NCT01339650 Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 a… Phase1 Fallopian Tube Completed 2011-05-06 2017-11-30 ClinicalTrials.gov
NCT01294384 Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in P… Phase3 Dry Eye Syndromes Completed 2011-05-01 2012-09-25 ClinicalTrials.gov
NCT01328366 Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Follo… — Psoriasis Completed 2011-05-01 2014-05-01 ClinicalTrials.gov
NCT01294384 Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in P… Phase3 Dry Eye Syndromes Completed 2011-05-01 2012-09-25 ClinicalTrials.gov
NCT01751373 Assessment and Management of Post-Stroke Spasticity With Botulinum Toxin-A Na Stroke Completed 2011-05-01 2014-11-01 ClinicalTrials.gov
NCT01341782 Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol I… Phase3 Secondary Hyperparathyroidism Completed 2011-05-01 2012-04-01 ClinicalTrials.gov
NCT01224015 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's… Phase3 Facial Rhytides Completed 2011-05-01 2012-02-01 ClinicalTrials.gov
NCT01341782 Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol I… Phase3 Secondary Hyperparathyroidism Completed 2011-05-01 2012-04-01 ClinicalTrials.gov
NCT01328366 Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Follo… — Psoriasis Completed 2011-05-01 2014-05-01 ClinicalTrials.gov
NCT01294384 Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in P… Phase3 Dry Eye Syndromes Completed 2011-05-01 2012-09-25 ClinicalTrials.gov
NCT01224015 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's… Phase3 Facial Rhytides Completed 2011-05-01 2012-02-01 ClinicalTrials.gov
NCT01751373 Assessment and Management of Post-Stroke Spasticity With Botulinum Toxin-A Na Stroke Completed 2011-05-01 2014-11-01 ClinicalTrials.gov
NCT01224015 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's… Phase3 Facial Rhytides Completed 2011-05-01 2012-02-01 ClinicalTrials.gov
NCT01751373 Assessment and Management of Post-Stroke Spasticity With Botulinum Toxin-A Na Stroke Completed 2011-05-01 2014-11-01 ClinicalTrials.gov
NCT01224015 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's… Phase3 Facial Rhytides Completed 2011-05-01 2012-02-01 ClinicalTrials.gov
NCT01751373 Assessment and Management of Post-Stroke Spasticity With Botulinum Toxin-A Na Stroke Completed 2011-05-01 2014-11-01 ClinicalTrials.gov
NCT01294384 Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in P… Phase3 Dry Eye Syndromes Completed 2011-05-01 2012-09-25 ClinicalTrials.gov
NCT01341782 Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol I… Phase3 Secondary Hyperparathyroidism Completed 2011-05-01 2012-04-01 ClinicalTrials.gov
NCT01328366 Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Follo… — Psoriasis Completed 2011-05-01 2014-05-01 ClinicalTrials.gov
NCT01341782 Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol I… Phase3 Secondary Hyperparathyroidism Completed 2011-05-01 2012-04-01 ClinicalTrials.gov
NCT01328366 Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Follo… — Psoriasis Completed 2011-05-01 2014-05-01 ClinicalTrials.gov
NCT01291108 Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost… Phase2 Glaucoma, Open-Angle Completed 2011-04-01 2011-10-01 ClinicalTrials.gov
NCT01333722 Acute Pain Study Following Bunionectomy Phase2 Pain Completed 2011-04-01 2011-06-01 ClinicalTrials.gov
NCT01608659 An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinu… — Facial Rhytides Completed 2011-04-01 2011-06-17 ClinicalTrials.gov
NCT01608659 An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinu… — Facial Rhytides Completed 2011-04-01 2011-06-17 ClinicalTrials.gov
NCT01346501 Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study)… — Rheumatoid Arthritis Completed 2011-04-01 2014-11-01 ClinicalTrials.gov
NCT01333722 Acute Pain Study Following Bunionectomy Phase2 Pain Completed 2011-04-01 2011-06-01 ClinicalTrials.gov
NCT01333722 Acute Pain Study Following Bunionectomy Phase2 Pain Completed 2011-04-01 2011-06-01 ClinicalTrials.gov
NCT01608659 An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinu… — Facial Rhytides Completed 2011-04-01 2011-06-17 ClinicalTrials.gov
NCT01346501 Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study)… — Rheumatoid Arthritis Completed 2011-04-01 2014-11-01 ClinicalTrials.gov
NCT01316224 Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic A… — Psoriasis Completed 2011-04-01 2014-04-01 ClinicalTrials.gov
NCT01291108 Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost… Phase2 Glaucoma, Open-Angle Completed 2011-04-01 2011-10-01 ClinicalTrials.gov
NCT01346501 Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study)… — Rheumatoid Arthritis Completed 2011-04-01 2014-11-01 ClinicalTrials.gov
NCT01316224 Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic A… — Psoriasis Completed 2011-04-01 2014-04-01 ClinicalTrials.gov
NCT01608659 An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinu… — Facial Rhytides Completed 2011-04-01 2011-06-17 ClinicalTrials.gov
NCT01333722 Acute Pain Study Following Bunionectomy Phase2 Pain Completed 2011-04-01 2011-06-01 ClinicalTrials.gov
NCT01291108 Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost… Phase2 Glaucoma, Open-Angle Completed 2011-04-01 2011-10-01 ClinicalTrials.gov
NCT01291108 Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost… Phase2 Glaucoma, Open-Angle Completed 2011-04-01 2011-10-01 ClinicalTrials.gov
NCT01346501 Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study)… — Rheumatoid Arthritis Completed 2011-04-01 2014-11-01 ClinicalTrials.gov
NCT01316224 Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic A… — Psoriasis Completed 2011-04-01 2014-04-01 ClinicalTrials.gov
NCT01316224 Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic A… — Psoriasis Completed 2011-04-01 2014-04-01 ClinicalTrials.gov
NCT01335126 Comparison of Tolerability and Clinical Performance of Two Emulsion-type Artifi… Phase3 Dry Eye Unknown 2011-03-01 2011-11-01 ClinicalTrials.gov
NCT01320293 Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab. Na Psoriasis Completed 2011-03-01 2015-03-01 ClinicalTrials.gov
NCT01314261 Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected… Phase2 Chronic Hepatitis C Completed 2011-03-01 2013-02-01 ClinicalTrials.gov
NCT01321424 Diurnal Variation in Tear Osmolarity — Dry Eye Disease Completed 2011-03-01 2016-03-01 ClinicalTrials.gov
NCT01319318 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana … — Vitrectomy Completed 2011-03-01 2012-06-01 ClinicalTrials.gov
NCT01744158 Exploring Hypertonia in Children With Cerebral Palsy — Cerebral Palsy. Unknown 2011-03-01 2014-01-01 ClinicalTrials.gov
NCT01387906 Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosi… Phase4 Hypotrichosis Completed 2011-03-01 2012-06-01 ClinicalTrials.gov
NCT01241240 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open… Phase3 Glaucoma, Open-Angle Completed 2011-03-01 2013-09-01 ClinicalTrials.gov
NCT01314261 Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected… Phase2 Chronic Hepatitis C Completed 2011-03-01 2013-02-01 ClinicalTrials.gov
NCT01241240 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open… Phase3 Glaucoma, Open-Angle Completed 2011-03-01 2013-09-01 ClinicalTrials.gov
NCT01314261 Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected… Phase2 Chronic Hepatitis C Completed 2011-03-01 2013-02-01 ClinicalTrials.gov
NCT01387906 Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosi… Phase4 Hypotrichosis Completed 2011-03-01 2012-06-01 ClinicalTrials.gov
NCT01241240 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open… Phase3 Glaucoma, Open-Angle Completed 2011-03-01 2013-09-01 ClinicalTrials.gov
NCT01744158 Exploring Hypertonia in Children With Cerebral Palsy — Cerebral Palsy. Unknown 2011-03-01 2014-01-01 ClinicalTrials.gov
NCT01282372 Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases … — Rheumatoid Arthritis Completed 2011-03-01 2014-07-01 ClinicalTrials.gov
NCT01387906 Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosi… Phase4 Hypotrichosis Completed 2011-03-01 2012-06-01 ClinicalTrials.gov
NCT01356758 Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With B… — Psoriasis Completed 2011-03-01 2015-11-01 ClinicalTrials.gov
NCT01744158 Exploring Hypertonia in Children With Cerebral Palsy — Cerebral Palsy. Unknown 2011-03-01 2014-01-01 ClinicalTrials.gov
NCT01320293 Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab. Na Psoriasis Completed 2011-03-01 2015-03-01 ClinicalTrials.gov
NCT01321424 Diurnal Variation in Tear Osmolarity — Dry Eye Disease Completed 2011-03-01 2016-03-01 ClinicalTrials.gov
NCT01356758 Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With B… — Psoriasis Completed 2011-03-01 2015-11-01 ClinicalTrials.gov
NCT01339936 Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of … Phase2 Dry Eye Syndrome Completed 2011-03-01 2012-05-01 ClinicalTrials.gov
NCT01335126 Comparison of Tolerability and Clinical Performance of Two Emulsion-type Artifi… Phase3 Dry Eye Unknown 2011-03-01 2011-11-01 ClinicalTrials.gov
NCT01319318 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana … — Vitrectomy Completed 2011-03-01 2012-06-01 ClinicalTrials.gov
NCT01321424 Diurnal Variation in Tear Osmolarity — Dry Eye Disease Completed 2011-03-01 2016-03-01 ClinicalTrials.gov
NCT01282372 Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases … — Rheumatoid Arthritis Completed 2011-03-01 2014-07-01 ClinicalTrials.gov
NCT01319318 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana … — Vitrectomy Completed 2011-03-01 2012-06-01 ClinicalTrials.gov
NCT01282372 Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases … — Rheumatoid Arthritis Completed 2011-03-01 2014-07-01 ClinicalTrials.gov
NCT01320293 Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab. Na Psoriasis Completed 2011-03-01 2015-03-01 ClinicalTrials.gov
NCT01319318 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana … — Vitrectomy Completed 2011-03-01 2012-06-01 ClinicalTrials.gov
NCT01282372 Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases … — Rheumatoid Arthritis Completed 2011-03-01 2014-07-01 ClinicalTrials.gov
NCT01321424 Diurnal Variation in Tear Osmolarity — Dry Eye Disease Completed 2011-03-01 2016-03-01 ClinicalTrials.gov
NCT01241240 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open… Phase3 Glaucoma, Open-Angle Completed 2011-03-01 2013-09-01 ClinicalTrials.gov
NCT01320293 Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab. Na Psoriasis Completed 2011-03-01 2015-03-01 ClinicalTrials.gov
NCT01339936 Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of … Phase2 Dry Eye Syndrome Completed 2011-03-01 2012-05-01 ClinicalTrials.gov
NCT01335126 Comparison of Tolerability and Clinical Performance of Two Emulsion-type Artifi… Phase3 Dry Eye Unknown 2011-03-01 2011-11-01 ClinicalTrials.gov
NCT01339936 Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of … Phase2 Dry Eye Syndrome Completed 2011-03-01 2012-05-01 ClinicalTrials.gov
NCT01356758 Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With B… — Psoriasis Completed 2011-03-01 2015-11-01 ClinicalTrials.gov
NCT01744158 Exploring Hypertonia in Children With Cerebral Palsy — Cerebral Palsy. Unknown 2011-03-01 2014-01-01 ClinicalTrials.gov
NCT01356758 Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With B… — Psoriasis Completed 2011-03-01 2015-11-01 ClinicalTrials.gov
NCT01387906 Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosi… Phase4 Hypotrichosis Completed 2011-03-01 2012-06-01 ClinicalTrials.gov
NCT01339936 Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of … Phase2 Dry Eye Syndrome Completed 2011-03-01 2012-05-01 ClinicalTrials.gov
NCT01335126 Comparison of Tolerability and Clinical Performance of Two Emulsion-type Artifi… Phase3 Dry Eye Unknown 2011-03-01 2011-11-01 ClinicalTrials.gov
NCT01314261 Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected… Phase2 Chronic Hepatitis C Completed 2011-03-01 2013-02-01 ClinicalTrials.gov
NCT01294371 Observational Program to Assess Routine Use of Add-back Therapy in Patients Wit… — Genital Endometriosis Completed 2011-02-01 2012-05-01 ClinicalTrials.gov
NCT01320735 Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therap… — Prostate Cancer Completed 2011-02-01 2014-05-01 ClinicalTrials.gov
NCT01265992 Study to Assess Patient Management Practices and Quality of Life With Paricalci… — Secondary Hyperparathyroidism Completed 2011-02-01 2012-11-01 ClinicalTrials.gov
NCT01265992 Study to Assess Patient Management Practices and Quality of Life With Paricalci… — Secondary Hyperparathyroidism Completed 2011-02-01 2012-11-01 ClinicalTrials.gov
NCT01737853 Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican P… — Glaucoma Primary Open Angle Completed 2011-02-01 2012-06-01 ClinicalTrials.gov
NCT01502020 A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Crea… Na Actinic Keratoses Completed 2011-02-01 2011-11-01 ClinicalTrials.gov
NCT01737853 Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican P… — Glaucoma Primary Open Angle Completed 2011-02-01 2012-06-01 ClinicalTrials.gov
NCT01294371 Observational Program to Assess Routine Use of Add-back Therapy in Patients Wit… — Genital Endometriosis Completed 2011-02-01 2012-05-01 ClinicalTrials.gov
NCT01320735 Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therap… — Prostate Cancer Completed 2011-02-01 2014-05-01 ClinicalTrials.gov
NCT01502020 A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Crea… Na Actinic Keratoses Completed 2011-02-01 2011-11-01 ClinicalTrials.gov
NCT01383681 Retrospective Study of Patients With Spasticity in the Spanish Population — Muscle Spasticity Completed 2011-02-01 2012-10-01 ClinicalTrials.gov
NCT01265992 Study to Assess Patient Management Practices and Quality of Life With Paricalci… — Secondary Hyperparathyroidism Completed 2011-02-01 2012-11-01 ClinicalTrials.gov
NCT01502020 A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Crea… Na Actinic Keratoses Completed 2011-02-01 2011-11-01 ClinicalTrials.gov
NCT01383681 Retrospective Study of Patients With Spasticity in the Spanish Population — Muscle Spasticity Completed 2011-02-01 2012-10-01 ClinicalTrials.gov
NCT01320735 Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therap… — Prostate Cancer Completed 2011-02-01 2014-05-01 ClinicalTrials.gov
NCT01294371 Observational Program to Assess Routine Use of Add-back Therapy in Patients Wit… — Genital Endometriosis Completed 2011-02-01 2012-05-01 ClinicalTrials.gov
NCT01737853 Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican P… — Glaucoma Primary Open Angle Completed 2011-02-01 2012-06-01 ClinicalTrials.gov
NCT01383681 Retrospective Study of Patients With Spasticity in the Spanish Population — Muscle Spasticity Completed 2011-02-01 2012-10-01 ClinicalTrials.gov
NCT01294371 Observational Program to Assess Routine Use of Add-back Therapy in Patients Wit… — Genital Endometriosis Completed 2011-02-01 2012-05-01 ClinicalTrials.gov
NCT01265992 Study to Assess Patient Management Practices and Quality of Life With Paricalci… — Secondary Hyperparathyroidism Completed 2011-02-01 2012-11-01 ClinicalTrials.gov
NCT01383681 Retrospective Study of Patients With Spasticity in the Spanish Population — Muscle Spasticity Completed 2011-02-01 2012-10-01 ClinicalTrials.gov
NCT01737853 Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican P… — Glaucoma Primary Open Angle Completed 2011-02-01 2012-06-01 ClinicalTrials.gov
NCT01320735 Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therap… — Prostate Cancer Completed 2011-02-01 2014-05-01 ClinicalTrials.gov
NCT01502020 A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Crea… Na Actinic Keratoses Completed 2011-02-01 2011-11-01 ClinicalTrials.gov
NCT01373424 The Dystonia Coalition Natural History and Biospecimen Repository for Isolated … — Dystonia Completed 2011-01-01 2020-09-30 ClinicalTrials.gov
NCT01217606 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open… Phase3 Glaucoma, Open-Angle Completed 2011-01-01 2015-06-01 ClinicalTrials.gov
NCT01284478 Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Ed… Phase2 Pseudophakic Cystoid Macular Edema, Completed 2011-01-01 2012-10-01 ClinicalTrials.gov
NCT01273597 Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Z… — Kidney Failure, Chronic Completed 2011-01-01 2011-11-01 ClinicalTrials.gov
NCT01273519 Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and … — Rheumatoid Arthritis Completed 2011-01-01 2013-01-01 ClinicalTrials.gov
NCT01272414 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Phase4 Graves Ophthalmopathy Withdrawn 2011-01-01 2012-02-01 ClinicalTrials.gov
NCT01217606 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open… Phase3 Glaucoma, Open-Angle Completed 2011-01-01 2015-06-01 ClinicalTrials.gov
NCT01373424 The Dystonia Coalition Natural History and Biospecimen Repository for Isolated … — Dystonia Completed 2011-01-01 2020-09-30 ClinicalTrials.gov
NCT02922179 Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics — Diabetes Completed 2011-01-01 2019-01-01 ClinicalTrials.gov
NCT01272414 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Phase4 Graves Ophthalmopathy Withdrawn 2011-01-01 2012-02-01 ClinicalTrials.gov
NCT01273519 Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and … — Rheumatoid Arthritis Completed 2011-01-01 2013-01-01 ClinicalTrials.gov
NCT01273597 Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Z… — Kidney Failure, Chronic Completed 2011-01-01 2011-11-01 ClinicalTrials.gov
NCT01284478 Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Ed… Phase2 Pseudophakic Cystoid Macular Edema, Completed 2011-01-01 2012-10-01 ClinicalTrials.gov
NCT01373424 The Dystonia Coalition Natural History and Biospecimen Repository for Isolated … — Dystonia Completed 2011-01-01 2020-09-30 ClinicalTrials.gov
NCT01217606 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open… Phase3 Glaucoma, Open-Angle Completed 2011-01-01 2015-06-01 ClinicalTrials.gov
NCT01284478 Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Ed… Phase2 Pseudophakic Cystoid Macular Edema, Completed 2011-01-01 2012-10-01 ClinicalTrials.gov
NCT01273597 Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Z… — Kidney Failure, Chronic Completed 2011-01-01 2011-11-01 ClinicalTrials.gov
NCT01273519 Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and … — Rheumatoid Arthritis Completed 2011-01-01 2013-01-01 ClinicalTrials.gov
NCT01272414 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Phase4 Graves Ophthalmopathy Withdrawn 2011-01-01 2012-02-01 ClinicalTrials.gov
NCT02922179 Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics — Diabetes Completed 2011-01-01 2019-01-01 ClinicalTrials.gov
NCT01217606 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open… Phase3 Glaucoma, Open-Angle Completed 2011-01-01 2015-06-01 ClinicalTrials.gov
NCT02922179 Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics — Diabetes Completed 2011-01-01 2019-01-01 ClinicalTrials.gov
NCT01272414 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Phase4 Graves Ophthalmopathy Withdrawn 2011-01-01 2012-02-01 ClinicalTrials.gov
NCT01273519 Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and … — Rheumatoid Arthritis Completed 2011-01-01 2013-01-01 ClinicalTrials.gov
NCT01273597 Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Z… — Kidney Failure, Chronic Completed 2011-01-01 2011-11-01 ClinicalTrials.gov
NCT01284478 Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Ed… Phase2 Pseudophakic Cystoid Macular Edema, Completed 2011-01-01 2012-10-01 ClinicalTrials.gov
NCT01373424 The Dystonia Coalition Natural History and Biospecimen Repository for Isolated … — Dystonia Completed 2011-01-01 2020-09-30 ClinicalTrials.gov
NCT02922179 Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics — Diabetes Completed 2011-01-01 2019-01-01 ClinicalTrials.gov
NCT00534339 EasyBand GOAL Trial Na Morbid Obesity Withdrawn 2010-12-01 2016-02-01 ClinicalTrials.gov
NCT01229410 Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System … Phase1 Vitrectomy Completed 2010-12-01 2011-10-01 ClinicalTrials.gov
NCT01229410 Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System … Phase1 Vitrectomy Completed 2010-12-01 2011-10-01 ClinicalTrials.gov
NCT01252147 Inter-rater and Intra-rater Reliability Study of the Global Eyelash Assessment … — Healthy Volunteers Completed 2010-12-01 2010-12-01 ClinicalTrials.gov
NCT01258309 Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthal… Phase3 Rhinitis, Allergic, Seasonal Completed 2010-12-01 2011-01-01 ClinicalTrials.gov
NCT01258309 Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthal… Phase3 Rhinitis, Allergic, Seasonal Completed 2010-12-01 2011-01-01 ClinicalTrials.gov
NCT00534339 EasyBand GOAL Trial Na Morbid Obesity Withdrawn 2010-12-01 2016-02-01 ClinicalTrials.gov
NCT01252147 Inter-rater and Intra-rater Reliability Study of the Global Eyelash Assessment … — Healthy Volunteers Completed 2010-12-01 2010-12-01 ClinicalTrials.gov
NCT01252147 Inter-rater and Intra-rater Reliability Study of the Global Eyelash Assessment … — Healthy Volunteers Completed 2010-12-01 2010-12-01 ClinicalTrials.gov
NCT00534339 EasyBand GOAL Trial Na Morbid Obesity Withdrawn 2010-12-01 2016-02-01 ClinicalTrials.gov
NCT01258309 Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthal… Phase3 Rhinitis, Allergic, Seasonal Completed 2010-12-01 2011-01-01 ClinicalTrials.gov
NCT01229410 Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System … Phase1 Vitrectomy Completed 2010-12-01 2011-10-01 ClinicalTrials.gov
NCT01252147 Inter-rater and Intra-rater Reliability Study of the Global Eyelash Assessment … — Healthy Volunteers Completed 2010-12-01 2010-12-01 ClinicalTrials.gov
NCT00534339 EasyBand GOAL Trial Na Morbid Obesity Withdrawn 2010-12-01 2016-02-01 ClinicalTrials.gov
NCT01258309 Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthal… Phase3 Rhinitis, Allergic, Seasonal Completed 2010-12-01 2011-01-01 ClinicalTrials.gov
NCT01229410 Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System … Phase1 Vitrectomy Completed 2010-12-01 2011-10-01 ClinicalTrials.gov
NCT01148225 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Int… Phase3 Uveitis Completed 2010-11-23 2018-05-21 ClinicalTrials.gov
NCT01148225 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Int… Phase3 Uveitis Completed 2010-11-23 2018-05-21 ClinicalTrials.gov
NCT01148225 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Int… Phase3 Uveitis Completed 2010-11-23 2018-05-21 ClinicalTrials.gov
NCT01148225 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Int… Phase3 Uveitis Completed 2010-11-23 2018-05-21 ClinicalTrials.gov
NCT01623479 An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) fo… — Eyelash Hypotrichosis Completed 2010-11-19 2011-09-01 ClinicalTrials.gov
NCT01623479 An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) fo… — Eyelash Hypotrichosis Completed 2010-11-19 2011-09-01 ClinicalTrials.gov
NCT01623479 An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) fo… — Eyelash Hypotrichosis Completed 2010-11-19 2011-09-01 ClinicalTrials.gov
NCT01623479 An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) fo… — Eyelash Hypotrichosis Completed 2010-11-19 2011-09-01 ClinicalTrials.gov
NCT01323829 EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Fl… Na High Tone Pelvic Floor Dysfunction Completed 2010-11-01 2013-12-01 ClinicalTrials.gov
NCT01319773 Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunt… Phase1 Dry Eye Syndromes Completed 2010-11-01 2011-01-01 ClinicalTrials.gov
NCT01298648 Special Investigation in Patients With Crohn's Disease (All Patients Investigat… — Crohn's Disease Completed 2010-11-01 2013-02-01 ClinicalTrials.gov
NCT01323829 EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Fl… Na High Tone Pelvic Floor Dysfunction Completed 2010-11-01 2013-12-01 ClinicalTrials.gov
NCT01156532 Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian… — Moderate to Severe Psoriasis Terminated 2010-11-01 2013-08-01 ClinicalTrials.gov
NCT01156532 Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian… — Moderate to Severe Psoriasis Terminated 2010-11-01 2013-08-01 ClinicalTrials.gov
NCT01298648 Special Investigation in Patients With Crohn's Disease (All Patients Investigat… — Crohn's Disease Completed 2010-11-01 2013-02-01 ClinicalTrials.gov
NCT01262339 BTX-A Treatment for Palmar Hyperhidrosis Phase2 Primary Focal Hyperhidrosis of the Hands Terminated 2010-11-01 2012-11-01 ClinicalTrials.gov
NCT01323829 EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Fl… Na High Tone Pelvic Floor Dysfunction Completed 2010-11-01 2013-12-01 ClinicalTrials.gov
NCT01319773 Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunt… Phase1 Dry Eye Syndromes Completed 2010-11-01 2011-01-01 ClinicalTrials.gov
NCT01319773 Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunt… Phase1 Dry Eye Syndromes Completed 2010-11-01 2011-01-01 ClinicalTrials.gov
NCT01156532 Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian… — Moderate to Severe Psoriasis Terminated 2010-11-01 2013-08-01 ClinicalTrials.gov
NCT01262339 BTX-A Treatment for Palmar Hyperhidrosis Phase2 Primary Focal Hyperhidrosis of the Hands Terminated 2010-11-01 2012-11-01 ClinicalTrials.gov
NCT01262339 BTX-A Treatment for Palmar Hyperhidrosis Phase2 Primary Focal Hyperhidrosis of the Hands Terminated 2010-11-01 2012-11-01 ClinicalTrials.gov
NCT01216943 Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or … Phase3 Glaucoma Completed 2010-11-01 2012-08-01 ClinicalTrials.gov
NCT01298648 Special Investigation in Patients With Crohn's Disease (All Patients Investigat… — Crohn's Disease Completed 2010-11-01 2013-02-01 ClinicalTrials.gov
NCT01262339 BTX-A Treatment for Palmar Hyperhidrosis Phase2 Primary Focal Hyperhidrosis of the Hands Terminated 2010-11-01 2012-11-01 ClinicalTrials.gov
NCT01216943 Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or … Phase3 Glaucoma Completed 2010-11-01 2012-08-01 ClinicalTrials.gov
NCT01216943 Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or … Phase3 Glaucoma Completed 2010-11-01 2012-08-01 ClinicalTrials.gov
NCT01298648 Special Investigation in Patients With Crohn's Disease (All Patients Investigat… — Crohn's Disease Completed 2010-11-01 2013-02-01 ClinicalTrials.gov
NCT01323829 EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Fl… Na High Tone Pelvic Floor Dysfunction Completed 2010-11-01 2013-12-01 ClinicalTrials.gov
NCT01319773 Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunt… Phase1 Dry Eye Syndromes Completed 2010-11-01 2011-01-01 ClinicalTrials.gov
NCT01156532 Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian… — Moderate to Severe Psoriasis Terminated 2010-11-01 2013-08-01 ClinicalTrials.gov
NCT01216943 Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or … Phase3 Glaucoma Completed 2010-11-01 2012-08-01 ClinicalTrials.gov
NCT01329380 Special Investigation in Patients With Ankylosing Spondylitis (All Patients Inv… — Ankylosing Spondylitis Completed 2010-10-27 2017-12-28 ClinicalTrials.gov
NCT01329380 Special Investigation in Patients With Ankylosing Spondylitis (All Patients Inv… — Ankylosing Spondylitis Completed 2010-10-27 2017-12-28 ClinicalTrials.gov
NCT01329380 Special Investigation in Patients With Ankylosing Spondylitis (All Patients Inv… — Ankylosing Spondylitis Completed 2010-10-27 2017-12-28 ClinicalTrials.gov
NCT01329380 Special Investigation in Patients With Ankylosing Spondylitis (All Patients Inv… — Ankylosing Spondylitis Completed 2010-10-27 2017-12-28 ClinicalTrials.gov
NCT01265823 Immediate Response With Adalimumab and Its Impact on Quality of Life and Other … Phase4 Psoriasis Completed 2010-10-01 2012-02-01 ClinicalTrials.gov
NCT01221298 A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiv… Phase2 Hepatitis C Completed 2010-10-01 2012-04-01 ClinicalTrials.gov
NCT01221298 A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiv… Phase2 Hepatitis C Completed 2010-10-01 2012-04-01 ClinicalTrials.gov
NCT01265823 Immediate Response With Adalimumab and Its Impact on Quality of Life and Other … Phase4 Psoriasis Completed 2010-10-01 2012-02-01 ClinicalTrials.gov
NCT01243671 A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease Phase3 Intestinal Behçet's Disease Completed 2010-10-01 2013-06-01 ClinicalTrials.gov
NCT01224782 Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyper… — Chronic Kidney Disease Completed 2010-10-01 2013-08-01 ClinicalTrials.gov
NCT01265823 Immediate Response With Adalimumab and Its Impact on Quality of Life and Other … Phase4 Psoriasis Completed 2010-10-01 2012-02-01 ClinicalTrials.gov
NCT01243671 A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease Phase3 Intestinal Behçet's Disease Completed 2010-10-01 2013-06-01 ClinicalTrials.gov
NCT01224782 Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyper… — Chronic Kidney Disease Completed 2010-10-01 2013-08-01 ClinicalTrials.gov
NCT01215786 Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared W… Phase1 Glaucoma, Open-Angle Completed 2010-10-01 2010-12-01 ClinicalTrials.gov
NCT01215786 Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared W… Phase1 Glaucoma, Open-Angle Completed 2010-10-01 2010-12-01 ClinicalTrials.gov
NCT01189279 Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients… Phase1 Alopecia Completed 2010-10-01 2011-02-01 ClinicalTrials.gov
NCT01177098 Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solu… Phase3 Glaucoma Completed 2010-10-01 2012-02-01 ClinicalTrials.gov
NCT01221298 A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiv… Phase2 Hepatitis C Completed 2010-10-01 2012-04-01 ClinicalTrials.gov
NCT01189279 Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients… Phase1 Alopecia Completed 2010-10-01 2011-02-01 ClinicalTrials.gov
NCT01177098 Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solu… Phase3 Glaucoma Completed 2010-10-01 2012-02-01 ClinicalTrials.gov
NCT01189279 Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients… Phase1 Alopecia Completed 2010-10-01 2011-02-01 ClinicalTrials.gov
NCT01215786 Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared W… Phase1 Glaucoma, Open-Angle Completed 2010-10-01 2010-12-01 ClinicalTrials.gov
NCT01224782 Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyper… — Chronic Kidney Disease Completed 2010-10-01 2013-08-01 ClinicalTrials.gov
NCT01243671 A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease Phase3 Intestinal Behçet's Disease Completed 2010-10-01 2013-06-01 ClinicalTrials.gov
NCT01221298 A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiv… Phase2 Hepatitis C Completed 2010-10-01 2012-04-01 ClinicalTrials.gov
NCT01177098 Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solu… Phase3 Glaucoma Completed 2010-10-01 2012-02-01 ClinicalTrials.gov
NCT01189279 Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients… Phase1 Alopecia Completed 2010-10-01 2011-02-01 ClinicalTrials.gov
NCT01177098 Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solu… Phase3 Glaucoma Completed 2010-10-01 2012-02-01 ClinicalTrials.gov
NCT01215786 Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared W… Phase1 Glaucoma, Open-Angle Completed 2010-10-01 2010-12-01 ClinicalTrials.gov
NCT01224782 Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyper… — Chronic Kidney Disease Completed 2010-10-01 2013-08-01 ClinicalTrials.gov
NCT01243671 A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease Phase3 Intestinal Behçet's Disease Completed 2010-10-01 2013-06-01 ClinicalTrials.gov
NCT01265823 Immediate Response With Adalimumab and Its Impact on Quality of Life and Other … Phase4 Psoriasis Completed 2010-10-01 2012-02-01 ClinicalTrials.gov
NCT01157364 Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients … Phase1 Open-Angle Glaucoma Completed 2010-09-23 2016-08-09 ClinicalTrials.gov
NCT01157364 Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients … Phase1 Open-Angle Glaucoma Completed 2010-09-23 2016-08-09 ClinicalTrials.gov
NCT01157364 Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients … Phase1 Open-Angle Glaucoma Completed 2010-09-23 2016-08-09 ClinicalTrials.gov
NCT01157364 Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients … Phase1 Open-Angle Glaucoma Completed 2010-09-23 2016-08-09 ClinicalTrials.gov
NCT01162421 A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure… Phase4 Rheumatoid Arthritis Completed 2010-09-01 2015-07-01 ClinicalTrials.gov
NCT01189760 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's… Phase3 Facial Rhytides Completed 2010-09-01 2011-09-01 ClinicalTrials.gov
NCT01225302 A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Ja… Phase1 Non-Small Cell Lung Cancer Completed 2010-09-01 2012-06-01 ClinicalTrials.gov
NCT01189760 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's… Phase3 Facial Rhytides Completed 2010-09-01 2011-09-01 ClinicalTrials.gov
NCT01185288 A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome … Phase4 Rheumatoid Arthritis Completed 2010-09-01 2013-01-01 ClinicalTrials.gov
NCT01166282 A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Ent… Phase3 Enthesitis Related Arthritis (ERA) Completed 2010-09-01 2015-12-01 ClinicalTrials.gov
NCT01185288 A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome … Phase4 Rheumatoid Arthritis Completed 2010-09-01 2013-01-01 ClinicalTrials.gov
NCT01225302 A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Ja… Phase1 Non-Small Cell Lung Cancer Completed 2010-09-01 2012-06-01 ClinicalTrials.gov
NCT01162421 A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure… Phase4 Rheumatoid Arthritis Completed 2010-09-01 2015-07-01 ClinicalTrials.gov
NCT01225302 A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Ja… Phase1 Non-Small Cell Lung Cancer Completed 2010-09-01 2012-06-01 ClinicalTrials.gov
NCT01166282 A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Ent… Phase3 Enthesitis Related Arthritis (ERA) Completed 2010-09-01 2015-12-01 ClinicalTrials.gov
NCT01271452 Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of… Phase4 Glabellar Lines Completed 2010-09-01 2011-04-01 ClinicalTrials.gov
NCT01166282 A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Ent… Phase3 Enthesitis Related Arthritis (ERA) Completed 2010-09-01 2015-12-01 ClinicalTrials.gov
NCT01202565 Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affect… — Moderate to Severe Plaque Psoriasis Completed 2010-09-01 2013-07-01 ClinicalTrials.gov
NCT01271452 Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of… Phase4 Glabellar Lines Completed 2010-09-01 2011-04-01 ClinicalTrials.gov
NCT01202565 Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affect… — Moderate to Severe Plaque Psoriasis Completed 2010-09-01 2013-07-01 ClinicalTrials.gov
NCT01162421 A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure… Phase4 Rheumatoid Arthritis Completed 2010-09-01 2015-07-01 ClinicalTrials.gov
NCT01225302 A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Ja… Phase1 Non-Small Cell Lung Cancer Completed 2010-09-01 2012-06-01 ClinicalTrials.gov
NCT01166282 A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Ent… Phase3 Enthesitis Related Arthritis (ERA) Completed 2010-09-01 2015-12-01 ClinicalTrials.gov
NCT01271452 Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of… Phase4 Glabellar Lines Completed 2010-09-01 2011-04-01 ClinicalTrials.gov
NCT01189760 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's… Phase3 Facial Rhytides Completed 2010-09-01 2011-09-01 ClinicalTrials.gov
NCT01185288 A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome … Phase4 Rheumatoid Arthritis Completed 2010-09-01 2013-01-01 ClinicalTrials.gov
NCT01202565 Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affect… — Moderate to Severe Plaque Psoriasis Completed 2010-09-01 2013-07-01 ClinicalTrials.gov
NCT01271452 Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of… Phase4 Glabellar Lines Completed 2010-09-01 2011-04-01 ClinicalTrials.gov
NCT01189760 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's… Phase3 Facial Rhytides Completed 2010-09-01 2011-09-01 ClinicalTrials.gov
NCT01185288 A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome … Phase4 Rheumatoid Arthritis Completed 2010-09-01 2013-01-01 ClinicalTrials.gov
NCT01202565 Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affect… — Moderate to Severe Plaque Psoriasis Completed 2010-09-01 2013-07-01 ClinicalTrials.gov
NCT01162421 A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure… Phase4 Rheumatoid Arthritis Completed 2010-09-01 2015-07-01 ClinicalTrials.gov
NCT01193231 A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorol… — Must be PRK Candidate Completed 2010-08-01 2011-04-01 ClinicalTrials.gov
NCT01191723 QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergota… Phase1 Healthy Completed 2010-08-01 2010-09-01 ClinicalTrials.gov
NCT01225341 Botulinum Toxin A for Herpes Labialis Na Herpes Labialis Terminated 2010-08-01 2012-06-01 ClinicalTrials.gov
NCT01087151 A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intens… Phase2 Chronic Lymphocytic Leukemia Completed 2010-08-01 2012-06-01 ClinicalTrials.gov
NCT01225341 Botulinum Toxin A for Herpes Labialis Na Herpes Labialis Terminated 2010-08-01 2012-06-01 ClinicalTrials.gov
NCT01197495 Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augment… Na Lip Augmentation Completed 2010-08-01 2015-06-15 ClinicalTrials.gov
NCT01193231 A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorol… — Must be PRK Candidate Completed 2010-08-01 2011-04-01 ClinicalTrials.gov
NCT01191723 QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergota… Phase1 Healthy Completed 2010-08-01 2010-09-01 ClinicalTrials.gov
NCT01122511 Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Su… Phase2 Subfoveal Choroidal Neovascularization Terminated 2010-08-01 2011-05-01 ClinicalTrials.gov
NCT01087151 A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intens… Phase2 Chronic Lymphocytic Leukemia Completed 2010-08-01 2012-06-01 ClinicalTrials.gov
NCT01176773 Safety and Effectiveness of Juvéderm® Ultra Lip Injectable Gel for Lip Enhancem… Na Lip Enhancement Completed 2010-08-01 2012-01-01 ClinicalTrials.gov
NCT01122511 Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Su… Phase2 Subfoveal Choroidal Neovascularization Terminated 2010-08-01 2011-05-01 ClinicalTrials.gov
NCT01087151 A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intens… Phase2 Chronic Lymphocytic Leukemia Completed 2010-08-01 2012-06-01 ClinicalTrials.gov
NCT01191723 QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergota… Phase1 Healthy Completed 2010-08-01 2010-09-01 ClinicalTrials.gov
NCT01087151 A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intens… Phase2 Chronic Lymphocytic Leukemia Completed 2010-08-01 2012-06-01 ClinicalTrials.gov
NCT01122511 Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Su… Phase2 Subfoveal Choroidal Neovascularization Terminated 2010-08-01 2011-05-01 ClinicalTrials.gov
NCT01193231 A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorol… — Must be PRK Candidate Completed 2010-08-01 2011-04-01 ClinicalTrials.gov
NCT01197495 Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augment… Na Lip Augmentation Completed 2010-08-01 2015-06-15 ClinicalTrials.gov
NCT01191723 QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergota… Phase1 Healthy Completed 2010-08-01 2010-09-01 ClinicalTrials.gov
NCT01193231 A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorol… — Must be PRK Candidate Completed 2010-08-01 2011-04-01 ClinicalTrials.gov
NCT01197495 Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augment… Na Lip Augmentation Completed 2010-08-01 2015-06-15 ClinicalTrials.gov
NCT01225341 Botulinum Toxin A for Herpes Labialis Na Herpes Labialis Terminated 2010-08-01 2012-06-01 ClinicalTrials.gov
NCT01176773 Safety and Effectiveness of Juvéderm® Ultra Lip Injectable Gel for Lip Enhancem… Na Lip Enhancement Completed 2010-08-01 2012-01-01 ClinicalTrials.gov
NCT01225341 Botulinum Toxin A for Herpes Labialis Na Herpes Labialis Terminated 2010-08-01 2012-06-01 ClinicalTrials.gov
NCT01176773 Safety and Effectiveness of Juvéderm® Ultra Lip Injectable Gel for Lip Enhancem… Na Lip Enhancement Completed 2010-08-01 2012-01-01 ClinicalTrials.gov
NCT01122511 Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Su… Phase2 Subfoveal Choroidal Neovascularization Terminated 2010-08-01 2011-05-01 ClinicalTrials.gov
NCT01176773 Safety and Effectiveness of Juvéderm® Ultra Lip Injectable Gel for Lip Enhancem… Na Lip Enhancement Completed 2010-08-01 2012-01-01 ClinicalTrials.gov
NCT01197495 Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augment… Na Lip Augmentation Completed 2010-08-01 2015-06-15 ClinicalTrials.gov
NCT01468558 Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconaz… Phase1 Healthy Completed 2010-07-01 2010-08-01 ClinicalTrials.gov
NCT01159743 A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Sin… — HIV Infection Completed 2010-07-01 2011-09-01 ClinicalTrials.gov
NCT01468558 Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconaz… Phase1 Healthy Completed 2010-07-01 2010-08-01 ClinicalTrials.gov
NCT01468558 Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconaz… Phase1 Healthy Completed 2010-07-01 2010-08-01 ClinicalTrials.gov
NCT01468558 Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconaz… Phase1 Healthy Completed 2010-07-01 2010-08-01 ClinicalTrials.gov
NCT01159743 A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Sin… — HIV Infection Completed 2010-07-01 2011-09-01 ClinicalTrials.gov
NCT01159743 A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Sin… — HIV Infection Completed 2010-07-01 2011-09-01 ClinicalTrials.gov
NCT01159743 A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Sin… — HIV Infection Completed 2010-07-01 2011-09-01 ClinicalTrials.gov
NCT01129531 A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic … Phase2 Neuralgia, Postherpetic Completed 2010-06-01 2012-01-01 ClinicalTrials.gov
NCT01134315 Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to… — Secondary Hyperparathyroidism Terminated 2010-06-01 2012-05-01 ClinicalTrials.gov
NCT01134315 Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to… — Secondary Hyperparathyroidism Terminated 2010-06-01 2012-05-01 ClinicalTrials.gov
NCT01129531 A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic … Phase2 Neuralgia, Postherpetic Completed 2010-06-01 2012-01-01 ClinicalTrials.gov
NCT01071096 Calcitonin Gene-related Peptide Levels in Chronic Migraine Phase4 Chronic Migraine Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01071096 Calcitonin Gene-related Peptide Levels in Chronic Migraine Phase4 Chronic Migraine Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01109056 Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primar… Phase2 Pterygium Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01109056 Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primar… Phase2 Pterygium Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01199224 To Determine the Food Effect and Bioavailability of Three Formulations of Velip… Phase1 Solid Tumors Completed 2010-06-01 2010-11-01 ClinicalTrials.gov
NCT01110499 Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost… Phase2 Ocular Hypertension Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01134315 Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to… — Secondary Hyperparathyroidism Terminated 2010-06-01 2012-05-01 ClinicalTrials.gov
NCT01243567 Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost… Phase4 Glaucoma, Open-Angle Completed 2010-06-01 2012-02-14 ClinicalTrials.gov
NCT01199224 To Determine the Food Effect and Bioavailability of Three Formulations of Velip… Phase1 Solid Tumors Completed 2010-06-01 2010-11-01 ClinicalTrials.gov
NCT01109056 Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primar… Phase2 Pterygium Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01110499 Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost… Phase2 Ocular Hypertension Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01023841 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotri… Phase4 Eyelash Hypotrichosis Completed 2010-06-01 2012-11-30 ClinicalTrials.gov
NCT01071096 Calcitonin Gene-related Peptide Levels in Chronic Migraine Phase4 Chronic Migraine Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01243567 Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost… Phase4 Glaucoma, Open-Angle Completed 2010-06-01 2012-02-14 ClinicalTrials.gov
NCT01023841 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotri… Phase4 Eyelash Hypotrichosis Completed 2010-06-01 2012-11-30 ClinicalTrials.gov
NCT01243567 Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost… Phase4 Glaucoma, Open-Angle Completed 2010-06-01 2012-02-14 ClinicalTrials.gov
NCT01129531 A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic … Phase2 Neuralgia, Postherpetic Completed 2010-06-01 2012-01-01 ClinicalTrials.gov
NCT01243567 Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost… Phase4 Glaucoma, Open-Angle Completed 2010-06-01 2012-02-14 ClinicalTrials.gov
NCT01199224 To Determine the Food Effect and Bioavailability of Three Formulations of Velip… Phase1 Solid Tumors Completed 2010-06-01 2010-11-01 ClinicalTrials.gov
NCT01071096 Calcitonin Gene-related Peptide Levels in Chronic Migraine Phase4 Chronic Migraine Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01023841 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotri… Phase4 Eyelash Hypotrichosis Completed 2010-06-01 2012-11-30 ClinicalTrials.gov
NCT01134315 Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to… — Secondary Hyperparathyroidism Terminated 2010-06-01 2012-05-01 ClinicalTrials.gov
NCT01129531 A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic … Phase2 Neuralgia, Postherpetic Completed 2010-06-01 2012-01-01 ClinicalTrials.gov
NCT01110499 Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost… Phase2 Ocular Hypertension Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01109056 Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primar… Phase2 Pterygium Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01199224 To Determine the Food Effect and Bioavailability of Three Formulations of Velip… Phase1 Solid Tumors Completed 2010-06-01 2010-11-01 ClinicalTrials.gov
NCT01023841 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotri… Phase4 Eyelash Hypotrichosis Completed 2010-06-01 2012-11-30 ClinicalTrials.gov
NCT01110499 Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost… Phase2 Ocular Hypertension Completed 2010-06-01 2011-06-01 ClinicalTrials.gov
NCT01177358 Botox in the Healing of Surgical Wounds of the Neck Phase2 Scar Completed 2010-05-31 2016-05-05 ClinicalTrials.gov
NCT01177358 Botox in the Healing of Surgical Wounds of the Neck Phase2 Scar Completed 2010-05-31 2016-05-05 ClinicalTrials.gov
NCT01177358 Botox in the Healing of Surgical Wounds of the Neck Phase2 Scar Completed 2010-05-31 2016-05-05 ClinicalTrials.gov
NCT01177358 Botox in the Healing of Surgical Wounds of the Neck Phase2 Scar Completed 2010-05-31 2016-05-05 ClinicalTrials.gov
NCT01628601 GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Wh… — Glaucoma, Open-Angle Completed 2010-05-01 2011-06-01 ClinicalTrials.gov
NCT01257906 Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.02… Na MILD TO SEVERE ACNE VULGARIS Completed 2010-05-01 2010-10-01 ClinicalTrials.gov
NCT01163617 The Usability and Injection Time of the Physiolis Syringe and Autoinjector in R… Phase2 Rheumatoid Arthritis Completed 2010-05-01 2010-11-01 ClinicalTrials.gov
NCT01130298 An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Sec… Phase1 Healthy Completed 2010-05-01 2010-05-01 ClinicalTrials.gov
NCT01628601 GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Wh… — Glaucoma, Open-Angle Completed 2010-05-01 2011-06-01 ClinicalTrials.gov
NCT01628601 GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Wh… — Glaucoma, Open-Angle Completed 2010-05-01 2011-06-01 ClinicalTrials.gov
NCT01121133 A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax Phase1 Lymphoma, Including Chronic Lymphocytic Leukemia Completed 2010-05-01 2011-05-01 ClinicalTrials.gov
NCT01161771 Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal … — Dry Eye Completed 2010-05-01 2010-12-01 ClinicalTrials.gov
NCT01257906 Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.02… Na MILD TO SEVERE ACNE VULGARIS Completed 2010-05-01 2010-10-01 ClinicalTrials.gov
NCT01161771 Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal … — Dry Eye Completed 2010-05-01 2010-12-01 ClinicalTrials.gov
NCT01099774 Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solutio… Phase3 Glaucoma Completed 2010-05-01 2011-04-29 ClinicalTrials.gov
NCT01064401 Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interfero… Phase3 Relapsing-Remitting Multiple Sclerosis Completed 2010-05-01 2014-07-01 ClinicalTrials.gov
NCT01121133 A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax Phase1 Lymphoma, Including Chronic Lymphocytic Leukemia Completed 2010-05-01 2011-05-01 ClinicalTrials.gov
NCT01130298 An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Sec… Phase1 Healthy Completed 2010-05-01 2010-05-01 ClinicalTrials.gov
NCT01133548 Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorptio… Phase1 Hypogonadism Completed 2010-05-01 2010-07-01 ClinicalTrials.gov
NCT01161771 Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal … — Dry Eye Completed 2010-05-01 2010-12-01 ClinicalTrials.gov
NCT01161771 Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal … — Dry Eye Completed 2010-05-01 2010-12-01 ClinicalTrials.gov
NCT01121133 A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax Phase1 Lymphoma, Including Chronic Lymphocytic Leukemia Completed 2010-05-01 2011-05-01 ClinicalTrials.gov
NCT01257906 Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.02… Na MILD TO SEVERE ACNE VULGARIS Completed 2010-05-01 2010-10-01 ClinicalTrials.gov
NCT01064401 Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interfero… Phase3 Relapsing-Remitting Multiple Sclerosis Completed 2010-05-01 2014-07-01 ClinicalTrials.gov
NCT01163617 The Usability and Injection Time of the Physiolis Syringe and Autoinjector in R… Phase2 Rheumatoid Arthritis Completed 2010-05-01 2010-11-01 ClinicalTrials.gov
NCT01130298 An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Sec… Phase1 Healthy Completed 2010-05-01 2010-05-01 ClinicalTrials.gov
NCT01099774 Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solutio… Phase3 Glaucoma Completed 2010-05-01 2011-04-29 ClinicalTrials.gov
NCT01130298 An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Sec… Phase1 Healthy Completed 2010-05-01 2010-05-01 ClinicalTrials.gov
NCT01163617 The Usability and Injection Time of the Physiolis Syringe and Autoinjector in R… Phase2 Rheumatoid Arthritis Completed 2010-05-01 2010-11-01 ClinicalTrials.gov
NCT01133548 Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorptio… Phase1 Hypogonadism Completed 2010-05-01 2010-07-01 ClinicalTrials.gov
NCT01628601 GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Wh… — Glaucoma, Open-Angle Completed 2010-05-01 2011-06-01 ClinicalTrials.gov
NCT01099774 Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solutio… Phase3 Glaucoma Completed 2010-05-01 2011-04-29 ClinicalTrials.gov
NCT01121133 A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax Phase1 Lymphoma, Including Chronic Lymphocytic Leukemia Completed 2010-05-01 2011-05-01 ClinicalTrials.gov
NCT01163617 The Usability and Injection Time of the Physiolis Syringe and Autoinjector in R… Phase2 Rheumatoid Arthritis Completed 2010-05-01 2010-11-01 ClinicalTrials.gov
NCT01099774 Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solutio… Phase3 Glaucoma Completed 2010-05-01 2011-04-29 ClinicalTrials.gov
NCT01133548 Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorptio… Phase1 Hypogonadism Completed 2010-05-01 2010-07-01 ClinicalTrials.gov
NCT01064401 Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interfero… Phase3 Relapsing-Remitting Multiple Sclerosis Completed 2010-05-01 2014-07-01 ClinicalTrials.gov
NCT01064401 Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interfero… Phase3 Relapsing-Remitting Multiple Sclerosis Completed 2010-05-01 2014-07-01 ClinicalTrials.gov
NCT01257906 Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.02… Na MILD TO SEVERE ACNE VULGARIS Completed 2010-05-01 2010-10-01 ClinicalTrials.gov
NCT01133548 Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorptio… Phase1 Hypogonadism Completed 2010-05-01 2010-07-01 ClinicalTrials.gov
NCT02061683 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocul… Phase4 Glaucoma, Open-Angle Completed 2010-04-19 2011-06-24 ClinicalTrials.gov
NCT02061683 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocul… Phase4 Glaucoma, Open-Angle Completed 2010-04-19 2011-06-24 ClinicalTrials.gov
NCT02061683 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocul… Phase4 Glaucoma, Open-Angle Completed 2010-04-19 2011-06-24 ClinicalTrials.gov
NCT02061683 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocul… Phase4 Glaucoma, Open-Angle Completed 2010-04-19 2011-06-24 ClinicalTrials.gov
NCT01162668 Assessment of Outcomes Following Bariatric Surgery for Mississippi State Employ… — Obesity Completed 2010-04-01 2014-06-01 ClinicalTrials.gov
NCT01422161 Study of Botulinum Toxin and Recovery of Hand Function After Stroke Phase3 Stroke With Hemiparesis Completed 2010-04-01 2015-10-01 ClinicalTrials.gov
NCT01110473 ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced He… Phase1 Acute Lymphoblastic Leukemia Completed 2010-04-01 2013-06-01 ClinicalTrials.gov
NCT01484990 A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects Wi… Phase1 Parkinson Disease Completed 2010-04-01 2010-09-01 ClinicalTrials.gov
NCT01110473 ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced He… Phase1 Acute Lymphoblastic Leukemia Completed 2010-04-01 2013-06-01 ClinicalTrials.gov
NCT01422161 Study of Botulinum Toxin and Recovery of Hand Function After Stroke Phase3 Stroke With Hemiparesis Completed 2010-04-01 2015-10-01 ClinicalTrials.gov
NCT01162668 Assessment of Outcomes Following Bariatric Surgery for Mississippi State Employ… — Obesity Completed 2010-04-01 2014-06-01 ClinicalTrials.gov
NCT01162668 Assessment of Outcomes Following Bariatric Surgery for Mississippi State Employ… — Obesity Completed 2010-04-01 2014-06-01 ClinicalTrials.gov
NCT01484990 A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects Wi… Phase1 Parkinson Disease Completed 2010-04-01 2010-09-01 ClinicalTrials.gov
NCT01422161 Study of Botulinum Toxin and Recovery of Hand Function After Stroke Phase3 Stroke With Hemiparesis Completed 2010-04-01 2015-10-01 ClinicalTrials.gov
NCT01110473 ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced He… Phase1 Acute Lymphoblastic Leukemia Completed 2010-04-01 2013-06-01 ClinicalTrials.gov
NCT01484990 A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects Wi… Phase1 Parkinson Disease Completed 2010-04-01 2010-09-01 ClinicalTrials.gov
NCT01162668 Assessment of Outcomes Following Bariatric Surgery for Mississippi State Employ… — Obesity Completed 2010-04-01 2014-06-01 ClinicalTrials.gov
NCT01422161 Study of Botulinum Toxin and Recovery of Hand Function After Stroke Phase3 Stroke With Hemiparesis Completed 2010-04-01 2015-10-01 ClinicalTrials.gov
NCT01484990 A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects Wi… Phase1 Parkinson Disease Completed 2010-04-01 2010-09-01 ClinicalTrials.gov
NCT01110473 ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced He… Phase1 Acute Lymphoblastic Leukemia Completed 2010-04-01 2013-06-01 ClinicalTrials.gov
NCT01051349 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2010-03-31 2016-08-25 ClinicalTrials.gov
NCT01051349 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2010-03-31 2016-08-25 ClinicalTrials.gov
NCT01051349 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2010-03-31 2016-08-25 ClinicalTrials.gov
NCT01051349 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2010-03-31 2016-08-25 ClinicalTrials.gov
NCT01628588 Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hyperten… — Glaucoma, Open-Angle Completed 2010-03-01 2010-12-01 ClinicalTrials.gov
NCT01113957 A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal … Phase2 Ovarian Cancer Completed 2010-03-01 2013-06-01 ClinicalTrials.gov
NCT01064882 Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Pr… Phase2 Eyelash Hypotrichosis Completed 2010-03-01 2010-07-01 ClinicalTrials.gov
NCT01064882 Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Pr… Phase2 Eyelash Hypotrichosis Completed 2010-03-01 2010-07-01 ClinicalTrials.gov
NCT01064882 Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Pr… Phase2 Eyelash Hypotrichosis Completed 2010-03-01 2010-07-01 ClinicalTrials.gov
NCT01086761 Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular… Phase1 Wet Age-Related Macular Degeneration Terminated 2010-03-01 2010-11-01 ClinicalTrials.gov
NCT01089062 Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (D… Phase1 Healthy Completed 2010-03-01 2010-12-01 ClinicalTrials.gov
NCT01123876 Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor … Phase1 Gastric Cancer Completed 2010-03-01 2015-01-01 ClinicalTrials.gov
NCT01163292 Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for P… — Rheumatoid Arthritis Completed 2010-03-01 2012-10-01 ClinicalTrials.gov
NCT01628588 Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hyperten… — Glaucoma, Open-Angle Completed 2010-03-01 2010-12-01 ClinicalTrials.gov
NCT01110486 ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Ad… Phase1 Advanced Solid Tumors Completed 2010-03-01 2013-09-01 ClinicalTrials.gov
NCT01163292 Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for P… — Rheumatoid Arthritis Completed 2010-03-01 2012-10-01 ClinicalTrials.gov
NCT01074008 A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity … Phase2 Hepatitis C Completed 2010-03-01 2012-01-01 ClinicalTrials.gov
NCT01074008 A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity … Phase2 Hepatitis C Completed 2010-03-01 2012-01-01 ClinicalTrials.gov
NCT01086761 Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular… Phase1 Wet Age-Related Macular Degeneration Terminated 2010-03-01 2010-11-01 ClinicalTrials.gov
NCT01113957 A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal … Phase2 Ovarian Cancer Completed 2010-03-01 2013-06-01 ClinicalTrials.gov
NCT01089062 Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (D… Phase1 Healthy Completed 2010-03-01 2010-12-01 ClinicalTrials.gov
NCT01095562 Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizop… Phase2 Cognitive Deficits in Schizophrenia Completed 2010-03-01 2011-09-01 ClinicalTrials.gov
NCT01095562 Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizop… Phase2 Cognitive Deficits in Schizophrenia Completed 2010-03-01 2011-09-01 ClinicalTrials.gov
NCT01113957 A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal … Phase2 Ovarian Cancer Completed 2010-03-01 2013-06-01 ClinicalTrials.gov
NCT01064882 Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Pr… Phase2 Eyelash Hypotrichosis Completed 2010-03-01 2010-07-01 ClinicalTrials.gov
NCT01074008 A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity … Phase2 Hepatitis C Completed 2010-03-01 2012-01-01 ClinicalTrials.gov
NCT01110486 ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Ad… Phase1 Advanced Solid Tumors Completed 2010-03-01 2013-09-01 ClinicalTrials.gov
NCT01123876 Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor … Phase1 Gastric Cancer Completed 2010-03-01 2015-01-01 ClinicalTrials.gov
NCT01628588 Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hyperten… — Glaucoma, Open-Angle Completed 2010-03-01 2010-12-01 ClinicalTrials.gov
NCT01628588 Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hyperten… — Glaucoma, Open-Angle Completed 2010-03-01 2010-12-01 ClinicalTrials.gov
NCT01086761 Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular… Phase1 Wet Age-Related Macular Degeneration Terminated 2010-03-01 2010-11-01 ClinicalTrials.gov
NCT01089062 Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (D… Phase1 Healthy Completed 2010-03-01 2010-12-01 ClinicalTrials.gov
NCT01074008 A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity … Phase2 Hepatitis C Completed 2010-03-01 2012-01-01 ClinicalTrials.gov
NCT01089062 Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (D… Phase1 Healthy Completed 2010-03-01 2010-12-01 ClinicalTrials.gov
NCT01110486 ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Ad… Phase1 Advanced Solid Tumors Completed 2010-03-01 2013-09-01 ClinicalTrials.gov
NCT01123876 Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor … Phase1 Gastric Cancer Completed 2010-03-01 2015-01-01 ClinicalTrials.gov
NCT01163292 Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for P… — Rheumatoid Arthritis Completed 2010-03-01 2012-10-01 ClinicalTrials.gov
NCT01123876 Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor … Phase1 Gastric Cancer Completed 2010-03-01 2015-01-01 ClinicalTrials.gov
NCT01086761 Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular… Phase1 Wet Age-Related Macular Degeneration Terminated 2010-03-01 2010-11-01 ClinicalTrials.gov
NCT01095562 Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizop… Phase2 Cognitive Deficits in Schizophrenia Completed 2010-03-01 2011-09-01 ClinicalTrials.gov
NCT01113957 A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal … Phase2 Ovarian Cancer Completed 2010-03-01 2013-06-01 ClinicalTrials.gov
NCT01163292 Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for P… — Rheumatoid Arthritis Completed 2010-03-01 2012-10-01 ClinicalTrials.gov
NCT01095562 Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizop… Phase2 Cognitive Deficits in Schizophrenia Completed 2010-03-01 2011-09-01 ClinicalTrials.gov
NCT01110486 ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Ad… Phase1 Advanced Solid Tumors Completed 2010-03-01 2013-09-01 ClinicalTrials.gov
NCT01020487 Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Ho… Phase3 Chronic Kidney Disease Stage 3 and 4 Completed 2010-02-01 2014-12-01 ClinicalTrials.gov
NCT01282411 Anatomic Outcomes Following Ozurdex Injections — Retinal Vein Occlusions Completed 2010-02-01 2011-07-01 ClinicalTrials.gov
NCT01042678 Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema Phase1 Diabetic Macular Edema Terminated 2010-02-01 2010-12-01 ClinicalTrials.gov
NCT01064830 Topical Cyclosporine Suspension for the Treatment of Brittle Nails Phase2 Brittle Nail Syndrome Completed 2010-02-01 2011-08-01 ClinicalTrials.gov
NCT06585189 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] — Metastatic Non Small Cell Lung Cancer Completed 2010-02-01 2023-04-13 ClinicalTrials.gov
NCT06607393 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] — Metastatic Nonsmall Cell Lung Cancer Completed 2010-02-01 2023-06-28 ClinicalTrials.gov
NCT06607601 CARE Initiative: Real-world Emulation of the PALOMA-2 Trial — Metastatic Breast Cancer Completed 2010-02-01 2023-07-20 ClinicalTrials.gov
NCT01064856 Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) Phase3 Peripheral Spondyloarthritis Completed 2010-02-01 2014-05-01 ClinicalTrials.gov
NCT01068964 Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With… Na Open-angle Glaucoma Completed 2010-02-01 2010-09-01 ClinicalTrials.gov
NCT01020487 Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Ho… Phase3 Chronic Kidney Disease Stage 3 and 4 Completed 2010-02-01 2014-12-01 ClinicalTrials.gov
NCT01632423 A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocul… — Glaucoma, Open-Angle Completed 2010-02-01 2010-11-01 ClinicalTrials.gov
NCT01632423 A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocul… — Glaucoma, Open-Angle Completed 2010-02-01 2010-11-01 ClinicalTrials.gov
NCT01076192 Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS… — Moderate-to-severe Chronic Plaque Psoriasis Completed 2010-02-01 2014-09-01 ClinicalTrials.gov
NCT01282411 Anatomic Outcomes Following Ozurdex Injections — Retinal Vein Occlusions Completed 2010-02-01 2011-07-01 ClinicalTrials.gov
NCT01068964 Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With… Na Open-angle Glaucoma Completed 2010-02-01 2010-09-01 ClinicalTrials.gov
NCT01282411 Anatomic Outcomes Following Ozurdex Injections — Retinal Vein Occlusions Completed 2010-02-01 2011-07-01 ClinicalTrials.gov
NCT01064830 Topical Cyclosporine Suspension for the Treatment of Brittle Nails Phase2 Brittle Nail Syndrome Completed 2010-02-01 2011-08-01 ClinicalTrials.gov
NCT01042678 Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema Phase1 Diabetic Macular Edema Terminated 2010-02-01 2010-12-01 ClinicalTrials.gov
NCT01282411 Anatomic Outcomes Following Ozurdex Injections — Retinal Vein Occlusions Completed 2010-02-01 2011-07-01 ClinicalTrials.gov
NCT00915525 Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for … Phase3 Overactive Bladder Completed 2010-02-01 2014-08-05 ClinicalTrials.gov
NCT01632423 A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocul… — Glaucoma, Open-Angle Completed 2010-02-01 2010-11-01 ClinicalTrials.gov
NCT01076192 Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS… — Moderate-to-severe Chronic Plaque Psoriasis Completed 2010-02-01 2014-09-01 ClinicalTrials.gov
NCT01076192 Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS… — Moderate-to-severe Chronic Plaque Psoriasis Completed 2010-02-01 2014-09-01 ClinicalTrials.gov
NCT01068964 Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With… Na Open-angle Glaucoma Completed 2010-02-01 2010-09-01 ClinicalTrials.gov
NCT01064830 Topical Cyclosporine Suspension for the Treatment of Brittle Nails Phase2 Brittle Nail Syndrome Completed 2010-02-01 2011-08-01 ClinicalTrials.gov
NCT01042678 Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema Phase1 Diabetic Macular Edema Terminated 2010-02-01 2010-12-01 ClinicalTrials.gov
NCT00915525 Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for … Phase3 Overactive Bladder Completed 2010-02-01 2014-08-05 ClinicalTrials.gov
NCT00915525 Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for … Phase3 Overactive Bladder Completed 2010-02-01 2014-08-05 ClinicalTrials.gov
NCT01020487 Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Ho… Phase3 Chronic Kidney Disease Stage 3 and 4 Completed 2010-02-01 2014-12-01 ClinicalTrials.gov
NCT00915525 Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for … Phase3 Overactive Bladder Completed 2010-02-01 2014-08-05 ClinicalTrials.gov
NCT01064856 Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) Phase3 Peripheral Spondyloarthritis Completed 2010-02-01 2014-05-01 ClinicalTrials.gov
NCT01064856 Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) Phase3 Peripheral Spondyloarthritis Completed 2010-02-01 2014-05-01 ClinicalTrials.gov
NCT06607601 CARE Initiative: Real-world Emulation of the PALOMA-2 Trial — Metastatic Breast Cancer Completed 2010-02-01 2023-07-20 ClinicalTrials.gov
NCT06607393 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] — Metastatic Nonsmall Cell Lung Cancer Completed 2010-02-01 2023-06-28 ClinicalTrials.gov
NCT06585189 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] — Metastatic Non Small Cell Lung Cancer Completed 2010-02-01 2023-04-13 ClinicalTrials.gov
NCT06585189 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] — Metastatic Non Small Cell Lung Cancer Completed 2010-02-01 2023-04-13 ClinicalTrials.gov
NCT06607393 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] — Metastatic Nonsmall Cell Lung Cancer Completed 2010-02-01 2023-06-28 ClinicalTrials.gov
NCT06607601 CARE Initiative: Real-world Emulation of the PALOMA-2 Trial — Metastatic Breast Cancer Completed 2010-02-01 2023-07-20 ClinicalTrials.gov
NCT01064856 Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) Phase3 Peripheral Spondyloarthritis Completed 2010-02-01 2014-05-01 ClinicalTrials.gov
NCT01632423 A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocul… — Glaucoma, Open-Angle Completed 2010-02-01 2010-11-01 ClinicalTrials.gov
NCT01020487 Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Ho… Phase3 Chronic Kidney Disease Stage 3 and 4 Completed 2010-02-01 2014-12-01 ClinicalTrials.gov
NCT01042678 Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema Phase1 Diabetic Macular Edema Terminated 2010-02-01 2010-12-01 ClinicalTrials.gov
NCT01076192 Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS… — Moderate-to-severe Chronic Plaque Psoriasis Completed 2010-02-01 2014-09-01 ClinicalTrials.gov
NCT06607601 CARE Initiative: Real-world Emulation of the PALOMA-2 Trial — Metastatic Breast Cancer Completed 2010-02-01 2023-07-20 ClinicalTrials.gov
NCT01064830 Topical Cyclosporine Suspension for the Treatment of Brittle Nails Phase2 Brittle Nail Syndrome Completed 2010-02-01 2011-08-01 ClinicalTrials.gov
NCT01068964 Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With… Na Open-angle Glaucoma Completed 2010-02-01 2010-09-01 ClinicalTrials.gov
NCT06607393 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] — Metastatic Nonsmall Cell Lung Cancer Completed 2010-02-01 2023-06-28 ClinicalTrials.gov
NCT06585189 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] — Metastatic Non Small Cell Lung Cancer Completed 2010-02-01 2023-04-13 ClinicalTrials.gov
NCT01199965 Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adu… Phase1 Healthy Subjects Completed 2010-01-01 2010-04-01 ClinicalTrials.gov
NCT01255891 Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Ad… Phase2 Adenocarcinoma of the Prostate Completed 2010-01-01 2023-09-01 ClinicalTrials.gov
NCT01199965 Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adu… Phase1 Healthy Subjects Completed 2010-01-01 2010-04-01 ClinicalTrials.gov
NCT01063816 A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects … Phase1 Advanced Solid Tumors Completed 2010-01-01 2016-08-01 ClinicalTrials.gov
NCT01063816 A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects … Phase1 Advanced Solid Tumors Completed 2010-01-01 2016-08-01 ClinicalTrials.gov
NCT01063816 A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects … Phase1 Advanced Solid Tumors Completed 2010-01-01 2016-08-01 ClinicalTrials.gov
NCT01255891 Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Ad… Phase2 Adenocarcinoma of the Prostate Completed 2010-01-01 2023-09-01 ClinicalTrials.gov
NCT01199965 Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adu… Phase1 Healthy Subjects Completed 2010-01-01 2010-04-01 ClinicalTrials.gov
NCT01199965 Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adu… Phase1 Healthy Subjects Completed 2010-01-01 2010-04-01 ClinicalTrials.gov
NCT01255891 Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Ad… Phase2 Adenocarcinoma of the Prostate Completed 2010-01-01 2023-09-01 ClinicalTrials.gov
NCT01255891 Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Ad… Phase2 Adenocarcinoma of the Prostate Completed 2010-01-01 2023-09-01 ClinicalTrials.gov
NCT01063816 A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects … Phase1 Advanced Solid Tumors Completed 2010-01-01 2016-08-01 ClinicalTrials.gov
NCT01833741 A Study of LUMIGAN® RC in the Clinical Setting Phase4 Glaucoma, Primary Open Angle Completed 2009-12-01 2011-03-01 ClinicalTrials.gov
NCT01170884 Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in … Phase4 Glaucoma Completed 2009-12-01 2010-09-01 ClinicalTrials.gov
NCT01163318 Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patient… — Rheumatoid Arthritis Completed 2009-12-01 2014-05-01 ClinicalTrials.gov
NCT01170884 Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in … Phase4 Glaucoma Completed 2009-12-01 2010-09-01 ClinicalTrials.gov
NCT01833741 A Study of LUMIGAN® RC in the Clinical Setting Phase4 Glaucoma, Primary Open Angle Completed 2009-12-01 2011-03-01 ClinicalTrials.gov
NCT01170884 Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in … Phase4 Glaucoma Completed 2009-12-01 2010-09-01 ClinicalTrials.gov
NCT01170884 Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in … Phase4 Glaucoma Completed 2009-12-01 2010-09-01 ClinicalTrials.gov
NCT01018875 Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheime… Phase2 Alzheimer's Disease Completed 2009-12-01 2011-02-01 ClinicalTrials.gov
NCT01163318 Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patient… — Rheumatoid Arthritis Completed 2009-12-01 2014-05-01 ClinicalTrials.gov
NCT01018875 Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheime… Phase2 Alzheimer's Disease Completed 2009-12-01 2011-02-01 ClinicalTrials.gov
NCT01833741 A Study of LUMIGAN® RC in the Clinical Setting Phase4 Glaucoma, Primary Open Angle Completed 2009-12-01 2011-03-01 ClinicalTrials.gov
NCT01163318 Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patient… — Rheumatoid Arthritis Completed 2009-12-01 2014-05-01 ClinicalTrials.gov
NCT01018875 Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheime… Phase2 Alzheimer's Disease Completed 2009-12-01 2011-02-01 ClinicalTrials.gov
NCT01018875 Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheime… Phase2 Alzheimer's Disease Completed 2009-12-01 2011-02-01 ClinicalTrials.gov
NCT01833741 A Study of LUMIGAN® RC in the Clinical Setting Phase4 Glaucoma, Primary Open Angle Completed 2009-12-01 2011-03-01 ClinicalTrials.gov
NCT01163318 Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patient… — Rheumatoid Arthritis Completed 2009-12-01 2014-05-01 ClinicalTrials.gov
NCT00660673 Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel … Phase3 Advanced Parkinson's Disease Completed 2009-11-13 2021-11-30 ClinicalTrials.gov
NCT00660673 Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel … Phase3 Advanced Parkinson's Disease Completed 2009-11-13 2021-11-30 ClinicalTrials.gov
NCT00660673 Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel … Phase3 Advanced Parkinson's Disease Completed 2009-11-13 2021-11-30 ClinicalTrials.gov
NCT00660673 Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel … Phase3 Advanced Parkinson's Disease Completed 2009-11-13 2021-11-30 ClinicalTrials.gov
NCT01010282 Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects Na Dry Eye Syndrome Completed 2009-11-01 2010-04-01 ClinicalTrials.gov
NCT01010282 Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects Na Dry Eye Syndrome Completed 2009-11-01 2010-04-01 ClinicalTrials.gov
NCT01013077 The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Con… Na Dry Eye Syndrome Completed 2009-11-01 2011-08-01 ClinicalTrials.gov
NCT01151904 Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared … Phase4 Glaucoma, Angle-Closure Terminated 2009-11-01 2012-02-01 ClinicalTrials.gov
NCT01026077 The Savella Pregnancy Registry — Fibromyalgia Terminated 2009-11-01 2024-10-09 ClinicalTrials.gov
NCT01151904 Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared … Phase4 Glaucoma, Angle-Closure Terminated 2009-11-01 2012-02-01 ClinicalTrials.gov
NCT01026077 The Savella Pregnancy Registry — Fibromyalgia Terminated 2009-11-01 2024-10-09 ClinicalTrials.gov
NCT00987727 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in S… Phase4 Dry Eye Syndromes Completed 2009-11-01 2010-09-01 ClinicalTrials.gov
NCT00958035 Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Ameri… Phase4 Hypotrichosis Completed 2009-11-01 2010-08-01 ClinicalTrials.gov
NCT01151904 Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared … Phase4 Glaucoma, Angle-Closure Terminated 2009-11-01 2012-02-01 ClinicalTrials.gov
NCT00987727 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in S… Phase4 Dry Eye Syndromes Completed 2009-11-01 2010-09-01 ClinicalTrials.gov
NCT01229423 Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subj… Phase4 Eyelash Hypotrichosis Completed 2009-11-01 2010-10-01 ClinicalTrials.gov
NCT00868413 Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclo… Phase1 Chronic Lymphocytic Leukemia Completed 2009-11-01 2013-05-01 ClinicalTrials.gov
NCT01026077 The Savella Pregnancy Registry — Fibromyalgia Terminated 2009-11-01 2024-10-09 ClinicalTrials.gov
NCT01013077 The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Con… Na Dry Eye Syndrome Completed 2009-11-01 2011-08-01 ClinicalTrials.gov
NCT01010282 Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects Na Dry Eye Syndrome Completed 2009-11-01 2010-04-01 ClinicalTrials.gov
NCT01229423 Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subj… Phase4 Eyelash Hypotrichosis Completed 2009-11-01 2010-10-01 ClinicalTrials.gov
NCT00958035 Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Ameri… Phase4 Hypotrichosis Completed 2009-11-01 2010-08-01 ClinicalTrials.gov
NCT01026077 The Savella Pregnancy Registry — Fibromyalgia Terminated 2009-11-01 2024-10-09 ClinicalTrials.gov
NCT00868413 Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclo… Phase1 Chronic Lymphocytic Leukemia Completed 2009-11-01 2013-05-01 ClinicalTrials.gov
NCT00987727 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in S… Phase4 Dry Eye Syndromes Completed 2009-11-01 2010-09-01 ClinicalTrials.gov
NCT00987727 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in S… Phase4 Dry Eye Syndromes Completed 2009-11-01 2010-09-01 ClinicalTrials.gov
NCT01151904 Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared … Phase4 Glaucoma, Angle-Closure Terminated 2009-11-01 2012-02-01 ClinicalTrials.gov
NCT01013077 The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Con… Na Dry Eye Syndrome Completed 2009-11-01 2011-08-01 ClinicalTrials.gov
NCT00958035 Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Ameri… Phase4 Hypotrichosis Completed 2009-11-01 2010-08-01 ClinicalTrials.gov
NCT00868413 Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclo… Phase1 Chronic Lymphocytic Leukemia Completed 2009-11-01 2013-05-01 ClinicalTrials.gov
NCT01229423 Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subj… Phase4 Eyelash Hypotrichosis Completed 2009-11-01 2010-10-01 ClinicalTrials.gov
NCT00958035 Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Ameri… Phase4 Hypotrichosis Completed 2009-11-01 2010-08-01 ClinicalTrials.gov
NCT01229423 Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subj… Phase4 Eyelash Hypotrichosis Completed 2009-11-01 2010-10-01 ClinicalTrials.gov
NCT00868413 Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclo… Phase1 Chronic Lymphocytic Leukemia Completed 2009-11-01 2013-05-01 ClinicalTrials.gov
NCT01010282 Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects Na Dry Eye Syndrome Completed 2009-11-01 2010-04-01 ClinicalTrials.gov
NCT01013077 The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Con… Na Dry Eye Syndrome Completed 2009-11-01 2011-08-01 ClinicalTrials.gov
NCT00973973 Efficacy and Safety Study of Elagolix in Women With Endometriosis Phase2 Endometriosis, Pain Completed 2009-10-12 2010-09-22 ClinicalTrials.gov
NCT00973973 Efficacy and Safety Study of Elagolix in Women With Endometriosis Phase2 Endometriosis, Pain Completed 2009-10-12 2010-09-22 ClinicalTrials.gov
NCT00973973 Efficacy and Safety Study of Elagolix in Women With Endometriosis Phase2 Endometriosis, Pain Completed 2009-10-12 2010-09-22 ClinicalTrials.gov
NCT00973973 Efficacy and Safety Study of Elagolix in Women With Endometriosis Phase2 Endometriosis, Pain Completed 2009-10-12 2010-09-22 ClinicalTrials.gov
NCT01004042 Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-de… Phase4 Depression Completed 2009-10-01 2010-04-01 ClinicalTrials.gov
NCT01083173 Surveillance of Kaletra in Korean Patients — HIV-1 Infection Completed 2009-10-01 2014-10-01 ClinicalTrials.gov
NCT00986401 Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Hea… Phase1 Healthy Completed 2009-10-01 2009-11-01 ClinicalTrials.gov
NCT00878449 A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplati… Phase1 Solid Tumors Completed 2009-10-01 2011-07-01 ClinicalTrials.gov
NCT01083173 Surveillance of Kaletra in Korean Patients — HIV-1 Infection Completed 2009-10-01 2014-10-01 ClinicalTrials.gov
NCT01083173 Surveillance of Kaletra in Korean Patients — HIV-1 Infection Completed 2009-10-01 2014-10-01 ClinicalTrials.gov
NCT00986401 Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Hea… Phase1 Healthy Completed 2009-10-01 2009-11-01 ClinicalTrials.gov
NCT00878449 A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplati… Phase1 Solid Tumors Completed 2009-10-01 2011-07-01 ClinicalTrials.gov
NCT01083173 Surveillance of Kaletra in Korean Patients — HIV-1 Infection Completed 2009-10-01 2014-10-01 ClinicalTrials.gov
NCT01009073 A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263… Phase1 Solid Tumors Completed 2009-10-01 2013-06-01 ClinicalTrials.gov
NCT00878449 A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplati… Phase1 Solid Tumors Completed 2009-10-01 2011-07-01 ClinicalTrials.gov
NCT01009073 A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263… Phase1 Solid Tumors Completed 2009-10-01 2013-06-01 ClinicalTrials.gov
NCT00986037 Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Ast… Phase1 Asthma Completed 2009-10-01 — ClinicalTrials.gov
NCT00991458 Study of Cyclosporine in Post-LASIK Patients Phase2 Laser In Situ Keratomileusis Completed 2009-10-01 2011-04-01 ClinicalTrials.gov
NCT01021761 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%),… Phase4 Cataracts Completed 2009-10-01 2010-01-01 ClinicalTrials.gov
NCT01004042 Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-de… Phase4 Depression Completed 2009-10-01 2010-04-01 ClinicalTrials.gov
NCT01001806 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (… Phase4 Cataracts Completed 2009-10-01 2010-01-01 ClinicalTrials.gov
NCT00991458 Study of Cyclosporine in Post-LASIK Patients Phase2 Laser In Situ Keratomileusis Completed 2009-10-01 2011-04-01 ClinicalTrials.gov
NCT00986401 Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Hea… Phase1 Healthy Completed 2009-10-01 2009-11-01 ClinicalTrials.gov
NCT00986401 Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Hea… Phase1 Healthy Completed 2009-10-01 2009-11-01 ClinicalTrials.gov
NCT00982566 Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With C… Phase1 Lymphoid Malignancy Completed 2009-10-01 2010-12-01 ClinicalTrials.gov
NCT00991458 Study of Cyclosporine in Post-LASIK Patients Phase2 Laser In Situ Keratomileusis Completed 2009-10-01 2011-04-01 ClinicalTrials.gov
NCT01001806 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (… Phase4 Cataracts Completed 2009-10-01 2010-01-01 ClinicalTrials.gov
NCT01004042 Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-de… Phase4 Depression Completed 2009-10-01 2010-04-01 ClinicalTrials.gov
NCT00878449 A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplati… Phase1 Solid Tumors Completed 2009-10-01 2011-07-01 ClinicalTrials.gov
NCT01001806 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (… Phase4 Cataracts Completed 2009-10-01 2010-01-01 ClinicalTrials.gov
NCT01021761 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%),… Phase4 Cataracts Completed 2009-10-01 2010-01-01 ClinicalTrials.gov
NCT01021761 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%),… Phase4 Cataracts Completed 2009-10-01 2010-01-01 ClinicalTrials.gov
NCT00982566 Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With C… Phase1 Lymphoid Malignancy Completed 2009-10-01 2010-12-01 ClinicalTrials.gov
NCT00986037 Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Ast… Phase1 Asthma Completed 2009-10-01 — ClinicalTrials.gov
NCT01009073 A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263… Phase1 Solid Tumors Completed 2009-10-01 2013-06-01 ClinicalTrials.gov
NCT01001806 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (… Phase4 Cataracts Completed 2009-10-01 2010-01-01 ClinicalTrials.gov
NCT01009073 A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263… Phase1 Solid Tumors Completed 2009-10-01 2013-06-01 ClinicalTrials.gov
NCT00982566 Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With C… Phase1 Lymphoid Malignancy Completed 2009-10-01 2010-12-01 ClinicalTrials.gov
NCT00986037 Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Ast… Phase1 Asthma Completed 2009-10-01 — ClinicalTrials.gov
NCT00991458 Study of Cyclosporine in Post-LASIK Patients Phase2 Laser In Situ Keratomileusis Completed 2009-10-01 2011-04-01 ClinicalTrials.gov
NCT01004042 Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-de… Phase4 Depression Completed 2009-10-01 2010-04-01 ClinicalTrials.gov
NCT01021761 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%),… Phase4 Cataracts Completed 2009-10-01 2010-01-01 ClinicalTrials.gov
NCT00986037 Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Ast… Phase1 Asthma Completed 2009-10-01 — ClinicalTrials.gov
NCT00982566 Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With C… Phase1 Lymphoid Malignancy Completed 2009-10-01 2010-12-01 ClinicalTrials.gov
NCT00887757 Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects Wi… Phase1 Solid Tumors Completed 2009-09-01 2011-11-01 ClinicalTrials.gov
NCT00995904 Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With … Phase2 Asthma Completed 2009-09-01 2009-11-01 ClinicalTrials.gov
NCT00910845 Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic O… Phase3 Overactive Bladder Completed 2009-09-01 2011-07-01 ClinicalTrials.gov
NCT00995904 Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With … Phase2 Asthma Completed 2009-09-01 2009-11-01 ClinicalTrials.gov
NCT01077128 Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adal… — Psoriasis Completed 2009-09-01 2012-09-01 ClinicalTrials.gov
NCT00910845 Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic O… Phase3 Overactive Bladder Completed 2009-09-01 2011-07-01 ClinicalTrials.gov
NCT00995904 Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With … Phase2 Asthma Completed 2009-09-01 2009-11-01 ClinicalTrials.gov
NCT01077128 Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adal… — Psoriasis Completed 2009-09-01 2012-09-01 ClinicalTrials.gov
NCT00910845 Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic O… Phase3 Overactive Bladder Completed 2009-09-01 2011-07-01 ClinicalTrials.gov
NCT01077128 Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adal… — Psoriasis Completed 2009-09-01 2012-09-01 ClinicalTrials.gov
NCT00887757 Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects Wi… Phase1 Solid Tumors Completed 2009-09-01 2011-11-01 ClinicalTrials.gov
NCT00995904 Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With … Phase2 Asthma Completed 2009-09-01 2009-11-01 ClinicalTrials.gov
NCT01077128 Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adal… — Psoriasis Completed 2009-09-01 2012-09-01 ClinicalTrials.gov
NCT00910845 Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic O… Phase3 Overactive Bladder Completed 2009-09-01 2011-07-01 ClinicalTrials.gov
NCT00887757 Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects Wi… Phase1 Solid Tumors Completed 2009-09-01 2011-11-01 ClinicalTrials.gov
NCT00887757 Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects Wi… Phase1 Solid Tumors Completed 2009-09-01 2011-11-01 ClinicalTrials.gov
NCT01976624 Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Ko… — Glaucoma, Open-Angle Completed 2009-08-01 2014-01-01 ClinicalTrials.gov
NCT00907426 Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashe… Phase3 Hypotrichosis Completed 2009-08-01 2011-05-01 ClinicalTrials.gov
NCT00894517 A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Pat… Phase1 Benign Prostatic Hyperplasia Completed 2009-08-01 2012-08-01 ClinicalTrials.gov
NCT00932477 Safety and Tolerability of Artificial Tears in Dry Eye Subjects Na Dry Eye Syndrome Completed 2009-08-01 2009-09-01 ClinicalTrials.gov
NCT01976624 Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Ko… — Glaucoma, Open-Angle Completed 2009-08-01 2014-01-01 ClinicalTrials.gov
NCT00894517 A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Pat… Phase1 Benign Prostatic Hyperplasia Completed 2009-08-01 2012-08-01 ClinicalTrials.gov
NCT00894517 A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Pat… Phase1 Benign Prostatic Hyperplasia Completed 2009-08-01 2012-08-01 ClinicalTrials.gov
NCT01976624 Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Ko… — Glaucoma, Open-Angle Completed 2009-08-01 2014-01-01 ClinicalTrials.gov
NCT00907426 Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashe… Phase3 Hypotrichosis Completed 2009-08-01 2011-05-01 ClinicalTrials.gov
NCT00978042 Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmen… Na Mid-facial Volume Deficit Related to Aging Completed 2009-08-01 2014-04-01 ClinicalTrials.gov
NCT00932477 Safety and Tolerability of Artificial Tears in Dry Eye Subjects Na Dry Eye Syndrome Completed 2009-08-01 2009-09-01 ClinicalTrials.gov
NCT00907426 Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashe… Phase3 Hypotrichosis Completed 2009-08-01 2011-05-01 ClinicalTrials.gov
NCT00894517 A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Pat… Phase1 Benign Prostatic Hyperplasia Completed 2009-08-01 2012-08-01 ClinicalTrials.gov
NCT00932477 Safety and Tolerability of Artificial Tears in Dry Eye Subjects Na Dry Eye Syndrome Completed 2009-08-01 2009-09-01 ClinicalTrials.gov
NCT00932477 Safety and Tolerability of Artificial Tears in Dry Eye Subjects Na Dry Eye Syndrome Completed 2009-08-01 2009-09-01 ClinicalTrials.gov
NCT00978042 Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmen… Na Mid-facial Volume Deficit Related to Aging Completed 2009-08-01 2014-04-01 ClinicalTrials.gov
NCT00907426 Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashe… Phase3 Hypotrichosis Completed 2009-08-01 2011-05-01 ClinicalTrials.gov
NCT00978042 Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmen… Na Mid-facial Volume Deficit Related to Aging Completed 2009-08-01 2014-04-01 ClinicalTrials.gov
NCT01976624 Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Ko… — Glaucoma, Open-Angle Completed 2009-08-01 2014-01-01 ClinicalTrials.gov
NCT00978042 Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmen… Na Mid-facial Volume Deficit Related to Aging Completed 2009-08-01 2014-04-01 ClinicalTrials.gov
NCT00788684 Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers Phase1 CD20-Positive Lymphoid Malignancies Completed 2009-07-21 2025-02-07 ClinicalTrials.gov
NCT00788684 Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers Phase1 CD20-Positive Lymphoid Malignancies Completed 2009-07-21 2025-02-07 ClinicalTrials.gov
NCT00788684 Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers Phase1 CD20-Positive Lymphoid Malignancies Completed 2009-07-21 2025-02-07 ClinicalTrials.gov
NCT00788684 Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers Phase1 CD20-Positive Lymphoid Malignancies Completed 2009-07-21 2025-02-07 ClinicalTrials.gov
NCT00939003 Study of Adalimumab in Patients With Axial Spondyloarthritis Phase3 Axial Spondyloarthritis Completed 2009-07-01 2013-08-01 ClinicalTrials.gov
NCT00891605 Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid T… Phase1 Solid Tumors Completed 2009-07-01 2012-07-01 ClinicalTrials.gov
NCT00932022 Trospium Chloride XR in Obese Female Patients With Overactive Bladder Phase4 Obesity Completed 2009-07-01 2011-12-01 ClinicalTrials.gov
NCT00932022 Trospium Chloride XR in Obese Female Patients With Overactive Bladder Phase4 Obesity Completed 2009-07-01 2011-12-01 ClinicalTrials.gov
NCT00891605 Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid T… Phase1 Solid Tumors Completed 2009-07-01 2012-07-01 ClinicalTrials.gov
NCT00932022 Trospium Chloride XR in Obese Female Patients With Overactive Bladder Phase4 Obesity Completed 2009-07-01 2011-12-01 ClinicalTrials.gov
NCT00939003 Study of Adalimumab in Patients With Axial Spondyloarthritis Phase3 Axial Spondyloarthritis Completed 2009-07-01 2013-08-01 ClinicalTrials.gov
NCT00932022 Trospium Chloride XR in Obese Female Patients With Overactive Bladder Phase4 Obesity Completed 2009-07-01 2011-12-01 ClinicalTrials.gov
NCT00986427 Restasis for Treatment of Brittle Nails Phase2 Brittle Nails Completed 2009-07-01 2012-12-01 ClinicalTrials.gov
NCT00986427 Restasis for Treatment of Brittle Nails Phase2 Brittle Nails Completed 2009-07-01 2012-12-01 ClinicalTrials.gov
NCT00891605 Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid T… Phase1 Solid Tumors Completed 2009-07-01 2012-07-01 ClinicalTrials.gov
NCT00986427 Restasis for Treatment of Brittle Nails Phase2 Brittle Nails Completed 2009-07-01 2012-12-01 ClinicalTrials.gov
NCT00939003 Study of Adalimumab in Patients With Axial Spondyloarthritis Phase3 Axial Spondyloarthritis Completed 2009-07-01 2013-08-01 ClinicalTrials.gov
NCT00986427 Restasis for Treatment of Brittle Nails Phase2 Brittle Nails Completed 2009-07-01 2012-12-01 ClinicalTrials.gov
NCT00939003 Study of Adalimumab in Patients With Axial Spondyloarthritis Phase3 Axial Spondyloarthritis Completed 2009-07-01 2013-08-01 ClinicalTrials.gov
NCT00891605 Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid T… Phase1 Solid Tumors Completed 2009-07-01 2012-07-01 ClinicalTrials.gov
NCT00935311 Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction Phase2 Pain Completed 2009-06-01 2009-08-01 ClinicalTrials.gov
NCT01629407 A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two… — Glaucoma, Open-Angle Completed 2009-06-01 2013-05-01 ClinicalTrials.gov
NCT03064815 The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies Na Spondyloarthropathy Completed 2009-06-01 2016-03-01 ClinicalTrials.gov
NCT00920764 A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Tr… Phase2 Chronic Kidney Disease Completed 2009-06-01 2010-05-01 ClinicalTrials.gov
NCT00669474 Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection i… Phase4 Essential Axillary Hyperhidrosis Terminated 2009-06-01 2011-08-01 ClinicalTrials.gov
NCT00824811 Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel Phase2 Epiphora Withdrawn 2009-06-01 — ClinicalTrials.gov
NCT01083186 Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience — Chronic Kidney Failure Completed 2009-06-01 2012-01-01 ClinicalTrials.gov
NCT00938704 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears … Phase4 Dry Eye Syndromes Completed 2009-06-01 2009-06-01 ClinicalTrials.gov
NCT03064815 The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies Na Spondyloarthropathy Completed 2009-06-01 2016-03-01 ClinicalTrials.gov
NCT00935311 Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction Phase2 Pain Completed 2009-06-01 2009-08-01 ClinicalTrials.gov
NCT00938704 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears … Phase4 Dry Eye Syndromes Completed 2009-06-01 2009-06-01 ClinicalTrials.gov
NCT00824811 Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel Phase2 Epiphora Withdrawn 2009-06-01 — ClinicalTrials.gov
NCT00669474 Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection i… Phase4 Essential Axillary Hyperhidrosis Terminated 2009-06-01 2011-08-01 ClinicalTrials.gov
NCT01083186 Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience — Chronic Kidney Failure Completed 2009-06-01 2012-01-01 ClinicalTrials.gov
NCT00920764 A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Tr… Phase2 Chronic Kidney Disease Completed 2009-06-01 2010-05-01 ClinicalTrials.gov
NCT01629407 A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two… — Glaucoma, Open-Angle Completed 2009-06-01 2013-05-01 ClinicalTrials.gov
NCT03064815 The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies Na Spondyloarthropathy Completed 2009-06-01 2016-03-01 ClinicalTrials.gov
NCT03064815 The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies Na Spondyloarthropathy Completed 2009-06-01 2016-03-01 ClinicalTrials.gov
NCT00920764 A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Tr… Phase2 Chronic Kidney Disease Completed 2009-06-01 2010-05-01 ClinicalTrials.gov
NCT00920764 A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Tr… Phase2 Chronic Kidney Disease Completed 2009-06-01 2010-05-01 ClinicalTrials.gov
NCT00669474 Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection i… Phase4 Essential Axillary Hyperhidrosis Terminated 2009-06-01 2011-08-01 ClinicalTrials.gov
NCT00824811 Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel Phase2 Epiphora Withdrawn 2009-06-01 — ClinicalTrials.gov
NCT00935311 Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction Phase2 Pain Completed 2009-06-01 2009-08-01 ClinicalTrials.gov
NCT00938704 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears … Phase4 Dry Eye Syndromes Completed 2009-06-01 2009-06-01 ClinicalTrials.gov
NCT01629407 A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two… — Glaucoma, Open-Angle Completed 2009-06-01 2013-05-01 ClinicalTrials.gov
NCT01083186 Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience — Chronic Kidney Failure Completed 2009-06-01 2012-01-01 ClinicalTrials.gov
NCT00669474 Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection i… Phase4 Essential Axillary Hyperhidrosis Terminated 2009-06-01 2011-08-01 ClinicalTrials.gov
NCT01629407 A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two… — Glaucoma, Open-Angle Completed 2009-06-01 2013-05-01 ClinicalTrials.gov
NCT00824811 Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel Phase2 Epiphora Withdrawn 2009-06-01 — ClinicalTrials.gov
NCT01083186 Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience — Chronic Kidney Failure Completed 2009-06-01 2012-01-01 ClinicalTrials.gov
NCT00938704 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears … Phase4 Dry Eye Syndromes Completed 2009-06-01 2009-06-01 ClinicalTrials.gov
NCT00935311 Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction Phase2 Pain Completed 2009-06-01 2009-08-01 ClinicalTrials.gov
NCT00908544 New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Pati… Na HIV Infections Completed 2009-05-15 2018-05-01 ClinicalTrials.gov
NCT00908544 New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Pati… Na HIV Infections Completed 2009-05-15 2018-05-01 ClinicalTrials.gov
NCT00908544 New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Pati… Na HIV Infections Completed 2009-05-15 2018-05-01 ClinicalTrials.gov
NCT00908544 New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Pati… Na HIV Infections Completed 2009-05-15 2018-05-01 ClinicalTrials.gov
NCT00884585 Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunct… Phase3 Atopic Conjunctivitis Completed 2009-05-01 2011-07-01 ClinicalTrials.gov
NCT00884585 Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunct… Phase3 Atopic Conjunctivitis Completed 2009-05-01 2011-07-01 ClinicalTrials.gov
NCT00884585 Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunct… Phase3 Atopic Conjunctivitis Completed 2009-05-01 2011-07-01 ClinicalTrials.gov
NCT00884585 Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunct… Phase3 Atopic Conjunctivitis Completed 2009-05-01 2011-07-01 ClinicalTrials.gov
NCT01078402 EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic A… — Ankylosing Spondylitis (AS) Completed 2009-04-01 2011-11-01 ClinicalTrials.gov
NCT00863551 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial Phase4 Elderly Completed 2009-04-01 2009-08-01 ClinicalTrials.gov
NCT00872196 A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Admi… Phase2 Hepatitis C Virus Infection Completed 2009-04-01 2010-04-01 ClinicalTrials.gov
NCT01078402 EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic A… — Ankylosing Spondylitis (AS) Completed 2009-04-01 2011-11-01 ClinicalTrials.gov
NCT00863551 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial Phase4 Elderly Completed 2009-04-01 2009-08-01 ClinicalTrials.gov
NCT01637246 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who… — Glaucoma, Open-Angle Completed 2009-04-01 2011-11-01 ClinicalTrials.gov
NCT01637246 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who… — Glaucoma, Open-Angle Completed 2009-04-01 2011-11-01 ClinicalTrials.gov
NCT00908050 Study of the Safety and Efficacy of Botox in Bruxism Phase4 Bruxism Completed 2009-04-01 2011-09-01 ClinicalTrials.gov
NCT01078402 EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic A… — Ankylosing Spondylitis (AS) Completed 2009-04-01 2011-11-01 ClinicalTrials.gov
NCT00948246 European Union (EU) Post-Market Study on Easyband® — Morbid Obesity Completed 2009-04-01 2011-12-01 ClinicalTrials.gov
NCT00908050 Study of the Safety and Efficacy of Botox in Bruxism Phase4 Bruxism Completed 2009-04-01 2011-09-01 ClinicalTrials.gov
NCT00872196 A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Admi… Phase2 Hepatitis C Virus Infection Completed 2009-04-01 2010-04-01 ClinicalTrials.gov
NCT01637246 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who… — Glaucoma, Open-Angle Completed 2009-04-01 2011-11-01 ClinicalTrials.gov
NCT00863551 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial Phase4 Elderly Completed 2009-04-01 2009-08-01 ClinicalTrials.gov
NCT00948246 European Union (EU) Post-Market Study on Easyband® — Morbid Obesity Completed 2009-04-01 2011-12-01 ClinicalTrials.gov
NCT00872196 A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Admi… Phase2 Hepatitis C Virus Infection Completed 2009-04-01 2010-04-01 ClinicalTrials.gov
NCT00863551 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial Phase4 Elderly Completed 2009-04-01 2009-08-01 ClinicalTrials.gov
NCT00872196 A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Admi… Phase2 Hepatitis C Virus Infection Completed 2009-04-01 2010-04-01 ClinicalTrials.gov
NCT00948246 European Union (EU) Post-Market Study on Easyband® — Morbid Obesity Completed 2009-04-01 2011-12-01 ClinicalTrials.gov
NCT01637246 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who… — Glaucoma, Open-Angle Completed 2009-04-01 2011-11-01 ClinicalTrials.gov
NCT01078402 EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic A… — Ankylosing Spondylitis (AS) Completed 2009-04-01 2011-11-01 ClinicalTrials.gov
NCT00908050 Study of the Safety and Efficacy of Botox in Bruxism Phase4 Bruxism Completed 2009-04-01 2011-09-01 ClinicalTrials.gov
NCT00908050 Study of the Safety and Efficacy of Botox in Bruxism Phase4 Bruxism Completed 2009-04-01 2011-09-01 ClinicalTrials.gov
NCT00948246 European Union (EU) Post-Market Study on Easyband® — Morbid Obesity Completed 2009-04-01 2011-12-01 ClinicalTrials.gov
NCT00851890 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral A… Phase2 Chronic Hepatitis C Virus Infection Completed 2009-03-01 2009-07-01 ClinicalTrials.gov
NCT00775437 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use Phase3 Juvenile Idiopathic Arthritis Completed 2009-03-01 2013-03-01 ClinicalTrials.gov
NCT00856414 Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correc… Phase4 Skin Aging Completed 2009-03-01 2009-04-01 ClinicalTrials.gov
NCT01095640 Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical … Na Acne Vulgaris Completed 2009-03-01 2009-12-01 ClinicalTrials.gov
NCT01078155 Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Met… — Rheumatoid Arthritis Completed 2009-03-01 2014-05-01 ClinicalTrials.gov
NCT01078155 Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Met… — Rheumatoid Arthritis Completed 2009-03-01 2014-05-01 ClinicalTrials.gov
NCT00874887 A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyed… Phase4 Anti-biotic Resistance Completed 2009-03-01 2009-10-01 ClinicalTrials.gov
NCT00775437 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use Phase3 Juvenile Idiopathic Arthritis Completed 2009-03-01 2013-03-01 ClinicalTrials.gov
NCT00851890 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral A… Phase2 Chronic Hepatitis C Virus Infection Completed 2009-03-01 2009-07-01 ClinicalTrials.gov
NCT00874887 A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyed… Phase4 Anti-biotic Resistance Completed 2009-03-01 2009-10-01 ClinicalTrials.gov
NCT01078155 Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Met… — Rheumatoid Arthritis Completed 2009-03-01 2014-05-01 ClinicalTrials.gov
NCT01095640 Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical … Na Acne Vulgaris Completed 2009-03-01 2009-12-01 ClinicalTrials.gov
NCT00856414 Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correc… Phase4 Skin Aging Completed 2009-03-01 2009-04-01 ClinicalTrials.gov
NCT01095640 Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical … Na Acne Vulgaris Completed 2009-03-01 2009-12-01 ClinicalTrials.gov
NCT01095640 Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical … Na Acne Vulgaris Completed 2009-03-01 2009-12-01 ClinicalTrials.gov
NCT00856414 Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correc… Phase4 Skin Aging Completed 2009-03-01 2009-04-01 ClinicalTrials.gov
NCT00856414 Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correc… Phase4 Skin Aging Completed 2009-03-01 2009-04-01 ClinicalTrials.gov
NCT00874887 A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyed… Phase4 Anti-biotic Resistance Completed 2009-03-01 2009-10-01 ClinicalTrials.gov
NCT00775437 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use Phase3 Juvenile Idiopathic Arthritis Completed 2009-03-01 2013-03-01 ClinicalTrials.gov
NCT00851890 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral A… Phase2 Chronic Hepatitis C Virus Infection Completed 2009-03-01 2009-07-01 ClinicalTrials.gov
NCT00851890 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral A… Phase2 Chronic Hepatitis C Virus Infection Completed 2009-03-01 2009-07-01 ClinicalTrials.gov
NCT01078155 Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Met… — Rheumatoid Arthritis Completed 2009-03-01 2014-05-01 ClinicalTrials.gov
NCT00874887 A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyed… Phase4 Anti-biotic Resistance Completed 2009-03-01 2009-10-01 ClinicalTrials.gov
NCT00775437 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use Phase3 Juvenile Idiopathic Arthritis Completed 2009-03-01 2013-03-01 ClinicalTrials.gov
NCT00870740 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2009-02-01 2012-10-01 ClinicalTrials.gov
NCT00870740 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2009-02-01 2012-10-01 ClinicalTrials.gov
NCT00809848 Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular H… Phase1 Ocular Hypertension Completed 2009-02-01 2009-05-01 ClinicalTrials.gov
NCT00733187 Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-8… Phase1 Advanced Solid Tumors Completed 2009-02-01 2012-06-01 ClinicalTrials.gov
NCT00809848 Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular H… Phase1 Ocular Hypertension Completed 2009-02-01 2009-05-01 ClinicalTrials.gov
NCT01421719 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bl… Phase4 Parkinson's Disease Completed 2009-02-01 2011-07-01 ClinicalTrials.gov
NCT00853099 A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active U… Phase3 Ulcerative Colitis Completed 2009-02-01 2013-08-01 ClinicalTrials.gov
NCT01421719 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bl… Phase4 Parkinson's Disease Completed 2009-02-01 2011-07-01 ClinicalTrials.gov
NCT00809848 Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular H… Phase1 Ocular Hypertension Completed 2009-02-01 2009-05-01 ClinicalTrials.gov
NCT00733187 Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-8… Phase1 Advanced Solid Tumors Completed 2009-02-01 2012-06-01 ClinicalTrials.gov
NCT00870740 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2009-02-01 2012-10-01 ClinicalTrials.gov
NCT00733187 Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-8… Phase1 Advanced Solid Tumors Completed 2009-02-01 2012-06-01 ClinicalTrials.gov
NCT00853099 A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active U… Phase3 Ulcerative Colitis Completed 2009-02-01 2013-08-01 ClinicalTrials.gov
NCT00850044 Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without R… Phase1 HCV Infection Completed 2009-02-01 — ClinicalTrials.gov
NCT00804908 A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Meta… Phase2 Melanoma Completed 2009-02-01 2016-01-01 ClinicalTrials.gov
NCT00804908 A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Meta… Phase2 Melanoma Completed 2009-02-01 2016-01-01 ClinicalTrials.gov
NCT00850044 Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without R… Phase1 HCV Infection Completed 2009-02-01 — ClinicalTrials.gov
NCT00870740 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2009-02-01 2012-10-01 ClinicalTrials.gov
NCT00850044 Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without R… Phase1 HCV Infection Completed 2009-02-01 — ClinicalTrials.gov
NCT01421719 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bl… Phase4 Parkinson's Disease Completed 2009-02-01 2011-07-01 ClinicalTrials.gov
NCT00853099 A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active U… Phase3 Ulcerative Colitis Completed 2009-02-01 2013-08-01 ClinicalTrials.gov
NCT00804908 A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Meta… Phase2 Melanoma Completed 2009-02-01 2016-01-01 ClinicalTrials.gov
NCT00733187 Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-8… Phase1 Advanced Solid Tumors Completed 2009-02-01 2012-06-01 ClinicalTrials.gov
NCT01421719 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bl… Phase4 Parkinson's Disease Completed 2009-02-01 2011-07-01 ClinicalTrials.gov
NCT00850044 Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without R… Phase1 HCV Infection Completed 2009-02-01 — ClinicalTrials.gov
NCT00804908 A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Meta… Phase2 Melanoma Completed 2009-02-01 2016-01-01 ClinicalTrials.gov
NCT00853099 A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active U… Phase3 Ulcerative Colitis Completed 2009-02-01 2013-08-01 ClinicalTrials.gov
NCT00809848 Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular H… Phase1 Ocular Hypertension Completed 2009-02-01 2009-05-01 ClinicalTrials.gov
NCT01076205 Safety and Effect on Quality of Life/Work Productivity of Humira in Patients Wi… — Rheumatoid Arthritis Completed 2009-01-12 2017-09-14 ClinicalTrials.gov
NCT01076205 Safety and Effect on Quality of Life/Work Productivity of Humira in Patients Wi… — Rheumatoid Arthritis Completed 2009-01-12 2017-09-14 ClinicalTrials.gov
NCT01076205 Safety and Effect on Quality of Life/Work Productivity of Humira in Patients Wi… — Rheumatoid Arthritis Completed 2009-01-12 2017-09-14 ClinicalTrials.gov
NCT01076205 Safety and Effect on Quality of Life/Work Productivity of Humira in Patients Wi… — Rheumatoid Arthritis Completed 2009-01-12 2017-09-14 ClinicalTrials.gov
NCT00357994 Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel… Phase3 Advanced Parkinson's Disease Completed 2009-01-01 2011-10-01 ClinicalTrials.gov
NCT01987765 Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunct… — Conjunctivitis, Allergic Completed 2009-01-01 2012-09-01 ClinicalTrials.gov
NCT00945295 Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus … Na Upper Limb Spasticity Completed 2009-01-01 2012-05-01 ClinicalTrials.gov
NCT00945295 Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus … Na Upper Limb Spasticity Completed 2009-01-01 2012-05-01 ClinicalTrials.gov
NCT00799227 Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic … Phase2 Diabetic Macular Edema Completed 2009-01-01 2009-12-01 ClinicalTrials.gov
NCT00808509 A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rhe… Phase4 Arthritis, Rheumatoid Completed 2009-01-01 2012-09-01 ClinicalTrials.gov
NCT00816517 Use of Botulinum Toxin to Treat Psoriasis Phase1 Psoriasis Vulgaris Completed 2009-01-01 2015-12-01 ClinicalTrials.gov
NCT00822523 Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via St… Na Muscle Strength Completed 2009-01-01 2015-07-01 ClinicalTrials.gov
NCT00827255 Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05% — Dry Eye Disease Completed 2009-01-01 2009-10-01 ClinicalTrials.gov
NCT00836017 CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinu… — Cervical Dystonia Completed 2009-01-01 2013-08-01 ClinicalTrials.gov
NCT00876447 A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overacti… Phase3 Overactive Bladder Completed 2009-01-01 2013-09-04 ClinicalTrials.gov
NCT00900666 Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Kne… Na Stiff Knee Gait Terminated 2009-01-01 2011-12-01 ClinicalTrials.gov
NCT00945295 Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus … Na Upper Limb Spasticity Completed 2009-01-01 2012-05-01 ClinicalTrials.gov
NCT01029535 Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Defi… Na Mid-face Volume Deficiency Completed 2009-01-01 2011-10-01 ClinicalTrials.gov
NCT00900666 Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Kne… Na Stiff Knee Gait Terminated 2009-01-01 2011-12-01 ClinicalTrials.gov
NCT00357994 Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel… Phase3 Advanced Parkinson's Disease Completed 2009-01-01 2011-10-01 ClinicalTrials.gov
NCT01987765 Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunct… — Conjunctivitis, Allergic Completed 2009-01-01 2012-09-01 ClinicalTrials.gov
NCT00876447 A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overacti… Phase3 Overactive Bladder Completed 2009-01-01 2013-09-04 ClinicalTrials.gov
NCT00357994 Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel… Phase3 Advanced Parkinson's Disease Completed 2009-01-01 2011-10-01 ClinicalTrials.gov
NCT00799227 Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic … Phase2 Diabetic Macular Edema Completed 2009-01-01 2009-12-01 ClinicalTrials.gov
NCT00808509 A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rhe… Phase4 Arthritis, Rheumatoid Completed 2009-01-01 2012-09-01 ClinicalTrials.gov
NCT00816517 Use of Botulinum Toxin to Treat Psoriasis Phase1 Psoriasis Vulgaris Completed 2009-01-01 2015-12-01 ClinicalTrials.gov
NCT00822523 Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via St… Na Muscle Strength Completed 2009-01-01 2015-07-01 ClinicalTrials.gov
NCT00827255 Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05% — Dry Eye Disease Completed 2009-01-01 2009-10-01 ClinicalTrials.gov
NCT00836017 CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinu… — Cervical Dystonia Completed 2009-01-01 2013-08-01 ClinicalTrials.gov
NCT00836017 CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinu… — Cervical Dystonia Completed 2009-01-01 2013-08-01 ClinicalTrials.gov
NCT01629433 Onabotulinumtoxina Intradetrusorial Injections and NGF Expression — Overactive Detrusor Completed 2009-01-01 2012-03-01 ClinicalTrials.gov
NCT00876447 A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overacti… Phase3 Overactive Bladder Completed 2009-01-01 2013-09-04 ClinicalTrials.gov
NCT00827255 Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05% — Dry Eye Disease Completed 2009-01-01 2009-10-01 ClinicalTrials.gov
NCT00900666 Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Kne… Na Stiff Knee Gait Terminated 2009-01-01 2011-12-01 ClinicalTrials.gov
NCT00822523 Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via St… Na Muscle Strength Completed 2009-01-01 2015-07-01 ClinicalTrials.gov
NCT00816517 Use of Botulinum Toxin to Treat Psoriasis Phase1 Psoriasis Vulgaris Completed 2009-01-01 2015-12-01 ClinicalTrials.gov
NCT00808509 A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rhe… Phase4 Arthritis, Rheumatoid Completed 2009-01-01 2012-09-01 ClinicalTrials.gov
NCT00799227 Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic … Phase2 Diabetic Macular Edema Completed 2009-01-01 2009-12-01 ClinicalTrials.gov
NCT00945295 Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus … Na Upper Limb Spasticity Completed 2009-01-01 2012-05-01 ClinicalTrials.gov
NCT01218737 Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administra… Phase3 Ocular Infection and Inflammation Completed 2009-01-01 2009-06-01 ClinicalTrials.gov
NCT00876447 A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overacti… Phase3 Overactive Bladder Completed 2009-01-01 2013-09-04 ClinicalTrials.gov
NCT01029535 Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Defi… Na Mid-face Volume Deficiency Completed 2009-01-01 2011-10-01 ClinicalTrials.gov
NCT01987765 Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunct… — Conjunctivitis, Allergic Completed 2009-01-01 2012-09-01 ClinicalTrials.gov
NCT01218737 Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administra… Phase3 Ocular Infection and Inflammation Completed 2009-01-01 2009-06-01 ClinicalTrials.gov
NCT01218737 Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administra… Phase3 Ocular Infection and Inflammation Completed 2009-01-01 2009-06-01 ClinicalTrials.gov
NCT00357994 Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel… Phase3 Advanced Parkinson's Disease Completed 2009-01-01 2011-10-01 ClinicalTrials.gov
NCT00900666 Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Kne… Na Stiff Knee Gait Terminated 2009-01-01 2011-12-01 ClinicalTrials.gov
NCT01629433 Onabotulinumtoxina Intradetrusorial Injections and NGF Expression — Overactive Detrusor Completed 2009-01-01 2012-03-01 ClinicalTrials.gov
NCT00799227 Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic … Phase2 Diabetic Macular Edema Completed 2009-01-01 2009-12-01 ClinicalTrials.gov
NCT00808509 A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rhe… Phase4 Arthritis, Rheumatoid Completed 2009-01-01 2012-09-01 ClinicalTrials.gov
NCT00816517 Use of Botulinum Toxin to Treat Psoriasis Phase1 Psoriasis Vulgaris Completed 2009-01-01 2015-12-01 ClinicalTrials.gov
NCT00822523 Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via St… Na Muscle Strength Completed 2009-01-01 2015-07-01 ClinicalTrials.gov
NCT00827255 Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05% — Dry Eye Disease Completed 2009-01-01 2009-10-01 ClinicalTrials.gov
NCT00836017 CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinu… — Cervical Dystonia Completed 2009-01-01 2013-08-01 ClinicalTrials.gov
NCT01629433 Onabotulinumtoxina Intradetrusorial Injections and NGF Expression — Overactive Detrusor Completed 2009-01-01 2012-03-01 ClinicalTrials.gov
NCT01029535 Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Defi… Na Mid-face Volume Deficiency Completed 2009-01-01 2011-10-01 ClinicalTrials.gov
NCT01987765 Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunct… — Conjunctivitis, Allergic Completed 2009-01-01 2012-09-01 ClinicalTrials.gov
NCT01218737 Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administra… Phase3 Ocular Infection and Inflammation Completed 2009-01-01 2009-06-01 ClinicalTrials.gov
NCT01029535 Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Defi… Na Mid-face Volume Deficiency Completed 2009-01-01 2011-10-01 ClinicalTrials.gov
NCT01629433 Onabotulinumtoxina Intradetrusorial Injections and NGF Expression — Overactive Detrusor Completed 2009-01-01 2012-03-01 ClinicalTrials.gov
NCT01073462 Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Card… — Secondary Hyperparathyroidism Completed 2008-12-01 2013-06-01 ClinicalTrials.gov
NCT00667446 Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of… Phase3 Precocious Completed 2008-12-01 2013-01-01 ClinicalTrials.gov
NCT01073462 Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Card… — Secondary Hyperparathyroidism Completed 2008-12-01 2013-06-01 ClinicalTrials.gov
NCT00834210 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monothera… Phase4 Acne Vulgaris Completed 2008-12-01 2009-09-01 ClinicalTrials.gov
NCT01073462 Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Card… — Secondary Hyperparathyroidism Completed 2008-12-01 2013-06-01 ClinicalTrials.gov
NCT00835198 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy… Phase4 Acne Vulgaris Completed 2008-12-01 2009-08-01 ClinicalTrials.gov
NCT00667446 Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of… Phase3 Precocious Completed 2008-12-01 2013-01-01 ClinicalTrials.gov
NCT00811850 Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Bloo… Phase4 Glaucoma Completed 2008-12-01 2009-12-01 ClinicalTrials.gov
NCT00811850 Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Bloo… Phase4 Glaucoma Completed 2008-12-01 2009-12-01 ClinicalTrials.gov
NCT01073462 Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Card… — Secondary Hyperparathyroidism Completed 2008-12-01 2013-06-01 ClinicalTrials.gov
NCT00811850 Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Bloo… Phase4 Glaucoma Completed 2008-12-01 2009-12-01 ClinicalTrials.gov
NCT00835198 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy… Phase4 Acne Vulgaris Completed 2008-12-01 2009-08-01 ClinicalTrials.gov
NCT00667446 Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of… Phase3 Precocious Completed 2008-12-01 2013-01-01 ClinicalTrials.gov
NCT00667446 Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of… Phase3 Precocious Completed 2008-12-01 2013-01-01 ClinicalTrials.gov
NCT00834210 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monothera… Phase4 Acne Vulgaris Completed 2008-12-01 2009-09-01 ClinicalTrials.gov
NCT00835198 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy… Phase4 Acne Vulgaris Completed 2008-12-01 2009-08-01 ClinicalTrials.gov
NCT00834210 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monothera… Phase4 Acne Vulgaris Completed 2008-12-01 2009-09-01 ClinicalTrials.gov
NCT00811850 Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Bloo… Phase4 Glaucoma Completed 2008-12-01 2009-12-01 ClinicalTrials.gov
NCT00834210 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monothera… Phase4 Acne Vulgaris Completed 2008-12-01 2009-09-01 ClinicalTrials.gov
NCT00835198 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy… Phase4 Acne Vulgaris Completed 2008-12-01 2009-08-01 ClinicalTrials.gov
NCT00797225 Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in … Phase2 Endometriosis Completed 2008-11-26 2010-02-24 ClinicalTrials.gov
NCT00797225 Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in … Phase2 Endometriosis Completed 2008-11-26 2010-02-24 ClinicalTrials.gov
NCT00797225 Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in … Phase2 Endometriosis Completed 2008-11-26 2010-02-24 ClinicalTrials.gov
NCT00797225 Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in … Phase2 Endometriosis Completed 2008-11-26 2010-02-24 ClinicalTrials.gov
NCT00888693 A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacody… Phase1 Schizophrenia Completed 2008-11-01 — ClinicalTrials.gov
NCT00888693 A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacody… Phase1 Schizophrenia Completed 2008-11-01 — ClinicalTrials.gov
NCT00850889 Juvederm Ultra With Lidocaine Compared With Restylane for the Correction of Nas… Phase4 Nasolabial Folds Completed 2008-11-01 2008-11-01 ClinicalTrials.gov
NCT00850889 Juvederm Ultra With Lidocaine Compared With Restylane for the Correction of Nas… Phase4 Nasolabial Folds Completed 2008-11-01 2008-11-01 ClinicalTrials.gov
NCT00850889 Juvederm Ultra With Lidocaine Compared With Restylane for the Correction of Nas… Phase4 Nasolabial Folds Completed 2008-11-01 2008-11-01 ClinicalTrials.gov
NCT00775411 Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular End… Phase2 Choroidal Neovascularization Completed 2008-11-01 2010-04-01 ClinicalTrials.gov
NCT00888693 A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacody… Phase1 Schizophrenia Completed 2008-11-01 — ClinicalTrials.gov
NCT00791323 Efficacy of Ketorolac 0.4% in Prostaglandin Suppression Phase4 Inflammation Completed 2008-11-01 2009-08-01 ClinicalTrials.gov
NCT00791323 Efficacy of Ketorolac 0.4% in Prostaglandin Suppression Phase4 Inflammation Completed 2008-11-01 2009-08-01 ClinicalTrials.gov
NCT00775411 Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular End… Phase2 Choroidal Neovascularization Completed 2008-11-01 2010-04-01 ClinicalTrials.gov
NCT00791323 Efficacy of Ketorolac 0.4% in Prostaglandin Suppression Phase4 Inflammation Completed 2008-11-01 2009-08-01 ClinicalTrials.gov
NCT00888693 A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacody… Phase1 Schizophrenia Completed 2008-11-01 — ClinicalTrials.gov
NCT00775411 Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular End… Phase2 Choroidal Neovascularization Completed 2008-11-01 2010-04-01 ClinicalTrials.gov
NCT00791323 Efficacy of Ketorolac 0.4% in Prostaglandin Suppression Phase4 Inflammation Completed 2008-11-01 2009-08-01 ClinicalTrials.gov
NCT00850889 Juvederm Ultra With Lidocaine Compared With Restylane for the Correction of Nas… Phase4 Nasolabial Folds Completed 2008-11-01 2008-11-01 ClinicalTrials.gov
NCT00775411 Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular End… Phase2 Choroidal Neovascularization Completed 2008-11-01 2010-04-01 ClinicalTrials.gov
NCT02075697 Spanish Registry of Systemic Treatments in Psoriasis — Psoriasis Unknown 2008-10-01 2025-10-01 ClinicalTrials.gov
NCT00707889 Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Com… Phase2 Advanced Colorectal Cancer Completed 2008-10-01 2012-05-01 ClinicalTrials.gov
NCT02075697 Spanish Registry of Systemic Treatments in Psoriasis — Psoriasis Unknown 2008-10-01 2025-10-01 ClinicalTrials.gov
NCT02075697 Spanish Registry of Systemic Treatments in Psoriasis — Psoriasis Unknown 2008-10-01 2025-10-01 ClinicalTrials.gov
NCT02075697 Spanish Registry of Systemic Treatments in Psoriasis — Psoriasis Unknown 2008-10-01 2025-10-01 ClinicalTrials.gov
NCT00707889 Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Com… Phase2 Advanced Colorectal Cancer Completed 2008-10-01 2012-05-01 ClinicalTrials.gov
NCT00707889 Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Com… Phase2 Advanced Colorectal Cancer Completed 2008-10-01 2012-05-01 ClinicalTrials.gov
NCT00707889 Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Com… Phase2 Advanced Colorectal Cancer Completed 2008-10-01 2012-05-01 ClinicalTrials.gov
NCT00799877 Chronic Plaque Psoriasis (Ps) Registry — Chronic Plaque Psoriasis Completed 2008-09-26 2023-02-13 ClinicalTrials.gov
NCT00799877 Chronic Plaque Psoriasis (Ps) Registry — Chronic Plaque Psoriasis Completed 2008-09-26 2023-02-13 ClinicalTrials.gov
NCT00799877 Chronic Plaque Psoriasis (Ps) Registry — Chronic Plaque Psoriasis Completed 2008-09-26 2023-02-13 ClinicalTrials.gov
NCT00799877 Chronic Plaque Psoriasis (Ps) Registry — Chronic Plaque Psoriasis Completed 2008-09-26 2023-02-13 ClinicalTrials.gov
NCT02029677 Appetite Suppression / Hormone Study Control Group — Morbid Obesity Active_Not_Recruiting 2008-09-01 2024-12-01 ClinicalTrials.gov
NCT00763321 Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate … Phase3 Chronic Low Back Pain Completed 2008-09-01 2009-04-01 ClinicalTrials.gov
NCT00763321 Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate … Phase3 Chronic Low Back Pain Completed 2008-09-01 2009-04-01 ClinicalTrials.gov
NCT00761150 Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate … Phase3 Chronic Low Back Pain Completed 2008-09-01 2009-03-01 ClinicalTrials.gov
NCT00756678 Efficacy and Acceptability of Two Lubricant Eye Drops Phase4 Dry Eye Syndromes Completed 2008-09-01 2009-08-01 ClinicalTrials.gov
NCT01076179 Kaletra in Combination With Antiretroviral Agents — Human Immunodeficiency Virus Completed 2008-09-01 2016-01-01 ClinicalTrials.gov
NCT02029677 Appetite Suppression / Hormone Study Control Group — Morbid Obesity Active_Not_Recruiting 2008-09-01 2024-12-01 ClinicalTrials.gov
NCT00756678 Efficacy and Acceptability of Two Lubricant Eye Drops Phase4 Dry Eye Syndromes Completed 2008-09-01 2009-08-01 ClinicalTrials.gov
NCT01076179 Kaletra in Combination With Antiretroviral Agents — Human Immunodeficiency Virus Completed 2008-09-01 2016-01-01 ClinicalTrials.gov
NCT00756678 Efficacy and Acceptability of Two Lubricant Eye Drops Phase4 Dry Eye Syndromes Completed 2008-09-01 2009-08-01 ClinicalTrials.gov
NCT00761150 Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate … Phase3 Chronic Low Back Pain Completed 2008-09-01 2009-03-01 ClinicalTrials.gov
NCT00763321 Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate … Phase3 Chronic Low Back Pain Completed 2008-09-01 2009-04-01 ClinicalTrials.gov
NCT00718380 A Phase 1 Study of ABT-869 in Subjects With Solid Tumors Phase1 Solid Tumor Completed 2008-09-01 2012-06-01 ClinicalTrials.gov
NCT00718380 A Phase 1 Study of ABT-869 in Subjects With Solid Tumors Phase1 Solid Tumor Completed 2008-09-01 2012-06-01 ClinicalTrials.gov
NCT02029677 Appetite Suppression / Hormone Study Control Group — Morbid Obesity Active_Not_Recruiting 2008-09-01 2024-12-01 ClinicalTrials.gov
NCT00718380 A Phase 1 Study of ABT-869 in Subjects With Solid Tumors Phase1 Solid Tumor Completed 2008-09-01 2012-06-01 ClinicalTrials.gov
NCT00718380 A Phase 1 Study of ABT-869 in Subjects With Solid Tumors Phase1 Solid Tumor Completed 2008-09-01 2012-06-01 ClinicalTrials.gov
NCT00763321 Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate … Phase3 Chronic Low Back Pain Completed 2008-09-01 2009-04-01 ClinicalTrials.gov
NCT00761150 Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate … Phase3 Chronic Low Back Pain Completed 2008-09-01 2009-03-01 ClinicalTrials.gov
NCT00756678 Efficacy and Acceptability of Two Lubricant Eye Drops Phase4 Dry Eye Syndromes Completed 2008-09-01 2009-08-01 ClinicalTrials.gov
NCT02029677 Appetite Suppression / Hormone Study Control Group — Morbid Obesity Active_Not_Recruiting 2008-09-01 2024-12-01 ClinicalTrials.gov
NCT01076179 Kaletra in Combination With Antiretroviral Agents — Human Immunodeficiency Virus Completed 2008-09-01 2016-01-01 ClinicalTrials.gov
NCT01076179 Kaletra in Combination With Antiretroviral Agents — Human Immunodeficiency Virus Completed 2008-09-01 2016-01-01 ClinicalTrials.gov
NCT00761150 Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate … Phase3 Chronic Low Back Pain Completed 2008-09-01 2009-03-01 ClinicalTrials.gov
NCT00850733 516-BOTOX Urinary Incontinence Detrusor — Urinary Incontinence Completed 2008-08-01 2009-09-01 ClinicalTrials.gov
NCT00726882 A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infe… Phase2 HCV Infection Completed 2008-08-01 2010-05-01 ClinicalTrials.gov
NCT00726882 A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infe… Phase2 HCV Infection Completed 2008-08-01 2010-05-01 ClinicalTrials.gov
NCT00726882 A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infe… Phase2 HCV Infection Completed 2008-08-01 2010-05-01 ClinicalTrials.gov
NCT00742560 A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclona… Phase2 Hematologic Cancer Completed 2008-08-01 2016-10-01 ClinicalTrials.gov
NCT00850733 516-BOTOX Urinary Incontinence Detrusor — Urinary Incontinence Completed 2008-08-01 2009-09-01 ClinicalTrials.gov
NCT00742560 A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclona… Phase2 Hematologic Cancer Completed 2008-08-01 2016-10-01 ClinicalTrials.gov
NCT00850733 516-BOTOX Urinary Incontinence Detrusor — Urinary Incontinence Completed 2008-08-01 2009-09-01 ClinicalTrials.gov
NCT00742560 A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclona… Phase2 Hematologic Cancer Completed 2008-08-01 2016-10-01 ClinicalTrials.gov
NCT00850733 516-BOTOX Urinary Incontinence Detrusor — Urinary Incontinence Completed 2008-08-01 2009-09-01 ClinicalTrials.gov
NCT00726882 A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infe… Phase2 HCV Infection Completed 2008-08-01 2010-05-01 ClinicalTrials.gov
NCT00742560 A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclona… Phase2 Hematologic Cancer Completed 2008-08-01 2016-10-01 ClinicalTrials.gov
NCT00783510 Juvenile Idiopathic Arthritis (JIA) Registry — Juvenile Idiopathic Arthritis Completed 2008-07-11 2024-02-01 ClinicalTrials.gov
NCT00783510 Juvenile Idiopathic Arthritis (JIA) Registry — Juvenile Idiopathic Arthritis Completed 2008-07-11 2024-02-01 ClinicalTrials.gov
NCT00783510 Juvenile Idiopathic Arthritis (JIA) Registry — Juvenile Idiopathic Arthritis Completed 2008-07-11 2024-02-01 ClinicalTrials.gov
NCT00783510 Juvenile Idiopathic Arthritis (JIA) Registry — Juvenile Idiopathic Arthritis Completed 2008-07-11 2024-02-01 ClinicalTrials.gov
NCT00735449 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in… Phase4 Glaucoma Completed 2008-07-01 2009-12-01 ClinicalTrials.gov
NCT00710580 Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in… Phase3 Moderate to Severe Plaque Psoriasis Completed 2008-07-01 2009-04-01 ClinicalTrials.gov
NCT00735449 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in… Phase4 Glaucoma Completed 2008-07-01 2009-12-01 ClinicalTrials.gov
NCT00645177 Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone… Phase2 Metastatic Breast Cancer Completed 2008-07-01 2009-12-01 ClinicalTrials.gov
NCT00661479 An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant… Phase1 Retinitis Pigmentosa Completed 2008-07-01 2010-05-01 ClinicalTrials.gov
NCT00735449 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in… Phase4 Glaucoma Completed 2008-07-01 2009-12-01 ClinicalTrials.gov
NCT00623636 Phase 3 Study of MAP0004 in Adult Migraineurs Phase3 Migraine Disorders Completed 2008-07-01 2011-01-01 ClinicalTrials.gov
NCT00623636 Phase 3 Study of MAP0004 in Adult Migraineurs Phase3 Migraine Disorders Completed 2008-07-01 2011-01-01 ClinicalTrials.gov
NCT00623636 Phase 3 Study of MAP0004 in Adult Migraineurs Phase3 Migraine Disorders Completed 2008-07-01 2011-01-01 ClinicalTrials.gov
NCT00710580 Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in… Phase3 Moderate to Severe Plaque Psoriasis Completed 2008-07-01 2009-04-01 ClinicalTrials.gov
NCT00710580 Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in… Phase3 Moderate to Severe Plaque Psoriasis Completed 2008-07-01 2009-04-01 ClinicalTrials.gov
NCT00645177 Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone… Phase2 Metastatic Breast Cancer Completed 2008-07-01 2009-12-01 ClinicalTrials.gov
NCT00735449 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in… Phase4 Glaucoma Completed 2008-07-01 2009-12-01 ClinicalTrials.gov
NCT00645177 Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone… Phase2 Metastatic Breast Cancer Completed 2008-07-01 2009-12-01 ClinicalTrials.gov
NCT00710580 Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in… Phase3 Moderate to Severe Plaque Psoriasis Completed 2008-07-01 2009-04-01 ClinicalTrials.gov
NCT00661479 An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant… Phase1 Retinitis Pigmentosa Completed 2008-07-01 2010-05-01 ClinicalTrials.gov
NCT00645177 Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone… Phase2 Metastatic Breast Cancer Completed 2008-07-01 2009-12-01 ClinicalTrials.gov
NCT00661479 An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant… Phase1 Retinitis Pigmentosa Completed 2008-07-01 2010-05-01 ClinicalTrials.gov
NCT00661479 An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant… Phase1 Retinitis Pigmentosa Completed 2008-07-01 2010-05-01 ClinicalTrials.gov
NCT00623636 Phase 3 Study of MAP0004 in Adult Migraineurs Phase3 Migraine Disorders Completed 2008-07-01 2011-01-01 ClinicalTrials.gov
NCT00716534 Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Ad… Phase2 Advanced or Metastatic Non-Small Cell Lung Cancer Completed 2008-06-01 2012-04-01 ClinicalTrials.gov
NCT00716534 Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Ad… Phase2 Advanced or Metastatic Non-Small Cell Lung Cancer Completed 2008-06-01 2012-04-01 ClinicalTrials.gov
NCT00696904 Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genot… Phase1 HCV Infection Completed 2008-06-01 — ClinicalTrials.gov
NCT00696904 Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genot… Phase1 HCV Infection Completed 2008-06-01 — ClinicalTrials.gov
NCT00716534 Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Ad… Phase2 Advanced or Metastatic Non-Small Cell Lung Cancer Completed 2008-06-01 2012-04-01 ClinicalTrials.gov
NCT00696904 Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genot… Phase1 HCV Infection Completed 2008-06-01 — ClinicalTrials.gov
NCT00696904 Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genot… Phase1 HCV Infection Completed 2008-06-01 — ClinicalTrials.gov
NCT00716534 Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Ad… Phase2 Advanced or Metastatic Non-Small Cell Lung Cancer Completed 2008-06-01 2012-04-01 ClinicalTrials.gov
NCT00658619 Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geogra… Phase2 Macular Degeneration Completed 2008-05-01 2011-04-08 ClinicalTrials.gov
NCT00686933 Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Def… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-05-01 2008-10-01 ClinicalTrials.gov
NCT00686933 Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Def… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-05-01 2008-10-01 ClinicalTrials.gov
NCT00686933 Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Def… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-05-01 2008-10-01 ClinicalTrials.gov
NCT00658619 Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geogra… Phase2 Macular Degeneration Completed 2008-05-01 2011-04-08 ClinicalTrials.gov
NCT00658619 Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geogra… Phase2 Macular Degeneration Completed 2008-05-01 2011-04-08 ClinicalTrials.gov
NCT00686374 Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demo… Phase3 Crohn's Disease Completed 2008-05-01 2017-04-04 ClinicalTrials.gov
NCT00686374 Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demo… Phase3 Crohn's Disease Completed 2008-05-01 2017-04-04 ClinicalTrials.gov
NCT00686374 Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demo… Phase3 Crohn's Disease Completed 2008-05-01 2017-04-04 ClinicalTrials.gov
NCT00686933 Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Def… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-05-01 2008-10-01 ClinicalTrials.gov
NCT00686374 Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demo… Phase3 Crohn's Disease Completed 2008-05-01 2017-04-04 ClinicalTrials.gov
NCT00658619 Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geogra… Phase2 Macular Degeneration Completed 2008-05-01 2011-04-08 ClinicalTrials.gov
NCT00773253 Botox for Cervical Dystonia Following EMG Mapping Phase4 Cervical Dystonia Completed 2008-04-01 2011-01-01 ClinicalTrials.gov
NCT00697697 A Study of 2 Doses of MAP0010 in Asthmatic Children Phase3 Asthma Terminated 2008-04-01 2009-12-01 ClinicalTrials.gov
NCT00773253 Botox for Cervical Dystonia Following EMG Mapping Phase4 Cervical Dystonia Completed 2008-04-01 2011-01-01 ClinicalTrials.gov
NCT00697697 A Study of 2 Doses of MAP0010 in Asthmatic Children Phase3 Asthma Terminated 2008-04-01 2009-12-01 ClinicalTrials.gov
NCT00697697 A Study of 2 Doses of MAP0010 in Asthmatic Children Phase3 Asthma Terminated 2008-04-01 2009-12-01 ClinicalTrials.gov
NCT00773253 Botox for Cervical Dystonia Following EMG Mapping Phase4 Cervical Dystonia Completed 2008-04-01 2011-01-01 ClinicalTrials.gov
NCT00697697 A Study of 2 Doses of MAP0010 in Asthmatic Children Phase3 Asthma Terminated 2008-04-01 2009-12-01 ClinicalTrials.gov
NCT00773253 Botox for Cervical Dystonia Following EMG Mapping Phase4 Cervical Dystonia Completed 2008-04-01 2011-01-01 ClinicalTrials.gov
NCT00533351 Safety and Efficacy of AGN201781 in Neuropathic Pain Phase2 Neuralgia Terminated 2008-03-01 2008-06-01 ClinicalTrials.gov
NCT00640185 Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Def… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-03-01 2008-08-01 ClinicalTrials.gov
NCT01083849 Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients … — Kidney Insufficiency Completed 2008-03-01 2013-12-01 ClinicalTrials.gov
NCT00640419 Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyp… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-03-01 2008-07-01 ClinicalTrials.gov
NCT00691197 Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear Phase2 Ametropia Completed 2008-03-01 2008-10-01 ClinicalTrials.gov
NCT00533351 Safety and Efficacy of AGN201781 in Neuropathic Pain Phase2 Neuralgia Terminated 2008-03-01 2008-06-01 ClinicalTrials.gov
NCT00691197 Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear Phase2 Ametropia Completed 2008-03-01 2008-10-01 ClinicalTrials.gov
NCT00640419 Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyp… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-03-01 2008-07-01 ClinicalTrials.gov
NCT00640185 Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Def… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-03-01 2008-08-01 ClinicalTrials.gov
NCT00691197 Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear Phase2 Ametropia Completed 2008-03-01 2008-10-01 ClinicalTrials.gov
NCT00533351 Safety and Efficacy of AGN201781 in Neuropathic Pain Phase2 Neuralgia Terminated 2008-03-01 2008-06-01 ClinicalTrials.gov
NCT00640419 Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyp… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-03-01 2008-07-01 ClinicalTrials.gov
NCT00640185 Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Def… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-03-01 2008-08-01 ClinicalTrials.gov
NCT00640419 Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyp… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-03-01 2008-07-01 ClinicalTrials.gov
NCT00640185 Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Def… Phase2 Attention-Deficit/Hyperactivity Disorder Completed 2008-03-01 2008-08-01 ClinicalTrials.gov
NCT00533351 Safety and Efficacy of AGN201781 in Neuropathic Pain Phase2 Neuralgia Terminated 2008-03-01 2008-06-01 ClinicalTrials.gov
NCT00691197 Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear Phase2 Ametropia Completed 2008-03-01 2008-10-01 ClinicalTrials.gov
NCT01083849 Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients … — Kidney Insufficiency Completed 2008-03-01 2013-12-01 ClinicalTrials.gov
NCT01083849 Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients … — Kidney Insufficiency Completed 2008-03-01 2013-12-01 ClinicalTrials.gov
NCT01083849 Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients … — Kidney Insufficiency Completed 2008-03-01 2013-12-01 ClinicalTrials.gov
NCT00619866 An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis Phase2 Endometriosis, Pain Completed 2008-02-19 2009-08-28 ClinicalTrials.gov
NCT00619866 An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis Phase2 Endometriosis, Pain Completed 2008-02-19 2009-08-28 ClinicalTrials.gov
NCT00619866 An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis Phase2 Endometriosis, Pain Completed 2008-02-19 2009-08-28 ClinicalTrials.gov
NCT00619866 An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis Phase2 Endometriosis, Pain Completed 2008-02-19 2009-08-28 ClinicalTrials.gov
NCT00390221 Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat R… Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2008-02-01 2011-08-01 ClinicalTrials.gov
NCT00616772 Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination W… Phase3 Coronary Artery Disease Completed 2008-02-01 2012-09-01 ClinicalTrials.gov
NCT00626002 Open Label Continuation Study in Moderate to Severe Psoriasis Phase3 Moderate to Severe Plaque Psoriasis Completed 2008-02-01 2011-10-01 ClinicalTrials.gov
NCT00626002 Open Label Continuation Study in Moderate to Severe Psoriasis Phase3 Moderate to Severe Plaque Psoriasis Completed 2008-02-01 2011-10-01 ClinicalTrials.gov
NCT00616772 Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination W… Phase3 Coronary Artery Disease Completed 2008-02-01 2012-09-01 ClinicalTrials.gov
NCT00518089 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial C… Phase3 Bacterial Conjunctivitis Completed 2008-02-01 2009-01-01 ClinicalTrials.gov
NCT00626002 Open Label Continuation Study in Moderate to Severe Psoriasis Phase3 Moderate to Severe Plaque Psoriasis Completed 2008-02-01 2011-10-01 ClinicalTrials.gov
NCT00518089 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial C… Phase3 Bacterial Conjunctivitis Completed 2008-02-01 2009-01-01 ClinicalTrials.gov
NCT00390221 Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat R… Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2008-02-01 2011-08-01 ClinicalTrials.gov
NCT00497146 The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac M… Phase3 Chronic Kidney Disease Completed 2008-02-01 2012-03-01 ClinicalTrials.gov
NCT00518089 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial C… Phase3 Bacterial Conjunctivitis Completed 2008-02-01 2009-01-01 ClinicalTrials.gov
NCT00497146 The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac M… Phase3 Chronic Kidney Disease Completed 2008-02-01 2012-03-01 ClinicalTrials.gov
NCT00390221 Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat R… Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2008-02-01 2011-08-01 ClinicalTrials.gov
NCT00497146 The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac M… Phase3 Chronic Kidney Disease Completed 2008-02-01 2012-03-01 ClinicalTrials.gov
NCT00497146 The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac M… Phase3 Chronic Kidney Disease Completed 2008-02-01 2012-03-01 ClinicalTrials.gov
NCT00390221 Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat R… Phase2 Relapsing-Remitting Multiple Sclerosis Completed 2008-02-01 2011-08-01 ClinicalTrials.gov
NCT00518089 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial C… Phase3 Bacterial Conjunctivitis Completed 2008-02-01 2009-01-01 ClinicalTrials.gov
NCT00616772 Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination W… Phase3 Coronary Artery Disease Completed 2008-02-01 2012-09-01 ClinicalTrials.gov
NCT00616772 Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination W… Phase3 Coronary Artery Disease Completed 2008-02-01 2012-09-01 ClinicalTrials.gov
NCT00626002 Open Label Continuation Study in Moderate to Severe Psoriasis Phase3 Moderate to Severe Plaque Psoriasis Completed 2008-02-01 2011-10-01 ClinicalTrials.gov
NCT01077232 Documentation of Humira in Psoriasis Patients in Routine Clinical Practice — Moderate to Severe Plaque Psoriasis Completed 2008-01-04 2019-06-30 ClinicalTrials.gov
NCT01077232 Documentation of Humira in Psoriasis Patients in Routine Clinical Practice — Moderate to Severe Plaque Psoriasis Completed 2008-01-04 2019-06-30 ClinicalTrials.gov
NCT01077232 Documentation of Humira in Psoriasis Patients in Routine Clinical Practice — Moderate to Severe Plaque Psoriasis Completed 2008-01-04 2019-06-30 ClinicalTrials.gov
NCT01077232 Documentation of Humira in Psoriasis Patients in Routine Clinical Practice — Moderate to Severe Plaque Psoriasis Completed 2008-01-04 2019-06-30 ClinicalTrials.gov
NCT01848028 PsoBest - The German Psoriasis Registry — Psoriasis Recruiting 2008-01-01 2032-12-01 ClinicalTrials.gov
NCT01848028 PsoBest - The German Psoriasis Registry — Psoriasis Recruiting 2008-01-01 2032-12-01 ClinicalTrials.gov
NCT01848028 PsoBest - The German Psoriasis Registry — Psoriasis Recruiting 2008-01-01 2032-12-01 ClinicalTrials.gov
NCT00335153 Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Dise… Phase3 Advanced Parkinson's Disease Completed 2008-01-01 2012-06-01 ClinicalTrials.gov
NCT01848028 PsoBest - The German Psoriasis Registry — Psoriasis Recruiting 2008-01-01 2032-12-01 ClinicalTrials.gov
NCT00335153 Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Dise… Phase3 Advanced Parkinson's Disease Completed 2008-01-01 2012-06-01 ClinicalTrials.gov
NCT00335153 Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Dise… Phase3 Advanced Parkinson's Disease Completed 2008-01-01 2012-06-01 ClinicalTrials.gov
NCT00335153 Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Dise… Phase3 Advanced Parkinson's Disease Completed 2008-01-01 2012-06-01 ClinicalTrials.gov
NCT00621933 Surveillance of Ocular Surface Flora (SURFACE) — Cataract Completed 2007-12-01 2008-11-01 ClinicalTrials.gov
NCT00621933 Surveillance of Ocular Surface Flora (SURFACE) — Cataract Completed 2007-12-01 2008-11-01 ClinicalTrials.gov
NCT00541242 Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With G… Phase4 Ocular Hypertension Completed 2007-12-01 2008-08-01 ClinicalTrials.gov
NCT00564681 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With C… Phase2 Cervical Dystonia Completed 2007-12-01 2009-12-01 ClinicalTrials.gov
NCT00569192 A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children Phase3 Asthma Completed 2007-12-01 2009-01-01 ClinicalTrials.gov
NCT00575016 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase2 Overactive Bladder Terminated 2007-12-01 2010-07-01 ClinicalTrials.gov
NCT00611403 Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Pat… Phase2 Dry Eye Syndromes Completed 2007-12-01 2009-06-01 ClinicalTrials.gov
NCT00621933 Surveillance of Ocular Surface Flora (SURFACE) — Cataract Completed 2007-12-01 2008-11-01 ClinicalTrials.gov
NCT00611403 Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Pat… Phase2 Dry Eye Syndromes Completed 2007-12-01 2009-06-01 ClinicalTrials.gov
NCT00895063 Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia Na Spasmodic Dysphonia Terminated 2007-12-01 2013-05-01 ClinicalTrials.gov
NCT00621933 Surveillance of Ocular Surface Flora (SURFACE) — Cataract Completed 2007-12-01 2008-11-01 ClinicalTrials.gov
NCT00611403 Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Pat… Phase2 Dry Eye Syndromes Completed 2007-12-01 2009-06-01 ClinicalTrials.gov
NCT00575016 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase2 Overactive Bladder Terminated 2007-12-01 2010-07-01 ClinicalTrials.gov
NCT00569192 A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children Phase3 Asthma Completed 2007-12-01 2009-01-01 ClinicalTrials.gov
NCT00564681 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With C… Phase2 Cervical Dystonia Completed 2007-12-01 2009-12-01 ClinicalTrials.gov
NCT00541242 Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With G… Phase4 Ocular Hypertension Completed 2007-12-01 2008-08-01 ClinicalTrials.gov
NCT00654758 A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxe… Phase1 Non-small Cell Lung Cancer Completed 2007-12-01 2010-05-01 ClinicalTrials.gov
NCT00654758 A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxe… Phase1 Non-small Cell Lung Cancer Completed 2007-12-01 2010-05-01 ClinicalTrials.gov
NCT00895063 Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia Na Spasmodic Dysphonia Terminated 2007-12-01 2013-05-01 ClinicalTrials.gov
NCT00895063 Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia Na Spasmodic Dysphonia Terminated 2007-12-01 2013-05-01 ClinicalTrials.gov
NCT00575016 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase2 Overactive Bladder Terminated 2007-12-01 2010-07-01 ClinicalTrials.gov
NCT00569192 A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children Phase3 Asthma Completed 2007-12-01 2009-01-01 ClinicalTrials.gov
NCT00654758 A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxe… Phase1 Non-small Cell Lung Cancer Completed 2007-12-01 2010-05-01 ClinicalTrials.gov
NCT00564681 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With C… Phase2 Cervical Dystonia Completed 2007-12-01 2009-12-01 ClinicalTrials.gov
NCT00895063 Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia Na Spasmodic Dysphonia Terminated 2007-12-01 2013-05-01 ClinicalTrials.gov
NCT00654758 A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxe… Phase1 Non-small Cell Lung Cancer Completed 2007-12-01 2010-05-01 ClinicalTrials.gov
NCT00541242 Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With G… Phase4 Ocular Hypertension Completed 2007-12-01 2008-08-01 ClinicalTrials.gov
NCT00611403 Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Pat… Phase2 Dry Eye Syndromes Completed 2007-12-01 2009-06-01 ClinicalTrials.gov
NCT00575016 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase2 Overactive Bladder Terminated 2007-12-01 2010-07-01 ClinicalTrials.gov
NCT00569192 A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children Phase3 Asthma Completed 2007-12-01 2009-01-01 ClinicalTrials.gov
NCT00541242 Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With G… Phase4 Ocular Hypertension Completed 2007-12-01 2008-08-01 ClinicalTrials.gov
NCT00564681 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With C… Phase2 Cervical Dystonia Completed 2007-12-01 2009-12-01 ClinicalTrials.gov
NCT00573794 Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With U… Phase3 Ulcerative Colitis Completed 2007-11-28 2016-12-01 ClinicalTrials.gov
NCT00573794 Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With U… Phase3 Ulcerative Colitis Completed 2007-11-28 2016-12-01 ClinicalTrials.gov
NCT00573794 Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With U… Phase3 Ulcerative Colitis Completed 2007-11-28 2016-12-01 ClinicalTrials.gov
NCT00573794 Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With U… Phase3 Ulcerative Colitis Completed 2007-11-28 2016-12-01 ClinicalTrials.gov
NCT00538304 A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or … Phase2 Glaucoma Completed 2007-11-01 2008-05-01 ClinicalTrials.gov
NCT00554970 A Study of 2 Doses of MAP0010 in Adult Asthmatics Phase2 Asthma Completed 2007-11-01 2008-03-01 ClinicalTrials.gov
NCT00538304 A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or … Phase2 Glaucoma Completed 2007-11-01 2008-05-01 ClinicalTrials.gov
NCT00462449 Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botuli… Na Upper Extremity Spasticity Completed 2007-11-01 2010-01-01 ClinicalTrials.gov
NCT00511706 Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular E… Phase2 Choroidal Neovascularization Completed 2007-11-01 2009-03-01 ClinicalTrials.gov
NCT00554970 A Study of 2 Doses of MAP0010 in Adult Asthmatics Phase2 Asthma Completed 2007-11-01 2008-03-01 ClinicalTrials.gov
NCT00462449 Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botuli… Na Upper Extremity Spasticity Completed 2007-11-01 2010-01-01 ClinicalTrials.gov
NCT00554970 A Study of 2 Doses of MAP0010 in Adult Asthmatics Phase2 Asthma Completed 2007-11-01 2008-03-01 ClinicalTrials.gov
NCT00462449 Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botuli… Na Upper Extremity Spasticity Completed 2007-11-01 2010-01-01 ClinicalTrials.gov
NCT00538304 A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or … Phase2 Glaucoma Completed 2007-11-01 2008-05-01 ClinicalTrials.gov
NCT00462449 Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botuli… Na Upper Extremity Spasticity Completed 2007-11-01 2010-01-01 ClinicalTrials.gov
NCT00538304 A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or … Phase2 Glaucoma Completed 2007-11-01 2008-05-01 ClinicalTrials.gov
NCT00511706 Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular E… Phase2 Choroidal Neovascularization Completed 2007-11-01 2009-03-01 ClinicalTrials.gov
NCT00511706 Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular E… Phase2 Choroidal Neovascularization Completed 2007-11-01 2009-03-01 ClinicalTrials.gov
NCT00511706 Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular E… Phase2 Choroidal Neovascularization Completed 2007-11-01 2009-03-01 ClinicalTrials.gov
NCT00554970 A Study of 2 Doses of MAP0010 in Adult Asthmatics Phase2 Asthma Completed 2007-11-01 2008-03-01 ClinicalTrials.gov
NCT00524264 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With… Phase3 Cataract Extraction Completed 2007-10-01 2008-04-01 ClinicalTrials.gov
NCT00549783 BOTOX® Economic Spasticity Trial (BEST) Phase4 Muscle Spasticity Completed 2007-10-01 2010-07-01 ClinicalTrials.gov
NCT00565201 Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and… Early_Phase1 Stroke Completed 2007-10-01 2011-12-01 ClinicalTrials.gov
NCT00524264 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With… Phase3 Cataract Extraction Completed 2007-10-01 2008-04-01 ClinicalTrials.gov
NCT00521456 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With… Phase3 Cataract Extraction Completed 2007-10-01 2008-03-01 ClinicalTrials.gov
NCT00514852 Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye Na Dry Eye Syndrome Completed 2007-10-01 2008-01-01 ClinicalTrials.gov
NCT00514852 Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye Na Dry Eye Syndrome Completed 2007-10-01 2008-01-01 ClinicalTrials.gov
NCT00521456 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With… Phase3 Cataract Extraction Completed 2007-10-01 2008-03-01 ClinicalTrials.gov
NCT00549783 BOTOX® Economic Spasticity Trial (BEST) Phase4 Muscle Spasticity Completed 2007-10-01 2010-07-01 ClinicalTrials.gov
NCT00549783 BOTOX® Economic Spasticity Trial (BEST) Phase4 Muscle Spasticity Completed 2007-10-01 2010-07-01 ClinicalTrials.gov
NCT00565201 Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and… Early_Phase1 Stroke Completed 2007-10-01 2011-12-01 ClinicalTrials.gov
NCT00524264 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With… Phase3 Cataract Extraction Completed 2007-10-01 2008-04-01 ClinicalTrials.gov
NCT00565201 Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and… Early_Phase1 Stroke Completed 2007-10-01 2011-12-01 ClinicalTrials.gov
NCT00514852 Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye Na Dry Eye Syndrome Completed 2007-10-01 2008-01-01 ClinicalTrials.gov
NCT00521456 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With… Phase3 Cataract Extraction Completed 2007-10-01 2008-03-01 ClinicalTrials.gov
NCT00524264 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With… Phase3 Cataract Extraction Completed 2007-10-01 2008-04-01 ClinicalTrials.gov
NCT00565201 Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and… Early_Phase1 Stroke Completed 2007-10-01 2011-12-01 ClinicalTrials.gov
NCT00514852 Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye Na Dry Eye Syndrome Completed 2007-10-01 2008-01-01 ClinicalTrials.gov
NCT00549783 BOTOX® Economic Spasticity Trial (BEST) Phase4 Muscle Spasticity Completed 2007-10-01 2010-07-01 ClinicalTrials.gov
NCT00521456 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With… Phase3 Cataract Extraction Completed 2007-10-01 2008-03-01 ClinicalTrials.gov
NCT00544713 Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK S… Na Dry Eye Syndrome Completed 2007-09-01 2008-06-01 ClinicalTrials.gov
NCT00539526 Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues Phase4 Open Angle Glaucoma Completed 2007-09-01 2008-09-01 ClinicalTrials.gov
NCT00528541 Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Typ… Phase4 Spasmodic Torticollis Completed 2007-09-01 2009-09-01 ClinicalTrials.gov
NCT00539526 Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues Phase4 Open Angle Glaucoma Completed 2007-09-01 2008-09-01 ClinicalTrials.gov
NCT00544713 Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK S… Na Dry Eye Syndrome Completed 2007-09-01 2008-06-01 ClinicalTrials.gov
NCT00544713 Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK S… Na Dry Eye Syndrome Completed 2007-09-01 2008-06-01 ClinicalTrials.gov
NCT00528541 Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Typ… Phase4 Spasmodic Torticollis Completed 2007-09-01 2009-09-01 ClinicalTrials.gov
NCT00539526 Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues Phase4 Open Angle Glaucoma Completed 2007-09-01 2008-09-01 ClinicalTrials.gov
NCT00539526 Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues Phase4 Open Angle Glaucoma Completed 2007-09-01 2008-09-01 ClinicalTrials.gov
NCT00528541 Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Typ… Phase4 Spasmodic Torticollis Completed 2007-09-01 2009-09-01 ClinicalTrials.gov
NCT00544713 Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK S… Na Dry Eye Syndrome Completed 2007-09-01 2008-06-01 ClinicalTrials.gov
NCT00528541 Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Typ… Phase4 Spasmodic Torticollis Completed 2007-09-01 2009-09-01 ClinicalTrials.gov
NCT00507936 Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain Phase2 Diabetic Neuralgia Completed 2007-08-01 2008-10-01 ClinicalTrials.gov
NCT00517790 Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) Phase2 Non-Small Cell Lung Cancer (NSCLC) Completed 2007-08-01 2012-06-01 ClinicalTrials.gov
NCT00509873 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial C… Phase3 Bacterial Conjunctivitis Completed 2007-08-01 2008-06-01 ClinicalTrials.gov
NCT00507936 Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain Phase2 Diabetic Neuralgia Completed 2007-08-01 2008-10-01 ClinicalTrials.gov
NCT00526617 A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients Phase1 Non-hematologic Malignancies Completed 2007-08-01 — ClinicalTrials.gov
NCT00526617 A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients Phase1 Non-hematologic Malignancies Completed 2007-08-01 — ClinicalTrials.gov
NCT00507936 Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain Phase2 Diabetic Neuralgia Completed 2007-08-01 2008-10-01 ClinicalTrials.gov
NCT00509873 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial C… Phase3 Bacterial Conjunctivitis Completed 2007-08-01 2008-06-01 ClinicalTrials.gov
NCT00517790 Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) Phase2 Non-Small Cell Lung Cancer (NSCLC) Completed 2007-08-01 2012-06-01 ClinicalTrials.gov
NCT00526617 A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients Phase1 Non-hematologic Malignancies Completed 2007-08-01 — ClinicalTrials.gov
NCT00517790 Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) Phase2 Non-Small Cell Lung Cancer (NSCLC) Completed 2007-08-01 2012-06-01 ClinicalTrials.gov
NCT00509873 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial C… Phase3 Bacterial Conjunctivitis Completed 2007-08-01 2008-06-01 ClinicalTrials.gov
NCT00526617 A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients Phase1 Non-hematologic Malignancies Completed 2007-08-01 — ClinicalTrials.gov
NCT00517790 Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) Phase2 Non-Small Cell Lung Cancer (NSCLC) Completed 2007-08-01 2012-06-01 ClinicalTrials.gov
NCT00509873 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial C… Phase3 Bacterial Conjunctivitis Completed 2007-08-01 2008-06-01 ClinicalTrials.gov
NCT00507936 Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain Phase2 Diabetic Neuralgia Completed 2007-08-01 2008-10-01 ClinicalTrials.gov
NCT00481091 A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocy… Phase1 Chronic Lymphocytic Leukemia Completed 2007-07-25 2022-05-12 ClinicalTrials.gov
NCT00481091 A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocy… Phase1 Chronic Lymphocytic Leukemia Completed 2007-07-25 2022-05-12 ClinicalTrials.gov
NCT00481091 A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocy… Phase1 Chronic Lymphocytic Leukemia Completed 2007-07-25 2022-05-12 ClinicalTrials.gov
NCT00481091 A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocy… Phase1 Chronic Lymphocytic Leukemia Completed 2007-07-25 2022-05-12 ClinicalTrials.gov
NCT00635193 Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Dox… Phase1 Ovarian Cancer, Primary Peritoneal Cancer Completed 2007-07-01 2009-10-01 ClinicalTrials.gov
NCT00635193 Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Dox… Phase1 Ovarian Cancer, Primary Peritoneal Cancer Completed 2007-07-01 2009-10-01 ClinicalTrials.gov
NCT00635193 Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Dox… Phase1 Ovarian Cancer, Primary Peritoneal Cancer Completed 2007-07-01 2009-10-01 ClinicalTrials.gov
NCT00635193 Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Dox… Phase1 Ovarian Cancer, Primary Peritoneal Cancer Completed 2007-07-01 2009-10-01 ClinicalTrials.gov
NCT00650156 Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild … Phase1 Rheumatoid Arthritis Completed 2007-06-01 — ClinicalTrials.gov
NCT00439140 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Terminated 2007-06-01 2012-12-01 ClinicalTrials.gov
NCT00432341 Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Mode… Phase4 Spasmodic Torticollis Terminated 2007-06-01 2009-06-01 ClinicalTrials.gov
NCT00650156 Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild … Phase1 Rheumatoid Arthritis Completed 2007-06-01 — ClinicalTrials.gov
NCT00650156 Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild … Phase1 Rheumatoid Arthritis Completed 2007-06-01 — ClinicalTrials.gov
NCT00439140 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Terminated 2007-06-01 2012-12-01 ClinicalTrials.gov
NCT00464438 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment o… Phase4 Bacterial Conjunctivitis Completed 2007-06-01 2008-09-01 ClinicalTrials.gov
NCT00486538 Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previo… Phase2 Advanced Renal Cell Carcinoma Completed 2007-06-01 2012-06-01 ClinicalTrials.gov
NCT00439140 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Terminated 2007-06-01 2012-12-01 ClinicalTrials.gov
NCT00432341 Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Mode… Phase4 Spasmodic Torticollis Terminated 2007-06-01 2009-06-01 ClinicalTrials.gov
NCT00486538 Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previo… Phase2 Advanced Renal Cell Carcinoma Completed 2007-06-01 2012-06-01 ClinicalTrials.gov
NCT00704275 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.0… Phase4 Dry Eye Unknown 2007-06-01 2008-10-01 ClinicalTrials.gov
NCT00464438 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment o… Phase4 Bacterial Conjunctivitis Completed 2007-06-01 2008-09-01 ClinicalTrials.gov
NCT00650156 Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild … Phase1 Rheumatoid Arthritis Completed 2007-06-01 — ClinicalTrials.gov
NCT00704275 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.0… Phase4 Dry Eye Unknown 2007-06-01 2008-10-01 ClinicalTrials.gov
NCT00486538 Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previo… Phase2 Advanced Renal Cell Carcinoma Completed 2007-06-01 2012-06-01 ClinicalTrials.gov
NCT00432341 Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Mode… Phase4 Spasmodic Torticollis Terminated 2007-06-01 2009-06-01 ClinicalTrials.gov
NCT00464438 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment o… Phase4 Bacterial Conjunctivitis Completed 2007-06-01 2008-09-01 ClinicalTrials.gov
NCT00704275 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.0… Phase4 Dry Eye Unknown 2007-06-01 2008-10-01 ClinicalTrials.gov
NCT00704275 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.0… Phase4 Dry Eye Unknown 2007-06-01 2008-10-01 ClinicalTrials.gov
NCT00439140 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Terminated 2007-06-01 2012-12-01 ClinicalTrials.gov
NCT00432341 Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Mode… Phase4 Spasmodic Torticollis Terminated 2007-06-01 2009-06-01 ClinicalTrials.gov
NCT00486538 Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previo… Phase2 Advanced Renal Cell Carcinoma Completed 2007-06-01 2012-06-01 ClinicalTrials.gov
NCT00464438 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment o… Phase4 Bacterial Conjunctivitis Completed 2007-06-01 2008-09-01 ClinicalTrials.gov
NCT00477802 Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose … Phase4 Parkinson Disease Terminated 2007-05-01 2008-12-01 ClinicalTrials.gov
NCT01083680 Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine — Crohn's Disease Completed 2007-05-01 2015-12-01 ClinicalTrials.gov
NCT00444886 Treatment of Thoracic Outlet Syndrome (TOS) With Botox Phase2 Thoracic Outlet Syndrome Completed 2007-05-01 2011-02-01 ClinicalTrials.gov
NCT00461292 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Completed 2007-05-01 2010-04-01 ClinicalTrials.gov
NCT00464685 Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic M… Phase2 Diabetic Macular Edema Completed 2007-05-01 2010-02-08 ClinicalTrials.gov
NCT00477802 Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose … Phase4 Parkinson Disease Terminated 2007-05-01 2008-12-01 ClinicalTrials.gov
NCT00464685 Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic M… Phase2 Diabetic Macular Edema Completed 2007-05-01 2010-02-08 ClinicalTrials.gov
NCT00461292 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Completed 2007-05-01 2010-04-01 ClinicalTrials.gov
NCT00444886 Treatment of Thoracic Outlet Syndrome (TOS) With Botox Phase2 Thoracic Outlet Syndrome Completed 2007-05-01 2011-02-01 ClinicalTrials.gov
NCT01083680 Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine — Crohn's Disease Completed 2007-05-01 2015-12-01 ClinicalTrials.gov
NCT00444886 Treatment of Thoracic Outlet Syndrome (TOS) With Botox Phase2 Thoracic Outlet Syndrome Completed 2007-05-01 2011-02-01 ClinicalTrials.gov
NCT00461292 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Completed 2007-05-01 2010-04-01 ClinicalTrials.gov
NCT00464685 Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic M… Phase2 Diabetic Macular Edema Completed 2007-05-01 2010-02-08 ClinicalTrials.gov
NCT00477802 Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose … Phase4 Parkinson Disease Terminated 2007-05-01 2008-12-01 ClinicalTrials.gov
NCT01083680 Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine — Crohn's Disease Completed 2007-05-01 2015-12-01 ClinicalTrials.gov
NCT01083680 Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine — Crohn's Disease Completed 2007-05-01 2015-12-01 ClinicalTrials.gov
NCT00444886 Treatment of Thoracic Outlet Syndrome (TOS) With Botox Phase2 Thoracic Outlet Syndrome Completed 2007-05-01 2011-02-01 ClinicalTrials.gov
NCT00461292 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Completed 2007-05-01 2010-04-01 ClinicalTrials.gov
NCT00464685 Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic M… Phase2 Diabetic Macular Edema Completed 2007-05-01 2010-02-08 ClinicalTrials.gov
NCT00477802 Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose … Phase4 Parkinson Disease Terminated 2007-05-01 2008-12-01 ClinicalTrials.gov
NCT00693420 Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Promi… Phase3 Eyelashes Completed 2007-04-01 2007-12-01 ClinicalTrials.gov
NCT00864604 Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tab… Phase1 Healthy Completed 2007-04-01 2007-05-01 ClinicalTrials.gov
NCT00864604 Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tab… Phase1 Healthy Completed 2007-04-01 2007-05-01 ClinicalTrials.gov
NCT00445198 A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or… Phase1 Small Cell Lung Cancer Completed 2007-04-01 2010-12-01 ClinicalTrials.gov
NCT00693420 Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Promi… Phase3 Eyelashes Completed 2007-04-01 2007-12-01 ClinicalTrials.gov
NCT00693420 Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Promi… Phase3 Eyelashes Completed 2007-04-01 2007-12-01 ClinicalTrials.gov
NCT00445198 A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or… Phase1 Small Cell Lung Cancer Completed 2007-04-01 2010-12-01 ClinicalTrials.gov
NCT00864604 Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tab… Phase1 Healthy Completed 2007-04-01 2007-05-01 ClinicalTrials.gov
NCT00693420 Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Promi… Phase3 Eyelashes Completed 2007-04-01 2007-12-01 ClinicalTrials.gov
NCT00445198 A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or… Phase1 Small Cell Lung Cancer Completed 2007-04-01 2010-12-01 ClinicalTrials.gov
NCT00864604 Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tab… Phase1 Healthy Completed 2007-04-01 2007-05-01 ClinicalTrials.gov
NCT00445198 A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or… Phase1 Small Cell Lung Cancer Completed 2007-04-01 2010-12-01 ClinicalTrials.gov
NCT00445705 Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome Phase2 Fibromyalgia Terminated 2007-03-01 2008-01-01 ClinicalTrials.gov
NCT00621335 A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt — Open Angle Glaucoma Completed 2007-03-01 2008-02-01 ClinicalTrials.gov
NCT00621335 A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt — Open Angle Glaucoma Completed 2007-03-01 2008-02-01 ClinicalTrials.gov
NCT00445003 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Phase3 Proliferative Diabetic Retinopathy Completed 2007-03-01 2010-07-01 ClinicalTrials.gov
NCT00621335 A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt — Open Angle Glaucoma Completed 2007-03-01 2008-02-01 ClinicalTrials.gov
NCT00441766 Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndro… Phase2 Irritable Bowel Syndrome Terminated 2007-03-01 2008-02-01 ClinicalTrials.gov
NCT00621335 A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt — Open Angle Glaucoma Completed 2007-03-01 2008-02-01 ClinicalTrials.gov
NCT00445705 Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome Phase2 Fibromyalgia Terminated 2007-03-01 2008-01-01 ClinicalTrials.gov
NCT00445003 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Phase3 Proliferative Diabetic Retinopathy Completed 2007-03-01 2010-07-01 ClinicalTrials.gov
NCT00441766 Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndro… Phase2 Irritable Bowel Syndrome Terminated 2007-03-01 2008-02-01 ClinicalTrials.gov
NCT00441766 Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndro… Phase2 Irritable Bowel Syndrome Terminated 2007-03-01 2008-02-01 ClinicalTrials.gov
NCT00445003 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Phase3 Proliferative Diabetic Retinopathy Completed 2007-03-01 2010-07-01 ClinicalTrials.gov
NCT00441766 Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndro… Phase2 Irritable Bowel Syndrome Terminated 2007-03-01 2008-02-01 ClinicalTrials.gov
NCT00445003 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Phase3 Proliferative Diabetic Retinopathy Completed 2007-03-01 2010-07-01 ClinicalTrials.gov
NCT00445705 Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome Phase2 Fibromyalgia Terminated 2007-03-01 2008-01-01 ClinicalTrials.gov
NCT00445705 Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome Phase2 Fibromyalgia Terminated 2007-03-01 2008-01-01 ClinicalTrials.gov
NCT00443391 A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyp… Phase2 Attention Deficit Hyperactivity Disorder Completed 2007-02-01 2008-10-01 ClinicalTrials.gov
NCT00443391 A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyp… Phase2 Attention Deficit Hyperactivity Disorder Completed 2007-02-01 2008-10-01 ClinicalTrials.gov
NCT00443391 A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyp… Phase2 Attention Deficit Hyperactivity Disorder Completed 2007-02-01 2008-10-01 ClinicalTrials.gov
NCT00443391 A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyp… Phase2 Attention Deficit Hyperactivity Disorder Completed 2007-02-01 2008-10-01 ClinicalTrials.gov
NCT00395057 A Study Using Intravitreal Injections of a Small Interfering RNA in Patients Wi… Phase2 Choroid Neovascularization Terminated 2007-01-01 2009-02-01 ClinicalTrials.gov
NCT00479596 This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical In… Phase2 Overactive Bladder Unknown 2007-01-01 2007-05-01 ClinicalTrials.gov
NCT00479596 This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical In… Phase2 Overactive Bladder Unknown 2007-01-01 2007-05-01 ClinicalTrials.gov
NCT00395057 A Study Using Intravitreal Injections of a Small Interfering RNA in Patients Wi… Phase2 Choroid Neovascularization Terminated 2007-01-01 2009-02-01 ClinicalTrials.gov
NCT00395057 A Study Using Intravitreal Injections of a Small Interfering RNA in Patients Wi… Phase2 Choroid Neovascularization Terminated 2007-01-01 2009-02-01 ClinicalTrials.gov
NCT02012764 The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Art… — Inflammatory Arthritis Active_Not_Recruiting 2007-01-01 2026-06-30 ClinicalTrials.gov
NCT02012764 The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Art… — Inflammatory Arthritis Active_Not_Recruiting 2007-01-01 2026-06-30 ClinicalTrials.gov
NCT00479596 This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical In… Phase2 Overactive Bladder Unknown 2007-01-01 2007-05-01 ClinicalTrials.gov
NCT02012764 The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Art… — Inflammatory Arthritis Active_Not_Recruiting 2007-01-01 2026-06-30 ClinicalTrials.gov
NCT02012764 The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Art… — Inflammatory Arthritis Active_Not_Recruiting 2007-01-01 2026-06-30 ClinicalTrials.gov
NCT00479596 This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical In… Phase2 Overactive Bladder Unknown 2007-01-01 2007-05-01 ClinicalTrials.gov
NCT00395057 A Study Using Intravitreal Injections of a Small Interfering RNA in Patients Wi… Phase2 Choroid Neovascularization Terminated 2007-01-01 2009-02-01 ClinicalTrials.gov
NCT00437658 Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatmen… Phase2 Endometriosis Completed 2006-12-11 2008-11-24 ClinicalTrials.gov
NCT00437658 Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatmen… Phase2 Endometriosis Completed 2006-12-11 2008-11-24 ClinicalTrials.gov
NCT00437658 Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatmen… Phase2 Endometriosis Completed 2006-12-11 2008-11-24 ClinicalTrials.gov
NCT00437658 Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatmen… Phase2 Endometriosis Completed 2006-12-11 2008-11-24 ClinicalTrials.gov
NCT00864357 A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets U… Phase1 Healthy Completed 2006-10-01 2006-10-01 ClinicalTrials.gov
NCT00381719 Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral … Phase2 Diabetic Neuropathy, Painful Completed 2006-10-01 2007-11-01 ClinicalTrials.gov
NCT00380783 Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Synd… Phase2 Cystitis, Interstitial Terminated 2006-10-01 2007-03-01 ClinicalTrials.gov
NCT00380783 Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Synd… Phase2 Cystitis, Interstitial Terminated 2006-10-01 2007-03-01 ClinicalTrials.gov
NCT00380783 Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Synd… Phase2 Cystitis, Interstitial Terminated 2006-10-01 2007-03-01 ClinicalTrials.gov
NCT00381719 Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral … Phase2 Diabetic Neuropathy, Painful Completed 2006-10-01 2007-11-01 ClinicalTrials.gov
NCT00864526 A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets U… Phase1 Healthy Completed 2006-10-01 2006-10-01 ClinicalTrials.gov
NCT00864357 A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets U… Phase1 Healthy Completed 2006-10-01 2006-10-01 ClinicalTrials.gov
NCT00864526 A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets U… Phase1 Healthy Completed 2006-10-01 2006-10-01 ClinicalTrials.gov
NCT00864357 A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets U… Phase1 Healthy Completed 2006-10-01 2006-10-01 ClinicalTrials.gov
NCT00864526 A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets U… Phase1 Healthy Completed 2006-10-01 2006-10-01 ClinicalTrials.gov
NCT00380783 Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Synd… Phase2 Cystitis, Interstitial Terminated 2006-10-01 2007-03-01 ClinicalTrials.gov
NCT00381719 Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral … Phase2 Diabetic Neuropathy, Painful Completed 2006-10-01 2007-11-01 ClinicalTrials.gov
NCT00864526 A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets U… Phase1 Healthy Completed 2006-10-01 2006-10-01 ClinicalTrials.gov
NCT00864357 A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets U… Phase1 Healthy Completed 2006-10-01 2006-10-01 ClinicalTrials.gov
NCT00381719 Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral … Phase2 Diabetic Neuropathy, Painful Completed 2006-10-01 2007-11-01 ClinicalTrials.gov
NCT00864279 A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting … Phase1 Healthy Completed 2006-08-01 2006-09-01 ClinicalTrials.gov
NCT00863902 A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fast… Phase1 Healthy Completed 2006-08-01 2006-09-01 ClinicalTrials.gov
NCT00864279 A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting … Phase1 Healthy Completed 2006-08-01 2006-09-01 ClinicalTrials.gov
NCT01097655 Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet — Human Immunodeficiency Virus Completed 2006-08-01 2016-01-01 ClinicalTrials.gov
NCT00440011 Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost… Phase4 Glaucoma Completed 2006-08-01 2007-10-01 ClinicalTrials.gov
NCT00311376 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Completed 2006-08-01 2010-05-01 ClinicalTrials.gov
NCT00440011 Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost… Phase4 Glaucoma Completed 2006-08-01 2007-10-01 ClinicalTrials.gov
NCT00440011 Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost… Phase4 Glaucoma Completed 2006-08-01 2007-10-01 ClinicalTrials.gov
NCT00759902 Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted … Phase1 Healthy Completed 2006-08-01 2006-10-01 ClinicalTrials.gov
NCT01097655 Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet — Human Immunodeficiency Virus Completed 2006-08-01 2016-01-01 ClinicalTrials.gov
NCT00759915 Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Con… Phase1 Healthy Completed 2006-08-01 2006-10-01 ClinicalTrials.gov
NCT00759902 Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted … Phase1 Healthy Completed 2006-08-01 2006-10-01 ClinicalTrials.gov
NCT00440011 Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost… Phase4 Glaucoma Completed 2006-08-01 2007-10-01 ClinicalTrials.gov
NCT00759915 Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Con… Phase1 Healthy Completed 2006-08-01 2006-10-01 ClinicalTrials.gov
NCT00863902 A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fast… Phase1 Healthy Completed 2006-08-01 2006-09-01 ClinicalTrials.gov
NCT00759902 Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted … Phase1 Healthy Completed 2006-08-01 2006-10-01 ClinicalTrials.gov
NCT00759915 Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Con… Phase1 Healthy Completed 2006-08-01 2006-10-01 ClinicalTrials.gov
NCT00863902 A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fast… Phase1 Healthy Completed 2006-08-01 2006-09-01 ClinicalTrials.gov
NCT00864279 A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting … Phase1 Healthy Completed 2006-08-01 2006-09-01 ClinicalTrials.gov
NCT01097655 Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet — Human Immunodeficiency Virus Completed 2006-08-01 2016-01-01 ClinicalTrials.gov
NCT00864279 A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting … Phase1 Healthy Completed 2006-08-01 2006-09-01 ClinicalTrials.gov
NCT00759902 Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted … Phase1 Healthy Completed 2006-08-01 2006-10-01 ClinicalTrials.gov
NCT00311376 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Completed 2006-08-01 2010-05-01 ClinicalTrials.gov
NCT01097655 Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet — Human Immunodeficiency Virus Completed 2006-08-01 2016-01-01 ClinicalTrials.gov
NCT00759915 Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Con… Phase1 Healthy Completed 2006-08-01 2006-10-01 ClinicalTrials.gov
NCT00863902 A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fast… Phase1 Healthy Completed 2006-08-01 2006-09-01 ClinicalTrials.gov
NCT00311376 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Completed 2006-08-01 2010-05-01 ClinicalTrials.gov
NCT00311376 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurog… Phase3 Overactive Bladder Completed 2006-08-01 2010-05-01 ClinicalTrials.gov
NCT00697801 Study of MAP0010 in Asthmatic Children and Adolescents Phase2 Asthma Completed 2006-07-01 2006-12-01 ClinicalTrials.gov
NCT01188057 A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fastin… Phase1 Healthy Completed 2006-07-01 2006-08-01 ClinicalTrials.gov
NCT00697801 Study of MAP0010 in Asthmatic Children and Adolescents Phase2 Asthma Completed 2006-07-01 2006-12-01 ClinicalTrials.gov
NCT01188057 A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fastin… Phase1 Healthy Completed 2006-07-01 2006-08-01 ClinicalTrials.gov
NCT00761592 Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm Phase4 Blepharospasm Completed 2006-07-01 2008-01-01 ClinicalTrials.gov
NCT00440141 Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.… Phase4 Glaucoma Completed 2006-07-01 2007-03-01 ClinicalTrials.gov
NCT00761592 Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm Phase4 Blepharospasm Completed 2006-07-01 2008-01-01 ClinicalTrials.gov
NCT01188057 A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fastin… Phase1 Healthy Completed 2006-07-01 2006-08-01 ClinicalTrials.gov
NCT00440141 Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.… Phase4 Glaucoma Completed 2006-07-01 2007-03-01 ClinicalTrials.gov
NCT01188057 A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fastin… Phase1 Healthy Completed 2006-07-01 2006-08-01 ClinicalTrials.gov
NCT00440141 Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.… Phase4 Glaucoma Completed 2006-07-01 2007-03-01 ClinicalTrials.gov
NCT00440141 Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.… Phase4 Glaucoma Completed 2006-07-01 2007-03-01 ClinicalTrials.gov
NCT00761592 Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm Phase4 Blepharospasm Completed 2006-07-01 2008-01-01 ClinicalTrials.gov
NCT00697801 Study of MAP0010 in Asthmatic Children and Adolescents Phase2 Asthma Completed 2006-07-01 2006-12-01 ClinicalTrials.gov
NCT00697801 Study of MAP0010 in Asthmatic Children and Adolescents Phase2 Asthma Completed 2006-07-01 2006-12-01 ClinicalTrials.gov
NCT00761592 Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm Phase4 Blepharospasm Completed 2006-07-01 2008-01-01 ClinicalTrials.gov
NCT01188031 A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Co… Phase1 Healthy Completed 2006-06-01 2006-07-01 ClinicalTrials.gov
NCT01188031 A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Co… Phase1 Healthy Completed 2006-06-01 2006-07-01 ClinicalTrials.gov
NCT00343187 A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlo… Phase2 Rash Terminated 2006-06-01 2007-07-01 ClinicalTrials.gov
NCT00348335 Efficacy of Topical Cyclosporin for Ocular Rosacea Phase4 Rosacea Completed 2006-06-01 2007-09-01 ClinicalTrials.gov
NCT00347828 Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of t… Phase4 Eye Infection Unknown 2006-06-01 2006-06-01 ClinicalTrials.gov
NCT00336349 A Study of Intra-dermal Injection of Botulinum Toxin Type A for the Diabetic Ne… Na Diabetes Mellitus Completed 2006-06-01 2007-12-01 ClinicalTrials.gov
NCT00343187 A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlo… Phase2 Rash Terminated 2006-06-01 2007-07-01 ClinicalTrials.gov
NCT00336349 A Study of Intra-dermal Injection of Botulinum Toxin Type A for the Diabetic Ne… Na Diabetes Mellitus Completed 2006-06-01 2007-12-01 ClinicalTrials.gov
NCT01188031 A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Co… Phase1 Healthy Completed 2006-06-01 2006-07-01 ClinicalTrials.gov
NCT01188031 A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Co… Phase1 Healthy Completed 2006-06-01 2006-07-01 ClinicalTrials.gov
NCT00348335 Efficacy of Topical Cyclosporin for Ocular Rosacea Phase4 Rosacea Completed 2006-06-01 2007-09-01 ClinicalTrials.gov
NCT00336349 A Study of Intra-dermal Injection of Botulinum Toxin Type A for the Diabetic Ne… Na Diabetes Mellitus Completed 2006-06-01 2007-12-01 ClinicalTrials.gov
NCT00343187 A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlo… Phase2 Rash Terminated 2006-06-01 2007-07-01 ClinicalTrials.gov
NCT00347828 Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of t… Phase4 Eye Infection Unknown 2006-06-01 2006-06-01 ClinicalTrials.gov
NCT00336349 A Study of Intra-dermal Injection of Botulinum Toxin Type A for the Diabetic Ne… Na Diabetes Mellitus Completed 2006-06-01 2007-12-01 ClinicalTrials.gov
NCT00343187 A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlo… Phase2 Rash Terminated 2006-06-01 2007-07-01 ClinicalTrials.gov
NCT00347828 Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of t… Phase4 Eye Infection Unknown 2006-06-01 2006-06-01 ClinicalTrials.gov
NCT00348335 Efficacy of Topical Cyclosporin for Ocular Rosacea Phase4 Rosacea Completed 2006-06-01 2007-09-01 ClinicalTrials.gov
NCT00347828 Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of t… Phase4 Eye Infection Unknown 2006-06-01 2006-06-01 ClinicalTrials.gov
NCT00348335 Efficacy of Topical Cyclosporin for Ocular Rosacea Phase4 Rosacea Completed 2006-06-01 2007-09-01 ClinicalTrials.gov
NCT00768183 Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Condi… Phase1 Healthy Completed 2006-05-01 2006-07-01 ClinicalTrials.gov
NCT00442312 Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost… Phase4 Glaucoma Unknown 2006-05-01 2006-11-01 ClinicalTrials.gov
NCT00333814 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Interm… Phase2 Intermediate Uveitis Completed 2006-05-01 2009-04-01 ClinicalTrials.gov
NCT00333996 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anteri… Phase2 Anterior Uveitis Terminated 2006-05-01 2007-03-01 ClinicalTrials.gov
NCT00333814 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Interm… Phase2 Intermediate Uveitis Completed 2006-05-01 2009-04-01 ClinicalTrials.gov
NCT00768183 Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Condi… Phase1 Healthy Completed 2006-05-01 2006-07-01 ClinicalTrials.gov
NCT00768183 Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Condi… Phase1 Healthy Completed 2006-05-01 2006-07-01 ClinicalTrials.gov
NCT00333996 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anteri… Phase2 Anterior Uveitis Terminated 2006-05-01 2007-03-01 ClinicalTrials.gov
NCT01086033 A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthrit… — Rheumatoid Arthritis Completed 2006-05-01 2012-07-01 ClinicalTrials.gov
NCT00333814 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Interm… Phase2 Intermediate Uveitis Completed 2006-05-01 2009-04-01 ClinicalTrials.gov
NCT00442312 Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost… Phase4 Glaucoma Unknown 2006-05-01 2006-11-01 ClinicalTrials.gov
NCT01086033 A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthrit… — Rheumatoid Arthritis Completed 2006-05-01 2012-07-01 ClinicalTrials.gov
NCT00768183 Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Condi… Phase1 Healthy Completed 2006-05-01 2006-07-01 ClinicalTrials.gov
NCT00442312 Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost… Phase4 Glaucoma Unknown 2006-05-01 2006-11-01 ClinicalTrials.gov
NCT00333996 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anteri… Phase2 Anterior Uveitis Terminated 2006-05-01 2007-03-01 ClinicalTrials.gov
NCT00333996 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anteri… Phase2 Anterior Uveitis Terminated 2006-05-01 2007-03-01 ClinicalTrials.gov
NCT01086033 A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthrit… — Rheumatoid Arthritis Completed 2006-05-01 2012-07-01 ClinicalTrials.gov
NCT00333814 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Interm… Phase2 Intermediate Uveitis Completed 2006-05-01 2009-04-01 ClinicalTrials.gov
NCT01086033 A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthrit… — Rheumatoid Arthritis Completed 2006-05-01 2012-07-01 ClinicalTrials.gov
NCT00442312 Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost… Phase4 Glaucoma Unknown 2006-05-01 2006-11-01 ClinicalTrials.gov
NCT00871364 A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Und… Phase1 Healthy Completed 2006-04-01 2006-05-01 ClinicalTrials.gov
NCT00325715 AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or … Phase1 Peptic Ulcer Completed 2006-04-01 2006-08-01 ClinicalTrials.gov
NCT00320281 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Followi… Phase4 Spinal Cord Injury Completed 2006-04-01 2008-08-01 ClinicalTrials.gov
NCT00871364 A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Und… Phase1 Healthy Completed 2006-04-01 2006-05-01 ClinicalTrials.gov
NCT00325715 AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or … Phase1 Peptic Ulcer Completed 2006-04-01 2006-08-01 ClinicalTrials.gov
NCT00320281 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Followi… Phase4 Spinal Cord Injury Completed 2006-04-01 2008-08-01 ClinicalTrials.gov
NCT00871364 A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Und… Phase1 Healthy Completed 2006-04-01 2006-05-01 ClinicalTrials.gov
NCT00325715 AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or … Phase1 Peptic Ulcer Completed 2006-04-01 2006-08-01 ClinicalTrials.gov
NCT00320281 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Followi… Phase4 Spinal Cord Injury Completed 2006-04-01 2008-08-01 ClinicalTrials.gov
NCT00871364 A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Und… Phase1 Healthy Completed 2006-04-01 2006-05-01 ClinicalTrials.gov
NCT00325715 AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or … Phase1 Peptic Ulcer Completed 2006-04-01 2006-08-01 ClinicalTrials.gov
NCT00320281 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Followi… Phase4 Spinal Cord Injury Completed 2006-04-01 2008-08-01 ClinicalTrials.gov
NCT00141518 Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health… Phase4 Advanced Idiopathic Parkinson's Disease Completed 2006-03-01 2011-04-01 ClinicalTrials.gov
NCT00168428 A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patie… Phase3 Migraine Disorders Completed 2006-03-01 2008-08-01 ClinicalTrials.gov
NCT00168428 A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patie… Phase3 Migraine Disorders Completed 2006-03-01 2008-08-01 ClinicalTrials.gov
NCT00168428 A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patie… Phase3 Migraine Disorders Completed 2006-03-01 2008-08-01 ClinicalTrials.gov
NCT00865111 A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets … Phase1 Healthy Completed 2006-03-01 2006-04-01 ClinicalTrials.gov
NCT00865111 A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets … Phase1 Healthy Completed 2006-03-01 2006-04-01 ClinicalTrials.gov
NCT00141518 Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health… Phase4 Advanced Idiopathic Parkinson's Disease Completed 2006-03-01 2011-04-01 ClinicalTrials.gov
NCT00168428 A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patie… Phase3 Migraine Disorders Completed 2006-03-01 2008-08-01 ClinicalTrials.gov
NCT00865111 A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets … Phase1 Healthy Completed 2006-03-01 2006-04-01 ClinicalTrials.gov
NCT00141518 Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health… Phase4 Advanced Idiopathic Parkinson's Disease Completed 2006-03-01 2011-04-01 ClinicalTrials.gov
NCT00865111 A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets … Phase1 Healthy Completed 2006-03-01 2006-04-01 ClinicalTrials.gov
NCT00141518 Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health… Phase4 Advanced Idiopathic Parkinson's Disease Completed 2006-03-01 2011-04-01 ClinicalTrials.gov
NCT01079182 Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondyli… — Ankylosing Spondylitis Completed 2006-01-01 2014-05-01 ClinicalTrials.gov
NCT00863863 A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under N… Phase1 Healthy Completed 2006-01-01 2006-01-01 ClinicalTrials.gov
NCT00347204 Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK Phase4 Myopia Completed 2006-01-01 2006-06-01 ClinicalTrials.gov
NCT01079182 Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondyli… — Ankylosing Spondylitis Completed 2006-01-01 2014-05-01 ClinicalTrials.gov
NCT00863863 A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under N… Phase1 Healthy Completed 2006-01-01 2006-01-01 ClinicalTrials.gov
NCT00529386 Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Phase1 Prostatitis Terminated 2006-01-01 2009-12-01 ClinicalTrials.gov
NCT00529386 Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Phase1 Prostatitis Terminated 2006-01-01 2009-12-01 ClinicalTrials.gov
NCT00863863 A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under N… Phase1 Healthy Completed 2006-01-01 2006-01-01 ClinicalTrials.gov
NCT01079182 Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondyli… — Ankylosing Spondylitis Completed 2006-01-01 2014-05-01 ClinicalTrials.gov
NCT00863863 A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under N… Phase1 Healthy Completed 2006-01-01 2006-01-01 ClinicalTrials.gov
NCT00529386 Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Phase1 Prostatitis Terminated 2006-01-01 2009-12-01 ClinicalTrials.gov
NCT01079182 Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondyli… — Ankylosing Spondylitis Completed 2006-01-01 2014-05-01 ClinicalTrials.gov
NCT00529386 Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Phase1 Prostatitis Terminated 2006-01-01 2009-12-01 ClinicalTrials.gov
NCT00347204 Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK Phase4 Myopia Completed 2006-01-01 2006-06-01 ClinicalTrials.gov
NCT00347204 Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK Phase4 Myopia Completed 2006-01-01 2006-06-01 ClinicalTrials.gov
NCT00347204 Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK Phase4 Myopia Completed 2006-01-01 2006-06-01 ClinicalTrials.gov
NCT00284518 Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symp… Phase2 Benign Prostatic Hyperplasia Completed 2005-12-01 2010-05-01 ClinicalTrials.gov
NCT00627679 Safety and Blood Level Study of Unit Dose Budesonide Phase1 Asthma Completed 2005-12-01 2006-05-01 ClinicalTrials.gov
NCT00300443 Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hy… Phase2 Ocular Hypertension Completed 2005-12-01 2007-06-01 ClinicalTrials.gov
NCT00284518 Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symp… Phase2 Benign Prostatic Hyperplasia Completed 2005-12-01 2010-05-01 ClinicalTrials.gov
NCT00300443 Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hy… Phase2 Ocular Hypertension Completed 2005-12-01 2007-06-01 ClinicalTrials.gov
NCT00300443 Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hy… Phase2 Ocular Hypertension Completed 2005-12-01 2007-06-01 ClinicalTrials.gov
NCT00627679 Safety and Blood Level Study of Unit Dose Budesonide Phase1 Asthma Completed 2005-12-01 2006-05-01 ClinicalTrials.gov
NCT00284518 Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symp… Phase2 Benign Prostatic Hyperplasia Completed 2005-12-01 2010-05-01 ClinicalTrials.gov
NCT00627679 Safety and Blood Level Study of Unit Dose Budesonide Phase1 Asthma Completed 2005-12-01 2006-05-01 ClinicalTrials.gov
NCT00627679 Safety and Blood Level Study of Unit Dose Budesonide Phase1 Asthma Completed 2005-12-01 2006-05-01 ClinicalTrials.gov
NCT00284518 Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symp… Phase2 Benign Prostatic Hyperplasia Completed 2005-12-01 2010-05-01 ClinicalTrials.gov
NCT00300443 Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hy… Phase2 Ocular Hypertension Completed 2005-12-01 2007-06-01 ClinicalTrials.gov
NCT00243542 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in… Phase4 Acne Vulgaris Completed 2005-11-01 2006-10-01 ClinicalTrials.gov
NCT00864500 Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotio… Phase1 Healthy Completed 2005-11-01 2006-02-01 ClinicalTrials.gov
NCT00292396 Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaq… Phase2 Psoriasis Completed 2005-11-01 2008-04-01 ClinicalTrials.gov
NCT00651612 Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma o… Phase3 Glaucoma Completed 2005-11-01 2007-01-01 ClinicalTrials.gov
NCT00249782 A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Ro… Phase2 Rosacea Completed 2005-11-01 2006-05-01 ClinicalTrials.gov
NCT00864500 Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotio… Phase1 Healthy Completed 2005-11-01 2006-02-01 ClinicalTrials.gov
NCT00243542 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in… Phase4 Acne Vulgaris Completed 2005-11-01 2006-10-01 ClinicalTrials.gov
NCT00243542 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in… Phase4 Acne Vulgaris Completed 2005-11-01 2006-10-01 ClinicalTrials.gov
NCT00249782 A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Ro… Phase2 Rosacea Completed 2005-11-01 2006-05-01 ClinicalTrials.gov
NCT00292396 Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaq… Phase2 Psoriasis Completed 2005-11-01 2008-04-01 ClinicalTrials.gov
NCT00292396 Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaq… Phase2 Psoriasis Completed 2005-11-01 2008-04-01 ClinicalTrials.gov
NCT00249782 A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Ro… Phase2 Rosacea Completed 2005-11-01 2006-05-01 ClinicalTrials.gov
NCT00243542 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in… Phase4 Acne Vulgaris Completed 2005-11-01 2006-10-01 ClinicalTrials.gov
NCT00651612 Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma o… Phase3 Glaucoma Completed 2005-11-01 2007-01-01 ClinicalTrials.gov
NCT00292396 Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaq… Phase2 Psoriasis Completed 2005-11-01 2008-04-01 ClinicalTrials.gov
NCT00864500 Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotio… Phase1 Healthy Completed 2005-11-01 2006-02-01 ClinicalTrials.gov
NCT00651612 Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma o… Phase3 Glaucoma Completed 2005-11-01 2007-01-01 ClinicalTrials.gov
NCT00249782 A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Ro… Phase2 Rosacea Completed 2005-11-01 2006-05-01 ClinicalTrials.gov
NCT00651612 Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma o… Phase3 Glaucoma Completed 2005-11-01 2007-01-01 ClinicalTrials.gov
NCT00864500 Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotio… Phase1 Healthy Completed 2005-11-01 2006-02-01 ClinicalTrials.gov
NCT00864435 A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Co… Phase1 Healthy Completed 2005-10-01 2005-11-01 ClinicalTrials.gov
NCT00864240 The Dose-response "Pilot" Study of Topically Delivered Clobetasol Propionate Lo… Phase1 Healthy Completed 2005-10-01 2005-10-01 ClinicalTrials.gov
NCT00864240 The Dose-response "Pilot" Study of Topically Delivered Clobetasol Propionate Lo… Phase1 Healthy Completed 2005-10-01 2005-10-01 ClinicalTrials.gov
NCT00864240 The Dose-response "Pilot" Study of Topically Delivered Clobetasol Propionate Lo… Phase1 Healthy Completed 2005-10-01 2005-10-01 ClinicalTrials.gov
NCT00864435 A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Co… Phase1 Healthy Completed 2005-10-01 2005-11-01 ClinicalTrials.gov
NCT00864435 A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Co… Phase1 Healthy Completed 2005-10-01 2005-11-01 ClinicalTrials.gov
NCT00864240 The Dose-response "Pilot" Study of Topically Delivered Clobetasol Propionate Lo… Phase1 Healthy Completed 2005-10-01 2005-10-01 ClinicalTrials.gov
NCT00864435 A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Co… Phase1 Healthy Completed 2005-10-01 2005-11-01 ClinicalTrials.gov
NCT00865761 A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Co… Phase1 Healthy Completed 2005-09-01 2005-09-01 ClinicalTrials.gov
NCT00395759 The Visual Effect of an Investigational Artificial Tear in the Tear Layer. Na Dry Eye Disease Completed 2005-09-01 2007-09-01 ClinicalTrials.gov
NCT00865657 A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Un… Phase1 Healthy Completed 2005-09-01 2005-09-01 ClinicalTrials.gov
NCT00865761 A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Co… Phase1 Healthy Completed 2005-09-01 2005-09-01 ClinicalTrials.gov
NCT00395759 The Visual Effect of an Investigational Artificial Tear in the Tear Layer. Na Dry Eye Disease Completed 2005-09-01 2007-09-01 ClinicalTrials.gov
NCT00243711 A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Inves… Phase2 Dry Eye Completed 2005-09-01 2006-04-01 ClinicalTrials.gov
NCT00243711 A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Inves… Phase2 Dry Eye Completed 2005-09-01 2006-04-01 ClinicalTrials.gov
NCT00865761 A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Co… Phase1 Healthy Completed 2005-09-01 2005-09-01 ClinicalTrials.gov
NCT00395759 The Visual Effect of an Investigational Artificial Tear in the Tear Layer. Na Dry Eye Disease Completed 2005-09-01 2007-09-01 ClinicalTrials.gov
NCT00865657 A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Un… Phase1 Healthy Completed 2005-09-01 2005-09-01 ClinicalTrials.gov
NCT00865657 A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Un… Phase1 Healthy Completed 2005-09-01 2005-09-01 ClinicalTrials.gov
NCT00865657 A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Un… Phase1 Healthy Completed 2005-09-01 2005-09-01 ClinicalTrials.gov
NCT00243711 A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Inves… Phase2 Dry Eye Completed 2005-09-01 2006-04-01 ClinicalTrials.gov
NCT00865761 A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Co… Phase1 Healthy Completed 2005-09-01 2005-09-01 ClinicalTrials.gov
NCT00395759 The Visual Effect of an Investigational Artificial Tear in the Tear Layer. Na Dry Eye Disease Completed 2005-09-01 2007-09-01 ClinicalTrials.gov
NCT00243711 A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Inves… Phase2 Dry Eye Completed 2005-09-01 2006-04-01 ClinicalTrials.gov
NCT00168415 A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis Phase4 Hyperhidrosis Completed 2005-08-01 2007-06-01 ClinicalTrials.gov
NCT00168415 A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis Phase4 Hyperhidrosis Completed 2005-08-01 2007-06-01 ClinicalTrials.gov
NCT00168415 A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis Phase4 Hyperhidrosis Completed 2005-08-01 2007-06-01 ClinicalTrials.gov
NCT01111240 Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal M… — Psoriatic Arthritis Completed 2005-08-01 2013-12-01 ClinicalTrials.gov
NCT00648986 Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle … Phase4 Brittle Nails Completed 2005-08-01 2006-12-01 ClinicalTrials.gov
NCT00648986 Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle … Phase4 Brittle Nails Completed 2005-08-01 2006-12-01 ClinicalTrials.gov
NCT00648986 Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle … Phase4 Brittle Nails Completed 2005-08-01 2006-12-01 ClinicalTrials.gov
NCT01111240 Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal M… — Psoriatic Arthritis Completed 2005-08-01 2013-12-01 ClinicalTrials.gov
NCT01111240 Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal M… — Psoriatic Arthritis Completed 2005-08-01 2013-12-01 ClinicalTrials.gov
NCT01111240 Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal M… — Psoriatic Arthritis Completed 2005-08-01 2013-12-01 ClinicalTrials.gov
NCT00648986 Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle … Phase4 Brittle Nails Completed 2005-08-01 2006-12-01 ClinicalTrials.gov
NCT00168415 A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis Phase4 Hyperhidrosis Completed 2005-08-01 2007-06-01 ClinicalTrials.gov
NCT01117480 Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA — Moderate-to-severe Rheumatoid Arthritis Completed 2005-07-01 2014-12-01 ClinicalTrials.gov
NCT00168454 A Research Study for Patients With Overactive Bladder Phase2 Overactive Bladder Completed 2005-07-01 2008-06-01 ClinicalTrials.gov
NCT01117480 Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA — Moderate-to-severe Rheumatoid Arthritis Completed 2005-07-01 2014-12-01 ClinicalTrials.gov
NCT01117480 Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA — Moderate-to-severe Rheumatoid Arthritis Completed 2005-07-01 2014-12-01 ClinicalTrials.gov
NCT01117480 Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA — Moderate-to-severe Rheumatoid Arthritis Completed 2005-07-01 2014-12-01 ClinicalTrials.gov
NCT00865891 A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets U… Phase1 Healthy Completed 2005-07-01 2005-07-01 ClinicalTrials.gov
NCT00865891 A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets U… Phase1 Healthy Completed 2005-07-01 2005-07-01 ClinicalTrials.gov
NCT00865891 A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets U… Phase1 Healthy Completed 2005-07-01 2005-07-01 ClinicalTrials.gov
NCT00168454 A Research Study for Patients With Overactive Bladder Phase2 Overactive Bladder Completed 2005-07-01 2008-06-01 ClinicalTrials.gov
NCT00168454 A Research Study for Patients With Overactive Bladder Phase2 Overactive Bladder Completed 2005-07-01 2008-06-01 ClinicalTrials.gov
NCT00168454 A Research Study for Patients With Overactive Bladder Phase2 Overactive Bladder Completed 2005-07-01 2008-06-01 ClinicalTrials.gov
NCT00865891 A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets U… Phase1 Healthy Completed 2005-07-01 2005-07-01 ClinicalTrials.gov
NCT00496964 Botox for Non-surgical Lateral Release in Patellofemoral Pain Phase3 Patellofemoral Pain Syndrome Terminated 2005-05-01 2008-06-01 ClinicalTrials.gov
NCT00496964 Botox for Non-surgical Lateral Release in Patellofemoral Pain Phase3 Patellofemoral Pain Syndrome Terminated 2005-05-01 2008-06-01 ClinicalTrials.gov
NCT00168337 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2005-05-01 2012-05-01 ClinicalTrials.gov
NCT00496964 Botox for Non-surgical Lateral Release in Patellofemoral Pain Phase3 Patellofemoral Pain Syndrome Terminated 2005-05-01 2008-06-01 ClinicalTrials.gov
NCT00864747 A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fa… Phase1 Healthy Completed 2005-05-01 2005-05-01 ClinicalTrials.gov
NCT00864747 A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fa… Phase1 Healthy Completed 2005-05-01 2005-05-01 ClinicalTrials.gov
NCT00822055 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Tim… Phase4 Open-Angle Glaucoma Completed 2005-05-01 2006-11-01 ClinicalTrials.gov
NCT00864747 A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fa… Phase1 Healthy Completed 2005-05-01 2005-05-01 ClinicalTrials.gov
NCT00864617 A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasti… Phase1 Healthy Completed 2005-05-01 2005-05-01 ClinicalTrials.gov
NCT00168337 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2005-05-01 2012-05-01 ClinicalTrials.gov
NCT00864617 A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasti… Phase1 Healthy Completed 2005-05-01 2005-05-01 ClinicalTrials.gov
NCT00864747 A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fa… Phase1 Healthy Completed 2005-05-01 2005-05-01 ClinicalTrials.gov
NCT00822055 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Tim… Phase4 Open-Angle Glaucoma Completed 2005-05-01 2006-11-01 ClinicalTrials.gov
NCT00864617 A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasti… Phase1 Healthy Completed 2005-05-01 2005-05-01 ClinicalTrials.gov
NCT00168337 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2005-05-01 2012-05-01 ClinicalTrials.gov
NCT00496964 Botox for Non-surgical Lateral Release in Patellofemoral Pain Phase3 Patellofemoral Pain Syndrome Terminated 2005-05-01 2008-06-01 ClinicalTrials.gov
NCT00168337 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2005-05-01 2012-05-01 ClinicalTrials.gov
NCT00822055 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Tim… Phase4 Open-Angle Glaucoma Completed 2005-05-01 2006-11-01 ClinicalTrials.gov
NCT00822055 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Tim… Phase4 Open-Angle Glaucoma Completed 2005-05-01 2006-11-01 ClinicalTrials.gov
NCT00864617 A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasti… Phase1 Healthy Completed 2005-05-01 2005-05-01 ClinicalTrials.gov
NCT00870571 A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets U… Phase1 Healthy Completed 2005-04-01 2005-05-01 ClinicalTrials.gov
NCT00870142 A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fas… Phase1 Healthy Completed 2005-04-01 2005-05-01 ClinicalTrials.gov
NCT00865215 A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Un… Phase1 Healthy Completed 2005-04-01 2005-04-01 ClinicalTrials.gov
NCT00865215 A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Un… Phase1 Healthy Completed 2005-04-01 2005-04-01 ClinicalTrials.gov
NCT00870571 A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets U… Phase1 Healthy Completed 2005-04-01 2005-05-01 ClinicalTrials.gov
NCT00870142 A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fas… Phase1 Healthy Completed 2005-04-01 2005-05-01 ClinicalTrials.gov
NCT00865215 A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Un… Phase1 Healthy Completed 2005-04-01 2005-04-01 ClinicalTrials.gov
NCT00870142 A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fas… Phase1 Healthy Completed 2005-04-01 2005-05-01 ClinicalTrials.gov
NCT00870571 A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets U… Phase1 Healthy Completed 2005-04-01 2005-05-01 ClinicalTrials.gov
NCT00865215 A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Un… Phase1 Healthy Completed 2005-04-01 2005-04-01 ClinicalTrials.gov
NCT00870142 A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fas… Phase1 Healthy Completed 2005-04-01 2005-05-01 ClinicalTrials.gov
NCT00870571 A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets U… Phase1 Healthy Completed 2005-04-01 2005-05-01 ClinicalTrials.gov
NCT00856999 Botox Cosmetic and the Young Patient With Glabellar Furrows Phase4 Glabellar Furrows Completed 2005-02-08 2010-11-17 ClinicalTrials.gov
NCT00856999 Botox Cosmetic and the Young Patient With Glabellar Furrows Phase4 Glabellar Furrows Completed 2005-02-08 2010-11-17 ClinicalTrials.gov
NCT00856999 Botox Cosmetic and the Young Patient With Glabellar Furrows Phase4 Glabellar Furrows Completed 2005-02-08 2010-11-17 ClinicalTrials.gov
NCT00856999 Botox Cosmetic and the Young Patient With Glabellar Furrows Phase4 Glabellar Furrows Completed 2005-02-08 2010-11-17 ClinicalTrials.gov
NCT00352807 Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract … Na Cataract Completed 2005-02-01 2005-12-01 ClinicalTrials.gov
NCT00151541 A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (… Phase3 Acne Vulgaris Completed 2005-02-01 2005-07-01 ClinicalTrials.gov
NCT00168389 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2005-02-01 2012-06-01 ClinicalTrials.gov
NCT00352807 Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract … Na Cataract Completed 2005-02-01 2005-12-01 ClinicalTrials.gov
NCT00250952 Study to Determine If the Volume Used to Dilute BOTOX Cosmetic™ for Injection A… Na Skin Wrinkling Completed 2005-02-01 2005-06-01 ClinicalTrials.gov
NCT00168389 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2005-02-01 2012-06-01 ClinicalTrials.gov
NCT00250952 Study to Determine If the Volume Used to Dilute BOTOX Cosmetic™ for Injection A… Na Skin Wrinkling Completed 2005-02-01 2005-06-01 ClinicalTrials.gov
NCT00168389 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2005-02-01 2012-06-01 ClinicalTrials.gov
NCT00352807 Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract … Na Cataract Completed 2005-02-01 2005-12-01 ClinicalTrials.gov
NCT00151541 A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (… Phase3 Acne Vulgaris Completed 2005-02-01 2005-07-01 ClinicalTrials.gov
NCT00250952 Study to Determine If the Volume Used to Dilute BOTOX Cosmetic™ for Injection A… Na Skin Wrinkling Completed 2005-02-01 2005-06-01 ClinicalTrials.gov
NCT00352807 Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract … Na Cataract Completed 2005-02-01 2005-12-01 ClinicalTrials.gov
NCT00250952 Study to Determine If the Volume Used to Dilute BOTOX Cosmetic™ for Injection A… Na Skin Wrinkling Completed 2005-02-01 2005-06-01 ClinicalTrials.gov
NCT00168389 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2005-02-01 2012-06-01 ClinicalTrials.gov
NCT00151541 A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (… Phase3 Acne Vulgaris Completed 2005-02-01 2005-07-01 ClinicalTrials.gov
NCT00151541 A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (… Phase3 Acne Vulgaris Completed 2005-02-01 2005-07-01 ClinicalTrials.gov
NCT00822081 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Tim… Phase4 Open-Angle Glaucoma Completed 2005-01-01 2006-04-01 ClinicalTrials.gov
NCT00168363 Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hyperten… Phase3 Glaucoma Completed 2005-01-01 2006-08-01 ClinicalTrials.gov
NCT00652496 Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily i… Phase2 Glaucoma Completed 2005-01-01 2005-05-01 ClinicalTrials.gov
NCT00822081 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Tim… Phase4 Open-Angle Glaucoma Completed 2005-01-01 2006-04-01 ClinicalTrials.gov
NCT00652496 Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily i… Phase2 Glaucoma Completed 2005-01-01 2005-05-01 ClinicalTrials.gov
NCT00822081 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Tim… Phase4 Open-Angle Glaucoma Completed 2005-01-01 2006-04-01 ClinicalTrials.gov
NCT00652496 Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily i… Phase2 Glaucoma Completed 2005-01-01 2005-05-01 ClinicalTrials.gov
NCT00652496 Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily i… Phase2 Glaucoma Completed 2005-01-01 2005-05-01 ClinicalTrials.gov
NCT00168363 Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hyperten… Phase3 Glaucoma Completed 2005-01-01 2006-08-01 ClinicalTrials.gov
NCT00822081 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Tim… Phase4 Open-Angle Glaucoma Completed 2005-01-01 2006-04-01 ClinicalTrials.gov
NCT00168363 Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hyperten… Phase3 Glaucoma Completed 2005-01-01 2006-08-01 ClinicalTrials.gov
NCT00168363 Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hyperten… Phase3 Glaucoma Completed 2005-01-01 2006-08-01 ClinicalTrials.gov
NCT00168298 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulti… Phase3 Macular Edema Completed 2004-11-01 2008-09-05 ClinicalTrials.gov
NCT01190748 Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Do… Phase1 Healthy Completed 2004-11-01 2004-12-01 ClinicalTrials.gov
NCT00871247 A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fed Conditio… Phase1 Healthy Completed 2004-11-01 2004-11-01 ClinicalTrials.gov
NCT00871247 A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fed Conditio… Phase1 Healthy Completed 2004-11-01 2004-11-01 ClinicalTrials.gov
NCT01190748 Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Do… Phase1 Healthy Completed 2004-11-01 2004-12-01 ClinicalTrials.gov
NCT01190748 Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Do… Phase1 Healthy Completed 2004-11-01 2004-12-01 ClinicalTrials.gov
NCT00871247 A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fed Conditio… Phase1 Healthy Completed 2004-11-01 2004-11-01 ClinicalTrials.gov
NCT01190748 Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Do… Phase1 Healthy Completed 2004-11-01 2004-12-01 ClinicalTrials.gov
NCT00363714 A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients W… Phase1 Age-Related Macular Degeneration Completed 2004-11-01 2007-04-01 ClinicalTrials.gov
NCT00168298 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulti… Phase3 Macular Edema Completed 2004-11-01 2008-09-05 ClinicalTrials.gov
NCT00168298 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulti… Phase3 Macular Edema Completed 2004-11-01 2008-09-05 ClinicalTrials.gov
NCT00363714 A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients W… Phase1 Age-Related Macular Degeneration Completed 2004-11-01 2007-04-01 ClinicalTrials.gov
NCT00871247 A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fed Conditio… Phase1 Healthy Completed 2004-11-01 2004-11-01 ClinicalTrials.gov
NCT00168298 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulti… Phase3 Macular Edema Completed 2004-11-01 2008-09-05 ClinicalTrials.gov
NCT00363714 A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients W… Phase1 Age-Related Macular Degeneration Completed 2004-11-01 2007-04-01 ClinicalTrials.gov
NCT00363714 A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients W… Phase1 Age-Related Macular Degeneration Completed 2004-11-01 2007-04-01 ClinicalTrials.gov
NCT00863915 A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally… Phase1 Healthy Completed 2004-10-01 2004-10-01 ClinicalTrials.gov
NCT00863915 A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally… Phase1 Healthy Completed 2004-10-01 2004-10-01 ClinicalTrials.gov
NCT00168324 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulti… Phase3 Macular Edema Completed 2004-10-01 2008-10-01 ClinicalTrials.gov
NCT00168324 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulti… Phase3 Macular Edema Completed 2004-10-01 2008-10-01 ClinicalTrials.gov
NCT00168324 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulti… Phase3 Macular Edema Completed 2004-10-01 2008-10-01 ClinicalTrials.gov
NCT00863915 A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally… Phase1 Healthy Completed 2004-10-01 2004-10-01 ClinicalTrials.gov
NCT00863915 A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally… Phase1 Healthy Completed 2004-10-01 2004-10-01 ClinicalTrials.gov
NCT00168324 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulti… Phase3 Macular Edema Completed 2004-10-01 2008-10-01 ClinicalTrials.gov
NCT00716742 Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patien… — Open-Angle Glaucoma Completed 2004-09-01 2009-09-01 ClinicalTrials.gov
NCT00717418 Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Dis… — Keratoconjunctivitis Sicca Completed 2004-09-01 2008-08-01 ClinicalTrials.gov
NCT00864162 A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions Phase1 Healthy Completed 2004-09-01 2004-10-01 ClinicalTrials.gov
NCT00114114 Dose-Response of Gonadal Steroids and Bone Turnover in Older Men Na Healthy Volunteers Completed 2004-09-01 2017-11-01 ClinicalTrials.gov
NCT00865371 A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets … Phase1 Healthy Completed 2004-09-01 2004-09-01 ClinicalTrials.gov
NCT00114114 Dose-Response of Gonadal Steroids and Bone Turnover in Older Men Na Healthy Volunteers Completed 2004-09-01 2017-11-01 ClinicalTrials.gov
NCT00716742 Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patien… — Open-Angle Glaucoma Completed 2004-09-01 2009-09-01 ClinicalTrials.gov
NCT00865371 A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets … Phase1 Healthy Completed 2004-09-01 2004-09-01 ClinicalTrials.gov
NCT00864162 A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions Phase1 Healthy Completed 2004-09-01 2004-10-01 ClinicalTrials.gov
NCT00717418 Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Dis… — Keratoconjunctivitis Sicca Completed 2004-09-01 2008-08-01 ClinicalTrials.gov
NCT00717418 Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Dis… — Keratoconjunctivitis Sicca Completed 2004-09-01 2008-08-01 ClinicalTrials.gov
NCT00716742 Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patien… — Open-Angle Glaucoma Completed 2004-09-01 2009-09-01 ClinicalTrials.gov
NCT00716742 Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patien… — Open-Angle Glaucoma Completed 2004-09-01 2009-09-01 ClinicalTrials.gov
NCT00717418 Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Dis… — Keratoconjunctivitis Sicca Completed 2004-09-01 2008-08-01 ClinicalTrials.gov
NCT00864162 A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions Phase1 Healthy Completed 2004-09-01 2004-10-01 ClinicalTrials.gov
NCT00114114 Dose-Response of Gonadal Steroids and Bone Turnover in Older Men Na Healthy Volunteers Completed 2004-09-01 2017-11-01 ClinicalTrials.gov
NCT00114114 Dose-Response of Gonadal Steroids and Bone Turnover in Older Men Na Healthy Volunteers Completed 2004-09-01 2017-11-01 ClinicalTrials.gov
NCT00865371 A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets … Phase1 Healthy Completed 2004-09-01 2004-09-01 ClinicalTrials.gov
NCT00865371 A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets … Phase1 Healthy Completed 2004-09-01 2004-09-01 ClinicalTrials.gov
NCT00864162 A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions Phase1 Healthy Completed 2004-09-01 2004-10-01 ClinicalTrials.gov
NCT00864344 A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Fasting… Phase1 Healthy Completed 2004-08-01 2004-08-01 ClinicalTrials.gov
NCT00864019 A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Non-fas… Phase1 Healthy Completed 2004-08-01 2004-08-01 ClinicalTrials.gov
NCT00864019 A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Non-fas… Phase1 Healthy Completed 2004-08-01 2004-08-01 ClinicalTrials.gov
NCT00865410 A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets … Phase1 Healthy Completed 2004-08-01 2004-09-01 ClinicalTrials.gov
NCT00864019 A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Non-fas… Phase1 Healthy Completed 2004-08-01 2004-08-01 ClinicalTrials.gov
NCT00865410 A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets … Phase1 Healthy Completed 2004-08-01 2004-09-01 ClinicalTrials.gov
NCT00865410 A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets … Phase1 Healthy Completed 2004-08-01 2004-09-01 ClinicalTrials.gov
NCT00864019 A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Non-fas… Phase1 Healthy Completed 2004-08-01 2004-08-01 ClinicalTrials.gov
NCT00865410 A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets … Phase1 Healthy Completed 2004-08-01 2004-09-01 ClinicalTrials.gov
NCT00864344 A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Fasting… Phase1 Healthy Completed 2004-08-01 2004-08-01 ClinicalTrials.gov
NCT00864344 A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Fasting… Phase1 Healthy Completed 2004-08-01 2004-08-01 ClinicalTrials.gov
NCT00864344 A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Fasting… Phase1 Healthy Completed 2004-08-01 2004-08-01 ClinicalTrials.gov
NCT00865462 A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Condi… Phase1 Healthy Completed 2004-07-01 2004-07-01 ClinicalTrials.gov
NCT00367133 Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2004-07-01 2008-10-01 ClinicalTrials.gov
NCT00211718 Intra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain Phase3 Arthritis Unknown 2004-07-01 2007-06-01 ClinicalTrials.gov
NCT00865462 A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Condi… Phase1 Healthy Completed 2004-07-01 2004-07-01 ClinicalTrials.gov
NCT00211718 Intra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain Phase3 Arthritis Unknown 2004-07-01 2007-06-01 ClinicalTrials.gov
NCT00367133 Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2004-07-01 2008-10-01 ClinicalTrials.gov
NCT00211718 Intra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain Phase3 Arthritis Unknown 2004-07-01 2007-06-01 ClinicalTrials.gov
NCT00367133 Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2004-07-01 2008-10-01 ClinicalTrials.gov
NCT00865462 A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Condi… Phase1 Healthy Completed 2004-07-01 2004-07-01 ClinicalTrials.gov
NCT00367133 Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema Phase3 Diabetic Macular Edema Completed 2004-07-01 2008-10-01 ClinicalTrials.gov
NCT00865462 A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Condi… Phase1 Healthy Completed 2004-07-01 2004-07-01 ClinicalTrials.gov
NCT00211718 Intra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain Phase3 Arthritis Unknown 2004-07-01 2007-06-01 ClinicalTrials.gov
NCT00168441 A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralg… Phase2 Postherpetic Neuralgia Completed 2004-06-01 2005-06-01 ClinicalTrials.gov
NCT00211679 Intra-articularInjection of Botulinum Toxin Type Phase2 Arthritis Unknown 2004-06-01 2007-06-01 ClinicalTrials.gov
NCT00211679 Intra-articularInjection of Botulinum Toxin Type Phase2 Arthritis Unknown 2004-06-01 2007-06-01 ClinicalTrials.gov
NCT00168441 A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralg… Phase2 Postherpetic Neuralgia Completed 2004-06-01 2005-06-01 ClinicalTrials.gov
NCT00863941 A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting C… Phase1 Healthy Completed 2004-06-01 2004-07-01 ClinicalTrials.gov
NCT00863941 A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting C… Phase1 Healthy Completed 2004-06-01 2004-07-01 ClinicalTrials.gov
NCT00211679 Intra-articularInjection of Botulinum Toxin Type Phase2 Arthritis Unknown 2004-06-01 2007-06-01 ClinicalTrials.gov
NCT00168441 A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralg… Phase2 Postherpetic Neuralgia Completed 2004-06-01 2005-06-01 ClinicalTrials.gov
NCT00211679 Intra-articularInjection of Botulinum Toxin Type Phase2 Arthritis Unknown 2004-06-01 2007-06-01 ClinicalTrials.gov
NCT00863941 A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting C… Phase1 Healthy Completed 2004-06-01 2004-07-01 ClinicalTrials.gov
NCT00863941 A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting C… Phase1 Healthy Completed 2004-06-01 2004-07-01 ClinicalTrials.gov
NCT00168441 A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralg… Phase2 Postherpetic Neuralgia Completed 2004-06-01 2005-06-01 ClinicalTrials.gov
NCT00782548 Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults Phase4 Healthy Completed 2004-05-01 2004-06-01 ClinicalTrials.gov
NCT00782548 Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults Phase4 Healthy Completed 2004-05-01 2004-06-01 ClinicalTrials.gov
NCT00782548 Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults Phase4 Healthy Completed 2004-05-01 2004-06-01 ClinicalTrials.gov
NCT00782548 Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults Phase4 Healthy Completed 2004-05-01 2004-06-01 ClinicalTrials.gov
NCT00850421 Pilot Study of BOTOX for Migraine Headaches Na Migraine Headache Terminated 2004-04-01 2010-04-01 ClinicalTrials.gov
NCT00850421 Pilot Study of BOTOX for Migraine Headaches Na Migraine Headache Terminated 2004-04-01 2010-04-01 ClinicalTrials.gov
NCT01077258 Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Rout… — Rheumatoid Arthritis Completed 2004-04-01 2013-02-01 ClinicalTrials.gov
NCT01077258 Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Rout… — Rheumatoid Arthritis Completed 2004-04-01 2013-02-01 ClinicalTrials.gov
NCT00850421 Pilot Study of BOTOX for Migraine Headaches Na Migraine Headache Terminated 2004-04-01 2010-04-01 ClinicalTrials.gov
NCT01077258 Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Rout… — Rheumatoid Arthritis Completed 2004-04-01 2013-02-01 ClinicalTrials.gov
NCT00850421 Pilot Study of BOTOX for Migraine Headaches Na Migraine Headache Terminated 2004-04-01 2010-04-01 ClinicalTrials.gov
NCT01077258 Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Rout… — Rheumatoid Arthritis Completed 2004-04-01 2013-02-01 ClinicalTrials.gov
NCT00651690 Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke U… Phase2 Stroke Completed 2004-03-01 2005-05-01 ClinicalTrials.gov
NCT00580502 Safety and Efficacy of Adjustable Gastric Band Operations for Patients With Bod… Phase2 Obesity Completed 2004-03-01 2012-09-01 ClinicalTrials.gov
NCT00580502 Safety and Efficacy of Adjustable Gastric Band Operations for Patients With Bod… Phase2 Obesity Completed 2004-03-01 2012-09-01 ClinicalTrials.gov
NCT00651690 Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke U… Phase2 Stroke Completed 2004-03-01 2005-05-01 ClinicalTrials.gov
NCT00405431 Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery? Na Glaucoma Completed 2004-03-01 2007-11-01 ClinicalTrials.gov
NCT00405431 Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery? Na Glaucoma Completed 2004-03-01 2007-11-01 ClinicalTrials.gov
NCT00580502 Safety and Efficacy of Adjustable Gastric Band Operations for Patients With Bod… Phase2 Obesity Completed 2004-03-01 2012-09-01 ClinicalTrials.gov
NCT00580502 Safety and Efficacy of Adjustable Gastric Band Operations for Patients With Bod… Phase2 Obesity Completed 2004-03-01 2012-09-01 ClinicalTrials.gov
NCT00651690 Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke U… Phase2 Stroke Completed 2004-03-01 2005-05-01 ClinicalTrials.gov
NCT00651690 Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke U… Phase2 Stroke Completed 2004-03-01 2005-05-01 ClinicalTrials.gov
NCT00405431 Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery? Na Glaucoma Completed 2004-03-01 2007-11-01 ClinicalTrials.gov
NCT00405431 Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery? Na Glaucoma Completed 2004-03-01 2007-11-01 ClinicalTrials.gov
NCT01075191 Kaletra: Therapy With Double Protease Inhibitors — Human Immunodeficiency Virus Completed 2004-01-01 2011-09-01 ClinicalTrials.gov
NCT01075191 Kaletra: Therapy With Double Protease Inhibitors — Human Immunodeficiency Virus Completed 2004-01-01 2011-09-01 ClinicalTrials.gov
NCT01075191 Kaletra: Therapy With Double Protease Inhibitors — Human Immunodeficiency Virus Completed 2004-01-01 2011-09-01 ClinicalTrials.gov
NCT01075191 Kaletra: Therapy With Double Protease Inhibitors — Human Immunodeficiency Virus Completed 2004-01-01 2011-09-01 ClinicalTrials.gov
NCT00430196 BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Inj… Phase4 Upper Limb Spasticity Completed 2003-12-01 2006-09-01 ClinicalTrials.gov
NCT00865267 The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment … Phase1 Healthy Completed 2003-12-01 2003-12-01 ClinicalTrials.gov
NCT00430196 BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Inj… Phase4 Upper Limb Spasticity Completed 2003-12-01 2006-09-01 ClinicalTrials.gov
NCT00430196 BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Inj… Phase4 Upper Limb Spasticity Completed 2003-12-01 2006-09-01 ClinicalTrials.gov
NCT00865267 The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment … Phase1 Healthy Completed 2003-12-01 2003-12-01 ClinicalTrials.gov
NCT00865267 The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment … Phase1 Healthy Completed 2003-12-01 2003-12-01 ClinicalTrials.gov
NCT00865267 The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment … Phase1 Healthy Completed 2003-12-01 2003-12-01 ClinicalTrials.gov
NCT00430196 BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Inj… Phase4 Upper Limb Spasticity Completed 2003-12-01 2006-09-01 ClinicalTrials.gov
NCT01129583 Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Sti… Na Post Traumatic Stiffness Completed 2003-11-01 2010-05-01 ClinicalTrials.gov
NCT00648999 Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients Phase4 Human Immunodeficiency Virus Completed 2003-11-01 2006-12-01 ClinicalTrials.gov
NCT00648999 Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients Phase4 Human Immunodeficiency Virus Completed 2003-11-01 2006-12-01 ClinicalTrials.gov
NCT00168480 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Phase4 Hyperhidrosis Completed 2003-11-01 2007-04-01 ClinicalTrials.gov
NCT00168480 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Phase4 Hyperhidrosis Completed 2003-11-01 2007-04-01 ClinicalTrials.gov
NCT00648999 Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients Phase4 Human Immunodeficiency Virus Completed 2003-11-01 2006-12-01 ClinicalTrials.gov
NCT01129583 Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Sti… Na Post Traumatic Stiffness Completed 2003-11-01 2010-05-01 ClinicalTrials.gov
NCT01129583 Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Sti… Na Post Traumatic Stiffness Completed 2003-11-01 2010-05-01 ClinicalTrials.gov
NCT00168480 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Phase4 Hyperhidrosis Completed 2003-11-01 2007-04-01 ClinicalTrials.gov
NCT01129583 Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Sti… Na Post Traumatic Stiffness Completed 2003-11-01 2010-05-01 ClinicalTrials.gov
NCT00648999 Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients Phase4 Human Immunodeficiency Virus Completed 2003-11-01 2006-12-01 ClinicalTrials.gov
NCT00168480 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Phase4 Hyperhidrosis Completed 2003-11-01 2007-04-01 ClinicalTrials.gov
NCT00661089 Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain… Na Post-stroke Shoulder Pain and Spasticity Completed 2003-09-01 2010-02-01 ClinicalTrials.gov
NCT00661089 Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain… Na Post-stroke Shoulder Pain and Spasticity Completed 2003-09-01 2010-02-01 ClinicalTrials.gov
NCT00661089 Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain… Na Post-stroke Shoulder Pain and Spasticity Completed 2003-09-01 2010-02-01 ClinicalTrials.gov
NCT00661089 Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain… Na Post-stroke Shoulder Pain and Spasticity Completed 2003-09-01 2010-02-01 ClinicalTrials.gov
NCT00865852 A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-f… Phase1 Healthy Completed 2003-08-01 2003-08-01 ClinicalTrials.gov
NCT00865072 A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasti… Phase1 Healthy Completed 2003-08-01 2003-08-01 ClinicalTrials.gov
NCT00865852 A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-f… Phase1 Healthy Completed 2003-08-01 2003-08-01 ClinicalTrials.gov
NCT00865852 A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-f… Phase1 Healthy Completed 2003-08-01 2003-08-01 ClinicalTrials.gov
NCT00865072 A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasti… Phase1 Healthy Completed 2003-08-01 2003-08-01 ClinicalTrials.gov
NCT00865852 A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-f… Phase1 Healthy Completed 2003-08-01 2003-08-01 ClinicalTrials.gov
NCT00865072 A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasti… Phase1 Healthy Completed 2003-08-01 2003-08-01 ClinicalTrials.gov
NCT00865072 A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasti… Phase1 Healthy Completed 2003-08-01 2003-08-01 ClinicalTrials.gov
NCT00865943 A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting … Phase1 Healthy Completed 2003-07-01 2003-08-01 ClinicalTrials.gov
NCT00865943 A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting … Phase1 Healthy Completed 2003-07-01 2003-08-01 ClinicalTrials.gov
NCT00865943 A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting … Phase1 Healthy Completed 2003-07-01 2003-08-01 ClinicalTrials.gov
NCT00865943 A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting … Phase1 Healthy Completed 2003-07-01 2003-08-01 ClinicalTrials.gov
NCT00652106 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase3 Glaucoma Completed 2003-06-01 2004-03-01 ClinicalTrials.gov
NCT00241215 Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cer… Phase4 Cervicobrachial Neuralgia Completed 2003-06-01 — ClinicalTrials.gov
NCT00864890 A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fed Conditio… Phase1 Healthy Completed 2003-06-01 2003-07-01 ClinicalTrials.gov
NCT00865085 A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fasting Cond… Phase1 Healthy Completed 2003-06-01 2003-07-01 ClinicalTrials.gov
NCT00864890 A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fed Conditio… Phase1 Healthy Completed 2003-06-01 2003-07-01 ClinicalTrials.gov
NCT00865085 A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fasting Cond… Phase1 Healthy Completed 2003-06-01 2003-07-01 ClinicalTrials.gov
NCT00865085 A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fasting Cond… Phase1 Healthy Completed 2003-06-01 2003-07-01 ClinicalTrials.gov
NCT00864890 A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fed Conditio… Phase1 Healthy Completed 2003-06-01 2003-07-01 ClinicalTrials.gov
NCT00241215 Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cer… Phase4 Cervicobrachial Neuralgia Completed 2003-06-01 — ClinicalTrials.gov
NCT00241215 Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cer… Phase4 Cervicobrachial Neuralgia Completed 2003-06-01 — ClinicalTrials.gov
NCT00652106 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase3 Glaucoma Completed 2003-06-01 2004-03-01 ClinicalTrials.gov
NCT00864890 A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fed Conditio… Phase1 Healthy Completed 2003-06-01 2003-07-01 ClinicalTrials.gov
NCT00865085 A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fasting Cond… Phase1 Healthy Completed 2003-06-01 2003-07-01 ClinicalTrials.gov
NCT00241215 Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cer… Phase4 Cervicobrachial Neuralgia Completed 2003-06-01 — ClinicalTrials.gov
NCT00652106 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase3 Glaucoma Completed 2003-06-01 2004-03-01 ClinicalTrials.gov
NCT00652106 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase3 Glaucoma Completed 2003-06-01 2004-03-01 ClinicalTrials.gov
NCT00332059 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2003-05-01 2004-09-01 ClinicalTrials.gov
NCT00332059 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2003-05-01 2004-09-01 ClinicalTrials.gov
NCT00332059 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2003-05-01 2004-09-01 ClinicalTrials.gov
NCT00652483 Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hy… Phase3 Glaucoma Completed 2003-05-01 2004-09-01 ClinicalTrials.gov
NCT00332059 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2003-05-01 2004-09-01 ClinicalTrials.gov
NCT00652483 Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hy… Phase3 Glaucoma Completed 2003-05-01 2004-09-01 ClinicalTrials.gov
NCT00652483 Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hy… Phase3 Glaucoma Completed 2003-05-01 2004-09-01 ClinicalTrials.gov
NCT00652483 Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hy… Phase3 Glaucoma Completed 2003-05-01 2004-09-01 ClinicalTrials.gov
NCT01853605 NATRELLE® 410 Full and Moderate Height/Projection Breast Implant Continued Acce… Na Breast Augmentation Terminated 2003-04-01 2014-08-01 ClinicalTrials.gov
NCT01853605 NATRELLE® 410 Full and Moderate Height/Projection Breast Implant Continued Acce… Na Breast Augmentation Terminated 2003-04-01 2014-08-01 ClinicalTrials.gov
NCT00651729 Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Po… Phase2 Stroke Completed 2003-04-01 2004-12-01 ClinicalTrials.gov
NCT00651729 Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Po… Phase2 Stroke Completed 2003-04-01 2004-12-01 ClinicalTrials.gov
NCT00651729 Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Po… Phase2 Stroke Completed 2003-04-01 2004-12-01 ClinicalTrials.gov
NCT00651729 Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Po… Phase2 Stroke Completed 2003-04-01 2004-12-01 ClinicalTrials.gov
NCT01853605 NATRELLE® 410 Full and Moderate Height/Projection Breast Implant Continued Acce… Na Breast Augmentation Terminated 2003-04-01 2014-08-01 ClinicalTrials.gov
NCT01853605 NATRELLE® 410 Full and Moderate Height/Projection Breast Implant Continued Acce… Na Breast Augmentation Terminated 2003-04-01 2014-08-01 ClinicalTrials.gov
NCT00865241 A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets… Phase1 Healthy Completed 2002-11-01 2002-11-01 ClinicalTrials.gov
NCT00864734 A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets… Phase1 Healthy Completed 2002-11-01 2002-11-01 ClinicalTrials.gov
NCT00865241 A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets… Phase1 Healthy Completed 2002-11-01 2002-11-01 ClinicalTrials.gov
NCT00864734 A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets… Phase1 Healthy Completed 2002-11-01 2002-11-01 ClinicalTrials.gov
NCT00865241 A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets… Phase1 Healthy Completed 2002-11-01 2002-11-01 ClinicalTrials.gov
NCT00651859 Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With O… Phase2 Glaucoma Completed 2002-11-01 2004-01-01 ClinicalTrials.gov
NCT00651859 Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With O… Phase2 Glaucoma Completed 2002-11-01 2004-01-01 ClinicalTrials.gov
NCT00864734 A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets… Phase1 Healthy Completed 2002-11-01 2002-11-01 ClinicalTrials.gov
NCT00651859 Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With O… Phase2 Glaucoma Completed 2002-11-01 2004-01-01 ClinicalTrials.gov
NCT00864734 A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets… Phase1 Healthy Completed 2002-11-01 2002-11-01 ClinicalTrials.gov
NCT00651859 Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With O… Phase2 Glaucoma Completed 2002-11-01 2004-01-01 ClinicalTrials.gov
NCT00865241 A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets… Phase1 Healthy Completed 2002-11-01 2002-11-01 ClinicalTrials.gov
NCT00199589 Treatment of Spastic Equinovarus Foot After Stroke Na Spastic Equinovarus Completed 2002-10-01 2007-12-01 ClinicalTrials.gov
NCT00199589 Treatment of Spastic Equinovarus Foot After Stroke Na Spastic Equinovarus Completed 2002-10-01 2007-12-01 ClinicalTrials.gov
NCT00199589 Treatment of Spastic Equinovarus Foot After Stroke Na Spastic Equinovarus Completed 2002-10-01 2007-12-01 ClinicalTrials.gov
NCT00199589 Treatment of Spastic Equinovarus Foot After Stroke Na Spastic Equinovarus Completed 2002-10-01 2007-12-01 ClinicalTrials.gov
NCT01155193 Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children i… — Respiratory Syncytial Virus Infections Completed 2002-09-01 2016-07-31 ClinicalTrials.gov
NCT01155193 Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children i… — Respiratory Syncytial Virus Infections Completed 2002-09-01 2016-07-31 ClinicalTrials.gov
NCT01155193 Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children i… — Respiratory Syncytial Virus Infections Completed 2002-09-01 2016-07-31 ClinicalTrials.gov
NCT01155193 Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children i… — Respiratory Syncytial Virus Infections Completed 2002-09-01 2016-07-31 ClinicalTrials.gov
NCT00179114 Vanderbilt University Spasticity Management Program Evaluation Plan Phase4 Spasticity Completed 2002-08-01 2006-02-01 ClinicalTrials.gov
NCT00179114 Vanderbilt University Spasticity Management Program Evaluation Plan Phase4 Spasticity Completed 2002-08-01 2006-02-01 ClinicalTrials.gov
NCT00179114 Vanderbilt University Spasticity Management Program Evaluation Plan Phase4 Spasticity Completed 2002-08-01 2006-02-01 ClinicalTrials.gov
NCT00179114 Vanderbilt University Spasticity Management Program Evaluation Plan Phase4 Spasticity Completed 2002-08-01 2006-02-01 ClinicalTrials.gov
NCT00487214 Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient … — Glaucoma, Open-Angle Completed 2002-06-01 2003-02-01 ClinicalTrials.gov
NCT00487214 Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient … — Glaucoma, Open-Angle Completed 2002-06-01 2003-02-01 ClinicalTrials.gov
NCT00487214 Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient … — Glaucoma, Open-Angle Completed 2002-06-01 2003-02-01 ClinicalTrials.gov
NCT00487214 Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient … — Glaucoma, Open-Angle Completed 2002-06-01 2003-02-01 ClinicalTrials.gov
NCT00865839 A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasti… Phase1 Healthy Completed 2002-03-01 2002-03-01 ClinicalTrials.gov
NCT00145106 Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Ac… Phase4 Acne Vulgaris Completed 2002-03-01 2002-08-01 ClinicalTrials.gov
NCT00865839 A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasti… Phase1 Healthy Completed 2002-03-01 2002-03-01 ClinicalTrials.gov
NCT00865839 A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasti… Phase1 Healthy Completed 2002-03-01 2002-03-01 ClinicalTrials.gov
NCT00145106 Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Ac… Phase4 Acne Vulgaris Completed 2002-03-01 2002-08-01 ClinicalTrials.gov
NCT00865839 A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasti… Phase1 Healthy Completed 2002-03-01 2002-03-01 ClinicalTrials.gov
NCT00145106 Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Ac… Phase4 Acne Vulgaris Completed 2002-03-01 2002-08-01 ClinicalTrials.gov
NCT00145106 Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Ac… Phase4 Acne Vulgaris Completed 2002-03-01 2002-08-01 ClinicalTrials.gov
NCT00168402 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Phase3 Hyperhidrosis Completed 2002-02-01 2005-10-01 ClinicalTrials.gov
NCT00168402 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Phase3 Hyperhidrosis Completed 2002-02-01 2005-10-01 ClinicalTrials.gov
NCT00168402 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Phase3 Hyperhidrosis Completed 2002-02-01 2005-10-01 ClinicalTrials.gov
NCT00168402 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Phase3 Hyperhidrosis Completed 2002-02-01 2005-10-01 ClinicalTrials.gov
NCT00178646 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Phase4 Stroke Completed 2002-01-01 2010-03-01 ClinicalTrials.gov
NCT00178646 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Phase4 Stroke Completed 2002-01-01 2010-03-01 ClinicalTrials.gov
NCT00178646 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Phase4 Stroke Completed 2002-01-01 2010-03-01 ClinicalTrials.gov
NCT00178646 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Phase4 Stroke Completed 2002-01-01 2010-03-01 ClinicalTrials.gov
NCT00035906 Research Study in Patients With Persistent Macular Edema Phase2 Diabetes Completed 2001-10-01 2004-08-01 ClinicalTrials.gov
NCT00035906 Research Study in Patients With Persistent Macular Edema Phase2 Diabetes Completed 2001-10-01 2004-08-01 ClinicalTrials.gov
NCT00035906 Research Study in Patients With Persistent Macular Edema Phase2 Diabetes Completed 2001-10-01 2004-08-01 ClinicalTrials.gov
NCT00035906 Research Study in Patients With Persistent Macular Edema Phase2 Diabetes Completed 2001-10-01 2004-08-01 ClinicalTrials.gov
NCT00865696 A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Con… Phase1 Healthy Completed 2001-09-01 2001-09-01 ClinicalTrials.gov
NCT00865384 A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting… Phase1 Healthy Completed 2001-09-01 2001-09-01 ClinicalTrials.gov
NCT00865384 A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting… Phase1 Healthy Completed 2001-09-01 2001-09-01 ClinicalTrials.gov
NCT00865696 A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Con… Phase1 Healthy Completed 2001-09-01 2001-09-01 ClinicalTrials.gov
NCT00865384 A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting… Phase1 Healthy Completed 2001-09-01 2001-09-01 ClinicalTrials.gov
NCT00865696 A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Con… Phase1 Healthy Completed 2001-09-01 2001-09-01 ClinicalTrials.gov
NCT00865384 A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting… Phase1 Healthy Completed 2001-09-01 2001-09-01 ClinicalTrials.gov
NCT00865696 A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Con… Phase1 Healthy Completed 2001-09-01 2001-09-01 ClinicalTrials.gov
NCT00332540 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2001-08-01 2003-08-01 ClinicalTrials.gov
NCT00332072 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2001-08-01 2003-08-01 ClinicalTrials.gov
NCT00332072 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2001-08-01 2003-08-01 ClinicalTrials.gov
NCT00332540 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2001-08-01 2003-08-01 ClinicalTrials.gov
NCT00332072 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2001-08-01 2003-08-01 ClinicalTrials.gov
NCT00332072 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2001-08-01 2003-08-01 ClinicalTrials.gov
NCT00332540 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2001-08-01 2003-08-01 ClinicalTrials.gov
NCT00332540 Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 2001-08-01 2003-08-01 ClinicalTrials.gov
NCT00025818 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye … Phase3 Keratoconjunctivitis Sicca Completed 2001-05-01 2003-03-01 ClinicalTrials.gov
NCT00025818 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye … Phase3 Keratoconjunctivitis Sicca Completed 2001-05-01 2003-03-01 ClinicalTrials.gov
NCT00025818 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye … Phase3 Keratoconjunctivitis Sicca Completed 2001-05-01 2003-03-01 ClinicalTrials.gov
NCT00025818 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye … Phase3 Keratoconjunctivitis Sicca Completed 2001-05-01 2003-03-01 ClinicalTrials.gov
NCT00865059 A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting… Phase1 Healthy Completed 2001-02-01 2001-03-01 ClinicalTrials.gov
NCT00865423 A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Con… Phase1 Healthy Completed 2001-02-01 2001-03-01 ClinicalTrials.gov
NCT00690339 Safety and Effectiveness of Style 410 Silicone-Filled Breast Implant Study Na Breast Augmentation Completed 2001-02-01 2012-12-01 ClinicalTrials.gov
NCT00690339 Safety and Effectiveness of Style 410 Silicone-Filled Breast Implant Study Na Breast Augmentation Completed 2001-02-01 2012-12-01 ClinicalTrials.gov
NCT00865059 A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting… Phase1 Healthy Completed 2001-02-01 2001-03-01 ClinicalTrials.gov
NCT00865423 A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Con… Phase1 Healthy Completed 2001-02-01 2001-03-01 ClinicalTrials.gov
NCT00865423 A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Con… Phase1 Healthy Completed 2001-02-01 2001-03-01 ClinicalTrials.gov
NCT00865423 A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Con… Phase1 Healthy Completed 2001-02-01 2001-03-01 ClinicalTrials.gov
NCT00690339 Safety and Effectiveness of Style 410 Silicone-Filled Breast Implant Study Na Breast Augmentation Completed 2001-02-01 2012-12-01 ClinicalTrials.gov
NCT00690339 Safety and Effectiveness of Style 410 Silicone-Filled Breast Implant Study Na Breast Augmentation Completed 2001-02-01 2012-12-01 ClinicalTrials.gov
NCT00865059 A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting… Phase1 Healthy Completed 2001-02-01 2001-03-01 ClinicalTrials.gov
NCT00865059 A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting… Phase1 Healthy Completed 2001-02-01 2001-03-01 ClinicalTrials.gov
NCT01277419 German Spondyloarthritis Inception Cohort — Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA) Recruiting 2000-07-01 2030-07-01 ClinicalTrials.gov
NCT01277419 German Spondyloarthritis Inception Cohort — Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA) Recruiting 2000-07-01 2030-07-01 ClinicalTrials.gov
NCT01277419 German Spondyloarthritis Inception Cohort — Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA) Recruiting 2000-07-01 2030-07-01 ClinicalTrials.gov
NCT01277419 German Spondyloarthritis Inception Cohort — Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA) Recruiting 2000-07-01 2030-07-01 ClinicalTrials.gov
NCT00168350 Memantine in Patients With Chronic Glaucoma Phase3 Open-Angle Glaucoma Completed 2000-03-01 2006-09-01 ClinicalTrials.gov
NCT00168350 Memantine in Patients With Chronic Glaucoma Phase3 Open-Angle Glaucoma Completed 2000-03-01 2006-09-01 ClinicalTrials.gov
NCT00168350 Memantine in Patients With Chronic Glaucoma Phase3 Open-Angle Glaucoma Completed 2000-03-01 2006-09-01 ClinicalTrials.gov
NCT00168350 Memantine in Patients With Chronic Glaucoma Phase3 Open-Angle Glaucoma Completed 2000-03-01 2006-09-01 ClinicalTrials.gov
NCT00332436 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 1999-12-01 2001-11-01 ClinicalTrials.gov
NCT00332436 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 1999-12-01 2001-11-01 ClinicalTrials.gov
NCT00332436 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 1999-12-01 2001-11-01 ClinicalTrials.gov
NCT00332436 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase3 Ocular Hypertension Completed 1999-12-01 2001-11-01 ClinicalTrials.gov
NCT00332345 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase2 Ocular Hypertension Completed 1999-07-01 1999-08-01 ClinicalTrials.gov
NCT00332345 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase2 Ocular Hypertension Completed 1999-07-01 1999-08-01 ClinicalTrials.gov
NCT00332345 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase2 Ocular Hypertension Completed 1999-07-01 1999-08-01 ClinicalTrials.gov
NCT00332345 Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients … Phase2 Ocular Hypertension Completed 1999-07-01 1999-08-01 ClinicalTrials.gov
NCT00864760 A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Con… Phase1 Healthy Completed 1999-06-01 1999-06-01 ClinicalTrials.gov
NCT00864760 A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Con… Phase1 Healthy Completed 1999-06-01 1999-06-01 ClinicalTrials.gov
NCT00864760 A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Con… Phase1 Healthy Completed 1999-06-01 1999-06-01 ClinicalTrials.gov
NCT00864760 A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Con… Phase1 Healthy Completed 1999-06-01 1999-06-01 ClinicalTrials.gov
NCT00689871 Safety and Effectiveness of Natrelle(TM) Cohesive Round Silicone-Filled Breast … Na Breast Augmentation Completed 1999-01-01 2011-08-01 ClinicalTrials.gov
NCT00689871 Safety and Effectiveness of Natrelle(TM) Cohesive Round Silicone-Filled Breast … Na Breast Augmentation Completed 1999-01-01 2011-08-01 ClinicalTrials.gov
NCT00689871 Safety and Effectiveness of Natrelle(TM) Cohesive Round Silicone-Filled Breast … Na Breast Augmentation Completed 1999-01-01 2011-08-01 ClinicalTrials.gov
NCT00689871 Safety and Effectiveness of Natrelle(TM) Cohesive Round Silicone-Filled Breast … Na Breast Augmentation Completed 1999-01-01 2011-08-01 ClinicalTrials.gov
NCT00864058 A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Co… Phase1 Healthy Completed 1998-01-01 1998-01-01 ClinicalTrials.gov
NCT00864058 A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Co… Phase1 Healthy Completed 1998-01-01 1998-01-01 ClinicalTrials.gov
NCT00864058 A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Co… Phase1 Healthy Completed 1998-01-01 1998-01-01 ClinicalTrials.gov
NCT00864058 A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Co… Phase1 Healthy Completed 1998-01-01 1998-01-01 ClinicalTrials.gov
NCT00864305 A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fastin… Phase1 Healthy Completed 1997-12-01 1998-01-01 ClinicalTrials.gov
NCT00691327 Adjunct Study of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants Na Breast Reconstruction Completed 1997-12-01 2012-12-01 ClinicalTrials.gov
NCT00691327 Adjunct Study of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants Na Breast Reconstruction Completed 1997-12-01 2012-12-01 ClinicalTrials.gov
NCT00691327 Adjunct Study of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants Na Breast Reconstruction Completed 1997-12-01 2012-12-01 ClinicalTrials.gov
NCT00864305 A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fastin… Phase1 Healthy Completed 1997-12-01 1998-01-01 ClinicalTrials.gov
NCT00691327 Adjunct Study of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants Na Breast Reconstruction Completed 1997-12-01 2012-12-01 ClinicalTrials.gov
NCT00864305 A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fastin… Phase1 Healthy Completed 1997-12-01 1998-01-01 ClinicalTrials.gov
NCT00864305 A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fastin… Phase1 Healthy Completed 1997-12-01 1998-01-01 ClinicalTrials.gov
NCT00262626 The Canadian Glaucoma Study Na Glaucoma Terminated 1995-02-01 1995-06-01 ClinicalTrials.gov
NCT00262626 The Canadian Glaucoma Study Na Glaucoma Terminated 1995-02-01 1995-06-01 ClinicalTrials.gov
NCT00262626 The Canadian Glaucoma Study Na Glaucoma Terminated 1995-02-01 1995-06-01 ClinicalTrials.gov
NCT00262626 The Canadian Glaucoma Study Na Glaucoma Terminated 1995-02-01 1995-06-01 ClinicalTrials.gov
NCT00404989 Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any M… — HIV Infections Recruiting 1989-01-01 2099-01-01 ClinicalTrials.gov
NCT00404989 Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any M… — HIV Infections Recruiting 1989-01-01 2099-01-01 ClinicalTrials.gov
NCT00404989 Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any M… — HIV Infections Recruiting 1989-01-01 2099-01-01 ClinicalTrials.gov
NCT00404989 Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any M… — HIV Infections Recruiting 1989-01-01 2099-01-01 ClinicalTrials.gov
Total clinical trials: 8360
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
ABBV-2001 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Iberdomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Mezigdomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Carfilzomib Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Daratumumab Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Dexamethasone Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Lenalidomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Etentamig Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Placebo Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Upadacitinib Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Oxaliplatin Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma ACTIVE_NOT_RECRUITING NCT06628310
Leucovorin Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma ACTIVE_NOT_RECRUITING NCT06628310
Fluorouracil Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma ACTIVE_NOT_RECRUITING NCT06628310
Budigalimab Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma ACTIVE_NOT_RECRUITING NCT06628310
Telisotuzumab Adizutecan Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma ACTIVE_NOT_RECRUITING NCT06628310
Irinotecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Oxaliplatin Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Folinic acid/ Leucovorina Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Fluorouracil Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Telisotuzumab adizutecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
Placebo Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Upadacitinib Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Risankizumab Other Phase PHASE3 Psoriatic Arthritis (PsA) COMPLETED NCT03671148
Placebo Other Phase PHASE3 Psoriatic Arthritis (PsA) COMPLETED NCT03671148
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Bevacizumab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Mirvetuximab Soravtansine Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Sitagliptin Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07567781
Pitavastatin Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07567781
Digoxin Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07567781
Metformin Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07567781
Midazolam Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07567781
ABBV-722 Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07567781
ABBV-8736 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT07413133
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Placebo for Nacresertib Other Phase PHASE1 Healthy Volunteer COMPLETED NCT07600762
Nacresertib Other Phase PHASE1 Healthy Volunteer COMPLETED NCT07600762
Placebo for Atogepant Other Phase PHASE3 Menstrual Migraine (MM) ACTIVE_NOT_RECRUITING NCT06806293
Atogepant Other Phase PHASE3 Menstrual Migraine (MM) ACTIVE_NOT_RECRUITING NCT06806293
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Placebo for Ubrogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06417775
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Venetoclax Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
ABBV-101 Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Placebo Other Phase PHASE3 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT06468228
Lutikizumab Other Phase PHASE3 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT06468228
Thioguanine Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Methotrexate Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Nelarabine Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Mercaptopurine Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Cytarabine Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Cyclophosphamide Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) Drug Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Bortezomib Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Venetoclax Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Dasatinib Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Calaspargase pegol Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Daunorubicin Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Vincristine Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Dexamethasone Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Placebo Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Upadacitinib Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Bevacizumab Other Phase PHASE1 Ovarian Cancer RECRUITING NCT07278336
ABBV-901 Other Phase PHASE1 Ovarian Cancer RECRUITING NCT07278336
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Standard of Care Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT03891446
Bimatoprost SR Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT03891446
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Bevacizumab Other Phase PHASE1 Ovarian Cancer RECRUITING NCT07278336
ABBV-901 Other Phase PHASE1 Ovarian Cancer RECRUITING NCT07278336
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Osimertinib Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT07155187
Standard of Care Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT07155187
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT07155187
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Aqueous PGE2 and inflammatory cytokines measurements Other Phase PHASE1 Diabetic Retinopathy COMPLETED NCT04505566
Placebo - Preservative-free artificial tears Other Phase PHASE1 Diabetic Retinopathy COMPLETED NCT04505566
Ketorolac 0.45% ophthalmic solution Other Phase PHASE1 Diabetic Retinopathy COMPLETED NCT04505566
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07136103
ABBV-277 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07136103
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Pomalidomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Dexamethasone Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Daratumumab Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
ABBV-453 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Placebo for BOTOX Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06137287
BOTOX Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06137287
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome RECRUITING NCT03874052
Ruxolitinib Other Phase PHASE1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome RECRUITING NCT03874052
Questionnaire Administration Other Phase PHASE1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome RECRUITING NCT03874052
Punch Biopsy Other Phase PHASE1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome RECRUITING NCT03874052
Echocardiography Test Other Phase PHASE1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome RECRUITING NCT03874052
Bone Marrow Biopsy Other Phase PHASE1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome RECRUITING NCT03874052
Bone Marrow Aspiration Other Phase PHASE1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome RECRUITING NCT03874052
Biospecimen Collection Other Phase PHASE1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome RECRUITING NCT03874052
Azacitidine Other Phase PHASE1 Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome RECRUITING NCT03874052
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Venetoclax Other Phase PHASE2 Marginal Zone Lymphoma ACTIVE_NOT_RECRUITING NCT04416451
Rituximab Other Phase PHASE2 Marginal Zone Lymphoma ACTIVE_NOT_RECRUITING NCT04416451
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Placebo for Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Pomalidomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Dexamethasone Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Daratumumab Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
ABBV-453 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Irinotecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Oxaliplatin Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Folinic acid/ Leucovorina Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Fluorouracil Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Telisotuzumab adizutecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Placebo for Topiramate Other Phase PHASE3 Migraine COMPLETED NCT05748483
Topiramate Other Phase PHASE3 Migraine COMPLETED NCT05748483
Placebo for Atogepant Other Phase PHASE3 Migraine COMPLETED NCT05748483
Atogepant Other Phase PHASE3 Migraine COMPLETED NCT05748483
Placebo Other Phase PHASE1 JAK1 GOF NOT_YET_RECRUITING NCT07670156
Upadacitinib Other Phase PHASE1 JAK1 GOF NOT_YET_RECRUITING NCT07670156
Ubrogepant Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07680686
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
CoolSculpting Elite System Other Phase PHASE4 Non-Surgical Fat Reduction COMPLETED NCT07122583
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Risankizumab Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07466550
Glecaprevir/pibrentasvir Other Phase PHASE1 Hepatitis C RECRUITING NCT07040319
Tagraxofusp Other Phase PHASE2 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) RECRUITING NCT07007052
Venetoclax Other Phase PHASE2 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) RECRUITING NCT07007052
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus RECRUITING NCT07607964
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Irinotecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Oxaliplatin Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Folinic acid/ Leucovorina Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Fluorouracil Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Telisotuzumab adizutecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Risankizumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Adalimumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Irinotecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Oxaliplatin Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Folinic acid/ Leucovorina Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Fluorouracil Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Telisotuzumab adizutecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
OnabotulinumtoxinA 145 UNT [Botox] Other Phase PHASE4 Drug-resistant Focal Seizure TERMINATED NCT05605756
ABBV-932 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06953934
Placebo Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07673120
ABBV-313 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07673120
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
Placebo for AGN-151607-DP Other Phase PHASE2 Upper Limb Essential Tremor RECRUITING NCT07673107
AGN-151607-DP Other Phase PHASE2 Upper Limb Essential Tremor RECRUITING NCT07673107
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Topiramate 100 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Propranolol 160 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Atogepant 60 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Venetoclax Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
ABBV-101 Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
Placebo Other Phase PHASE1 Moderate to Severe Glabellar Lines COMPLETED NCT06151561
AGN-151586 Other Phase PHASE1 Moderate to Severe Glabellar Lines COMPLETED NCT06151561
IMGN853 Other Phase PHASE2 Endometrial Cancer RECRUITING NCT03832361
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Bevacizumab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Mirvetuximab Soravtansine Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Placebo Other Phase PHASE3 Glabellar Lines COMPLETED NCT06308198
AGN-151586 Other Phase PHASE3 Glabellar Lines COMPLETED NCT06308198
Placebo Other Phase PHASE1 JAK1 GOF NOT_YET_RECRUITING NCT07670156
Upadacitinib Other Phase PHASE1 JAK1 GOF NOT_YET_RECRUITING NCT07670156
ABBV-8736 Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Trosunilimab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Lutikizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Risankizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
Placebo Other Phase PHASE1 Glabellar Lines COMPLETED NCT05496335
BOTOX Other Phase PHASE1 Glabellar Lines COMPLETED NCT05496335
AGN-151586 Other Phase PHASE1 Glabellar Lines COMPLETED NCT05496335
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Placebo Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06673238
ABBV-722 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06673238
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Bretisilocin Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07604558
Venetoclax Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
ABBV-101 Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Pomalidomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Dexamethasone Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Daratumumab Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
ABBV-453 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease RECRUITING NCT07599670
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Cytarabine Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03709758
Daunorubicin Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03709758
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03709758
Telisotuzumab Adizutecan Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Budigalimab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Azirkitug Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
Irinotecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Oxaliplatin Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Folinic acid/ Leucovorina Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Fluorouracil Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Telisotuzumab adizutecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Carboplatin Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Bevacizumab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Mirvetuximab Soravtansine Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Pomalidomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Dexamethasone Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Daratumumab Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
ABBV-453 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Placebo Other Phase PHASE3 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT06468228
Lutikizumab Other Phase PHASE3 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT06468228
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Carboplatin Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Bevacizumab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Mirvetuximab Soravtansine Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus RECRUITING NCT07607964
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Irinotecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Oxaliplatin Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Folinic acid/ Leucovorina Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Fluorouracil Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Telisotuzumab adizutecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Bevacizumab Other Phase PHASE1 Ovarian Cancer RECRUITING NCT07278336
ABBV-901 Other Phase PHASE1 Ovarian Cancer RECRUITING NCT07278336
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
ABBV-932 Other Phase PHASE2 Bipolar I or II Disorder RECRUITING NCT07220460
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
ABBV-547 Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07232004
ABBV-547 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07232004
Antidepressant Therapy (ADT) Drug Phase PHASE2 Generalized Anxiety Disorder (GAD) RECRUITING NCT06846320
Placebo for ABBV-932 Other Phase PHASE2 Generalized Anxiety Disorder (GAD) RECRUITING NCT06846320
ABBV-932 Other Phase PHASE2 Generalized Anxiety Disorder (GAD) RECRUITING NCT06846320
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03569293
Placebo for Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03569293
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
Rituximab Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07231952
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07231952
Pirtobrutinib Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07231952
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer RECRUITING NCT07525206
REFRESH OPTIVE UD Other Phase PHASE3 Dry Eye Disease ACTIVE_NOT_RECRUITING NCT07284381
ABBV-444 Other Phase PHASE3 Dry Eye Disease ACTIVE_NOT_RECRUITING NCT07284381
ABBV-969 Other Phase PHASE1 Metastatic Castration-Resistant Prostate Cancer ACTIVE_NOT_RECRUITING NCT06318273
ABBV-722 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT07502417
Ethinyl Estradiol + Levonorgestrel Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT07502417
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Itraconazole Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07649954
Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07649954
Irinotecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Oxaliplatin Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Folinic acid/ Leucovorina Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Fluorouracil Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Telisotuzumab adizutecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Bevacizumab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Mirvetuximab Soravtansine Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus RECRUITING NCT07607964
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Topiramate 100 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Propranolol 160 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Atogepant 60 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Venetoclax Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
ABBV-101 Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
Telisotuzumab Adizutecan Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Budigalimab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Azirkitug Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Atogepant Other Phase PHASE3 Chronic Migraine COMPLETED NCT05216263
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo for Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Venetoclax Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
ABBV-101 Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
Epcoritamab Other Phase PHASE2 Primary CNS Lymphoma (PCNSL) RECRUITING NCT06931652
NX-13 Placebo Other Phase PHASE2 Ulcerative Colitis TERMINATED NCT05785715
NX-13 750mg Other Phase PHASE2 Ulcerative Colitis TERMINATED NCT05785715
NX-13 250mg Other Phase PHASE2 Ulcerative Colitis TERMINATED NCT05785715
Paricalcitol Other Phase PHASE3 Chronic Kidney Disease (CKD) TERMINATED NCT04064827
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
SYFOVRE Other Phase PHASE1 Geographic Atrophy RECRUITING NCT07160179
ABBV-6628 Other Phase PHASE1 Geographic Atrophy RECRUITING NCT07160179
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease RECRUITING NCT07599670
Emraclidine Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07587008
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Pivekimab Sunirine Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT07306832
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
Combined Oral Contraceptive Other Phase PHASE3 Endometriosis ACTIVE_NOT_RECRUITING NCT04333576
Placebo Other Phase PHASE3 Endometriosis ACTIVE_NOT_RECRUITING NCT04333576
Elagolix Other Phase PHASE3 Endometriosis ACTIVE_NOT_RECRUITING NCT04333576
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Irinotecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Oxaliplatin Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Folinic acid/ Leucovorina Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Fluorouracil Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Telisotuzumab adizutecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
Venetoclax Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
ABBV-101 Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
Brimonidine tartrate ophthalmic solution eye drops Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Prednisolone acetate ophthalmic suspension 1% eye drops Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Lubricating Eye Drops Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Mirvetuximab Soravtansine Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Standard of care Other Approved Stroke NOT_YET_RECRUITING NCT07639632
Screener Other Approved Stroke NOT_YET_RECRUITING NCT07639632
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Placebo for Atogepant Other Phase PHASE3 Migraine COMPLETED NCT05861427
Atogepant Other Phase PHASE3 Migraine COMPLETED NCT05861427
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia COMPLETED NCT03573024
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia COMPLETED NCT03573024
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Standard of care Other Approved Stroke NOT_YET_RECRUITING NCT07639632
Screener Other Approved Stroke NOT_YET_RECRUITING NCT07639632
Pancrelipase Capsules Other Phase PHASE4 Exocrine Pancreatic Insufficiency RECRUITING NCT06477159
Venetoclax Oral Tablet [Venclexta] Other Phase PHASE2 Mantle Cell Lymphoma TERMINATED NCT05025423
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Glecaprevir/pibrentasvir Other Phase PHASE1 Hepatitis C RECRUITING NCT07040319
NB-UVB (narrow-band ultraviolet B) Phototherapy Drug Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
Placebo Other Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
Upadacitinib Other Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
Carboplatin Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Bevacizumab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Mirvetuximab Soravtansine Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Venetoclax Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
ABBV-101 Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus RECRUITING NCT07607964
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Irinotecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Oxaliplatin Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Folinic acid/ Leucovorina Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Fluorouracil Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Telisotuzumab adizutecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma RECRUITING NCT07490301
Venetoclax Oral Tablet [Venclexta] Other Phase PHASE2 Mantle Cell Lymphoma TERMINATED NCT05025423
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Placebo-Matching Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
ABBV-8736 Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Trosunilimab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Lutikizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Risankizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Bevacizumab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Mirvetuximab Soravtansine Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
ABBV-932 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06849791
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Cofetuzumab Pelidotin Other Phase PHASE1 Cancer TERMINATED NCT04189614
Positron Emission Tomography Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Ibrutinib Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Epcoritamab Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Computed Tomography Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Bone Marrow Biopsy Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Bone Marrow Aspiration Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Biospecimen Collection Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Olaparib Other Phase PHASE2 Ovary Cancer RECRUITING NCT05887609
Mirvetuximab Soravtansine-gynx Other Phase PHASE2 Ovary Cancer RECRUITING NCT05887609
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
Best Supportive Care (BSC) Other Phase PHASE3 Acute Myeloid Leukemia (AML) TERMINATED NCT04161885
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) TERMINATED NCT04161885
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) TERMINATED NCT04161885
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07566130
nacresertib Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07566130
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Placebo Other Phase PHASE3 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT06468228
Lutikizumab Other Phase PHASE3 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT06468228
Rituximab Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07231952
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07231952
Pirtobrutinib Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07231952
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Vedolizumab Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT06880744
Risankizumab Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT06880744
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
Carboplatin Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Bevacizumab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Mirvetuximab Soravtansine Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Venetoclax Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
ABBV-101 Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03607422
Placebo for Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03607422
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Placebo Other Phase PHASE3 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT06468228
Lutikizumab Other Phase PHASE3 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT06468228
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Pivekimab Sunirine Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT07306832
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Pomalidomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Dexamethasone Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Daratumumab Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
ABBV-453 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus RECRUITING NCT07607964
ABBV-932 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT06953934
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
ABBV-8736 Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Trosunilimab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Lutikizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Risankizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
ARTIA Reconstructive Tissue Matrix Other Phase PHASE3 Breast Reconstruction RECRUITING NCT06575192
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
HArmonyCa Lidocaine Injectable Gel Other Phase PHASE3 Mid Face Volume Deficit COMPLETED NCT05452070
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
Standard Chemotherapy Drug Phase PHASE1 Leukemia ACTIVE_NOT_RECRUITING NCT03319901
Venetoclax Other Phase PHASE1 Leukemia ACTIVE_NOT_RECRUITING NCT03319901
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04750226
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus RECRUITING NCT07607964
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Risankizumab Other Phase PHASE3 Crohn's Disease RECRUITING NCT05995353
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07570147
ABBV-1451 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07570147
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
ABBV-8736 Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Trosunilimab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Lutikizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Risankizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Telisotuzumab Adizutecan Other Phase PHASE3 Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06614192
Vedolizumab Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT06880744
Risankizumab Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT06880744
Placebo Other Phase PHASE3 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT06468228
Lutikizumab Other Phase PHASE3 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT06468228
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus NOT_YET_RECRUITING NCT07607964
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Punch biopsies of the skin at week 28 visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Punch biopsies of the skin at baseline visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Risankizumab-Rzaa Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus NOT_YET_RECRUITING NCT07607964
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Punch biopsies of the skin at week 28 visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Punch biopsies of the skin at baseline visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Risankizumab-Rzaa Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus NOT_YET_RECRUITING NCT07607964
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Punch biopsies of the skin at week 28 visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Punch biopsies of the skin at baseline visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Risankizumab-Rzaa Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian Cancer RECRUITING NCT06682988
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Placebo for Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) ACTIVE_NOT_RECRUITING NCT05094128
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus NOT_YET_RECRUITING NCT07607964
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Punch biopsies of the skin at week 28 visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Punch biopsies of the skin at baseline visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Risankizumab-Rzaa Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian Cancer RECRUITING NCT06682988
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Placebo for Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) ACTIVE_NOT_RECRUITING NCT05094128
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus NOT_YET_RECRUITING NCT07607964
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Punch biopsies of the skin at week 28 visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Punch biopsies of the skin at baseline visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Risankizumab-Rzaa Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian Cancer RECRUITING NCT06682988
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Placebo for Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) ACTIVE_NOT_RECRUITING NCT05094128
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus NOT_YET_RECRUITING NCT07607964
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Punch biopsies of the skin at week 28 visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Punch biopsies of the skin at baseline visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Risankizumab-Rzaa Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian Cancer RECRUITING NCT06682988
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Placebo for Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) ACTIVE_NOT_RECRUITING NCT05094128
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
ABBV-519 Other Phase PHASE1 Systemic Lupus Erythematosus NOT_YET_RECRUITING NCT07607964
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Punch biopsies of the skin at week 28 visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Punch biopsies of the skin at baseline visit Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Risankizumab-Rzaa Other Phase PHASE4 Psoriasis COMPLETED NCT04630652
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian Cancer RECRUITING NCT06682988
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) ACTIVE_NOT_RECRUITING NCT05094128
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) ACTIVE_NOT_RECRUITING NCT05094128
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian Cancer RECRUITING NCT06682988
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) ACTIVE_NOT_RECRUITING NCT05094128
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian Cancer RECRUITING NCT06682988
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) ACTIVE_NOT_RECRUITING NCT05094128
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian Cancer RECRUITING NCT06682988
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) ACTIVE_NOT_RECRUITING NCT05094128
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian Cancer RECRUITING NCT06682988
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) ACTIVE_NOT_RECRUITING NCT05094128
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Nacresertib Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07600762
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian Cancer RECRUITING NCT06682988
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) ACTIVE_NOT_RECRUITING NCT05094128
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05445778
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Bretisilocin Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07604558
Topiramate 100 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Propranolol 160 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Atogepant 60 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
KYBELLA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
SkinMedica Products Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
CoolSculpting Elite System Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
JUVÉDERM Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
OnabotulinumtoxinA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
Lumigan Vehicle Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Sham Administration Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Lumigan Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
AGN-193408 SR Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) NO_LONGER_AVAILABLE NCT04278235
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Nascertib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07600762
Nascertib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07600762
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Bretisilocin Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07604558
Topiramate 100 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Propranolol 160 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Atogepant 60 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
KYBELLA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
SkinMedica Products Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
CoolSculpting Elite System Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
JUVÉDERM Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
OnabotulinumtoxinA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
Lumigan Vehicle Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Sham Administration Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Lumigan Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
AGN-193408 SR Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) NO_LONGER_AVAILABLE NCT04278235
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Nascertib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07600762
Nascertib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07600762
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Bretisilocin Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07604558
Topiramate 100 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Propranolol 160 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Atogepant 60 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
KYBELLA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
SkinMedica Products Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
CoolSculpting Elite System Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
JUVÉDERM Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
OnabotulinumtoxinA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
Lumigan Vehicle Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Sham Administration Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Lumigan Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
AGN-193408 SR Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) NO_LONGER_AVAILABLE NCT04278235
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Nascertib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07600762
Nascertib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07600762
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Bretisilocin Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07604558
Topiramate 100 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Propranolol 160 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Atogepant 60 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
KYBELLA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
SkinMedica Products Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
CoolSculpting Elite System Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
JUVÉDERM Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
OnabotulinumtoxinA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
Lumigan Vehicle Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Sham Administration Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Lumigan Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
AGN-193408 SR Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) NO_LONGER_AVAILABLE NCT04278235
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Nascertib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07600762
Nascertib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07600762
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Bretisilocin Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07604558
Topiramate 100 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Propranolol 160 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Atogepant 60 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
KYBELLA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
SkinMedica Products Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
CoolSculpting Elite System Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
JUVÉDERM Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
OnabotulinumtoxinA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
Lumigan Vehicle Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Sham Administration Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Lumigan Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
AGN-193408 SR Other Phase PHASE1 Open-angle Glaucoma ACTIVE_NOT_RECRUITING NCT04499248
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) NO_LONGER_AVAILABLE NCT04278235
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Nascertib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07600762
Nascertib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07600762
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy RECRUITING NCT07592273
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Upadacitinib Other Phase PHASE4 Prurigo Nodularis TERMINATED NCT06773403
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Placebo for ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
ABBV-1758 Other Phase PHASE1 Alzheimer's Disease NOT_YET_RECRUITING NCT07599670
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Bortezomib + Lenalidomide + Dexamethasone Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Isatuximab Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Etentamig Other Phase PHASE1 Myeloma Multiple NOT_YET_RECRUITING NCT07600151
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Itraconazole Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-722 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07599761
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT05564650
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT06241313
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Artificial Tears Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Topical Steroid Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Sham Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Surabgene Lomparvovec Other Phase PHASE2 Diabetic Retinopathy NOT_YET_RECRUITING NCT07592273
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Botulinum Toxin Type A Other Phase PHASE2 Arthritis UNKNOWN NCT00211679
intra-articular botulinum toxin type a Other Phase PHASE3 Arthritis UNKNOWN NCT00211718
Botox Cosmetic™ Other Approved Skin Wrinkling COMPLETED NCT00250952
Trabeculectomy Other Approved Glaucoma TERMINATED NCT00262626
Argon laser trabeculoplasty Other Approved Glaucoma TERMINATED NCT00262626
Intraocular pressure reduction Other Approved Glaucoma TERMINATED NCT00262626
Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule) Other Phase PHASE4 Acne Vulgaris COMPLETED NCT00145106
Nepafenac (Nevanac) Other Phase PHASE4 Myopia COMPLETED NCT00347204
ketorolac (Acular LS) Other Phase PHASE4 Myopia COMPLETED NCT00347204
Zanaflex® Other Phase PHASE4 Upper Limb Spasticity COMPLETED NCT00430196
BOTOX® Other Phase PHASE4 Upper Limb Spasticity COMPLETED NCT00430196
Combigan Ophthalmic Solutiom Other Phase PHASE4 Glaucoma UNKNOWN NCT00442312
Combigan Ophthalmic Solutiom Other Phase PHASE4 Glaucoma UNKNOWN NCT00442312
Combigan Ophthalmic Solutiom Other Phase PHASE4 Glaucoma UNKNOWN NCT00442312
Botox Other Phase PHASE2 Overactive Bladder UNKNOWN NCT00479596
Brimonidine Purite Other Approved Cataract COMPLETED NCT00352807
Optiva artificial tear by Allergan Other Approved Dry Eye Disease COMPLETED NCT00395759
latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops Other Phase PHASE4 Glaucoma COMPLETED NCT00440141
latanoprost 0.005% eye drops and brimonidine 0.1% eye drops Other Phase PHASE4 Glaucoma COMPLETED NCT00440141
placebo capsule Other Phase PHASE2 Diabetic Neuropathy, Painful COMPLETED NCT00381719
AGN 203818 Other Phase PHASE2 Diabetic Neuropathy, Painful COMPLETED NCT00381719
placebo capsule Other Phase PHASE2 Diabetic Neuropathy, Painful COMPLETED NCT00381719
AGN 203818 Other Phase PHASE2 Diabetic Neuropathy, Painful COMPLETED NCT00381719
0.05% cyclosporin eye drop Other Phase PHASE4 Dry Eye UNKNOWN NCT00704275
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Upadacitinib Matching Placebo Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Upadacitinib 30mg Dose Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Upadacitinib Matching Placebo Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Upadacitinib 30mg Dose Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Upadacitinib Matching Placebo Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Upadacitinib 30mg Dose Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Upadacitinib Matching Placebo Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Upadacitinib 30mg Dose Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
adapalene 0.3% topical gel Other Approved Acne Vulgaris COMPLETED NCT01095640
adapalene 0.3% topical gel Other Approved Acne Vulgaris COMPLETED NCT01095640
adapalene 0.3% topical gel Other Approved Acne Vulgaris COMPLETED NCT01095640
Effexor® Tablets equivalent to 50 mg venlafaxine Other Phase PHASE1 Healthy COMPLETED NCT00871364
VENLAFAXINE TABLETS 50 mg , single dose Other Phase PHASE1 Healthy COMPLETED NCT00871364
Proscar® 5 mg Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00871247
Finasteride 5 mg Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00871247
NorvasC® 10 mg Tablets Other Phase PHASE1 Healthy COMPLETED NCT00870571
AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose Other Phase PHASE1 Healthy COMPLETED NCT00870571
Norvasc® 10 mg Tablets Other Phase PHASE1 Healthy COMPLETED NCT00870142
AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose Other Phase PHASE1 Healthy COMPLETED NCT00870142
Wellbutrin XL® 150 mg Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865462
Abrika Bupropion 150 mg XL Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865462
Wellbutrin XL® 150 mg Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865462
Abrika Bupropion 150 mg XL Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865462
Wellbutrin XL® 150 mg Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865462
Abrika Bupropion 150 mg XL Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865462
Wellbutrin SR® 150 mg Extended-Release Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865410
Abrika Bupropion 150 mg Extended-Released Tablet Other Phase PHASE1 Healthy COMPLETED NCT00865410
Wellbutrin SR® 150 mg Extended-Release Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865371
Abrika Bupropion 150 mg Extended-Released Tablet Other Phase PHASE1 Healthy COMPLETED NCT00865371
Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865111
Bupropion 150 mg Extended-Released Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865111
Coreg® 12.5 mg Tablets , single dose Other Phase PHASE1 Healthy COMPLETED NCT00864435
Carvedilol 12.5 mg Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864435
Zoloft® 100 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864344
Sertraline HCl 100 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864344
Zyrtec® 10 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864279
Cetirizine Hydrochloride 10 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864279
Atlace® 10 mg capsules, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864162
Ramipril10 mg Capsules, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864162
Zoloft® 100 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864019
Sertraline HCl 100 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864019
Atlace® 10 mg capsules, single dose Other Phase PHASE1 Healthy COMPLETED NCT00863915
Ramipril10 mg Capsules, single dose Other Phase PHASE1 Healthy COMPLETED NCT00863915
Zyrtec® 10 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00863902
Cetirizine Hydrochloride 10 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00863902
Grifulvin V® 125 mg/5 mL Suspension, single dose Other Phase PHASE1 Healthy COMPLETED NCT00863863
Griseofulvin 125 mg/5 mL Suspension, single dose Other Phase PHASE1 Healthy COMPLETED NCT00863863
Sham injection Other Phase PHASE2 Intermediate Uveitis COMPLETED NCT00333814
dexamethasone Other Phase PHASE2 Intermediate Uveitis COMPLETED NCT00333814
Dexamethasone Other Phase PHASE2 Intermediate Uveitis COMPLETED NCT00333814
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Upadacitinib Matching Placebo Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Upadacitinib 30mg Dose Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Placebo for Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Upadacitinib Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT05782907
Upadacitinib Matching Placebo Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Upadacitinib 30mg Dose Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Emraclidine Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07587008
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Placebo for Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Upadacitinib Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT05782907
Upadacitinib Matching Placebo Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Upadacitinib 30mg Dose Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Emraclidine Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07587008
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Placebo for Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Upadacitinib Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT05782907
Upadacitinib Matching Placebo Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Upadacitinib 30mg Dose Other Phase PHASE2 EoE NOT_YET_RECRUITING NCT07588568
Emraclidine Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07587008
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT02993523
Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Placebo for Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Upadacitinib Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT05782907
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Emraclidine Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07587008
Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Placebo for Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Upadacitinib Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT05782907
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Emraclidine Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07587008
Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Placebo for Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Upadacitinib Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT05782907
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Emraclidine Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07587008
Bimatoprost 0.03% ophthalmic solution Other Phase PHASE2 Glaucoma COMPLETED NCT00652496
Bimatoprost 0.02% ophthalmic solution Other Phase PHASE2 Glaucoma COMPLETED NCT00652496
Bimatoprost 0.015% formulation 2 ophthalmic solution Other Phase PHASE2 Glaucoma COMPLETED NCT00652496
Bimatoprost 0.015% formulation 1 ophthalmic solution Other Phase PHASE2 Glaucoma COMPLETED NCT00652496
Bimatoprost 0.01% ophthalmic solution Other Phase PHASE2 Glaucoma COMPLETED NCT00652496
Bimatoprost 0.03% ophthalmic solution Other Phase PHASE2 Glaucoma COMPLETED NCT00652496
Bimatoprost 0.02% ophthalmic solution Other Phase PHASE2 Glaucoma COMPLETED NCT00652496
Bimatoprost 0.015% formulation 2 ophthalmic solution Other Phase PHASE2 Glaucoma COMPLETED NCT00652496
Bimatoprost 0.015% formulation 1 ophthalmic solution Other Phase PHASE2 Glaucoma COMPLETED NCT00652496
Bimatoprost 0.01% ophthalmic solution Other Phase PHASE2 Glaucoma COMPLETED NCT00652496
Brimonidine ophthalmic solution 0.2% Other Phase PHASE3 Glaucoma COMPLETED NCT00652483
Brimonidine ophthalmic solution 0.1% Other Phase PHASE3 Glaucoma COMPLETED NCT00652483
Brimonidine 0.2% ophthalmic solution Other Phase PHASE3 Glaucoma COMPLETED NCT00652106
Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution Other Phase PHASE3 Glaucoma COMPLETED NCT00652106
0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution Other Phase PHASE3 Glaucoma COMPLETED NCT00652106
Bimatoprost Vehicle Ophthalmic Solution Other Phase PHASE2 Glaucoma COMPLETED NCT00651859
Bimatoprost 0.03% Ophthalmic Solution Other Phase PHASE2 Glaucoma COMPLETED NCT00651859
Bimatoprost 0.01% Ophthalmic Solution Other Phase PHASE2 Glaucoma COMPLETED NCT00651859
Concurrent brimonidine 0.2% and 0.5% timolol Other Phase PHASE3 Glaucoma COMPLETED NCT00651612
Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution Other Phase PHASE3 Glaucoma COMPLETED NCT00651612
Botulinum Toxin Type A Other Phase PHASE2 Stroke COMPLETED NCT00651729
Botulinum Toxin Type A Other Phase PHASE2 Stroke COMPLETED NCT00651729
Placebo Other Phase PHASE2 Stroke COMPLETED NCT00651690
Botulinum Toxin Type A Other Phase PHASE2 Stroke COMPLETED NCT00651690
Botulinum Toxin Type A Other Phase PHASE4 Hyperhidrosis COMPLETED NCT00168480
Botulinum Toxin Type A Other Phase PHASE4 Hyperhidrosis COMPLETED NCT00168415
Botulinic toxin (Botox) Other Approved Spastic Equinovarus COMPLETED NCT00199589
dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy. Drug Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822081
brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy. Drug Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822081
dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination Other Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822081
brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination Other Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822081
dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy. Drug Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822081
brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy. Drug Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822081
dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination Other Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822081
brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination Other Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822081
dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy Drug Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822055
brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy Drug Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822055
dorzolamide hcl 2%/timolol maleate 0.5% fixed combination Other Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822055
brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination Other Phase PHASE4 Open-Angle Glaucoma COMPLETED NCT00822055
Placebo Other Phase PHASE4 Parkinson Disease TERMINATED NCT00477802
Botulinum Toxin Type A Other Phase PHASE4 Parkinson Disease TERMINATED NCT00477802
ketorolac Other Phase PHASE3 Cataract Extraction COMPLETED NCT00524264
ketorolac eye drops Other Phase PHASE3 Cataract Extraction COMPLETED NCT00521456
Carboxymethylcellulose Other Approved Dry Eye Syndrome COMPLETED NCT00514852
Carboxymethylcellulose and Glycerin based artificial tear Other Approved Dry Eye Syndrome COMPLETED NCT00514852
CELEXATM 10 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865943
Citalopram HBr eq. 10 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865943
ADALAT® CC Extended Release Tablets 60 mg Other Phase PHASE1 Healthy COMPLETED NCT00865891
Nifedipine Extended Release tablets 60 mg, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865891
GLUCOPHAGE® XR 750 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865852
Metformin HCl 750 mg Extender Release tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865852
GLUCOPHAGE® XR 750 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865852
Metformin HCl 750 mg Extender Release tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865852
CLUCOPHAGE® XR 500 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865839
Metformin HCl 500 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865839
XANAX XR® 3 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865761
Alprazolam 3 mg Extended Release Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865761
REMERON® 15 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865696
Mirtazapine 15 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865696
REMERON® 15 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865696
Mirtazapine 15 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865696
XANAX XR® 3 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865657
Alprazolam 3 mg Extended Release Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865657
NEURONTIN® 800 mg Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865423
Gabapentin 800 mg Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865423
REMERON® 15 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865384
Mirtazapine 15 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865384
Ultravate® 0.05% ointment, single exposure Other Phase PHASE1 Healthy COMPLETED NCT00865267
CLUCOVANCE® 5 mg/500 mg Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865241
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg Other Phase PHASE1 Healthy COMPLETED NCT00865241
INDERAL® LA 160 mg Capsules, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865215
Propranolol Hydrochloride Extended Release Capsules 160 mg Other Phase PHASE1 Healthy COMPLETED NCT00865215
INDERAL® LA 160 mg Capsules, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865215
Propranolol Hydrochloride Extended Release Capsules 160 mg Other Phase PHASE1 Healthy COMPLETED NCT00865215
CelexaTM 40 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865085
Citalopram HBr 40 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865085
CelexaTM 40 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865085
Citalopram HBr 40 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865085
GLUCOPHAGE® XR 750 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865072
Metformin HCl 750 mg Extender Release tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865072
GLUCOPHAGE® XR 750 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865072
Metformin HCl 750 mg Extender Release tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865072
NEURONTIN® 800 mg Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865059
Gabapentin 800 mg Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865059
NEURONTIN® 800 mg Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865059
Gabapentin 800 mg Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00865059
CelexaTM 40 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864890
Citalopram HBr 40 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864890
CelexaTM 40 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864890
Citalopram HBr 40 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864890
NEURONTIN® 400 mg capsules, single dose (2 capsules) Other Phase PHASE1 Healthy COMPLETED NCT00864760
Gabapentin 800 mg tablets, single dose (1 tablet) Other Phase PHASE1 Healthy COMPLETED NCT00864760
INDERAL® LA 160 mg Capsules, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864747
Propranolol Hydrochloride Extended Release Capsules 160 mg Other Phase PHASE1 Healthy COMPLETED NCT00864747
CLUCOVANCE® 5 mg/500 mg Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864734
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg Other Phase PHASE1 Healthy COMPLETED NCT00864734
CLUCOVANCE® 5 mg/500 mg Tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864734
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg Other Phase PHASE1 Healthy COMPLETED NCT00864734
ADALAT® CC Extended Release Tablets 60 mg Other Phase PHASE1 Healthy COMPLETED NCT00864617
Nifedipine Extended Release tablets 60 mg, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864617
COMBONOX® tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864526
Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864526
COMBONOX® tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864357
Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864357
Gabapentin 400 mg capsules, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864305
NEURONTIN® 400 mg capsules Other Phase PHASE1 Healthy COMPLETED NCT00864305
Gabapentin 400 mg capsules Other Phase PHASE1 Healthy COMPLETED NCT00864305
Gabapentin 400 mg capsules, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864305
NEURONTIN® 400 mg capsules Other Phase PHASE1 Healthy COMPLETED NCT00864305
Gabapentin 400 mg capsules Other Phase PHASE1 Healthy COMPLETED NCT00864305
NEURONTIN® 400 mg capsules Other Phase PHASE1 Healthy COMPLETED NCT00864058
Gabapentin 400 mg capsules Other Phase PHASE1 Healthy COMPLETED NCT00864058
KADIAN (morphine sulfate extended-release) capsules Other Phase PHASE1 Healthy COMPLETED NCT00759915
morphine sulfate extended-release capsules Other Phase PHASE1 Healthy COMPLETED NCT00759915
KADIAN (morphine sulfate extended-release) capsules Other Phase PHASE1 Healthy COMPLETED NCT00759915
morphine sulfate extended-release capsules Other Phase PHASE1 Healthy COMPLETED NCT00759915
KADIAN (morphine sulfate extended-release) capsules Other Phase PHASE1 Healthy COMPLETED NCT00759902
morphine sulfate extended-release capsules Other Phase PHASE1 Healthy COMPLETED NCT00759902
KADIAN (morphine sulfate extended-release) capsules Other Phase PHASE1 Healthy COMPLETED NCT00759902
morphine sulfate extended-release capsules Other Phase PHASE1 Healthy COMPLETED NCT00759902
Wellbutrin XL® 150 mg Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00863941
Abrika Bupropion 150 mg XL Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT00863941
NIRAVAM TM 2 mg orally disintegrating tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT01188057
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG Other Phase PHASE1 Healthy COMPLETED NCT01188057
NIRAVAM TM 2 mg orally disintegrating tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT01188057
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG Other Phase PHASE1 Healthy COMPLETED NCT01188057
NIRAVAM TM 2 mg orally disintegrating tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT01188031
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG Other Phase PHASE1 Healthy COMPLETED NCT01188031
memantine Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT00168350
Vehicle Control Other Approved MILD TO SEVERE ACNE VULGARIS COMPLETED NCT01257906
ZIANA® Other Approved MILD TO SEVERE ACNE VULGARIS COMPLETED NCT01257906
CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL Other Approved MILD TO SEVERE ACNE VULGARIS COMPLETED NCT01257906
Vehicle Control Other Approved MILD TO SEVERE ACNE VULGARIS COMPLETED NCT01257906
ZIANA® Other Approved MILD TO SEVERE ACNE VULGARIS COMPLETED NCT01257906
CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL Other Approved MILD TO SEVERE ACNE VULGARIS COMPLETED NCT01257906
Botulinum Toxin Type A injection (BOTOX) Other Phase PHASE2 Thoracic Outlet Syndrome COMPLETED NCT00444886
Emulsion type artificial tear Other Phase PHASE3 Dry Eye UNKNOWN NCT01335126
ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM) Other Phase PHASE2 Rosacea COMPLETED NCT00249782
MetroGel® (metronidazole gel), 1.0% 1x/day Other Phase PHASE2 Rosacea COMPLETED NCT00249782
ACZONE (dapsone) Gel, 5%, 1x/day Other Phase PHASE2 Rosacea COMPLETED NCT00249782
ACZONE (dapsone) Gel, 5%, 2x/day Other Phase PHASE2 Rosacea COMPLETED NCT00249782
Vehicle control, 2x/day Other Phase PHASE2 Rosacea COMPLETED NCT00249782
ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM) Other Phase PHASE2 Rosacea COMPLETED NCT00249782
MetroGel® (metronidazole gel), 1.0% 1x/day Other Phase PHASE2 Rosacea COMPLETED NCT00249782
ACZONE (dapsone) Gel, 5%, 1x/day Other Phase PHASE2 Rosacea COMPLETED NCT00249782
ACZONE (dapsone) Gel, 5%, 2x/day Other Phase PHASE2 Rosacea COMPLETED NCT00249782
Vehicle control, 2x/day Other Phase PHASE2 Rosacea COMPLETED NCT00249782
Carboxymethylcellulose sodium and Glycerin Other Phase PHASE2 Dry Eye COMPLETED NCT00243711
Vehicle Other Phase PHASE4 Acne Vulgaris COMPLETED NCT00243542
ACZONE Gel, 5% Other Phase PHASE4 Acne Vulgaris COMPLETED NCT00243542
Vehicle Other Phase PHASE4 Acne Vulgaris COMPLETED NCT00243542
ACZONE Gel, 5% Other Phase PHASE4 Acne Vulgaris COMPLETED NCT00243542
Botulinum Toxin Type A Other Phase PHASE2 Postherpetic Neuralgia COMPLETED NCT00168441
Botulinum Toxin Type A Other Phase PHASE3 Hyperhidrosis COMPLETED NCT00168402
Botulinum Toxin Type A Other Phase PHASE3 Hyperhidrosis COMPLETED NCT00168402
brimonidine Other Phase PHASE3 Glaucoma COMPLETED NCT00168363
brimonidine Other Phase PHASE3 Glaucoma COMPLETED NCT00168363
Dapsone Topical Gel + vehicle control Other Phase PHASE3 Acne Vulgaris COMPLETED NCT00151541
Dapsone Topical Gel + benzoyl peroxide gel 4% Other Phase PHASE3 Acne Vulgaris COMPLETED NCT00151541
Dapsone Topical Gel + adapalene gel 0.1% Other Phase PHASE3 Acne Vulgaris COMPLETED NCT00151541
Dapsone Topical Gel + vehicle control Other Phase PHASE3 Acne Vulgaris COMPLETED NCT00151541
Dapsone Topical Gel + benzoyl peroxide gel 4% Other Phase PHASE3 Acne Vulgaris COMPLETED NCT00151541
Dapsone Topical Gel + adapalene gel 0.1% Other Phase PHASE3 Acne Vulgaris COMPLETED NCT00151541
DEX PS DDS® Other Phase PHASE2 Diabetes COMPLETED NCT00035906
Ophthalmic Emulsion Other Phase PHASE3 Keratoconjunctivitis Sicca COMPLETED NCT00025818
Refresh Contacts Other Approved Dry Eye UNKNOWN NCT01384851
Refresh Dry Eye Therapy Drug Approved Dry Eye UNKNOWN NCT01384851
Next Generation Emulsion Other Approved Dry Eye UNKNOWN NCT01384851
nepafenac Other Phase PHASE4 Cataracts COMPLETED NCT01021761
Bromfenac Other Phase PHASE4 Cataracts COMPLETED NCT01021761
Ketorolac Tromethamine Other Phase PHASE4 Cataracts COMPLETED NCT01021761
olopatadine hydrochloride 0.1% ophthalmic solution Other Phase PHASE3 Rhinitis, Allergic, Seasonal COMPLETED NCT01258309
olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution Other Phase PHASE3 Rhinitis, Allergic, Seasonal COMPLETED NCT01258309
olopatadine hydrochloride 0.1% ophthalmic solution Other Phase PHASE3 Rhinitis, Allergic, Seasonal COMPLETED NCT01258309
olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution Other Phase PHASE3 Rhinitis, Allergic, Seasonal COMPLETED NCT01258309
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Risankizumab Other Phase PHASE3 Crohn's Disease RECRUITING NCT05995353
Telisotuzumab vedotin Other Preclinical Non-Small Cell Lung Cancer (NSCLC) TEMPORARILY_NOT_AVAILABLE NCT04830202
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04379050
Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Placebo for Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Telisotuzumab Adizutecan Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Budigalimab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Azirkitug Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Placebo for Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) AVAILABLE NCT04278235
ABBV-383 (Etentamig) Other Phase PHASE1 Immunoglobulin Light Chain (AL) Amyloidosis RECRUITING NCT06158854
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Risankizumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Adalimumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Upadacitinib Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT05782907
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Emraclidine Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07587008
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo-Matching Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Placebo for Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Nab-Paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, budigalimab, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT03844048
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
AGN 203818 Other Phase PHASE2 Cystitis, Interstitial TERMINATED NCT00380783
Vehicle Control Other Phase PHASE2 Rash TERMINATED NCT00343187
ACZONE (dapsone) Gel, 5% Other Phase PHASE2 Rash TERMINATED NCT00343187
Dexamethasone Other Phase PHASE2 Anterior Uveitis TERMINATED NCT00333996
bimatoprost/timolol fixed combination Other Phase PHASE3 Ocular Hypertension COMPLETED NCT00332540
bimatoprost/timolol fixed combination Other Phase PHASE3 Ocular Hypertension COMPLETED NCT00332540
brimonidine/timolol fixed combination Other Phase PHASE3 Ocular Hypertension COMPLETED NCT00332436
brimonidine/timolol fixed combination Other Phase PHASE2 Ocular Hypertension COMPLETED NCT00332345
bimatoprost/timolol fixed combination Other Phase PHASE3 Ocular Hypertension COMPLETED NCT00332072
bimatoprost/timolol fixed combination Other Phase PHASE3 Ocular Hypertension COMPLETED NCT00332072
bimatoprost/timolol fixed combination Other Phase PHASE3 Ocular Hypertension COMPLETED NCT00332059
bimatoprost Other Phase PHASE2 Ocular Hypertension COMPLETED NCT00300443
bimatoprost Other Phase PHASE2 Ocular Hypertension COMPLETED NCT00300443
esomeprazole Other Phase PHASE1 Peptic Ulcer COMPLETED NCT00325715
AGN 201904 Other Phase PHASE1 Peptic Ulcer COMPLETED NCT00325715
esomeprazole Other Phase PHASE1 Peptic Ulcer COMPLETED NCT00325715
AGN 201904 Other Phase PHASE1 Peptic Ulcer COMPLETED NCT00325715
alacaftadine and naphazoline HCl & pheniramine maleate Other Phase PHASE4 Allergic Conjunctivitis UNKNOWN NCT01390961
Botulinum Toxin Type A Other Approved Diabetes Mellitus COMPLETED NCT00336349
sodium hyaluronate 0.18% (VISMED® Multi) Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00987727
carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD) Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00987727
sodium hyaluronate 0.18% (VISMED® Multi) Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00987727
carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD) Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00987727
moxifloxacin 0.5% eye drops Other Phase PHASE4 Bacterial Conjunctivitis COMPLETED NCT00464438
gatifloxacin Other Phase PHASE4 Bacterial Conjunctivitis COMPLETED NCT00464438
Lubricating Eye Drop Other Phase PHASE4 Inflammation COMPLETED NCT00791323
Ketorolac 0.4% Other Phase PHASE4 Inflammation COMPLETED NCT00791323
Lubricating Eye Drop Other Phase PHASE4 Inflammation COMPLETED NCT00791323
Ketorolac 0.4% Other Phase PHASE4 Inflammation COMPLETED NCT00791323
nepafenac 0.1% Other Phase PHASE4 Cataracts COMPLETED NCT01001806
bromfenac 0.09% Other Phase PHASE4 Cataracts COMPLETED NCT01001806
Ketorolac Tromethamine 0.45% Other Phase PHASE4 Cataracts COMPLETED NCT01001806
latanoprost 0.005% eye drops Other Phase PHASE4 Ocular Hypertension COMPLETED NCT00541242
bimatoprost 0.03% eye drops Other Phase PHASE4 Ocular Hypertension COMPLETED NCT00541242
sodium hyaluronate 0.18% Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00938704
carboxymethylcellulose 0.5% +glycerin 0.9% Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00938704
sodium hyaluronate 0.18% Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00938704
carboxymethylcellulose 0.5% +glycerin 0.9% Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00938704
Tretinoin Other Phase PHASE4 Acne Vulgaris COMPLETED NCT00835198
Dapsone; Tretinoin Other Phase PHASE4 Acne Vulgaris COMPLETED NCT00835198
Tazarotene Other Phase PHASE4 Acne Vulgaris COMPLETED NCT00834210
Dapsone Other Phase PHASE4 Acne Vulgaris COMPLETED NCT00834210
Tazarotene Other Phase PHASE4 Acne Vulgaris COMPLETED NCT00834210
Dapsone Other Phase PHASE4 Acne Vulgaris COMPLETED NCT00834210
Lubricating Eye Drops (blink® Tears) Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00756678
Lubricant Eye Drops (Optive™) Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00756678
Lubricating Eye Drops (blink® Tears) Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00756678
Lubricant Eye Drops (Optive™) Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT00756678
placebo eye drops Other Phase PHASE3 Bacterial Conjunctivitis COMPLETED NCT00509873
Gatifloxacin 0.5% eye drops Other Phase PHASE3 Bacterial Conjunctivitis COMPLETED NCT00509873
bimatoprost ophthalmic solution 0.03% Other Phase PHASE2 Eyelash Hypotrichosis COMPLETED NCT01064882
bimatoprost ophthalmic solution 0.015% Other Phase PHASE2 Eyelash Hypotrichosis COMPLETED NCT01064882
bimatoprost ophthalmic solution 0.005% Other Phase PHASE2 Eyelash Hypotrichosis COMPLETED NCT01064882
Carboxymethylcellulose Other Approved Dry Eye Syndrome COMPLETED NCT00544713
Carboxymethylcellulose and Glycerin based artificial tear Other Approved Dry Eye Syndrome COMPLETED NCT00544713
Carboxymethylcellulose Other Approved Dry Eye Syndrome COMPLETED NCT00544713
Carboxymethylcellulose and Glycerin based artificial tear Other Approved Dry Eye Syndrome COMPLETED NCT00544713
botulinum toxin type A Other Phase PHASE4 Spasmodic Torticollis COMPLETED NCT00528541
botulinum toxin type A Other Phase PHASE4 Spasmodic Torticollis COMPLETED NCT00528541
botulinum toxin type A Other Phase PHASE4 Spasmodic Torticollis TERMINATED NCT00432341
Metformin hydrochloride (Glucophage®) Other Phase PHASE1 Healthy COMPLETED NCT00986401
Trospium Chloride (Sanctura XR®) Other Phase PHASE1 Healthy COMPLETED NCT00986401
gatifloxacin ophthalmic solution 0.3% Other Phase PHASE4 Anti-biotic Resistance COMPLETED NCT00874887
moxifloxacin 0.5% HCI ophthalmic solution Other Phase PHASE4 Anti-biotic Resistance COMPLETED NCT00874887
gatifloxacin ophthalmic solution 0.3% Other Phase PHASE4 Anti-biotic Resistance COMPLETED NCT00874887
moxifloxacin 0.5% HCI ophthalmic solution Other Phase PHASE4 Anti-biotic Resistance COMPLETED NCT00874887
Artificial Tears REFRESH ENDURA® Other Phase PHASE2 Dry Eye Syndromes COMPLETED NCT00611403
Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) Other Phase PHASE2 Dry Eye Syndromes COMPLETED NCT00611403
Placebo (Vehicle Gel) Other Approved Acne Vulgaris COMPLETED NCT01501799
EPIDUO Other Approved Acne Vulgaris COMPLETED NCT01501799
adapalene 0.1% and benzoyl peroxide 2.5% topical gel Other Approved Acne Vulgaris COMPLETED NCT01501799
Placebo (Vehicle Gel) Other Approved Acne Vulgaris COMPLETED NCT01501799
EPIDUO Other Approved Acne Vulgaris COMPLETED NCT01501799
adapalene 0.1% and benzoyl peroxide 2.5% topical gel Other Approved Acne Vulgaris COMPLETED NCT01501799
Placebo (Vehicle Gel) Other Approved Acne Vulgaris COMPLETED NCT01501799
EPIDUO Other Approved Acne Vulgaris COMPLETED NCT01501799
adapalene 0.1% and benzoyl peroxide 2.5% topical gel Other Approved Acne Vulgaris COMPLETED NCT01501799
Vehicle Cream Other Approved Actinic Keratoses COMPLETED NCT01502020
imiquimod cream, 3.75% Other Approved Actinic Keratoses COMPLETED NCT01502020
Vehicle Cream Other Approved Actinic Keratoses COMPLETED NCT01502020
imiquimod cream, 3.75% Other Approved Actinic Keratoses COMPLETED NCT01502020
Vehicle Cream Other Approved Actinic Keratoses COMPLETED NCT01502020
imiquimod cream, 3.75% Other Approved Actinic Keratoses COMPLETED NCT01502020
vehicle sterile solution (placebo) Other Phase PHASE4 Hypotrichosis COMPLETED NCT00958035
bimatoprost ophthalmic 0.03% solution Other Phase PHASE4 Hypotrichosis COMPLETED NCT00958035
bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004% Other Preclinical Open-Angle Glaucoma COMPLETED NCT00716742
cyclosporine ophthalmic emulsion 0.05%, artificial tears Other Preclinical Keratoconjunctivitis Sicca COMPLETED NCT00717418
cyclosporine ophthalmic emulsion 0.05%, artificial tears Other Preclinical Keratoconjunctivitis Sicca COMPLETED NCT00717418
placebo Other Phase PHASE2 Irritable Bowel Syndrome TERMINATED NCT00441766
AGN 203818 Other Phase PHASE2 Irritable Bowel Syndrome TERMINATED NCT00441766
placebo Other Phase PHASE2 Irritable Bowel Syndrome TERMINATED NCT00441766
AGN 203818 Other Phase PHASE2 Irritable Bowel Syndrome TERMINATED NCT00441766
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Risankizumab Other Phase PHASE3 Crohn's Disease RECRUITING NCT05995353
Telisotuzumab vedotin Other Preclinical Non-Small Cell Lung Cancer (NSCLC) TEMPORARILY_NOT_AVAILABLE NCT04830202
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04379050
Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Placebo for Linaclotide Other Phase PHASE3 Functional Constipation (FC) COMPLETED NCT05652205
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Telisotuzumab Adizutecan Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Budigalimab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Azirkitug Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Placebo for Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) AVAILABLE NCT04278235
ABBV-383 (Etentamig) Other Phase PHASE1 Immunoglobulin Light Chain (AL) Amyloidosis RECRUITING NCT06158854
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Risankizumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Adalimumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Upadacitinib Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT05782907
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Emraclidine Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07587008
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo-Matching Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Placebo for Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Nab-Paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, budigalimab, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT03844048
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
topical bimatoprost Other Phase PHASE4 Hypotrichosis COMPLETED NCT01387906
Vehicle Other Phase PHASE2 Pterygium COMPLETED NCT01109056
cyclosporine ophthalmic emulsion 0.05% Other Phase PHASE2 Pterygium COMPLETED NCT01109056
Cataract Surgery and Limbal relaxing incision Procedure Preclinical Dry Eye COMPLETED NCT01161771
Fluorometholone Eye Drops (FML Forte®) Other Phase PHASE2 Epiphora WITHDRAWN NCT00824811
Lubricant Eye Drops (Refresh Endura™) Other Phase PHASE2 Epiphora WITHDRAWN NCT00824811
Cyclosporine Eye Drops (Restasis) Other Phase PHASE2 Epiphora WITHDRAWN NCT00824811
Placebo Other Phase PHASE4 Muscle Spasticity COMPLETED NCT00549783
Botulinum Toxin Type A 900kD Other Phase PHASE4 Muscle Spasticity COMPLETED NCT00549783
Placebo Other Phase PHASE4 Muscle Spasticity COMPLETED NCT00549783
Botulinum Toxin Type A 900kD Other Phase PHASE4 Muscle Spasticity COMPLETED NCT00549783
ranibizumab Other Phase PHASE2 Choroidal Neovascularization COMPLETED NCT00775411
dexamethasone Other Phase PHASE2 Choroidal Neovascularization COMPLETED NCT00775411
sham Other Phase PHASE2 Subfoveal Choroidal Neovascularization TERMINATED NCT01122511
ranibizumab Other Phase PHASE2 Subfoveal Choroidal Neovascularization TERMINATED NCT01122511
700 ug dexamethasone Other Phase PHASE2 Subfoveal Choroidal Neovascularization TERMINATED NCT01122511
Vehicle solution Other Phase PHASE3 Hypotrichosis COMPLETED NCT00907426
Bimatoprost 0.03% solution Other Phase PHASE3 Hypotrichosis COMPLETED NCT00907426
Any Fixed Combination Therapy Drug Preclinical Glaucoma, Open-Angle COMPLETED NCT01637246
bimatoprost 0.01% Other Preclinical Glaucoma, Open-Angle COMPLETED NCT01632423
Fixed combination 0.3 mg bimatoprost and 5 mg timolol Other Preclinical Glaucoma, Open-Angle COMPLETED NCT01628601
bimatoprost 0.01% Other Preclinical Glaucoma, Open-Angle COMPLETED NCT01628588
normal saline (placebo) Other Phase PHASE4 Glabellar Frown Lines COMPLETED NCT01391312
botulinum toxin Type A Other Phase PHASE4 Glabellar Frown Lines COMPLETED NCT01391312
normal saline (placebo) Other Phase PHASE4 Glabellar Frown Lines COMPLETED NCT01391312
botulinum toxin Type A Other Phase PHASE4 Glabellar Frown Lines COMPLETED NCT01391312
No treatment Drug Preclinical Healthy Volunteers COMPLETED NCT01252147
Dexamethasone Implant Other Phase PHASE2 Pseudophakic Cystoid Macular Edema, COMPLETED NCT01284478
No Intervention Other Preclinical Healthy Volunteers COMPLETED NCT01412086
BOTULINUM NEUROTOXIN TYPE-A Other Phase PHASE2 Sialorrhea UNKNOWN NCT01489904
Cyclosporine 0.010% Other Phase PHASE3 Atopic Conjunctivitis COMPLETED NCT00884585
Cyclosporine Vehicle Other Phase PHASE3 Atopic Conjunctivitis COMPLETED NCT00884585
Cyclosporine 0.010% Other Phase PHASE3 Atopic Conjunctivitis COMPLETED NCT00884585
Cyclosporine Vehicle Other Phase PHASE3 Atopic Conjunctivitis COMPLETED NCT00884585
placebo Other Phase PHASE3 Chronic Kidney Disease COMPLETED NCT00497146
paricalcitol Other Phase PHASE3 Chronic Kidney Disease COMPLETED NCT00497146
fluorouracil Other Phase PHASE2 Advanced Colorectal Cancer COMPLETED NCT00707889
folinic acid Other Phase PHASE2 Advanced Colorectal Cancer COMPLETED NCT00707889
oxaliplatin Other Phase PHASE2 Advanced Colorectal Cancer COMPLETED NCT00707889
bevacizumab Other Phase PHASE2 Advanced Colorectal Cancer COMPLETED NCT00707889
ABT-869 Other Phase PHASE2 Advanced Colorectal Cancer COMPLETED NCT00707889
bimatoprost vehicle solution Other Phase PHASE4 Hypotrichosis COMPLETED NCT01448525
bimatoprost ophthalmic solution 0.03% Other Phase PHASE4 Hypotrichosis COMPLETED NCT01448525
Refresh® Dry Eye therapy Drug Phase PHASE2 Brittle Nails COMPLETED NCT00986427
Restasis (cyclosporine ophthalmic emulsion) 0.05% Other Phase PHASE2 Brittle Nails COMPLETED NCT00986427
bimatoprost vehicle Other Phase PHASE2 Glaucoma, Open-Angle COMPLETED NCT01291108
bimatoprost Other Phase PHASE2 Glaucoma, Open-Angle COMPLETED NCT01291108
AGN-210669 Other Phase PHASE2 Glaucoma, Open-Angle COMPLETED NCT01291108
Ketoconazole Other Phase PHASE1 Healthy COMPLETED NCT01468558
IV DHE Other Phase PHASE1 Healthy COMPLETED NCT01468558
MAP0004 Other Phase PHASE1 Healthy COMPLETED NCT01468558
Ketoconazole Other Phase PHASE1 Healthy COMPLETED NCT01468558
IV DHE Other Phase PHASE1 Healthy COMPLETED NCT01468558
MAP0004 Other Phase PHASE1 Healthy COMPLETED NCT01468558
dextran 70 0.1%/hydroxypropyl methylcellulose 0.3% Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01732757
Olopatadine 0.2% Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01732757
Alcaftadine 0.25% Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01732757
dextran 70 0.1%/hydroxypropyl methylcellulose 0.3% Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01732757
Olopatadine 0.2% Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01732757
Alcaftadine 0.25% Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01732757
No Treatment Drug Preclinical Dry Eye Syndromes COMPLETED NCT01854905
OPTIVE PLUS® Other Preclinical Dry Eye Syndromes COMPLETED NCT01711424
Bimatoprost Other Preclinical Glaucoma, Open-Angle COMPLETED NCT01646151
Tear Sample Collection Other Preclinical Healthy Volunteers COMPLETED NCT01969162
Tear Sample Collection Other Preclinical Healthy Volunteers COMPLETED NCT01969162
botulinum toxin Type A (200U) Other Phase PHASE2 Overactive Bladder TERMINATED NCT00575016
botulinum toxin Type A (100U); botulinum toxin Type A (200U) Other Phase PHASE2 Overactive Bladder TERMINATED NCT00575016
botulinum toxin Type A (50U); botulinum toxin Type A (200U) Other Phase PHASE2 Overactive Bladder TERMINATED NCT00575016
Normal saline (Placebo); botulinum toxin Type A (200U) Other Phase PHASE2 Overactive Bladder TERMINATED NCT00575016
botulinum toxin Type A (200U) Other Phase PHASE2 Overactive Bladder TERMINATED NCT00575016
botulinum toxin Type A (100U); botulinum toxin Type A (200U) Other Phase PHASE2 Overactive Bladder TERMINATED NCT00575016
botulinum toxin Type A (50U); botulinum toxin Type A (200U) Other Phase PHASE2 Overactive Bladder TERMINATED NCT00575016
Normal saline (Placebo); botulinum toxin Type A (200U) Other Phase PHASE2 Overactive Bladder TERMINATED NCT00575016
Neurological Examination Other Preclinical Spasticity, Muscle COMPLETED NCT03250988
Belotero Balance® Other Approved Patients With Moderate to Severe Perioral Lines COMPLETED NCT01970397
JUVEDERM® Ultra XC Other Approved Patients With Moderate to Severe Perioral Lines COMPLETED NCT01970397
Belotero Balance® Other Approved Patients With Moderate to Severe Perioral Lines COMPLETED NCT01970397
JUVEDERM® Ultra XC Other Approved Patients With Moderate to Severe Perioral Lines COMPLETED NCT01970397
Punctal Plug Other Phase PHASE4 Dry Eye COMPLETED NCT01684436
Sham Other Phase PHASE3 Macular Edema COMPLETED NCT01660802
700 μg Dexamethasone Other Phase PHASE3 Macular Edema COMPLETED NCT01660802
botulinum toxin Type A Other Preclinical Facial Rhytides COMPLETED NCT01608659
Sham Injection Other Phase PHASE3 Macular Edema COMPLETED NCT00168324
350 µg Dexamethasone Other Phase PHASE3 Macular Edema COMPLETED NCT00168324
700 µg Dexamethasone Other Phase PHASE3 Macular Edema COMPLETED NCT00168324
Wild Blueberry extract 100mg Other Approved Cognitive Decline COMPLETED NCT02446314
Wild Blueberry Powder - 900 mg Other Approved Cognitive Decline COMPLETED NCT02446314
Wild Blueberry Powder - 450mg Other Approved Cognitive Decline COMPLETED NCT02446314
Placebo Other Approved Cognitive Decline COMPLETED NCT02446314
Wild Blueberry extract 100mg Other Approved Cognitive Decline COMPLETED NCT02446314
Wild Blueberry Powder - 900 mg Other Approved Cognitive Decline COMPLETED NCT02446314
Wild Blueberry Powder - 450mg Other Approved Cognitive Decline COMPLETED NCT02446314
Placebo Other Approved Cognitive Decline COMPLETED NCT02446314
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03255382
Fumaderm Other Phase PHASE3 Psoriasis COMPLETED NCT03255382
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Placebo for Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo-Matching Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Risankizumab Other Phase PHASE3 Crohn's Disease RECRUITING NCT05995353
Risankizumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Adalimumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Telisotuzumab vedotin Other Preclinical Non-Small Cell Lung Cancer (NSCLC) TEMPORARILY_NOT_AVAILABLE NCT04830202
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) AVAILABLE NCT04278235
Placebo for Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04379050
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
ABBV-383 (Etentamig) Other Phase PHASE1 Immunoglobulin Light Chain (AL) Amyloidosis RECRUITING NCT06158854
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Nab-Paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, budigalimab, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT03844048
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Telisotuzumab Adizutecan Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Budigalimab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Azirkitug Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Placebo for Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo-Matching Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Risankizumab Other Phase PHASE3 Crohn's Disease RECRUITING NCT05995353
Risankizumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Adalimumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Telisotuzumab vedotin Other Preclinical Non-Small Cell Lung Cancer (NSCLC) TEMPORARILY_NOT_AVAILABLE NCT04830202
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) AVAILABLE NCT04278235
Placebo for Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04379050
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
ABBV-383 (Etentamig) Other Phase PHASE1 Immunoglobulin Light Chain (AL) Amyloidosis RECRUITING NCT06158854
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Nab-Paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, budigalimab, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT03844048
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Telisotuzumab Adizutecan Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Budigalimab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Azirkitug Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
adapalene 0.3% gel Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01425320
dapsone 5% gel Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01425320
Fixed Combination dapsone/adapalene Formulation B Gel Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01425320
Fixed Combination dapsone/adapalene Formulation A Gel Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01425320
adapalene 0.3% gel Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01425320
dapsone 5% gel Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01425320
Fixed Combination dapsone/adapalene Formulation B Gel Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01425320
Fixed Combination dapsone/adapalene Formulation A Gel Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01425320
Krytantek Other Preclinical Glaucoma Primary Open Angle COMPLETED NCT01737853
Ganforti Other Preclinical Glaucoma Primary Open Angle COMPLETED NCT01737853
Krytantek Other Preclinical Glaucoma Primary Open Angle COMPLETED NCT01737853
Ganforti Other Preclinical Glaucoma Primary Open Angle COMPLETED NCT01737853
No intervention applicable Other Preclinical Cerebral Palsy. UNKNOWN NCT01744158
No intervention applicable Other Preclinical Cerebral Palsy. UNKNOWN NCT01744158
No intervention applicable Other Preclinical Cerebral Palsy. UNKNOWN NCT01744158
normal saline Other Phase PHASE2 Benign Prostatic Hyperplasia COMPLETED NCT00284518
botulinum toxin Type A Other Phase PHASE2 Benign Prostatic Hyperplasia COMPLETED NCT00284518
normal saline Other Phase PHASE2 Benign Prostatic Hyperplasia COMPLETED NCT00284518
botulinum toxin Type A Other Phase PHASE2 Benign Prostatic Hyperplasia COMPLETED NCT00284518
normal saline Other Phase PHASE2 Benign Prostatic Hyperplasia COMPLETED NCT00284518
botulinum toxin Type A Other Phase PHASE2 Benign Prostatic Hyperplasia COMPLETED NCT00284518
Lidocaine Other Phase PHASE2 Diabetic Neuropathic Pain COMPLETED NCT01589432
Placebo Other Phase PHASE2 Diabetic Neuropathic Pain COMPLETED NCT01589432
ABT-639 Other Phase PHASE2 Diabetic Neuropathic Pain COMPLETED NCT01589432
ABT-869 Other Phase PHASE2 Advanced Renal Cell Carcinoma COMPLETED NCT00486538
placebo Other Phase PHASE3 Moderate to Severe Plaque Psoriasis COMPLETED NCT00710580
etanercept Other Phase PHASE3 Moderate to Severe Plaque Psoriasis COMPLETED NCT00710580
ABT-874 Other Phase PHASE3 Moderate to Severe Plaque Psoriasis COMPLETED NCT00710580
placebo Other Phase PHASE2 Attention-Deficit/Hyperactivity Disorder COMPLETED NCT00640419
ABT-089 Other Phase PHASE2 Attention-Deficit/Hyperactivity Disorder COMPLETED NCT00640419
Placebo Other Phase PHASE2 Attention-Deficit/Hyperactivity Disorder COMPLETED NCT00640185
ABT-089 Other Phase PHASE2 Attention-Deficit/Hyperactivity Disorder COMPLETED NCT00640185
Liposomal Doxorubicin Other Phase PHASE1 Ovarian Cancer, Primary Peritoneal Cancer COMPLETED NCT00635193
M200 (Volociximab) Other Phase PHASE1 Ovarian Cancer, Primary Peritoneal Cancer COMPLETED NCT00635193
ABT-089 Other Phase PHASE2 Attention Deficit Hyperactivity Disorder COMPLETED NCT00443391
placebo Other Phase PHASE2 Psoriasis COMPLETED NCT00292396
Anti IL-12 monoclonal antibody/ABT-874 Other Phase PHASE2 Psoriasis COMPLETED NCT00292396
placebo Other Phase PHASE4 Obesity COMPLETED NCT00932022
Trospium Chloride, Extended Release (XR) Other Phase PHASE4 Obesity COMPLETED NCT00932022
ABT-089 Other Phase PHASE2 Attention-Deficit/Hyperactivity Disorder COMPLETED NCT00686933
Duloxetine Other Phase PHASE2 Diabetic Neuralgia COMPLETED NCT00507936
placebo Other Phase PHASE2 Diabetic Neuralgia COMPLETED NCT00507936
ABT-894 Other Phase PHASE2 Diabetic Neuralgia COMPLETED NCT00507936
Placebo for ABT-869 Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT00645177
paclitaxel Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT00645177
ABT-869 Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT00645177
ABT-874 Other Phase PHASE3 Moderate to Severe Plaque Psoriasis COMPLETED NCT00626002
ABT-874 Other Phase PHASE3 Moderate to Severe Plaque Psoriasis COMPLETED NCT00626002
ABT-874 Other Phase PHASE3 Moderate to Severe Plaque Psoriasis COMPLETED NCT00626002
latanoprost Other Phase PHASE4 Glaucoma, Angle-Closure TERMINATED NCT01151904
brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution Other Phase PHASE4 Glaucoma, Angle-Closure TERMINATED NCT01151904
Saline Other Phase PHASE4 Chronic Migraine COMPLETED NCT01071096
OnabotulinumtoxinA Other Phase PHASE4 Chronic Migraine COMPLETED NCT01071096
dexamethasone intravitreal implant 0.7 mg Other Preclinical Macular Edema COMPLETED NCT01445626
dexamethasone intravitreal implant 0.7 mg Other Preclinical Macular Edema COMPLETED NCT01445626
dextran 70 0.1%/hydroxypropyl methylcellulose 0.3% Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01470118
olopatadine 0.2% ophthalmic solution Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01470118
alcaftadine 0.25% ophthalmic solution Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01470118
dextran 70 0.1%/hydroxypropyl methylcellulose 0.3% Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01470118
olopatadine 0.2% ophthalmic solution Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01470118
alcaftadine 0.25% ophthalmic solution Other Phase PHASE4 Conjunctivitis, Allergic COMPLETED NCT01470118
Dapsone 5% Gel Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01785836
Dapsone Formulation C Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01785836
Dapsone Formulation B Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01785836
Dapsone Formulation A Other Phase PHASE1 Acne Vulgaris WITHDRAWN NCT01785836
normal saline Other Phase PHASE3 Overactive Bladder COMPLETED NCT00910845
onabotulinumtoxinA Other Phase PHASE3 Overactive Bladder COMPLETED NCT00910845
Adalimumab Other Phase PHASE4 Psoriasis COMPLETED NCT01265823
lopinavir/ritonavir Other Phase PHASE4 Human Immunodeficiency Virus COMPLETED NCT00648999
lopinavir/ritonavir Other Phase PHASE4 Human Immunodeficiency Virus COMPLETED NCT00648999
bimatoprost/timolol fixed combination ophthalmic solution Other Phase PHASE3 Glaucoma COMPLETED NCT01177098
bimatoprost /timolol formulation A fixed combination ophthalmic solution Other Phase PHASE3 Glaucoma COMPLETED NCT01177098
bimatoprost/timolol fixed combination ophthalmic solution Other Phase PHASE3 Glaucoma COMPLETED NCT01177098
bimatoprost /timolol formulation A fixed combination ophthalmic solution Other Phase PHASE3 Glaucoma COMPLETED NCT01177098
ABT-072 Other Phase PHASE2 Hepatitis C Virus Infection COMPLETED NCT00872196
ABT-869 0.10 mg/kg Other Phase PHASE2 Non-Small Cell Lung Cancer (NSCLC) COMPLETED NCT00517790
ABT-869 .25 mg/kg Other Phase PHASE2 Non-Small Cell Lung Cancer (NSCLC) COMPLETED NCT00517790
dexamethasone intravitreal implant 0.7 mg Other Preclinical Retinal Vein Occlusion COMPLETED NCT01411696
Sham (no implant) Other Phase PHASE1 Retinitis Pigmentosa COMPLETED NCT00661479
100 µg Brimonidine Tartrate Implant Other Phase PHASE1 Retinitis Pigmentosa COMPLETED NCT00661479
200 µg Brimonidine Tartrate Implant Other Phase PHASE1 Retinitis Pigmentosa COMPLETED NCT00661479
400 µg Brimonidine Tartrate Implant Other Phase PHASE1 Retinitis Pigmentosa COMPLETED NCT00661479
Sham (no implant) Other Phase PHASE1 Retinitis Pigmentosa COMPLETED NCT00661479
100 µg Brimonidine Tartrate Implant Other Phase PHASE1 Retinitis Pigmentosa COMPLETED NCT00661479
200 µg Brimonidine Tartrate Implant Other Phase PHASE1 Retinitis Pigmentosa COMPLETED NCT00661479
400 µg Brimonidine Tartrate Implant Other Phase PHASE1 Retinitis Pigmentosa COMPLETED NCT00661479
Paclitaxel Other Phase PHASE2 Advanced or Metastatic Non-Small Cell Lung Cancer COMPLETED NCT00716534
Carboplatin Other Phase PHASE2 Advanced or Metastatic Non-Small Cell Lung Cancer COMPLETED NCT00716534
Placebo for ABT-869 Other Phase PHASE2 Advanced or Metastatic Non-Small Cell Lung Cancer COMPLETED NCT00716534
ABT-869 Other Phase PHASE2 Advanced or Metastatic Non-Small Cell Lung Cancer COMPLETED NCT00716534
fluorouracil Other Phase PHASE2 Advanced Colorectal Cancer COMPLETED NCT00707889
folinic acid Other Phase PHASE2 Advanced Colorectal Cancer COMPLETED NCT00707889
oxaliplatin Other Phase PHASE2 Advanced Colorectal Cancer COMPLETED NCT00707889
bevacizumab Other Phase PHASE2 Advanced Colorectal Cancer COMPLETED NCT00707889
ABT-869 Other Phase PHASE2 Advanced Colorectal Cancer COMPLETED NCT00707889
maxacalcitol placebo Other Phase PHASE3 Secondary Hyperparathyroidism COMPLETED NCT01341782
paricalcitol placebo Other Phase PHASE3 Secondary Hyperparathyroidism COMPLETED NCT01341782
maxacalcitol Other Phase PHASE3 Secondary Hyperparathyroidism COMPLETED NCT01341782
paricalcitol Other Phase PHASE3 Secondary Hyperparathyroidism COMPLETED NCT01341782
FCR Other Phase PHASE1 Chronic Lymphocytic Leukemia COMPLETED NCT00868413
ABT-263 Other Phase PHASE1 Chronic Lymphocytic Leukemia COMPLETED NCT00868413
FCR Other Phase PHASE1 Chronic Lymphocytic Leukemia COMPLETED NCT00868413
ABT-263 Other Phase PHASE1 Chronic Lymphocytic Leukemia COMPLETED NCT00868413
Palivizumab Other Phase PHASE3 Respiratory Syncytial Virus Infection COMPLETED NCT01466062
Standard of Care Other Preclinical Glaucoma, Open-Angle COMPLETED NCT01629407
Standard of Care Other Preclinical Glaucoma, Open-Angle COMPLETED NCT01629407
botulinum toxin A (BTX-A) Other Approved Stiff Knee Gait TERMINATED NCT00900666
placebo Other Approved Stiff Knee Gait TERMINATED NCT00900666
botulinum toxin A (BTX-A) Other Approved Stiff Knee Gait TERMINATED NCT00900666
placebo Other Approved Stiff Knee Gait TERMINATED NCT00900666
Pars Plana Vitrectomy Other Preclinical Vitrectomy COMPLETED NCT01319318
Placebo (Vehicle for Cyclosporine) Other Phase PHASE2 Laser In Situ Keratomileusis COMPLETED NCT00991458
Cyclosporine 0.005% eye drops Other Phase PHASE2 Laser In Situ Keratomileusis COMPLETED NCT00991458
Cyclosporine 0.010% eye drops Other Phase PHASE2 Laser In Situ Keratomileusis COMPLETED NCT00991458
Placebo (Vehicle for Cyclosporine) Other Phase PHASE2 Laser In Situ Keratomileusis COMPLETED NCT00991458
Cyclosporine 0.005% eye drops Other Phase PHASE2 Laser In Situ Keratomileusis COMPLETED NCT00991458
Cyclosporine 0.010% eye drops Other Phase PHASE2 Laser In Situ Keratomileusis COMPLETED NCT00991458
dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution Other Phase PHASE3 Glaucoma WITHDRAWN NCT01284166
200 µg Brimonidine Tartrate Implant Other Phase PHASE1 Vitrectomy COMPLETED NCT01229410
400 µg Brimonidine Tartrate Implant Other Phase PHASE1 Vitrectomy COMPLETED NCT01229410
200 µg Brimonidine Tartrate Implant Other Phase PHASE1 Vitrectomy COMPLETED NCT01229410
400 µg Brimonidine Tartrate Implant Other Phase PHASE1 Vitrectomy COMPLETED NCT01229410
Calcitriol Other Preclinical Secondary Hyperparathyroidism TERMINATED NCT01134315
Paricalcitol Other Preclinical Secondary Hyperparathyroidism TERMINATED NCT01134315
Calcitriol Other Preclinical Secondary Hyperparathyroidism TERMINATED NCT01134315
Paricalcitol Other Preclinical Secondary Hyperparathyroidism TERMINATED NCT01134315
Calcitriol Other Preclinical Secondary Hyperparathyroidism TERMINATED NCT01134315
Paricalcitol Other Preclinical Secondary Hyperparathyroidism TERMINATED NCT01134315
Placebo and rehab Other Phase EARLY_PHASE1 Stroke COMPLETED NCT00565201
Botox and rehab Other Phase EARLY_PHASE1 Stroke COMPLETED NCT00565201
bimatoprost Formulation C Other Phase PHASE1 Alopecia COMPLETED NCT01189279
bimatoprost Formulation B Other Phase PHASE1 Alopecia COMPLETED NCT01189279
bimatoprost Formulation A Other Phase PHASE1 Alopecia COMPLETED NCT01189279
Ozurdex Other Preclinical Macular Edema COMPLETED NCT01945892
No Treatment Drug Preclinical Glaucoma, Open-Angle COMPLETED NCT01540370
bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution Other Phase PHASE3 Glaucoma COMPLETED NCT01216943
Bimatoprost 0.01% ophthalmic solution Other Preclinical Open-Angle Glaucoma COMPLETED NCT01568008
Bimatoprost 0.01% Other Phase PHASE4 Glaucoma, Primary Open Angle COMPLETED NCT01833741
Duloxetine Other Phase PHASE2 Diabetic Neuropathic Pain TERMINATED NCT01579279
Placebo Other Phase PHASE2 Diabetic Neuropathic Pain TERMINATED NCT01579279
ABT-652 12 mg - 18 mg Other Phase PHASE2 Diabetic Neuropathic Pain TERMINATED NCT01579279
ABT-652 12 mg Other Phase PHASE2 Diabetic Neuropathic Pain TERMINATED NCT01579279
ABT-652 6 mg Other Phase PHASE2 Diabetic Neuropathic Pain TERMINATED NCT01579279
Blink Contacts® Eye Drops Other Phase PHASE4 Contact Lens Related Dry Eye Syndrome COMPLETED NCT01543061
No treatment Drug Phase PHASE4 Contact Lens Related Dry Eye Syndrome COMPLETED NCT01543061
OPTIVEtm Plus Other Phase PHASE4 Contact Lens Related Dry Eye Syndrome COMPLETED NCT01543061
No Intervention Other Preclinical Facial Rhytides COMPLETED NCT01600729
No Intervention Other Preclinical Facial Rhytides COMPLETED NCT01600729
Placebo (saline) Other Phase PHASE1 Benign Prostatic Hyperplasia COMPLETED NCT00894517
Botulinum Toxin Type A Other Phase PHASE1 Benign Prostatic Hyperplasia COMPLETED NCT00894517
Placebo (saline) Other Phase PHASE1 Benign Prostatic Hyperplasia COMPLETED NCT00894517
Botulinum Toxin Type A Other Phase PHASE1 Benign Prostatic Hyperplasia COMPLETED NCT00894517
Placebo (saline) Other Phase PHASE1 Benign Prostatic Hyperplasia COMPLETED NCT00894517
Botulinum Toxin Type A Other Phase PHASE1 Benign Prostatic Hyperplasia COMPLETED NCT00894517
Placebo Other Phase PHASE2 Major Depressive Disorder TERMINATED NCT01741142
Escitalopram Other Phase PHASE2 Major Depressive Disorder TERMINATED NCT01741142
ABT-436 Other Phase PHASE2 Major Depressive Disorder TERMINATED NCT01741142
AGN-210669 vehicle ophthalmic solution Other Phase PHASE1 Ocular Hypertension COMPLETED NCT00809848
bimatoprost ophthalmic solution 0.03% Other Phase PHASE1 Ocular Hypertension COMPLETED NCT00809848
AGN-210669 ophthalmic solution, 0.025% Other Phase PHASE1 Ocular Hypertension COMPLETED NCT00809848
AGN-210669 ophthalmic solution, 0.05% Other Phase PHASE1 Ocular Hypertension COMPLETED NCT00809848
AGN-210669 ophthalmic solution, 0.075% Other Phase PHASE1 Ocular Hypertension COMPLETED NCT00809848
AGN-210669 vehicle ophthalmic solution Other Phase PHASE1 Ocular Hypertension COMPLETED NCT00809848
bimatoprost ophthalmic solution 0.03% Other Phase PHASE1 Ocular Hypertension COMPLETED NCT00809848
AGN-210669 ophthalmic solution, 0.025% Other Phase PHASE1 Ocular Hypertension COMPLETED NCT00809848
AGN-210669 ophthalmic solution, 0.05% Other Phase PHASE1 Ocular Hypertension COMPLETED NCT00809848
AGN-210669 ophthalmic solution, 0.075% Other Phase PHASE1 Ocular Hypertension COMPLETED NCT00809848
vehicle sterile solution Other Phase PHASE3 Eyelashes COMPLETED NCT00693420
Bimatoprost 0.03% sterile solution Other Phase PHASE3 Eyelashes COMPLETED NCT00693420
vehicle sterile solution Other Phase PHASE3 Eyelashes COMPLETED NCT00693420
Bimatoprost 0.03% sterile solution Other Phase PHASE3 Eyelashes COMPLETED NCT00693420
Rehabilitation Therapy Drug Approved Upper Limb Spasticity COMPLETED NCT00945295
Botulinum toxin type A, BoNT-A Other Approved Upper Limb Spasticity COMPLETED NCT00945295
ABT-348 and docetaxel Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01110486
ABT-348 and carboplatin Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01110486
ABT-348 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01110486
Placebo Other Phase PHASE2 Overactive Bladder COMPLETED NCT00168454
botulinum toxin Type A Other Phase PHASE2 Overactive Bladder COMPLETED NCT00168454
No treatment Drug Preclinical Muscle Spasticity COMPLETED NCT01383681
Placebo to AGN-214868 Other Phase PHASE2 Neuralgia, Postherpetic COMPLETED NCT01129531
AGN-214868 Other Phase PHASE2 Neuralgia, Postherpetic COMPLETED NCT01129531
Placebo to AGN-214868 Other Phase PHASE2 Neuralgia, Postherpetic COMPLETED NCT01129531
AGN-214868 Other Phase PHASE2 Neuralgia, Postherpetic COMPLETED NCT01129531
placebo (saline) Other Phase PHASE3 Migraine Disorders COMPLETED NCT00168428
Botulinum Toxin Type A Other Phase PHASE3 Migraine Disorders COMPLETED NCT00168428
Botulinum Toxin Type A 150kDa Other Phase PHASE4 Blepharospasm COMPLETED NCT00761592
Botulinum Toxin Type A 900kDa Other Phase PHASE4 Blepharospasm COMPLETED NCT00761592
Botulinum Toxin Type A 150kDa Other Phase PHASE4 Blepharospasm COMPLETED NCT00761592
Botulinum Toxin Type A 900kDa Other Phase PHASE4 Blepharospasm COMPLETED NCT00761592
Carboxymethylcellulose sodium, glycerin and polysorbate 80 Other Phase PHASE2 Dry Eye Syndrome COMPLETED NCT01339936
Placebo Other Phase PHASE1 Alzheimer's Disease COMPLETED NCT01908010
ABT-354 Other Phase PHASE1 Alzheimer's Disease COMPLETED NCT01908010
Placebo Other Phase PHASE1 Alzheimer's Disease COMPLETED NCT01908010
ABT-354 Other Phase PHASE1 Alzheimer's Disease COMPLETED NCT01908010
methotrexate Other Phase PHASE4 Arthritis, Rheumatoid COMPLETED NCT00808509
adalimumab Other Phase PHASE4 Arthritis, Rheumatoid COMPLETED NCT00808509
methotrexate Other Phase PHASE4 Arthritis, Rheumatoid COMPLETED NCT00808509
adalimumab Other Phase PHASE4 Arthritis, Rheumatoid COMPLETED NCT00808509
IV DHE Other Phase PHASE1 Healthy Subjects COMPLETED NCT01199965
MAP0004 Other Phase PHASE1 Healthy Subjects COMPLETED NCT01199965
Placebo Capsule Other Phase PHASE1 Healthy COMPLETED NCT01191723
Moxifloxacin Other Phase PHASE1 Healthy COMPLETED NCT01191723
Inhaler Placebo Other Phase PHASE1 Healthy COMPLETED NCT01191723
MAP0004 Other Phase PHASE1 Healthy COMPLETED NCT01191723
Placebo Capsule Other Phase PHASE1 Healthy COMPLETED NCT01191723
Moxifloxacin Other Phase PHASE1 Healthy COMPLETED NCT01191723
Inhaler Placebo Other Phase PHASE1 Healthy COMPLETED NCT01191723
MAP0004 Other Phase PHASE1 Healthy COMPLETED NCT01191723
IV Dihydroergotamine Mesylate (DHE) Other Phase PHASE1 Healthy COMPLETED NCT01089062
Placebo Inhaler Other Phase PHASE1 Healthy COMPLETED NCT01089062
IV Placebo (Saline) Other Phase PHASE1 Healthy COMPLETED NCT01089062
MAP0004 Other Phase PHASE1 Healthy COMPLETED NCT01089062
IV Dihydroergotamine Mesylate (DHE) Other Phase PHASE1 Healthy COMPLETED NCT01089062
Placebo Inhaler Other Phase PHASE1 Healthy COMPLETED NCT01089062
IV Placebo (Saline) Other Phase PHASE1 Healthy COMPLETED NCT01089062
MAP0004 Other Phase PHASE1 Healthy COMPLETED NCT01089062
IV Dihydroergotamine Mesylate (DHE) Other Phase PHASE1 Healthy COMPLETED NCT01089062
Placebo Inhaler Other Phase PHASE1 Healthy COMPLETED NCT01089062
IV Placebo (Saline) Other Phase PHASE1 Healthy COMPLETED NCT01089062
MAP0004 Other Phase PHASE1 Healthy COMPLETED NCT01089062
21ug MAP0020 Other Phase PHASE2 Asthma COMPLETED NCT00995904
42ug MAP0020 Other Phase PHASE2 Asthma COMPLETED NCT00995904
84ug MAP0020 Other Phase PHASE2 Asthma COMPLETED NCT00995904
21ug MAP0020 Other Phase PHASE2 Asthma COMPLETED NCT00995904
42ug MAP0020 Other Phase PHASE2 Asthma COMPLETED NCT00995904
84ug MAP0020 Other Phase PHASE2 Asthma COMPLETED NCT00995904
Placebo Other Phase PHASE2 Asthma COMPLETED NCT00697801
MAP0010 high dose Other Phase PHASE2 Asthma COMPLETED NCT00697801
MAP0010 low dose Other Phase PHASE2 Asthma COMPLETED NCT00697801
Placebo Other Phase PHASE2 Asthma COMPLETED NCT00697801
MAP0010 high dose Other Phase PHASE2 Asthma COMPLETED NCT00697801
MAP0010 low dose Other Phase PHASE2 Asthma COMPLETED NCT00697801
0.25mg MAP0010 Other Phase PHASE3 Asthma TERMINATED NCT00697697
0.135mg MAP0010 Other Phase PHASE3 Asthma TERMINATED NCT00697697
0.25mg MAP0010 Other Phase PHASE3 Asthma TERMINATED NCT00697697
0.135mg MAP0010 Other Phase PHASE3 Asthma TERMINATED NCT00697697
0.25mg MAP0010 Other Phase PHASE3 Asthma TERMINATED NCT00697697
0.135mg MAP0010 Other Phase PHASE3 Asthma TERMINATED NCT00697697
Leuprolide Acetate 3 Month Depot Other Phase PHASE3 Precocious COMPLETED NCT00667446
MAP0010 high dose Other Phase PHASE1 Asthma COMPLETED NCT00627679
MAP0010 intermediate dose Other Phase PHASE1 Asthma COMPLETED NCT00627679
MAP0010 low dose Other Phase PHASE1 Asthma COMPLETED NCT00627679
Budesonide Inhalation Suspension Other Phase PHASE1 Asthma COMPLETED NCT00627679
MAP0010 high dose Other Phase PHASE1 Asthma COMPLETED NCT00627679
MAP0010 intermediate dose Other Phase PHASE1 Asthma COMPLETED NCT00627679
MAP0010 low dose Other Phase PHASE1 Asthma COMPLETED NCT00627679
Budesonide Inhalation Suspension Other Phase PHASE1 Asthma COMPLETED NCT00627679
Placebo Other Phase PHASE3 Migraine Disorders COMPLETED NCT00623636
MAP0004 Other Phase PHASE3 Migraine Disorders COMPLETED NCT00623636
Placebo Other Phase PHASE3 Migraine Disorders COMPLETED NCT00623636
MAP0004 Other Phase PHASE3 Migraine Disorders COMPLETED NCT00623636
Placebo Other Phase PHASE3 Migraine Disorders COMPLETED NCT00623636
MAP0004 Other Phase PHASE3 Migraine Disorders COMPLETED NCT00623636
Placebo Other Phase PHASE3 Asthma COMPLETED NCT00569192
0.25mg MAP0010 Other Phase PHASE3 Asthma COMPLETED NCT00569192
0.135mg MAP0010 Other Phase PHASE3 Asthma COMPLETED NCT00569192
Placebo Other Phase PHASE3 Asthma COMPLETED NCT00569192
0.25mg MAP0010 Other Phase PHASE3 Asthma COMPLETED NCT00569192
0.135mg MAP0010 Other Phase PHASE3 Asthma COMPLETED NCT00569192
Budesonide inhalation suspension 0.5mg Other Phase PHASE2 Asthma COMPLETED NCT00554970
Budesonide inhalation suspension 0.25mg Other Phase PHASE2 Asthma COMPLETED NCT00554970
MAP0010 high dose Other Phase PHASE2 Asthma COMPLETED NCT00554970
MAP0010 low dose Other Phase PHASE2 Asthma COMPLETED NCT00554970
Budesonide inhalation suspension 0.5mg Other Phase PHASE2 Asthma COMPLETED NCT00554970
Budesonide inhalation suspension 0.25mg Other Phase PHASE2 Asthma COMPLETED NCT00554970
MAP0010 high dose Other Phase PHASE2 Asthma COMPLETED NCT00554970
MAP0010 low dose Other Phase PHASE2 Asthma COMPLETED NCT00554970
Budesonide inhalation suspension 0.5mg Other Phase PHASE2 Asthma COMPLETED NCT00554970
Budesonide inhalation suspension 0.25mg Other Phase PHASE2 Asthma COMPLETED NCT00554970
MAP0010 high dose Other Phase PHASE2 Asthma COMPLETED NCT00554970
MAP0010 low dose Other Phase PHASE2 Asthma COMPLETED NCT00554970
Normal Saline (Placebo) Other Phase PHASE3 Overactive Bladder TERMINATED NCT00439140
botulinum toxin Type A Other Phase PHASE3 Overactive Bladder TERMINATED NCT00439140
Bimatoprost 0.01% Other Phase PHASE4 Glaucoma, Open-Angle COMPLETED NCT01594970
Placebo Other Phase PHASE2 Chronic Low Back Pain COMPLETED NCT01364922
hydrocodone/acetaminophen extended release Other Phase PHASE2 Chronic Low Back Pain COMPLETED NCT01364922
ABT-333 Other Phase PHASE1 Relative Bioavailability COMPLETED NCT02052349
ABT-333 Other Phase PHASE1 Relative Bioavailability COMPLETED NCT02052349
OnabotulinumtoxinA Other Preclinical Chronic Migraine, Headache WITHDRAWN NCT01749423
OnabotulinumtoxinA Other Preclinical Chronic Migraine, Headache WITHDRAWN NCT01749423
botulinum toxin Type A Other Preclinical Muscle Spasticity COMPLETED NCT01387074
vehicle of AGN-229666 Other Phase PHASE2 Allergic Conjunctivitis COMPLETED NCT01754766
AGN-229666 Other Phase PHASE2 Allergic Conjunctivitis COMPLETED NCT01754766
vehicle of AGN-229666 Other Phase PHASE2 Allergic Conjunctivitis COMPLETED NCT01754766
AGN-229666 Other Phase PHASE2 Allergic Conjunctivitis COMPLETED NCT01754766
Placebo Other Phase PHASE3 Chronic Low Back Pain COMPLETED NCT00763321
ABT-712 Other Phase PHASE3 Chronic Low Back Pain COMPLETED NCT00763321
Placebo Other Phase PHASE3 Chronic Low Back Pain COMPLETED NCT00761150
ABT-712 Other Phase PHASE3 Chronic Low Back Pain COMPLETED NCT00761150
ABT-450/r/ABT-267 Other Phase PHASE1 Absolute Bioavailability COMPLETED NCT02052362
ABT-450/r/ABT-267 Other Phase PHASE1 Absolute Bioavailability COMPLETED NCT02052362
Adalimumab Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01561313
Adalimumab Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01502423
Adalimumab Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01502423
onabotulinumtoxinA 24 U Other Phase PHASE3 Facial Rhytides COMPLETED NCT01224015
onabotulinumtoxinA 44 U Other Phase PHASE3 Facial Rhytides COMPLETED NCT01224015
normal saline Other Phase PHASE3 Facial Rhytides COMPLETED NCT01224015
onabotulinumtoxinA 24 U Other Phase PHASE3 Facial Rhytides COMPLETED NCT01224015
onabotulinumtoxinA 44 U Other Phase PHASE3 Facial Rhytides COMPLETED NCT01224015
normal saline Other Phase PHASE3 Facial Rhytides COMPLETED NCT01224015
Methotrexate Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT01185288
Adalimumab Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT01185288
Placebo Other Phase PHASE2 Pain COMPLETED NCT01333722
Hydrocodone/Acetaminophen Extended Release Other Phase PHASE2 Pain COMPLETED NCT01333722
Placebo Other Phase PHASE2 Pain COMPLETED NCT00935311
Hydrocodone/Acetaminophen Immediate-release Other Phase PHASE2 Pain COMPLETED NCT00935311
ABT-712 Extended-release Other Phase PHASE2 Pain COMPLETED NCT00935311
minoxidil 2% solution Other Phase PHASE2 Alopecia COMPLETED NCT01325350
bimatoprost vehicle solution Other Phase PHASE2 Alopecia COMPLETED NCT01325350
bimatoprost Formulation C Other Phase PHASE2 Alopecia COMPLETED NCT01325350
bimatoprost Formulation B Other Phase PHASE2 Alopecia COMPLETED NCT01325350
bimatoprost Formulation A Other Phase PHASE2 Alopecia COMPLETED NCT01325350
minoxidil 5% solution Other Phase PHASE2 Alopecia COMPLETED NCT01325337
bimatoprost vehicle solution Other Phase PHASE2 Alopecia COMPLETED NCT01325337
bimatoprost Formulation C Other Phase PHASE2 Alopecia COMPLETED NCT01325337
bimatoprost Formulation B Other Phase PHASE2 Alopecia COMPLETED NCT01325337
bimatoprost Formulation A Other Phase PHASE2 Alopecia COMPLETED NCT01325337
Relestat Ophthalmic Solution 0.05% Other Preclinical Conjunctivitis, Allergic COMPLETED NCT01987765
No Intervention Other Preclinical Healthy Volunteers COMPLETED NCT01821534
No Intervention Other Preclinical Healthy Volunteers COMPLETED NCT01821534
EMG Guidance of Injection Other Approved High Tone Pelvic Floor Dysfunction COMPLETED NCT01323829
EMG Guidance of Injection Other Approved High Tone Pelvic Floor Dysfunction COMPLETED NCT01323829
Rifampin Other Phase PHASE1 Non-Hodgkin's Lymphoma WITHDRAWN NCT01969682
ABT-199 Other Phase PHASE1 Non-Hodgkin's Lymphoma WITHDRAWN NCT01969682
Rifampin Other Phase PHASE1 Non-Hodgkin's Lymphoma WITHDRAWN NCT01969682
ABT-199 Other Phase PHASE1 Non-Hodgkin's Lymphoma WITHDRAWN NCT01969682
Rifampin Other Phase PHASE1 Non-Hodgkin's Lymphoma WITHDRAWN NCT01969682
ABT-199 Other Phase PHASE1 Non-Hodgkin's Lymphoma WITHDRAWN NCT01969682
ABT-SLV176 Other Phase PHASE3 Hypogonadism WITHDRAWN NCT02082197
ABT-SLV176 Other Phase PHASE3 Hypogonadism WITHDRAWN NCT02082197
ABT-719 Other Phase PHASE2 Cardiothoracic Surgery TERMINATED NCT01897519
Placebo Other Phase PHASE2 Cardiothoracic Surgery TERMINATED NCT01897519
ABT-719 Other Phase PHASE2 Cardiothoracic Surgery TERMINATED NCT01897519
Placebo Other Phase PHASE2 Cardiothoracic Surgery TERMINATED NCT01897519
Adalimumab, new formulation Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01712178
Adalimumab, current formulation Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01712178
Adalimumab, new formulation Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01712178
Adalimumab, current formulation Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01712178
bimatoprost 0.01% ophthalmic solution Other Preclinical Glaucoma, Open-Angle COMPLETED NCT01589510
bimatoprost 0.01% ophthalmic solution Other Preclinical Glaucoma, Open-Angle COMPLETED NCT01589510
Functional Electrical Stimulation (FES) through the Ness H200 Other Approved Upper Extremity Spasticity COMPLETED NCT00462449
Tazorac Other Phase PHASE4 Brittle Nails COMPLETED NCT00648986
No Intervention Other Preclinical Cervical Dystonia COMPLETED NCT01814774
Navitoclax Other Phase PHASE2 Chronic Lymphocytic Leukemia COMPLETED NCT01557777
No Intervention Other Preclinical Cervical Dystonia COMPLETED NCT00836017
0.03% Bimatoprost Other Phase PHASE4 Glaucoma, Open-Angle COMPLETED NCT02020512
No Treatment Drug Preclinical Open-angle Glaucoma TERMINATED NCT01781962
Sham Other Phase PHASE3 Diabetic Macular Edema COMPLETED NCT00168389
Dexamethasone Other Phase PHASE3 Diabetic Macular Edema COMPLETED NCT00168389
Sham Other Phase PHASE3 Diabetic Macular Edema COMPLETED NCT00168337
Dexamethasone Other Phase PHASE3 Diabetic Macular Edema COMPLETED NCT00168337
bimatoprost ophthalmic solution 0.03% Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 7 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 6 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 5 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 4 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 3 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 2 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 1 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
bimatoprost ophthalmic solution 0.03% Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 7 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 6 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 5 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 4 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 3 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 2 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
AGN-210961 Formulation 1 Other Phase PHASE2 Ocular Hypertension COMPLETED NCT01110499
Normal Saline Other Phase PHASE1 Osteoarthritis COMPLETED NCT01518257
botulinum toxin Type A Other Phase PHASE1 Osteoarthritis COMPLETED NCT01518257
onabotulinumtoxinA Other Phase PHASE3 Muscle Spasticity WITHDRAWN NCT02145689
onabotulinumtoxinA Other Phase PHASE3 Muscle Spasticity WITHDRAWN NCT02145689
[14C]ABT-199 (GDC-0199) Other Phase PHASE1 Relapsed/Refractory Non-Hodgkin's Lymphoma WITHDRAWN NCT02095574
[14C]ABT-199 (GDC-0199) Other Phase PHASE1 Relapsed/Refractory Non-Hodgkin's Lymphoma WITHDRAWN NCT02095574
[14C]ABT-199 (GDC-0199) Other Phase PHASE1 Relapsed/Refractory Non-Hodgkin's Lymphoma WITHDRAWN NCT02095574
Open-label Adalimumab Other Phase PHASE3 Axial Spondyloarthritis COMPLETED NCT00939003
Placebo Other Phase PHASE3 Axial Spondyloarthritis COMPLETED NCT00939003
Adalimumab Other Phase PHASE3 Axial Spondyloarthritis COMPLETED NCT00939003
Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT01241240
bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy) Drug Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT01241240
Adalimumab Other Phase PHASE4 Moderate to Severe Plaque Psoriasis COMPLETED NCT01644396
Easyband (Telemetrically adjustable gastric banding device) Device Approved Morbid Obesity WITHDRAWN NCT00534339
Easyband (Telemetrically adjustable gastric banding device) Device Approved Morbid Obesity WITHDRAWN NCT00534339
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) Other Preclinical Age-related Volume Deficit in the Mid-face COMPLETED NCT01559064
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) Other Preclinical Age-related Volume Deficit in the Mid-face COMPLETED NCT01559064
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) Other Preclinical Age-related Volume Deficit in the Mid-face COMPLETED NCT01559064
hyaluronic acid gel Other Approved Lip Enhancement COMPLETED NCT01176773
hyaluronic acid gel Other Approved Lip Enhancement COMPLETED NCT01176773
Easyband® Other Preclinical Morbid Obesity COMPLETED NCT00948246
Easyband® Other Preclinical Morbid Obesity COMPLETED NCT00948246
Easyband® Other Preclinical Morbid Obesity COMPLETED NCT00948246
Natrelle(TM) Silicone-Filled Breast Implants Other Approved Breast Reconstruction COMPLETED NCT00691327
Natrelle(TM) Silicone-Filled Breast Implants Other Approved Breast Reconstruction COMPLETED NCT00691327
Style 410 Silicone-Filled Breast Implants Other Approved Breast Augmentation COMPLETED NCT00690339
Style 410 Silicone-Filled Breast Implants Other Approved Breast Augmentation COMPLETED NCT00690339
Natrelle(TM) Silicone-Filled Breast Implants Other Approved Breast Augmentation COMPLETED NCT00689871
Natrelle(TM) Silicone-Filled Breast Implants Other Approved Breast Augmentation COMPLETED NCT00689871
Track B Other Phase PHASE4 Hypotrichosis COMPLETED NCT01891487
Track A Other Phase PHASE4 Hypotrichosis COMPLETED NCT01891487
Brimonidine Tartrate Ophthalmic Solution 0.2% Other Phase PHASE2 Glaucoma COMPLETED NCT01863953
Vehicle Ophthalmic Solution Other Phase PHASE2 Glaucoma COMPLETED NCT01863953
Bimatoprost Ophthalmic Solution 0.01% Other Phase PHASE2 Glaucoma COMPLETED NCT01863953
Fixed-Combination Bimatoprost/Brimonidine Other Phase PHASE2 Glaucoma COMPLETED NCT01863953
BTX-A Other Phase PHASE2 Primary Focal Hyperhidrosis of the Hands TERMINATED NCT01262339
No Treatment Drug Preclinical Migraine Disorders COMPLETED NCT01648530
botulinum toxin Type A (32U) Other Phase PHASE3 Upper Facial Rhytides COMPLETED NCT01797094
botulinum toxin Type A (44U) Other Phase PHASE3 Upper Facial Rhytides COMPLETED NCT01797094
vehicle of bimatoprost solution 0.03 % Other Phase PHASE3 Idiopathic Eyelash Hypotrichosis COMPLETED NCT01698554
vehicle of bimatoprost formulation A solution Other Phase PHASE3 Idiopathic Eyelash Hypotrichosis COMPLETED NCT01698554
bimatoprost solution 0.03 % Other Phase PHASE3 Idiopathic Eyelash Hypotrichosis COMPLETED NCT01698554
bimatoprost formulation A solution Other Phase PHASE3 Idiopathic Eyelash Hypotrichosis COMPLETED NCT01698554
Ozurdex Intravitreal Injection (0.7 mg) Other Phase PHASE4 Macular Edema COMPLETED NCT01870440
Ozurdex Intravitreal Injection (0.7 mg) Other Phase PHASE4 Macular Edema COMPLETED NCT01870440
LAP-BAND® Adjustable Gastric Band (LAGB®) Other Phase PHASE2 Obesity COMPLETED NCT00580502
Saline Other Approved Post Traumatic Stiffness COMPLETED NCT01129583
Botulinum Toxin Type A Other Approved Post Traumatic Stiffness COMPLETED NCT01129583
Saline Other Approved Post Traumatic Stiffness COMPLETED NCT01129583
Botulinum Toxin Type A Other Approved Post Traumatic Stiffness COMPLETED NCT01129583
Intravitreal dexamethasone 0.7mg implant Other Phase PHASE4 Diabetes Mellitus UNKNOWN NCT02399657
tazarotene cream 0.1% Other Phase PHASE1 Acne Vulgaris COMPLETED NCT02218034
tazarotene gel 0.1% Other Phase PHASE1 Acne Vulgaris COMPLETED NCT02218034
AGN-190168 Formulation 2 Other Phase PHASE1 Acne Vulgaris COMPLETED NCT02218034
AGN-190168 Formulation 1 Other Phase PHASE1 Acne Vulgaris COMPLETED NCT02218034
Standard Therapy Drug Approved Stroke COMPLETED NCT01751373
Optimal muscle activation therapy Drug Approved Stroke COMPLETED NCT01751373
No Intervention Other Preclinical Macular Edema COMPLETED NCT02181530
Saline injection Other Phase PHASE4 Graves Ophthalmopathy WITHDRAWN NCT01272414
Botulinum Toxin Type A Other Phase PHASE4 Graves Ophthalmopathy WITHDRAWN NCT01272414
Saline injection Other Phase PHASE4 Graves Ophthalmopathy WITHDRAWN NCT01272414
Botulinum Toxin Type A Other Phase PHASE4 Graves Ophthalmopathy WITHDRAWN NCT01272414
Treatment with Botox Drug Phase PHASE4 Essential Axillary Hyperhidrosis TERMINATED NCT00669474
Suction curettage Other Phase PHASE4 Essential Axillary Hyperhidrosis TERMINATED NCT00669474
Voluma XC Other Approved Mandibular Hypoplasia UNKNOWN NCT02330016
Placebo Drug Delivery System Drug Phase PHASE1 Cataract TERMINATED NCT01605942
Dexamethasone Drug Delivery System Drug Phase PHASE1 Cataract TERMINATED NCT01605942
sham procedure Procedure Phase PHASE2 Macular Edema COMPLETED NCT02186119
ranibizumab Other Phase PHASE2 Macular Edema COMPLETED NCT02186119
abicipar pegol Other Phase PHASE2 Macular Edema COMPLETED NCT02186119
Carboxymethylcellulose sodium Other Phase PHASE2 Ametropia COMPLETED NCT00691197
Carboxymethylcellulose sodium and Glycerin Other Phase PHASE2 Ametropia COMPLETED NCT00691197
Anatomically shaped silicone gel-filled breast implants Other Approved Breast Augmentation TERMINATED NCT01853605
AGN-207281 vehicle ophthalmic solution (Placebo) Other Phase PHASE1 Glaucoma, Open-Angle COMPLETED NCT01215786
timolol ophthalmic solution 0.5% Other Phase PHASE1 Glaucoma, Open-Angle COMPLETED NCT01215786
AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo) Other Phase PHASE1 Glaucoma, Open-Angle COMPLETED NCT01215786
AGN-207281 vehicle ophthalmic solution (Placebo) Other Phase PHASE1 Glaucoma, Open-Angle COMPLETED NCT01215786
timolol ophthalmic solution 0.5% Other Phase PHASE1 Glaucoma, Open-Angle COMPLETED NCT01215786
AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo) Other Phase PHASE1 Glaucoma, Open-Angle COMPLETED NCT01215786
Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear Other Approved Dry Eye Syndrome COMPLETED NCT01010282
Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear Other Approved Dry Eye Syndrome COMPLETED NCT01010282
Glycerin and Polysorbate 80 based artificial tear Other Approved Dry Eye Syndrome COMPLETED NCT01010282
Dapsone Gel Other Phase PHASE4 Acne Vulgaris COMPLETED NCT02032407
Glycerin and Polysorbate 80 based artificial tear Other Approved Dry Eye Syndrome COMPLETED NCT00932477
Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear Other Approved Dry Eye Syndrome COMPLETED NCT00932477
Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear Other Approved Dry Eye Syndrome COMPLETED NCT00932477
cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B Other Phase PHASE1 Dry Eye Syndromes COMPLETED NCT01319773
cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05% Other Phase PHASE1 Dry Eye Syndromes COMPLETED NCT01319773
cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05% Other Phase PHASE1 Dry Eye Syndromes COMPLETED NCT01319773
cyclosporine ophthalmic emulsion Formulation B Other Phase PHASE1 Dry Eye Syndromes COMPLETED NCT01319773
cyclosporine ophthalmic emulsion Formulation A Other Phase PHASE1 Dry Eye Syndromes COMPLETED NCT01319773
AGN 203818 Other Phase PHASE2 Fibromyalgia TERMINATED NCT00445705
placebo Other Phase PHASE2 Fibromyalgia TERMINATED NCT00445705
Ranibizumab 500µg Other Phase PHASE2 Choroid Neovascularization TERMINATED NCT00395057
AGN 211745 Other Phase PHASE2 Choroid Neovascularization TERMINATED NCT00395057
onabotulinumtoxinA Other Preclinical Chronic Migraine, Headaches COMPLETED NCT01749410
No Intervention Other Preclinical Open-Angle Glaucoma COMPLETED NCT02348476
No Intervention Other Preclinical Open-Angle Glaucoma COMPLETED NCT02348476
Sham Cystoscopy Procedure Procedure Phase PHASE2 Interstitial Cystitis TERMINATED NCT01475253
LiRIS Placebo Other Phase PHASE2 Interstitial Cystitis TERMINATED NCT01475253
Lidocaine Releasing Intravesical System - LiRIS® Other Phase PHASE2 Interstitial Cystitis TERMINATED NCT01475253
bimatoprost/timolol Other Preclinical Glaucoma, Open-Angle COMPLETED NCT01976624
bimatoprost vehicle Other Phase PHASE3 Glaucoma TERMINATED NCT01426113
timolol ophthalmic solution Other Phase PHASE3 Glaucoma TERMINATED NCT01426113
bimatoprost ophthalmic solution formulation A Other Phase PHASE3 Glaucoma TERMINATED NCT01426113
Normal saline (Placebo); botulinum toxin Type A (300U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00461292
Normal saline (Placebo); botulinum toxin Type A (200U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00461292
botulinum toxin Type A (300U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00461292
botulinum toxin Type A (200U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00461292
Normal saline (placebo) Other Phase PHASE4 Chronic Migraine COMPLETED NCT01833130
OnabotulinumtoxinA Other Phase PHASE4 Chronic Migraine COMPLETED NCT01833130
Bimatoprost 0.01% Other Preclinical Glaucoma, Primary Open Angle COMPLETED NCT01814761
No Intervention Other Preclinical Muscle Spasticity WITHDRAWN NCT02145650
No Intervention Other Preclinical Muscle Spasticity WITHDRAWN NCT02145650
Juvéderm® VOLUMA XC Other Approved Mid-facial Volume Deficit Related to Aging COMPLETED NCT00978042
Juvéderm® VOLUMA XC Other Approved Mid-facial Volume Deficit Related to Aging COMPLETED NCT00978042
hypromellose 0.3% Other Phase PHASE4 Glaucoma COMPLETED NCT01881126
timolol 0.5% Other Phase PHASE4 Glaucoma COMPLETED NCT01881126
travatan 0.004% Other Phase PHASE4 Glaucoma COMPLETED NCT01881126
bimatoprost 0.01% Other Phase PHASE4 Glaucoma COMPLETED NCT01881126
hypromellose 0.3% Other Phase PHASE4 Glaucoma COMPLETED NCT01881126
timolol 0.5% Other Phase PHASE4 Glaucoma COMPLETED NCT01881126
travatan 0.004% Other Phase PHASE4 Glaucoma COMPLETED NCT01881126
bimatoprost 0.01% Other Phase PHASE4 Glaucoma COMPLETED NCT01881126
Bevacizumab Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT02036424
Ozurdex Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT02036424
Bevacizumab Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT02036424
Ozurdex Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT02036424
AGN-199201 Vehicle Other Phase PHASE2 Presbyopia COMPLETED NCT02197806
AGN-190584 Other Phase PHASE2 Presbyopia COMPLETED NCT02197806
AGN-199201 Other Phase PHASE2 Presbyopia COMPLETED NCT02197806
AGN-199201 Vehicle Other Phase PHASE2 Presbyopia COMPLETED NCT02197806
AGN-190584 Other Phase PHASE2 Presbyopia COMPLETED NCT02197806
AGN-199201 Other Phase PHASE2 Presbyopia COMPLETED NCT02197806
No intervention Other Preclinical Dry Eye Syndromes COMPLETED NCT01882413
No intervention Other Preclinical Dry Eye Syndromes COMPLETED NCT01882413
Normal Saline (Placebo); botulinum toxin Type A (300U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00311376
Normal Saline (Placebo); botulinum toxin Type A (200U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00311376
botulinum toxin Type A (300U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00311376
botulinum toxin Type A (200U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00311376
Normal Saline (Placebo); botulinum toxin Type A (300U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00311376
Normal Saline (Placebo); botulinum toxin Type A (200U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00311376
botulinum toxin Type A (300U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00311376
botulinum toxin Type A (200U) Other Phase PHASE3 Overactive Bladder COMPLETED NCT00311376
LiRIS® 400 mg Other Phase PHASE1 Chronic Interstitial Cystitis COMPLETED NCT01879683
LiRIS® 400 mg Other Phase PHASE1 Chronic Interstitial Cystitis COMPLETED NCT01879683
Ozurdex Other Approved Epiretinal Membrane UNKNOWN NCT01701518
Normal Saline Other Phase PHASE2 Cervical Dystonia COMPLETED NCT00564681
botulinum toxin type A Formulation 2 Other Phase PHASE2 Cervical Dystonia COMPLETED NCT00564681
botulinum toxin type A Other Phase PHASE2 Cervical Dystonia COMPLETED NCT00564681
No Intervention Other Preclinical Cervical Dystonia COMPLETED NCT02245958
hypromellose 0.3% Other Phase PHASE4 Glaucoma COMPLETED NCT02097719
timolol 0.5% Other Phase PHASE4 Glaucoma COMPLETED NCT02097719
travoprost 0.004% Other Phase PHASE4 Glaucoma COMPLETED NCT02097719
bimatoprost 0.01% Other Phase PHASE4 Glaucoma COMPLETED NCT02097719
hypromellose 0.3% Other Phase PHASE4 Glaucoma COMPLETED NCT02097719
timolol 0.5% Other Phase PHASE4 Glaucoma COMPLETED NCT02097719
travoprost 0.004% Other Phase PHASE4 Glaucoma COMPLETED NCT02097719
bimatoprost 0.01% Other Phase PHASE4 Glaucoma COMPLETED NCT02097719
Placebo Other Phase PHASE1 Healthy COMPLETED NCT01856556
NRX-1074 Other Phase PHASE1 Healthy COMPLETED NCT01856556
Placebo Other Phase PHASE1 Healthy COMPLETED NCT01856556
NRX-1074 Other Phase PHASE1 Healthy COMPLETED NCT01856556
LiRIS Placebo Other Phase PHASE2 Interstitial Cystitis TERMINATED NCT01824303
LiRIS 400 mg Other Phase PHASE2 Interstitial Cystitis TERMINATED NCT01824303
No intervention Other Preclinical Dry Eye Syndromes COMPLETED NCT02252744
NRX-1074 750 mg Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT02366364
NRX-1074 500 mg Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT02366364
NRX-1074 375 mg Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT02366364
Placebo Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT02366364
NRX-1074 750 mg Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT02366364
NRX-1074 500 mg Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT02366364
NRX-1074 375 mg Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT02366364
Placebo Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT02366364
placebo Other Phase PHASE2 Neuralgia TERMINATED NCT00533351
AGN201781 Other Phase PHASE2 Neuralgia TERMINATED NCT00533351
Trospium Chloride Other Phase PHASE4 Elderly COMPLETED NCT00863551
Vocal Exercise Other Approved Spasmodic Dysphonia TERMINATED NCT00895063
Cross-linked hyaluronic acid gel Other Approved Mid-face Volume Deficiency COMPLETED NCT01029535
Photographic Review Other Preclinical Healthy Volunteers COMPLETED NCT02417077
Normal Saline Other Phase PHASE3 Lateral Canthal Lines COMPLETED NCT02195687
botulinum toxin Type A Other Phase PHASE3 Lateral Canthal Lines COMPLETED NCT02195687
AGN-229666 Other Phase PHASE3 Conjunctivitis, Allergic COMPLETED NCT02082262
dexamethasone intravitreal implant Other Preclinical Macular Edema COMPLETED NCT01618266
dexamethasone intravitreal implant Other Preclinical Macular Edema COMPLETED NCT01618266
No Intervention Other Preclinical Migraine Disorders COMPLETED NCT01946126
No Intervention Other Preclinical Migraine Disorders COMPLETED NCT01946126
NRX-1074 10 mg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT02067793
NRX-1074 5 mg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT02067793
Placebo Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT02067793
NRX-1074 1 mg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT02067793
NRX-1074 10 mg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT02067793
NRX-1074 5 mg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT02067793
Placebo Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT02067793
NRX-1074 1 mg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT02067793
Placebo Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT01684163
GLYX-13 10 mg/kg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT01684163
GLYX-13 5 mg/kg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT01684163
Placebo Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT01684163
GLYX-13 10 mg/kg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT01684163
GLYX-13 5 mg/kg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT01684163
Bimatoprost Vehicle Other Phase PHASE2 Alopecia COMPLETED NCT01904721
Bimatoprost Solution 2 Other Phase PHASE2 Alopecia COMPLETED NCT01904721
Bimatoprost Solution 1 Other Phase PHASE2 Alopecia COMPLETED NCT01904721
injection of botulinum toxin type A. Other Phase PHASE1 Psoriasis Vulgaris COMPLETED NCT00816517
AGN-223575 Vehicle Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02155543
AGN-223575 Formulation C Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02155543
AGN-223575 Formulation B Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02155543
AGN-223575 Formulation A Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02155543
botulinum toxin Type A Other Preclinical Urinary Incontinence COMPLETED NCT02161159
Tafluprost Unit Dose Preservative Free 15microgram/ml Other Phase PHASE4 Ocular Hypertension UNKNOWN NCT02471105
Preserved Bimatoprost 0.01% Other Phase PHASE4 Ocular Hypertension UNKNOWN NCT02471105
sham procedure Procedure Phase PHASE2 Macular Degeneration COMPLETED NCT02181517
ranibizumab Other Phase PHASE2 Macular Degeneration COMPLETED NCT02181517
abicipar pegol Other Phase PHASE2 Macular Degeneration COMPLETED NCT02181517
Systematic Screening and Education Regimen Other Phase PHASE4 Multiple Sclerosis COMPLETED NCT01930799
Systematic Screening and Education Regimen Other Phase PHASE4 Multiple Sclerosis COMPLETED NCT01930799
dexamethasone 700 ㎍ intravitreal implant Other Preclinical Macular Edema COMPLETED NCT02188173
ABT-122 Other Phase PHASE2 Psoriatic Arthritis TERMINATED NCT02429895
Botulinum toxin serotype A Other Phase PHASE4 Cervicobrachial Neuralgia COMPLETED NCT00241215
Plicated-LAGB Other Approved Morbid Obesity TERMINATED NCT01564732
Standard-LAGB Other Approved Morbid Obesity TERMINATED NCT01564732
AGN-232411 Vehicle Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02420730
AGN-232411 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02420730
Botulinum Toxin Type A Other Phase PHASE4 Urinary Incontinence COMPLETED NCT02601287
Botulinum Toxin Type A Other Phase PHASE4 Urinary Incontinence COMPLETED NCT02601287
Dexamethasone Intravitreal Implant Other Approved Epiretinal Membrane TERMINATED NCT01410201
onabotulinumtoxinA Other Phase PHASE4 Chronic Migraine COMPLETED NCT02037425
4mg triamcinolone acetonide Other Phase PHASE3 Diabetic Macular Edema COMPLETED NCT00367133
1mg triamcinolone acetonide Other Phase PHASE3 Diabetic Macular Edema COMPLETED NCT00367133
Standard of Care Group Other Phase PHASE3 Diabetic Macular Edema COMPLETED NCT00367133
onabotulinumtoxinA Other Preclinical Urinary Bladder, Overactive COMPLETED NCT02557971
BIOCELL™ Textured 410 Implant Other Preclinical Breast Implantation COMPLETED NCT02132572
botulinum toxin Type A Other Preclinical Urinary Incontinence COMPLETED NCT02010788
botulinum toxin Type A Other Preclinical Urinary Incontinence COMPLETED NCT02010788
Normal Saline Other Phase PHASE3 Muscle Spasticity COMPLETED NCT01575054
botulinum toxin Type A Other Phase PHASE3 Muscle Spasticity COMPLETED NCT01575054
VYC-12 HA injectable gel Other Phase PHASE4 Skin Roughness COMPLETED NCT02877069
botulinum toxin Type A Other Preclinical Urinary Bladder, Overactive COMPLETED NCT02673047
Bimatoprost 1% Formulation B Other Phase PHASE1 Androgenetic Alopecia COMPLETED NCT02848300
Bimatoprost 1% Formulation A Other Phase PHASE1 Androgenetic Alopecia COMPLETED NCT02848300
OnabotulinumtoxinA Other Phase PHASE2 New Daily Persistent Headache TERMINATED NCT01920945
OnabotulinumtoxinA Other Phase PHASE2 New Daily Persistent Headache TERMINATED NCT01920945
Endura (artificial tears) Other Approved Glaucoma COMPLETED NCT00405431
Restasis Other Approved Glaucoma COMPLETED NCT00405431
Ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Chronic Hepatitis C Virus WITHDRAWN NCT02806362
Rescue medication Drug Phase PHASE2 Migraine COMPLETED NCT01657370
Placebo Other Phase PHASE2 Migraine COMPLETED NCT01657370
MK-1602 Other Phase PHASE2 Migraine COMPLETED NCT01657370
Placebo Other Phase PHASE3 Bladder Cancer TERMINATED NCT01410565
Apaziquone Other Phase PHASE3 Bladder Cancer TERMINATED NCT01410565
Placebo Other Phase PHASE3 Bladder Cancer TERMINATED NCT01410565
Apaziquone Other Phase PHASE3 Bladder Cancer TERMINATED NCT01410565
Placebo Other Phase PHASE3 Bladder Cancer TERMINATED NCT01410565
Apaziquone Other Phase PHASE3 Bladder Cancer TERMINATED NCT01410565
Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT01217606
bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy) Drug Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT01217606
sterile saline solution Other Phase PHASE3 Scleroderma COMPLETED NCT02165111
Onabotulinumtoxin A Other Phase PHASE3 Scleroderma COMPLETED NCT02165111
sterile saline solution Other Phase PHASE3 Scleroderma COMPLETED NCT02165111
Onabotulinumtoxin A Other Phase PHASE3 Scleroderma COMPLETED NCT02165111
Genteal® Lubricant Gel Drops Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT02455050
Systane® Gel Drops Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT02455050
Carboxymethylcellulose Sodium Based Eye Drops Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT02455050
onabotulinumtoxinA Other Phase PHASE4 Migraine Disorders COMPLETED NCT01516892
Intravenous Paricalcitol Other Phase PHASE4 Endstage Renal Disease UNKNOWN NCT03023748
duvelisib Other Phase PHASE1 Lymphoma COMPLETED NCT02598570
duvelisib Other Phase PHASE1 Lymphoma COMPLETED NCT02598570
Cystoscopic injection of Botox into the urinary bladder Other Phase PHASE4 Parkinson's Disease COMPLETED NCT01421719
vehicle Other Phase PHASE2 Brittle Nail Syndrome COMPLETED NCT01064830
topical cyclosporine ophthalmic suspension 0.05% Other Phase PHASE2 Brittle Nail Syndrome COMPLETED NCT01064830
Bimatoprost Other Phase PHASE1 Alopecia TERMINATED NCT02676310
OnabotulinumtoxinA Other Preclinical Torticollis COMPLETED NCT01655862
OnabotulinumtoxinA Other Preclinical Torticollis COMPLETED NCT01655862
Steroid plus NSAID eye drop combination therapy Drug Phase PHASE2 Macular Edema COMPLETED NCT01673191
Dexamethasone intravitreal implant Other Phase PHASE2 Macular Edema COMPLETED NCT01673191
Steroid plus NSAID eye drop combination therapy Drug Phase PHASE2 Macular Edema COMPLETED NCT01673191
Dexamethasone intravitreal implant Other Phase PHASE2 Macular Edema COMPLETED NCT01673191
placebo (normal saline) Other Phase PHASE3 Muscle Spasticity TERMINATED NCT02145676
onabotulinumtoxinA Other Phase PHASE3 Muscle Spasticity TERMINATED NCT02145676
sham procedure Procedure Phase PHASE2 Macular Degeneration COMPLETED NCT02181504
ranibizumab Other Phase PHASE2 Macular Degeneration COMPLETED NCT02181504
abicipar pegol Other Phase PHASE2 Macular Degeneration COMPLETED NCT02181504
sham procedure Procedure Phase PHASE2 Macular Degeneration COMPLETED NCT02181504
ranibizumab Other Phase PHASE2 Macular Degeneration COMPLETED NCT02181504
abicipar pegol Other Phase PHASE2 Macular Degeneration COMPLETED NCT02181504
Saline Other Phase PHASE1 Pruritus COMPLETED NCT02639052
Botox Other Phase PHASE1 Pruritus COMPLETED NCT02639052
Placebo Other Phase PHASE3 Crohn's Disease WITHDRAWN NCT01674413
Adalimumab PRN Other Phase PHASE3 Crohn's Disease WITHDRAWN NCT01674413
Adalimumab Other Phase PHASE3 Crohn's Disease WITHDRAWN NCT01674413
Placebo Other Phase PHASE3 Crohn's Disease WITHDRAWN NCT01674413
Adalimumab PRN Other Phase PHASE3 Crohn's Disease WITHDRAWN NCT01674413
Adalimumab Other Phase PHASE3 Crohn's Disease WITHDRAWN NCT01674413
Placebo Other Phase PHASE3 Crohn's Disease WITHDRAWN NCT01674413
Adalimumab PRN Other Phase PHASE3 Crohn's Disease WITHDRAWN NCT01674413
Adalimumab Other Phase PHASE3 Crohn's Disease WITHDRAWN NCT01674413
Normal Saline Other Phase PHASE2 Osteoarthritis COMPLETED NCT02230956
onabotulinumtoxinA Other Phase PHASE2 Osteoarthritis COMPLETED NCT02230956
Normal Saline Other Phase PHASE2 Osteoarthritis COMPLETED NCT02230956
onabotulinumtoxinA Other Phase PHASE2 Osteoarthritis COMPLETED NCT02230956
Ozurdex Other Phase PHASE3 Retinal Vein Occlusion COMPLETED NCT01449682
Ozurdex Other Phase PHASE3 Retinal Vein Occlusion COMPLETED NCT01449682
Cyclosporine 0.05% Ophthalmic Emulsion Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT02554981
AqueSys XEN 45 Glaucoma Implant Other Approved Glaucoma COMPLETED NCT02036541
Refresh Tears Lubricant Eye Drops (Allergan) Other Phase PHASE4 Glaucoma COMPLETED NCT01682460
botulinum toxin Type A Other Phase PHASE3 Migraine Disorders WITHDRAWN NCT03193359
placebo (sodium chloride 0.9 mg) Other Phase PHASE3 Migraine Disorders WITHDRAWN NCT03193346
botulinum toxin Type A Other Phase PHASE3 Migraine Disorders WITHDRAWN NCT03193346
placebo (sodium chloride 0.9 mg) Other Phase PHASE3 Migraine Disorders WITHDRAWN NCT03193346
botulinum toxin Type A Other Phase PHASE3 Migraine Disorders WITHDRAWN NCT03193346
Normal Saline Other Phase PHASE3 Facial Rhytides COMPLETED NCT02261493
OnabotulinumtoxinA Other Phase PHASE3 Facial Rhytides COMPLETED NCT02261493
Co-Latanoprost Other Phase PHASE4 POAG UNKNOWN NCT02792803
Apo-Latanoprost Other Phase PHASE4 POAG UNKNOWN NCT02792803
Xalatan Other Phase PHASE4 POAG UNKNOWN NCT02792803
Co-Latanoprost Other Phase PHASE4 POAG UNKNOWN NCT02792803
Apo-Latanoprost Other Phase PHASE4 POAG UNKNOWN NCT02792803
Xalatan Other Phase PHASE4 POAG UNKNOWN NCT02792803
Triamcinolone Other Phase PHASE4 Fat Reduction COMPLETED NCT03241563
Sodium Deoxycholate Other Phase PHASE4 Fat Reduction COMPLETED NCT03241563
Positron emission tomography (PET) Other Phase PHASE2 Alzheimer's Disease WITHDRAWN NCT02860065
CPC-201 Other Phase PHASE2 Alzheimer's Disease WITHDRAWN NCT02860065
Positron emission tomography (PET) Other Phase PHASE2 Alzheimer's Disease WITHDRAWN NCT02860065
CPC-201 Other Phase PHASE2 Alzheimer's Disease WITHDRAWN NCT02860065
Positron emission tomography (PET) Other Phase PHASE2 Alzheimer's Disease WITHDRAWN NCT02860065
CPC-201 Other Phase PHASE2 Alzheimer's Disease WITHDRAWN NCT02860065
Restylane® Other Approved Nasolabial Fold COMPLETED NCT02558283
JUVÉDERM® VOLIFT® with Lidocaine Other Approved Nasolabial Fold COMPLETED NCT02558283
Placebo (Normal Saline) Other Phase PHASE3 Migraine Disorders COMPLETED NCT01662492
Botulinum toxin type A Dose 2 Other Phase PHASE3 Migraine Disorders COMPLETED NCT01662492
Botulinum toxin type A Dose 1 Other Phase PHASE3 Migraine Disorders COMPLETED NCT01662492
AGN-195263 Vehicle Other Phase PHASE2 Meibomian Gland Dysfunction COMPLETED NCT01633788
AGN-195263 0.01% Other Phase PHASE2 Meibomian Gland Dysfunction COMPLETED NCT01633788
AGN-195263 0.03% Other Phase PHASE2 Meibomian Gland Dysfunction COMPLETED NCT01633788
AGN-195263 0.1% Other Phase PHASE2 Meibomian Gland Dysfunction COMPLETED NCT01633788
ABT-493/ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02446717
ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02446717
ABT-493, ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02446717
ABT-493/ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02446717
ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02446717
ABT-493, ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02446717
CPC-201 Other Phase PHASE2 Dementia of the Alzheimer's Type COMPLETED NCT02434666
CPC-201 Other Phase PHASE2 Dementia of the Alzheimer's Type COMPLETED NCT02434666
Placebo Other Phase PHASE2 Carpal Tunnel Syndrome COMPLETED NCT02070302
Botulinum Toxin Type A Other Phase PHASE2 Carpal Tunnel Syndrome COMPLETED NCT02070302
Placebo Other Phase PHASE3 Patellofemoral Pain Syndrome TERMINATED NCT00496964
Botulinum toxin A + exercise Other Phase PHASE3 Patellofemoral Pain Syndrome TERMINATED NCT00496964
Normal saline Other Phase PHASE4 Overactive Bladder COMPLETED NCT01945489
onabotulinumtoxinA Other Phase PHASE4 Overactive Bladder COMPLETED NCT01945489
amblyopia therapy Drug Preclinical Amblyopia COMPLETED NCT03341780
Study Photography + Personal & Medical History Collection Other Preclinical Loss of Facial Adipose Tissue UNKNOWN NCT03347747
Study Photography + Personal & Medical History Collection Other Preclinical Loss of Facial Adipose Tissue UNKNOWN NCT03347747
paclitaxel Other Phase PHASE1 Ovarian Cancer COMPLETED NCT02483104
carboplatin Other Phase PHASE1 Ovarian Cancer COMPLETED NCT02483104
veliparib Other Phase PHASE1 Ovarian Cancer COMPLETED NCT02483104
paclitaxel Other Phase PHASE1 Ovarian Cancer COMPLETED NCT02483104
carboplatin Other Phase PHASE1 Ovarian Cancer COMPLETED NCT02483104
veliparib Other Phase PHASE1 Ovarian Cancer COMPLETED NCT02483104
paclitaxel Other Phase PHASE1 Ovarian Cancer COMPLETED NCT02483104
carboplatin Other Phase PHASE1 Ovarian Cancer COMPLETED NCT02483104
veliparib Other Phase PHASE1 Ovarian Cancer COMPLETED NCT02483104
Veliparib Other Phase PHASE1 Oncology COMPLETED NCT01853306
Veliparib Other Phase PHASE1 Oncology COMPLETED NCT01853306
Whole Brain Radiation Other Phase PHASE1 Glioblastoma Multiforme COMPLETED NCT01800695
Temozolomide Other Phase PHASE1 Glioblastoma Multiforme COMPLETED NCT01800695
ABT-414 Other Phase PHASE1 Glioblastoma Multiforme COMPLETED NCT01800695
Levodopa-Carbidopa Other Phase PHASE1 Parkinson Disease COMPLETED NCT01484990
Levodopa-Carbidopa Other Phase PHASE1 Parkinson Disease COMPLETED NCT01484990
erlotinib Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01472016
cetuximab Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01472016
FOLFIRI Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01472016
docetaxel Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01472016
ABT-700 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01472016
linifanib Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01413893
new texture shaped breast implants Other Phase PHASE4 Breast Augmentation COMPLETED NCT01639755
new texture shaped breast implants Other Phase PHASE4 Breast Augmentation COMPLETED NCT01639755
New texture round breast implants Other Approved Breast Augmentation COMPLETED NCT01639742
New texture round breast implants Other Approved Breast Augmentation COMPLETED NCT01639742
Hyaluronic Acid Injectable Gel Other Approved Chin Retrusion COMPLETED NCT02559908
Hyaluronic Acid Injectable Gel Other Approved Chin Retrusion COMPLETED NCT02559908
botulinum toxin Type A Other Preclinical Urinary Incontinence COMPLETED NCT02072928
Placebo Other Phase PHASE3 Bladder Cancer TERMINATED NCT01469221
Apaziquone Other Phase PHASE3 Bladder Cancer TERMINATED NCT01469221
Placebo Other Phase PHASE3 Bladder Cancer TERMINATED NCT01469221
Apaziquone Other Phase PHASE3 Bladder Cancer TERMINATED NCT01469221
3D Imaging Other Approved Hypomastia COMPLETED NCT01964105
LiRIS Placebo Other Phase PHASE2 Cystitis, Interstitial COMPLETED NCT02411110
LiRIS® Other Phase PHASE2 Cystitis, Interstitial COMPLETED NCT02411110
intra-rectal Botulinum toxin A injection Other Phase PHASE2 Low Anterior Resection Syndrome COMPLETED NCT01589471
Seri Surgical Scaffold Other Approved Recurrent Ptosis of the Breast COMPLETED NCT02016612
Seri Surgical Scaffold Other Approved Recurrent Ptosis of the Breast COMPLETED NCT02016612
Dry eye exam Other Preclinical Dry Eye Syndromes COMPLETED NCT01826812
30 minutes sustained reading Other Preclinical Dry Eye Syndromes COMPLETED NCT01826812
Dry eye exam Other Preclinical Dry Eye Syndromes COMPLETED NCT01826812
30 minutes sustained reading Other Preclinical Dry Eye Syndromes COMPLETED NCT01826812
Palivizumab Other Phase PHASE3 Respiratory Syncytial Virus (RSV) COMPLETED NCT02968173
Palivizumab Other Phase PHASE3 Respiratory Syncytial Virus (RSV) COMPLETED NCT02968173
Palivizumab Other Phase PHASE3 Respiratory Syncytial Virus (RSV) COMPLETED NCT02968173
Methotrexate Other Phase PHASE3 Psoriasis COMPLETED NCT02196701
Adalimumab Other Phase PHASE3 Psoriasis COMPLETED NCT02196701
Methotrexate Other Phase PHASE3 Psoriasis COMPLETED NCT02196701
Adalimumab Other Phase PHASE3 Psoriasis COMPLETED NCT02196701
isolated 0.3% gatifloxacin and 1.0% prednisolone acetate Other Phase PHASE3 Ocular Infection and Inflammation COMPLETED NCT01218737
0.3% gatifloxacin and 1.0% prednisolone acetate association Other Phase PHASE3 Ocular Infection and Inflammation COMPLETED NCT01218737
Valsartan 80 mg Other Phase PHASE4 Hypertension Complicated COMPLETED NCT03180593
Valsartan 80 mg Other Phase PHASE4 Hypertension Complicated COMPLETED NCT03180593
Valsartan 80 mg Other Phase PHASE4 Hypertension Complicated COMPLETED NCT03180593
Cyclosporine New Ophthalmic Formulation Other Phase PHASE2 Dry Eye Syndromes TERMINATED NCT02013791
Sham Other Phase PHASE2 Dry Eye Syndromes TERMINATED NCT02013791
Vehicle Other Phase PHASE2 Dry Eye Syndromes TERMINATED NCT02013791
Cyclosporine New Ophthalmic Formulation Other Phase PHASE2 Dry Eye Syndromes TERMINATED NCT02013791
Sham Other Phase PHASE2 Dry Eye Syndromes TERMINATED NCT02013791
Vehicle Other Phase PHASE2 Dry Eye Syndromes TERMINATED NCT02013791
Ozurdex Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT01613716
Revolve System Other Approved Autologous Fat Grafting UNKNOWN NCT03544593
Revolve System Other Approved Autologous Fat Grafting UNKNOWN NCT03544593
Pegylated Interferon alpha 2-a (PegIFN) Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01854697
Telaprevir Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01854697
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01854697
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01854697
Telaprevir Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01854528
Pegylated Interferon a-2a (PegINF) Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01854528
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01854528
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01854528
Topiramate Other Phase PHASE4 Migraine Disorders COMPLETED NCT02191579
onabotulinumtoxinA Other Phase PHASE4 Migraine Disorders COMPLETED NCT02191579
bimatoprost 0.03% plus timolol 0.5% Other Phase PHASE4 Glaucoma, Open-Angle COMPLETED NCT02571712
Bimatoprost cutaneous solution 0.03% Other Preclinical Eyelash Hypotrichosis COMPLETED NCT02505776
Normal Saline (Placebo) Other Phase PHASE3 Pediatrics COMPLETED NCT01603602
botulinum toxin Type A Other Phase PHASE3 Pediatrics COMPLETED NCT01603602
Lucentis Other Phase PHASE4 Diabetic Macular Edema TERMINATED NCT02684084
Ozurdex Other Phase PHASE4 Diabetic Macular Edema TERMINATED NCT02684084
Sham (no implant) Other Phase PHASE2 Macular Degeneration COMPLETED NCT00658619
200 µg Brimonidine Tartrate Implant Other Phase PHASE2 Macular Degeneration COMPLETED NCT00658619
400 µg Brimonidine Tartrate Implant Other Phase PHASE2 Macular Degeneration COMPLETED NCT00658619
bimatoprost ophthalmic solution 0.01% Other Phase PHASE4 Glaucoma, Open-Angle COMPLETED NCT02863705
brimonidine tartrate/timolol malate Ophthalmic Solution Other Phase PHASE4 Glaucoma, Open-Angle COMPLETED NCT02863705
injections on posterior bladder wall excluding the trigone Other Phase PHASE4 Interstitial Cystitis COMPLETED NCT02297100
injections upper aspect of trigone of urinary bladder Other Phase PHASE4 Interstitial Cystitis COMPLETED NCT02297100
Onabotulinumtoxin A Other Phase PHASE4 Interstitial Cystitis COMPLETED NCT02297100
Normal saline injection Other Phase PHASE2 Chronic Testicular Pain COMPLETED NCT02058836
Botox Injection Other Phase PHASE2 Chronic Testicular Pain COMPLETED NCT02058836
Saline Other Approved Muscle Strength COMPLETED NCT00822523
Botulinum Toxin, Type A Other Approved Muscle Strength COMPLETED NCT00822523
Marvel AM Other Approved Blue Light Damage COMPLETED NCT03594721
Marvel AM Other Approved Blue Light Damage COMPLETED NCT03594721
bimatoprost 0.03% ophthalmic solution Other Phase PHASE4 Glaucoma COMPLETED NCT01298700
bimatoprost 0.01% ophthalmic solution Other Phase PHASE4 Glaucoma COMPLETED NCT01298700
Placebo Other Preclinical Subcutaneous Fat COMPLETED NCT03682471
Deoxycholic acid Injection Other Preclinical Subcutaneous Fat COMPLETED NCT03682471
Botox Other Phase PHASE2 Hypertrophic Scar UNKNOWN NCT03631368
Botox Other Phase PHASE2 Hypertrophic Scar UNKNOWN NCT03631368
Standard of Care Other Phase PHASE2 Osteomyelitis TERMINATED NCT03091439
Dalbavancin Other Phase PHASE2 Osteomyelitis TERMINATED NCT03091439
Standard of Care Other Phase PHASE2 Osteomyelitis TERMINATED NCT03091439
Dalbavancin Other Phase PHASE2 Osteomyelitis TERMINATED NCT03091439
Botulinum Toxin Type A Other Approved Migraine Headache TERMINATED NCT00850421
Botulinum Toxin Type A Other Approved Migraine Headache TERMINATED NCT00850421
LiRIS Placebo Other Phase PHASE2 Cystitis, Interstitial COMPLETED NCT02395042
LiRIS® Other Phase PHASE2 Cystitis, Interstitial COMPLETED NCT02395042
Teleneurological Examination Other Preclinical Spasticity, Muscle COMPLETED NCT03211390
Neurological Examination Other Preclinical Spasticity, Muscle COMPLETED NCT03211390
ribavirin Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) COMPLETED NCT02517528
ABT-333 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) COMPLETED NCT02517528
ABT-450/r/ABT-267 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) COMPLETED NCT02517528
Juvéderm® VOLUMA XC Other Approved Temple Hollowing TERMINATED NCT03166618
Normal Saline Other Phase PHASE2 Premature Ejaculation TERMINATED NCT01917006
OnabotulinumtoxinA Other Phase PHASE2 Premature Ejaculation TERMINATED NCT01917006
Simbrinza Three Times Daily (TID) Other Phase PHASE4 Glaucoma COMPLETED NCT02167035
Combigan Two Times Daily (BID) Other Phase PHASE4 Glaucoma COMPLETED NCT02167035
VTP-43742 Other Phase PHASE1 Psoriasis COMPLETED NCT03724292
Placebo Other Phase PHASE1 Psoriasis COMPLETED NCT03724292
VTP-43742 Other Phase PHASE1 Psoriasis COMPLETED NCT03724292
Placebo Other Phase PHASE1 Psoriasis COMPLETED NCT03724292
VTP-43742 Other Phase PHASE1 Psoriasis COMPLETED NCT03724292
Placebo Other Phase PHASE1 Psoriasis COMPLETED NCT03724292
Placebo 2 Other Phase PHASE1 Psoriasis COMPLETED NCT02555709
Placebo 1 Other Phase PHASE1 Psoriasis COMPLETED NCT02555709
VTP-43742 Other Phase PHASE1 Psoriasis COMPLETED NCT02555709
Placebo 2 Other Phase PHASE1 Psoriasis COMPLETED NCT02555709
Placebo 1 Other Phase PHASE1 Psoriasis COMPLETED NCT02555709
VTP-43742 Other Phase PHASE1 Psoriasis COMPLETED NCT02555709
Abicipar pegol Other Phase PHASE1 Macular Degeneration COMPLETED NCT03335852
botulinum toxin Type A Other Preclinical Migraine Disorders COMPLETED NCT01686581
Ozurdex (dexamethasone) Other Phase PHASE2 Diabetes COMPLETED NCT01787669
Avastin (Bevacizumab) Other Phase PHASE2 Diabetes COMPLETED NCT01787669
Vehicle Other Phase PHASE3 Dry Eye Syndromes TERMINATED NCT02965846
AGN-195263 Other Phase PHASE3 Dry Eye Syndromes TERMINATED NCT02965846
Placebo-matching Atogepant Other Phase PHASE2 Migraine, With or Without Aura COMPLETED NCT02848326
Atogepant Other Phase PHASE2 Migraine, With or Without Aura COMPLETED NCT02848326
SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen Other Approved Melasma COMPLETED NCT02977507
SkinMedica Rejuvenative Moisturizer Other Approved Melasma COMPLETED NCT02977507
SkinMedica Facial Cleanser Other Approved Melasma COMPLETED NCT02977507
4% Hydroquinone Topical Cream Other Approved Melasma COMPLETED NCT02977507
Lytera 2.0 Other Approved Melasma COMPLETED NCT02977507
Placebo-matching Ubrogepant Other Phase PHASE3 Migraine, With or Without Aura COMPLETED NCT02828020
Ubrogepant Other Phase PHASE3 Migraine, With or Without Aura COMPLETED NCT02828020
Placebo-matching Ubrogepant Other Phase PHASE3 Migraine, With or Without Aura COMPLETED NCT02828020
Ubrogepant Other Phase PHASE3 Migraine, With or Without Aura COMPLETED NCT02828020
Rescue medication Drug Phase PHASE2 Migraine COMPLETED NCT01613248
Placebo-matching MK-1602 Other Phase PHASE2 Migraine COMPLETED NCT01613248
MK-1602 Other Phase PHASE2 Migraine COMPLETED NCT01613248
botulinum toxin Type A Other Preclinical Migraine Disorders COMPLETED NCT01432379
JUVÉDERM® VOLUMA® XC Other Phase PHASE4 Facial Rhytides COMPLETED NCT02176356
JUVÉDERM® ULTRA PLUS XC Other Phase PHASE4 Facial Rhytides COMPLETED NCT02176356
JUVÉDERM® ULTRA XC Other Phase PHASE4 Facial Rhytides COMPLETED NCT02176356
bimatoprost ophthalmic solution 0.03% Other Phase PHASE4 Facial Rhytides COMPLETED NCT02176356
onabotulinumtoxinA Other Phase PHASE4 Facial Rhytides COMPLETED NCT02176356
JUVÉDERM® VOLUMA® XC Other Phase PHASE4 Facial Rhytides COMPLETED NCT02176356
JUVÉDERM® ULTRA PLUS XC Other Phase PHASE4 Facial Rhytides COMPLETED NCT02176356
JUVÉDERM® ULTRA XC Other Phase PHASE4 Facial Rhytides COMPLETED NCT02176356
bimatoprost ophthalmic solution 0.03% Other Phase PHASE4 Facial Rhytides COMPLETED NCT02176356
onabotulinumtoxinA Other Phase PHASE4 Facial Rhytides COMPLETED NCT02176356
A gel of hyaluronic acid (concentration of 20 mg/mL) Other Phase PHASE4 Nasolabial Folds COMPLETED NCT00850889
Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine Other Phase PHASE4 Nasolabial Folds COMPLETED NCT00850889
A gel of hyaluronic acid (concentration of 20 mg/mL) Other Phase PHASE4 Nasolabial Folds COMPLETED NCT00850889
Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine Other Phase PHASE4 Nasolabial Folds COMPLETED NCT00850889
A gel of hyaluronic acid (concentration of 20 mg/mL) Other Phase PHASE4 Nasolabial Folds COMPLETED NCT00850889
Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine Other Phase PHASE4 Nasolabial Folds COMPLETED NCT00850889
Restylane-L® Other Approved Lip Volume Enhancement COMPLETED NCT01579305
Juvéderm® Volbella with Lidocaine Other Approved Lip Volume Enhancement COMPLETED NCT01579305
Restylane-L® Other Approved Lip Volume Enhancement COMPLETED NCT01579305
Juvéderm® Volbella with Lidocaine Other Approved Lip Volume Enhancement COMPLETED NCT01579305
botulinum toxin type A Other Phase PHASE4 Glabellar Lines COMPLETED NCT01271452
bimatoprost 0.03% Other Phase PHASE4 Eyelash Hypotrichosis COMPLETED NCT01229423
botulinum toxin Type A Other Phase PHASE4 Skin Aging COMPLETED NCT00856414
on-label facial injection Other Approved Facial Photodamage COMPLETED NCT03559972
on-label facial injection Other Approved Facial Photodamage COMPLETED NCT03559972
onabotulinumtoxinA Other Preclinical Muscle Spasticity COMPLETED NCT01930786
Placebo Other Phase PHASE4 Irritable Bowel Syndrome With Diarrhea COMPLETED NCT02959983
Eluxadoline Other Phase PHASE4 Irritable Bowel Syndrome With Diarrhea COMPLETED NCT02959983
Placebo Other Phase PHASE4 Irritable Bowel Syndrome With Diarrhea COMPLETED NCT02959983
Eluxadoline Other Phase PHASE4 Irritable Bowel Syndrome With Diarrhea COMPLETED NCT02959983
Intravitreal anti-VEGF injection Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT02471651
Dexamethasone intravitreal implant (0.7 mg) Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT02471651
0.9% saline solution Other Phase PHASE2 Skin Quality COMPLETED NCT03097835
Topical anesthesia Other Phase PHASE2 Skin Quality COMPLETED NCT03097835
Hyper-Diluted Botox Other Phase PHASE2 Skin Quality COMPLETED NCT03097835
Solifenacin Other Phase PHASE2 Dementia of Alzheimer's Type COMPLETED NCT02549196
Donepezil Other Phase PHASE2 Dementia of Alzheimer's Type COMPLETED NCT02549196
Solifenacin Other Phase PHASE2 Dementia of Alzheimer's Type COMPLETED NCT02549196
Donepezil Other Phase PHASE2 Dementia of Alzheimer's Type COMPLETED NCT02549196
Solifenacin Other Phase PHASE2 Dementia of Alzheimer's Type COMPLETED NCT02549196
Donepezil Other Phase PHASE2 Dementia of Alzheimer's Type COMPLETED NCT02549196
Ribavirin Other Preclinical Chronic Hepatitis C COMPLETED NCT02725866
Dasabuvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02725866
Paritaprevir/ritonavir/ombitasvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02725866
Ribavirin Other Preclinical Chronic Hepatitis C COMPLETED NCT02725866
Dasabuvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02725866
Paritaprevir/ritonavir/ombitasvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02725866
Ribavirin Other Preclinical Chronic Hepatitis C COMPLETED NCT02725866
Dasabuvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02725866
Paritaprevir/ritonavir/ombitasvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02725866
Placebo-matching Ubrogepant Other Phase PHASE3 Migraine, With or Without Aura COMPLETED NCT02867709
Ubrogepant Other Phase PHASE3 Migraine, With or Without Aura COMPLETED NCT02867709
Botox Other Phase PHASE1 Prostatitis TERMINATED NCT00529386
Botox Other Phase PHASE1 Prostatitis TERMINATED NCT00529386
AGN-223575 vehicle ophthalmic solution Other Phase PHASE2 Dry Eye Syndromes COMPLETED NCT02435914
AGN-223575 ophthalmic solution Other Phase PHASE2 Dry Eye Syndromes COMPLETED NCT02435914
VOLBELLA® with lidocaine Other Approved Infra-orbital Skin Depressions COMPLETED NCT02176421
carboxymethylcellulose sodium based eye drops Other Phase PHASE3 Bilateral LASIK Surgery COMPLETED NCT01886690
carboxymethylcellulose sodium based new eye drop formulation Other Phase PHASE3 Bilateral LASIK Surgery COMPLETED NCT01886690
carboxymethylcellulose sodium based eye drop solution Other Phase PHASE3 Contact Lens Lubrication COMPLETED NCT01844388
carboxymethylcellulose based eye drop formula Other Phase PHASE3 Contact Lens Lubrication COMPLETED NCT01844388
Normal Saline Other Phase PHASE3 Lateral Canthus Rhytides COMPLETED NCT01797081
botulinum toxin Type A (12 U) Other Phase PHASE3 Lateral Canthus Rhytides COMPLETED NCT01797081
botulinum toxin Type A (24 U) Other Phase PHASE3 Lateral Canthus Rhytides COMPLETED NCT01797081
Crosslinked hyaluronic acid dermal filler Other Approved Moderate to Severe Nasolabial Folds COMPLETED NCT01680497
bimatoprost 0.03% Other Preclinical Eyelash Hypotrichosis COMPLETED NCT01623479
bimatoprost 0.03% Other Preclinical Eyelash Hypotrichosis COMPLETED NCT01623479
botulinum toxin Type A Other Preclinical Glabellar Lines COMPLETED NCT01608672
Carboxymethylcellulose Based Lubricant Eye Drops Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT01459588
Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT01459588
Carboxymethylcellulose Based Eye Drop Formulation B Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT01459588
Carboxymethylcellulose Based Eye Drop Formulation A Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT01459588
Carboxymethylcellulose Based Lubricant Eye Drops Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT01459588
Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT01459588
Carboxymethylcellulose Based Eye Drop Formulation B Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT01459588
Carboxymethylcellulose Based Eye Drop Formulation A Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT01459588
Sham Injection Other Phase PHASE2 Age-related Macular Degeneration COMPLETED NCT01397409
ranibizumab Other Phase PHASE2 Age-related Macular Degeneration COMPLETED NCT01397409
AGN-150998 Other Phase PHASE2 Age-related Macular Degeneration COMPLETED NCT01397409
carboxymethylcellulose sodium based Eye Drops Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT01294384
carboxymethylcellulose sodium based New Eye Drop Formulation 2 Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT01294384
carboxymethylcellulose sodium based New Eye Drop Formulation 1 Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT01294384
hyaluronic acid gel Other Approved Lip Augmentation COMPLETED NCT01197495
hyaluronic acid gel Other Approved Lip Augmentation COMPLETED NCT01197495
normal saline Other Phase PHASE3 Facial Rhytides COMPLETED NCT01189760
onabotulinumtoxinA 44 U Other Phase PHASE3 Facial Rhytides COMPLETED NCT01189760
onabotulinumtoxinA 24 U Other Phase PHASE3 Facial Rhytides COMPLETED NCT01189760
normal saline Other Phase PHASE3 Facial Rhytides COMPLETED NCT01189760
onabotulinumtoxinA 44 U Other Phase PHASE3 Facial Rhytides COMPLETED NCT01189760
onabotulinumtoxinA 24 U Other Phase PHASE3 Facial Rhytides COMPLETED NCT01189760
Olopatadine Other Phase PHASE3 Conjunctivitis, Allergic COMPLETED NCT02161146
Vehicle to AGN-229666 Other Phase PHASE3 Conjunctivitis, Allergic COMPLETED NCT02161146
AGN-229666 Other Phase PHASE3 Conjunctivitis, Allergic COMPLETED NCT02161146
dexamethasone implant Other Phase PHASE4 Macular Edema COMPLETED NCT01903720
dexamethasone implant Other Phase PHASE4 Macular Edema COMPLETED NCT01903720
botulinum toxin Type A Other Phase PHASE4 Glabellar Rhytides COMPLETED NCT01814670
Dexamethasone Intravitreal Implant Other Preclinical Macular Edema COMPLETED NCT01805323
Normal Saline Other Phase PHASE4 Facial Rhytides COMPLETED NCT01777620
onabotulinumtoxinA Other Phase PHASE4 Facial Rhytides COMPLETED NCT01777620
Normal Saline Other Phase PHASE4 Facial Rhytides COMPLETED NCT01777620
onabotulinumtoxinA Other Phase PHASE4 Facial Rhytides COMPLETED NCT01777620
botulinum toxin Type A Other Preclinical Facial Rhytides COMPLETED NCT01608659
ranibizumab Other Phase PHASE2 Macular Edema COMPLETED NCT01492400
dexamethasone Intravitreal Implant Other Phase PHASE2 Macular Edema COMPLETED NCT01492400
ranibizumab Other Phase PHASE2 Macular Edema COMPLETED NCT01492400
dexamethasone Intravitreal Implant Other Phase PHASE2 Macular Edema COMPLETED NCT01492400
Normal Saline Other Approved Facial Rhytides COMPLETED NCT01391299
botulinum toxin Type A Other Approved Facial Rhytides COMPLETED NCT01391299
Normal Saline Other Approved Facial Rhytides COMPLETED NCT01391299
botulinum toxin Type A Other Approved Facial Rhytides COMPLETED NCT01391299
Bimatoprost 0.03% Ophthalmic Solution Other Phase PHASE3 Glaucoma COMPLETED NCT01099774
Bimatoprost 0.03% Formulation B Ophthalmic Solution Other Phase PHASE3 Glaucoma COMPLETED NCT01099774
0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution Other Approved Open-angle Glaucoma COMPLETED NCT01068964
0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Other Approved Open-angle Glaucoma COMPLETED NCT01068964
Vehicle Sterile Solution Other Phase PHASE4 Eyelash Hypotrichosis COMPLETED NCT01023841
bimatoprost ophthalmic solution 0.03% Other Phase PHASE4 Eyelash Hypotrichosis COMPLETED NCT01023841
carboxymethylcellulose-based lubricant eye drops Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT02121847
cyclosporine 0.05% ophthalmic emulsion Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT02121847
carboxymethylcellulose-based lubricant eye drops Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT02121847
cyclosporine 0.05% ophthalmic emulsion Other Phase PHASE4 Dry Eye Syndromes COMPLETED NCT02121847
Bimatoprost 0.03% Other Phase PHASE4 Glaucoma, Open-Angle COMPLETED NCT02061683
Anti-VEGF Other Preclinical Retinal Vein Occlusion COMPLETED NCT01918371
Prostaglandin Analogue -Containing IOP-Lowering Therapy Drug Preclinical Glaucoma, Open-Angle COMPLETED NCT01735214
ranibizumab Other Phase PHASE4 Retinal Vein Occlusion COMPLETED NCT01427751
dexamethasone intravitreal implant Other Phase PHASE4 Retinal Vein Occlusion COMPLETED NCT01427751
latanoprost 0.005% ophthalmic solution Other Phase PHASE4 Glaucoma, Open-Angle COMPLETED NCT01243567
bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution Other Phase PHASE4 Glaucoma, Open-Angle COMPLETED NCT01243567
Bimatoprost Ophthalmic Solution Other Preclinical Glaucoma, Primary Open Angle COMPLETED NCT01853085
dexamethasone 700 ug intravitreal implant Other Preclinical Macular Edema COMPLETED NCT01571557
Sham Other Phase PHASE2 Geographic Atrophy TERMINATED NCT02087085
400 µg Brimonidine Implant Other Phase PHASE2 Geographic Atrophy TERMINATED NCT02087085
Sham Other Phase PHASE2 Geographic Atrophy TERMINATED NCT02087085
400 µg Brimonidine Implant Other Phase PHASE2 Geographic Atrophy TERMINATED NCT02087085
solifenacin placebo Other Phase PHASE3 Overactive Bladder COMPLETED NCT01767519
Botox placebo (normal saline) Other Phase PHASE3 Overactive Bladder COMPLETED NCT01767519
solifenacin Other Phase PHASE3 Overactive Bladder COMPLETED NCT01767519
BOTOX® Other Phase PHASE3 Overactive Bladder COMPLETED NCT01767519
solifenacin placebo Other Phase PHASE3 Overactive Bladder COMPLETED NCT01767519
Botox placebo (normal saline) Other Phase PHASE3 Overactive Bladder COMPLETED NCT01767519
solifenacin Other Phase PHASE3 Overactive Bladder COMPLETED NCT01767519
BOTOX® Other Phase PHASE3 Overactive Bladder COMPLETED NCT01767519
Dexamethasone Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT00799227
Dexamethasone Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT00799227
latanoprost 0.005% Other Phase PHASE4 Glaucoma COMPLETED NCT00735449
timolol maleate 0.5% Other Phase PHASE4 Glaucoma COMPLETED NCT00735449
Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% Other Phase PHASE4 Glaucoma COMPLETED NCT00735449
placebo Other Phase PHASE2 Glaucoma COMPLETED NCT00538304
bimatoprost eye drops Other Phase PHASE2 Glaucoma COMPLETED NCT00538304
placebo Other Phase PHASE2 Glaucoma COMPLETED NCT00538304
bimatoprost eye drops Other Phase PHASE2 Glaucoma COMPLETED NCT00538304
placebo eye drops Other Phase PHASE3 Bacterial Conjunctivitis COMPLETED NCT00518089
Gatifloxacin 0.5% eye drops Other Phase PHASE3 Bacterial Conjunctivitis COMPLETED NCT00518089
placebo eye drops Other Phase PHASE3 Bacterial Conjunctivitis COMPLETED NCT00518089
Gatifloxacin 0.5% eye drops Other Phase PHASE3 Bacterial Conjunctivitis COMPLETED NCT00518089
Sham Injection Other Phase PHASE3 Macular Edema COMPLETED NCT00168324
350 µg Dexamethasone Other Phase PHASE3 Macular Edema COMPLETED NCT00168324
700 µg Dexamethasone Other Phase PHASE3 Macular Edema COMPLETED NCT00168324
Sham Injection Other Phase PHASE3 Macular Edema COMPLETED NCT00168298
350 µg Dexamethasone Other Phase PHASE3 Macular Edema COMPLETED NCT00168298
700 µg Dexamethasone Other Phase PHASE3 Macular Edema COMPLETED NCT00168298
Dapsone 5% Gel Other Phase PHASE1 Acne Vulgaris COMPLETED NCT01773122
Dapsone Formulation C Other Phase PHASE1 Acne Vulgaris COMPLETED NCT01773122
Dapsone Formulation B Other Phase PHASE1 Acne Vulgaris COMPLETED NCT01773122
Dapsone Formulation A Other Phase PHASE1 Acne Vulgaris COMPLETED NCT01773122
Dapsone 5% Gel Other Phase PHASE1 Acne Vulgaris COMPLETED NCT01773122
Dapsone Formulation C Other Phase PHASE1 Acne Vulgaris COMPLETED NCT01773122
Dapsone Formulation B Other Phase PHASE1 Acne Vulgaris COMPLETED NCT01773122
Dapsone Formulation A Other Phase PHASE1 Acne Vulgaris COMPLETED NCT01773122
bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops Other Phase PHASE4 Glaucoma COMPLETED NCT01170884
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution Other Phase PHASE4 Glaucoma COMPLETED NCT01170884
fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution Other Phase PHASE4 Glaucoma COMPLETED NCT00811850
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution Other Phase PHASE4 Glaucoma COMPLETED NCT00811850
latanoprost 0.005% eye drops Other Phase PHASE4 Open Angle Glaucoma COMPLETED NCT00539526
travoprost 0.004% Other Phase PHASE4 Open Angle Glaucoma COMPLETED NCT00539526
Bimatoprost 0.03% Other Phase PHASE4 Open Angle Glaucoma COMPLETED NCT00539526
Laser Photocoagulation Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT00464685
Sham injection Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT00464685
Dexamethasone Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT00464685
Laser Photocoagulation Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT00464685
Sham injection Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT00464685
Dexamethasone Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT00464685
Cyclosporine Ophthalmic Emulsion 0.05% Other Preclinical Dry Eye Disease COMPLETED NCT00827255
sham Other Phase PHASE2 Choroidal Neovascularization COMPLETED NCT00511706
ranibizumab Other Phase PHASE2 Choroidal Neovascularization COMPLETED NCT00511706
dexamethasone Other Phase PHASE2 Choroidal Neovascularization COMPLETED NCT00511706
travoprost 0.004% eye drops Other Phase PHASE4 Glaucoma COMPLETED NCT00440011
bimatoprost 0.03% eye drops Other Phase PHASE4 Glaucoma COMPLETED NCT00440011
travoprost 0.004% eye drops Other Phase PHASE4 Glaucoma COMPLETED NCT00440011
bimatoprost 0.03% eye drops Other Phase PHASE4 Glaucoma COMPLETED NCT00440011
Placebo Other Phase PHASE3 Leiomyoma COMPLETED NCT02147197
Ulipristal acetate (UPA) Other Phase PHASE3 Leiomyoma COMPLETED NCT02147197
Placebo (Normal Saline) Other Phase PHASE3 Urinary Incontinence COMPLETED NCT01600716
OnabotulinumtoxinA Other Phase PHASE3 Urinary Incontinence COMPLETED NCT01600716
botulinum toxin Type A Other Phase PHASE3 Overactive Bladder COMPLETED NCT00915525
No treatment Drug Preclinical Health COMPLETED NCT01518270
Botulinum Toxin Type A 200U Other Phase PHASE3 Overactive Bladder COMPLETED NCT00876447
Botulinum Toxin Type A 300U Other Phase PHASE3 Overactive Bladder COMPLETED NCT00876447
Injectable sodium deoxycholate with Triamcinolone acetate Other Phase PHASE4 Adiposity COMPLETED NCT03361176
Injectable sodium deoxycholate Other Phase PHASE4 Adiposity COMPLETED NCT03361176
Control Other Approved Moderate to Severe Nasolabial Folds COMPLETED NCT01976663
JUVEDERM VOLIFT® XC Other Approved Moderate to Severe Nasolabial Folds COMPLETED NCT01976663
Placebo Other Phase PHASE1 Human Abuse Potential COMPLETED NCT03799900
Ketamine Other Phase PHASE1 Human Abuse Potential COMPLETED NCT03799900
Rapastinel Other Phase PHASE1 Human Abuse Potential COMPLETED NCT03799900
Placebo Other Phase PHASE1 Human Abuse Potential COMPLETED NCT03799900
Ketamine Other Phase PHASE1 Human Abuse Potential COMPLETED NCT03799900
Rapastinel Other Phase PHASE1 Human Abuse Potential COMPLETED NCT03799900
Eye wash Other Approved Dry Eye COMPLETED NCT03332342
Eye wash Other Approved Dry Eye COMPLETED NCT03332342
Normal saline Other Phase PHASE2 Masseter Muscle Hypertrophy COMPLETED NCT02010775
botulinum toxin Type A Other Phase PHASE2 Masseter Muscle Hypertrophy COMPLETED NCT02010775
injection of NaCl 0.9% Other Phase PHASE3 COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO COMPLETED NCT01821573
botulinum toxin type A Other Phase PHASE3 COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO COMPLETED NCT01821573
Skin Imaging Other Approved Skin Care COMPLETED NCT03302559
Sunscreen Other Approved Skin Care COMPLETED NCT03302559
Moisturizing lotion Other Approved Skin Care COMPLETED NCT03302559
Facial cleanser Other Approved Skin Care COMPLETED NCT03302559
Retinol Complex 0.5 Other Approved Skin Care COMPLETED NCT03302559
Skin Imaging Other Approved Skin Care COMPLETED NCT03302559
Sunscreen Other Approved Skin Care COMPLETED NCT03302559
Moisturizing lotion Other Approved Skin Care COMPLETED NCT03302559
Facial cleanser Other Approved Skin Care COMPLETED NCT03302559
Retinol Complex 0.5 Other Approved Skin Care COMPLETED NCT03302559
Optive® Fusion + Optive® Gel Drop Other Approved Dry Eye COMPLETED NCT03208673
Placebo Other Phase PHASE3 Stroke With Hemiparesis COMPLETED NCT01422161
Botulinum Toxin commonly known as BOTOX® Other Phase PHASE3 Stroke With Hemiparesis COMPLETED NCT01422161
Dexamethasone pellet Other Phase PHASE4 Uveitis, Intermediate COMPLETED NCT02049476
Test product (B) Exemestane Other Phase PHASE1 Healthy WITHDRAWN NCT01760980
Reference product (A) Aromasin (Exemestane) Other Phase PHASE1 Healthy WITHDRAWN NCT01760980
bimatoprost vehicle solution Other Phase PHASE3 Eyelash Hypotrichosis COMPLETED NCT01391286
bimatoprost solution 0.03% Other Phase PHASE3 Eyelash Hypotrichosis COMPLETED NCT01391286
bimatoprost vehicle solution Other Phase PHASE3 Eyelash Hypotrichosis COMPLETED NCT01391273
bimatoprost solution 0.03% Other Phase PHASE3 Eyelash Hypotrichosis COMPLETED NCT01391273
bimatoprost vehicle solution Other Phase PHASE3 Eyelash Hypotrichosis COMPLETED NCT01391273
bimatoprost solution 0.03% Other Phase PHASE3 Eyelash Hypotrichosis COMPLETED NCT01391273
Clobex TM 0.05% Lotion, single exposure Other Phase PHASE1 Healthy COMPLETED NCT00864500
Clobetasol Propionate 0.05% lotion, single exposure Other Phase PHASE1 Healthy COMPLETED NCT00864500
Clobex TM (Clobetasol) 0.05% Lotion, single exposure Other Phase PHASE1 Healthy COMPLETED NCT00864240
Ketamine Matched Placebo Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Alprazolam Matched Placebo Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Rapastinel Matched Placebo Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Ketamine Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Alprazolam Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Rapastinel Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Ketamine Matched Placebo Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Alprazolam Matched Placebo Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Rapastinel Matched Placebo Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Ketamine Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Alprazolam Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Rapastinel Other Phase PHASE1 Driving Performance COMPLETED NCT03814733
Placebo Other Phase PHASE3 Depressive Disorder, Major WITHDRAWN NCT03855865
Vortioxetine Other Phase PHASE3 Depressive Disorder, Major WITHDRAWN NCT03855865
Rapastinel Other Phase PHASE3 Depressive Disorder, Major WITHDRAWN NCT03855865
Placebo Other Phase PHASE3 Depressive Disorder, Major WITHDRAWN NCT03855865
Vortioxetine Other Phase PHASE3 Depressive Disorder, Major WITHDRAWN NCT03855865
Rapastinel Other Phase PHASE3 Depressive Disorder, Major WITHDRAWN NCT03855865
Botox Other Phase PHASE4 Glabellar Furrows COMPLETED NCT00856999
Placebo Other Phase PHASE2 Diabetes Mellitus COMPLETED NCT02357420
Relamorelin Other Phase PHASE2 Diabetes Mellitus COMPLETED NCT02357420
Placebo Other Phase PHASE2 Fecal Incontinence WITHDRAWN NCT03489265
Eluxadoline 100 mg Other Phase PHASE2 Fecal Incontinence WITHDRAWN NCT03489265
Moisturizing Lotion Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Towel Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Sunscreen Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Cleanser Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Vehicle Foam Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Finacea® (Azelaic Acid) Foam Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Generic Azelaic Acid Foam Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Moisturizing Lotion Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Towel Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Sunscreen Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Cleanser Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Vehicle Foam Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Finacea® (Azelaic Acid) Foam Other Phase PHASE3 Rosacea COMPLETED NCT03287791
Generic Azelaic Acid Foam Other Phase PHASE3 Rosacea COMPLETED NCT03287791
dexamethasone intravitreal implant Other Preclinical Non-infectious Uveitis TERMINATED NCT02951975
JUVÉDERM VOLUMA® XC injectable gel with needle Other Approved Age-related Volume Deficit in the Mid-face COMPLETED NCT03438266
JUVÉDERM VOLUMA® XC injectable gel with cannula Other Approved Age-related Volume Deficit in the Mid-face COMPLETED NCT03438266
Botulinum Toxin Type A Other Phase PHASE3 Pediatrics COMPLETED NCT01603641
Botulinum Toxin Type A Other Phase PHASE3 Pediatrics COMPLETED NCT01603615
Usual Care Other Phase PHASE3 Migraine, With or Without Aura COMPLETED NCT02873221
Placebo-matching Ubrogepant Other Phase PHASE3 Migraine, With or Without Aura COMPLETED NCT02873221
Ubrogepant Other Phase PHASE3 Migraine, With or Without Aura COMPLETED NCT02873221
Bevacizumab Other Phase PHASE2 Macular Edema TERMINATED NCT01471054
Ozurdex Other Phase PHASE2 Macular Edema TERMINATED NCT01471054
Bevacizumab Other Phase PHASE2 Macular Edema TERMINATED NCT01471054
Ozurdex Other Phase PHASE2 Macular Edema TERMINATED NCT01471054
silk surgical scaffold Other Approved Mastopexy COMPLETED NCT02293798
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03255382
Fumaderm Other Phase PHASE3 Psoriasis COMPLETED NCT03255382
Placebo Other Phase PHASE3 Breast Cancer COMPLETED NCT01591746
Botulinum Toxin Type A Other Phase PHASE3 Breast Cancer COMPLETED NCT01591746
Placebo Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02932943
Rapastinel Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02932943
Placebo Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02932943
Rapastinel Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02932943
Facial Cleanser Other Preclinical Skin Care COMPLETED NCT03767400
Skin Imaging Other Preclinical Skin Care COMPLETED NCT03767400
Risankizumab Other Phase PHASE2 Psoriasis COMPLETED NCT02203851
Risankizumab Other Phase PHASE2 Psoriasis COMPLETED NCT02203851
Placebo Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02943577
Rapastinel Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02943577
Placebo Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02943577
Rapastinel Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02943577
Vehicle to AGN-199201 Other Phase PHASE3 Erythema COMPLETED NCT02131636
AGN-199201 Other Phase PHASE3 Erythema COMPLETED NCT02131636
Oxymetazoline HCL Cream 1.0% Other Phase PHASE3 Erythema COMPLETED NCT02095158
AGN-199201 Vehicle Other Phase PHASE2 Rosacea COMPLETED NCT01735201
AGN-199201 Dose C Other Phase PHASE2 Rosacea COMPLETED NCT01735201
AGN-199201 Dose B Other Phase PHASE2 Rosacea COMPLETED NCT01735201
AGN-199201 Dose A Other Phase PHASE2 Rosacea COMPLETED NCT01735201
AGN-199201 Vehicle Other Phase PHASE2 Rosacea COMPLETED NCT01735201
AGN-199201 Dose C Other Phase PHASE2 Rosacea COMPLETED NCT01735201
AGN-199201 Dose B Other Phase PHASE2 Rosacea COMPLETED NCT01735201
AGN-199201 Dose A Other Phase PHASE2 Rosacea COMPLETED NCT01735201
No Intervention Other Preclinical Erythema COMPLETED NCT01636765
AGN-199201 Vehicle Other Phase PHASE1 Rosacea COMPLETED NCT01579084
AGN-199201 Formulation C Other Phase PHASE1 Rosacea COMPLETED NCT01579084
AGN-199201 Formulation B Other Phase PHASE1 Rosacea COMPLETED NCT01579084
AGN-199201 Formulation A Other Phase PHASE1 Rosacea COMPLETED NCT01579084
OnabotulinumtoxinA Other Phase PHASE3 Urinary Incontinence COMPLETED NCT01852045
OnabotulinumtoxinA Other Phase PHASE3 Urinary Incontinence COMPLETED NCT01852045
Rapastinel (225 mg/450 mg IV administration) Other Phase PHASE2 Major Depressive Disorder TERMINATED NCT02192099
Rapastinel (225 mg/450 mg IV administration) Other Phase PHASE2 Major Depressive Disorder TERMINATED NCT02192099
Placebo Other Phase PHASE3 Asthma COMPLETED NCT02495168
Symbicort® (Budesonide/Formoterol Fumarate Dihydrate) Other Phase PHASE3 Asthma COMPLETED NCT02495168
Generic Budesonide/Formoterol Fumarate Dihydrate Other Phase PHASE3 Asthma COMPLETED NCT02495168
Placebo Other Phase PHASE3 Asthma COMPLETED NCT02495168
Symbicort® (Budesonide/Formoterol Fumarate Dihydrate) Other Phase PHASE3 Asthma COMPLETED NCT02495168
Generic Budesonide/Formoterol Fumarate Dihydrate Other Phase PHASE3 Asthma COMPLETED NCT02495168
Venetoclax Other Phase PHASE1 Cancer COMPLETED NCT02391480
ABBV-075 Other Phase PHASE1 Cancer COMPLETED NCT02391480
Venetoclax Other Phase PHASE1 Cancer COMPLETED NCT02391480
ABBV-075 Other Phase PHASE1 Cancer COMPLETED NCT02391480
Venetoclax Other Phase PHASE1 Cancer COMPLETED NCT02391480
ABBV-075 Other Phase PHASE1 Cancer COMPLETED NCT02391480
extended intervention Other Approved Cross-Sectional Study COMPLETED NCT03079375
basic intervention Other Approved Cross-Sectional Study COMPLETED NCT03079375
extended intervention Other Approved Cross-Sectional Study COMPLETED NCT03079375
basic intervention Other Approved Cross-Sectional Study COMPLETED NCT03079375
extended intervention Other Approved Cross-Sectional Study COMPLETED NCT03079375
basic intervention Other Approved Cross-Sectional Study COMPLETED NCT03079375
Placebo Tablet Other Phase PHASE3 Diarrhea COMPLETED NCT02498418
Xifaxan® Other Phase PHASE3 Diarrhea COMPLETED NCT02498418
Rifaximin Other Phase PHASE3 Diarrhea COMPLETED NCT02498418
Vehicle Cream Other Phase PHASE3 Actinic Keratosis COMPLETED NCT02120898
Zyclara® Other Phase PHASE3 Actinic Keratosis COMPLETED NCT02120898
Imiquimod Other Phase PHASE3 Actinic Keratosis COMPLETED NCT02120898
Vehicle Cream Other Phase PHASE3 Actinic Keratosis COMPLETED NCT02120898
Zyclara® Other Phase PHASE3 Actinic Keratosis COMPLETED NCT02120898
Imiquimod Other Phase PHASE3 Actinic Keratosis COMPLETED NCT02120898
Placebo (saline) Other Phase PHASE4 Urinary Bladder, Overactive COMPLETED NCT03052764
onabotulinumtoxinA Other Phase PHASE4 Urinary Bladder, Overactive COMPLETED NCT03052764
AGN-214868 Placebo (Vehicle) Other Phase PHASE2 Neuralgia, Postherpetic TERMINATED NCT01678924
AGN-214868 Other Phase PHASE2 Neuralgia, Postherpetic TERMINATED NCT01678924
AGN-214868 Placebo (Vehicle) Other Phase PHASE2 Neuralgia, Postherpetic TERMINATED NCT01678924
AGN-214868 Other Phase PHASE2 Neuralgia, Postherpetic TERMINATED NCT01678924
Nabumetone 750 mg tablets, single dose Other Phase PHASE1 Healthy COMPLETED NCT00864604
Vehicle Foam Other Phase PHASE3 ACTINIC KERATOSIS COMPLETED NCT03200912
Generic Ingenol Mebutate Other Phase PHASE3 ACTINIC KERATOSIS COMPLETED NCT03200912
Ingenol Mebutate (Picato®) Other Phase PHASE3 ACTINIC KERATOSIS COMPLETED NCT03200912
placebo Other Phase PHASE3 Rosacea COMPLETED NCT02289352
Brimonidine Other Phase PHASE3 Rosacea COMPLETED NCT02289352
placebo Other Phase PHASE3 Rosacea COMPLETED NCT02289352
Brimonidine Other Phase PHASE3 Rosacea COMPLETED NCT02289352
Usual Care Other Phase PHASE4 Bacterial Infections COMPLETED NCT03233438
Dalbavancin Other Phase PHASE4 Bacterial Infections COMPLETED NCT03233438
OnabotulinumtoxinA 50 UNT [Botox Cosmetic] Other Phase PHASE4 Aging NOT_YET_RECRUITING NCT04240535
placebo Other Phase PHASE3 BACTERIAL VAGINOSIS COMPLETED NCT02210689
clindamycin phosphate vaginal cream 2% Other Phase PHASE3 BACTERIAL VAGINOSIS COMPLETED NCT02210689
placebo Other Phase PHASE3 BACTERIAL VAGINOSIS COMPLETED NCT02210689
clindamycin phosphate vaginal cream 2% Other Phase PHASE3 BACTERIAL VAGINOSIS COMPLETED NCT02210689
Intranasal Tear Neurostimulator Other Approved Dry Eye Syndromes COMPLETED NCT02313454
Intranasal Tear Neurostimulator Other Approved Dry Eye Syndromes COMPLETED NCT02313454
Endura, Refresh artificial tears Other Approved Dry Eye TERMINATED NCT02199964
Cyclosporin 0.05% emulsion Other Approved Dry Eye TERMINATED NCT02199964
No Intervention Other Preclinical Leiomyoma COMPLETED NCT02580578
No Intervention Other Preclinical Leiomyoma COMPLETED NCT02580578
Placebo-matching Rapastinel Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02951988
Rapastinel Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02951988
Placebo-matching Rapastinel Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02951988
Rapastinel Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02951988
Placebo-matching Rapastinel Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02951988
Rapastinel Other Phase PHASE3 Depressive Disorder, Major COMPLETED NCT02951988
Botulinum toxin A Other Phase PHASE4 Cervical Dystonia COMPLETED NCT00773253
bimatoprost 0.03% Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 10 µg generation 1 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 15 µg generation 1 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 6 µg generation 2 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 10 µg generation 2 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 15 µg generation 2 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 20 µg generation 2 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 0.03% Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 10 µg generation 1 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 15 µg generation 1 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 6 µg generation 2 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 10 µg generation 2 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 15 µg generation 2 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
bimatoprost 20 µg generation 2 Other Phase PHASE1 Open-Angle Glaucoma COMPLETED NCT01157364
Lytera Other Approved Photoaging COMPLETED NCT03661697
Basic Skin Care Regimen Other Approved Photoaging COMPLETED NCT03661697
Laser Therapy Drug Approved Photoaging COMPLETED NCT03661697
Lytera Other Approved Photoaging COMPLETED NCT03661697
Basic Skin Care Regimen Other Approved Photoaging COMPLETED NCT03661697
Laser Therapy Drug Approved Photoaging COMPLETED NCT03661697
Optive Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT02871440
Optive Advanced Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT02871440
Omega 3 Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT02871440
Optive Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT02871440
Optive Advanced Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT02871440
Omega 3 Other Phase PHASE3 Dry Eye Syndromes COMPLETED NCT02871440
Placebo Other Phase PHASE3 Acne Vulgaris COMPLETED NCT02616614
Clindamycin/benzoyl peroxide gel Other Phase PHASE3 Acne Vulgaris COMPLETED NCT02616614
Onexton Other Phase PHASE3 Acne Vulgaris COMPLETED NCT02616614
Pimecrolimus Cream, 1% Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT02791308
Vehicle cream Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT02791308
Pimecrolimus Cream 1% (Valeant) Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT02791308
onabotulinumtoxinA Other Phase PHASE4 Healthy COMPLETED NCT03373162
Placebo/Vehicle cream Other Phase PHASE3 Moderate to Severe Papulopustular Rosacea COMPLETED NCT02840461
Ivermectin Cream, 1% Other Phase PHASE3 Moderate to Severe Papulopustular Rosacea COMPLETED NCT02840461
Finacea Other Phase PHASE3 Rosacea COMPLETED NCT02120924
Vehicle Other Phase PHASE3 Rosacea COMPLETED NCT02120924
Azelaic acid Other Phase PHASE3 Rosacea COMPLETED NCT02120924
CPC-201 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT02185053
CPC-201 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT02185053
CPC-201 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT02185053
Timolol Vehicle (placebo) Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02247804
Sham: Applicator Without Needle Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02247804
Active Comparator: Timolol 0.5% Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02247804
Bimatoprost SR Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02247804
Vehicle foam Other Phase PHASE3 Acne Vulgaris COMPLETED NCT02267746
Tazarotene (Actavis) Other Phase PHASE3 Acne Vulgaris COMPLETED NCT02267746
Tazarotene (Fabior™) Other Phase PHASE3 Acne Vulgaris COMPLETED NCT02267746
placebo gel Other Phase PHASE3 Acne COMPLETED NCT02651220
Adapalene and Benzoyl Peroxide Gel Other Phase PHASE3 Acne COMPLETED NCT02651220
Epiduo® Forte Gel Other Phase PHASE3 Acne COMPLETED NCT02651220
Placebo Other Approved Osteoarthritis COMPLETED NCT02495857
Euflexxa IA injection Other Approved Osteoarthritis COMPLETED NCT02495857
Hyaluronate Injectable Viscosupplement Other Approved Osteoarthritis COMPLETED NCT02495857
Placebo Other Phase PHASE3 Ankle Sprain COMPLETED NCT02324270
Diclofenac epolamine Other Phase PHASE3 Ankle Sprain COMPLETED NCT02324270
Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection Other Approved Breast Augmentation TERMINATED NCT01785069
Avinza (morphine sulfate sustained-release) capsules Other Phase PHASE4 Healthy COMPLETED NCT00782548
KADIAN (morphine sulfate sustained-release) capsules Other Phase PHASE4 Healthy COMPLETED NCT00782548
KADIAN Capsule + alcohol (under fed conditions) Other Phase PHASE1 Healthy COMPLETED NCT00768183
morphine sulfate IR oral solution + water Other Phase PHASE1 Healthy COMPLETED NCT00768183
KADIAN Capsule + water (under fasting conditions) Other Phase PHASE1 Healthy COMPLETED NCT00768183
KADIAN Capsule + alcohol (under fasting conditions) Other Phase PHASE1 Healthy COMPLETED NCT00768183
Rapastinel Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03668600
Rapastinel Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03668600
Radiotherapy Drug Phase PHASE1 Non-small Cell Lung Cancer Stage III TERMINATED NCT02412371
Veliparib Other Phase PHASE1 Non-small Cell Lung Cancer Stage III TERMINATED NCT02412371
Carboplatin Other Phase PHASE1 Non-small Cell Lung Cancer Stage III TERMINATED NCT02412371
Placebo for Veliparib Other Phase PHASE1 Non-small Cell Lung Cancer Stage III TERMINATED NCT02412371
Paclitaxel Other Phase PHASE1 Non-small Cell Lung Cancer Stage III TERMINATED NCT02412371
Radiotherapy Drug Phase PHASE1 Non-small Cell Lung Cancer Stage III TERMINATED NCT02412371
Veliparib Other Phase PHASE1 Non-small Cell Lung Cancer Stage III TERMINATED NCT02412371
Carboplatin Other Phase PHASE1 Non-small Cell Lung Cancer Stage III TERMINATED NCT02412371
Placebo for Veliparib Other Phase PHASE1 Non-small Cell Lung Cancer Stage III TERMINATED NCT02412371
Paclitaxel Other Phase PHASE1 Non-small Cell Lung Cancer Stage III TERMINATED NCT02412371
Placebo Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03675776
Rapastinel Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03675776
Placebo Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03675776
Rapastinel Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03675776
Sham Procedure Procedure Phase PHASE3 Macular Degeneration COMPLETED NCT02462486
Ranibizumab Other Phase PHASE3 Macular Degeneration COMPLETED NCT02462486
Abicipar Pegol Other Phase PHASE3 Macular Degeneration COMPLETED NCT02462486
Abicipar pegol Other Phase PHASE2 Macular Degeneration COMPLETED NCT03539549
Pancrelipase Other Phase PHASE2 Pancreatic Cancer TERMINATED NCT03469258
TrueTear Other Approved Cataract COMPLETED NCT03637348
Placebo Other Phase PHASE2 Depressive Disorder, Major TERMINATED NCT03352453
Rapastinel Other Phase PHASE2 Depressive Disorder, Major TERMINATED NCT03352453
Placebo Other Phase PHASE2 Depressive Disorder, Major TERMINATED NCT03352453
Rapastinel Other Phase PHASE2 Depressive Disorder, Major TERMINATED NCT03352453
Placebo Other Phase PHASE2 Depressive Disorder, Major TERMINATED NCT03352453
Rapastinel Other Phase PHASE2 Depressive Disorder, Major TERMINATED NCT03352453
Placebo Other Phase PHASE4 Chronic Migraine COMPLETED NCT01700387
Topiramate Other Phase PHASE4 Chronic Migraine COMPLETED NCT01700387
onabotulinumtoxinA Other Phase PHASE4 Chronic Migraine COMPLETED NCT01700387
Mometasone nasal spray Other Phase PHASE3 Seasonal Allergic Rhinitis COMPLETED NCT01850823
Mometasone Nasal Spray Other Phase PHASE3 Seasonal Allergic Rhinitis COMPLETED NCT01850823
placebo Other Phase PHASE3 Seasonal Allergic Rhinitis COMPLETED NCT01850823
Mometasone nasal spray Other Phase PHASE3 Seasonal Allergic Rhinitis COMPLETED NCT01850823
Mometasone Nasal Spray Other Phase PHASE3 Seasonal Allergic Rhinitis COMPLETED NCT01850823
placebo Other Phase PHASE3 Seasonal Allergic Rhinitis COMPLETED NCT01850823
Placebo Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03560518
Rapastinel Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03560518
Placebo Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03560518
Rapastinel Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03560518
Refresh Endura Other Phase PHASE4 Primary Sjogren Syndrome COMPLETED NCT02004067
Restasis Other Phase PHASE4 Primary Sjogren Syndrome COMPLETED NCT02004067
Ceftazidime-avibactam Other Preclinical Bacterial Infections COMPLETED NCT04358991
Placebo Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03614156
Rapastinel Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03614156
Placebo Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03614156
Rapastinel Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03614156
Placebo Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03614156
Rapastinel Other Phase PHASE3 Depressive Disorder, Major TERMINATED NCT03614156
placebo Other Phase PHASE4 Spinal Cord Injury COMPLETED NCT00320281
botulinum toxin A Other Phase PHASE4 Spinal Cord Injury COMPLETED NCT00320281
placebo Other Phase PHASE4 Spinal Cord Injury COMPLETED NCT00320281
botulinum toxin A Other Phase PHASE4 Spinal Cord Injury COMPLETED NCT00320281
ZELTIQ thermoelectric device Device Approved Subcutaneous Fat UNKNOWN NCT04553627
Thermalon Dry Eye Compress Other Approved Meibomian Glands COMPLETED NCT03226769
TrueTear™ Other Approved Meibomian Glands COMPLETED NCT03226769
Telemedicine follow-up visit Other Preclinical Cervical Dystonia COMPLETED NCT03969537
Telemedicine follow-up visit Other Preclinical Cervical Dystonia COMPLETED NCT03969537
Bevacizumab Injectable Product Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT04619303
Dexamethasone intravitreal implant Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT04619303
Placebo (Saline) Other Approved Post-stroke Shoulder Pain and Spasticity COMPLETED NCT00661089
Botulinum Toxin Type A - OnabotulinumtoxinA Other Approved Post-stroke Shoulder Pain and Spasticity COMPLETED NCT00661089
Placebo (Saline) Other Approved Post-stroke Shoulder Pain and Spasticity COMPLETED NCT00661089
Botulinum Toxin Type A - OnabotulinumtoxinA Other Approved Post-stroke Shoulder Pain and Spasticity COMPLETED NCT00661089
Phacoemulsification Other Preclinical Glaucoma COMPLETED NCT03868254
XEN Group Other Preclinical Glaucoma COMPLETED NCT03868254
Laser Photocoagulation Other Phase PHASE3 Macular Edema COMPLETED NCT02121262
Dexamethasone Other Phase PHASE3 Macular Edema COMPLETED NCT02121262
Laser Photocoagulation Other Phase PHASE3 Macular Edema COMPLETED NCT02121262
Dexamethasone Other Phase PHASE3 Macular Edema COMPLETED NCT02121262
adalimumab (ADA) Other Phase PHASE4 Psoriatic Arthritis COMPLETED NCT02814175
methotrexate (MTX) Other Phase PHASE4 Psoriatic Arthritis COMPLETED NCT02814175
adalimumab (ADA) Other Phase PHASE4 Psoriatic Arthritis COMPLETED NCT02814175
methotrexate (MTX) Other Phase PHASE4 Psoriatic Arthritis COMPLETED NCT02814175
Bacteriostatic normal saline Other Approved Herpes Labialis TERMINATED NCT01225341
onabotulinumtoxinA Other Approved Herpes Labialis TERMINATED NCT01225341
Bacteriostatic normal saline Other Approved Herpes Labialis TERMINATED NCT01225341
onabotulinumtoxinA Other Approved Herpes Labialis TERMINATED NCT01225341
AGN-190584 Vehicle Other Phase PHASE2 Presbyopia COMPLETED NCT02780115
AGN-199201 Vehicle Other Phase PHASE2 Presbyopia COMPLETED NCT02780115
AGN-190584 ophthalmic solution Other Phase PHASE2 Presbyopia COMPLETED NCT02780115
AGN-199201 ophthalmic solution Other Phase PHASE2 Presbyopia COMPLETED NCT02780115
AGN-190584 Vehicle Other Phase PHASE2 Presbyopia COMPLETED NCT02780115
AGN-199201 Vehicle Other Phase PHASE2 Presbyopia COMPLETED NCT02780115
AGN-190584 ophthalmic solution Other Phase PHASE2 Presbyopia COMPLETED NCT02780115
AGN-199201 ophthalmic solution Other Phase PHASE2 Presbyopia COMPLETED NCT02780115
AGN-199201 vehicle Other Phase PHASE2 Presbyopia COMPLETED NCT02595528
AGN-199201 + AGN-190584 Combination Other Phase PHASE2 Presbyopia COMPLETED NCT02595528
AGN-190584 vehicle Other Phase PHASE2 Presbyopia COMPLETED NCT02595528
AGN-190584 ophthalmic solution Other Phase PHASE2 Presbyopia COMPLETED NCT02595528
AGN-199201 ophthalmic solution Other Phase PHASE2 Presbyopia COMPLETED NCT02595528
AGN-199201 vehicle Other Phase PHASE2 Presbyopia COMPLETED NCT02595528
AGN-199201 + AGN-190584 Combination Other Phase PHASE2 Presbyopia COMPLETED NCT02595528
AGN-190584 vehicle Other Phase PHASE2 Presbyopia COMPLETED NCT02595528
AGN-190584 ophthalmic solution Other Phase PHASE2 Presbyopia COMPLETED NCT02595528
AGN-199201 ophthalmic solution Other Phase PHASE2 Presbyopia COMPLETED NCT02595528
No-treatment control Drug Approved Nose Enhancement COMPLETED NCT03430986
JUVÉDERM® VOLUMA® with Lidocaine Other Approved Nose Enhancement COMPLETED NCT03430986
Juvéderm® VOLUMA™ with Lidocaine Other Phase PHASE4 Contour COMPLETED NCT03425253
BELKYRA® Other Phase PHASE4 Contour COMPLETED NCT03425253
Botox Other Phase PHASE4 Stroke COMPLETED NCT00178646
Botox Other Phase PHASE4 Stroke COMPLETED NCT00178646
Botulinum Toxin Type A Other Phase PHASE4 Depression COMPLETED NCT01004042
Irinotecan Other Phase PHASE2 Cancer TERMINATED NCT03368859
ABT-165 Other Phase PHASE2 Cancer TERMINATED NCT03368859
Fluorouracil - infusion Other Phase PHASE2 Cancer TERMINATED NCT03368859
Bevacizumab Other Phase PHASE2 Cancer TERMINATED NCT03368859
Fluorouracil - bolus Other Phase PHASE2 Cancer TERMINATED NCT03368859
Leucovorin Other Phase PHASE2 Cancer TERMINATED NCT03368859
Irinotecan Other Phase PHASE2 Cancer TERMINATED NCT03368859
ABT-165 Other Phase PHASE2 Cancer TERMINATED NCT03368859
Fluorouracil - infusion Other Phase PHASE2 Cancer TERMINATED NCT03368859
Bevacizumab Other Phase PHASE2 Cancer TERMINATED NCT03368859
Fluorouracil - bolus Other Phase PHASE2 Cancer TERMINATED NCT03368859
Leucovorin Other Phase PHASE2 Cancer TERMINATED NCT03368859
bimatoprost 0.03% ophthalmic solution Other Phase EARLY_PHASE1 Dermatochalasis COMPLETED NCT02830776
TrueTear™ Application Other Approved Dry Eye Syndromes TERMINATED NCT03274999
Galcanezumab Other Phase PHASE1 Migraine COMPLETED NCT04179474
Erenumab Other Phase PHASE1 Migraine COMPLETED NCT04179474
Ubrogepant Other Phase PHASE1 Migraine COMPLETED NCT04179474
Galcanezumab Other Phase PHASE1 Migraine COMPLETED NCT04179474
Erenumab Other Phase PHASE1 Migraine COMPLETED NCT04179474
Ubrogepant Other Phase PHASE1 Migraine COMPLETED NCT04179474
intravitreal bevacizumab Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT01571232
dexamethasone intravitreal implant Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT01571232
CoolSculpting® System Other Approved Body Fat Disorder COMPLETED NCT04142450
Deoxycholic Acid Other Phase PHASE4 Brassiere Strap Fat (BSF) COMPLETED NCT04089722
Refresh Tears 0.5% Lubricant Eye Drops Other Phase PHASE2 Congenital Hereditary Endothelial Dystrophy of Cornea UNKNOWN NCT04843839
Nepafenac 0.1% Oph Susp Other Phase PHASE2 Congenital Hereditary Endothelial Dystrophy of Cornea UNKNOWN NCT04843839
Normal saline Other Phase PHASE2 Masseter Muscle Prominence COMPLETED NCT03861936
OnabotulinumtoxinA Other Phase PHASE2 Masseter Muscle Prominence COMPLETED NCT03861936
Normal saline Other Phase PHASE2 Masseter Muscle Prominence COMPLETED NCT03861936
OnabotulinumtoxinA Other Phase PHASE2 Masseter Muscle Prominence COMPLETED NCT03861936
pancrelipase Other Phase PHASE4 Celiac Disease TERMINATED NCT02475369
pancrelipase Other Phase PHASE4 Celiac Disease TERMINATED NCT02475369
Eluxadoline Other Phase PHASE4 Irritable Bowel Syndrome With Diarrhea COMPLETED NCT03441581
Atogepant Other Phase PHASE3 Episodic Migraine COMPLETED NCT03700320
Standard of Care (SOC) Migraine Preventive Medication Drug Phase PHASE3 Episodic Migraine COMPLETED NCT03700320
Atogepant Other Phase PHASE3 Episodic Migraine COMPLETED NCT03700320
Standard of Care (SOC) Migraine Preventive Medication Drug Phase PHASE3 Episodic Migraine COMPLETED NCT03700320
Atogepant Other Phase PHASE3 Episodic Migraine COMPLETED NCT03700320
Standard of Care (SOC) Migraine Preventive Medication Drug Phase PHASE3 Episodic Migraine COMPLETED NCT03700320
Placebo Other Phase PHASE3 Episodic Migraine COMPLETED NCT03777059
Atogepant Other Phase PHASE3 Episodic Migraine COMPLETED NCT03777059
Juvéderm® VOLIFT™ with Lidocaine Other Phase PHASE4 Lip Augmentation COMPLETED NCT03796728
Timolol Vehicle (placebo) Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02250651
Active Comparator: Timolol 0.5% Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02250651
Sham: Applicator Without Needle Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02250651
Bimatoprost SR Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02250651
Relamorelin Other Phase PHASE3 Gastroparesis TERMINATED NCT03285308
Placebo Other Phase PHASE3 Gastroparesis TERMINATED NCT03285308
Relamorelin Other Phase PHASE3 Gastroparesis TERMINATED NCT03426345
Placebo Other Phase PHASE3 Gastroparesis TERMINATED NCT03426345
Relamorelin Other Phase PHASE3 Gastroparesis TERMINATED NCT03426345
Placebo Other Phase PHASE3 Gastroparesis TERMINATED NCT03426345
Intranasal Tear Neurostimulator (ITN) [TrueTear®] Other Approved Dry Eye Syndromes TERMINATED NCT03827564
Juvederm® VOLITE Other Approved Healthy Adults COMPLETED NCT04206293
Placebos Other Phase PHASE4 None (i.e. Healthy Volunteers) UNKNOWN NCT03249311
Duloxetine Other Phase PHASE4 None (i.e. Healthy Volunteers) UNKNOWN NCT03249311
Levomilnacipran Other Phase PHASE4 None (i.e. Healthy Volunteers) UNKNOWN NCT03249311
OnabotulinumtoxinA Other Phase EARLY_PHASE1 Glabellar Frown Lines UNKNOWN NCT05083286
OnabotulinumtoxinA Other Phase EARLY_PHASE1 Glabellar Frown Lines UNKNOWN NCT05083286
Ceftaroline Fosamil Other Phase PHASE1 Hematogenously Acquired Staphylococcus Aureus Osteomyelitis COMPLETED NCT02335905
botulinum toxin Other Phase PHASE2 Non-relaxing Puborectalis Syndrome TERMINATED NCT01780636
JUVÉDERM VOLBELLA® XC injectable gel Other Phase PHASE3 Infraorbital Hollowing COMPLETED NCT03418545
JUVÉDERM VOLBELLA® XC injectable gel Other Phase PHASE3 Infraorbital Hollowing COMPLETED NCT03418545
Placebo Other Phase PHASE1 Facial Fine Lines COMPLETED NCT04631588
Botox Other Phase PHASE1 Facial Fine Lines COMPLETED NCT04631588
XEN45 gel stent implantation Other Approved Glaucoma UNKNOWN NCT05130554
Ultrasound Other Approved Spasticity COMPLETED NCT02334683
Electrical stimulation Other Approved Spasticity COMPLETED NCT02334683
Ultrasound Other Approved Spasticity COMPLETED NCT02334683
Electrical stimulation Other Approved Spasticity COMPLETED NCT02334683
Relamorelin 10 μg Other Phase PHASE3 Gastroparesis TERMINATED NCT03786380
Relamorelin Other Phase PHASE3 Gastroparesis TERMINATED NCT03420781
Placebo Other Phase PHASE3 Gastroparesis TERMINATED NCT03420781
Pilocarpine HCl Ophthalmic Solution Other Phase PHASE3 Presbyopia COMPLETED NCT03804268
Vehicle Other Phase PHASE3 Presbyopia COMPLETED NCT03804268
Pilocarpine HCl Ophthalmic Solution Other Phase PHASE3 Presbyopia COMPLETED NCT03804268
Vehicle Other Phase PHASE3 Presbyopia COMPLETED NCT03804268
Vehicle Other Phase PHASE3 Presbyopia COMPLETED NCT03857542
Pilocarpine HCl Ophthalmic Solution Other Phase PHASE3 Presbyopia COMPLETED NCT03857542
Vehicle Other Phase PHASE3 Presbyopia COMPLETED NCT03857542
Pilocarpine HCl Ophthalmic Solution Other Phase PHASE3 Presbyopia COMPLETED NCT03857542
Botox Other Phase PHASE4 Stroke TERMINATED NCT03367429
Sham Selective Laser Trabeculoplasty Other Phase PHASE3 Glaucoma COMPLETED NCT02636946
Selective Laser Trabeculoplasty Other Phase PHASE3 Glaucoma COMPLETED NCT02636946
Sham Bimatoprost SR Other Phase PHASE3 Glaucoma COMPLETED NCT02636946
Bimatoprost SR Other Phase PHASE3 Glaucoma COMPLETED NCT02636946
Control Other Approved Pigmentation COMPLETED NCT03065582
Topical Product C Other Approved Pigmentation COMPLETED NCT03065582
Topical Product B Other Approved Pigmentation COMPLETED NCT03065582
Topical Product A Other Approved Pigmentation COMPLETED NCT03065582
Placebo Other Phase PHASE2 Covid19 TERMINATED NCT04500418
Cenicriviroc (CVC) Other Phase PHASE2 Covid19 TERMINATED NCT04500418
Placebo Other Phase PHASE1 Myofascial Pain Syndromes COMPLETED NCT02173405
OnabotulinumtoxinA Other Phase PHASE1 Myofascial Pain Syndromes COMPLETED NCT02173405
Atogepant Other Phase PHASE3 Episodic Migraine COMPLETED NCT03939312
Placebo Other Phase PHASE2 Dystonia Disorder UNKNOWN NCT04277247
Botulinum toxin type A Other Phase PHASE2 Dystonia Disorder UNKNOWN NCT04277247
Androderm® Other Phase PHASE4 Hypogonadism COMPLETED NCT04320745
Trabeculectomy Other Phase PHASE4 Glaucoma COMPLETED NCT03654885
XEN-45 Gel Stent Other Phase PHASE4 Glaucoma COMPLETED NCT03654885
EARFOLD® Other Phase PHASE4 Prominent Ears COMPLETED NCT03194269
Juvéderm® VOLIFT™ with Lidocaine Other Phase PHASE4 Marionette Lines Forehead Contouring COMPLETED NCT05077488
Dalbavancin Other Phase PHASE4 Skin Infection TERMINATED NCT03372941
Juvéderm® VOLIFT with Lidocaine Other Phase PHASE4 Skin Depressions COMPLETED NCT04390581
Placebo Other Phase PHASE2 HIV Infections WITHDRAWN NCT04334915
Cenicriviroc Mesylate (CVC) Other Phase PHASE2 HIV Infections WITHDRAWN NCT04334915
BOTOX® Other Phase PHASE3 Urinary Incontinence TERMINATED NCT02097121
No-treatment control Drug Phase PHASE3 Jawline Definition COMPLETED NCT03712137
VOLUX XC Other Phase PHASE3 Jawline Definition COMPLETED NCT03712137
Placebo Other Phase PHASE3 Chronic Migraine COMPLETED NCT03855137
Atogepant 60 mg Other Phase PHASE3 Chronic Migraine COMPLETED NCT03855137
Atogepant 30 mg Other Phase PHASE3 Chronic Migraine COMPLETED NCT03855137
JUVÉDERM VOLUX® Other Preclinical Chin Retrusion COMPLETED NCT04687046
JUVÉDERM VOLUX® Other Preclinical Chin Retrusion COMPLETED NCT04687046
Vehicle Other Phase PHASE3 Presbyopia COMPLETED NCT04983589
Pilocarpine HCl Other Phase PHASE3 Presbyopia COMPLETED NCT04983589
Vehicle Other Phase PHASE3 Presbyopia COMPLETED NCT04983589
Pilocarpine HCl Other Phase PHASE3 Presbyopia COMPLETED NCT04983589
OZURDEX Other Phase PHASE4 Macular Edema COMPLETED NCT03908307
Normal saline pyloric injection Other Phase PHASE4 Bariatric Surgery COMPLETED NCT03701919
Botulinum toxin pyloroplasty Other Phase PHASE4 Bariatric Surgery COMPLETED NCT03701919
Placebo Other Phase PHASE2 Platysma Prominence COMPLETED NCT03915067
BOTOX® purified neurotoxin complex Other Phase PHASE2 Platysma Prominence COMPLETED NCT03915067
XEN45 Other Phase PHASE3 Glaucoma COMPLETED NCT03362931
Atogepant Other Phase PHASE3 Chronic Migraine COMPLETED NCT04829747
Placebo arm Other Phase PHASE4 Bruxism COMPLETED NCT00908050
Botulinum toxin type A Other Phase PHASE4 Bruxism COMPLETED NCT00908050
CoolSculpting® System Other Approved Non-invasive Fat Reduction COMPLETED NCT03909100
CoolSculpting® System Other Approved Non-invasive Fat Reduction COMPLETED NCT03909100
TrueTear Intranasal Tear Neurostimulator Other Approved Dry Eye Syndromes COMPLETED NCT03719885
TrueTear Intranasal Tear Neurostimulator Other Approved Dry Eye Syndromes COMPLETED NCT03719885
Placebo Other Phase PHASE2 Glabellar Lines COMPLETED NCT04096326
AGN-151586 Other Phase PHASE2 Glabellar Lines COMPLETED NCT04096326
Metronidazole Gel Other Phase PHASE4 Vaginosis, Bacterial COMPLETED NCT02392026
Metronidazole Gel Other Phase PHASE4 Vaginosis, Bacterial COMPLETED NCT02392026
JUVÉDERM VOLUX® Other Phase PHASE3 Chin Retrusion COMPLETED NCT04559984
JUVÉDERM VOLUX® Other Phase PHASE3 Chin Retrusion COMPLETED NCT04559984
Placebo Other Phase PHASE3 Episodic Migraine COMPLETED NCT04740827
Atogepant 60 mg Other Phase PHASE3 Episodic Migraine COMPLETED NCT04740827
SkinMedica Other Phase PHASE4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality COMPLETED NCT03712449
BELKYRA® Other Phase PHASE4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality COMPLETED NCT03712449
BOTOX Cosmetic® Other Phase PHASE4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality COMPLETED NCT03712449
JUVÉDERM® Other Phase PHASE4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality COMPLETED NCT03712449
SkinMedica Other Phase PHASE4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality COMPLETED NCT03712449
BELKYRA® Other Phase PHASE4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality COMPLETED NCT03712449
BOTOX Cosmetic® Other Phase PHASE4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality COMPLETED NCT03712449
JUVÉDERM® Other Phase PHASE4 Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality COMPLETED NCT03712449
Reminyl 4 mg Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT01190748
Galantamine 4 mg Tablet, single dose Other Phase PHASE1 Healthy COMPLETED NCT01190748
XEN Glaucoma Stent Other Preclinical Refractory Glaucoma COMPLETED NCT04303897
XEN Glaucoma Stent Other Preclinical Refractory Glaucoma COMPLETED NCT04303897
No-treatment control Drug Phase PHASE3 Temple Hollowing COMPLETED NCT04414397
JUVÉDERM® VOLUMA® XC Other Phase PHASE3 Temple Hollowing COMPLETED NCT04414397
Levothyroxine Other Phase PHASE2 Hypothyroidism COMPLETED NCT04124705
Armour® Thyroid Other Phase PHASE2 Hypothyroidism COMPLETED NCT04124705
Aflibercept Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT04411693
Dexamethasone implant Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT04411693
Aflibercept Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT04411693
Dexamethasone implant Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT04411693
Corneal topography: Pentacam Other Approved Glaucoma, Open-Angle COMPLETED NCT04602923
Corneal topography: OPD-Scan Other Approved Glaucoma, Open-Angle COMPLETED NCT04602923
Normal Saline Other Phase PHASE2 Scar COMPLETED NCT01177358
Botulinum Toxin Type A Other Phase PHASE2 Scar COMPLETED NCT01177358
Normal Saline Other Phase PHASE2 Scar COMPLETED NCT01177358
Botulinum Toxin Type A Other Phase PHASE2 Scar COMPLETED NCT01177358
Normal Saline Other Phase PHASE2 Scar COMPLETED NCT01177358
Botulinum Toxin Type A Other Phase PHASE2 Scar COMPLETED NCT01177358
HArmonyCa Injectable Gel Other Phase PHASE4 Soft Tissue Augmentation COMPLETED NCT05119777
VOLBELLA with Lidocaine Other Phase PHASE3 Infraorbital Hollowing COMPLETED NCT05088980
JUVÉDERM® VOLUMA® with Lidocaine Other Phase PHASE3 Temple Hollowing COMPLETED NCT04891419
Juvéderm Volbella XC Other Phase PHASE2 Dermatological Non-Disease COMPLETED NCT04755595
Juvéderm Voluma XC Other Phase PHASE2 Dermatological Non-Disease COMPLETED NCT04755595
Botox Cosmetic Injectable Product Other Phase PHASE2 Dermatological Non-Disease COMPLETED NCT04755595
Juvéderm Volbella XC Other Phase PHASE2 Dermatological Non-Disease COMPLETED NCT04755595
Juvéderm Voluma XC Other Phase PHASE2 Dermatological Non-Disease COMPLETED NCT04755595
Botox Cosmetic Injectable Product Other Phase PHASE2 Dermatological Non-Disease COMPLETED NCT04755595
HArmonyCa Lidocaine Injectable Gel Other Phase PHASE3 Mid Face Volume Deficit COMPLETED NCT05452070
New Emulsion, Optive, Soothe Other Approved Dry Eye Syndrome COMPLETED NCT01013077
Soothe, New Emulsion, Optive Other Approved Dry Eye Syndrome COMPLETED NCT01013077
Optive, Soothe, New Emulsion Other Approved Dry Eye Syndrome COMPLETED NCT01013077
Formulation C: OnabotulinumtoxinA Other Phase PHASE2 Glabellar Lines COMPLETED NCT05013424
Formulation B: OnabotulinumtoxinA Other Phase PHASE2 Glabellar Lines COMPLETED NCT05013424
Formulation A: OnabotulinumtoxinA Other Phase PHASE2 Glabellar Lines COMPLETED NCT05013424
Placebo Other Phase PHASE2 Forehead Lines COMPLETED NCT05152576
OnabotulinumtoxinA X Other Phase PHASE2 Forehead Lines COMPLETED NCT05152576
Placebo Other Phase PHASE2 Forehead Lines COMPLETED NCT05152576
OnabotulinumtoxinA X Other Phase PHASE2 Forehead Lines COMPLETED NCT05152576
Placebo Other Phase PHASE2 Glabellar Lines COMPLETED NCT05100199
OnabotulinumtoxinA X Other Phase PHASE2 Glabellar Lines COMPLETED NCT05100199
Ozurdex Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT03832179
Aflibercept Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT03832179
Ranibizumab Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT03832179
Bevacizumab Other Phase PHASE4 Diabetic Macular Edema COMPLETED NCT03832179
Aqueous PGE2 and inflammatory cytokines measurements Other Phase PHASE1 Diabetic Retinopathy ACTIVE_NOT_RECRUITING NCT04505566
Placebo - Preservative-free artificial tears Other Phase PHASE1 Diabetic Retinopathy ACTIVE_NOT_RECRUITING NCT04505566
Ketorolac 0.45% ophthalmic solution Other Phase PHASE1 Diabetic Retinopathy ACTIVE_NOT_RECRUITING NCT04505566
onabotulinumtoxin A Other Phase EARLY_PHASE1 Stress Urinary Incontinence SUSPENDED NCT04984317
Cyclophosphamide Other Phase PHASE1 Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05577000
Fludarabine Other Phase PHASE1 Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05577000
Manufactured Anti-BCMA CAR-T cells Other Phase PHASE1 Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05577000
Placebo Other Phase PHASE3 Essential Head Tremor COMPLETED NCT02555982
BOTOX ® 200 Unités Other Phase PHASE3 Essential Head Tremor COMPLETED NCT02555982
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Placebo for Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo-Matching Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Risankizumab Other Phase PHASE3 Crohn's Disease RECRUITING NCT05995353
Risankizumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Adalimumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Telisotuzumab vedotin Other Preclinical Non-Small Cell Lung Cancer (NSCLC) TEMPORARILY_NOT_AVAILABLE NCT04830202
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) AVAILABLE NCT04278235
Placebo for Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04379050
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
ABBV-383 (Etentamig) Other Phase PHASE1 Immunoglobulin Light Chain (AL) Amyloidosis RECRUITING NCT06158854
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Nab-Paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, budigalimab, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT03844048
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Telisotuzumab Adizutecan Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Budigalimab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Azirkitug Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
New formulation adalimumab Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01752855
New formulation adalimumab Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01752855
placebo Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01549834
ABT-126 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01549834
placebo Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01549834
ABT-126 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01549834
ABT-126 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01527916
donepezil Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01527916
placebo Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01527916
ABT-126 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01527916
donepezil Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01527916
placebo Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01527916
Ritonavir Other Phase PHASE2 Hepatitis C COMPLETED NCT01221298
Ribavirin Other Phase PHASE2 Hepatitis C COMPLETED NCT01221298
ABT-072 Other Phase PHASE2 Hepatitis C COMPLETED NCT01221298
ABT-450 Other Phase PHASE2 Hepatitis C COMPLETED NCT01221298
Ritonavir Other Phase PHASE2 Hepatitis C COMPLETED NCT01221298
Ribavirin Other Phase PHASE2 Hepatitis C COMPLETED NCT01221298
ABT-072 Other Phase PHASE2 Hepatitis C COMPLETED NCT01221298
ABT-450 Other Phase PHASE2 Hepatitis C COMPLETED NCT01221298
Placebo Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
Ribavirin Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
Peginterferon alpha-2a Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
Ritonavir Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
ABT-333 Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
ABT-072 Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
ABT-450 Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
Placebo Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
Ribavirin Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
Peginterferon alpha-2a Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
Ritonavir Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
ABT-333 Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
ABT-072 Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
ABT-450 Other Phase PHASE2 Hepatitis C COMPLETED NCT01074008
ABT-333 Other Phase PHASE2 HCV Infection COMPLETED NCT00726882
Blood sample collection only Other Phase PHASE2 HCV Infection COMPLETED NCT00726882
ABT-333 Other Phase PHASE2 HCV Infection COMPLETED NCT00726882
Blood sample collection only Other Phase PHASE2 HCV Infection COMPLETED NCT00726882
ABT-333 Other Phase PHASE2 HCV Infection COMPLETED NCT00726882
Blood sample collection only Other Phase PHASE2 HCV Infection COMPLETED NCT00726882
J-tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
PEG tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
CADD-Legacy® 1400 ambulatory infusion pump Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
Placebo (PBO) oral capsules Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
Placebo gel Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
Levodopa carbidopa intestinal gel (LCIG) Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
J-tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
PEG tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
CADD-Legacy® 1400 ambulatory infusion pump Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
Placebo (PBO) oral capsules Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
Placebo gel Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
Levodopa carbidopa intestinal gel (LCIG) Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00357994
J-tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
PEG tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
CADD-Legacy® 1400 ambulatory infusion pump Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
Levodopa-carbidopa intestinal gel Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
J-tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
PEG tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
CADD-Legacy® 1400 ambulatory infusion pump Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
Levodopa-carbidopa intestinal gel Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
J-tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
PEG tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
CADD-Legacy® 1400 ambulatory infusion pump Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
Levodopa-carbidopa intestinal gel Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00335153
placebo Other Phase PHASE3 Plaque Psoriasis COMPLETED NCT01646073
Adalimumab Other Phase PHASE3 Plaque Psoriasis COMPLETED NCT01646073
placebo Other Phase PHASE3 Plaque Psoriasis COMPLETED NCT01646073
Adalimumab Other Phase PHASE3 Plaque Psoriasis COMPLETED NCT01646073
Ritonavir Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01464827
Ribavirin Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01464827
ABT-267 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01464827
ABT-333 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01464827
ABT-450 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01464827
Ritonavir Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01464827
Ribavirin Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01464827
ABT-267 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01464827
ABT-333 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01464827
ABT-450 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01464827
Immediate post-screening treatment education Drug Approved HIV UNKNOWN NCT01892228
ABT-333 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT02534870
ABT-450/r/ABT-267 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT02534870
ABT-333 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT02534870
ABT-450/r/ABT-267 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT02534870
ABT-333 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT02534870
ABT-450/r/ABT-267 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT02534870
ABT-530 Other Phase PHASE1 Hepatic Impairment COMPLETED NCT02296905
ABT-493 Other Phase PHASE1 Hepatic Impairment COMPLETED NCT02296905
ABT-530 Other Phase PHASE1 Hepatic Impairment COMPLETED NCT02296905
ABT-493 Other Phase PHASE1 Hepatic Impairment COMPLETED NCT02296905
placebo Other Phase PHASE2 Non-Small -Cell Lung Cancer COMPLETED NCT01560104
paclitaxel Other Phase PHASE2 Non-Small -Cell Lung Cancer COMPLETED NCT01560104
Carboplatin Other Phase PHASE2 Non-Small -Cell Lung Cancer COMPLETED NCT01560104
Veliparib Other Phase PHASE2 Non-Small -Cell Lung Cancer COMPLETED NCT01560104
placebo Other Phase PHASE2 Non-Small -Cell Lung Cancer COMPLETED NCT01560104
paclitaxel Other Phase PHASE2 Non-Small -Cell Lung Cancer COMPLETED NCT01560104
Carboplatin Other Phase PHASE2 Non-Small -Cell Lung Cancer COMPLETED NCT01560104
Veliparib Other Phase PHASE2 Non-Small -Cell Lung Cancer COMPLETED NCT01560104
biological treatment Drug Preclinical Psoriasis COMPLETED NCT01356758
biological treatment Drug Preclinical Psoriasis COMPLETED NCT01356758
Adalimumab Other Phase PHASE3 Juvenile Idiopathic Arthritis COMPLETED NCT00775437
Adalimumab Other Phase PHASE3 Juvenile Idiopathic Arthritis COMPLETED NCT00775437
Placebo Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT01670240
Adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT01670240
Placebo Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT01670240
Adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT01670240
ABT-530 Other Phase PHASE1 Renal Impairment COMPLETED NCT02442258
ABT-493 Other Phase PHASE1 Renal Impairment COMPLETED NCT02442258
ABT-530 Other Phase PHASE1 Renal Impairment COMPLETED NCT02442258
ABT-493 Other Phase PHASE1 Renal Impairment COMPLETED NCT02442258
Placebo Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT02531178
ABBV-257 Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT02531178
Placebo Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT02531178
ABBV-257 Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT02531178
Adalimumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT01958827
Adalimumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT01958827
ABT-122 Other Phase PHASE2 Psoriatic Arthritis TERMINATED NCT02429895
Ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
Dasabuvir Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
Ombitasvir/Paritaprevir/Ritonavir Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
Ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
Dasabuvir Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
Ombitasvir/Paritaprevir/Ritonavir Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
Ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
Dasabuvir Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
Ombitasvir/Paritaprevir/Ritonavir Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
Ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
Dasabuvir Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
Ombitasvir/Paritaprevir/Ritonavir Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02216422
ritonavir Other Phase PHASE2 Hepatitis C Virus COMPLETED NCT01458535
ribavirin Other Phase PHASE2 Hepatitis C Virus COMPLETED NCT01458535
ABT-267 Other Phase PHASE2 Hepatitis C Virus COMPLETED NCT01458535
ABT-450 Other Phase PHASE2 Hepatitis C Virus COMPLETED NCT01458535
ritonavir Other Phase PHASE2 Hepatitis C Virus COMPLETED NCT01458535
ribavirin Other Phase PHASE2 Hepatitis C Virus COMPLETED NCT01458535
ABT-267 Other Phase PHASE2 Hepatitis C Virus COMPLETED NCT01458535
ABT-450 Other Phase PHASE2 Hepatitis C Virus COMPLETED NCT01458535
jejunal extension tube (J-tube) Other Phase PHASE4 Advanced Idiopathic Parkinson's Disease COMPLETED NCT00141518
percutaneous endoscopic gastrostomy tube (PEG tube) Other Phase PHASE4 Advanced Idiopathic Parkinson's Disease COMPLETED NCT00141518
CADD-Legacy® 1400 ambulatory infusion pump Other Phase PHASE4 Advanced Idiopathic Parkinson's Disease COMPLETED NCT00141518
Levodopa-carbidopa intestinal gel (LCIG) Other Phase PHASE4 Advanced Idiopathic Parkinson's Disease COMPLETED NCT00141518
jejunal extension tube (J-tube) Other Phase PHASE4 Advanced Idiopathic Parkinson's Disease COMPLETED NCT00141518
percutaneous endoscopic gastrostomy tube (PEG tube) Other Phase PHASE4 Advanced Idiopathic Parkinson's Disease COMPLETED NCT00141518
CADD-Legacy® 1400 ambulatory infusion pump Other Phase PHASE4 Advanced Idiopathic Parkinson's Disease COMPLETED NCT00141518
Levodopa-carbidopa intestinal gel (LCIG) Other Phase PHASE4 Advanced Idiopathic Parkinson's Disease COMPLETED NCT00141518
Venetoclax Other Phase PHASE1 Chronic Lymphocytic Leukemia WITHDRAWN NCT02640833
Duvelisib Other Phase PHASE1 Chronic Lymphocytic Leukemia WITHDRAWN NCT02640833
Venetoclax Other Phase PHASE1 Chronic Lymphocytic Leukemia WITHDRAWN NCT02640833
Duvelisib Other Phase PHASE1 Chronic Lymphocytic Leukemia WITHDRAWN NCT02640833
DSM265 25% SDD powder for suspension Other Phase PHASE1 Healthy Volunteers TERMINATED NCT02750384
DSM265 50% SDD granules Other Phase PHASE1 Healthy Volunteers TERMINATED NCT02750384
DSM265 25% SDD powder for suspension Other Phase PHASE1 Healthy Volunteers TERMINATED NCT02750384
DSM265 50% SDD granules Other Phase PHASE1 Healthy Volunteers TERMINATED NCT02750384
DSM265 25% SDD powder for suspension Other Phase PHASE1 Healthy Volunteers TERMINATED NCT02750384
DSM265 50% SDD granules Other Phase PHASE1 Healthy Volunteers TERMINATED NCT02750384
FOLFIRI Other Phase PHASE1 Breast Cancer COMPLETED NCT02033551
Paclitaxel Other Phase PHASE1 Breast Cancer COMPLETED NCT02033551
Carboplatin Other Phase PHASE1 Breast Cancer COMPLETED NCT02033551
Veliparib Other Phase PHASE1 Breast Cancer COMPLETED NCT02033551
FOLFIRI Other Phase PHASE1 Breast Cancer COMPLETED NCT02033551
Paclitaxel Other Phase PHASE1 Breast Cancer COMPLETED NCT02033551
Carboplatin Other Phase PHASE1 Breast Cancer COMPLETED NCT02033551
Veliparib Other Phase PHASE1 Breast Cancer COMPLETED NCT02033551
Technetium labelled glucosamine Other Preclinical Rheumatoid Arthritis NO_LONGER_AVAILABLE NCT01789151
Technetium labelled glucosamine Other Preclinical Rheumatoid Arthritis NO_LONGER_AVAILABLE NCT01789151
Methotrexate Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT01162421
adalimumab Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT01162421
Methotrexate Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT01162421
adalimumab Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT01162421
ABT-122 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02141997
adalimumab Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02141997
ABT-122 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02141997
adalimumab Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02141997
BI 655066 (low medium i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
Placebo, s.c. Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (high i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (low s.c. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (very low i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (high medium i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (low i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (high s.c. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
Placebo, i.v. Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (very high i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (low medium i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
Placebo, s.c. Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (high i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (low s.c. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (very low i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (high medium i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (low i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (high s.c. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
Placebo, i.v. Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
BI 655066 (very high i.v. dose) Other Phase PHASE1 Psoriasis COMPLETED NCT01577550
ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV Infection Genotype 1) COMPLETED NCT02399345
sofosbuvir (SOF) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV Infection Genotype 1) COMPLETED NCT02399345
ombitasvir/paritaprevir/ritonavir, dasabuvir Other Phase PHASE3 Chronic Hepatitis C Virus (HCV Infection Genotype 1) COMPLETED NCT02399345
ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV Infection Genotype 1) COMPLETED NCT02399345
sofosbuvir (SOF) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV Infection Genotype 1) COMPLETED NCT02399345
ombitasvir/paritaprevir/ritonavir, dasabuvir Other Phase PHASE3 Chronic Hepatitis C Virus (HCV Infection Genotype 1) COMPLETED NCT02399345
Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA] Other Approved Psoriasis COMPLETED NCT01320293
Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA] Other Approved Psoriasis COMPLETED NCT01320293
Intravenous Paricalcitol Other Phase PHASE4 Endstage Renal Disease UNKNOWN NCT03023748
ABT-806 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01406119
ABT-806 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01406119
ABT-555 Other Phase PHASE1 Multiple Sclerosis TERMINATED NCT02606630
PET/CT imaging Other Phase PHASE4 Ankylosing Spondyloarthritis UNKNOWN NCT02634541
Adalimumab Other Phase PHASE4 Ankylosing Spondyloarthritis UNKNOWN NCT02634541
PET/CT imaging Other Phase PHASE4 Ankylosing Spondyloarthritis UNKNOWN NCT02634541
Adalimumab Other Phase PHASE4 Ankylosing Spondyloarthritis UNKNOWN NCT02634541
Matched Placebo - Sugar Pill Other Phase PHASE2 Alcohol Dependence COMPLETED NCT01613014
ABT-436 Other Phase PHASE2 Alcohol Dependence COMPLETED NCT01613014
Matched Placebo - Sugar Pill Other Phase PHASE2 Alcohol Dependence COMPLETED NCT01613014
ABT-436 Other Phase PHASE2 Alcohol Dependence COMPLETED NCT01613014
Hydroxychloroquine Other Phase PHASE2 Prostate Cancer TERMINATED NCT01828476
ABT-263 Other Phase PHASE2 Prostate Cancer TERMINATED NCT01828476
Abiraterone Other Phase PHASE2 Prostate Cancer TERMINATED NCT01828476
Placebo Other Phase PHASE3 Nail Psoriasis COMPLETED NCT02016482
Adalimumab Other Phase PHASE3 Nail Psoriasis COMPLETED NCT02016482
Dexamethasone Other Phase PHASE1 Multiple Myeloma WITHDRAWN NCT02951117
ABBV-838 Other Phase PHASE1 Multiple Myeloma WITHDRAWN NCT02951117
Venetoclax Other Phase PHASE1 Multiple Myeloma WITHDRAWN NCT02951117
Dexamethasone Other Phase PHASE1 Multiple Myeloma WITHDRAWN NCT02951117
ABBV-838 Other Phase PHASE1 Multiple Myeloma WITHDRAWN NCT02951117
Venetoclax Other Phase PHASE1 Multiple Myeloma WITHDRAWN NCT02951117
Chama cha MamaToto Other Approved Pregnancy Related UNKNOWN NCT03187873
Placebo Other Phase PHASE1 Healthy COMPLETED NCT02596217
ABBV-066 Other Phase PHASE1 Healthy COMPLETED NCT02596217
Placebo Other Phase PHASE1 Healthy COMPLETED NCT02596217
ABBV-066 Other Phase PHASE1 Healthy COMPLETED NCT02596217
ribavirin Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02219477
dasabuvir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02219477
ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02219477
ABT-122 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02433340
ABT-122 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02433340
ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02442271
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02442271
ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02442271
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02442271
ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02442271
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02442271
ABT-122 Other Phase PHASE2 Psoriatic Arthritis COMPLETED NCT02349451
adalimumab Other Phase PHASE2 Psoriatic Arthritis COMPLETED NCT02349451
ABT-122 Other Phase PHASE2 Psoriatic Arthritis COMPLETED NCT02349451
adalimumab Other Phase PHASE2 Psoriatic Arthritis COMPLETED NCT02349451
Placebo for ABT-981 Other Phase PHASE2 Erosive Hand Osteoarthritis COMPLETED NCT02384538
ABT-981 Other Phase PHASE2 Erosive Hand Osteoarthritis COMPLETED NCT02384538
Placebo for ABT-981 Other Phase PHASE2 Erosive Hand Osteoarthritis COMPLETED NCT02384538
ABT-981 Other Phase PHASE2 Erosive Hand Osteoarthritis COMPLETED NCT02384538
Atrasentan placebo group Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT01424319
Atrasentan high dose group Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT01424319
Atrasentan low dose group Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT01424319
Atrasentan placebo group Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT01424319
Atrasentan high dose group Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT01424319
Atrasentan low dose group Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT01424319
ribavirin Other Phase PHASE3 Hepatitis C Virus COMPLETED NCT02265237
ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Hepatitis C Virus COMPLETED NCT02265237
Risankizumab Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Midazolam Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Metoprolol Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Omeprazole Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Warfarin Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Caffeine Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Risankizumab Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Midazolam Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Metoprolol Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Omeprazole Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Warfarin Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Caffeine Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Risankizumab Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Midazolam Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Metoprolol Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Omeprazole Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Warfarin Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
Caffeine Other Phase PHASE1 Psoriasis COMPLETED NCT02772601
ribavirin Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02476617
dasabuvir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02476617
ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02476617
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02651194
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02651194
Ribavirin Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02442284
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02442284
Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02517515
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02517515
Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02517515
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02517515
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02493855
Dasabuvir Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02493855
Ombitasvir/ABT-450/Ritonavir Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02493855
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02493855
Dasabuvir Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02493855
Ombitasvir/ABT-450/Ritonavir Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02493855
Placebo Other Phase PHASE1 Psoriasis TERMINATED NCT03145948
ABBV-553 Other Phase PHASE1 Psoriasis TERMINATED NCT03145948
Placebo Other Phase PHASE1 Psoriasis TERMINATED NCT03145948
ABBV-553 Other Phase PHASE1 Psoriasis TERMINATED NCT03145948
Placebo Other Phase PHASE1 Psoriasis TERMINATED NCT03145948
ABBV-553 Other Phase PHASE1 Psoriasis TERMINATED NCT03145948
ribavirin Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01782495
ombitasvir/paritaprevir/ritonavir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01782495
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01782495
ribavirin Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01782495
ombitasvir/paritaprevir/ritonavir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01782495
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01782495
ribavirin Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01782495
ombitasvir/paritaprevir/ritonavir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01782495
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01782495
Ribavirin Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02207088
dasabuvir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02207088
ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02207088
Ribavirin Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02207088
dasabuvir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02207088
ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02207088
Placebo Other Phase PHASE1 Breast Cancer COMPLETED NCT02009631
Veliparib (ABT-888) Other Phase PHASE1 Breast Cancer COMPLETED NCT02009631
Placebo Other Phase PHASE1 Breast Cancer COMPLETED NCT02009631
Veliparib (ABT-888) Other Phase PHASE1 Breast Cancer COMPLETED NCT02009631
Ketoconazole Other Phase PHASE1 Non-Hodgkin's Lymphoma COMPLETED NCT01969669
ABT-199 Other Phase PHASE1 Non-Hodgkin's Lymphoma COMPLETED NCT01969669
Placebo Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT01853033
ABT-122 Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT01853033
ABT-414 Other Phase PHASE1 Squamous Cell Tumors COMPLETED NCT01741727
ABT-414 Other Phase PHASE1 Squamous Cell Tumors COMPLETED NCT01741727
Tofacitinib Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT01741493
Placebo Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT01741493
ABT-494 Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT01741493
Tofacitinib Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT01741493
Placebo Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT01741493
ABT-494 Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT01741493
Placebo Other Phase PHASE1 Osteoarthritis COMPLETED NCT01668511
ABT-981 Other Phase PHASE1 Osteoarthritis COMPLETED NCT01668511
Placebo Other Phase PHASE1 Osteoarthritis COMPLETED NCT01668511
ABT-981 Other Phase PHASE1 Osteoarthritis COMPLETED NCT01668511
paclitaxel Other Phase PHASE1 Solid Tumors COMPLETED NCT01617928
carboplatin Other Phase PHASE1 Solid Tumors COMPLETED NCT01617928
veliparib (ABT-888) Other Phase PHASE1 Solid Tumors COMPLETED NCT01617928
paclitaxel Other Phase PHASE1 Solid Tumors COMPLETED NCT01617928
carboplatin Other Phase PHASE1 Solid Tumors COMPLETED NCT01617928
veliparib (ABT-888) Other Phase PHASE1 Solid Tumors COMPLETED NCT01617928
paclitaxel Other Phase PHASE1 Solid Tumors COMPLETED NCT01617928
carboplatin Other Phase PHASE1 Solid Tumors COMPLETED NCT01617928
veliparib (ABT-888) Other Phase PHASE1 Solid Tumors COMPLETED NCT01617928
radiation Other Phase PHASE1 Locally Advanced Rectal Cancer COMPLETED NCT01589419
capecitabine Other Phase PHASE1 Locally Advanced Rectal Cancer COMPLETED NCT01589419
veliparib Other Phase PHASE1 Locally Advanced Rectal Cancer COMPLETED NCT01589419
radiation Other Phase PHASE1 Locally Advanced Rectal Cancer COMPLETED NCT01589419
capecitabine Other Phase PHASE1 Locally Advanced Rectal Cancer COMPLETED NCT01589419
veliparib Other Phase PHASE1 Locally Advanced Rectal Cancer COMPLETED NCT01589419
ABT-348 and azacitidine Other Phase PHASE1 Acute Lymphoblastic Leukemia COMPLETED NCT01110473
ABT-348 Other Phase PHASE1 Acute Lymphoblastic Leukemia COMPLETED NCT01110473
ABT-348 and azacitidine Other Phase PHASE1 Acute Lymphoblastic Leukemia COMPLETED NCT01110473
ABT-348 Other Phase PHASE1 Acute Lymphoblastic Leukemia COMPLETED NCT01110473
irinotecan (weekly schedule) Other Phase PHASE1 Solid Tumors COMPLETED NCT01009073
irinotecan (3-week schedule) Other Phase PHASE1 Solid Tumors COMPLETED NCT01009073
erlotinib Other Phase PHASE1 Solid Tumors COMPLETED NCT01009073
ABT-263 Other Phase PHASE1 Solid Tumors COMPLETED NCT01009073
irinotecan (weekly schedule) Other Phase PHASE1 Solid Tumors COMPLETED NCT01009073
irinotecan (3-week schedule) Other Phase PHASE1 Solid Tumors COMPLETED NCT01009073
erlotinib Other Phase PHASE1 Solid Tumors COMPLETED NCT01009073
ABT-263 Other Phase PHASE1 Solid Tumors COMPLETED NCT01009073
Placebo for ritonavir Other Phase PHASE1 HCV Infection COMPLETED NCT00850044
placebo for ABT-450 Other Phase PHASE1 HCV Infection COMPLETED NCT00850044
ritonavir Other Phase PHASE1 HCV Infection COMPLETED NCT00850044
ABT-450 Other Phase PHASE1 HCV Infection COMPLETED NCT00850044
Placebo for ritonavir Other Phase PHASE1 HCV Infection COMPLETED NCT00850044
placebo for ABT-450 Other Phase PHASE1 HCV Infection COMPLETED NCT00850044
ritonavir Other Phase PHASE1 HCV Infection COMPLETED NCT00850044
ABT-450 Other Phase PHASE1 HCV Infection COMPLETED NCT00850044
adalimumab Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT00650156
adalimumab Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT00650156
linifanib Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01413893
Matching Placebo Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT01380704
ABT-436 Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT01380704
Matching Placebo Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT01380704
ABT-436 Other Phase PHASE1 Major Depressive Disorder COMPLETED NCT01380704
Paclitaxel Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT01225302
Carboplatin Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT01225302
Linifanib Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT01225302
Paclitaxel Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT01225302
Carboplatin Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT01225302
Linifanib Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT01225302
veliparib Other Phase PHASE1 Solid Tumors COMPLETED NCT01199224
veliparib Other Phase PHASE1 Solid Tumors COMPLETED NCT01199224
Rifampin Other Phase PHASE1 Lymphoma, Including Chronic Lymphocytic Leukemia COMPLETED NCT01121133
navitoclax Other Phase PHASE1 Lymphoma, Including Chronic Lymphocytic Leukemia COMPLETED NCT01121133
Rifampin Other Phase PHASE1 Lymphoma, Including Chronic Lymphocytic Leukemia COMPLETED NCT01121133
navitoclax Other Phase PHASE1 Lymphoma, Including Chronic Lymphocytic Leukemia COMPLETED NCT01121133
Placebo Other Phase PHASE1 Asthma COMPLETED NCT00986037
ABT-308 Other Phase PHASE1 Asthma COMPLETED NCT00986037
Placebo Other Phase PHASE1 Asthma COMPLETED NCT00986037
ABT-308 Other Phase PHASE1 Asthma COMPLETED NCT00986037
ABT-263 Other Phase PHASE1 Lymphoid Malignancy COMPLETED NCT00982566
paclitaxel Other Phase PHASE1 Solid Tumors COMPLETED NCT00891605
ABT-263 Other Phase PHASE1 Solid Tumors COMPLETED NCT00891605
paclitaxel Other Phase PHASE1 Solid Tumors COMPLETED NCT00891605
ABT-263 Other Phase PHASE1 Solid Tumors COMPLETED NCT00891605
Placebo Other Phase PHASE1 Schizophrenia COMPLETED NCT00888693
ABT-288 Other Phase PHASE1 Schizophrenia COMPLETED NCT00888693
gemcitabine Other Phase PHASE1 Solid Tumors COMPLETED NCT00887757
ABT-263 Other Phase PHASE1 Solid Tumors COMPLETED NCT00887757
gemcitabine Other Phase PHASE1 Solid Tumors COMPLETED NCT00887757
ABT-263 Other Phase PHASE1 Solid Tumors COMPLETED NCT00887757
ABT-869 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT00733187
ABT-869 Other Phase PHASE1 Solid Tumor COMPLETED NCT00718380
ABT-869 Other Phase PHASE1 Solid Tumor COMPLETED NCT00718380
ABT-869 Other Phase PHASE1 Solid Tumor COMPLETED NCT00718380
Placebo Other Phase PHASE1 HCV Infection COMPLETED NCT00696904
ABT-333 Other Phase PHASE1 HCV Infection COMPLETED NCT00696904
M200 (Volociximab), Carboplatin, Paclitaxel Other Phase PHASE1 Non-small Cell Lung Cancer COMPLETED NCT00654758
M200 (Volociximab), Carboplatin, Paclitaxel Other Phase PHASE1 Non-small Cell Lung Cancer COMPLETED NCT00654758
Temozolomide Other Phase PHASE1 Non-hematologic Malignancies COMPLETED NCT00526617
ABT-888 Other Phase PHASE1 Non-hematologic Malignancies COMPLETED NCT00526617
Temozolomide Other Phase PHASE1 Non-hematologic Malignancies COMPLETED NCT00526617
ABT-888 Other Phase PHASE1 Non-hematologic Malignancies COMPLETED NCT00526617
ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02487199
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02487199
ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02487199
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02487199
Placebo Other Phase PHASE3 Obsessive Compulsive Disorder COMPLETED NCT01933919
Fluvoxamine maleate Other Phase PHASE3 Obsessive Compulsive Disorder COMPLETED NCT01933919
Glecaprevir-pibrentasvir Other Phase PHASE4 Hepatitis C UNKNOWN NCT03364725
Testosterone Gel 1.62% Other Phase PHASE1 Hypogonadism COMPLETED NCT01133548
Testosterone Gel 1.62% Other Phase PHASE1 Hypogonadism COMPLETED NCT01133548
Testosterone Gel 1.62% Other Phase PHASE1 Healthy COMPLETED NCT01130298
ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection TERMINATED NCT02504099
ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Chronic Hepatitis C Infection TERMINATED NCT02504099
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Chronic Hepatitis C Infection TERMINATED NCT02504099
Ribavirin Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02356562
Sofosbuvir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02356562
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02356562
Ribavirin Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02356562
Sofosbuvir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02356562
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02356562
ABT-767 Other Phase PHASE1 Fallopian Tube COMPLETED NCT01339650
ABT-767 Other Phase PHASE1 Fallopian Tube COMPLETED NCT01339650
adalimumab Other Phase PHASE3 Hidradenitis Suppurativa COMPLETED NCT01635764
adalimumab Other Phase PHASE3 Hidradenitis Suppurativa COMPLETED NCT01635764
Adalimumab Other Approved Crohn Disease COMPLETED NCT02539849
FOS Other Approved Crohn Disease COMPLETED NCT02539849
Adalimumab Other Approved Crohn Disease COMPLETED NCT02539849
FOS Other Approved Crohn Disease COMPLETED NCT02539849
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02068222
ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02068222
ABT-450/ritonavir (r) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02068222
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02068222
ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02068222
ABT-450/ritonavir (r) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02068222
adalimumab Other Phase PHASE4 Moderate to Severe Crohn's Disease COMPLETED NCT02148718
adalimumab Other Phase PHASE4 Moderate to Severe Crohn's Disease COMPLETED NCT02148718
ABBV-221 Other Phase PHASE1 Head and Neck Squamous Cell Carcinoma TERMINATED NCT02365662
ABBV-221 Other Phase PHASE1 Head and Neck Squamous Cell Carcinoma TERMINATED NCT02365662
ABBV-221 Other Phase PHASE1 Head and Neck Squamous Cell Carcinoma TERMINATED NCT02365662
SC-007 Other Phase PHASE1 Colorectal Cancer (CRC) TERMINATED NCT03253185
SC-007 Other Phase PHASE1 Colorectal Cancer (CRC) TERMINATED NCT03253185
SC-007 Other Phase PHASE1 Colorectal Cancer (CRC) TERMINATED NCT03253185
ABT-126 Other Phase PHASE2 Schizophrenia TERMINATED NCT01834638
ABT-126 Other Phase PHASE2 Schizophrenia TERMINATED NCT01834638
veliparib (ABT-888) Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT02210663
Adalimumab Other Phase PHASE4 RheumatoId Arthritis UNKNOWN NCT02035800
Adalimumab Other Phase PHASE4 RheumatoId Arthritis UNKNOWN NCT02035800
Placebo Other Phase PHASE1 Multiple Sclerosis COMPLETED NCT02601885
ABT-555 Other Phase PHASE1 Multiple Sclerosis COMPLETED NCT02601885
Adalimumab Other Phase PHASE4 Psoriasis COMPLETED NCT01866592
Adalimumab Other Phase PHASE4 Psoriasis COMPLETED NCT01866592
Placebo for adalimumab Other Phase PHASE2 Crohn's Disease COMPLETED NCT02015793
Adalimumab Other Phase PHASE2 Crohn's Disease COMPLETED NCT02015793
Placebo for adalimumab Other Phase PHASE2 Crohn's Disease COMPLETED NCT02015793
Adalimumab Other Phase PHASE2 Crohn's Disease COMPLETED NCT02015793
J-tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01960842
PEG tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01960842
CADD-Legacy® 1400 ambulatory infusion pump Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01960842
Levodopa-carbidopa intestinal gel Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01960842
J-tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01960842
PEG tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01960842
CADD-Legacy® 1400 ambulatory infusion pump Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01960842
Levodopa-carbidopa intestinal gel Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01960842
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01911845
ABT-333 Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01911845
ABT-450/r/ABT-267 Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01911845
Placebo Other Phase PHASE3 Axial Spondyloarthritis COMPLETED NCT01808118
adalimumab Other Phase PHASE3 Axial Spondyloarthritis COMPLETED NCT01808118
Placebo Other Phase PHASE3 Axial Spondyloarthritis COMPLETED NCT01808118
adalimumab Other Phase PHASE3 Axial Spondyloarthritis COMPLETED NCT01808118
ABT-450/ritonavir, ABT-267 Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01672983
ABT-450/ritonavir, ABT-267 Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT01672983
Placebo Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02023099
ABT-450/r/ABT-267 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02023099
ABT-199 Other Phase PHASE2 Acute Myelogenous Leukemia COMPLETED NCT01994837
ABT-199 Other Phase PHASE2 Acute Myelogenous Leukemia COMPLETED NCT01994837
temozolomide Other Phase PHASE2 Ovarian Cancer COMPLETED NCT01113957
pegylated liposomal doxorubicin Other Phase PHASE2 Ovarian Cancer COMPLETED NCT01113957
ABT-888 Other Phase PHASE2 Ovarian Cancer COMPLETED NCT01113957
temozolomide Other Phase PHASE2 Ovarian Cancer COMPLETED NCT01113957
pegylated liposomal doxorubicin Other Phase PHASE2 Ovarian Cancer COMPLETED NCT01113957
ABT-888 Other Phase PHASE2 Ovarian Cancer COMPLETED NCT01113957
Placebo Other Phase PHASE2 Cognitive Deficits in Schizophrenia COMPLETED NCT01095562
ABT-126 Other Phase PHASE2 Cognitive Deficits in Schizophrenia COMPLETED NCT01095562
Placebo Other Phase PHASE2 Cognitive Deficits in Schizophrenia COMPLETED NCT01095562
ABT-126 Other Phase PHASE2 Cognitive Deficits in Schizophrenia COMPLETED NCT01095562
placebo Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01018875
donepezil Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01018875
ABT-288 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01018875
placebo Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01018875
donepezil Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01018875
ABT-288 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01018875
placebo Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01018875
donepezil Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01018875
ABT-288 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT01018875
1.75 mg Atrasentan QD Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
0.75 mg Atrasentan QD Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
0.25 mg Atrasentan QD Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
Placebo for Atrasentan 0.2 mg/mL solution Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
1.75 mg Atrasentan QD Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
0.75 mg Atrasentan QD Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
0.25 mg Atrasentan QD Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
Placebo for Atrasentan 0.2 mg/mL solution Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
1.75 mg Atrasentan QD Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
0.75 mg Atrasentan QD Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
0.25 mg Atrasentan QD Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
Placebo for Atrasentan 0.2 mg/mL solution Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT00920764
etoposide/cisplatin Other Phase PHASE1 Solid Tumors COMPLETED NCT00878449
ABT-263 Other Phase PHASE1 Solid Tumors COMPLETED NCT00878449
Placebo Other Phase PHASE2 Melanoma COMPLETED NCT00804908
ABT-888 Other Phase PHASE2 Melanoma COMPLETED NCT00804908
temozolomide Other Phase PHASE2 Melanoma COMPLETED NCT00804908
Placebo Other Phase PHASE2 Melanoma COMPLETED NCT00804908
ABT-888 Other Phase PHASE2 Melanoma COMPLETED NCT00804908
temozolomide Other Phase PHASE2 Melanoma COMPLETED NCT00804908
ABT-263 Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT00445198
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01609933
pegylated interferon alpha-2a (pegIFN) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01609933
ABT-267 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01609933
ABT-450/r Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01609933
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01609933
pegylated interferon alpha-2a (pegIFN) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01609933
ABT-267 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01609933
ABT-450/r Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01609933
Adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT01550965
Adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT01550965
paricalcitol Other Phase PHASE3 End-Stage Renal Disease COMPLETED NCT01382212
paricalcitol Other Phase PHASE3 End-Stage Renal Disease COMPLETED NCT01382212
paricalcitol Other Phase PHASE3 End-Stage Renal Disease COMPLETED NCT01382212
Placebo for ABT-267 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01314261
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01314261
Pegylated interferon (pegIFN) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01314261
ABT-267 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01314261
Placebo for ABT-267 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01314261
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01314261
Pegylated interferon (pegIFN) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01314261
ABT-267 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01314261
Adalimumab delivered in Physiolis autoinjector Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Adalimumab delivered in current autoinjector Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Adalimumab delivered in Physiolis syringe Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Adalimumab delivered in current syringe Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Adalimumab delivered in Physiolis autoinjector Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Adalimumab delivered in current autoinjector Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Adalimumab delivered in Physiolis syringe Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Adalimumab delivered in current syringe Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Adalimumab delivered in Physiolis autoinjector Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Adalimumab delivered in current autoinjector Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Adalimumab delivered in Physiolis syringe Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Adalimumab delivered in current syringe Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01163617
Placebo Other Phase PHASE3 Chronic Kidney Disease Stage 3 and 4 COMPLETED NCT01020487
Paricalcitol Other Phase PHASE3 Chronic Kidney Disease Stage 3 and 4 COMPLETED NCT01020487
Placebo Other Phase PHASE3 Chronic Kidney Disease Stage 3 and 4 COMPLETED NCT01020487
Paricalcitol Other Phase PHASE3 Chronic Kidney Disease Stage 3 and 4 COMPLETED NCT01020487
Ribavirin Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT00851890
Pegylated interferon Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT00851890
Placebo for ABT-333 Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT00851890
ABT-333 Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT00851890
Ribavirin Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT00851890
Pegylated interferon Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT00851890
Placebo for ABT-333 Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT00851890
ABT-333 Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT00851890
Adalimumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT00686374
Adalimumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT00686374
Atorvastatin Other Phase PHASE3 Coronary Artery Disease COMPLETED NCT00616772
Placebo Other Phase PHASE3 Coronary Artery Disease COMPLETED NCT00616772
ABT-335 Other Phase PHASE3 Coronary Artery Disease COMPLETED NCT00616772
Atorvastatin Other Phase PHASE3 Coronary Artery Disease COMPLETED NCT00616772
Placebo Other Phase PHASE3 Coronary Artery Disease COMPLETED NCT00616772
ABT-335 Other Phase PHASE3 Coronary Artery Disease COMPLETED NCT00616772
Elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT01931670
placebo Other Phase PHASE3 Endometriosis COMPLETED NCT01931670
Elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT01931670
placebo Other Phase PHASE3 Endometriosis COMPLETED NCT01931670
placebo Other Phase PHASE2 Endometriosis, Pain COMPLETED NCT00619866
Elagolix Other Phase PHASE2 Endometriosis, Pain COMPLETED NCT00619866
placebo Other Phase PHASE2 Endometriosis, Pain COMPLETED NCT00619866
Elagolix Other Phase PHASE2 Endometriosis, Pain COMPLETED NCT00619866
Placebo to Leuprorelin Acetate Other Phase PHASE2 Endometriosis COMPLETED NCT00797225
Placebo to Elagolix Other Phase PHASE2 Endometriosis COMPLETED NCT00797225
Elagolix Other Phase PHASE2 Endometriosis COMPLETED NCT00797225
Leuprorelin Acetate Depot Other Phase PHASE2 Endometriosis COMPLETED NCT00797225
Placebo to Leuprorelin Acetate Other Phase PHASE2 Endometriosis COMPLETED NCT00797225
Placebo to Elagolix Other Phase PHASE2 Endometriosis COMPLETED NCT00797225
Elagolix Other Phase PHASE2 Endometriosis COMPLETED NCT00797225
Leuprorelin Acetate Depot Other Phase PHASE2 Endometriosis COMPLETED NCT00797225
Dexamethasone Other Phase PHASE1 Multiple Myeloma TERMINATED NCT02462525
Pomalidomide Other Phase PHASE1 Multiple Myeloma TERMINATED NCT02462525
ABBV-838 Other Phase PHASE1 Multiple Myeloma TERMINATED NCT02462525
Dexamethasone Other Phase PHASE1 Multiple Myeloma TERMINATED NCT02462525
Pomalidomide Other Phase PHASE1 Multiple Myeloma TERMINATED NCT02462525
ABBV-838 Other Phase PHASE1 Multiple Myeloma TERMINATED NCT02462525
Dexamethasone Other Phase PHASE1 Multiple Myeloma TERMINATED NCT02462525
Pomalidomide Other Phase PHASE1 Multiple Myeloma TERMINATED NCT02462525
ABBV-838 Other Phase PHASE1 Multiple Myeloma TERMINATED NCT02462525
placebo Other Phase PHASE3 Endometriosis COMPLETED NCT01620528
elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT01620528
placebo Other Phase PHASE3 Endometriosis COMPLETED NCT01620528
elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT01620528
Elagolix Other Phase PHASE2 Endometriosis, Pain COMPLETED NCT00973973
Placebo Other Phase PHASE2 Endometriosis, Pain COMPLETED NCT00973973
Elagolix Other Phase PHASE2 Endometriosis, Pain COMPLETED NCT00973973
Placebo Other Phase PHASE2 Endometriosis, Pain COMPLETED NCT00973973
Placebo to DMPA-SC Other Phase PHASE2 Endometriosis COMPLETED NCT00437658
Placebo to Elagolix Other Phase PHASE2 Endometriosis COMPLETED NCT00437658
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) Other Phase PHASE2 Endometriosis COMPLETED NCT00437658
Elagolix Other Phase PHASE2 Endometriosis COMPLETED NCT00437658
Placebo to DMPA-SC Other Phase PHASE2 Endometriosis COMPLETED NCT00437658
Placebo to Elagolix Other Phase PHASE2 Endometriosis COMPLETED NCT00437658
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) Other Phase PHASE2 Endometriosis COMPLETED NCT00437658
Elagolix Other Phase PHASE2 Endometriosis COMPLETED NCT00437658
paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin Other Phase PHASE4 Chronic Hepatitis C COMPLETED NCT03710252
Adalimumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT02185014
Adalimumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT02185014
Calcifediol Other Phase PHASE4 Secondary Hyperparathyroidism Due to Renal Causes COMPLETED NCT01939977
Paricalcitol Other Phase PHASE4 Secondary Hyperparathyroidism Due to Renal Causes COMPLETED NCT01939977
Calcifediol Other Phase PHASE4 Secondary Hyperparathyroidism Due to Renal Causes COMPLETED NCT01939977
Paricalcitol Other Phase PHASE4 Secondary Hyperparathyroidism Due to Renal Causes COMPLETED NCT01939977
Calcifediol Other Phase PHASE4 Secondary Hyperparathyroidism Due to Renal Causes COMPLETED NCT01939977
Paricalcitol Other Phase PHASE4 Secondary Hyperparathyroidism Due to Renal Causes COMPLETED NCT01939977
Fluorouracil infusion Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
Bevacizumab Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
FOLFIRI Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
Modified FOLFIRI Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
Placebo Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
Veliparib Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
Fluorouracil infusion Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
Bevacizumab Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
FOLFIRI Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
Modified FOLFIRI Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
Placebo Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
Veliparib Other Phase PHASE2 Untreated Metastatic Colorectal Cancer COMPLETED NCT02305758
Placebo Other Phase PHASE2 Crohn Disease COMPLETED NCT02031276
risankizumab SC Other Phase PHASE2 Crohn Disease COMPLETED NCT02031276
risankizumab IV Other Phase PHASE2 Crohn Disease COMPLETED NCT02031276
Placebo Other Phase PHASE2 Crohn Disease COMPLETED NCT02031276
risankizumab SC Other Phase PHASE2 Crohn Disease COMPLETED NCT02031276
risankizumab IV Other Phase PHASE2 Crohn Disease COMPLETED NCT02031276
Placebo Other Phase PHASE2 Crohn Disease COMPLETED NCT02031276
risankizumab SC Other Phase PHASE2 Crohn Disease COMPLETED NCT02031276
risankizumab IV Other Phase PHASE2 Crohn Disease COMPLETED NCT02031276
ABBV-176 Other Phase PHASE1 Advanced Solid Tumors Cancer TERMINATED NCT03145909
ABBV-176 Other Phase PHASE1 Advanced Solid Tumors Cancer TERMINATED NCT03145909
SC-005 Other Phase PHASE1 Breast Cancer TERMINATED NCT03316794
SC-005 Other Phase PHASE1 Breast Cancer TERMINATED NCT03316794
SC-005 Other Phase PHASE1 Breast Cancer TERMINATED NCT03316794
Rovalpituzumab tesirine Other Phase PHASE3 Small Cell Lung Cancer WITHDRAWN NCT03334487
Dexamethasone Other Phase PHASE3 Small Cell Lung Cancer WITHDRAWN NCT03334487
Rovalpituzumab tesirine Other Phase PHASE3 Small Cell Lung Cancer WITHDRAWN NCT03334487
Dexamethasone Other Phase PHASE3 Small Cell Lung Cancer WITHDRAWN NCT03334487
Rovalpituzumab tesirine Other Phase PHASE3 Small Cell Lung Cancer WITHDRAWN NCT03334487
Dexamethasone Other Phase PHASE3 Small Cell Lung Cancer WITHDRAWN NCT03334487
placebo Other Phase PHASE3 Crohn's Disease COMPLETED NCT02499783
adalimumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT02499783
placebo Other Phase PHASE3 Crohn's Disease COMPLETED NCT02499783
adalimumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT02499783
Adalimumab Other Phase PHASE3 Generalized Pustular Psoriasis (GPP) COMPLETED NCT02533375
Adalimumab Other Preclinical Ankylosing Spondylitis COMPLETED NCT02333383
Adalimumab Other Preclinical Rheumatoid Arthritis COMPLETED NCT01768858
Adalimumab Other Preclinical Rheumatoid Arthritis COMPLETED NCT01768858
Adalimumab Other Preclinical Rheumatoid Arthritis COMPLETED NCT01768858
Glecaprevir/pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03069365
ABBV-399 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT03311477
ABBV-399 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT03311477
Ribavirin Other Preclinical Chronic Hepatitis C COMPLETED NCT02581189
Dasabuvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02581189
Ombitasvir/paritaprevir/ritonavir Other Preclinical Chronic Hepatitis C COMPLETED NCT02581189
Ribavirin Other Preclinical Chronic Hepatitis C COMPLETED NCT02581189
Dasabuvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02581189
Ombitasvir/paritaprevir/ritonavir Other Preclinical Chronic Hepatitis C COMPLETED NCT02581189
ABBV-085 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT02565758
ABBV-085 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT02565758
ABBV-085 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT02565758
risankizumab Other Phase PHASE2 Asthma COMPLETED NCT02443298
placebo Other Phase PHASE2 Asthma COMPLETED NCT02443298
risankizumab Other Phase PHASE2 Asthma COMPLETED NCT02443298
placebo Other Phase PHASE2 Asthma COMPLETED NCT02443298
risankizumab Other Phase PHASE2 Asthma COMPLETED NCT02443298
placebo Other Phase PHASE2 Asthma COMPLETED NCT02443298
Placebo Other Phase PHASE3 Diabetic Nephropathy TERMINATED NCT01858532
Atrasentan Other Phase PHASE3 Diabetic Nephropathy TERMINATED NCT01858532
Creon36™ Other Phase PHASE2 Chronic Pancreatitis COMPLETED NCT02849704
Ribavirin Other Preclinical Chronic Hepatitis C COMPLETED NCT02582671
Dasabuvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02582671
Ombitasvir/paritaprevir/ritonavir Other Preclinical Chronic Hepatitis C COMPLETED NCT02582671
Ribavirin Other Preclinical Chronic Hepatitis C COMPLETED NCT02582671
Dasabuvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02582671
Ombitasvir/paritaprevir/ritonavir Other Preclinical Chronic Hepatitis C COMPLETED NCT02582671
Ribavirin Other Preclinical Chronic Hepatitis C COMPLETED NCT02582671
Dasabuvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02582671
Ombitasvir/paritaprevir/ritonavir Other Preclinical Chronic Hepatitis C COMPLETED NCT02582671
Ribavirin Other Preclinical Chronic Hepatitis C, Genotype 1 or 4 COMPLETED NCT02581163
Dasabuvir Other Preclinical Chronic Hepatitis C, Genotype 1 or 4 COMPLETED NCT02581163
Ombitasvir/paritaprevir/ritonavir Other Preclinical Chronic Hepatitis C, Genotype 1 or 4 COMPLETED NCT02581163
caremessage Other Approved Medication Adherence COMPLETED NCT03052231
caremessage Other Approved Medication Adherence COMPLETED NCT03052231
Atrasentan Other Phase PHASE2 Nephropathy COMPLETED NCT02118714
Atrasentan Other Phase PHASE2 Nephropathy COMPLETED NCT02118714
ABBV-181 Other Phase PHASE1 Cancer TERMINATED NCT03138408
SC-004 Other Phase PHASE1 Cancer TERMINATED NCT03138408
ABBV-181 Other Phase PHASE1 Cancer TERMINATED NCT03138408
SC-004 Other Phase PHASE1 Cancer TERMINATED NCT03138408
placebo for risankizumab Other Phase PHASE2 Psoriasis COMPLETED NCT03000075
risankizumab Other Phase PHASE2 Psoriasis COMPLETED NCT03000075
placebo for risankizumab Other Phase PHASE2 Psoriasis COMPLETED NCT03000075
risankizumab Other Phase PHASE2 Psoriasis COMPLETED NCT03000075
placebo for risankizumab Other Phase PHASE2 Psoriasis COMPLETED NCT03000075
risankizumab Other Phase PHASE2 Psoriasis COMPLETED NCT03000075
risankizumab Other Phase PHASE2 Psoriatic Arthritis COMPLETED NCT02986373
risankizumab Other Phase PHASE2 Psoriatic Arthritis COMPLETED NCT02986373
placebo for risankizumab Other Phase PHASE2 Arthritis, Psoriatic COMPLETED NCT02719171
risankizumab Other Phase PHASE2 Arthritis, Psoriatic COMPLETED NCT02719171
risankizumab Other Phase PHASE2 Ankylosing Spondylitis (AS) COMPLETED NCT02047110
placebo for risankizumab Other Phase PHASE2 Ankylosing Spondylitis (AS) COMPLETED NCT02047110
risankizumab Other Phase PHASE2 Ankylosing Spondylitis (AS) COMPLETED NCT02047110
placebo for risankizumab Other Phase PHASE2 Ankylosing Spondylitis (AS) COMPLETED NCT02047110
risankizumab Other Phase PHASE2 Ankylosing Spondylitis (AS) COMPLETED NCT02047110
placebo for risankizumab Other Phase PHASE2 Ankylosing Spondylitis (AS) COMPLETED NCT02047110
Rituximab Other Phase PHASE2 Follicular Lymphoma COMPLETED NCT02187861
Bendamustine Other Phase PHASE2 Follicular Lymphoma COMPLETED NCT02187861
Venetoclax Other Phase PHASE2 Follicular Lymphoma COMPLETED NCT02187861
Rituximab Other Phase PHASE2 Follicular Lymphoma COMPLETED NCT02187861
Bendamustine Other Phase PHASE2 Follicular Lymphoma COMPLETED NCT02187861
Venetoclax Other Phase PHASE2 Follicular Lymphoma COMPLETED NCT02187861
lamivudine Other Preclinical HIV-1 Infection COMPLETED NCT02581202
lopinavir/ritonavir Other Preclinical HIV-1 Infection COMPLETED NCT02581202
lamivudine Other Preclinical HIV-1 Infection COMPLETED NCT02581202
lopinavir/ritonavir Other Preclinical HIV-1 Infection COMPLETED NCT02581202
Placebo Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT02198651
Adalimumab Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT02198651
Placebo Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT02198651
Adalimumab Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT02198651
Adalimumab Other Preclinical Rheumatoid Arthritis COMPLETED NCT01736189
Adalimumab Other Preclinical Rheumatoid Arthritis COMPLETED NCT01736189
Adalimumab Other Preclinical Rheumatoid Arthritis COMPLETED NCT01736189
Non-steroidal Anti-inflammatory Drugs (NSAIDs) Drug Phase PHASE4 Axial Spondyloarthritis TERMINATED NCT02897115
Adalimumab Other Phase PHASE4 Axial Spondyloarthritis TERMINATED NCT02897115
Non-steroidal Anti-inflammatory Drugs (NSAIDs) Drug Phase PHASE4 Axial Spondyloarthritis TERMINATED NCT02897115
Adalimumab Other Phase PHASE4 Axial Spondyloarthritis TERMINATED NCT02897115
Non-steroidal Anti-inflammatory Drugs (NSAIDs) Drug Phase PHASE4 Axial Spondyloarthritis TERMINATED NCT02897115
Adalimumab Other Phase PHASE4 Axial Spondyloarthritis TERMINATED NCT02897115
Placebo Other Phase PHASE2 Psoriasis COMPLETED NCT03217734
Methotrexate Other Phase PHASE2 Psoriasis COMPLETED NCT03217734
Adalimumab Other Phase PHASE2 Psoriasis COMPLETED NCT03217734
Placebo Other Phase PHASE2 Psoriasis COMPLETED NCT03217734
Methotrexate Other Phase PHASE2 Psoriasis COMPLETED NCT03217734
Adalimumab Other Phase PHASE2 Psoriasis COMPLETED NCT03217734
ABT-414 Other Preclinical Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis NO_LONGER_AVAILABLE NCT03123952
ABT-414 Other Preclinical Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis NO_LONGER_AVAILABLE NCT03123952
ABT-414 Other Preclinical Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis NO_LONGER_AVAILABLE NCT03123952
PTV/r/OBV/DSV Other Phase PHASE4 Hepatitis Viruses COMPLETED NCT02874066
PTV/r/OBV/DSV Other Phase PHASE4 Hepatitis Viruses COMPLETED NCT02874066
EXVIERA Other Phase PHASE4 HCV Coinfection COMPLETED NCT03050905
VEKIRAX Other Phase PHASE4 HCV Coinfection COMPLETED NCT03050905
EXVIERA Other Phase PHASE4 HCV Coinfection COMPLETED NCT03050905
VEKIRAX Other Phase PHASE4 HCV Coinfection COMPLETED NCT03050905
Adalimumab Other Preclinical Hidradenitis Suppurativa COMPLETED NCT02739828
Adalimumab Other Preclinical Hidradenitis Suppurativa COMPLETED NCT02739828
Adalimumab Other Preclinical Hidradenitis Suppurativa COMPLETED NCT02739828
ABT450r-ABT267-ABT333 +/- Ribavirin Other Phase PHASE4 Hepatitis C COMPLETED NCT02734173
Fecal calprotectin Other Approved Spondyloarthropathy COMPLETED NCT03064815
PROMETHEUS® IBD sgi Diagnostic™ Other Approved Spondyloarthropathy COMPLETED NCT03064815
colonoscopy Other Approved Spondyloarthropathy COMPLETED NCT03064815
Videocapsule endoscopy Other Approved Spondyloarthropathy COMPLETED NCT03064815
Fecal calprotectin Other Approved Spondyloarthropathy COMPLETED NCT03064815
PROMETHEUS® IBD sgi Diagnostic™ Other Approved Spondyloarthropathy COMPLETED NCT03064815
colonoscopy Other Approved Spondyloarthropathy COMPLETED NCT03064815
Videocapsule endoscopy Other Approved Spondyloarthropathy COMPLETED NCT03064815
ABBV-8E12 Other Preclinical Primary Tauopathy Corticobasal Degeneration Syndrome (CBD) NO_LONGER_AVAILABLE NCT03744546
ABBV-8E12 Other Preclinical Primary Tauopathy Corticobasal Degeneration Syndrome (CBD) NO_LONGER_AVAILABLE NCT03744546
dexamethasone Other Phase PHASE2 Multiple Myeloma WITHDRAWN NCT03785184
lenalidomide Other Phase PHASE2 Multiple Myeloma WITHDRAWN NCT03785184
venetoclax Other Phase PHASE2 Multiple Myeloma WITHDRAWN NCT03785184
dexamethasone Other Phase PHASE2 Multiple Myeloma WITHDRAWN NCT03785184
lenalidomide Other Phase PHASE2 Multiple Myeloma WITHDRAWN NCT03785184
venetoclax Other Phase PHASE2 Multiple Myeloma WITHDRAWN NCT03785184
Placebo Other Phase PHASE2 Knee Osteoarthritis COMPLETED NCT02087904
ABT-981 Other Phase PHASE2 Knee Osteoarthritis COMPLETED NCT02087904
Placebo Other Phase PHASE2 Knee Osteoarthritis COMPLETED NCT02087904
ABT-981 Other Phase PHASE2 Knee Osteoarthritis COMPLETED NCT02087904
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03212521
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03212521
rovalpituzumab tesirine Other Preclinical Small Cell Lung Cancer NO_LONGER_AVAILABLE NCT03503890
rovalpituzumab tesirine Other Preclinical Small Cell Lung Cancer NO_LONGER_AVAILABLE NCT03503890
rovalpituzumab tesirine Other Preclinical Small Cell Lung Cancer NO_LONGER_AVAILABLE NCT03503890
Adalimumab Other Preclinical Rheumatoid Arthritis COMPLETED NCT02668640
Adalimumab Other Preclinical Rheumatoid Arthritis COMPLETED NCT02668640
Adalimumab Other Preclinical Rheumatoid Arthritis COMPLETED NCT02668640
Standard of Care (SOC) Physiotherapy Drug Preclinical Axial Spondyloarthritis TERMINATED NCT03258814
Active Supervised Training (AST) Other Preclinical Axial Spondyloarthritis TERMINATED NCT03258814
Standard of Care (SOC) Physiotherapy Drug Preclinical Axial Spondyloarthritis TERMINATED NCT03258814
Active Supervised Training (AST) Other Preclinical Axial Spondyloarthritis TERMINATED NCT03258814
Placebo Other Phase PHASE3 Psoriasis COMPLETED NCT02672852
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT02672852
Placebo Other Phase PHASE3 Psoriasis COMPLETED NCT02672852
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT02672852
Placebo Other Phase PHASE3 Psoriasis COMPLETED NCT02672852
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT02672852
Patient support program Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
Ribavirin Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
Dasabuvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
Ombitasvir/paritaprevir/ritonavir Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
Patient support program Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
Ribavirin Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
Dasabuvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
Ombitasvir/paritaprevir/ritonavir Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
Patient support program Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
Ribavirin Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
Dasabuvir Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
Ombitasvir/paritaprevir/ritonavir Other Preclinical Chronic Hepatitis C COMPLETED NCT02803138
carboplatin Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT02944396
veliparib Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT02944396
paclitaxel Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT02944396
nivolumab Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT02944396
pemetrexed Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT02944396
carboplatin Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT02944396
veliparib Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT02944396
paclitaxel Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT02944396
nivolumab Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT02944396
pemetrexed Other Phase PHASE1 Non-Small Cell Lung Cancer COMPLETED NCT02944396
Adalimumab Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT02056184
Adalimumab Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT02056184
Adalimumab Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT02056184
AbbVie Care 2.0 Other Preclinical Rheumatoid Arthritis COMPLETED NCT02750800
Adalimumab Other Preclinical Rheumatoid Arthritis COMPLETED NCT02750800
AbbVie Care 2.0 Other Preclinical Rheumatoid Arthritis COMPLETED NCT02750800
Adalimumab Other Preclinical Rheumatoid Arthritis COMPLETED NCT02750800
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03235349
estradiol/norethindrone acetate (E2/NETA) Other Phase PHASE3 Endometriosis TERMINATED NCT03343067
elagolix Other Phase PHASE3 Endometriosis TERMINATED NCT03343067
estradiol/norethindrone acetate (E2/NETA) Other Phase PHASE3 Endometriosis TERMINATED NCT03343067
elagolix Other Phase PHASE3 Endometriosis TERMINATED NCT03343067
estradiol/norethindrone acetate (E2/NETA) Other Phase PHASE3 Endometriosis TERMINATED NCT03343067
elagolix Other Phase PHASE3 Endometriosis TERMINATED NCT03343067
ABBV-8E12 Other Phase PHASE1 Progressive Supranuclear Palsy (PSP) COMPLETED NCT03413319
ABBV-8E12 Other Phase PHASE1 Progressive Supranuclear Palsy (PSP) COMPLETED NCT03413319
Adalimumab Other Preclinical Psoriasis COMPLETED NCT01387815
Adalimumab Other Preclinical Psoriasis COMPLETED NCT01387815
ribavirin Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02609659
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02609659
ribavirin Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02609659
ombitasvir/paritaprevir/ritonavir and dasabuvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02609659
ABT-199 Other Phase PHASE1 Non-Hodgkin's Lymphoma COMPLETED NCT01969695
ABT-199 Other Phase PHASE1 Non-Hodgkin's Lymphoma COMPLETED NCT01969695
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03222583
Placebo Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03222583
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03222583
Placebo Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03222583
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03222583
Placebo Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03222583
pibrentasvir Other Preclinical Hepatitis C Virus Infection APPROVED_FOR_MARKETING NCT03123965
glecaprevir Other Preclinical Hepatitis C Virus Infection APPROVED_FOR_MARKETING NCT03123965
pibrentasvir Other Preclinical Hepatitis C Virus Infection APPROVED_FOR_MARKETING NCT03123965
glecaprevir Other Preclinical Hepatitis C Virus Infection APPROVED_FOR_MARKETING NCT03123965
ABBV-181 Other Phase PHASE1 Colorectal Cancer TERMINATED NCT03035279
SC-006 Other Phase PHASE1 Colorectal Cancer TERMINATED NCT03035279
ABBV-181 Other Phase PHASE1 Colorectal Cancer TERMINATED NCT03035279
SC-006 Other Phase PHASE1 Colorectal Cancer TERMINATED NCT03035279
Ribavirin 200Mg Tablet Other Phase PHASE3 Hepatitis C COMPLETED NCT03092375
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg Other Phase PHASE3 Hepatitis C COMPLETED NCT03092375
Ribavirin 200Mg Tablet Other Phase PHASE3 Hepatitis C COMPLETED NCT03092375
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg Other Phase PHASE3 Hepatitis C COMPLETED NCT03092375
Punch Biopsy Other Approved Psoriasis COMPLETED NCT03048721
Skin Tape Stripping Other Approved Psoriasis COMPLETED NCT03048721
Punch Biopsy Other Approved Psoriasis COMPLETED NCT03048721
Skin Tape Stripping Other Approved Psoriasis COMPLETED NCT03048721
Punch Biopsy Other Approved Psoriasis COMPLETED NCT03048721
Skin Tape Stripping Other Approved Psoriasis COMPLETED NCT03048721
DSM265 25% SDD, 400 mg fasted Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03637517
DSM265-TPGS 34% SDD, 400 mg fed Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03637517
DSM265-TPGS 34% SDD, 400 mg fasted Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03637517
DSM265 25% SDD, 400 mg fasted Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03637517
DSM265-TPGS 34% SDD, 400 mg fed Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03637517
DSM265-TPGS 34% SDD, 400 mg fasted Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03637517
Etoposide Other Phase PHASE1 Small Cell Lung Cancer TERMINATED NCT02819999
Cisplatin Other Phase PHASE1 Small Cell Lung Cancer TERMINATED NCT02819999
Rovalpituzumab Tesirine Other Phase PHASE1 Small Cell Lung Cancer TERMINATED NCT02819999
Etoposide Other Phase PHASE1 Small Cell Lung Cancer TERMINATED NCT02819999
Cisplatin Other Phase PHASE1 Small Cell Lung Cancer TERMINATED NCT02819999
Rovalpituzumab Tesirine Other Phase PHASE1 Small Cell Lung Cancer TERMINATED NCT02819999
Etoposide Other Phase PHASE1 Small Cell Lung Cancer TERMINATED NCT02819999
Cisplatin Other Phase PHASE1 Small Cell Lung Cancer TERMINATED NCT02819999
Rovalpituzumab Tesirine Other Phase PHASE1 Small Cell Lung Cancer TERMINATED NCT02819999
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03219216
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03219216
Pancreatic Enzyme Other Phase PHASE2 Short Bowel Syndrome COMPLETED NCT03097029
Pancreatic Enzyme Other Phase PHASE2 Short Bowel Syndrome COMPLETED NCT03097029
Risankizumab 180 mg SC Other Phase PHASE2 Crohn Disease COMPLETED NCT02513459
Risankizumab 600 mg IV Other Phase PHASE2 Crohn Disease COMPLETED NCT02513459
Risankizumab 180 mg SC Other Phase PHASE2 Crohn Disease COMPLETED NCT02513459
Risankizumab 600 mg IV Other Phase PHASE2 Crohn Disease COMPLETED NCT02513459
adalimumab Other Phase PHASE3 Hidradenitis Suppurativa COMPLETED NCT02904902
adalimumab Other Phase PHASE3 Hidradenitis Suppurativa COMPLETED NCT02904902
Adalimumab Other Phase PHASE4 Hidradenitis Suppurativa (HS) COMPLETED NCT02808975
Placebo Other Phase PHASE4 Hidradenitis Suppurativa (HS) COMPLETED NCT02808975
Adalimumab Other Phase PHASE4 Hidradenitis Suppurativa (HS) COMPLETED NCT02808975
Placebo Other Phase PHASE4 Hidradenitis Suppurativa (HS) COMPLETED NCT02808975
Placebo Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT02289690
Etoposide Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT02289690
Carboplatin Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT02289690
Veliparib Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT02289690
Placebo Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT02289690
Etoposide Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT02289690
Carboplatin Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT02289690
Veliparib Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT02289690
Lomustine Other Phase PHASE2 Glioblastoma COMPLETED NCT02343406
Temozolomide Other Phase PHASE2 Glioblastoma COMPLETED NCT02343406
Depatuxizumab mafodotin Other Phase PHASE2 Glioblastoma COMPLETED NCT02343406
Prednisone Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Vincristine Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Doxorubicin Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Rituximab Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Obinutuzumab Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Cyclophosphamide Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Venetoclax Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Prednisone Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Vincristine Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Doxorubicin Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Rituximab Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Obinutuzumab Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Cyclophosphamide Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Venetoclax Other Phase PHASE1 Lymphoma, Non-Hodgkin COMPLETED NCT02055820
Placebo for Elagolix Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02654054
Estradiol/Norethindrone Acetate Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02654054
Placebo for Estradiol/Norethindrone Acetate Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02654054
Elagolix Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02654054
Placebo for Elagolix Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02654054
Estradiol/Norethindrone Acetate Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02654054
Placebo for Estradiol/Norethindrone Acetate Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02654054
Elagolix Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02654054
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03089944
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT03089944
Intensity modulated radiation therapy Drug Phase PHASE1 Pancreatic Cancer COMPLETED NCT01908478
Gemcitabine Other Phase PHASE1 Pancreatic Cancer COMPLETED NCT01908478
Veliparib Other Phase PHASE1 Pancreatic Cancer COMPLETED NCT01908478
Intensity modulated radiation therapy Drug Phase PHASE1 Pancreatic Cancer COMPLETED NCT01908478
Gemcitabine Other Phase PHASE1 Pancreatic Cancer COMPLETED NCT01908478
Veliparib Other Phase PHASE1 Pancreatic Cancer COMPLETED NCT01908478
Placebo Other Phase PHASE2 Atopic Dermatitis COMPLETED NCT02925117
Upadacitinib Other Phase PHASE2 Atopic Dermatitis COMPLETED NCT02925117
Placebo Other Phase PHASE2 Atopic Dermatitis COMPLETED NCT02925117
Upadacitinib Other Phase PHASE2 Atopic Dermatitis COMPLETED NCT02925117
Nivolumab Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT02955251
ABBV-428 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT02955251
Nivolumab Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT02955251
ABBV-428 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT02955251
Nivolumab Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT02955251
ABBV-428 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT02955251
E2/NETA placebo Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01817530
1 mg estradiol / 0.5 mg norethindrone acetate Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01817530
0.5 mg estradiol / 0.1 mg norethindrone acetate Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01817530
Elagolix Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01817530
Elagolix placebo Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01817530
Jejunal extension tube Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT02799381
Percutaneous endoscopic gastrostomy tube Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT02799381
CADD-Legacy ambulatory infusion pump Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT02799381
Levodopa-Carbidopa Intestinal Gel (LCIG) Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT02799381
Optimized antiparkinsonian treatment Drug Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT02799381
ABT-414 Other Phase PHASE1 Malignant Glioma COMPLETED NCT02590263
Temozolomide Other Phase PHASE1 Malignant Glioma COMPLETED NCT02590263
Whole Brain Radiation Other Phase PHASE1 Malignant Glioma COMPLETED NCT02590263
ABT-414 Other Phase PHASE1 Malignant Glioma COMPLETED NCT02590263
Temozolomide Other Phase PHASE1 Malignant Glioma COMPLETED NCT02590263
Whole Brain Radiation Other Phase PHASE1 Malignant Glioma COMPLETED NCT02590263
ABT-530 Other Phase PHASE2 Hepatitis C COMPLETED NCT02441283
ABT-493 Other Phase PHASE2 Hepatitis C COMPLETED NCT02441283
ABT-530 Other Phase PHASE2 Hepatitis C COMPLETED NCT02441283
ABT-493 Other Phase PHASE2 Hepatitis C COMPLETED NCT02441283
Placebo Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT02065557
Adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT02065557
Placebo Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT02065557
Adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT02065557
Dexamethasone Other Phase PHASE1 Malignant Melanoma TERMINATED NCT02709889
Rovalpituzumab tesirine Other Phase PHASE1 Malignant Melanoma TERMINATED NCT02709889
Endoscopic balloon dilatation Other Phase PHASE4 Crohn Disease UNKNOWN NCT03220841
Thiopurine Other Phase PHASE4 Crohn Disease UNKNOWN NCT03220841
Adalimumab Injection Other Phase PHASE4 Crohn Disease UNKNOWN NCT03220841
Endoscopic balloon dilatation Other Phase PHASE4 Crohn Disease UNKNOWN NCT03220841
Thiopurine Other Phase PHASE4 Crohn Disease UNKNOWN NCT03220841
Adalimumab Injection Other Phase PHASE4 Crohn Disease UNKNOWN NCT03220841
Endoscopic balloon dilatation Other Phase PHASE4 Crohn Disease UNKNOWN NCT03220841
Thiopurine Other Phase PHASE4 Crohn Disease UNKNOWN NCT03220841
Adalimumab Injection Other Phase PHASE4 Crohn Disease UNKNOWN NCT03220841
Capecitabine Other Phase PHASE1 Breast Cancer TERMINATED NCT04274933
Venetoclax Other Phase PHASE1 Breast Cancer TERMINATED NCT04274933
Capecitabine Other Phase PHASE1 Breast Cancer TERMINATED NCT04274933
Venetoclax Other Phase PHASE1 Breast Cancer TERMINATED NCT04274933
Liver vein catheterization Other Preclinical Hepatitis C COMPLETED NCT02526641
Galactose Elimination Capacity (GEC) Other Preclinical Hepatitis C COMPLETED NCT02526641
Functional Hepatic Nitrogen Clearance (FHNC) Other Preclinical Hepatitis C COMPLETED NCT02526641
Placebo to veliparib Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Paclitaxel Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Veliparib Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Carboplatin Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Placebo to veliparib Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Paclitaxel Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Veliparib Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Carboplatin Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Placebo to veliparib Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Paclitaxel Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Veliparib Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Carboplatin Other Phase PHASE3 Squamous Non-Small Cell Lung Cancer COMPLETED NCT02106546
Placebo Other Phase PHASE3 Ulcerative Colitis (UC) COMPLETED NCT02065622
Adalimumab Other Phase PHASE3 Ulcerative Colitis (UC) COMPLETED NCT02065622
ABBV-927 Other Phase PHASE1 Head and Neck Cancer TERMINATED NCT03818542
ABBV-368 Other Phase PHASE1 Head and Neck Cancer TERMINATED NCT03818542
ABBV-181 Other Phase PHASE1 Head and Neck Cancer TERMINATED NCT03818542
ABBV-927 Other Phase PHASE1 Head and Neck Cancer TERMINATED NCT03818542
ABBV-368 Other Phase PHASE1 Head and Neck Cancer TERMINATED NCT03818542
ABBV-181 Other Phase PHASE1 Head and Neck Cancer TERMINATED NCT03818542
ABBV-927 Other Phase PHASE1 Head and Neck Cancer TERMINATED NCT03818542
ABBV-368 Other Phase PHASE1 Head and Neck Cancer TERMINATED NCT03818542
ABBV-181 Other Phase PHASE1 Head and Neck Cancer TERMINATED NCT03818542
rovalpituzumab tesirine Other Phase PHASE2 Cancer COMPLETED NCT03543358
rovalpituzumab tesirine Other Phase PHASE2 Cancer COMPLETED NCT03543358
rovalpituzumab tesirine Other Phase PHASE2 Cancer COMPLETED NCT03543358
Veliparib Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
Carboplatin Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
Paclitaxel Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
Doxorubicin Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
Placebo Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
Cyclophosphamide Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
Veliparib Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
Carboplatin Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
Paclitaxel Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
Doxorubicin Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
Placebo Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
Cyclophosphamide Other Phase PHASE3 Triple Negative Breast Cancer COMPLETED NCT02032277
ombitasvir, paritaprevir/r, dasabuvir Other Phase PHASE4 Hepatitis C, Chronic COMPLETED NCT02461745
ombitasvir, paritaprevir/r, dasabuvir + ribavirin Other Phase PHASE4 Hepatitis C, Chronic COMPLETED NCT02461745
ombitasvir, paritaprevir/r, dasabuvir Other Phase PHASE4 Hepatitis C, Chronic COMPLETED NCT02461745
ombitasvir, paritaprevir/r, dasabuvir + ribavirin Other Phase PHASE4 Hepatitis C, Chronic COMPLETED NCT02461745
placebo for rizankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03518047
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03518047
placebo for rizankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03518047
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03518047
Placebo solution for IV infusion on Day 15 Other Phase PHASE2 Progressive Supranuclear Palsy (PSP) TERMINATED NCT03391765
ABBV-8E12 Other Phase PHASE2 Progressive Supranuclear Palsy (PSP) TERMINATED NCT03391765
Placebo solution for IV infusion on Day 15 Other Phase PHASE2 Progressive Supranuclear Palsy (PSP) TERMINATED NCT03391765
ABBV-8E12 Other Phase PHASE2 Progressive Supranuclear Palsy (PSP) TERMINATED NCT03391765
Placebo solution for IV infusion on Day 15 Other Phase PHASE2 Progressive Supranuclear Palsy (PSP) TERMINATED NCT03391765
ABBV-8E12 Other Phase PHASE2 Progressive Supranuclear Palsy (PSP) TERMINATED NCT03391765
ABBV-8E12 Other Phase PHASE2 Progressive Supranuclear Palsy TERMINATED NCT02985879
Placebo Other Phase PHASE2 Progressive Supranuclear Palsy TERMINATED NCT02985879
ABBV-8E12 Other Phase PHASE2 Progressive Supranuclear Palsy TERMINATED NCT02985879
Placebo Other Phase PHASE2 Progressive Supranuclear Palsy TERMINATED NCT02985879
ABBV-8E12 Other Phase PHASE2 Progressive Supranuclear Palsy TERMINATED NCT02985879
Placebo Other Phase PHASE2 Progressive Supranuclear Palsy TERMINATED NCT02985879
Irinotecan Other Phase PHASE2 Cancer TERMINATED NCT03368859
ABT-165 Other Phase PHASE2 Cancer TERMINATED NCT03368859
Fluorouracil - infusion Other Phase PHASE2 Cancer TERMINATED NCT03368859
Bevacizumab Other Phase PHASE2 Cancer TERMINATED NCT03368859
Fluorouracil - bolus Other Phase PHASE2 Cancer TERMINATED NCT03368859
Leucovorin Other Phase PHASE2 Cancer TERMINATED NCT03368859
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Cancer TERMINATED NCT04274907
Venetoclax Other Phase PHASE1 Non Small Cell Lung Cancer TERMINATED NCT04274907
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Cancer TERMINATED NCT04274907
Venetoclax Other Phase PHASE1 Non Small Cell Lung Cancer TERMINATED NCT04274907
Placebo Other Phase PHASE3 Crohn's Disease COMPLETED NCT02065570
Adalimumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT02065570
Placebo Other Phase PHASE3 Crohn's Disease COMPLETED NCT02065570
Adalimumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT02065570
Dexamethasone Other Phase PHASE3 Small Cell Lung Cancer COMPLETED NCT03061812
Topotecan Other Phase PHASE3 Small Cell Lung Cancer COMPLETED NCT03061812
Rovalpituzumab tesirine Other Phase PHASE3 Small Cell Lung Cancer COMPLETED NCT03061812
Pemetrexed Other Phase PHASE3 Non-squamous Non-small Cell Lung Cancer COMPLETED NCT02264990
Veliparib Other Phase PHASE3 Non-squamous Non-small Cell Lung Cancer COMPLETED NCT02264990
Cisplatin Other Phase PHASE3 Non-squamous Non-small Cell Lung Cancer COMPLETED NCT02264990
Carboplatin Other Phase PHASE3 Non-squamous Non-small Cell Lung Cancer COMPLETED NCT02264990
Paclitaxel Other Phase PHASE3 Non-squamous Non-small Cell Lung Cancer COMPLETED NCT02264990
Pemetrexed Other Phase PHASE3 Non-squamous Non-small Cell Lung Cancer COMPLETED NCT02264990
Veliparib Other Phase PHASE3 Non-squamous Non-small Cell Lung Cancer COMPLETED NCT02264990
Cisplatin Other Phase PHASE3 Non-squamous Non-small Cell Lung Cancer COMPLETED NCT02264990
Carboplatin Other Phase PHASE3 Non-squamous Non-small Cell Lung Cancer COMPLETED NCT02264990
Paclitaxel Other Phase PHASE3 Non-squamous Non-small Cell Lung Cancer COMPLETED NCT02264990
Venetoclax (RP2D) Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Irinotecan 60 mg/m2 Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Venetoclax 600 Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Venetoclax 400 Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Venetoclax 200 MG Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Venetoclax 100 MG Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Venetoclax 50 MG Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Venetoclax (RP2D) Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Irinotecan 60 mg/m2 Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Venetoclax 600 Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Venetoclax 400 Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Venetoclax 200 MG Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Venetoclax 100 MG Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
Venetoclax 50 MG Other Phase PHASE1 Relapsed Small Cell Lung Cancer WITHDRAWN NCT04543916
adalimumab Other Phase PHASE3 Pyoderma Gangrenosum COMPLETED NCT03311464
Placebo solution for risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03875482
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03875482
Placebo solution for risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03875482
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03875482
No pancreatic enzyme replacement therapy Drug Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
PERTZYE Other Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
other non-sponsor pancreatic enzyme replacement therapy Drug Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
ZENPEP Other Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
CREON Other Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
PANCREAZE Other Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
ULTRESA Other Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
No pancreatic enzyme replacement therapy Drug Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
PERTZYE Other Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
other non-sponsor pancreatic enzyme replacement therapy Drug Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
ZENPEP Other Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
CREON Other Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
PANCREAZE Other Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
ULTRESA Other Preclinical Fibrosing Colonopathy TERMINATED NCT01652157
ABBV-744 Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT03360006
ABBV-744 Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT03360006
ABBV-744 Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT03360006
rituximab / IDEC-C2B8 Other Phase PHASE1 Non-Hodgkin Lymphoma (NHL) COMPLETED NCT02265731
venetoclax Other Phase PHASE1 Non-Hodgkin Lymphoma (NHL) COMPLETED NCT02265731
azacitadine Other Phase PHASE1 Non-Hodgkin Lymphoma (NHL) COMPLETED NCT02265731
rituximab / IDEC-C2B8 Other Phase PHASE1 Non-Hodgkin Lymphoma (NHL) COMPLETED NCT02265731
venetoclax Other Phase PHASE1 Non-Hodgkin Lymphoma (NHL) COMPLETED NCT02265731
azacitadine Other Phase PHASE1 Non-Hodgkin Lymphoma (NHL) COMPLETED NCT02265731
dexamethasone Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma COMPLETED NCT01794507
bortezomib Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma COMPLETED NCT01794507
ABT-199 Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma COMPLETED NCT01794507
Paclitaxel Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Carboplatin Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Veliparib, tablet Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Veliparib, capsule Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Paclitaxel Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Carboplatin Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Veliparib, tablet Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Veliparib, capsule Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05268068
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05268068
Placebo Other Phase PHASE4 Uterine Fibroids COMPLETED NCT03886220
Elagolix Other Phase PHASE4 Uterine Fibroids COMPLETED NCT03886220
Pneumococcal 13-valent conjugate vaccine (PCV-13) Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02049138
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02049138
Pneumococcal 13-valent conjugate vaccine (PCV-13) Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02049138
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02049138
Epcoritamab Other Preclinical Lymphoma NO_LONGER_AVAILABLE NCT05692050
Epcoritamab Other Preclinical Lymphoma NO_LONGER_AVAILABLE NCT05692050
Daratumumab Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Pomalidomide Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Carfilzomib Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Dexamethasone Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Lemzoparlimab Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Daratumumab Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Pomalidomide Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Carfilzomib Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Dexamethasone Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Lemzoparlimab Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Placebo Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04223804
ABBV-181 Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04223804
ABBV-CLS-7262 Other Phase PHASE1 Healthy COMPLETED NCT05763459
ABBV-CLS-7262 Other Phase PHASE1 Healthy COMPLETED NCT05763459
Placebo for venetoclax Other Phase PHASE3 Relapsed/Refractory Multiple Myeloma COMPLETED NCT02755597
Dexamethasone Other Phase PHASE3 Relapsed/Refractory Multiple Myeloma COMPLETED NCT02755597
Bortezomib Other Phase PHASE3 Relapsed/Refractory Multiple Myeloma COMPLETED NCT02755597
Venetoclax Other Phase PHASE3 Relapsed/Refractory Multiple Myeloma COMPLETED NCT02755597
Placebo for venetoclax Other Phase PHASE3 Relapsed/Refractory Multiple Myeloma COMPLETED NCT02755597
Dexamethasone Other Phase PHASE3 Relapsed/Refractory Multiple Myeloma COMPLETED NCT02755597
Bortezomib Other Phase PHASE3 Relapsed/Refractory Multiple Myeloma COMPLETED NCT02755597
Venetoclax Other Phase PHASE3 Relapsed/Refractory Multiple Myeloma COMPLETED NCT02755597
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Placebo for Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Placebo for Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Azacitidine Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
Venetoclax Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Matching Placebo for PVEK Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Pivekimab Sunirine Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
Emraclidine Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
Placebo-Matching Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Risankizumab Other Phase PHASE3 Crohn's Disease RECRUITING NCT05995353
Risankizumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Adalimumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Telisotuzumab vedotin Other Preclinical Non-Small Cell Lung Cancer (NSCLC) TEMPORARILY_NOT_AVAILABLE NCT04830202
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) AVAILABLE NCT04278235
Placebo for Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04379050
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
ABBV-383 (Etentamig) Other Phase PHASE1 Immunoglobulin Light Chain (AL) Amyloidosis RECRUITING NCT06158854
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Liposomal daunorubicin and cytarabine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Daunorubicin Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Idarubicin Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Cytarabine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Nab-Paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, budigalimab, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
TTX-030, nab-paclitaxel and gemcitabine Other Phase PHASE2 Pancreatic Cancer COMPLETED NCT06119217
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT03844048
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Iberdomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Etentamig Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Telisotuzumab Adizutecan Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Budigalimab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Azirkitug Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Placebo for Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Liposomal daunorubicin and cytarabine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Daunorubicin Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Idarubicin Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Cytarabine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Iberdomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Etentamig Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Matching Placebo for PVEK Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Pivekimab Sunirine Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
Emraclidine Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Azacitidine Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
Venetoclax Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT03781167
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT03781167
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT03781167
Midazolam Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05895266
ABBV-903 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05895266
Midazolam Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05895266
ABBV-903 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05895266
Placebo Other Phase PHASE4 Hypogonadism COMPLETED NCT03518034
AndroGel® Other Phase PHASE4 Hypogonadism COMPLETED NCT03518034
BOTOX Dose C Other Phase PHASE2 Ventral Hernia WITHDRAWN NCT05606757
BOTOX Dose B Other Phase PHASE2 Ventral Hernia WITHDRAWN NCT05606757
Placebo for BOTOX Other Phase PHASE2 Ventral Hernia WITHDRAWN NCT05606757
BOTOX Dose A Other Phase PHASE2 Ventral Hernia WITHDRAWN NCT05606757
BOTOX Dose C Other Phase PHASE2 Ventral Hernia WITHDRAWN NCT05606757
BOTOX Dose B Other Phase PHASE2 Ventral Hernia WITHDRAWN NCT05606757
Placebo for BOTOX Other Phase PHASE2 Ventral Hernia WITHDRAWN NCT05606757
BOTOX Dose A Other Phase PHASE2 Ventral Hernia WITHDRAWN NCT05606757
Placebo for Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Liposomal daunorubicin and cytarabine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Daunorubicin Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Idarubicin Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Cytarabine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Iberdomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Etentamig Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Matching Placebo for PVEK Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Pivekimab Sunirine Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
Emraclidine Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Azacitidine Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
Venetoclax Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
Placebo for Upadacitinib Other Phase PHASE3 Atopic Dermatitis (AD) WITHDRAWN NCT04666675
Upadacitinib Other Phase PHASE3 Atopic Dermatitis (AD) WITHDRAWN NCT04666675
Placebo for Upadacitinib Other Phase PHASE3 Atopic Dermatitis (AD) WITHDRAWN NCT04666675
Upadacitinib Other Phase PHASE3 Atopic Dermatitis (AD) WITHDRAWN NCT04666675
Placebo for Upadacitinib Other Phase PHASE3 Atopic Dermatitis (AD) WITHDRAWN NCT04666675
Upadacitinib Other Phase PHASE3 Atopic Dermatitis (AD) WITHDRAWN NCT04666675
Standard cytotherapy Drug Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Nivolumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Ramucirumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Bemarituzumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
ABT-806 Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Trastuzumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Standard cytotherapy Drug Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Nivolumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Ramucirumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Bemarituzumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
ABT-806 Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Trastuzumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Standard cytotherapy Drug Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Nivolumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Ramucirumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Bemarituzumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
ABT-806 Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Trastuzumab Other Phase PHASE2 Adenocarcinoma COMPLETED NCT02213289
Placebo Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT01893996
Adalimumab Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT01893996
Placebo Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT01893996
Adalimumab Other Phase PHASE4 Rheumatoid Arthritis COMPLETED NCT01893996
Radiation Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Temozolomide Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Depatuxizumab mafodotin Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Ophthalmic steroid ointment Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Cold compress Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Vasoconstrictor eye drops Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Steroid eye drops Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Radiation Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Temozolomide Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Depatuxizumab mafodotin Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Ophthalmic steroid ointment Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Cold compress Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Vasoconstrictor eye drops Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Steroid eye drops Other Phase PHASE3 Glioblastoma Multiforme TERMINATED NCT03419403
Placebo for upadacitinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
Placebo for elsubrutinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
Elsubrutinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
Placebo for upadacitinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
Placebo for elsubrutinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
Elsubrutinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
Placebo for upadacitinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
Placebo for elsubrutinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
Elsubrutinib Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03682705
ABBV-321 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT03234712
Placebo for ABBV-157 Other Phase PHASE1 Psoriasis COMPLETED NCT03922607
ABBV-157 Other Phase PHASE1 Psoriasis COMPLETED NCT03922607
Placebo for ABBV-157 Other Phase PHASE1 Psoriasis COMPLETED NCT03922607
ABBV-157 Other Phase PHASE1 Psoriasis COMPLETED NCT03922607
Autoinjector Other Phase PHASE3 Psoriasis COMPLETED NCT03875508
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03875508
Autoinjector Other Phase PHASE3 Psoriasis COMPLETED NCT03875508
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03875508
Autoinjector Other Phase PHASE3 Psoriasis COMPLETED NCT03875508
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03875508
ABT-SLV187 Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT02082249
ABT-SLV187 Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT02082249
ABT-SLV187 Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT02082249
Dexamethasone Other Phase PHASE2 Multiple Myeloma TERMINATED NCT03567616
Pomalidomide Other Phase PHASE2 Multiple Myeloma TERMINATED NCT03567616
Venetoclax Other Phase PHASE2 Multiple Myeloma TERMINATED NCT03567616
Dexamethasone Other Phase PHASE2 Multiple Myeloma TERMINATED NCT03567616
Pomalidomide Other Phase PHASE2 Multiple Myeloma TERMINATED NCT03567616
Venetoclax Other Phase PHASE2 Multiple Myeloma TERMINATED NCT03567616
Dexamethasone Other Phase PHASE2 Multiple Myeloma TERMINATED NCT03567616
Pomalidomide Other Phase PHASE2 Multiple Myeloma TERMINATED NCT03567616
Venetoclax Other Phase PHASE2 Multiple Myeloma TERMINATED NCT03567616
Placebo Other Phase PHASE1 Alzheimer's Disease TERMINATED NCT02573740
ABT-957 Other Phase PHASE1 Alzheimer's Disease TERMINATED NCT02573740
Placebo Other Phase PHASE1 Alzheimer's Disease TERMINATED NCT02573740
ABT-957 Other Phase PHASE1 Alzheimer's Disease TERMINATED NCT02573740
Placebo for ABT-957 Other Phase PHASE1 Alzheimer's Disease TERMINATED NCT02220738
ABT-957 Other Phase PHASE1 Alzheimer's Disease TERMINATED NCT02220738
Placebo for ABT-957 Other Phase PHASE1 Alzheimer's Disease TERMINATED NCT02220738
ABT-957 Other Phase PHASE1 Alzheimer's Disease TERMINATED NCT02220738
Placebo Other Phase PHASE2 Acute Kidney Injury COMPLETED NCT01777165
ABT-719 Other Phase PHASE2 Acute Kidney Injury COMPLETED NCT01777165
Placebo Other Phase PHASE2 Acute Kidney Injury COMPLETED NCT01777165
ABT-719 Other Phase PHASE2 Acute Kidney Injury COMPLETED NCT01777165
Placebo Other Phase PHASE2 Acute Kidney Injury COMPLETED NCT01777165
ABT-719 Other Phase PHASE2 Acute Kidney Injury COMPLETED NCT01777165
Placebo Other Phase PHASE2 Schizophrenia COMPLETED NCT01678755
ABT-126 Other Phase PHASE2 Schizophrenia COMPLETED NCT01678755
Placebo Other Phase PHASE2 Schizophrenia COMPLETED NCT01678755
ABT-126 Other Phase PHASE2 Schizophrenia COMPLETED NCT01678755
Placebo Other Phase PHASE2 Schizophrenia COMPLETED NCT01655680
ABT-126 Other Phase PHASE2 Schizophrenia COMPLETED NCT01655680
Placebo Other Phase PHASE2 Schizophrenia COMPLETED NCT01655680
ABT-126 Other Phase PHASE2 Schizophrenia COMPLETED NCT01655680
placebo Other Phase PHASE3 Hidradenitis Suppurativa (HS) COMPLETED NCT01468207
adalimumab Other Phase PHASE3 Hidradenitis Suppurativa (HS) COMPLETED NCT01468207
placebo Other Phase PHASE3 Hidradenitis Suppurativa (HS) COMPLETED NCT01468207
adalimumab Other Phase PHASE3 Hidradenitis Suppurativa (HS) COMPLETED NCT01468207
Placebo Other Phase PHASE3 Peripheral Spondyloarthritis COMPLETED NCT01064856
Adalimumab Other Phase PHASE3 Peripheral Spondyloarthritis COMPLETED NCT01064856
Placebo Other Phase PHASE3 Peripheral Spondyloarthritis COMPLETED NCT01064856
Adalimumab Other Phase PHASE3 Peripheral Spondyloarthritis COMPLETED NCT01064856
Placebo Other Phase PHASE3 Peripheral Spondyloarthritis COMPLETED NCT01064856
Adalimumab Other Phase PHASE3 Peripheral Spondyloarthritis COMPLETED NCT01064856
adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT00573794
adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT00573794
adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT00573794
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT02292719
Sofosbuvir Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT02292719
OBV/PTV/r Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT02292719
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT02292719
Sofosbuvir Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT02292719
OBV/PTV/r Other Phase PHASE2 Chronic Hepatitis C Virus Infection COMPLETED NCT02292719
Dasabuvir Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02219503
Ombitasvir/Paritaprevir/Ritonavir Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02219503
Dasabuvir Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02219503
Ombitasvir/Paritaprevir/Ritonavir Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT02219503
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01995071
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01995071
ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01995071
ABT-493 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01995071
Ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01995071
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01995071
ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01995071
ABT-493 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT01995071
ribavirin Other Phase PHASE2 Hepatitis C Virus Infection COMPLETED NCT01939197
ABT-333 Other Phase PHASE2 Hepatitis C Virus Infection COMPLETED NCT01939197
ABT-450/r/ABT-267 Other Phase PHASE2 Hepatitis C Virus Infection COMPLETED NCT01939197
ribavirin Other Phase PHASE2 Hepatitis C Virus Infection COMPLETED NCT01939197
ABT-333 Other Phase PHASE2 Hepatitis C Virus Infection COMPLETED NCT01939197
ABT-450/r/ABT-267 Other Phase PHASE2 Hepatitis C Virus Infection COMPLETED NCT01939197
Placebo for Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01833533
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01833533
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01833533
Placebo for Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01833533
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01833533
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01833533
Placebo for ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01767116
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01767116
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01767116
Placebo for ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01767116
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01767116
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01767116
Placebo for ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01716585
Placebo for ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01716585
Placebo for ABT-450/r/ABT-267 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01716585
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01716585
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01716585
Placebo for ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01716585
Placebo for ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01716585
Placebo for ABT-450/r/ABT-267 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01716585
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01716585
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01716585
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01674725
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01674725
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01674725
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01674725
placebo Other Phase PHASE3 Hidradenitis Suppurativa (HS) COMPLETED NCT01468233
adalimumab Other Phase PHASE3 Hidradenitis Suppurativa (HS) COMPLETED NCT01468233
placebo Other Phase PHASE3 Hidradenitis Suppurativa (HS) COMPLETED NCT01468233
adalimumab Other Phase PHASE3 Hidradenitis Suppurativa (HS) COMPLETED NCT01468233
placebo for adalimumab Other Phase PHASE3 Enthesitis Related Arthritis (ERA) COMPLETED NCT01166282
adalimumab Other Phase PHASE3 Enthesitis Related Arthritis (ERA) COMPLETED NCT01166282
placebo for adalimumab Other Phase PHASE3 Enthesitis Related Arthritis (ERA) COMPLETED NCT01166282
adalimumab Other Phase PHASE3 Enthesitis Related Arthritis (ERA) COMPLETED NCT01166282
adalimumab Other Phase PHASE3 Uveitis COMPLETED NCT01148225
adalimumab Other Phase PHASE3 Uveitis COMPLETED NCT01148225
secukinumab Other Phase PHASE3 Psoriasis COMPLETED NCT03478787
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03478787
Elagolix Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02925494
Estradiol/Norethindrone Acetate Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02925494
Elagolix Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02925494
Estradiol/Norethindrone Acetate Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02925494
ABT-493 coformulated with ABT-530 Other Phase PHASE3 Hepatitis C Virus Infection COMPLETED NCT02738138
ABT-493 coformulated with ABT-530 Other Phase PHASE3 Hepatitis C Virus Infection COMPLETED NCT02738138
glecaprevir/pibrentasvir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02692703
glecaprevir/pibrentasvir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02692703
Placebo for Elagolix Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02691494
Estradiol/Norethindrone Acetate Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02691494
Placebo for Estradiol/Norethindrone Acetate Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02691494
Elagolix Other Phase PHASE3 Uterine Fibroids COMPLETED NCT02691494
ABT-493/ABT-530 Other Phase PHASE3 Hepatitis C Virus Infection COMPLETED NCT02642432
ABT-493/ABT-530 Other Phase PHASE3 Hepatitis C Virus Infection COMPLETED NCT02642432
ABT-493/ABT-530 Other Phase PHASE3 Hepatitis C Virus COMPLETED NCT02636595
ABT-493/ABT-530 Other Phase PHASE3 Hepatitis C Virus COMPLETED NCT02636595
ABT-493/ABT-530 Other Phase PHASE3 Hepatitis C Virus COMPLETED NCT02636595
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02604017
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02604017
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02604017
ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02243280
ABT-493 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02243280
Elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT02143713
Elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT02143713
Elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT01760954
Elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT01760954
Progesterone Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01441635
Estradiol Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01441635
Estradiol/Norethindrone acetate (E2/NETA) Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01441635
Placebo Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01441635
Elagolix Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01441635
Progesterone Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01441635
Estradiol Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01441635
Estradiol/Norethindrone acetate (E2/NETA) Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01441635
Placebo Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01441635
Elagolix Other Phase PHASE2 Heavy Uterine Bleeding COMPLETED NCT01441635
ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02723084
sofosbuvir (SOF) Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02723084
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02723084
ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02723084
sofosbuvir (SOF) Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02723084
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02723084
OBV/PTV/r Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02707952
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02707952
OBV/PTV/r Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02707952
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02707952
OBV/PTV/r Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02707952
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C Virus COMPLETED NCT02707952
Placebo for ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02640482
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection COMPLETED NCT02640482
Levodopa-carbidopa Immediate Release (LC-IR) Tablets Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01736176
Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J) Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01736176
Levodopa-Carbidopa Intestinal Gel Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01736176
Levodopa-carbidopa Immediate Release (LC-IR) Tablets Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01736176
Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J) Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01736176
Levodopa-Carbidopa Intestinal Gel Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT01736176
Placebo for adalimumab Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03823391
Adalimumab Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03823391
Placebo for ABBV-3373 Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03823391
ABBV-3373 Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03823391
Placebo for adalimumab Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03823391
Adalimumab Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03823391
Placebo for ABBV-3373 Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03823391
ABBV-3373 Other Phase PHASE2 Rheumatoid Arthritis (RA) COMPLETED NCT03823391
blood drawing Other Approved Chronic Hepatitis C COMPLETED NCT03155113
blood drawing Other Approved Chronic Hepatitis C COMPLETED NCT03155113
Vinorelbine Other Preclinical Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation NO_LONGER_AVAILABLE NCT02985658
Cisplatin Other Preclinical Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation NO_LONGER_AVAILABLE NCT02985658
Veliparib Other Preclinical Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation NO_LONGER_AVAILABLE NCT02985658
Vinorelbine Other Preclinical Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation NO_LONGER_AVAILABLE NCT02985658
Cisplatin Other Preclinical Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation NO_LONGER_AVAILABLE NCT02985658
Veliparib Other Preclinical Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation NO_LONGER_AVAILABLE NCT02985658
ABBV-467 Other Phase PHASE1 Multiple Myeloma (MM) TERMINATED NCT04178902
ABBV-467 Other Phase PHASE1 Multiple Myeloma (MM) TERMINATED NCT04178902
ABBV-467 Other Phase PHASE1 Multiple Myeloma (MM) TERMINATED NCT04178902
ABBV-467 Other Phase PHASE1 Multiple Myeloma (MM) TERMINATED NCT04178902
Dexamethasone Other Phase PHASE3 Small Cell Lung Cancer TERMINATED NCT03033511
Rovalpituzumab tesirine Other Phase PHASE3 Small Cell Lung Cancer TERMINATED NCT03033511
Placebo for rovalpituzumab tesirine Other Phase PHASE3 Small Cell Lung Cancer TERMINATED NCT03033511
Placebo for dexamethasone Other Phase PHASE3 Small Cell Lung Cancer TERMINATED NCT03033511
Dexamethasone Other Phase PHASE3 Small Cell Lung Cancer TERMINATED NCT03033511
Rovalpituzumab tesirine Other Phase PHASE3 Small Cell Lung Cancer TERMINATED NCT03033511
Placebo for rovalpituzumab tesirine Other Phase PHASE3 Small Cell Lung Cancer TERMINATED NCT03033511
Placebo for dexamethasone Other Phase PHASE3 Small Cell Lung Cancer TERMINATED NCT03033511
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02966795
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT02966795
Long- and intermediate- acting insulins Other Preclinical Diabetes COMPLETED NCT02922179
placebo for adalimumab Other Phase PHASE3 Psoriasis COMPLETED NCT02694523
placebo for risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT02694523
adalimumab Other Phase PHASE3 Psoriasis COMPLETED NCT02694523
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT02694523
placebo for adalimumab Other Phase PHASE3 Psoriasis COMPLETED NCT02694523
placebo for risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT02694523
adalimumab Other Phase PHASE3 Psoriasis COMPLETED NCT02694523
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT02694523
placebo for ustekinumab Other Phase PHASE3 Psoriasis COMPLETED NCT02684370
ustekinumab Other Phase PHASE3 Psoriasis COMPLETED NCT02684370
placebo for risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT02684370
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT02684370
Rovalpituzumab tesirine Other Phase PHASE2 Small Cell Lung Cancer COMPLETED NCT02674568
Rovalpituzumab tesirine Other Phase PHASE2 Small Cell Lung Cancer COMPLETED NCT02674568
Daclatasvir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02640157
Sofosbuvir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02640157
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02640157
Daclatasvir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02640157
Sofosbuvir Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02640157
ABT-493/ABT-530 Other Phase PHASE3 Chronic Hepatitis C COMPLETED NCT02640157
dasabuvir Other Phase PHASE3 Hepatitis C Infection COMPLETED NCT02582632
ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Hepatitis C Infection COMPLETED NCT02582632
dasabuvir Other Phase PHASE3 Hepatitis C Infection COMPLETED NCT02582632
ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Hepatitis C Infection COMPLETED NCT02582632
dasabuvir Other Phase PHASE3 Hepatitis C Infection COMPLETED NCT02582632
ombitasvir/paritaprevir/ritonavir Other Phase PHASE3 Hepatitis C Infection COMPLETED NCT02582632
RBV Other Phase PHASE3 HCV COMPLETED NCT02247401
2 DAA Other Phase PHASE3 HCV COMPLETED NCT02247401
ABT-493/ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02243293
ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02243293
ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02243293
ABT-493 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02243293
ABT-493/ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02243293
ribavirin (RBV) Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02243293
ABT-530 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02243293
ABT-493 Other Phase PHASE2 Chronic Hepatitis C COMPLETED NCT02243293
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02066389
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02066389
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02066389
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02066389
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02066389
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02066389
Ribavirin Other Phase PHASE3 Hepatitis C Virus COMPLETED NCT02023112
ABT-450/r/ABT-267 Other Phase PHASE3 Hepatitis C Virus COMPLETED NCT02023112
Ribavirin Other Phase PHASE3 Hepatitis C Virus COMPLETED NCT02023112
ABT-450/r/ABT-267 Other Phase PHASE3 Hepatitis C Virus COMPLETED NCT02023112
Ribavirin (RBV) Other Phase PHASE2 Hepatitis C, Chronic COMPLETED NCT01685203
ABT-267 Other Phase PHASE2 Hepatitis C, Chronic COMPLETED NCT01685203
ABT-450/r Other Phase PHASE2 Hepatitis C, Chronic COMPLETED NCT01685203
Ribavirin (RBV) Other Phase PHASE2 Hepatitis C, Chronic COMPLETED NCT01685203
ABT-267 Other Phase PHASE2 Hepatitis C, Chronic COMPLETED NCT01685203
ABT-450/r Other Phase PHASE2 Hepatitis C, Chronic COMPLETED NCT01685203
Darbepoetin alfa Other Phase PHASE4 Moderate to Severe Secondary Hyperparathyroidism COMPLETED NCT01506947
Paricalcitol Other Phase PHASE4 Moderate to Severe Secondary Hyperparathyroidism COMPLETED NCT01506947
Darbepoetin alfa Other Phase PHASE4 Moderate to Severe Secondary Hyperparathyroidism COMPLETED NCT01506947
Paricalcitol Other Phase PHASE4 Moderate to Severe Secondary Hyperparathyroidism COMPLETED NCT01506947
Placebo for ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01715415
Placebo for ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01715415
Placebo for ABT-450/r/ABT-267 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01715415
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01715415
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01715415
Placebo for ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01715415
Placebo for ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01715415
Placebo for ABT-450/r/ABT-267 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01715415
Ribavirin Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01715415
ABT-450/r/ABT-267, ABT-333 Other Phase PHASE3 Chronic Hepatitis C Infection COMPLETED NCT01715415
ABT-126 Other Phase PHASE2 Alzheimer's Disease TERMINATED NCT01690195
ABT-126 Other Phase PHASE2 Alzheimer's Disease TERMINATED NCT01690195
Bendamustine Other Phase PHASE1 Non-Hodgkin's Lymphoma COMPLETED NCT01594229
Rituximab Other Phase PHASE1 Non-Hodgkin's Lymphoma COMPLETED NCT01594229
ABT-199 Other Phase PHASE1 Non-Hodgkin's Lymphoma COMPLETED NCT01594229
Veliparib Other Phase PHASE1 Gastric Cancer COMPLETED NCT01123876
Veliparib Other Phase PHASE1 Gastric Cancer COMPLETED NCT01123876
gemcitabine Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01063816
carboplatin Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01063816
veliparib (ABT-888) Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01063816
gemcitabine Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01063816
carboplatin Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01063816
veliparib (ABT-888) Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01063816
Rovalpituzumab tesirine Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT03086239
Rovalpituzumab tesirine Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT03086239
placebo for ustekinumab Other Phase PHASE3 Psoriasis COMPLETED NCT02684357
placebo for risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT02684357
ustekinumab Other Phase PHASE3 Psoriasis COMPLETED NCT02684357
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT02684357
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01960855
ABT-494 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01960855
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01960855
ABT-494 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01960855
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01960855
ABT-494 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01960855
Placebo for ABBV-2B04 Other Phase PHASE1 CoronaVirus Disease-2019 (COVID-19) COMPLETED NCT04644120
ABBV-2B04 Other Phase PHASE1 CoronaVirus Disease-2019 (COVID-19) COMPLETED NCT04644120
Placebo for ABBV-47D11 Other Phase PHASE1 CoronaVirus Disease-2019 (COVID-19) COMPLETED NCT04644120
ABBV-47D11 Other Phase PHASE1 CoronaVirus Disease-2019 (COVID-19) COMPLETED NCT04644120
Placebo for upadacitinib Other Phase PHASE2 Rheumatoid Arthritis (RA) TERMINATED NCT03823378
Placebo for elsubrutinib Other Phase PHASE2 Rheumatoid Arthritis (RA) TERMINATED NCT03823378
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis (RA) TERMINATED NCT03823378
Elsubrutinib Other Phase PHASE2 Rheumatoid Arthritis (RA) TERMINATED NCT03823378
Placebo Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT02955212
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT02955212
Placebo Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT02955212
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT02955212
Placebo Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT02955212
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT02955212
Ribavirin solution Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Dasabuvir mini tablet Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Ritonavir mini tablet Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Paritaprevir mini tablet Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Ombitasvir mini tablet Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Ribavirin Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Dasabuvir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Ombitasvir/paritaprevir/ritonavir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Ribavirin solution Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Dasabuvir mini tablet Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Ritonavir mini tablet Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Paritaprevir mini tablet Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Ombitasvir mini tablet Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Ribavirin Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Dasabuvir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Ombitasvir/paritaprevir/ritonavir Other Phase PHASE2 Chronic Hepatitis C Infection COMPLETED NCT02486406
Venetoclax Other Phase PHASE1 Acute Lymphoblastic Leukemia (ALL) COMPLETED NCT03181126
Chemotherapy Drug Phase PHASE1 Acute Lymphoblastic Leukemia (ALL) COMPLETED NCT03181126
Navitoclax Other Phase PHASE1 Acute Lymphoblastic Leukemia (ALL) COMPLETED NCT03181126
Venetoclax Other Phase PHASE1 Acute Lymphoblastic Leukemia (ALL) COMPLETED NCT03181126
Chemotherapy Drug Phase PHASE1 Acute Lymphoblastic Leukemia (ALL) COMPLETED NCT03181126
Navitoclax Other Phase PHASE1 Acute Lymphoblastic Leukemia (ALL) COMPLETED NCT03181126
Venetoclax Other Phase PHASE1 Acute Lymphoblastic Leukemia (ALL) COMPLETED NCT03181126
Chemotherapy Drug Phase PHASE1 Acute Lymphoblastic Leukemia (ALL) COMPLETED NCT03181126
Navitoclax Other Phase PHASE1 Acute Lymphoblastic Leukemia (ALL) COMPLETED NCT03181126
Paclitaxel Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT01506609
Temozolomide Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT01506609
Carboplatin Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT01506609
Veliparib Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT01506609
Placebo Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT01506609
Paclitaxel Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT01506609
Temozolomide Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT01506609
Carboplatin Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT01506609
Veliparib Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT01506609
Placebo Other Phase PHASE2 Metastatic Breast Cancer COMPLETED NCT01506609
Placebo Other Phase PHASE2 Osteoarthritis, Knee COMPLETED NCT02471118
Adalimumab 40 mg Other Phase PHASE2 Osteoarthritis, Knee COMPLETED NCT02471118
Mavyret Other Phase PHASE4 Chronic Kidney Disease COMPLETED NCT02946034
Viekira Pak ± ribavirin Other Phase PHASE4 Chronic Kidney Disease COMPLETED NCT02946034
Mavyret Other Phase PHASE4 Chronic Kidney Disease COMPLETED NCT02946034
Viekira Pak ± ribavirin Other Phase PHASE4 Chronic Kidney Disease COMPLETED NCT02946034
CREON Other Phase PHASE4 Exocrine Pancreatic Insufficiency (EPI) WITHDRAWN NCT04315311
CREON Other Phase PHASE4 Exocrine Pancreatic Insufficiency (EPI) WITHDRAWN NCT04315311
CREON Other Phase PHASE4 Exocrine Pancreatic Insufficiency (EPI) WITHDRAWN NCT04315311
Risankizumab Other Phase PHASE2 Dermatitis COMPLETED NCT03706040
Placebo Other Phase PHASE2 Dermatitis COMPLETED NCT03706040
Risankizumab Other Phase PHASE2 Dermatitis COMPLETED NCT03706040
Placebo Other Phase PHASE2 Dermatitis COMPLETED NCT03706040
Risankizumab Other Phase PHASE2 Dermatitis COMPLETED NCT03706040
Placebo Other Phase PHASE2 Dermatitis COMPLETED NCT03706040
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03022045
AMG 176 Other Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT03797261
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT03797261
AMG 176 Other Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT03797261
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT03797261
AMG 176 Other Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT03797261
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT03797261
upadacitinib 15mg/day Other Phase PHASE3 Rheumatoid Arthritis UNKNOWN NCT05121298
upadacitinib 15mg/day Other Phase PHASE3 Rheumatoid Arthritis UNKNOWN NCT05121298
Paclitaxel Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Carboplatin Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Veliparib, tablet Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Veliparib, capsule Other Phase PHASE1 Cancer - Ovarian WITHDRAWN NCT03400306
Placebo ABBV-0805 Other Phase PHASE1 Parkinson's Disease WITHDRAWN NCT04127695
ABBV-0805 Other Phase PHASE1 Parkinson's Disease WITHDRAWN NCT04127695
Placebo ABBV-0805 Other Phase PHASE1 Parkinson's Disease WITHDRAWN NCT04127695
ABBV-0805 Other Phase PHASE1 Parkinson's Disease WITHDRAWN NCT04127695
ABT-199 (Safety Expansion Cohort) Other Phase PHASE2 Chronic Lymphocytic Leukemia COMPLETED NCT01889186
ABT-199 (Main Cohort) Other Phase PHASE2 Chronic Lymphocytic Leukemia COMPLETED NCT01889186
Placebo Other Phase PHASE2 Sjogren's Syndrome (SS) WITHDRAWN NCT05217472
Ravagalimab Other Phase PHASE2 Sjogren's Syndrome (SS) WITHDRAWN NCT05217472
Ravaglimab Other Phase PHASE2 Sjogren's Syndrome (SS) WITHDRAWN NCT05217472
Alvocidib Other Phase PHASE1 Acute Myeloid Leukemia (AML) COMPLETED NCT03441555
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia (AML) COMPLETED NCT03441555
Alvocidib Other Phase PHASE1 Acute Myeloid Leukemia (AML) COMPLETED NCT03441555
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia (AML) COMPLETED NCT03441555
Sleep Headband Other Phase PHASE1 Atopic Dermatitis TERMINATED NCT04262791
Wrist Actigraphy Device Device Phase PHASE1 Atopic Dermatitis TERMINATED NCT04262791
Sleep Headband Other Phase PHASE1 Atopic Dermatitis TERMINATED NCT04262791
Wrist Actigraphy Device Device Phase PHASE1 Atopic Dermatitis TERMINATED NCT04262791
ABT-199 Other Phase PHASE1 Chronic Lymphocytic Leukemia COMPLETED NCT01328626
ABT-199 Other Phase PHASE1 Chronic Lymphocytic Leukemia COMPLETED NCT01328626
Upadacitinib Other Phase PHASE3 Ulcerative Colitis (UC) COMPLETED NCT03653026
Placebo Other Phase PHASE3 Ulcerative Colitis (UC) COMPLETED NCT03653026
Upadacitinib Other Phase PHASE3 Ulcerative Colitis (UC) COMPLETED NCT03653026
Placebo Other Phase PHASE3 Ulcerative Colitis (UC) COMPLETED NCT03653026
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05274100
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05274087
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05274087
risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05283694
risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05283694
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05283681
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05283681
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05283681
Dalbavancin Other Phase PHASE1 Bacterial Infections TERMINATED NCT02688790
Dalbavancin Other Phase PHASE1 Bacterial Infections TERMINATED NCT02688790
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05305222
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05305222
Placebo Other Phase PHASE3 Schizophrenia TERMINATED NCT03593213
Cariprazine Other Phase PHASE3 Schizophrenia TERMINATED NCT03593213
Placebo Other Phase PHASE3 Schizophrenia TERMINATED NCT03593213
Cariprazine Other Phase PHASE3 Schizophrenia TERMINATED NCT03593213
Placebo Other Phase PHASE2 Generalized Anxiety Disorder WITHDRAWN NCT04965272
Cariprazine 3.0 mg/day Other Phase PHASE2 Generalized Anxiety Disorder WITHDRAWN NCT04965272
Cariprazine 1.5 mg/day Other Phase PHASE2 Generalized Anxiety Disorder WITHDRAWN NCT04965272
Cariprazine 0.75 mg/day Other Phase PHASE2 Generalized Anxiety Disorder WITHDRAWN NCT04965272
Placebo Other Phase PHASE2 Generalized Anxiety Disorder WITHDRAWN NCT04965272
Cariprazine 3.0 mg/day Other Phase PHASE2 Generalized Anxiety Disorder WITHDRAWN NCT04965272
Cariprazine 1.5 mg/day Other Phase PHASE2 Generalized Anxiety Disorder WITHDRAWN NCT04965272
Cariprazine 0.75 mg/day Other Phase PHASE2 Generalized Anxiety Disorder WITHDRAWN NCT04965272
Cariprazine Other Phase PHASE1 Autism Spectrum Disorder COMPLETED NCT04382885
Cariprazine Other Phase PHASE1 Autism Spectrum Disorder COMPLETED NCT04382885
Cariprazine Other Phase PHASE1 Autism Spectrum Disorder COMPLETED NCT04382885
ABBV-181 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03000257
Rovalpituzumab Tesirine Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03000257
Venetoclax Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03000257
ABBV-181 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03000257
Rovalpituzumab Tesirine Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03000257
Venetoclax Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03000257
Standard of Care Other Phase PHASE2 Endocarditis TERMINATED NCT03148756
Dalbavancin Other Phase PHASE2 Endocarditis TERMINATED NCT03148756
Standard of Care Other Phase PHASE2 Endocarditis TERMINATED NCT03148756
Dalbavancin Other Phase PHASE2 Endocarditis TERMINATED NCT03148756
ABBV-181 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT03071757
ABBV-368 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT03071757
ABBV-181 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT03071757
ABBV-368 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT03071757
Ribavirin Other Phase PHASE3 Hepatitis C Virus Infection COMPLETED NCT02939989
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus Infection COMPLETED NCT02939989
Sofosbuvir Other Phase PHASE3 Hepatitis C Virus Infection COMPLETED NCT02939989
Ribavirin Other Phase PHASE3 Hepatitis C Virus Infection COMPLETED NCT02939989
Glecaprevir/Pibrentasvir Other Phase PHASE3 Hepatitis C Virus Infection COMPLETED NCT02939989
Sofosbuvir Other Phase PHASE3 Hepatitis C Virus Infection COMPLETED NCT02939989
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT04509622
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT04509622
ABT199 Other Phase PHASE2 Waldenstrom Macroglobulinemia COMPLETED NCT02677324
ABT199 Other Phase PHASE2 Waldenstrom Macroglobulinemia COMPLETED NCT02677324
Risankizumab Other Preclinical Crohn's Disease NO_LONGER_AVAILABLE NCT03914261
Risankizumab Other Preclinical Crohn's Disease NO_LONGER_AVAILABLE NCT03914261
Veliparib Other Preclinical Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound NO_LONGER_AVAILABLE NCT03123211
ABT-199 and Ibrutinib Combination Other Phase PHASE1 Lymphoma, Mantle-Cell COMPLETED NCT02419560
Placebo Other Phase PHASE2 CoronaVirus Induced Disease-2019 (COVID-19) COMPLETED NCT04375397
Ibrutinib Other Phase PHASE2 CoronaVirus Induced Disease-2019 (COVID-19) COMPLETED NCT04375397
Placebo Other Phase PHASE2 CoronaVirus Induced Disease-2019 (COVID-19) COMPLETED NCT04375397
Ibrutinib Other Phase PHASE2 CoronaVirus Induced Disease-2019 (COVID-19) COMPLETED NCT04375397
Placebo Other Phase PHASE2 CoronaVirus Induced Disease-2019 (COVID-19) COMPLETED NCT04375397
Ibrutinib Other Phase PHASE2 CoronaVirus Induced Disease-2019 (COVID-19) COMPLETED NCT04375397
Placebo Other Phase PHASE2 Polycystic Ovary Syndrome COMPLETED NCT03951077
Elagolix Other Phase PHASE2 Polycystic Ovary Syndrome COMPLETED NCT03951077
Placebo Other Phase PHASE2 Polycystic Ovary Syndrome COMPLETED NCT03951077
Elagolix Other Phase PHASE2 Polycystic Ovary Syndrome COMPLETED NCT03951077
risankizumab IV Other Phase PHASE3 Crohn's Disease COMPLETED NCT03104413
risankizumab SC Other Phase PHASE3 Crohn's Disease COMPLETED NCT03104413
placebo for risankizumab IV Other Phase PHASE3 Crohn's Disease COMPLETED NCT03104413
risankizumab IV Other Phase PHASE3 Crohn's Disease COMPLETED NCT03104413
risankizumab SC Other Phase PHASE3 Crohn's Disease COMPLETED NCT03104413
placebo for risankizumab IV Other Phase PHASE3 Crohn's Disease COMPLETED NCT03104413
Ubrogepant Other Phase PHASE1 Migraine COMPLETED NCT04818515
Atogepant Other Phase PHASE1 Migraine COMPLETED NCT04818515
Ubrogepant Other Phase PHASE1 Migraine COMPLETED NCT04818515
Atogepant Other Phase PHASE1 Migraine COMPLETED NCT04818515
Ubrogepant Other Phase PHASE1 Migraine COMPLETED NCT04818515
Atogepant Other Phase PHASE1 Migraine COMPLETED NCT04818515
Upadacitinib Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT02819635
Placebo Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT02819635
risankizumab SC Other Phase PHASE3 Crohn's Disease COMPLETED NCT03105128
risankizumab IV Other Phase PHASE3 Crohn's Disease COMPLETED NCT03105128
placebo for risankizumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT03105128
risankizumab SC Other Phase PHASE3 Crohn's Disease COMPLETED NCT03105128
risankizumab IV Other Phase PHASE3 Crohn's Disease COMPLETED NCT03105128
placebo for risankizumab Other Phase PHASE3 Crohn's Disease COMPLETED NCT03105128
Ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02167945
ABT-333 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02167945
ABT-450/r/ABT-267 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02167945
Ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02167945
ABT-333 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02167945
ABT-450/r/ABT-267 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02167945
Colonoscopy Other Approved CD COMPLETED NCT03498625
Colonoscopy Other Approved CD COMPLETED NCT03498625
Colonoscopy Other Approved CD UNKNOWN NCT03487900
Colonoscopy Other Approved CD UNKNOWN NCT03487900
Placebo for risankizumab Other Phase PHASE2 Hidradenitis Suppurativa COMPLETED NCT03926169
Risankizumab Other Phase PHASE2 Hidradenitis Suppurativa COMPLETED NCT03926169
Placebo for risankizumab Other Phase PHASE2 Hidradenitis Suppurativa COMPLETED NCT03926169
Risankizumab Other Phase PHASE2 Hidradenitis Suppurativa COMPLETED NCT03926169
Placebo for risankizumab Other Phase PHASE2 Hidradenitis Suppurativa COMPLETED NCT03926169
Risankizumab Other Phase PHASE2 Hidradenitis Suppurativa COMPLETED NCT03926169
Upadacitinib Other Phase PHASE3 Crohn's Disease COMPLETED NCT03345836
Matching Placebo for Upadacitinib Other Phase PHASE3 Crohn's Disease COMPLETED NCT03345836
Upadacitinib Other Phase PHASE3 Crohn's Disease COMPLETED NCT03345836
Matching Placebo for Upadacitinib Other Phase PHASE3 Crohn's Disease COMPLETED NCT03345836
Glecaprevir/pibrentasvir Other Phase PHASE3 Hepatitis C, Acute COMPLETED NCT02634008
Ribavirin Other Phase PHASE3 Hepatitis C, Acute COMPLETED NCT02634008
Dasabuvir Other Phase PHASE3 Hepatitis C, Acute COMPLETED NCT02634008
Paritaprevir/ritonavir/ombitasvir Other Phase PHASE3 Hepatitis C, Acute COMPLETED NCT02634008
placebo for ABBV-8E12 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT02880956
ABBV-8E12 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT02880956
placebo for ABBV-8E12 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT02880956
ABBV-8E12 Other Phase PHASE2 Alzheimer's Disease COMPLETED NCT02880956
Cytarabine Other Phase PHASE1 Acute Myelogenous Leukemia COMPLETED NCT02287233
Venetoclax Other Phase PHASE1 Acute Myelogenous Leukemia COMPLETED NCT02287233
Cytarabine Other Phase PHASE1 Acute Myelogenous Leukemia COMPLETED NCT02287233
Venetoclax Other Phase PHASE1 Acute Myelogenous Leukemia COMPLETED NCT02287233
Cytarabine Other Phase PHASE1 Acute Myelogenous Leukemia COMPLETED NCT02287233
Venetoclax Other Phase PHASE1 Acute Myelogenous Leukemia COMPLETED NCT02287233
ABBV-184 Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT04272203
ABBV-184 Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT04272203
Venetoclax Other Phase PHASE1 Renal Impairment COMPLETED NCT04810598
Venetoclax Other Phase PHASE1 Renal Impairment COMPLETED NCT04810598
Venetoclax Other Phase PHASE1 Renal Impairment COMPLETED NCT04810598
Antidepressant Therapy (ADT) Drug Phase PHASE3 Major Depressive Disorder COMPLETED NCT03739203
Placebo Other Phase PHASE3 Major Depressive Disorder COMPLETED NCT03739203
Cariprazine Other Phase PHASE3 Major Depressive Disorder COMPLETED NCT03739203
Antidepressant Therapy (ADT) Drug Phase PHASE3 Major Depressive Disorder COMPLETED NCT03739203
Placebo Other Phase PHASE3 Major Depressive Disorder COMPLETED NCT03739203
Cariprazine Other Phase PHASE3 Major Depressive Disorder COMPLETED NCT03739203
Tilavonemab Other Phase PHASE2 Alzheimer's Disease TERMINATED NCT03712787
Tilavonemab Other Phase PHASE2 Alzheimer's Disease TERMINATED NCT03712787
Placebo Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04799353
Budigalimab Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04799353
Placebo Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04799353
Budigalimab Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04799353
Placebo Other Phase PHASE3 Major Depressive Disorder COMPLETED NCT03738215
Cariprazine Other Phase PHASE3 Major Depressive Disorder COMPLETED NCT03738215
Placebo Other Phase PHASE3 Major Depressive Disorder COMPLETED NCT03738215
Cariprazine Other Phase PHASE3 Major Depressive Disorder COMPLETED NCT03738215
Placebo for ABBV-990 Other Phase PHASE1 Healthy Volunteers TERMINATED NCT05475821
ABBV-990 Other Phase PHASE1 Healthy Volunteers TERMINATED NCT05475821
Home titration Other Preclinical Parkinson Disease COMPLETED NCT04196647
Home titration Other Preclinical Parkinson Disease COMPLETED NCT04196647
methotrexate Other Phase PHASE3 Psoriasis COMPLETED NCT03219437
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03219437
methotrexate Other Phase PHASE3 Psoriasis COMPLETED NCT03219437
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03219437
Placebo Other Phase PHASE4 Anxiety Disorders,Generalized Anxiety Disorder COMPLETED NCT03924323
Escitalopram Other Phase PHASE4 Anxiety Disorders,Generalized Anxiety Disorder COMPLETED NCT03924323
Placebo for ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04380142
Levodopa/Carbidopa (LD/CD) Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04380142
Placebo for Levodopa/Carbidopa (LD/CD) Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04380142
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04380142
Placebo for ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04380142
Levodopa/Carbidopa (LD/CD) Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04380142
Placebo for Levodopa/Carbidopa (LD/CD) Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04380142
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) COMPLETED NCT04380142
Placebo for Upadacitinib Other Phase PHASE3 Crohn's Disease COMPLETED NCT03345849
Upadacitinib Other Phase PHASE3 Crohn's Disease COMPLETED NCT03345849
Placebo for Upadacitinib Other Phase PHASE3 Crohn's Disease COMPLETED NCT03345849
Upadacitinib Other Phase PHASE3 Crohn's Disease COMPLETED NCT03345849
Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J) Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00660673
CADD-Legacy® 1400 ambulatory infusion pump Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00660673
Levodopa-Carbidopa Intestinal Gel (LCIG) Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00660673
Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J) Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00660673
CADD-Legacy® 1400 ambulatory infusion pump Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00660673
Levodopa-Carbidopa Intestinal Gel (LCIG) Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT00660673
Placebo Other Phase PHASE3 Palmoplantar Pustulosis (PPP) COMPLETED NCT04451720
Risankizumab Other Phase PHASE3 Palmoplantar Pustulosis (PPP) COMPLETED NCT04451720
Cedirogant Other Phase PHASE1 Hepatic Impairment TERMINATED NCT05376839
Comparator 2 Other Preclinical Psoriasis WITHDRAWN NCT04799990
Comparator 1 Other Preclinical Psoriasis WITHDRAWN NCT04799990
Risankizumab Other Preclinical Psoriasis WITHDRAWN NCT04799990
Comparator 2 Other Preclinical Psoriasis WITHDRAWN NCT04799990
Comparator 1 Other Preclinical Psoriasis WITHDRAWN NCT04799990
Risankizumab Other Preclinical Psoriasis WITHDRAWN NCT04799990
FOLFIRI Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03082209
Bevacizumab Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03082209
Venetoclax Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03082209
ABBV-621 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03082209
FOLFIRI Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03082209
Bevacizumab Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03082209
Venetoclax Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03082209
ABBV-621 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03082209
AndroGel 1.62% Other Phase PHASE4 Hypogonadism COMPLETED NCT04274894
AndroGel 1.62% Other Phase PHASE4 Hypogonadism COMPLETED NCT04274894
Ibrutinib Other Phase PHASE2 Leukemia COMPLETED NCT03873493
Venetoclax Other Phase PHASE2 Leukemia COMPLETED NCT03873493
Ibrutinib Other Phase PHASE2 Leukemia COMPLETED NCT03873493
Venetoclax Other Phase PHASE2 Leukemia COMPLETED NCT03873493
Venetoclax Other Phase PHASE2 Chronic Lymphocytic Leukemia COMPLETED NCT02141282
Dinaciclib Other Phase PHASE1 Cancer - Acute Myeloid Leukemia TERMINATED NCT03484520
Venetoclax Other Phase PHASE1 Cancer - Acute Myeloid Leukemia TERMINATED NCT03484520
Navocaftor Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05538585
Galicaftor Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05538585
Navocaftor Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05538585
Galicaftor Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05538585
Epcoritamab Other Preclinical Lymphoma NO_LONGER_AVAILABLE NCT05692050
ABBV-992 Other Phase PHASE1 B-cell Lymphoma TERMINATED NCT04804254
ABBV-623 Other Phase PHASE1 B-cell Lymphoma TERMINATED NCT04804254
ABBV-992 Other Phase PHASE1 B-cell Lymphoma TERMINATED NCT04804254
ABBV-623 Other Phase PHASE1 B-cell Lymphoma TERMINATED NCT04804254
Placebo Other Phase PHASE2 Hidradenitis Suppurativa (HS) COMPLETED NCT04430855
Upadacitinib Other Phase PHASE2 Hidradenitis Suppurativa (HS) COMPLETED NCT04430855
Placebo Other Phase PHASE2 Hidradenitis Suppurativa (HS) COMPLETED NCT04430855
Upadacitinib Other Phase PHASE2 Hidradenitis Suppurativa (HS) COMPLETED NCT04430855
Placebo Other Phase PHASE2 Hidradenitis Suppurativa (HS) COMPLETED NCT04430855
Upadacitinib Other Phase PHASE2 Hidradenitis Suppurativa (HS) COMPLETED NCT04430855
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706847
Placebo Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706847
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706847
Placebo Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706847
Midazolam Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05530278
Navocaftor Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05530278
ABBV-576 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05530278
Galicaftor Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05530278
Midazolam Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05530278
Navocaftor Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05530278
ABBV-576 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05530278
Galicaftor Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05530278
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT02980731
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT02980731
ABBV-181 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT04196283
Nab-paclitaxel Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT04196283
Tilsotolimod Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT04196283
ABBV-368 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT04196283
ABBV-181 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT04196283
Nab-paclitaxel Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT04196283
Tilsotolimod Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT04196283
ABBV-368 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT04196283
Dexamethasone Other Phase PHASE3 Macular Edema COMPLETED NCT04976777
Approved DEX PS DDS Applicator Other Phase PHASE3 Macular Edema COMPLETED NCT04976777
Updated DEX PS DDS Applicator Other Phase PHASE3 Macular Edema COMPLETED NCT04976777
Dexamethasone Other Phase PHASE3 Macular Edema COMPLETED NCT04976777
Approved DEX PS DDS Applicator Other Phase PHASE3 Macular Edema COMPLETED NCT04976777
Updated DEX PS DDS Applicator Other Phase PHASE3 Macular Edema COMPLETED NCT04976777
Topical Corticosteroids (TCS) Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03661138
Placebo for upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03661138
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03661138
Daratumumab Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Pomalidomide Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Carfilzomib Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Dexamethasone Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Lemzoparlimab Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04895410
Placebo Other Phase PHASE2 Ankylosing Spondylitis (AS) COMPLETED NCT03178487
Upadacitinib Other Phase PHASE2 Ankylosing Spondylitis (AS) COMPLETED NCT03178487
Placebo Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04223804
ABBV-181 Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04223804
ABBV-154 Dose Formulation B Other Phase PHASE1 ABBV-154 COMPLETED NCT05556226
ABBV-154 Dose Formulation A Other Phase PHASE1 ABBV-154 COMPLETED NCT05556226
Ravagalimab 300 mg Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03695185
Ravagalimab 600 mg Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03695185
Ravagalimab 300 mg Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03695185
Ravagalimab 600 mg Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03695185
Ravagalimab 300 mg Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03695185
Ravagalimab 600 mg Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03695185
Decitabine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03941964
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03941964
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03941964
Decitabine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03941964
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03941964
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03941964
ABBV-951 Other Phase PHASE1 Parkinson's Disease COMPLETED NCT05094050
ABBV-951 Other Phase PHASE1 Parkinson's Disease COMPLETED NCT05094050
ABBV-552 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05686980
ABBV-552 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05686980
Ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02219490
ABT-333 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02219490
ABT-450/r/ABT-267 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02219490
Ribavirin (RBV) Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02219490
ABT-333 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02219490
ABT-450/r/ABT-267 Other Phase PHASE3 Chronic Hepatitis C Virus (HCV) Infection Genotype 1 COMPLETED NCT02219490
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02756611
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02756611
Dexamethasone Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma COMPLETED NCT01794520
Venetoclax Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma COMPLETED NCT01794520
Dexamethasone Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma COMPLETED NCT01794520
Venetoclax Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma COMPLETED NCT01794520
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02675426
Placebo Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02675426
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02675426
Placebo Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02675426
Risankizumab Dose B Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05567029
Risankizumab Dose A Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05567029
Risankizumab Dose B Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05567029
Risankizumab Dose A Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05567029
Glecaprevir + Pibrentasvir Pediatric Formulation Other Phase PHASE2 Hepatitis C Virus (HCV) COMPLETED NCT03067129
Glecaprevir/Pibrentasvir Adult Formulation Other Phase PHASE2 Hepatitis C Virus (HCV) COMPLETED NCT03067129
azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) COMPLETED NCT02966782
venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) COMPLETED NCT02966782
azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) COMPLETED NCT02966782
venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) COMPLETED NCT02966782
azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) COMPLETED NCT02966782
venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) COMPLETED NCT02966782
Placebo for ABT-414 Other Phase PHASE3 Glioblastoma COMPLETED NCT02573324
Radiation Other Phase PHASE3 Glioblastoma COMPLETED NCT02573324
Depatuxizumab mafodotin Other Phase PHASE3 Glioblastoma COMPLETED NCT02573324
Temozolomide Other Phase PHASE3 Glioblastoma COMPLETED NCT02573324
Placebo for ABT-414 Other Phase PHASE3 Glioblastoma COMPLETED NCT02573324
Radiation Other Phase PHASE3 Glioblastoma COMPLETED NCT02573324
Depatuxizumab mafodotin Other Phase PHASE3 Glioblastoma COMPLETED NCT02573324
Temozolomide Other Phase PHASE3 Glioblastoma COMPLETED NCT02573324
Azacitidine Other Phase PHASE1 Acute Myelogenous Leukemia TERMINATED NCT02203773
Decitabine Other Phase PHASE1 Acute Myelogenous Leukemia TERMINATED NCT02203773
ABT-199 Other Phase PHASE1 Acute Myelogenous Leukemia TERMINATED NCT02203773
Posaconazole Other Phase PHASE1 Acute Myelogenous Leukemia TERMINATED NCT02203773
venetoclax Other Phase PHASE1 Malignancies COMPLETED NCT03236857
chemotherapy Drug Phase PHASE1 Malignancies COMPLETED NCT03236857
venetoclax Other Phase PHASE1 Malignancies COMPLETED NCT03236857
chemotherapy Drug Phase PHASE1 Malignancies COMPLETED NCT03236857
Epcoritamab Other Preclinical Large B-cell Lymphoma APPROVED_FOR_MARKETING NCT05733650
Placebo Other Phase PHASE3 Migraine COMPLETED NCT04492020
Ubrogepant 100 mg Other Phase PHASE3 Migraine COMPLETED NCT04492020
Placebo Other Phase PHASE3 Migraine COMPLETED NCT04492020
Ubrogepant 100 mg Other Phase PHASE3 Migraine COMPLETED NCT04492020
Therapy Education Drug Phase PHASE4 Ulcerative Colitis RECRUITING NCT04183608
e-Monitoring Other Phase PHASE4 Ulcerative Colitis RECRUITING NCT04183608
Calprotectin Other Phase PHASE4 Ulcerative Colitis RECRUITING NCT04183608
Adalimumab Other Phase PHASE4 Ulcerative Colitis RECRUITING NCT04183608
Therapy Education Drug Phase PHASE4 Ulcerative Colitis RECRUITING NCT04183608
e-Monitoring Other Phase PHASE4 Ulcerative Colitis RECRUITING NCT04183608
Calprotectin Other Phase PHASE4 Ulcerative Colitis RECRUITING NCT04183608
Adalimumab Other Phase PHASE4 Ulcerative Colitis RECRUITING NCT04183608
Placebo Other Phase PHASE4 Exocrine Pancreatic Insufficiency (EPI) TERMINATED NCT03859869
Pancrelipase Other Phase PHASE4 Exocrine Pancreatic Insufficiency (EPI) TERMINATED NCT03859869
Rituximab Other Phase PHASE1 Small Lymphocytic Lymphoma COMPLETED NCT01682616
ABT-199 Other Phase PHASE1 Small Lymphocytic Lymphoma COMPLETED NCT01682616
Rituximab Other Phase PHASE1 Small Lymphocytic Lymphoma COMPLETED NCT01682616
ABT-199 Other Phase PHASE1 Small Lymphocytic Lymphoma COMPLETED NCT01682616
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02720523
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02720523
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02720523
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02720523
Upadacitinib Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02720523
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02720523
Placebo Other Phase PHASE1 Glabellar Lines COMPLETED NCT05496335
BOTOX Other Phase PHASE1 Glabellar Lines COMPLETED NCT05496335
AGN-151586 Other Phase PHASE1 Glabellar Lines COMPLETED NCT05496335
Placebo Other Phase PHASE1 Glabellar Lines COMPLETED NCT05496335
BOTOX Other Phase PHASE1 Glabellar Lines COMPLETED NCT05496335
AGN-151586 Other Phase PHASE1 Glabellar Lines COMPLETED NCT05496335
LUMIGAN Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT04285580
Bimatoprost SR Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT04285580
LUMIGAN Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT04285580
Bimatoprost SR Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT04285580
ABT-263 Other Phase PHASE1 Chronic Lymphocytic Leukemia COMPLETED NCT00481091
Placebo ABBV-2222 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
ABBV-2222 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
Placebo ABBV-3067 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
ABBV-3067 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
Placebo ABBV-2222 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
ABBV-2222 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
Placebo ABBV-3067 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
ABBV-3067 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
Placebo ABBV-2222 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
ABBV-2222 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
Placebo ABBV-3067 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
ABBV-3067 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03969888
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706873
Placebo to Methotrexate Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706873
Methotrexate Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706873
Placebo to Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706873
Questionnaires and dry eye tests Other Preclinical Dry Eye UNKNOWN NCT05938985
Questionnaires and dry eye tests Other Preclinical Dry Eye UNKNOWN NCT05938985
ABBV-903 Tablet Form 2 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05836506
ABBV-903 Tablet Form 1 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05836506
ABBV-903 Tablet Form 2 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05836506
ABBV-903 Tablet Form 1 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05836506
Ilorasertib Other Phase PHASE2 Advanced Cancers TERMINATED NCT02478320
Ilorasertib Other Phase PHASE2 Advanced Cancers TERMINATED NCT02478320
Placebo for upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
Upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
Placebo for elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
Elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
Placebo for upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
Upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
Placebo for elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
Elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
Placebo for upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
Upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
Placebo for elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
Elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT03978520
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4. Other Phase PHASE1 Locally Advanced or Metastatic Solid Tumor(s) TERMINATED NCT04424641
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4. Other Phase PHASE1 Locally Advanced or Metastatic Solid Tumor(s) TERMINATED NCT04424641
Placebo to match OBV/PTV/r and DSV Other Phase PHASE4 Hepatitis C, Chronic TERMINATED NCT03003338
OBV/PTV/r and DSV Other Phase PHASE4 Hepatitis C, Chronic TERMINATED NCT03003338
Placebo to match OBV/PTV/r and DSV Other Phase PHASE4 Hepatitis C, Chronic TERMINATED NCT03003338
OBV/PTV/r and DSV Other Phase PHASE4 Hepatitis C, Chronic TERMINATED NCT03003338
Placebo to match OBV/PTV/r and DSV Other Phase PHASE4 Hepatitis C, Chronic TERMINATED NCT03003338
OBV/PTV/r and DSV Other Phase PHASE4 Hepatitis C, Chronic TERMINATED NCT03003338
Surveys Other Approved Inflammatory Bowel Diseases COMPLETED NCT03757533
Health Coaching Other Approved Inflammatory Bowel Diseases COMPLETED NCT03757533
Surveys Other Approved Inflammatory Bowel Diseases COMPLETED NCT03757533
Health Coaching Other Approved Inflammatory Bowel Diseases COMPLETED NCT03757533
Surveys Other Approved Inflammatory Bowel Diseases COMPLETED NCT03757533
Health Coaching Other Approved Inflammatory Bowel Diseases COMPLETED NCT03757533
Hypofractionated WPRT Other Phase PHASE2 Prostate Cancer ACTIVE_NOT_RECRUITING NCT04197141
Conventionally-fractionated WPRT Other Phase PHASE2 Prostate Cancer ACTIVE_NOT_RECRUITING NCT04197141
Hypofractionated WPRT Other Phase PHASE2 Prostate Cancer ACTIVE_NOT_RECRUITING NCT04197141
Conventionally-fractionated WPRT Other Phase PHASE2 Prostate Cancer ACTIVE_NOT_RECRUITING NCT04197141
Ruxolitinib Other Phase PHASE1 Myelofibrosis (MF) TERMINATED NCT04480086
Navitoclax Other Phase PHASE1 Myelofibrosis (MF) TERMINATED NCT04480086
Mivebresib Other Phase PHASE1 Myelofibrosis (MF) TERMINATED NCT04480086
Ruxolitinib Other Phase PHASE1 Myelofibrosis (MF) TERMINATED NCT04480086
Navitoclax Other Phase PHASE1 Myelofibrosis (MF) TERMINATED NCT04480086
Mivebresib Other Phase PHASE1 Myelofibrosis (MF) TERMINATED NCT04480086
Venetoclax Other Preclinical Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT03873857
Venetoclax Other Preclinical Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT03873857
Pancrelipase Other Phase PHASE4 Cystic Fibrosis COMPLETED NCT03924947
Placebo Other Phase PHASE3 Bipolar I Disorder COMPLETED NCT03573297
Cariprazine Other Phase PHASE3 Bipolar I Disorder COMPLETED NCT03573297
Placebo Other Phase PHASE3 Bipolar I Disorder COMPLETED NCT03573297
Cariprazine Other Phase PHASE3 Bipolar I Disorder COMPLETED NCT03573297
Placebo Other Phase PHASE3 Bipolar I Disorder COMPLETED NCT03573297
Cariprazine Other Phase PHASE3 Bipolar I Disorder COMPLETED NCT03573297
Venetoclax Other Phase PHASE1 Castration Levels of Testosterone COMPLETED NCT03751436
Enzalutamide Other Phase PHASE1 Castration Levels of Testosterone COMPLETED NCT03751436
Venetoclax Other Phase PHASE1 Castration Levels of Testosterone COMPLETED NCT03751436
Enzalutamide Other Phase PHASE1 Castration Levels of Testosterone COMPLETED NCT03751436
Rituximab Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02005471
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02005471
Bendamustine Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02005471
Rituximab Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02005471
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02005471
Bendamustine Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02005471
ABBV-903 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05995366
ABBV-903 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05995366
Itraconazole Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05691699
Placebo for ABBV-903 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05691699
ABBV-903 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05691699
Itraconazole Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05691699
Placebo for ABBV-903 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05691699
ABBV-903 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05691699
Midazolam Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05895266
ABBV-903 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT05895266
Placebo for ABBV-903 Other Phase PHASE1 Healthy Volunteers TERMINATED NCT06009237
ABBV-903 Other Phase PHASE1 Healthy Volunteers TERMINATED NCT06009237
Placebo for ABBV-903 Other Phase PHASE1 Healthy Volunteers TERMINATED NCT06009237
ABBV-903 Other Phase PHASE1 Healthy Volunteers TERMINATED NCT06009237
Placebo for ABBV-903 Other Phase PHASE1 Healthy Volunteers TERMINATED NCT06009237
ABBV-903 Other Phase PHASE1 Healthy Volunteers TERMINATED NCT06009237
Placebo for ABBV-903 Other Phase PHASE1 Healthy Volunteers TERMINATED NCT06009237
ABBV-903 Other Phase PHASE1 Healthy Volunteers TERMINATED NCT06009237
Risankizumab Other Phase PHASE3 Plaque Psoriasis COMPLETED NCT04102007
Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT02549092
Nasojejunal (NJ) tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT02549092
Levodopa-Carbidopa Intestinal Gel Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT02549092
Optimized Medical Treatment Drug Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT02549092
Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT02549092
Nasojejunal (NJ) tube Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT02549092
Levodopa-Carbidopa Intestinal Gel Other Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT02549092
Optimized Medical Treatment Drug Phase PHASE3 Advanced Parkinson's Disease COMPLETED NCT02549092
Placebo Other Phase PHASE2 Psoriasis TERMINATED NCT05044234
Cedirogant Other Phase PHASE2 Psoriasis TERMINATED NCT05044234
Placebo Other Phase PHASE2 Psoriasis TERMINATED NCT05044234
Cedirogant Other Phase PHASE2 Psoriasis TERMINATED NCT05044234
Placebo Other Phase PHASE2 Psoriasis TERMINATED NCT05044234
Cedirogant Other Phase PHASE2 Psoriasis TERMINATED NCT05044234
Venetoclax Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05909553
ABBV-181 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01946074
ABT-165 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01946074
FOLFIRI Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01946074
paclitaxel Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01946074
ABBV-181 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01946074
ABT-165 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01946074
FOLFIRI Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01946074
paclitaxel Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT01946074
placebo Other Phase PHASE2 Multiple Sclerosis (MS) COMPLETED NCT03737812
elezanumab Other Phase PHASE2 Multiple Sclerosis (MS) COMPLETED NCT03737812
placebo Other Phase PHASE2 Multiple Sclerosis (MS) COMPLETED NCT03737812
elezanumab Other Phase PHASE2 Multiple Sclerosis (MS) COMPLETED NCT03737812
placebo Other Phase PHASE2 Multiple Sclerosis (MS) COMPLETED NCT03737851
elezanumab Other Phase PHASE2 Multiple Sclerosis (MS) COMPLETED NCT03737851
placebo Other Phase PHASE2 Multiple Sclerosis (MS) COMPLETED NCT03737851
elezanumab Other Phase PHASE2 Multiple Sclerosis (MS) COMPLETED NCT03737851
ABT-494 Other Phase PHASE2 Crohn's Disease COMPLETED NCT02365649
Placebo Other Phase PHASE2 Crohn's Disease COMPLETED NCT02365649
ABT-494 Other Phase PHASE2 Crohn's Disease COMPLETED NCT02365649
Placebo Other Phase PHASE2 Crohn's Disease COMPLETED NCT02365649
Placebo Methotrexate Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706951
Placebo Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706951
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706951
Methotrexate Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02706951
Vehicle Other Phase PHASE1 Presbyopia TERMINATED NCT04403763
AGN-241622 Other Phase PHASE1 Presbyopia TERMINATED NCT04403763
Vehicle Other Phase PHASE1 Presbyopia TERMINATED NCT04403763
AGN-241622 Other Phase PHASE1 Presbyopia TERMINATED NCT04403763
Vehicle Other Phase PHASE1 Presbyopia TERMINATED NCT04403763
AGN-241622 Other Phase PHASE1 Presbyopia TERMINATED NCT04403763
Budigalimab Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT03639194
ABBV-011 Other Phase PHASE1 Small Cell Lung Cancer COMPLETED NCT03639194
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT04912063
Azacitidine Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT04912063
Lemzoparlimab Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT04912063
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT04912063
Azacitidine Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT04912063
Lemzoparlimab Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT04912063
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT04912063
Azacitidine Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT04912063
Lemzoparlimab Other Phase PHASE1 Acute Myeloid Leukemia (AML) TERMINATED NCT04912063
Placebo Other Phase PHASE2 COVID-19 COMPLETED NCT04372628
Lopinavir/Ritonavir 400 mg/100 mg Other Phase PHASE2 COVID-19 COMPLETED NCT04372628
Placebo Other Phase PHASE2 COVID-19 COMPLETED NCT04372628
Lopinavir/Ritonavir 400 mg/100 mg Other Phase PHASE2 COVID-19 COMPLETED NCT04372628
Placebo Other Phase PHASE2 COVID-19 COMPLETED NCT04372628
Lopinavir/Ritonavir 400 mg/100 mg Other Phase PHASE2 COVID-19 COMPLETED NCT04372628
Venetoclax Oral Tablet Other Phase PHASE1 Relapsed Adult AML ACTIVE_NOT_RECRUITING NCT04330820
Venetoclax Oral Tablet Other Phase PHASE1 Relapsed Adult AML UNKNOWN NCT04330820
Placebo for ABBV-382 Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04554966
ABBV-382 Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04554966
Placebo for ABBV-382 Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04554966
ABBV-382 Other Phase PHASE1 Human Immunodeficiency Virus (HIV) COMPLETED NCT04554966
Aflibercept Other Phase PHASE4 Diabetic Macular Edema UNKNOWN NCT05990829
Ozurdex Other Phase PHASE4 Diabetic Macular Edema UNKNOWN NCT05990829
Aflibercept Other Phase PHASE4 Diabetic Macular Edema UNKNOWN NCT05990829
Ozurdex Other Phase PHASE4 Diabetic Macular Edema UNKNOWN NCT05990829
ABBV-CLS-7262 Other Phase PHASE1 Healthy COMPLETED NCT06145607
ABBV-CLS-7262 Other Phase PHASE1 Healthy COMPLETED NCT06145607
Ubrogepant Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05892757
Atogepant Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05892757
Ubrogepant Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05892757
Atogepant Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05892757
Placebo Other Phase PHASE4 Hypogonadism COMPLETED NCT03518034
AndroGel® Other Phase PHASE4 Hypogonadism COMPLETED NCT03518034
Placebo Other Phase PHASE4 Hypogonadism COMPLETED NCT03518034
AndroGel® Other Phase PHASE4 Hypogonadism COMPLETED NCT03518034
Lutikizumab Dose B Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06067568
Lutikizumab Dose A Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06067568
Lutikizumab Dose B Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06067568
Lutikizumab Dose A Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06067568
Lutikizumab Dose B Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06067568
Lutikizumab Dose A Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06067568
Placebo to upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03738397
Placebo to dupilumab Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03738397
Dupilumab Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03738397
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03738397
Placebo to upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03738397
Placebo to dupilumab Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03738397
Dupilumab Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03738397
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03738397
dexamethasone implant Other Preclinical Diabetic Macular Edema UNKNOWN NCT06332690
dexamethasone implant Other Preclinical Diabetic Macular Edema RECRUITING NCT06332690
CREON Other Preclinical Chronic Pancreatitis COMPLETED NCT04949828
Placebo Other Phase PHASE1 Moderate to Severe Glabellar Lines COMPLETED NCT06151561
AGN-151586 Other Phase PHASE1 Moderate to Severe Glabellar Lines COMPLETED NCT06151561
Unspecific group training Other Approved Parkinson's Disease COMPLETED NCT02048605
Psycho-social CBT based training Other Approved Parkinson's Disease COMPLETED NCT02048605
AGN-190584 Other Phase PHASE4 Presbyopia WITHDRAWN NCT05624320
AGN-190584 Other Phase PHASE4 Presbyopia WITHDRAWN NCT05624320
ABBV-552 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06278766
ABBV-552 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06278766
Apremilast Other Phase PHASE4 Psoriasis COMPLETED NCT04908475
Risankizumab Other Phase PHASE4 Psoriasis COMPLETED NCT04908475
Apremilast Other Phase PHASE4 Psoriasis COMPLETED NCT04908475
Risankizumab Other Phase PHASE4 Psoriasis COMPLETED NCT04908475
Veliparib Other Phase PHASE2 Cancer WITHDRAWN NCT03044795
Veliparib Other Phase PHASE2 Cancer WITHDRAWN NCT03044795
Venetoclax Other Preclinical Myelofibrosis NO_LONGER_AVAILABLE NCT03592576
Navitoclax Other Preclinical Myelofibrosis NO_LONGER_AVAILABLE NCT03592576
Venetoclax Other Preclinical Myelofibrosis NO_LONGER_AVAILABLE NCT03592576
Navitoclax Other Preclinical Myelofibrosis NO_LONGER_AVAILABLE NCT03592576
Sham Selective Laser Trabeculoplasty Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02507687
Selective Laser Trabeculoplasty Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02507687
Sham Bimatoprost SR Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02507687
Bimatoprost SR Other Phase PHASE3 Glaucoma, Open-Angle COMPLETED NCT02507687
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06054425
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06054425
Placebo Other Phase PHASE2 Post-Operative Atrial Fibrillation COMPLETED NCT03779841
AGN-151607 Other Phase PHASE2 Post-Operative Atrial Fibrillation COMPLETED NCT03779841
Placebo Other Phase PHASE2 Post-Operative Atrial Fibrillation COMPLETED NCT03779841
AGN-151607 Other Phase PHASE2 Post-Operative Atrial Fibrillation COMPLETED NCT03779841
AGN-151586 Other Phase PHASE3 Glabellar Lines COMPLETED NCT05248867
Placebo Other Phase PHASE3 Glabellar Lines COMPLETED NCT05248867
AGN-151586 Other Phase PHASE3 Glabellar Lines COMPLETED NCT05248867
Placebo Other Phase PHASE3 Glabellar Lines COMPLETED NCT05248867
AGN-151586 Other Phase PHASE3 Glabellar Lines COMPLETED NCT05248893
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04905810
Decitabine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04905810
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04905810
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04905810
Decitabine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04905810
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04905810
Leuprolide Acetate (LA) Other Phase PHASE3 Central Precocious Puberty (CPP) COMPLETED NCT03695237
Leuprolide Acetate (LA) Other Phase PHASE3 Central Precocious Puberty (CPP) COMPLETED NCT03695237
Leuprolide Acetate (LA) Other Phase PHASE3 Central Precocious Puberty (CPP) COMPLETED NCT03695237
18F-FluorApoTrace Other Phase EARLY_PHASE1 Diffuse Large B Cell Lymphoma TERMINATED NCT05048732
18F-FluorApoTrace Other Phase EARLY_PHASE1 Diffuse Large B Cell Lymphoma TERMINATED NCT05048732
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT04713592
Placebo for Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT04713592
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT04713592
Placebo for Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT04713592
RGX-314 Other Phase PHASE2 Neovascular Age-related Macular Degeneration ENROLLING_BY_INVITATION NCT03999801
Venetoclax Other Phase PHASE1 Healthy Volunteers WITHDRAWN NCT06070948
Venetoclax Other Phase PHASE1 Healthy Volunteers WITHDRAWN NCT06070948
Pemetrexed Other Phase PHASE3 Non-Small Cell Lung Cancer WITHDRAWN NCT06093503
Carboplatin Other Phase PHASE3 Non-Small Cell Lung Cancer WITHDRAWN NCT06093503
Cisplatin Other Phase PHASE3 Non-Small Cell Lung Cancer WITHDRAWN NCT06093503
Osimertinib Other Phase PHASE3 Non-Small Cell Lung Cancer WITHDRAWN NCT06093503
Telisotuzumab Vedotin Other Phase PHASE3 Non-Small Cell Lung Cancer WITHDRAWN NCT06093503
Pemetrexed Other Phase PHASE3 Non-Small Cell Lung Cancer WITHDRAWN NCT06093503
Carboplatin Other Phase PHASE3 Non-Small Cell Lung Cancer WITHDRAWN NCT06093503
Cisplatin Other Phase PHASE3 Non-Small Cell Lung Cancer WITHDRAWN NCT06093503
Osimertinib Other Phase PHASE3 Non-Small Cell Lung Cancer WITHDRAWN NCT06093503
Telisotuzumab Vedotin Other Phase PHASE3 Non-Small Cell Lung Cancer WITHDRAWN NCT06093503
Moxifloxacin 400mg Other Phase PHASE1 Healthy COMPLETED NCT06310876
Placebo Other Phase PHASE1 Healthy COMPLETED NCT06310876
ABBV-CLS-7262 Other Phase PHASE1 Healthy COMPLETED NCT06310876
Moxifloxacin 400mg Other Phase PHASE1 Healthy COMPLETED NCT06310876
Placebo Other Phase PHASE1 Healthy COMPLETED NCT06310876
ABBV-CLS-7262 Other Phase PHASE1 Healthy COMPLETED NCT06310876
Placebo for ABBV-950 Other Phase PHASE1 Upper Limb Spasticity TERMINATED NCT05956509
BOTOX Other Phase PHASE1 Upper Limb Spasticity TERMINATED NCT05956509
ABBV-950 Other Phase PHASE1 Upper Limb Spasticity TERMINATED NCT05956509
Placebo for ABBV-950 Other Phase PHASE1 Upper Limb Spasticity TERMINATED NCT05956509
BOTOX Other Phase PHASE1 Upper Limb Spasticity TERMINATED NCT05956509
ABBV-950 Other Phase PHASE1 Upper Limb Spasticity TERMINATED NCT05956509
Cytochrome P450 (CYP) Substrates Other Phase PHASE1 Ulcerative Colitis (UC) COMPLETED NCT04254783
Risankizumab Other Phase PHASE1 Ulcerative Colitis (UC) COMPLETED NCT04254783
Cytochrome P450 (CYP) Substrates Other Phase PHASE1 Ulcerative Colitis (UC) COMPLETED NCT04254783
Risankizumab Other Phase PHASE1 Ulcerative Colitis (UC) COMPLETED NCT04254783
ABBV-119 Other Phase PHASE2 Cystic Fibrosis (CF) TERMINATED NCT04853368
Navocaftor Other Phase PHASE2 Cystic Fibrosis (CF) TERMINATED NCT04853368
Placebo Other Phase PHASE2 Cystic Fibrosis (CF) TERMINATED NCT04853368
Galicaftor Other Phase PHASE2 Cystic Fibrosis (CF) TERMINATED NCT04853368
ABBV-576 Other Phase PHASE2 Cystic Fibrosis (CF) TERMINATED NCT04853368
ABBV-119 Other Phase PHASE2 Cystic Fibrosis (CF) TERMINATED NCT04853368
Navocaftor Other Phase PHASE2 Cystic Fibrosis (CF) TERMINATED NCT04853368
Placebo Other Phase PHASE2 Cystic Fibrosis (CF) TERMINATED NCT04853368
Galicaftor Other Phase PHASE2 Cystic Fibrosis (CF) TERMINATED NCT04853368
ABBV-576 Other Phase PHASE2 Cystic Fibrosis (CF) TERMINATED NCT04853368
No intervention, this is an observational study Other Preclinical Acute Pancreatitis COMPLETED NCT03063398
No intervention, this is an observational study Other Preclinical Acute Pancreatitis COMPLETED NCT03063398
Placebo for upadacitinib Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT03086343
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT03086343
Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion) Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT03086343
Abatacept Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT03086343
Placebo for upadacitinib Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT03086343
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT03086343
Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion) Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT03086343
Abatacept Other Phase PHASE3 Rheumatoid Arthritis (RA) COMPLETED NCT03086343
[14C] ABBV-CLS-7262 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06425003
[14C] ABBV-CLS-7262 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06425003
CREON Other Phase PHASE4 Cystic Fibrosis COMPLETED NCT05069597
CREON Other Phase PHASE4 Cystic Fibrosis COMPLETED NCT05069597
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT03406156
Bendamustine Other Phase PHASE3 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT03406156
Obinutuzumab Other Phase PHASE3 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT03406156
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT03406156
Bendamustine Other Phase PHASE3 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT03406156
Obinutuzumab Other Phase PHASE3 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT03406156
Ubrogepant 100 MG [Ubrelvy] Other Phase PHASE4 Headache, Migraine ACTIVE_NOT_RECRUITING NCT05503082
Ubrogepant 50 MG [Ubrelvy] Other Phase PHASE4 Headache, Migraine ACTIVE_NOT_RECRUITING NCT05503082
Ubrogepant 100 MG [Ubrelvy] Other Phase PHASE4 Headache, Migraine ACTIVE_NOT_RECRUITING NCT05503082
Ubrogepant 50 MG [Ubrelvy] Other Phase PHASE4 Headache, Migraine ACTIVE_NOT_RECRUITING NCT05503082
Placebo Other Phase PHASE3 Platysma Prominence COMPLETED NCT04994535
OnabotulinumtoxinA Other Phase PHASE3 Platysma Prominence COMPLETED NCT04994535
Placebo Other Phase PHASE3 Platysma Prominence COMPLETED NCT04994535
OnabotulinumtoxinA Other Phase PHASE3 Platysma Prominence COMPLETED NCT04994535
Placebo Other Phase PHASE4 Social Anxiety Disorder COMPLETED NCT05384483
Cariprazine Other Phase PHASE4 Social Anxiety Disorder COMPLETED NCT05384483
Placebo Other Phase PHASE4 Social Anxiety Disorder COMPLETED NCT05384483
Cariprazine Other Phase PHASE4 Social Anxiety Disorder COMPLETED NCT05384483
Placebo Microcrystalline Cellulose Other Approved Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin WITHDRAWN NCT05894109
zinc citrate 50 mg Other Approved Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin WITHDRAWN NCT05894109
Clindamycin Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
Cefadroxil Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
Flucloxacillin Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
Oxacillin Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
Vancomycin Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
Dalbavancin Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
Clindamycin Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
Cefadroxil Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
Flucloxacillin Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
Oxacillin Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
Vancomycin Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
Dalbavancin Other Phase PHASE3 Methicillin-Resistant Staphylococcus Aureus COMPLETED NCT02814916
OnabotulinumtoxinA 145 UNT [Botox] Other Phase PHASE4 Drug-resistant Focal Seizure TERMINATED NCT05605756
Epcoritamab Other Phase PHASE2 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT05451810
Epcoritamab Other Phase PHASE2 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT05451810
Osimertinib Other Phase PHASE1 Solid Tumor COMPLETED NCT04720976
Sotorasib Other Phase PHASE1 Solid Tumor COMPLETED NCT04720976
Pembrolizumab Other Phase PHASE1 Solid Tumor COMPLETED NCT04720976
Binimetinib Other Phase PHASE1 Solid Tumor COMPLETED NCT04720976
JAB-3312 Other Phase PHASE1 Solid Tumor COMPLETED NCT04720976
VOLITE XC Other Phase PHASE3 Neck Lines COMPLETED NCT05316233
VOLITE XC Other Phase PHASE3 Neck Lines COMPLETED NCT05316233
Placebo Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT04073303
Botulinum Toxin Type A Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT04073303
Breath Test Other Preclinical IBD ACTIVE_NOT_RECRUITING NCT04827368
Breath Test Other Preclinical IBD ACTIVE_NOT_RECRUITING NCT04827368
Lenalidomide Other Phase PHASE3 Follicular Lymphoma (FL) ACTIVE_NOT_RECRUITING NCT05409066
Rituximab Other Phase PHASE3 Follicular Lymphoma (FL) ACTIVE_NOT_RECRUITING NCT05409066
Epcoritamab Other Phase PHASE3 Follicular Lymphoma (FL) ACTIVE_NOT_RECRUITING NCT05409066
Lenalidomide Other Phase PHASE3 Follicular Lymphoma (FL) ACTIVE_NOT_RECRUITING NCT05409066
Rituximab Other Phase PHASE3 Follicular Lymphoma (FL) ACTIVE_NOT_RECRUITING NCT05409066
Epcoritamab Other Phase PHASE3 Follicular Lymphoma (FL) ACTIVE_NOT_RECRUITING NCT05409066
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04086264
IMGN632 Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04086264
Azacitidine Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04086264
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04086264
IMGN632 Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04086264
Azacitidine Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04086264
Bevacizumab Other Phase PHASE3 Metastatic Colorectal Cancer RECRUITING NCT06614192
Trifluridine/Tipiracil Other Phase PHASE3 Metastatic Colorectal Cancer RECRUITING NCT06614192
Telisotuzumab Adizutecan Other Phase PHASE3 Metastatic Colorectal Cancer RECRUITING NCT06614192
Bevacizumab Other Phase PHASE3 Metastatic Colorectal Cancer RECRUITING NCT06614192
Trifluridine/Tipiracil Other Phase PHASE3 Metastatic Colorectal Cancer RECRUITING NCT06614192
Telisotuzumab Adizutecan Other Phase PHASE3 Metastatic Colorectal Cancer RECRUITING NCT06614192
VEGFR TKI Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT04417465
PD-1 inhibitor Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT04417465
ABBV-CLS-579 Other Phase PHASE1 Advanced Solid Tumors Cancer COMPLETED NCT04417465
Adalimumab Other Phase PHASE2 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT06257875
Lutikizumab Other Phase PHASE2 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT06257875
Venetoclax Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06742086
Venetoclax Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06742086
Venetoclax Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06742086
risankizumab Other Phase PHASE2 Psoriasis COMPLETED NCT05283135
risankizumab Other Phase PHASE2 Psoriasis COMPLETED NCT05283135
risankizumab Other Phase PHASE2 Psoriasis COMPLETED NCT05283135
Carboplatin Other Phase PHASE2 High Grade Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05456685
Mirvetuximab soravtansine Other Phase PHASE2 High Grade Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05456685
Placebo Other Phase PHASE1 Glabellar Lines COMPLETED NCT06834789
OnabotulinumtoxinA Other Phase PHASE1 Glabellar Lines COMPLETED NCT06834789
AGN-151586 Other Phase PHASE1 Glabellar Lines COMPLETED NCT06834789
Topical corticosteroids (TCS) Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT03568318
Upadacitinib Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT03568318
Placebo Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT03568318
Topical corticosteroids (TCS) Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT03568318
Upadacitinib Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT03568318
Placebo Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT03568318
GUB014295-PLACEBO Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06144684
GUB014295 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06144684
Bevacizumab Other Phase PHASE1 Ovarian Cancer RECRUITING NCT07278336
ABBV-901 Other Phase PHASE1 Ovarian Cancer RECRUITING NCT07278336
Upadacitinib Other Preclinical Crohn Disease AVAILABLE NCT04159597
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) AVAILABLE NCT04278235
SYFOVRE Other Phase PHASE1 Geographic Atrophy RECRUITING NCT07160179
ABBV-6628 Other Phase PHASE1 Geographic Atrophy RECRUITING NCT07160179
SYFOVRE Other Phase PHASE1 Geographic Atrophy RECRUITING NCT07160179
ABBV-6628 Other Phase PHASE1 Geographic Atrophy RECRUITING NCT07160179
Risankizumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Adalimumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Risankizumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Adalimumab Other Phase PHASE3 Juvenile Psoriatic Arthritis RECRUITING NCT06100744
Placebo Other Phase PHASE3 Glabellar Lines COMPLETED NCT05248880
AGN-151586 Other Phase PHASE3 Glabellar Lines COMPLETED NCT05248880
Placebo Other Phase PHASE3 Glabellar Lines COMPLETED NCT05248880
AGN-151586 Other Phase PHASE3 Glabellar Lines COMPLETED NCT05248880
Prednisolone Other Phase PHASE3 Takayasu Arteritis (TAK) ACTIVE_NOT_RECRUITING NCT04161898
Placebo for Upadacitinib Other Phase PHASE3 Takayasu Arteritis (TAK) ACTIVE_NOT_RECRUITING NCT04161898
Upadacitinib Other Phase PHASE3 Takayasu Arteritis (TAK) ACTIVE_NOT_RECRUITING NCT04161898
Pivekimab Sunirine Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT06034470
Multigated Acquisition Scan Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT06034470
Idarubicin Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT06034470
Granulocyte Colony-Stimulating Factor Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT06034470
Fludarabine Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT06034470
Echocardiography Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT06034470
Cytarabine Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT06034470
Bone Marrow Biopsy Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT06034470
Bone Marrow Aspiration Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT06034470
Biospecimen Collection Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT06034470
Pomalidomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Dexamethasone Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Daratumumab Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
ABBV-453 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Pomalidomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Dexamethasone Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Daratumumab Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
ABBV-453 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
ABBV-722 Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07361367
No Intervention Other Phase PHASE3 Breast Reconstruction RECRUITING NCT06575192
ARTIA Reconstructive Tissue Matrix Other Phase PHASE3 Breast Reconstruction RECRUITING NCT06575192
Placebo for Risankizumab Other Phase PHASE4 Genital Psoriasis COMPLETED NCT05969223
Risankizumab Other Phase PHASE4 Genital Psoriasis COMPLETED NCT05969223
Placebo for Risankizumab Other Phase PHASE4 Genital Psoriasis COMPLETED NCT05969223
Risankizumab Other Phase PHASE4 Genital Psoriasis COMPLETED NCT05969223
Bendamustine Other Phase PHASE3 Follicular Lymphoma (FL) RECRUITING NCT06191744
Obinutuzumab Other Phase PHASE3 Follicular Lymphoma (FL) RECRUITING NCT06191744
Cyclophosphamide Other Phase PHASE3 Follicular Lymphoma (FL) RECRUITING NCT06191744
Vincristine Other Phase PHASE3 Follicular Lymphoma (FL) RECRUITING NCT06191744
Doxorubicin Other Phase PHASE3 Follicular Lymphoma (FL) RECRUITING NCT06191744
Lenalidomide Other Phase PHASE3 Follicular Lymphoma (FL) RECRUITING NCT06191744
Rituximab Other Phase PHASE3 Follicular Lymphoma (FL) RECRUITING NCT06191744
Prednisone Other Phase PHASE3 Follicular Lymphoma (FL) RECRUITING NCT06191744
Epcoritamab Other Phase PHASE3 Follicular Lymphoma (FL) RECRUITING NCT06191744
Placebo Other Phase PHASE3 Systemic Lupus Erythematosus RECRUITING NCT05843643
Upadacitinib Other Phase PHASE3 Systemic Lupus Erythematosus RECRUITING NCT05843643
Placebo Other Phase PHASE3 Systemic Lupus Erythematosus RECRUITING NCT05843643
Upadacitinib Other Phase PHASE3 Systemic Lupus Erythematosus RECRUITING NCT05843643
Vedolizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT06880744
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT06880744
Vedolizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT06880744
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT06880744
ABBV-101 Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
ABBV-101 Other Phase PHASE1 Hematologic Cancer ACTIVE_NOT_RECRUITING NCT05753501
Upadacitinib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07425899
ABBV-722 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07425899
ABBV-438 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT07409246
ABBV-932 Other Phase PHASE2 Bipolar I or II Disorder RECRUITING NCT07220460
ABBV-932 Other Phase PHASE2 Bipolar I or II Disorder RECRUITING NCT07220460
Gemcitabine Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT06508658
Oxaliplatin Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT06508658
Lenalidomide Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT06508658
Rituximab Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT06508658
Epcoritamab Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT06508658
Gemcitabine Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT06508658
Oxaliplatin Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT06508658
Lenalidomide Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT06508658
Rituximab Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT06508658
Epcoritamab Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT06508658
Placebo for Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Telisotuzumab Vedotin Other Phase PHASE2 Lung Non-Small Cell Carcinoma RECRUITING NCT07323641
Survey Administration Other Phase PHASE2 Lung Non-Small Cell Carcinoma RECRUITING NCT07323641
Osimertinib Other Phase PHASE2 Lung Non-Small Cell Carcinoma RECRUITING NCT07323641
Magnetic Resonance Imaging Other Phase PHASE2 Lung Non-Small Cell Carcinoma RECRUITING NCT07323641
Computed Tomography Other Phase PHASE2 Lung Non-Small Cell Carcinoma RECRUITING NCT07323641
Biospecimen Collection Other Phase PHASE2 Lung Non-Small Cell Carcinoma RECRUITING NCT07323641
Biopsy Procedure Procedure Phase PHASE2 Lung Non-Small Cell Carcinoma RECRUITING NCT07323641
Placebo for Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Liposomal daunorubicin and cytarabine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Daunorubicin Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Idarubicin Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Cytarabine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Iberdomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Etentamig Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Matching Placebo for PVEK Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Pivekimab Sunirine Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
Emraclidine Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Azacitidine Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
Venetoclax Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
ethinyl estradiol/levonorgestrel Other Phase PHASE1 Hematologic Malignancies RECRUITING NCT03557619
Venetoclax Other Phase PHASE1 Hematologic Malignancies RECRUITING NCT03557619
ethinyl estradiol/levonorgestrel Other Phase PHASE1 Hematologic Malignancies RECRUITING NCT03557619
Venetoclax Other Phase PHASE1 Hematologic Malignancies RECRUITING NCT03557619
ethinyl estradiol/levonorgestrel Other Phase PHASE1 Hematologic Malignancies RECRUITING NCT03557619
Venetoclax Other Phase PHASE1 Hematologic Malignancies RECRUITING NCT03557619
Placebo Other Phase PHASE4 Overactive Detrusor COMPLETED NCT01192568
Oxybutynin Other Phase PHASE4 Overactive Detrusor COMPLETED NCT01192568
Carboplatin Other Preclinical Metastatic Non Small Cell Lung Cancer COMPLETED NCT06585189
Cisplatin Other Preclinical Metastatic Non Small Cell Lung Cancer COMPLETED NCT06585189
Pemetrexed Other Preclinical Metastatic Non Small Cell Lung Cancer COMPLETED NCT06585189
Pembrolizumab Other Preclinical Metastatic Non Small Cell Lung Cancer COMPLETED NCT06585189
Carboplatin Other Preclinical Metastatic Non Small Cell Lung Cancer COMPLETED NCT06585189
Cisplatin Other Preclinical Metastatic Non Small Cell Lung Cancer COMPLETED NCT06585189
Pemetrexed Other Preclinical Metastatic Non Small Cell Lung Cancer COMPLETED NCT06585189
Pembrolizumab Other Preclinical Metastatic Non Small Cell Lung Cancer COMPLETED NCT06585189
RGX-314 Other Phase PHASE2 Neovascular Age-related Macular Degeneration COMPLETED NCT04832724
RGX-314 Other Phase PHASE2 Neovascular Age-related Macular Degeneration COMPLETED NCT04832724
Placebo for Upadacitinib Other Phase PHASE3 Atopic Dermatitis WITHDRAWN NCT06390722
Upadacitinib Other Phase PHASE3 Atopic Dermatitis WITHDRAWN NCT06390722
Placebo for Upadacitinib Other Phase PHASE3 Atopic Dermatitis WITHDRAWN NCT06390722
Upadacitinib Other Phase PHASE3 Atopic Dermatitis WITHDRAWN NCT06390722
Placebo for Upadacitinib Other Phase PHASE3 Atopic Dermatitis WITHDRAWN NCT06390722
Upadacitinib Other Phase PHASE3 Atopic Dermatitis WITHDRAWN NCT06390722
Placebo for Albendazole Other Phase PHASE2 Onchocerciasis TERMINATED NCT04913610
Albendazole Other Phase PHASE2 Onchocerciasis TERMINATED NCT04913610
Placebo for ABBV-4083 Other Phase PHASE2 Onchocerciasis TERMINATED NCT04913610
ABBV-4083 Other Phase PHASE2 Onchocerciasis TERMINATED NCT04913610
Placebo for Albendazole Other Phase PHASE2 Onchocerciasis TERMINATED NCT04913610
Albendazole Other Phase PHASE2 Onchocerciasis TERMINATED NCT04913610
Placebo for ABBV-4083 Other Phase PHASE2 Onchocerciasis TERMINATED NCT04913610
ABBV-4083 Other Phase PHASE2 Onchocerciasis TERMINATED NCT04913610
ABBV-903 Other Phase PHASE1 Healthy Volunteers WITHDRAWN NCT06078202
Letrozole Other Preclinical Metastatic Breast Cancer COMPLETED NCT06607601
Palbociclib Other Preclinical Metastatic Breast Cancer COMPLETED NCT06607601
Letrozole Other Preclinical Metastatic Breast Cancer COMPLETED NCT06607601
Palbociclib Other Preclinical Metastatic Breast Cancer COMPLETED NCT06607601
Carboplatin Other Preclinical Metastatic Nonsmall Cell Lung Cancer COMPLETED NCT06607393
Cisplatin Other Preclinical Metastatic Nonsmall Cell Lung Cancer COMPLETED NCT06607393
Pemetrexed Other Preclinical Metastatic Nonsmall Cell Lung Cancer COMPLETED NCT06607393
Pembrolizumab Other Preclinical Metastatic Nonsmall Cell Lung Cancer COMPLETED NCT06607393
Carboplatin Other Preclinical Metastatic Nonsmall Cell Lung Cancer COMPLETED NCT06607393
Cisplatin Other Preclinical Metastatic Nonsmall Cell Lung Cancer COMPLETED NCT06607393
Pemetrexed Other Preclinical Metastatic Nonsmall Cell Lung Cancer COMPLETED NCT06607393
Pembrolizumab Other Preclinical Metastatic Nonsmall Cell Lung Cancer COMPLETED NCT06607393
Juvéderm® VOLUMA® with Lidocaine Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
Juvéderm® VOLIFT® with Lidocaine Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
Juvéderm® VOLBELLA® with Lidocaine Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
BOTOX®/VISTABEL® Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
Juvéderm® VOLUMA® with Lidocaine Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
Juvéderm® VOLIFT® with Lidocaine Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
Juvéderm® VOLBELLA® with Lidocaine Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
BOTOX®/VISTABEL® Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
Juvéderm® VOLUMA® with Lidocaine Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
Juvéderm® VOLIFT® with Lidocaine Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
Juvéderm® VOLBELLA® with Lidocaine Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
BOTOX®/VISTABEL® Other Phase PHASE4 Facial Corrections COMPLETED NCT05647551
Placebo Other Phase PHASE2 Crohn's Disease TERMINATED NCT05068284
ABBV-154 Other Phase PHASE2 Crohn's Disease TERMINATED NCT05068284
Placebo Other Phase PHASE2 Crohn's Disease TERMINATED NCT05068284
ABBV-154 Other Phase PHASE2 Crohn's Disease TERMINATED NCT05068284
ABBV-668 ER Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06477926
ABBV-668 IR Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06477926
ABBV-668 ER Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06477926
ABBV-668 IR Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06477926
ABBV-668 ER Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06477926
ABBV-668 IR Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06477926
Ubrogepant Other Phase PHASE4 Episodic Migraine COMPLETED NCT05264129
Atogepant Other Phase PHASE4 Episodic Migraine COMPLETED NCT05264129
Ubrogepant Other Phase PHASE4 Episodic Migraine COMPLETED NCT05264129
Atogepant Other Phase PHASE4 Episodic Migraine COMPLETED NCT05264129
Placebo Other Phase PHASE2 Non-Segmental Vitiligo COMPLETED NCT04927975
Upadacitinib Other Phase PHASE2 Non-Segmental Vitiligo COMPLETED NCT04927975
Placebo Other Phase PHASE2 Non-Segmental Vitiligo COMPLETED NCT04927975
Upadacitinib Other Phase PHASE2 Non-Segmental Vitiligo COMPLETED NCT04927975
Placebo Other Phase PHASE2 Non-Segmental Vitiligo COMPLETED NCT04927975
Upadacitinib Other Phase PHASE2 Non-Segmental Vitiligo COMPLETED NCT04927975
Placebo Other Phase PHASE2 Rheumatoid Arthritis (RA) TERMINATED NCT04888585
ABBV-154 Other Phase PHASE2 Rheumatoid Arthritis (RA) TERMINATED NCT04888585
Vehicle Other Phase PHASE3 Presbyopia COMPLETED NCT04837482
AGN-190584 Other Phase PHASE3 Presbyopia COMPLETED NCT04837482
Vehicle Other Phase PHASE3 Presbyopia COMPLETED NCT04837482
AGN-190584 Other Phase PHASE3 Presbyopia COMPLETED NCT04837482
ABBV-444 Other Phase PHASE3 Dry Eye Syndrome COMPLETED NCT05878067
ABBV-444 Other Phase PHASE3 Dry Eye Syndrome COMPLETED NCT05878067
Glucocorticoid Other Phase PHASE2 Polymyalgia Rheumatica TERMINATED NCT04972968
Placebo Other Phase PHASE2 Polymyalgia Rheumatica TERMINATED NCT04972968
ABBV-154 Other Phase PHASE2 Polymyalgia Rheumatica TERMINATED NCT04972968
Glucocorticoid Other Phase PHASE2 Polymyalgia Rheumatica TERMINATED NCT04972968
Placebo Other Phase PHASE2 Polymyalgia Rheumatica TERMINATED NCT04972968
ABBV-154 Other Phase PHASE2 Polymyalgia Rheumatica TERMINATED NCT04972968
Glucocorticoid Other Phase PHASE2 Polymyalgia Rheumatica TERMINATED NCT04972968
Placebo Other Phase PHASE2 Polymyalgia Rheumatica TERMINATED NCT04972968
ABBV-154 Other Phase PHASE2 Polymyalgia Rheumatica TERMINATED NCT04972968
Ravagalimab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06402513
Ravagalimab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06402513
Ravagalimab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06402513
Placebo to Veliparib Other Phase PHASE3 Ovarian Cancer TERMINATED NCT02470585
Carboplatin Other Phase PHASE3 Ovarian Cancer TERMINATED NCT02470585
Paclitaxel Other Phase PHASE3 Ovarian Cancer TERMINATED NCT02470585
Veliparib Other Phase PHASE3 Ovarian Cancer TERMINATED NCT02470585
ABBV-951 Other Phase PHASE1 Parkinson's Disease (PD) COMPLETED NCT03374917
ABBV-951 Other Phase PHASE1 Parkinson's Disease (PD) COMPLETED NCT03374917
ABBV-951 Other Phase PHASE1 Parkinson's Disease (PD) COMPLETED NCT03033498
ABBV-951 Other Phase PHASE1 Parkinson's Disease (PD) COMPLETED NCT03033498
ABBV-951 Other Phase PHASE1 Parkinson's Disease (PD) COMPLETED NCT03033498
Placebo Other Phase PHASE3 Platysma Prominence COMPLETED NCT04949399
OnabotulinumtoxinA Other Phase PHASE3 Platysma Prominence COMPLETED NCT04949399
Placebo Other Phase PHASE3 Platysma Prominence COMPLETED NCT04949399
OnabotulinumtoxinA Other Phase PHASE3 Platysma Prominence COMPLETED NCT04949399
standard of care chemotherapy plus gemtuzumab ozogamicin Drug Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT05904106
Venetoclax plus Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT05904106
OnabotulinumtoxinA Other Phase PHASE3 Platysma Prominence COMPLETED NCT05134649
OnabotulinumtoxinA Other Phase PHASE3 Platysma Prominence COMPLETED NCT05134649
Ibrutinib 420 mg Other Phase PHASE1 Breast Neoplasms ACTIVE_NOT_RECRUITING NCT03379428
Ibrutinib 840 mg Other Phase PHASE1 Breast Neoplasms ACTIVE_NOT_RECRUITING NCT03379428
Ibrutinib 560 mg Other Phase PHASE1 Breast Neoplasms ACTIVE_NOT_RECRUITING NCT03379428
Trastuzumab Other Phase PHASE1 Breast Neoplasms ACTIVE_NOT_RECRUITING NCT03379428
Ibrutinib 420 mg Other Phase PHASE1 Breast Neoplasms ACTIVE_NOT_RECRUITING NCT03379428
Ibrutinib 840 mg Other Phase PHASE1 Breast Neoplasms ACTIVE_NOT_RECRUITING NCT03379428
Ibrutinib 560 mg Other Phase PHASE1 Breast Neoplasms ACTIVE_NOT_RECRUITING NCT03379428
Trastuzumab Other Phase PHASE1 Breast Neoplasms ACTIVE_NOT_RECRUITING NCT03379428
Androgen suppression plus radiation therapy Drug Phase PHASE2 Adenocarcinoma of the Prostate COMPLETED NCT01255891
Androgen suppression plus radiation therapy Drug Phase PHASE2 Adenocarcinoma of the Prostate COMPLETED NCT01255891
MRE Other Approved Crohn Disease RECRUITING NCT05420233
MRE Other Approved Crohn Disease RECRUITING NCT05420233
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03047395
risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT03047395
IMGN632 Other Phase PHASE1 Blastic Plasmacytoid Dendritic Cell Neoplasm ACTIVE_NOT_RECRUITING NCT03386513
IMGN632 Other Phase PHASE1 Blastic Plasmacytoid Dendritic Cell Neoplasm ACTIVE_NOT_RECRUITING NCT03386513
Placebo for E2/NETA Other Phase PHASE3 Endometriosis COMPLETED NCT03213457
Elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT03213457
Placebo for Elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT03213457
Estradiol/Norethindrone Acetate Other Phase PHASE3 Endometriosis COMPLETED NCT03213457
Placebo for E2/NETA Other Phase PHASE3 Endometriosis COMPLETED NCT03213457
Elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT03213457
Placebo for Elagolix Other Phase PHASE3 Endometriosis COMPLETED NCT03213457
Estradiol/Norethindrone Acetate Other Phase PHASE3 Endometriosis COMPLETED NCT03213457
Ibrutinib Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Obinutuzumab Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Bendamustine Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Rituximab Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Cyclophosphamide Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Fludarabine Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Ibrutinib Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Obinutuzumab Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Bendamustine Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Rituximab Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Cyclophosphamide Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Fludarabine Other Phase PHASE3 Chronic Lymphocytic Leukemia COMPLETED NCT02950051
Obinutuzumab Other Phase PHASE3 Chronic Lymphoid Leukemia ACTIVE_NOT_RECRUITING NCT04608318
Venetoclax Other Phase PHASE3 Chronic Lymphoid Leukemia ACTIVE_NOT_RECRUITING NCT04608318
Ibrutinib Other Phase PHASE3 Chronic Lymphoid Leukemia ACTIVE_NOT_RECRUITING NCT04608318
Obinutuzumab Other Phase PHASE3 Chronic Lymphoid Leukemia ACTIVE_NOT_RECRUITING NCT04608318
Venetoclax Other Phase PHASE3 Chronic Lymphoid Leukemia ACTIVE_NOT_RECRUITING NCT04608318
Ibrutinib Other Phase PHASE3 Chronic Lymphoid Leukemia ACTIVE_NOT_RECRUITING NCT04608318
Obinutuzumab Other Phase PHASE3 Chronic Lymphoid Leukemia ACTIVE_NOT_RECRUITING NCT04608318
Venetoclax Other Phase PHASE3 Chronic Lymphoid Leukemia ACTIVE_NOT_RECRUITING NCT04608318
Ibrutinib Other Phase PHASE3 Chronic Lymphoid Leukemia ACTIVE_NOT_RECRUITING NCT04608318
Lenalidomide Other Phase PHASE1 B-Cell Non-Hodgkin Lymphoma ACTIVE_NOT_RECRUITING NCT05201248
Prednisone Other Phase PHASE1 B-Cell Non-Hodgkin Lymphoma ACTIVE_NOT_RECRUITING NCT05201248
Vincristine Other Phase PHASE1 B-Cell Non-Hodgkin Lymphoma ACTIVE_NOT_RECRUITING NCT05201248
Doxorubicin Other Phase PHASE1 B-Cell Non-Hodgkin Lymphoma ACTIVE_NOT_RECRUITING NCT05201248
Rituximab Other Phase PHASE1 B-Cell Non-Hodgkin Lymphoma ACTIVE_NOT_RECRUITING NCT05201248
Cyclophosphamide Other Phase PHASE1 B-Cell Non-Hodgkin Lymphoma ACTIVE_NOT_RECRUITING NCT05201248
Epcoritamab Other Phase PHASE1 B-Cell Non-Hodgkin Lymphoma ACTIVE_NOT_RECRUITING NCT05201248
modified FOLFIRINOX Other Phase PHASE1 Pancreatic Cancer TERMINATED NCT04807972
Budiglimab Other Phase PHASE1 Pancreatic Cancer TERMINATED NCT04807972
ABBV-927 Other Phase PHASE1 Pancreatic Cancer TERMINATED NCT04807972
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT04195698
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT04195698
Placebo for Upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Placebo for Elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Placebo for Upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Placebo for Elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Placebo for Upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Upadacitinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Placebo for Elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Elsubrutinib Other Phase PHASE2 Systemic Lupus Erythematosus (SLE) COMPLETED NCT04451772
Upadacitinib Other Phase PHASE4 Prurigo Nodularis RECRUITING NCT06773403
risankizumab SC Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03398148
placebo for risankizumab Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03398148
risankizumab IV Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03398148
risankizumab SC Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03398148
placebo for risankizumab Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03398148
risankizumab IV Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03398148
risankizumab SC Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03398148
placebo for risankizumab Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03398148
risankizumab IV Other Phase PHASE2 Ulcerative Colitis (UC) COMPLETED NCT03398148
Placebo for ABBV-141 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06148181
ABBV-141 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06148181
OnabotulinumtoxinA 145 UNT [Botox] Other Phase PHASE4 Drug-resistant Focal Seizure TERMINATED NCT05605756
Lutikizumab Other Phase PHASE2 Hidradenitis Suppurativa RECRUITING NCT06524635
Itraconazole (ITZ) Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06722430
Icalcaprant Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06722430
Itraconazole (ITZ) Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06722430
Icalcaprant Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06722430
Icalcaprant Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06722417
Icalcaprant Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06722417
Methotrexate Other Preclinical Juvenile Idiopathic Arthritis COMPLETED NCT00783510
adalimumab Other Preclinical Juvenile Idiopathic Arthritis COMPLETED NCT00783510
Methotrexate Other Preclinical Juvenile Idiopathic Arthritis COMPLETED NCT00783510
adalimumab Other Preclinical Juvenile Idiopathic Arthritis COMPLETED NCT00783510
Methotrexate Other Preclinical Juvenile Idiopathic Arthritis COMPLETED NCT00783510
adalimumab Other Preclinical Juvenile Idiopathic Arthritis COMPLETED NCT00783510
Bimatoprost Sustained Release Implant Other Preclinical Open-angle Glaucoma NO_LONGER_AVAILABLE NCT05338606
Bimatoprost Sustained Release Implant Other Preclinical Open-angle Glaucoma NO_LONGER_AVAILABLE NCT05338606
Upadacitinib (ABT-494) Other Phase PHASE1 Atopic Dermatitis COMPLETED NCT03646604
Upadacitinib (ABT-494) Other Phase PHASE1 Atopic Dermatitis COMPLETED NCT03646604
Upadacitinib (ABT-494) Other Phase PHASE1 Atopic Dermatitis COMPLETED NCT03646604
HAC 20L Other Phase PHASE2 Nasolabial Folds COMPLETED NCT06018987
No-Treatment Control Drug Phase PHASE2 Nasolabial Folds COMPLETED NCT06018987
HAC 20L Other Phase PHASE2 Nasolabial Folds COMPLETED NCT06018987
No-Treatment Control Drug Phase PHASE2 Nasolabial Folds COMPLETED NCT06018987
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT05601882
Dupilumab Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT05601882
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT05601882
Dupilumab Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT05601882
Celecoxib Other Phase PHASE1 Myeloproliferative Neoplasm ACTIVE_NOT_RECRUITING NCT04041050
Ruxolitinib Other Phase PHASE1 Myeloproliferative Neoplasm ACTIVE_NOT_RECRUITING NCT04041050
Navitoclax Other Phase PHASE1 Myeloproliferative Neoplasm ACTIVE_NOT_RECRUITING NCT04041050
Celecoxib Other Phase PHASE1 Myeloproliferative Neoplasm ACTIVE_NOT_RECRUITING NCT04041050
Ruxolitinib Other Phase PHASE1 Myeloproliferative Neoplasm ACTIVE_NOT_RECRUITING NCT04041050
Navitoclax Other Phase PHASE1 Myeloproliferative Neoplasm ACTIVE_NOT_RECRUITING NCT04041050
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06487572
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06487572
Drug: Placebo for ABBV-1088 Drug Phase PHASE1 Healthy Volunteers COMPLETED NCT06414798
Drug: ABBV-1088 Drug Phase PHASE1 Healthy Volunteers COMPLETED NCT06414798
Drug: Placebo for ABBV-1088 Drug Phase PHASE1 Healthy Volunteers COMPLETED NCT06414798
Drug: ABBV-1088 Drug Phase PHASE1 Healthy Volunteers COMPLETED NCT06414798
Paclitaxel Other Phase PHASE3 Metastatic Breast Cancer COMPLETED NCT02163694
Carboplatin Other Phase PHASE3 Metastatic Breast Cancer COMPLETED NCT02163694
Veliparib Other Phase PHASE3 Metastatic Breast Cancer COMPLETED NCT02163694
Veliparib Placebo Other Phase PHASE3 Metastatic Breast Cancer COMPLETED NCT02163694
Paclitaxel Other Phase PHASE3 Metastatic Breast Cancer COMPLETED NCT02163694
Carboplatin Other Phase PHASE3 Metastatic Breast Cancer COMPLETED NCT02163694
Veliparib Other Phase PHASE3 Metastatic Breast Cancer COMPLETED NCT02163694
Veliparib Placebo Other Phase PHASE3 Metastatic Breast Cancer COMPLETED NCT02163694
Lab work Other Phase EARLY_PHASE1 Infertility COMPLETED NCT04445025
Leuprolide Acetate 3.75 MG/ML Other Phase EARLY_PHASE1 Infertility COMPLETED NCT04445025
Elagolix 200 MG Other Phase EARLY_PHASE1 Infertility COMPLETED NCT04445025
Lab work Other Phase EARLY_PHASE1 Infertility COMPLETED NCT04445025
Leuprolide Acetate 3.75 MG/ML Other Phase EARLY_PHASE1 Infertility COMPLETED NCT04445025
Elagolix 200 MG Other Phase EARLY_PHASE1 Infertility COMPLETED NCT04445025
ABT-263 Other Phase PHASE1 CD20-Positive Lymphoid Malignancies COMPLETED NCT00788684
rituximab Other Phase PHASE1 CD20-Positive Lymphoid Malignancies COMPLETED NCT00788684
ABT-263 Other Phase PHASE1 CD20-Positive Lymphoid Malignancies COMPLETED NCT00788684
rituximab Other Phase PHASE1 CD20-Positive Lymphoid Malignancies COMPLETED NCT00788684
Glecaprevir and Pibrentasvir Other Phase PHASE4 Hepatitis C TERMINATED NCT05582681
HCV education from a health care provider Other Phase PHASE4 Hepatitis C TERMINATED NCT05582681
Cepheid POC HCV Viremia (RNA) test Other Phase PHASE4 Hepatitis C TERMINATED NCT05582681
Glecaprevir and Pibrentasvir Other Phase PHASE4 Hepatitis C TERMINATED NCT05582681
HCV education from a health care provider Other Phase PHASE4 Hepatitis C TERMINATED NCT05582681
Cepheid POC HCV Viremia (RNA) test Other Phase PHASE4 Hepatitis C TERMINATED NCT05582681
Budigalimab Other Phase PHASE1 Hepatocellular Carcinoma (HCC) RECRUITING NCT06487559
Livmoniplimab Other Phase PHASE1 Hepatocellular Carcinoma (HCC) RECRUITING NCT06487559
Budigalimab Other Phase PHASE1 Hepatocellular Carcinoma (HCC) RECRUITING NCT06487559
Livmoniplimab Other Phase PHASE1 Hepatocellular Carcinoma (HCC) RECRUITING NCT06487559
ELAPR002f Injectable Gel Other Phase PHASE2 Skin Quality Deficit COMPLETED NCT06151535
ELAPR002f Injectable Gel Other Phase PHASE2 Skin Quality Deficit COMPLETED NCT06151535
ELAPR002f Injectable Gel Other Phase PHASE2 Skin Quality Deficit COMPLETED NCT06151535
ABBV-787 Other Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT06068868
ABBV-787 Other Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT06068868
Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay Other Phase PHASE1 AL Amyloidosis WITHDRAWN NCT05486481
Daratumumab Other Phase PHASE1 AL Amyloidosis WITHDRAWN NCT05486481
Dexamethasone Other Phase PHASE1 AL Amyloidosis WITHDRAWN NCT05486481
Venetoclax Other Phase PHASE1 AL Amyloidosis WITHDRAWN NCT05486481
Venetoclax Other Phase PHASE2 Chronic Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT05701215
Venetoclax Other Phase PHASE2 Chronic Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT05701215
Placebo for ABBV-932 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06024239
ABBV-932 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06024239
Placebo for ABBV-932 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06024239
ABBV-932 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06024239
Placebo for Atogepant Other Phase PHASE3 Migraine COMPLETED NCT05861427
Atogepant Other Phase PHASE3 Migraine COMPLETED NCT05861427
Placebo for Atogepant Other Phase PHASE3 Migraine COMPLETED NCT05861427
Atogepant Other Phase PHASE3 Migraine COMPLETED NCT05861427
Placebo for Atogepant Other Phase PHASE3 Migraine COMPLETED NCT05861427
Atogepant Other Phase PHASE3 Migraine COMPLETED NCT05861427
Elagolix Other Phase PHASE4 Mild Autonomous Cortisol Excess TERMINATED NCT05038878
Placebo Other Phase PHASE3 Glabellar Lines COMPLETED NCT06308198
AGN-151586 Other Phase PHASE3 Glabellar Lines COMPLETED NCT06308198
Placebo Other Phase PHASE3 Glabellar Lines COMPLETED NCT06308198
AGN-151586 Other Phase PHASE3 Glabellar Lines COMPLETED NCT06308198
Placebo Other Phase PHASE3 Glabellar Lines COMPLETED NCT06308198
AGN-151586 Other Phase PHASE3 Glabellar Lines COMPLETED NCT06308198
No Interventions Other Preclinical Interstitial Lung Disease RECRUITING NCT06644144
Placebo Other Phase PHASE2 Panic Disorder COMPLETED NCT05941442
Darigabat Other Phase PHASE2 Panic Disorder COMPLETED NCT05941442
Placebo Other Phase PHASE2 Panic Disorder COMPLETED NCT05941442
Darigabat Other Phase PHASE2 Panic Disorder COMPLETED NCT05941442
Emraclidine Other Phase PHASE1 Renal Impairment COMPLETED NCT05940402
Emraclidine Other Phase PHASE1 Hepatic Impairment COMPLETED NCT05935033
Emraclidine Other Phase PHASE1 Hepatic Impairment COMPLETED NCT05935033
Placebo Other Phase PHASE3 Autism Spectrum Disorder COMPLETED NCT05439616
Cariprazine Other Phase PHASE3 Autism Spectrum Disorder COMPLETED NCT05439616
Placebo Other Phase PHASE3 Autism Spectrum Disorder COMPLETED NCT05439616
Cariprazine Other Phase PHASE3 Autism Spectrum Disorder COMPLETED NCT05439616
Placebo Other Phase PHASE3 Parkinson Disease COMPLETED NCT04542499
Tavapadon Other Phase PHASE3 Parkinson Disease COMPLETED NCT04542499
Placebo Other Phase PHASE3 Parkinson Disease COMPLETED NCT04542499
Tavapadon Other Phase PHASE3 Parkinson Disease COMPLETED NCT04542499
Placebo Other Phase PHASE3 Parkinson Disease COMPLETED NCT04542499
Tavapadon Other Phase PHASE3 Parkinson Disease COMPLETED NCT04542499
Glecaprevir/Pibrentasvir (GLE/PIB) Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT04903626
Glecaprevir/Pibrentasvir (GLE/PIB) Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT04903626
Glecaprevir/Pibrentasvir (GLE/PIB) Other Phase PHASE3 Hepatitis C Virus (HCV) COMPLETED NCT04903626
Epcoritamab Other Phase PHASE1 Non-hodgkin Lymphoma ACTIVE_NOT_RECRUITING NCT05206357
Telehealth in Parole/Probation Office Other Approved Hepatitis C COMPLETED NCT05413785
Telehealth in Parole/Probation Office Other Approved Hepatitis C COMPLETED NCT05413785
Telehealth in Parole/Probation Office Other Approved Hepatitis C COMPLETED NCT05413785
Placebo Other Phase PHASE1 Healthy Participants COMPLETED NCT05644977
Emraclidine Other Phase PHASE1 Healthy Participants COMPLETED NCT05644977
Placebo Other Phase PHASE1 Healthy Participants COMPLETED NCT05644977
Emraclidine Other Phase PHASE1 Healthy Participants COMPLETED NCT05644977
Placebo for BOTOX Other Phase PHASE2 Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) COMPLETED NCT05141006
BOTOX Other Phase PHASE2 Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) COMPLETED NCT05141006
Placebo for BOTOX Other Phase PHASE2 Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) COMPLETED NCT05141006
BOTOX Other Phase PHASE2 Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) COMPLETED NCT05141006
Placebo for BOTOX Other Phase PHASE2 Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) COMPLETED NCT05141006
BOTOX Other Phase PHASE2 Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) COMPLETED NCT05141006
Placebo Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT04073303
Botulinum Toxin Type A Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT04073303
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03573024
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03573024
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03573024
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03573024
Epcoritamab Other Phase PHASE1 Non-Hodgkin Lymphoma RECRUITING NCT06447376
Siltuximab Other Phase PHASE1 Non-Hodgkin Lymphoma RECRUITING NCT06447376
Epcoritamab Other Phase PHASE1 Non-Hodgkin Lymphoma RECRUITING NCT06447376
Siltuximab Other Phase PHASE1 Non-Hodgkin Lymphoma RECRUITING NCT06447376
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06571266
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06571266
Atogepant Other Phase PHASE3 Chronic Migraine COMPLETED NCT05216263
Atogepant Other Phase PHASE3 Chronic Migraine COMPLETED NCT05216263
Dexamethasone Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04570631
Bortezomib Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04570631
Eftozanermin alfa Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04570631
Dexamethasone Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04570631
Bortezomib Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04570631
Eftozanermin alfa Other Phase PHASE1 Multiple Myeloma TERMINATED NCT04570631
Ustekinumab Other Phase PHASE3 Psoriasis COMPLETED NCT04435600
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT04435600
Ustekinumab Other Phase PHASE3 Psoriasis COMPLETED NCT04435600
Risankizumab Other Phase PHASE3 Psoriasis COMPLETED NCT04435600
Lifitegrast 5% Ophthalmic Solution Other Phase PHASE1 Dry Eye Disease COMPLETED NCT04030962
AGN-231868 Vehicle Other Phase PHASE1 Dry Eye Disease COMPLETED NCT04030962
AGN-242428 Vehicle Other Phase PHASE1 Dry Eye Disease COMPLETED NCT04030962
AGN-231868 Other Phase PHASE1 Dry Eye Disease COMPLETED NCT04030962
AGN-242428 Other Phase PHASE1 Dry Eye Disease COMPLETED NCT04030962
Lifitegrast 5% Ophthalmic Solution Other Phase PHASE1 Dry Eye Disease COMPLETED NCT04030962
AGN-231868 Vehicle Other Phase PHASE1 Dry Eye Disease COMPLETED NCT04030962
AGN-242428 Vehicle Other Phase PHASE1 Dry Eye Disease COMPLETED NCT04030962
AGN-231868 Other Phase PHASE1 Dry Eye Disease COMPLETED NCT04030962
AGN-242428 Other Phase PHASE1 Dry Eye Disease COMPLETED NCT04030962
Telisotuzumab Adizutecan Other Phase PHASE1 Colorectal Cancer RECRUITING NCT06464692
Telisotuzumab Adizutecan Other Phase PHASE1 Colorectal Cancer RECRUITING NCT06464692
Placebo for Topiramate Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Topiramate Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Placebo for Topiramate Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Topiramate Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Placebo for Topiramate Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Topiramate Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Placebo for Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Atogepant Other Phase PHASE3 Migraine ACTIVE_NOT_RECRUITING NCT05748483
Budigalimab Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT03821935
Livmoniplimab Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT03821935
Budigalimab Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT03821935
Livmoniplimab Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT03821935
Budigalimab Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT03821935
Livmoniplimab Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT03821935
Adalimumab Other Approved Crohn Disease ACTIVE_NOT_RECRUITING NCT03261102
Adalimumab Other Approved Crohn Disease ACTIVE_NOT_RECRUITING NCT03261102
Placebo for ABBV-382 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06632938
ABBV-382 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06632938
Placebo for ABBV-382 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06632938
ABBV-382 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06632938
Placebo for ABBV-382 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06632938
ABBV-382 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06632938
CVL-865 Other Phase PHASE2 Seizures COMPLETED NCT04244175
Placebo Other Phase PHASE2 Seizures COMPLETED NCT04244175
CVL-865 Other Phase PHASE2 Seizures COMPLETED NCT04244175
Placebo Other Phase PHASE2 Seizures COMPLETED NCT04244175
Programmed Cell Death-1 (PD-1) Inhibitor Other Phase PHASE1 Advanced Solid Tumor Cancer RECRUITING NCT04777994
Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) Other Phase PHASE1 Advanced Solid Tumor Cancer RECRUITING NCT04777994
ABBV-CLS-484 Other Phase PHASE1 Advanced Solid Tumor Cancer RECRUITING NCT04777994
Epcoritamab, lenalidomide and rituximab Other Phase PHASE2 Relapsed/Refractory Large B-cell Lymphoma RECRUITING NCT06414148
Epcoritamab Other Phase PHASE2 Relapsed/Refractory Large B-cell Lymphoma RECRUITING NCT06414148
Epcoritamab, lenalidomide and rituximab Other Phase PHASE2 Relapsed/Refractory Large B-cell Lymphoma RECRUITING NCT06414148
Epcoritamab Other Phase PHASE2 Relapsed/Refractory Large B-cell Lymphoma RECRUITING NCT06414148
ABBV-932 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06300580
ABBV-932 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06300580
ABBV-932 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06300580
Standard Chemotherapy Drug Phase PHASE1 Leukemia RECRUITING NCT03319901
Venetoclax Other Phase PHASE1 Leukemia RECRUITING NCT03319901
Standard Chemotherapy Drug Phase PHASE1 Leukemia RECRUITING NCT03319901
Venetoclax Other Phase PHASE1 Leukemia RECRUITING NCT03319901
Saline Active Control Other Phase PHASE3 Atrophic Acne Scars ACTIVE_NOT_RECRUITING NCT05995340
ELAPR002f Injectable Gel Other Phase PHASE3 Atrophic Acne Scars ACTIVE_NOT_RECRUITING NCT05995340
Saline Active Control Other Phase PHASE3 Atrophic Acne Scars ACTIVE_NOT_RECRUITING NCT05995340
ELAPR002f Injectable Gel Other Phase PHASE3 Atrophic Acne Scars ACTIVE_NOT_RECRUITING NCT05995340
Saline Active Control Other Phase PHASE3 Atrophic Acne Scars ACTIVE_NOT_RECRUITING NCT05995340
ELAPR002f Injectable Gel Other Phase PHASE3 Atrophic Acne Scars ACTIVE_NOT_RECRUITING NCT05995340
Adalimumab Other Phase PHASE4 Non-infectious Intermediate Posterior- or Pan-uveitis COMPLETED NCT05414201
Adalimumab Other Phase PHASE4 Non-infectious Intermediate Posterior- or Pan-uveitis COMPLETED NCT05414201
ABT-199 Other Phase PHASE2 Chronic Lymphocytic Leucemia COMPLETED NCT02401503
GA101 Other Phase PHASE2 Chronic Lymphocytic Leucemia COMPLETED NCT02401503
Bendamustine Other Phase PHASE2 Chronic Lymphocytic Leucemia COMPLETED NCT02401503
Venetoclax Oral Tablet [Venclexta] Other Phase PHASE2 Mantle Cell Lymphoma TERMINATED NCT05025423
Venetoclax Oral Tablet [Venclexta] Other Phase PHASE2 Mantle Cell Lymphoma TERMINATED NCT05025423
Venetoclax Oral Tablet [Venclexta] Other Phase PHASE2 Mantle Cell Lymphoma TERMINATED NCT05025423
Sanacoach Parkinson (SCP) Other Approved Parkinson Disease ACTIVE_NOT_RECRUITING NCT05164783
No Intervention Other Preclinical Diabetic Retinopathy, DR ENROLLING_BY_INVITATION NCT05296447
No Intervention Other Preclinical Diabetic Retinopathy, DR ENROLLING_BY_INVITATION NCT05296447
No intervention. Other Preclinical Neovascular Age-Related Macular Degeneration (nAMD) ENROLLING_BY_INVITATION NCT05210803
No intervention. Other Preclinical Neovascular Age-Related Macular Degeneration (nAMD) ENROLLING_BY_INVITATION NCT05210803
No intervention. Other Preclinical Neovascular Age-Related Macular Degeneration (nAMD) ENROLLING_BY_INVITATION NCT05210803
Venetoclax Other Phase PHASE3 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03539744
Dexamethasone Other Phase PHASE3 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03539744
Pomalidomide Other Phase PHASE3 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03539744
Venetoclax Other Phase PHASE3 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03539744
Dexamethasone Other Phase PHASE3 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03539744
Pomalidomide Other Phase PHASE3 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03539744
Upadacitinib Oral Product Other Phase PHASE3 Colitis, Ulcerative RECRUITING NCT06660693
Upadacitinib Oral Product Other Phase PHASE3 Colitis, Ulcerative RECRUITING NCT06660693
Tavapadon Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06895356
Tavapadon Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06895356
NX-13 Placebo Other Phase PHASE2 Ulcerative Colitis TERMINATED NCT05785715
NX-13 750mg Other Phase PHASE2 Ulcerative Colitis TERMINATED NCT05785715
NX-13 250mg Other Phase PHASE2 Ulcerative Colitis TERMINATED NCT05785715
NX-13 Placebo Other Phase PHASE2 Ulcerative Colitis TERMINATED NCT05785715
NX-13 750mg Other Phase PHASE2 Ulcerative Colitis TERMINATED NCT05785715
NX-13 250mg Other Phase PHASE2 Ulcerative Colitis TERMINATED NCT05785715
Venetoclax Other Phase PHASE2 Marginal Zone Lymphoma ACTIVE_NOT_RECRUITING NCT04416451
Rituximab Other Phase PHASE2 Marginal Zone Lymphoma ACTIVE_NOT_RECRUITING NCT04416451
Osimertinib Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT04721015
Docetaxel Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT04721015
ABBV-637 Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT04721015
Osimertinib Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT04721015
Docetaxel Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT04721015
ABBV-637 Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT04721015
Venetoclax Other Phase PHASE2 Mantle Cell Lymphoma (MCL) COMPLETED NCT04477486
Ibrutinib Other Phase PHASE2 Mantle Cell Lymphoma (MCL) COMPLETED NCT04477486
Venetoclax Other Phase PHASE2 Mantle Cell Lymphoma (MCL) COMPLETED NCT04477486
Ibrutinib Other Phase PHASE2 Mantle Cell Lymphoma (MCL) COMPLETED NCT04477486
Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) Other Preclinical Dry Eye COMPLETED NCT06443775
Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) Other Preclinical Dry Eye COMPLETED NCT06443775
Placebo for CVC 300 mg Other Phase PHASE2 HIV-1-infection COMPLETED NCT05630885
Placebo for CVC 150 mg Other Phase PHASE2 HIV-1-infection COMPLETED NCT05630885
CVC 300 mg Other Phase PHASE2 HIV-1-infection COMPLETED NCT05630885
CVC 150 mg Other Phase PHASE2 HIV-1-infection COMPLETED NCT05630885
Placebo for CVC 300 mg Other Phase PHASE2 HIV-1-infection COMPLETED NCT05630885
Placebo for CVC 150 mg Other Phase PHASE2 HIV-1-infection COMPLETED NCT05630885
CVC 300 mg Other Phase PHASE2 HIV-1-infection COMPLETED NCT05630885
CVC 150 mg Other Phase PHASE2 HIV-1-infection COMPLETED NCT05630885
Ruxolitinib Other Phase PHASE1 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04454658
Navitoclax Other Phase PHASE1 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04454658
ABBV-744 Other Phase PHASE1 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04454658
Ruxolitinib Other Phase PHASE1 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04454658
Navitoclax Other Phase PHASE1 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04454658
ABBV-744 Other Phase PHASE1 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04454658
Placebo Other Phase PHASE1 Alzheimer Disease COMPLETED NCT06406348
ALIA-1758 Other Phase PHASE1 Alzheimer Disease COMPLETED NCT06406348
Placebo Other Phase PHASE1 Alzheimer Disease COMPLETED NCT06406348
ALIA-1758 Other Phase PHASE1 Alzheimer Disease COMPLETED NCT06406348
Placebo Other Phase PHASE1 Alzheimer Disease COMPLETED NCT06406348
ALIA-1758 Other Phase PHASE1 Alzheimer Disease COMPLETED NCT06406348
100mg Eluxadoline Other Phase PHASE3 Irritable Bowel Syndrome ENROLLING_BY_INVITATION NCT04880876
25mg Eluxadoline Other Phase PHASE3 Irritable Bowel Syndrome ENROLLING_BY_INVITATION NCT04880876
100mg Eluxadoline Other Phase PHASE3 Irritable Bowel Syndrome ENROLLING_BY_INVITATION NCT04880876
25mg Eluxadoline Other Phase PHASE3 Irritable Bowel Syndrome ENROLLING_BY_INVITATION NCT04880876
Comparator Other Preclinical Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment RECRUITING NCT04846959
Risankizumab Other Preclinical Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment RECRUITING NCT04846959
Comparator Other Preclinical Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment RECRUITING NCT04846959
Risankizumab Other Preclinical Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment RECRUITING NCT04846959
Comparator Other Preclinical Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment RECRUITING NCT04846959
Risankizumab Other Preclinical Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment RECRUITING NCT04846959
Venetoclax Other Phase PHASE1 Refractory Follicular Lymphoma COMPLETED NCT02956382
Ibrutinib Other Phase PHASE1 Refractory Follicular Lymphoma COMPLETED NCT02956382
Venetoclax Other Phase PHASE1 Refractory Follicular Lymphoma COMPLETED NCT02956382
Ibrutinib Other Phase PHASE1 Refractory Follicular Lymphoma COMPLETED NCT02956382
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT06673238
ABBV-722 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT06673238
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT06673238
ABBV-722 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT06673238
Ubrogepant Other Phase PHASE3 Migraine ENROLLING_BY_INVITATION NCT05127954
Ubrogepant Other Phase PHASE3 Migraine ENROLLING_BY_INVITATION NCT05127954
Atogepant 60 mg Other Phase PHASE3 Chronic Migraine COMPLETED NCT04437433
Atogepant 60 mg Other Phase PHASE3 Chronic Migraine COMPLETED NCT04437433
Elagolix Placebo Other Phase PHASE3 Heavy Menstrual Bleeding COMPLETED NCT03271489
E2/NETA Placebo Other Phase PHASE3 Heavy Menstrual Bleeding COMPLETED NCT03271489
Estradiol /norethindrone acetate (E2/NETA) Other Phase PHASE3 Heavy Menstrual Bleeding COMPLETED NCT03271489
Elagolix Other Phase PHASE3 Heavy Menstrual Bleeding COMPLETED NCT03271489
Elagolix Placebo Other Phase PHASE3 Heavy Menstrual Bleeding COMPLETED NCT03271489
E2/NETA Placebo Other Phase PHASE3 Heavy Menstrual Bleeding COMPLETED NCT03271489
Estradiol /norethindrone acetate (E2/NETA) Other Phase PHASE3 Heavy Menstrual Bleeding COMPLETED NCT03271489
Elagolix Other Phase PHASE3 Heavy Menstrual Bleeding COMPLETED NCT03271489
CVL-231 30 mg Other Phase PHASE2 Schizophrenia COMPLETED NCT05443724
Placebo Other Phase PHASE3 Parkinson Disease COMPLETED NCT04201093
Tavapadon Other Phase PHASE3 Parkinson Disease COMPLETED NCT04201093
Upadacitinib Other Phase PHASE4 Atopic Dermatitis COMPLETED NCT05507580
Upadacitinib Other Phase PHASE4 Atopic Dermatitis COMPLETED NCT05507580
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia ACTIVE_NOT_RECRUITING NCT04273139
IBRUTINIB Other Phase PHASE2 Waldenstrom Macroglobulinemia ACTIVE_NOT_RECRUITING NCT04273139
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia ACTIVE_NOT_RECRUITING NCT04273139
IBRUTINIB Other Phase PHASE2 Waldenstrom Macroglobulinemia ACTIVE_NOT_RECRUITING NCT04273139
ABT-494 Other Phase PHASE2 Crohn's Disease (CD) COMPLETED NCT02782663
ABT-494 Other Phase PHASE2 Crohn's Disease (CD) COMPLETED NCT02782663
Placebo Other Phase PHASE1 ALS TERMINATED NCT04948645
Fosigotifator Other Phase PHASE1 ALS TERMINATED NCT04948645
Placebo Other Phase PHASE1 ALS TERMINATED NCT04948645
Fosigotifator Other Phase PHASE1 ALS TERMINATED NCT04948645
onabotulinum toxin A Other Phase PHASE2 Neuropathic Pain COMPLETED NCT03848143
Placebo Other Phase PHASE3 Myelodysplastic Syndrome (MDS) ACTIVE_NOT_RECRUITING NCT04401748
Azacitidine Other Phase PHASE3 Myelodysplastic Syndrome (MDS) ACTIVE_NOT_RECRUITING NCT04401748
Venetoclax Other Phase PHASE3 Myelodysplastic Syndrome (MDS) ACTIVE_NOT_RECRUITING NCT04401748
Placebo Other Phase PHASE3 Myelodysplastic Syndrome (MDS) ACTIVE_NOT_RECRUITING NCT04401748
Azacitidine Other Phase PHASE3 Myelodysplastic Syndrome (MDS) ACTIVE_NOT_RECRUITING NCT04401748
Venetoclax Other Phase PHASE3 Myelodysplastic Syndrome (MDS) ACTIVE_NOT_RECRUITING NCT04401748
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) ACTIVE_NOT_RECRUITING NCT04379050
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) ACTIVE_NOT_RECRUITING NCT04379050
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) ACTIVE_NOT_RECRUITING NCT04379050
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) ACTIVE_NOT_RECRUITING NCT04379050
Upadacitinib Other Phase PHASE1 Juvenile Idiopathic Arthritis (JIA) ACTIVE_NOT_RECRUITING NCT03725007
Risankizumab Other Phase PHASE3 Psoriatic Arthritis ACTIVE_NOT_RECRUITING NCT03675308
Placebo Other Phase PHASE3 Psoriatic Arthritis ACTIVE_NOT_RECRUITING NCT03675308
Risankizumab Other Phase PHASE3 Psoriatic Arthritis ACTIVE_NOT_RECRUITING NCT03675308
Placebo Other Phase PHASE3 Psoriatic Arthritis ACTIVE_NOT_RECRUITING NCT03675308
Risankizumab Other Phase PHASE3 Psoriatic Arthritis ACTIVE_NOT_RECRUITING NCT03675308
Placebo Other Phase PHASE3 Psoriatic Arthritis ACTIVE_NOT_RECRUITING NCT03675308
Placebo for Upadacitinib Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03345823
Upadacitinib Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03345823
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Venetoclax Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Azacitidine Other Phase PHASE1 Myelodysplastic Syndromes (MDS) ACTIVE_NOT_RECRUITING NCT02942290
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT02629159
Placebo for Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT02629159
Adalimumab Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT02629159
Placebo for Adalimumab Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT02629159
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT02629159
Placebo for Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT02629159
Adalimumab Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT02629159
Placebo for Adalimumab Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT02629159
Donor Lymphocyte Infusion Other Phase PHASE1 Acute Myeloid Leukemia SUSPENDED NCT06158100
Azacitidine Other Phase PHASE1 Acute Myeloid Leukemia SUSPENDED NCT06158100
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia SUSPENDED NCT06158100
ABBV-932 Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT06953934
ABBV-932 Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT06953934
Etentamig Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05286229
Etentamig Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05286229
Gemcitabine Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Paclitaxel Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Docetaxel Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Budigalimab Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Livmoniplimab Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Gemcitabine Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Paclitaxel Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Docetaxel Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Budigalimab Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Livmoniplimab Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Gemcitabine Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Paclitaxel Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Docetaxel Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Budigalimab Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Livmoniplimab Other Phase PHASE2 Urothelial Carcinoma ACTIVE_NOT_RECRUITING NCT06632951
Atogepant Other Phase PHASE3 Migraine Prophylaxis ENROLLING_BY_INVITATION NCT05707949
Atogepant Other Phase PHASE3 Migraine Prophylaxis ENROLLING_BY_INVITATION NCT05707949
Placebo Other Phase PHASE3 Ulcerative Colitis (UC) WITHDRAWN NCT05316220
Mesalamine Other Phase PHASE3 Ulcerative Colitis (UC) WITHDRAWN NCT05316220
Placebo Other Phase PHASE3 Ulcerative Colitis (UC) WITHDRAWN NCT05316220
Mesalamine Other Phase PHASE3 Ulcerative Colitis (UC) WITHDRAWN NCT05316220
Azacitidine Other Phase PHASE4 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT05144243
Venetoclax Other Phase PHASE4 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT05144243
Risankizumab Other Phase PHASE3 Psoriasis ACTIVE_NOT_RECRUITING NCT04862286
Risankizumab Other Phase PHASE3 Psoriasis ACTIVE_NOT_RECRUITING NCT04862286
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) ACTIVE_NOT_RECRUITING NCT04750226
ABBV-951 Other Phase PHASE3 Parkinson's Disease (PD) ACTIVE_NOT_RECRUITING NCT04750226
Nab-paclitaxel Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT03893955
Carboplatin Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT03893955
ABBV-181 Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT03893955
ABBV-368 Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT03893955
ABBV-927 Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT03893955
Nab-paclitaxel Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT03893955
Carboplatin Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT03893955
ABBV-181 Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT03893955
ABBV-368 Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT03893955
ABBV-927 Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT03893955
Restylane® Perlane® Lidocaine Other Phase PHASE3 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07032597
HArmonyCa Lidocaine Injectable Gel Other Phase PHASE3 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07032597
Restylane® Perlane® Lidocaine Other Phase PHASE3 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07032597
HArmonyCa Lidocaine Injectable Gel Other Phase PHASE3 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07032597
Restylane® Perlane® Lidocaine Other Phase PHASE3 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07032597
HArmonyCa Lidocaine Injectable Gel Other Phase PHASE3 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07032597
Placebo Other Phase PHASE3 Forehead Lines ACTIVE_NOT_RECRUITING NCT06794866
OnabotulinumtoxinA Other Phase PHASE3 Forehead Lines ACTIVE_NOT_RECRUITING NCT06794866
Placebo Other Phase PHASE3 Forehead Lines ACTIVE_NOT_RECRUITING NCT06794866
OnabotulinumtoxinA Other Phase PHASE3 Forehead Lines ACTIVE_NOT_RECRUITING NCT06794866
Sorafenib Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Lenvatinib Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Livmoniplimab Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Budigalimab Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Sorafenib Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Lenvatinib Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Livmoniplimab Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Budigalimab Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Sorafenib Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Lenvatinib Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Livmoniplimab Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Budigalimab Other Phase PHASE2 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT05822752
Lenalidomide Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05308654
Daratumumab Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05308654
Dexamethasone Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05308654
ABBV-453 Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05308654
Lenalidomide Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05308654
Daratumumab Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05308654
Dexamethasone Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05308654
ABBV-453 Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05308654
Bortezomib Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Venetoclax Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Daratumumab Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Dexamethasone Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Bortezomib Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Venetoclax Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Daratumumab Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Dexamethasone Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Bortezomib Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Venetoclax Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Daratumumab Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Dexamethasone Other Phase PHASE2 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03314181
Risankizumab On-Body Injector (OBI) Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03105102
Risankizumab SC Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03105102
Placebo for Risankizumab IV Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03105102
Risankizumab IV Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03105102
Placebo for Risankizumab SC Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03105102
Risankizumab On-Body Injector (OBI) Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03105102
Risankizumab SC Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03105102
Placebo for Risankizumab IV Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03105102
Risankizumab IV Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03105102
Placebo for Risankizumab SC Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT03105102
Erlotinib Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Telisotuzumab vedotin Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Nivolumab Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Osimertinib Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Erlotinib Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Telisotuzumab vedotin Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Nivolumab Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Osimertinib Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Erlotinib Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Telisotuzumab vedotin Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Nivolumab Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Osimertinib Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02099058
Tremelimumab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Bevacizumab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Atezolizumab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Durvalumab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Budigalimab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Livmoniplimab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Tremelimumab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Bevacizumab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Atezolizumab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Durvalumab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Budigalimab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Livmoniplimab Other Phase PHASE2 Hepatocellular Carcinoma RECRUITING NCT06109272
Positron Emission Tomography Other Phase PHASE1 Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder RECRUITING NCT06672705
Epcoritamab Other Phase PHASE1 Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder RECRUITING NCT06672705
Computed Tomography Other Phase PHASE1 Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder RECRUITING NCT06672705
Biospecimen Collection Other Phase PHASE1 Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder RECRUITING NCT06672705
Biopsy Other Phase PHASE1 Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder RECRUITING NCT06672705
Optive MEGA-3 (OM3) Other Preclinical Dry Eye COMPLETED NCT06439394
Optive MEGA-3 (OM3) Other Preclinical Dry Eye COMPLETED NCT06439394
Optive MEGA-3 (OM3) Other Preclinical Dry Eye COMPLETED NCT06439394
Fluorescence Imaging Other Phase PHASE2 IBD RECRUITING NCT03938701
Adalimumab-800CW Other Phase PHASE2 IBD RECRUITING NCT03938701
Fluorescence Imaging Other Phase PHASE2 IBD RECRUITING NCT03938701
Adalimumab-800CW Other Phase PHASE2 IBD RECRUITING NCT03938701
Fluorescence Imaging Other Phase PHASE2 IBD RECRUITING NCT03938701
Adalimumab-800CW Other Phase PHASE2 IBD RECRUITING NCT03938701
Bimatoprost (SR) Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT03850782
Bimatoprost (SR) Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT03850782
Bimatoprost (SR) Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT03850782
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) ACTIVE_NOT_RECRUITING NCT02993523
Placebo for BOTOX Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06137287
BOTOX Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06137287
Venetoclax Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Questionnaire Administration Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Multigated Acquisition Scan Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Lumbar Puncture Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Echocardiography Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Cytarabine Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Cladribine Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Bone Marrow Biopsy Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Bone Marrow Aspiration Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Biospecimen Collection Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Azacitidine Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Pegylated liposomal doxorubicin Other Phase PHASE3 Epithelial Ovarian Cancer COMPLETED NCT04209855
Topotecan Other Phase PHASE3 Epithelial Ovarian Cancer COMPLETED NCT04209855
Paclitaxel Other Phase PHASE3 Epithelial Ovarian Cancer COMPLETED NCT04209855
Mirvetuximab Soravtansine Other Phase PHASE3 Epithelial Ovarian Cancer COMPLETED NCT04209855
Placebo Other Phase PHASE3 Forehead Lines COMPLETED NCT06174688
BOTOX Other Phase PHASE3 Forehead Lines COMPLETED NCT06174688
Placebo Other Phase PHASE3 Forehead Lines COMPLETED NCT06174688
BOTOX Other Phase PHASE3 Forehead Lines COMPLETED NCT06174688
Standard of Care Other Phase PHASE3 Open-Angle Glaucoma ACTIVE_NOT_RECRUITING NCT03891446
Bimatoprost SR Other Phase PHASE3 Open-Angle Glaucoma ACTIVE_NOT_RECRUITING NCT03891446
Standard of Care Other Phase PHASE3 Open-Angle Glaucoma ACTIVE_NOT_RECRUITING NCT03891446
Bimatoprost SR Other Phase PHASE3 Open-Angle Glaucoma ACTIVE_NOT_RECRUITING NCT03891446
Risankizumab Other Phase PHASE3 Psoriatic Arthritis (PsA) ACTIVE_NOT_RECRUITING NCT03671148
Placebo Other Phase PHASE3 Psoriatic Arthritis (PsA) ACTIVE_NOT_RECRUITING NCT03671148
Risankizumab Other Phase PHASE3 Psoriatic Arthritis (PsA) ACTIVE_NOT_RECRUITING NCT03671148
Placebo Other Phase PHASE3 Psoriatic Arthritis (PsA) ACTIVE_NOT_RECRUITING NCT03671148
Risankizumab Other Phase PHASE3 Psoriatic Arthritis (PsA) ACTIVE_NOT_RECRUITING NCT03671148
Placebo Other Phase PHASE3 Psoriatic Arthritis (PsA) ACTIVE_NOT_RECRUITING NCT03671148
Placebo Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07136103
ABBV-277 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07136103
Placebo Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07136103
ABBV-277 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07136103
Placebo for risankizumab Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT06063967
Risankizumab SC Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT06063967
Placebo for risankizumab Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT06063967
Risankizumab SC Other Phase PHASE3 Crohn's Disease ACTIVE_NOT_RECRUITING NCT06063967
Itraconazole Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT07071532
ABBV-932 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT07071532
Itraconazole Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT07071532
ABBV-932 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT07071532
Upadacitinib Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104374
Placebo Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104374
Upadacitinib Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104374
Placebo Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104374
Emraclidine 30 mg Other Phase PHASE2 Schizophrenia COMPLETED NCT05227690
Emraclidine 10 mg Other Phase PHASE2 Schizophrenia COMPLETED NCT05227690
Placebo Other Phase PHASE2 Schizophrenia COMPLETED NCT05227690
Emraclidine 30 mg Other Phase PHASE2 Schizophrenia COMPLETED NCT05227690
Emraclidine 10 mg Other Phase PHASE2 Schizophrenia COMPLETED NCT05227690
Placebo Other Phase PHASE2 Schizophrenia COMPLETED NCT05227690
Emraclidine 30 mg Other Phase PHASE2 Schizophrenia COMPLETED NCT05227690
Emraclidine 10 mg Other Phase PHASE2 Schizophrenia COMPLETED NCT05227690
Placebo Other Phase PHASE2 Schizophrenia COMPLETED NCT05227690
Placebo Other Phase PHASE2 Irritable Bowel Syndrome RECRUITING NCT03339128
Eluxadoline Other Phase PHASE2 Irritable Bowel Syndrome RECRUITING NCT03339128
Placebo Other Phase PHASE2 Irritable Bowel Syndrome RECRUITING NCT03339128
Eluxadoline Other Phase PHASE2 Irritable Bowel Syndrome RECRUITING NCT03339128
Placebo Other Phase PHASE2 Irritable Bowel Syndrome RECRUITING NCT03339128
Eluxadoline Other Phase PHASE2 Irritable Bowel Syndrome RECRUITING NCT03339128
Radiation Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Erwinia asparaginase Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Pegaspargase Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Intrathecal Triples Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Leucovorin Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Etoposide Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Cyclophosphamide Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Mercaptopurine Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Methotrexate Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Blinatumomab Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Cytarabine Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Dasatinib Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Calaspargase Pegol Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Vincristine Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Dexamethasone Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Navitoclax Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Venetoclax Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Radiation Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Erwinia asparaginase Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Pegaspargase Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Intrathecal Triples Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Leucovorin Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Etoposide Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Cyclophosphamide Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Mercaptopurine Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Methotrexate Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Blinatumomab Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Cytarabine Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Dasatinib Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Calaspargase Pegol Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Vincristine Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Dexamethasone Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Navitoclax Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Venetoclax Other Phase PHASE1 Refractory Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05192889
Placebo to Adalimumab Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
Placebo to Upadacitinib Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
Upadacitinib Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
Adalimumab Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
Placebo to Adalimumab Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
Placebo to Upadacitinib Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
Upadacitinib Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
Adalimumab Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
Placebo to Adalimumab Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
Placebo to Upadacitinib Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
Upadacitinib Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
Adalimumab Other Phase PHASE3 Psoriatic Arthritis COMPLETED NCT03104400
MedicWise Other Approved Crohn Disease RECRUITING NCT06742385
MedicWise Other Approved Crohn Disease RECRUITING NCT06742385
Loncastuximab Tesirine and Epcoritamab Other Phase PHASE2 Aggressive Diffuse Large B-cell Lymphoma NOT_YET_RECRUITING NCT07197307
Loncastuximab Tesirine and Epcoritamab Other Phase PHASE2 Aggressive Diffuse Large B-cell Lymphoma NOT_YET_RECRUITING NCT07197307
Fosigotifator Other Phase PHASE1 Vanishing White Matter Disease RECRUITING NCT05757141
Placebo Other Phase PHASE1 Major Depressive Disorder (MDD) TERMINATED NCT06618118
Fosigotifator Other Phase PHASE1 Major Depressive Disorder (MDD) TERMINATED NCT06618118
Placebo Other Phase PHASE1 Major Depressive Disorder (MDD) TERMINATED NCT06618118
Fosigotifator Other Phase PHASE1 Major Depressive Disorder (MDD) TERMINATED NCT06618118
Placebo Other Phase PHASE1 Major Depressive Disorder (MDD) TERMINATED NCT06618118
Fosigotifator Other Phase PHASE1 Major Depressive Disorder (MDD) TERMINATED NCT06618118
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03069352
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03069352
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03069352
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03069352
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03069352
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03069352
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03069352
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03069352
Placebo Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT03069352
ABBV-101 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06887010
ABBV-101 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06887010
ABBV-101 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06887010
Best Supportive Care (BSC) Other Phase PHASE3 Acute Myeloid Leukemia (AML) TERMINATED NCT04161885
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) TERMINATED NCT04161885
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) TERMINATED NCT04161885
Best Supportive Care (BSC) Other Phase PHASE3 Acute Myeloid Leukemia (AML) TERMINATED NCT04161885
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) TERMINATED NCT04161885
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) TERMINATED NCT04161885
Placebo for ABBV-552 Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05771428
ABBV-552 Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05771428
Placebo for ABBV-552 Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05771428
ABBV-552 Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05771428
Placebo for ABBV-552 Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05771428
ABBV-552 Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05771428
Obinutuzumab Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT05105841
Ibrutinib Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT05105841
Venetoclax Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT05105841
Biospecimen Collection Other Phase PHASE1 Acute Biphenotypic Leukemia RECRUITING NCT04797767
Bone Marrow Biopsy Other Phase PHASE1 Acute Biphenotypic Leukemia RECRUITING NCT04797767
Bone Marrow Aspiration Other Phase PHASE1 Acute Biphenotypic Leukemia RECRUITING NCT04797767
Venetoclax Other Phase PHASE1 Acute Biphenotypic Leukemia RECRUITING NCT04797767
Recombinant Granulocyte Colony-Stimulating Factor Other Phase PHASE1 Acute Biphenotypic Leukemia RECRUITING NCT04797767
Mitoxantrone Other Phase PHASE1 Acute Biphenotypic Leukemia RECRUITING NCT04797767
Cytarabine Other Phase PHASE1 Acute Biphenotypic Leukemia RECRUITING NCT04797767
Cladribine Other Phase PHASE1 Acute Biphenotypic Leukemia RECRUITING NCT04797767
Adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT02632175
Adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT02632175
Adalimumab Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT02632175
Carboplatin Other Phase PHASE1 Advanced Solid Tumors ACTIVE_NOT_RECRUITING NCT05599984
Budigalimab Other Phase PHASE1 Advanced Solid Tumors ACTIVE_NOT_RECRUITING NCT05599984
Cisplatin Other Phase PHASE1 Advanced Solid Tumors ACTIVE_NOT_RECRUITING NCT05599984
ABBV-706 Other Phase PHASE1 Advanced Solid Tumors ACTIVE_NOT_RECRUITING NCT05599984
Carboplatin Other Phase PHASE1 Advanced Solid Tumors ACTIVE_NOT_RECRUITING NCT05599984
Budigalimab Other Phase PHASE1 Advanced Solid Tumors ACTIVE_NOT_RECRUITING NCT05599984
Cisplatin Other Phase PHASE1 Advanced Solid Tumors ACTIVE_NOT_RECRUITING NCT05599984
ABBV-706 Other Phase PHASE1 Advanced Solid Tumors ACTIVE_NOT_RECRUITING NCT05599984
Placebo Other Phase PHASE3 Schizophrenia TERMINATED NCT05368558
Cariprazine Other Phase PHASE3 Schizophrenia TERMINATED NCT05368558
Placebo Other Phase PHASE3 Schizophrenia TERMINATED NCT05368558
Cariprazine Other Phase PHASE3 Schizophrenia TERMINATED NCT05368558
Pancrelipase Capsules Other Phase PHASE4 Exocrine Pancreatic Insufficiency RECRUITING NCT06477159
Telisotuzumab Vedotin Other Phase PHASE2 Non Small Cell Lung Cancer TERMINATED NCT05513703
Telisotuzumab Vedotin Other Phase PHASE2 Non Small Cell Lung Cancer TERMINATED NCT05513703
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03569293
Placebo for Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03569293
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03569293
Placebo for Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03569293
Budigalimab Other Phase PHASE1 Solid Tumors TERMINATED NCT06158958
ABBV-303 Other Phase PHASE1 Solid Tumors TERMINATED NCT06158958
Cariprazine Flexible Dose Other Phase PHASE3 Schizophrenia COMPLETED NCT04578756
Cariprazine Flexible Dose Other Phase PHASE3 Schizophrenia COMPLETED NCT04578756
Epcoritamab Other Phase PHASE2 Marginal Zone Lymphoma RECRUITING NCT06796998
Carboplatin Other Phase PHASE2 High Grade Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05456685
Mirvetuximab soravtansine Other Phase PHASE2 High Grade Ovarian Cancer ACTIVE_NOT_RECRUITING NCT05456685
Placebo Other Phase PHASE2 Schizophrenia COMPLETED NCT05227703
Emraclidine 30 mg Other Phase PHASE2 Schizophrenia COMPLETED NCT05227703
Emraclidine 15 mg Other Phase PHASE2 Schizophrenia COMPLETED NCT05227703
Placebo for ABBV-382 Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
ABBV-382 Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
Placebo for Budigalimab Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
Budigalimab Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
Placebo for ABBV-382 Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
ABBV-382 Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
Placebo for Budigalimab Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
Budigalimab Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
Placebo for ABBV-382 Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
ABBV-382 Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
Placebo for Budigalimab Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
Budigalimab Other Phase PHASE2 Human Immuno-deficiency Virus (HIV) Disease TERMINATED NCT06032546
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT05029882
Trifluridine/Tipiracil Other Phase PHASE1 Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT05029882
ABBV-400 Other Phase PHASE1 Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT05029882
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT05029882
Trifluridine/Tipiracil Other Phase PHASE1 Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT05029882
ABBV-400 Other Phase PHASE1 Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT05029882
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT05029882
Trifluridine/Tipiracil Other Phase PHASE1 Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT05029882
ABBV-400 Other Phase PHASE1 Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT05029882
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07222709
ABBV-1042 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07222709
Itraconazole (ITZ) Other Phase PHASE1 Healthy Volunteer TERMINATED NCT06579300
Placebo for ABBV-1088 Other Phase PHASE1 Healthy Volunteer TERMINATED NCT06579300
ABBV-1088 Other Phase PHASE1 Healthy Volunteer TERMINATED NCT06579300
Itraconazole (ITZ) Other Phase PHASE1 Healthy Volunteer TERMINATED NCT06579300
Placebo for ABBV-1088 Other Phase PHASE1 Healthy Volunteer TERMINATED NCT06579300
ABBV-1088 Other Phase PHASE1 Healthy Volunteer TERMINATED NCT06579300
Itraconazole (ITZ) Other Phase PHASE1 Healthy Volunteer TERMINATED NCT06579300
Placebo for ABBV-1088 Other Phase PHASE1 Healthy Volunteer TERMINATED NCT06579300
ABBV-1088 Other Phase PHASE1 Healthy Volunteer TERMINATED NCT06579300
Olaparib Other Phase PHASE2 Ovary Cancer RECRUITING NCT05887609
Mirvetuximab Soravtansine-gynx Other Phase PHASE2 Ovary Cancer RECRUITING NCT05887609
Punch biopsies of the skin at week 28 visit Other Phase PHASE4 Psoriasis ACTIVE_NOT_RECRUITING NCT04630652
Punch biopsies of the skin at baseline visit Other Phase PHASE4 Psoriasis ACTIVE_NOT_RECRUITING NCT04630652
Risankizumab-Rzaa Other Phase PHASE4 Psoriasis ACTIVE_NOT_RECRUITING NCT04630652
Punch biopsies of the skin at week 28 visit Other Phase PHASE4 Psoriasis ACTIVE_NOT_RECRUITING NCT04630652
Punch biopsies of the skin at baseline visit Other Phase PHASE4 Psoriasis ACTIVE_NOT_RECRUITING NCT04630652
Risankizumab-Rzaa Other Phase PHASE4 Psoriasis ACTIVE_NOT_RECRUITING NCT04630652
Obinutuzumab Other Phase PHASE3 Chronic Lymphocytic Leukemia RECRUITING NCT06428019
Acalabrutinib Other Phase PHASE3 Chronic Lymphocytic Leukemia RECRUITING NCT06428019
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia RECRUITING NCT06428019
Telisotuzumab vedotin Other Phase PHASE2 Non-small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT03539536
Obinutuzumab Other Phase PHASE3 Lymphocytic Leukemia, Chronic COMPLETED NCT02242942
Venetoclax Other Phase PHASE3 Lymphocytic Leukemia, Chronic COMPLETED NCT02242942
Chlorambucil Other Phase PHASE3 Lymphocytic Leukemia, Chronic COMPLETED NCT02242942
Obinutuzumab Other Phase PHASE3 Lymphocytic Leukemia, Chronic COMPLETED NCT02242942
Venetoclax Other Phase PHASE3 Lymphocytic Leukemia, Chronic COMPLETED NCT02242942
Chlorambucil Other Phase PHASE3 Lymphocytic Leukemia, Chronic COMPLETED NCT02242942
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
Emraclidine Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
Emraclidine Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
NB-UVB (narrow-band ultraviolet B) Phototherapy Drug Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
Placebo Other Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
Upadacitinib Other Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
NB-UVB (narrow-band ultraviolet B) Phototherapy Drug Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
Placebo Other Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
Upadacitinib Other Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
NB-UVB (narrow-band ultraviolet B) Phototherapy Drug Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
Placebo Other Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
Upadacitinib Other Phase PHASE3 Vitiligo ACTIVE_NOT_RECRUITING NCT06118411
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Placebo for Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT06417775
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Liposomal daunorubicin and cytarabine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Daunorubicin Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Idarubicin Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Cytarabine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Liposomal daunorubicin and cytarabine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Daunorubicin Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Idarubicin Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Cytarabine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT04801797
Risankizumab Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06937619
Risankizumab Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06937619
Placebo Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06399718
BOTOX Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06399718
Placebo Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06399718
BOTOX Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06399718
Trabeculectomy Other Phase PHASE4 Open-angle Glaucoma RECRUITING NCT05821855
XEN45 Glaucoma Treatment System Drug Phase PHASE4 Open-angle Glaucoma RECRUITING NCT05821855
Trabeculectomy Other Phase PHASE4 Open-angle Glaucoma RECRUITING NCT05821855
XEN45 Glaucoma Treatment System Drug Phase PHASE4 Open-angle Glaucoma RECRUITING NCT05821855
Combined Oral Contraceptive Other Phase PHASE3 Endometriosis ACTIVE_NOT_RECRUITING NCT04333576
Placebo Other Phase PHASE3 Endometriosis ACTIVE_NOT_RECRUITING NCT04333576
Elagolix Other Phase PHASE3 Endometriosis ACTIVE_NOT_RECRUITING NCT04333576
Combined Oral Contraceptive Other Phase PHASE3 Endometriosis ACTIVE_NOT_RECRUITING NCT04333576
Placebo Other Phase PHASE3 Endometriosis ACTIVE_NOT_RECRUITING NCT04333576
Elagolix Other Phase PHASE3 Endometriosis ACTIVE_NOT_RECRUITING NCT04333576
Placebo Other Phase PHASE3 Parkinson Disease COMPLETED NCT04223193
Tavapadon Other Phase PHASE3 Parkinson Disease COMPLETED NCT04223193
Placebo Other Phase PHASE3 Parkinson Disease COMPLETED NCT04223193
Tavapadon Other Phase PHASE3 Parkinson Disease COMPLETED NCT04223193
Saline Control Other Phase PHASE3 Acne Scars RECRUITING NCT07207369
ELAPR002f Injectable Gel Other Phase PHASE3 Acne Scars RECRUITING NCT07207369
Saline Control Other Phase PHASE3 Acne Scars RECRUITING NCT07207369
ELAPR002f Injectable Gel Other Phase PHASE3 Acne Scars RECRUITING NCT07207369
BOTOX Other Phase PHASE4 Upper Facial Lines COMPLETED NCT06218251
Venetoclax combined with Orelabrutinib Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) RECRUITING NCT06958705
Venetoclax combined with Acalabrutinib Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) RECRUITING NCT06958705
Venetoclax combined with Zanubrutinib Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) RECRUITING NCT06958705
Venetoclax combined with Ibrutinib Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) RECRUITING NCT06958705
Venetoclax combined with Orelabrutinib Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) RECRUITING NCT06958705
Venetoclax combined with Acalabrutinib Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) RECRUITING NCT06958705
Venetoclax combined with Zanubrutinib Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) RECRUITING NCT06958705
Venetoclax combined with Ibrutinib Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) RECRUITING NCT06958705
FCR Other Phase PHASE2 Intermediate Risk Chronic Lymphocytic Leukemia COMPLETED NCT04010968
venetoclax and ibrutinib (I+VEN) Other Phase PHASE2 Intermediate Risk Chronic Lymphocytic Leukemia COMPLETED NCT04010968
FCR Other Phase PHASE2 Intermediate Risk Chronic Lymphocytic Leukemia COMPLETED NCT04010968
venetoclax and ibrutinib (I+VEN) Other Phase PHASE2 Intermediate Risk Chronic Lymphocytic Leukemia COMPLETED NCT04010968
DRC Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT05099471
Venetoclax; Rituximab Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT05099471
Control Other Phase PHASE3 Perioral Lines COMPLETED NCT05454033
JUVÉDERM® VOLITE™ Other Phase PHASE3 Perioral Lines COMPLETED NCT05454033
First line therapy Drug Preclinical CLL/SLL ACTIVE_NOT_RECRUITING NCT05590702
First line therapy Drug Preclinical CLL/SLL ACTIVE_NOT_RECRUITING NCT05590702
Usual care Other Approved Hepatitis C Virus Infection, Response to Therapy of COMPLETED NCT04677153
Test and treat plus peer mentors Other Approved Hepatitis C Virus Infection, Response to Therapy of COMPLETED NCT04677153
Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03607422
Placebo for Upadacitinib Other Phase PHASE3 Atopic Dermatitis COMPLETED NCT03607422
Carboplatin Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Bevacizumab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Mirvetuximab Soravtansine Other Phase PHASE2 Ovarian Cancer RECRUITING NCT07059845
Paricalcitol Other Phase PHASE3 Chronic Kidney Disease (CKD) TERMINATED NCT04064827
Paricalcitol Other Phase PHASE3 Chronic Kidney Disease (CKD) TERMINATED NCT04064827
Control Other Phase PHASE3 Neck Lines COMPLETED NCT05741034
JUVÉDERM® VOLITE™ Other Phase PHASE3 Neck Lines COMPLETED NCT05741034
Control Other Phase PHASE3 Neck Lines COMPLETED NCT05741034
JUVÉDERM® VOLITE™ Other Phase PHASE3 Neck Lines COMPLETED NCT05741034
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Quality-of-Life Assessment Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Laboratory Biomarker Analysis Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Biospecimen Collection Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Bone Marrow Biopsy Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Decitabine Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Venetoclax Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Navitoclax Other Phase PHASE1 Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING NCT05564650
Venetoclax Other Phase PHASE2 Lymphoma, Mantle-Cell COMPLETED NCT03567876
Venetoclax Other Phase PHASE2 Lymphoma, Mantle-Cell COMPLETED NCT03567876
Gilteritinib Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Etoposide Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Mitoxantrone Hydrochloride Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Idarubicin Hydrochloride Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Fludarabine Phosphate Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Daunorubicin Hydrochloride Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Gemtuzumab Ozogamicin Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Cytarabine Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Placebo Other Phase PHASE3 Episodic Migraine TERMINATED NCT05028569
BOTOX Other Phase PHASE3 Episodic Migraine TERMINATED NCT05028569
Placebo Other Phase PHASE3 Episodic Migraine TERMINATED NCT05028569
BOTOX Other Phase PHASE3 Episodic Migraine TERMINATED NCT05028569
Placebo Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06068855
BOTOX Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06068855
Placebo Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06068855
BOTOX Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06068855
Placebo Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05291234
ABBV-916 Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05291234
Placebo Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05291234
ABBV-916 Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05291234
Placebo Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05291234
ABBV-916 Other Phase PHASE2 Alzheimer's Disease (AD) COMPLETED NCT05291234
Docetaxel Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03595059
Paclitaxel Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03595059
ABBV-155 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03595059
Docetaxel Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03595059
Paclitaxel Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03595059
ABBV-155 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03595059
Docetaxel Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03595059
Paclitaxel Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03595059
ABBV-155 Other Phase PHASE1 Advanced Solid Tumors COMPLETED NCT03595059
Placebo Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06387394
BOTOX Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06387394
Placebo Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06387394
BOTOX Other Phase PHASE3 Masseter Muscle Prominence COMPLETED NCT06387394
CVL-865 Other Phase PHASE2 Seizures TERMINATED NCT04686786
CVL-865 Other Phase PHASE2 Seizures TERMINATED NCT04686786
Irinotecan Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Fluorouracil Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Folinic Acid Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Bevacizumab Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
ABBV-400 Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Irinotecan Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Fluorouracil Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Folinic Acid Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Bevacizumab Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
ABBV-400 Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Irinotecan Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Fluorouracil Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Folinic Acid Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Bevacizumab Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
ABBV-400 Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Irinotecan Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Fluorouracil Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Folinic Acid Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
Bevacizumab Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
ABBV-400 Other Phase PHASE2 Unresectable Metastatic Colorectal Cancer ACTIVE_NOT_RECRUITING NCT06107413
ABBV-383 (Etentamig) Other Phase PHASE1 Immunoglobulin Light Chain (AL) Amyloidosis RECRUITING NCT06158854
ABBV-383 (Etentamig) Other Phase PHASE1 Immunoglobulin Light Chain (AL) Amyloidosis RECRUITING NCT06158854
ABBV-383 (Etentamig) Other Phase PHASE1 Immunoglobulin Light Chain (AL) Amyloidosis RECRUITING NCT06158854
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Placebo Other Phase PHASE1 Obesity RECRUITING NCT07291232
ABBV-295 Other Phase PHASE1 Obesity RECRUITING NCT07291232
Risankizumab Other Phase PHASE2 Psoriatic Arthritis RECRUITING NCT06865105
Lutikizumab Other Phase PHASE2 Psoriatic Arthritis RECRUITING NCT06865105
Risankizumab Other Phase PHASE2 Psoriatic Arthritis RECRUITING NCT06865105
Lutikizumab Other Phase PHASE2 Psoriatic Arthritis RECRUITING NCT06865105
Atogepant 60 mg Other Phase PHASE3 Episodic Migraine COMPLETED NCT04686136
Daratumumab Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05259839
Pomalidomide Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05259839
Lenalidomide Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05259839
Dexamethasone Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05259839
Etentamig Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05259839
Daratumumab Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05259839
Pomalidomide Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05259839
Lenalidomide Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05259839
Dexamethasone Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05259839
Etentamig Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma ACTIVE_NOT_RECRUITING NCT05259839
Placebo Other Phase PHASE2 Acute Ischemic Stroke COMPLETED NCT04309474
Elezanumab Other Phase PHASE2 Acute Ischemic Stroke COMPLETED NCT04309474
Placebo Other Phase PHASE2 Acute Ischemic Stroke COMPLETED NCT04309474
Elezanumab Other Phase PHASE2 Acute Ischemic Stroke COMPLETED NCT04309474
Rituximab Other Phase PHASE2 Follicular Lymphoma RECRUITING NCT05783609
Epcoritamab Other Phase PHASE2 Follicular Lymphoma RECRUITING NCT05783609
ABBV-668 Other Phase PHASE2 Ulcerative Colitis COMPLETED NCT05570006
ABBV-668 Other Phase PHASE2 Ulcerative Colitis COMPLETED NCT05570006
Tavapadon Other Phase PHASE3 Parkinson Disease COMPLETED NCT04760769
Tavapadon Other Phase PHASE3 Parkinson Disease COMPLETED NCT04760769
Upadacitinib Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT07023302
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT07023302
Venetoclax Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) RECRUITING NCT02966756
Venetoclax Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) RECRUITING NCT02966756
Venetoclax Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) RECRUITING NCT02966756
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06946524
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06946524
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06946524
HAC 22L Other Phase PHASE3 Facial Volume Deficit COMPLETED NCT05818709
HAC 22L Other Phase PHASE3 Facial Volume Deficit COMPLETED NCT05818709
Upadacitinib Other Phase PHASE3 Ulcerative Colitis ACTIVE_NOT_RECRUITING NCT05782907
Pivekimab Sunirine Other Phase PHASE1 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07306832
Pivekimab Sunirine Other Phase PHASE1 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07306832
Placebo for ABBV-932 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT07024797
ABBV-932 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT07024797
Placebo for ABBV-932 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT07024797
ABBV-932 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT07024797
Placebo for ABBV-932 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT07024797
ABBV-932 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT07024797
ABBV-1354 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT07219017
Levothyroxine Other Phase PHASE2 Hypothyroidism RECRUITING NCT06345339
Armour Thyroid Other Phase PHASE2 Hypothyroidism RECRUITING NCT06345339
Levothyroxine Other Phase PHASE2 Hypothyroidism RECRUITING NCT06345339
Armour Thyroid Other Phase PHASE2 Hypothyroidism RECRUITING NCT06345339
Telisotuzumab Vedotin Other Phase PHASE2 Lung Non-Small Cell Carcinoma NOT_YET_RECRUITING NCT07323641
Survey Administration Other Phase PHASE2 Lung Non-Small Cell Carcinoma NOT_YET_RECRUITING NCT07323641
Osimertinib Other Phase PHASE2 Lung Non-Small Cell Carcinoma NOT_YET_RECRUITING NCT07323641
Magnetic Resonance Imaging Other Phase PHASE2 Lung Non-Small Cell Carcinoma NOT_YET_RECRUITING NCT07323641
Computed Tomography Other Phase PHASE2 Lung Non-Small Cell Carcinoma NOT_YET_RECRUITING NCT07323641
Biospecimen Collection Other Phase PHASE2 Lung Non-Small Cell Carcinoma NOT_YET_RECRUITING NCT07323641
Biopsy Procedure Procedure Phase PHASE2 Lung Non-Small Cell Carcinoma NOT_YET_RECRUITING NCT07323641
Venetoclax Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04572763
Copanlisib Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04572763
Venetoclax Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04572763
Copanlisib Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04572763
CoolSculpting Elite System Other Phase PHASE4 Non-Surgical Fat Reduction ACTIVE_NOT_RECRUITING NCT07122583
CoolSculpting Elite System Other Phase PHASE4 Non-Surgical Fat Reduction ACTIVE_NOT_RECRUITING NCT07122583
ABBV-453 Other Phase PHASE1 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT06291220
Obinutuzumab Other Phase PHASE1 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT06291220
ABBV-453 Other Phase PHASE1 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT06291220
Obinutuzumab Other Phase PHASE1 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT06291220
ABBV-453 Other Phase PHASE1 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT06291220
Obinutuzumab Other Phase PHASE1 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT06291220
Cytarabine Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT05342584
Daunorubicin Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT05342584
Venetoclax Oral Tablet Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT05342584
Cytarabine Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT05342584
Daunorubicin Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT05342584
Venetoclax Oral Tablet Other Phase PHASE1 Acute Myeloid Leukemia RECRUITING NCT05342584
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian RECRUITING NCT06682988
Mirvetuximab Soravtansine Other Phase PHASE2 Advanced High-Grade Epithelial Ovarian RECRUITING NCT06682988
Mirvetuximab soravtansine Other Phase PHASE2 Ovarian Cancer COMPLETED NCT05041257
Best Available Therapy (BAT) Drug Phase PHASE3 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04468984
Ruxolitinib Other Phase PHASE3 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04468984
Navitoclax Other Phase PHASE3 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04468984
Best Available Therapy (BAT) Drug Phase PHASE3 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04468984
Ruxolitinib Other Phase PHASE3 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04468984
Navitoclax Other Phase PHASE3 Myelofibrosis (MF) ACTIVE_NOT_RECRUITING NCT04468984
ABBV-181 Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02988960
ABBV-927 Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02988960
ABBV-181 Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02988960
ABBV-927 Other Phase PHASE1 Advanced Solid Tumors Cancer ACTIVE_NOT_RECRUITING NCT02988960
Placebo Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07306754
ABBV-243 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07306754
Placebo Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07306754
ABBV-243 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT07306754
Azacitidine Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
Venetoclax Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
Placebo for ABBV-932 Other Phase PHASE2 Bipolar I Disorder COMPLETED NCT06605599
ABBV-932 Other Phase PHASE2 Bipolar I Disorder COMPLETED NCT06605599
Placebo for ABBV-932 Other Phase PHASE2 Bipolar I Disorder COMPLETED NCT06605599
ABBV-932 Other Phase PHASE2 Bipolar I Disorder COMPLETED NCT06605599
Adalimumab Matching Placebo Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT05814627
Upadacitinib Matching Placebo Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT05814627
Adalimumab Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT05814627
Upadacitinib Other Phase PHASE3 Rheumatoid Arthritis ACTIVE_NOT_RECRUITING NCT05814627
Placebo Other Phase PHASE3 Ulcerative Colitis (UC) ACTIVE_NOT_RECRUITING NCT03006068
Upadacitinib (ABT-494) Other Phase PHASE3 Ulcerative Colitis (UC) ACTIVE_NOT_RECRUITING NCT03006068
Placebo Other Phase PHASE3 Ulcerative Colitis (UC) ACTIVE_NOT_RECRUITING NCT03006068
Upadacitinib (ABT-494) Other Phase PHASE3 Ulcerative Colitis (UC) ACTIVE_NOT_RECRUITING NCT03006068
AGN-151597 Other Phase PHASE1 Advanced Retinitis Pigmentosa COMPLETED NCT02556736
AGN-151597 Other Phase PHASE1 Advanced Retinitis Pigmentosa COMPLETED NCT02556736
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Gemtuzumab Ozogamicin Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Cytarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fludarabine Other Phase PHASE3 Acute Myeloid Leukemia RECRUITING NCT05183035
Fosigotifator Other Preclinical Vanishing White Matter NO_LONGER_AVAILABLE NCT06594016
Fosigotifator Other Preclinical Vanishing White Matter NO_LONGER_AVAILABLE NCT06594016
Fosigotifator Other Preclinical Vanishing White Matter NO_LONGER_AVAILABLE NCT06594016
Rituximab Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Prednisone Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Positron Emission Tomography Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Multigated Acquisition Scan Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Fludeoxyglucose F-18 Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Etoposide Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Epcoritamab Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Echocardiography Test Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Doxorubicin Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Cyclophosphamide Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Computed Tomography Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Bone Marrow Biopsy Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Bone Marrow Aspiration Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Biospecimen Collection Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Itraconazole Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06698926
Placebo Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06698926
ABBV-CLS-616 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06698926
Itraconazole Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06698926
Placebo Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06698926
ABBV-CLS-616 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06698926
Itraconazole Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06698926
Placebo Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06698926
ABBV-CLS-616 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT06698926
GUB014295-PLACEBO Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06144684
GUB014295 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06144684
ABBV-319 Other Phase PHASE1 Diffuse Large B-Cell Lymphoma RECRUITING NCT05512390
Cytarabine Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03709758
Daunorubicin Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03709758
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03709758
Cytarabine Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03709758
Daunorubicin Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03709758
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03709758
Atogepant Other Preclinical Chronic Migraine RECRUITING NCT06603558
Itraconazole (ITZ) Other Phase PHASE1 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT06084481
ABBV-400 Other Phase PHASE1 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT06084481
Itraconazole (ITZ) Other Phase PHASE1 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT06084481
ABBV-400 Other Phase PHASE1 Hepatocellular Carcinoma ACTIVE_NOT_RECRUITING NCT06084481
Placebo for BOTOX Other Phase PHASE2 Upper Limb Essential Tremor (UL ET) COMPLETED NCT05216250
BOTOX Other Phase PHASE2 Upper Limb Essential Tremor (UL ET) COMPLETED NCT05216250
Placebo for BOTOX Other Phase PHASE2 Upper Limb Essential Tremor (UL ET) COMPLETED NCT05216250
BOTOX Other Phase PHASE2 Upper Limb Essential Tremor (UL ET) COMPLETED NCT05216250
Placebo for BOTOX Other Phase PHASE2 Upper Limb Essential Tremor (UL ET) COMPLETED NCT05216250
BOTOX Other Phase PHASE2 Upper Limb Essential Tremor (UL ET) COMPLETED NCT05216250
placebo for risankizumab Other Phase PHASE3 Ulcerative Colitis (UC) ACTIVE_NOT_RECRUITING NCT03398135
risankizumab Other Phase PHASE3 Ulcerative Colitis (UC) ACTIVE_NOT_RECRUITING NCT03398135
placebo for risankizumab Other Phase PHASE3 Ulcerative Colitis (UC) ACTIVE_NOT_RECRUITING NCT03398135
risankizumab Other Phase PHASE3 Ulcerative Colitis (UC) ACTIVE_NOT_RECRUITING NCT03398135
Navitoclax Other Phase PHASE2 Myelofibrosis (MF) COMPLETED NCT03222609
Ruxolitinib Other Phase PHASE2 Myelofibrosis (MF) COMPLETED NCT03222609
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Placebo Other Phase PHASE2 Migraine RECRUITING NCT06602479
MEDI0618 Other Phase PHASE2 Migraine RECRUITING NCT06602479
Antidepressant Therapy (ADT) Drug Phase PHASE2 Generalized Anxiety Disorder (GAD) RECRUITING NCT06846320
Placebo for ABBV-932 Other Phase PHASE2 Generalized Anxiety Disorder (GAD) RECRUITING NCT06846320
ABBV-932 Other Phase PHASE2 Generalized Anxiety Disorder (GAD) RECRUITING NCT06846320
Antidepressant Therapy (ADT) Drug Phase PHASE2 Generalized Anxiety Disorder (GAD) RECRUITING NCT06846320
Placebo for ABBV-932 Other Phase PHASE2 Generalized Anxiety Disorder (GAD) RECRUITING NCT06846320
ABBV-932 Other Phase PHASE2 Generalized Anxiety Disorder (GAD) RECRUITING NCT06846320
Amrubicin Other Phase PHASE3 Small Cell Lung Cancer NOT_YET_RECRUITING NCT07365241
Lurbinectedin Other Phase PHASE3 Small Cell Lung Cancer NOT_YET_RECRUITING NCT07365241
Topotecan Other Phase PHASE3 Small Cell Lung Cancer NOT_YET_RECRUITING NCT07365241
ABBV-706 Other Phase PHASE3 Small Cell Lung Cancer NOT_YET_RECRUITING NCT07365241
Amrubicin Other Phase PHASE3 Small Cell Lung Cancer NOT_YET_RECRUITING NCT07365241
Lurbinectedin Other Phase PHASE3 Small Cell Lung Cancer NOT_YET_RECRUITING NCT07365241
Topotecan Other Phase PHASE3 Small Cell Lung Cancer NOT_YET_RECRUITING NCT07365241
ABBV-706 Other Phase PHASE3 Small Cell Lung Cancer NOT_YET_RECRUITING NCT07365241
ABBV-291 Other Phase PHASE1 Non-Hodgkin's Lymphoma RECRUITING NCT06667687
ABBV-291 Other Phase PHASE1 Non-Hodgkin's Lymphoma RECRUITING NCT06667687
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07007091
Risankizumab Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07007091
Decitabine Other Phase PHASE1 Myeloid Malignancy ACTIVE_NOT_RECRUITING NCT05455294
Venetoclax Other Phase PHASE1 Myeloid Malignancy ACTIVE_NOT_RECRUITING NCT05455294
Navitoclax Other Phase PHASE1 Myeloid Malignancy ACTIVE_NOT_RECRUITING NCT05455294
Decitabine Other Phase PHASE1 Myeloid Malignancy ACTIVE_NOT_RECRUITING NCT05455294
Venetoclax Other Phase PHASE1 Myeloid Malignancy ACTIVE_NOT_RECRUITING NCT05455294
Navitoclax Other Phase PHASE1 Myeloid Malignancy ACTIVE_NOT_RECRUITING NCT05455294
Decitabine Other Phase PHASE1 Myeloid Malignancy ACTIVE_NOT_RECRUITING NCT05455294
Venetoclax Other Phase PHASE1 Myeloid Malignancy ACTIVE_NOT_RECRUITING NCT05455294
Navitoclax Other Phase PHASE1 Myeloid Malignancy ACTIVE_NOT_RECRUITING NCT05455294
ABBV-706 Other Preclinical Small Cell Lung Cancer AVAILABLE NCT07310277
Glecaprevir/pibrentasvir Other Phase PHASE1 Hepatitis C NOT_YET_RECRUITING NCT07040319
Inotuzumab Ozogamicin Other Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05016947
Dexamethasone Other Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05016947
Venetoclax Other Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05016947
Inotuzumab Ozogamicin Other Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05016947
Dexamethasone Other Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05016947
Venetoclax Other Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05016947
Inotuzumab Ozogamicin Other Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05016947
Dexamethasone Other Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05016947
Venetoclax Other Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING NCT05016947
Upadacitinib Other Preclinical Crohn Disease AVAILABLE NCT04159597
Upadacitinib Other Preclinical Crohn Disease AVAILABLE NCT04159597
Venetoclax Other Preclinical Chronic Lymphocytic Leukemia (CLL) AVAILABLE NCT03123029
Venetoclax Other Preclinical Chronic Lymphocytic Leukemia (CLL) AVAILABLE NCT03123029
Venetoclax Other Preclinical Chronic Lymphocytic Leukemia (CLL) AVAILABLE NCT03123029
Oral Prednisone - Hospital Dose Steroids Other Phase PHASE4 Ulcerative Colitis Acute RECRUITING NCT07258771
Oral prednisolone Taper Other Phase PHASE4 Ulcerative Colitis Acute RECRUITING NCT07258771
Oral Upadacitinib Placebo Other Phase PHASE4 Ulcerative Colitis Acute RECRUITING NCT07258771
Intravenous Methylprednisolone Other Phase PHASE4 Ulcerative Colitis Acute RECRUITING NCT07258771
Oral Upadacitinib Other Phase PHASE4 Ulcerative Colitis Acute RECRUITING NCT07258771
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Upadacitinib Other Preclinical Axial Spondylarthritis (r-axSpA) RECRUITING NCT05094128
Venetoclax Other Phase PHASE1 Blastic Plasmacytoid Dendritic Cell Neoplasm COMPLETED NCT03485547
Venetoclax Other Phase PHASE1 Blastic Plasmacytoid Dendritic Cell Neoplasm COMPLETED NCT03485547
Venetoclax Other Phase PHASE1 Blastic Plasmacytoid Dendritic Cell Neoplasm COMPLETED NCT03485547
Elezanumab Other Preclinical Acute Spinal Cord Injury (SCI) AVAILABLE NCT04278235
Alternately treated with VA/low CHA regimen Other Phase PHASE2 Intensive Chemotherapy Unfit RECRUITING NCT07172204
Alternately treated with VA/low CHA regimen Other Phase PHASE2 Intensive Chemotherapy Unfit RECRUITING NCT07172204
Placebo Other Phase PHASE2 Autosomal Dominant Polycystic Kidney Disease RECRUITING NCT06902558
ABBV-CLS-628 Other Phase PHASE2 Autosomal Dominant Polycystic Kidney Disease RECRUITING NCT06902558
Placebo Other Phase PHASE2 Autosomal Dominant Polycystic Kidney Disease RECRUITING NCT06902558
ABBV-CLS-628 Other Phase PHASE2 Autosomal Dominant Polycystic Kidney Disease RECRUITING NCT06902558
Placebo Other Phase PHASE2 Autosomal Dominant Polycystic Kidney Disease RECRUITING NCT06902558
ABBV-CLS-628 Other Phase PHASE2 Autosomal Dominant Polycystic Kidney Disease RECRUITING NCT06902558
Telisotuzumab Adizutecan Other Preclinical Solid Tumors AVAILABLE NCT05982873
Telisotuzumab Adizutecan Other Preclinical Solid Tumors AVAILABLE NCT05982873
Telisotuzumab vedotin Other Preclinical Non-Small Cell Lung Cancer (NSCLC) AVAILABLE NCT04830202
Telisotuzumab vedotin Other Preclinical Non-Small Cell Lung Cancer (NSCLC) AVAILABLE NCT04830202
Telisotuzumab vedotin Other Preclinical Non-Small Cell Lung Cancer (NSCLC) AVAILABLE NCT04830202
TNB-383B Other Phase PHASE1 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03933735
TNB-383B Other Phase PHASE1 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03933735
TNB-383B Other Phase PHASE1 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT03933735
Obinutuzumab Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) RECRUITING NCT04895436
Venetoclax Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) RECRUITING NCT04895436
Obinutuzumab Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) RECRUITING NCT04895436
Venetoclax Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) RECRUITING NCT04895436
Obinutuzumab Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) RECRUITING NCT04895436
Venetoclax Other Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) RECRUITING NCT04895436
Tavapadon Other Preclinical Parkinson Disease AVAILABLE NCT07158827
Tavapadon Other Preclinical Parkinson Disease AVAILABLE NCT07158827
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07145918
Emraclidine Other Phase PHASE2 Schizophrenia RECRUITING NCT07145918
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Tocilizumab Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Upadacitinib Other Phase PHASE3 Juvenile Idiopathic Arthritis RECRUITING NCT05609630
Biospecimen Collection Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Lumbar Puncture Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Bone Marrow Aspiration and Biopsy Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Blinatumomab Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Venetoclax Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Rituximab Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Prednisone Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Methotrexate Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Dasatinib Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Biospecimen Collection Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Lumbar Puncture Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Bone Marrow Aspiration and Biopsy Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Blinatumomab Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Venetoclax Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Rituximab Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Prednisone Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Methotrexate Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Dasatinib Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Biospecimen Collection Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Lumbar Puncture Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Bone Marrow Aspiration and Biopsy Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Blinatumomab Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Venetoclax Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Rituximab Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Prednisone Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Methotrexate Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Dasatinib Other Phase PHASE1 B Acute Lymphoblastic Leukemia RECRUITING NCT04872790
Risankizumab Other Phase PHASE3 Ulcerative Colitis RECRUITING NCT07071519
Placebo Other Phase PHASE2 Spinal Cord Injury (SCI) COMPLETED NCT04295538
Elezanumab Other Phase PHASE2 Spinal Cord Injury (SCI) COMPLETED NCT04295538
Placebo Other Phase PHASE2 Spinal Cord Injury (SCI) COMPLETED NCT04295538
Elezanumab Other Phase PHASE2 Spinal Cord Injury (SCI) COMPLETED NCT04295538
ABBV-787 Other Preclinical Acute Myeloid Leukemia NO_LONGER_AVAILABLE NCT06439966
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
Etentamig (ABBV-383) Other Phase PHASE1 Multiple Myeloma RECRUITING NCT05650632
ABBV-525 Other Phase PHASE1 Diffuse Large B-Cell Lymphoma RECRUITING NCT05618028
ABBV-525 Other Phase PHASE1 Diffuse Large B-Cell Lymphoma RECRUITING NCT05618028
ABBV-525 Other Phase PHASE1 Diffuse Large B-Cell Lymphoma RECRUITING NCT05618028
Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Placebo Other Phase PHASE2 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT05139602
Lutikizumab Other Phase PHASE2 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT05139602
Placebo Other Phase PHASE2 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT05139602
Lutikizumab Other Phase PHASE2 Hidradenitis Suppurativa ACTIVE_NOT_RECRUITING NCT05139602
Levonorgestrel/Ethinyl Estradiol Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07414784
ABBV-295 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07414784
Levonorgestrel/Ethinyl Estradiol Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07414784
ABBV-295 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07414784
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Budigalimab Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
ABBV-711 Other Phase PHASE1 Advanced Squamous Tumors RECRUITING NCT07241039
Carfilzomib Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Daratumumab Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Dexamethasone Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Lenalidomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Etentamig Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Carfilzomib Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Daratumumab Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Dexamethasone Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Lenalidomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Etentamig Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06892522
Placebo Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06774313
ABBV-142 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06774313
Placebo Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06774313
ABBV-142 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06774313
Control Other Phase PHASE2 Skin Quality Deficit COMPLETED NCT06547125
JUVÉDERM® VOLITE™ Other Phase PHASE2 Skin Quality Deficit COMPLETED NCT06547125
Control Other Phase PHASE2 Skin Quality Deficit COMPLETED NCT06547125
JUVÉDERM® VOLITE™ Other Phase PHASE2 Skin Quality Deficit COMPLETED NCT06547125
Prednisolone Other Phase PHASE3 Takayasu Arteritis (TAK) ACTIVE_NOT_RECRUITING NCT04161898
Placebo for Upadacitinib Other Phase PHASE3 Takayasu Arteritis (TAK) ACTIVE_NOT_RECRUITING NCT04161898
Upadacitinib Other Phase PHASE3 Takayasu Arteritis (TAK) ACTIVE_NOT_RECRUITING NCT04161898
Positron Emission Tomography Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Ibrutinib Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Epcoritamab Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Computed Tomography Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Bone Marrow Biopsy Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Bone Marrow Aspiration Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Biospecimen Collection Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Positron Emission Tomography Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Ibrutinib Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Epcoritamab Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Computed Tomography Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Bone Marrow Biopsy Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Bone Marrow Aspiration Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Biospecimen Collection Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Positron Emission Tomography Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Ibrutinib Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Epcoritamab Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Computed Tomography Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Bone Marrow Biopsy Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Bone Marrow Aspiration Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
Biospecimen Collection Other Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma RECRUITING NCT06536049
IMGN151 Other Phase PHASE1 Endometrial Cancer ACTIVE_NOT_RECRUITING NCT05527184
JUVÉDERM ULTRA PLUS XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
JUVÉDERM ULTRA XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
SKINVIVE by JUVÉDERM Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
JUVÉDERM VOLLURE XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
JUVÉDERM VOLBELLA XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
JUVÉDERM VOLUMA XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
JUVÉDERM VOLUX XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
JUVÉDERM ULTRA PLUS XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
JUVÉDERM ULTRA XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
SKINVIVE by JUVÉDERM Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
JUVÉDERM VOLLURE XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
JUVÉDERM VOLBELLA XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
JUVÉDERM VOLUMA XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
JUVÉDERM VOLUX XC Other Phase PHASE4 Mid Face Volume Deficit ACTIVE_NOT_RECRUITING NCT07186595
Placebo Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT07141199
ABBV-8736 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT07141199
Pomalidomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Dexamethasone Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Daratumumab Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
ABBV-453 Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06953960
Placebo Other Phase PHASE2 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT06718101
Lutikizumab Other Phase PHASE2 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT06718101
Upadacitinib Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT06701331
Placebo Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT06701331
Upadacitinib Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT06701331
Placebo Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT06701331
Upadacitinib Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT06701331
Placebo Other Phase PHASE3 Atopic Dermatitis ACTIVE_NOT_RECRUITING NCT06701331
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
Telisotuzumab Vedotin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06568939
Carboplatin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Cisplatin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Pemetrexed Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Pembrolizumab Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Budigalimab Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Livmoniplimab Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Carboplatin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Cisplatin Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Pemetrexed Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Pembrolizumab Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Budigalimab Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Livmoniplimab Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT06236438
Bevacizumab Other Phase PHASE3 Ovarian Cancer RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer RECRUITING NCT05445778
Bevacizumab Other Phase PHASE3 Ovarian Cancer RECRUITING NCT05445778
Mirvetuximab soravtansine plus Bevacizumab Other Phase PHASE3 Ovarian Cancer RECRUITING NCT05445778
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
ABBV-932 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06849791
ABBV-932 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06849791
ABBV-932 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06849791
No Intervention Other Phase PHASE3 Breast Reconstruction RECRUITING NCT06575192
ARTIA Reconstructive Tissue Matrix Other Phase PHASE3 Breast Reconstruction RECRUITING NCT06575192
Deucravacitinib Other Phase PHASE4 Moderate Plaque Psoriasis ACTIVE_NOT_RECRUITING NCT06333860
Risankizumab Other Phase PHASE4 Moderate Plaque Psoriasis ACTIVE_NOT_RECRUITING NCT06333860
Placebo Other Phase PHASE3 Spondyloarthritis COMPLETED NCT04169373
Upadacitinib Other Phase PHASE3 Spondyloarthritis COMPLETED NCT04169373
Placebo Other Phase PHASE3 Spondyloarthritis COMPLETED NCT04169373
Upadacitinib Other Phase PHASE3 Spondyloarthritis COMPLETED NCT04169373
Placebo Other Phase PHASE3 Spondyloarthritis COMPLETED NCT04169373
Upadacitinib Other Phase PHASE3 Spondyloarthritis COMPLETED NCT04169373
Placebo Other Phase PHASE3 Spondyloarthritis COMPLETED NCT04169373
Upadacitinib Other Phase PHASE3 Spondyloarthritis COMPLETED NCT04169373
Placebo Other Phase PHASE3 Giant Cell Arteritis (GCA) COMPLETED NCT03725202
Corticosteroid (CS) Other Phase PHASE3 Giant Cell Arteritis (GCA) COMPLETED NCT03725202
Upadacitinib Other Phase PHASE3 Giant Cell Arteritis (GCA) COMPLETED NCT03725202
Placebo Other Phase PHASE3 Giant Cell Arteritis (GCA) COMPLETED NCT03725202
Corticosteroid (CS) Other Phase PHASE3 Giant Cell Arteritis (GCA) COMPLETED NCT03725202
Upadacitinib Other Phase PHASE3 Giant Cell Arteritis (GCA) COMPLETED NCT03725202
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT06511882
Decitabine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT06511882
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia RECRUITING NCT06511882
Thioguanine Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Methotrexate Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Nelarabine Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Mercaptopurine Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Cytarabine Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Cyclophosphamide Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) Drug Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Bortezomib Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Venetoclax Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Dasatinib Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Calaspargase pegol Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Daunorubicin Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Vincristine Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Dexamethasone Other Phase PHASE2 T-cell Acute Lymphoblastic Leukemia RECRUITING NCT06390319
Risankizumab Other Phase PHASE4 Inflammatory Bowel Disease COMPLETED NCT06346288
Breast Milk Sampling Other Phase PHASE4 Inflammatory Bowel Disease COMPLETED NCT06346288
XEN45 (Glaucoma Gel Stent) Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT05411198
XEN45 (Glaucoma Gel Stent) Other Phase PHASE3 Open-Angle Glaucoma COMPLETED NCT05411198
Placebo Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06895343
ABBV-701 Other Phase PHASE1 Healthy Volunteer ACTIVE_NOT_RECRUITING NCT06895343
CC-99282 Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Polatuzumab Vedotin Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Prednisone Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Doxorubicin Hydrochloride [HCl] Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Cyclophosphamide Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Rituximab Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Ibrutinib Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Lenalidomide Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Epcoritamab Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
ABBV-8736 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07413133
ABBV-8736 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07413133
Placebo Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Upadacitinib Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Placebo Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Upadacitinib Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Placebo Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Upadacitinib Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Placebo Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Upadacitinib Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT05889182
Placebo-Matching Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Placebo-Matching Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Ubrogepant Other Phase PHASE3 Migraine RECRUITING NCT05125302
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03844815
Decitabine Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03844815
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03844815
Decitabine Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT03844815
ABBV-547 Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07232004
ABBV-547 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07232004
ABBV-547 Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07232004
ABBV-547 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07232004
ABBV-547 Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07232004
ABBV-547 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07232004
Durysta, Bimatoprost Intracameral Implant 10 µg Other Phase PHASE4 Glaucoma RECRUITING NCT07217678
Durysta, Bimatoprost Intracameral Implant 10 µg Other Phase PHASE4 Glaucoma RECRUITING NCT07217678
Durysta, Bimatoprost Intracameral Implant 10 µg Other Phase PHASE4 Glaucoma RECRUITING NCT07217678
Venetoclax Other Phase PHASE2 Chronic Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT05768711
Venetoclax Other Phase PHASE2 Chronic Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT05768711
Venetoclax Other Phase PHASE2 Chronic Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT05768711
Placebo for Atogepant Other Phase PHASE3 Menstrual Migraine (MM) RECRUITING NCT06806293
Atogepant Other Phase PHASE3 Menstrual Migraine (MM) RECRUITING NCT06806293
Placebo for Atogepant Other Phase PHASE3 Menstrual Migraine (MM) RECRUITING NCT06806293
Atogepant Other Phase PHASE3 Menstrual Migraine (MM) RECRUITING NCT06806293
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Telisotuzumab Adizutecan Other Phase PHASE2 Solid Tumors Harboring MET Amplification RECRUITING NCT07196644
Standard of Care Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT07155187
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT07155187
Standard of Care Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT07155187
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Small Cell Lung Cancer RECRUITING NCT07155187
Placebo Other Phase PHASE2 Apathy in Dementia TERMINATED NCT04958031
CVL-871 3.0 mg Other Phase PHASE2 Apathy in Dementia TERMINATED NCT04958031
CVL-871 1.0 mg Other Phase PHASE2 Apathy in Dementia TERMINATED NCT04958031
Placebo Other Phase PHASE2 Apathy in Dementia TERMINATED NCT04958031
CVL-871 3.0 mg Other Phase PHASE2 Apathy in Dementia TERMINATED NCT04958031
CVL-871 1.0 mg Other Phase PHASE2 Apathy in Dementia TERMINATED NCT04958031
Risankizumab Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07466550
Risankizumab Other Phase PHASE1 Healthy Volunteer NOT_YET_RECRUITING NCT07466550
venetoclax + azacitidine +/- donor lymphocyte infusion Other Phase PHASE1 MDS ACTIVE_NOT_RECRUITING NCT05226455
REFRESH OPTIVE UD Other Phase PHASE3 Dry Eye Disease RECRUITING NCT07284381
ABBV-444 Other Phase PHASE3 Dry Eye Disease RECRUITING NCT07284381
REFRESH OPTIVE UD Other Phase PHASE3 Dry Eye Disease RECRUITING NCT07284381
ABBV-444 Other Phase PHASE3 Dry Eye Disease RECRUITING NCT07284381
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Standard of Care Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Telisotuzumab Adizutecan Other Phase PHASE2 Colorectal Cancer RECRUITING NCT07023289
Rituximab Other Phase PHASE2 Lymphoma RECRUITING NCT06510309
Venetoclax Other Phase PHASE2 Lymphoma RECRUITING NCT06510309
Rituximab Other Phase PHASE2 Lymphoma RECRUITING NCT06510309
Venetoclax Other Phase PHASE2 Lymphoma RECRUITING NCT06510309
Rituximab Other Phase PHASE2 Lymphoma RECRUITING NCT06510309
Venetoclax Other Phase PHASE2 Lymphoma RECRUITING NCT06510309
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Dexamethasone Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Bortezomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Selinexor Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Elotuzumab Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Pomalidomide Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Carfilzomib Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Etentamig Other Phase PHASE3 Multiple Myeloma RECRUITING NCT06158841
Epcoritamab Other Phase PHASE2 Primary CNS Lymphoma (PCNSL) RECRUITING NCT06931652
Epcoritamab Other Phase PHASE2 Primary CNS Lymphoma (PCNSL) RECRUITING NCT06931652
Risankizumab Other Phase PHASE3 Crohn's Disease RECRUITING NCT05995353
Risankizumab Other Phase PHASE3 Crohn's Disease RECRUITING NCT05995353
XEN63 Glaucoma Treatment System Drug Phase PHASE3 Primary Open Angle Glaucoma RECRUITING NCT06822738
Placebo Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT06468228
Lutikizumab Other Phase PHASE3 Hidradenitis Suppurativa RECRUITING NCT06468228
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Placebo-Matching Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Atogepant Other Phase PHASE3 Episodic Migraine RECRUITING NCT05711394
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT03844048
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia ACTIVE_NOT_RECRUITING NCT03844048
Placebo for Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Placebo for Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Icalcaprant Other Phase PHASE2 Major Depressive Disorder RECRUITING NCT07276997
Lumigan Vehicle Other Phase PHASE1 Open-angle Glaucoma RECRUITING NCT04499248
Sham Administration Other Phase PHASE1 Open-angle Glaucoma RECRUITING NCT04499248
Lumigan Other Phase PHASE1 Open-angle Glaucoma RECRUITING NCT04499248
AGN-193408 SR Other Phase PHASE1 Open-angle Glaucoma RECRUITING NCT04499248
Navitoclax Other Phase PHASE3 Myelofibrosis (MF) COMPLETED NCT04472598
Ruxolitinib Other Phase PHASE3 Myelofibrosis (MF) COMPLETED NCT04472598
Placebo for Navitoclax Other Phase PHASE3 Myelofibrosis (MF) COMPLETED NCT04472598
Navitoclax Other Phase PHASE3 Myelofibrosis (MF) COMPLETED NCT04472598
Ruxolitinib Other Phase PHASE3 Myelofibrosis (MF) COMPLETED NCT04472598
Placebo for Navitoclax Other Phase PHASE3 Myelofibrosis (MF) COMPLETED NCT04472598
Irinotecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma NOT_YET_RECRUITING NCT07490301
Oxaliplatin Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma NOT_YET_RECRUITING NCT07490301
Folinic acid/ Leucovorina Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma NOT_YET_RECRUITING NCT07490301
Fluorouracil Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma NOT_YET_RECRUITING NCT07490301
Telisotuzumab adizutecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma NOT_YET_RECRUITING NCT07490301
Irinotecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma NOT_YET_RECRUITING NCT07490301
Oxaliplatin Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma NOT_YET_RECRUITING NCT07490301
Folinic acid/ Leucovorina Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma NOT_YET_RECRUITING NCT07490301
Fluorouracil Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma NOT_YET_RECRUITING NCT07490301
Telisotuzumab adizutecan Other Phase PHASE2 Metastatic Pancreatic Ductal Adenocarcinoma NOT_YET_RECRUITING NCT07490301
Cofetuzumab Pelidotin Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT04189614
Cofetuzumab Pelidotin Other Phase PHASE1 Cancer ACTIVE_NOT_RECRUITING NCT04189614
ABBV-324 Other Phase PHASE1 Hepatocellular Cancer RECRUITING NCT06858813
Lenvatinib Other Phase PHASE1 Hepatocellular Cancer RECRUITING NCT06858813
ABBV-324 Other Phase PHASE1 Hepatocellular Cancer RECRUITING NCT06858813
Lenvatinib Other Phase PHASE1 Hepatocellular Cancer RECRUITING NCT06858813
Brimonidine tartrate ophthalmic solution eye drops Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Prednisolone acetate ophthalmic suspension 1% eye drops Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Lubricating Eye Drops Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Mirvetuximab Soravtansine Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Brimonidine tartrate ophthalmic solution eye drops Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Prednisolone acetate ophthalmic suspension 1% eye drops Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Lubricating Eye Drops Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Mirvetuximab Soravtansine Other Phase PHASE2 Recurrent Ovarian Cancer RECRUITING NCT06365853
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
KYBELLA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
SkinMedica Products Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
CoolSculpting Elite System Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
JUVÉDERM Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
OnabotulinumtoxinA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
KYBELLA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
SkinMedica Products Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
CoolSculpting Elite System Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
JUVÉDERM Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
OnabotulinumtoxinA Other Phase PHASE4 Facial Contouring COMPLETED NCT06783621
Intravenous (IV) Etentamig Other Phase PHASE1 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT06223516
Subcutaneous (SC) Etentamig Other Phase PHASE1 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT06223516
Intravenous (IV) Etentamig Other Phase PHASE1 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT06223516
Subcutaneous (SC) Etentamig Other Phase PHASE1 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT06223516
Intravenous (IV) Etentamig Other Phase PHASE1 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT06223516
Subcutaneous (SC) Etentamig Other Phase PHASE1 Multiple Myeloma ACTIVE_NOT_RECRUITING NCT06223516
Iberdomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Etentamig Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Iberdomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Etentamig Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Oxaliplatin Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma RECRUITING NCT06628310
Leucovorin Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma RECRUITING NCT06628310
Fluorouracil Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma RECRUITING NCT06628310
Budigalimab Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma RECRUITING NCT06628310
Telisotuzumab Adizutecan Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma RECRUITING NCT06628310
Oxaliplatin Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma RECRUITING NCT06628310
Leucovorin Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma RECRUITING NCT06628310
Fluorouracil Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma RECRUITING NCT06628310
Budigalimab Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma RECRUITING NCT06628310
Telisotuzumab Adizutecan Other Phase PHASE2 Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma RECRUITING NCT06628310
ABBV-722 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07502417
Ethinyl Estradiol + Levonorgestrel Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07502417
ABBV-722 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07502417
Ethinyl Estradiol + Levonorgestrel Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07502417
Upadacitinib Other Phase PHASE4 UC - Ulcerative Colitis NOT_YET_RECRUITING NCT07502339
Venetoclax Other Phase PHASE2 Relapsed or Refractory Acute Myeloid Leukemia (AML) RECRUITING NCT06660368
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen Other Phase PHASE2 Relapsed or Refractory Acute Myeloid Leukemia (AML) RECRUITING NCT06660368
ABBV-8736 Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Trosunilimab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Lutikizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Risankizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
ABBV-8736 Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Trosunilimab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Lutikizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Risankizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
ABBV-8736 Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Trosunilimab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Lutikizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Risankizumab Other Phase PHASE2 Crohn's Disease RECRUITING NCT06548542
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
Topiramate 100 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Propranolol 160 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Atogepant 60 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Topiramate 100 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Propranolol 160 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Atogepant 60 mg Other Phase PHASE4 Migraine RECRUITING NCT06972056
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Placebo Other Phase PHASE4 Psoriatic Arthritis RECRUITING NCT06454188
Upadacitinib 15 MG [Rinvoq] Other Phase PHASE4 Psoriatic Arthritis RECRUITING NCT06454188
Placebo Other Phase PHASE4 Psoriatic Arthritis RECRUITING NCT06454188
Upadacitinib 15 MG [Rinvoq] Other Phase PHASE4 Psoriatic Arthritis RECRUITING NCT06454188
Telisotuzumab Adizutecan Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Bevacizumab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Budigalimab Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Azirkitug Other Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT05005403
Placebo for ABBV-142 Other Phase PHASE2 Idiopathic Pulmonary Fibrosis RECRUITING NCT07230288
ABBV-142 Other Phase PHASE2 Idiopathic Pulmonary Fibrosis RECRUITING NCT07230288
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Placebo for AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
AGN-151607-DP Other Phase PHASE2 Ventral Hernia RECRUITING NCT07226791
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Olaparib Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Bevacizumab Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Carboplatin Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
IMGN151 Other Phase PHASE2 Gynecologic Cancers RECRUITING NCT07024784
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Placebo for Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Icalcaprant Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT06696755
Upadacitinib Other Phase PHASE3 Crohn's Disease RECRUITING NCT06332534
Placebo for Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Placebo for ABBV-295 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07514260
ABBV-295 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07514260
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Dupilumab Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06461897
Upadacitinib Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06461897
Dupilumab Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06461897
Upadacitinib Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06461897
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Ustekinumab Other Phase PHASE3 Crohn's Disease (CD) ACTIVE_NOT_RECRUITING NCT04524611
Risankizumab Other Phase PHASE3 Crohn's Disease (CD) ACTIVE_NOT_RECRUITING NCT04524611
Investigator's Choice Chemotherapy Drug Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT07226752
Epcoritamab Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT07226752
Investigator's Choice Chemotherapy Drug Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT07226752
Epcoritamab Other Phase PHASE3 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT07226752
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
ABBV-969 Other Phase PHASE1 Metastatic Castration-Resistant Prostate Cancer RECRUITING NCT06318273
ABBV-969 Other Phase PHASE1 Metastatic Castration-Resistant Prostate Cancer RECRUITING NCT06318273
ABBV-969 Other Phase PHASE1 Metastatic Castration-Resistant Prostate Cancer RECRUITING NCT06318273
Lenalidomide Other Phase PHASE2 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT05660967
Epcoritamab Other Phase PHASE2 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT05660967
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Rituximab and Lenalidomide Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, ifosfamide, carboplatin, and etoposide phosphate Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
Lenalidomide Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
Epcoritamab Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
gemcitabine and oxaliplatin Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab and bendamustine Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab and lenalidomide Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
Rituximab and Lenalidomide Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, ifosfamide, carboplatin, and etoposide phosphate Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
Lenalidomide Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
Epcoritamab Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
gemcitabine and oxaliplatin Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab and bendamustine Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab and lenalidomide Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
Rituximab and Lenalidomide Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, ifosfamide, carboplatin, and etoposide phosphate Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
Lenalidomide Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
Epcoritamab Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
gemcitabine and oxaliplatin Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab and bendamustine Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab and lenalidomide Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04663347
Investigator's Choice Chemotherapy Drug Phase PHASE3 Diffuse Large B-cell Lymphoma ACTIVE_NOT_RECRUITING NCT04628494
Epcoritamab Other Phase PHASE3 Diffuse Large B-cell Lymphoma ACTIVE_NOT_RECRUITING NCT04628494
Investigator's Choice Chemotherapy Drug Phase PHASE3 Diffuse Large B-cell Lymphoma ACTIVE_NOT_RECRUITING NCT04628494
Epcoritamab Other Phase PHASE3 Diffuse Large B-cell Lymphoma ACTIVE_NOT_RECRUITING NCT04628494
Rituximab and lenalidomide Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Epcoritamab (maintenance) Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Gemcitabine and oxaliplatin Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Epcoritamab Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Epcoritamab (monotherapy) Drug Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Rituximab and lenalidomide Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Epcoritamab (maintenance) Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Gemcitabine and oxaliplatin Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Epcoritamab Other Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Epcoritamab (monotherapy) Drug Phase PHASE1 Diffuse Large B Cell Lymphoma ACTIVE_NOT_RECRUITING NCT04542824
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT04102020
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT04102020
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT04102020
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT04102020
Azacitidine Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT04102020
Venetoclax Other Phase PHASE3 Acute Myeloid Leukemia (AML) COMPLETED NCT04102020
Epcoritamab Other Phase PHASE1 DLBCL ACTIVE_NOT_RECRUITING NCT03625037
Epcoritamab Other Phase PHASE1 DLBCL ACTIVE_NOT_RECRUITING NCT03625037
Placebo for ABBV-142 Other Phase PHASE2 Idiopathic Pulmonary Fibrosis RECRUITING NCT07230288
ABBV-142 Other Phase PHASE2 Idiopathic Pulmonary Fibrosis RECRUITING NCT07230288
Obinutuzumab Other Phase PHASE3 Chronic Lymphocytic Leukemia RECRUITING NCT06428019
Acalabrutinib Other Phase PHASE3 Chronic Lymphocytic Leukemia RECRUITING NCT06428019
Venetoclax Other Phase PHASE3 Chronic Lymphocytic Leukemia RECRUITING NCT06428019
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer NOT_YET_RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer NOT_YET_RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer NOT_YET_RECRUITING NCT07525206
Trifluridine/Tipiracil Other Phase PHASE3 Colorectal Cancer NOT_YET_RECRUITING NCT07525206
Bevacizumab Other Phase PHASE3 Colorectal Cancer NOT_YET_RECRUITING NCT07525206
Telisotuzumab adizutecan Other Phase PHASE3 Colorectal Cancer NOT_YET_RECRUITING NCT07525206
Venetoclax Other Phase PHASE2 Waldenstrom Macroglobulinemia RECRUITING NCT07387471
Venetoclax Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Questionnaire Administration Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Multigated Acquisition Scan Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Lumbar Puncture Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Echocardiography Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Cytarabine Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Cladribine Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Bone Marrow Biopsy Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Bone Marrow Aspiration Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Biospecimen Collection Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Azacitidine Other Phase PHASE2 Acute Monocytic Leukemia RECRUITING NCT06504459
Olaparib Other Phase PHASE2 Ovary Cancer RECRUITING NCT05887609
Mirvetuximab Soravtansine-gynx Other Phase PHASE2 Ovary Cancer RECRUITING NCT05887609
CC-99282 Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Polatuzumab Vedotin Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Prednisone Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Doxorubicin Hydrochloride [HCl] Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Cyclophosphamide Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Rituximab Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Ibrutinib Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Lenalidomide Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Epcoritamab Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
CC-99282 Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Polatuzumab Vedotin Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Prednisone Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Doxorubicin Hydrochloride [HCl] Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Cyclophosphamide Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Rituximab Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Ibrutinib Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Lenalidomide Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Epcoritamab Other Phase PHASE2 Non-Hodgkin Lymphoma RECRUITING NCT05283720
Usual care Other Approved Hepatitis C Virus Infection, Response to Therapy of COMPLETED NCT04677153
Test and treat plus peer mentors Other Approved Hepatitis C Virus Infection, Response to Therapy of COMPLETED NCT04677153
Ustekinumab Other Phase PHASE3 Crohn's Disease (CD) ACTIVE_NOT_RECRUITING NCT04524611
Risankizumab Other Phase PHASE3 Crohn's Disease (CD) ACTIVE_NOT_RECRUITING NCT04524611
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Pivekimab Sunirine Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT06034470
Multigated Acquisition Scan Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT06034470
Idarubicin Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT06034470
Granulocyte Colony-Stimulating Factor Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT06034470
Fludarabine Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT06034470
Echocardiography Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT06034470
Cytarabine Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT06034470
Bone Marrow Biopsy Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT06034470
Bone Marrow Aspiration Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT06034470
Biospecimen Collection Other Phase PHASE1 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT06034470
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Placebo for ABBV-295 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07514260
ABBV-295 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07514260
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Panitumumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Bevacizumab Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Leucovorin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Oxaliplatin Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Fluorouracil Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Telisotuzumab Adizutecan Other Phase PHASE2 Metastatic Colorectal Cancer RECRUITING NCT06820463
Deucravacitinib Other Phase PHASE4 Moderate Plaque Psoriasis COMPLETED NCT06333860
Risankizumab Other Phase PHASE4 Moderate Plaque Psoriasis COMPLETED NCT06333860
Deucravacitinib Other Phase PHASE4 Moderate Plaque Psoriasis COMPLETED NCT06333860
Risankizumab Other Phase PHASE4 Moderate Plaque Psoriasis COMPLETED NCT06333860
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Upadacitinib Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07425899
ABBV-722 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07425899
Risankizumab Other Phase PHASE4 Inflammatory Bowel Disease COMPLETED NCT06346288
Breast Milk Sampling Other Phase PHASE4 Inflammatory Bowel Disease COMPLETED NCT06346288
Risankizumab Other Phase PHASE4 Inflammatory Bowel Disease COMPLETED NCT06346288
Breast Milk Sampling Other Phase PHASE4 Inflammatory Bowel Disease COMPLETED NCT06346288
Rituximab Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Prednisone Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Positron Emission Tomography Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Multigated Acquisition Scan Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Fludeoxyglucose F-18 Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Etoposide Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Epcoritamab Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Echocardiography Test Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Doxorubicin Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Cyclophosphamide Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Computed Tomography Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Bone Marrow Biopsy Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Bone Marrow Aspiration Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Biospecimen Collection Other Phase PHASE2 B-Cell Non-Hodgkin Lymphoma RECRUITING NCT07097363
Gilteritinib Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Etoposide Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Mitoxantrone Hydrochloride Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Idarubicin Hydrochloride Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Fludarabine Phosphate Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Daunorubicin Hydrochloride Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Gemtuzumab Ozogamicin Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Cytarabine Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia SUSPENDED NCT05955261
ABBV-722 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07361367
Glecaprevir/pibrentasvir Other Phase PHASE1 Hepatitis C RECRUITING NCT07040319
Placebo for Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Atogepant Other Phase PHASE3 Migraine RECRUITING NCT06241313
Placebo Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Upadacitinib Other Phase PHASE3 Alopecia Areata RECRUITING NCT06012240
Cisplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pemetrexed Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Carboplatin Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Budigalimab Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Telisotuzumab Adizutecan Other Phase PHASE1 Non Small Cell Lung Carcinoma RECRUITING NCT06772623
Ranibizumab Control Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Surabgene Lomparvovec (ABBV-RGX-314) Other Phase PHASE3 Neovascular Age-related Macular Degeneration RECRUITING NCT07007065
Placebo for Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Atogepant Other Phase PHASE3 Chronic Migraine RECRUITING NCT06810505
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Liposomal daunorubicin and cytarabine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Daunorubicin Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Idarubicin Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Cytarabine Other Phase PHASE2 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING NCT04801797
Pemetrexed Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Carboplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Cisplatin Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Osimertinib (Osi) Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Telisotuzumab Adizutecan Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Standard of Care Other Phase PHASE2 Non-Squamous Non-Small Cell Lung Cancer RECRUITING NCT07005102
Iberdomide Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Etentamig Other Phase PHASE1 Multiple Myeloma RECRUITING NCT06896916
Bevacizumab Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Mirvetuximab Soravtansine Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Carboplatin Other Phase PHASE2 Epithelial Ovarian Cancer RECRUITING NCT06890338
Dexamethasone Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Daratumumab Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Lenalidomide Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Etentamig Other Phase PHASE2 Multiple Myeloma RECRUITING NCT07095452
Ravagalimab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Placebo Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lutikizumab Other Phase PHASE2 Rheumatoid Arthritis RECRUITING NCT06972446
Lurbinectedin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Carboplatin Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Etoposide Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Atezolizumab Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
ABBV-706 Other Phase PHASE2 Small Cell Lung Cancer RECRUITING NCT07155174
Matching Placebo for PVEK Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Venetoclax Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Pivekimab Sunirine Other Phase PHASE2 Acute Myeloid Leukemia NOT_YET_RECRUITING NCT07581002
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
Emraclidine Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07219030
ABBV-319 Other Phase PHASE1 Dry Eye Syndrome RECRUITING NCT06977724
VOLUMA XC Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
NOA VOLUME Other Phase PHASE3 Mid Face Volume Deficit RECRUITING NCT06734351
Upadacitinib 30mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Dupilumab 300mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Upadacitinib 15mg Dose Other Phase PHASE3 Atopic Dermatitis RECRUITING NCT06389136
Placebo Other Phase PHASE3 Depression RECRUITING NCT04777357
Cariprazine Other Phase PHASE3 Depression RECRUITING NCT04777357
Docetaxel Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Telisotuzumab Vedotin Other Phase PHASE3 Non Small Cell Lung Cancer RECRUITING NCT04928846
Azacitidine Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
Venetoclax Other Phase PHASE4 Acute Myeloid Leukemia RECRUITING NCT07044687
Total products: 10330